<SEC-DOCUMENT>0000950123-19-009310.txt : 20191029
<SEC-HEADER>0000950123-19-009310.hdr.sgml : 20191029
<ACCEPTANCE-DATETIME>20191004075642
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-19-009310
CONFORMED SUBMISSION TYPE:	DRS/A
PUBLIC DOCUMENT COUNT:		68
FILED AS OF DATE:		20191004
<PUBLIC-REL-DATE>20191029
DATE AS OF CHANGE:		20191004

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			I-Mab
		CENTRAL INDEX KEY:			0001778016
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-02758
		FILM NUMBER:		191137618

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
		BUSINESS PHONE:		862160578000

	MAIL ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS/A
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>As confidentially submitted to the Securities and Exchange Commission on October 4,
2019 </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">F-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of Registrant as specified in its charter) </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of Registrant&#146;s name into English) </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Cayman Islands</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not Applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Shanghai, 201210 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>People&#146;s Republic of China </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>+86 21-6057-8000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address,
including zip code, and telephone number, including area code, of Registrant&#146;s principal executive offices) </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to:</I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Z. Julie Gao, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Skadden,&nbsp;Arps,&nbsp;Slate,&nbsp;Meagher&nbsp;&amp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Flom&nbsp;LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>c/o&nbsp;42/F,&nbsp;Edinburgh&nbsp;Tower, The Landmark</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>15 Queen&#146;s Road Central</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Hong Kong</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>+852
3740-4700</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Haiping Li, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Skadden, Arps, Slate, Meagher&nbsp;&amp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Flom&nbsp;LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>c/o JingAn
Kerry Center, Tower II, 46/F</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>1539 Nanjing West Road</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Shanghai, the People&#146;s Republic of China</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>+86 <FONT STYLE="white-space:nowrap">21-6193-8200</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Li He, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>James C. Lin, Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Davis
Polk&nbsp;&amp; Wardwell&nbsp;LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>c/o 18/F, The Hong Kong Club Building</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>3A Chater Road, Central</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Hong Kong</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>+852
2533-3300</B></P></TD></TR>
</TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration
statement. </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to
Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective
amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933. Emerging growth
company.&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#134; provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">&#134; The term &#147;new or revised financial accounting standard&#148; refers to any update issued by the Financial Accounting Standards Board to its
Accounting Standards Codification after April&nbsp;5, 2012. </P> <P STYLE="margin-top:0pt;margin-bottom:0pt;page-break-before:always"></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF
REGISTRATION FEE </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>securities to be registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed<BR>maximum<BR>aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>offering price<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Amount of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>registration fee</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares, par value US$0.0001 per share<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">American depositary shares issuable upon deposit of ordinary shares registered hereby will be registered under a
separate registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;F-6</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;).</FONT> Each American
depositary share represents &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Includes ordinary shares that are issuable upon the exercise of the underwriters&#146; over-allotment option.
Also includes ordinary shares initially offered and sold outside the United States that may be resold from time to time in the United States either as part of their distribution or within 40 days after the later of the effective date of this
registration statement and the date the shares are first bona fide offered to the public. These ordinary shares are not being registered for the purpose of sales outside the United States. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of determining the amount of registration fee in accordance with Rule 457(o)
under the Securities Act of 1933. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>The Registrant
hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become
effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine.
</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#eb0029"><B>The information in this preliminary prospectus is not complete and may be changed.
These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting offers to buy these
securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#eb0029">Subject to Completion. Dated
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; American Depositary Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[LOGO] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">I-MAB</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Representing &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Ordinary Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This is an initial public offering of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; American depositary shares (the
&#147;ADSs&#148;), by <FONT STYLE="white-space:nowrap">I-Mab.</FONT> Each ADS represents &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of our ordinary shares, par value US$0.0001 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for the ADSs or our shares. We anticipate that the initial public offering price will
be between US$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and US$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS. We intend to apply to list the ADSs on the Nasdaq Global Market under
the symbol &#147;IMAB.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; under applicable U.S. federal securities laws and are
eligible for reduced public company reporting requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Investing in our ADSs involves risks. See &#147;<A HREF="#rom713200_4">Risk Factors
</A>&#148; beginning on page 18 for factors you should consider before buying the&nbsp;ADSs. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the United States Securities
and Exchange Commission nor any other regulatory body has approved or disapproved of these securities, or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>PRICE US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PER ADS </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per ADS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For a description of compensation payable to the underwriters, see &#147;Underwriting.&#148;
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted the underwriters an option to purchase up to an additional
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ADSs within 30 days from the date of this prospectus at the initial public offering price, less the underwriting discounts and commissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters expect to deliver the ADSs against payment in U.S. dollars in New York, New York on or about
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="bottom" ALIGN="center"><B>CICC</B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Prospectus dated
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Page intentionally left blank for graphics] </P>
<P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>Page</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_3">SUMMARY CONSOLIDATED FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_5">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_7">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_8">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_9">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_10">ENFORCEABILITY OF CIVIL LIABILITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_11">CORPORATE HISTORY AND STRUCTURE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_12">SELECTED CONSOLIDATED FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_13">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_14">INDUSTRY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_15">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_16">REGULATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_17">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_18">PRINCIPAL SHAREHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_19">RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_20">DESCRIPTION OF SHARE CAPITAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_21">DESCRIPTION OF AMERICAN DEPOSITARY SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_22">SHARES ELIGIBLE FOR FUTURE SALES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_23">TAXATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_24">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_25">EXPENSES RELATED TO THIS OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_26">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_27">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_28">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom713200_29">INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in this prospectus or in any related free writing prospectus. We have not authorized anyone
to provide you with information different from that contained in this prospectus or in any related free writing prospectus. We are offering to sell, and seeking offers to buy the ADSs, only in jurisdictions where offers and sales are permitted. The
information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of the&nbsp;ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we have nor any of the underwriters has taken any action to permit a public offering of the ADSs outside the United&nbsp;States or to
permit the possession or distribution of this prospectus or any filed free writing prospectus outside the United&nbsp;States. Persons outside the United&nbsp;States who come into possession of this prospectus or any filed free writing prospectus
must inform themselves about and observe any restrictions relating to the offering of the ADSs and the distribution of this prospectus or any filed free writing prospectus outside the United&nbsp;States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Until &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2019 (the 25th day after the date of this prospectus), all
dealers that buy, sell or trade ADSs, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the obligation of dealers to deliver a prospectus when acting as underwriters and with respect to
their unsold allotments or subscriptions. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary is qualified in its entirety by, and should be read in conjunction with, the more detailed information and financial
statements appearing elsewhere in this prospectus. In addition to this summary, we urge you to read the entire prospectus carefully, especially the risks of investing in our ADSs discussed under &#147;Risk Factors,&#148; before deciding whether to
invest in our ADSs. This prospectus contains information from an industry report commissioned by us and prepared by Frost&nbsp;&amp; Sullivan, an independent research firm, to provide information regarding our industry and our market position. We
refer to this report as the Frost&nbsp;&amp; Sullivan Report. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly
differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
were founded to capture the opportunities presented by the confluence of two major developments&#151;the emergence of an attractive and growing biologics market in China, and the revolutionary scientific breakthroughs in cancer and autoimmune
disease medicines. We believe we are well-positioned to become a biotech leader in China because of our innovative discovery expertise, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fit-for-purpose</FONT></FONT> technology
platforms, biomarker-enabled translational medicine capabilities, and clinical development capabilities. These integrated capabilities are further enhanced by our deep understanding of China&#146;s biologics regulatory framework and our direct
access to extensive <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trial resources in China. To date, we have developed an innovative pipeline of more than 10 clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage
assets through our internal research and development efforts and <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements with global pharmaceutical and biotech companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercial Opportunities in China and Our Unique Position </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are fully aware of the competitive and regulatory challenges we face as an innovative clinical stage biotech company based in China,
including need to raise significant capital, significant competition from global and other China-based biopharmaceutical companies, less streamlined regulatory pathway compared to countries with long-established regulatory systems, and potential
implementation challenges and uncertainties of the recent government reform of the drug approval system. However, with these challenges in mind, we have been mitigating the risks through our internal R&amp;D system that integrates multi-functional
aspects of our drug development process to proactively deal with some of the regulatory challenges mentioned above. Furthermore, through our Beijing office which focuses on regulatory matters, we have established an effective communication channel
with the regulatory agencies to discuss and resolve various regulatory issues promptly and effectively. We see vast opportunities for immuno-oncology and autoimmune biologics therapies in China. First, both the incidence and mortality of cancers in
China have been increasing in recent years and are outpacing those in the United States and the rest of the world. Second, many innovative biologics approved to treat cancer and autoimmune diseases in the United States and Europe are not yet
available in China. Third, the Chinese government has implemented new policies and regulations to simplify the review and approval cycle of clinical trials and new drug applications to encourage biologics innovation. Fourth, there has been a
continuous and rapid increase in personal disposable income in China coupled with ongoing improvement in basic national health insurance coverage, making innovative biologics more accessible to more Chinese patients. According to the
Frost&nbsp;&amp; Sullivan Report, China&#146;s biologics market is growing faster than the global biologics market and is expected to reach approximately RMB1.3 trillion (US$189.4 billion) by 2030 in terms of sales revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe we are uniquely positioned as a China-based global player to tap into these vast commercial opportunities. This is best
demonstrated by our short journey in becoming one of the top clinical stage </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
immunology companies in China. According to the Frost &amp; Sullivan Report, we are ranked as top clinical stage China-based immunology companies as measured by the innovative quality and number
of investigational drugs and drug candidates under clinical and pre-clinical development in our pipeline, amount of pre-IPO financing raised (in excess of US$400 million in three years), pre-IPO valuation and recognition and awards earned in the
biotech industry. For example, in March 2019, Genetic Engineering &amp; Biotechnology News (GEN) recognized us as a top 10 immuno-oncology start-up in the world. We were the only China-based company recognized therein. To date, our research and
development capabilities encompass discovery, biologics CMC development, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development and clinical development with footprints in Shanghai, Beijing and the United States. We are now at a critical
juncture to transition from a clinical stage biotech company into a fully integrated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> global biopharmaceutical company in the next few years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Unique Business Model </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To achieve our
mission and capitalize on these commercial opportunities, we have developed a business model built on two pillars: a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> China strategy and a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-PoC</FONT></FONT> (proof of concept) global strategy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT> China Strategy </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> China strategy focuses on seeking opportunities to <FONT STYLE="white-space:nowrap">in-license</FONT> the development and commercialization rights of
investigational drugs from global biopharmaceutical companies for Greater China. We only select investigational drugs that have the potential to become novel or highly differentiated medicines. Through our substantial
<FONT STYLE="white-space:nowrap">in-house</FONT> research and development efforts, we build additional data packages to meet the requirements of the National Medical Products Administration (the &#147;NMPA&#148;) to ensure programs are ready for
late-stage or registrational clinical development. Our internal development capabilities combined with our deep insight into China&#146;s regulatory framework and our clinical network enable us to efficiently navigate through the drug development
process to registration. To date, we have built an innovative China Portfolio consisting of five investigational drugs with an aim for near-term product launch. All of these investigational drugs have met the related pre-set safety and preliminary
efficacy endpoints in Phase 1 or Phase 2 clinical trials in Europe, the United States or elsewhere and are either in or ready for Phase 2 or Phase 3 clinical trials in China. TJ202 is undergoing two registrational trials, a monotherapy trial and a
combination therapy trial in relapsed or refractory multiple myeloma in Greater China, and we will soon initiate a Phase 1b trial in systemic lupus erythematosus (&#147;SLE&#148;) in the first half of 2020. For TJ101, we expect to submit an
investigational new drug (&#147;IND&#148;) for a Phase 3 registrational trial in China by early 2020. For enoblituzumab, we expect to initiate either a registrational trial (pending the NMPA&#146;s regulatory approval) or a Phase 2 trial by the end
of 2020. As a result, the investigational drugs in our China Portfolio are positioned for a series of new drug applications (NDAs) in China with the submission of the first NDA expected in 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-PoC</FONT></FONT> Global Strategy </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-PoC</FONT></FONT> global strategy focuses on advancing our own
novel or differentiated biologics towards clinical validation in the United States. First, we seek PoC of these drug candidates in the United&nbsp;States by conducting early phase clinical trials with a set of safety and efficacy endpoints and
leveraging the FDA&#146;s streamlined regulatory system for innovative drug discovery, including a predictable timeline towards approval. Second, we will use the data generated to advance clinical development in China, which we believe confers
several advantages, including access to China&#146;s large patient pool, extensive clinical trial resources through collaborations with leading hospitals in China, and a regulatory pathway for fast-track approval of drugs supported by solid overseas
clinical data. Building on this approach, we typically <FONT STYLE="white-space:nowrap">out-license</FONT> the global rights (excluding Greater China) of these investigational drugs following clinical validation in the United States, while retaining
the Greater China rights for further development and commercialization. We believe this approach will allow Chinese patients to benefit from our most advanced treatments concurrently or soon after their market
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approvals elsewhere. To date, we have created a Global Portfolio that consists of two molecular classes&#151;monoclonal antibodies and <FONT STYLE="white-space:nowrap">bi-specific</FONT>
antibodies, which are internally generated. They are highly innovative molecules compared to global competitor assets in the same or related classes of drug candidates. Three investigational drugs in our Global Portfolio (TJM2, TJC4 and TJD5) are in
Phase 1 trials in the United States. We have obtained IND approval from the NMPA for TJD5 in September 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These two strategies and the
resulting two portfolios complement each other and enable us to achieve a balance among our ambition to develop novel and highly differentiated drugs, our goal to efficiently advance our pipeline assets towards commercialization and the inherent
development risks. With this goal in mind, we are also aware that the intended novelty and key differentiation of our investigational drugs or drug candidates are subject to pivotal clinical validation and approval by the relevant regulatory
authorities. There is no assurance that any such investigational drug or drug candidate will receive regulatory approval. See &#147;Risk Factors&#148; for a detailed description of the risks related to the development and commercialization of our
drug candidates. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Capabilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our
Innovative Discovery Expertise </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Built by an elite group of seasoned immunologists with extensive academic research and drug
development experience, our discovery engine has generated a panel of internally developed innovative drug molecules in a short span of four years. Among them, 11 innovative drug molecules have met our standard of novelty or high differentiation and
have advanced toward further development. This achievement is a testament to our discovery team&#146;s acumen and technical prowess in translating target biology into points of innovation or differentiation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discovery of TJC4 showcases our innovative research capabilities. Not settling on performing routine or traditional antibody screening, we
set a specific goal to identify and select a unique CD47 antibody that is free from binding to red blood cells (RBC) among all CD47 antibody leads that naturally bind to RBCs. As a result, we selected by design, our proprietary CD47 antibody (TJC4),
a rare epitope that uniquely spares binding to RBCs as a differentiation point from other CD47 antibodies that typically cause inherent hematologic side effects. Having confirmed the RBC-sparing property in a series of in vitro assays as well as
multiple monkey studies, we are conducting a Phase 1 clinical trial for TJC4 in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Another example of our R&amp;D
capability relates to our novel <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody panel that represents a new wave of oncology drug candidates. We created novel biological properties of these
<FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies that are capable of enriching immune cells in tumors through dual targeting of <FONT STYLE="white-space:nowrap">PD-L1</FONT> and immune cells for a synergistic anti-tumor effect. These <FONT
STYLE="white-space:nowrap">bi-specific</FONT> drug candidates have been shown to exhibit unique properties that render tumors more responsive to treatment. Our discovery expertise, when combined with our <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#147;fit-for-purpose&#148;</FONT></FONT> antibody engineering technology platforms, becomes a powerful engine of innovation to create novel molecules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fit-for-Purpose</FONT></FONT> Technology Platforms </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our proprietary antibody engineering platforms enable us to accurately capture the biological properties of
<FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies and retain good manufacturability and druggability of the molecules. To date, we have created seven novel <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage <FONT
STYLE="white-space:nowrap">bi-specific</FONT> drug molecules. In addition to our own <FONT STYLE="white-space:nowrap">Ig-scFv</FONT> <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody platform, we partnered with ABL Bio and WuXi Biologics
to access their antibody engineering platforms in order to increase the probability of success, as different molecular configurations require different technologies. Furthermore, our proprietary antibody-cytokine technology has enabled another form
of <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies such as <FONT STYLE="white-space:nowrap">TJ-L1I7</FONT> and <FONT STYLE="white-space:nowrap">TJ-C4GM</FONT> that link a tumor-engaging antibody with an immuno-modulatory cytokine.
Superior to monoclonal antibodies or cytokines alone, this class of <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies has demonstrated unique properties capable of concentrating the drug molecules in tumors for a desired target effect
with reduced systemic toxicity of cytokines or creating biologic synergy that can potentially translate into better treatment outcome. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Biomarker-Enabled Translational Medicine Capabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we focus on developing innovative drug molecules, the ability to apply relevant biomarkers that link a drug response to treatment effects is
critical for early-stage clinical trials of our investigational drugs. This translational medicine capability requires cross-functional knowledge and unique skills to link the target biology of an investigational drug to clinical responses. We have
been developing tailor-made biomarkers for each of our investigational drugs, which are used to select potential responders, predict and measure target engagement, support dose determination and enable timely informed decisions on advancing our
assets to the next phase of clinical development. For example, for the development of TJD5, we intend to use CD73 in tumor tissue in combination with other tumor biomarkers to stratify potential target patient populations in our clinical trial. To
that end, we have developed assays to measure CD73 expression and activity in tumor tissues. Furthermore, we have developed specialized assays to measure TJD5 drug concentrations in tumor tissues. By linking drug concentration with its activity in
the same tumor location, these data help us determine appropriate dose selection for further clinical studies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Clinical Development
Capabilities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our clinical development capabilities are highlighted by a global team of clinical scientists, industry physicians,
data management specialists, biostatisticians, clinical operation staff and drug safety experts. Our clinical team accounts for approximately 80% of our entire R&amp;D organization&#146;s headcount and 80% of our budget allocation. The skillset of
our clinical development team is highlighted by a combination of extensive global pharma experience, local drug development and operational experience with clinical networks in China and the United States. The team is driven by high ethical
standards, clinical science and passion for improving the lives of patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our clinical development capabilities are also highlighted
by our ability to integrate internal core development functions, which encompass regulatory affairs, translational medicine, clinical research and operations, data management, biostatistics, clinical safety and pharmacovigilance, portfolio and
project management, and global drug supplies. We also effectively leverage external resources, including clinical contract research organizations, academic clinical centers and/or networks, and global pharmaceutical or biotech partnerships.
Furthermore, we have established and implemented a robust internal clinical governance system to safeguard patient safety and data reporting. Our current clinical development capabilities are strategically based in Shanghai, Beijing, and the United
States to cover Phase 1 through Phase 3 clinical trials in China and early-stage clinical trials in the United&nbsp;States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our clinical
development capabilities are best demonstrated by our rapid implementation of seven ongoing clinical trials, including four Phase 1/2 and registrational trials in Greater China and three Phase 1 trials in the United States within the past three
years. To ensure regulatory approval and subsequent product launch as currently planned, we strive to reach the following critical clinical milestones by the end of 2020&#150;&#150;14 active clinical programs consisting of three Phase 3 or
registrational trials in China, three Phase 2 trials in China and eight Phase 1 trials in the United States and China. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Global Strategic
Collaborations </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established an excellent track record of <FONT STYLE="white-space:nowrap">in-licensing</FONT> and <FONT
STYLE="white-space:nowrap">out-licensing</FONT> deals with our global and regional partners. These <FONT STYLE="white-space:nowrap">in-licensing</FONT> deals enable us to acquire multiple innovative clinical stage assets with favorable clinical data
packages. We have quickly built our China Portfolio through <FONT STYLE="white-space:nowrap">in-licensing</FONT> deals with global biotech partners, including MorphoSys, Genexine, MacroGenics and Ferring (as the sublicensee under our agreement with
Ferring related to Olamkicept TJ301). Over the past three years, we have established more than 10 global and regional partnerships with reputable pharma or biotech companies. Our partners selected us among
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
many China-based companies with the belief that we are an ideal partner in China given our strength in science and drug development capability, our outstanding track record of execution of
rapidly progressing drug development programs in China and the United States and our vision and network to tap into business opportunities and the growing pharmaceutical market in China. For example, MorphoSys, MacroGenics and Genexine all stated
that we are an ideal or the best partner in China in their press releases or public announcements. The <FONT STYLE="white-space:nowrap">out-licensing</FONT> deals enable us to streamline our pipeline and focus our resources on the most valuable
assets. In addition, we seek <FONT STYLE="white-space:nowrap">co-development</FONT> opportunities to share development costs and risks and territorial commercial rights with our partners. In the past two years, we have
<FONT STYLE="white-space:nowrap">out-licensed</FONT> three <FONT STYLE="white-space:nowrap">de-prioritized</FONT> assets and initiated four <FONT STYLE="white-space:nowrap">co-development</FONT> programs with partners such as ABL Bio, Everest
Medicines and WuXi Biologics. The revenue from <FONT STYLE="white-space:nowrap">out-licensing</FONT> and <FONT STYLE="white-space:nowrap">co-development</FONT> deals is expected to continue to grow as our pipeline progresses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Drug Pipeline </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The chart below
summarizes the development status of our drug pipeline. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g95n07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Notes: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#3d72ff"><FONT STYLE="FONT-FAMILY:'WINGDINGS 2'">&#233;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">(i) TJ202 has two ongoing registrational trials, a monotherapy trial and a combination therapy trial in relapsed
or refractory multiple myeloma in Greater China, and we will soon initiate a Phase 1b trial in systemic lupus erythematosus (&#147;SLE&#148;); (ii) for TJ101, we expect to submit an IND for a Phase 3 registrational trial in China by early 2020; and
(iii)&nbsp;for enoblituzumab, we expect to initiate either a registrational trial (pending the NMPA&#146;s regulatory approval) or a Phase 2 trial by the end of 2020. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">We are collaborating with Everest Medicines Limited (&#147;Everest&#148;) to co-develop and commercialize TJ202
in Greater China for all indications in hematologic oncology. Everest is primarily responsible for sharing with us, by the proportion of 75% for Everest and 25% for us, the development costs of TJ202. We and Everest will share TJ202&#146;s profit
and loss in proportion to the costs that each of us incur in developing the product. We and Everest will also split out-license revenue according to the proportion of development costs incurred, with us getting an additional 5% share and Everest
receiving 5% less. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Our <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody panel consists of (i)&nbsp;five <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1-based</FONT></FONT> <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies, including <FONT STYLE="white-space:nowrap">TJ-L1C4</FONT><B>
</B><FONT STYLE="white-space:nowrap">(PD-L1</FONT> and CD47), <FONT STYLE="white-space:nowrap">TJ-L1D5</FONT><B> </B><FONT STYLE="white-space:nowrap">(PD-L1</FONT> and CD73), <FONT STYLE="white-space:nowrap">TJ-L1H3</FONT> <FONT
STYLE="white-space:nowrap">(PD-L1</FONT> and <FONT STYLE="white-space:nowrap">B7-H3),</FONT> <FONT STYLE="white-space:nowrap">TJ-L14B</FONT> <FONT STYLE="white-space:nowrap">(PD-L1</FONT> and <FONT STYLE="white-space:nowrap">4-1BB)</FONT> and
TJ-L1I7 (anti-PD-L1 and IL-7 cytokine fusion), <FONT STYLE="white-space:nowrap">(ii)&nbsp;TJ-C4GM</FONT> (anti-CD47 and <FONT STYLE="white-space:nowrap">GM-CSF</FONT> cytokine fusion), and <FONT STYLE="white-space:nowrap">(iii)&nbsp;TJ-CLDN4B</FONT>
(Claudin 18.2 and <FONT STYLE="white-space:nowrap">4-1BB).</FONT> </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Highlights of Our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT> China Portfolio </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> China strategy is demonstrated by our China Portfolio, which consists of novel or highly differentiated investigational drugs. TJ202, TJ107, enoblituzumab and
TJ101 are the four anchor assets in our China Portfolio. While we have been diligently pursuing our fast-to-market China strategy, we are aware that there is no assurance that we will always be successful in commercializing any of our product
candidates in our China Portfolio in an accelerated manner. See &#147;Risk Factors&#148; for a detailed description of the risks related to the development and commercialization of our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJ202 is a differentiated CD38 antibody originally developed by MorphoSys that meets the pre-set clinical safety and preliminary efficacy
endpoints from a clinical trial conducted in the European Union (EU). <FONT STYLE="white-space:nowrap">In-licensed</FONT> from MorphoSys, TJ202 is being developed to address the current unmet needs and commercial opportunities in China for multiple
myeloma and potentially autoimmune diseases, such as SLE. We own an exclusive license to develop TJ202 in Greater China. We believe TJ202, if approved, is potentially highly differentiated compared with the currently marketed CD38 antibody. First,
under a similar <FONT STYLE="white-space:nowrap">pre-medication</FONT> condition with dexamethasone, anti-pyretics and anti-histamines, TJ202 has demonstrated a significantly shorter infusion time and lower infusion reaction rate. Second, unlike the
currently marketed CD38 antibody, TJ202 does not down-regulate CD38 expression on the surface of bone marrow myeloma cells in vitro, maintaining sensitivity of myeloma cells to TJ202 for repeated treatments. We have entered into a collaboration
arrangement with Everest, under which we and Everest will share development costs and commercial rights of TJ202 in multiple myeloma in Greater China, while we retain full rights for all other indications. TJ202 is undergoing a Phase 2
registrational trial as a third-line monotherapy and a Phase 3 trial in combination with lenalidomide as a second-line therapy, both in patients with relapsed/refractory multiple myeloma in Greater China. We aim to submit an NDA for TJ202 as a
monotherapy in 2021, followed by another NDA submission for TJ202 as a combination therapy. Moreover, we believe TJ202 has great market potential in the treatment of pathogenic antibody-mediated autoimmune diseases, such as SLE, where there is a
significant unmet need for more effective therapies. An IND application for a trial in SLE is expected to be submitted in the fourth quarter of 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJ107 is the first long-acting recombinant human IL-7 known to boost cancer-fighting T lymphocytes by increasing their number and function and
is being developed as a potential oncology investigational drug. The clinical safety and effect of TJ107 on T cells have been investigated in multiple previous and ongoing clinical trials in South Korea and the United States. TJ107 is being
positioned to address a huge unmet medical need in oncology. First, TJ107 can be an oncology-care agent to treat cancer treatment-related lymphopenia (low blood lymphocyte levels), a common condition that occurs in cancer patients who have received
chemotherapy or radiation therapy, and there is no approved treatment for this condition. According to the Frost&nbsp;&amp; Sullivan Report, in Greater China, the incidence of lymphopenia reached 1.5&nbsp;million in 2018 and is estimated to increase
to 1.7&nbsp;million in 2023 and further to 2.0&nbsp;million in 2030. This condition causes further damage to patients&#146; already compromised immune system and weakens its ability to fight cancers. Second, TJ107 has been shown to synergize with a
PD-1 antibody in a tumor animal model potentially through increased T lymphocyte activation and proliferation. We are conducting a Phase 1b trial in China to determine a suitable dose range for subsequent trials. We expect to start a Phase 2 trial
in glioblastoma multiforme patients with lymphopenia in the second half of 2020. We are coordinating our study globally with Genexine, which is conducting a Phase 2 clinical trial in South Korea and parallel clinical trials in the United States
towards clinical PoC. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enoblituzumab is a humanized antibody directed at <FONT STYLE="white-space:nowrap">B7-H3,</FONT> a member of
the B7 family of T cell checkpoint regulators that is widely expressed across multiple tumor types and plays a key role in the regulation of immune response against cancers. Similar to other inhibitors of the B7 family such as <FONT
STYLE="white-space:nowrap">PD-L1,</FONT> targeting <FONT STYLE="white-space:nowrap">B7-H3</FONT> potentially provides a treatment option for a variety of cancers expressing <FONT STYLE="white-space:nowrap">B7-H3.</FONT> Enoblituzumab was originally
developed by MacroGenics, and we own the Greater China rights of this product. In multiple clinical trials conducted by MacroGenics, when combined with pembrolizumab in recurrent or metastatic squamous cell carcinoma of the
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
head and neck (&#147;SCCHN&#148;) and <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (&#147;NSCLC&#148;), enoblituzumab has shown favorable clinical results that warrant
further investigation. We plan to conduct a registrational trial (if approved by the NMPA) in China in patients with recurrent or metastatic SCCHN by the end of 2020. Further clinical development is being planned together with MacroGenics to extend
to other cancer indications in China and globally. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJ101, if approved, is a potential highly differentiated long-acting human growth
hormone that is being developed as a weekly treatment for pediatric growth hormone deficiency as compared to currently available daily regimens of recombinant human growth hormone (rhGH). TJ101 was originally developed by Genexine, and we own the
Greater China rights of this product, which has the potential to address an important clinical need and to cover a significant market gap in pediatric growth hormone deficiency. According to the Frost&nbsp;&amp; Sullivan Report, there are
approximately 3.4&nbsp;million pediatric patients with growth hormone deficiency in 2018 in Greater China, but only 3.7% of them receive growth hormone therapies, which are mostly daily regimens. In a previous Phase 2 trial conducted by Genexine in
South Korea and the EU, both weekly and <FONT STYLE="white-space:nowrap">bi-weekly</FONT> administration of TJ101 demonstrated similar therapeutic effects to daily injection of Genotropin, a short-acting rhGH. We expect to submit an IND for a Phase
3 registrational trial in China by early 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Highlights of Our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-PoC</FONT></FONT> Global Portfolio </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-PoC</FONT></FONT> global strategy is demonstrated by our Global Portfolio, which mainly consists of our internally developed novel or differentiated biologics. Our Global Portfolio
focuses on two molecular classes&#150;&#150;monoclonal antibodies and <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies. While we have been diligently pursuing our fast-to-PoC global strategy, we are aware that there is no assurance
that we will always be successful in achieving PoC or pivotal development milestones for any of our product candidates in our Global Portfolio in an accelerated manner. See &#147;Risk Factors&#148; for a detailed description of the risks related to
the development and commercialization of our drug candidates. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Monoclonal antibodies</I>&#151;Among the five monoclonal antibody
drug candidates, TJM2, TJC4 and TJD5 are undergoing Phase 1 clinical trials in the United States. We have obtained IND approval from the NMPA for TJD5 in September 2019. TJ210 and TJX7 are at the CMC stage and are expected to be ready for IND
submissions and subsequent Phase 1 clinical trials in 2020 in the United States. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJC4 is an internally discovered, fully human
monoclonal antibody targeting CD47, which is one of the most promising immuno-oncology targets after <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1.</FONT></FONT> Blocking CD47 activates tumor-engulfing macrophages, a
component of the innate immune system as an important cancer-fighting mechanism. CD47 antibodies are being actively pursued in clinical trials by a few global companies. However, current development efforts on CD47 antibody drugs are hampered by
hematologic side effects (such as anemia) due to their inherent binding to human RBCs. For example, at least two clinical trials conducted by other companies have been suspended. Unlike competitor investigational drugs, TJC4 is a rare antibody
originally selected, by design, to purposefully avoid or minimize inherent binding to RBCs while maintaining a high antibody affinity and tumor killing properties. TJC4&#146;s unique property of minimal RBC binding and no significant hematologic
changes has been extensively validated in a whole series of robust in vitro assays and primate studies. In a GLP toxicology study involving 40 monkeys, no hematologic side-effects were seen even with repeated injections of 100 mg/kg doses. This
unique property may enable TJC4 to be used safely at higher doses to explore its treatment potential in cancers, differentiating it from other clinical stage CD47 investigational antibody drugs. TJC4 is being evaluated in a Phase 1 clinical trial
with cancer patients in the United States, and no anemia has been observed in the first cohort of patients so far. In parallel, leveraging the Phase 1 data generated in the United States, we plan to begin a Phase 1 clinical trial of TJC4 in AML
patients by the end of 2019 in China, followed by a separate clinical trial in NHL patients in China. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Bi-specific</FONT> antibody panel</I>&#151;This novel
antibody class represents an emerging and fast-moving area of new drug discovery. <FONT STYLE="white-space:nowrap">Bi-specific</FONT> antibodies are typically constructed to have a dual specificity of two selected antibodies or combined properties
of an antibody linked with a cytokine, previously called an immuno-cytokine. According to the Frost&nbsp;&amp; Sullivan Report, checkpoint inhibitors targeting
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> had global sales of US$16.3 billion in 2018 and are predicted to reach US$63.4 billion in global sales by 2030. However, despite the recent success of
checkpoint inhibitors, clinical efficacy of these drugs has been unsatisfactory. It is estimated that over 60% of cancer patients, including those with melanoma, renal cell cancer, colorectal cancer, <FONT STYLE="white-space:nowrap">non-small</FONT>
cell lung cancer, urothelial cancer and head and neck squamous cell carcinoma, do not respond to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> monotherapies. In addition, some patients develop resistance
after initial treatment with these therapies. As a result, the standard of care today leaves many cancer patients underserved. There is consensus among cancer immunologists that tumors that do not respond to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> treatment have poor immunologic features, such as an absence or paucity of tumor-fighting immune cells or the presence of dysfunctional immune cells within the tumors, collectively known as
&#147;cold tumors.&#148; We believe that <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> <FONT STYLE="white-space:nowrap">non-responders</FONT> can be better treated with novel <FONT
STYLE="white-space:nowrap">bi-specific</FONT> antibodies. The unique and superior properties of these <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies over <FONT STYLE="white-space:nowrap">PD-L1</FONT> inhibitors alone stem from a
second targeting component attached to the <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody moiety of the <FONT STYLE="white-space:nowrap">bi-specific</FONT> molecules, thereby enabling them to elicit a sufficient immune response and
converting a &#147;cold tumor&#148; to an immune-active &#147;hot tumor.&#148; Such unique properties of <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies cannot be substituted by a combination of the
<FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody with a selected second component (either cytokine or antibody) in a free form. The underlying mechanism is such that the second component must be structurally integrated with the tumor-engaging <FONT
STYLE="white-space:nowrap">PD-L1</FONT> antibody in order to concentrate and function inside the tumor, which cannot be readily achieved by the two free agents used in combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have successfully generated a panel of five <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies in which our proprietary <FONT
STYLE="white-space:nowrap">PD-L1</FONT> antibody acts as the backbone (the first signal) and is linked with various second components (the second signal) including a <FONT STYLE="white-space:nowrap">4-1BB</FONT> agonist antibody <FONT
STYLE="white-space:nowrap">(TJ-L14B),</FONT> a <FONT STYLE="white-space:nowrap">B7-H3</FONT> antibody <FONT STYLE="white-space:nowrap">(TJ-L1H3),</FONT> a CD73 antibody <FONT STYLE="white-space:nowrap">(TJ-L1D5),</FONT> a CD47 antibody <FONT
STYLE="white-space:nowrap">(TJ-L1C4)</FONT> and an IL-7 cytokine (TJ-L1I7), which are shown to work synergistically with the <FONT STYLE="white-space:nowrap">PD-L1</FONT> backbone in various assays and cancer animal models. This unique panel of <FONT
STYLE="white-space:nowrap">bi-specific</FONT> antibodies is only made possible by our proprietary and partnered antibody engineering technologies and the availability of our proprietary monoclonal antibodies. Furthermore, we have generated two other
<FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies <FONT STYLE="white-space:nowrap">(TJ-C4GM</FONT> and <FONT STYLE="white-space:nowrap">TJ-CLDN4B)</FONT> that are tailor-made to function as novel fortified antibodies by linking TJC4
with an engineered <FONT STYLE="white-space:nowrap">GM-CSF</FONT> cytokine for the treatment of solid tumors and by linking our <FONT STYLE="white-space:nowrap">Claudin-18.2</FONT> antibody with a <FONT STYLE="white-space:nowrap">4-1BB</FONT>
antibody as a unique gastric cancer treatment agent that only activates T cells conditionally upon tumor engagement. All <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies have been validated in a series of robust <I>in vitro</I> and
<I>in vivo</I> studies for biology <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> providing a solid basis for clinical validation in cancer patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to achieve our
goal by pursuing the following strategies: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Rapidly advance our China Portfolio towards commercialization. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expand our research and development capabilities and footprint in the United States to advance our Global
Portfolio. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Build our manufacturing capabilities. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Maximize the value of our pipeline. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Challenges </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our ADSs involves risks. If any of these risks actually occurs, our business, financial condition or results of operations would
likely be materially adversely affected. In such case, the trading price of our ADSs would likely decline, and you may lose all or part of your investment. The following is a summary of some of the principal risks that we face: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have a limited operating history, which may make it difficult to evaluate our current business and predict our
future performance. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We recorded net cash outflow from operating activities since our inception. We may need to obtain additional
financing to fund our operations, and if we are unable to obtain such financing, we may be unable to complete the development and commercialization of our major drug candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We depend substantially on the success of our investigational drugs and drug candidates, all of which are in
clinical or pre-clinical development, respectively, and our ability to identify additional investigational drugs and drug candidates. If we are unable to successfully identify new investigational drugs or drug candidates, complete clinical
development, obtain regulatory approval and commercialize them, or experience significant delays in doing so, our business will be materially harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may not be able to identify, discover or <FONT STYLE="white-space:nowrap">in-license</FONT> new drug
candidates, and may allocate our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may later prove to be more profitable, or for which there is a greater likelihood of
success. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if we receive regulatory approval for our drug candidates, we will be subject to ongoing regulatory
obligations and continued regulatory review, which may result in significant additional expenses and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our drug candidates.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our drug candidates may fail to achieve the degree of market acceptance by physicians, patients, third-party
payors and others in the medical community necessary for commercial success. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As we rely on third parties to conduct our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and
clinical trials, if we lose our relationships with these third parties or if they do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug
candidates and our business could be substantially harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to obtain and maintain patent and other intellectual property protection for our drug
candidates, or if the scope of such intellectual property rights obtained is not sufficiently broad, third parties could develop and commercialize products and technologies similar or identical to ours and compete directly against us, and our
ability to successfully commercialize any product or technology may be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Changes in the political and economic policies of the PRC government may materially and adversely affect our
business, financial condition and results of operations and may result in our inability to sustain our growth and expansion strategies.</P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please see &#147;Risk Factors,&#148; &#147;Special Note Regarding Forward-Looking Statements&#148; and other information included in this
prospectus for a discussion of these and other risks and uncertainties that we face. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate History and Structure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We commenced our operations in November 2014, when our predecessor Third Venture Biopharma (Nanjing) Co., Ltd (&#147;Third Venture&#148;) was
established. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> was established in June 2016 under the laws of
the Cayman Islands as our offshore holding company. In July 2016, <FONT STYLE="white-space:nowrap">I-Mab</FONT> established <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited
<FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Hong Kong&#148;), as its intermediary holding company. In August 2016, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong established a wholly-owned PRC subsidiary, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Shanghai) Co., Ltd. <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Shanghai&#148;). In September 2016, the assets and operations of Third Venture were consolidated into <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Shanghai. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2017, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong acquired a
controlling interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Tianjin&#148;), formerly known as Tasgen <FONT
STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd., a company focused on CMC management of biologics in China. Through an internal corporate restructuring, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin became the 100% owner of <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Shanghai in September 2017 and <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong acquired the remaining interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin in May 2018, becoming the 100%
owner of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2018, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong
established in Maryland, United States, a wholly-owned subsidiary <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Limited <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> US&#148;), as the hub for the discovery and development of the
drug candidates in our Global Portfolio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following diagram illustrates our corporate structure, including our principal subsidiaries,
as of the date of this prospectus: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g69u35.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implication of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a company with less than US$1.07&nbsp;billion in revenue for our last fiscal year, we qualify as an &#147;emerging growth company&#148;
pursuant to the Jumpstart Our Business Startups Act of 2012, as amended (the &#147;JOBS Act&#148;). An emerging growth company may take advantage of specified reduced reporting and other requirements compared to those that are otherwise applicable
generally to public companies. These provisions include an exemption from the auditor attestation requirement under Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 in the assessment of the emerging growth company&#146;s internal control over
financial reporting. The JOBS Act also provides that an emerging growth company does not need to comply with any new or revised financial accounting standards until such date that a private company is otherwise required to comply with such new or
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
revised accounting standards. However, we have elected to &#147;opt out&#148; of this provision and, as a result, we will comply with new or revised accounting standards as required when they are
adopted for public companies. This decision to opt out of the extended transition period under the JOBS Act is irrevocable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will
remain an emerging growth company until the earliest of (a)&nbsp;the last day of the fiscal year during which we have total annual gross revenues of at least US$1.07&nbsp;billion; (b)&nbsp;the last day of our fiscal year following the fifth
anniversary of the completion of this offering; (c)&nbsp;the date on which we have, during the preceding three-year period, issued more than US$1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt; or (d)&nbsp;the date on
which we are deemed to be a &#147;large accelerated filer&#148; under the United States Securities Exchange Act of 1934, as amended, (the &#147;Exchange Act&#148;), which would occur if the market value of our ADSs that are held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> exceeds US$700&nbsp;million as of the last business day of our most recently completed second fiscal quarter. Once we cease to be an emerging growth company, we will not be entitled to the exemptions
provided in the JOBS Act discussed above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai, People&#146;s
Republic of China. Our telephone number at this address is +86 <FONT STYLE="white-space:nowrap">21-6057-8000.</FONT> Our registered office in the Cayman Islands is located at Vistra (Cayman) Limited, P.O. Box 31119 Grand Pavilion, Hibiscus Way, 802
West Bay Road, Grand Cayman, <FONT STYLE="white-space:nowrap">KY1-1205,</FONT> Cayman Islands. Our agent for service of process in the United States is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, located at
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investors should submit any inquiries to the address or through
the telephone number of our principal executive offices. Our main website is <FONT STYLE="white-space:nowrap">http://www.i-mabbiopharma.com/en/.</FONT> The information contained on our website is not a part of this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conventions that Apply to this Prospectus </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated or the context otherwise requires, and for purposes of this prospectus only: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;ADRs&#148; refer to the American depositary receipts that evidence our ADSs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;ADSs&#148; refer to our American depositary shares, each of which represents
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;China&#148; or &#147;the PRC&#148; refers to the People&#146;s Republic of China, excluding, for the
purposes of this prospectus only, Hong Kong, Macau and Taiwan, and &#147;Greater China&#148; does not exclude Hong Kong, Macau and Taiwan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;China Portfolio&#148; refers to our investigational drugs of which we
<FONT STYLE="white-space:nowrap">in-license</FONT> Greater China rights from reputable global biopharmaceutical companies and rely on our own research and development capabilities to advance into pivotal clinical trials and commercialize in Greater
China with an aim for near-term product launch; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Global Portfolio&#148; refers to our own proprietary novel or differentiated drug candidates that we are
advancing towards clinical validation in the United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">&#147;I-Mab,&#148;</FONT> &#147;we,&#148; &#147;us,&#148; &#147;our
company&#148; and &#147;our&#148; refer to <FONT STYLE="white-space:nowrap">I-Mab,</FONT> a Cayman Islands exempted company, and its subsidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;RMB&#148; refers to the legal currency of China; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;shares&#148; or &#147;ordinary shares&#148; refer to our ordinary shares, par value US$0.0001 per share;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;US$,&#148; &#147;U.S. dollars,&#148; &#147;$,&#148; and &#147;dollars&#148; refer to the legal currency of
the United States. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context indicates otherwise, all information in this prospectus assumes no
exercise by the underwriters of their option to purchase additional ADSs. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our reporting currency is RMB. This prospectus also
contains translations of certain foreign currency amounts into U.S. dollars for the convenience of the reader. Unless otherwise stated, all translations from RMB to U.S. dollars were made at a rate of RMB6.8650 to US$1.00, the exchange rate in
effect as of June&nbsp;28, 2019 as set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System. We make no representation that any RMB or U.S. dollar amounts referred to in this prospectus could have been or
could be converted into U.S. dollars or RMB, as the case may be, at any particular rate, or at all. On September 27, 2019, the noon buying rate for RMB was RMB7.1218 to US$1.00. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_2"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Offering price </P></TD>
<TD>We currently estimate that the initial public offering price will be between US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">ADSs offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ADSs (or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ADSs if the underwriters exercise their option to purchase additional ADSs in full).
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">ADSs outstanding immediately after this offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ADSs (or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ADSs if the underwriters exercise their option to purchase additional ADSs in full).
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Ordinary shares issued and outstanding immediately after this offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares if the underwriters exercise their option to purchase additional ADSs in
full). This number assumes the conversion, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, of all of our outstanding preferred shares into our ordinary shares immediately upon the completion of
this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">The ADSs </P></TD>
<TD>Each ADS represents &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares, par value US$0.0001 per share. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The depositary will hold ordinary shares underlying your ADSs. You will have rights as provided in the deposit agreement among us, the depositary and holders and beneficial owners of ADSs from time to time.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We do not expect to pay dividends in the foreseeable future. If, however, we declare dividends on our ordinary shares, the depositary will pay you the cash dividends and other distributions it receives on our ordinary
shares after deducting its fees and expenses in accordance with the terms set forth in the deposit agreement. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">You may surrender your ADSs to the depositary in exchange for ordinary shares. The depositary will charge you fees for any such exchange. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We may amend or terminate the deposit agreement without your consent. If you continue to hold your ADSs after an amendment to the deposit agreement, you agree to be bound by the deposit agreement as amended.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To better understand the terms of the ADSs, you should carefully read the &#147;Description of American Depositary Shares&#148; section of this prospectus. You should also read the deposit agreement, which is filed as
an exhibit to the registration statement that includes this prospectus. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares </P></TD>
<TD>We have granted to the underwriters an option, exercisable within 30&nbsp;days from the date of this prospectus, to purchase up to an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ADSs. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We expect that we will receive net proceeds of approximately US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million from this offering, or approximately
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters exercise their option to purchase additional ADSs in full, assuming an initial public offering price of
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS, which is the midpoint of the estimated range of the initial public offering price, after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We intend to use the net proceeds from this offering to (i)&nbsp;research and development of our existing and future drug candidates, (ii)&nbsp;potential investments in the establishment of our own manufacturing
capacities and building research facilities in the United&nbsp;States, and (iii)&nbsp;general corporate purposes. See &#147;Use of Proceeds&#148; for more information. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Lock-up</FONT> </P></TD>
<TD>[We, our directors and executive officers, our current shareholders [and certain of our option holders] have agreed with the underwriters not to sell, transfer or otherwise dispose of any ADSs, ordinary shares or similar securities for a period
of [180] days after the date of this prospectus, subject to certain exceptions. In addition, we will not authorize or permit&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , as depositary, to accept any deposit of any
ordinary shares or issue any ADSs for 180 days after the date of this prospectus unless we expressly consent to such deposit or issuance and we have agreed not to provide such consent without the prior written consent of the representatives on
behalf of the underwriters. The foregoing does not affect the right of ADS holders to cancel their ADSs and withdraw the underlying ordinary shares. See &#147;Shares Eligible for Future Sales&#148; and &#147;Underwriting.&#148;] </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">[Directed ADS Program </P></TD>
<TD>At our request, the underwriters have reserved for sale, at the initial public offering price, up to an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs offered in this offering to some of our directors,
officers, employees, business associates and related persons through a directed ADS program.] </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Listing </P></TD>
<TD>We intend to apply to have the ADSs listed on the Nasdaq Global Market under the symbol &#147;IMAB.&#148; Our ADSs and shares will not be listed on any other stock exchange or traded on any automated quotation system. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Payment and settlement </P></TD>
<TD>The underwriters expect to deliver the ADSs against payment therefor through the facilities of The Depository Trust Company on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Depositary </P></TD>
<TD></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_3"></A>SUMMARY CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary consolidated statements of comprehensive loss data for the years ended December&nbsp;31, 2017 and 2018, summary
consolidated statements of balance sheet data as of December&nbsp;31, 2017 and 2018 and summary consolidated statements of cash flow data for the years ended December&nbsp;31, 2017 and 2018 have been derived from our audited consolidated financial
statements included elsewhere in this prospectus. The following summary consolidated statements of comprehensive loss data for the six months ended June 30, 2018 and 2019, summary consolidated balance sheet data as of June 30, 2019 and summary
consolidated statements of cash flow data for the six months ended June 30, 2018 and 2019 are derived from our unaudited interim condensed consolidated financial statements included elsewhere in this prospectus. Our consolidated financial statements
are prepared and presented in accordance with accounting principles generally accepted in the United States of America (&#147;U.S. GAAP&#148;). Our historical results are not necessarily indicative of results expected for future periods. You should
read this Summary Consolidated Financial Data section together with our consolidated financial statements and the related notes and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; included
elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>(in thousands, except for share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Summary Consolidated Statements of Comprehensive Loss Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Revenues</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Licensing and collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Research and development expenses<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(267,075</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(426,028</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,058</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(202,693<B></B></TD>
<TD NOWRAP VALIGN="bottom">)<B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(265,084</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,614</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Administrative expenses<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,671</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,687<B></B></TD>
<TD NOWRAP VALIGN="bottom">)<B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(574,584</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83,698</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280,955</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(438,638</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,895</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(200,003<B></B></TD>
<TD NOWRAP VALIGN="bottom">)<B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(824,668</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(120,127</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,097<B></B><B></B></TD>
<TD NOWRAP VALIGN="bottom">)<B></B> <B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other income (expenses), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,444</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,594<B></B></TD>
<TD NOWRAP VALIGN="bottom">)<B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,027</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,854</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Loss before income tax expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(401,111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58,428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(166,720<B></B></TD>
<TD NOWRAP VALIGN="bottom">)<B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(857,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(251</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B></B>&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Net loss attributable to <FONT STYLE="white-space:nowrap">I-Mab</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58,679</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(166,720<B></B></TD>
<TD NOWRAP VALIGN="bottom">)<B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(857,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Other comprehensive income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Foreign currency translation adjustments, net of nil tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,446<B></B><B></B></TD>
<TD NOWRAP VALIGN="bottom">)<B></B> <B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(724</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total comprehensive loss attributable to
<FONT STYLE="white-space:nowrap">I-Mab</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(292,322</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(349,144</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(50,859</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(174,166</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(862,309</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(125,610</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Net loss attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58,679</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(166,720<B></B></TD>
<TD NOWRAP VALIGN="bottom">)<B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(857,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Weighted-average number of ordinary shares used in calculating net loss per shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,742,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,397,663<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,184,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,184,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Net loss per share attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8.99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26.06<B></B><B></B></TD>
<TD NOWRAP VALIGN="bottom">)<B></B> <B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17.38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8.99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26.06<B></B><B></B></TD>
<TD NOWRAP VALIGN="bottom">)<B></B> <B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17.38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Note: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Share-based compensation expenses were allocated as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Administrative expenses*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,039</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,520</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>513</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,929</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>366,356</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,366</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE></DIV>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">The above share-based compensation expenses do not include the expenses arising from the repurchase of share
awards held by a director of our company during the six months ended June 30, 2019. See Note 17 (d) to our unaudited interim condensed consolidated financial statements included elsewhere in this prospectus for more details. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents our summary consolidated balance sheet data as of December&nbsp;31, 2017 and 2018 and June&nbsp;30, 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Summary Consolidated Statements of Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,588,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,269,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepayments and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">691,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,036,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">296,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,604,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease right-of-use assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,025,345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,375,938</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>346,094</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,955,338</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>284,827</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>309,151</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>415,684</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>60,550</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>491,037</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>71,528</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,015,989</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,915,358</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>424,670</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,915,358</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>424,670</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares (US$0.0001 par value, 500,000,000 shares authorized as of December 31, 2018 and
June&nbsp;30, 2019, 8,363,719 and 8,363,719 shares authorized, issued and outstanding as of December&nbsp;31, 2018 and June&nbsp;30, 2019, respectively)<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>6</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Treasury stock<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>(1</TD>
<TD NOWRAP VALIGN="bottom"><B></B>)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0</TD>
<TD NOWRAP VALIGN="bottom">) &nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>52,369</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income <B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>5,691</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>(357,860</TD>
<TD NOWRAP VALIGN="bottom"><B></B>)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,014,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(147,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,871,826</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(272,663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(299,795</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(955,104</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(139,126</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,451,057</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(211,371</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities, mezzanine equity and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,025,345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,375,938</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>346,094</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,955,338</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>284,827</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents our summary consolidated statements of cash flow data for the
years ended December&nbsp;31, 2017 and 2018 and the six months ended June&nbsp;30, 2018 and 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Summary Consolidated Statements of Cash Flow Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(252,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,889</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,653</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(389,034</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,669</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net cash (used in) generated from investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157,665</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net cash (used in) generated from financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">758,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,479,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,370</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Effect of exchange rate changes on cash and cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,737</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,093</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(451</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,268,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(264,071</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,466</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, beginning of the year/period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, end of the year/period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">504,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,416,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An investment in our ADSs involves significant risks. You should carefully consider all of the information in this prospectus, including the
risks and uncertainties described below, before making an investment in our ADSs. Any of the following risks could have a material adverse effect on our business, financial condition and results of operations. In any such case, the market price of
our ADSs could decline, and you may lose all or part of your investment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Position and Need for Additional Capital
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage biopharmaceutical company with a limited operating history. Our operations to date have focused on
organizing and staffing our operations, business planning, raising capital, establishing our intellectual property portfolio and conducting <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trials of our drug candidates. We have not
yet demonstrated an ability to successfully manufacture, obtain marketing approvals for or commercialize our drug candidates. We have no products approved for commercial sale and have not generated any revenue from product sales. Consequently, any
predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
focused on the discovery and development of innovative drugs for the treatment of various immuno-oncological and immuno-inflammatory diseases. Our limited operating history, particularly in light of the rapidly evolving drug research and development
industry in which we operate and the changing regulatory and market environments we encounter, may make it difficult to evaluate our prospects for future performance. As a result, any assessment of our future performance or viability is subject to
significant uncertainty. We will encounter risks and difficulties frequently experienced by early-stage companies in rapidly evolving fields as we seek to transition to a company capable of supporting commercial activities. If we do not address
these risks and difficulties successfully, our business will suffer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred net losses in each period since our inception and anticipate
that we will continue to incur net losses for the foreseeable future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investment in the development of biopharmaceutical products
is highly speculative as it entails substantial upfront capital expenditures and significant risks that a drug candidate may fail to demonstrate efficacy and/or safety to gain regulatory or marketing approvals or become commercially viable. To date,
we have financed our activities primarily through private placements. While we have generated revenue from licensing and collaboration deals, we have not generated any revenue from commercial product sales to date, and we continue to incur
significant research and development expenses and other expenses related to our ongoing operations. As a result, we are not profitable and have incurred net losses in each period since our inception. In 2017, 2018 and the six months ended June 30,
2019, our net loss was RMB298.2&nbsp;million, RMB402.8&nbsp;million (US$58.7 million) and RMB857.3 million (US$124.9 million), respectively. Substantially all of our net losses have resulted from costs incurred in connection with our research and
development programs and from general and administrative costs associated with our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to incur net losses
in the foreseeable future, and that these net losses will increase as we carry out certain activities relating to our development, including, but not limited to, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conducting clinical trials of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing clinical trial materials through contract manufacturing organizations, or CMOs, in and out of
China; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seeking regulatory approvals for our drug candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commercializing our drug candidates for which we have obtained marketing approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completing the construction of and maintaining our manufacturing facilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hiring additional clinical, operational, financial, quality control and scientific personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing a sales, marketing and commercialization team for any future products that have obtained regulatory
approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seeking to identify additional drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining, maintaining, expanding and protecting our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enforcing and defending any intellectual property-related claims; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> other drug candidates, intellectual property
and technologies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Typically, it takes many years to develop one new drug from the time it is discovered to when it
becomes available for treating patients. During the process, we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend
partially on the rate of the future growth of our expenses, our ability to generate revenues and the timing and amount of milestone payments and other payments that we receive from or pay to third parties. If any of our drug candidates fails during
clinical trials or does not gain regulatory approval, or, even if approved, fails to achieve market acceptance, our business may not become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in
subsequent periods thereafter. Our prior losses and expected future losses have had, and will continue to have, an adverse effect on our working capital and shareholders&#146; equity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We recorded net cash outflow from operating activities since our inception. Even if we consummate this offering, we may need to obtain additional
financing to fund our operations. If we are unable to obtain such financing, we may be unable to complete the development and commercialization of our major drug candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, our operations have consumed substantial amounts of cash. We had raised in excess of US$400&nbsp;million in pre-IPO
financing in the past three years. We spent RMB252.2&nbsp;million, RMB280.7&nbsp;million (US$40.9 million) and RMB389.0 million (US$56.7 million) in net cash to finance our operations in 2017, 2018 and the six months ended June 30, 2019,
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our expenses to increase significantly in connection with our ongoing activities, particularly as we advance the
clinical development of our clinical-stage drug candidates, continue the research and development of our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage drug candidates and initiate additional clinical trials of, and seek regulatory
approval for, these and other future drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if we obtain regulatory approvals for any of our drug candidates, we
expect to incur significant commercialization expenses relating to product manufacturing, marketing, sales and distribution and post-approval commitments to continue monitoring the efficacy and safety data of our future products on the market. In
particular, costs that may be required for the manufacture of any drug candidate that has received regulatory approval may be substantial as we may need to modify or increase our production capacity in the future at manufacturing facilities. We may
also incur expenses as we create additional infrastructure to support our operations as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations through public or private
equity offerings, debt financing, collaborations or licensing arrangements or other sources. If we are unable to raise capital when needed or on acceptable terms, we could be forced to delay, limit, reduce or terminate our research and development
programs or any future commercialization efforts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to the interests to the holders of our ADSs and our
shareholders, restrict our operations or require us to relinquish rights to our technologies or drug candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may seek
additional funding through a combination of equity offerings, debt financings, collaborations, licensing arrangements, strategic alliances or partnerships and government grants or subsidies. To the extent that we raise additional capital through the
sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a holder of our ADSs. The incurrence of additional indebtedness
or the issuance of certain equity securities could give rise to increased fixed payment obligations and also result in certain additional restrictive covenants, such as limitations on our ability to incur additional debt or issue additional equity,
limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. In addition, the issuance of additional equity securities, or the
possibility of such issuance, may cause the market price of our ADSs to decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event we enter into collaborations or licensing
arrangements in order to raise capital, we may be required to accept unfavorable terms, including relinquishing or licensing to a third party our rights to technologies or drug candidates on unfavorable terms, which we would have otherwise sought to
develop or commercialize on our own or reserve for future potential arrangements when we are more likely to achieve more favorable terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks
Related to Clinical Development of Our Drug Candidates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical development involves a lengthy and expensive process with an uncertain outcome,
and results of earlier studies and trials may not be predictive of future trial results. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive and can
take many years to complete, and its outcome is inherently uncertain. While our exclusive focus is to develop drug candidates with potential to become novel or highly differentiated drugs in China and globally, we cannot guarantee that we are able
to achieve this for each of our drug candidates. Failure can occur at any time during the clinical development process. The results of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and early clinical trials of our drug candidates may
not be predictive of the results of later-stage clinical trials. Drug candidates during later stages of clinical trials may fail to show the desired results in safety and efficacy despite having progressed through
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and initial clinical trials and despite the level of scientific rigor in the study, design and adequacy of execution. In some instances, there can be significant variability in safety
and/or efficacy results between different trials of the same drug candidate due to numerous factors, including, but not limited to, differences in individual patient conditions, including genetic differences, and other compounding factors, such as
other medications or <FONT STYLE="white-space:nowrap">pre-existing</FONT> medical conditions. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of any trials we conduct,
results may differ from earlier trials due to the larger number of clinical trial sites and additional countries and languages involved in such trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in
advanced clinical trials due to a lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. We cannot guarantee that our future clinical trial results will be favorable based on currently available clinical
and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend substantially on the success of our drug candidates, all of which are in <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> or clinical development, and our ability to identify additional drug candidates. If we are unable to successfully identify new drug candidates, complete clinical development, obtain regulatory approval
and commercialize our drug candidates, or experience significant delays in doing so, our business will be materially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business will depend on the successful development, regulatory approval and commercialization of our drug candidates for the treatment of
patients with our targeted indications, all of which are still in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical development, and other new drug candidates that we may identify and develop. As of the date of this prospectus, we
have obtained IND approvals from the NMPA for four of our drug candidates, TJ301, TJ107, TJC4 and TJD5. In addition, we have obtained IND approvals from the FDA for three of our drug candidates, </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
TJC4, TJD5 and TJM2; from the Taiwan Food and Drug Administration (the &#147;TFDA&#148;) for two of our drug candidates, TJ202 and TJ301; and from the Korea Ministry of Food and Drug Safety (the
&#147;MFDS&#148;) for TJ301. However, we cannot guarantee that we are able to obtain regulatory approvals for our other existing drug candidates in a timely manner, or at all. In addition, none of our drug candidates has been approved for marketing
in China or any other jurisdiction. Each of our drug candidates will require additional <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and/or clinical development, regulatory approvals in multiple jurisdictions, development of manufacturing
supply and capacity, substantial investment and significant marketing efforts before we generate any revenue from product sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
success of our drug candidates will depend on several factors, including but not limited to the successful completion of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and/or clinical trials or studies, receipt of regulatory approvals from
applicable regulatory authorities for planned clinical trials, future clinical trials or drug registrations, establishing adequate manufacturing capabilities and capacities, commercialization of our existing drug candidates, hiring sufficient
technical experts to oversee all development and regulatory activities and license renewal and meeting of the safety requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we
do not achieve one or more of these in a timely manner or at all, we could experience significant delays in our ability to obtain approval for our drug candidates, which would materially harm our business and we may not be able to generate
sufficient revenues and cash flows to continue our operations. As a result, our financial condition, results of operations and prospects will be materially and adversely harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to identify, discover or <FONT STYLE="white-space:nowrap">in-license</FONT> new drug candidates, and may allocate our limited
resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may later prove to be more profitable, or for which there is a greater likelihood of success. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although a substantial amount of our effort will focus on the continued clinical testing, potential approval, and commercialization of our
existing drug candidates, the success of our business depends in part upon our ability to identify, license, discover, develop, or commercialize additional drug candidates. Research programs to identify new drug candidates require substantial
technical, financial, and human resources. We may focus our efforts and resources on potential programs or drug candidates that ultimately prove to be unsuccessful. Our research programs or licensing efforts may fail to identify, discover or <FONT
STYLE="white-space:nowrap">in-license</FONT> new drug candidates for clinical development and commercialization for a number of reasons, including, without limitation, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our research or business development methodology or search criteria and process may be unsuccessful in
identifying potential drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our potential drug candidates may be shown to have harmful side effects or may have other characteristics that
may make the products unmarketable or unlikely to receive marketing approval; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it may take greater human and financial resources to identify additional therapeutic opportunities for our drug
candidates or to develop suitable potential drug candidates through internal research programs than we possess, thereby limiting our ability to diversify and expand our drug portfolio. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we have limited financial and managerial resources, we focus on research programs and drug candidates for specific indications. As a
result, we may forgo or delay pursuit of opportunities with other drug candidates or for other indications that later may prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us
to fail to capitalize on viable commercial products or profitable market opportunities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, there can be no assurance that we
will ever be able to identify additional therapeutic opportunities for our drug candidates or to develop suitable potential drug candidates through internal research programs, which could materially adversely affect our future growth and prospects.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we encounter delays or difficulties enrolling patients in our clinical trials, our clinical
development progress could be delayed or otherwise adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to initiate or continue clinical trials
for our drug candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the NMPA, the FDA, or similar regulatory authorities, or if there are delays in the enrollment of
eligible patients as a result of the competitive clinical enrollment environment. The inability to enroll a sufficient number of patients who meet the applicable criteria for our clinical trials would result in significant delays. As of the date of
this prospectus, we have initiated clinical trials for TJ301 in South Korea, Taiwan and China, for TJ107 in China, for TJ202 in Taiwan, and for TJM2, TJC4 and TJD5 in the United States. In addition, we expect to initiate clinical trials for TJC4 by
the end of 2019 in China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, some of our competitors have ongoing clinical trials for drug candidates that treat the same
indications as our drug candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in the clinical trials of our competitors&#146; drug candidates, which may further delay our clinical trial enrollments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient enrollment for our clinical trials may be affected by other factors, including but not limited to the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">severity of the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">total size and nature of the relevant patient population; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">design and eligibility criteria for the clinical trial in question; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">perceived risks and benefits of the drug candidate under study; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our resources to facilitate timely enrollment in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient referral practices of physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">availability of competing therapies also undergoing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our investigators&#146; or clinical trial sites&#146; efforts to screen and recruit eligible patients; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">proximity and availability of clinical trial sites for prospective patients. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we are able to enroll a sufficient number of patients in our clinical trials, delays in patient enrollment may result in increased
costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our drug candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If clinical trials of our drug candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise
produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our drug candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approval for the sale of our drug candidates, we must conduct extensive clinical trials to demonstrate the safety
and efficacy of our drug candidates in humans. We may experience numerous unexpected events during, or as a result of, clinical trials that could delay or prevent our ability to receive regulatory approval or commercialize our drug candidates,
including, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators, institutional review boards, or IRBs, or ethics committees may not authorize us or our investigators
to commence a clinical trial or conduct a clinical trial at a prospective trial site; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to reach agreements on acceptable terms with prospective CROs and trial sites, the terms of which
can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing issues, including problems with manufacturing, supply quality, compliance with good manufacturing
practice, or GMP, or obtaining sufficient quantities of a drug candidate from third parties for use in a clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials of our drug candidates may produce negative or inconclusive results, and we may decide to conduct
additional clinical trials or abandon drug development programs, or regulators may require us to do so; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of patients required for clinical trials of our drug candidates may be larger than we anticipate,
enrollment may be insufficient or slower than we anticipate or patients may drop out at a higher rate than we anticipate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our third-party contractors, including clinical investigators, may fail to comply with regulatory requirements or
meet their contractual obligations to us in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we might have to suspend or terminate clinical trials of our drug candidates for various reasons, including a
finding of a lack of clinical response or other unexpected characteristics or a finding that participants are being exposed to unacceptable health risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators, IRBs or ethics committees may require that we or our investigators suspend or terminate clinical
research or not rely on the results of clinical research for various reasons, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of clinical trials of our drug candidates may be greater than we anticipate; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the supply or quality of our drug candidates, companion diagnostics or other materials necessary to conduct
clinical trials of our drug candidates may be insufficient or inadequate. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are required to conduct additional
clinical trials or other testing of our drug candidates beyond those that we currently plan, if we are unable to successfully complete clinical trials of our drug candidates or other testing, if the results of these trials or tests are not positive
or are only modestly positive or if they raise safety concerns, we may (i)&nbsp;be delayed in obtaining regulatory approval for our drug candidates; (ii)&nbsp;obtain approval for indications that are not as broad as intended; (iii)&nbsp;not obtain
regulatory approval at all; (iv)&nbsp;have the drug removed from the market after obtaining regulatory approval; (v)&nbsp;be subject to additional post-marketing testing requirements; (vi)&nbsp;be subject to restrictions on how the drug is
distributed or used; or (vii)&nbsp;be unable to obtain reimbursement for use of the drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant clinical trial delays may also
increase our development costs and could shorten any periods during which we have the exclusive right to commercialize our drug candidates or allow our competitors to bring drugs to market before we do. This could impair our ability to commercialize
our drug candidates and may harm our business and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Obtaining Regulatory Approval for Our Drug Candidates
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>All material aspects of the research, development and commercialization of pharmaceutical products are heavily regulated. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All jurisdictions in which we intend to conduct our pharmaceutical-industry activities regulate these activities in great depth and detail. We
intend to focus our activities in the major markets of China and the United&nbsp;States. These jurisdictions strictly regulate the pharmaceutical industry, and in doing so they employ broadly similar regulatory strategies, including regulation of
product development and approval, manufacturing, and marketing, sales and distribution of products. However, there are differences in the regulatory regimes that make for a more complex and costly regulatory compliance burden for a company like us
that plans to operate in these regions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process of obtaining regulatory approvals and compliance with appropriate laws and
regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirements at any time during the product development process and approval process, or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could
include: refusal to approve pending applications; withdrawal of an approval; license revocation; clinical hold; voluntary or mandatory product recalls; product seizures; total or partial suspension of production or distribution; injunctions; fines;
refusals of government contracts; providing restitution; undergoing disgorgement; or other civil or criminal penalties. Failure to comply with these regulations could have a material adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory approval processes of the NMPA, the FDA and other comparable regulatory authorities are time-consuming and may evolve over time, and if
we are ultimately unable to obtain regulatory approval for our drug candidates, our business will be substantially harmed. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
time required to obtain the approval of the NMPA, the FDA and other comparable regulatory authorities is inherently uncertain and depends on numerous factors, including the substantial discretion of the regulatory authorities. Generally, such
approvals take many years to obtain following the commencement of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials, although they are typically provided within 12 to 18 months after clinical trials are completed. In
addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a drug candidate&#146;s clinical development and may vary among jurisdictions. As of the date of this
prospectus, we have obtained IND approvals from the NMPA for TJ301, TJ107, TJC4 and TJD5. In addition, we have obtained IND approvals from the FDA for TJC4, TJD5 and TJM2, from the TFDA for TJ202 and TJ301 and from the MFDS for TJ301. However, we
cannot guarantee that we are able to obtain regulatory approvals for our other existing drug candidates or any drug candidates we may discover, <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire and seek to develop in the future. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our drug candidates could fail to receive the regulatory approval of the NMPA, the FDA or a comparable regulatory authority for many
reasons, including, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disagreement with the design or implementation of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to demonstrate that a drug candidate is safe and effective and potent for its proposed indication;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of our clinical trial results to meet the level of statistical significance required for approval;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of our clinical trial process to pass relevant good clinical practice (&#147;GCP&#148;) inspections;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to demonstrate that a drug candidate&#146;s clinical and other benefits outweigh its safety risks;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disagreement with our interpretation of data from <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insufficient data collected from the clinical trials of our drug candidates to support the submission and filing
of a new drug application, or NDA, or other submissions or to obtain regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of our drug candidates to pass current Good Manufacturing Practice (&#147;cGMP&#148;), inspections during
the regulatory review process or across the production cycle of our drug; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of our clinical sites to pass audits carried by out by the NMPA, the FDA or comparable regulatory
authorities, resulting in a potential invalidation of our research data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">findings by the NMPA, the FDA or comparable regulatory authorities of deficiencies related to our manufacturing
processes or the facilities of third-party manufacturers with whom we contract for clinical and commercial supplies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in approval policies or regulations that render our <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
and clinical data insufficient for approval; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of our clinical trial process to keep up with any scientific or technological advancements required by
approval policies or regulations. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The NMPA, the FDA or a comparable regulatory authority may require more information,
including additional <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical data, to support approval, which may delay or prevent approval and our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercialization plans. Even if we were to obtain approval, regulatory authorities may approve any of our drug candidates for fewer or more limited indications than we request, grant approval
contingent on the performance of costly post-marketing clinical trials, or approve a drug candidate with an indication that is not desirable for the successful commercialization of that drug candidate. Any of the foregoing scenarios could materially
harm the commercial prospects of our drug candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The absence of patent linkage, patent term extension and data and market exclusivity for
NMPA-approved pharmaceutical products could increase the risk of early generic competition with our products in China. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
United States, the Federal Food, Drug and Cosmetic Act, as amended by the law generally referred to as &#147;Hatch-Waxman,&#148; provides the opportunity for patent-term restoration, meaning a patent term extension of up to five years to reflect
patent term lost during certain portions of product development and the FDA regulatory review process. Hatch-Waxman also has a process for patent linkage, pursuant to which the FDA will stay approval of certain
<FONT STYLE="white-space:nowrap">follow-on</FONT> applications during the pendency of litigation between the <FONT STYLE="white-space:nowrap">follow-on</FONT> applicant and the patent holder or licensee, generally for a period of 30 months. Finally,
Hatch-Waxman provides for statutory exclusivities that can prevent submission or approval of certain <FONT STYLE="white-space:nowrap">follow-on</FONT> marketing applications. For example, federal law provides a five-year period of exclusivity within
the United States to the first applicant to obtain approval of a new chemical entity and three years of exclusivity protecting certain innovations to previously approved active ingredients where the applicant was required to conduct new clinical
investigations to obtain approval for the modification. Similarly, the United States Orphan Drug Act provides seven years of market exclusivity for certain drugs to treat rare diseases, where the FDA designates the drug candidate as an orphan drug
and the drug is approved for the designated orphan indication. These provisions, designed to promote innovation, can prevent competing products from entering the market for a certain period of time after the FDA grants marketing approval for the
innovative product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of any FDA marketing approval process for any drug candidates we
may develop, one or more of our U.S. patents, if issued, may be eligible for limited patent term extension under Hatch-Waxman. Hatch-Waxman permits a patent extension term of up to five years as compensation for patent term lost during clinical
trials and the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of drug approval, only one patent may be extended and only those claims covering the approved
drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to
apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Furthermore, the applicable time period or the scope of patent protection afforded could be less
than we request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In China, however, there is no currently effective law or regulation providing for patent term extension, patent
linkage, or data exclusivity (referred to as regulatory data protection). Therefore, a lower-cost generic drug can emerge onto the market much more quickly. Chinese regulators have set forth a framework for integrating patent linkage and data
exclusivity into the Chinese regulatory regime, as well as for establishing a pilot program for patent term extension. To be implemented, this framework will require adoption of regulations. To date, no regulations have been issued. These factors
result in weaker protection for us against generic competition in China than could be available to us in the United States. For instance, the patents we have in China are not yet eligible to be extended for patent term lost during clinical trials
and the regulatory review process. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our
business, financial condition, results of operations, and prospects could be materially harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our drug candidates may cause undesirable adverse events or have other properties that could delay or
prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Undesirable adverse events caused by our drug candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials
and may result in a more restrictive label, a delay or denial of regulatory approval by the NMPA, the FDA or other comparable regulatory authorities, or a significant change in our clinical protocol or even our development plan. In particular, as is
the case with drugs treating cancers and auto-immune diseases, it is likely that there may be side effects, such as nausea, fatigue and infusion-related reactions, associated with the use of certain of our drug candidates. Results of our trials
could reveal a high and unacceptable severity or prevalence of certain adverse events. In such an event, our trials could be suspended or terminated and the NMPA, the FDA or other comparable regulatory authorities could order us to cease further
development of, or deny approval of, our drug candidates for any or all targeted indications. Adverse events related to our drug candidates may affect patient recruitment or the ability of enrolled subjects to complete the trial, and could result in
potential liability claims. Any of these occurrences may significantly harm our reputation, business, financial condition and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if we or others identify undesirable side effects caused by those of our existing drug candidates that have received regulatory
approval, or our other drug candidates after having received regulatory approval, this may lead to potentially significant negative consequences which include, but are not limited to, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may suspend marketing of the drug candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may withdraw their approvals of or revoke the licenses for the drug candidate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require additional warnings on the label; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA may require the establishment of a Risk Evaluation and Mitigation Strategy, or REMS, or the NMPA or a
comparable regulatory authority may require the establishment of a similar strategy that may, for instance, restrict distribution of our drugs and impose burdensome implementation requirements on us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to conduct specific post-marketing studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be subjected to litigation proceedings and held liable for harm caused to subjects or patients; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining market acceptance of any particular drug candidate that is approved and
could significantly harm our business, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, combination therapy, such as using our wholly-owned
drug candidates as well as third-party agents, may involve unique adverse events that could be exacerbated compared with adverse events from monotherapies. Results of our trials could reveal a high and unacceptable severity or prevalence of adverse
events. These types of adverse events could be caused by our drug candidates and could cause us or regulatory authorities to interrupt, delay or halt clinical trials and may result in a more restrictive indication or the delay or denial of
regulatory approval by the NMPA, the FDA or other comparable regulatory authority. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain the NMPA approval for our drug
candidates to be eligible for an expedited registration pathway as innovative drug candidates, the time and cost we incur to obtain regulatory approvals may increase. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The NMPA has mechanisms in place for expedited review and approval for drug candidates that are innovative drug applications, provided such
drug or drug candidate has a new and clearly defined structure, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pharmacological property and apparent clinical value and has not been marketed anywhere in the world. However, there is no assurance that an innovative drug designation will be granted by the
NMPA for any of our drug candidates. Moreover, an innovative drug designation, which is typically granted only towards the end of a drug&#146;s developmental stage, does not increase the likelihood that our drug candidates will receive regulatory
approval on a fast-track basis, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, there have been recent regulatory initiatives in China in relation to clinical trial
approvals, the evaluation and approval of certain drugs and medical devices and the simplification and acceleration of the clinical trial process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, the regulatory process in China is evolving and subject to change. Any future policies, or changes to current polices might
require us to change our planned clinical study design or otherwise spend additional resources and effort to obtain approval of our drug candidates. In addition, policy changes may contain significant limitations related to use restrictions for
certain age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. If we are unable to obtain regulatory approval for our drug candidates in the PRC, or any approval
contains significant limitations, we may not be able to obtain sufficient funding or generate sufficient revenue to continue the development of our drug candidates or any other drug candidate that we may
<FONT STYLE="white-space:nowrap">in-license,</FONT> acquire or develop in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive regulatory approval for our drug
candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expenses and we may be subject to penalties if we fail to comply with regulatory requirements or experience
unanticipated problems with our drug candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the NMPA, the FDA or a comparable regulatory authority approves any of our
drug candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the drug will be subject to extensive and ongoing regulatory requirements on
pharmacovigilance. These requirements include submissions of safety and other post-marketing information and reports, registration, random quality control testing, adherence to any chemistry, manufacturing, and controls (&#147;CMC&#148;),
variations, continued compliance with current cGMPs, and GCPs and potential post-approval studies for the purposes of license renewal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any regulatory approvals that we receive for our drug candidates may also be subject to limitations on the approved indicated uses for which
the drug may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing studies, including Phase 4 studies for the surveillance and monitoring of the safety and efficacy of the drug. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, once a drug is approved by the NMPA, the FDA or a comparable regulatory authority for marketing, it is possible that there could
be a subsequent discovery of previously unknown problems with the drug, including problems with third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements. If any of the foregoing occurs with respect to
our drug products, it may result in, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the drug, withdrawal of the drug from the market, or voluntary
or mandatory drug recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters or holds on our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal by the NMPA, the FDA or comparable regulatory authorities to approve pending applications or supplements
to approved applications filed by us, or suspension or revocation of drug license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal by the NMPA, the FDA or comparable regulatory authorities to accept any of our other IND approvals, NDAs
or BLAs; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">drug seizure or detention, or refusal to permit the import or export of drugs; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil, administrative or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any government investigation of alleged violations of law could require us to expend significant time and resources and could generate
negative publicity. Moreover, regulatory policies may change or additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our drug candidates. If we are not able to maintain regulatory compliance, we
may lose the regulatory approvals that we have already obtained and may not achieve or sustain profitability, which in turn could significantly harm our business, financial condition and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Illegal and/or parallel imports and counterfeit pharmaceutical products may reduce demand for our future approved drug candidates and could have a
negative impact on our reputation and business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The illegal importation of competing products from countries where government
price controls or other market dynamics result in lower prices may adversely affect the demand for our future approved drug candidates and, in turn, may adversely affect our sales and profitability in China and other countries where we commercialize
our products. Unapproved foreign imports of prescription drugs are illegal under the current laws of China. However, illegal imports may continue to occur or even increase as the ability of patients and other customers to obtain these lower priced
imports continues to grow. Furthermore, cross-border imports from lower-priced markets (which are known as parallel imports) into higher-priced markets could harm sales of our future drug products and exert commercial pressure on pricing within one
or more markets. In addition, competent government authorities may expand consumers&#146; ability to import lower priced versions of our future approved products or competing products from outside China or other countries where we operate. Any
future legislation or regulations that increase consumer access to lower priced medicines from outside China or other countries where we operate could have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain products distributed or sold in the pharmaceutical market may be manufactured without proper licenses or approvals, or be fraudulently
mislabeled with respect to their content or manufacturers. These products are generally referred to as counterfeit pharmaceutical products. The counterfeit pharmaceutical product control and enforcement system, particularly in developing markets
such as China, may be inadequate to discourage or eliminate the manufacturing and sale of counterfeit pharmaceutical products imitating our products. Since counterfeit pharmaceutical products in many cases have very similar appearances compared with
the authentic pharmaceutical products but are generally sold at lower prices, counterfeits of our products could quickly erode the demand for our future approved drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, counterfeit pharmaceutical products are not expected to meet our or our collaborators&#146; rigorous manufacturing and testing
standards. A patient who receives a counterfeit pharmaceutical product may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit pharmaceutical products sold under our or
our collaborators&#146; brand name(s). In addition, thefts of inventory at warehouses, plants or while <FONT STYLE="white-space:nowrap">in-transit,</FONT> which are not properly stored and which are sold through unauthorized channels, could
adversely impact patient safety, our reputation and our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Commercialization of Our Drug Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our drug candidates may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community
necessary for commercial success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if our drug candidates receive regulatory approval, they may nonetheless fail to gain
sufficient market acceptance by physicians and patients and others in the medical community. Physicians and patients may prefer other drugs or drug candidates to ours. If our drug candidates do not achieve an adequate level of acceptance, we may not
generate significant revenue from sales of our drugs or drug candidates and may not become profitable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of market acceptance of our drug candidates, if and only when they are approved
for commercial sale, will depend on a number of factors, including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical indications for which our drug candidates are approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">physicians, hospitals and patients considering our drug candidates as a safe and effective treatment;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether our drug candidates have achieved the perceived advantages of our drug candidates over alternative
treatments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product labeling or package insert requirements of the NMPA, the FDA or other comparable regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations or warnings contained in the labeling approved by the NMPA, the FDA or other comparable regulatory
authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timing of market introduction of our drug candidates as well as competitive drugs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost of treatment in relation to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">availability of adequate coverage and reimbursement under the national and provincial reimbursement drug lists in
the PRC, or from third-party payors and government authorities in the United States or any other jurisdictions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">willingness of patients to pay any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses in the absence of coverage and reimbursement by third-party payors and government authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">relative convenience and ease of administration, including as compared with alternative treatments and
competitive therapies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of our sales and marketing efforts. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our drug candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals or others in the medical
community, we will not be able to generate significant revenue or become profitable. Even if our drugs achieve market acceptance, we may not be able to maintain such market acceptance over time if new products or technologies are introduced which
are more favorably received than our drugs, are more cost effective or render our drugs obsolete. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face intense competition and rapid
technological change and the possibility that our competitors may develop therapies that are similar, more advanced, or more effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our
drug candidates. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and
significant technological change. While our exclusive focus is to develop drug candidates with potential to become novel or highly differentiated drugs, we continue to face competition with respect to our current drug candidates, and will face
competition with respect to any drug candidates that we may seek to develop or commercialize in the future. Our competitors include major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. We are
developing our drug candidate for the treatment of cancer in competition with a number of large biopharmaceutical companies that currently market and sell drugs or are pursuing the development of drugs also for the treatment of cancer. Some of these
competitive drugs and therapies are based on scientific approaches that are the same as or similar to our approach, and others are based on entirely different approaches. For details, see &#147;Business&#151;Our Drug Pipeline.&#148; Potential
competitors further include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development,
manufacturing and commercialization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our competitors have substantially greater financial, technical, and other
resources, such as larger research and development staff and experienced marketing and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being
concentrated in our competitors. As a result, these companies may obtain regulatory approval from the NMPA, the FDA or other comparable regulatory authorities more rapidly than we are able to and may be more effective in selling and marketing their
products as well. For example, the NMPA has recently accelerated market approval of drugs for diseases with high unmet medical need. In particular, the NMPA may review and approve drugs that have gained regulatory market approval in the United
States, the European Union or Japan in the recent ten years without requiring further clinical trials in China. This may lead to potential increased competition from drugs which have already obtained approval in other jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large,
established companies. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing,
acquiring, or licensing on an exclusive basis, products that are more effective or less costly than any drug candidate that we may develop, or achieve earlier patent protection, regulatory approval, product commercialization, and market penetration
than we do. Additionally, technologies developed by our competitors may render our potential drug candidates uneconomical or obsolete, and we may not be successful in marketing our drug candidates against competitors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The manufacture of biopharmaceutical products is a complex process which requires significant expertise and capital investment, and if we encounter
problems in establishing our manufacturing capabilities or manufacturing our future products, our business could suffer. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
limited experience in managing the manufacturing process. The manufacture of biopharmaceutical products is a complex process, in part due to strict regulatory requirements. As of the date of this prospectus, we have no existing manufacturing
infrastructure or capabilities. If we are unable to identify an appropriate production site or a suitable partner to develop our manufacturing infrastructure, or fail to do so in a timely manner, this may lead to significant delays in the
manufacturing of our drug candidates once regulatory and marketing approvals have been obtained. The investment for building a new biologics manufacturing facility that is compliant with cGMP regulations may also be a significant upfront cost for
us. In turn, this could materially harm our commercialization plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, problems may arise during the manufacturing process for
a variety of reasons, including equipment malfunction, failure to follow specific protocols and procedures, problems with raw materials, delays related to the construction of new facilities or expansion of any future manufacturing facilities,
including changes in manufacturing production sites and limits to manufacturing capacity due to regulatory requirements, changes in the types of products produced, increases in the prices of raw materials, physical limitations that could inhibit
continuous supply, <FONT STYLE="white-space:nowrap">man-made</FONT> or natural disasters and environmental factors. If problems arise during the production of a batch of future products, that batch of future products may have to be discarded and we
may experience product shortages or incur added expenses. This could, among other things, lead to increased costs, lost revenue, damage to customer relationships, time and expense spent investigating the cause and, depending on the cause, similar
losses with respect to other batches or products. If problems are not discovered before such product is released to the market, recall and product liability costs may also be incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have no experience in launching and marketing drug candidates. We may not be able to effectively build and manage our sales network, or benefit from
third-party collaborators&#146; sales network. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no sales, marketing or commercial product distribution
capabilities and have no experience in marketing drugs. We intend to develop an <FONT STYLE="white-space:nowrap">in-house</FONT> marketing organization and sales force, which will require significant capital expenditures, management resources and
time. We will have to compete with other biopharmaceutical companies to recruit, hire, train and retain marketing and sales personnel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable or decide not to establish internal sales, marketing and commercial
distribution capabilities for any or all of the drugs we develop, we will likely pursue collaborative arrangements regarding the sales and marketing of our drugs. However, there can be no assurance that we will be able to establish or maintain such
collaborative arrangements, or, if we are able to do so, that they will have effective sales forces. Any revenue we receive will depend on the efforts of such third parties, which may not be successful. We may have little or no control over the
marketing and sales efforts of such third parties, and our revenue from product sales may be lower than if we had commercialized our drug candidates ourselves. We will also face competition in our search for third parties to assist us with the sales
and marketing efforts of our drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that we will be able to develop
<FONT STYLE="white-space:nowrap">in-house</FONT> sales and commercial distribution capabilities or establish or maintain relationships with third-party collaborators to successfully commercialize any product, and as a result, we may not be able to
generate product sales revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we are able to commercialize any approved drug candidates, reimbursement may be limited or unavailable in
certain market segments for our drug candidates, and we may be subject to unfavorable pricing regulations, which could harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulations that govern regulatory approvals, pricing and reimbursement for new therapeutic products vary widely from country to country.
Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or licensing approval is granted. In some <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a drug in a particular country, but then be subject to price
regulations that delay our commercial launch of the drug and negatively impact the revenues we are able to generate from the sale of the drug in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more
drug candidates, even if our drug candidates obtain regulatory approval. For example, according to a statement, Opinions on Reforming the Review and Approval Process for Pharmaceutical Products and Medical Devices, issued by the PRC State Council in
August 2015, the enterprises applying for new drug approval will be required to undertake that the selling price of new drug on PRC mainland market shall not be higher than the comparable market prices of the product in its country of origin or
PRC&#146;s neighboring markets, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to commercialize any drugs successfully also will depend in part on the extent
to which reimbursement for these drugs and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health
insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the global healthcare industry is cost containment. Government authorities and these third-party payors
have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that companies provide them with predetermined discounts from list prices and are
challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any drug that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Reimbursement may impact the
demand for, or the price of, any drug for which we obtain regulatory approval. Obtaining reimbursement for our drugs may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a
physician. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any drug candidate that we successfully develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be significant delays in obtaining reimbursement for approved drug candidates, and coverage may be more limited than the purposes
for which the drug candidates are approved by the NMPA, the FDA or other comparable regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs,
including research, development, manufacture, sale and distribution. Interim payments for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Payment rates may vary according to the use of the drug
and the clinical setting in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which it is used, may be based on payments allowed for lower cost drugs that are already reimbursed, and may be incorporated into existing payments for other services. Net prices for drugs may be
reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future weakening of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the
United States. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any future approved drug candidates and any new drugs that we develop could have a material adverse effect on
our business, our operating results, and our overall financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Current and future legislation may increase the difficulty and cost for
us to obtain marketing approval of and commercialize our drug candidates and affect the prices we may obtain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States
and certain other jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our drug candidates, restrict post-approval
activities and affect our ability to sell profitably any drug candidates for which we obtain marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Patient Protection
and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, became law. The ACA is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of
healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. Among
the provisions of the ACA of importance to our drug candidates are the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and
biologic products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new
government investigative powers, and enhanced penalties for noncompliance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extension of manufacturers&#146; Medicaid rebate liability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of eligibility criteria for Medicaid programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of the entities eligible for discounts under the Public Health Service Act&#146;s pharmaceutical
pricing program; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">new requirements to report to CMS financial arrangements with physicians and teaching hospitals;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new requirement to annually report to the FDA drug samples that manufacturers and distributors provide to
physicians; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative
clinical effectiveness research, along with funding for such research. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legislative and regulatory proposals have been
made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or
interpretations will be changed, or what the impact of such changes on the marketing approvals, if any, of our drug candidates may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#146;s approval process may significantly delay or
prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing conditions and other requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As we <FONT STYLE="white-space:nowrap">out-license</FONT> some of our commercialization rights and
engage in other forms of collaboration worldwide, including conducting clinical trials abroad, we may be exposed to specific risks of conducting our business and operations in international markets. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Markets outside of China form an important component of our growth strategy, as we <FONT STYLE="white-space:nowrap">out-license</FONT> some of
our commercialization rights to third parties outside the PRC and conduct certain of our clinical trials abroad. If we fail to obtain applicable licenses or fail to enter into strategic collaboration arrangements with third parties in these markets,
or if these collaboration arrangements turn out unsuccessful, our revenue-generating growth potential will be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, international business relationships subject us to additional risks that may materially adversely affect our ability to attain or
sustain profitable operations, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">efforts to enter into collaboration or licensing arrangements with third parties in connection with our
international sales, marketing and distribution efforts may increase our expenses or divert our management&#146;s attention from the acquisition or development of drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in a specific country&#146;s or region&#146;s political and cultural climate or economic condition;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differing regulatory requirements for drug approvals and marketing internationally; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty of effective enforcement of contractual provisions in local jurisdictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potentially reduced protection for intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential third-party patent rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unexpected changes in tariffs, trade barriers and regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic weakness, including inflation or political instability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with tax, employment, immigration and labor laws for employees traveling abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects of applicable <FONT STYLE="white-space:nowrap">non-PRC</FONT> tax structures and potentially adverse
tax consequences; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">currency fluctuations, which could result in increased operating expenses and reduced revenue, and other
obligations incidental to doing business in another country; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">workforce uncertainty and labor unrest; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential for <FONT STYLE="white-space:nowrap">so-called</FONT> parallel importing, which is what happens
when a local seller, faced with high or higher local prices, opts to import goods from an international market with low or lower prices rather than buying them locally; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of our employees and contracted third parties to comply with Office of Foreign Assets Control rules and
regulations and the Foreign Corrupt Practices Act of the United States, and other applicable rules and regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities
abroad; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from <FONT STYLE="white-space:nowrap">geo-political</FONT> actions, including
war and terrorism, or natural disasters, including earthquakes, volcanoes, typhoons, floods, hurricanes and fires. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These and other risks may materially adversely affect our ability to attain or sustain revenue from international markets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If safety, efficacy, or other issues arise with any medical product that is used in combination with our drug candidates, we may be unable to market
such drug candidate or may experience significant regulatory delays or supply shortages, and our business could be materially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to develop certain of our drug candidates for use as a combination therapy. If the NMPA, the FDA or another comparable regulatory
agency revokes its approval of another therapeutic we use in combination with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our drug candidates, we will not be able to market our drug candidates in combination with such revoked therapeutic. If safety or efficacy issues arise with these or other therapeutics that we
seek to combine with our drug candidates in the future, we may experience significant regulatory delays, and we may be required to redesign or terminate the applicable clinical trials. In addition, if manufacturing or other issues result in a supply
shortage of any component of our combination drug candidates or if we cannot secure supply of any component of our drug candidates at commercially reasonable or acceptable prices, we may not be able to complete clinical development of our drug
candidates on our current timeline or within our current budget, or at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lack of third-party combination drugs may materially and adversely
affect demand for our drugs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our drug candidates may be administered in combination with drugs of other pharmaceutical companies
as one regimen. In addition, we often use such third-party drugs in our development and clinical trials as controls for our studies. As a result, both the results of our clinical trials and the sales of our drugs may be affected by the availability
of these third-party drugs. If other pharmaceutical companies discontinue these combination drugs, regimens that use these combination drugs may no longer be prescribed, and we may not be able to introduce or find an alternative drug to be used in
combination with our drugs at all or in a timely manner and on a cost-effective basis. As a result, demand for our drugs may be lowered, which would in turn materially and adversely affect our business and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Reliance on Third Parties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As
we rely on third parties to conduct our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials, if we lose our relationships with these third parties or if they do not successfully carry out their contractual duties or meet
expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug candidates and our business could be substantially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have relied on and plan to continue to rely on third-party contract research organization (&#147;CROs&#148;) to monitor and manage data for
some of our ongoing <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical programs. We rely on these parties for the execution of our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trials, and control only certain
aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs does not relieve
us of our regulatory responsibilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also rely on third parties to assist in conducting our
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies in accordance with Good Laboratory Practices (&#147;GLP&#148;). We and our CROs are required to comply with GCP, GLP and other regulatory regulations and guidelines enforced by the NMPA,
the FDA and comparable foreign regulatory authorities for all of our drug candidates in clinical development. Regulatory authorities enforce these GCP, GLP or other regulatory requirements through periodic inspections of trial sponsors,
investigators and trial sites. If we or any of our CROs fail to comply with applicable GCP, GLP or other regulatory requirements, the relevant data generated in our clinical trials may be deemed unreliable and the NMPA, the FDA or other comparable
regulatory authorities may require us to perform additional clinical studies before approving our marketing applications. There can be no assurance that upon inspection by a given regulatory authority, such regulatory authority will determine that
any of our clinical trials complies with GCP requirements. In addition, our clinical trials must be conducted with drug candidates or products produced under cGMP requirements. Failure to comply with these regulations may require us to repeat <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trials, which would delay the regulatory approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our CROs have the
right to terminate their agreements with us in the event of an unrectified material breach. If any of our relationships with our third-party CROs is terminated, we may not be able to (i)&nbsp;enter into arrangements with alternative CROs or do so on
commercially reasonable terms or (ii)&nbsp;meet our desired clinical development timelines. In addition, there is a natural transition period when a new CRO commences work, and the new CRO may not provide the same type or level of services as the
original provider and data from our clinical trials may be compromised as a result. There is also a need for relevant technology to be transferred to the new CRO, which may take time and further delay our development timelines. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except for remedies available to us under our agreements with our CROs, we cannot control
whether or not our CROs devote sufficient time and resources to our ongoing clinical, nonclinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> programs. If our CROs do not successfully carry out their contractual duties or obligations or
meet expected deadlines or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended,
delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our drug candidates. As a result, our results of operations and the commercial prospects for our drug candidates would be harmed and our
costs could increase. In turn, our ability to generate revenues could be delayed or compromised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we rely on third parties, our
internal capacity to perform these functions is limited. Outsourcing these functions involves certain risks that third parties may not perform to our standards, may not produce results in a timely manner or may fail to perform at all. In addition,
the use of third-party service providers requires us to disclose our proprietary information to these third parties, which could increase the risk that such information will be misappropriated. We currently have a small number of employees, which
limits the internal resources we have available to identify and monitor our third-party service providers. To the extent we are unable to identify and successfully manage the performance of third-party service providers in the future, our business
may be adversely affected. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material
adverse impact on our business, financial condition and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to rely on third parties to manufacture at least a portion of our drug
candidate supplies, and we intend to rely on third parties for at least a portion of the manufacturing process of our drug candidates, if approved. Our business could be harmed if those third parties fail to provide us with sufficient quantities of
product or fail to do so at acceptable quality levels or prices. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we plan to either construct or acquire a facility that
will be used as our clinical-scale manufacturing and processing facility, we intend to also partially rely on third-party vendors to manufacture supplies and process our drug candidates. We have not yet manufactured or processed our drug candidates
on a commercial scale and may not be able to do so for any of our drug candidates. We have limited experience in managing the manufacturing process, and our process may be more difficult or expensive than the approaches currently in use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our anticipated reliance on third-party manufacturers exposes us to certain risks, including, but not limited to, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to identify manufacturers on acceptable terms or at all because the number of potential
manufacturers is limited and the NMPA, the FDA or other comparable regulatory authorities must approve any manufacturers as part of their regulatory oversight of our drug candidates. This approval would require new testing and cGMP-compliance
inspections by the NMPA, the FDA or other comparable regulatory authorities. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our drugs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our contract manufacturers may have little or no experience with manufacturing our drug candidates, and therefore
may require a significant amount of support from us in order to implement and maintain the infrastructure and processes required to manufacture our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our contract manufacturers may have limited capacity or limited manufacturing slots, which may affect the
timeline for the production of our drugs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our contract manufacturers might be unable to timely manufacture our drug candidates or produce the quantity and
quality required to meet our clinical and commercial needs, if any; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">contract manufacturers may not be able to execute our manufacturing procedures and other logistical support
requirements appropriately; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our future contract manufacturers may not perform as agreed, may not devote sufficient resources to our drugs, or
may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our drugs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our contract manufacturers are subject to ongoing periodic unannounced inspections by the NMPA and the FDA to
ensure strict compliance with cGMP and other government regulations in the PRC and the United States, respectively, and by other comparable regulatory authorities for corresponding regulatory requirements. We do not have control over third-party
manufacturers&#146; compliance with these regulations and requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not own, or may have to share, the intellectual property rights to any improvements made by our
third-party manufacturers in the manufacturing process for our drugs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our contract manufacturers could breach or terminate their agreements with us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our contract manufacturers may be unable to sustain their business and become bankrupt as a result;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">raw materials and components used in the manufacturing process, particularly those for which we have no other
source or supplier, may not be available or may not be suitable or acceptable for use due to material or component defects; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">products and components from our third-party manufacturers may be subject to additional customs and import
charges, which may cause us to incur delays or additional costs as a result; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our contract manufacturers and critical reagent suppliers may be subject to inclement weather, as well as natural
or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our contract manufacturers may have unacceptable or inconsistent product quality success rates and yields.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of these risks could delay or prevent the completion of our clinical trials or the approval of any of our drug
candidates by the NMPA, the FDA or other comparable regulatory authorities, result in higher costs or adversely impact the commercialization of our drug candidates. In addition, we will rely on third parties to perform certain specification tests on
our drug candidates prior to delivery to patients. If these tests are not appropriately done and test data is not reliable, patients could be put at risk of serious harm and the NMPA, the FDA or other comparable regulatory authorities could place
significant restrictions on our company until deficiencies are remedied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manufacture of biopharmaceutical products is complex and
requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Currently, our drug raw materials for our manufacturing activities are supplied by multiple source suppliers.
We have agreements for the supply of drug materials with manufacturers or suppliers that we believe have sufficient capacity to meet our demands. In addition, we believe that adequate alternative sources for such supplies exist. However, there is a
risk that, if supplies are interrupted, our business would be materially harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturers of biopharmaceutical products often
encounter difficulties in production, particularly in scaling up or out, validating the production process, and assuring high reliability of the manufacturing process, including the absence of contamination. These problems include logistics and
shipping, difficulties with production costs and yields, quality control, including stability of the product, product testing, operator error and availability of qualified personnel, as well as compliance with strictly enforced regulations in the
PRC, the United States and other applicable jurisdictions. Further, if contaminants are discovered in the supply of our drug candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of
time for us to investigate and remedy the contamination. There can be no assurance that any stability failures or other issues relating to the manufacture of our drug candidates will not occur in the future. Additionally, our contract manufacturers
may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environment. If our contract manufacturers were to encounter </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any of these difficulties, or otherwise fail to comply with their contractual obligations, our ability to provide our drug candidate to patients in clinical trials would be jeopardized. Any delay
or interruption in the supply of clinical trial supplies could delay the completion of our clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to begin new
clinical trials at additional expense or terminate clinical trials completely. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have entered into collaborations and may form or seek
collaborations or strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may form or seek strategic alliances, create joint ventures or collaborations, or enter into additional licensing arrangements with third
parties that we believe will complement or augment our development and commercialization efforts with respect to our drug candidates and any future drug candidates that we may develop. Any of these relationships may require us to incur recurring or <FONT
STYLE="white-space:nowrap">non-recurring</FONT> expenses and other charges, increase our near and long-term expenditures, issue securities that dilute the value of our ADSs, or disrupt our management and business. For example, we have entered into a
license and collaboration agreement with MorphoSys AG (&#147;MorphoSys&#148;), pursuant to which we <FONT STYLE="white-space:nowrap">in-licensed</FONT> from MorphoSys the development and commercialization rights of TJ202 in Greater China.
Furthermore, we have entered into a product collaboration agreement with Everest Medicines Limited (&#147;Everest&#148;), pursuant to which we and Everest agreed to share the development cost and economic interest in TJ202 with respect to multiple
myeloma. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or
other alternative arrangements for our drug candidates because they may be deemed to be at too early a stage of development for collaborative effort and third parties may not view our drug candidates as having the requisite potential to demonstrate
safety and efficacy. If and when we collaborate with a third party for the development and commercialization of a drug candidate, we can expect to relinquish some or all of the control over the future success of that drug candidate to the third
party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, collaborations involving our drug candidates are subject to specific risks, which include, but are not limited to, the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators have significant discretion in determining the efforts and resources that they will apply to a
collaboration; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not pursue the development and commercialization of our drug candidates or may elect not to
continue or renew the development or commercialization programs based on clinical trial results, change in their strategic focus due to the acquisition of competitive drugs, availability of funding, or other external factors, such as a business
combination that diverts resources or creates competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, discontinue a
clinical trial, repeat or conduct new clinical trials, or require a new formulation of a drug candidate for clinical testing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators could independently develop, or develop with third parties, drugs that compete directly or
indirectly with our drug candidates or future drugs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators with marketing and distribution rights to one or more of our drug candidates or future drugs may
not commit sufficient resources to their marketing and distribution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual
property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not always be cooperative or responsive in providing their services in a clinical trial;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes may arise between us and a collaborator that cause a delay or termination of the research, development
or commercialization of our drug candidates, or that result in costly litigation or arbitration that diverts management attention and resources; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue
further development or commercialization of the applicable drug candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may own or <FONT STYLE="white-space:nowrap">co-own</FONT> intellectual property covering our drug
candidates or future drugs that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, if we enter into collaboration agreements and strategic partnerships or license our drugs, we may not be able to realize the
benefit of such transactions if we are unable to successfully integrate these agreements or partnerships with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither can we be certain that, following a strategic transaction or license, we will be able to achieve the revenue or specific net income
that justifies such transaction. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a drug candidate, reduce or delay its development program
or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own
expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter
into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our drug candidates or bring them to market and generate product sales
revenue, which would harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain and maintain patent and other intellectual property protection for our drug candidates, or if the scope of such intellectual
property rights obtained is not sufficiently broad, third parties could develop and commercialize products and technologies similar or identical to ours and compete directly against us, and our ability to successfully commercialize any product or
technology may be adversely affected. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in large part on our ability to protect our proprietary technology
and drug candidates from competition by obtaining, maintaining, defending and enforcing our intellectual property rights, including patent rights. As of September 30, 2019, our owned patent portfolio consist of five patents and 165 patent
applications primarily in connection with the drug candidates in our Global Portfolio, including 22 Patent Cooperation Treaty (&#147;PCT&#148;) patent applications, 10 U.S. patent applications, 13 PRC patent applications and 120 patent applications
in other jurisdictions. In addition, as of September 30, 2019, we <FONT STYLE="white-space:nowrap">in-licensed</FONT> the Greater China rights relating to 19 issued patents and 25 pending patent applications primarily in connection with TJ202,
TJ101, TJ301, enoblituzumab and TJ107. We seek to protect the drug candidates and technology that we consider commercially important by filing patent applications in China, the United States and other countries or regions, relying on trade secrets
or pharmaceutical regulatory protection or employing a combination of these methods. This process is expensive and time-consuming, and we or our licensors may not be able to file and prosecute all necessary or desirable patent applications in all
jurisdictions at a reasonable cost or in a timely manner. It is also possible that we or our licensors will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions
and has in recent years been the subject of much litigation. As a result, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which
protect our technology or drug candidates or which effectively prevent others from commercializing competitive technologies and drug candidates. The patent examination process may require us or our licensors to narrow the scope of the claims of our
or our licensors&#146; pending and future patent applications, which may limit the scope of patent protection that may be obtained. We cannot assure that all of the potentially relevant prior art relating to our patents and patent applications has
been found. If such prior art exists, it can invalidate a patent or prevent a patent application from being issued as a patent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if
patents do issue on any of these applications, there can be no assurance that a third party will not challenge their validity, enforceability, or scope, which may result in the patent claims being narrowed or invalidated, or that we will obtain
sufficient claim scope in those patents to prevent a third party from competing successfully with our drug candidates. We may become involved in interference, <I>inter partes</I> review, post grant review, ex parte reexamination, derivation,
opposition or similar other proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize
our technology or drug candidates and compete directly with us, or result in our inability to manufacture or commercialize drug candidates without infringing third-party patent rights. Thus, even if our patent applications issue as patents, they may
not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our competitors may be able to circumvent our patents by developing similar or alternative technologies or drug candidates in a <FONT
STYLE="white-space:nowrap">non-infringing</FONT> manner. The issuance of a patent is not conclusive as to its scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the
United&nbsp;States and other countries. Such challenges may result in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop or prevent us from stopping others from using or commercializing similar or
identical technology and drug candidates, or limit the duration of the patent protection of our technology and drug candidates. Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents
protecting such assets might expire before or shortly after such assets are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing drug candidates similar or identical to
ours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the
value of our patents or narrow the scope of our patent protection. Under the America Invents Act (&#147;AIA&#148;) enacted in 2011, the United States moved to this
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-to-file</FONT></FONT> system in early 2013 from the previous system under which the first to make the claimed invention was entitled to the patent. Assuming the other
requirements for patentability are met, the first to file a patent application is entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States
and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or
that we were the first to file for patent protection of such inventions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We enjoy only limited geographical protection with respect to certain
patents and may not be able to protect our intellectual property rights throughout the world, including in the PRC. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing and
prosecuting patent applications and defending patents covering our drug candidates in all countries throughout the world could be prohibitively expensive. Competitors may use our and our licensors&#146; technologies in jurisdictions where we have
not obtained patent protection to develop their own drug candidates and, further, may export otherwise infringing drug candidates to territories, including the PRC, where we and our licensors have patent protection, but enforcement rights are not as
strong as that in the United States or Europe. These drug candidates may compete with our drug candidates, and our and our licensors&#146; patents or other intellectual property rights may not be effective or sufficient to prevent them from
competing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The laws of some jurisdictions, including the PRC, do not protect intellectual property
rights to the same extent as the laws or rules and regulations in the United States and Europe, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. The legal systems of certain
countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of
competing drug candidates in violation of our proprietary rights generally. Proceedings to enforce our patent rights in other jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other
aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing as patents, and could provoke third parties to assert claims against us. We may not prevail in any
lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant
commercial advantage from the intellectual property that we develop or license. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or
maintain similar efforts in all jurisdictions in which we may wish to market our drug candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our
ability to successfully commercialize our drug candidates in all of our expected significant foreign markets. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual
property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some countries also have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In
addition, some countries limit the enforceability of patents against government agencies or government contractors. In those countries, the patent owner may have limited remedies, which could materially diminish the value of such patents. If we or
any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance and annuity fees on any issued patent are due to be paid to the United States Patent and Trademark Office
(&#147;USPTO&#148;) and foreign patent agencies over the lifetime of a patent. In addition, the USPTO and other foreign patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the
patent application process. While an inadvertent failure to make payment of such fees or to comply with such provisions can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are
situations in which such <FONT STYLE="white-space:nowrap">non-compliance</FONT> will result in the abandonment or lapse of the patent or patent application, and the partial or complete loss of patent rights in the relevant jurisdiction. <FONT
STYLE="white-space:nowrap">Non-compliance</FONT> events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, and
<FONT STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal documents within prescribed time limits. If we or our licensors fail to maintain the patents and patent applications covering our drug
candidates or if we or our licensors otherwise allow our patents or patent applications to be abandoned or lapse, our competitors might be able to enter the market, which would hurt our competitive position and could impair our ability to
successfully commercialize our drug candidates in any indication for which they are approved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and other intellectual
property may be subject to further priority disputes or to inventorship disputes and similar proceedings. If we or our licensors are unsuccessful in any of these proceedings, we may be required to obtain licenses from third parties, which may not be
available on commercially reasonable terms or at all, or to modify or cease the development, manufacture and commercialization of one or more of the drug candidates we may develop, which could have a material adverse impact on our business.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our
owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> If we or our licensors are unsuccessful in any interference proceedings or
other priority or validity disputes (including any patent oppositions) to which we or they are subject, we may lose valuable intellectual property rights through the loss of one or more patents owned or licensed or our owned or licensed patent
claims may be narrowed, invalidated, or held unenforceable. In addition, if we or our licensors are unsuccessful in any inventorship disputes to which we or they are subject, we may lose valuable intellectual property rights, such as exclusive
ownership of, or the exclusive right to use, our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents. If we or our licensors are unsuccessful in any interference proceeding or other priority or inventorship dispute, we may be
required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all,
or may be <FONT STYLE="white-space:nowrap">non-exclusive.</FONT> If we are unable to obtain and maintain such licenses, we may need to modify or cease the development, manufacture, and commercialization of one or more of our drug candidates. The
loss of exclusivity or the narrowing of our owned and licensed patent claims could limit our ability to stop others from using or commercializing similar or identical drug products. Any of the foregoing could result in a material adverse effect on
our business, financial condition, results of operations, or prospects. Even if we are successful in an interference proceeding or other similar priority or inventorship disputes, it could result in substantial costs and be a distraction to our
management and other employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Claims that our drug candidates or the sale or use of our future products infringe, misappropriate or otherwise
violate the patents or other intellectual property rights of third parties could result in costly litigation or could require substantial time and money to resolve, even if litigation is avoided. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot guarantee that our drug candidates or the sale or use of our future products do not and will not in the future infringe,
misappropriate or otherwise violate third-party patents or other intellectual property rights. Third parties might allege that we are infringing their patent rights or that we have misappropriated their trade secrets, or that we are otherwise
violating their intellectual property rights, whether with respect to the manner in which we have conducted our research, or with respect to the use or manufacture of the compounds we have developed or are developing. Litigation relating to patents
and other intellectual property rights in the biopharmaceutical and pharmaceutical industries is common, including patent infringement lawsuits. The various markets in which we plan to operate are subject to frequent and extensive litigation
regarding patents and other intellectual property rights. Some claimants may have substantially greater resources than we have and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer
periods of time than we could. Third parties might resort to litigation against us or other parties we have agreed to indemnify, which litigation could be based on either existing intellectual property or intellectual property that arises in the
future. For example, we are aware of a third-party U.S. patent and its counterpart European patents that relate to the use of antibodies having specificity to PD-L1 to treat cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is also possible that we failed to identify, or may in the future fail to identify, relevant patents or patent applications held by third
parties that cover our drug candidates. Publication of discoveries in the scientific or patent literature often lags behind actual discoveries. Therefore, we cannot be certain that we were the first to invent, or the first to file patent
applications on, our drug candidates or for their uses, or that our drug candidates will not infringe patents that are currently issued or that are issued in the future. In the event that a third party has also filed a patent application covering
one of our drug candidates or a similar invention, our patent application may be regarded as a competing application and may not be approved in the end. Additionally, pending patent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our products or their use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a third party were to assert claims of patent infringement against us, even if we believe such third-party claims are without merit, a
court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able to block our ability to commercialize the applicable product unless we obtained a license
under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our compositions,
formulations, or methods of treatment, prevention, or use, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product unless we obtained a license or until such patent expires or is finally
determined to be invalid or unenforceable. In addition, defending such claims would cause us to incur substantial expenses and could cause us to pay substantial damages, if we are found to be infringing a third party&#146;s patent rights. These
damages potentially include increased damages and attorneys&#146; fees if we are found to have infringed such rights willfully. In order to avoid or settle potential claims with respect to any patent or other intellectual property rights of third
parties, we may choose or be required to seek a license from a third party and be required to pay license fees or royalties or both, which could be substantial. These licenses may not be available on acceptable terms, or at all. Even if we were able
to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a drug candidate, or be forced, by court order or
otherwise, to modify or cease some or all aspects of our business operations, if, as a result of actual or threatened patent or other intellectual property claims, we are unable to enter into licenses on acceptable terms. Further, we could be found
liable for significant monetary damages as a result of claims of intellectual property infringement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Defending against claims of patent
infringement, misappropriation of trade secrets or other violations of intellectual property rights could be costly and time-consuming, regardless of the outcome. Furthermore, because of the substantial amount of discovery required in connection
with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. Thus, even if we were to ultimately prevail, or to settle at an early stage, such
litigation could burden us with substantial unanticipated costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issued patents covering one or more of our drug candidates could be found invalid
or unenforceable if challenged in court. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite measures we take to obtain and maintain patent and other intellectual property
rights with respect to our drug candidates, our intellectual property rights could be challenged or invalidated. For example, if we were to initiate legal proceedings against a third party to enforce a patent covering one of our drug candidates, the
defendant could counterclaim that our patent is invalid and/or unenforceable. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or <FONT
STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, SIPO, or the applicable foreign
counterpart, or made a misleading statement, during prosecution. Although we believe that we have conducted our patent prosecution in accordance with a duty of candor and in good faith, the outcome following legal assertions of invalidity and
unenforceability during patent litigation is unpredictable. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on a drug candidate. Even
if a defendant does not prevail on a legal assertion of invalidity and/or unenforceability, our patent claims may be construed in a manner that would limit our ability to enforce such claims against the defendant and others. Even if we establish
infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may not be an adequate remedy. In addition, if the breadth or strength of protection provided by our
patents is threatened, it could dissuade companies from collaborating with us to license, develop, or commercialize our current or future drug candidates. Any loss of patent protection could have a material adverse impact on one or more of our drug
candidates and our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enforcing our intellectual property rights against third parties may also cause such third
parties to file other counterclaims against us, which could be costly to defend and could require us to pay substantial damages, cease the sale of certain drugs or enter into a license agreement and pay royalties (which may not be possible on
commercially reasonable terms or at all). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property litigation may lead to unfavorable publicity which may harm our reputation and
cause the market price of our ADSs to decline, and any unfavorable outcome from such litigation could limit our research and development activities and/or our ability to commercialize our drug candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the course of any intellectual property litigation, there could be public announcements of the results of hearings, rulings on motions,
and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our drug candidates, future drugs, programs or intellectual property could be diminished.
Accordingly, the market price of our ADSs may decline. Such announcements could also harm our reputation or the market for our drug candidates, which could have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of intellectual property litigation, there can be no assurance that we would prevail, even if the case against us is weak or
flawed. If third parties successfully assert their intellectual property rights against us, prohibitions against using certain technologies, or prohibitions against commercializing our drug candidates, could be imposed by a court or by a settlement
agreement between us and a plaintiff. In addition, if we are unsuccessful in defending against allegations that we have infringed, misappropriated or otherwise violated the patent or other intellectual property rights of others, we may be forced to
pay substantial damage awards to the plaintiff. Additionally, we may be required to obtain a license from the intellectual property owner in order to continue our research and development programs or to commercialize any resulting product. It is
possible that the necessary license will not be available to us on commercially acceptable terms, or at all. This may not be technically or commercially feasible, may render our products less competitive, or may delay or prevent the launch of our
products to the market. Any of the foregoing could limit our research and development activities, our ability to commercialize one or more drug candidates, or both. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most of our competitors are larger than we are and have substantially greater resources. They are, therefore, likely to be able to sustain the
costs of complex intellectual property litigation longer than we could. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to conduct our clinical trials,
continue our internal research programs, <FONT STYLE="white-space:nowrap">in-license</FONT> needed technology, or enter into strategic partnerships that would help us bring our drug candidates to market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, any future intellectual property litigation, interference or other administrative proceedings will result in additional expense
and distraction of our personnel. An adverse outcome in such litigation or proceedings may expose us or any future strategic partners to loss of our proprietary position, expose us to significant liabilities, or require us to seek licenses that may
not be available on commercially acceptable terms, if at all, each of which could have a material adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in patent
law could diminish the value of patents in general, thereby impairing our ability to protect our drug candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case
with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patent rights. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity, and is
therefore costly, time-consuming, and inherently uncertain. In addition, the United States has recently enacted and is implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent
protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created
uncertainty with respect to the value of patents once obtained, if any. Depending on decisions by the U.S. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our
existing patents and patents that we might obtain in the future. For example, in a recent case, <I>Assoc. for Molecular Pathology v. Myriad Genetics,</I><I></I><I>&nbsp;Inc.</I>, the U.S. Supreme Court held that certain claims to naturally-occurring
substances are not patentable. Although we do not believe that our currently issued patents and any patents that may issue from our pending patent applications directed to our drug candidates if issued in their currently pending forms, as well as
patent rights licensed by us, will be found invalid based on this decision, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patent rights. There could be similar changes in the laws of
foreign jurisdictions that may impact the value of our patent rights or our other intellectual property rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the
confidentiality of our trade secrets, our business and competitive position would be harmed. We also may be subject to claims that our employees, consultants, or advisers have wrongfully used or disclosed alleged trade secrets of their former
employers or claims asserting ownership of what we regard as our own intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our issued patents and
pending patent applications, we rely on trade secret and confidential information, including unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary information, to maintain our competitive position and to
protect our drug candidates. We seek to protect this trade secret and confidential information, in part, by entering into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties that have access to them,
such as our employees, corporate collaborators, outside scientific collaborators, sponsored researchers, contract manufacturers, consultants, advisers and other third parties. We also enter into confidentiality and invention or patent assignment
agreements with our employees and consultants. However, any of these parties may breach such agreements and disclose our proprietary information, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party
illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming, and the outcome is unpredictable. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other
third party, we would have no right to prevent them from using that technology or information to compete with us and our competitive position would be harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, many of our employees, consultants, and advisers, including our senior management, were previously employed at other
biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants, and advisers, including members of our senior management, executed proprietary rights, <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT STYLE="white-space:nowrap">non-competition</FONT> agreements in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information
or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any
such individual&#146;s former employer. We are not aware of any threatened or pending claims related to these matters or concerning the agreements with our senior management, but in the future litigation may be necessary to defend against such
claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in
substantial costs and be a distraction to management. In addition, while we typically require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such
intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own, and furthermore, the assignment of intellectual property rights may not be
self-executing, or the assignment agreements may be breached, each of which may result in claims by or against us related to the ownership of such intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying
monetary damages, we may lose valuable intellectual property rights. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs, be a distraction to our management and scientific personnel
and have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in obtaining or maintaining necessary rights for our development pipeline
through acquisitions and <FONT STYLE="white-space:nowrap">in-licenses.</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because our programs may involve additional drug
candidates that may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire and maintain licenses or other rights to use these proprietary rights. We may be unable to
acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> any compositions, methods of use, or other intellectual property rights from third parties that we identify. The licensing and acquisition of third-party intellectual property rights is a
competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive
advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be
unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual
property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or drug candidate, which could have a material adverse effect on our business, financial condition, results of
operations and prospects for growth. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our rights to develop and commercialize our drug candidates are subject, in part, to the terms and conditions
of licenses granted to us by others. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on licenses to certain patent rights and other intellectual property from third
parties that are important or necessary to the development of our drug candidates. These and other licenses may not provide exclusive rights to use such intellectual property in all relevant fields of use and in all territories in which we may wish
to develop or commercialize our drug products. As a result, we may not be able to prevent competitors from developing and commercializing competitive drug products in territories included in all of our licenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not have the right to control the preparation, filing, prosecution, maintenance, enforcement, and defense of patents and patent
applications covering the drug candidates that we license from third parties. Moreover, we have not had and do not have primary control over these activities for certain of our patents or patent applications and other intellectual property rights
that we jointly own with certain of our licensors and <FONT STYLE="white-space:nowrap">sub-licensors.</FONT> Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced, and
defended in a manner consistent with the best interests of our business. If our licensors fail to prosecute, maintain, enforce and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be
reduced or eliminated, and our right to develop and commercialize any of our drugs that are subject of such licensed rights could be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the license agreements with some of our licensors, the licensors may have the right to control enforcement of our
licensed patents or defense of any claims asserting the invalidity or unenforceability of these patents. Even if we are permitted to pursue the enforcement or defense of our licensed patents, we will require the cooperation of our licensors and any
applicable patent owners and such cooperation may not be provided to us. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our
interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business.
If we lose any of our licensed intellectual property, our right to develop and commercialize any of our drug candidates that are subject of such licensed rights could be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our licensors may have relied on third party consultants or collaborators or on funds from third parties such that our licensors
are not the sole and exclusive owners of the patents we <FONT STYLE="white-space:nowrap">in-license.</FONT> This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In spite of our best efforts, our licensors might conclude that we have materially breached
our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize drug products covered by these license agreements. If such licenses are terminated, we may be required seek
alternative <FONT STYLE="white-space:nowrap">in-license</FONT> arrangements, which may not be available on commercially reasonable terms or at all, or may be <FONT STYLE="white-space:nowrap">non-exclusive.</FONT> If these <FONT
STYLE="white-space:nowrap">in-licenses</FONT> are terminated, or if the underlying patents fail to provide the intended exclusivity, we may need to modify or cease the development, manufacture, and commercialization of one or more of our drug
candidates and competitors would have the freedom to seek regulatory approval of, and to market, products identical to ours. In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses,
we may agree to amend our existing licenses in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties (potentially including our competitors) to receive licenses to a portion of the
intellectual property that is subject to our existing licenses. Any of these events could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise
experience disruptions to our business relationships with our licensors, we could be required to pay monetary damages or could lose license rights that are important to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business relies, in large part, on our ability to develop and commercialize drug candidates we have licensed from third parties, and we
have entered into license agreements with third parties providing us with rights to various third-party intellectual property, including rights in patents and patent applications. Our licenses may not encumber all intellectual property rights owned
or controlled by the affiliates of our licensors and relevant to our drug candidates, and we may need to obtain additional licenses from our existing licensors and others to advance our research or allow commercialization of drug candidates we may
develop. In such case, we may need to obtain additional licenses which may not be available on an exclusive basis, on commercially reasonable terms or at a reasonable cost, if at all. In that event, we may be required to expend significant time and
resources to redesign our drug candidates or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to
develop or commercialize the affected drug candidates, which could harm our business, financial condition, results of operations, and prospects significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if our licensors breach the license agreements, we may not be able to enforce such agreements against our licensors&#146; parent
entity or affiliates. Under each of our license and intellectual property-related agreements, in exchange for licensing or sublicensing us the right to develop and commercialize the applicable drug candidates, our licensors will be eligible to
receive from us milestone payments, tiered royalties from commercial sales of such drug candidates, assuming relevant approvals from government authorities are obtained, or other payments. Our license and intellectual property-related agreements
also require us to comply with other obligations including development and diligence obligations, providing certain information regarding our activities with respect to such drug candidates and/or maintaining the confidentiality of information we
receive from our licensors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply with our obligations under our current or future license agreements, our counterparties
may have the right to terminate these agreements and, upon the effective date of such termination, have the right to <FONT STYLE="white-space:nowrap">re-obtain</FONT> the licensed and <FONT STYLE="white-space:nowrap">sub-licensed</FONT> technology
and intellectual property. If any of our licensors terminate any of our licenses, we might not be able to develop, manufacture or market any drug or drug candidate that is covered by the licenses provided for under these agreements and other third
parties may be able to market drug candidates similar or identical to ours. In such case, we may have to negotiate new or reinstated agreements with less favorable terms, and may be required to provide a grant back license to the licensors under our
own intellectual property with respect to the terminated products. We may also face claims for monetary damages or other penalties under these agreements. While we would expect to exercise all rights and remedies available to us, including seeking
to cure any breach by us, and otherwise seek to preserve our rights under the intellectual property rights licensed and sublicensed to us, we may not be able to do so in a timely manner, at an acceptable
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cost or at all. In particular, some of the milestone payments are payable upon our drug candidates reaching development milestones before we have commercialized, or received any revenue from,
sales of such drug candidate, and we cannot guarantee that we will have sufficient resources to make such milestone payments. Any uncured, material breach under the license agreements could result in our loss of exclusive rights and may lead to a
complete termination of our rights to the applicable drug candidate. Any of the foregoing could have a material adverse effect on our business, financial conditions, results of operations, and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible that we may be unable to obtain any additional licenses at a reasonable cost or on reasonable terms, if at all. Certain of our
license agreements also require us to meet development thresholds to maintain the license, including establishing a set timeline for developing and commercializing products. Disputes may arise regarding intellectual property subject to a license
agreement, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which our technology and processes infringe, misappropriate or violate intellectual property of the
licensor that is not subject to the license agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sublicensing of patent and other rights under our collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from
the joint creation or use of intellectual property by our licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the agreements under which we license intellectual property or technology from third parties are complex, and certain provisions
in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or
technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover,
if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected drug
candidates, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual
property rights do not necessarily protect us from all potential threats to our competitive advantage. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future
protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are
illustrative: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make compounds that are similar to our drug candidates but that are not covered by the
claims of the patents that we own or have exclusively licensed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we might not have been the first to make the inventions covered by the issued patents or pending patent
applications that we own or may in the future exclusively license, which could result in the patents applied for not being issued or being invalidated after issuing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we might not have been the first to file patent applications covering certain of our inventions, which could
result in the patents applied for not being issued or being invalidated after issuing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our intellectual property rights; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our pending patent applications will not lead to issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that we own or have exclusively licensed may not provide us with any competitive advantages, or
may be held invalid or unenforceable, as a result of legal challenges by our competitors or other third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may obtain patents for certain compounds many years before we receive regulatory approval for drugs containing
such compounds, and because patents have a limited life, which may begin to run prior to the commercial sale of the related drugs, the commercial value of our patents may be limited; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors might conduct research and development activities in countries where we do not have patent rights
and then use the information learned from such activities to develop competitive drugs for commercialization in our major markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may fail to develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may fail to apply for or obtain adequate intellectual property protection in all the jurisdictions in which we
operate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third parties may gain unauthorized access to our intellectual property due to potential lapses in our
information systems; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may have an adverse effect on our business, for example by preventing us from
commercializing one or more of our drug candidates for one or more indications. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of the aforementioned threats to
our competitive advantage could have a material adverse effect on our business and future prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names are not
adequately protected, we may not be able to build name recognition in our markets of interest and our competitive position may be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own registered trademarks. We may not be able to obtain trademark protection in territories that we consider of significant importance to
us. In addition, any of our trademarks or trade names, whether registered or unregistered, may be challenged, opposed, infringed, cancelled, circumvented or declared generic, or determined to be infringing on other marks, as applicable. We may not
be able to protect our rights to these trademarks and trade names, which we will need to build name recognition by potential collaborators or customers in our markets of interest. Over the long term, if we are unable to establish name recognition
based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Terms of our future
patents may not be sufficient to effectively protect our drug candidates and business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In many countries where we file
applications for patents, the term of an issued patent is generally 20 years from the earliest claimed filing date of a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application in the applicable country. Although various extensions
may be available, the life of a patent and the protection it affords are limited. Even if we obtain patents covering our drug candidates, we may still be open to competition from other companies, as well as generic medications once the patent life
has expired for a drug. While there are patent regulations in the PRC in respect of regulatory data protection of new drugs containing new chemical components, there are currently no other clear mechanisms providing patent term extension or patent
linkages for other drugs in the PRC. Therefore, it is possible that a lower-cost generic drug can emerge onto the market much more quickly. PRC regulators have set out a framework for integrating patent linkage and data exclusivity into the PRC
regulatory regime, as well as for establishing a pilot program for patent term extension. This framework will require adoption of regulations to be implemented, although no such regulations have been issued to date. These factors may result in
weaker protection for us against generic competition in the PRC than could be available to us in other jurisdictions, such as the United States. In addition, patents which we expect to obtain in the PRC may not be eligible to be extended for patent
terms lost during clinical trials and the regulatory review process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to obtain patent term extensions or if such extensions are less than
requested for, our competitors may obtain approval of competing products following our patent expirations and our business, financial condition, results of operations and prospects could be materially harmed as a result. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain additional protection under the Hatch-Waxman Amendments and similar legislation in other countries extending the terms of our
patents, if issued, relating to our drug candidates, our business may be materially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration
and specifics of FDA regulatory approval for our drug candidates, one or more of our U.S. patents, if issued, may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984 (the
&#147;Hatch-Waxman Amendments&#148;). The Hatch-Waxman Amendments permit a patent term extension of up to five years as compensation for patent term lost during drug development and the FDA regulatory review process. Patent term extensions, however,
cannot extend the remaining term of a patent beyond a total of 14&nbsp;years from the date of drug approval by the FDA, and only one patent can be extended for a particular drug. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The application for patent term extension is subject to approval by the USPTO, in conjunction with the FDA. We may not be granted an extension
because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent
protection afforded could be less than we request. If we are unable to obtain a patent term extension for a given patent or the term of any such extension is less than we request, the period during which we will have the right to exclusively market
our drug will be shortened and our competitors may obtain earlier approval of competing drugs, and our ability to generate revenues could be materially adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Industry, Business and Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to attract, retain and motivate senior management and qualified scientific employees. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are highly dependent on the expertise of the members of our research and development team, as well as the principal members of our
management. We have entered into employment letter agreements with our executive officers, but each of them may terminate their employment with us at any time with prior written notice. In addition, we currently do not have <FONT
STYLE="white-space:nowrap">&#147;key-man&#148;</FONT> insurance for any of our executive officers or other key personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recruiting, retaining and motivating qualified management, scientific, clinical, manufacturing and sales and marketing personnel will also be
critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement
our business strategy. Further, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required
to successfully develop, gain regulatory approval of and commercialize drugs. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the
competition among numerous biopharmaceutical companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, our management will be
required to devote significant time to new compliance initiatives from our status as a public company, which may require us to recruit more management personnel. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to increase the size and capabilities of our organization, and we may experience difficulties in managing our growth. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to experience significant growth in the number of our employees and consultants and the scope of our operations, particularly in the
areas of clinical development, regulatory affairs and business development. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train
additional qualified personnel. Due to our limited financial resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to
significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations, and have a material adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The data and information that we gather in our research and development process could be inaccurate or incomplete, which could harm our business,
reputation, financial condition and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We collect, aggregate, process, and analyze data and information from
our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, manufacturing technology development programs and clinical programs. We also engage in substantial information gathering following the identification of a promising drug candidate.
Because data in the healthcare industry is fragmented in origin, inconsistent in format, and often incomplete, the overall quality of data collected or accessed in the healthcare industry is often subject to challenge, the degree or amount of data
which is knowingly or unknowingly absent or omitted can be material, and we often discover data issues and errors when monitoring and auditing the quality of our data. If we make mistakes in the capture, input, or analysis of these data, our ability
to advance the development of our drug candidates may be materially harmed and our business, prospects and reputation may suffer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also
engage in the procurement of regulatory approvals necessary for the development and commercialization of our products under development, for which we manage and submit data to governmental entities. These processes and submissions are governed by
complex data processing and validation policies and regulations. Notwithstanding such policies and regulations, interim, <FONT STYLE="white-space:nowrap">top-line</FONT> or preliminary data from our clinical trials that we announce or publish from
time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data, in which case we may be exposed to liability to a customer, court or
government agency that concludes that our storage, handling, submission, delivery, or display of health information or other data was wrongful or erroneous. Although we maintain insurance coverage for clinical trials, this coverage may prove to be
inadequate or could cease to be available to us on acceptable terms, if at all. Even unsuccessful claims could result in substantial costs and diversion of management time, attention, and resources. A claim brought against us that is uninsured or
under-insured could harm our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we rely on CROs, our partners and
other third parties to monitor and manage data for some of our ongoing <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical programs and control only certain aspects of their activities. If any of our CROs, our partners or other third
parties does not perform to our standards in terms of data accuracy or completeness, data from those <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trials may be compromised as a result, and our reliance on these parties does not
relieve us of our regulatory responsibilities. For a detailed discussion, see &#147;&#151;Risks Related to Our Reliance on Third Parties&#151;As we rely on third parties to conduct our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and
clinical trials, if we lose our relationships with these third parties or if they do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug
candidates and our business could be substantially harmed&#148; above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to liability lawsuits arising from our clinical trials.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently carry liability insurance covering our clinical trials. Although we maintain such insurance, any claim that may be
brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or which is in excess of the limits of our insurance coverage. Our insurance policies also contain various
exclusions, and we may be subject to particular liability claims for which we have no coverage. We will have to pay any amount awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our
insurance, and we may not have, or be able to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obtain, sufficient capital to pay such amounts. In addition, if we cannot successfully defend ourselves against such claims, we may incur substantial liabilities and be required to suspend or
delay our ongoing clinical trials. Even a successful defense would require significant financial and management resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regardless of
the merits or eventual outcome, liability claims may result in significant negative consequences to our business and prospects, including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for our drug candidates or any resulting products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of other clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a diversion of our management&#146;s time and resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to commercialize our drug candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a decline in the market price of our ADSs. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have limited insurance coverage, and any claims beyond our insurance coverage may result in our incurring substantial costs and a diversion of
resources. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain insurance policies that are required under PRC laws and regulations as well as insurance based on our
assessment of our operational needs and industry practice. We also maintain liability insurance covering our clinical trials. In line with industry practice in the PRC, we have elected not to maintain certain types of insurances, such as business
interruption insurance or <FONT STYLE="white-space:nowrap">key-man</FONT> insurance. Our insurance coverage may be insufficient to cover any claim for product liability, damage to our fixed assets or employee injuries. Any liability or damage to, or
caused by, our facilities or our personnel beyond our insurance coverage may result in our incurring substantial costs and a diversion of resources. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disruptions in the financial markets and economic conditions could affect our ability to raise capital. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Global economies could suffer dramatic downturns as the result of a deterioration in the credit markets and related financial crisis as well as
a variety of other factors including, extreme volatility in security prices, severely diminished liquidity and credit availability, ratings downgrades of certain investments and declining valuations of others. In the past, governments have taken
unprecedented actions in an attempt to address and rectify these extreme market and economic conditions by providing liquidity and stability to the financial markets. If these actions are not successful, the return of adverse economic conditions may
cause a significant impact on our ability to raise capital, if needed, on a timely basis and on acceptable terms or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
there is considerable uncertainty over the long-term effects of the expansionary monetary and fiscal policies adopted by the central banks and financial authorities of some of the world&#146;s leading economies, including the United States and
China. There have been concerns over unrest and terrorist threats in the Middle East, Europe and Africa and over the conflicts involving Ukraine, Syria and North Korea. There have also been concerns on the relationship among China and other Asian
countries, which may result in or intensify potential conflicts in relation to territorial disputes or the trade related disputes between the United States and China. In addition, the U.K. held a referendum on June&nbsp;23, 2016 on its membership in
the European Union, in which a majority of voters in the U.K. voted to exit the European Union (commonly referred to as &#147;Brexit&#148;). The U.K.&#146;s departure from the European Union remains uncertain. Brexit could adversely affect European
and worldwide economic and market conditions and could contribute to instability in global financial and foreign exchange markets. It is unclear whether these challenges and uncertainties will be contained or resolved, and what effects they may have
on the global political and economic conditions in the long term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, consultants, commercial partners and vendors may engage in
misconduct or other improper activities, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of fraud, misconduct or other illegal activities by our employees, independent contractors, consultants, commercial
partners and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that fails to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">comply with the laws of the NMPA, the FDA and other comparable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide true, complete and accurate information to the NMPA, the FDA and other comparable regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">comply with manufacturing standards we have established; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">comply with healthcare fraud and abuse laws in the PRC, the United States and similar fraudulent misconduct laws
in other applicable jurisdictions; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">report financial information or data accurately or to disclose unauthorized activities to us.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, our founder, Dr.&nbsp;Jingwu Zhang Zang, was the corresponding author of a research paper prepared by
scientists at GSK China&#146;s research center and published in Nature Medicine in 2010. The paper was retracted in 2013 as a result of misrepresentation of certain data for which Dr.&nbsp;Zang admitted his management oversight. In addition,
Dr.&nbsp;Zang received a warning letter from the FDA in March 1999 relating to the lack of IND approval before the initiation of a clinical research study in human subjects. For details, please see &#147;Management&#151;Certain Past Incidents.&#148;
We cannot assure you that there will not be any inquiries, investigations or other actions against Dr.&nbsp;Zang by any regulatory or government authorities or any negative publicity against Dr.&nbsp;Zang or us regarding these incidents, any of
which could distract Dr.&nbsp;Zang and our management&#146;s attention and negatively affect our business and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
we obtain approval of any of our drug candidates and begin commercializing those drugs in the PRC, the United States or other applicable jurisdictions, our potential exposure under the laws of such jurisdictions will increase significantly and our
costs associated with compliance with such laws are also likely to increase. These laws may impact, among other things, our current activities with principal investigators and research patients, as well as future sales, marketing and education
programs. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and
other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally.
Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is not always possible to identify and deter misconduct by employees and other parties, and the precautions we take to detect and prevent
this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such
actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we engage in future acquisitions or strategic partnerships, this may increase our capital
requirements, dilute the value of your investment in our ADSs, cause us to incur debt or assume contingent liabilities, and subject us to other risks. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary products, intellectual property
rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased operating expenses and cash requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the assumption of additional indebtedness or contingent liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance of our equity securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assimilation of operations, intellectual property and products of an acquired company, including difficulties
associated with integrating new personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the diversion of our management&#146;s attention from our existing product programs and initiatives in pursuing
such a strategic merger or acquisition; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business
relationships; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks and uncertainties associated with the assimilation of operations, corporate culture and personnel of the
acquired business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that
party and its existing drugs or drug candidates and regulatory approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in
undertaking the acquisition or even to offset the associated acquisition and maintenance costs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in accounting principles relating to recognition and measurement of our investments that may have a
significant impact on our financial results. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if we undertake acquisitions, we may issue dilutive
securities, assume or incur debt obligations, incur large <FONT STYLE="white-space:nowrap">one-time</FONT> expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate
suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with applicable anti-bribery laws, our reputation may be harmed and we could be subject to penalties and significant expenses that
have a material adverse effect on our business, financial condition and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to anti-bribery laws
in China that generally prohibit companies and their intermediaries from making payments to government officials for the purpose of obtaining or retaining business or securing any other improper advantage. In addition, although currently our primary
operating business is in China, we are subject to the Foreign Corrupt Practices Act (the &#147;FCPA&#148;). The FCPA generally prohibits us from making improper payments to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> officials for the purpose
of obtaining or retaining business. Although we have policies and procedures designed to ensure that we, our employees and our agents comply with anti-bribery laws, there is no assurance that such policies or procedures will prevent our agents,
employees and intermediaries from engaging in bribery activities. Failure to comply with anti-bribery laws could disrupt our business and lead to severe criminal and civil penalties, including imprisonment, criminal and civil fines, loss of our
export licenses, suspension of our ability to do business with the government, denial of government reimbursement for our products and/or exclusion from participation in government healthcare programs. Other remedial measures could
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
include further changes or enhancements to our procedures, policies, and controls and potential personnel changes and/or disciplinary actions, any of which could have a material adverse effect on
our business, financial condition, results of operations and liquidity. We could also be adversely affected by any allegation that we violated such laws. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any failure to comply with applicable regulations and industry standards or obtain various licenses and permits could harm our reputation and our
business, results of operations and prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A number of governmental agencies or industry regulatory bodies in the PRC, the
United States and other applicable jurisdictions impose strict rules, regulations and industry standards governing biopharmaceutical research and development activities, which apply to us. Our or our CROs&#146; failure to comply with such
regulations could result in the termination of ongoing research, administrative penalties imposed by regulatory bodies or the disqualification of data for submission to regulatory authorities. This could harm our business, reputation, prospects for
future work and results of operations. For example, if we or our CROs were to treat research animals inhumanely or in violation of international standards set out by the Association for Assessment and Accreditation of Laboratory Animal Care, it
could revoke any such accreditation and the accuracy of our animal research data could be questioned. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we or our CROs or other contractors or
consultants fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and third parties, such as our CROs or other contractors or consultants, are subject to numerous environmental, health and safety laws and
regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and
radioactive and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these
materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with
civil or criminal fines and penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we
may incur due to injuries to our employees resulting from the use of or exposure to hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or
toxic tort claims that may be asserted against us in connection with our storage, use or disposal of biological, hazardous or radioactive materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may be required to incur substantial costs to comply with current or future environmental, health and safety laws and
regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we face allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with laws and encounter sanctions, our reputation, revenues and
liquidity may suffer, and our drug candidates and future drugs could be subject to restrictions or withdrawal from the market. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
government investigation of alleged violations of laws could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and
adversely affect our ability to commercialize and generate revenues from our drugs. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.
Additionally, if we are unable to generate revenues from our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product sales, our potential for achieving profitability will be diminished and the capital necessary to fund our operations will be increased. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our internal computer systems, or those used by our CROs or other contractors or consultants, may fail or suffer security breaches. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although to our knowledge we have not experienced any material system failure or security breach to date, if such an event were to occur and
cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in
our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we partially rely on our third-party research institution collaborators for research and development of our drug candidates and other
third parties for the manufacture of our drug candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate
disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our drug candidates could be delayed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to comply with existing or future laws and regulations related to privacy or data security could lead to government enforcement actions, which
could include civil or criminal fines or penalties, private litigation, other liabilities, and/or adverse publicity. Compliance or the failure to comply with such laws could increase the costs of our products and services, could limit their use or
adoption, and could otherwise negatively affect our operating results and business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulatory framework for the collection,
use, safeguarding, sharing, transfer and other processing of personal information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Regulatory authorities in virtually every jurisdiction in which we operate
have implemented and are considering a number of legislative and regulatory proposals concerning personal data protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory
authorities in China have implemented and are considering a number of legislative and regulatory proposals concerning data protection. For example, China&#146;s Cyber Security Law, which became effective in June 2017, created China&#146;s first
national-level data protection for &#147;network operators,&#148; which may include all organizations in China that provide services over the internet or another information network. Numerous regulations, guidelines and other measures are expected
to be adopted under the umbrella of the Cyber Security Law. Drafts of some of these measures have now been published, including the draft rules on cross-border transfers published by the China Cyberspace Administration in 2017, which may, upon
enactment, require security review before transferring human health-related data out of China. In addition, certain industry-specific laws and regulations affect the collection and transfer of personal data in China. For example, the PRC State
Council promulgated Regulations on the Administration of Human Genetic Resources in May 2019 and will become effective in July 2019, which require approval from the Science and Technology Administration Department of the State Council where human
genetic resources, or HGR, are involved in any international collaborative project and additional approval for any export or cross-border transfer of the HGR samples or associated data. It is possible that these laws may be interpreted and applied
in a manner that is inconsistent with our practices, potentially resulting in confiscation of HGR samples and associated data and administrative fines. In addition, the interpretation and application of data protection laws in China and elsewhere
are often uncertain and in flux. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, we are subject to laws and regulations that address privacy, personal information
protection and data security at both the federal and state levels. Numerous laws and regulations, including security breach notification laws, health information privacy laws, and consumer protection laws, govern the collection, use, disclosure and
protection of health-related and other personal information. Given the variability </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and evolving state of these laws, we face uncertainty as to the exact interpretation of the new requirements, and we may be unsuccessful in implementing all measures required by regulators or
courts in their interpretation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory authorities in Europe have implemented and are considering a number of legislative and
regulatory proposals concerning data protection. For example, the General Data Protection Regulation (EU) 2016/679, or GDPR, which became effective in May 2018, imposes a broad range of strict requirements on companies subject to the GDPR, such as
us, including, but not limited to, requirements relating to having legal bases for processing personal information relating to identifiable individuals and transferring such information outside the European Economic Area (including to the United
States), providing details to those individuals regarding the processing of their personal information, keeping personal information secure, having data processing agreements with third parties who process personal information, responding to
individuals&#146; requests to exercise their rights in respect of their personal information, reporting security breaches involving personal data to the competent national data protection authority and affected individuals, and recordkeeping. The
GDPR substantially increases the penalties to which we could be subject in the event of any <FONT STYLE="white-space:nowrap">non-compliance,</FONT> including fines of up to 10,000,000 Euros or up to 2% of our total worldwide annual turnover for
certain comparatively minor offenses, or up to 20,000,000 Euros or up to 4% of our total worldwide annual turnover for more serious offenses. Given the new law, we face uncertainty as to the exact interpretation of the new requirements, and we may
be unsuccessful in implementing all measures required by data protection authorities or courts in interpretation of the new law. National laws of member states of the European Union are in the process of being adapted to the requirements under the
GDPR. Because the GDPR specifically gives member states flexibility with respect to certain matters, national laws may partially deviate from the GDPR and impose different obligations from country to country, leading to additional complexity and
uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that we will continue to face uncertainty as to whether our efforts to comply with evolving obligations under
global data protection, privacy and security laws will be sufficient. Any failure or perceived failure by us to comply with applicable laws and regulations could result in reputational damage or proceedings or actions against us by governmental
entities, individuals or others. These proceedings or actions could subject us to significant civil or criminal penalties and negative publicity, result in the delayed or halted transfer or confiscation of certain personal information, require us to
change our business practices, increase our costs and materially harm our business, prospects, financial condition and results of operations. In addition, our current and future relationships with customers, vendors, pharmaceutical partners and
other third parties could be negatively affected by any proceedings or actions against us or current or future data protection obligations imposed on them under applicable law, including the GDPR. In addition, a data breach affecting personal
information, including health information, could result in significant legal and financial exposure and reputational damage that could potentially have an adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Natural disasters, acts of war or terrorism or other factors beyond our control may adversely affect the economy, infrastructure and livelihood
of the people in the regions where we conduct our business. Our operations may be under the threat of floods, earthquakes, sandstorms, snowstorms, fire or drought, power, water or fuel shortages, failures, malfunction and breakdown of information
management systems, unexpected maintenance or technical problems, or may be susceptible to potential wars or terrorist attacks. Serious natural disasters may result in loss of lives, injury, destruction of assets and disruption of our business and
operations. Acts of war or terrorism may also injure our employees, cause loss of lives, disrupt our business network and destroy our markets. Any of these factors and other factors beyond our control could have an adverse effect on the overall
business sentiment and environment, cause uncertainties in the regions where we conduct business, cause our business to suffer in ways that we cannot predict and materially and adversely impact our business, financial conditions and results of
operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have identified two material weaknesses in our internal controls, and if we fail to implement and
maintain an effective system of internal controls to remediate our material weaknesses over financial reporting, we may be unable to accurately report our results of operations, meet our reporting obligations or prevent fraud. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, we have been a private company with limited accounting personnel and other resources with which to address our internal
controls. In the course of auditing our consolidated financial statements, we and our independent registered public accounting firm identified two material weaknesses and control deficiencies in our internal control over financial reporting. As
defined in the standards established by the U.S. Public Company Accounting Oversight Board, a &#147;material weakness&#148; is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a
reasonable possibility that a material misstatement of the company&#146;s annual or interim financial statements will not be prevented or detected on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The material weaknesses that have been identified relate to (i)&nbsp;our lack of sufficient and competent financial reporting and accounting
personnel with appropriate knowledge of U.S. GAAP and the reporting and compliance requirements of the United States Securities and Exchange Commission, or the SEC, to formalize key controls over financial reporting and to prepare consolidated
financial statements and related disclosures; and (ii)&nbsp;our lack of sufficient documented financial closing policies and procedures, specifically those related to (a)&nbsp;accounting for licensing and collaboration agreements and (b)&nbsp;period
end expenses <FONT STYLE="white-space:nowrap">cut-off</FONT> and accruals. These material weaknesses, if not timely remedied, may lead to significant misstatements in our consolidated financial statements in the future. Following the identification
of the material weaknesses and other control deficiencies, we have taken measures and plan to continue to take measures to remediate these deficiencies. See &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#151;Internal Control over Financial Reporting.&#148; However, the implementation of those measures may not fully remediate the material weaknesses in a timely manner. Our failure to correct these deficiencies or our failure to discover
and address any other deficiencies could result in inaccuracies in our financial statements and impair our ability to comply with applicable financial reporting requirements and related regulatory filings on a timely basis. Moreover, ineffective
internal control over financial reporting could significantly hinder our ability to prevent fraud. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering,
we will become subject to the Sarbanes-Oxley Act of 2002. Section&nbsp;404 of the Sarbanes-Oxley Act, or Section&nbsp;404, requires that we include a report from management on the effectiveness of our internal control over financial reporting in our
annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> beginning with our annual report for the fiscal year ending December&nbsp;31, 2020. In addition, once we cease to be an &#147;emerging growth company&#148; as defined in the JOBS
Act, our independent registered public accounting firm must attest to and report on the effectiveness of our internal control over financial reporting. Our management may conclude that our internal control over financial reporting is not effective.
Moreover, even if our management concludes that our internal control over financial reporting is effective, our independent registered public accounting firm, after conducting its own independent testing, may issue an adverse report if it is not
satisfied with our internal controls or the level at which our controls are documented, designed, operated or reviewed, or if it interprets the relevant requirements differently from us. In addition, once we have become a public company, our
reporting obligations may place a significant strain on our management, operational and financial resources and systems for the foreseeable future. We may be unable to timely complete our evaluation testing and any required remediation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the course of documenting and testing our internal control procedures, in order to satisfy the requirements of Section&nbsp;404, we may
identify other weaknesses and deficiencies in our internal control over financial reporting. In addition, if we fail to maintain the adequacy of our internal control over financial reporting, as these standards are modified, supplemented or amended
from time to time, we may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting in accordance with Section&nbsp;404. If we fail to establish and maintain adequate internal controls, we could
suffer material misstatements in our financial statements and fail to meet our reporting obligations, which would likely cause investors to lose confidence in our reported financial information. This could limit our access to capital markets,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adversely affect our results of operations and lead to a decline in the trading price of the ADSs. Additionally, ineffective internal controls could expose us to an increased risk of fraud or
misuse of corporate assets and subject us to potential delisting from the stock exchange on which we list or to other regulatory investigations and civil or criminal sanctions. We could also be required to restate our historical financial
statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our auditor, like other independent registered public accounting firms operating in China, is not permitted to be subject to inspection
by Public Company Accounting Oversight Board, and consequently investors may be deprived of the benefits of such inspection. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
auditor, the independent registered public accounting firm that issued the audit report included elsewhere in this registration statement, as an auditor of companies that are traded publicly in the United States and a firm registered with the Public
Company Accounting Oversight Board (United States), or PCAOB, is subject to laws in the United States pursuant to which the PCAOB conducts regular inspections to assess its compliance with applicable professional standards. Our auditor is located
in, and organized under the laws of, the PRC, which is a jurisdiction where the PCAOB, has been unable to conduct inspections without the approval of the Chinese authorities. In May 2013, PCAOB announced that it had entered into a Memorandum of
Understanding on Enforcement Cooperation with the CSRC and the PRC Ministry of Finance, which establishes a cooperative framework between the parties for the production and exchange of audit documents relevant to investigations undertaken by PCAOB,
the CSRC or the PRC Ministry of Finance in the United States and the PRC, respectively. PCAOB continues to be in discussions with the China Securities Regulatory Commission, or CSRC, and the PRC Ministry of Finance to permit joint inspections in
China of audit firms that are registered with PCAOB and audit Chinese companies that trade on U.S. exchanges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December 7, 2018, the
SEC and the PCAOB issued a joint statement highlighting continued challenges faced by the U.S. regulators in their oversight of financial statement audits of U.S.-listed companies with significant operations in China. However, it remains unclear
what further actions, if any, the SEC and PCAOB will take to address the problem. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This lack of PCAOB inspections in China prevents the
PCAOB from fully evaluating audits and quality control procedures of our independent registered public accounting firm. As a result, we and investors in our ordinary shares are deprived of the benefits of such PCAOB inspections. The inability of the
PCAOB to conduct inspections of auditors in China makes it more difficult to evaluate the effectiveness of our independent registered public accounting firm&#146;s audit procedures or quality control procedures as compared to auditors outside of
China that are subject to PCAOB inspections, which could cause investors and potential investors in our stock to lose confidence in our audit procedures and reported financial information and the quality of our financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Proceedings instituted by the SEC against &#147;big four&#148; PRC-based accounting firms, including our independent registered public accounting firm,
could result in financial statements being determined to not be in compliance with the requirements of the Exchange Act. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Starting
in 2011 &#147;big four&#148; PRC-based accounting firms, including our independent registered public accounting firm, were affected by a conflict between U.S. and Chinese law. Specifically, for certain U.S.-listed companies operating and audited in
mainland China, the SEC and the PCAOB sought to obtain from the Chinese firms access to their audit work papers and related documents. The firms were, however, advised and directed that under Chinese law, they could not respond directly to the U.S.
regulators on those requests, and that requests by foreign regulators for access to such papers in China had to be channeled through the CSRC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In late 2012, this impasse led the SEC to commence administrative proceedings under Rule 102(e) of its Rules of Practice and also under the
Sarbanes-Oxley Act of 2002 against the Chinese accounting firms, including our independent registered public accounting firm. A first instance trial of the proceedings in July 2013 in the SEC&#146;s internal administrative court resulted in an
adverse judgment against the firms. The administrative law </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
judge proposed penalties on the firms including a temporary suspension of their right to practice before the SEC, although that proposed penalty did not take effect pending review by the
Commissioners of the SEC. On February 6, 2015, before a review by the Commissioner had taken place, the firms reached a settlement with the SEC. Under the settlement, the SEC accepted that future requests by the SEC for the production of documents
will normally be made to the CSRC. The firms were to receive matching Section 106 requests, and were required to abide by a detailed set of procedures with respect to such requests, which in substance require them to facilitate production via the
CSRC. If they failed to meet specified criteria, the SEC retained authority to impose a variety of additional remedial measures on the firms depending on the nature of the failure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the settlement, the underlying proceeding against the four China-based accounting firms was deemed dismissed with prejudice
four years after entry of the settlement. The four-year mark occurred on February 6, 2019. While we cannot predict if the SEC will further challenge the four China-based accounting firms&#146; compliance with U.S. law in connection with U.S.
regulatory requests for audit work papers or if the results of such a challenge would result in the SEC imposing penalties such as suspensions. If additional remedial measures are imposed on the &#147;big four&#148; PRC-based accounting firms,
including our independent registered public accounting firm, we could be unable to timely file future financial statements in compliance with the requirements of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event the &#147;big four&#148; PRC-based accounting firms become subject to additional legal challenges by the SEC or PCAOB, depending
upon the final outcome, listed companies in the United States with major PRC operations may find it difficult or impossible to retain auditors in respect of their operations in China, which could result in financial statements being determined to
not be in compliance with the requirements of the Exchange Act, including possible delisting. Moreover, any negative news about any such future proceedings against these audit firms may cause investor uncertainty regarding China-based, U.S.-listed
companies and the market price of our common stock may be adversely affected. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our independent registered public accounting firm
was denied, even temporarily, the ability to practice before the SEC and we were unable to timely find another registered public accounting firm to audit and issue an opinion on our financial statements, our financial statements could be determined
not to be in compliance with the requirements of the Exchange Act. Such a determination could ultimately lead to the delisting of the ADSs from the Nasdaq Global Market or deregistration from the SEC, or both, which would substantially reduce or
effectively terminate the trading of the ADSs in the United States. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our reputation is important to our business success. Negative publicity
may adversely affect our reputation and business prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any negative publicity concerning us, our affiliates or any entity
that shares the <FONT STYLE="white-space:nowrap">&#147;I-Mab&#148;</FONT> name, even if untrue, could adversely affect our reputation and business prospects. There can be no assurance that negative publicity about us or any of our affiliates or any
entity that shares the <FONT STYLE="white-space:nowrap">&#147;I-Mab&#148;</FONT> name would not damage our brand image or have a material adverse effect on our business, results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Negative publicity with respect to us, our management, employees, business partners, affiliates, or our industry, may materially and adversely affect
our reputation, business, results of operations and prospect. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our reputation is vulnerable to many threats that can be difficult
or impossible to control, and costly or impossible to remediate. Negative publicity about us, such as alleged misconduct or improper activities, or negative rumors relating to us, our management, employees, business partners or affiliates, can harm
our business and results of operations, even if they are unsubstantiated or are satisfactorily addressed. For example, a number of media reported that our founder, Dr.&nbsp;Jingwu Zhang Zang, was involved in misrepresentation of certain data in a
research paper prepared by scientists at GSK China&#146;s research center and published in Nature Medicine in 2010, for which Dr.&nbsp;Zang was the corresponding author, and consequently Dr.&nbsp;Zang was dismissed by GSK in 2013. In addition,
Dr.&nbsp;Zang received a warning letter from the FDA in March 1999 relating to the lack of IND </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval before the initiation of a clinical research study in human subjects. For details, please see &#147;Management&#151;Certain Past Incidents.&#148; To the best of our knowledge,
Dr.&nbsp;Zang was not and is not subject to any legal or regulatory charges, proceedings or disciplinary actions in connection with these incidents. However, we cannot assure you that there will not be any inquiries, investigations or other actions
against Dr.&nbsp;Zang by any regulatory or government authorities in the future. Any regulatory inquiries or investigations or other actions against Dr.&nbsp;Zang or our other management, any perceived unethical, fraudulent, or inappropriate
business conduct by us or perceived wrong doing by any key member of our management team or other employees, our business partners or our affiliates, could harm our reputation and materially adversely affect our business. Regardless of the merits or
final outcome of any such regulatory inquiries or investigations or other actions, our reputation may be substantially damaged, which may impede our ability to attract and retain talents and business partners and grow our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, any negative media publicity about the biopharmaceutical industry in general or product or service quality problems of other
companies in the industry, including our peers, may also negatively impact our reputation. If we are unable to maintain a good reputation, our ability to attract and retain key employees and business partners could be harmed which in turn may
materially and adversely affect our business, results of operations and prospect. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Change in business prospects of acquisitions may result in
impairment to our goodwill, which could negatively affect our reported results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We acquired a controlling interest
in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin in July 2017 and the remaining interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin in May 2018. In connection with our acquisition of
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin, we identified RMB148.8&nbsp;million of intangible assets and RMB162.6&nbsp;million of goodwill of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin attributable to core technology and
synergy effects expected from combining the operation of the discovery and development of innovative biologics and the development of clinical stage biologics. We are required to test our goodwill annually, or more frequently if events or changes in
circumstances indicate that it might be impaired. Goodwill is allocated to cash-generating units or groups of cash-generating units for the purpose of impairment testing. An impairment loss of goodwill is recognized for the amount by which the
relevant cash-generating unit&#146;s or group of cash-generating unit&#146;s carrying amount exceeds its recoverable amount, and we would be required to write down the carrying value of our goodwill during the period in which it is determined to be
impaired, which would materially and adversely affect our results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to changing law and regulations regarding
regulatory matters, corporate governance and public disclosure that have increased both our costs and the risk of <FONT STYLE="white-space:nowrap">non-compliance.</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are or will be subject to rules and regulations by various governing bodies, including, for example, once we have become a public company,
the SEC, which is charged with the protection of investors and the oversight of companies whose securities are publicly traded, and the various regulatory authorities in China and the Cayman Islands, and to new and evolving regulatory measures under
applicable law. Our efforts to comply with new and changing laws and regulations have resulted in and are likely to continue to result in, increased general and administrative expenses and a diversion of management time and attention from
revenue-generating activities to compliance activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, because these laws, regulations and standards are subject to varying
interpretations, their application in practice may evolve over time as new guidance becomes available. This evolution may result in continuing uncertainty regarding compliance matters and additional costs necessitated by ongoing revisions to our
disclosure and governance practices. If we fail to address and comply with these regulations and any subsequent changes, we may be subject to penalty and our business may be harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Doing Business in China </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The pharmaceutical industry in China is highly regulated and such regulations are subject to change which may affect approval and commercialization of
our drugs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development operations and manufacturing facilities are in China, which we believe confers clinical,
commercial and regulatory advantages. The pharmaceutical industry in China is subject to comprehensive government regulation and supervision, encompassing the approval, registration, manufacturing, packaging, licensing and marketing of new drugs.
See &#147;Regulation&#148; for a discussion of the regulatory requirements that are applicable to our current and planned business activities in China. In recent years, the regulatory framework in China regarding the pharmaceutical industry has
undergone significant changes, and we expect that it will continue to undergo significant changes. Any such changes or amendments may result in increased compliance costs on our business or cause delays in or prevent the successful development or
commercialization of our drug candidates in China and reduce the current benefits we believe are available to us from developing and manufacturing drugs in China. PRC authorities have become increasingly vigilant in enforcing laws in the
pharmaceutical industry and any failure by us or our partners to maintain compliance with applicable laws and regulations or obtain and maintain required licenses and permits may result in the suspension or termination of our business activities in
China. We believe our strategy and approach are aligned with the PRC government&#146;s regulatory policies, but we cannot ensure that our strategy and approach will continue to be aligned. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in the political and economic policies of the PRC government may materially and adversely affect our business, financial condition and results
of operations and may result in our inability to sustain our growth and expansion strategies.</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A significant portion of our
operations are in China. Our financial condition and results of operations are affected to a large extent by economic, political and legal developments in China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PRC economy differs from the economies of most developed countries in many respects, including the extent of government involvement, level
of development, growth rate, control of foreign exchange and allocation of resources. Although the PRC government has implemented measures emphasizing the utilization of market forces for economic reform, the reduction of state ownership of
productive assets, and the establishment of improved corporate governance in business enterprises, a substantial portion of productive assets in China is still owned by the government. In addition, the PRC government continues to play a significant
role in regulating industrial development by imposing industrial policies. The PRC government also exercises significant control over China&#146;s economic growth by allocating resources, controlling payment of foreign currency-denominated
obligations, setting monetary policy, regulating financial services and institutions and providing preferential treatment to particular industries or companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the PRC economy has experienced significant growth in the past four decades, growth has been uneven, both geographically and among
various sectors of the economy. The PRC government has implemented various measures to encourage economic growth and guide the allocation of resources. Some of these measures may benefit the overall PRC economy, but may also have a negative effect
on us. Our business, financial condition and results of operations could be materially and adversely affected by government control over capital investments or changes in tax regulations that are applicable to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the PRC government had, in the past, implemented certain measures, including interest rate increases, to control the pace of
economic growth. These measures may cause decreased economic activity in China, which may adversely affect our business and results of operations. More generally, if the business environment in China deteriorates from the perspective of domestic or
international investment, our business in China may also be adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There are uncertainties regarding the interpretation and enforcement of PRC laws, rules and
regulations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary business is governed by PRC laws and regulations. Our primary business operation is supervised by
relevant regulatory authorities in China. The PRC legal system is a civil law system based on written statutes and, unlike the common law system, prior court decisions can only be cited as reference and have limited precedential value. Additionally,
written statutes in the PRC are often principle-oriented and require detailed interpretations by the enforcement bodies to further apply and enforce such laws. Since 1979, the PRC government has developed a comprehensive system of laws, rules and
regulations in relation to economic matters, such as foreign investment, corporate organization and governance, commerce, taxation and trade. However, the interpretation and enforcement of these laws, rules and regulations involve uncertainties and
may not be as consistent or predictable as in other more developed jurisdictions. As these laws and regulations are continually evolving in response to changing economic and other conditions, and because of the limited volume of published cases and
their <FONT STYLE="white-space:nowrap">non-binding</FONT> nature, any particular interpretation of PRC laws and regulations may not be definitive. Moreover, we cannot predict the effect of future developments in the PRC legal system and regulatory
structure. Such unpredictability towards our contractual, property and procedural rights as well as our rights licensed, approved or granted by the competent regulatory authority could adversely affect our business and impede our ability to continue
our operations. In addition, the PRC legal system is based in part on government policies and internal rules, some of which are not published on a timely basis, if at all, and which may have a retroactive effect. Hence, we may not be aware of
violation of these policies and rules until after such violation has occurred. Further, the legal protections available to us and our investors under these laws, rules and regulations may be limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, any administrative or court proceedings in China may be protracted, resulting in substantial costs and diversion of resources and
management attention. Since PRC administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be more difficult to evaluate the outcome of administrative and court
proceedings and the level of legal protection we enjoy than in more developed legal systems. These uncertainties may impede our ability to enforce various contracts we have entered into and could materially and adversely affect our business,
financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience difficulties in effecting service of legal process, enforcing foreign judgments
or bringing actions in China against us or our management named in the prospectus based on foreign laws. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a company
incorporated under the laws of the Cayman Islands, we conduct substantially all of our operations in China and substantially all of our assets are located in China. In addition, all our senior executive officers reside within China for a significant
portion of the time and some of them are PRC nationals. As a result, it may be difficult for you to effect service of process upon us or those persons inside China. It may also be difficult for you to enforce in U.S. courts judgments obtained in
U.S. courts based on the civil liability provisions of the U.S. federal securities laws against us and our officers and directors as none of them currently resides in the United States or has substantial assets located in the United States. In
addition, there is uncertainty as to whether the courts of the Cayman Islands or the PRC would recognize or enforce judgments of U.S. courts against us or such persons predicated upon the civil liability provisions of the securities laws of the
United States or any state. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The recognition and enforcement of foreign judgments are provided for under the PRC Civil Procedures Law. PRC
courts may recognize and enforce foreign judgments in accordance with the requirements of the PRC Civil Procedures Law based either on treaties between China and the country where the judgment is made or on principles of reciprocity between
jurisdictions. China does not have any treaties or other forms of written arrangement with the United States that provide for the reciprocal recognition and enforcement of foreign judgments. In addition, according to the PRC Civil Procedures Law,
the PRC courts will not enforce a foreign judgment against us or our directors and officers if they decide that the judgment violates the basic principles of PRC laws or national sovereignty, security or the public interest. As a result, it is
uncertain whether and on what basis a PRC court would enforce a judgment rendered by a court in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be restricted from transferring our scientific data abroad. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;17, 2018, the General Office of the PRC State Council promulgated the Measures for the Management of Scientific Data, or the
Scientific Data Measures, which provide a broad definition of scientific data and relevant rules for the management of scientific data. According to the Scientific Data Measures, enterprises in China must seek governmental approval before any
scientific data involving a state secret may be transferred abroad or to foreign parties. Further, any researcher conducting research funded, at least in part, by the PRC government is required to submit relevant scientific data for management by
the entity to which such researcher is affiliated before such data may be published in any foreign academic journal. Currently, as the term &#147;state secret&#148; is not clearly defined, there is no assurance that we can always obtain relevant
approvals for sending scientific data (such as the results of our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials conducted within China) abroad, or to our foreign partners in China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to obtain the necessary approvals in a timely manner, or at all, our research and development of drug candidates may be
hindered, which may materially and adversely affect our business, results of operations, financial conditions and prospects. If relevant government authorities consider the transmission of our scientific data to be in violation of the requirements
under the Scientific Data Measures, we may be subject to specific administrative penalties imposed by those government authorities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in U.S.
and international trade policies, particularly with regard to China, may adversely impact our business and operating results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
U.S. government has recently made statements and taken certain actions that may lead to potential changes to U.S. and international trade policies, including imposing several rounds of tariffs affecting certain products manufactured in China. In
March 2018, U.S. President Donald J. Trump announced the imposition of tariffs on steel and aluminum entering the United States and in June 2018 announced further tariffs targeting goods imported from China. Recently both China and the U.S. have
each imposed tariffs indicating the potential for further trade barriers. It is unknown whether and to what extent new tariffs (or other new laws or regulations) will be adopted, or the effect that any such actions would have on us or our industry.
While we have not started commercialization of drug candidates, any unfavorable government policies on international trade, such as capital controls or tariffs, may affect the demand for our drug products, the competitive position of our drug
products, the hiring of scientists and other research and development personnel, and import or export of raw materials in relation to drug development, or prevent us from selling our drug products in certain countries. If any new tariffs,
legislation and/or regulations are implemented, or if existing trade agreements are renegotiated or, in particular, if the U.S. government takes retaliatory trade actions due to the recent U.S.-China trade tension, such changes could have an adverse
effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are classified as a PRC resident enterprise for PRC income tax
purposes, such classification could result in unfavorable tax consequences to us and our <FONT STYLE="white-space:nowrap">non-PRC</FONT> shareholders or ADS holders. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the PRC Enterprise Income Tax Law and its implementation rules, an enterprise established outside of the PRC with &#147;de facto
management body&#148; within China is considered a &#147;resident enterprise&#148; and will be subject to the enterprise income tax on its global income at the rate of 25%. The implementation rules define the term &#147;de facto management
body&#148; as the body that exercises full and substantial control and overall management over the business, productions, personnel, accounts and properties of an enterprise. In 2009, the SAT issued the Circular of the State Administration of
Taxation on Issues Relating to Identification of <FONT STYLE="white-space:nowrap">PRC-Controlled</FONT> Overseas Registered Enterprises as Resident Enterprises in Accordance With the De Facto Standards of Organizational Management, or Circular 82,
which provides certain specific criteria for determining whether the &#147;de facto management body&#148; of a <FONT STYLE="white-space:nowrap">PRC-controlled</FONT> enterprise that is incorporated offshore is located in China. Although this
Circular only applies to offshore enterprises controlled by PRC enterprises or PRC enterprise groups, not those controlled by PRC individuals or foreigners, the criteria set forth in the circular may reflect the SAT&#146;s general position on how
the &#147;de facto management body&#148; text should be applied in determining the tax resident </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
status of all offshore enterprises. According to Circular 82, an offshore incorporated enterprise controlled by a PRC enterprise or a PRC enterprise group will be regarded as a PRC tax resident
by virtue of having its &#147;de facto management body&#148; in China and will be subject to PRC enterprise income tax on its global income if all of the following conditions are met: (i)&nbsp;the primary location of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operational management is in China; (ii)&nbsp;decisions relating to the enterprise&#146;s financial and human resource matters are made or are subject to approval
by organizations or personnel in China; (iii)&nbsp;the enterprise&#146;s primary assets, accounting books and records, company seals, and board and shareholder resolutions, are located or maintained in China; and (iv)&nbsp;at least 50% of voting
board members or senior executives habitually reside in China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our PRC counsel, JunHe LLP, has advised us that, based on its
understanding of the current PRC Laws and Regulations, I-Mab should not be considered as a PRC resident enterprise for PRC tax income purposes. However, the tax resident status of an enterprise is subject to determination by the PRC tax authorities
and uncertainties remain with respect to the interpretation of the term &#147;de facto management body.&#148; If the PRC tax authorities determine that we are a PRC resident enterprise for enterprise income tax purposes, we could be subject to PRC
tax at a rate of 25% on our worldwide income, which could materially reduce our net income, and we may be required to withhold a 10% withholding tax from dividends we pay to our shareholders that are
<FONT STYLE="white-space:nowrap">non-resident</FONT> enterprises (including the holders of our ADSs). In addition, <FONT STYLE="white-space:nowrap">non-resident</FONT> enterprise shareholders (including our ADS holders) may be subject to PRC tax on
gains realized on the sale or other disposition of ADSs or ordinary shares, if such income is treated as sourced from within China. Furthermore, if we are deemed a PRC resident enterprise, dividends payable to our
<FONT STYLE="white-space:nowrap">non-PRC</FONT> individual shareholders (including our ADS holders) and any gain realized on the transfer of ADSs or ordinary shares by such shareholders may be subject to PRC tax at a rate of 10% in the case of <FONT
STYLE="white-space:nowrap">non-PRC</FONT> enterprises or a rate of 20% in the case of <FONT STYLE="white-space:nowrap">non-PRC</FONT> individuals unless a reduced rate is available under an applicable tax treaty. It is unclear whether <FONT
STYLE="white-space:nowrap">non-PRC</FONT> shareholders of our company would be able to claim the benefits of any tax treaties between their country of tax residence and the PRC in the event that we are treated as a PRC resident enterprise. Any such
tax may reduce the returns on your investment in the ADSs or ordinary shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to renew our current leases or locate desirable alternatives
for our leased properties could materially and adversely affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We lease properties for our offices and
laboratories. We may not be able to successfully extend or renew such leases upon expiration of the current term on commercially reasonable terms or at all, and may therefore be forced to relocate our affected operations. This could disrupt our
operations and result in significant relocation expenses, which could adversely affect our business, financial condition and results of operations. In addition, we compete with other businesses for premises at certain locations or of desirable
sizes. As a result, even though we could extend or renew our leases, rental payments may significantly increase as a result of the high demand for the leased properties. In addition, we may not be able to locate desirable alternative sites for our
current leased properties as our business continues to grow and failure in relocating our affected operations could adversely affect our business and operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain of our leasehold interests in leased properties have not been registered with the relevant PRC governmental authorities as required by relevant
PRC laws. The failure to register leasehold interests may expose us to potential fines. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not registered certain of our
lease agreements with the relevant government authorities. Under the relevant PRC laws and regulations, we may be required to register and file with the relevant government authority executed leases. The failure to register the lease agreements for
our leased properties will not affect the validity of these lease agreements, but the competent housing authorities may order us to register the lease agreements in a prescribed period of time and impose a fine ranging from RMB1,000 to RMB10,000 for
each non-registered lease if we fail to complete the registration within the prescribed timeframe. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have granted, and may continue to grant, options and other types of awards under our share
incentive plans, which may result in increased share-based compensation expenses. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted an Amended and Restated 2017
Employee Stock Option Plan (the &#147;2017 Plan&#148;) and a 2018 Employee Stock Option Plan (the &#147;2018 Plan&#148;), for the purpose of granting share-based compensation awards to employees, directors and consultants to incentivize their
performance and align their interests with ours. We recognize expenses in our consolidated financial statements in accordance with U.S. GAAP. As of the date of this prospectus, options to purchase a total of 9,859,381 ordinary shares and 13,536,588
ordinary shares have been granted and outstanding under the 2017 Plan and 2018 Plan, respectively. See &#147;Management&#151;Share Incentive Plans.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the granting of share-based compensation is of significant importance to our ability to attract and retain key personnel and
employees, and we will continue to grant share-based compensation to employees in the future. As a result, our expenses associated with share-based compensation may increase, which may have an adverse effect on our results of operations. We <FONT
STYLE="white-space:nowrap">may&nbsp;re-evaluate&nbsp;the</FONT> vesting <FONT STYLE="white-space:nowrap">schedules,&nbsp;lock-up&nbsp;period,</FONT> exercise price or other key terms applicable to the grants under our currently effective share
incentive plans from time to time. If we choose to do so, we may experience substantial change in our share-based compensation charges in the reporting periods following this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fluctuations in exchange rates could have a material and adverse effect on our results of operations and the value of your investment. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The value of RMB against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in political and
economic conditions in China and by China&#146;s foreign exchange policies. On July&nbsp;21, 2005, the PRC government changed its <FONT STYLE="white-space:nowrap">decade-old</FONT> policy of pegging the value of RMB to the U.S. dollar, and RMB
appreciated more than 20% against the U.S. dollar over the following three years. Between July 2008 and June 2010, this appreciation halted and the exchange rate between RMB and the U.S. dollar remained within a narrow band. Since June 2010, RMB has
fluctuated against the U.S. dollar, at times significantly and unpredictably. On November&nbsp;30, 2015, the Executive Board of the International Monetary Fund completed the regular five-year review of the basket of currencies that make up the
Special Drawing Right, or the SDR, and decided that with effect from October&nbsp;1, 2016, RMB is determined to be a freely usable currency and will be included in the SDR basket as a fifth currency, along with the U.S. dollar, the Euro, the
Japanese yen and the British pound. In the fourth quarter of 2016, RMB has depreciated significantly in the backdrop of a surging U.S. dollar and persistent capital outflows of China. This depreciation halted in 2017, and RMB appreciated
approximately 7% against the U.S. dollar during this <FONT STYLE="white-space:nowrap">one-year</FONT> period. With the development of the foreign exchange market and progress towards interest rate liberalization and RMB internationalization, the PRC
government may in the future announce further changes to the exchange rate system, and we cannot assure you that RMB will not appreciate or depreciate significantly in value against the U.S. dollar in the future. It is difficult to predict how
market forces or PRC or U.S. government policy may impact the exchange rate between RMB and the U.S. dollar in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant
revaluation of RMB may have a material and adverse effect on your investment. For example, to the extent that we need to convert U.S. dollars we receive from this offering into RMB for our operations, appreciation of RMB against the U.S. dollar
would have an adverse effect on the RMB amount we would receive from the conversion. Conversely, if we decide to convert our RMB into U.S. dollars for the purpose of making payments for dividends on our ordinary shares or ADSs or for other business
purposes, appreciation of the U.S. dollar against RMB would have a negative effect on the U.S. dollar amount available to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Very
limited hedging options are available in China to reduce our exposure to exchange rate fluctuations. To date, we have not entered into any hedging transactions in an effort to reduce our exposure to foreign currency exchange risk. While we may
decide to enter into hedging transactions in the future, the availability and effectiveness of these hedges may be limited and we may not be able to adequately hedge our exposure or at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
In addition, our currency exchange losses may be magnified by PRC exchange control regulations that restrict our ability to convert RMB into foreign currency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the PRC government imposes controls on the convertibility of RMB into foreign currencies and, in certain cases, the remittance of
currency out of China. We receive substantially all of our revenues in RMB. Under our current corporate structure, our Cayman Islands holding company primarily relies on dividend payments from our PRC subsidiary to fund any cash and financing
requirements we may have. Under existing PRC foreign exchange regulations, payments of current account items, including profit distributions, interest payments and trade and service-related foreign exchange transactions, can be made in foreign
currencies without prior approval of the State Administration of Foreign Exchange, or SAFE, by complying with certain procedural requirements. Specifically, under the existing exchange restrictions, without prior approval of SAFE, cash generated
from the operations of our PRC subsidiaries in China may be used to pay dividends to our company. However, approval from or registration with appropriate government authorities is required where RMB is to be converted into foreign currency and
remitted out of China to pay capital expenses, such as the repayment of loans denominated in foreign currencies. As a result, we need to obtain SAFE approval to use cash generated from the operations of our PRC subsidiaries to pay off their
respective debt in a currency other than RMB owed to entities outside China, or to make other capital expenditure payments outside China in a currency other than RMB. In light of the flood of capital outflows of China, the PRC government may from
time to time impose more restrictive foreign exchange policies and step up scrutiny of major outbound capital movement. More restrictions and a substantial vetting process may be required by SAFE or other government authorities to regulate
cross-border transactions falling under the capital account. The PRC government may at its discretion restrict access to foreign currencies for current account transactions in the future. If the foreign exchange control system prevents us from
obtaining sufficient foreign currencies to satisfy our foreign currency demands, we may not be able to pay dividends in foreign currencies to our shareholders, including holders of our ADSs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain PRC regulations may make it more difficult for us to pursue growth through acquisitions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Regulations on Mergers and Acquisitions of Domestic Enterprises by Foreign Investors, or the M&amp;A Rules, adopted by six PRC regulatory
agencies in 2006 and amended in 2009, established additional procedures and requirements that could make merger and acquisition activities by foreign investors more time-consuming and complex. Such regulation requires, among other things, that the
Ministry of Commerce, or MOFCOM, be notified in advance of any change of control transaction in which a foreign investor acquires control of a PRC domestic enterprise and involves any of the following circumstances: (i)&nbsp;any important industry
is concerned; (ii)&nbsp;such transaction involves factors that impact or may impact national economic security; or (iii)&nbsp;such transaction will lead to a change in control of a domestic enterprise which holds a famous trademark or PRC
time-honored brand. We do not expect that this offering will trigger MOFCOM <FONT STYLE="white-space:nowrap">pre-notification</FONT> under each of the above-mentioned circumstances or any review by other PRC government authorities, except as
disclosed below in &#147;&#151;The approval of the CSRC may be required in connection with this offering, and, if required, we cannot predict whether we will be able to obtain such approval.&#148; Moreover, the Anti-Monopoly Law promulgated by the
Standing Committee of National People&#146;s Congress which became effective in 2008 requires that transactions which are deemed concentrations and involve parties with specified turnover thresholds must be cleared by State Administration for Market
Regulation (the &#147;SAMR&#148;), the successive authority of MOFCOM, before they can be completed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may rely on dividends and other
distributions on equity paid by our PRC subsidiaries to fund any cash and financing requirements we may have, and any limitation on the ability of our PRC subsidiaries to make payments to us could have a material and adverse effect on our ability to
conduct our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a Cayman Islands holding company and we may rely on dividends and other distributions on equity paid
by our PRC subsidiaries for our cash and financing requirements, including the funds necessary to pay dividends and other cash distributions to our shareholders and service any debt we may incur. If any of our PRC subsidiaries incur debt on its own
behalf in the future, the instruments governing the debt may restrict their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ability to pay dividends or make other distributions to us. Under PRC laws and regulations, our PRC subsidiaries, each of which is a wholly foreign-owned enterprise may pay dividends only out of
its respective accumulated profits as determined in accordance with PRC accounting standards and regulations. In addition, a wholly foreign-owned enterprise is required to set aside at least 10% of its
<FONT STYLE="white-space:nowrap">after-tax</FONT> profits each year, if any, to fund a certain statutory reserve fund, until the aggregate amount of such fund reaches 50% of its registered capital. At its discretion, a wholly foreign-owned
enterprise may allocate a portion of its <FONT STYLE="white-space:nowrap">after-tax</FONT> profits based on PRC accounting standards to a staff welfare and bonus fund. The reserve fund and staff welfare and bonus fund cannot be distributed to us as
dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our PRC subsidiaries generate primarily all of their revenue in RMB, which is not freely convertible into other currencies. As
result, any restriction on currency exchange may limit the ability of our PRC subsidiaries to use their RMB revenues to pay dividends to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PRC government may continue to strengthen its capital controls, and more restrictions and a substantial vetting process may be put forward
by SAFE for cross-border transactions falling under both the current account and the capital account. Any limitation on the ability of our PRC subsidiaries to pay dividends or make other kinds of payments to us could materially and adversely limit
our ability to grow, make investments or acquisitions that could be beneficial to our business, pay dividends, or otherwise fund and conduct our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the PRC Enterprise Income Tax Law and its implementation rules provide that a withholding tax rate of up to 10% will be
applicable to dividends payable by PRC companies to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-PRC-resident</FONT></FONT> enterprises unless otherwise exempted or reduced according to treaties or arrangements between the
PRC central government and governments of other countries or regions where the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-PRC-resident</FONT></FONT> enterprises are incorporated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>PRC regulations relating to offshore investment activities by PRC residents may limit our PRC subsidiaries&#146; ability to change their registered
capital or distribute profits to us or otherwise expose us or our PRC resident beneficial owners to liability and penalties under PRC laws. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2014, SAFE promulgated the Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents&#146; Offshore
Investment and Financing and Roundtrip Investment Through Special Purpose Vehicles, or SAFE Circular 37. SAFE Circular 37 requires PRC residents (including PRC individuals and PRC corporate entities as well as foreign individuals that are deemed as
PRC residents for foreign exchange administration purpose) to register with SAFE or its local branches in connection with their direct or indirect offshore investment activities. SAFE Circular 37 further requires amendment to the SAFE registrations
in the event of any changes with respect to the basic information of the offshore special purpose vehicle, such as changes of a PRC individual shareholder, name and operation term, or any significant changes with respect to the offshore special
purpose vehicle, such as increase or decrease of capital contribution, share transfer or exchange, or mergers or divisions. SAFE Circular 37 is applicable to our shareholders who are PRC residents. If our shareholders who are PRC residents fail to
make the required registration or to update the previously filed registration, our PRC subsidiaries may be prohibited from distributing their profits or the proceeds from any capital reduction, share transfer or liquidation to us, and we may also be
prohibited from making additional capital contributions into our PRC subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2015, SAFE promulgated a Notice on Further
Simplifying and Improving Foreign Exchange Administration Policy on Direct Investment, or SAFE Notice 13, effective June 2015. Under SAFE Notice 13, applications for foreign exchange registration of inbound foreign direct investments and outbound
overseas direct investments, including those required under SAFE Circular 37, will be filed with qualified banks instead of SAFE. The qualified banks will directly examine the applications and accept registrations under the supervision of SAFE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our shareholders who we are aware of being subject to the SAFE regulations have completed the initial registrations with the local SAFE
branch or qualified banks as required by SAFE Circular 37. However, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we may not be informed of the identities of all the PRC residents holding direct or indirect interests in our company, and we cannot provide any assurance that these PRC residents will comply
with our request to make or obtain any applicable registrations or continuously comply with all requirements under SAFE Circular 37 or other related rules. The failure or inability of the relevant shareholders to comply with the registration
procedures set forth in these regulations may subject us to fines and legal sanctions, such as restrictions on our cross-border investment activities, on the ability of our wholly foreign-owned subsidiaries in China to distribute dividends and the
proceeds from any reduction in capital, share transfer or liquidation to us. Moreover, failure to comply with the various foreign exchange registration requirements described above could result in liability under PRC law for circumventing applicable
foreign exchange restrictions. As a result, our business operations and our ability to distribute profits could be materially and adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any failure to comply with PRC regulations regarding our employee equity incentive plans may subject the PRC plan participants or us to fines and other
legal or administrative sanctions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our directors, executive officers and other employees who are PRC citizens or who have
resided in China for a continuous period of not less than one year and who will be granted restricted shares or options are subject to the Notice on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating in
Stock Incentive Plan of Overseas Publicly Listed Company, issued by SAFE in February 2012, according to which, employees, directors, supervisors and other management members participating in any share incentive plan of an overseas publicly listed
company who are PRC citizens or who are <FONT STYLE="white-space:nowrap">non-PRC</FONT> citizens residing in China for a continuous period of not less than one year, subject to limited exceptions, are required to register with SAFE through a
domestic qualified agent, which could be a PRC subsidiary of such overseas listed company, and complete certain other procedures. In addition, an overseas entrusted institution must be retained to handle matters in connection with the exercise or
sale of stock options and the purchase or sale of shares and interests. Failure to complete the SAFE registrations may subject them to fines and legal sanctions and may also limit our ability to make payments under our equity incentive plans or
receive dividends or sales proceeds related thereto, or our ability to contribute additional capital into our wholly foreign-owned enterprises in China and limit our wholly foreign-owned enterprises&#146; ability to distribute dividends to us. We
also face regulatory uncertainties that could restrict our ability to adopt additional equity incentive plans for our directors and employees under PRC law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the SAT has issued circulars concerning employee share options or restricted shares. Under these circulars, employees working in
China who exercise share options, or whose restricted shares vest, will be subject to PRC individual income tax. The PRC subsidiaries of an overseas listed company have obligations to file documents related to employee share options or restricted
shares with relevant tax authorities and to withhold individual income taxes of those employees related to their share options or restricted shares. If the employees fail to pay, or the PRC subsidiaries fail to withhold applicable income taxes, the
PRC subsidiaries may face sanctions imposed by the tax authorities or other PRC government authorities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>PRC regulation of loans to and direct
investment in PRC entities by offshore holding companies and governmental control of currency conversion may delay or prevent us from using the proceeds of this offering to make loans to our PRC subsidiaries in China, which could materially and
adversely affect our liquidity and our ability to fund and expand our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an offshore holding company conducting our
operations in China through our PRC subsidiaries. We may make loans to our PRC subsidiaries subject to the approval from governmental authorities and limitation on the available loan amount, or we may make additional capital contributions to our
wholly foreign-owned subsidiaries in China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any loans to our wholly foreign-owned subsidiaries in China, which are treated as
foreign-invested enterprises under PRC law, are subject to PRC regulations and foreign exchange loan registrations. For example, loans by us to our wholly foreign-owned subsidiaries in China to finance their activities cannot exceed statutory
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limits and must be registered with the local counterpart of SAFE. In addition, a foreign-invested enterprise shall use its capital pursuant to the principle of authenticity and <FONT
STYLE="white-space:nowrap">self-use</FONT> within its business scope. The capital of a foreign-invested enterprise shall not be used for the following purposes: (i)&nbsp;directly or indirectly used for payment beyond the business scope of the
enterprises or the payment prohibited by relevant laws and regulations; (ii)&nbsp;directly or indirectly used for investment in securities or investments other than banks&#146; principal-secured products unless otherwise provided by relevant laws
and regulations; (iii)&nbsp;the granting of loans to <FONT STYLE="white-space:nowrap">non-affiliated</FONT> enterprises, except where it is expressly permitted in the business license; and (iv)&nbsp;paying the expenses related to the purchase of
real estate that is not for <FONT STYLE="white-space:nowrap">self-use</FONT> (except for the foreign-invested real estate enterprises). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SAFE promulgated the Notice of the State Administration of Foreign Exchange on Reforming the Administration of Foreign Exchange Settlement of
Capital of Foreign-invested Enterprises, or SAFE Circular 19, effective June 2015, in replacement of the Circular on the Relevant Operating Issues Concerning the Improvement of the Administration of the Payment and Settlement of Foreign Currency
Capital of Foreign-Invested Enterprises, the Notice from the State Administration of Foreign Exchange on Relevant Issues Concerning Strengthening the Administration of Foreign Exchange Businesses, and the Circular on Further Clarification and
Regulation of the Issues Concerning the Administration of Certain Capital Account Foreign Exchange Businesses. According to SAFE Circular 19, the flow and use of RMB capital converted from foreign currency-denominated registered capital of a
foreign-invested company is regulated such that RMB capital may not be used for the issuance of RMB entrusted loans, the repayment of inter-enterprise loans or the repayment of banks loans that have been transferred to a third party. Although SAFE
Circular 19 allows RMB capital converted from foreign currency-denominated registered capital of a foreign-invested enterprise to be used for equity investments within China, it also reiterates the principle that RMB converted from the foreign
currency-denominated capital of a foreign-invested company may not be directly or indirectly used for purposes beyond its business scope. Thus, it is unclear whether SAFE will permit such capital to be used for equity investments in China in actual
practice. SAFE promulgated the Notice of the State Administration of Foreign Exchange on Reforming and Standardizing the Foreign Exchange Settlement Management Policy of Capital Account, or SAFE Circular 16, effective on June&nbsp;9, 2016, which
reiterates some of the rules set forth in SAFE Circular 19, but changes the prohibition against using RMB capital converted from foreign currency-denominated registered capital of a foreign-invested company to issue RMB entrusted loans to a
prohibition against using such capital to issue loans to <FONT STYLE="white-space:nowrap">non-associated</FONT> enterprises. Violations of SAFE Circular 19 and SAFE Circular 16 could result in administrative penalties. SAFE Circular 19 and SAFE
Circular 16&nbsp;may significantly limit our ability to transfer any foreign currency we hold, including the net proceeds from this offering, to our PRC subsidiaries, which may adversely affect our liquidity and our ability to fund and expand our
business in China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In light of the various requirements imposed by PRC regulations on loans to and direct investment in PRC entities by
offshore holding companies, we cannot assure you that we will be able to complete the necessary government registrations or obtain the necessary government approvals on a timely basis, if at all, with respect to future loans to our PRC subsidiaries
or future capital contributions by us to our wholly foreign-owned subsidiaries in China. As a result, uncertainties exist as to our ability to provide prompt financial support to our PRC subsidiaries when needed. If we fail to complete such
registrations or obtain such approvals, our ability to use the proceeds we expect to receive from this offering and to capitalize or otherwise fund our PRC operations may be negatively affected, which could materially and adversely affect our
liquidity and our ability to fund and expand our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We and our shareholders face uncertainties with respect to indirect transfers of equity
interests in PRC resident enterprises or other assets attributable to a PRC establishment of a <FONT STYLE="white-space:nowrap">non-PRC</FONT> company. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;3, 2015, the SAT issued the Bulletin on Issues of Enterprise Income Tax and Indirect Transfers of Assets by <FONT
STYLE="white-space:nowrap">Non-PRC</FONT> Resident Enterprises, or Bulletin 7. Pursuant to this Bulletin, an &#147;indirect transfer&#148; of &#147;PRC taxable assets,&#148; including equity interests in a PRC resident enterprise, by <FONT
STYLE="white-space:nowrap">non-PRC</FONT> resident enterprises may be recharacterized and treated as a direct transfer of PRC taxable assets, if such arrangement does not have a reasonable commercial purpose and was established for the purpose of
avoiding payment of PRC enterprise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
income tax. As a result, gains derived from such indirect transfer may be subject to PRC enterprise income tax. When determining whether there is a &#147;reasonable commercial purpose&#148; of
the transaction arrangement, factors to be taken into consideration include: whether the main value of the equity interest of the relevant offshore enterprise derives from PRC taxable assets; whether the assets of the relevant offshore enterprise
mainly consist of direct or indirect investment in China or if its income mainly derives from China; whether the offshore enterprise and its subsidiaries directly or indirectly holding PRC taxable assets have real commercial nature which is
evidenced by their actual function and risk exposure; the duration of existence of the business model and organizational structure; the replicability of the transaction by direct transfer of PRC taxable assets; and the tax situation of such indirect
transfer and applicable tax treaties or similar arrangements. On October&nbsp;17, 2017, the SAT issued the Announcement of the State Administration of Taxation on Issues Concerning the Withholding of
<FONT STYLE="white-space:nowrap">Non-resident</FONT> Enterprise Income Tax at Source, or Bulletin 37, which came into effect on December&nbsp;1, 2017. Bulletin 37 further clarifies the practice and procedure of the withholding of non-resident
enterprise income tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Late payment of applicable tax will subject the transferor to default interest. Gains derived from the sale of
shares by investors are not subject to the PRC enterprise income tax pursuant to Bulletin 7 where such shares were acquired in a transaction through a public stock exchange. However, the sale of ADSs or ordinary shares by a <FONT
STYLE="white-space:nowrap">non-PRC</FONT> resident enterprise outside a public stock exchange may be subject to PRC enterprise income tax under Bulletin 7. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are uncertainties as to the application of Bulletin 7. Bulletin 7&nbsp;may be determined by the tax authorities to be applicable to the
sale of the shares of our offshore subsidiaries or investments where PRC taxable assets are involved. The transferors and transferees may be subject to the tax filing and withholding or tax payment obligation, while our PRC subsidiaries may be
requested to assist in the filing. Furthermore, we, our <FONT STYLE="white-space:nowrap">non-resident</FONT> enterprises and PRC subsidiaries may be required to spend valuable resources to comply with Bulletin 7 or to establish that we and our <FONT
STYLE="white-space:nowrap">non-resident</FONT> enterprises should not be taxed under Bulletin 7, for our previous and future restructuring or disposal of shares of our offshore subsidiaries, which may have a material adverse effect on our financial
condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PRC tax authorities have the discretion under Bulletin 7 to make adjustments to the taxable
capital gains based on the difference between the fair value of the taxable assets transferred and the cost of investment. If the PRC tax authorities make adjustments to the taxable income of the transactions under Bulletin 7 / Bulletin 37, our
income tax costs associated with such potential acquisitions or disposals will increase, which may have an adverse effect on our financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The approval of the CSRC may be required in connection with this offering, and, if required, we cannot predict whether we will be able to obtain such
approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The M&amp;A Rules require overseas special purpose vehicles that are controlled by PRC companies or individuals and
formed for the purpose of seeking a public listing on an overseas stock exchange through acquisitions of PRC domestic companies using shares of such special purpose vehicles or held by its shareholders as consideration to obtain the approval of the
CSRC, prior to the listing and trading of such special purpose vehicle&#146;s securities on an overseas stock exchange. However, the application of the M&amp;A Rules remains unclear. If CSRC approval is required, it is uncertain whether it would be
possible for us to obtain the approval, and any failure to obtain or delay in obtaining CSRC approval for this offering would subject us to sanctions imposed by the CSRC and other PRC regulatory agencies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our PRC counsel has advised us based on their understanding of the current PRC laws, rules and regulations that the CSRC&#146;s approval may
not be required for the listing and trading of our ADSs on the Nasdaq Stock Market in the context of this offering, given that: (i)&nbsp;the CSRC currently has not issued any definitive rule or interpretation concerning whether offerings like ours
in this prospectus are subject to this regulation, <FONT STYLE="white-space:nowrap">(ii)&nbsp;I-Mab</FONT> Tianjin was not acquired by a connected merger or by acquisition of equity interest or assets of a PRC domestic
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
company owned by PRC companies or individuals as defined under the M&amp;A Rules and <FONT STYLE="white-space:nowrap">(iii)&nbsp;I-Mab</FONT> Shanghai was incorporated as a wholly foreign-owned
enterprise by means of direct investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, our PRC counsel has further advised us that there remain some uncertainties as to how
the M&amp;A Rules will be interpreted or implemented in the context of an overseas offering and its opinions summarized above are subject to any new laws, rules and regulations or detailed implementations and interpretations in any form relating to
the M&amp;A Rules. We cannot assure you that relevant PRC government agencies, including the CSRC, would reach the same conclusion as we do. If it is determined that CSRC approval is required for this offering, we may face sanctions by the CSRC or
other PRC regulatory agencies for failure to seek CSRC approval for this offering. These sanctions may include fines and penalties on our operations in China, limitations on our operating privileges in China, delays in or restrictions on the
repatriation of the proceeds from this offering into the PRC, restrictions on or prohibition of the payments or remittance of dividends by our subsidiaries in China, or other actions that could have a material and adverse effect on our business,
financial condition, results of operations, reputation and prospects, as well as the trading price of our ADSs. The CSRC or other PRC regulatory agencies may also take actions requiring us, or making it advisable for us, to halt this offering before
the settlement and delivery of the ADSs that we are offering. Consequently, if you engage in market trading or other activities in anticipation of and prior to the settlement and delivery of the ADSs we are offering, you would be doing so at the
risk that the settlement and delivery may not occur. In addition, if the CSRC or other regulatory agencies later promulgate new rules or explanations requiring that we obtain their approvals for this offering, we may be unable to obtain a waiver of
such approval requirements, if and when procedures are established to obtain such a waiver. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent litigation and negative publicity surrounding
China-based companies listed in the U.S. may result in increased regulatory scrutiny of us and negatively impact the trading price of the ADSs and could have a material adverse effect upon our business, including our results of operations, financial
condition, cash flows and prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that litigation and negative publicity surrounding companies with operations in
China that are listed in the U.S. have negatively impacted stock prices for such companies. Various equity-based research organizations have published reports on China-based companies after examining, among other things, their corporate governance
practices, related party transactions, sales practices and financial statements that have led to special investigations and stock suspensions on national exchanges. Any similar scrutiny of us, regardless of its lack of merit, could result in a
diversion of management resources and energy, potential costs to defend ourselves against rumors, decreases and volatility in the ADS trading price, and increased directors and officers insurance premiums and could have a material adverse effect
upon our business, including our results of operations, financial condition, cash flows and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our ADSs and This Offering
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There has been no public market for our shares or ADSs prior to this offering, and you may not be able to resell our ADSs at or above the price
you paid, or at all. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this initial public offering, there has been no public market for our shares or ADSs. We will
apply to list our ADSs on the Nasdaq Stock Market. Our shares will not be listed on any exchange or quoted for trading on any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> trading system. If an
active trading market for our ADSs does not develop after this offering, the market price and liquidity of our ADSs will be materially and adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Negotiations with the underwriters will determine the initial public offering price for our ADSs which may bear no relationship to their
market price after the initial public offering. We cannot assure you that an active trading market for our ADSs will develop or that the market price of our ADSs will not decline below the initial public offering price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The trading price of our ADSs may be volatile, which could result in substantial losses to you.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading price of our ADSs can be volatile and fluctuate widely in response to a variety of factors, many of which are beyond
our control. In addition, the performance and fluctuation of the market prices of other companies with business operations located mainly in the PRC that have listed their securities in the United&nbsp;States may affect the volatility in the price
of and trading volumes for our ADSs. Some of these companies have experienced significant volatility. The trading performances of these PRC companies&#146; securities may affect the overall investor sentiment towards other PRC companies listed in
the United States and consequently may impact the trading performance of our ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to market and industry factors, the price
and trading volume for our ADSs may be highly volatile for specific business reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of regulatory approval or a complete response letter, or specific label indications or patient
populations for a drug&#146;s use, or changes or delays in the regulatory review process; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of therapeutic innovations, new products, acquisitions, strategic relationships, joint ventures or
capital commitments by us or our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse actions taken by regulatory agencies with respect to our clinical trials, manufacturing supply chain or
sales and marketing activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any adverse changes to our relationship with manufacturers or suppliers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of our testing and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of our efforts to acquire or license additional drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in the level of expenses related to our existing drugs and drug candidates or <FONT
STYLE="white-space:nowrap">pre-clinical,</FONT> clinical development and commercialization programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any intellectual property infringement actions in which we may become involved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements concerning our competitors or the pharmaceutical industry in general; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fluctuations in product revenue, sales and marketing expenses and profitability; manufacture, supply or
distribution shortages; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in our results of operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements about our results of operations that are not in line with analyst expectations, the risk of which
is enhanced because it is our policy not to give guidance on results of operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publication of operating or industry metrics by third parties, including government statistical agencies, that
differ from expectations of industry or financial analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in financial estimates by securities research analysts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">media reports, whether or not true, about our business, our competitors or our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or departures of our management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fluctuations of exchange rates between the RMB and the U.S. dollar; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">release or expiry of <FONT STYLE="white-space:nowrap">lock-up</FONT> or other transfer restrictions on our
outstanding ordinary shares or ADSs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales or perceived potential sales of additional ordinary shares or ADSs by us, our executive officers and
directors or our shareholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic and market conditions and overall fluctuations in the U.S. equity markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in accounting principles; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes or developments in the PRC or global regulatory environment. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the stock market, in general, and pharmaceutical and biotechnology companies
have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our ADSs,
regardless of our actual operating performance. Further, the current volatility in the financial markets and related factors beyond our control may cause the market price of our ADSs to decline rapidly and unexpectedly. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>After the completion of this offering, we may face an increased risk of securities class action litigation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, securities class action litigation has often been brought against a company following a significant decline in the market price
of its securities. This risk is especially relevant for us because biotechnology and biopharmaceutical companies have experienced significant share price volatilities in recent years. If we were to face lawsuits, it could lead to substantial costs
and a distraction of management&#146;s attention and resources, which could harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish
research or publish inaccurate or unfavorable research about our business, or if they adversely change their recommendations regarding our ADSs, the market price for our ADSs and trading volume could decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our ADSs will depend in part on the research and reports that securities or industry analysts publish about us or our
business. If research analysts do not establish and maintain adequate research coverage or if one or more of the analysts who covers us downgrades our ADSs or publishes inaccurate or unfavorable research about our business, the market price for our
ADSs would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which, in turn, could cause the market price or trading volume
for our ADSs to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because our initial public offering price is substantially higher than our net tangible book value per share, you will
experience immediate and substantial dilution. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you purchase ADSs in this offering, you will pay more for your ADSs than the
amount paid by our existing shareholders for their ordinary shares on a per ADS basis. As a result, you will experience immediate and substantial dilution of
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS, representing the difference between the initial public offering price of
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS and our adjusted net tangible book value per ADS as of December&nbsp;31, 2018, after giving effect to our sale of the ADSs offered in this
offering. In addition, you may experience further dilution to the extent that our ordinary shares are issued upon the exercise of share options. See &#147;Dilution&#148; for a more complete description of how the value of your investment in the ADSs
will be diluted upon completion of this&nbsp;offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we do not expect to pay dividends in the foreseeable future after this offering, you
must rely on price appreciation of our ADSs for return on your investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently intend to retain most, if not all, of our
available funds and any future earnings after this offering to fund the development and growth of our business. As a result, we do not expect to pay any cash dividends in the foreseeable future. Therefore, you should not rely on an investment in our
ADSs as a source for any future dividend income. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has complete discretion as to whether to distribute dividends,
subject to certain requirements of Cayman Islands law. In addition, our shareholders may by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our directors. Under Cayman Islands law, a Cayman Islands
company may pay a dividend out of either profit or share premium account of the company, provided that in no circumstances may a dividend be paid out of share premium if this would result in the company being unable to pay its debts as they fall due
in the ordinary course of business. Even if our board of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
directors decides to declare and pay dividends, the timing, amount and form of future dividends, if any, will depend on our future results of operations and cash flow, our capital requirements
and surplus, the amount of distributions, if any, received by us from our subsidiaries, our financial condition, contractual restrictions and other factors deemed relevant by our board of directors. Accordingly, the return on your investment in our
ADSs will likely depend entirely upon any future price appreciation of our ADSs. There is no guarantee that our ADSs will appreciate in value after this offering or even maintain the price at which you purchased the ADSs. You may not realize a
return on your investment in our ADSs and you may even lose your entire investment in our ADSs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Substantial future sales or perceived potential
sales of our ADSs in the public market could cause the price of our ADSs to decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of our ADSs in the public market after
this offering, or the perception that these sales could occur, could cause the market price of our ADSs to decline. Upon completion of this offering, we will have
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issued and outstanding, including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
ordinary shares represented by ADSs, assuming the underwriters do not exercise their over-allotment option. All ADSs sold in this offering will be freely transferable without restriction or additional registration under the United States Securities
Act of 1933, as amended, or the Securities Act. The remaining ordinary shares issued and outstanding after this offering will be available for sale, upon the expiration of the <FONT STYLE="white-space:nowrap">[180]-day</FONT> <FONT
STYLE="white-space:nowrap">lock-up</FONT> period beginning from the date of this prospectus, subject to volume and other restrictions as applicable under Rules 144 and 701 under the Securities Act. Any or all of these shares may be released prior to
the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period at the discretion of the representatives of the underwriters of this offering. To the extent shares are released before the expiration of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> period and sold into the market, the market price of our ADSs could decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After
completion of this offering, certain holders of our ordinary shares may cause us to register under the Securities Act the sale of their shares, subject to the <FONT STYLE="white-space:nowrap">[180]-day</FONT>
<FONT STYLE="white-space:nowrap">lock-up</FONT> period in connection with this offering. Registration of these shares under the Securities Act would result in ADSs representing these shares becoming freely tradable without restriction under the
Securities Act immediately upon the effectiveness of the registration. Sales of these registered shares in the form of ADSs in the public market could cause the price of our ADSs to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The voting rights of holders of ADSs are limited by the terms of the deposit agreement, and you may not be able to exercise the same rights as our
shareholders. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of ADSs do not have the same rights as our shareholders. As a holder of our ADSs, you will not have any
direct right to attend general meetings of our shareholders or to cast any votes at such meetings. As an ADS holder, you will only be able to exercise the voting rights carried by the underlying ordinary shares indirectly by giving voting
instructions to the depositary in accordance with the provisions of the deposit agreement. Under the deposit agreement, you may vote only by giving voting instructions to the depositary. Upon receipt of your voting instructions, the depositary will
try, as far as is practicable, to vote the ordinary shares underlying your ADSs in accordance with your instructions. If we ask for your instructions, then upon receipt of your voting instructions, the depositary will try to vote the underlying
ordinary shares in accordance with these instructions. If we do not instruct the depositary to ask for your instructions, the depositary may still vote in accordance with instructions you give, but it is not required to do so. You will not be able
to directly exercise your right to vote with respect to the underlying ordinary shares unless you withdraw the shares, and become the registered holder of such shares prior to the record date for the general meeting. When a general meeting is
convened, you may not receive sufficient advance notice of the meeting to withdraw the shares underlying your ADSs and become the registered holder of such shares to allow you to attend the general meeting and to vote directly with respect to any
specific matter or resolution to be considered and voted upon at the general meeting. In addition, under our post-offering memorandum and articles of association that will become effective prior to completion of this offering, for the purposes of
determining those shareholders who are entitled to attend and vote at any general meeting, our directors may close our register of members and/or fix in advance a record date for such meeting, and such closure of our register of members or the
setting of such a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
record date may prevent you from withdrawing the ordinary shares underlying your ADSs and becoming the registered holder of such shares prior to the record date, so that you would not be able to
attend the general meeting or to vote directly. If we ask for your instructions, the depositary will notify you of the upcoming vote and will arrange to deliver our voting materials to you. We have agreed to give the depositary notice of shareholder
meetings sufficiently in advance of such meetings. Nevertheless, we cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote the underlying ordinary shares represented by your ADSs.
In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for their manner of carrying out your voting instructions. This means that you may not be able to exercise your right to direct how the
shares underlying your ADSs are voted and you may have no legal remedy if the shares underlying your ADSs are not voted as you requested. In addition, in your capacity as an ADS holder, you will not be able to call a shareholders&#146; meeting.
Except in limited circumstances, the depositary for our ADSs will give us a discretionary proxy to vote the ordinary shares underlying your ADSs if you do not vote at shareholders&#146; meetings, which could adversely affect your interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[Under the deposit agreement for the ADSs, if you do not vote, the depositary will give us a discretionary proxy to vote the ordinary shares
underlying your ADSs at shareholders&#146; meetings unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have instructed the depositary that we do not wish a discretionary proxy to be given; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have informed the depositary that there is substantial opposition as to a matter to be voted on at the
meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a matter to be voted on at the meeting would have a material adverse impact on shareholders; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the voting at the meeting is to be made on a show of hands.] </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The effect of this discretionary proxy is that you cannot prevent our ordinary shares underlying your ADSs from being voted, except under the
circumstances described above. This may make it more difficult for shareholders to influence the management of our company. Holders of our ordinary shares are not subject to this discretionary proxy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Your right to participate in any future rights offerings may be limited, which may cause dilution to your holdings. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may from time to time distribute rights to our shareholders, including rights to acquire our securities. However, we cannot make rights
available to you in the United States unless we register both the rights and the securities to which the rights relate under the Securities Act or an exemption from the registration requirements is available. Under the deposit agreement, the
depositary will not make rights available to you unless both the rights and the underlying securities to be distributed to ADS holders are either registered under the Securities Act or exempt from registration under the Securities Act. We are under
no obligation to file a registration statement with respect to any such rights or securities or to endeavor to cause such a registration statement to be declared effective and we may not be able to establish a necessary exemption from registration
under the Securities Act. Accordingly, you may be unable to participate in our rights offerings and may experience dilution in your holdings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You
may not receive cash dividends if the depositary decides it is impractical to make them available to you. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary will pay
cash dividends on the ADSs only to the extent that we decide to distribute dividends on our ordinary shares or other deposited securities, and we do not have any present plan to pay any cash dividends on our ordinary shares in the foreseeable
future. To the extent that there is a distribution, the depositary of our ADSs has agreed to pay to you the cash dividends or other distributions it or the custodian receives on our ordinary shares or other deposited securities after deducting its
fees and expenses. You will receive these distributions in proportion to the number of ordinary shares your ADSs represent. However, the depositary may, at its discretion, decide that it is inequitable or impractical to make a distribution available
to any holders of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ADSs. For example, the depositary may determine that it is not practicable to distribute certain property through the mail, or that the value of certain distributions may be less than the cost of
mailing them. In these cases, the depositary may decide not to distribute such property to you. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may be subject to limitations on transfer of
your ADSs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Your ADSs are transferable on the books of the depositary. However, the depositary may close its transfer books at any
time or from time to time when it deems expedient in connection with the performance of its duties. The depositary may close its books from time to time for a number of reasons, including in connection with corporate events such as a rights
offering, during which time the depositary needs to maintain an exact number of ADS holders on its books for a specified period. The depositary may also close its books in emergencies, and on weekends and public holidays. In addition, the depositary
may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary deems it advisable to do so because of any requirement of law or of any
government or governmental body, or under any provision of the deposit agreement, or for any other reason. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain judgments obtained against us by
our shareholders may not be enforceable. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an exempted company incorporated under the laws of the Cayman Islands. We conduct
our operations in China and substantially all of our assets are located in China. In addition, our directors and executive officers, and some of the experts named in this prospectus, reside within China, and most of the assets of these persons are
located within China. As a result, it may be difficult or impossible for you to bring an action against us or against these individuals in the United States in the event that you believe that your rights have been infringed under the U.S. federal
securities laws or otherwise. Even if you are successful in bringing an action of this kind, the laws of the Cayman Islands and of the PRC may render you unable to enforce a judgment against our assets or the assets of our directors and officers.
For more information regarding the relevant laws of the Cayman Islands and China, see &#147;Enforceability of Civil Liabilities.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ADSs holders
may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes to the plaintiff(s) in any such action. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The deposit agreement governing the ADSs representing our ordinary shares provides that, subject to the depositary&#146;s right to require a
claim to be submitted to arbitration, the federal or state courts in the City of New&nbsp;York have exclusive jurisdiction to hear and determine claims arising under the deposit agreement and in that regard, to the fullest extent permitted by law,
ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our shares, the ADSs or the deposit agreement, including any claim under the U.S. federal securities laws. Also, we may
amend or terminate the deposit agreement without your consent. If you continue to hold your ADSs after an amendment to the deposit agreement, you agree to be bound by the deposit agreement as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable based on
the facts and circumstances of that case in accordance with the applicable U.S. state and federal law. To our knowledge, the enforceability of a contractual <FONT STYLE="white-space:nowrap">pre-dispute</FONT> jury trial waiver in connection with
claims arising under the U.S. federal securities laws has not been finally adjudicated by the United States Supreme Court. However, we believe that a contractual <FONT STYLE="white-space:nowrap">pre-dispute</FONT> jury trial waiver provision is
generally enforceable, including under the laws of the State of New York, which govern the deposit agreement. In determining whether to enforce a contractual <FONT STYLE="white-space:nowrap">pre-dispute</FONT> jury trial waiver provision, courts
will generally consider whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. We believe that this is the case with respect to the deposit agreement and the ADSs. It is advisable that you consult legal counsel
regarding the jury waiver provision before investing in the ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you or any other holders or beneficial owners of ADSs bring a claim
against us or the depositary in connection with matters arising under the deposit agreement or the ADSs, including claims under U.S. federal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities laws, you or such other holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits
against us and/or the depositary. If a lawsuit is brought against us and/or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, in which the trial would be conducted according to
different civil procedures and may result in different outcomes than a trial by jury would have had, including results that could be less favorable to the plaintiff(s) in any such action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nevertheless, if this jury trial waiver provision is not enforced, to the extent a court action proceeds, it would proceed under the terms of
the deposit agreement with a jury trial. No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with any substantive provision of
the U.S. federal securities laws and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may face difficulties in protecting your interests, and
your ability to protect your rights through U.S. courts may be limited, because we are incorporated under Cayman Islands law. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
are an exempted company incorporated under the laws of the Cayman Islands with limited liability. Our corporate affairs are governed by our memorandum and articles of association, the Companies Law (2018 Revision) of the Cayman Islands, which we
refer to as the Companies Law, and the common law of the Cayman Islands. The rights of shareholders to take action against our directors, actions by our minority shareholders and the fiduciary duties of our directors to us under Cayman Islands law
are to a large extent governed by the common law of the Cayman Islands. The common law of the Cayman Islands is derived in part from comparatively limited judicial precedent in the Cayman Islands as well as from the common law of England, the
decisions of whose courts are of persuasive authority, but are not binding, on a court in the Cayman Islands. The rights of our shareholders and the fiduciary duties of our directors under Cayman Islands law are not as clearly established as they
would be under statutes or judicial precedent in some jurisdictions in the United States. In particular, the Cayman Islands has a less developed body of securities laws than the United States. Some U.S. states, such as Delaware, have more fully
developed and judicially interpreted bodies of corporate law than the Cayman Islands. In addition, Cayman Islands companies may not have standing to initiate a shareholder derivative action in a federal court of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholders of Cayman Islands exempted companies like us have no general rights under Cayman Islands law to inspect corporate records or to
obtain copies of lists of shareholders of these companies. Our directors have discretion under our post-offering articles of association that will become effective immediately prior to completion of this offering to determine whether or not, and
under what conditions, our corporate records may be inspected by our shareholders, but are not obliged to make them available to our shareholders. This may make it more difficult for you to obtain the information needed to establish any facts
necessary for a shareholder motion or to solicit proxies from other shareholders in connection with a proxy contest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of all
of the above, our public shareholders may have more difficulty in protecting their interests in the face of actions taken by management, members of the board of directors or controlling shareholders than they would as public shareholders of a
company incorporated in the United States. For a discussion of significant differences between the provisions of the Companies Law and the laws applicable to companies incorporated in the United States and their shareholders, see &#147;Description
of Share Capital&#151;Differences in Corporate Law.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have not determined a specific use for a portion of the net proceeds from this
offering and we may use these proceeds in ways with which you may not agree. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not determined a specific use for a portion
of the net proceeds of this offering, and our management will have considerable discretion in deciding how to apply these proceeds. You will not have the opportunity to assess whether the proceeds are being used appropriately before you make your
investment decision. You must rely on the judgment of our management regarding the application of the net proceeds of this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
offering. We cannot assure you that the net proceeds will be used in a manner that would improve our results of operations or increase our ADS price, nor that these net proceeds will be placed
only in investments that generate income or appreciate in value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The post-offering memorandum and articles of association that we plan to adopt and
that will become effective immediately prior to the completion of this offering will contain anti-takeover provisions that could discourage a third party from acquiring us and adversely affect the rights of holders of our ordinary shares and the
ADSs. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to conditionally adopt an amended and restated memorandum and articles of association that will become effective
immediately prior to the completion of this offering, which we refer to as the post-offering memorandum and articles of association. Our post-offering memorandum and articles of association will contain provisions to limit the ability of others to
acquire control of our company or cause us to engage in change of control transactions. These provisions could have the effect of depriving our shareholders of an opportunity to sell their shares at a premium over prevailing market prices by
discouraging third parties from seeking to obtain control of our company in a tender offer or similar transaction. Our board of directors has the authority, without further action by our shareholders, to issue preferred shares in one or more series
and to fix their designations, powers, preferences, privileges, and relative participating, optional or special rights and the qualifications, limitations or restrictions, including dividend rights, conversion rights, voting rights, terms of
redemption and liquidation preferences, any or all of which may be greater than the rights associated with our ordinary shares, in the form of ADS or otherwise. Preferred shares could be issued quickly with terms calculated to delay or prevent a
change in control of our company or make removal of management more difficult. If our board of directors decides to issue preferred shares, the price of our ADSs may fall and the voting and other rights of the holders of our ordinary shares and ADSs
may be materially and adversely affected. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an emerging growth company within the meaning of the Securities Act and may take advantage of
certain reduced reporting requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; as defined in the U.S. Jumpstart Our
Business Startups Act of 2012, or the JOBS Act, and we may take advantage of certain exemptions from various requirements applicable to other public companies that are not emerging growth companies including, most significantly, not being required
to comply with the auditor attestation requirements of Section&nbsp;404 of Sarbanes-Oxley Act of 2002 for so long as we are an emerging growth company. As a result, if we elect not to comply with such auditor attestation requirements, our investors
may not have access to certain information they may deem important. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The JOBS Act also provides that an emerging growth company does not
need to comply with any new or revised financial accounting standards until such date that a private company is otherwise required to comply with such new or revised accounting standards. However, we have elected to &#147;opt out&#148; of this
provision and, as a result, we will comply with new or revised accounting standards as required when they are adopted for public companies. This decision to opt out of the extended transition period under the JOBS Act is irrevocable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are a foreign private issuer within the meaning of the rules under the Exchange Act, and as such we are exempt from certain provisions applicable to
U.S. domestic public companies. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we qualify as a foreign private issuer under the Exchange Act, we are exempt from certain
provisions of the securities rules and regulations in the United States that are applicable to U.S. domestic issuers, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> or current reports on Form <FONT STYLE="white-space:nowrap">8-K;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sections of the Exchange Act regulating the solicitation of proxies, consents, or authorizations in respect
of a security registered under the Exchange Act; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading
activities and liability for insiders who profit from trades made in a short period of time; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the selective disclosure rules by issuers of material nonpublic information under Regulation FD promulgated by
SEC. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be required to file an annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> within four
months of the end of each fiscal year. In addition, we intend to publish our results on a quarterly basis as press releases, distributed pursuant to the rules and regulations of the Nasdaq Stock Market. Press releases relating to financial results
and material events will also be furnished to the SEC on Form <FONT STYLE="white-space:nowrap">6-K.</FONT> However, the information we are required to file with or furnish to the SEC will be less extensive and less timely compared to that required
to be filed with the SEC by U.S. domestic issuers. As a result, you may not be afforded the same protections or information that would be made available to you were you investing in a U.S. domestic issuer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As an exempted company incorporated in the Cayman Islands, we are permitted to adopt certain home country practices in relation to corporate governance
matters that differ significantly from the Nasdaq Stock Market&#146;s corporate governance requirements; these practices may afford less protection to shareholders than they would enjoy if we complied fully with the Nasdaq Stock Market&#146;s
corporate governance requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a Cayman Islands company listed on the Nasdaq Stock Market, we are subject to the Nasdaq
Stock Market&#146;s corporate governance requirements. However, the Nasdaq Stock Market rules permit a foreign private issuer like us to follow the corporate governance practices of its home country. Certain corporate governance practices in the
Cayman Islands, which is our home country, may differ significantly from the Nasdaq Stock Market&#146;s corporate governance requirements. For example, neither the Companies Law nor our post-offering memorandum and articles of association that will
become effective immediately prior to the completion of this offering requires a majority of our directors to be independent and we could include <FONT STYLE="white-space:nowrap">non-independent</FONT> directors as members of our compensation
committee and nominating committee, and our independent directors would not necessarily hold regularly scheduled meetings at which only independent directors are present. Currently, we do not plan to rely on home country practice with respect to our
corporate governance after we complete this offering. However, if we choose to follow home country practice in the future, our shareholders may be afforded less protection than they otherwise would under the Nasdaq Stock Market&#146;s corporate
governance requirements applicable to U.S. domestic issuers. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There can be no assurance that we will not be classified as a passive foreign
investment company, or PFIC, for U.S. federal income tax purposes for any taxable year, which could subject U.S. investors in our ADSs or ordinary shares to significant adverse U.S. income tax consequences. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be a passive foreign investment company, or PFIC, for any taxable year if either (i)&nbsp;75% or more of our gross income for such year
consists of certain types of &#147;passive&#148; income or (ii) 50% or more of the average quarterly value of our assets (as determined on the basis of fair market value) during such year produce or are held for the production of passive income (the
&#147;asset test&#148;). No assurance can be given with respect to our PFIC status for the current taxable year or any future taxable year. The determination of whether we are or will become a PFIC is uncertain because it is a fact-intensive inquiry
made on an annual basis that will depend, in part, on the composition of our income and assets. Fluctuations in the market price of our ADSs may cause us to be a PFIC for the current or subsequent taxable years because the value of our assets for
purposes of the asset test may be determined by reference to the market price of our ADSs from time to time (which may be volatile for biopharmaceutical companies, such as ours, that have not yet achieved commercialization with respect to any of
their products). The composition of our income and assets may also be affected by how, and how quickly, we use our liquid assets and the cash raised in this offering. Under circumstances where our revenue from activities that produce passive income
increases relative to our revenue from activities that produce non-passive income, or where we determine not to deploy cash for active purposes, our risk of being a PFIC will substantially increase. Because there are uncertainties in the application
of the relevant rules, it is possible that the IRS may challenge </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our classification or valuation of certain income and assets, each of which may result in our being or becoming a PFIC for the current or subsequent taxable years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are a PFIC in any taxable year, a U.S. Holder (as defined in &#147;Taxation&#151;United States Federal Income Tax Considerations&#148;)
may incur significantly increased U.S. income tax on gain recognized on the sale or other disposition of the ADSs or ordinary shares and on the receipt of distributions on the ADSs or ordinary shares to the extent such gain or distribution is
treated as an &#147;excess distribution&#148; under the U.S. federal income tax rules and such holder may be subject to burdensome reporting requirements. Further, if we are a PFIC for any year during which a U.S. holder holds our ADSs or ordinary
shares, we generally will continue to be treated as a PFIC for all succeeding years during which such U.S. holder holds our ADSs or ordinary shares. For more information see &#147;Taxation&#151;United States Federal Income Tax
Considerations&#151;Passive Foreign Investment Company Considerations.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur increased costs and become subject to additional rules
and regulations as a result of being a public company, particularly after we cease to qualify as an &#147;emerging growth company.&#148; </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley
Act of 2002, as well as rules&nbsp;subsequently implemented by the SEC and the Nasdaq Global Market, impose various requirements on the corporate governance practices of public companies. As a company with less than US$1.07&nbsp;billion in net
revenues for our last fiscal year, we qualify as an &#147;emerging growth company&#148; pursuant to the JOBS Act. An emerging growth company may take advantage of specified reduced reporting and other requirements that are otherwise applicable
generally to public companies. These provisions include exemption from the auditor attestation requirement under Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 in the assessment of the emerging growth company&#146;s internal control over
financial reporting and permission to delay adopting new or revised accounting standards until such time as those standards apply to private companies. However, we have elected to &#147;opt out&#148; of the provision that allows us to delay adopting
new or revised accounting standards and, as a result, we will comply with new or revised accounting standards as required when they are adopted for public companies. This decision to opt out of the extended transition period under the JOBS Act is
irrevocable. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect these rules&nbsp;and regulations to increase our legal and financial compliance costs and to make some
corporate activities more time-consuming and costly. After we are no longer an &#147;emerging growth company,&#148; we expect to incur significant expenses and devote substantial management effort toward ensuring compliance with the requirements of
Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 and the other rules&nbsp;and regulations of the SEC. We also expect that operating as a public company will make it more difficult and more expensive for us to obtain director and officer liability
insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. In addition, we will incur additional costs associated with our public company reporting
requirements. It may also be more difficult for us to find qualified persons to serve on our board of directors or as executive officers. We are currently evaluating and monitoring developments with respect to these rules&nbsp;and regulations, and
we cannot predict or estimate with any degree of certainty the amount of additional costs we may incur or the timing of such costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
the past, shareholders of a public company often brought securities class action suits against the company following periods of instability in the market price of that company&#146;s securities. If we were involved in a class action suit, it could
divert a significant amount of our management&#146;s attention and other resources from our business and operations, which could harm our results of operations and require us to incur significant expenses to defend the suit. Any such class action
suit, whether or not successful, could harm our reputation and restrict our ability to raise capital in the future. In addition, if a claim is successfully made against us, we may be required to pay significant damages, which could have a material
adverse effect on our financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements that reflect our current expectations and views of future events. The forward-looking
statements are contained principally in the sections entitled &#147;Prospectus Summary,&#148; &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and &#147;Business.&#148;
Known and unknown risks, uncertainties and other factors, including those listed under &#147;Risk Factors,&#148; may cause our actual results, performance or achievements to be materially different from those expressed or implied by the
forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You can identify some of these forward-looking statements by words or phrases such as &#147;may,&#148;
&#147;will,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;aim,&#148; &#147;estimate,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;believe,&#148; &#147;is/are likely to,&#148; &#147;potential,&#148; &#147;continue&#148; or other
similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events that we believe may affect our financial condition, results of operations, business strategy and financial
needs. These forward-looking statements include statements relating to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of initiation and completion, and the progress of our drug discovery and research programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and likelihood of regulatory filings and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance our drug candidates into drugs, and the successful completion of clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval, pricing and reimbursement of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commercialization of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market opportunities and competitive landscape of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the payment, receipt and timing of any milestone payments in relation to the licensing agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimates of our costs, expenses, future revenues, capital expenditures and our needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain senior management and key employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our future business development, financial condition and results of operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future developments, trends, conditions and competitive landscape in the industry and markets in which we
operate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our strategies, plans, objectives and goals and our ability to successfully implement these strategies, plans,
objectives and goals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to continue to maintain our market position in China&#146;s biopharmaceutical and biotechnology
industries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify and integrate suitable acquisition targets; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to regulatory and operating conditions in our industry and markets. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements involve various risks and uncertainties. Although we believe that our expectations expressed in these
forward-looking statements are reasonable, our expectations may later be found to be incorrect. Our actual results could be materially different from our expectations. Important risks and factors that could cause our actual results to be materially
different from our expectations are generally set forth in &#147;Prospectus Summary&#151;Our Challenges,&#148; &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148;
&#147;Business,&#148; &#147;Regulation&#148; and other sections in this prospectus. You should read thoroughly this prospectus and the documents that we refer to with the understanding that our actual future results may be materially different from
and worse than what we expect. We qualify all of our forward-looking statements by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains certain data and information that we obtained from various
government and private publications. Statistical data in these publications also include projections based on a number of assumptions. The biopharmaceutical industry may not grow at the rate projected by market data, or at all. Failure of this
market to grow at the projected rate may have a material and adverse effect on our business and the market price of our ADSs. In addition, the rapidly evolving nature of the biopharmaceutical industry results in significant uncertainties for any
projections or estimates relating to the growth prospects or future condition of our market. Furthermore, if any one or more of the assumptions underlying the market data are later found to be incorrect, actual results may differ from the
projections based on these assumptions. You should not place undue reliance on these forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forward-looking
statements made in this prospectus relate only to events or information as of the date on which the statements are made in this prospectus. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking
statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this prospectus and the documents that we refer to
in this prospectus and have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that we will receive net proceeds from this offering of approximately
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or approximately US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters exercise their option to purchase
additional ADSs in full, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. These estimates are based upon an assumed initial public offering price of
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS, which is the <FONT STYLE="white-space:nowrap">mid-point</FONT> of the price range shown on the cover page of this prospectus. A US$1.00 increase (decrease) in the
assumed initial public offering price of US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS would increase (decrease) the net proceeds to us from this offering by
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming the number of ADSs offered by us as set forth on the cover page of this prospectus remains the same, and after deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary purposes of this offering are to create a public market for our
shares for the benefit of all shareholders, retain talented employees by providing them with equity incentives, and obtain additional capital. We plan to use the net proceeds of this offering as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million for research
and development of our existing and future drug candidates, including: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">approximately US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to fund the
ongoing two registrational trials, as well as a planned exploratory trial in SLE, for TJ202; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">approximately US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to fund the
planned registrational trial&nbsp;for enoblituzumab and the milestone payments in connection with development of enoblituzumab; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">approximately US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to fund the
planned registrational trial for TJ101; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">approximately US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to fund the
ongoing Phase 2 trial for TJ301 and the milestone payments in connection with development of TJ301; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">approximately US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to fund the
ongoing Phase 1b trial and planned phase 2 trial for TJ107 and the milestone payments in connection with development of TJ107; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">approximately US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to fund the
ongoing Phase 1 trial both in the United States and China for TJC4; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">approximately US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to fund the
ongoing Phase 1 trial in the United States and the planned Phase 1 trial in China for TJD5; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">approximately US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to fund the
ongoing Phase 1 trial in the United States and the planned Phase 1b trial in China for TJM2; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million for potential
investments in the establishment of our own manufacturing capacities, including the construction of our manufacturing facility in Hangzhou, China and for expanding our U.S. presence by building research facilities, including a translational medicine
laboratory, in the United States; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million&nbsp;for
general corporate purposes (including working capital needs), potential strategic alliances, investments or acquisitions, although we have not identified any specific alliances, investment or acquisition opportunities as of the date of this
prospectus. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing represents our current intentions based upon our present plans and business conditions to use
and allocate the net proceeds of this offering. Our management, however, will have significant flexibility and discretion to apply the net proceeds of this offering. If an unforeseen event occurs or business conditions change, we may use the
proceeds of this offering differently than as described in this prospectus. See &#147;Risk Factors&#151;Risks Related to Our ADSs and This Offering&#151;We have not determined a specific use for a portion of the net proceeds from this offering and
we may use these proceeds in ways with which you may not agree.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending any use described above, we plan to invest the net proceeds
from this offering in short-term, interest-bearing, debt instruments or demand deposits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has complete discretion on whether to pay dividends, subject to certain requirements of Cayman Islands law. Even if our
board of directors decides to pay dividends on our ordinary shares, the form, frequency and amount will depend upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other
factors that our board of directors may deem relevant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have any present plan to pay any cash dividends on our ordinary shares
in the foreseeable future after this offering. We currently intend to retain most, if not all, of our available funds and any future earnings to operate and expand our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a holding company incorporated in the Cayman Islands. We may rely on dividends from our subsidiaries in China for our cash
requirements, including any payment of dividends to our shareholders. PRC regulations may restrict the ability of our PRC subsidiaries to pay dividends to us. See &#147;Regulation&#151;PRC Regulation&#151;Regulations Relating to Foreign Exchange and
the Dividend Distribution.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we pay any dividends on our ordinary shares, we will pay those dividends which are payable in respect
of the ordinary shares underlying our ADSs to the depositary, as the registered holder of such ordinary shares, and the depositary then will pay such amounts to our ADS holders in proportion to the ordinary shares underlying the ADSs held by such
ADS holders, subject to the terms of the deposit agreement, including the fees and expenses payable thereunder. See &#147;Description of American Depositary Shares.&#148; Cash dividends on our ordinary shares, if any, will be paid in U.S. dollars.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_8"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our capitalization as of June 30, 2019: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma basis to reflect the automatic conversion of all of our issued and outstanding preferred shares
into ordinary shares on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis immediately upon the completion of this offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma as adjusted basis to reflect (i)&nbsp;the automatic conversion of all of our issued and
outstanding preferred shares into ordinary shares on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis immediately upon the completion of this offering and (ii)&nbsp;the sale of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares represented by ADSs by us in this offering at an assumed initial public offering price of
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS, which is the <FONT STYLE="white-space:nowrap">mid-point</FONT> of the estimated range of the initial public offering price shown on the cover page of this
prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, assuming the underwriters do not exercise their option to purchase additional ADSs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this table together with our consolidated financial statements and the related notes included elsewhere in this prospectus and
the information under &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June 30, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A convertible preferred shares (US$0.0001 par value, 30,227,056 shares authorized, issued
and outstanding as of June 30, 2019)<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>687,482</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B convertible preferred shares (US$0.0001 par value, 30,305,212 shares authorized, issued
and outstanding as of June 30, 2019)<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>921,243</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C convertible preferred shares (US$0.0001 par value, 31,046,360 shares authorized, issued
and outstanding as of June 30, 2019)<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>1,306,633</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable non-controlling interests<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>&#151;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>&#151;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,915,358</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>424,670</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&#151;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&#151;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares (US$0.0001 par value, 500,000,000 shares authorized as of June 30, 2019, 8,363,719
shares authorized, issued and outstanding as of June 30, 2019)<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>6</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Treasury stock<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>(1</TD>
<TD NOWRAP VALIGN="bottom"><B></B>)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,381,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income <B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,871,826</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(272,663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,921,977</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(279,968</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,451,057</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(211,371</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,514,452</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>220,604</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total mezzanine equity and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,955,338</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>284,827</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,955,338</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>284,827</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Note: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">The pro forma and pro forma as adjusted equity securities are reflected using a rate of RMB6.8650 to US$1.00,
the exchange rate in effect as of the end of June 2019. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_9"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our ADSs, your interest will be diluted to the extent of the difference between the initial public offering price per ADS and
our net tangible book value per ADS after this offering. Dilution results from the fact that the initial public offering price per ordinary share is substantially in excess of the book value per ordinary share attributable to the existing
shareholders for our presently outstanding ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our net tangible book value as of June 30, 2019 was approximately
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share as of that date and
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS. Net tangible book value represents the amount of our total consolidated tangible assets, less the amount of our total consolidated liabilities. Dilution is
determined by subtracting net tangible book value per ordinary share, after giving effect to the additional proceeds we will receive from this offering, from the assumed initial public offering price of
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, which is the midpoint of the estimated initial public offering price range set forth on the cover page of this prospectus adjusted to reflect the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Without taking into account any other changes in net tangible book value after June 30, 2019, other than to give effect to our sale of the
ADSs offered in this offering at the assumed initial public offering price of US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS, which is the midpoint of the estimated range of the initial public offering price,
after deduction of the underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of June 30, 2019 would have been
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , or US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share and
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS. This represents an immediate increase in net tangible book value of US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share
and US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS to the existing shareholders and an immediate dilution in net tangible book value of US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per ordinary share and US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS to investors purchasing ADSs in this offering. The following table illustrates such dilution: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Ordinary&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;ADS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value as of June 30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value after giving effect to the conversion of our preferred
shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value after giving effect to the conversion of our
preferred shares and this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amount of dilution in net tangible book value to new investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A US$1.00 increase (decrease) in the assumed initial public offering price of
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS would increase (decrease) our pro forma as adjusted net tangible book value after giving effect to this offering by
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, the pro forma as adjusted net tangible book value per ordinary share and per ADS after giving effect to this offering by
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share and US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS and the dilution in pro forma as adjusted net tangible book value
per ordinary share and per ADS to new investors in this offering by US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share and US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per
ADS, assuming no change to the number of ADSs offered by us as set forth on the cover page of this prospectus, and after deducting underwriting discounts and commissions and other offering expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes, on a pro forma as adjusted basis as of June 30, 2019, the
differences between existing shareholders and the new investors with respect to the number of ordinary shares (represented by ADSs or shares) purchased from us, the total consideration paid and the average price per ordinary share and per ADS paid
before deducting the underwriting discounts and commissions and estimated offering expenses. The total number of ordinary shares does not include ordinary shares underlying the ADSs issuable upon the exercise of the over-allotment option granted to
the underwriters. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Ordinary&nbsp;Shares&nbsp;Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR>Price&nbsp;Per<BR>Ordinary<BR>Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR>Price&nbsp;Per<BR>ADS</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro forma as adjusted information discussed above is illustrative only. Our net tangible book value
following the completion of this offering is subject to adjustment based on the actual initial public offering price of our ADSs and other terms of this offering determined at pricing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discussion and tables above assume no exercise of any outstanding share options outstanding as of the date of this prospectus. As of the
date of this prospectus, there are &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares issuable upon exercise of outstanding share options at a weighted average exercise price of
US$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, and there are &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares available for future issuance upon the exercise of future
grants under our share incentive plans. To the extent that any of these options are exercised, there will be further dilution to new investors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_10"></A>ENFORCEABILITY OF CIVIL LIABILITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are incorporated under the laws of the Cayman Islands as an exempted company with limited liability. We are incorporated in the Cayman
Islands because of certain benefits associated with being a Cayman Islands exempted company, such as political and economic stability, an effective judicial system, a favorable tax system, the absence of foreign exchange control or currency
restrictions and the availability of professional and support services. However, the Cayman Islands has a less developed body of securities laws than the United&nbsp;States and provides less protection for investors. In addition, Cayman Islands
companies do not have standing to sue before the federal courts of the United&nbsp;States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most of our assets are located outside the
United&nbsp;States. In addition, most of our directors and officers are nationals or residents of jurisdictions other than the United&nbsp;States and all or a substantial portion of their assets are located outside the United&nbsp;States. As a
result, it may be difficult for investors to effect service of process within the United&nbsp;States upon us or these persons, or to enforce judgments obtained in U.S.&nbsp;courts against us or them, including judgments predicated upon the civil
liability provisions of the securities laws of the United&nbsp;States or any state in the United&nbsp;States. It may also be difficult for you to enforce judgments obtained in U.S.&nbsp;courts based on the civil liability provisions of the
U.S.&nbsp;federal securities laws against us and our officers and&nbsp;directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have appointed
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as our agent to receive service of process with respect to any action brought against us in the U.S.&nbsp;District Court for the Southern District of New&nbsp;York in
connection with this offering under the federal securities laws of the United&nbsp;States or the securities laws of any state in the United&nbsp;States or any action brought against us in the Supreme Court of the State of New&nbsp;York in the County
of New&nbsp;York in connection with this offering under the securities laws of the State of New&nbsp;York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conyers Dill&nbsp;&amp;
Pearman, our counsel as to Cayman Islands law, has advised us that there is uncertainty as to whether the courts of the Cayman Islands would (1)&nbsp;recognize or enforce judgments of U.S.&nbsp;courts obtained against us or our directors or officers
that are predicated upon the civil liability provisions of the federal securities laws of the United&nbsp;States or the securities laws of any state in the United&nbsp;States, or (2)&nbsp;entertain original actions brought in the Cayman Islands
against us or our directors or officers that are predicated upon the federal securities laws of the United&nbsp;States or the securities laws of any state in the United&nbsp;States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conyers Dill&nbsp;&amp; Pearman has informed us that the uncertainty with regard to Cayman Islands law relates to whether a judgment obtained
from the U.S. courts under civil liability provisions of the securities law will be determined by the courts of the Cayman Islands as penal or punitive in nature. The courts of the Cayman Islands may not recognize or enforce such judgments against a
Cayman company, and because such a determination has not yet been made by a court of the Cayman Islands, it is uncertain whether such civil liability judgments from U.S. courts would be enforceable in the Cayman Islands. Conyers Dill&nbsp;&amp;
Pearman has further advised us that the courts of the Cayman Islands would recognize as a valid judgment, a final and conclusive judgment in personam obtained in the federal or state courts of the United States under which a sum of money is payable
(other than a sum of money payable in respect of multiple damages, taxes or other charges of a like nature or in respect of a fine or other penalty) or, in certain circumstances, an in personam judgment for
<FONT STYLE="white-space:nowrap">non-monetary</FONT> relief, and would give a judgment based thereon provided that (a)&nbsp;such courts had proper jurisdiction over the parties subject to such judgment; (b)&nbsp;such courts did not contravene the
rules of natural justice of the Cayman Islands; (c)&nbsp;such judgment was not obtained by fraud; (d)&nbsp;the enforcement of the judgment would not be contrary to the public policy of the Cayman Islands; (e)&nbsp;no new admissible evidence relevant
to the action is submitted prior to the rendering of the judgment by the courts of the Cayman Islands; and (f)&nbsp;there is due compliance with the correct procedures under the laws of the Cayman Islands. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">JunHe LLP, our counsel as to PRC law, has advised us that there is uncertainty as to whether the courts of China would (1)&nbsp;recognize or
enforce judgments of United States courts obtained against us or our directors or officers predicated upon the civil liability provisions of the securities laws of the United States or any state in the United States, or (2)&nbsp;entertain original
actions brought in each respective jurisdiction against us or our directors or officers predicated upon the securities laws of the United States or any state in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">JunHe LLP has further advised us that the recognition and enforcement of foreign judgments
are provided for under the PRC Civil Procedures Law. The PRC courts may recognize and enforce foreign judgments in accordance with the requirements of the PRC Civil Procedures Law based either on treaties between China and the country where the
judgment is made or on principles of reciprocity between jurisdictions. China does not have any treaties or other form of reciprocal arrangements with the United States or the Cayman Islands that provide for the reciprocal recognition and
enforcement of foreign judgments. In addition, according to the PRC Civil Procedures Law, courts in China will not enforce a foreign judgment against us or our directors and officers if they decide that the judgment violates the basic principles of
PRC law or national sovereignty, security or public interest. As a result, it is uncertain whether and on what basis a PRC court would enforce a judgment rendered by a court in the United States or in the Cayman Islands. Under the PRC Civil
Procedures Law, foreign shareholders may initiate actions based on PRC law before a PRC court against a company for disputes, if the plaintiff can establish a sufficient contact with China for a PRC court to exercise jurisdiction and has a direct
interest, cause of action and a concrete claim. The action may be initiated by a shareholder through filing a complaint with the PRC court. The PRC court will determine whether to accept the complaint in accordance with the PRC Civil Procedures Law.
The shareholder may participate in the action by itself or entrust any other person or PRC legal counsel to participate on behalf of such shareholder. In addition, it will be difficult for U.S. shareholders to originate actions against us in China
in accordance with PRC laws because we are incorporated under the laws of the Cayman Islands and it will be difficult for U.S. shareholders, by virtue only of holding our ADSs or ordinary shares, to establish a connection to China for a PRC court to
have jurisdiction as required under the PRC Civil Procedures Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_11"></A>CORPORATE HISTORY AND STRUCTURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We commenced our operations in November 2014, when our predecessor Third Venture Biopharma (Nanjing) Co., Ltd (&#147;Third Venture&#148;) was
established. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> was established in June 2016 under the laws of the Cayman Islands as our
offshore holding company. In July 2016, <FONT STYLE="white-space:nowrap">I-Mab</FONT> established <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Hong Kong&#148;), as its
intermediary holding company. In August 2016, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong established a wholly-owned PRC subsidiary, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Shanghai) Co., Ltd. <FONT
STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Shanghai&#148;). In September 2016, the assets and operations of Third Venture were consolidated into <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2017, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong acquired a controlling interest in
<FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Tianjin&#148;), formerly known as Tasgen
<FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd., a company focused on CMC management of biologics in China. Through an internal corporate restructuring, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin became the 100% owner
of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai in September 2017 and <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong acquired the remaining interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin in May 2018, becoming
the 100% owner of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2018, <FONT STYLE="white-space:nowrap">I-Mab</FONT>
Hong Kong established in Maryland, United States, a wholly-owned subsidiary <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Limited <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> US&#148;), as the hub for the discovery and
development of the drug candidates in our Global Portfolio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following diagram illustrates our corporate structure, including our
principal subsidiaries, as of the date of this prospectus: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g69u35.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_12"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following selected consolidated statements of comprehensive loss data for the years ended December&nbsp;31, 2017 and 2018, selected
consolidated balance sheet data as of December&nbsp;31, 2017 and 2018 and selected consolidated statements of cash flow data for the years ended December&nbsp;31, 2017 and 2018 have been derived from our audited consolidated financial statements
included elsewhere in this prospectus. The following selected consolidated statements of comprehensive loss data for the six months ended June&nbsp;30, 2018 and 2019, selected consolidated balance sheet data as of June&nbsp;30, 2019 and selected
consolidated statements of cash flow data for the six months ended June&nbsp;30, 2018 and 2019 are derived from our unaudited interim condensed consolidated financial statements included elsewhere in this prospectus. Our consolidated financial
statements are prepared and presented in accordance with accounting principles generally accepted in the U.S. GAAP. Our historical results are not necessarily indicative of results expected for future periods. You should read this Selected
Consolidated Financial Data section together with our consolidated financial statements and the related notes and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; included elsewhere in this
prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>(in thousands, except for share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Selected Consolidated Statements of Comprehensive Loss Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenues</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensing and collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(267,075</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(426,028</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,058</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(202,693</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(265,084</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,614</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,671</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,687</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(574,584</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83,698</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280,955</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(438,638</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,895</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(200,003</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(824,668</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(120,127</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,704</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,097</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expenses), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,444</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,594</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,027</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,854</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before income tax expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(401,111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58,428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(166,720</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(857,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(251</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to <FONT STYLE="white-space:nowrap">I-Mab</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58,679</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(166,720</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(857,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive income</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustments, net of nil tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,446</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(724</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss attributable to
<FONT STYLE="white-space:nowrap">I-Mab</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(292,322</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(349,144</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(50,858</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(174,166</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(862,309</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(125,610</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58,679</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(166,720</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(857,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted-average number of ordinary shares used in calculating net loss per shares</B></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,742,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,397,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,184,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,184,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss per share attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8.99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26.06</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17.38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8.99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26.06</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17.38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Note: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Share-based compensation expenses were allocated as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Administrative expenses*</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,039</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,520</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>513</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,929</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>366,356</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,366</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">The above share-based compensation expenses do not include the expenses arising from the repurchase of share
awards held by a director of our company during the six months ended June 30, 2019. See Note 17 (d) to our unaudited interim condensed consolidated financial statements included elsewhere in this prospectus for more details. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents our selected consolidated statements of balance sheet data as of December&nbsp;31, 2017 and 2018 and June 30,
2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Selected Consolidated Statements of Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Current assets</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,588,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,269,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Prepayments and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">691,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,036,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">296,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,604,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Operating lease right-of-use assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,025,345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,375,938</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>346,094</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,955,338</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>284,827</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>309,151</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>415,684</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>60,551</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>484,954</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>70,641</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,015,989</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,915,358</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>424,670</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,915,358</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>424,670</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Ordinary shares (US$0.0001 par value, 500,000,000 shares authorized as of December 31, 2018 and
June 30, 2019, 8,363,719 and 8,363,719 shares authorized, issued and outstanding as of December&nbsp;31, 2018 and June 30, 2019, respectively)<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>6</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Treasury stock<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>(1</TD>
<TD NOWRAP VALIGN="bottom"><B></B>)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Additional paid-in capital<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>52,369</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accumulated other comprehensive income <B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>5,691</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accumulated deficit<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>(357,860</TD>
<TD NOWRAP VALIGN="bottom"><B></B>)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,014,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(147,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,871,826</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(272,663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(299,795</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(955,104</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(139,127</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,451,057</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(211,371</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total liabilities, mezzanine equity and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,025,345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,375,938</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>346,094</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,955,338</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>284,827</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents our selected consolidated statements of cash flow data for the
years ended December&nbsp;31, 2017 and 2018 and the six months ended June 30, 2018 and 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Selected Consolidated Statements of Cash Flow Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(252,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,889</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,653</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(389,034</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,669</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net cash (used in) generated from investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157,665</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net cash (used in) generated from financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">758,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,479,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,370</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Effect of exchange rate changes on cash and cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,737</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,093</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(451</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,268,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(264,071</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,466</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, beginning of the year/period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, end of the year/period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">504,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,416,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(206,389</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_13"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the section
entitled &#147;Selected Consolidated Financial Data&#148; and our consolidated financial statements and the consolidated financial statements of <FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin)
Co., Ltd. <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Tianjin&#148;) and the related notes included elsewhere in this prospectus. This discussion contains forward-looking statements that reflect our current expectations and views of future
events, which may involve risks and uncertainties. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth
under &#147;Risk Factors&#148; and elsewhere in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We acquired a controlling interest in
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin on July&nbsp;15, 2017 and have consolidated the results of operations of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin and its subsidiaries since July&nbsp;15, 2017. In this section, when
discussing historical facts and operating results for the period before July&nbsp;15, 2017, &#147;we,&#148; &#147;us,&#148; &#147;our company&#148; and &#147;our&#148; refer to <FONT STYLE="white-space:nowrap">I-Mab</FONT> and its then subsidiaries,
and do not include <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin or its subsidiaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly
differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
were founded to capture the opportunities presented by the confluence of two major developments&#150;&#150;the emergence of an attractive and growing biologics market in China, and the revolutionary scientific breakthroughs in cancer and autoimmune
disease medicines. We believe we are well-positioned to become a biotech leader in China because of our innovative discovery expertise, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fit-for-purpose</FONT></FONT> technology
platforms, biomarker-enabled translational medicine capabilities, and clinical development capabilities. These integrated capabilities are further enhanced by our deep understanding of China&#146;s biologics regulatory framework and our direct
access to extensive <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trial resources in China. To date, we have developed an innovative pipeline of more than 10 clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage
assets through our internal research and development efforts and <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements with global pharmaceutical and biotech companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are fully aware of the competitive and regulatory challenges we face as an innovative clinical stage biotech company based in China,
including need to raise significant capital, significant competition from global and other China-based biopharmaceutical companies, less streamlined regulatory pathway compared to countries with long-established regulatory systems, and potential
implementation challenges and uncertainties of the recent government reform of the drug approval system. However, with these challenges in mind, we have been mitigating the risks through our internal R&amp;D system that integrates multi-functional
aspects of our drug development process to proactively deal with some of the regulatory challenges mentioned above. Furthermore, through our Beijing office which focuses on regulatory matters, we have established an effective communication channel
with the regulatory agencies to discuss and resolve various regulatory issues promptly and effectively. We see vast opportunities for immuno-oncology and autoimmune biologics therapies in China. First, both the incidence and mortality of cancers in
China have been increasing in recent years and are outpacing those in the United States and the rest of the world. Second, many innovative biologics approved to treat cancer and autoimmune diseases in the United States and Europe are not yet
available in China. Third, the Chinese government has implemented new policies and regulations to simplify the review and approval cycle of clinical trials and new drug applications to encourage biologics innovation. Fourth, there has been a
continuous and rapid increase in personal disposable income in China coupled with ongoing improvement in basic national health insurance coverage, making innovative biologics more accessible to more Chinese patients. According to the
Frost&nbsp;&amp; Sullivan Report, China&#146;s biologics market is growing faster than the global biologics market and is expected to reach approximately RMB1.3 trillion (US$189.4 billion) by 2030 in terms of sales revenue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe we are uniquely positioned as a China-based global player to tap into these vast
commercial opportunities. This is best demonstrated by our short journey in becoming one of the top clinical stage immunology companies in China. According to the Frost &amp; Sullivan Report, we are ranked as top clinical stage China-based
immunology companies as measured by the innovative quality and number of investigational drugs and drug candidates under clinical and pre-clinical development in our pipeline, amount of pre-IPO financing raised (in excess of US$400 million in three
years), pre-IPO valuation and recognition and awards earned in the biotech industry. For example, in March 2019, Genetic Engineering &amp; Biotechnology News (GEN) recognized us as a top 10 immuno-oncology start-up in the world. We were the only
China-based company recognized therein. To date, our research and development capabilities encompass discovery, biologics CMC development, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development and clinical development with footprints in
Shanghai, Beijing and the United States. We are now at a critical juncture to transition from a clinical stage biotech company into a fully integrated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> global
biopharmaceutical company in the next few years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the commencement of our operation in 2014, we have devoted most of our efforts and
financial resources to organize and staff our operations, business planning, raise capital, establish our intellectual property portfolio and conduct pre-clinical and clinical trials of our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We had raised in excess of US$400&nbsp;million in pre-IPO financing in the past three years. We have not generated any revenue from product
sales, and as a result, we have never been profitable and have incurred net losses since the commencement of our operations. In 2017, 2018 and the six months ended June 30, 2019, our net loss was RMB298.2&nbsp;million, RMB402.8&nbsp;million (US$58.7
million) and RMB857.3 million (US$124.9 million), respectively. We do not expect to generate product revenue unless and until we obtain marketing approval for and commercialize a drug candidate, and we cannot assure you that we will ever generate
significant revenue or profits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Factors Affecting Our Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our results of operations, financial condition, and the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year</FONT></FONT> comparability of our financial results have been, and are expected to continue to be, principally affected by the below factors: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cost and Expenses Structure </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
results of operations are significantly affected by our cost structure, which primarily consists of research and development expenses and administrative expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development activities are central to our business model. We believe our ability to successfully develop drug candidates will be
the primary factor affecting our long-term competitiveness, as well as our future growth and development. Developing high-quality drug candidates requires a significant investment of resources over a prolonged period of time, and a core part of our
strategy is to continue making sustained investments in this area. Since our inception, we have focused our resources on our research and development activities, including conducting <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and
clinical trials, and activities related to regulatory filings for our drug candidates. Our research and development expenses primarily include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to development of our pipeline assets under all stages including discovery, pre-clinical testing or
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent license fees and other fees under the licensing, collaboration and development agreements with respect to
our in-licensed drug candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">employee salaries and related benefit costs, including share-based compensation expenses, for research and
development personnel. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At this time, we are unable to predict when, if ever, we will be able to achieve profitability.
Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods thereafter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
This is due to the numerous risks and uncertainties associated with developing such drug candidates, including the uncertainty of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful enrollment in and completion of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing an appropriate safety profile; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receipt of marketing approvals from applicable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commercializing the drug candidates, if and when approved, whether alone or in collaboration with others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continued acceptable safety profiles of the products following approval; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">retention of key research and development personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any change in the outcome of any of these variables with respect to the development of any of our drug candidates would significantly change
the costs, timing and viability associated with the development of that drug candidate. We expect research and development costs to continue to increase for the foreseeable future as we expand our operations and our development programs progress,
including as we continue to support and advance the clinical trials of our drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our administrative expenses consist primarily
of employee salaries and related benefit costs. Other administrative expenses include professional fees for consulting and auditing as well as other direct and allocated expenses for rental expenses for our facilities, travel costs and other
supplies used in administrative activities. We expect our administrative expenses to increase in the future to support our pipeline assets and research and development efforts, and the commercialization of our drug candidates once approval is
obtained. We also anticipate that our administrative expenses will increase as we operate as a public company following the completion of this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue from <FONT STYLE="white-space:nowrap">Out-Licensing</FONT> Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We continue to seek <FONT STYLE="white-space:nowrap">out-licensing</FONT> opportunities for our
<FONT STYLE="white-space:nowrap">de-prioritized</FONT> assets to streamline our pipeline. In 2017 and 2018 and for the six months ended June 30, 2019, our revenue consisted primarily of payments from granting licenses to use and otherwise exploit
certain of our intellectual properties linked to our <FONT STYLE="white-space:nowrap">de-prioritized</FONT> assets. See &#147;Business&#151;Licensing and Collaboration Arrangements&#148; for more information on the existing <FONT
STYLE="white-space:nowrap">out-licensing</FONT> arrangements. In addition, after validating clinical safety and preliminary efficacy of a drug candidate in our Global Portfolio in clinical trials in the United States, we may elect to <FONT
STYLE="white-space:nowrap">out-license</FONT> the global rights (excluding Greater China) of such drug candidate, while retaining the Greater China rights for further development and commercialization. But we may also choose to retain these rights
for the United States or other countries or regions as we may deem fit. Before the commercialization of one or more of our drug candidates, we expect that the majority of our revenue will continue to be generated from
<FONT STYLE="white-space:nowrap">out-licensing</FONT> our intellectual properties. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding for Our Operations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the periods presented, we funded our operations primarily from financing through the issuance and sale of preferred shares and
convertible promissory notes in private placement transactions. Going forward, in the event of successful commercialization of one or more of our drug candidates, we expect to fund our operations in part with revenue generated from sales of our
commercialized drug products. However, with the continuing expansion of our business and our product pipeline, we may require further funding through public or private offerings, debt financing, collaboration, and licensing arrangements or other
sources. Any fluctuation in our ability to fund our operations will impact our cash flow plan and our results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Ability to Commercialize Our Drug Candidates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business and results of operations depend on our ability to commercialize our drug candidates, once and if those candidates are approved
for marketing by the respective health authority. Currently, our pipeline consists of more than ten drug candidates ranging in development status from <FONT STYLE="white-space:nowrap">pre-clinical</FONT> to late-stage clinical programs. Although we
currently do not have any product approved for commercial sale and have not generated any revenue from product sales, we expect to generate revenue from sales of a drug candidate after we complete the clinical development, obtain regulatory
approval, and successfully commercialize such drug candidate. Our late-stage investigational drugs at or potentially near pivotal trials are TJ202, TJ101, TJ301 and enoblituzumab. See &#147;Business&#151;Our Drug Pipeline&#148; for more information
on the development status of our various drug candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Effect of Our Acquisition of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We acquired a controlling interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin on July&nbsp;15, 2017 and the
remaining interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin in May 2018. Since our acquisition of the controlling interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin on July&nbsp;15, 2017,
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin has been consolidated into our results of operations. Shortly after we acquired the controlling interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin, we integrated the operations of <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Tianjin into our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin did not
generate any external revenue from July&nbsp;15, 2017 to June 30, 2019. In connection with our acquisition of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin, we identified RMB148.8&nbsp;million of intangible assets and RMB162.6&nbsp;million
of goodwill of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin. Goodwill is not amortized, but impairment of goodwill assessment is performed on an least an annual basis on December&nbsp;31 or whenever events or changes in circumstances
indicate that the carrying value of the assets may not be recoverable. No impairment was identified as of December&nbsp;31, 2017 and 2018 and June 30, 2019. Impairment charges could substantially affect our results of operations in the periods of
such charges. In addition, impairment charges would negatively impact our financial ratios and could limit our ability to obtain financing in the future. See &#147;Risk Factors&#151;Risks Related to Our Industry, Business and
Operations&#150;&#150;Change in business prospects of acquisitions may result in impairment to our goodwill, which could negatively affect our reported results of operations.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Components of Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenues
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from product sales for the
foreseeable future before the successful commercialization of one or more of our drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generated substantially all of our
revenues for the years ended December&nbsp;31, 2017 and 2018 and the six months ended June 30, 2019 from granting licenses to use and otherwise exploit certain of our intellectual properties in connection with our
<FONT STYLE="white-space:nowrap">de-prioritized</FONT> assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses primarily consist of: (i)&nbsp;payroll and other related expenses of research and development personnel,
(ii)&nbsp;fees associated with the exclusive development rights of our <FONT STYLE="white-space:nowrap">in-licensed</FONT> drug candidates, (iii)&nbsp;fees for services provided by contract research organizations, investigators and clinical trial
sites that conduct our clinical studies, and (iv)&nbsp;expenses relating to the development of our drug candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current research and development activities primarily relate to the clinical development of the following investigational drugs: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">TJ202, a potential highly differentiated CD38 antibody for multiple myeloma and autoimmune diseases, if approved;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">TJ107, the first long-acting recombinant human IL-7 with the potential for cancer treatment-related lymphopenia
and cancer immunotherapy, if approved; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">TJ101, a potential highly differentiated long-acting growth hormone for growth hormone deficiency, if approved;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">TJ301, a potential highly differentiated <FONT STYLE="white-space:nowrap">IL-6</FONT> blocker for ulcerative
colitis and other autoimmune diseases, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Enoblituzumab, the most advanced clinical stage humanized B7-H3 antibody as a potential immuno-oncology
treatment, if approved; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">TJC4, a potential highly differentiated CD47 monoclonal antibody with unique
<FONT STYLE="white-space:nowrap">RBC-sparing</FONT> differentiation, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">TJD5, a potential highly differentiated CD73 antibody for immuno-oncology, if approved; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">TJM2, a <FONT STYLE="white-space:nowrap">GM-CSF</FONT> monoclonal antibody for rheumatoid arthritis and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CAR-T-related</FONT></FONT> therapies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incurred research
and development expenses of RMB267.1&nbsp;million and RMB426.0&nbsp;million (US$62.1 million) for the years ended December&nbsp;31, 2017 and 2018, respectively, representing 91.3% and 86.5% of our total research and development and administrative
expenses for the corresponding periods. We incurred research and development expenses of RMB265.1&nbsp;million (US$38.6&nbsp;million) for the six months ended June 30, 2019. We expect our research and development expenses to continue to increase for
the foreseeable future, as we continue to expand our operations and to advance our pipeline and our drug candidates toward later stages. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Administrative expenses primarily consist of salaries and related benefit costs, including share-based compensation, for employees engaged in
managerial and administrative positions or involved in general corporate functions, professional fees for consulting and auditing as well as other direct and allocated expenses for rental expenses for our facilities, travel costs and other supplies
used in administrative activities. For the years ended December&nbsp;31, 2017 and 2018 and the six months ended June 30, 2019, our administrative expenses amounted to RMB25.4&nbsp;million, RMB66.4&nbsp;million (US$9.7 million) and RMB574.6 million
(US$83.7 million), respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense consist primarily of interest expenses on our (i)&nbsp;short-term bank borrowings and (ii)&nbsp;convertible promissory notes
issued to certain investors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Income </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income consists primarily of interest income derived from our term deposit and restricted cash pledged as collateral for a working
capital loan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expenses), Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income consists primarily of income from other financial assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other expenses consist primarily of the net loss resulting from the conversion of a portion of our convertible promissory notes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Change of Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fair value change of warrants consists primarily of the <FONT STYLE="white-space:nowrap">non-cash</FONT> items incurred in connection with
changes in the fair value of our warrant liabilities that we issued to certain investors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Taxation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cayman Islands </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">I-Mab,</FONT> our holding entity, is incorporated in the Cayman Islands. Under the current laws of the Cayman Islands, <FONT STYLE="white-space:nowrap">I-Mab</FONT> is not subject to tax on income or capital gain.
Additionally, the Cayman Islands does not impose a withholding tax on payments of dividends to shareholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hong Kong </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited is incorporated in Hong Kong. Companies registered in Hong Kong are
subject to Hong Kong profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Hong Kong tax laws. The applicable tax rate is 16.5% in Hong Kong. For the years ended
December&nbsp;31, 2017 and 2018 and the six months ended June 30, 2019, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited did not make any provisions for Hong Kong profit tax as there were no assessable profits derived from
or earnings in Hong Kong for any of the periods presented. Under the Hong Kong tax law, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited is exempted from income tax on its foreign-derived income and there are no withholding
taxes in Hong Kong on remittance of dividends. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Ltd. is incorporated in Maryland and is subject to U.S. federal corporate income tax
at a rate of 21%. It is also subject to state income tax in Maryland at a rate of 8.25%. <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Ltd. has no taxable income for all periods presented and therefore no provision for income taxes is
required. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>China </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
March&nbsp;16, 2007, the National People&#146;s Congress of PRC enacted a new Corporate Income Tax Law (&#147;new CIT law&#148;), under which Foreign Investment Enterprises (&#147;FIEs&#148;) and domestic companies would be subject to corporate
income tax at a uniform rate of 25%. The new CIT law became effective on January&nbsp;1, 2008. Under the new CIT law, preferential tax treatments will continue to be granted to entities which conduct businesses in certain encouraged sectors and to
entities otherwise classified as &#147;High and New Technology Enterprises.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai
has been qualified as a &#147;High and New Technology Enterprise&#148; and enjoys a preferential income tax rate of 15% from 2018 to 2020. No provision for income taxes has been accrued because all of our PRC subsidiaries are in cumulative loss
positions for all the periods presented. <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin is subject to the statutory income tax at a rate of 25%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered more likely than not that some portion or
all of the deferred tax assets will not be realized in the foreseeable future. In making such determination, we evaluate a variety of positive and negative factors including our operating history, accumulated deficit, the existence of taxable
temporary differences and reversal periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred net accumulated operating losses for income tax purposes since our
inception. We believe that it is more likely than not that these net accumulated operating losses will not be utilized in the future. Therefore, we have provided full valuation allowances for the deferred tax assets as of December&nbsp;31, 2017 and
2018 and June 30, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We evaluate each uncertain tax position (including the potential application of interest and penalties) based on
the technical merits, and measure the unrecognized benefits associated with the tax positions. As of December&nbsp;31, 2017 and 2018 and June 30, 2019, we did not have any significant unrecognized uncertain tax positions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of our consolidated results of operations for the periods indicated. This information should be read
together with our consolidated financial statements and related notes included elsewhere in this prospectus. The operating results in any period are not necessarily indicative of the results that may be expected for any future period. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Six Months Ended June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>(in thousands, except for share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenues</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensing and collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(267,075</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(426,028</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,058</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(202,693</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(265,084</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,614</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,671</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,687</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(574,584</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83,698</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280,955</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(438,638</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,895</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(200,003</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(824,668</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(120,127</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,704</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,097</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expenses), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,444</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,594</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,027</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,854</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before income tax expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(401,111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58,428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(166,720</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(857,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(251</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58,679</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(166,720</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(857,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Note:
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Share-based compensation expenses were allocated as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Six Months Ended June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Administrative expenses*</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,039</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,520</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>513</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,929</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>366,356</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,366</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">The above share-based compensation expenses do not include the expenses arising from the repurchase of share
awards held by a director of our company during the six months ended June 30, 2019. See Note 17 (d) to our unaudited interim condensed consolidated financial statements included elsewhere in this prospectus for more details. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of </B><B>Six</B><B> Months Ended </B><B>June 30, 2019 and 2018</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenues </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenues generated
from licensing and collaboration decreased by 29.8% from RMB21.4 million for the six months ended June 30, 2018 to RMB15.0 million (US$2.2 million) for the six months ended June 30, 2019. Our revenues generated in the six months ended June 30, 2018
solely consisted of HDYM&#146;s upfront payment to us pursuant to our out-licensing arrangement with HDYM. Our revenues generated in the six months ended June 30, 2019 solely consisted of CSPC entity&#146;s upfront payment to us pursuant to our
out-licensing arrangement with CSPC entity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth a breakdown of the major components of our research and development expenses in absolute amounts and as a
percentage of our total research and development expenses for the periods indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Six Months Ended June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CRO service fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">In-licensed patent right fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee benefit expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Material costs for drug candidates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">265,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development expenses increased by 30.8% from RMB202.7 million for the six months ended June
30, 2018 to RMB265.1 million (US$38.6 million) for the six months ended June 30, 2019, primarily attributable to (i) an increase in the CRO service fees from RMB87.2 million for the six months ended June 30, 2018 to RMB144.8 million (US$21.1
million) for the six months ended June 30, 2019, as we initiated a few more research and development programs and advanced some of our existing investigational drugs into more advanced clinical development stages; and (ii) an increase in employee
benefit expenses of employees involved in research and development from RMB20.8 million for the six months ended June 30, 2018 to RMB44.8 million (US$6.5&nbsp;million) for the six months ended June 30, 2019, due to an increase in the headcount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the six months ended June 30, 2019, 81.7% and 18.3% of our total research and development expenses were attributable to clinical programs
and preclinical programs, respectively. In the six months ended June 30, 2018, 86.0% and 14.0% of our total research and development expenses were attributable to clinical programs and preclinical programs, respectively. For the six months ended
June 30, 2019, TJ202 represented approximately 63.8% of our external research and development expenses, which primarily included licensing fees and payments to CROs and CMOs. For the six months ended June 30, 2018, TJ107 represented approximately
46.3% of our external research and development expenses, which primarily included licensing fees and payments to CROs and CMOs. No other programs represented a significant amount of research and development expenses in the six months ended June 30,
2019 and 2018. Though we manage our external research and development expenses by program, we do not allocate our internal research and development expenses by program because our employees and internal resources may be engaged in projects for
multiple programs at any time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our administrative expenses increased from RMB18.7 million for the six months ended June 30, 2018 to RMB574.6 million (US$83.7 million) for the
six months ended June 30, 2019, primarily attributable to (i) stock options granted to a director of our company under the 2018 Plan, (ii) repurchase of share awards held by a director of our company, (iii) the increase in employee benefit expenses
due to headcount increase, and (iv) the increase in third-party professional expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Income </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recorded RMB1.0 million of interest income for the six months ended June 30, 2018 and RMB12.9 million (US$1.9 million) of interest income
for the six months ended June 30, 2019. The change was primarily attributable to the interest income derived from bank deposits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recorded RMB9.1 million of interest expense for the six months ended June 30, 2018 and RMB1.9 million (US$0.3 million) of interest expense
for the six months ended June 30, 2019. The change was primarily attributable to the interest expense related to our convertible promissory notes, which were converted in June and July 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expenses), Net </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
recorded RMB21.6 million of other expenses for the six months ended June 30, 2018 and RMB0.3 million (US$0.04 million) of other income for the six months ended June 30, 2019. The change was primarily attributable to the conversion of a portion of
our convertible promissory notes during the six months ended June&nbsp;30, 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Change of Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recorded a gain from change in the fair value of warrant liability of RMB63.0 million for the six months ended June 30, 2018, and a loss
from change in the fair value of warrant liability of RMB43.9 million (US$6.4 million) for the six months ended June 30, 2019. The change was primarily attributable to (i) the change in fair value of warrants due to the increase in the valuation of
our company, and (ii) the modification in 2018 that added certain forfeiture conditions to the warrants, which increased the possibility of forfeiture of the warrants and therefore resulted in a reduction in our warrant liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of Twelve Months Ended December&nbsp;31, 2018 and 2017 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenues </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenues generated
from licensing and collaboration increased by 365.4% from RMB11.6&nbsp;million for the year ended December&nbsp;31, 2017 to RMB53.8&nbsp;million (US$7.8 million) for the year ended December&nbsp;31, 2018. Our revenues generated for the year ended
December 31, 2017 consisted solely of HDYM&#146;s milestone payment to us pursuant to our out-licensing arrangement with it. Our revenues generated for the year ended December 31, 2018 consisted of both HDYM&#146;s milestone payment and ABL
Bio&#146;s upfront payment to us pursuant to our out-licensing arrangements with them, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth a breakdown of the major components of our research and development expenses in absolute amounts and as a
percentage of our total research and development expenses for the periods indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CRO service fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">In-licensed</FONT> patent right fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employment benefit expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Material costs for drug candidates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development expenses increased by 59.5% from RMB267.1&nbsp;million for the year ended
December&nbsp;31, 2017 to RMB426.0&nbsp;million (US$62.1 million) for the year ended December&nbsp;31, 2018, primarily </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
attributable to (i)&nbsp;an increase in the CRO service fees from RMB83.0&nbsp;million in 2017 to RMB212.3&nbsp;million (US$30.9 million) in 2018, as we initiated a few more research and
development programs and advanced some of our existing investigational drugs into more advanced clinical development stages; and (ii)&nbsp;an increase in employee benefit expenses of employees involved in research and development from
RMB26.8&nbsp;million in 2017 to RMB56.6&nbsp;million (US$8.2 million) in 2018, due to an increase in the headcount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2018, 72.3% and
27.7% of our total research and development expenses were attributable to clinical programs and pre-clinical programs, respectively. In 2017, 77.5% and 22.5% of our total research and development expenses were attributable to clinical programs and
pre-clinical programs, respectively. In 2018, TJ107 and TJ202 represented approximately 25.0% and 9.9% of our external research and development expenses, which primarily included licensing fees and payments to CROs and CMOs. In 2017, TJ202
represented approximately 59.1% of our external research and development expenses, which primarily included licensing fees and payments to CROs and CMOs. No other programs represented a significant amount of research and development expenses in 2018
and 2017. Though we manage our external research and development expenses by program we do not allocate our internal research and development expenses by program because our employees and internal resources may be engaged in projects for multiple
programs at any time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our administrative expenses increased from RMB25.4&nbsp;million for the year ended December&nbsp;31, 2017 to RMB66.4&nbsp;million (US$9.7
million) for the year ended December&nbsp;31, 2018, primarily attributable to (i) the increase in employee benefit expenses due to headcount increase, and (ii) the increase in third-party professional expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Income </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recorded
RMB0.9 million of interest income for the year ended December 31, 2017 and RMB4.6 million (US$0.7 million) of interest income for the year ended December 31, 2018. The change was primarily attributable to the interest income derived from our bank
deposits. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recorded RMB5.6 million of interest expense for the year ended December 31, 2017 and RMB11.7 million (US$1.7 million) of interest expense
for the year ended December 31, 2018. The change was primarily attributable to (i) the interest expense accrued on the one-year bank borrowing facilities we entered into in the third quarter of 2017 and 2018, respectively; and (ii) the interest
expense related to our convertible promissory notes, which were converted in June and July 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expenses), Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recorded RMB1.5&nbsp;million of other income for the year ended December&nbsp;31, 2017 and RMB16.8&nbsp;million (US$2.4 million) of other
expenses for the year ended December&nbsp;31, 2018. The change was primarily attributable to the net loss resulting from the conversion of a portion of our convertible promissory notes, partially offset by an increase in the income from the other
financial assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Change of Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recorded a loss from change in the fair value of warrant liability of RMB14.0&nbsp;million for the year ended December&nbsp;31, 2017, and a
gain from change in the fair value of warrant liability of RMB61.4&nbsp;million (US$8.9 million) for the year ended December&nbsp;31, 2018. The change was primarily attributable to (i)&nbsp;the change in fair value of warrants due to the increase in
the valuation of our company, and (ii)&nbsp;the modification in 2018 that added certain forfeiture conditions to the warrants, which increased the possibility of forfeiture of the warrants and therefore resulted in a reduction in our warrant
liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, we have incurred net losses and negative cash flows from our operations. Substantially all of our losses have resulted from
funding our research and development programs and administrative costs associated with our operations. We incurred net losses of RMB298.2&nbsp;million, RMB402.8&nbsp;million (US$58.7&nbsp;million) and RMB857.3 million (US$124.9 million) for the
years ended December&nbsp;31, 2017 and 2018 and the six months ended June 30, 2019, respectively. Our primary use of cash is to fund our research and development activities. We used RMB252.2&nbsp;million, RMB280.7&nbsp;million (US$40.9 million) and
RMB389.0 million (US$56.7&nbsp;million) in cash for our operating activities for the years ended December&nbsp;31, 2017 and 2018 and the six months ended June 30, 2019, respectively. Historically, we have financed our operations principally through
proceeds from the issuance and sale of preferred shares and convertible promissory notes in private placement transactions. For more information of our equity financing, see &#147;Description of Share Capital&#151;History of Securities
Issuances.&#148; As of June 30, 2019, we had cash, cash equivalents and restricted cash of RMB1,416.9&nbsp;million (US$206.4 million). Our cash, cash equivalents and restricted cash consist primarily of cash in bank and on hand. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of our cash flows for the periods presented: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Six Months Ended June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>2017</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>2018</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>2018</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><FONT STYLE="font-size:8pt"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(252,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,889</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,653<B></B></TD>
<TD NOWRAP VALIGN="bottom">)<B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(389,034</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,669</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) generated from investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157,665</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,400<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>158,056</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) generated from financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">758,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,479,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,116<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>(30,000</TD>
<TD NOWRAP VALIGN="bottom"><B></B>)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,370</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash and cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,737</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,093</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(451</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,268,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,126<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>(264,071</TD>
<TD NOWRAP VALIGN="bottom"><B></B>)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,466</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, beginning of the year/period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>1,680,931</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, end of the year/period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">504,839<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>1,416,860</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not expect to generate any revenue from product sales unless and until we obtain regulatory
approval of and commercialize one of our current or future drug candidates. We anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek
regulatory approvals for, our drug candidates and begin to commercialize any approved products. Upon the completion of this offering, we expect to incur additional costs associated with operating as a public company. In addition, subject to
obtaining regulatory approval of any of our drug candidates, we expect to incur significant commercialization expenses for product sales, marketing and manufacturing. Accordingly, we anticipate that we will need substantial additional funding in
connection with our continuing operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our current operating plan, we believe that our current cash and cash equivalents and
proceeds from this offering will be sufficient to meet our current and anticipated working capital requirements and capital expenditures for at least the next 12 months. In that time, we expect that our expenses will increase substantially as we
fund new and ongoing research and development activities and working capital needs. We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of the
numerous risks and uncertainties associated with the development and commercialization of our drug candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures necessary to complete the development and
commercialization of our drug candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After this offering, we may decide to enhance our liquidity position or increase our cash
reserve for future operations and investments through additional financing. The issuance and sale of additional equity would result in further dilution to our shareholders and ADS holders, and the terms of these securities may include liquidation or
other preferences that adversely affect your rights as an ADS holder. The incurrence of indebtedness would result in increased fixed obligations and could result in operating covenants that would restrict our operations, which could potentially
dilute your interest. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or research programs
or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future
commercialization efforts or grant rights to develop and market products or drug candidates that we would otherwise prefer to develop and market ourselves. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2019, 14% of our cash and cash equivalents were denominated in RMB and held in China. In utilizing the proceeds we expect to
receive from this offering, we may make additional capital contributions to our PRC subsidiaries, establish new PRC subsidiaries and make capital contributions to these new PRC subsidiaries, make loans to our PRC subsidiaries, or acquire offshore
entities with business operations in China in offshore transactions. However, most of these uses are subject to PRC regulations and approvals. See &#147;Risk Factors&#151;Risks Related to Doing Business in China&#151;PRC regulation of loans to and
direct investment in PRC entities by offshore holding companies and governmental control of currency conversion may delay or prevent us from using the proceeds of this offering to make loans to our PRC subsidiaries in China, which could materially
and adversely affect our liquidity and our ability to fund and expand our business&#148; and &#147;Use of Proceeds&#148; for more information on the related PRC rules and regulations on the use of proceeds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the majority of our future revenues will be denominated in RMB. Under existing PRC foreign exchange regulations, payments of
current account items, including profit distributions, interest payments and trade and service-related foreign exchange transactions, can be made in foreign currencies without prior SAFE approval as long as certain routine procedural requirements
are fulfilled. Therefore, our PRC subsidiaries are allowed to pay dividends in foreign currencies to us without prior SAFE approval by following certain routine procedural requirements. However, approval from or registration with competent
government authorities is required where RMB is to be converted into foreign currency and remitted out of China to pay capital expenses such as the repayment of loans denominated in foreign currencies. The PRC government may at its discretion
restrict access to foreign currencies for current account transactions in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Operating Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the six months ended June 30, 2019 was RMB389.0 million (US$56.7 million). Our net loss was RMB857.3
million (US$124.9 million) for the same period. The difference between our net loss and our net cash used in operating activities was primarily attributable to certain non-cash expenses or gains, including share-based compensation of RMB366.4
million (US$53.4 million) and fair value loss of warrants of RMB43.9 million (US$6.4 million), and changes in certain working capital items, including an increase in the research and development funding of RMB51.6 million (US$7.5 million), partially
offset by an decrease in advance from customers of RMB14.2 million (US$2.1 million). The change in share-based compensation was attributable to issuances of share rewards to a director in 2019. The change in fair value of warrant liabilities was
attributable to the increase in the valuation of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the year ended December&nbsp;31,
2018 was RMB280.7&nbsp;million (US$40.9 million). Our net loss was RMB402.8&nbsp;million (US$58.7 million) for the same period. The difference between our net loss and our net cash used in operating activities was primarily attributable to certain <FONT
STYLE="white-space:nowrap">non-cash</FONT> expenses or gains, including fair value gains of warrants of RMB61.4&nbsp;million (US$8.9 million), and changes in certain working capital items, including (i)&nbsp;an increase in the research and
development funding of RMB178.7&nbsp;million (US$26.0 million) and (ii)&nbsp;an increase in accruals and other payables of RMB55.6&nbsp;million </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(US$8.1 million), partially offset by an increase in prepayments and other receivables of RMB76.3&nbsp;million (US$11.1 million). The accruals and other payables principally consist of accrued
external research and development activities related expenses and staff salaries and welfare payables. The change in fair value of warrant liabilities was attributable to the exercise of part of the warrants issued in 2017 and the modification in
2018 that added certain forfeiture conditions to the warrants. Prepayments and other receivables primarily consist of our prepayment to CRO partners and value-added tax recoverable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the year ended December&nbsp;31, 2017 was RMB252.2&nbsp;million. Our net loss was
RMB298.2&nbsp;million. The difference between our net loss and our net cash used in operating activities was primarily attributable to certain <FONT STYLE="white-space:nowrap">non-cash</FONT> expenses or gains, including the fair value loss of
warrant liabilities of RMB14.0&nbsp;million, and changes in certain working capital items, including (i)&nbsp;an increase in contract liabilities of RMB15.8&nbsp;million and (ii)&nbsp;a decrease in prepayments and other receivables of
RMB8.8&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Investing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash generated from investing activities for the six months ended June 30, 2019 was RMB158.1 million (US$23.0 million). The net cash
increase was primarily attributable to RMB160.0 million (US$23.3 million) of the cash received from disposal of other financial assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash generated from investing activities for the year ended December&nbsp;31, 2018 was RMB9.5&nbsp;million (US$1.4 million). The net cash
increase was primarily attributable to RMB40.0&nbsp;million (US$5.8 million) of the cash received from disposal of other financial assets, partially offset by RMB30.0&nbsp;million (US$4.4 million) of the cash used in other financial assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities for the year ended December&nbsp;31, 2017 was RMB157.7&nbsp;million. The net cash decrease was primarily
attributable to RMB369.0&nbsp;million of investments in other financial assets, partially offset by RMB133.0&nbsp;million of proceeds from disposal of other financial assets and RMB93.3&nbsp;million of cash acquired from acquisition of <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Tianjin. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Financing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in financing activities for the six months ended June 30, 2019 was RMB30.0 million (US$4.4 million), primarily attributable to
the repayment of bank borrowings of RMB80.0 million (US$11.7 million), partially offset by the proceeds of bank borrowings of RMB50.0 million (US$7.3 million). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash generated from financing activities in the year ended December&nbsp;31, 2018 was RMB1,479.7&nbsp;million (US$215.5 million),
primarily attributable to (i)&nbsp;proceeds from issuance of RMB1,306.6&nbsp;million (US$190.3 million) convertible preferred shares and (ii)&nbsp;receipt of RMB132.3&nbsp;million (US$19.3 million) resulting from the exercise of warrants by
investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash generated from financing activities in the year ended December&nbsp;31, 2017 was RMB758.6&nbsp;million, primarily
attributable to proceeds of our issuance of RMB346.5&nbsp;million convertible preferred shares, RMB161.2&nbsp;million redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest and RMB99.0&nbsp;million proceeds from bank borrowings.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Capital Expenditures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our capital expenditures were incurred for purposes of purchasing property, equipment and software. Our capital expenditures were
RMB20.3&nbsp;million, RMB14.4&nbsp;million (US$2.1 million) and RMB1.9 million (US$0.3 million) in the years ended December&nbsp;31, 2017 and 2018 and the six months ended June 30, 2019, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our capital expenditures in 2019 will primarily consist of purchase of intangible assets and the costs relating to construction
of our manufacturing facility in Hangzhou, China. We intend to fund our future capital expenditures with our existing cash and proceeds from this offering. We will continue to make capital expenditures to meet the expected growth of our business.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our contractual obligations as of December&nbsp;31, 2018: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than&nbsp;1&nbsp;year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">1-3</FONT> years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">3-5</FONT> years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than&nbsp;5&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="38" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease commitments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operating lease commitments relate to leases for our office premises pursuant to <FONT
STYLE="white-space:nowrap">non-cancellable</FONT> operating lease agreements. Other than as shown above, we did not have any significant capital and other commitments, long-term obligations or guarantees as of December&nbsp;31, 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Commitments and Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not entered into any financial guarantees or other commitments to guarantee the payment obligations of any third parties. In addition,
we have not entered into any derivative contracts that are indexed to our shares and classified as shareholder&#146;s equity or that are not reflected in our consolidated financial statements. Furthermore, we do not have any retained or contingent
interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or
credit support to us or engages in leasing, hedging or product development services with us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Internal Control Over Financial Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, we have been a private company with limited accounting personnel and other resources with which to address our internal
control over financial reporting. In connection with the audits of our consolidated financial statements included in this prospectus, we and our independent registered public accounting firm identified the following material weaknesses and other
control deficiencies in our internal control over financial reporting. As defined in the standards established by the U.S. Public Company Accounting Oversight Board, a &#147;material weakness&#148; is a deficiency, or combination of deficiencies, in
internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company&#146;s annual or interim financial statements will not be prevented or detected on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The material weaknesses that have been identified relate to (i)&nbsp;our lack of sufficient and competent financial reporting and accounting
personnel with appropriate knowledge of U.S. GAAP and SEC reporting and compliance requirements, to formalize key controls over financial reporting and to prepare consolidated financial statements and related disclosures; and (ii)&nbsp;our lack of
sufficient documented financial closing policies and procedures, specifically those related to (a)&nbsp;accounting for licensing and collaboration agreements and (b)&nbsp;period end expenses <FONT STYLE="white-space:nowrap">cut-off</FONT> and
accruals. These material weaknesses, if not timely remedied, may lead to significant misstatements in our consolidated financial statements in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have implemented and plan to implement a number of measures to address the material weaknesses that have been identified in connection with
the audits of our consolidated financial statements as of and for the years ended December&nbsp;31, 2017 and 2018 and the review of the consolidated financial statements as of and for the six months ended June 30, 2019. We have hired additional
qualified financial and accounting staff with working experience of U.S. GAAP and SEC reporting requirements, and plan to continue such hiring efforts. We intend to conduct regular and continuous U.S. GAAP accounting and financial reporting training
programs for our financial reporting and accounting personnel. We further intend to establish sufficient and formal financial closing policies and procedures, specifically those related to accounting for licensing and collaboration arrangements and
period end <FONT STYLE="white-space:nowrap">cut-off</FONT> and accruals. We plan to, as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">work-in-progress,</FONT></FONT> engage an external consulting firm to assist us to assess
Sarbanes-Oxley Act compliance requirements and improve our overall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
internal controls. Furthermore, we plan to prepare more detailed guidance on accounting policies, manuals and closing procedures to improve the quality and accuracy of our period end financing
closing process. We will continue to implement these and other measures to remediate our internal control deficiencies. We may incur significant costs in the implementation of such measures. However, the implementation of these measures may not
fully address the deficiencies in our internal control over financial reporting, and we cannot assure you that all of these measures will be sufficient to remediate our material weakness in time, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a company with less than US$1.07&nbsp;billion in revenue for our last fiscal year, we qualify as an &#147;emerging growth company&#148;
pursuant to the JOBS Act. An emerging growth company may take advantage of specified reduced reporting and other requirements that are otherwise applicable generally to public companies. These provisions include exemption from the auditor
attestation requirement under Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 in the assessment of the emerging growth company&#146;s internal control over financial reporting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Inflation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, inflation in China
has not materially affected our results of operations. According to the National Bureau of Statistics of China, the year-over-year percent changes in the consumer price index for January&nbsp;2017, 2018 and 2019 were increases of 2.5%, 1.5% and
1.7%, respectively. Although we have not been materially affected by inflation in the past, we may be affected if China experiences higher rates of inflation in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Holding Company Structure </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a
holding company with no material operations of its own. We currently conduct our operations primarily through our PRC subsidiaries. As a result, our ability to pay dividends depends upon dividends paid by our PRC subsidiaries. If our existing PRC
subsidiaries or any newly formed ones incur debt on their own behalf in the future, the instruments governing their debt may restrict their ability to pay dividends to us. In addition, our wholly foreign-owned subsidiaries in China are permitted to
pay dividends to us only out of its retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. Under PRC law, each of our subsidiaries and their subsidiaries in China is required to set aside at least 10%
of its <FONT STYLE="white-space:nowrap">after-tax</FONT> profits each year, if any, to fund certain statutory reserve funds until such reserve funds reach 50% of their registered capital. In addition, our wholly foreign-owned subsidiaries in China
may allocate a portion of their <FONT STYLE="white-space:nowrap">after-tax</FONT> profits based on PRC accounting standards to enterprise expansion funds and staff bonus and welfare funds at their discretion, and their subsidiaries may allocate a
portion of their <FONT STYLE="white-space:nowrap">after-tax</FONT> profits based on PRC accounting standards to a surplus fund at their discretion. The statutory reserve funds and the discretionary funds are not distributable as cash dividends.
Remittance of dividends by a wholly foreign-owned company out of China is subject to examination by the banks designated by SAFE. Our PRC subsidiaries have not paid dividends and will not be able to pay dividends until they generate accumulated
profits and meet the requirements for statutory reserve funds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Interest and Credit Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We had cash, cash equivalents and restricted cash of RMB412.7&nbsp;million, RMB1,680.9&nbsp;million (US$244.9 million) and RMB1,416.9 million
(US$206.4 million) as of December&nbsp;31, 2017 and 2018 and June 30, 2019, respectively. Our exposure to interest rate risk primarily relates to the interest income generated by excess cash, which is mostly held in interest-bearing bank deposits.
Interest-earning instruments carry a degree of interest rate risk. We have not been exposed to material risks due to changes in interest rates, and we have not used any derivative financial instruments to manage our interest risk exposure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our credit risk is primarily attributable to the carrying amounts of cash and cash equivalents. The carrying amounts of cash and cash
equivalents represent the maximum amount of loss due to credit risk. We mainly place </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or invest cash and cash equivalents with state-owned or reputable financial institutions in the PRC, and reputable financial institutions outside of the PRC. We do not believe that our cash and
cash equivalents have significant risk of default or illiquidity, and we will continually monitor the credit worthiness of these financial institutions. While we believe our cash and cash equivalents do not contain excessive risk, future investments
may be subject to adverse changes in market value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Exchange Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most of our revenues and expenses are denominated in RMB. Our management considers that the business is not exposed to any significant foreign
exchange risk and we have not used any derivative financial instruments to hedge exposure to such risk. Although our exposure to foreign exchange risks should be limited in general, the value of your investment in our ADSs will be affected by the
exchange rate between U.S. dollar and RMB because the value of our business is effectively denominated in RMB, while our ADSs will be traded in U.S. dollars. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">RMB is not freely convertible into foreign currencies for capital account transactions. The value of RMB against the U.S. dollar and other
currencies is affected by, among other things, changes in China&#146;s political and economic conditions and China&#146;s foreign exchange prices. On July&nbsp;21, 2005, the PRC government changed its policy of pegging the value of the RMB to the
U.S. dollar. Following the removal of the U.S. dollar peg, the RMB appreciated more than 20% against the U.S. dollar over the following three years. Between July 2008 and June 2010, this appreciation halted and the exchange rate between the RMB and
the U.S. dollar remained within a narrow band. Since June 2010, the PRC government has allowed the RMB to appreciate slowly against the U.S. dollar again, and it has appreciated more than 10% since June 2010. On August&nbsp;11, 2015, the
People&#146;s Bank of China announced plans to improve the central parity rate of the RMB against the U.S. dollar by authorizing market-makers to provide parity to the China Foreign Exchange Trading Center operated by the People&#146;s Bank of China
with reference to the interbank foreign exchange market closing rate of the previous day, the supply and demand for foreign currencies as well as changes in exchange rates of major international currencies. Effective from October&nbsp;1, 2016, the
International Monetary Fund added RMB to its Special Drawing Rights currency basket. Such change and additional future changes may increase volatility in the trading value of the RMB against foreign currencies. The PRC government may adopt further
reforms of its exchange rate system, including making the RMB freely convertible in the future. Accordingly, it is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between RMB and the U.S. dollar
in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that we need to convert U.S. dollars into RMB for our operations, appreciation of RMB against the U.S.
dollar would reduce the RMB amount we receive from the conversion. Conversely, if we decide to convert RMB into U.S. dollars for the purpose of making payments for dividends on our ordinary shares or ADSs, servicing our outstanding debt, or for
other business purposes, appreciation of the U.S. dollar against the RMB would reduce the U.S. dollar amounts available to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June
30, 2019, we had <FONT STYLE="white-space:nowrap">RMB-denominated</FONT> cash, cash equivalents and restricted cash of RMB171.6&nbsp;million (US$25.0 million). A 10% depreciation of RMB against U.S. dollar based on the foreign exchange rate on June
30, 2019 would result in a decrease of US$2.5&nbsp;million in cash and cash equivalents. A 10% appreciation of RMB against U.S. dollar based on the foreign exchange rate on June 30, 2019 would result in an increase of US$2.5&nbsp;million in cash and
cash equivalents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared
in accordance with U.S. GAAP. The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure
of contingent assets and liabilities at </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used when accounting for amounts recorded in
connection with acquisitions, including initial fair value determinations of assets and liabilities and other intangible assets as well as subsequent fair value measurements. Additionally, estimates are used in determining items such as useful lives
of property, plant and equipment, write-down of inventories, allowance for doubtful accounts, share-based compensation, impairment of long-lived assets, impairment of other intangible asset and goodwill, taxes on income, tax valuation allowances and
revenues from research and development projects. Actual results could differ from those estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We adopted Accounting Standard Codification (&#147;ASC&#148;) 606, Revenue from Contracts with Customers (Topic 606) (&#147;ASC 606&#148;) for
all periods presented. Consistent with the criteria of Topic 606, we recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange
for those goods or services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs
the following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction price, including variable consideration, if any; (iv)&nbsp;allocate the
transaction price to the performance obligations in the contract; and (v)&nbsp;recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that the entity will
collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once a contract is
determined to be within the scope of ASC 606 at contract inception, we review the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. We recognize as revenue the amount of the
transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At contract inception, we analyze its collaboration arrangements to assess whether they are within the scope of ASC 808, Collaborative
Arrangements (&#147;ASC 808&#148;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the
commercial success of such activities. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, we first determine if the collaboration is deemed to be within the scope of ASC 808 and those that are more reflective
of a vendor-customer relationship and therefore within the scope of ASC 606. For the collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our collaborative arrangements may contain more than one unit of account, or performance obligation, including grants of licenses to
intellectual property rights, agreement to provide research and development services and other deliverables. The collaborative arrangements do not include a right of return for any deliverable. As part of the accounting for these arrangements, we
must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. In developing the stand-alone selling price for a performance obligation, we consider competitor
pricing for a similar or identical product, market awareness of and perception of the product, expected product life and current market trends. In general, the consideration allocated to each performance obligation is recognized when the respective
obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is not constrained. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When the timing of the delivery of product is different from the timing of payments made by
the customers, we recognizes either a contract asset (performance precedes the contractual due date) or a contract liability (customer payment precedes performance). Our contractual payment terms are typically due in no more than 30&nbsp;days from
invoicing. In limited situations, certain customer contractual payment terms require us to bill in arrears; thus, we satisfy some or all of our performance obligations before we are contractually entitled to bill the customer. In these situations,
billing occurs subsequent to revenue recognition, which results in a contract asset. For example, certain of the contractual arrangements do not permit us to bill until the completion of the production of the samples. In other limited situations,
certain customer contractual payment terms allow us to bill in advance; thus, we receive customer cash payment before satisfying some or all of its performance obligations. In these situations, billing occurs in advance of revenue recognition, which
results in contract liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Licenses of Intellectual Property </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upfront <FONT STYLE="white-space:nowrap">non-refundable</FONT> payments for licensing our intellectual property are evaluated to determine if
the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, we recognize revenues from <FONT STYLE="white-space:nowrap">non-refundable,</FONT>
<FONT STYLE="white-space:nowrap">up-front</FONT> fees allocated to the license at a point in time, when the license is transferred to the licensee and the licensee is able to use and benefit from the license. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Services </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The portion of the transaction price allocated to research and development services performance obligations is deferred and recognized as
collaboration revenue over time as delivery or performance of such services occurs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Milestone Payments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, we evaluate whether the
milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount
method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each
subsequent reporting period, we <FONT STYLE="white-space:nowrap">re-evaluate</FONT> the probability of achieving such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such
adjustments are recorded on a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> basis, which would affect revenues and earnings in the period of adjustment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Royalties </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i)&nbsp;when the
related sales occur, or (ii)&nbsp;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Elements of research and development expenses primarily include: (1)&nbsp;payroll and other related expenses of personnel engaged in research
and development activities, <FONT STYLE="white-space:nowrap">(2)&nbsp;in-licensed</FONT> patent rights fee of exclusive development rights of drugs granted to us, (3)&nbsp;expenses related to <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
testing of our technologies under development and clinical trials such as payments to contract research organizations (&#147;CRO&#148;), investigators and clinical trial sites that conduct our clinical studies, (4)&nbsp;costs to develop the drug
candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses, and (5)&nbsp;other research and development expenses. Research and development expenses are charged to expense as incurred when these
expenditures relate to our research and development services and have no alternative future uses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acquired rights to develop and commercialize drug candidates. Upfront payments that
relate to the acquisition of a new drug compound, as well as <FONT STYLE="white-space:nowrap">pre-commercial</FONT> milestone payments, are immediately expensed as acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development
in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#147;business&#148; as defined under U.S. GAAP, the drug has not achieved regulatory approval for
marketing and, absent obtaining such approval, has no established alternative future use. Milestone payments made to third parties subsequent to regulatory approval would be capitalized as intangible assets and amortized over the estimated remaining
useful life of the related product. The conditions enabling capitalization of development expenses as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We grant restricted shares and stock options to eligible employees and account for share-based compensation in accordance with ASC 718,
<I>Compensation</I>&#151;<I>Stock Compensation.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Employees&#146; share-based compensation awards are measured at the grant date fair
value of the awards and recognized as expenses (i) immediately at the grant date if no vesting conditions are required; (ii) for share-based awards granted with only service conditions, using the graded vesting method net of estimated forfeitures
over the vesting period; or (iii) for share-based awards granted with service conditions and the occurrence of an initial public offering as performance condition cumulative share-based compensation expenses for the options that have satisfied the
service condition should be recorded upon the completion of the initial public offering using the graded vesting method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A change in any
of the terms or conditions of share-based awards is accounted for as a modification of the awards. We calculate incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the
original awards immediately before its terms are modified at the modification date. For vested awards, we recognize incremental compensation cost in the period when the modification occurs. For awards not being fully vested, we recognize the sum of
the incremental compensation expense and the remaining unrecognized compensation expense for the original awards over the remaining requisite service period after modification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Share-based compensation in relation to the restricted shares is measured based on the fair market value of our ordinary shares at the grant
date of the award. Prior to the listing, estimation of the fair value of our ordinary shares involves significant assumptions that might not be observable in the market, and a number of complex and subjective variables, including discount rate, and
subjective judgments regarding our projected financial and operating results, its unique business risks, the liquidity of its ordinary shares and its operating history and prospects at the time the grants are made. Share-based compensation in
relation to the share options is estimated using the Binominal Option Pricing Model. The determination of the fair value of share options is affected by the share price of our ordinary shares as well as the assumptions regarding a number of complex
and subjective variables, including the expected share price volatility, risk-free interest rate, exercise multiple and expected dividend yield. The fair value of these awards was determined with the assistance from an independent valuation firm.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted ordinary shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During
the year ended December&nbsp;31, 2016, we issued 4,019,554 ordinary shares to Mr. Zang Jingwu Zhang, Ms. Qian Lili, Mr. Wang Zhengyi and Mr. Fang Lei (collectively the &#147;Founders&#148;), and we recorded share-based compensation expense of
RMB18.7&nbsp;million for issuance and grant of 3,650,253 ordinary shares to the Founders in June 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2016, the Founders
entered into an arrangement with our other investors, and the 87,441 ordinary shares issued to the Founders in June 2016 were cancelled, and out of the remaining 3,932,113 ordinary shares </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
held by the Founders, 70% became restricted and subject to service vesting conditions, that shall vest 20%, 20% and 30% over the next three years, respectively, and these unvested restricted
shares will be vested immediately upon the listing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred share-based compensation was measured for the restricted shares using the
estimated fair value of our ordinary shares of US$0.77 at the date of imposition of the restriction in October 2016, and was amortized to the consolidated statements of comprehensive loss by using graded vesting method over the vesting term of
3&nbsp;years. The following table summarizes our Founders&#146; restricted shares activities for the years ended December&nbsp;31, 2017 and 2018 and the six months ended June 30, 2018 and 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Numbers<BR>of&nbsp;shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>average<BR>grant&nbsp;date<BR>fair&nbsp;value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,752,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(786,423</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2017 and June 30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,966,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(786,423</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2018 and June 30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,179,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shared-based compensation expense in relation to the restricted ordinary shares recognized in the years
ended December&nbsp;31, 2017 and 2018 and the six months ended June 30, 2018 and 2019 was RMB7,039&nbsp;thousand and RMB3,520&nbsp;thousand, RMB1,929 thousand and RMB1,026 thousand, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shared-based compensation expenses relating to restricted shares were included in: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months</B><br><B>Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2017 Employee Stock Option Plan (&#147;2017 Plan&#148;). </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2017, we adopted the 2017 Plan. Under the 2017 Plan, a maximum aggregate number of 13,376,865 shares that may be issued pursuant to
all awards granted were approved. Stock options granted to an employee under the 2017 Plan will be exercisable upon the completion of a listing and the employee renders service to us in accordance with a stipulated service schedule starting from the
employee&#146;s date of employment. Employees are generally subject to a three-year service schedule, under which an employee earns an entitlement to vest in 50% of the option grants on the second anniversary of the grant date, a vesting of the
remaining fifty percent 50% on the third anniversary of the applicable grant date. The stock options under the 2017 Plan, to the extent then vested, shall become exercisable only upon the earlier of (i)&nbsp;a listing, and (ii)&nbsp;occurrence of a
change in control. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We granted 11,051,230, 1,470,000, 305,000 and nil stock options to employees, all with an exercise price of US$1,
for the years ended December&nbsp;31, 2017 and 2018 and the six months ended June 30, 2018 and 2019, respectively. No options are exercisable as of December&nbsp;31, 2017 and 2018, June 30, 2018 and 2019 and prior to the completion of a listing.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the stock options activities for the years ended
December&nbsp;31, 2017 and 2018 and the six months ended June 30, 2018 and 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number&nbsp;of<br>shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Weighted<br>average<br>exercise<br>price<br>US$</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Weighted<br>average<br>remaining<br>contractual<br>term</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Aggregate<br>intrinsic<br>value<br>US$</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,051,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other addition (note)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">710,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,761,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,470,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(226,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,005,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(266,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repurchased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,435,215</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of June 30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,304,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of June 30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Note:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Other addition represented the modified share options that originally granted to two senior management employees
in October 2016 (see &#147;&#151;other share-based compensation&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock options granted to the employees were
measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62.34</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">61.32%-62.13</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">61.54%-62.13</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N/A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate (per annum)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.32</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">2.81%-3.06</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">2.81%-2.92</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N/A</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise multiple</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N/A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N/A</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contractual term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N/A</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expected volatility was estimated based on the historical volatility of comparable peer public companies
with a time horizon close to the expected term of our options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of our options in effect
at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As we did not have sufficient
information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as we have never declared or paid any cash dividends on its shares, and we do not
anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no stock
options granted to employees under 2017 Plan for the six months ended June 30, 2019. Since the exercisability is dependent upon the listing, and it is not probable that this performance condition can be achieved until a listing is effective, no
share-based compensation expense relating to the 2017 Plan was recorded for the years ended December&nbsp;31, 2017 and 2018 and the six months ended June 30, 2018 and 2019. We will recognize compensation expenses relating to options vested
cumulatively upon the completion of our listing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2018 Employee Stock Option Plan (&#147;2018 Plan&#148;) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;22, 2019, our company adopted the 2018 Plan. Under 2018 Plan, the maximum aggregate number of ordinary shares which may be
issued pursuant to all awards is 14,005,745, subject to further amendment. If our company successfully lists on an internationally recognized securities exchange for a Qualified Public Offering by December&nbsp;31, 2019, the maximum aggregate number
of ordinary shares which may be issued shall be 15,452,620. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock options granted to an employee under the 2018 Plan will be generally
exercisable when our company completes a listing and the employee renders service to our company in accordance with a stipulated service schedule starting from the employee&#146;s date of employment. Employees are generally subject to a two-year
vesting schedule consisting of a cliff vesting of 50% of the stock options on the first anniversary of the applicable vesting commencement date and a vesting of the remaining 50% on the second anniversary of the applicable vesting commencement date.
If a listing occurs at any time prior to any stock option granted under the 2018 Plan becoming fully vested, to the extent such stock option has been granted and is outstanding, any such stock option shall vest in full with immediate effect upon the
listing. Except as otherwise approved by the Board of Directors, any vested portion of the stock options shall become exercisable upon the earlier of six months after a listing or the occurrence of a change in control; provided, however, that in
each case, no stock option of an employee shall become exercisable until the third anniversary of such employee&#146;s employment commencement date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the 2018 Plan adopted on February 22, 2019, the 10,893,028 stock options granted to a director of our company under the 2018 Plan
were fully vested and exercisable upon the adoption of 2018 Plan. Out of these 10,893,028 stock options, 454,940 stock options have been repurchased by our company (see Note 17 (d) to our unaudited interim condensed consolidated financial statements
for further details). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amounts of shared-based compensation expense in relation to the stock options (except for those repurchased by
a director of our company as described in Note 17 (d) to our unaudited interim condensed consolidated financial statements) recognized in the six months ended June 30, 2019 was RMB365,330, which were allocated to our administrative expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the stock options activities for the six months ended June&nbsp;30, 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Number&nbsp;of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Weighted</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">average</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">exercise</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">price</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">US$</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Weighted</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">average</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">remaining</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">contractual</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">term</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Aggregate</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">intrinsic</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">value</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">US$</P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of January&nbsp;1, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,893,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repurchased (Note 17 (d))</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(454,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,438,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,438,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock options granted to the employees were measured at fair value on the dates of grant using the Binomial
Option Pricing Model with the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="28%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56.307</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate (per annum)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.752</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise multiple</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contractual term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expected volatility was estimated based on the historical volatility of comparable peer
public companies with a time horizon close to the expected term of our company&#146;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected
term of our company&#146;s options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested
options. As our company did not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as our company has never declared or
paid any cash dividends on its shares, and our company does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Repurchase of share awards held by a director </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;22, 2019, the amendment and restated 2017 equity incentive plan was approved by the Board of Directors of our company,
pursuant to which only the 3,435,215 stock options held by a director of our company under the 2017 equity incentive plan became fully vested and exercisable on February&nbsp;22, 2019. As a result of the performance condition being waived, the
shares held by a director of our company were accounted for as a Type III modification where a condition that our company expects will not be satisfied is changed to a condition that our company expects will be satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, on the same day, our company repurchased such 3,435,215 stock options under the amendment and restated 2017 equity incentive
plan that was held by a director of our company along with 454,940 of his stock options under the 2018 equity incentive plan for which the share awards also became fully vested and exercisable, at a total consideration of US$21,902 (equivalent to
approximately RMB148,308) at an average share price of US$5.63 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our company recorded the total payment of US$21,902 (equivalent
to approximately RMB148,308) as share-based compensation costs in the condensed statement of comprehensive loss. There was no impact to the overall stockholder&#146;s equity balance as the amended shares vested immediately and were repurchased. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other share-based compensation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the
year ended December&nbsp;31, 2016, we recorded share-based compensation expense of RMB3.3&nbsp;million for issuance and grant of 710,366 stock options to two senior management employees in October 2016, as rewards for their services they had
performed in the past and in exchange for their full-time devotion and professional expertise. Stock options granted to the two employees were exercisable once granted, with an exercise price of US$0.06. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2017, in connection with the adoption of the 2017 Plan, we amended the stock option agreement with the two aforementioned
employees, under which the stock options would become exercisable only upon the earlier of (i)&nbsp;a listing, and (ii)&nbsp;occurrence of a change in control that defined in the stock option agreements. As the modification of terms and conditions
of share-based compensation were not beneficial to its employees, no further accounting impact was resulting from it. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of
Ordinary Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to estimate the fair value of the ordinary shares on grant dates of share-based compensation
awards/share option to our employees and the issuance of financial instruments to investors. Therefore, our board of directors has estimated the fair value of our ordinary shares on various dates, with inputs from management, considering the
third-party valuations. The valuations of our ordinary shares were performed using methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants Audit and Accounting Practice Aid Series: Valuation
of Privately-Held-Company Equity Securities Issued as Compensation, or the AICPA Practice Guide. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our board of directors considered various objective and subjective factors,
along with inputs from management and the independent third-party valuation firm, to determine the fair value of our ordinary shares, including: external market conditions affecting the biopharmaceutical industry, trends within the biopharmaceutical
industry, the prices at which we sold convertible preferred shares, the superior rights and preference of the convertible preferred shares or other senior securities relative to our ordinary shares at the time of each grant and the likelihood of
achieving a liquidity event such as an initial public offering. The option-pricing method was used to allocate the enterprise&#146;s value to preferred shares or other senior securities and ordinary shares, taking into account the guidance
prescribed by the AICPA Practice Guide. This method treats ordinary shares and convertible preferred shares or other senior securities as call options on the enterprise&#146;s value, with exercise prices based on their respective payoffs upon a
liquidity event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the enterprise&#146;s value, we applied the market approach/backsolve method based on pricing from recent
transactions in our own securities. The basis for application of this method is our transactions in equity securities with unrelated parties or among unrelated parties themselves. No evidence is observed to indicate these transactions are not <FONT
STYLE="white-space:nowrap">arm&#146;s-length</FONT> transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors determined the fair value of our share options
and the restricted shares as of the dates of grant, taking into consideration the various objective and subjective factors described above, including the conclusion of valuation of our ordinary shares as of dates close to the grant dates of our
share options and the restricted shares. We computed the per share estimated fair value for share options based on the binomial option pricing model and the per share estimated fair value for restricted shares based on per share estimated fair value
of ordinary shares as of the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once public trading market of the ADSs has been established in connection with the completion
of this offering, it will no longer be necessary for our board of directors to estimate the fair value of our ordinary shares in connection with our accounting for granted share options and restricted shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our financial assets and liabilities primarily comprise of cash and cash equivalents, restricted cash, other financial assets, contract assets,
other receivables, short-term borrowings, accruals and other payables and warrant liabilities. As of December&nbsp;31, 2017 and 2018, and June 30, 2019 except for other financial assets and warrants liabilities, the carrying values of these
financial assets and liabilities approximated their fair values because of their generally short maturities. We report other financial assets and warrant liabilities at fair value at each balance sheet date and changes in fair value are reflected in
the consolidated statements of comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We measure our financial assets and liabilities using inputs from the following three
levels of the fair value hierarchy. The three levels are as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level&nbsp;1 inputs are unadjusted quoted prices in active markets
for identical assets that the management has the ability to access at the measurement date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level&nbsp;2 inputs include quoted prices for
similar assets in active markets, quoted prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable for the asset (i.e., interest rates, yield curves, etc.), and inputs that are derived
principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level&nbsp;3
includes unobservable inputs that reflect the management&#146;s assumptions about the assumptions that market participants would use in pricing the asset. The management develops these inputs based on the best information available, including the
own data. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We measured our short-term investments at fair value on a recurring basis. As our other
financial assets and derivative liabilities are not traded in an active market with readily observable prices, we use significant unobservable inputs to measure the fair value of other financial assets, and derivatives liabilities. These instruments
are categorized in the Level&nbsp;3 valuation hierarchy based on the significance of unobservable factors in the overall fair value measurement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A list
of recently issued accounting pronouncements that are relevant to us is included in note 2 &#147;Principal Accounting Policies &#150; 2.24 Recent Accounting Pronouncements&#148; of our consolidated financial statements included elsewhere in this
prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_14"></A>INDUSTRY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We see vast commercial opportunities for immuno-oncology and autoimmune biologics therapies. In 2018, approximately 60.8% of the
antibody-based biologics in terms of global sales revenue targeted conditions in these areas, according to the Frost&nbsp;&amp; Sullivan Report. In China, the need for efficacious drugs to treat cancer and autoimmune diseases is rising due to
limited availability of such medicines and delayed access to global innovative medicines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The figure below illustrates the historical and
projected market sizes of immune-oncology therapies and autoimmune disease treatment globally and in China. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g07g87.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The figure below illustrates the unmet medical need for autoimmune diseases globally and in China. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g78p43.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g02t31.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the recent success of checkpoint inhibitors, such as <FONT STYLE="white-space:nowrap">PD-1</FONT>
and <FONT STYLE="white-space:nowrap">PD-L1,</FONT> clinical efficacy of these drugs has not lived up to expectations. The Frost&nbsp;&amp; Sullivan Report estimates that more than 60% of cancer patients, including those with melanoma, renal cell
cancer, colorectal cancer, <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, urothelial cancer and head and neck squamous cell carcinoma, do not respond to PD-1/PD-L1 monotherapies. Even for the tumor type with a high tumor
mutational burden (i.e., the total number of mutations with coding region of a tumor cell genome) the ORR rarely exceeds 30% for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies. Similar findings
are observed using <FONT STYLE="white-space:nowrap">PD-L1</FONT> as a biomarker in the treatment of NSCLC with pembrolizumab: the average ORR is 41% for PD-L1 positive tumor and 13% for PD-L1 negative tumor. The immuno-oncology field has been
diligently seeking a more efficacious therapy with treatment agent(s) that works synergistically with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies. Such a novel combination therapy may provide
an effective treatment option for those who do not respond to current <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies. For example, our investigational drugs, including TJ107, enoblituzumab, TJC4,
and TJD5, are intended to work as combination therapies with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> regimens to address unmet medical needs in oncology. Currently, our target indications in the
area of immuno-oncology cover a variety of hematologic malignancies, such as multiple myeloma, lymphoma and solid tumors, such as head and neck cancer, and cancer treatment-related lymphopenia. For autoimmune diseases, our target indications include
systemic lupus erythematosus, ulcerative colitis, rheumatoid arthritis and other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IL-6-implicated</FONT></FONT> autoimmune diseases. The discussion below provides (i)&nbsp;an overview
of the market trends and growth drivers in China&#146;s biologics market and (ii)&nbsp;an overview of the competitive landscape and key segments with respect to our most advanced clinical stage product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Trends and Growth Drivers of Biologics Market in China </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the Frost&nbsp;&amp; Sullivan Report, the growth of China&#146;s biologics market is attributable, in particular, to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Large and Growing Oncology and Autoimmune Disease Patient Populations</I>&#151;China&#146;s oncology patient
population, especially treatment-naive patients, has been increasing over the years. New cases of cancers in China reached 4.3&nbsp;million in 2018 and are projected to reach 4.9&nbsp;million in 2023. China also has a large autoimmune disease
population. In 2018, systemic lupus erythematosus, ulcerative colitis and rheumatoid arthritis affected approximately 1.0&nbsp;million, 0.4&nbsp;million and 5.9&nbsp;million patients in China, respectively. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Unmet Demands for Innovative Biologics Therapies Targeting Oncology</I>&#151;Many biologics, especially
monoclonal antibodies, have proved to have superior efficacy and less side effects for treating cancer. However, many antibody drugs approved to treat cancer in the United States are not available in China. From 1997 to 2018, 37 therapeutic
antibodies were launched globally, but only seven of them are marketed in China. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Unmet Demands for Effective Therapies Targeting Autoimmune Diseases</I>&#151;To date, there are no curative
therapies for many autoimmune diseases. Targeted biologics that aim to improve physical functioning and prevent irreversible tissue or organ damage offer a promising trajectory. This class of
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
biologics is expected to stimulate the biologics market that targets autoimmune diseases in China. The sales revenue of this market was RMB2.5 billion in 2018 and is projected to increase to
RMB87.8 billion in 2030, representing a compound annual growth rate (&#147;CAGR&#148;) of 34.6%. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Increasing Cost Burden of Autoimmune Diseases</I>&#151;Autoimmune diseases have been reported to be on the
rise in China, making this poorly understood category of diseases a public health issue at levels comparable to heart disease and cancer. Because of a lack of effective treatment and awareness amongst the general public and medical practitioners,
the associated cost of autoimmune diseases accounts for a significant portion of the rising cost of healthcare burden in China. Innovative biologic treatments, as a means of reducing healthcare spending while ensuring improved public health, can
help address the mounting pressure surrounding autoimmune diseases. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Increasing Investment in Biologics</I>&#151;Research and development in innovative biologics therapies is the
key to industry growth. Discovery and development of new biologics is a long, difficult and expensive process. Research and development investment for biologics in China is expected to continue rising in the future, leading to more new products
entering the market. The continuous launch of new products will further drive the growth of China&#146;s biologics industry. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Favorable Environment for Clinical Trials</I>&#151;With nearly a
<FONT STYLE="white-space:nowrap">one-fourth</FONT> of the world&#146;s cancer patient population, China provides an excellent opportunity to access a large patient pool and clinical resources for oncology drug development and market demands. The
Chinese government has taken initiatives to address regulatory challenges that previously caused a lag in clinical trial applications of therapeutic biologics. Notably, in October 2017, the General Office of the CPC Central Committee and the General
Office of the State Council issued the Opinions on Deepening the Reform of the Evaluation and Approval Systems and Encouraging Innovation on Drugs and Medical Devices, which aims to improve the regulatory approval process and encourage technological
innovation for new drugs. In addition, in July 2018, the NMPA implemented Technical Guidelines for Accepting Data from Overseas Clinical Trials of Drugs, which significantly shortens the registration process and provides potential clinical trial
exemptions for drugs that have robust clinical data from trials conducted overseas. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Increasing Affordability</I>&#151;The average disposable income of the Chinese population is expected to
continue growing rapidly, increasing the willingness and ability of patients to pay for medications. In 2019, households with an annual disposable income of over US$30,000 accounted for 38.1% of the total households in China and are expected to
increase to 56.5% of the total households in China by 2023. As more Chinese households increase their spending power, they can afford more expensive medical treatments, particularly for life-threatening diseases. In addition, inclusion of a drug in
the National Reimbursement Drug List (&#147;NRDL&#148;) typically results in a much higher sales volume and significant sales growth despite a reduction in price. Such inclusion is expected to be implemented for innovative biologics on a regular
basis, suggesting that more biologics are expected to be covered by the NRDL in the future, further increasing the affordability of biologics in China. As biologics become increasingly affordable to the general public, they will be used more
commonly as a treatment for oncology and autoimmune diseases. As a result, the market size of the biologics industry in China is expected to continue to grow. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Multiple Myeloma </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Multiple myeloma (&#147;MM&#148;) is a type of blood cancer that starts in the bone marrow and is characterized by excessive proliferation of
malignant plasma cells that accumulate in the bone marrow, where they displace and suppress healthy blood progenitor cell populations, cause destructive lytic bone lesions (rounded, <FONT STYLE="white-space:nowrap">punched-out</FONT> areas of the
bone), diffuse osteoporosis, bone pain, and produce abnormal proteins that accumulate in the urine, and anemia. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Greater China, new cases of MM reached approximately 20,500 in 2018 and is expected to
increase to approximately 23,700 in 2023, representing a CAGR of 2.9%, according to the Frost&nbsp;&amp; Sullivan Report. MM is primarily a disease of the elderly, and this population of patients 65 years and older continues to grow at a fast clip
in China. In fact, the new incidence of MM in China is projected to reach approximately 28,300 in 2030, representing a CAGR of 2.6% from 2023 to 2030. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Treatment of MM </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MM treatment is
individualized but generally includes small molecules drugs and biologics. The primary treatment regimens are cytoreductive chemotherapies, in combination with stem cell transplants, aimed at achieving a cure, if possible. In addition, MM patients
require substantial supportive therapy aimed at managing complications of the disease (such as bone damage) and ameliorating the side effects of treatment. There are a number of drug classes for MM treatment, including monoclonal antibodies,
immunomodulatory drugs, proteasome inhibitors, chemotherapy, histone deacetylase inhibitors, and steroids. A patient&#146;s individual treatment plan is based on factors such as age and general health, results of laboratory and cytogenetic (genomic)
tests, symptoms and disease complications, prior myeloma treatment as well as the patient&#146;s lifestyle, goals, views on quality of life, and personal preferences. In addition, many cancer centers have developed their own guidelines for treating
MM. In China, drugs approved for treating relapsed or refractory MM (&#147;RRMM&#148;) include daratumumab (Darzalex from Janssen), lenalidomide (Revlimid from Celgene), thalidomide (Thalomid from Celgene) bortezomib (Velcade from Takeda), and
ixazomib (Ninlaro from Takeda). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unmet Medical Need </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, there is no curative treatment for RRMM. Although the currently marketed CD38 antibody product is efficacious, it takes a long time
to be administered by IV infusion (up to six hours) and causes a high infusion reaction rate (&#147;IRR&#148;). In clinical trials, approximately half of all patients experience an infusion reaction, which may include fever, chills, nausea,
bronchospasm, hypoxia, dyspnea, hypertension, laryngeal edema and pulmonary edema. Thus, there is a need for a safer and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">convenient-to-use</FONT></FONT> drug. Such a drug may be
combined with other therapeutic agents for better treatment effects in RRMM. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Competitive Landscape </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are various monotherapy agents and combination treatments currently under clinical development targeting different lines of MM therapies.
Our TJ202, if approved, is a potentially highly differentiated CD38 monoclonal antibody and could be the second antibody therapy for MM to launch in China. The following tables illustrate the competitive landscape of biologic MM therapies targeting
CD38 antibody in China and the rest of the world. (<I>Source: Frost</I><I></I><I>&nbsp;&amp; Sullivan Report</I>) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Marketed CD38 Antibody Drug for
Treating MM </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; "><B>Product</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FDA<BR>Approval<BR>Time</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NMPA<BR>Approval<BR>Time</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Patent</B><br><B>Expiry&nbsp;in&nbsp;the<BR>U.S.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Global&nbsp;Sales&nbsp;Revenue&nbsp;in<BR>2018 (in Bn, US$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daratumumab IV</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Johnson&nbsp;&amp; Johnson</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investigational CD38 Antibody Drugs for Treating MM </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; "><B>Investigational Drugs<SUP STYLE="font-size:85%; vertical-align:top">
(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Global&nbsp;Status</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>China&nbsp;Status</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daratumumab SC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Johnson&nbsp;&amp;&nbsp;Johnson</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Phase 3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N/A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Isatuximab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">ImmunoGen&nbsp;and&nbsp;Sanofi</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">BLA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Phase 3</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TJ202<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>N/A</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Phase 3</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">TAK-079</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Takeda</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Phase 1/2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N/A</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Notes: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Investigational drugs prior to Phase 2 clinical trials are not included in this table. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">In November 2017, we and MorphoSys entered into an exclusive regional licensing agreement to develop and
commercialize MOR202, which we refer to as TJ202 in this prospectus, in Greater China (including Taiwan, Hong Kong and Macao). TJ202 is currently undergoing two registrational clinical trials in relapsed/refractory multiple myeloma in Greater China.
We aim to submit a new drug application (&#147;NDA&#148;) to the NMPA for TJ202 as a monotherapy in 2021. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Historical and Forecast
Market Size of MM Therapeutics Globally and in China </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following diagrams illustrate the market size of all MM therapeutics in
terms of sales revenue globally and in China. (<I>Source: Frost</I><I></I><I>&nbsp;&amp; Sullivan Report</I>) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Global MM Therapeutics
Market Size (2014-2030E) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g90r82.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>China MM Therapeutics Market Size (2014-2030E) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g94p77.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Head and Neck Cancer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Head and neck cancers
occur in various parts of the head and neck, including the mouth, nose, throat, larynx,&nbsp;sinuses, and salivary glands. More than 90% of head and neck cancers are classified as squamous cell carcinomas (&#147;SCCHN&#148;), which begins in the
squamous cells that line the moist, mucosal surfaces inside the head and neck. Symptoms of head and neck cancers may include a lump or sore that does not heal, a sore throat that does not go away, difficulty swallowing or breathing, a change or
hoarseness in the voice,&nbsp;unusual bleeding, and facial swelling. According to the Frost&nbsp;&amp; Sullivan Report, in Greater China, new cases of head and neck cancer reached approximately 140,200 in 2018 and are predicted to increase to
approximately 155,300 in 2023, representing a CAGR of 2.1%, and new cases of head and neck cancers in China are projected to grow, reaching approximately 173,400 in 2030 with a CAGR of 1.6% from 2023 to 2030. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Treatment of Head and Neck Cancer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The treatment principles and regimens for head and neck cancer in China are similar to those in the rest of the world. Treatment strategies
often depend on the location and stage of the cancer, the patient&#146;s physical status, and response to prior treatments. Early-stage disease is primarily treated with surgical resection, while patients with locally advanced, recurrent or
metastatic disease are typically treated with drug therapy. The combination of surgery and drug therapy, with or without radiation therapy, is the current standard of care for Stage 3 SCCHN patients with locally advanced disease. Platinum-based
chemotherapy regimens are widely used as first-line therapies for Stage 4 and distant relapse patients. Erbitux (cetuximab from Eli Lilly and Merck KGaA) was approved in 2006 as a first-line treatment of locally advanced SCCHN in combination with
radiation therapy. Regimens containing Erbitux, platinum-based chemotherapy, and <FONT STYLE="white-space:nowrap">5-fluorouracil,</FONT> known as EXTREME, are often considered as the standard of care for first-line treatment of distant relapse
SCCHN. Second-line therapy is highly varied, including single-agent docetaxel or paclitaxel, Erbitux monotherapy, or Erbitux/pacitaxel combination therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2016, <FONT STYLE="white-space:nowrap">PD-1</FONT> inhibitors were approved globally as a second-line therapy and more recently, Keytruda
(pembrolizumab from Merck&nbsp;&amp; Co), as a single agent or in combination with chemotherapy, was approved by the FDA as a first-line therapy for metastatic or unresectable recurrent SCCHN, but no <FONT STYLE="white-space:nowrap">PD-1</FONT>
inhibitors have been approved for this indication in China. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unmet Medical Need </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to Datamonitor Healthcare&#146;s epidemiology forecast (2016-2036), 76% of all actively treated patients with SCCHN have Stage 3,
Stage 4, local relapse or distant relapse disease, but efficacious treatment options are limited for these patients. For example, only about 35% of all patients with distant relapse SCCHN respond to EXTREME, and the resulting overall median survival
is only 10.1 months. In addition, about half of the patients on first-line therapies need later line therapies. In addition, the average ORR for second-line <FONT STYLE="white-space:nowrap">PD-1</FONT> therapies has been less than 15%. As such,
SCCHN patients, especially those with late stage or relapsed disease, need more efficacious treatments with fewer side effects, which represents a significant unmet medical need. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Competitive Landscape </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our enoblituzumab is the only conventional <FONT STYLE="white-space:nowrap">B7-H3</FONT> antibody in clinical development globally. The
following table illustrates the competitive landscape of investigational <FONT STYLE="white-space:nowrap">B7-H3</FONT> antibody drugs in China and the rest of the world. (<I>Source: Frost</I><I></I><I>&nbsp;&amp; Sullivan Report</I>) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="11" NOWRAP><FONT STYLE="font-size:10pt"><B>Investigational <FONT STYLE="white-space:nowrap">B7-H3</FONT> Antibody Drugs</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; "><B>Investigational Drugs</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Drug Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Indications</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Global Status</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>China&nbsp;Status</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">131</SUP><FONT STYLE="white-space:nowrap">I-Omburtamab</FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">Radio-labeled</FONT> antibody</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">Y-mAbs</FONT> Therapeutics</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CNS/leptomeningeal metastases of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">neuroblastoma</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Pivotal&nbsp;Phase&nbsp;2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Enoblituzumab<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Monoclonal antibody</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>MacroGenics <FONT STYLE="white-space:nowrap">I-Mab</FONT><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Solid tumors</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Phase 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>N/A</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">MGC-018</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">Antibody-Drug</FONT> Conjugate</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">MacroGenics</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Solid tumors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 1/2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">124</SUP><FONT STYLE="white-space:nowrap">I-Omburtamab</FONT></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Radio-labeled antibody</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">Y-mAbs</FONT> Therapeutics</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Glioma</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Note: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">We have the development and commercialization rights for enoblituzumab in Greater China pursuant to a
partnership agreement with MacroGenics. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Historical and Forecast Market Size of Head and Neck Cancer Therapeutics Globally and in
China </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following diagrams illustrate the size of the head and neck cancer drug market in terms of sales revenue in global and
China markets. (<I>Source: Frost</I><I></I><I>&nbsp;&amp; Sullivan Report</I>) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Global Head and Neck Cancer Therapeutics Market Size
(2014-2030E) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g31m68.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>China Head and Neck Cancer Therapeutics Market Size (2014-2030E) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g86o18.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cancer Treatment-Related Lymphopenia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lymphopenia is a decrease in lymphocyte cell count that is lower than the <FONT STYLE="white-space:nowrap">age-appropriate</FONT> reference
level. Cancer patients who undergo chemotherapy and/or radiation therapy often develop severe lymphopenia (&lt;500&nbsp;cells/mm3), which further damages their already compromised immune systems and their ability to fight against cancers. According
to the Frost&nbsp;&amp; Sullivan Report, more than 85% of cancer patients receive chemotherapy or radiation therapy, and approximately 43% of them develop lymphopenia. Furthermore, there is a <FONT STYLE="white-space:nowrap">two-fold</FONT> increase
in the risk of early cancer death associated with severe lymphopenia. Currently no drug is available for cancer treatment-related lymphopenia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Greater China, according to the Frost&nbsp;&amp; Sullivan Report, the incidence of lymphopenia reached 1.5&nbsp;million in 2018 and is
estimated to increase to 1.7&nbsp;million in 2023 and further to 2.0&nbsp;million in 2030. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Treatment of Cancer Treatment-Related Lymphopenia
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is currently no guideline and no specific or effective treatment for cancer treatment-related lymphopenia. Most patients
with cancer treatment-related lymphopenia are clinically monitored without specific treatment both globally and in China. Proleukin is a recombinant human <FONT STYLE="white-space:nowrap">IL-2</FONT> that has shown some therapeutic effect in
promoting overall T cell populations in cancers, which also include tumor-protecting T regulatory (Treg) cells. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unmet Medical Need </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is currently no <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug for cancer treatment-related lymphopenia. There remains a
substantial need for an effective treatment for lymphopenia as prolonged lymphopenia often correlates with shortened survival time as reported in the medical literature (Grossman et al., J Natl Compr Canc Netw. 2015 October ; 13(10):
1225&#150;1231). Proleukin has a limited effect on lymphopenia with serious side effects. There are global research and development efforts to find effective T cell cytokines capable of selectively promoting proliferation of tumor-fighting T cells
but not tumor-protecting Treg cells. These efforts include <FONT STYLE="white-space:nowrap">IL-7,</FONT> <FONT STYLE="white-space:nowrap">IL-12</FONT> and <FONT STYLE="white-space:nowrap">IL-15,</FONT> all of which are in early stages of
development. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Competitive Landscape </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are only two <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IL-7-based</FONT></FONT> investigational drugs, TJ107
(efineptakin) and <FONT STYLE="white-space:nowrap">CYT-107.</FONT> (<I>Source: Frost</I><I></I><I>&nbsp;&amp; Sullivan Report</I>) </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Investigational Drugs of Recombinant Human <FONT STYLE="white-space:nowrap">IL-7</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; "><B>Investigational<BR>Drugs</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Drug Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Indications</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Global&nbsp;Status</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>China&nbsp;Status</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Efineptakin<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Long-acting&nbsp;rhIL-7</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Lymphopenia and cancer</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>N/A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Phase&nbsp;1b/2a</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Efineptakin<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Long-acting&nbsp;rhIL-7</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Genexine&nbsp;Inc. (KOSDAQ: 095700)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Solid tumors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">CYT-107</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">Glycosylated&nbsp;rhIL-7</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Revimmune</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Sepsis and septic shock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Note: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">We have the development and commercialization rights for efineptakin in Greater China pursuant to a partnership
agreement with Genexine. We are conducting clinical trials in China as part of the coordinated global clinical development plan. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Forecast Market Size of Potential Cancer Treatment-Related Lymphopenia Globally and in China </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the Frost&nbsp;&amp; Sullivan Report, since most patients with cancer treatment-related lymphopenia are not actively treated,
there is currently no such drug market globally or in China. However, there is a huge market potential as the following diagrams illustrate the forecast size of the market when an effective drug for treatment-related lymphopenia becomes available.
(<I>Source: Frost</I><I></I><I>&nbsp;&amp; Sullivan Report</I>) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Global Cancer Treatment-Related Lymphopenia Market Size (2023E-2030E)
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g83v20.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>China Cancer Treatment-Related Lymphopenia Market Size (2023E-2030E) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g43c34.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Systemic Lupus Erythematosus </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Systemic lupus
erythematosus (&#147;SLE&#148;) is a chronic, multi-system and incurable autoimmune disease that can potentially lead to serious organ damage, systemic complications and even death. Patients with SLE have aberrant production of auto-antibodies
(antibodies against self-antigens) by CD38-positive plasma cells, and dysregulated CD38-positive pathogenic B cells. As part of the disease mechanism, immune complexes induced by auto-antibodies are formed and deposit in the kidneys and cause tissue
damage. Common symptoms of SLE include painful and swollen joints, unexplained fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, extreme fatigue, and red rashes that most commonly appear on the face, and these symptoms vary widely
among patients and fluctuate unpredictably over time as the disease progresses. More importantly, at the advanced stage of the disease, patients can develop renal damage and renal failure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the Frost&nbsp;&amp; Sullivan Report, SLE had an estimated prevalence of approximately 1.04&nbsp;million in 2018 in Greater
China, which is projected to increase to 1.08&nbsp;million in 2023, representing a CAGR of 0.8%. Cases of SLE in China are projected to increase to 1.11 million in 2030. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Treatment of Systemic Lupus Erythematosus </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, there is a significant unmet medical need for more effective therapies for SLE. Since SLE is a chronic disease, current treatments
aim to manage symptoms and reduce the frequency of disease flares. Patients with mild SLE are often managed by <FONT STYLE="white-space:nowrap">non-steroidal</FONT> anti-inflammatory drugs, while more severe patients may need corticosteroids or
immunosuppressants. Combination treatments can also be used as disease-modifying treatment regimens, aiming to control the disease and prevent chronic tissue damage. Approved by the FDA in 2011 and by the NMPA in July 2019, Benlysta (belimumab), a <FONT
STYLE="white-space:nowrap">B-lymphocyte</FONT> stimulator (BLyS)-specific inhibitor developed by GSK, is currently the world&#146;s only biologic approved to treat SLE. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unmet Medical Need </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The effect of
symptomatic treatments for SLE, including <FONT STYLE="white-space:nowrap">non-steroidal</FONT> anti-inflammatory drugs, is short-lived and often very limited. The therapeutic role of corticosteroids or immunosuppressants in the long-term management
of SLE is hampered by severe drug-related side effects and lack of a disease-modifying effect. As </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
auto-antibodies and resulting immune complexes produced by CD38-positive B cells and plasma cells act at the core of the pathogenesis of SLE, direct inhibition and selective depletion of
pathogenic B cells and plasma cells are believed to offer better treatment options. TJ202 has the potential to offer such a <FONT STYLE="white-space:nowrap">disease-modifying</FONT> treatment option. In addition, the advantages of TJ202 include
convenience of use and a lower IRR, making it a more favorable treatment agent in the long-term clinical management of SLE if approved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Competitive
Landscape </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables illustrate the competitive landscape of the biologics treating SLE in China and the rest of the
world. (<I>Source: Frost</I><I></I><I>&nbsp;&amp; Sullivan Report</I>) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Marketed Biological Products for SLE </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; "><B>Product</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Company</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FDA<BR>Approval<BR>Time</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NMPA<BR>Approval<BR>Time</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Patent<BR>Expiry&nbsp;in<BR>the U.S.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Global&nbsp;Sales&nbsp;Revenue&nbsp;in<BR>2018 (in Bn, US$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Belimumab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">BLyS</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">GSK</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Investigational Drugs for SLE in China </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; "><B>Investigational Drugs<SUP STYLE="font-size:85%; vertical-align:top">
(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Target</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Drug Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Global&nbsp;Status</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>China&nbsp;Status</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">RCT-18</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">BLyS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Antibody&nbsp;fusion protein</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Rong Chang</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ustekinumab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">IL-12/23</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Monoclonal antibody</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Johnson&nbsp;&amp; Johnson</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TJ202</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>CD38</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Monoclonal antibody</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>N/A</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>IND 2019</B></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Note: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Competing investigational biologics that are prior to Phase 3 clinical trials are not included in this table.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Historical and Forecast Market Size of SLE Therapeutics Globally and in China </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following diagrams illustrate the size of the SLE drug market in terms of sales revenue in the global and China markets. (<I>Source:
Frost</I><I></I><I>&nbsp;&amp; Sullivan Report</I>) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Global SLE Therapeutics Market Size (2014-2030E) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g85v78.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>China SLE Therapeutics Market Size (2014-2030E) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g67b87.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ulcerative Colitis </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ulcerative colitis
(&#147;UC&#148;) is an inflammatory bowel disease (&#147;IBD&#148;) that causes chronic and often relapsing inflammation and ulceration of the colon and rectum, in which the lining of the colon and rectum become inflamed and develop tiny open sores,
or ulcers, which produce pus and mucous. This combination of inflammation and ulceration can cause abdominal discomfort and frequent emptying of the colon. UC patients </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
experience recurrent flares of abdominal pain and bloody diarrhea. Other UC symptoms include fatigue, weight loss, and fever. Disease complications may include megacolon, inflammation of the eye,
joints, or liver, and colon cancer. According to the Frost&nbsp;&amp; Sullivan Report, in Greater China, UC affected approximately 370,100 patients in 2018, which is predicted to increase to approximately 543,700 cases in 2023, representing a CAGR
of 8.0%. Greater China has a relatively lower UC incidence and prevalence compared to those in Western countries, but the absolute number of patients is predicted to increase to approximately 918,300 in 2030 with a CAGR of 7.8% from 2023 to 2030, as
a result of the increasingly westernized lifestyle in Greater China. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Treatment of UC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, there is no curative treatment for UC. Most of the approved biologics for UC are <FONT STYLE="white-space:nowrap">TNF-&#945;</FONT>
inhibitors. Vedolizumab (Entyvio), an integrin &#945;4&szlig;7 antibody that blocks lymphocytes from accumulating in the intestinal wall, is currently the only <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">non-anti-TNF-&#945;</FONT></FONT></FONT> biologic approved for UC. Vedolizumab is also in a Phase 3 trial in China. In May 2018, tofacitinib (Xeljanz), which is a small molecule Jak1/3 kinase inhibitor, became the first
oral medication approved for chronic use in moderate to severe UC in the United States. In China, <FONT STYLE="white-space:nowrap">non-steroidal</FONT> anti-inflammatory drugs, such as <FONT STYLE="white-space:nowrap">5-aminosalicylic</FONT> acids <FONT
STYLE="white-space:nowrap">(&#147;5-ASAs&#148;),</FONT> and corticosteroids or other immunosuppressants, including azathioprine, mercaptopurine and cyclosporine, are often used as an initial treatment and throughout the course of clinical management
with limited treatment efficacy. Approved by the NMPA in 2019, infliximab (Remicade), which is a <FONT STYLE="white-space:nowrap">TNF-&#945;</FONT> inhibitor, is currently the only biologic approved to treat UC in China. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unmet Medical Need </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The incidence
of UC is increasing rapidly, but UC patients, especially those with a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> disease, have few treatment options, which have limited treatment efficacy and
considerable side-effects. For example, Jak1/3 kinase inhibitors can carry the risk of serious infections and malignancies. <FONT STYLE="white-space:nowrap">TNF-&#945;</FONT> inhibitors also have inherent side effects and do not work in all
patients. According to the Frost&nbsp;&amp; Sullivan Report, approximately 45% patients are considered treatment <FONT STYLE="white-space:nowrap">non-responders</FONT> to <FONT STYLE="white-space:nowrap">TNF-&#945;</FONT> drugs among all autoimmune
diseases. Thus, there is a substantial unmet medical need in UC for a treatment agent(s) that is efficacious and safe through pathways beyond the traditional drug targets. TJ301 is believed to potentially fulfill such a product profile as it works
through the <FONT STYLE="white-space:nowrap">IL-6</FONT> trans-signaling pathway. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Competitive Landscape </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our TJ301 is the only clinical stage selective <FONT STYLE="white-space:nowrap">interleukin-6</FONT>
<FONT STYLE="white-space:nowrap">(&#147;IL-6&#148;)</FONT> inhibitor that works through the trans-signaling mechanism. It is a potential highly differentiated <FONT STYLE="white-space:nowrap">IL-6</FONT> blocker for UC, if approved. The following
table illustrates the competitive landscape of investigational biologics for treating UC that are in late-stage development in China and the rest of the world. (<I>Source: Frost</I><I></I><I>&nbsp;&amp; Sullivan Report</I>) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; "><B>Product<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Company</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Global&nbsp;Status</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>China&nbsp;Status</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vedolizumab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#945;4&szlig;7&nbsp;integrin</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Takeda</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Approved</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ustekinumab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IL-12/IL-23</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Johnson&nbsp;&amp;&nbsp;Johnson</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">NDA&nbsp;filed</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risankizumab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">IL-23</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">AbbVie</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mirikizumab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">IL-23</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Eli Lilly</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Etrolizumab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&szlig;7 integrin</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Roche</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ontamalimab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">MAdCAM</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Takeda/Shire</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Spesolimab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">IL-36</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Boehringer<BR>Ingelheim</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase 2/3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Olamkicept TJ301<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">IL-6</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Phase 2</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Phase&nbsp;2</B></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Notes: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Competing investigational biologics that are prior to Phase 3 clinical trials are not included in this table.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">We have the development and commercialization rights for olamkicept in Greater China pursuant to a partnership
agreement with Ferring Pharmaceuticals. A regional multi-center Phase 2 trial in China, Taiwan and South Korea sponsored by <FONT STYLE="white-space:nowrap">I-Mab</FONT> is ongoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Historical and Forecast Market Size of UC Therapeutics Globally and in China </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following diagrams illustrate the size of the UC drug market in terms of sales revenue in the global and China markets. (<I>Source:
Frost</I><I></I><I>&nbsp;&amp; Sullivan Report</I>) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Global Ulcerative Colitis Therapeutics Market Size (2014-2030E) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g93x36.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>China Ulcerative Colitis Therapeutics Market Size (2014-2030E) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g22d25.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Growth Hormone Deficiency </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Growth hormone deficiency
(&#147;GHD&#148;) is an endocrine disorder that occurs when the production of growth hormone, normally secreted by the pituitary gland, is disrupted. Since growth hormone plays a critical role in stimulating body growth and development and is
involved in the production of muscle protein and the breakdown of fats, deficiency in growth hormone affects numerous physiological processes, resulting in short stature in children and other physical ailments in both children (&#147;PGHD&#148;) and
adults (&#147;AGHD&#148;). According to the Frost&nbsp;&amp; Sullivan Report, PGHD affected approximately 3.4&nbsp;million patients in 2018 in Greater China. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Treatment of PGHD </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The widely adopted treatment for PGHD is patient-specific growth hormone replacement therapy, which is given in a calculated weight-based
dosing regimen. Currently, short-acting recombinant human growth hormone (&#147;rhGH&#148;) is commonly used for the long-term treatment of children and adults with inadequate endogenous growth hormone secretion. There are certain safety concerns
related to long-term use of pegylated drugs, such as potential renal toxicity, cellular vacuolation and formation of anti-polyethylene glycol antibodies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approved by the NMPA in 2014, Jintrolong (developed by GeneScience) is currently the only long-acting pegylated rhGH in China. Other companies
in China currently developing long-acting rhGH include Anhui Anke Biotechnology, Xiamen Amoytop Biotech, and Generon Pharmaceutical Technology. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unmet Medical Need </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to
the Frost&nbsp;&amp; Sullivan Report, only 3.7% of all PGHD patients in China were receiving growth hormone replacement therapy in 2018, which consists of daily injections of rhGH before sleep. This dosing regimen puts a substantial burden on
pediatric patients and their families because it requires drug preparation and needle injection every day, which is painful and extremely inconvenient, often resulting in poor patient compliance. More importantly, studies have shown that skipping
just one or two doses in a week can significantly reduce the efficacy of the treatment. Therefore, there is a substantial medical need for long-acting growth hormone therapies that are similarly efficacious but with reduced injection frequency, and
the market potential for such a long-acting rhGH in China is largely untapped. In addition, recombinant human growth hormone therapy has been included in the National Reimbursement Drug List (NRDL) in China. Inclusion of a drug in the NRDL typically
results in a much higher sales volume and significant sales growth despite a reduction in price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Competitive Landscape </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our TJ101 is the only <FONT STYLE="white-space:nowrap">Fc-based</FONT> long-acting rhGH ready for a Phase 3 clinical trial in China. The
following tables illustrate the competitive landscape of long-acting growth hormone products and product candidates in China and the rest of the world. (<I>Source: Frost</I><I></I><I>&nbsp;&amp; Sullivan Report</I>) </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Marketed Products of Long-acting GH </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; "><B>Product</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Drug Form</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Company</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FDA<BR>Approval</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NMPA<BR>Approval</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Patent<BR>Expiry&nbsp;in<BR>China</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Global&nbsp;Sales&nbsp;Revenue&nbsp;in<BR>2018 (in Bn, RMB)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jintrolong</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">PEGylated&nbsp;GH</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">GeneScience</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investigational Drugs of Long-acting rhGH </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; "><B>Investigational
Drug<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Drug Form</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Company</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Global&nbsp;Status</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>China&nbsp;Status</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NNC0195-0092</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">PEGylated&nbsp;hGH</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Novo&nbsp;Nordisk</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Phase 3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N/A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ACP&#151;001</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">TransCon hGH</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Ascendis</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Phase&nbsp;3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N/A</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>eftansomatropin TJ101</B><SUP STYLE="font-size:85%; vertical-align:top"></SUP><FONT
STYLE="font-size:6.5pt"><SUP STYLE="font-size:85%; vertical-align:top">(2)<B></B></SUP><B></B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Hy-Fc</FONT></B><BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Fc&nbsp;fusion&nbsp;protein)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>N/A</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Phase&nbsp;3&nbsp;ready</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">eftansomatropin <FONT STYLE="white-space:nowrap">GX-H9</FONT><SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Genexine</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Phase&nbsp;3&nbsp;ready</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N/A</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">PEG-rhGH</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">PEGylated GH</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Anhui Anke</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Phase&nbsp;2/3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Y-shaped pegylated somatropin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">PEGylated hGH</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Xiamen<BR>Amoytop</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase&nbsp;2/3</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Notes:
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Competing investigational biologics that are prior to Phase 2 clinical trials are not included in this table.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">TJ101 and <FONT STYLE="white-space:nowrap">GX-H9</FONT> are the same investigational drug. We have the
development and commercialization rights for TJ101 in Greater China pursuant to a partnership agreement with Genexine. We plan to submit an IND for a Phase 3 clinical trial (pending the NPMA&#146;s approval) in China in mid-2020.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Historical and Forecast Market Size of PGHD Therapeutics Globally and in China </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following diagram illustrates the size of the PGHD drug market in terms of sales revenue in the global and China markets. (<I>Source:
Frost</I><I></I><I>&nbsp;&amp; Sullivan Report</I>) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Global PGHD Therapeutics Market Size (2014-2030E) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g11t09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>China PGHD Therapeutics Market Size (2014-2030E) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g49s71.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_15"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage
biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were founded to capture the opportunities presented by the confluence of two major developments&#150;&#150;the emergence of an attractive
and growing biologics market in China, and the revolutionary scientific breakthroughs in cancer and autoimmune disease medicines. We believe we are well-positioned to become a biotech leader in China because of our innovative discovery expertise, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fit-for-purpose</FONT></FONT> technology platforms, biomarker-enabled translational medicine capabilities, and clinical development capabilities. These integrated capabilities are further
enhanced by our deep understanding of China&#146;s biologics regulatory framework and our direct access to extensive <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trial resources in China. To date, we have developed an innovative
pipeline of more than 10 clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage assets through our internal research and development efforts and <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements with global
pharmaceutical and biotech companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercial Opportunities in China and Our Unique Position </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are fully aware of the competitive and regulatory challenges we face as an innovative clinical stage biotech company based in China,
including need to raise significant capital, significant competition from global and other China-based biopharmaceutical companies, less streamlined regulatory pathway compared to countries with long-established regulatory systems, and potential
implementation challenges and uncertainties of the recent government reform of the drug approval system. However, with these challenges in mind, we have been mitigating the risks through our internal R&amp;D system that integrates multi-functional
aspects of our drug development process to proactively deal with some of the regulatory challenges mentioned above. Furthermore, through our Beijing office which focuses on regulatory matters, we have established an effective communication channel
with the regulatory agencies to discuss and resolve various regulatory issues promptly and effectively. Despite these challenges, we see vast opportunities for immuno-oncology and autoimmune biologics therapies in China. First, both the incidence
and mortality of cancers in China have been increasing in recent years and are outpacing those in the United States and the rest of the world. Second, many innovative biologics approved to treat cancer and autoimmune diseases in the United States
and Europe are not yet available in China. Third, the Chinese government has implemented new policies and regulations to simplify the review and approval cycle of clinical trials and new drug applications to encourage biologics innovation. Fourth,
there has been a continuous and rapid increase in personal disposable income in China coupled with ongoing improvement in basic national health insurance coverage, making innovative biologics more accessible to more Chinese patients. According to
the Frost&nbsp;&amp; Sullivan Report, China&#146;s biologics market is growing faster than the global biologics market and is expected to reach approximately RMB1.3 trillion (US$189.4 billion) by 2030 in terms of sales revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe we are uniquely positioned as a China-based global player to tap into these vast commercial opportunities. This is best
demonstrated by our short journey in becoming one of the top clinical stage immunology companies in China. According to the Frost &amp; Sullivan Report, we are ranked as top clinical stage China-based immunology companies as measured by the
innovative quality and number of investigational drugs and drug candidates under clinical and pre-clinical development in our pipeline, amount of pre-IPO financing raised (in excess of US$400 million in three years), pre-IPO valuation and
recognition and awards earned in the biotech industry. For example, in March 2019, Genetic Engineering &amp; Biotechnology News (GEN) recognized us as a top 10 immuno-oncology start-up in the world. We were the only China-based company recognized
therein. We had raised in excess of US$400&nbsp;million in pre-IPO financing in the past three years. To date, our research and development capabilities encompass discovery, biologics CMC development,
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> development and clinical development with footprints in Shanghai, Beijing and the United States. We are now at a critical juncture to transition from a clinical stage biotech company into a fully
integrated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> global biopharmaceutical company in the next few years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Unique Business Model </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To achieve our mission and capitalize on these commercial opportunities, we have developed a business model built on two pillars: a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> China strategy and a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-PoC</FONT></FONT> (proof of concept) global strategy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT> China Strategy </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> China strategy focuses on seeking
opportunities to <FONT STYLE="white-space:nowrap">in-license</FONT> the development and commercialization rights of investigational drugs from global biopharmaceutical companies for Greater China. We only select investigational drugs that have the
potential to become novel or highly differentiated medicines. Through our substantial <FONT STYLE="white-space:nowrap">in-house</FONT> research and development efforts, we build additional data packages to meet the requirements of the National
Medical Products Administration (the &#147;NMPA&#148;) to ensure programs are ready for late-stage or registrational clinical development. Our internal development capabilities combined with our deep insight into China&#146;s regulatory framework
and our clinical network enable us to efficiently navigate through the drug development process to registration. To date, we have built an innovative China Portfolio consisting of five investigational drugs with an aim for near-term product launch.
All of these investigational drugs have met the related pre-set safety and preliminary efficacy endpoints in Phase 1 or Phase 2 clinical trials in Europe, the United States or elsewhere and are either in or ready for Phase 2 or Phase 3 clinical
trials in China. TJ202 is undergoing two registrational trials, a monotherapy trial and a combination therapy trial in relapsed or refractory multiple myeloma in Greater China, and we will soon initiate a Phase 1b trial in systemic lupus
erythematosus (&#147;SLE&#148;) in the first half of 2020. For TJ101, we expect to submit an IND for a Phase 3 registrational trial in China by early 2020. For enoblituzumab, we expect to initiate either a registrational trial (pending the
NMPA&#146;s regulatory approval) or a Phase 2 trial by the end of 2020. As a result, the investigational drugs in our China Portfolio are positioned for a series of new drug applications (NDAs) in China with the submission of the first NDA expected
in 2021. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-PoC</FONT></FONT> Global Strategy </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-PoC</FONT></FONT> global strategy focuses on advancing our own
novel or differentiated biologics towards clinical validation in the United States. First, we seek PoC of these drug candidates in the United States by conducting early phase clinical trials with a set of safety and efficacy endpoints and leveraging
the FDA&#146;s streamlined regulatory system for innovative drug discovery, including a predictable timeline towards approval. Second, we will use the data generated to advance clinical development in China, which we believe confers several
advantages, including access to China&#146;s large patient pool, extensive clinical trial resources through collaborations with leading hospitals in China, and a regulatory pathway for fast-track approval of drugs supported by solid overseas
clinical data. Building on this approach, we typically <FONT STYLE="white-space:nowrap">out-license</FONT> the global rights (excluding Greater China) of these investigational drugs following clinical validation in the United States, while retaining
the Greater China rights for further development and commercialization. We believe this approach will allow Chinese patients to benefit from our most advanced treatments concurrently or soon after their market approvals elsewhere. To date, we have
created a Global Portfolio that consists of two molecular classes&#151;monoclonal antibodies and <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies, which are internally generated. They are highly innovative molecules compared to global
competitor assets in the same or related classes of drug candidates. Three investigational drugs in our Global Portfolio (TJM2, TJC4 and TJD5) are in Phase 1 trials in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These two strategies and the resulting two portfolios complement each other and enable us to achieve a balance among our ambition to develop
novel or highly differentiated drugs, our goal to efficiently advance our pipeline assets towards commercialization and the inherent development risks. With this goal in mind, we are also aware that the intended novelty and key differentiation of
our investigational drugs or drug candidates are subject to pivotal clinical validation and approval by the relevant regulatory authorities. There is no assurance that any such investigational drug or drug candidate will receive regulatory approval.
See &#147;Risk Factors&#148; for a detailed description of the risks related to the development and commercialization of our drug candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Capabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Innovative Discovery Expertise </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Built by an elite group of seasoned immunologists with extensive academic research and drug development experience, our discovery engine has
generated a panel of internally developed innovative drug molecules in a short span of four years. Among them, 11 innovative drug molecules have met our standard of novel or high differentiation and have advanced toward further development. This
achievement is a testament to our discovery team&#146;s acumen and technical prowess in translating target biology into points of innovation or differentiation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discovery of TJC4 showcases our innovative research capabilities. Not settling on performing routine or traditional antibody screening, we
set a specific goal to identify and select a unique CD47 antibody that is free from binding to red blood cells (RBC) among all CD47 antibody leads that naturally bind to RBCs. As a result, we selected by design, our proprietary CD47 antibody (TJC4),
a rare epitope that uniquely spares binding to RBCs as a differentiation point from other CD47 antibodies that typically cause inherent hematologic side effects. Having confirmed the RBC-sparing property in a series of in vitro assays as well as
multiple monkey studies, we are conducting a Phase 1 clinical trial for TJC4 in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Another example of our R&amp;D
capability relates to our novel <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody panel that represents a new wave of oncology drug candidates. We created novel biological properties of these
<FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies that are capable of enriching immune cells in tumors through dual targeting of <FONT STYLE="white-space:nowrap">PD-L1</FONT> and immune cells for a synergistic anti-tumor effect. These <FONT
STYLE="white-space:nowrap">bi-specific</FONT> drug candidates have been shown to exhibit unique properties that render tumors more responsive to treatment. Our discovery expertise, when combined with our <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#147;fit-for-purpose&#148;</FONT></FONT> antibody engineering technology platforms, becomes a powerful engine of innovation to create novel molecules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fit-for-Purpose</FONT></FONT> Technology Platforms </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our proprietary antibody engineering platforms enable us to accurately capture the biological properties of
<FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies and retain good manufacturability and druggability of the molecules. To date, we have created seven novel <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage <FONT
STYLE="white-space:nowrap">bi-specific</FONT> drug molecules. In addition to our own <FONT STYLE="white-space:nowrap">Ig-scFv</FONT> <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody platform, we partnered with ABL Bio and WuXi Biologics
to access their antibody engineering platforms in order to increase the probability of success, as different molecular configurations require different technologies. Furthermore, our proprietary antibody-cytokine technology has enabled another form
of <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies such as <FONT STYLE="white-space:nowrap">TJ-L1I7</FONT> and <FONT STYLE="white-space:nowrap">TJ-C4GM</FONT> that link a tumor-engaging antibody with an immuno-modulatory cytokine.
Superior to monoclonal antibodies or cytokines alone, this class of <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies has demonstrated unique properties capable of concentrating the drug molecules in tumors for a desired target effect
with reduced systemic toxicity of cytokines or creating biologic synergy that can potentially translate into better treatment outcome. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our
Biomarker-Enabled Translational Medicine Capabilities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we focus on developing innovative drug molecules, the ability to apply
relevant biomarkers that link a drug response to treatment effects is critical for early-stage clinical trials of our investigational drugs. This translational medicine capability requires cross-functional knowledge and unique skills to link the
target biology of an investigational drug to clinical responses. We have been developing tailor-made biomarkers for each of our investigational drugs, which are used to select potential responders, predict and measure target engagement, support dose
determination and enable timely informed decisions on advancing our assets to the next phase of clinical development. For example, for the development of TJD5, we intend to use CD73 in tumor tissue in combination with other tumor biomarkers to
stratify potential target patient populations in our clinical trial. To that end, we have developed assays to measure CD73 expression and activity in tumor tissues. Furthermore, we have developed specialized assays to measure TJD5 drug
concentrations in tumor tissues. By linking drug concentration with its activity in the same tumor location, these data help us determine appropriate dose selection for further clinical studies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Clinical Development Capabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our clinical development capabilities are highlighted by a global team of clinical scientists, industry physicians, data management
specialists, biostatisticians, clinical operation staff and drug safety experts. Our clinical team accounts for approximately 80% of our entire R&amp;D organization&#146;s headcount and 80% of our budget allocation. The skillset of our clinical
development team is highlighted by a combination of extensive global pharma experience, local drug development and operational experience with clinical networks in China and the United States. The team is driven by high ethical standards, clinical
science and passion for improving the lives of patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our clinical development capabilities are also highlighted by our ability to
integrate internal core development functions, which encompass regulatory affairs, translational medicine, clinical research and operations, data management, biostatistics, clinical safety and pharmacovigilance, portfolio and project management, and
global drug supplies. We also effectively leverage external resources, including clinical contract research organizations, academic clinical centers and/or networks, and global pharmaceutical or biotech partnerships. Furthermore, we have established
and implemented a robust internal clinical governance system to safeguard patient safety and data reporting. Our current clinical development capabilities are strategically based in Shanghai, Beijing, and the United States to cover Phase 1 through
Phase 3 clinical trials in China and early-stage clinical trials in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our clinical development capabilities are best
demonstrated by our rapid implementation of seven ongoing clinical trials, including four Phase 1/2 and registrational trials in Greater China and three Phase 1 trials in the United States within the past three years. To ensure regulatory approval
and subsequent product launch as currently planned, we strive to reach the following critical clinical milestones by the end of 2020&#150;&#150;14 active clinical programs consisting of three Phase 3 or registrational trials in China, three Phase 2
trials in China and eight Phase 1 trials in the United States and China. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Global Strategic Collaborations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established an excellent track record of <FONT STYLE="white-space:nowrap">in-licensing</FONT> and
<FONT STYLE="white-space:nowrap">out-licensing</FONT> deals with our global and regional partners. These <FONT STYLE="white-space:nowrap">in-licensing</FONT> deals enable us to acquire multiple innovative clinical stage assets with favorable
clinical data packages. We have quickly built our China Portfolio through <FONT STYLE="white-space:nowrap">in-licensing</FONT> deals with global biotech partners, including MorphoSys, Genexine, MacroGenics and Ferring (as the sublicensee under our
agreement with Ferring related to Olamkicept TJ301). Over the past three years, we have established more than 10 global and regional partnerships with reputable pharma or biotech companies. Our partners selected us among many China-based companies
with the belief that we are an ideal partner in China given our strength in science and drug development capability, our outstanding track record of execution of rapidly progressing drug development programs in China and the United States and our
vision and network to tap into business opportunities and the growing pharmaceutical market in China. For example, MorphoSys, MacroGenics and Genexine all stated that we are an ideal or the best partner in China in their press releases or public
announcements. The <FONT STYLE="white-space:nowrap">out-licensing</FONT> deals enable us to streamline our pipeline and focus our resources on the most valuable assets. In addition, we seek <FONT STYLE="white-space:nowrap">co-development</FONT>
opportunities to share development costs and risks and territorial commercial rights with our partners. In the past two years, we have <FONT STYLE="white-space:nowrap">out-licensed</FONT> three <FONT STYLE="white-space:nowrap">de-prioritized</FONT>
assets and initiated four <FONT STYLE="white-space:nowrap">co-development</FONT> programs with partners such as ABL Bio, Everest Medicines and WuXi Biologics. The revenue from <FONT STYLE="white-space:nowrap">out-licensing</FONT> and <FONT
STYLE="white-space:nowrap">co-development</FONT> deals is expected to continue to grow as our pipeline progresses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Drug Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The chart below summarizes the development status of our drug pipeline. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g95n07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Notes: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#3d72ff"><FONT STYLE="FONT-FAMILY:'WINGDINGS 2'">&#233;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">(i) TJ202 has two ongoing registrational trials, a monotherapy trial and a combination therapy trial in relapsed
or refractory multiple myeloma in Greater China, and we will soon initiate a Phase 1b trial in systemic lupus erythematosus (&#147;SLE&#148;); (ii) for TJ101, we expect to submit an IND for a Phase 3 registrational trial in China by early 2020; and
(iii)&nbsp;for enoblituzumab, we expect to initiate either a registrational trial (pending the NMPA&#146;s regulatory approval) or a Phase 2 trial by the end of 2020. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">We are collaborating with Everest Medicines Limited (&#147;Everest&#148;) to co-develop and commercialize TJ202
in Greater China for all indications in hematologic oncology. Everest is primarily responsible for sharing with us, by the proportion of 75% for Everest and 25% for us, the development costs of TJ202. We and Everest will share TJ202&#146;s profit
and loss in proportion to the costs that each of us incur in developing the product. We and Everest will also split out-license revenue according to the proportion of development costs incurred, with us getting an additional 5% share and Everest
receiving 5% less. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Our <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody panel consists of (i)&nbsp;five <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1-based</FONT></FONT> <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies, including <FONT STYLE="white-space:nowrap">TJ-L1C4</FONT><B>
</B><FONT STYLE="white-space:nowrap">(PD-L1</FONT> and CD47), <FONT STYLE="white-space:nowrap">TJ-L1D5</FONT><B> </B><FONT STYLE="white-space:nowrap">(PD-L1</FONT> and CD73), <FONT STYLE="white-space:nowrap">TJ-L1H3</FONT> <FONT
STYLE="white-space:nowrap">(PD-L1</FONT> and <FONT STYLE="white-space:nowrap">B7-H3),</FONT> <FONT STYLE="white-space:nowrap">TJ-L14B</FONT> <FONT STYLE="white-space:nowrap">(PD-L1</FONT> and <FONT STYLE="white-space:nowrap">4-1BB)</FONT> and
TJ-L1I7 (anti-PD-L1 and IL-7 cytokine fusion), <FONT STYLE="white-space:nowrap">(ii)&nbsp;TJ-C4GM</FONT> (anti-CD47 and <FONT STYLE="white-space:nowrap">GM-CSF</FONT> cytokine fusion), and <FONT STYLE="white-space:nowrap">(iii)&nbsp;TJ-CLDN4B</FONT>
(Claudin 18.2 and <FONT STYLE="white-space:nowrap">4-1BB).</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Highlights of Our <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT> China Portfolio </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">fast-to-market</FONT></FONT> China strategy is demonstrated by our China Portfolio, which consists of novel or highly differentiated investigational drugs. TJ202, TJ107, enoblituzumab and TJ101 are the four anchor assets
in our China Portfolio. While we have been diligently pursuing our fast-to-market China strategy, we are aware that there is no assurance that we will always be successful in commercializing any of our product candidates in our China Portfolio in an
accelerated manner. See &#147;Risk Factors&#148; for a detailed description of the risks related to the development and commercialization of our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJ202 is a differentiated CD38 antibody originally developed by MorphoSys that meets the pre-set clinical safety and preliminary efficacy
endpoints from a clinical trial conducted in the European Union (EU). <FONT STYLE="white-space:nowrap">In-licensed</FONT> from MorphoSys, TJ202 is being developed to address the current unmet needs and commercial opportunities in China for multiple
myeloma and potentially autoimmune diseases, such as SLE. We own an exclusive license to develop TJ202 in Greater China. We believe TJ202, if approved, is potentially highly differentiated compared </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with the currently marketed CD38 antibody. First, under a similar <FONT STYLE="white-space:nowrap">pre-medication</FONT> condition with dexamethasone, anti-pyretics and anti-histamines, TJ202 has
demonstrated a significantly shorter infusion time and lower infusion reaction rate. Second, unlike the currently marketed CD38 antibody, TJ202 does not down-regulate CD38 expression on the surface of bone marrow myeloma cells in vitro, maintaining
sensitivity of myeloma cells to TJ202 for repeated treatments. We have entered into a collaboration arrangement with Everest, under which we and Everest will share development costs and commercial rights of TJ202 in multiple myeloma in Greater
China, while we retain full rights for all other indications. TJ202 is undergoing a Phase 2 registrational trial as a third-line monotherapy and a Phase 3 trial in combination with lenalidomide as a second-line therapy, both in patients with
relapsed/refractory multiple myeloma in Greater China. We aim to submit an NDA for TJ202 as a monotherapy in 2021, followed by another NDA submission for TJ202 as a combination therapy. Moreover, we believe TJ202 has great market potential in the
treatment of pathogenic antibody-mediated autoimmune diseases, such as SLE, where there is a significant unmet need for more effective therapies. An IND application for a trial in SLE is expected to be submitted in the fourth quarter of 2019. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJ107 is the first long-acting recombinant human IL-7 known to boost cancer-fighting T lymphocytes by increasing their number and function
and is being developed as a potential oncology investigational drug. The clinical safety and effect of TJ107 on T cells have been investigated in multiple previous and ongoing clinical trials in South Korea and the United States. TJ107 is being
positioned to address a huge unmet medical need in oncology. First, TJ107 can be an oncology-care agent to treat cancer treatment-related lymphopenia (low blood lymphocyte levels), a common condition that occurs in cancer patients who have received
chemotherapy or radiation therapy, and there is no approved treatment for this condition. According to the Frost&nbsp;&amp; Sullivan Report, in Greater China, the incidence of lymphopenia reached 1.5&nbsp;million in 2018 and is estimated to increase
to 1.7&nbsp;million in 2023 and further to 2.0&nbsp;million in 2030. This condition causes further damage to patients&#146; already compromised immune system and weakens its ability to fight cancers. Second, TJ107 has been shown to synergize with a
PD-1 antibody in a tumor animal model potentially through increased T&nbsp;lymphocyte activation and proliferation. We are conducting a Phase 1b trial in China to determine a suitable dose range for for subsequent trials. We expect to start a Phase
2 trial in glioblastoma multiforme patients with lymphopenia in the second half of 2020. We are coordinating our study globally with Genexine, which is conducting a Phase 2 clinical trial in South Korea and parallel clinical trials in the United
States towards clinical PoC. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enoblituzumab is a humanized antibody directed at <FONT STYLE="white-space:nowrap">B7-H3,</FONT> a
member of the B7 family of T cell checkpoint regulators that is widely expressed across multiple tumor types and plays a key role in the regulation of immune response against cancers. Similar to other inhibitors of the B7 family such as <FONT
STYLE="white-space:nowrap">PD-L1,</FONT> targeting <FONT STYLE="white-space:nowrap">B7-H3</FONT> potentially provides a treatment option for a variety of cancers expressing <FONT STYLE="white-space:nowrap">B7-H3.</FONT> Enoblituzumab was originally
developed by MacroGenics, and we own the Greater China rights of this product. In multiple clinical trials conducted by MacroGenics, when combined with pembrolizumab in recurrent or metastatic squamous cell carcinoma of the head and neck
(&#147;SCCHN&#148;) and <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (&#147;NSCLC&#148;), enoblituzumab has shown favorable clinical results that warrant further investigation. We plan to conduct a registrational trial (if
approved by the NMPA) in China in patients with recurrent or metastatic SCCHN by the end of 2020. Further clinical development is being planned together with MacroGenics to extend to other cancer indications in China and globally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJ101, if approved, is a potential highly differentiated long-acting human growth hormone that is being developed as a weekly treatment for
pediatric growth hormone deficiency as compared to currently available daily regimens of recombinant human growth hormone (rhGH). TJ101 was originally developed by Genexine, and we own the Greater China rights of this product, which has the
potential to address an important clinical need and to cover a significant market gap in pediatric growth hormone deficiency. According to the Frost&nbsp;&amp; Sullivan Report, there are approximately 3.4&nbsp;million pediatric patients with growth
hormone deficiency in 2018 in Greater China, but only 3.7% of them receive growth hormone therapies, which are mostly daily regimens. In a previous Phase 2 trial conducted by Genexine in South Korea and the EU, both weekly and <FONT
STYLE="white-space:nowrap">bi-weekly</FONT> administration of TJ101 demonstrated similar therapeutic effects to daily injection of Genotropin, a short-acting rhGH. We expect to submit an IND for a Phase 3 registrational trial in China by early 2020.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Highlights of Our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-PoC</FONT></FONT> Global Portfolio </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-PoC</FONT></FONT> global strategy is demonstrated by our Global Portfolio, which mainly consists of our internally developed novel or differentiated biologics. Our Global Portfolio
focuses on two molecular classes&#151;monoclonal antibodies and <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies. While we have been diligently pursuing our fast-to-PoC global strategy, we are aware that there is no assurance that we
will always be successful in achieving PoC or pivotal development milestones for any of our product candidates in our Global Portfolio in an accelerated manner. See &#147;Risk Factors&#148; for a detailed description of the risks related to the
development and commercialization of our drug candidates. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Monoclonal antibodies</I>&#151;Among the five monoclonal antibody drug
candidates, TJM2, TJC4 and TJD5 are undergoing Phase 1 clinical trials in the United States. We have obtained IND approval from the NMPA for TJD5 in September 2019. TJ210 and TJX7 are at the CMC stage and are expected to be ready for investigational
new drug (&#147;IND&#148;) submissions and subsequent Phase 1 clinical trials in 2020 in the United States. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJC4 is an internally
discovered, fully human monoclonal antibody targeting CD47, which is one of the most promising immuno-oncology targets after <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1.</FONT></FONT> Blocking CD47 activates
tumor-engulfing macrophages, a component of the innate immune system as an important cancer-fighting mechanism. CD47 antibodies are being actively pursued in clinical trials by a few global companies. However, current development efforts on CD47
antibody drugs are hampered by hematologic side effects (such as anemia) due to their inherent binding to human RBCs. For example, at least two clinical trials conducted by other companies have been suspended. Unlike competitor investigational
drugs, TJC4 is a rare antibody originally selected, by design, to purposefully avoid or minimize inherent binding to RBCs while maintaining a high antibody affinity and tumor killing properties. TJC4&#146;s unique property of minimal RBC binding and
no significant hematologic changes has been extensively validated in a whole series of robust in vitro assays and primate studies. In a GLP toxicology study involving 40 monkeys, no hematologic side-effects were seen even with repeated injections of
100 mg/kg doses. This unique property may enable TJC4 to be used safely at higher doses to explore its treatment potential in cancers, differentiating it from other clinical stage CD47 investigational antibody drugs. TJC4 is being evaluated in a
Phase 1 clinical trial with cancer patients in the United States, and no anemia has been observed in the first cohort of patients so far. In parallel, leveraging the Phase 1 data generated in the United States, we plan to begin a Phase 1 clinical
trial of TJC4 in AML patients by the end of 2019 in China, followed by a separate clinical trial in NHL patients in China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT
STYLE="white-space:nowrap">Bi-specific</FONT> antibody panel</I>&#151;This novel antibody class represents an emerging and fast-moving area of new drug discovery. <FONT STYLE="white-space:nowrap">Bi-specific</FONT> antibodies are typically
constructed to have a dual specificity of two selected antibodies or combined properties of an antibody linked with a cytokine, previously called an immuno-cytokine. According to the Frost&nbsp;&amp; Sullivan Report, checkpoint inhibitors targeting <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> had global sales of US$16.3&nbsp;billion in 2018 and are predicted to reach US$63.4&nbsp;billion in global sales by 2030. However, despite the recent success of
checkpoint inhibitors, clinical efficacy of these drugs has been unsatisfactory. It is estimated that over 60% of cancer patients, including those with melanoma, renal cell cancer, colorectal cancer, <FONT STYLE="white-space:nowrap">non-small</FONT>
cell lung cancer, urothelial cancer and head and neck squamous cell carcinoma, do not respond to PD-1/PD-L1 monotherapies. In addition, some patients develop resistance after initial treatment with these therapies. As a result, the standard of care
today leaves many cancer patients underserved. There is consensus among cancer immunologists that tumors that do not respond to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> treatment have poor
immunologic features, such as an absence or paucity of tumor-fighting immune cells or the presence of dysfunctional immune cells within the tumors, collectively known as &#147;cold tumors.&#148; We believe that <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> <FONT STYLE="white-space:nowrap">non-responders</FONT> can be better treated with novel <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies. The unique and superior properties of these <FONT
STYLE="white-space:nowrap">bi-specific</FONT> antibodies over <FONT STYLE="white-space:nowrap">PD-L1</FONT> inhibitors alone stem from a second targeting component attached to the <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody moiety of the <FONT
STYLE="white-space:nowrap">bi-specific</FONT> molecules, thereby enabling them to elicit a sufficient immune response and converting a &#147;cold tumor&#148; to an immune-active &#147;hot tumor.&#148; Such unique properties of <FONT
STYLE="white-space:nowrap">bi-specific</FONT> antibodies cannot be substituted by a combination of the <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody with a selected second component (either cytokine or antibody) in a free form. The
underlying mechanism is such that the second component must be structurally integrated with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
tumor-engaging <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody in order to concentrate and function inside the tumor, which cannot be readily achieved by the two free agents used in
combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have successfully generated a panel of five <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies in which our
proprietary <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody acts as the backbone (the first signal) and is linked with various second components (the second signal) including a <FONT STYLE="white-space:nowrap">4-1BB</FONT> agonist antibody <FONT
STYLE="white-space:nowrap">(TJ-L14B),</FONT> a <FONT STYLE="white-space:nowrap">B7-H3</FONT> antibody <FONT STYLE="white-space:nowrap">(TJ-L1H3),</FONT> a CD73 antibody <FONT STYLE="white-space:nowrap">(TJ-L1D5),</FONT> a CD47 antibody <FONT
STYLE="white-space:nowrap">(TJ-L1C4)</FONT> and an IL-7 cytokine (TJ-L1I7), which are shown to work synergistically with the <FONT STYLE="white-space:nowrap">PD-L1</FONT> backbone in various assays and cancer animal models. This unique panel of <FONT
STYLE="white-space:nowrap">bi-specific</FONT> antibodies is only made possible by our proprietary and partnered antibody engineering technologies and the availability of our proprietary monoclonal antibodies. Furthermore, we have generated two other
<FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies <FONT STYLE="white-space:nowrap">(TJ-C4GM</FONT> and <FONT STYLE="white-space:nowrap">TJ-CLDN4B)</FONT> that are tailor-made to function as novel fortified antibodies by linking TJC4
with an engineered <FONT STYLE="white-space:nowrap">GM-CSF</FONT> cytokine for the treatment of solid tumors and by linking our <FONT STYLE="white-space:nowrap">Claudin-18.2</FONT> antibody with a <FONT STYLE="white-space:nowrap">4-1BB</FONT>
antibody as a unique gastric cancer treatment agent that only activates T cells conditionally upon tumor engagement. All <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies have been validated in a series of robust <I>in vitro</I> and
<I>in vivo</I> studies for biology <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> providing a solid basis for clinical validation in cancer patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moving forward, we strive
to become a fully integrated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> global biopharmaceutical company whose capabilities encompass drug discovery, GMP manufacturing,
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical development and commercialization. To achieve this goal, we intend to pursue the following strategies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rapidly advance our China Portfolio towards commercialization </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to pursue the most efficient pathway to NDA approval for the investigational drugs in our China Portfolio. In the next 12 months, we
expect to make significant advances with our China Portfolio. All of the clinical assets of our China Portfolio are expected to undergo Phase 2, Phase 3 or registrational clinical trials in 2020. We plan to submit NDAs to the NMPA for these products
in sequence from 2021 to 2024. With respect to commercialization capabilities, we plan to initially partner with a specialty pharmaceutical company that has existing commercial capabilities and infrastructure in China to jointly market our leading
products. Once we have acquired commercial experience and developed a distribution network, we plan to build a robust internal sales and marketing platform. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expand our research and development capabilities and footprint in the United States to advance our Global Portfolio </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of our global strategy, we plan to expand our research and development capabilities in the United States to include regulatory affairs,
translational medicine, drug formulation and clinical operations. These specific research and development functions in the United States are complementary to and an integral part of our overall research and development capabilities to support
clinical development of our Global Portfolio. Currently, three of our investigational antibody drugs (TJM2, TJC4 and TJD5) are in clinical trials in the United States. We aim to continue advancing the ongoing clinical trials to Phase 2 for clinical
validation and to initiate multiple new clinical programs by the end of 2020 or early 2021 in the United States. In addition, we intend to expand our operational footprint in the United States to create an independent multi-functional business
entity covering global business development, investor relations and corporate communications and other operational capabilities. We are in the process of assembling an integrated management team with global experience and extensive track record
dedicated to overseeing our operations in the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Build our manufacturing capabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe it is advantageous that we own and control our GMP manufacturing process in order to ensure quality and secure production slots for
clinical trial materials and commercial supplies. We plan to commence the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
construction of our own comprehensive biologics manufacturing facility by the end of 2019 in Hangzhou, China. At this planned manufacturing facility, we intend to produce drug substance and drug
product for clinical use as well as future commercial use. We envisage this facility to include a pilot GMP manufacturing plant with two <FONT STYLE="white-space:nowrap">500-liter</FONT> and two <FONT STYLE="white-space:nowrap">2,000-liter</FONT>
single-use bioreactors, and upon completion of the construction, a commercial scale manufacturing plant with eight more <FONT STYLE="white-space:nowrap">2,000-liter</FONT> single-use bioreactors with filling and finishing lines. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Maximize the value of our pipeline </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our successful <FONT STYLE="white-space:nowrap">in-licensing</FONT> efforts, we have established a good track record of <FONT
STYLE="white-space:nowrap">out-licensing</FONT> collaborations and <FONT STYLE="white-space:nowrap">co-development</FONT> partnerships. For the years ended December&nbsp;31, 2017 and 2018 and the six months ended June 30, 2019, we recorded revenues
of RMB11.6&nbsp;million, RMB53.8&nbsp;million and RMB15.0 million (US$2.2 million) from upfront and milestone payments through two <FONT STYLE="white-space:nowrap">out-licensing</FONT> deals, respectively. We have reached cost-sharing <FONT
STYLE="white-space:nowrap">co-development</FONT> deals for some of our drug candidates with multiple global and regional partners. These achievements have not only demonstrated our ability to optimize our pipeline but also provided a sustainable
revenue stream. Going forward, we plan to enhance our <FONT STYLE="white-space:nowrap">out-licensing</FONT> efforts. We expect that the revenue generated from <FONT STYLE="white-space:nowrap">out-licensing</FONT> opportunities will continue to
increase and will account for the majority of our net revenue before the commercialization of our marketed products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Drug Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>China Portfolio </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TJ202: A Potential Highly
Differentiated CD38 Antibody for Multiple Myeloma and Autoimmune Diseases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Summary </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJ202 (MOR202) is a fully human, highly differentiated monoclonal antibody directed against CD38. TJ202, if approved, is positioned as a
potential highly differentiated anti-CD38 therapy for multiple myeloma (&#147;MM&#148;), either as a monotherapy or as a combination therapy with other anti-cancer agents. We aim to demonstrate the advantages of TJ202, including its shorter infusion
time, lower infusion reaction rate (&#147;IRR&#148;) and potentially sustained efficacy compared to other CD38 antibodies, in our ongoing clinical trials in China. Additionally, as pathogenic CD38-positive B cells and plasma cells are strongly
implicated in the disease progression of pathogenic antibody-mediated autoimmune diseases, we believe the therapeutic value of TJ202 can be extended to these diseases that have significant unmet medical needs. We have begun to explore its
therapeutic application in systemic lupus erythematosus (&#147;SLE&#148;) and later in other autoimmune diseases. In November 2017, we obtained an exclusive license from MorphoSys to develop TJ202 in Greater China. The development of TJ202 is driven
by a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> strategy. We have started a Phase 2 registrational trial for a third-line monotherapy and a Phase 3 trial in combination with lenalidomide as a
second-line therapy, both in patients with relapsed or refractory MM (&#147;RRMM&#148;) in Greater China. We aim to submit an NDA for TJ202 as a monotherapy in 2021, followed by another NDA submission for TJ202 as a combination therapy. An IND
application for a trial in SLE is expected to be submitted in the fourth quarter of 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Therapeutic Options and Current Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Multiple Myeloma (MM) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
treatment options and investigational drugs under development in China include: (i)&nbsp;for small molecule drugs, two or three approved drugs known as doublets or triplets are used. VRD triplet (Velcade (bortezomib), Revlimid (lenalidomide) and
dexamethasone) has recently been approved for overseas frontline treatment and is recommended in China in the 2017 version of treatment guideline. VCD triplet (Velcade, cyclophosphamide and dexamethasone) is the most widely adopted first-line
treatment in China due to its lower cost. In 2017, lenalidomide and bortezomib were included in the National Reimbursement Drug List in China; (ii)&nbsp;with respect to CD38 antibody therapy, daratumumab (from Johnson&nbsp;&amp; Johnson) received
conditional NDA approval from the NMPA in July 2019, and isatuximab (from Sanofi) is in a Phase 3 trial in China; and (iii)&nbsp;for <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapy, several Phase 1 or 2 clinical trials are ongoing in China.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, there is no curative treatment for MM. Although the currently marketed CD38
antibody in China is efficacious, it takes a long time to be administered by IV infusion (up to six hours) and causes a high infusion reaction rate (&#147;IRR&#148;). In clinical trials, approximately half of all patients experience an infusion
reaction, symptoms of which may include fever, chills, nausea, bronchospasm, hypoxia, dyspnea, hypertension, laryngeal edema and pulmonary edema. Thus, there is a need for a safer and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">convenient-to-use</FONT></FONT> drug. Such a drug may be combined with other therapeutic agents for better treatment effects in MM. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Systemic Lupus Erythematosus (SLE) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients with mild SLE are often given <FONT STYLE="white-space:nowrap">non-steroidal</FONT> anti-inflammatory drugs, while more severe
patients may need corticosteroids or immunosuppressants. Approved by the FDA in 2011 and by the NMPA in July 2019, Benlysta (belimumab), a <FONT STYLE="white-space:nowrap">B-lymphocyte</FONT> stimulator (BLyS)-specific inhibitor developed by GSK, is
currently the world&#146;s only biologic approved to treat SLE. However, there remains a significant unmet medical need beyond belimumab for SLE in China and the rest of the world. As dysregulated CD38-positive B cells and auto-antibodies produced
by CD38-positive plasma cells and resulting immune complexes are at the core of the pathogenesis of SLE, direct inhibition and selective depletion of pathogenic B cells and plasma cells are believed to offer better treatment options. Our TJ202 has
the potential to offer such a disease-modifying treatment option. In addition, as described below, the advantages of our TJ202 include convenience of use and a lower IRR, making it a more favorable treatment agent in the long-term clinical
management of SLE if approved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advantages of TJ202 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJ202, if approved, is a potentially highly differentiated CD38 monoclonal antibody and could be the second antibody therapy for MM to launch
in China. A Phase 2a trial of TJ202 in MM showed a level of treatment effects comparable to that observed in trials of the currently marketed CD38 antibody. However, available trial data from MorphoSys and Johnson &amp; Johnson indicate that with
similar <FONT STYLE="white-space:nowrap">pre-medications</FONT> of dexamethasone, anti-pyretics and anti-histamines, TJ202 required only a short infusion time of 0.5 to 2 hours, compared to 3.5 to 6.5 hours for the currently marketed CD38 antibody.
Moreover, the IRR was as low as 7% for TJ202, compared to 48% for the currently marketed CD38 antibody. The advantages of TJ202 associated with infusion may be attributed to its lack of antibody CDC activity and are likely to translate into clinical
benefits in terms of tolerability and convenience of use as well as economic benefits due to the cost and length of hospital stay. In addition, unlike the currently marketed CD38 antibody, TJ202 treatment does not down-regulate CD38 expression on
the surface of bone marrow myeloma cells in vitro, maintaining sensitivity of malignant myeloma cells to repeated TJ202 treatments. As TJ202 is being considered for long-term treatment management of autoimmune diseases, we believe such clinical
differentiation is critical. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For autoimmune diseases, TJ202 has advantages over other B cell-targeting therapies such as CD20 antibodies,
as it specifically targets malfunctioned CD38<SUP STYLE="font-size:85%; vertical-align:top">high</SUP> B cells and pathogenic plasma cells involved in autoimmune diseases while CD20 antibodies target most B cells, including those involved in normal
immune functions and regulatory functions, but not plasma cells producing pathogenic antibodies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Mechanism of Action </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJ202 binds to CD38 overexpressed on the surface of target cells and kills them by inducing antibody-dependent cellular cytotoxicity
(&#147;ADCC&#148;) and antibody-dependent cellular phagocytosis (&#147;ADCP&#148;). The target cells are the malignant plasma cells in MM and a group of dysregulated CD38<SUP STYLE="font-size:85%; vertical-align:top">high</SUP> B cells and plasma
cells that produce pathogenic antibodies in autoimmune conditions such as SLE. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g63r89.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>TJ202 kills CD38-bearing tumor cells by inducing ADCC and ADCP.</I></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Summary of Clinical Results </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MorphoSys has conducted a Phase 1/2a study in adult patients with relapsed or refractory MM in Austria and Germany. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Study Design</I>. The open-label, multicenter, dose-escalation study was designed to characterize the safety profile and preliminary
efficacy of TJ202 in adults with RRMM. A 3+3 dose escalation design was used to establish the maximum tolerated dose (&#147;MTD&#148;), recommended dose and dosing regimen of TJ202 as monotherapy, weekly or
<FONT STYLE="white-space:nowrap">bi-weekly,</FONT> with or without dexamethasone (&#147;DEX&#148;), and in combination with pomalidomide (&#147;POM&#148;) and DEX or lenalidomide (&#147;LEN&#148;) and DEX standard regimens. The MTD and recommended
dose and dosing regimens were to be confirmed in three confirmation cohorts of at least six evaluable subjects each. TJ202 dose levels in this study ranged from 0.01 mg/kg to 16.0 mg/kg, administered by intravenous (&#147;IV&#148;) infusion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical study results as of the data cutoff date, December&nbsp;31, 2017, are summarized as follows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Safety</I>. TJ202 was well tolerated in patients with RRMM, as a single agent and in combination with DEX, or with POM/DEX, or with
LEN/DEX. The MTD of TJ202 was not reached. In the 56 patients from three groups receiving combination regimens, grade <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>3 adverse events (&#147;AEs&#148;) were mainly in the hematological system reflected
by a decrease of various blood cells. This was as expected, because of decreased bone marrow function due to the presence of myeloma as well as the expression of CD38 on various cell lineages of the myeloid and lymphoid compartments. Most of the
hematological adverse events were transient and generally manageable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJ202 was administered as a
<FONT STYLE="white-space:nowrap">two-hour</FONT> IV infusion at first dose and infusion time could be reduced to as short as 30 minutes at subsequent doses without obvious safety concerns. Among all cohorts, infusion-related reactions, including
tachycardia, pyrexia and hypersensitivity, occurred in 18 of 91 patients (19.8%) and were mostly mild to moderate. In the combination cohorts containing DEX, a very low IRR (4 out of 56 patients (7%)) was observed. These results compared favorably
with the historical data of the currently marketed CD38 antibody. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Clinical Efficacy</I>. Preliminary efficacy results were based on 56 patients from three
groups treated with TJ202 combination therapies. No responses were observed for the monotherapy groups which were primarily serving for dose escalation. TJ202 in combination with low dose DEX, POM/DEX or LEN/DEX demonstrated an overall response rate
(&#147;ORR&#148;) of 28%, 48% and 65%, respectively. Durable responses were observed as median progression-free survival (&#147;PFS&#148;) was of 8.4 months and 17.5 months for the DEX and the POM/DEX combination groups, respectively, and PFS levels
were not reached for the LEN/DEX combination group, as there were not sufficient events of progression recorded. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g95p44.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Figure:</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>Best overall response and ORR. Patients were treated with TJ202 (MOR202) in combination with low dose of DEX (40 mg for 75 years old and younger, or 20 mg for older than 75 years old), POM (4 mg) /Dex or LEN (25 mg)/Dex. Dex:
dexamethasone; POM: pomalidomide; LEN: lenalidomide; ITT: intent to treat; NE: not evaluable; PD: progressive disease; SD: stable disease; MR: minimal response; PR: partial response; VGPR: very good partial response; CR: complete response; sCR:
stringent complete response; ORR: overall response rate. (Source: MorphoSys)</I></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The definitions of PD, SD, MR, PR, VGPR, CR and sCR and how these responses were measured for multiple myeloma
are set forth in the table below. <I>(Source: International Myeloma Working Group Uniform Response Criteria (2006) and European Group for Blood and Marrow Transplantation Criteria)</I> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Response subcategory</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Criteria<SUP STYLE="font-size:85%; vertical-align:top">a</SUP></B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">sCR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;CR as defined below plus</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">Normal free light chain ratio (FLC) and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">Absence of clonal cells in bone marrow<SUP STYLE="font-size:85%; vertical-align:top">b</SUP> by immunohistochemistry or immunofluorescence<SUP
STYLE="font-size:85%; vertical-align:top">c</SUP></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Negative immunofixation on the serum and urine and</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Disappearance of any soft tissue plasmacytomas and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;&lt;5% plasma cells in bone
marrow<SUP STYLE="font-size:85%; vertical-align:top">b</SUP></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Response subcategory</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Criteria<SUP STYLE="font-size:85%; vertical-align:top">a</SUP></B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VGPR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Serum and urine M-protein detectable by immunofixation but not
electrophoresis or</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>90% reduction in serum
M-protein plus urine M-protein level &lt;100 mg/24&nbsp;hours</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>50% reduction of serum
M-protein and reduction in 24-hour urinary <FONT STYLE="white-space:nowrap">M-protein</FONT> by <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>90% or to &lt;200&nbsp;mg/24&nbsp;hours</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;If the serum and urine M-protein were unmeasurable,
a&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>50% decrease in the difference between levels of involved and uninvolved free-light-chains instead of the M-protein criteria</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;In addition to the above-listed criteria, if present at baseline, a
<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>50% reduction in the size of soft tissue plasmacytomas was also required</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MR<SUP STYLE="font-size:85%; vertical-align:top">d,e</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;25&#150;49% reduction in level of serum M-protein</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;50&#150;89% reduction in 24-hour urinary M-protein, which still exceeds 200 mg/24 hours. If
present at baseline, 25&#150;49% reduction in the size of soft tissue plasmacytomas (by radiography or clinical examination)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;No increase in the size or number of lytic bone lesions (development of a compression fracture did
not exclude response)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SD<SUP STYLE="font-size:85%; vertical-align:top">f</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Not meeting criteria for CR, VGPR, PR, MR, or PD</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTE: Required any 1 or more of the following:</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Increase of <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>25% from nadir in</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Serum M-component and/or (absolute increase
<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>0.5&nbsp;g/dL)<SUP STYLE="font-size:85%; vertical-align:top">g</SUP></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Urine M-component and/or (absolute increase
<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>200&nbsp;mg/24&nbsp;hours)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Only in subjects
without measurable serum and urine M-protein levels: the difference between involved and uninvolved FLC levels. Absolute increase &gt;10&nbsp;mg/dL.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Bone marrow plasma cell percentage: absolute %
<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>&nbsp;10%<SUP STYLE="font-size:85%; vertical-align:top">h</SUP></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the
size of existing bone lesions or soft tissue plasmacytomas</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Development of hypercalcemia
(corrected serum calcium &gt;11.5 mg/dL or 2.65&nbsp;mmol/L) that could be attributed solely to the plasma cell proliferative disorder</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Notes:</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:8pt; font-family:Times New Roman">a&#8195;&#8194;All response categories required 2&nbsp;consecutive assessments made at any time before the institution
of any new therapy; all categories also required no known evidence of progressive or new bone lesions if radiographic studies were performed. Radiographic studies were not required to satisfy these response requirements.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:8pt; font-family:Times New Roman">b&#8195;&#8201;&#8201;Confirmation with repeat bone marrow biopsy not needed.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:8pt; font-family:Times New Roman">c&#8195;&#8194;Presence/absence of clonal cells was based upon the <FONT STYLE="FONT-FAMILY:SYMBOL">&#107;</FONT>/<FONT
STYLE="FONT-FAMILY:SYMBOL">&#108;</FONT> ratio. An abnormal <FONT STYLE="FONT-FAMILY:SYMBOL">&#107;</FONT>/<FONT STYLE="FONT-FAMILY:SYMBOL">&#108;</FONT> ratio by immunohistochemistry and/or immunofluorescence required a minimum of 100 plasma cells
for analysis. An abnormal ratio reflecting presence of an abnormal clone is <FONT STYLE="FONT-FAMILY:SYMBOL">&#107;</FONT>/<FONT STYLE="FONT-FAMILY:SYMBOL">&#108;</FONT> of &gt;4:1 or &lt;1:2.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:8pt; font-family:Times New Roman">d&#8195;&#8201;&#8201;MR also included subjects in whom some, but not all, the criteria for PR were fulfilled, provided
the remaining criteria satisfied the requirements for MR.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:8pt; font-family:Times New Roman">e&#8195;&#8194;The response criterion MR did not apply to
subjects who presented with serum FLCs only.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:8pt; font-family:Times New Roman">f&#8195;&#8194;&#8202;Per the International Myeloma Working Group
Uniform Response Criteria, stable disease was not recommended for use as an indicator of response; stability of disease is best described by providing the time to progression estimates.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:8pt; font-family:Times New Roman">g&#8195;&#8201;&#8201;For progressive disease, serum M-component increases of
<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>1&nbsp;g/dL were sufficient to define relapse if starting M-component was <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>5 g/dL.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:8pt; font-family:Times New Roman">h&#8195;&#8201;&#8201;Relapse from CR has the 5% cut-off versus 10% for other categories of relapse.</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Pharmacodynamics</I>. As a pharmacodynamic marker, serum myeloma (M)&nbsp;protein levels were used to
evaluate severity and clinical response. The median relative change in M protein levels from baseline to post-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
baseline nadir for TJ202 in combination with low doses of DEX, POM/DEX or LEN/DEX was <FONT STYLE="white-space:nowrap">-13%,</FONT> <FONT STYLE="white-space:nowrap">-58%</FONT> and <FONT
STYLE="white-space:nowrap">-81%,</FONT> respectively. The data below show strong effects of TJ202 in reducing M protein levels. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g36d33.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>The relative change in M protein levels from baseline to post-baseline nadir. Patients were treated with TJ202 (MOR202) in combination with low doses of DEX, POM/DEX or LEN/DEX. S: serum sample; U:&nbsp;urine sample. (Source:
MorphoSys)</I></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Pharmacokinetics (&#147;PK&#148;)</I>. The PK of TJ202 in humans was well characterized by a <FONT
STYLE="white-space:nowrap">two-compartment</FONT> model at dose levels greater than 4 mg/kg. At these doses, stable or even increasing trough levels could be observed over time suggesting the potential for full target occupancy, especially at the
highest dose level (16&nbsp;mg/kg). For most subjects, steady state at 16 mg/kg was observed after the fourth infusion. Terminal half-life at high-dose levels (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 4 mg/kg) was at approximately two weeks.
Pharmacokinetics of TJ202 were generally consistent across different individuals and dosing days and not affected by the <FONT STYLE="white-space:nowrap">co-medications.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Immunogenicity</I>. No anti-drug antibody (&#147;ADA&#148;) against TJ202 was observed as of the
<FONT STYLE="white-space:nowrap">cut-off</FONT> date. Thus, risk of ADA induction for TJ202 in humans is considered low. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Development Plan
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately after <FONT STYLE="white-space:nowrap">in-licensing</FONT> TJ202, we formulated a robust clinical development strategy
with an aim for an NDA submission by 2021. With an approved IND, we have started a <FONT STYLE="white-space:nowrap">single-arm</FONT> registrational trial with TJ202 and DEX as a third-line therapy for RRMM patients in Greater China using ORR as the
primary endpoint (NCT03860038). Dosing of the first patient took place in March 2019. Data from this <FONT STYLE="white-space:nowrap">82-patient</FONT> study are expected to be the major package supporting registrational filing for conditional
approval in 2021. In parallel, we started a Phase 3 registrational trial combining TJ202 with LEN and DEX as a second-line combination therapy in RRMM patients (NCT03952091). We plan to enroll 291 patients for full approval. Dosing of the first
patient took place in Taiwan in April 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our clinical development plan for SLE starts with a Phase 1b clinical trial to explore dose
range, clinical safety and tolerability as well as TJ202&#146;s profiles of PK and pharmacodynamics (&#147;PD&#148;) in SLE patients. We expect to file an IND application in the fourth quarter of 2019 and start this trial in the first half of 2020.
</P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TJ107 (Efineptakin): The First Long-acting Recombinant Human IL-7 with the Potential for Cancer Treatment-related Lymphopenia and Cancer
Immunotherapy </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Summary </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJ107 (international nonproprietary name (&#147;INN&#148;): efineptakin) is the world&#146;s first and only long-acting recombinant human <FONT
STYLE="white-space:nowrap">interleukin-7</FONT> <FONT STYLE="white-space:nowrap">(&#147;rhIL-7&#148;),</FONT> which is being developed as a T lymphocyte-booster for cancer-related immunotherapy. Due to its advantages in terms of selective immune
functions, improved stability, developability, and extended half-life, TJ107 is differentiated from an earlier generation of short-acting <FONT STYLE="white-space:nowrap">rhIL-7</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and T cell growth factor <FONT STYLE="white-space:nowrap">(interleukin-2).</FONT> In December 2017, we acquired exclusive rights from Genexine to develop and commercialize TJ107 in Greater China.
We plan to position TJ107 first as a monotherapy or an oncology care product for cancer patients with cancer treatment-related lymphopenia (low blood lymphocyte levels) induced by chemotherapy or radiation therapy. This target indication covers a
large population of cancer patients who develop cancer treatment-related lymphopenia, a condition that weakens the ability to receive continued chemotherapy or radiation therapy and leads to worsened disease prognosis and clinical outcome.
Currently, there is no treatment available for this condition. Second, TJ107 is expected to show a therapeutic effect as a combination therapy with immune checkpoint inhibitors, i.e.,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies, due to its inherent selective T cell-boosting properties. <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> studies have indicated that TJ107
exerted additional anti-tumor effect when combined with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies. If proven efficacious in clinical studies, we believe such a combination therapy, can
potentially treat a large population of cancer patients who do not respond or respond poorly to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies. We are conducting a Phase 1b study in China to
determine a suitable dose range for subsequent trials. We expect to start a Phase 2 trial in glioblastoma mutliforme patients with lymphopenia in the second half of 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Therapeutic Options and Current Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the target therapeutic indications of TJ107 is cancer treatment-related lymphopenia. Cancer patients who undergo chemotherapy and/or
radiation therapy often develop cancer treatment-related lymphopenia, which further damages their already compromised immune systems and their ability to fight against cancers. According to the Frost&nbsp;&amp; Sullivan Report, more than 85% of all
cancer patients receive chemotherapy or radiation therapy, and 43% of these patients develop lymphopenia, which represents a significant unmet medical need, as currently no drug is available for the treatment of lymphopenia. Advanced solid tumor is
another indication of TJ107 as a combination therapy with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> treatments. As more than 60% cancer patients either do not respond or respond poorly to current <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies, there are intense attempts to identify an effective agent that can work synergistically with <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies to increase the probability of treatment success. TJ107 is believed to provide such a treatment option, which is supported by <FONT STYLE="white-space:nowrap">pre-clinical</FONT> reports
that <FONT STYLE="white-space:nowrap">IL-7</FONT> exhibits a synergistic effect with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> antibodies in the treatment of cancers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advantages of TJ107 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJ107 has an
advantage over other T lymphocyte cytokines with therapeutic potential in oncology. <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> and clinical results generated so far indicate that TJ107 has a favorable immune function profile over
recombinant human <FONT STYLE="white-space:nowrap">interleukin-2</FONT> <FONT STYLE="white-space:nowrap">(&#147;rhIL-2&#148;)</FONT> in that TJ107 activates and expands tumor-fighting CD4, CD8 and natural killer T cells but spares tumor-protecting
Treg cells. By contrast, <FONT STYLE="white-space:nowrap">rhIL-2</FONT> is a well-known inducer of Tregs, which suppresses tumor-fighting effector T cells. Furthermore, <FONT STYLE="white-space:nowrap">rhIL-2</FONT> has a narrow therapeutic window
and causes serious side effects such as capillary leak syndrome, breathing problems, serious infections, and seizures. A polyethylene glycol (PEG)-conjugated <FONT STYLE="white-space:nowrap">IL-2</FONT> variant recently developed by Nektar
Therapeutics has yielded mixed results, indicating the complexity associated with using <FONT STYLE="white-space:nowrap">IL-2</FONT> as a cancer treatment. Owing to its preferred immune function and molecular profiles demonstrated in <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> and Phase 1/2 clinical trials, we believe that TJ107 is a superior T cell cytokine investigational drug for cancer treatment-related lymphopenia and cancer immunotherapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJ107, as an engineered <FONT STYLE="white-space:nowrap">rhIL-7,</FONT> has the advantages of improved stability and half-life extension
through Genexine&#146;s proprietary hybrid fragment crystallizable region (&#147;hyFc&#148;). Introducing a few hydrophilic amino acid residues to the <FONT STYLE="white-space:nowrap">N-terminus</FONT> of <FONT STYLE="white-space:nowrap">IL-7</FONT>
overcomes stability issues that hampered the development of previous <FONT STYLE="white-space:nowrap">rhIL-7</FONT> drug candidates. Furthermore, application of the hyFc technology enhances <FONT STYLE="white-space:nowrap">IL-7&#146;s</FONT>
function, increases its half-life (from 48 to 112 hours after a single subcutaneous (&#147;SC&#148;) dose in clinical studies), and allows for a robust purification process. By contrast, the half-life of first-generation <FONT
STYLE="white-space:nowrap">rhIL-7</FONT> was reported to be about 12 hours after SC dosing in human subjects. The hyFc in TJ107 is also <FONT STYLE="white-space:nowrap">non-cytolytic,</FONT> so it will not damage the T cells to which it binds.
Unlike TJ107, the previous <FONT STYLE="white-space:nowrap">rhIL-7</FONT> drug candidates adopt <FONT STYLE="white-space:nowrap">non-glycosylated</FONT> (CYT <FONT STYLE="white-space:nowrap">99-007)</FONT> or glycosylated <FONT
STYLE="white-space:nowrap">(CYT-107)</FONT> forms of short-acting <FONT STYLE="white-space:nowrap">rhIL-7</FONT> and were developed by Revimmune Inc (formerly known </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as Cytheris SA). These molecules had low stability, low production yield, and a short half-life because <FONT STYLE="white-space:nowrap">IL-7</FONT> protein is intrinsically unstable and prone to
aggregation. However, the preliminary clinical results from Phase 1 and Phase 2 trials in patients with AIDS did show an increase of T lymphocytes following treatment with CYT-107 (Thiebaut R et al., PLoS Comput Biol., 2014). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Mechanism of Action </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">IL-7</FONT> is a cytokine essential for the survival and homeostatic proliferation of naive and memory T cells (see figure below). <FONT STYLE="white-space:nowrap">IL-7</FONT> is critically involved in restoring T cells to
normal levels in the event of lymphopenia by stimulating T cell proliferation. <FONT STYLE="white-space:nowrap">IL-7</FONT> exerts its functions by binding to and activating the <FONT STYLE="white-space:nowrap">IL-7</FONT> receptor, which is
expressed primarily on lymphocytes, including the lymphoid precursors, developing T and B cells, naive T cells, and memory T cells, but not on tumor-protecting Tregs. TJ107 as a monotherapy may enhance anti-tumor immunity by augmenting the number
and functionality of T&nbsp;cells, whereas TJ107 in combination with an immune checkpoint inhibitor, cancer vaccine or <FONT STYLE="white-space:nowrap">CAR-T</FONT> may improve the anti-tumor response by restoring T cell numbers, reconstituting T
cell pools and reinvigorating exhausted T cells. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g59k87.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>Role of <FONT STYLE="white-space:nowrap">IL-7</FONT> in T cell maintenance and proliferation.</I></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Summary of Clinical Results </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1 trial has been conducted by Genexine
in South Korea. This was a randomized, double-blind, placebo-controlled, single ascending dose study, to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic properties of 20 or 60 &micro;g/kg TJ107 via SC or intramuscular
(&#147;IM&#148;) administration in healthy volunteers. Each dose group consisted of 10 subjects, eight of whom were administered TJ107 and two were given placebo via the same route of administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Safety</I>. TJ107 was well-tolerated in all 30 subjects without serious adverse events. The most common adverse events were transient Grade
1 or 2 injection site skin reactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Pharmacodynamics (&#147;PD&#148;)</I>. Because <FONT STYLE="white-space:nowrap">IL-7</FONT>
promotes the survival and proliferation of T cells, absolute lymphocyte count (&#147;ALC&#148;) in the peripheral blood was used as a reliable and convenient PD marker for TJ107 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(see figure below). ALC initially decreased transiently in all TJ107 groups. This effect is often termed margination, which is a physiological phenomenon common to many cytokines as a result of
increased adherence of cytokine-stimulated white blood cells to the blood vessels and subsequent trafficking to tissues and lymphoid organs. ALC recovered in approximately seven days, reaching a maximum value at close to 21 days, before gradually
declining. This result indicated that a single dose of TJ107 had a long-lasting effect of increasing lymphocyte levels. Overall, a greater increase in ALC was observed in Cohort 2 compared with Cohort 1, demonstrating a dose-dependent response.
Additionally, a higher increase in ALC was observed in Cohort 3 compared with Cohort 2, which was consistent with the results of an animal study, where IM injection induced a more effective increase in lymphocytes than SC injection. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g27s64.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>Median fold changes of ALC following a single dose of TJ107 in humans. Cohort 1: 20 &micro;g/kg, SC; Cohort 2: 60 &micro;g/kg, SC; and Cohort 3: 60 &micro;g/kg, IM. (Source: Genexine)</I></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJ107 treatment resulted in a substantial increase in the number of CD4 and CD8 T cells, natural killer
T&nbsp;cells, naive T cells, central memory, effector memory, and terminally differentiated effector memory T cells, without affecting the number of B cells, natural killer cells, monocytes or Tregs. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g95b62.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g99a02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>Median fold changes of T cells and subsets following a single dose of TJ107 in human subjects. Cohort 1: 20 &micro;g/kg, SC; Cohort 2: 60 &micro;g/kg, SC; Cohort 3: 60 &micro;g/kg, IM. (A)&nbsp;CD3+T cells, (B)&nbsp;CD4+T
cells, (C)CD8 + T cells, (D)&nbsp;Natural Killer T cells, and (E)&nbsp;regulatory T cells (Treg). (Source: Genexine)</I></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Pharmacokinetics</I>. TJ107 was slowly absorbed, particularly after SC administration,
and was slowly removed, resulting in a half-life of 48 to 112 hours, longer than that reported for the first generation <FONT STYLE="white-space:nowrap">rhIL-7</FONT> (about 12 hours). Intramuscular TJ107 showed approximately <FONT
STYLE="white-space:nowrap">two-fold</FONT> greater exposure than SC administration at the same dose level of 60 &micro;g/kg. The higher plasma exposure of TJ107 after IM administration was well-correlated with a more robust PD effect on ALC in
Cohort 3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Immunogenicity</I>. ADAs were detected in 22 of 24 subjects treated with TJ107. One subject in Cohort 3 was positive for
ADAs before treatment. Neutralizing antibodies were observed in 42% and 46% of the subjects within one to two months following administration, respectively, but only one person still harbored neutralizing ADAs five months after administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical relevance of ADA was evaluated during long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> monitoring. ALC levels were
maintained above the baseline values, endogenous <FONT STYLE="white-space:nowrap">IL-7</FONT> was maintained at normal levels, and no specific adverse events associated with ADAs were observed. These results are consistent with well-documented
reports that a normal individual can harbor <FONT STYLE="white-space:nowrap">pre-existing</FONT> auto-antibodies for cytokines such as <FONT STYLE="white-space:nowrap">IL-2,</FONT> <FONT STYLE="white-space:nowrap">IL-3,</FONT> <FONT
STYLE="white-space:nowrap">IL-4,</FONT> and <FONT STYLE="white-space:nowrap">IL-7,</FONT> and that these anti-cytokine antibodies tend to serve as a reservoir and carrier of the cytokines in the blood, extending the half-life of these cytokines and
preserving their functions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Development Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By leveraging the results of Genexine&#146;s ongoing clinical trials in South Korea and the United States, we aim to rapidly advance the
clinical development of TJ107 for approval in Greater China. Currently, a Phase 1b trial in China is ongoing to investigate the safety, tolerability and PK/PD response of TJ107 in patients with advanced solid cancers. The clinical trial
(NCT04001075) is designed to include: (i)&nbsp;dose escalation of TJ107 using a conventional &#147;3 + 3&#148; study design to identify a safe and active dose range and (ii)&nbsp;dose expansion to confirm the safety and obtain preliminary evidence
of efficacy. We have finished the dose escalation for the first patient cohort, and the safety and tolerability profile as well as the PK/PD response are consistent with other ongoing studies of TJ107. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After determining the recommended Phase 2 dose (&#147;RP2D&#148;) in the Phase 1b trial, we expect to start a Phase&nbsp;2 trial in
glioblastoma multiforme patients with lymphopenia in the second half of 2020. Based on results from the subgroup of patients with lymphopenia in the Phase 1b trial, we plan to further develop TJ107 monotherapy in cancer treatment-related
lymphopenia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Genexine has initiated a dose-finding trial in combination with checkpoint inhibitors in patients with solid tumors.
Meanwhile, Genexine is also sponsoring additional early-stage clinical trials in advanced solid tumors, including glioblastoma and high-risk skin cancer, in the United States and South Korea. The safety, pharmacology and preliminary efficacy data
from these ongoing studies are expected to significantly facilitate our clinical development of TJ107 in Greater China. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TJ101: A Potential highly
differentiated Long-Acting Growth Hormone for Growth Hormone Deficiency </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Summary </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJ101, if approved, is a potential highly differentiated long-acting recombinant human growth hormone (&#147;rhGH&#148;) (INN: eftansomatropin)
being developed as a more convenient and effective therapy for growth hormone deficiency (&#147;GHD&#148;), for which there is substantial unmet medical need in China. TJ101 met the pre-set safety endpoints in three multi-regional clinical trials
conducted in Europe and Asia and preliminary efficacy endpoints in <FONT STYLE="white-space:nowrap">pre-pubertal</FONT> growth hormone naive pediatric growth hormone deficient (&#147;PGHD&#148;) patients. In contrast to marketed short-acting rhGH
such as Genotropin, TJ101 showed similar efficacy results in a weekly (vs. daily) regimen. Furthermore, TJ101 has not shown the safety concerns typically associated with approved pegylated drugs. We
<FONT STYLE="white-space:nowrap">in-licensed</FONT> the China rights to TJ101 from Genexine and are positioning TJ101 as a highly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
differentiated growth hormone replacement therapy because of its advantages over a daily regimen in terms of injection frequency (weekly vs. daily) and safety profile (natural protein-based vs.
pegylated long-acting rhGH), especially in pediatric patients. We are preparing for a registrational Phase 3 trial in China to validate the efficacy, safety, pharmacodynamics, and pharmacokinetics of TJ101 in PGHD, with a plan for IND submission in
the first half of 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Therapeutic Options and Current Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current therapeutic indication is PGHD. The widely adopted treatment for PGHD is patient-specific growth hormone replacement therapy, which
is given in a calculated weight-based dosing regimen. Currently, short-acting recombinant human growth hormone (&#147;rhGH&#148;) is commonly used for the long-term treatment of children and adults with inadequate endogenous growth hormone
secretion. There are certain safety concerns related to long-term use of pegylated drugs, such as potential renal toxicity, cellular vacuolation and formation of anti-polyethylene glycol antibodies. Approved by the NMPA in 2014, Jintrolong
(developed by GeneScience) is currently the only long-acting pegylated rhGH in China, according to the Frost &amp; Sullivan Report. Other companies in China currently developing long-acting rhGH include Anhui Anke Biotechnology, Xiamen Amoytop
Biotech, and Generon Pharmaceutical Technology. Our TJ101 is the only <FONT STYLE="white-space:nowrap">Fc-based</FONT> long-acting rhGH ready for a Phase 3 clinical trial in China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the Frost&nbsp;&amp; Sullivan Report, only 3.7% of all PGHD patients in China were receiving growth hormone replacement therapy
in 2018, which primarily consists of daily injections of rhGH before sleep. This dosing regimen puts a substantial burden on pediatric patients and their families because it requires drug preparation and needle injection every day, which is painful
and extremely inconvenient, often resulting in poor patient compliance. More importantly, studies have shown that skipping just one or two doses in a week can markedly reduce the efficacy of the treatment. Therefore, there is a substantial unmet
medical need for long-acting growth hormone therapies that are similarly efficacious but with reduced injection frequency, and the market potential for such a long-acting rhGH in China is largely untapped. In addition, recombinant human growth
hormone therapy has been included in the National Reimbursement Drug List (NRDL) in China. Inclusion of a drug in the NRDL typically results in a much higher sales volume and significant sales growth despite a reduction in price. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advantages of TJ101 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that
TJ101 has the following advantages: (i)&nbsp;when compared to the daily regimen of rhGH, TJ101 is expected to be a more convenient therapy with better patient compliance due to a reduced dosing frequency to either weekly or twice-monthly
administration, while maintaining similar efficacy; and (ii)&nbsp;TJ101 has not shown safety concerns typically associated with pegylated drugs, such as potential renal toxicity, <FONT STYLE="white-space:nowrap">pre-existing</FONT> or
treatment-induced <FONT STYLE="white-space:nowrap">anti-PEG</FONT> antibodies, and cellular vacuolation in macrophages, renal tubule cells and the choroid plexus epithelial cells. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Mechanism of Action </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Like endogenous
growth hormone, TJ101 stimulates the production of insulin-like growth factor 1 <FONT STYLE="white-space:nowrap">(&#147;IGF-1&#148;)</FONT> in the liver, which has growth-stimulating effects on a variety of tissues, including osteoblast and
chondrocyte activities that stimulate bone growth. Thus, <FONT STYLE="white-space:nowrap">IGF-1</FONT> is a reliable pharmacodynamic marker and more importantly, the key mediator of TJ101&#146;s growth-promoting activity. TJ101 is based on
Genexine&#146;s patented hyFc technology. The hyFc part consists of a portion of human immunoglobulin D (&#147;IgD&#148;) and G<SUB STYLE="font-size:85%; vertical-align:bottom">4</SUB>
(&#147;IgG<SUB STYLE="font-size:85%; vertical-align:bottom">4</SUB>&#148;). The former contains a flexible hinge, and the latter is responsible for half-life extension through neonatal Fc receptor (&#147;FcRn&#148;)-mediated recycling. Additionally,
TJ101&#146;s increased molecular weight (103 kilodalton) is expected to reduce renal clearance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g31j43.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>Schematic presentation of the structure of TJ101. CH2 &amp; CH3: Constant regions 2 &amp; 3 of antibody heavy chains, respectively; hGH: human growth hormone. (Source: Genexine)</I></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Summary of Clinical Results </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Genexine has completed three clinical trials with TJ101, including one Phase 1 trial in healthy adult volunteers, one Phase 1b/2 multi-regional
trial in adults with GHD, and one Phase 2 multi-regional trial in PGHD in Europe, altogether involving 32 healthy subjects and 99 patients with GHD and PGHD. Overall, TJ101 was shown to be well-tolerated, and clinical efficacy endpoint achieved by
weekly or twice-monthly TJ101 administration was comparable to that of daily administration of Genotropin. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 1 Clinical Trial </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> trial of TJ101 was a randomized,
double-blind, placebo-controlled single dose-ascending study in four groups of healthy subjects. A total of 32 subjects were enrolled, and 31 completed the study. TJ101 was shown to be well-tolerated at all dose levels studied (0.2&#150;1.6 mg/kg).
TJ101 was detectable in the blood until Day 7 for the 0.2 mg/kg dose group, Day 14 for the 0.4 and 0.8 mg/kg dose groups, and Day 21 for the 1.6 mg/kg dose group. A single subcutaneous (&#147;SC&#148;) injection of TJ101 at dose levels of 0.4 mg/kg
and higher increased <FONT STYLE="white-space:nowrap">IGF-1</FONT> and <FONT STYLE="white-space:nowrap">IGF-binding</FONT> <FONT STYLE="white-space:nowrap">protein-3</FONT> <FONT STYLE="white-space:nowrap">(&#147;IGFBP-3&#148;)</FONT> levels for at
least one week. No safety concerns were identified. TJ101 showed a half-life ranging from 69.2 to 138 hours. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 2 Clinical Trial in PGHD </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Study Design. </I>The Phase 2 trial in PGHD was a randomized, open-label, active-controlled study to assess the safety, tolerability,
efficacy, pharmacokinetics, and pharmacodynamics of weekly and twice-monthly doses of TJ101, as compared to a daily injection of Genotropin, which is currently the standard of care for PGHD. Subjects were randomly assigned to receive one of three
doses of TJ101 (0.8 mg/kg/weekly, 1.2 mg/kg/weekly or 2.4 mg/kg/twice monthly) or 0.03 mg/kg/daily of Genotropin for up to 24 months. The primary clinical endpoint was annualized height velocity (aHV) in centimeters (cm)&nbsp;per year (equivalent to
annual growth rate), measured at six months. A total of 56 subjects were randomized at 27 centers in nine European countries and South Korea. Fifty two subjects completed the six-month treatment (through Visit 7), meeting the primary endpoint. Two
subjects withdrew from the study before first drug administration, and two subjects discontinued due to treatment-related adverse events (&#147;AEs&#148;). Genexine and its <FONT STYLE="white-space:nowrap">co-developer</FONT> Handok presented the
latest interim results of the Phase 2 clinical trial for PGHD in March 2018 at the Endocrine Society&#146;s annual meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Safety.
</I>No study drug-related serious adverse events (&#147;SAEs&#148;) or death were observed. The tolerability of TJ101 was consistent with known properties of marketed products. The AE incidence rate was generally similar across the TJ101 cohorts
treated with three different dose levels (ranging between 69.2% and 84.6%) and the Genotropin cohort (57.1%). A total of two (14.3%), three (23.1%), two (15.4%), and zero subjects experienced treatment-related AEs in the 0.8 mg/kg/week, 1.2
mg/kg/week, and 2.4&nbsp;mg/kg/twice monthly TJ101 groups, and the 0.03 mg/kg/daily Genotropin group, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Two subjects withdrew from the study due to treatment-related AEs. One subject from Cohort 2
(1.2 mg/kg/week of TJ101) discontinued due to retinal vascular disorder. The Data and Safety Monitoring Board (&#147;DSMB&#148;) reviewed this case independently, concluding that the retinal finding was more likely to be of completely different
etiology than treatment-induced intracranial hypertension. One subject from Cohort 3 (2.4 mg/kg/twice monthly of TJ101) discontinued due to pseudopapilloedema (optic disc drusen), which was assessed by the principal investigator to be mild with
continuous frequency and possibly related to the study drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Injection site reactions (&#147;ISRs&#148;) were reported by 13 out of 40
subjects (32.5%) in the TJ101 cohorts. Pain was the most prominent and common symptom observed in 10 subjects. Also, six subjects reported redness, four reported itching, and one reported bruising, swelling and warmness. With respect to the
Genotropin cohort, pain was the only ISR reported in 683 cases by 11 out of 14 subjects (78.5%). None of the ISRs led to discontinuation of treatment, and most of the reported ISRs posed no issue for the subjects and were resolved quickly. No safety
signal was detected in laboratory parameters or vital signs for either TJ101 or Genotropin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Pharmacokinetics.</I> Half-life of TJ101
was 77.75&#150;141.95 hours after a single dose and 43.92&#150;55.66 hours (compared to 5.27 hours for Genotropin) after three months of multiple-dose administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Immunogenicity. </I>Formation of treatment-emergent ADA with neutralizing property was reported in two subjects (one from Cohort 2 and one
from Cohort 3) out of a total of 40 subjects randomized and dosed with TJ101. With respect to the Genotropin cohort, the presence of treatment-emergent ADA with neutralizing property was not observed in any subject. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Clinical Efficacy. </I>Subcutaneous administration of TJ101 over the dose range of 0.8 mg/kg/week&#150;2.4 mg/kg/twice monthly resulted in
an increase in aHV over the <FONT STYLE="white-space:nowrap">six-month</FONT> study period.<I> </I>Subjects who<I> </I>received TJ101 at 0.8 mg/kg weekly, 1.2 mg/kg weekly, and 2.4 mg/kg twice monthly showed growth rates of 11.50, 11.54, and 11.86
cm/year, respectively, while the growth rate in the control group treated with Genotropin was approximately 11.24 cm/year. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g29v69.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>The aHV at six months indicated comparable growth rates between all doses of TJ101 (both weekly and twice-monthly treatment) and the active comparator, Genotropin. (Source: Genexine)</I></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Pharmacodynamics.</I> The growth-promoting effect of TJ101 was accompanied by elevated serum <FONT
STYLE="white-space:nowrap">IGF-1</FONT> levels. This hormone is an important biomarker, which mediates growth hormone&#146;s biological effects. The Standard Deviation Score (&#147;SDS&#148;), which is a calculated score with reference to the normal
<FONT STYLE="white-space:nowrap">age-</FONT> and <FONT STYLE="white-space:nowrap">sex-matched</FONT> <FONT STYLE="white-space:nowrap">IGF-1</FONT> levels, is a standardized parameter to compare <FONT STYLE="white-space:nowrap">IGF-1</FONT> levels
across laboratories and populations. Mean <FONT STYLE="white-space:nowrap">IGF-1</FONT> SDS at the beginning of the study was below the lower limit of the normal range in all treatment arms. Following initiation of treatment, the <FONT
STYLE="white-space:nowrap">IGF-1</FONT> SDS values quickly normalized by five days (Visit&nbsp;2) and three weeks (Visit 3) after the initial treatment, respectively, for the TJ101 treatment arms and the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Genotropin treatment arm. <FONT STYLE="white-space:nowrap">IGF-1</FONT> responses were maintained throughout the intended dosing interval, supporting both the weekly and twice monthly treatment
regimens. <FONT STYLE="white-space:nowrap">IGF-1</FONT> mean peak levels were mostly within the upper limit of the physiologic range, which is considered safe in clinical practice. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Development Plan </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on
Genexine&#146;s Phase 2 study in PGHD, we are preparing to conduct a registrational Phase 3, randomized, active-controlled, and multi-center study in China to assess the efficacy, safety, and pharmacokinetics of TJ101 in PGHD. The primary objective
is to demonstrate <FONT STYLE="white-space:nowrap">non-inferiority</FONT> of 1.2 mg/kg/week of TJ101 administered SC, based on aHV after 26 weeks of treatment, compared to the active control Jintropin, a daily rhGH marketed in China. We have
finalized the study design with key opinion leaders, and our development plan and study design have been discussed with the NMPA through a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">face-to-face</FONT></FONT> <FONT
STYLE="white-space:nowrap">pre-IND</FONT> meeting. We expect to submit an IND application in the first half of 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TJ301: A Potential Highly
Differentiated <FONT STYLE="white-space:nowrap">IL-6</FONT> Blocker for Ulcerative Colitis and other Autoimmune Diseases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Summary </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJ301 (INN: olamkicept) is the only clinical stage selective <FONT STYLE="white-space:nowrap">interleukin-6</FONT> <FONT
STYLE="white-space:nowrap">(&#147;IL-6&#148;)</FONT> inhibitor that works through the trans-signaling mechanism. <FONT STYLE="white-space:nowrap">IL-6</FONT> is an important cytokine driver in the propagation and maintenance of chronic inflammation
in autoimmune diseases. Compared to the approved antibody drugs that directly block <FONT STYLE="white-space:nowrap">IL-6</FONT> or <FONT STYLE="white-space:nowrap">IL-6</FONT> receptor <FONT STYLE="white-space:nowrap">(&#147;IL-6R&#148;),</FONT>
TJ301 is expected to provide a novel alternative for the treatment of <FONT STYLE="white-space:nowrap">IL-6</FONT> mediated inflammation without affecting some of the normal physiological functions of <FONT STYLE="white-space:nowrap">IL-6,</FONT>
e.g., acute immune response against infection and metabolic regulation. TJ301 demonstrated therapeutic effects in pre-clinical animal models of autoimmune diseases, including inflammatory colitis. Moreover, the safety and tolerability profile of
TJ301 was studied in three clinical trials in Germany involving 128 subjects. We believe that TJ301 has the potential to become a highly differentiated therapy to target autoimmune diseases. We acquired an exclusive license from Ferring
Pharmaceuticals to develop and commercialize TJ301 in Greater China and South Korea with an option of licensing worldwide rights. As part of our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> strategy
for TJ301, we are conducting a Phase 2 clinical trial in ulcerative colitis (&#147;UC&#148;) for the following reasons: (i)&nbsp;TJ301 was shown to be effective in animal models of colitis; (ii)&nbsp;an exploratory Phase&nbsp;2a biomarker trial
showed promising interim treatment effects of TJ301 in UC patients; and (iii)&nbsp;even though UC incidence is increasing rapidly, innovative biologic treatments for this disease are lacking in China. We expect to obtain interim data from this Phase
2 clinical trial by the second half of 2020. After clinical efficacy and differentiation are validated for UC, we plan to develop TJ301 in other inflammation indications, in which the pathogenic role of <FONT STYLE="white-space:nowrap">IL-6</FONT>
is clinically proven by approved <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-IL-6</FONT></FONT> biologics. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Therapeutic
Options and Current Development </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current therapeutic indication for development is UC. UC and Crohn&#146;s disease (&#147;CD&#148;)
are the main types of inflammatory bowel disease (&#147;IBD&#148;), which cause chronic and often relapsing inflammation of the large and small intestines, respectively. Anti-inflammatory drugs, such as
<FONT STYLE="white-space:nowrap">5-aminosalicylic</FONT> acids <FONT STYLE="white-space:nowrap">(&#147;5-ASAs&#148;)</FONT> and corticosteroids, are often used as initial treatment for UC. Immune system suppressors are also used to control
inflammation in patients with UC, including azathioprine, mercaptopurine, and cyclosporine. Biologics that inhibit tumor necrosis factor alpha <FONT STYLE="white-space:nowrap">(TNF-&#945;),</FONT> including infliximab (Remicade), adalimumab
(Humira), and golimumab (Simponi), are efficacious in some UC patients who fail to respond to conventional therapies. Entyvio, an integrin &#945;<SUB STYLE="font-size:85%; vertical-align:bottom">4</SUB>&szlig;<SUB
STYLE="font-size:85%; vertical-align:bottom">7 </SUB>antibody that blocks lymphocytes from accumulating in the intestinal wall, is the first and, to date, the only <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">non-anti-TNF-&#945;</FONT></FONT></FONT> biologics approved for UC. In China, Remicade is currently the only biologic approved for treatment of UC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is a substantial unmet medical need in UC for a treatment agent(s) that is efficacious and safe through pathways beyond the traditional
drug targets. The incidence of UC is increasing rapidly, but UC patients, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
especially those with a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> disease, have few treatment options, which have limited efficacy and
considerable side-effects. For example, Jak1/3 kinase inhibitors can carry the risk of serious infections and malignancies. <FONT STYLE="white-space:nowrap">TNF-&#945;</FONT> inhibitors also have inherent side effects and do not work in all
patients. According to the Frost&nbsp;&amp; Sullivan Report, approximately 45% patients with autoimmune diseases are considered treatment <FONT STYLE="white-space:nowrap">non-responders</FONT> to <FONT STYLE="white-space:nowrap">TNF-&#945;</FONT>
drugs and less than one third the UC patients taking <FONT STYLE="white-space:nowrap">TNF-&#945;</FONT> drugs achieve drug free remission. Thus, as the only clinical stage selective <FONT STYLE="white-space:nowrap">interleukin-6</FONT> <FONT
STYLE="white-space:nowrap">(&#147;IL-6&#148;)</FONT> inhibitor that works through the trans-signaling mechanism, we believe TJ301 has the potential to become a highly differentiated <FONT STYLE="white-space:nowrap">IL-6</FONT> blocker for UC, if
approved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advantages of TJ301 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
existing <FONT STYLE="white-space:nowrap">IL-6</FONT> or <FONT STYLE="white-space:nowrap">IL-6R</FONT> blockers cause total inhibition of <FONT STYLE="white-space:nowrap">IL-6</FONT> signaling and are associated with significant adverse events in
the clinic, such as infection, gastrointestinal perforation, metabolic disturbances, and insulin resistance. TJ301 is expected to provide a novel alternative as it works through a different mechanism, the trans-signaling pathway. This key advantage
has been demonstrated in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and three clinical trials conducted in Germany. The results indicated that TJ301 has no side effects on lipid, glucose or bone metabolism, and it has no agonistic
activities that could activate receptors or trigger detrimental immune cascades. We expect that selective inhibition of <FONT STYLE="white-space:nowrap">IL-6</FONT> trans-signaling is an effective and safer approach to the treatment of chronic
inflammation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Mechanism of Action </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJ301 is a homodimer of a fusion protein consisting of the extracellular domains of human glycoprotein130 (&#147;gp130&#148;) and the fragment
crystallizable (Fc) domain of human IgG<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB>. Mimicking the function of endogenous soluble gp130, TJ301 works as a decoy by binding to a complex consisting of
<FONT STYLE="white-space:nowrap">IL-6</FONT> and soluble <FONT STYLE="white-space:nowrap">IL-6</FONT> receptor <FONT STYLE="white-space:nowrap">(&#147;sIL-6R&#148;),</FONT> thereby preventing TJ301 from stimulating the trans-signaling pathway in
cells that do not express <FONT STYLE="white-space:nowrap">IL-6R.</FONT> The gp130 part selectively binds the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IL-6/sIL-6R</FONT></FONT> complex with high affinity (Kd=130 pM), whereas
the Fc part initiates dimerization and offers longer half-life for the molecule. TJ301 is not expected to affect the beneficial effects of <FONT STYLE="white-space:nowrap">IL-6,</FONT> such as the acute immune response against infection mediated by
the classical pathway. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g75i90.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>Classical signaling and trans-signaling pathways of <FONT STYLE="white-space:nowrap">IL-6.</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-IL-6R</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-IL-6</FONT></FONT> block both pathways, whereas TJ301 blocks only trans-signaling. <FONT STYLE="white-space:nowrap">IL-6R:</FONT> <FONT STYLE="white-space:nowrap">IL-6</FONT> receptor;
<FONT STYLE="white-space:nowrap">sIL-6R:</FONT> Soluble <FONT STYLE="white-space:nowrap">IL-6</FONT> receptor.</I></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Summary of Clinical Results </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ferring Pharmaceuticals has completed two Phase 1 trials to evaluate TJ301&#146;s preliminary safety and clinical pharmacology. TJ301 was shown
to be well-tolerated based on the clinical results collected from a total </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of 112 subjects exposed to the drug. In addition, a Phase 2a biomarker study in active IBD (known as the FUTURE study) has been completed in Germany with promising pharmacodynamic and clinical
responses observed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Phase 1 Clinical Trial: Single Dose Ascending Trial </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Study Design. </I>The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> trial of TJ301 was a
single dose, placebo-controlled, single-blind, randomized within dose, and parallel group dose-escalating trial. The trial recruited both healthy subjects and patients with Crohn&#146;s Disease (&#147;CD&#148;) in clinical remission. The primary
objective was to examine the safety, tolerability and pharmacokinetics after a single dose of TJ301. Several dose levels were tested, ranging from 0.75&nbsp;mg to 750 mg, with each dose level including six subjects receiving TJ301 and two receiving
placebo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Pharmacokinetics. </I>In healthy subjects and CD patients, TJ301 showed similar terminal half-life of 4.3 to 5.1 days. The
maximum concentration (C<SUB STYLE="font-size:85%; vertical-align:bottom">max</SUB>) in plasma and the area under curve (&#147;AUC&#148;) of the plasma drug concentration-time curve were dose proportional. For SC administration of TJ301 (60 mg), the
C<SUB STYLE="font-size:85%; vertical-align:bottom">max</SUB> was approximately 1.0 &micro;g/mL at 2.3 days, and the bioavailability was approximately 48%. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g19d04.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Single dose pharmacokinetic profile of TJ301. Left, healthy subjects (colored lines) and IBD patients in remission (gray lines) received a single IV infusion at 75 mg (blue lines), 300 mg (magenta lines) or 600&nbsp;mg (red
lines) fixed doses. Right, healthy subjects received a single SC injection at 60 mg. LLOQ: lower limit of quantitation. (Source: Ferring Pharmaceuticals)</I></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Safety. </I>TJ301 was well-tolerated when administered as a single IV dose at up to 750 mg and as a single
SC dose at 60 mg. No apparent dose-related AE was observed. Infusion was discontinued in two subjects due to mild to moderate infusion-related reactions, with skin symptoms such as urticaria and swelling, which were rapidly resolved. Only one
healthy subject in the 300 mg group showed <FONT STYLE="white-space:nowrap">non-neutralizing</FONT> treatment-emergent ADAs at the <FONT STYLE="white-space:nowrap">follow-up</FONT> visit five to six weeks after administration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Phase 1 Clinical Trial: Multiple Dose Ascending Trial </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Study Design. </I>This trial was a placebo-controlled, double-blind, and randomized dose-escalating trial in healthy subjects. A total of 24
healthy subjects were randomized into three dose groups and received four weekly infusions of TJ301 at 75 mg, 300 mg or 600 mg. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Pharmacokinetics</I>. PK characteristics were similar on the first and last treatment
days of the multiple dose-ascending trial and were similar to results in the single dose-ascending study. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g61j34.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>Multiple dose pharmacokinetic profile of TJ301. Healthy subjects received weekly IV infusions at 75 mg (blue lines), 300 mg (magenta lines) or 600 mg (gray lines) fixed doses. LLOQ, lower limit of quantitation. (Source:
Ferring Pharmaceuticals)</I></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Safety. </I>There were only a few mild or moderate AEs reported across all treatment groups. One subject
from the 600 mg group withdrew due to mild infusion-related reactions with urticaria and pruritus 30 minutes after administrating the first dose. No apparent dose-related trends or treatment-related change in vital signs, electrocardiogram or
clinical chemistry parameters were observed. No ADAs were reported by any subject. Overall, TJ301 was well-tolerated when administered by IV at up to 600 mg once weekly for four weeks. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Overall Summary of Treatment-Emergent Adverse Events </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>75&nbsp;mg<BR>(N = 6)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>300 mg<BR>(N = 6)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>600 mg<BR>(N = 6)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Placebo<BR>(N = 6)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total Active<BR>(N = 18)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">n&nbsp;(%)&nbsp;E</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">n&nbsp;(%)&nbsp;E</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">n&nbsp;(%)&nbsp;E</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">n&nbsp;(%)&nbsp;E</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">n&nbsp;(%)&nbsp;E</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Any TEAE<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6&nbsp;(100)&nbsp;13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2&nbsp;(33)&nbsp;5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4&nbsp;(67)&nbsp;6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6&nbsp;(100)&nbsp;14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12&nbsp;(67)&nbsp;24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serious TEAEs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adverse Drug Reactions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6&nbsp;(100)&nbsp;11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2&nbsp;(33)&nbsp;2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3&nbsp;(50)&nbsp;5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4&nbsp;(67)&nbsp;6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11&nbsp;(61)&nbsp;18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TEAEs Leading to Withdrawal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(17)&nbsp;1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(6)&nbsp;1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deaths</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Source:
Ferring Pharmaceuticals </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Note: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Reasonably possibly related to treatment; N: number of subjects exposed; n: number of subjects with AE; %:
n/N*100; E: number of AEs </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Phase 2a Biomarker Study in Active IBD (FUTURE Study) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Study Design. </I>This was an open-label exploratory study to assess the mechanisms of molecular activity (effects on biomarkers), safety
and tolerability of TJ301 in adult patients with active IBD. Nine UC patients and seven CD patients were dosed with TJ301 (600 mg, IV, q2w) for up to 12 weeks followed by 42 days of safety <FONT STYLE="white-space:nowrap">follow-up.</FONT> Patients
enrolled had moderately to severe active UC or ileocolonic CD with median disease duration of 5.3 (UC) and 6.9 (CD) years and with immunologically active inflammation <FONT STYLE="white-space:nowrap">(C-reactive</FONT> protein &gt;5 mg/l), who had
failed conventional therapies and had no prior biologics treatment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary endpoint was the proportion of patients with reduced mucosal expression of a
predefined set of inflammation-relevant genes (TNFA, IL1A, REG1A, IL8, IL1B and LILRA) as a composite score. Objective assessments included centrally read endoscopies, histology readings, and various explorative molecular parameters and inflammatory
biomarkers. The trial was sponsored and conducted by the University Hospital Schleswig Holstein and Paul-Ehrlich Institute <FONT STYLE="white-space:nowrap">(EUDRA-CT</FONT> <FONT STYLE="white-space:nowrap">2016-000205-36),</FONT> with financial and
material support from Ferring Pharmaceuticals. The study has been completed, and the abstract of the results is expected to be presented at the United European Gastroenterology Week meeting in late 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Safety.</I> TJ301 was well-tolerated. Reported AEs were unspecific in nature and showed no signs of immune suppression. Five SAEs were
observed, none of which were life-threatening or deemed to be related to TJ301. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Pharmacokinetics.</I> After single and repeated IV
administration of TJ301 (600 mg, Q2W) to patients with UC and CD, similar serum exposure was observed after the first and last dosing events, with respect to Cmax and total exposure over 14 days. Maximal serum drug concentration after each dosing
was reached at the end of infusion. The mean terminal half-life of TJ301 after the last administration was approximately 5.1 days. Circulating biological activity of TJ301 was confirmed by whole-blood STAT3 phosphorylation assays in all patients. A
minimal and transient ADA production was observed in three patients. ADAs were only detected at week 12 and week 15, but no longer detectable at week 18. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g37e21.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Time course of the mean serum concentration of TJ301.</I></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Pharmacodynamics.</I> In the assessment of the primary endpoint, it was observed that clinical remission
was associated with a significant reduction of <FONT STYLE="white-space:nowrap">IL-1B,</FONT> <FONT STYLE="white-space:nowrap">IL-8</FONT> and REG1A gene expression in the intestinal mucosa. Pathway analysis of blood transcriptome signatures showed
an early molecular anti-inflammatory signature as early as four hours after treatment in all patients, irrespective of treatment outcome, which indicated a thorough inhibitory effect of <FONT STYLE="white-space:nowrap">IL-6</FONT> trans-signaling
blockade on inflammatory pathways. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Clinical Efficacy</I>. A preliminary clinical response was observed in both UC and CD patients,
which appeared to be stronger in patients with UC than those with CD. Overall, 55% of UC patients (5/9) responded to TJ301, with 22% (2/9) reaching clinical remission, whereas 29% of CD patients (2/7) responded to TJ301, with 14% (1/7) reaching
clinical remission. All three patients in clinical remission showed a fast and thorough induction of clinical, endoscopic, and immunologic remission within the first four weeks. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Development Plan </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
positioning TJ301 as a differentiated <FONT STYLE="white-space:nowrap">IL-6</FONT> blocker for a number of autoimmune diseases. The first target indication is active stage UC that is not well-controlled by conventional therapies such as mesalazine.
With a goal of developing TJ301 as a second-line therapy for mild UC and first-line therapy for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
UC, we have initiated a multi-regional Phase 2 clinical trial in Taiwan, South Korea, and China to assess the pharmacokinetics, safety, and efficacy of TJ301 in patients with active UC
(NCT03235752). This is a randomized, double-blind, and placebo-controlled clinical trial with three treatment arms. We plan to enroll 90 patients. A total of 30 patients have been dosed. We expect to obtain interim data from this Phase 2 clinical
trial by the second half of 2020. Besides UC, we are evaluating the possibility of extending TJ301 to other autoimmune conditions where there is significant unmet medical need in China. We expect to initiate a second clinical trial for chronic
inflammatory disorders, such as neuromyelitis optica, systemic sclerosis, Castleman&#146;s disease, and system vasculitis, in which <FONT STYLE="white-space:nowrap">IL-6</FONT> is implicated as a key pathogenic cytokine. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Enoblituzumab: The Most Advanced Clinical Stage Humanized B7-H3 Antibody as a Potential Immuno-oncology Treatment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Summary </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enoblituzumab is a humanized
antibody directed at <FONT STYLE="white-space:nowrap">B7-H3,</FONT> a member of the B7 family of T cell checkpoint regulators. <FONT STYLE="white-space:nowrap">B7-H3</FONT> is a promising immuno-oncology drug target as it is widely expressed across
multiple tumor types and plays a key role in regulating immune response against cancers. Increasing <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical evidence suggests that antibodies targeting the two T cell checkpoint <FONT
STYLE="white-space:nowrap">molecules&#150;&#150;B7-H3</FONT> and <FONT STYLE="white-space:nowrap">PD-1&#150;&#150;work</FONT> synergistically in treating cancer. Given <FONT STYLE="white-space:nowrap">B7-H3&#146;s</FONT> critical role, enoblituzumab
has a wide range of cancer applications as either a monotherapy or in combination with <FONT STYLE="white-space:nowrap">PD-1</FONT> therapies. At the molecular level, enoblituzumab is engineered to possess an enhanced anti-tumor ADCC function and is
at the forefront in global clinical development. Originally developed by MacroGenics, enoblituzumab has been evaluated in multiple clinical trials as a monotherapy or in combination with CTLA-4 or PD-1 therapies in patients with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">B7-H3-expressing</FONT></FONT> cancers. Enoblituzumab is also being evaluated in a neoadjuvant Phase 2 study as a single agent in patients with intermediate and high-risk localized prostate
cancer. The clinical studies so far have shown that enoblituzumab is well-tolerated, and it increased CD8 T cell infiltration in tumors with more focused T cell repertoires in patients treated with enoblituzumab as a monotherapy. Recent clinical
studies conducted by MacroGenics indicate that combination therapy with enoblituzumab and pembrolizumab correlates with preliminary anti-tumor effects in recurrent or metastatic squamous cell carcinoma of the head and neck (&#147;SCCHN&#148;) and <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (&#147;NSCLC&#148;). We recently acquired the development and commercial rights of enoblituzumab from MacroGenics for Greater China. Our initial clinical development plan includes a
registrational trial (if approved by the NMPA) in patients with recurrent or metastatic SCCHN in China by the end of 2020. As more clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data become available, further clinical trials will
be planned together with MacroGenics to extend enoblituzumab to other cancer indications in China and globally. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Therapeutic Options and Current
Development </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our initial therapeutic indication is head and neck cancer. Head and neck cancers occur in various parts of the head and
neck, including the mouth, nose, throat and salivary glands. More than 90% of head and neck cancers are classified as SCCHN, which begin in the squamous cells that line the moist, mucosal surfaces inside the head and neck. The treatment principles
and regimens for head and neck cancer in China are similar to those in the rest of the world. Treatment strategies often depend on the location and stage of the cancer, the patient&#146;s physical status, and response to prior treatments.
Early-stage disease is primarily treated with surgical resection, while patients with locally advanced, recurrent or metastatic disease are typically treated with drug therapy. The combination of surgery and drug therapy, with or without radiation
therapy, is the current standard of care for Stage 3 SCCHN patients with locally advanced disease. Platinum-based chemotherapy regimens are widely used as first-line therapies for Stage 4 and distant relapse patients. Erbitux (cetuximab from Eli
Lilly and Merck KGaA) was approved in 2006 as a first-line treatment of locally advanced SCCHN in combination with radiation therapy. Regimens containing Erbitux, platinum-based chemotherapy, and
<FONT STYLE="white-space:nowrap">5-fluorouracil,</FONT> known as EXTREME, are often considered as the standard of care for first-line treatment of distant relapse SCCHN. However, only about 35% of patients respond to EXTREME, and the resulting
overall median survival is only 10.1 months. Furthermore, about half of the patients on first-line therapies need later-line therapies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, even second-line therapy is highly varied, including single-agent docetaxel or
paclitaxel, Erbitux monotherapy, and Erbitux and pacitaxel combination therapy. In 2016, <FONT STYLE="white-space:nowrap">PD-1</FONT> inhibitors were approved globally as second-line therapies. Recently, Keytruda (pembrolizumab from Merck&nbsp;&amp;
Co), used as a single agent or in combination with chemotherapy, was approved by the FDA as first-line therapy for patients with metastatic or unresectable recurrent SCCHN. The average ORR for second-line therapies has been less than 15%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As such, we believe that SCCHN patients, especially those with late stage or relapsed disease, need more efficacious treatments with fewer
side effects, which represents a significant unmet medical need for immunotherapy and targeted therapy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advantages of Enoblituzumab </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enoblituzumab is the most advanced clinical stage humanized B7-H3 antibody as a potential immuno-oncology treatment. The foregoing statement
applies only to conventional therapeutic <FONT STYLE="white-space:nowrap">B7-H3</FONT> antibodies and does not include radio-labeled <FONT STYLE="white-space:nowrap">B7-H3</FONT> antibodies in development by
<FONT STYLE="white-space:nowrap">Y-mabs</FONT> Therapeutics. Targeting <FONT STYLE="white-space:nowrap">B7-H3</FONT> offers several advantages over other target options within the class of T cell checkpoint molecules. First, <FONT
STYLE="white-space:nowrap">B7-H3</FONT> is a tumor-associated antigen that is over-expressed in a variety of solid tumors while its expression in normal tissues is rather limited, enabling the tumor killing mechanism of enoblituzumab. Second, <FONT
STYLE="white-space:nowrap">B7-H3</FONT> is a unique checkpoint whose expression in tumors is associated with disease prognosis. For example, biomarker analysis of more than 400 NSCLC patients revealed that among all the elevated immune checkpoint
inhibitors, including <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1,</FONT></FONT> <FONT STYLE="white-space:nowrap">PD-L2,</FONT> <FONT STYLE="white-space:nowrap">B7-H3,</FONT>
<FONT STYLE="white-space:nowrap">TIM-3,</FONT> BTLA and CTLA4, only <FONT STYLE="white-space:nowrap">B7-H3</FONT> is negatively correlated with clinical efficacies of neoadjuvant treatments (Lou et al., Clinical Cancer Research, 2016). Furthermore,
recent studies have shown that when combined with a <FONT STYLE="white-space:nowrap">PD-1</FONT> antibody, a blockade of <FONT STYLE="white-space:nowrap">B7-H3</FONT> results in superior treatment effects in relevant cancer animal models while
another study indicates that <FONT STYLE="white-space:nowrap">B7-H3</FONT> expression correlates with a lack of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> response (Yonesaka et al., Clinical Cancer
Research, 2018). The advantages summarized above make <FONT STYLE="white-space:nowrap">B7-H3</FONT> a favorable tumor target for immuno-therapeutic intervention. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Mechanism of Action </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enoblituzumab
(MGA271) is an investigational humanized immunoglobulin (IgG1/kappa monoclonal antibody) that binds to B7 homolog 3 <FONT STYLE="white-space:nowrap">(B7-H3).</FONT> This antibody consists of an engineered human IgG1 fragment crystallizable (Fc)
domain that imparts increased affinity for the human activating Fc gamma receptor (Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R) IIIA (CD16A) and decreased affinity for the human inhibitory Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>RIIB
(CD32B). The engineered Fc domain confers enoblituzumab with enhanced target-specific antibody-dependent cellular cytotoxicity (&#147;ADCC&#148;) in vitro and anti-tumor activity in preclinical studies. Therefore, enhanced cytolysis of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">B7-H3-expressing</FONT></FONT> tumor cells is a mechanism that supports the development of this molecule as an antineoplastic agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, data suggest that enoblituzumab impacts <FONT STYLE="white-space:nowrap">T-cell</FONT> homeostasis in vivo. Cancer patients
display a more narrowly focused <FONT STYLE="white-space:nowrap">T-cell</FONT> repertoire following enoblituzumab treatment compared to their baseline repertoire distribution. Moreover, enhanced local <FONT STYLE="white-space:nowrap">T-cell</FONT>
infiltration has been observed in prostate cancer patients treated with enoblituzumab. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These data are consistent with the notion that enoblituzumab is capable of engaging both
innate and adaptive immunity as mediators of its anti-tumor activity. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g93a29.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>Enoblituzumab contributes to the coordination and engagement of innate and adaptive immunity to mediate tumor regression. Enoblituzumab binds to tumor cells, activates innate immune cells such as natural killer cells (NK
cells) to kill cancer cells through ADCC. The released tumor antigens may then be presented by antigen-presenting cells, such as macrophages, which, in concert with <FONT STYLE="white-space:nowrap">PD-1</FONT> blockade, can promote tumor-specific <FONT
STYLE="white-space:nowrap">T-cell</FONT> immunity. (Source: MacroGenics)</I></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Summary of Clinical Results </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Phase 1 Study of Enoblituzumab Monotherapy </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Study Design.</I> This was an open-label, multi-dose, <FONT STYLE="white-space:nowrap">single-arm,</FONT> multi-center, and dose-escalation
study to define safety, tolerability, maximum tolerated dose (&#147;MTD&#148;), PK, immunogenicity, and potential anti-tumor activity of enoblituzumab in patients with refractory cancers that express <FONT STYLE="white-space:nowrap">B7-H3</FONT>
conducted by MacroGenics. In the dose escalation segment of the study, six doses (0.15&#150;15 mg/kg QW) were evaluated in a conventional &#147;3+3&#148; design. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No MTD or dose-limiting toxicity (&#147;DLT&#148;) was observed in the dose escalation phase, so the highest administered dose, 15 mg/kg, was
used in the cohort expansion, in which patients received weekly infusions of enoblituzumab in eight-week cycles for up to 12 cycles. Tumor evaluation was carried out by both Response Evaluation Criteria in Solid Tumors (&#147;RECIST&#148;) and
immune-related response criteria (&#147;irRC&#148;) with an initial response assessment after eight weeks. This entailed seven tumor-specific cohorts, including melanoma (post-checkpoint inhibitor failure, n=31), head and neck cancer (n=19),
prostate cancer (n=34), triple-negative breast cancer (n=17), renal cell carcinoma (n=16), NSCLC (n=8), and bladder cancer (n=12). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Safety.</I> Interim data analysis as of the data <FONT STYLE="white-space:nowrap">cut-off</FONT> date of April&nbsp;13, 2017, indicates
that enoblituzumab is well-tolerated. Treatment-related AEs (per investigator assessment) were experienced by 134 out of 170 (78.8%) patients, most of which were infusion-related reactions (n=62, 36.5%), fatigue (n=54, 31.8%), nausea (n=32, 18.8%),
and chills (n=24, 14.1%). Only three out of 179 patients (1.7%) had a treatment-related discontinuation, and 13 (7.3%) patients experienced treatment-related Grade 3 or higher AEs (fatigue, infusion-related reactions, and nausea), assessed based on
Common Terminology Criteria for Adverse Events (CTCAE) criteria version 4.0. Mild to moderate infusion-related reactions were managed with low dose steroids or a decrease of the infusion rate. No severe immune-mediated toxicity was observed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Pharmacokinetics.</I> Preliminary analysis and population PK modeling based on 18
patients dosed at 15&nbsp;mg/kg indicate that PK of enoblituzumab was characterized primarily by target-mediated drug disposition and was consistent with a typical human IgG1 with near-linear PK. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Efficacy.</I> Evidence of decreased size of target and <FONT STYLE="white-space:nowrap">non-target</FONT> lesions as well as extended time
to progression were observed across a broad range of tumors, including heavily pretreated cancers. Three patients achieved PR (partial responses) by RECIST out of a total of approximately 71 patients being evaluated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Phase 1 Study of Enoblituzumab in Combination with Pembrolizumab </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Study Design.</I> This is an open-label, dose escalation, cohort expansion, and efficacy <FONT STYLE="white-space:nowrap">follow-up</FONT>
study of enoblituzumab in combination with pembrolizumab conducted by MacroGenics. The dose escalation phase is designed to characterize the safety and tolerability of the combination and to define the maximum tolerated or maximum administered dose.
Three dose levels of enoblituzumab (3, 10, 15 mg/kg, IV, QW) have been evaluated in combination with pembrolizumab (2 mg/kg, IV, Q3W). No MTD has been identified, and so the maximum administered dose of enoblituzumab (15 mg/kg) in combination with
pembrolizumab was given to additional cohorts of patients enrolled during the cohort expansion phase. The efficacy <FONT STYLE="white-space:nowrap">follow-up</FONT> period consists of the <FONT STYLE="white-space:nowrap">two-year</FONT> period after
administering the final dose of the study drug. All tumor evaluations are carried out by both RECIST and irRC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A total of 133 patients
with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">B7-H3-expressing</FONT></FONT> melanoma, squamous cell carcinoma of the head and neck (SCCHN), <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer
(&#147;NSCLC&#148;), and urothelial cancer have been treated in the study. The interim results as of the data <FONT STYLE="white-space:nowrap">cut-off</FONT> date, October&nbsp;12, 2018, were presented at the 2018 Annual Meeting of the Society for
Immunotherapy of Cancer (SITC), which showed an ORR (overall response rate) that compared favorably with historical experience with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> monotherapy in <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/PD-L1</FONT></FONT></FONT> naive patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Safety.</I> The combination of enoblituzumab and pembrolizumab demonstrated acceptable tolerability in patients treated to date. Grade 3 or
higher AEs, assessed based on Common Terminology Criteria for Adverse Events (CTCAE) criteria version 4.0, occurred in 27.1% of all patients. Drug-related AEs of all grades included infusion-related reactions (n=73, 54.9%), fatigue (n=37, 27.8%),
rash (n=14, 10.5%), and nausea (n=12, 9.0%). The incidence of immune-related AEs in the study was comparable to that observed in patients who received anti <FONT STYLE="white-space:nowrap">PD-1</FONT> monotherapy. Nine patients experienced
drug-related AEs leading to treatment discontinuation. Drug-related AEs and immune-related AEs of special interest are summarized in the table below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Drug-Related and Immune-Related Adverse Events </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>During Combination Treatment with Enoblituzumab and Pembrolizumab </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="13%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No.&nbsp;(%)&nbsp;of&nbsp;Patients</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; "><B>Drug-Related AEs
(</B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B>5% of Patients)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Grades&nbsp;Total<BR>(N=133)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B>&nbsp;Grade&nbsp;3</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(N=133)</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Any adverse event</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115&nbsp;(86.5)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">36&nbsp;(27.1)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Infusion-related reaction</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73&nbsp;(54.9)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">9&nbsp;(6.8)</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fatigue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37&nbsp;(27.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2&nbsp;(1.5)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14&nbsp;(10.5)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">1&nbsp;(0.8)</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nausea</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12&nbsp;(9.0)</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">0&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pyrexia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12&nbsp;(9.0)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">0&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lipase increased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11&nbsp;(8.3)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">8&nbsp;(6.0)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arthralgia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10&nbsp;(7.5)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">0&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decreased appetite</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9&nbsp;(6.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2&nbsp;(1.5)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diarrhea</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9&nbsp;(6.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">1&nbsp;(0.8)</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hypothyroidism</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8&nbsp;(6.0)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">0&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anemia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7&nbsp;(5.3)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">1&nbsp;(0.8)</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pneumonitis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7&nbsp;(5.3)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2&nbsp;(1.5)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7&nbsp;(5.3)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">0&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="13%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No. (%) of Patients</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; "><B>Immune-Related Adverse Events of Special Interest
(AESI)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Grades&nbsp;Total<BR>(N=133)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B>&nbsp;Grade&nbsp;3</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(N=133)</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pneumonitis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5&nbsp;(3.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2&nbsp;(1.5)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Myocarditis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2&nbsp;(1.5)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">1&nbsp;(0.8)</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diarrhea</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(0.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">1&nbsp;(0.8)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adrenal insufficiency</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(0.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">1&nbsp;(0.8)</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Colitis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(0.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">0&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Drug-related AEs: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">- Leading to treatment discontinuation: 6.8% (9 patients) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">- Leading to death: 0.8% (1 patient with pneumonitis) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nature of events consistent with enoblituzumab or pembrolizumab alone </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Source: MacroGenics. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Clinical
Efficacy.</I> As of October&nbsp;12, 2018, the <FONT STYLE="white-space:nowrap">cut-off</FONT> date of the most recent data analysis, preliminary results indicated that among the 18 response-evaluable SCCHN patients who had not previously received <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies, six patients (33.3%) had confirmed partial responses (&#147;PRs&#148;). Among the subset of patients with 10% or higher
<FONT STYLE="white-space:nowrap">B7-H3</FONT> tumor expression, six out of 15 (40.0%) had confirmed PRs (see figure below) compared to previously reported SCCHN patients treated with <FONT STYLE="white-space:nowrap">PD-1</FONT> monotherapy, which
achieved ORRs ranging from 13% to 16%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Anti-tumor Activity in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-PD-1/PD-L1-Naive</FONT></FONT></FONT></FONT> SCCHN Patients </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g27e81.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Source: MacroGenics </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among 14 response-evaluable NSCLC patients who had not previously received
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies and were <FONT STYLE="white-space:nowrap">PD-L1</FONT> negative, i.e., <FONT STYLE="white-space:nowrap">PD-L1</FONT> less or equal to 1%, five
patients (35.7%) had confirmed PRs (see figure below). Objective response rates ranging from 8% to 17% were reported in <FONT STYLE="white-space:nowrap">PD-L1</FONT> negative NSCLC patients treated with <FONT STYLE="white-space:nowrap">PD-1</FONT>
monotherapy. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Anti-tumor Activity in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1-Naive</FONT></FONT> NSCLC
Patients Who are <FONT STYLE="white-space:nowrap">PD-L1</FONT> Negative <FONT STYLE="white-space:nowrap">(PD-L1</FONT> &lt; 1%) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tumor Volume Change
from Baseline (%) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g05c03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Source: MacroGenics </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the two figures above, CR (complete response) means the disappearance of all target
lesions, with the reduction of all pathological lymph nodes to &lt;10 mm; PR (partial response) means at least a 30% decrease in the sum of the target lesions, in comparison to the baseline sum diameter; PD (progressive disease) means a 20% increase
in the sum of the diameters in comparison to the smallest sum of diameters with an absolute increase of at least 5 mm, provided that any new lesion is considered progressive disease; and SD (stable disease) means meeting neither the criteria for
partial response nor for progressive disease, in comparison to the smallest sum of diameters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Development Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to develop enoblituzumab as a second-line combination therapy with a <FONT STYLE="white-space:nowrap">PD-1</FONT> antibody in a
registrational clinical trial (pending regulatory approval by the NMPA) or a Phase 2 trial in patients with recurrent or metastatic SCCHN by the end of 2020. The primary efficacy endpoint of this study will be objective response rate (ORR) performed
by central review. In addition, we are planning to explore enoblituzumab development in a variety of <FONT STYLE="white-space:nowrap">B7-H3</FONT> expressing solid tumors. MacroGenics plans to combine enoblituzumab and a <FONT
STYLE="white-space:nowrap">PD-1</FONT> antibody with and without chemotherapy in a <FONT STYLE="white-space:nowrap">two-part</FONT> Phase 2 study for first-line treatment of patients with recurrent or metastatic SCCHN not curable by localized
therapy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Global Portfolio </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TJM2: A <FONT
STYLE="white-space:nowrap">GM-CSF</FONT> Monoclonal Antibody for Rheumatoid Arthritis and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CAR-T-related</FONT></FONT> Therapies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Summary </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJM2 is an internally discovered
neutralizing antibody against human granulocyte-macrophage colony-stimulating factor <FONT STYLE="white-space:nowrap">(&#147;GM-CSF&#148;),</FONT> an important cytokine that plays a critical role in chronic inflammation and destruction in autoimmune
diseases such as rheumatoid arthritis (&#147;RA&#148;). TJM2 is expected to be the first clinical stage GM-CSF monoclonal antibody in China. TJM2 is a humanized IgG1 that displays high affinity binding to
<FONT STYLE="white-space:nowrap">GM-CSF</FONT> and blocks its signaling and downstream effects. TJM2 is being developed for the treatment of autoimmune and inflammatory diseases, including RA, cytokine release syndrome (&#147;CRS&#148;) and
neuroinflammation from <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapy. We have begun a first-in-human single dose study in healthy volunteers in the United States. We filed an IND application with the NMPA in August 2019 for a multiple-dose
Phase 1b study in Chinese patients with RA and may expand to other autoimmune and inflammatory indications with high unmet medical need, where <FONT STYLE="white-space:nowrap">GM-CSF</FONT> is known as a pathogenic cytokine in disease activity and
progression. TJM2 is expected to be the first compound of its class to enter clinical trial in China in early 2020. If approved, it is expected to provide an effective treatment option as a disease-modifying anti-rheumatic drug (&#147;DMARD&#148;)
therapy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Therapeutic Options and Current Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current therapeutic indication is RA, a systemic chronic inflammatory disease considered to be one of the most prevalent immune-mediated
inflammatory diseases. RA is nearly always polyarticular and causes joint destruction, deformity, and loss of function. Extra-articular manifestations include cardiopulmonary diseases, eye diseases, Sjogren&#146;s syndrome, rheumatoid vasculitis and
neurological diseases. Current therapies for RA in China include traditional Chinese medicine, corticosteroids, and DMARDs, including immunosuppressants and targeted therapies such as TNF inhibitors. Although the market for RA has become more
competitive in China, new medicines targeting different pathways with greater clinical efficacy and safety remain a significant unmet need. Our <FONT STYLE="white-space:nowrap">GM-CSF</FONT> antibody targets an entirely different disease pathway and
has these desired characteristics to treat RA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical evidence supporting the role of a <FONT STYLE="white-space:nowrap">GM-CSF</FONT>
antibody in RA is highlighted in a few recent global studies. For example, both otilimab (MOR103), a <FONT STYLE="white-space:nowrap">GM-CSF</FONT> antibody from MorphoSys and GSK, and mavrilimumab, a <FONT STYLE="white-space:nowrap">GM-CSF</FONT>
receptor antibody from Medimmune, have shown an early onset of clinical responses </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in Phase 2 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trials with RA patients. In addition to RA, attempts to develop a <FONT
STYLE="white-space:nowrap">GM-CSF</FONT> antibody for treating other autoimmune diseases, such as ankylosing spondylitis, are being studied by Amgen and Takeda. These autoimmune conditions involve the same autoimmune cell types, including
macrophages, and neutrophils and the same connective tissues such as bones, joints, and tendons. Given the large patient population affected and the burden of these diseases, we are keen to explore the therapeutic role of TJM2 in treating these
diseases, if initial studies in RA patients meet primary end-points. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The therapeutic role of TJM2 goes beyond autoimmune diseases. A
recent study indicates that <FONT STYLE="white-space:nowrap">GM-CSF</FONT> plays a critical role in serious side effects associated with chimeric antigen receptor <FONT STYLE="white-space:nowrap">(CAR)-T</FONT> therapy, such as cytokine release
syndrome (&#147;CRS&#148;) and neurotoxicity. As <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapy has become an effective treatment option for certain cancer types, finding a treatment solution for <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">CAR-T-related</FONT></FONT> toxicities that occur frequently and can turn into a serious and potentially fatal condition becomes an urgent need. These severe toxicities add to the morbidity and mortality of <FONT
STYLE="white-space:nowrap">CAR-T</FONT> therapy. CRS is caused by a massive release of circulating cytokines by expanding <FONT STYLE="white-space:nowrap">CAR-T</FONT> cells, and <FONT STYLE="white-space:nowrap">GM-CSF</FONT> is one of the key
cytokines of CRS. Currently, there are no effective therapies to prevent CRS or neurotoxicity. Tocilizumab, an <FONT STYLE="white-space:nowrap">IL-6</FONT> receptor antagonist, is approved for severe CRS with limited therapeutic coverage. Recent
studies indicate that neutralizing <FONT STYLE="white-space:nowrap">GM-CSF</FONT> <I>in vivo</I> may ameliorate and potentially prevent CRS and neuroinflammation without affecting <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell activity.
Humanigen recently teamed up with Kite to evaluate lenzilumab, a <FONT STYLE="white-space:nowrap">GM-CSF</FONT> antibody, as a preventive or treatment agent in association with Yescarta, an approved CD19-directed
<FONT STYLE="white-space:nowrap">CAR-T</FONT> therapy. In parallel with an RA clinical trial, we are seeking opportunities to co-develop TJM2 as a treatment option for CRS associated with CAR-T therapy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advantages of TJM2 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on reported
clinical findings with front-runner <FONT STYLE="white-space:nowrap">GM-CSF</FONT> antibodies compared to other RA biologics that are clinically used, we have the following expectations: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Fast onset of therapeutic effect</I>. Because <FONT STYLE="white-space:nowrap">GM-CSF</FONT> acts at a
relatively early stage in the inflammatory cascade, <FONT STYLE="white-space:nowrap">GM-CSF</FONT> blockade is expected to take effect after just a few initial doses and provide quick symptomatic relief to patients. This fast onset of clinical
responses in RA has been shown in Phase 2 clinical trials on otilimab and mavrilimumab (NCT01023256 and NCT01050998); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Convenience and increased patient compliance</I>. Given the favorable development profile (high affinity,
excellent PK, clean immunogenicity and concentrated formulation) exhibited by TJM2 thus far, the clinically active dose for TJM2 is expected to be low, which is advantageous for chronic maintenance of the disease by subcutaneous administration. This
provides convenience to the patients and will likely increase patient compliance; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Analgesic effect on inflammatory pain</I>. Because the <FONT STYLE="white-space:nowrap">GM-CSF</FONT> receptor
is also expressed on sensory neurons and is involved in <FONT STYLE="white-space:nowrap">RA-associated</FONT> inflammatory pain, <FONT STYLE="white-space:nowrap">GM-CSF</FONT> blockade is expected to provide relief for inflammatory pain, which
provides additional clinical benefits to patients. This analgesic effect has been shown in a Phase 2 clinical trial on mavrilimumab (NCT01706926). </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Mechanism of Action </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">GM-CSF</FONT> is a central driver cytokine in orchestrating an innate immune response during inflammation. It is responsible for myeloid cell proliferation and functions, such as chemotaxis, adhesion, phagocytosis, and
microbial killing. Importantly, <FONT STYLE="white-space:nowrap">GM-CSF</FONT> can polarize macrophages into a <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> M1 phenotype and is known to induce an inflammatory cascade involving other <FONT
STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokines such as TNF, <FONT STYLE="white-space:nowrap">IL-1,</FONT> <FONT STYLE="white-space:nowrap">IL-6,</FONT> <FONT STYLE="white-space:nowrap">IL-12,</FONT> and
<FONT STYLE="white-space:nowrap">IL-23.</FONT> It is evident that <FONT STYLE="white-space:nowrap">GM-CSF</FONT> plays a crucial role in the pathogenesis and disease progression of multiple autoimmune conditions. The action of <FONT
STYLE="white-space:nowrap">GM-CSF</FONT> is mediated by binding of its cognate receptor on target cells and subsequent phosphorylation of signal transducer and activator of transcription 5 (&#147;STAT5&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJM2 specifically binds to human <FONT STYLE="white-space:nowrap">GM-CSF</FONT> with high affinity and can block <FONT
STYLE="white-space:nowrap">GM-CSF</FONT> from binding to its receptor, thereby preventing downstream signaling and target cell activation. As a result, it can effectively inhibit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inflammatory responses mediated by macrophages, neutrophils, and dendritic cells, leading to reduced tissue inflammation and damage. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g93q99.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>Figure:&nbsp;&nbsp;&nbsp;&nbsp;Role</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>of <FONT STYLE="white-space:nowrap">GM-CSF</FONT> in orchestrating coordinated immune response.</I>
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Summary of <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> Results </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A series of nonclinical studies have been conducted to evaluate the pharmacology, PK, and toxicology profiles of TJM2. The completed
pharmacology studies included evaluation of the binding affinity and specificity to <FONT STYLE="white-space:nowrap">GM-CSF,</FONT> species cross-reactivity, blockade of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GM-CSF/GM-CSFR</FONT></FONT> interaction, inhibition on phosphorylation of STAT5 in peripheral blood mononuclear cells (&#147;PBMCs&#148;) from human or cynomolgus monkeys, and <I>in
vivo</I> activity in monkey RA models. The PK profile of TJM2 in cynomolgus monkeys was characterized following a single IV injection and a single SC injection. Toxicokinetics (&#147;TK&#148;) was studied in conjunction with a <FONT
STYLE="white-space:nowrap">GLP-compliant</FONT> multilevel (0, 20, 60, 200 mg/kg) and four-week repeat-dose general toxicology study in cynomolgus monkeys. The no observed adverse effect level (&#147;NOAEL&#148;), which is the highest dosage level
at which chronic exposure to the substance shows no adverse effects, was considered to be 60&nbsp;mg/kg. The nonclinical studies performed to date have demonstrated an acceptable pharmacological profile to allow TJM2 to progress to clinical studies
in healthy volunteers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>In Vitro Pharmacodynamics </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJM2 specifically binds to <FONT STYLE="white-space:nowrap">GM-CSF</FONT> at <FONT STYLE="white-space:nowrap">sub-nanomolar</FONT> affinity.
TJM2 cross-reacts with monkey <FONT STYLE="white-space:nowrap">GM-CSF</FONT> but not rat or murine <FONT STYLE="white-space:nowrap">GM-CSF.</FONT> TJM2 inhibited
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GM-CSF-dependent</FONT></FONT> proliferation of a human erythroleukemic cell line and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GM-CSF-induced</FONT></FONT>
STAT5 phosphorylation in human PBMCs in a concentration-dependent manner. TJM2 demonstrated no hemolytic potential at a concentration of 105.5 mg/mL when incubated with rabbit blood cells. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Pharmacokinetics in Cynomolgus Monkeys </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The systemic exposure in monkeys after a single IV injection of TJM2 appeared to increase proportionally with doses from 5, 25 to 50 mg/kg. The
mean half-life was 217&#150;241 hours, the mean maximum observed concentration (C<SUB STYLE="font-size:85%; vertical-align:bottom">max</SUB>) were 112&#150;1220 &micro;g/mL, and the mean exposure
(AUC<SUB STYLE="font-size:85%; vertical-align:bottom"><FONT STYLE="white-space:nowrap">0-last</FONT></SUB>) were 14800&#150;124000 &micro;g*h/mL in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the dose range of 5&#150;50 mg/kg. TJM2 also exhibited linear PK behavior in terms of C<SUB STYLE="font-size:85%; vertical-align:bottom">max</SUB> (50.2&#150;504 &micro;g/mL) and AUC following a
single subcutaneous (&#147;SC&#148;) injection at 5, 25 to 50 mg/kg, with the mean T<SUB STYLE="font-size:85%; vertical-align:bottom">1/2</SUB> being 215&#150;242 hours and the mean bioavailability ranging from 73 to 79%. No apparent sex difference
was observed in main PK&nbsp;parameters. The elimination rate of TJM2 was independent of the dose route. ADAs were of low titers and detected only in one animal on two occasions, namely, before dosing and on Day 42
<FONT STYLE="white-space:nowrap">post-IV</FONT> dose, which did not affect the PK profile. ADA was clean for the SC administration. These results indicate that TJM2 is not a strong immunogen to cynomolgus monkeys. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>In Vivo Pharmacodynamics in Cynomolgus Monkeys </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Type II collagen-induced arthritis (&#147;CIA&#148;) is a recognized animal model for RA, and drugs approved for RA&nbsp;have shown efficacy in
this model. TJM2 was tested in a monkey CIA model. The animals were immunized with type II collagen to induce the disease. Once the animals exhibited signs of disease (joint swelling), weekly injections of vehicle control or 40 mg/kg TJM2 for four
weeks were initiated. TJM2 significantly decreased the severity of CIA as measured by the arthritis score over the entire treatment period (see figure below) and inhibited STAT5 phosphorylation in monkey PBMCs 24 hours after treatment. In the second
dose response experiment, TJM2 was found to reduce STAT5 phosphorylation in PBMCs from CIA monkeys obtained 24&nbsp;hours after treatment across different dosing levels. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g34g52.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Weekly treatment with 40 mg/kg of TJM2 reduced disease severity (arthritis score) in a monkey CIA model.</I></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Repeat-Dose Toxicology Study in Cynomolgus Monkeys </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">GLP-compliant</FONT> four-week repeat-dose toxicology study with a
<FONT STYLE="white-space:nowrap">30-day</FONT> recovery was conducted in cynomolgus monkeys to evaluate the potential toxicity of TJM2. Forty cynomolgus monkeys were randomly assigned into four groups (5/sex/group) and were given five weekly doses
of TJM2 at 20, 60 or 200 mg/kg via IV&nbsp;injection. Following the fourth dose, TK parameters, including time of maximum concentration (T<SUB STYLE="font-size:85%; vertical-align:bottom">max</SUB>),
C<SUB STYLE="font-size:85%; vertical-align:bottom">max</SUB>, AUC<SUB STYLE="font-size:85%; vertical-align:bottom"><FONT STYLE="white-space:nowrap">0-t</FONT></SUB>, and clearance (CL), were similar to those following the first dose. No apparent sex
difference was observed. All samples were detected as <FONT STYLE="white-space:nowrap">ADA-negative</FONT> throughout the study period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No TJM2-related death or moribund sacrifices occurred in this study. Pulmonary granulomas were observed in one male animal given 200 mg/kg
dose, in which TJM2-relation could not be completely excluded. Minimal congestion and alveolar protein were observed in one male animal given 20 mg/kg dose during the recovery period, which had uncertain relation to TJM2 effect and was not
considered adverse due to the lack of impact on respiratory functions and their absence in animals given higher doses of TJM2 or terminal sacrificed animals. Other than the above observations, TJM2 did not exhibit apparent impact on other study
endpoints, including safety pharmacology parameters, immunotoxicity, especially cytokine production, or local effect on the injection sites. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the study results, the NOAEL was considered to be 60 mg/kg. The corresponding mean
C<SUB STYLE="font-size:85%; vertical-align:bottom">max</SUB> and AUC<SUB STYLE="font-size:85%; vertical-align:bottom"><FONT STYLE="white-space:nowrap">0-t</FONT></SUB> following the fourth dose were 2010 &micro;g/mL and 117000 &micro;g*h/mL for
males, respectively, and 1930 &micro;g/mL and 119000 &micro;g*h/mL for females, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Development Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on these <FONT STYLE="white-space:nowrap">pre-clinical</FONT> results, we have initiated a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-human</FONT></FONT> study in healthy volunteers in the United States. This randomized, double-blind, placebo-controlled, and single dose-ascending study (NCT03794180) is designed to assess the safety,
tolerability, PK/PD, and immunogenicity of TJM2 (referred to as TJ003234) IV infusion. We have enrolled and completed dosing of four planned cohorts, with each cohort consisting of eight subjects. Data from this clinical trial facilitated IND filing
with the NMPA in China in August 2019 for a multiple-dose Phase 1b study in patients with RA in the first half of 2020. We also intend to investigate the efficacy of TJM2 in reducing or preventing CRS and neurotoxicity associated with <FONT
STYLE="white-space:nowrap">CAR-T</FONT> therapy through collaborations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TJC4: A Potential Highly Differentiated CD47 Antibody for Immuno-Oncology
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Summary </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJC4 is a fully
human CD47 monoclonal antibody that we have discovered and developed internally for cancer immunotherapy. CD47 has emerged as one of the most promising immuno-oncology targets. Unlike other immuno-oncology targets being explored, the CD47-SIRP&#945;
pathway is involved in tumor progression by delivering a &#147;don&#146;t eat me&#148; signal to tumor-engulfing macrophages, thereby protecting tumors from natural attacks by macrophages. Blockade of this pathway by CD47 antibody represents one of
the most effective tumor killing mechanisms. However, due to the inherent epitope sharing between tumor cells and normal red blood cells (&#147;RBCs&#148;), the first-wave of clinical stage CD47 antibodies were found in clinical trials to bind to
RBCs and cause significant hematologic adverse effects, such as severe anemia, which has hampered the development of these CD47 antibodies as a potential cancer therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We developed TJC4 by design to possess a unique property or differentiation, to minimize binding to RBCs while retaining anti-tumor activities
in line with other antibodies of the same class. This key differentiation is achieved through additional RBC counter-screening to select rare antibody clones that bind to CD47 with high affinity but do not bind to or bind minimally to RBCs. The
proportion of RBC-sparing CD47 antibody leads among all CD47 antibody leads we identified after screening was 0.5%. TJC4 has been validated in a series of <I>in vitro</I> and <I>in vivo</I> <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
studies, which have consistently shown a unique <FONT STYLE="white-space:nowrap">RBC-sparing</FONT> profile comprised of minimal RBC binding, lack of hemagglutination and no significant adverse hematologic changes in cynomolgus monkeys even when
used at a high dose (100 mg/kg). Our pre-clinical data thus far indicate that TJC4, if approved, is a potentially highly differentiated anti-tumor CD47 antibody with the advantage of minimizing hematologic side effects. We have obtained the IND
approval from the FDA and the NMPA, respectively. We have initiated a Phase 1 clinical trial in the United States to study the safety profile, especially the hematologic profile, of TJC4 and to assess its pharmacokinetics, pharmacodynamics and early
anti-tumor signals in cancer patients, and no anemia has been observed in the first cohort of patients so far. We expect to obtain safety data of TJC4 by the first half of 2020. In parallel, leveraging the Phase 1 data generated in the United
States, we plan to begin a Phase 1 clinical trial of TJC4 in acute myeloid leukemia (&#147;AML&#148;) patients in China by the end of 2019, followed by a separate clinical trial in non-Hodgkin&#146;s lymphoma (&#147;NHL&#148;) patients in China.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Therapeutic Options and Current Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to evaluate the therapeutic role of TJC4 in a variety of solid tumors, such as cancers of the ovary, lung, liver, pancreas, breast and
colon, and hematological malignancies such as AML, lymphoblastic leukemia, and NHL. Although <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies represent a new paradigm in cancer treatment, less than
40% of cancer patients have a clinically meaningful response to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> treatment. As a result, targeting other immune components or cells involved in the immune
system&#146;s anti-tumor mechanism has become an area of hot pursuit in the field of immuno-oncology. TJC4 is one such innovative and promising therapeutic antibody, which is capable of mobilizing macrophage functions for effective and direct
tumor-killing. Currently, a number of CD47 antibodies are in clinical development by Forty-Seven, Inc., Celgene, Surface Oncology and Arch Oncology. The most advanced asset, 5F9 from Forty-Seven, Inc., is in Phase 2 clinical studies for multiple
cancer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indications. However, almost all clinical trials with CD47 antibodies so far have shown significant hematologic adverse effects, presumably due to inherent
<FONT STYLE="white-space:nowrap">RBC-binding</FONT> properties of generic CD47 antibodies, and as a result, some clinical studies had to be terminated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advantages of TJC4 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJC4 has similar
nanomolar binding affinity as other CD47 antibodies and exhibits comparable anti-tumor activity. The key advantage of TJC4 is its minimal binding to RBCs, thus potentially avoiding or minimizing inherent hematologic adverse effects typically seen in
other CD47 antibodies in clinical trials. This differentiated property of TJC4 is due to its unique epitope interaction as revealed by crystallography, which appears different from those recognized by other CD47 antibodies currently in clinical
development. The differentiation of TJC4 is highlighted in a series of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies summarized as the following: (i)&nbsp;TJC4 displays only minimal <FONT STYLE="white-space:nowrap">RBC-binding</FONT>
even at high antibody concentrations by flow cytometry; (ii)&nbsp;TJC4 does not induce RBC agglutination even in a high dose range; and (iii)&nbsp;most importantly, TJC4 does not cause significant hematologic changes or systemic toxicologic effects
even at high doses in multiple cynomolgus monkey studies, including a pivotal <FONT STYLE="white-space:nowrap">4-week</FONT> GLP toxicity study. Taken together, TJC4 has a potentially better clinical safety profile and may be used at higher doses to
explore its anti-tumor potential compared to other clinical stage competitor molecules. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g57c81.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Table:</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>Differentiated product profile of TJC4. (Sources for comparator antibodies: American Society of Hematology publication, PLOS One publication, World Intellectual Property Organization and company data)</I></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Mechanism of Action </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJC4 blocks the interaction between CD47 expressed on cancer cells and SIRP&#945; expressed on macrophages, leading to increased phagocytosis
of cancer cells by macrophages. In addition to stimulating the phagocytosis of cancer cells, CD47 blockade was shown to support other anti-tumor mechanisms, such as the enhancement of ADCC, direct induction of apoptosis (programmed cell death) of
cancer cells by CD47 cross-linking, induction of differentiation of cancer stem cells, and inhibition of metastasis. Blockade of CD47 by TJC4 may also promote the development of anti-tumor T cell responses, resulting from increased tumor antigen
presentation by professional antigen-presenting cells such as macrophages and dendritic cells. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g21v73.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Targeting the CD47/SIRP</I>&#945;<I></I><I> myeloid-specific immune checkpoint. CD47 is highly expressed on many different types of cancers. SIRP</I>&#945;<I></I><I> is an inhibitory receptor expressed on macrophages and other
myeloid immune cells. When CD47 binds to SIRP</I>&#945;<I></I><I>, it causes the inhibition of phagocytosis. CD47 antibodies disrupt the CD47/SIRP</I>&#945;<I></I><I> axis and enable the phagocytosis of cancer cells.</I></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Summary of <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> Results </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>CD47-related In Vitro and In Vivo Anti-tumor Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJC4 exhibits high-affinity binding to human CD47 protein and CD47-expressing tumor cells at the nanomolar level and effectively blocks
interaction of CD47 with its receptor SIRP&#945;. As compared with other CD47 antibodies currently under clinical development, TJC4 demonstrated comparable potency in the enhanced macrophage-mediated phagocytosis of Raji tumor cells (see Figure A
below) and comparable anti-tumor activity in the <FONT STYLE="white-space:nowrap">HL-60</FONT> leukemia and Raji xenograft models (see Figure B below). Moreover, when combined with rituximab, TJC4 exhibited a markedly enhanced inhibition on tumor
growth in a diffuse large B cell lymphoma (DLBCL) animal model, through the synergistic effect of both agents (see Figure C below). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g30a67.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>In vitro and in vivo anti-tumor activity of TJC4. (A) In vitro phagocytosis of Raji cells by primary human macrophages in the presence of different doses of TJC4 or comparator CD47 antibodies. (B)&nbsp;In vivo anti-tumor activity
of TJC4 mono-treatment in Raji xenograft model. (C)&nbsp;In vivo anti-tumor activity of TJC4 (5 mg/kg, BIW) in combination with Rituximab (5 mg/kg, BIW) in the DLBCL model.</I></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Assessment of Potential CD47-related In Vitro and In Vivo Hematologic Effects </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">First, in a representative flow cytometric analysis (see Figure A below), TJC4 showed minimal binding to human RBCs compared to comparator CD47
antibodies used at the same concentration (1 &micro;g/ml). The minimal binding of TJC4 to RBCs was confirmed when compared with other CD47 antibodies across multiple concentrations in another flow cytometric experiment (see Figure B below). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g99f98.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Binding of CD47 monoclonal antibodies to RBCs. (A)&nbsp;Representative graph of the staining of human RBCs with CD47 monoclonal antibodies or control IgG (1 &micro;g/ml); (B) Dose dependent binding of CD47 monoclonal antibodies
with human RBCs from different healthy donors (n = 3). MFI: mean fluorescence intensity.</I></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Second, as CD47 is expressed on normal RBCs, binding of CD47 antibodies to the surface of RBCs could
cross-link the RBCs into lattices and prevent them from precipitating into compact pellets, which is a phenomenon termed hemagglutination. Our results showed that TJC4 did not induce RBC agglutination across a wide range of antibody concentrations,
while a comparator antibody caused significant hemagglutination starting at a concentration of 0.3 &micro;g/ml. Results from a representative experiment are shown below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g11b01.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Hemagglutination by CD47 monoclonal antibodies. Left: representative graph of hemagglutination (haze appearance) or lack thereof (precipitate) by different concentrations of control IgG, TJC4, and comparator antibodies. Right:
quantification through an index determined by the area of RBC occupation in the presence of the test antibodies, normalized to that of IgG control.</I></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Thirdly, <I>in vivo</I> safety studies were performed in cynomolgus monkeys to assess the
effects of TJC4 on the hematology parameters. Whereas a single bolus IV injection of the comparator antibody caused a significant drop in the number of RBCs and hemoglobin (&#147;HGB&#148;) levels, treatment with TJC4 at a dose of 10 mg/kg did not
significantly affect the number of RBCs, HGB levels or reticulocyte or platelet counts (see figure below). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g61p76.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Hematological parameters in <FONT STYLE="white-space:nowrap">non-human</FONT> primates treated with a single dose of CD47 antibodies. On Day 0, naive cynomolgus monkeys were IV injected with PBS control (n=2), TJC4 (n=2, 10
mg/kg) or a comparator antibody (n=2, 10 mg/kg). Blood cells were counted, twice before drug injection (baseline) and at 3, 6, 10, 14 and 21 days post-injection.</I></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, in a four-week GLP toxicology study, TJC4 treatment did not induce significant overall toxicologic
changes. Only mild decreases in the number of RBCs, HGB and hematocrit were found, which reached nadir at Day 4 post-first administration and then gradually recovered to the normal range following administration. The changes were not dose-dependent.
Compared with the placebo control, the average decrease of RBCs in the treated animals was approximately 6% to 9% with only one animal showing an 18% drop at a dose of 30&nbsp;mg/kg. No <FONT STYLE="white-space:nowrap">RBC-associated</FONT> changes
were noted in histopathologic examinations or in bone marrow smears (including erythrocytic series). Therefore, NOAEL was defined at 100 mg/kg. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Four-week GLP Toxicology Study in Monkeys </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g61w04.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Figure:</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>No anemia in non-human primates (male) at a high dose range.</I></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Development Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have recently initiated a Phase 1 clinical trial in patients with advanced cancer in the United States. The clinical trial (NCT03934814) is
designed to assess the safety of TJC4 and, in particular, to confirm the hematologic safety profile, including anemia and other potential changes of the hematologic parameters. The clinical trial includes typical dose escalation schemes up to
30&nbsp;mg/kg and cohort expansions in cancer patients. We expected to obtain safety data of TJC4 by the first half of 2020. In the same clinical trial, we also intend to evaluate the pharmacokinetics, pharmacodynamics and preliminary efficacy
signals of TJC4 as a single agent and in combination with a <FONT STYLE="white-space:nowrap">PD-1</FONT> inhibitor or rituximab in patients with advanced solid tumors and relapsed or refractory lymphoma. The first cohort of four patients has been
enrolled and dosed at 1 mg/kg and no anemia has been observed so far. In parallel, leveraging the Phase 1 data generated in the United States, we plan to begin a Phase 1 clinical trial of TJC4 in AML patients in China by the end of 2019, followed by
a separate clinical trial in NHL patients. The goals of our global and China clinical development plans are to (i)&nbsp;advance clinical development of TJC4 in NHL and AML towards registration, and (ii)&nbsp;explore TJC4&#146;s treatment efficacy in
various solid tumors in combination with <FONT STYLE="white-space:nowrap">PD-1</FONT> therapies, including ovarian cancer, gastric cancer, hepatocellular carcinoma, renal cell carcinoma, NSCLC and urothelial carcinoma, in which CD47 is highly
expressed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TJD5: A Potential Highly Differentiated CD73 Antibody for Cancer Treatment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Summary </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJD5 is an internally
developed, humanized inhibitory antibody against human CD73. CD73 is a homodimeric enzyme expressed in tumors and plays a critical role in suppressing immune cells in tumor micro-environment. TJD5 displays
<FONT STYLE="white-space:nowrap">sub-nanomolar</FONT> binding affinity to CD73 and inhibits its nucleotidase activity. <I>In vitro</I>, TJD5 completely reversed the <FONT STYLE="white-space:nowrap">AMP-</FONT> or tumor cell-mediated suppression of T
cells. <I>In vivo</I>, when combined with a <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody, TJD5 exhibited a superior or synergistic inhibitory effect on tumor growth. The key differentiation of TJD5 when compared to some of the other
clinical stage antibodies of the same class, is related to its novel epitope, which works through a unique intra-dimer binding mode, resulting in a complete inhibition of the enzymatic activity and avoiding the aberrant pharmacological property
known as the &#147;hook effect.&#148; With this particular mode of action, TJD5, if approved, has the potential to become a highly differentiated CD73 antibody. We have initiated a Phase 1 clinical trial in cancer patients in partnership with TRACON
Pharmaceuticals in the United States. Safety data of TJD5 is expected by the first half of 2020. We have obtained IND approval from the NMPA for TJD5 in September 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Therapeutic Options and Current Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite recent breakthroughs with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies,
clinical <FONT STYLE="white-space:nowrap">non-response</FONT> rates to such treatments remains high in cancer patients (exceeding 60%). This <FONT STYLE="white-space:nowrap">non-responsiveness</FONT> to these standard treatments is partly due to the
fact that T cells within an inhibitory tumor environment are suppressed and fail to respond to stimulation induced by <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies. CD73, which converts
extracellular adenosine monophosphate (&#147;AMP&#148;) to adenosine, is implicated in one of the protective mechanisms of tumors that evade immune attack by creating an adenosine-rich microenvironment inhibitory to immune cells. <FONT
STYLE="white-space:nowrap">Pre-clinical</FONT> studies have indicated that the inhibition of CD73 renders T cells more responsive to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies by altering the
tumor micro-environment, resulting in a superior anti-tumor effect. As CD73 is widely expressed in various cancers, a combination therapy of TJD5 with a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT>
antibody may increase the likelihood of treatment success in cancer patients who do not respond to standard <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies. The potential cancer indications of
TJD5 include thyroid cancer, lung cancer, colorectal cancer, stomach cancer, urothelial cancer, endometrial cancer, head and neck cancer, breast cancer, ovarian cancer, and melanoma, in which CD73 is widely expressed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A number of global companies are running active clinical development programs with CD73 antibodies. MEDI-9447 from Medimmune and <FONT
STYLE="white-space:nowrap">BMS-986179</FONT> from Bristol-Myers Squibb are the two most advanced CD73 antibodies, which are in Phase 1/2 clinical trials. <FONT STYLE="white-space:nowrap">BMS-986179</FONT> is being studied as a single agent and in
combination with nivolumab (a <FONT STYLE="white-space:nowrap">PD-1</FONT> antibody) for the treatment of advanced colorectal, esophageal, gastric, ovarian, and pancreatic cancers. MedImmune is testing MEDI-9447 for the treatment of solid tumors as
a single </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agent or in combination with durvalumab (a <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody) or chemotherapy. <FONT STYLE="white-space:nowrap">NZV-930</FONT> (from Novartis) and <FONT
STYLE="white-space:nowrap">CPI-006</FONT> (from Corvus) have entered Phase 1 clinical trials for the treatment of solid tumors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advantages of TJD5
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Extracellular AMP can be generated from ATP, cyclic AMP and nicotinamide adenine dinucleotide (&#147;NAD&#148;) through separate
biochemical pathways, all of which converge to CD73 to generate adenosine. Thus, CD73 antibody is expected to block adenosine generation more completely than other related pathways. Further, CD73 antibody works through a substrate non-competitive
fashion and has advantages over small molecule inhibitors targeting the adenosine pathway through a substrate competing fashion. More importantly, TJD5, if approved, is potentially highly differentiated among the clinical stage CD73 antibodies as it
binds to a novel epitope in the <FONT STYLE="white-space:nowrap">C-terminal</FONT> domain of CD73 without causing a &#147;hook effect.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJD5 has the following key advantages: (i)&nbsp;TJD5 exhibits a typical dose-response curve without the &#147;hook effect&#148; and with a
complete inhibition of both soluble and surface-bound CD73 and (ii)&nbsp;TJD5 has a non-competitive inhibitory effect that is not blunted by high levels of CD73 enzyme substrates, which would be expected for small-molecule competitive blockers.
These pharmacological properties may translate into efficient target inhibition in tumors and superior anti-tumor activity, especially in an adenosine-rich micro-environment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Mechanism of Action </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adenosine is a
potent immunosuppressive signaling molecule abundant in the tumor microenvironment. CD73 is the rate-limiting enzyme that generates adenosine from extracellular AMP. TJD5 allosterically inhibits the CD73 enzyme by preventing the inactive CD73 dimer
from changing into the active conformation in a substrate non-competitive manner. This results in a decrease in adenosine production in the tumor micro-environment, increasing T cell anti-tumor activity. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g53f99.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Schematic diagram of CD73-catalyzed adenosine (Ado) generation and immunosuppression by Ado in the tumor microenvironment.</I></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Summary of <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> Results </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Inhibition of CD73 by TJD5. </I>As shown in the figure below, TJD5 displayed complete inhibition of soluble CD73 enzymatic activity (IC<SUB
STYLE="font-size:85%; vertical-align:bottom">50</SUB>= 0.22 n<I>M</I>) without the &#147;hook effect&#148; in contrast to the comparator molecule, which at higher concentrations caused a paradoxical rebound of enzymatic activity presumably due to
its inter-dimer binding mode. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g00i34.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>Figure:&nbsp;&nbsp;&nbsp;&nbsp;Inhibition</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>of soluble CD73 enzymatic activity by CD73 antibodies.</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restoration of T Cell Activity by TJD5 In Vitro. </I>We observed that AMP inhibited interferon gamma
<FONT STYLE="white-space:nowrap">(IFN-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>) production by CD4 or CD8 T cells through adenosine generation, mimicking the suppressive tumor microenvironment where AMP is abundantly produced. However,
this suppression could be reversed by TJD5 in a concentration-dependent manner. Moreover, in an experimental system where CD73<SUP STYLE="font-size:85%; vertical-align:top">high</SUP> human ovarian cell line <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SK-OV-3</FONT></FONT> and human T cells were <FONT STYLE="white-space:nowrap">co-cultured,</FONT> addition of TJD5 restored T cell activity as measured by IFN<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> production in a
concentration-dependent manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>In Vivo Anti-tumor Activity of TJD5. </I>TJD5 monotherapy showed a moderate anti-tumor effect in a
mouse xenograft model bearing A375 melanoma cells. To examine whether TJD5 can enhance the anti-tumor activity of the <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody, we evaluated the therapeutic effects of TJD5 used as a single agent and in
combination with a <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody in the same A375 melanoma model. The combination treatment group resulted in 68% inhibition of tumor growth which is significantly better than the vehicle and TJD5
monotherapy. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g01c14.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Figure:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>In vivo anti-tumor activity of TJD5 and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> in A375 melanoma xenograft model. Mice were treated with PBS control, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> (10 mg/kg), TJD5 (5 mg/kg) or a combination of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> and TJD5 twice a week for
three weeks. Tumor volumes as percentages relative to baseline (day 0) for each treated group (n=7 per group) (left) and for each individual mouse (right) were plotted.</I></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Pharmacokinetics of TJD5 in Cynomolgus Monkeys</I>. Following a single IV injection of TJD5 at 5, 25 and
50&nbsp;mg/kg, the mean Cmax ranged dose-proportionally from 136 to 1430 &micro;g/mL, and the systemic exposure indicated by the AUC0-last increased in a <FONT STYLE="white-space:nowrap">non-linear</FONT> manner, ranging from 4020 to 135000
hr*&micro;g/mL. Mean half-life was 44.9 hours, 61.5 hours and 104 hours, respectively, reflecting decreased clearance of TJD5 with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
increasing dose. No apparent sex difference was observed in the main PK parameters. Positive ADAs against TJD5 were detected in the majority of the animals, without an apparent impact on systemic
exposure. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g713200g93m30.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><I>Figure:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Concentration-time profile of TJD5 in cynomolgus monkeys.</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Repeat-dose Toxicology Study of TJD5 in Cynomolgus Monkeys. </I>A four-week GLP toxicity study was conducted in cynomolgus monkeys followed
by a <FONT STYLE="white-space:nowrap">six-week</FONT> recovery period to evaluate the potential toxicity of TJD5. Forty cynomolgus monkeys were randomly assigned into four groups (5/sex/group) and given five weekly doses of TJD5 at 20, 60 or 200
mg/kg via IV injection. Systemic exposures (Cmax and AUC<SUB STYLE="font-size:85%; vertical-align:bottom"><FONT STYLE="white-space:nowrap">0-t</FONT></SUB>) generally increased dose-proportionately, and the Day 22 values were generally higher than
those on Day 1, with mean accumulation ratios (AR) ranging between 1.65 and 2.19. No apparent sex difference was observed. Positive TJD5 antibodies were detected in the majority of animals following repeat administration at all doses, while no
significant impact was observed on the TK profiles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The only TJD5-related effect was decreased monocyte chemoattractant protein 1 <FONT
STYLE="white-space:nowrap">(MCP-1)</FONT> on Day 1 (24 or 48 hours post-dosing) in treated animals. Due to a lack of corresponding findings or impact on the well-being of the animals, this effect was not considered adverse. No abnormality was
observed in other study endpoints, including safety pharmacology parameters and immunotoxicity. The no observed adverse effect level (NOAEL) was defined at 200 mg/kg. This dose level corresponded to the mean C<SUB
STYLE="font-size:85%; vertical-align:bottom">max</SUB> and AUC values of 6890&nbsp;&micro;g/mL and 594000 &micro;g*hr/mL in males, respectively, and 6450 &micro;g/mL and 501000 &micro;g*hr/mL in females, respectively, on Day 22 of the dosing phase.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Development Plan </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
current clinical development plan is to develop TJD5 in the United States and China in parallel. In the United States, we have initiated a Phase 1 clinical trial in patients with advanced solid tumors in partnership with TRACON Pharmaceuticals,
Inc., which will be responsible for conducting the clinical trial in the United States (TJD5 is referred to as TJ004309, NCT03835949). Three patients have been dosed so far. After determining the RP2D, the trial will enroll additional patients with
advanced solid tumors to confirm tolerability and to explore preliminary efficacy of the combination therapy with atezolizumab. Safety data of TJD5 is expected by the first half of 2020. In China, we plan to begin a clinical trial to evaluate the
safety, tolerability, PK/PD, and potential efficacy primarily in patients with lung cancer. We have obtained IND approval from the NMPA for TJD5 in September 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Pre-clinical</FONT> Assets (Monoclonal antibodies) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJ210 and TJX7 are monoclonal antibodies currently at the CMC stage, moving towards IND submission and clinical trials in the United States by
2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>TJ210: A Potential Highly Differentiated Antibody Targeting Myeloid Derived Suppressor Cells in Cancers
and Autoimmune Diseases </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJ210 is a fully human, high affinity antibody against human C5aR1 for the treatment of cancers and
potentially autoimmune diseases. Tumors produce large amounts of complement factor C5a to attract C5aR1-expressing myeloid derived suppressor cells (&#147;MDSCs&#148;), M2 macrophages and neutrophils. These myeloid cells critically contribute to an
immunosuppressive microenvironment as part of the evading mechanism of tumors and are associated with poor prognosis and resistance to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies in many
cancers. Inhibition of C5a or its receptor C5aR in mice leads to markedly reduced MDSCs and has an inhibitory effect on tumor growth in various tumor-bearing animal models. The C5aR-blocking antibody has been shown to have significant therapeutic
activity when combined with <FONT STYLE="white-space:nowrap">PD-1</FONT> therapies in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1-resistant</FONT></FONT> tumor models. TJ210 exerts strong anti-tumor activity by blocking
the activation and migration of C5aR1-expressing myeloid cells and has a highly differentiated potential, if approved, as it binds to a novel epitope and possesses superior functional properties. Compared to the only competitor antibody from Innate
Pharma, TJ210 shows a more potent anti-tumor effect, especially when C5a concentrations are high, and binds to C5a receptors in both humans and monkeys, making <FONT STYLE="white-space:nowrap">pre-clinical</FONT> safety assessment possible. In
addition, TJ210 has therapeutic potential in multiple inflammatory and autoimmune indications, in which the role of the C5a/C5aR axis has been validated. We partnered with the original developer of TJ210, MorphoSys, for Greater China rights and
shared global rights. TJ210 is progressing towards IND submission by 2020 in the United States, and we plan to work jointly with MorphoSys to develop this asset. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>TJX7: A Novel CXCL13 Antibody for Autoimmune Diseases </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TJX7 is an internally discovered novel humanized neutralizing antibody targeting the CXCL13 chemokine. CXCL13, through its receptor CXCR5,
plays a key role in forming germinal centers, which are critical for immune response. The role of CXCL13 in forming germinal centers is to guide the migration of germinal center B cells and follicular T cells within the lymphoid organs and
facilitate their interaction, maturation and function. One of the key pathogenic features in autoimmune diseases is related to the aberrant formation of ectopic germinal centers formed in affected organs, contributing to chronic inflammation and
tissue destruction. Elevated serum CXCL13 levels, CXCR5-expressing T cells and pathogenic germinal center B cells and even ectopic germinal center formation are found in multiple autoimmune diseases, including Sj&ouml;gren&#146;s syndrome, RA,
multiple sclerosis, and SLE. TJX7 is being developed for the treatment of autoimmune disorders and has been shown to bind to CXCL13 with <FONT STYLE="white-space:nowrap">sub-nanomolar</FONT> affinity, effectively blocking the interaction between
CXCL13 and CXCR5 and the downstream signaling. TJX7 has been shown to completely inhibit the migration of primary human tonsil B cells. Pharmacodynamic studies in mice and cynomolgus monkeys have confirmed TJX7&#146;s inhibitory effects on germinal
center formation and antibody production. Results generated so far indicate that TJX7 may provide a new therapeutic angle in the treatment of autoimmune diseases as it acts uniquely at the core of tissue pathologies. TJX7 is currently under CMC and <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> development. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Pre-clinical</FONT> Assets <FONT
STYLE="white-space:nowrap">(Bi-Specific</FONT> Antibody Panel) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1-based</FONT></FONT>
<FONT STYLE="white-space:nowrap">Bi-specific</FONT> Antibodies</I>. As previously discussed, this panel of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1-based</FONT></FONT>
<FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies is designed according to the scientific rationale that a <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody, when engineered with a selected second immune component such as a
cytokine or another antibody, is able to convert &#147;cold tumors,&#148; which typically do not respond to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> inhibitors, to &#147;hot tumors,&#148; which are
more sensitive to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies. Such <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1-based</FONT></FONT>
<FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies are expected to increase the probability of treatment success in patients who do not respond to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT>
treatment. Based on this concept, we have generated a panel of <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies using our proprietary <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody sequence as the backbone (the first signal),
linked to a second component (the second signal) of selected immune properties. The second signals for this panel of <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies include <FONT STYLE="white-space:nowrap">IL-7</FONT> cytokine
(expanding T effector cells), <FONT STYLE="white-space:nowrap">4-1BB</FONT> and <FONT STYLE="white-space:nowrap">B7-H3</FONT> antibodies (activating T cells synergistically with <FONT STYLE="white-space:nowrap">PD-L1),</FONT> CD47 antibody (adding
the macrophage killing mechanism) and CD73 antibody (altering tumor microenvironment). We strive to validate all bi-specific </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
antibodies through a series of robust <I>in vitro</I> and <I>in vivo</I> studies for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> thus
providing a solid basis for further development, expecting at least one IND submission in the United States in 2020. Collectively, we have demonstrated that the second paired component must be structurally integrated with the tumor-engaging <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> backbone to concentrate and function effectively inside tumors, which cannot be achieved by simply combining two free agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Fortified&#148; <FONT STYLE="white-space:nowrap">Bi-specific</FONT> Antibodies for Specific Cancer Therapeutic Purposes. </I><FONT
STYLE="white-space:nowrap">TJ-C4GM</FONT> is a &#147;fortified&#148; version of the CD47 antibody, which is specifically designed for the treatment of solid tumors through the <FONT STYLE="white-space:nowrap">CD47-mediated</FONT> macrophage killing
mechanism. As the majority of tumor-associated macrophages adopt an anti-inflammatory and tumor-promoting M2 phenotype rather than a <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> M1 phenotype, they are less efficient in phagocytosis in
response to CD47 blockade. Thus, treatment of solid tumors with the CD47 antibody may exhibit limited efficacy. <FONT STYLE="white-space:nowrap">TJ-C4GM</FONT> is a novel molecule composed of TJC4 with an engineered
<FONT STYLE="white-space:nowrap">GM-CSF</FONT> moiety fused at the <FONT STYLE="white-space:nowrap">C-terminus</FONT> of the antibody heavy chain. GM-CSF is a potent cytokine known to convert tumor-resident M2 macrophages into tumor-engulfing M1
macrophages, which enables TJ-C4GM to exert a better phagocytic effect in solid tumors. These unique functional properties of <FONT STYLE="white-space:nowrap">TJ-C4GM</FONT> are confirmed in a series of <I>in vitro</I> and <I>in vivo</I> tumor
animal models, in which <FONT STYLE="white-space:nowrap">TJ-C4GM</FONT> exerts superior anti-tumor activity against solid tumors, which cannot be achieved by TJC4 or <FONT STYLE="white-space:nowrap">GM-CSF</FONT> used either alone or in combination.
<FONT STYLE="white-space:nowrap">TJ-C4GM</FONT> is currently at the CMC and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development stage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">TJ-CLDN4B</FONT> is a <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody targeting both Claudin18.2
(CLDN18.2), a tumor antigen preferentially expressed in gastric and pancreatic cancers, and <FONT STYLE="white-space:nowrap">4-1BB,</FONT> a co-stimulatory molecule on T cells. CLDN18.2 is a tight junction molecule normally expressed only on
epithelial cells of the gastric mucosa, which is inaccessible by antibodies under normal conditions, making it a highly attractive tumor target. Although a CLDN18.2 monoclonal antibody (claudiximab) was active in a Phase 2 trial, only the CLDN18.2
high-expressing tumors seemed to be susceptible. In collaboration with ABL Bio, we developed a <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody, <FONT STYLE="white-space:nowrap">TJ-CLDN4B,</FONT> which provides two key advantages over
current CLDN18.2 antibodies and <FONT STYLE="white-space:nowrap">4-1BB</FONT> agonistic antibodies. First, <FONT STYLE="white-space:nowrap">TJ-CLDN4B</FONT> is capable of binding to tumor cells even with low levels of CLDN18.2 expression, making it
more suitable for a broader patient population. Second, only upon tumor cell engagement by <FONT STYLE="white-space:nowrap">TJ-CLDN4B</FONT> are T cells activated. In contrast, other <FONT STYLE="white-space:nowrap">pan-activating</FONT> <FONT
STYLE="white-space:nowrap">4-1BB</FONT> antibodies that activate T cells regardless of tumor engagement are prone to liver toxicity as seen in clinical studies. In a humanized mouse model, <FONT STYLE="white-space:nowrap">TJ-CLDN4B</FONT> suppressed
tumor growth to a greater extent than anti-CLDN18.2 or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-4-1BB</FONT></FONT> alone or in combination. <FONT STYLE="white-space:nowrap">TJ-CLDN4B</FONT> is currently at the CMC and <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> development stage. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Licensing and Collaboration Arrangements </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with MorphoSys (MOR202/TJ202) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2017, we entered into a license and collaboration agreement with MorphoSys AG (&#147;MorphoSys&#148;) with respect to the
development and commercialization of MOR202/TJ202, MorphoSys&acute;s proprietary investigational antibody against CD38 (the &#147;CD38 product&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under this agreement, MorphoSys granted to us an exclusive, royalty-bearing, sublicensable license to exploit MOR202/TJ202 for any human
therapeutic or diagnostic purpose in the licensed territory, namely Greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to this agreement, we granted to MorphoSys an
exclusive license to our rights in any inventions that we make while exploiting MOR202/TJ202 under this agreement, solely to exploit MOR202/TJ202 outside of Greater China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also received the right to sublicense to affiliates and third parties acting as contract manufacturers, contract research organizations,
distributors or wholesalers without prior written consent, as well as the right to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sublicense to other third parties with the prior written consent of MorphoSys, not to be unreasonably withheld, delayed or conditioned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are solely responsible for the development and commercialization of MOR202/TJ202 in Greater China, and must use commercially reasonable
efforts as we develop and commercialize MOR202/TJ202. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to this agreement, we paid to MorphoSys an upfront license fee of
US$20.0&nbsp;million. We also agreed to make milestone payments to MorphoSys, conditioned upon the achievement of certain development, regulatory and commercial milestones, in the aggregate amount of US$98.5&nbsp;million. Such milestones include
first patient dosed in human clinical trials, marketing approval, and first annual net sales of CD38 products covered by the agreement in excess of a certain amount. As of the date of this prospectus, we have made milestone payments of US$8.0
million to MorphoSys. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we are required to pay tiered low-teens royalties to MorphoSys on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis during the term, commencing with the first commercial sale of a relevant
licensed product in Greater China. The end of the royalty term is linked to (i)&nbsp;the expiration, invalidation or abandonment of relevant patent claims, (ii)&nbsp;10 years from the date of first commercial sale of such CD38 product, and
(iii)&nbsp;marketing exclusivity for such relevant licensed product. To date, we have not paid any royalties to MorphoSys. Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect until the expiration of
our last payment obligation under the agreement. This agreement may be terminated by either party for the other party&#146;s uncured material breach, bankruptcy or insolvency. In addition, we have the right to terminate the agreement for convenience
at any time after a certain specified time period upon a notice period that varies based upon the stage of development. MorphoSys has the right to terminate the agreement if we challenge its patents. To the extent that we terminate for convenience
or MorphoSys terminates for our material breach, bankruptcy, insolvency or patent challenge, among other things, all licenses and rights granted by MorphoSys to us will automatically terminate and the licenses and rights granted by us to MorphoSys
will survive. In the event of such termination, we must also grant to MorphoSys an exclusive, royalty-bearing, sublicensable license under certain of our intellectual property relating to the licensed product to exploit MOR202/TJ202 for any human
therapeutic or diagnostic purpose in Greater China. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Assignment and License Agreement with Genexine (TJ101) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2015, <FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> Tianjin Co., Ltd., known as
Tasgen <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. at the time (which subsequently became our subsidiary following the Acquisition) <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Tianjin&#148;), entered into an
intellectual property assignment and license agreement with Genexine, Inc. (&#147;Genexine&#148;), further amended in December 2017, with respect to four licensed products, namely <FONT STYLE="white-space:nowrap">GX-H9</FONT> (TJ101), <FONT
STYLE="white-space:nowrap">GX-G3</FONT> (TJ102), <FONT STYLE="white-space:nowrap">GX-G8</FONT> and <FONT STYLE="white-space:nowrap">GX-P2</FONT> and one assigned product, <FONT STYLE="white-space:nowrap">GX-G6</FONT> (TJ103). Under this agreement,
Genexine (i)&nbsp;granted to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin an exclusive, <FONT STYLE="white-space:nowrap">non-transferable,</FONT> sublicensable license to use and otherwise exploit certain intellectual property to engage in <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> and clinical development, manufacturing, sale and distribution of the above-mentioned licensed products for (A)&nbsp;the treatment of any disease with respect to
<FONT STYLE="white-space:nowrap">GX-H9</FONT> and <FONT STYLE="white-space:nowrap">GX-G3</FONT> in China (which, for clarity excludes, Hong Kong, Macau and Taiwan), (B) the treatment of chemically induced diarrhea, with respect to <FONT
STYLE="white-space:nowrap">GX-G8</FONT> anywhere in the world and (C)&nbsp;the treatment of rheumatoid arthritis and lupus (not including psoriasis) with respect to <FONT STYLE="white-space:nowrap">GX-P2</FONT> anywhere in the world and further
(ii)&nbsp;assigned to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin a certain Chinese patent and related <FONT STYLE="white-space:nowrap">know-how</FONT> related to the assigned product (TJ103) and granted
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin an exclusive license to exploit the assigned intellectual property to engage in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical development, manufacturing, sale and distribution
of the assigned product (TJ103) for the treatment of any disease in China (which, for clarity, excludes Hong Kong, Macau and Taiwan). <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin will also receive an exclusive license to any improvements
that Genexine develops or acquires related to any of the aforementioned products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under this agreement,
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin paid an aggregate upfront license fee of US$13.0&nbsp;million in relation to the patents, patent applications, <FONT STYLE="white-space:nowrap">know-how,</FONT> data and information in connection
with the four licensed products and a purchase fee of US$7.0&nbsp;million in connection with the assigned product (TJ103). <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin also agreed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to make certain milestone payments, including milestone payments in the aggregate amount of US$40.0&nbsp;million for <FONT STYLE="white-space:nowrap">GX-H9,</FONT> US$25.0&nbsp;million for TJ103
and US$15.0&nbsp;million for <FONT STYLE="white-space:nowrap">GX-G3,</FONT> conditioned upon the achievement of certain net sales targets. As of the date of this prospectus, I-Mab Tianjin has made milestone payments of US$0.4 million to Genexine.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of this agreement is 30 years unless terminated earlier in accordance with the terms thereof. This agreement may be terminated
by either party for the other party&#146;s uncured material breach, bankruptcy or insolvency, in the event of force majeure or a PRC regulatory requirement to make material alteration or modification to the contractual rights or obligations of this
agreement which has the effect of preventing the parties from achieving their business objectives, or upon the termination of a certain subscription agreement or a certain joint venture agreement entered into by I-Mab Tianjin and Genexine in October
2015 (provided that the termination of such subscription agreement or joint venture agreement was not due to the material breach of the party electing to terminate this agreement). Genexine has the right to terminate the agreement if we fail to use
commercially reasonable efforts to obtain regulatory approvals for commercializing the licensed product in the agreed period due to our own fault or if we cease to pursue clinical development or product registration or to conduct licensed activities
on a reasonable scale as approved by our board of directors. During the term of this agreement, if <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin develops or acquires any improvement, modification or alteration to the licensed products, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Tianjin will become the sole legal owner of such improvements, modifications and alterations and has full power, right and authority to grant licenses or transfer ownership of the same. <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Tianjin is required to promptly notify Genexine in writing giving details of any such improvements, modifications or alterations and provide Genexine with such explanations or trainings to enable Genexine to
legally and effectively use the same. Additionally, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin shall grant to Genexine a fully paid up, royalty-free, exclusive license to use any such improvements, modifications and alterations anywhere
outside of the territory for which <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin is licensed under this agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with
Genexine (GX-I7/TJ107) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2017, we entered into an intellectual property license agreement with Genexine with respect to <FONT
STYLE="white-space:nowrap">GX-I7,</FONT> a long-acting <FONT STYLE="white-space:nowrap">IL-7</FONT> cytokine. Under this agreement, Genexine granted to us an exclusive, sublicensable and transferable license to use and otherwise exploit certain
intellectual property (including improvements subsequently developed or acquired by Genexine) in connection with the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical development, manufacturing, sale and distribution of <FONT
STYLE="white-space:nowrap">GX-I7</FONT> to treat cancers in the field of oncology in China, Hong Kong, Macau and Taiwan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under this
agreement, we paid an upfront license fee of US$12.0&nbsp;million to Genexine. We also agreed to make milestone payments in the aggregate amount of US$23.0&nbsp;million, conditioned upon the achievement of certain development milestones, including
completion of Phase 2 and Phase 3 clinical studies and NDA or BLA approval in any of China, Hong Kong, Macau or Taiwan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, we
agreed to make milestone payments in the aggregate amount of US$525.0&nbsp;million, conditioned upon the achievement of certain cumulative net sales of <FONT STYLE="white-space:nowrap">GX-I7</FONT> up to US$2,000 million. We also are required to pay
Genexine a <FONT STYLE="white-space:nowrap">low-single-digit</FONT> percentage royalty in respect of the total annual net sales of <FONT STYLE="white-space:nowrap">GX-I7.</FONT> The aforesaid milestones and royalties (other than the upfront payment)
will be reduced by 50% following the entry of a generic version of <FONT STYLE="white-space:nowrap">GX-I7</FONT> in China, Hong Kong, Macau and Taiwan without the consent or authorization of us or any of our sublicensees. As of the date of this
prospectus, no milestone payments or royalties are due under this agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless terminated earlier in accordance with the terms
thereof, this agreement will remain in effect until the later of (i)&nbsp;the expiry of the last to expire patent of the licensed intellectual property that includes a valid claim for China, Hong Kong, Macau or Taiwan. and that covers the
composition of <FONT STYLE="white-space:nowrap">GX-I7;</FONT> and (ii) 15 years from the date of the first commercial sale of <FONT STYLE="white-space:nowrap">GX-I7.</FONT> This agreement may be terminated by either party for the other party&#146;s
uncured material breach, bankruptcy or insolvency, in the event of force majeure or regulatory requirement to make material alteration or modification to the contractual rights or obligations of this agreement which has the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effect of preventing the parties from achieving their business objectives, or by mutual agreement of both parties. Genexine has the right to terminate the agreement if we fail to use commercially
reasonable efforts to obtain regulatory approvals or other registrations necessary for commercializing the licensed product in the agreed period due to our fault or if we cease to pursue clinical development or product registration or to conduct
licensed activities on a reasonable scale as agreed (&#147;Development and Commercialization Termination Events&#148;). Such Development and Commercialization Termination Events expressly include our failure to reach certain development milestones
or commercially launch the licensed product in the agreed period. To the extent that we terminate as a result of a regulatory requirement to make material alteration or modification to the contractual rights or obligations of this agreement or
Genexine terminates for our material breach, bankruptcy or insolvency, force majeure, or the Development and Commercialization Termination Events, we cannot develop, manufacture, market, promote, sell, offer for sale, distribute or otherwise make
available any competing product for a certain period after such termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the term of this agreement, if we develop or acquire
any improvement, modification or alteration to the licensed product, we will own such improvements, modifications or alterations and provide Genexine details thereof, whether patentable or not. Additionally, we shall grant to Genexine a fully paid
up, royalty-free. exclusive license (with a right to sublicense) to use any such improvements, modifications or alterations anywhere outside of China, Hong Kong, Macau and Taiwan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with Ferring (TJ301) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2016, we entered into a license and sublicense agreement with Ferring International Center SA (&#147;Ferring&#148;) with respect to
(i)&nbsp;FE301, an <FONT STYLE="white-space:nowrap">interleukin-6</FONT> inhibitor, and (ii)&nbsp;all pharmaceutical formulations in finished packaged form containing FE301 covered by certain patents or patent applications. Under this agreement,
Ferring granted to us an exclusive, sublicensable license (excluding any <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license that Ferring granted to Conaris Research Institute AG under a licensing agreement entered into in November 2008)
under certain Ferring intellectual property to research, develop, make, have made, import, use, sell and offer to sell FE301 (and the licensed products containing FE301) in China, Hong Kong, Macau, Taiwan and South Korea. We also have an option to
receive an exclusive, sublicensable license under certain Ferring intellectual property to research, develop, make, have made, import, use, sell and offer to sell FE301 (and the licensed products containing FE301) in the countries in North America,
the European Union and Japan that are mutually agreed upon by the parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to use commercially reasonable efforts to
obtain approval of FE301 and to promote, market, distribute and sell it in China, Hong Kong, Macau, Taiwan, and South Korea. Such activities are to be at our own cost and expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under this agreement, we paid to Ferring an upfront license fee of US$2.0&nbsp;million. We also agreed to make milestone payments to Ferring,
in the aggregate amount of US$14.5&nbsp;million, conditioned on the achievement of certain development milestones in the licensed territory, including completion of Phase 1b and Phase 2a clinical studies and the submission and approval of the new
drug application. Further, if we exercise our option to receive a license in any of the mutually agreed upon countries in North America, the European Union and Japan, we are required to pay to Ferring an additional US$3.0&nbsp;million as an upfront
license fee (upon the exercise of the option), and milestone fees up to the aggregate amount of US$30.0&nbsp;million, conditioned upon the licensed product achieving certain development milestones in certain countries in the option territory. As of
the date of this prospectus, no milestone payments are due under this agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we agreed to pay Ferring tiered royalties
ranging from the <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> to high-single-digit percentages of annual net sales for countries in China, Hong Kong, Macau, Taiwan, and South Korea, and from the high-single-digits to 10% of annual net
sales for the mutually agreed upon countries in North America, the European Union and Japan. To date, we have not paid any royalties to Ferring. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The royalty term commences with the first commercial sale of the licensed product in the
relevant country and ends upon the later of (i) 15 years from the date of launch, and (ii)&nbsp;the expiry of the last to expire patent of Ferring that includes a valid claim covering the development, making, using or selling of the licensed
compound or licensed product in the licensed territory and/or option territory. Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect until the later of the expiry of the royalty term, and the first
date on which we are not conducting any necessary and outstanding clinical study with respect to the licensed product or seeking to obtain any necessary and pending regulatory approval for the licensed product, if applicable. This agreement may be
terminated by either party for the other party&#146;s uncured material breach, bankruptcy or insolvency. In addition, in the event that the original licensor terminates its license to Ferring governing any of the intellectual property sublicensed to
us under this agreement, Ferring has the right to terminate this agreement with respect to such sublicenses in which case both parties will discuss in good faith how to resolve and mitigate to mutual satisfaction. To the extent that Ferring
terminates for our material breach, bankruptcy or insolvency, among other things, all licenses and rights granted by Ferring to us will automatically terminate and the licenses and rights we granted to Ferring will survive and automatically become
irrevocable with the right to sublicense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the term of the licensing agreement, if we develop or acquire any improvement,
modification, enhancement or addition to the licensed product, we will own and retain all rights, title and interest therein, and grant to Ferring a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> fully paid, royalty-free, worldwide license
thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration Agreement with MacroGenics (enoblituzumab) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2019, we entered into a license and collaboration agreement with MacroGenics, Inc. for development and commercialization of an <FONT
STYLE="white-space:nowrap">Fc-optimized</FONT> antibody known as enoblituzumab that targets <FONT STYLE="white-space:nowrap">B7-H3,</FONT> including in combination with other agents, such as the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody known as MGA012, in the People&#146;s Republic of China, Hong Kong, Macau and Taiwan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under this agreement, MacroGenics granted to us an exclusive, sublicenseable, royalty-bearing license to MacroGenics&#146; patents and <FONT
STYLE="white-space:nowrap">know-how</FONT> to develop and commercialize the enoblituzumab product, and a combination regimen of enoblituzumab and MGA012, in Greater China during the term of the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In exchange for these rights, in addition to certain financial consideration, we granted to MacroGenics a royalty-free, sublicenseable,
license outside of Greater China, to our patents and <FONT STYLE="white-space:nowrap">know-how</FONT> that are related to the enoblituzumab product or useful or necessary for MacroGenics to develop or commercialize the enoblituzumab product or a
product containing MGA012, and combinations thereof. The license is <FONT STYLE="white-space:nowrap">(i)&nbsp;non-exclusive</FONT> with respect to the enoblituzumab product, and (ii)&nbsp;exclusive with regard to MGA012. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless prohibited by applicable laws and regulations, which include all international, national, federal, state, regional, provincial,
municipal and local government laws, rules, and regulations that apply to either us or MacroGenics or to the conduct of the collaboration under this agreement (including Good Manufacturing Practice, Good Clinical Practices, General Biological
Products Standards, and the laws, rules and regulations of the International Conference on Harmonisation, the United States, China, Hong Kong, Macau, and Taiwan, each as may be then in effect, as applicable and amended from time to time), we will <FONT
STYLE="white-space:nowrap">co-own</FONT> all clinical data generated pursuant to this agreement in any clinical trial conducted solely in Greater China, and, to the extent that such joint ownership is not legally permitted, MacroGenics will be the
sole and exclusive owner of such clinical data. MacroGenics will solely and exclusively own all other clinical data generated pursuant to this agreement. We are not aware of any applicable laws or regulations that would prohibit us from jointly
owning such clinical data and, to our knowledge, we currently qualify for such joint ownership with MacroGenics under this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to this agreement, we paid MacroGenics an upfront payment of US$15.0 million. We also agreed to pay MacroGenics development and
regulatory milestone fees of up to US$135.0 million and tiered double-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
digit royalties (ranging from <FONT STYLE="white-space:nowrap">mid-teens</FONT> to twenty percent) based on annual net sales in the territories. As of the date of this prospectus, no milestone
payments or royalties are due under this agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are responsible for, and must use commercially reasonable efforts, to develop and
commercialize the enoblituzumab product (which includes the enoblituzumab product in combination with MGA012) in Greater China. This includes conducting all clinical studies required for approval, participating in a planned, global Phase 3 trial (or
another mutually agreeable global clinical trial) of the enoblituzumab combination product, the conduct of at least two Phase 2 or Phase 3 trials each targeting <FONT STYLE="white-space:nowrap">B7-H3</FONT> expressing patient populations, and
submissions to regulatory authorities in Greater China. MacroGenics is responsible for, and must use commercially reasonable efforts to, develop and commercialize the enoblituzumab product (which includes the enoblituzumab product in combination
with MGA012) in the rest of the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are responsible for all development costs in Greater China. MacroGenics is responsible for all
development costs in the rest of the world, except that we are responsible for 20% of the costs incurred in (i)&nbsp;activities supporting global clinical trials in which we participate, (ii)&nbsp;certain CMC activities for material intended to be
used in clinical trials in Greater China, and (iii)&nbsp;companion diagnostic development and validation for indications being studied in Greater China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect, on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">region-by-region</FONT></FONT> basis, until the later of (i)&nbsp;the twelfth (12th) anniversary of the first
commercial sale of an enoblituzumab product in such country or region, (ii)&nbsp;the expiration of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> MacroGenics patent licensed under this agreement,
which will occur in October 2036, and (iii)&nbsp;the expiration of the latest data exclusivity period for the enoblituzumab product in such country or region. Since there is currently no data exclusivity protection period in China, Hong Kong, Macau
or Taiwan, this agreement will remain in effect until the later of clauses (i) and (ii). This agreement may be terminated by either party for the other party&#146;s uncured material breach, safety reasons or force majeure. In addition, we have the
right to terminate the agreement for convenience at any time after a certain specified time period upon advance notice to MacroGenics. MacroGenics has the right to terminate the agreement if we challenge its patents. To the extent that we terminate
for convenience or MacroGenics terminates for our material breach, patent challenge or safety reasons, all licenses and rights granted by MacroGenics to us will automatically terminate and the licenses and rights granted by us to MacroGenics will
survive and automatically become exclusive and worldwide. To the extent that we terminate for MacroGenics&#146; material breach or safety reasons, among other things, all licenses and rights granted by MacroGenics to us will automatically terminate.
The licenses and rights granted by us to MacroGenics will also automatically terminate to the extent we terminate for MacroGenics&#146; material breach. To the extent we terminate for safety reasons, such licenses and rights will terminate only with
respect to the licensed territory and will otherwise survive outside the licensed territory. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other
<FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2018, we entered into a license and collaboration
agreement with MorphoSys for MorphoSys&#146;s proprietary antibody (MOR210/TJ210) directed against C5aR (the &#147;C5aR Agreement&#148;). Under this agreement, MorphoSys granted to us an exclusive, royalty-bearing license to explore, develop and
commercialize MOR210/TJ210 in Greater China and South Korea. <FONT STYLE="white-space:nowrap">I-Mab</FONT> will perform and fund all global development activities related to the development of MOR210/TJ210 in Greater China and South Korea, including
all relevant clinical trials (including in the U.S. and China) and all development activities required for IND filing in the US as well as CMC development of manufacturing processes. As of the date of this prospectus, we have made an upfront payment
of US$3.5 million to MorphoSys and no milestone payments or royalties are due under this agreement. MorphoSys retains rights in respect of development and commercialization of MOR210/TJ210 in the rest of the world. Additionally, MorphoSys maintains
the right to conduct activities in Greater China and South Korea that enable MorphoSys to exploit MOR210/TJ210 outside of those countries. Pursuant to the C5aR Agreement, we are required to use commercially reasonable efforts as we develop and
commercialize MOR210/TJ210 in Greater China and South Korea. This agreement may be terminated by either party for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other party&#146;s uncured material breach, bankruptcy or insolvency. In addition, we have the right to terminate the agreement for convenience at any time after a certain specified time period
upon a notice period that varies based upon the stage of development and for safety reasons. MorphoSys has the right to terminate the agreement if we challenge its patents. To the extent that we terminate for convenience or MorphoSys terminates for
our material breach, bankruptcy, insolvency or patent challenge, among other things, all licenses and rights granted by MorphoSys to us will automatically terminate and the licenses and rights granted by us to MorphoSys will survive. In the event of
such termination, in addition to other obligations, we must grant to MorphoSys an exclusive, royalty-bearing, sublicensable license under certain of our intellectual property relating to the licensed product to exploit MOR210/TJ210 in Greater China
and South Korea. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Out-Licensing</FONT> Arrangements </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with ABL Bio </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July
2018, we entered into a license and collaboration agreement with ABL Bio (the &#147;ABL Bio License&#148;). Under the ABL Bio License, we granted to ABL Bio exclusive, worldwide (excluding Greater China, royalty-bearing rights to develop and
commercialize a bispecific antibody (the &#147;BsAb&#148;) using certain of our monoclonal antibody sequences. ABL Bio has developed expertise in the area of bispecific antibodies for cancer treatment and has developed proprietary intellectual
property around the BsAb technology, and the license allows ABL Bio to further develop and commercialize the BsAb based on monoclonal antibodies licensed from us under the ABL Bio License. ABL Bio granted to us an exclusive, royalty-free,
sublicensable license under its interest in the BsAb and related <FONT STYLE="white-space:nowrap">know-how</FONT> (including improvements thereto) to exploit the licensed BsAb in Greater China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the ABL Bio License, we and ABL Bio each are responsible for using commercially reasonable efforts to develop the licensed products
through the completion of in vivo studies, and ABL Bio is responsible for using commercially reasonable efforts thereafter. We agreed to split costs fifty-fifty (50:50) with ABL Bio through the completion of in vivo studies, with ABL Bio responsible
for all costs and activities following that time. ABL Bio is responsible for all development and commercialization activities, subject to our input through a joint committee comprised of an equal number of our and ABL Bio&#146;s representatives
(though ABL Bio has final decision-making authority). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the license, ABL Bio paid us an upfront fee of
US$2.5&nbsp;million and agrees to make milestone payments in the aggregate amount of US$97.5&nbsp;million conditioned upon achieving certain research, clinical development and sales milestones. Further, ABL Bio agreed to pay us royalties at <FONT
STYLE="white-space:nowrap">mid-single-digit</FONT> percentages in respect of the total annual net sales of the licensed BsAb product.<B><I> </I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, ABL Bio granted to us an exclusive, royalty-free, sublicensable license to use its BsAb technology solely to exploit the licensed
BsAb product for all indications in Greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also agreed that, during the term of the ABL Bio License, neither we nor ABL Bio
would develop independently from the other a bispecific antibody that uses the same pair of antibodies as the bispecific antibody molecules created under the ABL Bio License. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ABL Bio License will continue to be in effect until expiration of the last payment obligation thereunder, unless earlier terminated
according to its terms. The ABL Bio License may be terminated by either party for the other party&#146;s uncured material breach or in the event that the other party challenges its patents. In addition, after a certain specified time period, ABL Bio
may terminate the ABL Bio License upon a notice period that varies based upon the stage of development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon expiration (but not
termination) of the ABL Bio License, we and ABL Bio will each retain our respective licenses granted under the ABL Bio License. If the ABL Bio License is terminated pursuant to ABL Bio&#146;s right to terminate at will or due to ABL Bio&#146;s
material breach, all rights and obligations (including all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
licenses granted) shall terminate and upon our request, we and ABL Bio will negotiate in good faith regarding our takeover of the exploitation of the BsAb product outside of Greater China in
exchange for reasonable compensation. Such negotiation will include, among other things, ABL Bio&#146;s assignment of assets related to the licensed BsAb product and the continuation of the licenses granted to us under the ABL Bio License. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with CSPC Entity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
December 2018, we entered into a product development agreement (the &#147;CSPC Agreement&#148;) with an entity controlled by CSPC Pharmaceutical Group Limited (01093.HK) (&#147;CSPC entity&#148;). Under the CSPC Agreement, we granted to CSPC entity
exclusive, <FONT STYLE="white-space:nowrap">non-transferable,</FONT> <FONT STYLE="white-space:nowrap">non-irrevocable</FONT> and sublicensable rights under our patent rights in China to develop and commercialize TJ103 for treating type 2 diabetes
mellitus and any other potential therapeutic applications. CSPC entity&#146;s right to sublicense is conditioned on our prior written consent, which we cannot unreasonably withhold, other than sublicense to CSPC entity&#146;s affiliates. CSPC entity
is a comprehensive pharmaceutical and drug manufacturing company, with an increasing focus on its research and development of new products focusing the therapeutic area of oncology, among others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the CSPC Agreement, CSPC entity is responsible for using commercially reasonable efforts to develop, obtain market approval and
commercialize the licensed products, while we are responsible for using commercially reasonable efforts to transfer the manufacturing technology of the licensed products to CSPC entity and assist or guide CSPC entity in the continued optimization of
such manufacturing technology thereafter. CSPC entity has final decision-making authority with respect to product development (though the research plan shall be jointly developed by both parties and any changes to the plan shall be discussed and
approved by the joint development committee) and commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also agreed that, during the term of the CSPC Agreement, we shall
not develop, either for ourselves or for third parties, any other hyFc platform technology-based long-acting recombinant <FONT STYLE="white-space:nowrap">GLP-1</FONT> Fc fusion proteins that may be in a competitive position with TJ103. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the license, CSPC entity paid us an upfront fee of RMB15.0&nbsp;million and agreed to make milestone payments in an
aggregate amount of RMB135.0&nbsp;million conditioned upon achieving certain clinical development and regulatory approval milestones, including completion of Phase 2 and Phase 3 clinical studies and obtaining NDA approval or market approval.
Further, we will also be entitled to tiered royalties ranging from mid-single-digit percentages to 10 percent in respect of the total annual net sales of the products after their commercialization in China. The royalty term shall terminate at the
later of: (i)&nbsp;the expiry date of the underlying patents of the licensed products with application numbers 201410851771.1 and 201580071643.8 (final grant of rights requested relating to <FONT STYLE="white-space:nowrap">GLP-1)</FONT> in China,
whichever is later; and (ii)&nbsp;the <FONT STYLE="white-space:nowrap">ten-year</FONT> anniversary of the initial commercialization of the product developed under the CSPC Agreement. We expect any patents that may issue under the aforementioned
patent application numbers 201410851771.1 and 201580071643.8 will expire between 2034 and 2035, before taking into account any extension that may be obtained through patent term extensions or adjustments, or term reduction due to filing of terminal
disclaimers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless terminated earlier in accordance with the terms thereof, the CSPC Agreement will remain in effect until the
termination of the royalty term. This agreement may be terminated by either party for the other party&#146;s uncured material breach, bankruptcy or insolvency or force majeure. We have the right to terminate the agreement if CSPC entity fails to use
commercially reasonable efforts to obtain regulatory approvals for commercializing the licensed product in the period stipulated by its board of directors due to its own fault or if CSPC entity ceases to pursue clinical development or product
registration as determined by its board of directors. CSPC entity has the right to terminate the agreement if we fail to resolve certain intellectual property disputes relating to TJ103 within six months after signing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the term of the CSPC Agreement, CSPC entity shall have exclusive, royalty-free rights in China to any work product generated by us, and
be responsible for any patent application and maintenance costs of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
work product. CSPC entity shall have all rights to any work product generated by itself under the CSPC Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other <FONT STYLE="white-space:nowrap">Out-Licensing</FONT> Arrangements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2017, our subsidiary <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai entered into a technology transfer agreement (the
&#147;HDYM License&#148;) with Ningbo Hou De Yi Min Information Technology Co., Ltd. (&#147;HDYM&#148;) and Hangzhou HealSun Biopharm Co., Ltd. (&#147;HealSun&#148;) with respect to <FONT STYLE="white-space:nowrap">PD-L1</FONT> humanized monoclonal
antibodies. HealSun is a portfolio company of Lepu Biotech (


<IMG SRC="g713200g84s38.jpg" ALT="LOGO">
). Under the HDYM License, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai agreed to grant to HDYM exclusive (even to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai itself), worldwide and sublicensable
rights to develop, manufacture, have manufactured, use, sell, have sold, import, or otherwise exploit certain <FONT STYLE="white-space:nowrap">PD-L1</FONT> related patents, patent applications, know-hows, data and information of <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Shanghai, relevant cell lines as well as any <FONT STYLE="white-space:nowrap">PD-L1</FONT> monoclonal antibody arising from such cell lines for the treatment of diseases. Further, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Shanghai and its cooperative party HealSun agreed to provide subsequent research and development services on such intellectual property to HDYM, including the selection and examination of innovative <FONT
STYLE="white-space:nowrap">PD-L1</FONT> humanized monoclonal antibodies, cultivation and selection of stable cell lines, establishment of cell bank, research and development of manufacturing processes and preparation of samples, toxicological and
pharmacological testing, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> pharmaceutical experiment report drafting, and application for and registration of clinical trials. If any party breaches the agreement and fails to cure, the
non-breaching parties may terminate this agreement. In addition, in the event that the development of the licensed product encounters insurmountable technical difficulties, this agreement may be terminated by mutual agreement of all parties. To the
extent that the agreement is terminated for HDYM&#146;s breach, all licenses and rights granted by us to HDYM will automatically terminate and be re-assigned to us. To the extent that the agreement is terminated due to material difficulty, HDYM will
have all rights to dispose of any development data and technology held by HealSun and us under this agreement and neither HealSun or us may use such development data and technology without HDYM&#146;s consent. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>C.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Collaboration Arrangements </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration Agreement with Everest </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
January 2018, we entered into a collaboration agreement with Everest whereby both parties agreed to collaborate to <FONT STYLE="white-space:nowrap">co-develop</FONT> MorphoSys&#146; proprietary CD38 antibody (TJ202 or the CD38 product) and
commercialize the CD38 product in Greater China for all indications in hematologic oncology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the agreement, we and Everest
established a joint steering committee with equal representation from each party to, among other things, coordinate and oversee the development and commercialization regarding the CD38 product. All decisions of the joint steering committee shall be
made by unanimous vote. We have final decision-making authority on matters related to the development of the CD38 product, provided that Everest has the right to opt out of sharing of development cost increases for new work or clinical trials added
to the initial development plan and budget. Everest has final decision-making authority on matters related to the commercialization of the CD38 product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the agreement, we are primarily responsible for using commercially reasonable efforts to carry out the development, manufacture and
supply of the CD38 product, and we are also responsible for seeking regulatory approval of the CD38 product. Everest is primarily responsible for sharing with us, by the proportion of 75% for Everest and 25% for us, the development costs of the CD38
product, including payments due to MorphoSys under the License and Collaboration Agreement, dated November&nbsp;30, 2017, between us and MorphoSys. We are not required to make any upfront, milestone or royalty payments to Everest under this
agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The joint steering committee will decide whether we or Everest shall be responsible for conducting the commercialization of
the CD38 product pursuant to the commercialization plan approved by the committee. If Everest is selected to be responsible for commercialization, we shall grant an exclusive royalty-free license to Everest to commercialize the CD38 product for all
indications in hematologic oncology in Greater China. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and Everest will share the CD38 product&#146;s profit and loss in proportion to the costs
that each of us incur in developing the product. The parties will also split <FONT STYLE="white-space:nowrap">out-license</FONT> revenue according to the proportion of development costs incurred, with us getting an additional five percent (5%) share
and Everest receiving five percent (5%) less. Everest cannot share in any profit from the commercialization of CD38 product until it has fulfilled its payment obligations under this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we want to develop the CD38 product for indications other than hematologic oncology in Greater China, we must first provide notice of such
intent to Everest and, at their election, negotiate with them in good faith regarding such rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement shall continue as
effective so long as we and Everest continue to develop the CD38 product for any indications in hematologic oncology in Greater China. This agreement may be terminated by either party for the other party&#146;s uncured material breach, bankruptcy or
insolvency. In addition, if we fail to initiate or conduct any material development activities in relation to any therapeutic, prophylactic or palliative CD38 product for a period of three months (other than as a result of a regulatory requirement),
Everest will have the right to terminate this agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon any termination of the agreement, the terminating party has the right to
continue the development and commercialization of CD38 product. If Everest is the rightful terminating party, we shall reasonably cooperate with Everest to, among other things, (i)&nbsp;assign the MorphoSys license to Everest (subject to the terms
and conditions of such license); (ii) grant to Everest an exclusive license to all intellectual property rights we own or control to further develop, manufacture, and commercialize the CD38 product; and (iii)&nbsp;transfer the development,
manufacture and commercialization of the CD38 product to Everest, including providing reasonable technical assistance and assigning to Everest any agreement with third party vendors pertaining to the development, manufacture and commercialization of
the CD38 product. In addition, the terminating party that elects to continue the development and commercialization of the CD38 product shall be solely responsible for the cost and expense of such development and commercialization after termination.
In the event that such continuing party successfully develops and commercializes the CD38 product, it shall pay to the other party a percentage of the product profit and <FONT STYLE="white-space:nowrap">out-license</FONT> income generated therefrom
in accordance with the terms of this agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Collaboration Arrangements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2018, we entered into a collaboration agreement with ABL Bio whereby both parties agreed to collaborate to develop three <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1-based</FONT></FONT> bispecific antibodies by using ABL Bio&#146;s proprietary BsAb technology and commercialize them in their respective territories, which, collectively, include the
PRC, Hong Kong, Macau, Taiwan and South Korea, and other territories throughout the rest of the world if both parties agree to do so in such other territories during the performance of the agreement. This agreement may be terminated by either party
for the other party&#146;s uncured material breach or in the event that the other party challenges its patents. Also, if a party encounters insurmountable technical difficulties and risks, which cannot be resolved by such party within a certain
period thereafter despite all reasonable efforts, such party will have the right to terminate this agreement and will no longer have the right to develop the licensed product. As of the date of this prospectus, ABL Bio has not made any upfront,
milestone or royalty payments to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2018, we entered into a collaboration and platform technology license agreement with
WuXi Biologics Ireland Limited (&#147;WuXi Biologics&#148;), whereby both parties agreed to collaborate in the research and development of at least three bispecific antibodies for our company to commercialize them worldwide. Such bispecific
antibodies shall be created using our proprietary monoclonal antibodies and WuXi Biologics&#146; proprietary WuXiBody platform technology for generating bispecific antibodies, shall be developed and manufactured through the exclusive service of WuXi
Biologics. This agreement may be terminated by either party for the other party&#146;s uncured material breach, bankruptcy or insolvency. WuXi Biologics has the right to terminate this agreement if we challenge its patents. We have the right to
terminate this agreement if we decide to end the development and commercialization of the licensed product in the licensed territory due to scientific, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
technical, or commercial reasons. As of the date of this prospectus, we have made an up-front payment of US$0.9 million to Wuxi Biologics and no milestone payments or royalties are due under this
agreement. In April 2019, we extended our existing partnership with WuXi Biologics (Shanghai) Co., Ltd. (&#147;WuXi Biologics Shanghai&#148;). We entered into a long-term, strategic collaboration agreement with WuXi Biologics Shanghai to facilitate
the CMC development and GMP manufacturing of both clinical and commercial supplies of certain of our monoclonal and bispecific antibodies and fusion products, leveraging WuXi Biologics&#146; and its affiliates&#146; expertise in this area and
supporting our <FONT STYLE="white-space:nowrap">pre-existing</FONT> collaboration and platform technology license agreement with WuXi Biologics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2018, we entered into collaboration agreements with TRACON Pharmaceuticals, Inc. (&#147;TRACON&#148;), whereby we and TRACON
agreed to (1)&nbsp;collaborate to <FONT STYLE="white-space:nowrap">co-develop</FONT> our proprietary CD73 antibody, TJD5 and (2)&nbsp;collaborate to <FONT STYLE="white-space:nowrap">co-develop</FONT> up to five BsAbs. Both agreements may be
terminated by either party for the other party&#146;s uncured material breach, bankruptcy or insolvency or for safety reasons. In addition, the agreement in respect of TJD5 may be terminated by us: (i) for convenience within a certain period upon
completing different clinical stages subject to certain payments and royalties, based on the clinical stage, that would be owed to TRACON upon the exercise of such termination for convenience; (ii) in the event that TRACON causes the Phase 1 study
timeline to be delayed beyond the agreed extension periods; or (iii) if we decide to end the development of the collaborative product prior to its first commercial sale. Further, prior to the first commercial sale, TRACON may deem this agreement to
be terminated by us if it reasonably believes that we have discontinued all meaningful development of the collaborative product for at least 12 months and certain other conditions are met. As of the date of this prospectus, no payments or royalties
are due under this agreement. Additionally, in March 2019, we agreed with TRACON and F. Hoffmann-La Roche Ltd (&#147;Roche&#148;) on a clinical supply agreement for Roche to supply Atezolizumab for use in clinical studies under the collaboration
agreement with TRACON. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for our drug candidates and
other commercially important products, technologies, inventions and <FONT STYLE="white-space:nowrap">know-how,</FONT> as well as on our ability to defend and enforce our patents including any patent that we have or may issue from our patent
applications, preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and proprietary rights of other parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September 30, 2019, our owned patent portfolio consist of (i) five issued patents, including two issued in the U.S., one issued in the
PRC and two issued in Korea; and (ii) 165 pending patent applications, including 22 PCT patent applications, 10 U.S. patent applications, 13 PRC patent applications and 120 patent applications in other jurisdictions. Our owned patents and patent
applications primarily relate to the drug candidates in our Global Portfolio. Furthermore, as of September 30, 2019, we in-licensed the Greater China rights relating to (i) 19 issued patents, including 12 issued in the PRC, five issued in Hong Kong
and two issued in Taiwan; and (ii) 25 pending patent applications, including three PCT patent applications, 11 PRC patent applications, seven Hong Kong patent applications, three Taiwan patent applications and one Korean patent application. The
in-licensed patents and patent applications primarily relate to TJ202, TJ101, TJ301, enoblituzumab and TJ107. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="top" ALIGN="left"><U>TJ202</U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U></U>As of September 30, 2019, we exclusively licensed from MorphoSys eight issued patents (including five
issued in the PRC, two issued in Hong Kong and one issued in Taiwan) and six pending patent applications (including three in the PRC and three in Hong Kong) relating to TJ202. The licensed patents include composition of matter patents in China, Hong
Kong and Taiwan. The patents (including patent applications if issued) in this portfolio are expected to expire between 2025 and 2037, before taking into account any extension that may be obtained through patent term extension or adjustment, or term
reduction due to filing of terminal disclaimers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="top" ALIGN="left"><U>TJ101</U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U></U>As of September 30, 2019, we (i) exclusively licensed from Genexine two pending PRC patent applications
directly relating to TJ101 and (ii) exclusively licensed from Genexine </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
three issued patents in the PRC and one pending PRC patent application relating to a hyFc platform that develops TJ101. The licensed patents include composition of matter patents in China. The
patents (including patent applications if issued) in this portfolio are expected to expire between 2028 and 2037, before taking into account any extension that may be obtained through patent term extension or adjustment, or term reduction due to
filing of terminal disclaimers. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="top" ALIGN="left"><U>TJ301</U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U></U>As of September 30, 2019, we exclusively licensed from Ferring one issued patent in the PRC relating to
TJ301. The licensed patent relates to composition of matter. This patent is expected to expire in 2027, before taking into account any extension that may be obtained through patent term extension or adjustment, or term reduction due to filing of
terminal disclaimers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="top" ALIGN="left"><U>Enoblituzumab</U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of September 30, 2019, we exclusively licensed from MacroGenics six issued patents (including two issued in
the PRC, three issued in Hong Kong and one issued in Taiwan) and eight pending patent applications (including two in the PRC, four in Hong Kong and two in Taiwan) relating to enoblituzumab. The patents (including patent applications if issued) in
this portfolio are expected to expire between 2023 and 2036, before taking into account any extension that may be obtained through patent term extension or adjustment, or term reduction due to filing of terminal disclaimers. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="top" ALIGN="left"><U>TJ107</U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of September 30, 2019, we (i) exclusively licensed from Genexine one pending PRC patent application directly
relating to TJ107 and (ii) exclusively license from Genexine three issued patents in the PRC and one pending PRC patent application relating to a hyFc platform that develops TJ107. The patents (including patent applications if issued) in this
portfolio are expected to expire between 2028 and 2036, before taking into account any extension that may be obtained through patent term extension or adjustment, or term reduction due to filing of terminal disclaimers. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="top" ALIGN="left"><U>TJM2</U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of September 30, 2019, we owned one pending PCT patent application that relates to TJM2 and it has entered
national phases in China, the United States and 22 other jurisdictions. We expect that any patent that may issue under this application will expire in 2037, before taking into account any extension that may be obtained through patent term extension
or adjustment, or term reduction due to filing of terminal disclaimers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="top" ALIGN="left"><U>TJC4</U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of September 30, 2019, we owned two pending PCT patent applications and one of them has entered national
phases in the PRC, the United States and 22 other jurisdictions. We expect that any patents that may issue under these applications will expire between 2037 and 2038, before taking into account any extension that may be obtained through patent term
extension or adjustment, or term reduction due to filing of terminal disclaimers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="top" ALIGN="left"><U>TJD5</U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of September 30, 2019, we owned one pending PCT patent application and it has entered national phases in the
PRC, the United States, and 21 other jurisdictions. We expect that any patent that may issue under this application will expire in 2038, before taking into account any extension that may be obtained through patent term extension or adjustment, or
term reduction due to filing of terminal disclaimers. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of a patent depends upon the laws of the country in
which it is issued. In most jurisdictions, a patent term is 20 years from the earliest filing date of a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. Under the PRC Patent Law, the term of patent protection starts from
the date of application. Patents relating to inventions are effective for twenty years, and utility models and designs are effective for ten years from the date of application. There are no patent term adjustments or patent term extensions available
in the PRC for issued patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patents, we rely upon unpatented trade secrets and
<FONT STYLE="white-space:nowrap">know-how</FONT> and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> can be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
difficult to protect. We seek to protect our proprietary information, in part, by executing confidentiality agreements with our partners, collaborators, scientific advisors, employees,
consultants and other third parties, and invention assignment agreements with our consultants and employees. We have also executed agreements requiring assignment of inventions with selected scientific advisors and collaborators. The confidentiality
agreements we enter into are designed to protect our proprietary information and the agreements or clauses requiring assignment of inventions to us are designed to grant us ownership of technologies that are developed through our relationship with
the respective counterparty. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes or that these agreements will afford us adequate
protection of our intellectual property and proprietary information rights. If any of the partners, collaborators, scientific advisors, employees and consultants who are parties to these agreements breaches or violates the terms of any of these
agreements or otherwise discloses our proprietary information, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, as of September 30, 2019, we had (i)&nbsp;three registered trademarks in Hong Kong, four registered trademarks in the PRC, eight
trademark applications in the PRC and six trademark applications in the United States; (ii)&nbsp;nine domain names in the PRC, including <I><FONT STYLE="white-space:nowrap">www.i-mabbiopharma.com</FONT></I>, four domain names in Hong Kong and two
domain names in the United States and (iii) 12 software copyrights in the PRC. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information on these and other risks related
to intellectual property, see &#147;Risk Factors&#151;Risks Related to Our Intellectual Property.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing and Supply </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our manufacturing strategy for our drug candidates consists of two progressive steps, involving (i) using contract development and
manufacturing organizations (&#147;CDMOs&#148;) and (ii) establishing our own capabilities and infrastructure, including a manufacturing facility. We believe that development of our own manufacturing facility will provide us with enhanced control of
material supply for both clinical trials and the commercial market, enable the more rapid implementation of process changes and help us achieve better long-term margins. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently outsource the manufacturing of clinical trial material for our internally developed, IND enabling projects to leading CDMOs in
China such as WuXi Biologics, and the manufacturing of clinical trial material for clinical stage projects which were <FONT STYLE="white-space:nowrap">in-licensed</FONT> from our global partners to reputable global CDMOs, which have established
track records for both clinical trial material supply and commercial material supply. We have assembled a seasoned internal team with deep experience in this area to drive and monitor this process. For contingency planning purposes, we have also
established relationships with other CDMOs. We expect to continue our outsourcing relationships with contract manufacturers to meet the ongoing needs for the development of our drug candidates. We have framework agreements with these external
service providers, under which they provide services to us on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">project-by-project</FONT></FONT> basis. We also monitor the manufacturing activities of clinical trial material at CDMO
to ensure the compliance with local and international cGMP and applicable regulations. Currently, our contract manufacturers obtain raw materials and supplies for the manufacturing activities from multiple suppliers who we believe have sufficient
capacity to meet our demands. We typically order materials and services on a purchase order basis. We also enter into long-term capacity or minimum supply arrangements with them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe it is advantageous that we own and control our GMP manufacturing process in order to ensure quality and secure production slots for
clinical trial materials and commercial supplies. We plan to commence the construction of our own state-of-the-art biologics manufacturing facility in Hangzhou, China by the end of 2019. At this manufacturing facility, we plan to produce drug
substance and drug product for clinical or, in the future, commercial use. We expect this facility to include a pilot GMP manufacturing plant with two <FONT STYLE="white-space:nowrap">500-liter</FONT> and two
<FONT STYLE="white-space:nowrap">2,000-liter</FONT> single use bioreactors, and upon completion of the construction, a commercial scale manufacturing plant with eight more <FONT STYLE="white-space:nowrap">2,000-liter</FONT> single use bioreactors
with filling and finishing lines. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturing is subject to extensive regulations governing quality management systems,
manufacturing processes and controls, personnel training, and operating procedures. The CDMOs will be required to operate under cGMP conditions. These cGMP conditions are regulatory requirements for the production of pharmaceuticals for human use.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>R&amp;D Governance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
established robust governance regime for all stages of our research and development activities, through our internal discovery, CMC, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical development programs, and through product
acquisition and <FONT STYLE="white-space:nowrap">in-licensing</FONT> strategies. The research and development governance regime has enabled our senior management to continuously oversee and monitor our company&#146;s research and development
activities for complying with applicable laws, regulations, rules, guidelines and internal policies. The research and development governance regime has been put in practice and has operated independently of the Chief Executive Officer&#146;s
responsibilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established various governance and decision-making committees, composed of senior representatives from the
respective functional units to review, discuss and determine, for instance, whether a drug candidate molecule is qualified to move forward into the next stage or not, what data package is considered appropriate and compliant to be submitted to
regulatory agencies and how clinical safety of our investigational drugs will be monitored and reported. These committees make decisions over the critical &#147;checkpoints&#148; of our research and development activities and include our
(i)&nbsp;Science Committee, (ii)&nbsp;IND Scientific Advisory Committee, (iii)&nbsp;R&amp;D Project/Program/Portfolio Governance, (iv)&nbsp;Medical Safety Council, (v)&nbsp;Safety Management Team, and (vi) Quality Committees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Science Committee for Early Stage Research of Drug Candidates </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Science Committee is composed of selected functional heads and members of the leadership, including Dr. Taylor B. Guo, Dr. Zheru Zhang, Dr.
Joan Huaqiong Shen, Dr. Jane Meng, Yuan Meng, Dr. Weimin Tang, Dr. Chao Zhang and Dr. Zhengyi Wang, chaired by Dr.&nbsp;Taylor&nbsp;B. Guo. The Science Committee will collaborate with the management team to enhance our company&#146;s research
practices and assist management in evaluating scientific aspects of potential <FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities, collaborations and new technologies that may bolster our pipeline and research and development
capabilities. The Science Committee&#146;s responsibilities include: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving the target review package submitted by our discovery group; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">providing governance on the quality and integrity of drug candidates, before entering into CMC process
development; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">examining the experimental data and scientific evidence supporting the drug candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations on our company&#146;s resource allocation in further development; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">setting the direction for scientific and technical review of potential
<FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, our Corporate Compliance Function led
by Mr.&nbsp;Thomas Song has taken a number of steps to review the integrity and reliability of the experimental data submitted with the selected drug candidate. The design, operation and monitoring of this data integrity program is integral to our
quality control and assurance system, and is independent with respect to our research and development unit and Science Committee, to ensure the compliance with the principles of scientific data integrity, including controls over changes to, and
deletions of source of data. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>IND Scientific Advisory Committee for Drug Candidates Entering into Clinical Development Stage </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our IND Scientific Advisory Committee is composed of Dr.&nbsp;Joan Huaqiong Shen, Dr.&nbsp;Zheru Zhang, Dr.&nbsp;Jane Meng and Rebecca Zhang.
The IND Scientific Advisory Committee is accountable for our IND </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
application strategy and the data quality of our IND registration dossier before submission to the FDA, the NMPA and other comparable authorities. Our IND Scientific Advisory Committee advises
the project team on policy matters and provides overall direction of new drug studies, and to that extent serves as a standing modality committee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>R&amp;D Project/Program/Portfolio Governance (&#147;IP3 Governance&#148;) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our IP3 Governance is composed of Dr.&nbsp;Joan Huaqiong Shen, Dr.&nbsp;Zheru Zhang and Dr.&nbsp;Chao Zhang, with Dr. Joan Huaqiong Shen
serving as the chair. Our IP3 Governance is a decision-making body that assesses and approves research and development portfolio strategy and execution proposals from a multi-discipline perspective, with an integrated approach incorporating
scientific, clinical and commercial considerations. Our IP3 Governance aims to ensure that the project, program and/or portfolio-related decisions are logical, robust and repeatable and that our investments in research and development activities is
aligned with our vision and strategy. The IP3 Governance responsibilities include: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and determining the <FONT STYLE="white-space:nowrap">in-licensing</FONT> and <FONT
STYLE="white-space:nowrap">out-licensing</FONT> strategic plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performing reviews on critical research and development stage gates, including clinical asset selection, GLP
pharmacology and toxicology studies, FIH studies, clinical development and regulatory submission; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing product development strategy and monitoring project timeline and costs. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Medical Safety Council (&#147;MSC&#148;) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our MSC is composed of selected research and development functional heads and Subject Matter Experts, including Yuan Meng, Dr. Joan Huaqiong
Shen, Michelle Yang, Rebecca Zhang, Dr. Taylor B. Guo, Dr. Jane Meng, Dr. Claire Xu and Zhengsong Zhang, chaired by Yuan Meng, Head of Medical Office. Our MSC is the highest medical safety governance body engaged in setting standards for protecting
the medical safety of patients and users of our products, and providing strategic direction in product vigilance and patient or user safety. The MSC&#146;s responsibilities include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing standards and policies, and identifying best practices related to medical safety;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">providing oversight of all medical safety relevant activities, and overseeing the implementation of our
company&#146;s medical safety standard, as well as the outcomes of the periodic audits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">addressing safety information that could result in a significant change in the benefit-risk profile of our
products; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving FIH studies and any other issues with respect to the safety of human exposure during
early development stage. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Safety Management Teams (&#147;SMT&#148;) for Product-Related Safety System </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our SMT is composed of representatives from each research and development function, including Yuan Meng, program lead, clinical physician (on
program level), representatives of regulatory affairs (on program level), representatives of project management (on project level), external business partner (if applicable) and representatives of medical affairs (if applicable), chaired by Yuan
Meng. The SMT is a product-based, cross-functional collaborative team responsible for the review and evaluation of medical safety data arising from any source throughout the product lifecycle. Our SMT performs assessments to identify changes in
safety profiles or potential safety signals. Based on these safety evaluations, the SMT will determine the appropriate safety-related actions to be taken with respect to the product based on its benefit-risk profile for subjects in clinical trials
and for patients treated with the marketed product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our SMT works closely with and escalates safety issues, as appropriate, to the MSC to
fulfill our medical safety obligations. Our SMT is responsible for reviewing available safety information from multiple sources on a regular basis and make final decisions on safety in a timely manner with appropriate cross-functional input. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Quality Committees </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have formed two
Quality Committees, namely, I-Mab Biopharma Quality Management Review and R&amp;D Quality Council. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I-Mab Biopharma Quality Management
Review (&#147;I-Mab QMR&#148;) is composed of Dr. Joan Huaqiong Shen, Dr. Zheru Zhang, Yuan Meng, Thomas Song and Rebecca Zhang, co-chaired by R&amp;D Quality Assurance officer Niri Wu and CMC Quality Assurance officer Jack Qin. I-Mab QMR is a
company-level cross-functional senior leadership meeting to provide management oversight of our company&#146;s Quality Management System (&#147;QMS&#148;) and the compliance status of our company&#146;s regulated activities with applicable laws,
regulations, policies and procedures, focusing on R&amp;D and CMC GXP activities. To ensure our Corporate Quality Plan is set, key QMS elements are established and maintained, quality requirements are met, and trends, changes and risks are
identified and addressed proactively. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">R&amp;D Quality Council is composed of representatives from each research and development
function, including Dr. Joan Huaqiong Shen, Niri Wu, Yuan Meng, Michelle Yang, Dr. Claire Xu, Dr. Jane Meng, Rebecca Zhang and heads of therapeutic areas (in China and the United States), chaired by Dr. Joan Huaqiong Shen. R&amp;D Quality Council is
a governance body that oversees the performance of the QMS and serves as the final decision-making body for critical quality issues that affect subject and patient safety, data integrity and compliance with global and local regulatory authorities.
The QMS encompasses the structure, responsibilities and procedures that enable the organization to identify, measure, control and enhance core regulated processes and activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Code of Conduct </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a Code
of Conduct that is applicable to many aspects of our business operation, such as business ethics, responsible research and development activities, IP and data protection, workplace ethics and other corporate governance topics, as well as
implementing high ethical standards that are mandatory for our employees. In addition, we have adopted an employee handbook which describes the compliance management system implemented at <FONT STYLE="white-space:nowrap">I-Mab</FONT> to ensure
compliance with applicable legal and regulatory requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quality Control and Assurance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the research and development governance regime described above, we have established an independent quality control and assurance
system and devote significant attention to quality control for the designing, manufacturing and testing of our drug candidates. Our Assurance Board is composed of Dr.&nbsp;Joan Huaqiong Shen, Dr.&nbsp;Zheru Zhang and Thomas Song. Our senior
management is firmly committed to delivering our quality performance, actively involved in allocating sufficient resources to quality management system and setting quality governance mechanism. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trials, the overall quality management outlines the implementation of
our business policies and procedures in order to consistently comply with the regulatory requirements, including Good Laboratory Practices, or GLP; Good Clinical Practices, or GCP; Good Pharmacovigilance Practice, or GVP and other applicable
regulatory requirements in the performance of the trials. This includes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">predefined policies and procedures to manage <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical
studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dedicated resources and personnel with well delineated roles and responsibilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">quality risk management across the product lifecycle; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continuous quality management system improvement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">non-conformance</FONT> management via quality issue management process;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">development and execution of quality audit program; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory inspection readiness. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For CMC, we have established a quality management system to oversee the process development and API and drug production at the CDMOs. This
system takes a holistic approach bringing senior management, quality assurance team and company policies together to create an efficient and agile quality culture.&nbsp;Our CMC quality commitment includes, but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ensure that the product manufacturing, releasing, packaging, storage, and shipment meets all specifications and
the requirements of the FDA and/or NMPA&#146;s quality system regulations, cGMP or other applicable laws and regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review of process deviations and changes, root cause analysis, impact assessment, corrective and preventative
actions, and validation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ensure the consistency of key quality practices with our CDMOs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">proactive quality system review based on audits, process data analysis, equipment condition, and periodic review
of internal and external sources of data; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assessment of regulatory guidance and ensure readiness for regulatory inspections. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We had 59, 134 and 160
employees as of December&nbsp;31, 2017 and 2018 and June 30, 2019, respectively. As of June 30, 2019, 149 employees were located in China and 11 were located outside China. The table below sets forth our employees by function as of June 30, 2019:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chemistry, manufacturing and controls</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compliance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Business and corporate development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recruit our employees primarily through recruitment websites, recruiters, internal referrals and job fairs.
We recruit our employees based on their qualification and potential. We promote culture diversity, and our employees come from the United States, Taiwan and South Korea, in addition to China. The remuneration package of our employees includes
salary, benefits and bonus. Our compensation programs are designed to remunerate our employees based on their performance, measured against specified objective criteria. We are required to make contributions to social insurance and housing provident
funds in accordance with PRC laws and regulations from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We provide new hire training to our employees and periodic <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">on-the-job</FONT></FONT> training to enhance the skills and knowledge of our employees. We have not established a labor union. We have not experienced any material labor disputes or strikes
that may have a material and adverse effect on our business, financial condition or results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We enter into standard confidentiality and employment agreements with our key management and
research staff. The contracts with our key personnel typically include a standard <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement that prohibits the employee from competing with us, directly or indirectly, during his or her employment
and for one year after the termination of his or her employment. The contracts also typically include undertakings regarding assignment of innovations and discoveries made during the course of his or her employment. For further details regarding the
terms of confidentiality and employment agreements with our key management, see &#147;Management.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our headquarter is located in Shanghai, China, where we lease and occupy approximately 2,479 square meters as office space and laboratories. We
currently lease approximately 235 square meters of office space in Beijing, approximately 54 square meters of office space in Tianjin, approximately 49 square meters of office space in Chengdu, approximately 105 square meters of office space and
laboratories in Hong Kong, and approximately 441 square meters of office space and laboratories in Maryland. The terms of these leases range from one year to five years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time we
may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a
material adverse effect on our business, results of operations, financial condition or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and
other factors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Internal Control and Risk Management </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have implemented various risk management policies and measures to identify, assess and manage risks arising from our operations. In
addition, we have codified risk categories identified by our management, internal and external reporting mechanisms, remedial measures and contingency management as part of our policies. For details on major risks identified by our management, see
&#147;Risk Factors&#148; in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To monitor the ongoing implementation of our risk management policies and corporate
governance measures following this offering, we have adopted or will adopt, among other things, the following risk management and internal control measures: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the establishment of an audit committee responsible for overseeing our financial records, internal control
procedures and risk management systems. See &#147;Management&#151;Committees of the Board of Directors&#148; in this prospectus for information of our audit committee members and detailed description of the responsibility of our audit committee; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the engagement of external legal advisors to advise us on compliance with relevant regulatory requirements and
applicable laws to which we will be subject to as a public company, where necessary. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, we have adopted or will
adopt before this offering, various internal regulations against corrupt and fraudulent activities, including measures against bribery and the misuse of company assets. Key measures and procedures to implement such regulations include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorizing our compliance department to assume responsibility for our anti-corruption and anti-fraud measures,
including handling complaints, conducting internal investigations and ensuring protection for whistleblowers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">providing anti-corruption compliance training to our senior management and employees on a periodic basis to
enhance their knowledge and compliance with applicable laws and regulations, including relevant policies and prohibitions against <FONT STYLE="white-space:nowrap">non-compliance</FONT> set out in our employee handbook; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating and undertaking rectification measures with respect to any identified corrupt or fraudulent activity,
including proposing and establishing preventative measures to avoid future <FONT STYLE="white-space:nowrap">non-compliance.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will continue to implement and enforce these measures and procedures to ensure ongoing compliance with all applicable laws and regulations,
including the prevention of our employees from engaging in corruption, bribery or other improper conduct. During the periods presented, we were not subject to any government investigation or litigation with respect to claims or allegations relating
to monetary and <FONT STYLE="white-space:nowrap">non-monetary</FONT> bribery activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also designated responsible personnel to
monitor our ongoing compliance with relevant laws and regulations that govern our business operations, and to oversee the implementation of any necessary measures. Meanwhile, we plan to provide our directors, senior management and relevant employees
with continuing training programs and updates regarding relevant laws and regulations on a regular basis, with a view to proactively identifying concerns or issues relating to any potential <FONT STYLE="white-space:nowrap">non-compliance.</FONT>
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_16"></A>REGULATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRC Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to a
variety of PRC laws, rules and regulations affecting many aspects of our business. This section summarizes the principal PRC laws, rules and regulations that we believe are relevant to our business and operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulations on Company Establishment and Foreign Investment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Company Law </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
establishment, operation and management of companies in China is governed by the PRC Company Law, which was passed by the Standing Committee of the National People&#146;s Congress (the &#147;NPC&#148;), on December&nbsp;29, 1993 and came into effect
on July&nbsp;1, 1994 and was latest revised or amended on October&nbsp;26, 2018, respectively. In light of the PRC Company Law, companies established in the PRC are either in the form of a limited liability company or a joint stock company. The PRC
Company Law applies to both PRC domestic companies and foreign-invested companies, unless otherwise provided in the relevant foreign investment laws and regulations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Investment Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;15, 2019, the NPC approved the PRC Foreign Investment Law, which will become effective on January&nbsp;1, 2020 and replace the
three existing laws on foreign investment in China, namely, the PRC Equity Joint Venture Law, the PRC Cooperation Joint Venture Law and the Wholly Foreign-Owned Enterprise Law, together with their implementation rules and ancillary regulations. The
Foreign Investment Law embodies an expected PRC regulatory trend to rationalize its foreign investment regulatory regime in line with prevailing international practice and the legislative efforts to unify the corporate legal requirements for both
foreign and domestic invested enterprises in China. The Foreign Investment Law establishes the basic framework for the access to, and the promotion, protection and administration of foreign investments in view of investment protection and fair
competition. According to the Foreign Investment Law, &#147;foreign investment&#148; refer to investment activities directly or indirectly conducted by one or more natural persons, business entities, or other organizations of a foreign country
(collectively referred to as &#147;foreign investor&#148;) within China, and &#147;investment activities&#148; include the following activities: (i)&nbsp;a foreign investor, individually or together with other investors, establishes a
foreign-invested enterprise within China; (ii)&nbsp;a foreign investor acquires stock shares, equity shares, shares in assets, or other similar rights and interests of an enterprise within China; (iii)&nbsp;a foreign investor, individually or
together with other investors, invests in a new construction project within China; and (iv)&nbsp;investments in other means as provided by the laws, administrative regulations or the State Council. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Regulations Relating to Foreign Investment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the interim period before the Foreign Investment Law becomes effective, investments in the PRC by foreign investors, particularly the
establishment procedures, examination and approval procedures, registered capital, foreign exchange, taxation and labor matters of a wholly foreign-owned enterprise, are subject to the Wholly Foreign-Owned Enterprise Law of the PRC promulgated on
April&nbsp;12, 1986 and amended on October&nbsp;31, 2000 and September&nbsp;3, 2016, respectively, the Detailed Implementing Rules for the Wholly Foreign-Owned Enterprise Law of the People&#146;s Republic China promulgated on December&nbsp;12, 1990
and amended on April&nbsp;12, 2001 and February&nbsp;19, 2014, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore,
<FONT STYLE="white-space:nowrap">PRC-based</FONT> investments by foreign investors shall also be regulated by the Catalogue for the Guidance of Foreign Investment Industries (2017 Revision) issued on June&nbsp;28, 2017 and effective from
July&nbsp;28, 2017, and the Special Management Measures (Negative List) for the Access of Foreign Investment (2018)&nbsp;issued on June&nbsp;28, 2018 and effective from July&nbsp;28, 2018. According to the aforesaid catalogue and management
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
measures, foreign-invested industries fall into four categories, namely, &#147;encouraged,&#148; &#147;permitted,&#148; &#147;restricted&#148; and &#147;prohibited,&#148; and certain ownership
requirements, requirements for senior executives and other special management measures shall apply to foreign investors with regard to the access of foreign investments in certain categories. The Special Management Measures (Negative List) for the
Access of Foreign Investment (2019) and the Catalogue of Industries for Encouraging Foreign Investment (2019 Version), which became effective on July 30, 2019, further reduce restrictions on the foreign investment and replaced the Special Management
Measures (Negative List) for the Access of Foreign Investment (2018). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Interim Administrative Measures for the
Record-filing of the Incorporation and Change of Foreign-invested Enterprises, foreign-invested enterprises investing in categories not subject to the special management measures are only required to complete an online registration of their
incorporation and any changes with the Ministry of Commerce (the &#147;MOFCOM&#148;), or its local counterparts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>M&amp;A Rules
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the Provisions on the Merger or Acquisition of Domestic Enterprises by Foreign Investors jointly issued by the
MOFCOM, the State Assets Supervision and Administration Commission of the State Council, the State Administration of Taxation (the &#147;SAT&#148;), the State Administration for Industry and Commerce (now known as the State Administration for Market
Regulation), the China Securities Regulatory Commission and the State Administration of Foreign Exchange (the &#147;SAFE&#148;), on August&nbsp;8, 2006 and amended by the MOFCOM on June&nbsp;22, 2009, among other things, (i)&nbsp;the purchase of an
equity interest or subscription to the increase in the registered capital of <FONT STYLE="white-space:nowrap">non-foreign-invested</FONT> enterprises, (ii)&nbsp;the establishment of foreign-invested enterprises to purchase and operate the assets of <FONT
STYLE="white-space:nowrap">non-foreign-invested</FONT> enterprises, or (iii)&nbsp;the purchase of the assets of <FONT STYLE="white-space:nowrap">non-foreign-invested</FONT> enterprises and the use of such assets to establish foreign-invested
enterprises to operate such assets, in each case, by foreign investors shall be subject to the Provisions on the Merger or Acquisition of Domestic Enterprises by Foreign Investors. Particularly, application shall be made for examination and approval
of the acquisition of any company in China affiliating to a domestic company, enterprise or natural person, which is made in the name of an oversea company established or controlled by such domestic company, enterprise or natural person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>PRC Drug Regulation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Drug
Administration Law of the PRC promulgated by the Standing Committee of the NPC on September&nbsp;20, 1984 and effective from July&nbsp;1, 1985 and amended on February&nbsp;28, 2001, December&nbsp;28, 2013 and April&nbsp;24, 2015, respectively, and
the Implementing Measures of the Drug Administration Law promulgated by the State Council on August&nbsp;4, 2002 and effective from September&nbsp;15, 2002 and amended on February&nbsp;6, 2016 and March&nbsp;2, 2019, respectively, have jointly
established the legal framework for the administration of pharmaceutical products in China, including the research, development and manufacturing of new drugs. The Drug Administration Law applies to entities and individuals engaged in the
development, production, trade, application, supervision and administration of pharmaceutical products, which regulates and provides for a framework for the administration of pharmaceutical manufacturers, pharmaceutical trading companies and
medicinal preparations of medical institutions, and the development, research, manufacturing, distribution, packaging, pricing and advertisements of pharmaceutical products. The Implementing Measures of the Drug Administration Law, on the other
hand, provides detailed implementation regulations for the Drug Administration Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August 26, 2019, the Standing Committee of the NPC
promulgated the amended Drug Administration Law, which will become effective on December 1, 2019. The amendment will bring a series of changes to the drug supervision and administration system, including but not limited to the clarification of the
drug marketing authorization holder system, pursuant to which the marketing authorization holder shall assume responsibilities for non-clinical studies, clinical trials, manufacturing and marketing, post-marketing studies, monitoring, reporting and
handling of adverse reactions of the drug. The amendment also stipulates that the State supports the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
innovation of drugs with clinical value and specific or special effects on human diseases, encourages the development of drugs with new therapeutic mechanisms and have multi-targeted, systematic
regulatory and intervention functions on human body and promotes the technological advancement of drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to follow the
above-mentioned regulations in respect of our <FONT STYLE="white-space:nowrap">non-clinical</FONT> research, clinical trials and production of new drugs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Regulatory Authorities and Recent Government Reorganization </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pharmaceutical products and medical devices and equipment in China are monitored and supervised on a national scale by the NMPA (formerly known
as the China Food and Drug Administration, or the &#147;CFDA&#148;), while the local provincial medical products administrative authorities are responsible for the supervision and administration of drugs within their respective administrative
regions. Pursuant to the Decision of the First Session of the Thirteenth National People&#146;s Congress on the State Council Institutional Reform Proposal made by the NPC on March&nbsp;17, 2018, the NMPA is no longer an independent agency and its
duties shall be performed by the newly established State Administration for Market Regulation, into which the various agencies responsible for, among other areas, consumer protection, advertising, anticorruption, pricing, fair competition and
intellectual property, have been merged. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The NMPA is still the chief drug regulatory agency and implements the same laws, regulations,
rules, and guidelines as the CFDA, and the NMPA regulates almost all of the key stages of the life cycle of pharmaceutical products, including <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies, clinical trials, marketing approvals,
manufacturing, advertising and promotion, distribution, and pharmacovigilance (i.e., post-marketing safety reporting obligations). The Center for Drug Evaluation (the &#147;CDE&#148;), which remains under the NMPA, conducts the technical evaluation
of each drug and biologic application for safety and effectiveness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Formed on March&nbsp;2018, the National Health Commission (the
&#147;NHC&#148;) (formerly known as the Ministry of Health (&#147;MOH&#148;) and the National Health and Family Planning Commission (&#147;NHFPC&#148;)) is China&#146;s chief healthcare regulator. It is primarily responsible for overseeing the
operation of medical institutions, which also serve as clinical trial sites, and regulating the licensure of hospitals and medical personnel. The NHC plays a significant role in drug reimbursement. Furthermore, the NHC and its local counterparts at
or below provincial-level local governments also oversee and organize public medical institutions&#146; centralized bidding and procurement process for pharmaceutical products, which is the chief means through which public hospitals and their
internal pharmacies acquire drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also, as part of its 2018 reorganization, the PRC government formed a new State Medical Insurance
Bureau (the &#147;SMIB&#148;), which focuses on regulating reimbursement under the state-sponsored insurance plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I><FONT
STYLE="white-space:nowrap">Non-Clinical</FONT> Research </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August 4, 2003, the NMPA promulgated the Administrative Measures for
Good Laboratories Practice of <FONT STYLE="white-space:nowrap">Non-clinical</FONT> Laboratory, which was revised on July&nbsp;27, 2017, to improve the quality of <FONT STYLE="white-space:nowrap">non-clinical</FONT> research, and began to conduct the
Good Laboratories Practice. Pursuant to the Circular on Administrative Measures for Certification of Good Laboratory Practice for <FONT STYLE="white-space:nowrap">Non-clinical</FONT> Laboratory issued by the NMPA on April&nbsp;16, 2007, the NMPA is
responsible for the certification of <FONT STYLE="white-space:nowrap">non-clinical</FONT> research institutions nationwide and local provincial medical products administrative authorities is in charge of the daily supervision of non-clinical
research institution. The NMPA decides whether an institution is qualified for undertaking pharmaceutical <FONT STYLE="white-space:nowrap">non-clinical</FONT> research by evaluating such institution&#146;s organizational administration, its research
personnel, its equipment and facilities, and its operation and management of <FONT STYLE="white-space:nowrap">non-clinical</FONT> pharmaceutical projects. A Good Laboratory Practice Certification will be issued by the NMPA if all the relevant
requirements are satisfied, which will also be published on the NMPA&#146;s website. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Regulations for the Administration of Affairs Concerning Experimental
Animals promulgated by the State Science and Technology Commission on November&nbsp;14, 1988 and amended on January&nbsp;8, 2011, July&nbsp;18, 2013 and March&nbsp;1, 2017, respectively, by the State Council, the Administrative Measures on Good
Practice of Experimental Animals jointly promulgated by the State Science and Technology Commission and the State Bureau of Quality and Technical Supervision on December&nbsp;11, 1997, and the Administrative Measures on the Certificate for
Experimental Animals (Trial) promulgated by the State Science and Technology Commission and other regulatory authorities on December&nbsp;5, 2001, a Certificate for Use of Laboratory Animals is required for performing experimentation on animals.
Applicants must satisfy the following conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Laboratory animals must be qualified and sourced from institutions that have Certificates for Production of
Laboratory Animals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The environment and facilities for the animals&#146; living and propagating must meet national requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The animals&#146; feed and water must meet national requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The animals&#146; feeding and experimentation must be conducted by professionals, specialized and skilled
workers, or other trained personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The management systems must be effective and efficient; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The applicable entity must follow other requirements as stipulated by Chinese laws and regulations.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Pre-clinical</FONT> and Clinical Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The NMPA requires supporting <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data for the registration applications for imported and
domestic drugs. <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> work, including pharmacology and toxicology studies, must satisfy the requirements of the Administrative Measures for Good Laboratories Practice of
<FONT STYLE="white-space:nowrap">Non-clinical</FONT> Laboratory. No approval is required from the NMPA to conduct <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Trials and Registration of New Drugs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Categories </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to
the Administrative Measures for Drug Registration promulgated by the NMPA on July&nbsp;10, 2007 and effective from October&nbsp;1, 2007, which provides the standards and requirements for clinical trials and drug registration applications, drug
registration applications are divided into three different types, namely, New Drug Application, Generic Drug Application, and Imported Drug Application. Drugs are categorized based on their working mechanism, including chemical medicine, biological
product or traditional Chinese or natural medicine. As provided in the Administrative Measures for Drug Registration, the Drug Administration Law and Implementing Measures of the Drug Administration Law, upon completion of <FONT
STYLE="white-space:nowrap">non-clinical</FONT> research, clinical trials shall be conducted for the application of new drug registration, upon approval from NMPA or authorized institutions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to engaging with the NMPA on research and development approval, an applicant shall determine the registration category for its drug
candidate (subject to ultimate confirmation by the NMPA), which will determine the requirements for its clinical trial and marketing application. There are five categories for small molecule drugs: Category 1 (&#147;innovative drugs&#148;) refers to
drugs with a new chemical entity that have not been marketed anywhere in the world; Category 2 (&#147;improved new drugs&#148;) refers to drugs with a new indication, dosage form, route of administration, combination, or certain formulation changes
not previously approved anywhere in the world; Categories 3 and 4 refer to generic drugs that reference an innovator drug (or certain well-known generic drugs) marketed either abroad or in China, respectively; and Category 5 refers to innovative or
generic drugs that have already been marketed abroad but are not yet approved in China (i.e., various imported drugs). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Approval </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All clinical trials conducted in China must be approved and conducted at hospitals accredited by the NMPA. For imported drugs, proof of foreign
approval is required prior to the trial, unless the drug has never been approved anywhere in the world. In addition to a standalone trial in China, imported drug applicants may establish a site in China as part of an international multi-center trial
(the &#147;IMCT&#148;) at the outset of the global trial. Domestically manufactured drugs are not subject to foreign approval requirements, and by contrast to prior practice, the NMPA has recently decided to also permit such drugs to be tested and
developed through an IMCT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the NMPA has adopted a notification system for clinical trials of new drugs. Pursuant to the
Opinions on Deepening the Reform of the Evaluation and Approval Systems and Encouraging Innovation on Drugs and Medical Devices (the &#147;Innovation Opinion&#148;) and the Announcement on Adjusting the Evaluation and Approval Procedure of Drug
Clinical Trial, clinical trials may be commenced as long as the applicant has not received any objections from the CDE within 60 business days of application filing, as opposed to the lengthier prior clinical trial
<FONT STYLE="white-space:nowrap">pre-approval</FONT> process, in which an affirmative approval from the NMPA must be obtained to commence clinical trials. The number of trial sites in China may increase due to the shortening of the accreditation
timeline resulting from the replacement of the <FONT STYLE="white-space:nowrap">pre-approval</FONT> procedure with the notification procedure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Drug Clinical Trial Registration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Administrative Measures for Drug Registration, upon obtaining the clinical trial approval and before commencing a clinical
trial, the applicant shall file a registration with the NMPA containing various details of the clinical trial, including the clinical study protocol, the name of the principal researcher of the leading institution, names of participating
institutions and researchers, an approval letter from the ethics committee, and a sample of the Informed Consent Form, with a copy sent to the competent provincial administration departments where the trial institutions will be located. On
September&nbsp;6, 2013, the NMPA released the Announcement on Drug Clinical Trial Information Platform, providing that for all clinical trials approved by the NMPA and conducted in China, instead of the aforementioned registration filed with the
NMPA, clinical trial registration shall be completed and trial information shall be published through the Drug Clinical Trial Information Platform. The applicant shall complete trial <FONT STYLE="white-space:nowrap">pre-registration</FONT> within
one month after obtaining the clinical trial approval to obtain the trial&#146;s unique registration number and shall complete registration of certain <FONT STYLE="white-space:nowrap">follow-up</FONT> information before the first subject&#146;s
enrollment in the trial. If approval of the foregoing <FONT STYLE="white-space:nowrap">pre-registration</FONT> and registration is not obtained within one year after obtaining the clinical trial approval, the applicant shall submit an explanation,
and if the procedure is not completed within three years, the clinical trial approval shall automatically expire. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Human Genetic
Resources Approval </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;10, 1998, the Ministry of Science and Technology and the MOH jointly established the rules for
protecting and utilizing human genetic resources in China. On July&nbsp;2, 2015, the Ministry of Science and Technology issued the Service Guide for Administrative Licensing Items concerning Examination and Approval of Sampling, Collecting, Trading,
Exporting Human Genetic Resources, or Taking Such Resources out of the PRC, which provides that foreign-invested sponsors that sample and collect human genetic resources in clinical trials shall be required to file with the China Human Genetic
Resources Management Office through its online system. On October&nbsp;26, 2017, the Ministry of Science and Technology issued the Circular on Optimizing the Administrative Examination and Approval of Human Genetic Resources, which simplified the
approval for sampling and collecting human genetic resources for the purpose of commercializing a drug in the PRC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;10, 2019,
the State Council of PRC issued the National Regulations on the Management of Human Genetic Resources, which formalized the approval requirements pertinent to research collaborations between Chinese and foreign-owned entities. Pursuant to this new
rule, a new notification system (as opposed to the advance approval approach originally in place) is put in place for clinical trials using China&#146;s human genetic resources at clinical institutions without involving the export of human genetic
resources outside of China. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Trial Exemptions and Acceptance of Foreign Data </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The NMPA may reduce its requirements for clinical trials and data, depending on the drug and the existing data. The NMPA has granted waivers
for all or part of trials and has stated that it will accept data generated abroad (even if not as part of a global study), including early phase data, that meets its requirements. On July&nbsp;6, 2018, the NMPA issued the Technical Guidance
Principles on Accepting Foreign Drug Clinical Trial Data (the &#147;Guidance Principles&#148;) as one of the implementing rules for the Innovation Opinion. According to the Guidance Principles, the data of foreign clinical trials must meet the
authenticity, completeness, accuracy and traceability requirements, and such data must be obtained in consistency with the relevant requirements under the Good Clinical Trial Practice (GCP) of the International Conference on Harmonization of
Technical Requirements for Registration of Pharmaceuticals for Human Use (the &#147;ICH&#148;). Clinical trial sponsors must be attentive to potentially meaningful ethnic differences in the subject population. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The NMPA now officially permits, and its predecessor agencies have permitted on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis in the past, drugs approved outside of China to be approved in China on a conditional basis without <FONT STYLE="white-space:nowrap">pre-approval</FONT> clinical trials being conducted in
China. Specifically, in 2018, the NMPA issued the Procedures for Reviewing and Approval of Clinical Urgently Needed Overseas New Drugs, permitting drugs that have been approved within the last ten years in the United States, the European Union or
Japan and that prevent or treat orphan diseases or prevent or treat serious life-threatening illnesses for which there is either no effective therapy in China or for which the foreign-approved drug would have clear clinical advantages. Applicants
will be required to establish a risk mitigation plan and may be required to complete trials in China after the drug has been marketed. The CDE has developed a list of qualifying drugs that meet the foregoing criteria. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Clinical Trial Process and Good Clinical Practices </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Typically, drug clinical trials in China have four phases. Phase 1 refers to the initial clinical pharmacology and human safety evaluation
studies. Phase 2 refers to the preliminary evaluation of a drug candidate&#146;s therapeutic efficacy and safety for target indication(s) in patients. Phase 3 (often the pivotal study) refers to clinical trials that further verify the drug
candidate&#146;s therapeutic efficacy and safety on patients with target indication(s) and ultimately provide sufficient evidence for the review of a drug registration application. Phase 4 refers to a new drug&#146;s post-marketing study to assess
therapeutic effectiveness and adverse reactions when the drug is widely used, to evaluate overall benefit-risk relationships of the drug when used among the general population or specific groups and to adjust the administration dose, etc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;6, 2003, the NMPA promulgated the Administration of Quality of Drug Clinical Practice (the &#147;GCP&#148;) to improve the
quality of clinical trials. On February&nbsp;19, 2004, the NMPA issued the Circular on Measures for Certification of Drug Clinical Institutions (Trial), providing that the NMPA is responsible for the certification of clinical trial institutions
nationwide and that the NHFPC is responsible for the certification of clinical trial institutions within its duties. The NMPA requires that the different phases of clinical trials in China receive ethics committee approval prior to the approval of
the clinical trials and that the clinical trials shall comply with GCP. Under the Circular on Measures for Certification of Drug Clinical Institutions (Trial), the NMPA and the NHFPC shall decide whether an institution is qualified for undertaking
pharmaceutical clinical trials upon evaluating the institution&#146;s organizational administration, research personnel, equipment and facilities, management system and standard operational rules. Pursuant to the Circular on Measures for
Certification of Good Laboratory Practice for Non-clinical Laboratory, a Good Laboratory Practice Certification will be issued by the NMPA if all the relevant requirements are satisfied, which will also be published on the NMPA&#146;s website.
Pursuant to the Opinions on Deepening the Reform of the Evaluation and Approval System and Inspiring Innovation of Drugs and Medical Devices and Equipment, the accreditation of the institutions for drug clinical trials shall be subject to
record-filing administration. The conduct of clinical trials must adhere to the Good Laboratory Practice, and the protocols must be approved by the ethics committees of each study site. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Reform of Evaluation and Approval System for Drugs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;9, 2015, the State Council promulgated the Opinions on the Reform of Evaluation and Approval System for Drugs and Medical
Devices and Equipment, which establishes the reform framework of the evaluation and approval system for drugs, medical devices and equipment, indicating the enhancement of the standard of approval for drug registration and accelerating the
evaluation and approval process for innovative drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;11, 2015, the NMPA issued the Circular Concerning Several Policies
on Drug Registration Review and Approval, which further clarifies the measures and policies with regard to the simplification and acceleration of the approval process for drugs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the Decision of the NMPA on Adjusting the Approval Procedures under the Administrative Approval Items for Certain Drugs made on
March&nbsp;17, 2017 and effective from May&nbsp;1, 2017, the approval for a clinical trial application can be directly issued by the CDE under the NMPA on behalf of the NMPA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;8, 2017, the General Office of the State Council promulgated the Innovation Opinions, which further promotes the structural
adjustment to and technical innovations of drugs, medical devices and equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;21, 2017, the NMPA promulgated the
Opinions on Encouraging the Prioritized Evaluation and Approval for Drug Innovations, replacing the Opinions on Priority Review and Approval for Resolving Drug Registration Applications Backlog promulgated on February&nbsp;24, 2016, which provides
for fast track clinical trial approval or drug registration pathway to innovative drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;23, 2018, the NMPA and the NHC
jointly issued the Circular on Issues Concerning Optimizing Drug Registration Review and Approval, which further simplifies and accelerates the clinical trial approval process. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Special Examination and Fast Track Approval for Innovative Drugs under Current Reform Frame </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Provisions on the Administration of Special Examination and Approval of Registration of New Drugs promulgated by the NMPA on
January&nbsp;7, 2009, the NMPA conducts special examination and approval for new drug registration applications when, among others, (1)&nbsp;the effective constituent of a drug extracted from plants, animals, minerals, etc., as well as the
preparations thereof, have never been marketed in China, or the material medicines and the preparations thereof are newly discovered; (2)&nbsp;the chemical raw material medicines as well as the preparations thereof and the biological product have
not been approved for marketing anywhere in the world; (3)&nbsp;the new drugs are for treating AIDS, malignant tumors and rare diseases, etc., and have obvious advantages in clinical treatment; or (4)&nbsp;the new drugs are for treating diseases
with no effective methods of treatment. The Provisions on the Administration of Special Examination and Approval of Registration of New Drugs provides that the applicant may file for special examination and approval at the clinical trial application
stage if the drug candidate falls within items (1)&nbsp;or (2). The provisions provide that for drug candidates that fall within items (3)&nbsp;or (4), the application for special examination and approval cannot be made until filing for production.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Circular Concerning Several Policies on Drug Registration Review and Approval issued on November&nbsp;11, 2015 further clarifies the
above-mentioned policy, potentially simplifying and accelerating the approval process of clinical trials: (x)&nbsp;a <FONT STYLE="white-space:nowrap">one-time</FONT> umbrella approval procedure allowing the overall approval of all phases of a new
drug&#146;s clinical trials, replacing the current <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">phase-by-phase</FONT></FONT> application and approval procedure, will be adopted for new drugs&#146; clinical trial applications;
and (y)&nbsp;a fast track drug registration or clinical trial approval pathway for the following applications: (i)&nbsp;registration of innovative new drugs treating AIDS, malignant tumors, serious infectious diseases and rare diseases;
(ii)&nbsp;registration of pediatric drugs; (iii)&nbsp;registration of drugs treating specific or prevalent diseases in elders; (iv)&nbsp;registration of drugs listed in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
national major science and technology projects or national key research and development plan; (v)&nbsp;registration of innovative drugs using advanced technology, using innovative treatment
methods, or having distinctive clinical benefits; (vi)&nbsp;registration of foreign innovative drugs to be manufactured locally in China; (vii)&nbsp;concurrent applications for new drug clinical trials which are already approved in the United States
or the European Union or concurrent drug registration applications for drugs which have applied to the competent drug approval authorities for marketing authorization and passed such authorities&#146; onsite inspections in the United States or
European Union and are manufactured using the same production line in China; and (viii)&nbsp;clinical trial approval for drugs with urgent clinical need and patent expiry within three years, and manufacturing authorization applications for drugs
with urgent clinical need and patent expiry within one year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Opinions on Encouraging the Prioritized Evaluation and Approval for Drug
Innovations promulgated on December&nbsp;21, 2017 provides that a fast track clinical trial approval or drug registration pathway will be available to both innovative drugs with distinctive clinical benefits, which have not been sold within or
outside China, and drugs using advanced technology, innovative treatment methods or having distinctive treatment advantages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Opinions
on the Reform of Evaluation and Approval System for Drugs and Medical Devices and Equipment promulgated on August&nbsp;9, 2015 provides that the composition of the examiner team of the CDE shall be strengthened by, among other actions,
(1)&nbsp;recruiting professional evaluation talent from the public, (2)&nbsp;engaging relevant experts to participate in technological examination and evaluation, and (3)&nbsp;establishing a system of chief professional positions. Additionally, the
Opinions on Encouraging the Prioritized Evaluation and Approval for Drug Innovations emphasizes the improvement of the examination and evaluation system, which requires the establishment of a new drug examination and evaluation team comprising
professionals specialized in clinical medicine, pharmaceutical sciences, pharmacology, toxicology and statistics. As a result, since 2015, the NMPA and the CDE have started a large-scale expansion of examiners, which could greatly accelerate the new
drug approval process in China. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Manufacturing and Distribution </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the Drug Administration Law, all facilities that manufacture drugs in China must receive a drug manufacturing license from the
local drug regulatory authority. Each drug manufacturing license issued to a pharmaceutical manufacturing enterprise is effective for a period of five years. Any enterprise holding a drug manufacturing license is subject to review by the relevant
regulatory authorities on an annual basis. A separate certification of compliance with Good Manufacturing Practice (the &#147;GMP&#148;) is also required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, to conduct sales, importation, shipping and storage (collectively, the &#147;distribution activities&#148;), a company must obtain
a Drug Distribution License from the local drug regulatory authority, subject to renewal every five years. A separate certification of compliance with the NMPA&#146;s drug good supply practice (the &#147;GSP&#148;), is also required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">China has implemented a <FONT STYLE="white-space:nowrap">&#147;Two-Invoice</FONT> System&#148; to control the distribution of prescription
drugs. The <FONT STYLE="white-space:nowrap">&#147;Two-Invoice</FONT> System&#148; generally requires that no more than two invoices be issued throughout the distribution chain: one from the manufacturer to a distributor and another from the
distributor to the <FONT STYLE="white-space:nowrap">end-user</FONT> hospital. This excludes the sale of products invoiced from the manufacturer to its wholly-owned or controlled distributors, or for imported drugs, to its exclusive distributor, or
from a distributor to its wholly-owned or controlled subsidiary (or between its wholly-owned or controlled subsidiaries). However, the system still significantly limits the options for companies to use multiple distributors to reach a larger
geographic area in China. Compliance with the <FONT STYLE="white-space:nowrap">Two-Invoice</FONT> System is a prerequisite for pharmaceutical companies to participate in the procurement processes of public hospitals, which currently provide most of
China&#146;s healthcare services. Manufacturers and distributors that fail to implement the <FONT STYLE="white-space:nowrap">Two-Invoice</FONT> System may lose their qualifications to participate in the bidding process. <FONT
STYLE="white-space:nowrap">Non-compliant</FONT> manufacturers may also be blacklisted from engaging in drug sales to public hospitals in a locality. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">Two-Invoice</FONT> System was first implemented in 11
provinces involved in pilot comprehensive medical reforms, and the program has been expanded to nearly all provinces, each with its own individual rules for the program. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>New Drug Application </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Administrative Measures for Drug Registration, when Phases 1, 2 and 3 clinical trials have been completed, the applicant may
apply to the NMPA for approval of a new drug application. The NMPA shall then determine whether to approve the application according to the comprehensive evaluation opinion provided by the CDE of the NMPA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>International Multi-center Clinical Trials Regulations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;30, 2015, the NMPA promulgated the Notice on Issuing the International Multi-Center Clinical Trial Guidelines (Trial),
effective as of March&nbsp;1, 2015, to provide guidance on the regulation of the application, implementation and administration of international multi-center clinical trials in China. Pursuant to the Notice on Issuing the International Multi-Center
Clinical Trial Guidelines (Trial), international multi-center clinical trial applicants may simultaneously perform clinical trials in different centers using the same clinical trial protocol. Where the applicant plans to make use of the data derived
from the international multi-center clinical trials for its application to the NMPA for approval of a new drug application, such international multi-center clinical trials shall satisfy, in addition to the requirements set forth in the Drug
Administration Law and its implementation measures, the Administrative Measures for Drug Registration and other relevant laws and regulations, the following requirements: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The applicant shall first conduct an overall evaluation on the global clinical trial data and further make trend
analysis of the Asian and Chinese clinical trial data. In the analysis of Chinese clinical trial data, the applicant shall consider the representativeness of the research subjects, i.e., the participating patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The applicant shall analyze whether the amount of Chinese research subjects is sufficient to assess and
adjudicate the safety and effectiveness of the drug under clinical trial, and satisfy the statistical and relevant legal requirements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The onshore and offshore international multi-center clinical trial research centers shall be subject to <FONT
STYLE="white-space:nowrap">on-site</FONT> inspections by competent PRC governmental agencies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">International
multi-center clinical trials shall follow international prevailing GCP principles and ethics requirements. Applications shall ensure the truthfulness, reliability and trustworthiness of clinical trials results; the researchers shall have the
qualification and capability to perform relevant clinical trials; and an ethics committee shall continuously review the trials and protect the subjects&#146; interests, benefits and safety. Before the performance of the international multi-center
clinical trial, applicants shall obtain clinical trial approvals or complete filings pursuant to requirements under the local regulations where clinical trials are conducted, and register and disclose the information of all major researchers and
clinical trial organizations on the NMPA drug clinical trial information platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Opinions on Deepening the Reform of
the Evaluation and Approval System and Inspiring Innovation of Drugs and Medical Devices and Equipment, clinical trial data obtained from foreign centers may be used to apply for registration in China as long as such data meet the relevant
requirements for the registration of drugs and medical devices in China. When using international multi-center clinical trial data to support new drug applications in China, applicants shall submit the completed global clinical trial report,
statistical analysis report and database, along with relevant supporting data in accordance with <FONT STYLE="white-space:nowrap">ICH-CTD</FONT> (International Conference on Harmonization-Common Technical Document) content and format requirements;
subgroup research results summary and comparative analysis shall also be conducted concurrently. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Pilot Plan for the Marketing Authorization Holder System </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Opinions on the Reform of Evaluation and Approval System for Drugs and Medical Devices and Equipment promulgated on
August&nbsp;9, 2015, the State Council published the policy for carrying out a pilot plan for the drug marketing authorization holder mechanism. Under the authorization of the Standing Committee of the NPC, the State Council issued the Pilot Plan
for the Drug Marketing Authorization Holder Mechanism on May&nbsp;26, 2016, providing a detailed pilot plan for the drug marketing authorization holder mechanism in ten provinces in China. Under the drug marketing authorization holder mechanism,
domestic drug research and development institutions and individuals in the pilot regions are eligible to be holders of drug registrations without having to become drug manufacturers. The marketing authorization holders may engage contract
manufacturers for manufacturing, provided that the contract manufacturers are licensed and <FONT STYLE="white-space:nowrap">GMP-certified</FONT> and are also located within the pilot regions. Drugs that qualify for the drug marketing authorization
holder mechanism include: (1)&nbsp;new drugs (including biological products for curative uses of Class&nbsp;I, Class&nbsp;VII and biosimilars under the Administration of Drug Registration) approved after the implementation of the drug marketing
authorization holder mechanism; (2)&nbsp;generic drugs approved as Category 3 or 4 drugs under the Reform Plan for Registration Category of Chemical Medicine issued by the NMPA on March&nbsp;4, 2016; (3)&nbsp;previously approved generics that have
passed equivalence assessments against their original drugs; and (4)&nbsp;previously approved drugs whose licenses were held by drug manufacturers originally located within the pilot regions but have moved out of the pilot regions due to corporate
mergers or other reasons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;15, 2017, the NMPA issued the Circular on the Matters Relating to Promotion of the Pilot Program
for the Drug Marketing Authorization Holder System, clarifying that the marketing authorization holder shall be responsible for managing the whole manufacturing and marketing chain and the whole life cycle of drugs and shall assume full legal
liabilities for the <FONT STYLE="white-space:nowrap">non-clinical</FONT> drug study, clinical trials, manufacturing, marketing and distribution and adverse drug reaction monitoring. The marketing authorization holder is permitted to entrust several
drug manufacturers under the drug quality management system established by the marketing authorization holder. The marketing authorization holder shall submit a report of drug manufacturing, marketing, prescription, techniques, pharmacovigilance,
quality control measures and certain other matters to the NMPA within 20 working days after the end of each year. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Administrative
Observation Periods for New Drugs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the Implementing Measures of the Drug Administration Law, the NMPA may, for the
purposes of protecting public health, set an administrative observation period of not more than five years for a new drug produced by a drug manufacturer. During the administrative observation period, no approval shall be given to any other
manufacturer to produce or import the said drug. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Inferiority</FONT> Standard </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In China, a drug may receive regulatory approval without showing superiority in its primary endpoint. Rather, a drug may be approved for use if
it shows <FONT STYLE="white-space:nowrap">non-inferiority</FONT> in its primary endpoint and superiority in one of its secondary endpoints. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Packaging of Pharmaceutical Products </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Administration of Quality of Drug Clinical Practice, the applicant shall be responsible for proper packaging and labeling of
drugs for clinical trials, and in double-blinded clinical trials, the test drug shall be consistent with the control drug or placebo in appearance, odor, packaging, labeling, and certain other features. According to the Measures for the
Administration of Pharmaceutical Packaging promulgated on February&nbsp;12, 1988 and effective from September&nbsp;1, 1988, pharmaceutical packaging must comply with national and professional standards. If there is no national or professional
standard available, an applicant may formulate and implement its own standards after obtaining the approval of the provincial administration or bureau of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
standards. The applicant must reapply if it needs to change its own packaging standards. Drugs that have not been developed and approved for packaging standards must not be sold or marketed in
the PRC (except for drugs for the military). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>National List of Essential Drugs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;18, 2009, the MOH and eight other ministries and commissions in the PRC issued the Provisional Measures on the Administration of
the National List of Essential Drugs which was revised on February&nbsp;13, 2015 aim to promote essential medicines sold to consumers at fair prices in the PRC and ensure that the general public in the PRC has equal access to the drugs contained in
the National List of Essential Drugs. The MOH promulgated the National List of Essential Drugs on March&nbsp;13, 2013 and on September 30, 2018. According to these regulations, basic healthcare institutions funded by the government shall store up
and use drugs listed in the National List of Essential Drugs. The drugs listed in the National List of Essential Drugs shall be purchased by centralized tender process and shall be subject to the price control by the National Development and Reform
Commission (the &#147;NDRC&#148;). Remedial drugs in the National List of Essential Drugs are all listed in the NRDL and the purchase price of such drugs is entitled to reimbursement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Government Price Controls </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Chinese government has abolished the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">15-year-old</FONT></FONT> <FONT
STYLE="white-space:nowrap">government-led</FONT> pricing system for drugs. On May&nbsp;4, 2015, the NDRC and six other ministries and commissions in the PRC issued the Opinion on Promoting Drug Pricing Reform, which lifted the government-prescribed
maximum retail price for most drugs, except for narcotic drugs and Class&nbsp;I psychotropic drugs. The government regulates drug prices mainly by establishing a consolidated procurement mechanism, restructuring medical insurance reimbursement
standards and strengthening the regulation of medical and pricing practices as discussed below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Centralized Procurement and Tenders
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the current regulations, public medical institutions owned by the government or owned by State-owned or controlled
enterprises are required to purchase pharmaceutical products through centralized online procurement processes. There are exceptions for drugs on the National List of Essential Drugs, which have their own procurement rules, and for certain drugs
subject to the central government&#146;s special control, such as toxic, radioactive and narcotic drugs and traditional Chinese medicines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The centralized procurement process takes the form of public tenders operated by provincial or municipal-level government agencies. The
centralized tender process is typically conducted once every year. The bids are assessed by a committee randomly selected from a database of experts. The committee members assess the bids based on a number of factors, including, but not limited to,
bid price, product quality, clinical effectiveness, product safety, level of technology, qualifications and reputation of the manufacturer, after-sale services and innovation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The State Council approved state-run centralized medicine procurement and 11 pilot cities for the program in a circular issued on January 17,
2019. It is an effort to deepen reform of the medical and health sector and optimize the pricing system of drugs. According to the circular, in the 11 pilot cities drugs will be selected from generic brands for centralized medicine procurement. The
selected drugs must pass the consistency evaluation on quality and effectiveness. The policy is aimed at lowering drug costs for patients, reducing transaction costs for enterprises, regulating drug use of institutions, and improving the centralized
medicine procurement and pricing system. The centralized procurement is open to all approved enterprises that can produce drugs on the procurement list in China. Clinical effects, adverse reactions, and batch stability of the drugs will be
considered, and their consistency will be the main criteria for evaluation, while production capacity and stability of the supplier will also be considered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Commercial Insurance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;25, 2016, the State Council issued the Plan for Healthy China 2030. According to the Plan, the country will establish a
multi-level medical security system built around basic medical insurance, with other forms of insurance supplementing the basic medical insurance, including serious illness insurance for urban and rural residents, commercial health insurance and
medical assistance. Furthermore, the Plan encourages enterprises and individuals to participate in commercial health insurance and various forms of supplementary insurance. The evolving medical insurance system makes innovative drugs more affordable
and universally available to the Chinese population, which renders greater opportunities to drug manufacturers that focus on the research and development of innovative drugs, such as high-cost cancer therapeutics. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare System Reform </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PRC
government recently promulgated several healthcare reform policies and regulations to reform the healthcare system. On March&nbsp;17, 2009, the State Council issued the Guidelines on Strengthening the Reform of Healthcare System. On
December&nbsp;27, 2016, the State Council issued the Notice on the Issuance of the 13th Five-year Plan on Strengthening the Reform of Healthcare System. On April&nbsp;25, 2017, the General Office of the State Council issued the Notice on the Main
Tasks of Strengthening the Reform of Healthcare System in 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Highlights of the aforementioned healthcare reform policies and
regulations include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">One of the main objectives of the reform is to establish a basic healthcare system that covers both urban and
rural residents and provides Chinese citizens with safe, effective, convenient and affordable healthcare services. By 2020, a basic healthcare system covering both urban and rural residents shall be established. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Another main objective of the reform is to improve the healthcare system through the development of a graded
hierarchical healthcare system, modern hospital management, basic medical insurance, drug supply support and comprehensive supervision. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The reforms aimed to promote orderly market competition and improve the efficiency and quality of the healthcare
system to meet the various medical need of the Chinese population. From 2009, basic public healthcare services such as preventive healthcare, maternal and child healthcare and health education have been provided to urban and rural residents. In the
meantime, the reforms also encourage innovations by pharmaceutical companies to eliminate pharmaceutical products that fail to demonstrate reliable efficacy and positive risk-benefit ratio. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The key tasks of the reform were as follows: (1)&nbsp;to deepen the reform of public hospitals; (2)&nbsp;to
accelerate the development of a graded diagnosis and treatment system; (3)&nbsp;to consolidate and improve the universal medical insurance system; (4)&nbsp;to guarantee drug supply; (5)&nbsp;to establish and improve a comprehensive supervision
system; (6)&nbsp;to cultivate talented health-care practitioners; (7)&nbsp;to stabilize and perfect the basic public health service equalization system; (8)&nbsp;to advance the construction of health information technology; (9)&nbsp;to accelerate
the development of the health services industry generally and (10)&nbsp;to strengthen organization and implementation. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Chronic Diseases Prevention and Treatment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Guiding Opinion of the General Office of the State Council on Promoting the Construction of the Hierarchical Healthcare System
issued by the General Office of the State Council on September&nbsp;8, 2015 and the Notice on Promoting Pilot Work for Hierarchical Healthcare System jointly promulgated by the NHFPC and the State Administration of Traditional Chinese Medicine on
August&nbsp;19, 2016, the hierarchical healthcare system is expected to be gradually improved, and the framework for division and coordination among medical and health institutions shall be substantially established by 2017, and a diagnosis and
treatment model featuring objectives, such as initial diagnosis of common diseases and frequent diseases at primary hospitals and separate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treatment of acute and chronic diseases, are expected to be gradually established. According to the Guiding Opinion of the General Office of the State Council on Promoting the Construction of the
Hierarchical Healthcare System, several chronic diseases, including hypertension, diabetes, cancer and cardiovascular and cerebrovascular diseases, are pilot diseases under the hierarchical healthcare system. Primary healthcare institutions,
rehabilitation hospitals and nursing institutions may provide treatment, rehabilitation and nursing services for patients with chronic diseases, patients in stable conditions, elderly patients, and advanced cancer patients who have clear diagnosis
and stable disease conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;22, 2017, the General Office of the State Council issued the Notice on the Medium and
Long-Term Plan for Chronic Disease Prevention and Treatment in China (2017-2025), which sets up the objectives of the management of diabetes patients, targeting the involvement of 35&nbsp;million diabetic patients by 2020 and 40&nbsp;million by 2025
in chronic disease management. The Notice on the Medium and Long-Term Plan for Chronic Disease Prevention and Treatment in China (2017-2025) reaffirms that the hierarchical healthcare system of chronic diseases such as diabetes shall be promoted and
encourages the initial diagnosis of common diseases and frequent diseases at primary hospitals. In addition, social participation in regional medical services, health management and chronic disease prevention services, as well as investments in the
field of chronic disease prevention by social capital, are encouraged. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual Property Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">China became a member of the World Trade Organization and a party to the Agreement on Trade-Related Aspects of Intellectual Property Rights on
December&nbsp;11, 2001. China has also entered into several international conventions on intellectual property rights, including, but not limited to, the Paris Convention for the Protection of Industrial Property, the Madrid Agreement Concerning the
International Registration of Marks, and the Patent Cooperation Treaty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Patents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the PRC Patent Law promulgated by the Standing Committee of the NPC on March&nbsp;12, 1984 and amended on September&nbsp;4, 1992,
August&nbsp;25, 2000 and December&nbsp;27, 2008, respectively, and effective from October&nbsp;1, 2009, and the Implementation Rules of the Patent Law of the PRC promulgated by the State Council on June&nbsp;15, 2001 and amended on December&nbsp;28,
2002 and January&nbsp;9, 2010, respectively, patents in China fall into three categories: invention, utility model and design. An invention patent is granted to a new technical solution proposed in respect of a product or method or an improvement of
a product or method. A utility model is granted to a new technical solution that is practicable for application and proposed in respect of the shape, structure or a combination of both of a product. A design patent is granted to the new design of a
certain product in shape, pattern or a combination of both and in color, shape and pattern combinations aesthetically suitable for industrial application. Under the PRC Patent Law, the term of patent protection starts from the date of application.
Patents relating to invention are effective for twenty years, and utility models and designs are effective for ten years from the date of application. The PRC Patent Law adopts the principle of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system, which provides that where more than one person files a patent application for the same invention, a patent will be granted to the person who files the application first. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Existing patents can become narrowed, invalid or unenforceable due to a variety of grounds, including lack of novelty, creativity, and
deficiencies in patent application. In China, a patent must have novelty, creativity and practical applicability. Under the PRC Patent Law, novelty means that before a patent application is filed, no identical invention or utility model has been
publicly disclosed in any publication in China or overseas or has been publicly used or made known to the public by any other means, whether in or outside of China, nor has any other person filed with the patent authority an application that
describes an identical invention or utility model and is recorded in patent application documents or patent documents published after the filing date. Creativity means that, compared with existing technology, an invention has prominent substantial
features and represents notable progress, and a utility model has substantial features and represents any progress. Practical applicability </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
means an invention or utility model can be manufactured or used and may produce positive results. Patents in China are filed with the State Intellectual Property Office (the &#147;SIPO&#148;).
Normally, the SIPO publishes an application for an invention patent within 18 months after the filing date, which may be shortened at the request of applicant. The applicant must apply to the SIPO for a substantive examination within three years
from the date of application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Article 20 of the PRC Patent Law provides that, for an invention or utility model completed in China, any
applicant (not just Chinese companies and individuals), before filing a patent application outside of China, must first submit it to the SIPO for a confidential examination. Failure to comply with this requirement will result in the denial of any
Chinese patent for the relevant invention. This added requirement of confidential examination by the SIPO has raised concerns by foreign companies who conduct research and development activities in China or outsource research and development
activities to service providers in China. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Patent Enforcement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unauthorized use of patents without consent from owners of patents, forgery of the patents belonging to other persons, or engagement in other
patent infringement acts, will subject the infringers to infringement liability. Serious offenses such as forgery of patents may be subject to criminal penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When a dispute arises out of infringement of the patent owner&#146;s patent right, Chinese law requires that the parties first attempt to
settle the dispute through mutual consultation. However, if the dispute cannot be settled through mutual consultation, the patent owner, or an interested party who believes the patent is being infringed, may either file a civil legal suit or file an
administrative complaint with the relevant patent administration authority. A Chinese court may issue a preliminary injunction upon the patent owner&#146;s or an interested party&#146;s request before instituting any legal proceedings or during the
proceedings. Damages for infringement are calculated as the loss suffered by the patent holder arising from the infringement, and if the loss suffered by the patent holder arising from the infringement cannot be determined, the damages for
infringement shall be calculated as the benefit gained by the infringer from the infringement. If it is difficult to ascertain damages in this manner, damages may be determined by using a reasonable multiple of the license fee under a contractual
license. Statutory damages may be awarded in the circumstances where the damages cannot be determined by the above-mentioned calculation standards. The damage calculation methods shall be applied in the aforementioned order. Generally, the patent
owner has the burden of proving that the patent is being infringed. However, if the owner of an invention patent for manufacturing process of a new product alleges infringement of its patent, the alleged infringer has the burden of proof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Medical Patent Compulsory License </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the PRC Patent Law, for the purpose of public health, the SIPO may grant a compulsory license for manufacturing patented drugs and
exporting them to countries or regions covered under relevant international treaties to which the PRC has acceded. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Trade Secrets
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the PRC Anti-Unfair Competition Law promulgated by the Standing Committee of the NPC on September&nbsp;2, 1993 and
amended on November&nbsp;4, 2017 and April&nbsp;23, 2019, respectively, the term &#147;trade secrets&#148; refers to technical and business information that is unknown to the public, has utility, may create business interests or profits for its
legal owners or holders, and is maintained as a secret by its legal owners or holders. Under the PRC Anti-Unfair Competition Law, business persons are prohibited from infringing others&#146; trade secrets by (1)&nbsp;obtaining the trade secrets from
the legal owners or holders by any unfair methods, such as theft, bribery, fraud, coercion, electronic intrusion, or any other illicit means; (2)&nbsp;disclosing, using or permitting others to use the trade secrets obtained illegally under item
(1)&nbsp;above; (3)&nbsp;disclosing, using or permitting others to use the trade secrets, in violation of any contractual agreements or any requirements of the legal owners or holders to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
keep such trade secrets in confidence; or (4) instigating, inducing or assisting others to disclose, use or permit others to use the trade secrets, in violation of any contractual agreements or
any requirement of the legal owners or holders to keep such trade secret in confidence. If a third party knows or should have known of the above-mentioned illegal conduct but nevertheless obtains, uses or discloses trade secrets of others, the third
party may be deemed to have committed a misappropriation of the others&#146; trade secrets. The parties whose trade secrets are being misappropriated may petition for administrative corrections, and regulatory authorities may terminate any illegal
activities and impose fines on the infringing parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Trademarks </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Trademark Law of the PRC promulgated by the Standing Committee of the NPC on August&nbsp;23, 1982 and amended on
February&nbsp;22, 1993, October&nbsp;27, 2001 and August&nbsp;30, 2013, respectively, and effective from May&nbsp;1, 2014, which has been amended on April&nbsp;23, 2019 and will become effective from November&nbsp;1, 2019, the period of validity for
a registered trademark is ten years, commencing from the date of registration. The registrant shall go through the formalities for renewal within twelve months prior to the expiry date of the trademark if continued use is intended. Where the
registrant fails to do so, a grace period of six months may be granted. The validity period for each renewal of registration is ten years, commencing from the day immediately after the expiry of the preceding period of validity for the trademark. In
the absence of a renewal upon expiry, the registered trademark shall be cancelled. Industrial and commercial administrative authorities have the authority to investigate any behavior in infringement of the exclusive right under a registered
trademark in accordance with the law. In case of a suspected criminal offense, the case shall be timely referred to a judicial authority and decided according to the law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Domain Names </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Domain names are protected under the Measures on Administration of Domain Names for the Chinese Internet promulgated by the Ministry of
Industry and Information Technology, on November&nbsp;5, 2004 and effective from December&nbsp;20, 2004, which was replaced by the Administrative Measures on the Internet Domain Names issued by the Ministry of Industry and Information Technology on
August&nbsp;24, 2017 and effective from November&nbsp;1, 2017, and the Implementing Rules on Registration of Domain Names issued by China Internet Network Information Center on May&nbsp;28, 2012, which became effective on May&nbsp;29, 2012. The
Ministry of Industry and Information Technology is the main regulatory body responsible for the administration of PRC internet domain names. Domain name registrations are handled through domain name service agencies established under the relevant
regulations, and the applicants become domain name holders upon successful registration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product Liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Product Quality Law of the PRC promulgated by the Standing Committee of the NPC on February&nbsp;22, 1993 and amended on July&nbsp;8, 2000,
August&nbsp;27, 2009 and December&nbsp;29, 2018, respectively, is the principal governing law relating to the supervision and administration of product quality. According to the Product Quality Law, manufacturers shall be liable for the quality of
products produced by them, and sellers shall take measures to ensure the quality of the products sold by them. A manufacturer shall be liable for compensating for any bodily injuries or property damages, other than the defective product itself,
resulting from the defects in the product, unless the manufacturer is able to prove that: (1)&nbsp;the product has never been distributed; (2)&nbsp;the defects causing injuries or damages did not exist at the time when the product was distributed;
or (3)&nbsp;the science and technology at the time when the product was distributed was at a level incapable of detecting the defects. A seller shall be liable for compensating for any bodily injuries or property damages of others caused by the
defects in the product if such defects are attributable to the seller. A seller shall pay compensation if it fails to indicate either the manufacturer or the supplier of the defective product. A person who is injured or whose property is damaged by
the defects in the product may claim for compensation from the manufacturer or the seller. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the General Principles of the Civil Law of the PRC promulgated by the NPC on
April&nbsp;12, 1986 and amended on August&nbsp;27, 2009, both manufacturers and sellers shall be held liable where the defective products result in property damages or bodily injuries to others. Pursuant to the Tort Liability Law of the PRC
promulgated by the Standing Committee of the NPC on December&nbsp;26, 2009 and effective from July&nbsp;1, 2010, manufacturers shall assume tort liabilities where the defects in products cause damages to others. Sellers shall assume tort liabilities
where the defects in products that have caused damages to others are attributable to the sellers. The aggrieved party may claim for compensation from the manufacturer or the seller of the defected product that has caused damage. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulation of Commercial Bribery </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pharmaceutical companies involved in a criminal investigation or administrative proceedings related to bribery are listed in the Adverse
Records of Commercial Briberies by their respective provincial health and family planning administrative department. Pursuant to the Provisions on the Establishment of Adverse Records of Commercial Briberies in the Medicine Purchase and Sales
Industry which became effective on March&nbsp;1, 2014, provincial health and family planning administrative departments formulate the implementing measures for establishment of Adverse Records of Commercial Briberies. Where a pharmaceutical company
or its agent is listed in the Adverse Records of Commercial Briberies on one occasion, it will be prohibited from participating in the procurement bidding process or selling its products to public medical institutions located in the local
provincial-level region for two years from the publication of the adverse records. The evaluation points of such pharmaceutical company or agent in respect of the procurement bidding process and procurement by public medical institutions must be
credited by public medical institutions in the other provincial-level regions for two years from the publication of the adverse records. Where a pharmaceutical company or its agent is listed in the Adverse Records of Commercial Briberies on two or
more occasions within five years, it will be prohibited from participating in the procurement bidding process or selling its products to all public medical institutions in the PRC for two years from the publication of these adverse records. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulations Relating to Employee Stock Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February&nbsp;2012, the SAFE promulgated the Notices on Issues Concerning the Foreign Exchange Administration for Domestic Individuals
Participating in Stock Incentive Plans of Overseas Publicly Listed Companies (the &#147;Stock Option Rules&#148;), which replaced the Application Procedures of Foreign Exchange Administration for Domestic Individuals Participating in Employee Stock
Ownership Plans or Stock Option Plans of Overseas Publicly Listed Companies issued by the SAFE on March&nbsp;28, 2007. In accordance with the Stock Option Rules and relevant rules and regulations, PRC citizens or
<FONT STYLE="white-space:nowrap">non-PRC</FONT> citizens residing in China for a continuous period of not less than one year, who participate in any stock incentive plan of an overseas publicly listed company, subject to a few exceptions, are
required to register with the SAFE through a domestic qualified agent, which could be a PRC subsidiary of such overseas listed company, and complete certain procedures. We and our employees who are PRC citizens or who reside in China for a
continuous period of not less than one year and who participate in our stock incentive plan will be subject to such regulation. In addition, the SAT has issued circulars concerning employee share options or restricted shares. Under these circulars,
employees working in the PRC who exercise share options, or whose restricted shares vest, will be subject to PRC individual income tax (the &#147;IIT&#148;). The PRC subsidiaries of an overseas listed company have obligations to file documents
related to employee share options or restricted shares with relevant tax authorities and to withhold IIT of those employees related to their share options or restricted shares. If the employees fail to pay, or the PRC subsidiaries fail to withhold,
their IIT according to relevant laws, rules and regulations, the PRC subsidiaries may face sanctions imposed by the tax authorities or other PRC government authorities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulations Relating to Foreign Exchange and the Dividend Distribution </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Exchange Control </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The State Council promulgated the PRC Regulation for the Foreign Exchange on January&nbsp;29, 1996, which was amended on January&nbsp;14, 1997
and August&nbsp;5, 2008, respectively. On June&nbsp;20, 1996, the People&#146;s Bank of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">215 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
China promulgated the Regulation on the Administration of the Foreign Exchange Settlement, Sales and Payment, which came into effect on July&nbsp;1, 1996. Pursuant to the above-mentioned
regulations, foreign exchanges required for distribution of profits and payment of dividends may be purchased from designated foreign exchange banks in the PRC upon presentation of a board resolution authorizing the distribution of profits or
payment of dividends. The Regulation on the Administration of the Foreign Exchange Settlement, Sales and Payment removed the previous restrictions on convertibility of foreign exchange in respect of current account items, including the distribution
of dividends, interest and royalty payments, trade and service-related foreign exchange transactions, while foreign exchange transactions in respect of capital account items, such as direct investment, loan, securities investment and repatriation of
investment, remain subject to the approval of the SAFE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;19, 2012, the SAFE issued the Operating Rules for Foreign
Exchange Issues with Regard to Direct Investment under Capital Account as an appendix to the Circular of the SAFE on Further Improving and Adjusting the Foreign Exchange Policies on Direct Investment, which was issued on November&nbsp;19, 2012 and
amended on May&nbsp;4, 2015. According to the Circular of the SAFE on Further Improving and Adjusting the Foreign Exchange Policies on Direct Investment, (i)&nbsp;the opening of and payment into foreign exchange accounts under direct investment
accounts are no longer subject to approval by the SAFE; (ii)&nbsp;reinvestment with the legal income of foreign investors in China is no longer subject to approval by the SAFE; (iii)&nbsp;the procedures for capital verification and confirmation that
foreign-funded enterprises need to go through are simplified; (iv)&nbsp;the purchase and external payment of foreign exchange under direct investment accounts are no longer subject to approval by the SAFE; (v)&nbsp;domestic transfer of foreign
exchange under direct investment accounts is no longer subject to approval by the SAFE; and (vi)&nbsp;the administration over the conversion of foreign exchange capital of foreign-funded enterprises is improved. On February&nbsp;13, 2015, the SAFE
issued the Circular on Further Simplifying and Improving Foreign Exchange Administration Policies in Respect of Direct Investment, which came into effect on June&nbsp;1, 2015, providing that the banks, instead of the SAFE, can directly handle the
foreign exchange registration and approval under foreign direct investment, while the SAFE and its branches indirectly supervise the foreign exchange registration and approval under foreign direct investment through the banks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;11, 2013, the SAFE promulgated the Provisions on the Administration of Foreign Exchange in Foreign Direct Investments by Foreign
Investors, which became effective on May&nbsp;13, 2013, and relevant supporting documents that regulate and clarify the administration over foreign exchange administration in foreign direct investments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;30, 2015, the SAFE released the Circular on the Reform of the Management Method for the Settlement of Foreign Exchange Capital
of Foreign-invested Enterprises, which came into effect on June&nbsp;1, 2015 and superseded the Notice on the Relevant Operating Issues Concerning the Improvement of the Administration of Payment and Settlement of Foreign Currency Capital of
Foreign-funded Enterprises issued by the SAFE on August&nbsp;29, 2008. The Circular on the Reform of the Management Method for the Settlement of Foreign Exchange Capital of Foreign-invested Enterprises has made certain adjustments to some regulatory
requirements on the settlement of foreign exchange capital of foreign-invested enterprises, and some foreign exchange restrictions provided in the Notice on the Relevant Operating Issues Concerning the Improvement of the Administration of Payment
and Settlement of Foreign Currency Capital of Foreign-funded Enterprises. On June&nbsp;9, 2016, the SAFE issued the Circular on the Reform and Standardization of the Management Policy of the Settlement of Capital Projects. Under the Circular on the
Reform and Standardization of the Management Policy of the Settlement of Capital Projects and the Circular on the Reform of the Management Method for the Settlement of Foreign Exchange Capital of Foreign-invested Enterprises, the settlement of
foreign exchange by foreign-invested enterprises shall be governed by the policy of foreign exchange settlement on a discretionary basis. However, the aforementioned circulars also reiterate that the settlement of foreign exchange shall only be used
for its own operation purposes within the business scope of the foreign-invested enterprises and following the principles of authenticity. Considering that these circulars are relatively new, it is unclear how they will be implemented, and there
exist great uncertainties with respect to their interpretation and implementation by the authorities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">216 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SAFE promulgated the Circular on Relevant Issues Concerning Foreign Exchange Control on
Domestic Residents&#146; Offshore Investment and Financing and Roundtrip Investment through Special Purpose Vehicles on July 4, 2014, which requires PRC residents to register with local branches of the SAFE in connection with their direct
establishment or indirect control of an offshore entity for the purpose of overseas investment and financing, with such PRC residents&#146; legally owned assets or equity interests in domestic enterprises or offshore assets or interests as a
&#147;special purpose vehicle&#148; as defined therein. The aforesaid circular further requires amendment to the registration in the event of any significant changes with respect to the special purpose vehicle. Failure to comply with the SAFE
registration requirements under the Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents&#146; Offshore Investment and Financing and Roundtrip Investment through Special Purpose Vehicles could result in liabilities
under PRC law for evasion of foreign exchange controls. The Circular on Further Simplifying and Improving Foreign Exchange Administration Policies in Respect of Direct Investment, provides that local banks, instead of the SAFE, can directly handle
the initial foreign exchange registration and amendment registration under the Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents&#146; Offshore Investment and Financing and Roundtrip Investment through Special
Purpose Vehicles. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Dividend Distribution </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the PRC Company Law, the Wholly Foreign-Owned Enterprise Law of the PRC and the Detailed Implementing Rules for the Wholly
Foreign-Owned Enterprise Law of the People&#146;s Republic China, foreign-invested enterprises in the PRC may pay dividends only out of their accumulated profits as determined in accordance with PRC accounting standards and regulations. In addition,
a foreign-invested enterprise is required to set aside at least 10% of its accumulated profits each year to fund certain reserve funds, until the accumulative amount of such fund reaches 50% of its registered capital. These wholly foreign-owned
companies may also allocate a portion of their <FONT STYLE="white-space:nowrap">after-tax</FONT> profits based on PRC accounting standards to employee welfare and bonus funds. Amounts allocated to these reserve funds and employee welfare and bonus
funds reduce the amount distributable as cash dividends. Upon approval of the competent governmental authorities, foreign investors may utilize RMB dividends to invest or <FONT STYLE="white-space:nowrap">re-invest</FONT> in enterprises established
in China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;26, 2017, the SAFE issued the Notice on Improving the Check of Authenticity and Compliance to Further Promote
Foreign Exchange Control, which stipulates several capital control measures with respect to outbound remittance of profits from domestic entities to offshore entities, including the following: (i)&nbsp;under the principle of genuine transaction,
banks shall check board resolutions regarding profit distribution, the original version of tax filing records and audited financial statements; and (ii)&nbsp;domestic entities shall hold income to account for previous years&#146; losses before
remitting the profits. Moreover, domestic entities shall provide detailed explanations of the sources of capital and the utilization arrangements and board resolutions, contracts and other proof when completing the registration procedures in
connection with an outbound investment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulations Relating to Labor </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Labor Law and Labor Contract Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the PRC Labor Law promulgated by the Standing Committee of the NPC on July&nbsp;5, 1994 and effective from January&nbsp;1, 1995 and
amended on August&nbsp;27, 2009 and December&nbsp;29, 2018, respectively, the PRC Labor Contract Law promulgated by the Standing Committee of the NPC on June&nbsp;29, 2007 and effective from January&nbsp;1, 2008 and amended on December&nbsp;28, 2012
and effective from July&nbsp;1, 2013, and the Implementing Regulations of the Employment Contracts Law of the PRC promulgated by the State Council on September&nbsp;18, 2008, labor contracts in written form shall be executed to establish labor
relationships between employers and employees. Wages cannot be lower than the local minimum wage. The employer must establish a system for labor safety and sanitation, strictly abide by the state rules and standards, provide education regarding
labor safety and sanitation to its employees, provide employees with labor safety and sanitary conditions and necessary protection materials in compliance with the state rules and standards, and carry out regular health examinations for employees
engaged in work involving occupational hazards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">217 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Social Insurance and Housing Provident Funds </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under applicable PRC laws, including the Social Insurance Law of the PRC which became effective on July&nbsp;1, 2011 and was amended on
December&nbsp;19, 2018, the Interim Regulations on the Collection and Payment of Social Security Funds promulgated by the State Council on January&nbsp;22, 1999 and amended on March&nbsp;24, 2019, and the Regulations on the Administration of Housing
Provident Funds promulgated by the State Council on April&nbsp;3, 1999 and amended on March&nbsp;24, 2002 and March&nbsp;24, 2019, respectively, employers are required to contribute, on behalf of their employees, to a number of social security
funds, including funds for basic pension insurance, unemployment insurance, basic medical insurance, occupational injury insurance, maternity insurance and housing provident funds. These payments are made to local administrative authorities, and any
employer who fails to contribute may be fined and ordered to pay the deficit amount within a stipulated time limit. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulations Relating to
Enterprise Income Tax </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Enterprise Income Tax Law of the PRC effective as of January&nbsp;1, 2008 and as amended on
February&nbsp;24, 2017 and December&nbsp;29, 2018, respectively, the income tax rate for both domestic and foreign-invested enterprises is 25% with certain exceptions. To clarify certain provisions in the Enterprise Income Tax Law, the State Council
promulgated the Implementation Rules of the Enterprise Income Tax Law on December&nbsp;6, 2007, which became effective on January&nbsp;1, 2008. Under the Enterprise Income Tax Law and the Implementation Rules of the Enterprise Income Tax Law,
enterprises are classified as either &#147;resident enterprises&#148; or <FONT STYLE="white-space:nowrap">&#147;non-resident</FONT> enterprises.&#148; Besides enterprises established within the PRC, enterprises established outside of China whose
&#147;de facto management bodies&#148; are located in China are considered &#147;resident enterprises&#148; and subject to the uniform 25% enterprise income tax rate for their global income. In addition, the Enterprise Income Tax Law provides that a
<FONT STYLE="white-space:nowrap">non-resident</FONT> enterprise refers to an entity established under foreign law whose &#147;de facto management bodies&#148; are not within the PRC, but has an establishment or place of business in the PRC, or does
not have an establishment or place of business in the PRC but has income sourced within the PRC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Implementation Rules of the
Enterprise Income Tax Law provide that since January&nbsp;1, 2008, an income tax rate of 10% shall normally be applicable to dividends declared to <FONT STYLE="white-space:nowrap">non-PRC</FONT> resident enterprise investors that do not have an
establishment or place of business in the PRC, or have such establishment or place of business but the relevant income is not effectively connected with the establishment or place of business, to the extent such dividends are derived from sources
within the PRC. The income tax on the dividends may be reduced pursuant to a tax treaty between China and the jurisdictions in which the <FONT STYLE="white-space:nowrap">non-PRC</FONT> shareholders reside. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other PRC National- and Provincial-Level Laws and Regulations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to changing regulations under many other laws and regulations administered by governmental authorities at the national,
provincial and municipal levels, some of which are or may become applicable to our business. For example, regulations control the confidentiality of patients&#146; medical information and the circumstances under which patient medical information may
be released for inclusion in our databases, or released by us to third parties. These laws and regulations governing both the disclosure and the use of confidential patient medical information may become more restrictive in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also comply with numerous additional national and provincial laws relating to matters such as safe working conditions, manufacturing
practices, environmental protection and fire hazard control. We believe that we are currently in compliance with these laws and regulations; however, we may be required to incur significant costs to comply with these laws and regulations in the
future. Unanticipated changes in existing regulatory requirements or adoption of new requirements could therefore have a material adverse effect on our business, results of operations and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">218 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Government Regulation and Product Approval in the United States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and other regulatory authorities in the United States at federal, state and local levels, as well as in foreign countries, extensively
regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, recordkeeping, approval, advertising, promotion, marketing,
post-approval monitoring and post-approval reporting of biological products. Along with third-party contractors, we will be required to navigate the various <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> clinical and commercial approval
requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our drug candidates. The processes for obtaining regulatory approvals in the United States and in foreign
jurisdictions, along with subsequent compliance with applicable laws and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government policies may change and additional government regulations may be enacted that could prevent or delay further development or
regulatory approval of any of our drug candidates, or anticipated manufacturing processes, disease indications, or labeling. We cannot predict the likelihood, nature or extent of government regulation that might arise from future legislative or
administrative action. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Review and Approval for Licensing Biologics in the United States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates our current drug candidates as biological products, or biologics, under the Federal Food, Drug, and
Cosmetic Act (the &#147;FDCA&#148;), the Public Health Service Act and associated implementing regulations. Biologics, like other drugs, are used for the treatment, prevention or cure of disease in humans. In contrast to chemically synthesized small
molecular weight drugs, which have a well-defined structure and can be thoroughly characterized, biologics are generally derived from living material (human, animal, or microorganism) and are complex in structure, and thus are usually not fully
characterized. Biologics include immunomedicines for cancer and other diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biologics are also subject to other federal, state and
local statutes and regulations. The failure to comply with applicable statutory and regulatory requirements at any time during the product development process, approval process or after approval may subject a sponsor or applicant to administrative
or judicial enforcement actions. These actions could include the suspension or termination of clinical trials by the FDA, the FDA&#146;s refusal to approve pending applications or supplemental applications, withdrawal of an approval, &#147;Warning
Letters&#148; (official messages from the FDA to a manufacturer or other organization that it has violated some rule in a federally regulated activity) or &#147;Untitled Letters&#148; (initial correspondences from the FDA with a regulated industry
that cite violations that do not meet the threshold of regulatory significance for a Warning Letter and request correction of the violation), product recalls, product seizures, total or partial suspension of production or distribution, import
detention, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA, the Department of Justice (the &#147;DOJ&#148;), or other governmental
entities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An applicant seeking approval to market and distribute a biologic in the United States typically must undertake the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of <FONT STYLE="white-space:nowrap">non-clinical</FONT> laboratory tests and animal studies performed
in accordance with the FDA&#146;s good laboratory practice (the &#147;GLP&#148;), regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an application for an Investigational New Drug (&#147;IND&#148;), which must become
effective before clinical trials may begin and must be updated annually or when significant changes are made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacture, labeling and distribution of an investigational drug in compliance with current good manufacturing
practice (the &#147;cGMP&#148;); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">219 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an independent institutional review board (the &#147;IRB&#148;), or ethics committee at each clinical
site before each clinical trial may be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials in accordance with the FDA&#146;s current Good
Clinical Practices requirements (the &#147;cGCP&#148;), to establish the safety, purity and potency of the proposed biological drug candidate for its intended purpose; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparation of and submission to the FDA of a biologics license application (&#147;BLA&#148;), after completion
of all pivotal clinical trials requesting marketing approval for one or more proposed indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA Advisory Committee review, where appropriate or if applicable, as may be
requested by the FDA to assist with its review; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the
proposed product, or components thereof, are produced to assess compliance with cGMP and data integrity requirements to assure that the facilities, methods and controls are adequate to preserve the biologic&#146;s identity, safety, quality, purity
and potency; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of FDA audits of selected clinical investigation sites to assure compliance with cGCP
requirements and the integrity of the clinical data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payment of user fees under the Prescription Drug User Fee Act (the &#147;PDUFA&#148;), for the relevant year;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining FDA review and approval of the BLA to permit commercial marketing of the licensed biologic for
particular indications for use in the United States; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with any post-approval requirements, including the potential requirement to implement a Risk
Evaluation and Mitigation Strategy (the &#147;REMS&#148;), and the potential requirement to conduct post-approval studies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The testing and approval process requires substantial time, effort and financial resources and we cannot be certain that any approvals for our
drug candidates will be granted on a timely basis, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, legislation is drafted, introduced and passed in the
Congress of the United States that could significantly change the statutory provisions governing the testing, approval, manufacturing and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations and policies are
often revised or interpreted by the agency in ways that may significantly affect our business and our drug candidates. It is impossible to predict whether further legislative changes will be enacted or whether FDA regulations, guidance, policies or
interpretations will be changed or what the effect of such changes, if any, may be. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Pre-clinical</FONT> and
Clinical Development in the United States </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before a BLA applicant can begin testing the potential asset in human subjects, the
applicant must first conduct <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies. <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> studies include laboratory evaluations of product chemistry, toxicity and formulation, as well as in
vitro and animal studies to assess the potential safety and activity of the biologic for initial testing in humans and to establish a rationale for therapeutic use. <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> studies are subject to federal
regulations and requirements, including GLP regulations. The results of an applicant&#146;s <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies are submitted to the FDA as part of an IND. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. An IND is an exemption from
the FDCA that allows an unapproved drug to be shipped in interstate commerce for use in an investigational clinical trial. Such authorization must be secured prior to interstate shipment. In support of a request for an IND, applicants must submit a
range of information, including <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data, manufacturing information and a detailed protocol for each clinical trial. Any subsequent protocol amendments must be submitted to the FDA as part of the IND.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Human clinical trials may not begin until an IND is effective. The IND automatically becomes
effective 30&nbsp;days after receipt by the FDA, unless the FDA raises safety concerns or questions about the proposed clinical trial within the <FONT STYLE="white-space:nowrap">30-day</FONT> time period. In such a case, the IND may be placed on
clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may also place a clinical hold or partial clinical hold on such trial following commencement of a clinical trial under an IND. A
clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND.
For example, a specific protocol or part of a protocol is not allowed to proceed, while other protocols may do so. No more than 30 days after the imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor with a written
explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination
on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators
in accordance with cGCP regulations, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things,
the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product
development and for any subsequent protocol amendments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A sponsor may choose, but is not required, to conduct a foreign clinical study
under an IND. When a foreign clinical study is conducted under an IND, all FDA IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with cGCP
regulations in order to use the study as support for an IND or application for marketing approval, including review and approval by an independent ethics committee and informed consent from subjects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial
and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding
that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some
trials also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board (the &#147;DSMB&#148;). DSMBs provide authorization for whether or not a trial may move
forward at designated check points based on access to certain data from the trial and may halt the clinical trial if a DSMB determines that there is an unacceptable safety risk for subjects or based on other grounds, such as no demonstration of
efficacy. Other grounds for suspension or termination may be made based on evolving business objectives and/or competitive climate. There are also requirements governing the reporting of ongoing clinical trials and clinical trial results to public
registries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Trials </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of BLA approval, clinical trials are typically conducted in the following sequential phases that may overlap or be combined: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 1: The investigational product is initially introduced into a small number of healthy human subjects or
patients with the target disease or condition. These trials are designed to test the safety, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">221 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
dosage tolerance, absorption, metabolism and distribution of the investigational product in humans and the side effects associated with increasing doses. These trials may also yield early
evidence of effectiveness. In the case of some products for severe or life-threatening diseases, especially when the product is suspected or known to be unavoidably toxic, the initial human testing may be conducted in patients.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 2: The investigational product is administered to a limited patient population with a specified disease or
condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and
more expensive Phase 3 clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 3: The investigational product is administered to an expanded patient population generally at multiple
geographically dispersed clinical trial sites to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety. These clinical trials are intended to generate sufficient data to
statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval by the FDA. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more
information about the product, referred to as Phase 4 trials. Such post-approval trials, when applicable, are conducted following initial approval, typically to develop additional data and information relating to the biological characteristics of
the product and treatment of patients in the intended therapeutic indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Progress reports detailing the results of the clinical
trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. In addition, IND safety reports must be submitted to the FDA for any of the following: suspected serious and unexpected adverse reactions;
findings from epidemiological studies, pooled analysis of multiple studies, animal or in vitro testing, or other clinical studies, whether or not conducted under an IND, and whether or not conducted by the sponsor, that suggest a significant risk in
humans exposed to the drug; and any clinically important increase in the rate of a serious suspected adverse reaction over such rate listed in the protocol or investigator brochure, which is a comprehensive document summarizing the body of
information about an investigational product obtained during clinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore,
the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of
a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the drug has been associated with unexpected serious harm to patients. The FDA
will typically inspect one or more clinical sites to assure compliance with cGCP and the integrity of the clinical data submitted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During
clinical development, the sponsor often refines the indication and endpoints on which the BLA will be based. For endpoints based on patient-reported outcomes (the &#147;PROs&#148;), and observer-reported outcomes (the &#147;OROs&#148;), the process
typically is an iterative one. The FDA has issued guidance on the framework it uses to evaluate PRO instruments. Although the agency may offer advice on optimizing PRO and ORO instruments during the clinical development process, the FDA usually
reserves final judgment until it reviews the BLA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies often complete additional animal studies,
and develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be
capable of consistently producing quality batches of the drug candidate and, among other things, must develop methods for testing the identity, strength, quality, purity and potency of the final drug. Additionally, appropriate packaging must be
selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">222 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>BLA Submission and Review </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming successful completion of all required clinical testing in accordance with all applicable regulatory requirements, an applicant may
submit a BLA requesting licensing to market the biologic for one or more indications in the United States. The BLA must include the results of product development, <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and clinical trials;
detailed information on the product&#146;s chemistry, manufacture and controls; and proposed labeling. Under the Prescription Drug User Fee Amendments, a BLA submission is subject to an application user fee, unless a waiver or exemption applies.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA will initially review the BLA for completeness before accepting it for filing. Under the FDA&#146;s procedures, the agency has 60
days from its receipt of a BLA to determine whether the application will be accepted for filing and substantive review. If the agency determines that the application does not meet this initial threshold standard, the FDA may refuse to file the
application and request additional information, in which case the application must be resubmitted with the requested information and review of the application delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With certain exceptions, BLAs must include a pediatric assessment, generally based on clinical trial data, of the safety and effectiveness of
the biologic in relevant pediatric populations. Under certain circumstances, the FDA may waive or defer the requirement for a pediatric assessment, either at the sponsor&#146;s request or by the agency&#146;s initiative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the BLA is accepted for filing, the FDA reviews the BLA to determine, among other things, whether a product is safe, pure and potent and
if the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#146;s continued identity, strength, quality, safety, purity and potency. The FDA may convene an advisory committee to provide
clinical insight on application review questions. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the
manufacturing processes and facilities comply with cGMP and are adequate to assure consistent production of the product within required specifications. In addition, the FDA expects that all data be reliable and accurate, and requires sponsors to
implement meaningful and effective strategies to manage data integrity risks. Data integrity is an important component of the sponsor&#146;s responsibility to ensure the safety, efficacy and quality of its product or products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA will typically inspect one or more clinical sites to assure compliance with cGCP regulations before approving a BLA. If the FDA
determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any
requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FDA performance goals generally provide for action on a BLA within ten months of filing, which (as discussed above) typically occurs within 60
days of submission, but that deadline is extended in certain circumstances. Furthermore, the review process is often significantly extended by FDA requests for additional information or clarification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee.
Typically, an advisory committee consists of a panel that includes clinicians and other experts who will review, evaluate and provide a recommendation as to whether the application should be approved and, if so, under what conditions. The FDA is not
bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions and usually has followed such recommendations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its components
will be produced, the FDA may issue an approval letter or a Complete Response Letter (the &#147;CRL&#148;). An approval letter authorizes commercial marketing of the biologic with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">223 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
specific prescribing information for specific indications. A CRL will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data
supporting the application are inadequate to support approval, the FDA may issue the CRL without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. If and when the deficiencies have been
addressed to the FDA&#146;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. In issuing the CRL, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including
requests for additional data, information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, and may require additional testing or information and/or require post-marketing studies
and clinical trials. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the approval process, the FDA will determine whether a REMS is necessary to assure the safe use of the biologic. A REMS is a safety
strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans or
elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. If the FDA concludes that a REMS is needed, the BLA sponsor must submit a proposed REMS and the FDA will not approve the BLA
without a REMS that the agency has determined is acceptable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the Pediatric Research Equity Act of 2003 (the
&#147;PREA&#148;), as amended and reauthorized, certain applications or supplements must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to
support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until
after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA approves a
product, it may limit the approved indications for use for the product, or require that contraindications, warnings or precautions be included in the product labeling. The FDA may also require that post-approval studies, including Phase 4 clinical
trials, be conducted to further assess the drug&#146;s safety after approval. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may also require testing and surveillance programs to monitor the product after commercialization. For biologics, such testing may
include official lot release, which requires the manufacturer to perform certain tests on each lot of the product before it is released for distribution. The manufacturer then typically must submit samples of each lot of product to the FDA, together
with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#146;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products itself,
before releasing the lots for distribution by the manufacturer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After approval, many types of changes to the approved product, such as
adding new indications, manufacturing changes and additional labeling claims, are often subject to further testing requirements and FDA review and approval, depending on the nature of the post-approval change. The FDA may withdraw the product
approval if compliance with <FONT STYLE="white-space:nowrap">pre-</FONT> and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, reporting of certain deviations
and adverse experiences, product sampling and distribution and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">224 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to FDA review and approval.
There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their third-party contractors are required to register their
establishments with the FDA and certain state agencies. These establishments are subject to routine and periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and data integrity requirements, which impose
certain procedural and documentation requirements to assure quality of manufacturing and product. The FDA has increasingly observed cGMP violations involving data integrity during site inspections and investigating compliance with data integrity
requirements is a significant focus of its oversight. Requirements with respect to data integrity include, among other things, controls to ensure data are complete and secure; activities documented at the time of performance; audit trail
functionality; authorized access and limitations; validated computer systems; and review of records for accuracy, completeness and compliance with established standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Post-approval changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require FDA
approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly,
manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP, data integrity, pharmacovigilance (i.e., post-marketing safety reporting obligations) and other aspects of
regulatory compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may withdraw a product approval if compliance with regulatory requirements and standards is not maintained
or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with
regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-approval studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a
REMS. Other potential consequences include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market
or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, Warning Letters, Untitled Letters or holds on post-approval clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or
revocation of existing product approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal of the FDA to permit the import or export of products that it believes
present safety problems by issuing an Import Alert; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">permanent injunctions and consent decrees, including the imposition of civil or criminal penalties; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voluntary product recall. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates the marketing, labeling, advertising and promotion of prescription drug products placed on the market. A company
can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA&#146;s regulation includes, among other things, standards and
regulations for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities and promotional
activities involving the Internet and social media. Promotional claims relating to a product&#146;s safety or effectiveness are prohibited before the drug is approved. After approval, a product generally may not be promoted for uses that are not
approved by the FDA, as reflected in the product&#146;s prescribing information. In the United States, healthcare professionals are generally permitted to prescribe drugs for such uses not described in the drug&#146;s labeling, known as <FONT
STYLE="white-space:nowrap">off-label</FONT> uses, because the FDA does not regulate the practice of medicine. However, FDA regulations impose rigorous restrictions on manufacturers&#146; communications, prohibiting the promotion of <FONT
STYLE="white-space:nowrap">off-label</FONT> uses. It may be permissible, under very specific, narrow conditions, for a manufacturer to engage in <FONT STYLE="white-space:nowrap">non-promotional,</FONT>
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">225 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">non-misleading</FONT> communication regarding <FONT STYLE="white-space:nowrap">off-label</FONT> information, such as distributing scientific or medical journal
information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a company is found to have promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses, it may become subject to
adverse public relations and administrative and judicial enforcement by the FDA, the DOJ or the Office of the Inspector General of the Department of Health and Human Services, as well as other federal and state authorities. This could subject a
company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes products. The federal government has
levied large civil and criminal fines against companies for alleged improper promotion, and has also requested that companies enter into consent decrees and permanent injunctions under which specified promotional conduct is changed or curtailed.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of prescription drugs and biologics are subject to the Drug Supply Chain Security Act (the &#147;DSCSA&#148;), which
requires manufacturers and other stakeholders to comply with product identification, tracing, verification, detection and response, notification and licensing requirements. In addition, the Prescription Drug Marketing Act (the &#147;PDMA&#148;), and
its implementing regulations, and state laws limit the distribution of prescription pharmaceutical product samples, and the DSCSA imposes requirements to ensure accountability in distribution and to identify and remove prescription drug and
biological products that may be counterfeit, stolen, contaminated, or otherwise harmful from the market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Term Restoration and Marketing
Exclusivity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After approval, owners of relevant drug or biological product patents may apply for up to a five-year patent extension
to restore a portion of patent term lost during product development and FDA review of a BLA if approval of the application is the first permitted commercial marketing or use of a biologic containing the active ingredient under the Drug Price
Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act. The allowable patent term extension is calculated as <FONT STYLE="white-space:nowrap">one-half</FONT> of the product&#146;s testing phase, which is the time
between IND and BLA submission, and all of the review phase, which is the time between BLA submission and approval, up to a maximum of five years. The time can be shortened if the FDA determines that the applicant did not pursue approval with due
diligence. The total patent term after the extension may not exceed more than 14 years from the date of FDA approval of the product. Only one patent claiming each approved product is eligible for restoration and the patent holder must apply for
restoration within 60 days of approval. The United States Patent and Trademark Office (the &#147;USPTO&#148;), in consultation with the FDA, reviews and approves the application for patent term restoration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent
extension increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is reduced by one year. The director of the USPTO must determine that approval of the
drug candidate covered by the patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a drug candidate for which a BLA has not been submitted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expedited Development and Review Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA is required to facilitate the development and expedite the review of pharmaceutical products that are intended for the treatment of a
serious or life-threatening condition for which there is no effective treatment and which demonstrate the potential to address unmet medical need for the condition. Under the fast track program, the sponsor of a new drug candidate may request the
FDA to designate the product for a specific indication as a fast track product concurrent with or after the filing of the IND for the drug candidate. The FDA must determine if the drug candidate qualifies for fast track designation within 60 days
after receipt of the sponsor&#146;s request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">226 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to other benefits, such as the ability to have more frequent interactions with
the FDA, the agency may initiate review of sections of a fast track product&#146;s BLA before the application is complete. This rolling review is available if the applicant provides and the FDA approves a schedule for the submission of the remaining
information and the applicant pays applicable user fees. However, the FDA&#146;s PDUFA review period for a fast track application does not begin until the last section of the BLA is submitted. In addition, the fast track designation may be withdrawn
by the FDA if the agency believes that the designation is no longer supported by data emerging in the clinical trial process. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare Regulation
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Pharmaceutical Coverage and Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the
United States, sales of any products for which we may receive regulatory approval for commercial sale will depend in part on the availability of coverage and reimbursement from third-party payors. Third-party payors include government authorities,
managed care providers, private health insurers and other organizations. Third-party payors establish the coverage and reimbursement policies for pharmaceutical products, and the marketability of any products for which we may receive regulatory
approval for commercial sale depends on those payors&#146; coverage policies and reimbursement rates. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include one or more of our drug
candidates, if approved. Third-party payors, together with regulators and others, are increasingly challenging the prices charged for pharmaceutical products and health services, in addition to their cost-effectiveness, safety and efficacy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, no uniform policy for coverage and reimbursement exists in the United States. Third-party payors often rely upon Medicare
coverage policy and payment limitations in setting their own coverage and reimbursement policies, but also have their own methods and approval process apart from Medicare determinations. Therefore, coverage and reimbursement rates can vary
significantly from payor to payor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, obtaining coverage and adequate reimbursement is a time-consuming and costly process. We may
be required to provide scientific and clinical support for the use of any product to each third-party payor separately with no assurance that approval will be obtained, and we may need to conduct expensive pharmacoeconomic studies in order to
demonstrate the cost-effectiveness of our products. We cannot be certain that our drug candidates will be considered cost-effective by third-party payors. This process could delay the market acceptance of any drug candidates for which we may receive
approval and could have a negative effect on our future revenues and operating results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Other U.S. Healthcare Laws and Compliance
Requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, our business may be subject to healthcare fraud and abuse regulation and enforcement by both
the federal government and the states in which we conduct our business, particularly once third-party reimbursement becomes available for one or more of our products. The healthcare fraud and abuse laws and regulations that may affect our ability to
operate include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting,
receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease,
order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under the Medicare and Medicaid programs, or other federal healthcare programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal civil and criminal false claims laws and civil monetary penalty laws, including the civil False
Claims Act, or FCA, which prohibits, among other things, knowingly presenting, or causing to be </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">227 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
presented, claims for payment of government funds that are false or fraudulent, or knowingly making, or using or causing to be made or used, a false record or statement material to a false or
fraudulent claim to avoid, decrease, or conceal an obligation to pay money to the federal government; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal Health Insurance Portability and Accountability Act of 1996 (the &#147;HIPAA&#148;), which, among
other things, prohibits executing a scheme to defraud any healthcare benefit program, including private third-party payors, and prohibits (i)&nbsp;knowingly and willfully falsifying, concealing or covering up a material fact or making any materially
false, fictitious or fraudulent statement or representation and (ii)&nbsp;making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of
or payment for healthcare benefits, items or services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (the
&#147;HITECH&#148;), and their respective implementing regulations, which impose requirements relating to the privacy, security and transmission of individually identifiable health information held by covered entities, including health plans,
healthcare clearinghouses and certain healthcare providers, and their business associates, individuals or entities that perform certain services on behalf of a covered entity that involve the use or disclosure of individually identifiable health
information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates and gave state attorneys general new authority to file civil actions for damages or
injunctions in federal courts to enforce HIPAA and seek attorneys&#146; fees and costs associated with pursuing federal civil actions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal Physician Payments Sunshine Act, being implemented as the Open Payments Program, which requires
manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare and
Medicaid Services (the &#147;CMS&#148;), information related to direct or indirect payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held in a company by physicians and their
immediate family members. Beginning in 2022, applicable manufacturers will also be required to report information regarding payments and transfers of value provided to physician assistants, nurse practitioners, clinical nurse specialists, certified
nurse anesthetists and certified nurse-midwives; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. state and local laws and regulations, such as state anti-kickback and false claims laws, which may apply to
sales or marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers; state laws that require pharmaceutical companies
to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state laws that
restrict the ability of manufacturers to offer <FONT STYLE="white-space:nowrap">co-pay</FONT> support to patients for certain prescription drugs; state laws that require drug manufacturers to report information related to clinical trials, or
information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws that require drug manufacturers to report information on the pricing of certain drugs; state laws and
local ordinances that require identification or licensing of sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often
are not preempted by HIPAA, thus complicating compliance efforts. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be required to spend substantial time and
money to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations. Even then, governmental authorities may conclude that our business practices do not comply with current or future statutes,
regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If governmental authorities find that our operations violate any of these laws or any other governmental regulations that may apply to us, we may
be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, individual </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">228 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and additional reporting obligations and oversight if we become subject to a corporate integrity
agreement or other agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and we may be required to curtail or restructure our operations. Moreover, we expect that there will continue to be
federal and state laws and regulations, proposed and implemented, that could impact our operations and business. In addition, the approval and commercialization of any drug candidate we develop outside the United States will also likely subject us
to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. The extent to which future legislation or regulations, if any, relating to health care fraud and abuse laws or enforcement, may be enacted or what effect such
legislation or regulation would have on our business remains uncertain. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare Reform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States there have been, and continue to be, several legislative and regulatory changes and proposed reforms of the healthcare
system to contain costs, improve quality and expand access to care. In the United States, there have been and continue to be a number of healthcare-related legislative initiatives that have significantly affected the pharmaceutical industry. For
example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the &#147;ACA&#148;), was passed in March 2010, substantially changing the way healthcare is financed by
both governmental and private insurers and significantly impacting the U.S. pharmaceutical industry. Among other things, the ACA subjects biologics to potential competition by lower-cost biosimilars; addresses a new methodology by which rebates owed
by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and
extends the rebate program to individuals enrolled in Medicaid managed care organizations; establishes annual fees and taxes on manufacturers of certain branded prescription drugs; and creates a new Medicare Part D coverage gap discount program in
which, as a condition of coverage of its products under Medicare Part D, manufacturers must now agree to offer 70% <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of
applicable brand drugs to eligible beneficiaries during their coverage gap period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the provisions of the ACA have yet to be fully
implemented, while certain provisions have been subject to judicial and Congressional challenges. In addition, there have been efforts by the Trump Administration to repeal or replace certain aspects of the ACA and to alter the implementation of the
ACA and related laws. For example, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, bills affecting the implementation of certain
taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017 (the &#147;Tax Act&#148;), includes a provision repealing, effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility
payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year commonly referred to as the &#147;individual mandate.&#148; On January&nbsp;22, 2018, President Trump signed a continuing
resolution on appropriations for fiscal year 2018 that delayed the implementation of certain <FONT STYLE="white-space:nowrap">ACA-mandated</FONT> fees, including the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;Cadillac&#148; tax on
certain high cost employer-sponsored insurance plans, the annual fee imposed on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share and the medical device excise
tax on <FONT STYLE="white-space:nowrap">non-exempt</FONT> medical devices. The Bipartisan Budget Act of 2018 (the &#147;BBA&#148;), among other things, amends the ACA, effective January&nbsp;1, 2019, to reduce the coverage gap in most Medicare drug
plans, commonly referred to as the &#147;donut hole.&#148; In addition, in July 2018, the CMS issued a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA
risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. Additional legislative changes or regulatory changes related to the ACA remain possible. In
December 2018, a United States District Court Judge for the Northern District of Texas ruled that the entire ACA is unconstitutional because the tax penalty associated with the &#147;individual mandate&#148; was repealed by Congress as part of the
Tax Act. This ruling is under appeal and stayed pending appeal. While the United States District Court Judge for the Northern District of Texas, as well as the Trump Administration and the CMS, have stated that the ruling will have no effect while
this appeal is pending, it is unclear how this decision, subsequent appeals and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">229 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other efforts to invalidate the ACA, regulations promulgated under the ACA or portions thereof, will impact the ACA and its implementation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing
practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing; reduce the cost of prescription
drugs under Medicare; review the relationship between pricing and manufacturer patient programs; and reform government program reimbursement methodologies for drugs. For example, the Trump Administration released a &#147;Blueprint&#148; to lower
drug prices and reduce <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain
federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs of drug products paid by consumers.
On January&nbsp;31, 2019, Office of the Inspector General of the Department of Health and Human Services proposed modifications to the federal Anti-Kickback Statute discount safe harbor for the purpose of reducing the cost of drug products to
consumers which, among other things, if finalized, will remove safe harbor protection from rebates paid by manufacturers to Medicare Part D plans, Medicaid managed care organizations and pharmacy benefit managers working with these organizations.
Although a number of these, and other proposed measures may require additional authorization to become effective, Congress and the Trump Administration have each indicated that they will continue to seek new legislative and/or administrative
measures to control drug costs. Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement
limitations, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare
authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, on May&nbsp;30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for
certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without
enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to
Try Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">230 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_17"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors and Executive Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table sets forth information regarding our directors and executive officers as of the date of this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Directors and Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position/Title</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jingwu Zhang Zang, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Founder and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wei Fu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Zheru Zhang, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director and President</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joan Huaqiong Shen, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director and Head of Research and Development</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jielun Zhu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director and Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mengjiao Jiang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jie Yu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lin Li, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lili Qian, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Vice President of Operations</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weimin Tang, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Executive Vice President of Global Business Development</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yunhan Lin, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Vice President of Corporate Development</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Neil Warma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">General Manager of I-Mab US</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Jingwu Zhang Zang</I>, M.D., Ph.D., is our founder and director. Prior to founding our company,
Dr. Zang served as the chief scientific officer and president of Simcere Pharmaceutical Group and Bioscikin Co., Ltd. from September 2013 to April 2016. Dr.&nbsp;Zang held senior management positions at GlaxoSmithKline (GSK), as the global senior
vice president and head of GSK&#146;s Research and Development in China from April 2007 to June 2013. The academic career of Dr. Zang started in Dr. Willems Institute and University of Limburg in Belgium. Dr. Zang became a professor at Baylor
College of Medicine in Houston and later joined the Chinese Academy of Sciences as the founding director of the Institute of Health Sciences and as a co-director of Institute Pasteur Shanghai, an independent
<FONT STYLE="white-space:nowrap">non-profit</FONT> life science institute to address public health problems in China, where he served as its director from October 2004 to September 2006. Dr.&nbsp;Zang also served as a director of Shanghai Institute
of Immunology from June 2002 to April 2007. Dr.&nbsp;Zang received his M.D. from Shanghai Second Medical University (now part of Shanghai Jiaotong University) in 1984, and his Ph.D. in neuroimmunology from the University of Brussels in 1990.
Dr.&nbsp;Zang conducted his post-doctoral work at Harvard Medical School in 1992, and obtained his U.S. medical license from the Texas Medical Board through a clinical residency at Baylor College of Medicine in Houston. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Wei Fu</I> has served as our director since June 2018. Mr.&nbsp;Fu was appointed by the <FONT STYLE="white-space:nowrap">C-Bridge</FONT>
entities pursuant to our shareholders agreement dated July&nbsp;6, 2018. Mr.&nbsp;Fu has served as the chief executive officer and a managing partner of <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Capital Investment Management, Ltd. since April
2014. Mr.&nbsp;Fu currently also serves on the board of several private companies. From August 2011 to December 2013, Mr.&nbsp;Fu served as the general manager of the investment department at Far East Horizon International, a financial services
organization. Mr.&nbsp;Fu served as a partner and the head of the Beijing office of Themes Investment Management Ltd, a private equity firm specializing in healthcare and environmental businesses, from July 2010 to July 2011. From March 2008 to
April 2010, Mr.&nbsp;Fu worked as an associate director of the private equity department at Standard Chartered Business Consulting (Beijing) Co., Ltd, where he was mainly responsible for private equity investment in relation to infrastructure
projects. Mr.&nbsp;Fu received his bachelor&#146;s degree in electrical engineering and business administration from Nanyang Technological University in Singapore in February 2005. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Zheru Zhang</I>, Ph.D., has served as our director and president since September 2017. Prior to joining our company, Dr.&nbsp;Zhang served
as the president at Tasgen <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. from November 2015 to April 2017, as the chief executive officer at Shanghai <FONT STYLE="white-space:nowrap">JMT-Bio</FONT> Co., Ltd. from October 2012
to October 2015, as a vice </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">231 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
president, research and development at Celltrion Inc. from March 2008 to October 2012, as a group leader for the development of analytics and drug products at Johnson&nbsp;&amp; Johnson (NYSE:
JNJ) from January 2006 to March 2008, and as a research investigator at Bristol-Myers Squibb Company from May 2000 to January 2006, focusing on bioanalytical development and protein therapeutics development, respectively. Dr.&nbsp;Zhang received his
master&#146;s degree in chemistry from Suzhou University in 1991, and his Ph.D. in chemistry from University of Alberta in Canada in 2000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Joan Huaqiong Shen</I>, M.D., Ph.D., has served as our head of discovery and clinical development since September 2017 and as our director
since July 2019. Prior to joining our company, Dr.&nbsp;Shen served as the vice president and development head of Janssen Pharmaceutical Companies of Johnson&nbsp;&amp; Johnson from September 2015 to September 2017. Dr.&nbsp;Shen was the chief
medical officer and vice president in Jiangsu Hengrui Medicine, Co., Ltd. (SHA: 600276) from May 2013 to August 2015. Dr.&nbsp;Shen served as the head of the China clinical department and a senior director at Pfizer (China) Research and Development
Co., Ltd. from August 2011 to May 2013. Prior to that, Dr.&nbsp;Shen worked as a senior medical director at Pfizer Inc. (NYSE:&nbsp;PFE) from November 2009 to August 2011. From August 2005 to November 2009, Dr.&nbsp;Shen was the medical director at
Wyeth Research, a leading pharmaceutical company. Dr.&nbsp;Shen worked as a clinical research physician at Eli Lilly and Company (NYSE: LLY) from September 2003 to August 2005. Dr.&nbsp;Shen received her M.D. from Southeast University Medical
College in 1983, master&#146;s degree in anatomy from West China University of Medical Sciences, currently Sichuan University School of Medicine in 1989, and her Ph.D. in anatomy/neuroscience from the Indiana University School of Medicine in 1996.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Jielun Zhu</I> has served as our chief financial officer since August 2018 and as our director since July 2019. Prior to joining
our company, Mr.&nbsp;Zhu held positions as a managing director and the head of healthcare investment banking, Asia, at Jefferies Hong Kong Limited from December 2015 to July 2018, advising biotechnology and healthcare clients globally on initial
public offerings, mergers and acquisitions and other strategic transactions. From August 2008 to December 2015, Mr.&nbsp;Zhu worked at the Deutsche Bank Group in its Hong Kong branch, with his last position being a director in the corporate finance
division. He worked as an investment banker at UBS Investment Bank in Hong Kong from July 2007 to July 2008. Mr.&nbsp;Zhu received his bachelor&#146;s degree of arts with honors in mathematics-economics from Wesleyan University in May 2000 and
master&#146;s degree in business administration from the Harvard Business School with Distinction in June 2007. Mr.&nbsp;Zhu was awarded the Chartered Financial Analyst (CFA) charter by the CFA Institute in January 2012. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Mengjiao Jiang</I> has served as our director since September 2017. Ms.&nbsp;Jiang was appointed by the
<FONT STYLE="white-space:nowrap">C-Bridge</FONT> entities pursuant to our shareholders agreement dated July&nbsp;6, 2018. Ms.&nbsp;Jiang is a managing director of <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Capital Investment Management, Ltd.,
a healthcare-dedicated private equity firm, and has served as a partner and a managing director since January, 2014. Ms.&nbsp;Jiang currently also serves on the board of several private companies. Ms.&nbsp;Jiang served as a director at International
Far East Horizon International, a financial services organization, from March 2012 to December 2013. Prior to that, Ms.&nbsp;Jiang served at ARC China Inc. as a managing director from May 2008 to June 2011. Ms.&nbsp;Jiang received her
bachelor&#146;s degree in economics with a political science double major from Wellesley College in Massachusetts in May 2003. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Jie
Yu</I> has served as our director since July 2019. Mr.&nbsp;Yu was appointed by the Tasly entities pursuant to our shareholders agreement dated July&nbsp;6, 2018. Mr.&nbsp;Yu has served as the secretary of the board at Tasly Pharmaceutical Group
Co., Ltd. since November 2016. Prior to that, Mr.&nbsp;Yu was a director of brand management office at China Minsheng Investment Co., Ltd., an international private capital investment group, from March 2015 to October 2016. Mr.&nbsp;Yu worked as the
head of the brand management department and the head of Chinese media affairs department at Huawei Technologies Co., Ltd. from April 2001 to March 2015. Mr.&nbsp;Yu received his bachelor&#146;s degree in management from Harbin Normal University in
1998 and master&#146;s degree in management from Northeast Forestry University in 2001. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Lin</I> <I>Li</I>, Ph.D. has served as our
director since July 2018. Dr.&nbsp;Li was appointed by the Hony entity pursuant to our shareholders agreement dated July&nbsp;6, 2018. Dr.&nbsp;Li has served as an investment director at Hony Capital since
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">232 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
December 2016. Dr.&nbsp;Li worked as an associate at Snow Lake Capital (HK) Limited from November 2014 to November 2016. Dr.&nbsp;Li served as a senior investment manager in the cross-border
investment group at Hony Capital from April 2012 to October 2014. Prior to that, he worked as an associate in the corporate finance department of Goldman Sachs Gao Hua Securities Company Limited in Beijing from July 2010 to April 2012. Dr.&nbsp;Li
received his bachelor&#146;s degree in biology from Peking University in July 2000, Ph.D. in biology from Boston University in 2006, and master&#146;s degree in business administration from the Harvard Business School in 2010. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Lili Qian</I>, Ph.D., has served as the vice president of operations since June 2016 and our director from September 2017 to July 2019.
Dr.&nbsp;Qian worked at Bioscikin Biopharma Technology Co., Ltd. from January 2016 to May 2016, serving as the secretary to the board of directors and president office manager. Prior to that, Dr.&nbsp;Qian held various positions at Simcere
Pharmaceutical Group as the president assistant and a project management manager from October 2013 to December 2015, and as a business development manager from July 2013 to October 2013. She was the project leader of the national key laboratory of
protein and plant genetic engineering at Peking University from September 2007 to June 2013. Dr.&nbsp;Qian received her bachelor&#146;s degree in biochemistry from University of British Columbia in 2005 and her Ph.D. in biochemistry and molecular
biology from Peking University in 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Weiming Tang</I>, Ph.D., has served as our executive vice president of global business
development since April 2018. Prior to joining our company, Dr.&nbsp;Tang served as an executive director and a business director at Hengrui Therapeutics, Inc. from July 2015 to April 2018. Dr.&nbsp;Tang served as the vice president and a business
director at Crown Bioscience Inc., a <FONT STYLE="white-space:nowrap">pre-clinical</FONT> contract research organization, from July 2011 to July 2015. Prior to that, Dr.&nbsp;Tang served as the vice president and a business director at ShanghaiBio
Corporation Shanghai Biotechnology Cooperation, a biotech company based in Shanghai, from October 2010 to July 2011. Dr.&nbsp;Tang received his bachelor&#146;s degree in plant pathology from Zhejiang University in 1986, master&#146;s degree in
microbiology from Chinese Academy of Sciences in 1989, and Ph.D. in biochemistry from Rutgers University, New Jersey in 1997. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Yunhan Lin</I>, Ph.D., has served as our vice president of corporate development since September 2017. Prior to joining our Company,
Dr.&nbsp;Lin served as the head of business development at Mycenax Biotech Inc., a Taiwan-based public pharmaceutical company, from January 2016 to September 2017. Prior to that, Dr.&nbsp;Lin served as the head of business development at SynCore
Biotechnology Co., Ltd, a Taiwan-based public biopharmaceutical company, from February 2012 to December 2015. Dr.&nbsp;Lin worked as a science project deputy manager at Sinphar Pharmaceutical Co, Ltd., a Taiwan-based pharmaceutical company, from
September 2001 to January 2012. Dr.&nbsp;Lin received his bachelor&#146;s degree in applied chemistry from Providence University, Taiwan in 2000, master&#146;s degree in chemistry from Fu Jen Catholic University, Taiwan in 2003, and Ph.D. in
chemistry from Tamkang University, Taiwan in 2008. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Neil Warma</I> has served as the general manager of I-Mab US since September 2019.
Mr. Warma is currently an advisor to several companies and serves on the board of directors of several biotechnology companies and BioHouston, a non-profit tax-exempt 501(c)(3) corporation founded by Houston area academic/research institutions.
Prior to joining our Company, Mr. Warma served as the president and chief executive officer of Opexa Therapeutics, currently Acer Therapeutics Inc. (Nasdaq: OPXA), from June 2008 to September 2017, and as its director from September 2008 to
September 2017. At Opexa Therapeutics, he also served as acting chief financial officer from March 2016 to September 2017, and previously served in such role from March 2009 to August 2012. From July 2004 to September 2007, Mr. Warma served as
president and chief executive officer of Viron Therapeutics Inc., a privately-held clinical stage biopharmaceutical company. Mr.&nbsp;Warma co-founded MedExact USA, Inc., an Internet company providing clinical information and services to physicians
and pharmaceutical companies in 2000 and served as president until 2003. From 1992 to 2000, Mr. Warma held senior positions of increasing responsibility at Novartis Pharmaceuticals (previously Ciba-Geigy Ltd.) at its corporate headquarters in Basel,
Switzerland. While at Novartis, Mr. Warma served as the Head of International Pharma Policy &amp; Advocacy and in senior management within global marketing where he worked on the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">233 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
international launch of a gastrointestinal product. Mr. Warma obtained an honors degree specializing in neuroscience from the University of Toronto in 1984 and an International M.B.A. from the
Schulich School of Management at York University in Toronto in 1992. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Scientific Advisory Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our scientific advisory board provide scientific, portfolio and project strategy advice to us, including the evaluation of
research and development strategies. The members of our scientific advisory board receive cash compensation for their services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Howard
Weiner</I>, M.D., has served on our scientific advisory board since July 2019. Dr. Weiner is the Robert L. Kroc Professor of Neurology at the Harvard Medical School, Director of the Partners Multiple Sclerosis (&#147;MS&#148;) Center and Co-Director
of Center for Neurologic Diseases at Brigham &amp; Women&#146;s Hospital in Boston. The Partners MS Center is the first integrated MS Center that combines clinical care, MRI imaging and immune monitoring to the MS patient as part of the 2000 patient
CLIMB cohort study. Dr. Weiner has pioneered immunotherapy in MS and has investigated immune mechanisms in nervous system diseases including MS, Alzheimer&#146;s disease, amyotrophic lateral sclerosis, stroke and brain tumors. Dr. Weiner has also
pioneered the investigation of the mucosal immune system for the treatment of autoimmune and other diseases and the use of anti-CD3 to induce regulatory T cells for the treatment of these diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eric K. Rowinsky</I>, M.D., has served on our scientific advisory board since June 2019. Dr.&nbsp;Rowinsky is an independent consultant
and/or board member of various public and private companies and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">not-for-profit</FONT></FONT> efforts. Since 2017, Dr.&nbsp;Rowinsky has served as an advisor to <FONT
STYLE="white-space:nowrap">C-Bridge</FONT> Capital and the U.S. Chief Medical Officer for Everest Medicines, Inc. Since 2015, Dr.&nbsp;Rowinsky has served as an Executive Director and President at Rgenix Inc. and as the Chief Scientific Officer of
Clearpath Development Co. From 2005 to 2015, Dr.&nbsp;Rowinsky held various positions with various biotechnology companies. At ImClone Systems (now a wholly-owned subsidiary of Eli Lilly), Dr.&nbsp;Rowinsky and his team developed and registered
cetuximab (Erbitux) and ramucirumab in five indications and two other monoclonal antibodies in North America and elsewhere. Dr.&nbsp;Rowinsky has been an Adjunct Professor of Medicine at New York University School of Medicine since 2005. From 1987
to 2005, Dr.&nbsp;Rowinsky held various academic and research positions with various universities and research institutions including the Institute for Drug Development of the Cancer Therapy and Research Center in San Antonio, where he held the SBC
Endowed Chair for Early Drug Development, and the Johns Hopkins University School of Medicine. Dr.&nbsp;Rowinsky received his B.A. degree from New York University and his M.D. from the Vanderbilt University School of Medicine and completed
fellowship training at the Johns Hopkins University School of Medicine. Dr.&nbsp;Rowinsky received the career development award of the American Cancer Society and the 6th Annual Emil J. Freireich Award. He has also served on the Board of Scientific
Counselors of the NCI. Dr.&nbsp;Rowinsky is the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Editor-in-Chief</FONT></FONT> of Investigational New Drugs, an Editorial Board Member of Cancer Research and several other oncology
journals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Patricia LoRusso</I>, D.O., M.A., Ph.D., has served on our scientific advisory board since July 2019. Dr.&nbsp;LoRusso is
currently a professor of medicine and a clinical scholar in medical oncology and Associate Director of Innovative Medicine at Yale Cancer Center in New Haven, Connecticut, USA, where she is also Director of Early Therapeutics Disease-Aligned Team.
Dr LoRusso&#146;s expertise is in testing new treatments on patient volunteers with advanced-stage cancer. She heads the early clinical trials program at Yale Cancer Center. She has served as the co-leader of the Stand Up To Cancer/Melanoma Research
Alliance&#150;funded Melanoma Dream Team, a Komen Promise grant <FONT STYLE="white-space:nowrap">co-Principal</FONT> Investigator, and has been a Principal Investigator of the National Cancer Institute Phase 1/early phase clinical trials program
grant in excess of 20 years. She is currently primary investigator or <FONT STYLE="white-space:nowrap">co-investigator</FONT> of numerous clinical trials. Prior to joining Yale in August 2014, Dr.&nbsp;LoRusso served in numerous leadership roles at
Wayne State University&#146;s Barbara Karmanos Cancer Institute for more than 25 years, most recently as director of the Phase 1 Clinical Trials Program and of the Eisenberg Center for Experimental Therapeutics. Dr.&nbsp;LoRusso also worked as a
director in Karmanos Cancer Institute, a cancer research and provider network, from 1997 to 2014.Dr.&nbsp;LoRusso received her B.A. degree of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">234 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
science in religion/religious studies and biology, her master&#146;s degree at Yale University, her D.O. and Ph.D. from Michigan State University, and completed fellowship training at Wayne State
University. Dr.&nbsp;LuRosso served as co-chair of the National Cancer Institute Cancer Therapy Evaluation Program (NCI CTEP) Investigational Drug Steering Committee, a prior parent member of the NCI&#146;s Quick Trials Clinical Subcommittee, and
has served as either an ad hoc or an appointed member on multiple study sections and has reviewed for Komen Promise grants, numerous SPORE and P01 study sections, and translational research grants. She has served on the education and scientific
committees of the American Society of Clinical Oncology, the Scientific Committee of the American Association for Cancer Research as well as a Vice-Chair for the 2019 AACR annual meeting. She is a member of the NCI Board of Scientific Council and
has served on the Board of Directors for the American Association for Cancer Research. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Yi-Long Wu</I>, M.D., FACS, has served on our
scientific advisory board since August 2019. YI-Long Wu is a tenured professor of Guangdong Provincial People&#146;s Hospital, Guangdong Academy of Medical Sciences and Guangdong Lung Cancer Institute. He is the former President of Chinese Society
of Clinical Oncology (CSCO), the Chief of the WUJIEPING Oncology Medical Foundation, the vice-director of the Precision Medicine of the Chinese Medical Doctor Association, the President of Chinese Thoracic Oncology Group (C-TONG), the President of
International Chinese Society of Thoracic Surgery (ICSTS), a Fellow of the American College of Surgeons, a Member of Board of Directors of the International Association Study of Lung Cancer (IASLC), the Chairman of European Society for Medical
Oncology (ESMO) in China, the Chairman of Federation of Asia Clinical Oncology (FACO), a past Member of the International Affairs Committee of American Society of Clinical Oncology (ASCO), and a former Member of staging committee of the IASLC. He
graduated from Sun Yat-sen University of Medical Sciences in 1982 and completed his thoracic surgery training in Germany in 1989. His main research interests are the multidisciplinary synthetic therapy on lung cancer in translation medicine and
evidence-based medicine in oncology. He is leading the Chinese lung cancer research field and has been the Principal Investigator or Co-PI of more than 120 international or national multicenter clinical trials. He has contributed 20 books on cancer
and has published more than 300 articles in peer-reviewed journals including<I> J Clin Oncol, Lancet Oncol, New Engl J Med, Cancer Cell and J Thorac Oncol</I>. He also serves on the editorial boards of <I>Cancer Letters, Annals of Surgical Oncology,
Lung Cancer Management, International Journal of Biological Marker and General Thoracic and Cardiovascular Surgery</I>. He is Editor-in-Chief of <I>Journal of Evidence-based Medicine, Journal of Thoracic Oncology (Chinese Edition), and The
Oncologist (Chinese Edition)</I><I> </I>etc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Timothy Yap</I>, Ph.D., has served on our scientific advisory board since August 2019.
Dr. Yap is a medical oncologist and physician-scientist based at the University of Texas MD Anderson Cancer Center. He is an Associate Professor in the Department for Investigational Cancer Therapeutics (Phase I Program), and the Department of
Thoracic/Head and Neck Medical Oncology. Dr. Yap is the Medical Director of the Institute for Applied Cancer Science, a drug discovery biopharmaceutical unit where drug discovery and clinical translation are seamlessly integrated. He is also the
Associate Director of Translational Research in the Institute for Personalized Cancer Therapy, which is an integrated research and clinical trials program aimed at implementing personalized cancer therapy and improving patient outcomes. Prior to his
current position, Dr. Yap was a Consultant Medical Oncologist at The Royal Marsden Hospital in London, UK and National Institute for Health Research BRC Clinician Scientist at The Institute of Cancer Research, London, UK. Dr. Yap gained his BSc
degree with First Class Honors in Immunology and Infectious Diseases at Imperial College London, UK, and was awarded the Huggett Memorial Prize. His BSc laboratory research involved an immunogenetics study under the supervision of Professor Charles
Bangham. He subsequently went on to attain his Medical degree from Imperial College London, UK, before completing general medical training in Oxford. Dr. Yap&#146;s main research focuses on the first-in-human and combinatorial development of
molecularly targeted agents and immunotherapies, and their acceleration through clinical studies using novel predictive and pharmacodynamic biomarkers. Dr. Yap leads immuno-oncology clinical and associated translational studies, including novel
agents targeting PD-1/PD-L1, ICOS, IDO, LAG3, TIM3, STING, TGFbeta, adenosine A2A receptor and fucosylation. He was previously the UK Chief Investigator for the CheckMate 331 Phase III trial in relapsed small cell lung
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">235 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cancer and the KEYNOTE-158 Phase II biomarker study in advanced solid tumors and multiple novel immunotherapy combination phase I trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Roy S. Herbst, MD, PhD</I>, has served on our scientific advisory board since July 2019. Dr. Roy S. Herbst is an Ensign Professor of
Medicine (Medical Oncology) and Professor of Pharmacology, the Chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital, and an Associate Cancer Center Director for Translational Research, Yale Cancer Center in New Haven, CT. Dr.
Herbst is nationally recognized for his leadership and expertise in lung cancer treatment and research. He is best known for his work in developmental therapeutics and the personalized therapy of non-small cell lung cancer, in particular the process
of linking genetic abnormalities of cancer cells to novel therapies. Prior to his appointment at Yale, Dr. Herbst was the Barnhart Distinguished Professor and Chief of the Section of Thoracic Medical Oncology in the Department of Thoracic/Head and
Neck Medical Oncology, at The University of Texas M.D. Anderson Cancer Center (UT-MDACC) in Houston, Texas. He also served as Professor in the Department of Cancer Biology and Co-Director of the Phase I Clinical Trials Program. He has led the Phase
I development of several of the new generation of targeted agents for non-small cell lung cancer (NSCLC), including gefitinib, erlotinib, cetuximab, and bevacizumab. More recently, he participated in the successful registration of pembrolizumab for
the treatment of advanced non-small cell lung cancer, following the successful Yale-led KEYNOTE 10 study of the immune therapy drug commonly used to treat other cancers. He was co-leader for the BATTLE-1 clinical trial program, co-leads the
subsequent BATTLE-2 clinical trial program, and served as a Co-program Leader of the Developmental Therapeutics Program for the YCC Support Grant. Dr. Herbst&#146;s laboratory work is focused on immunotherapy angiogenesis; dual epidermal growth
factor receptor (EGFR)/vascular endothelial growth factor receptor (VEGFR) inhibition in NSCLC, and targeting KRAS-activated pathways. More recently, he has explored predictive biomarkers for the use of immunotherapy agents. This work has been
translated from the preclinical to clinical setting in multiple Phase II and III studies which he has led. After earning a B.S. and M.S. degree from Yale University, Dr. Herbst earned his M.D. at Cornell University Medical College and his Ph.D. in
molecular cell biology at The Rockefeller University in New York City, New York. His postgraduate training included an internship and residency in medicine at Brigham and Women&#146;s Hospital in Boston, Massachusetts. His clinical fellowships in
medicine and hematology were completed at the Dana-Farber Cancer Institute and Brigham and Women&#146;s Hospital, respectively. Subsequently, Dr. Herbst completed a M.S. degree in clinical translational research at Harvard University in Cambridge,
Massachusetts. Dr. Herbst is an author or co-author of more than 275 publications, including peer-reviewed journal articles, abstracts, and book chapters. His work has been published in many prominent journals, such as the Journal of Clinical
Oncology, Clinical Cancer Research, Lancet, the New England Journal of Medicine, and Nature. Dr. Herbst was a member of the National Cancer Policy Forum (1998-2014) for which he organized an Institute of Medicine meeting focused on policy issues in
personalized medicine. He is a member of ASCO and, as a member of AACR, he chairs the Tobacco Task Force. He is a fellow of the American College of Physicians and an elected member of the Association of American Physicians. Dr. Herbst is also a
member of the medical advisory committee for the Lung Cancer Research Foundation and chair of the communications committee for ASCO and the International Association for the Study of Lung Cancer. He is currently the Vice Chair for Developmental
Therapeutics for the Southwestern Oncology Group (SWOG) Lung Committee, Principal Investigator of the SWOG 0819 trial, and steering committee chair for the Lung Master Protocol (Lung MAP). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Past Incidents </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From June 2007 to
June 2013, our founder, Dr.&nbsp;Jingwu Zhang Zang worked and held senior management positions at GlaxoSmithKline (&#147;GSK&#148;), as a global senior vice president, and head of GSK&#146;s Research and Development in China. Dr.&nbsp;Zang was
dismissed by GSK in June 2013 after GSK became aware of misrepresentation of certain data in a research paper entitled &#147;Crucial role of <FONT STYLE="white-space:nowrap">interleukin-7</FONT> in T helper type 17 survival and expansion in
autoimmune disease,&#148; which was prepared by scientists at GSK China&#146;s research center and published in Nature Medicine in 2010. Dr.&nbsp;Zang was the corresponding author of the paper, primarily handling manuscript editing and
communications with editors and reviewers of the paper. According to Dr.&nbsp;Zang and the first author of the paper, Dr.&nbsp;Zang, as the head of GSK China&#146;s research center and a member of GSK&#146;s
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">236 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
global senior management, was neither involved in nor aware of the mislabeled samples relating to the misrepresented data referenced in the paper at the time when the paper was prepared and
published. Nonetheless, Dr.&nbsp;Zang admitted his management oversight as the corresponding author and agreed to retract the paper. The paper was retracted by GSK in September 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From 1996 to 2002, Dr.&nbsp;Zang was employed by Baylor College of Medicine in Houston, Texas initially as an associate professor and was
later promoted to full professor. At that time, Dr.&nbsp;Zang&#146;s team was conducting a clinical study on <FONT STYLE="white-space:nowrap">T-cell</FONT> vaccination for the treatment of multiple sclerosis after approval by Baylor&#146;s
Institutional Review Board (&#147;IRB&#148;). Dr.&nbsp;Zang was led to believe that such clinical research would not require FDA approval. In March 1999, the Food and Drug Administration, or the FDA, issued a warning letter to Dr.&nbsp;Zang stating
that the clinical study did require IND approval from the FDA in addition to the approval from the IRB and requested the study to be suspended. The study was suspended and later <FONT STYLE="white-space:nowrap">re-initiated</FONT> and successfully
completed after the IND approval was obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the best of our knowledge, Dr.&nbsp;Zang was not and is not subject to any legal or
regulatory charges, proceedings or disciplinary actions in connection with the above incidents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For risks related to the above incidents,
please see &#147;Risk Factors&#151;Risks Related to Our Industry, Business and Operations&#151;Negative publicity with respect to us, our management, employees, business partners, affiliates, or our industry, may materially and adversely affect our
reputation, business, results of operations and prospect.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the measures and systems we have in place to ensure the integrity and
legal compliance of our R&amp;D process and business operations, please see &#147;Business&#151;R&amp;D Governance&#148; and &#147;Business&#151;Quality Control and Assurance.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of
directors will consist of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; directors upon the SEC&#146;s declaration of effectiveness of our registration statement on Form <FONT STYLE="white-space:nowrap">F-1,</FONT> of which
this prospectus forms a part. A director is not required to hold any shares in our company by way of qualification. Subject to the Nasdaq Global Market rules and disqualification by the chairman of the relevant board meeting, a director may vote
with respect to any contract, proposed contract or arrangement in which he is interested. A director who is interested in a contract proposed contract or arrangement shall declare the nature of his or her interest at the earliest meeting of the
board at which it is practicable for him or her to do so, either specifically or by way of a general notice. The directors may exercise all the powers of our company to borrow money, mortgage its undertaking, property and uncalled capital, and issue
debentures or other securities whenever money is borrowed or as security for any obligation of our company or of any third party. None of our directors who are not our executive officers has a service contract with us that provides for benefits upon
termination of service. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of the Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will establish three committees under the board of directors immediately upon the effectiveness of our registration statement on Form <FONT
STYLE="white-space:nowrap">F-1,</FONT> of which this prospectus forms a part: an audit committee, a compensation committee and a nominating and corporate governance committee. We will adopt a charter for each of the three committees. Each
committee&#146;s members and functions are described below. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Audit Committee</I>. Our audit committee will consist
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; will be the chairman of our audit committee. We have determined that each of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; satisfies the &#147;independence&#148; requirements of Rule 5605(c)(2) of the Nasdaq Stock Market
Rules and meets the independence standards under Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act. We have determined that &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; qualifies as an &#147;audit
committee financial expert.&#148; The audit committee will oversee our accounting and financial reporting processes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">237 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and the audits of the financial statements of our company. The audit committee will be responsible for, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing the independent auditors and <FONT STYLE="white-space:nowrap">pre-approving</FONT> all auditing and <FONT
STYLE="white-space:nowrap">non-auditing</FONT> services permitted to be performed by the independent auditors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing with the independent auditors any audit problems or difficulties and management&#146;s response;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing the annual audited financial statements with management and the independent auditors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the adequacy and effectiveness of our accounting and internal control policies and procedures and any
steps taken to monitor and control major financial risk exposures; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving all proposed related party transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">meeting separately and periodically with management and the independent auditors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitoring compliance with our code of business conduct and ethics, including reviewing the adequacy and
effectiveness of our procedures to ensure proper compliance. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Compensation Committee</I>. Our compensation
committee will consist of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; will be the chairman of our compensation committee. We have determined that each of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; satisfies the
&#147;independence&#148; requirements of Rule 5605(a)(2) of the Nasdaq Stock Market Rules. The compensation committee will assist the board in reviewing and approving the compensation structure, including all forms of compensation, relating to our
directors and executive officers. Our chief executive officer may not be present at any committee meeting during which his compensation is deliberated. The compensation committee will be responsible for, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving, or recommending to the board for its approval, the compensation for our chief executive
officer and other executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to the board for determination with respect to the compensation of our directors who
are not our employees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing periodically and approving any incentive compensation or equity plans, programs or similar
arrangements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selecting compensation consultant, legal counsel or other adviser only after taking into consideration all
factors relevant to that person&#146;s independence from management. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Nominating and Corporate Governance
Committee</I>. Our nominating and corporate governance committee will consist of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; will be the chairman of our nominating and corporate governance committee. We have determined that
each of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; satisfies the
&#147;independence&#148; requirements of Rule 5605(a)(2) of the Nasdaq Stock Market Rules. The nominating and corporate governance committee will assist the board of directors in selecting individuals qualified to become our directors and in
determining the composition of the board and its committees. The nominating and corporate governance committee will be responsible for, among other things: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selecting and recommending to the board nominees for election by the shareholders or appointment by the board;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing annually with the board the current composition of the board with regards to characteristics such as
independence, knowledge, skills, experience and diversity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making recommendations on the frequency and structure of board meetings and monitoring the functioning of the
committees of the board; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advising the board periodically with regards to significant developments in the law and practice of corporate
governance as well as our compliance with applicable laws and regulations, and making recommendations to the board on all matters of corporate governance and on any remedial action to be taken. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">238 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Duties of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Cayman Islands law, our directors owe fiduciary duties to our company, including a duty of loyalty, a duty to act honestly, and a duty to
act in what they consider in good faith to be in our best interests. Our directors must also exercise their powers only for a proper purpose. Our directors also have a duty to exercise skills they actually possess and with such care and diligence
that a reasonably prudent person would exercise in comparable circumstances. It was previously considered that a director need not exhibit in the performance of his or her duties a greater degree of skill than what may reasonably be expected from a
person of his or her knowledge and experience. However, English and Commonwealth courts have moved towards an objective standard with regard to the required skill and care, and these authorities are likely to be followed in the Cayman Islands. In
fulfilling their duty of care to us, our directors must ensure compliance with our memorandum and articles of association, as amended from time to time, and the class rights vested thereunder in the holders of the shares. Our company has the right
to seek damages if a duty owed by our directors is breached. A shareholder may in certain limited circumstances have the right to seek damages in our name if a duty owed by the directors is breached. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has all the powers necessary for managing, and for directing and supervising, our business affairs. The functions and
powers of our board of directors include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">convening shareholders&#146; annual general meetings and reporting its work to shareholders at such meetings;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">declaring dividends and other distributions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing officers and determining the term of office of the officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exercising the borrowing powers of our company and mortgaging the property of our company; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving the transfer of shares in our company, including the registration of such shares in our share register.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Terms of Directors and Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors may be elected by an ordinary resolution of our shareholders. Alternatively, our board of directors may, by the affirmative vote
of a simple majority of the directors present and voting at a board meeting appoint any person as a director to fill a casual vacancy on our board or as an addition to the existing board. Our directors (other than independent directors) are not
automatically subject to a term of office and hold office until such time as they are removed from office by an ordinary resolution of our shareholders. Our independent directors hold office until the earlier of (i) the date on which the independent
director ceases to be a member of the board for any reason; (ii) the date of termination of an independent director&#146;s director agreement, which may be terminated by either the independent director or by us with a 30-day advance written notice
or such other shorter period as mutually agreed; or (iii) three years from the effective date of the director agreement, subject to the terms of the then-current memorandum and articles of association of our company. In addition, a director will
cease to be a director if he or she (i)&nbsp;becomes bankrupt or makes any arrangement or composition with his or her creditors; (ii)&nbsp;dies or is found to be or becomes of unsound mind; (iii)&nbsp;resigns his or her office by notice in writing;
(iv)&nbsp;without special leave of absence from our board, is absent from meetings of our board for three consecutive meetings and our board resolves that his or her office be vacated; or (v)&nbsp;is removed from office pursuant to any other
provision of our articles of association. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our officers are appointed by and serve at the discretion of the board of directors, and may be
removed by our board of directors. Under our post-offering articles of association, the board of directors may appoint one or more of their number to the office of managing director upon like terms, but any such appointment shall ipso facto
terminate if any managing director ceases for any cause to be a director, or if our company by ordinary resolution of shareholders resolves that his tenure of office be terminated. In addition, the board of directors may appoint any natural person
or corporation to be a secretary (and if need be an assistant secretary or assistant secretaries) who shall hold office for such term, at such remuneration and upon such conditions and with such </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">239 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
powers as they think fit. Any secretary or assistant secretary so appointed by the board of directors may be removed by the board of directors or by ordinary resolution of shareholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>[Employment Agreements and Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into employment agreements with each of our executive officers. Under these agreements, each of our executive officers is
employed for a specified time period. We may terminate employment for cause, at any time, without advance notice or remuneration, for certain acts of the executive officer, such as conviction or plea of guilty to a felony or any crime involving
moral turpitude, negligent or dishonest acts to our detriment, or misconduct or a failure to perform agreed duties. We may also terminate an executive officer&#146;s employment without cause upon a three month prior written notice. In such case of
termination by us, we will provide severance payments to the executive officer as expressly required by applicable law of the jurisdiction where the executive officer is based. The executive officer may resign at any time with a three month prior
written notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each executive officer has agreed to hold, both during and after the termination or expiry of his or her employment
agreement, in strict confidence and not to use, except as required in the performance of his or her duties in connection with the employment or pursuant to applicable law, any of our confidential information or trade secrets, any confidential
information or trade secrets of our clients or prospective clients, or the confidential or proprietary information of any third party received by us and for which we have confidential obligations. The executive officers have also agreed to disclose
in confidence to us all inventions, designs and trade secrets which they conceive, develop or reduce to practice during the executive officer&#146;s employment with us and to assign all right, title and interest in them to us, and assist us in
obtaining and enforcing patents, copyrights and other legal rights for these inventions, designs and trade secrets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, each
executive officer has agreed to be bound by <FONT STYLE="white-space:nowrap">non-competition</FONT> and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> restrictions during the term of his or her employment and typically for one year
following the last date of employment. Specifically, each executive officer has agreed not to (i)&nbsp;approach our suppliers, clients, customers or contacts or other persons or entities introduced to the executive officer in his or her capacity as
a representative of us for the purpose of doing business with such persons or entities that will harm our business relationships with these persons or entities; (ii)&nbsp;assume employment with or provide services to any of our competitors, or
engage, whether as principal, partner, licensor or otherwise, any of our competitors, without our express consent; or (iii)&nbsp;seek directly or indirectly, to solicit the services of any of our employees who is employed by us on or after the date
of the executive officer&#146;s termination, or in the year preceding such termination, without our express consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also entered
into indemnification agreements with each of our directors and executive officers. Under these agreements, we agree to indemnify our directors and executive officers against certain liabilities and expenses incurred by such persons in connection
with claims made by reason of their being a director or officer of our company.] </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation of Directors and Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the fiscal year ended December&nbsp;31, 2018, we paid an aggregate of approximately RMB22.1&nbsp;million (US$3.2 million) in cash to our
executive officers, and we did not pay any compensation to our directors who are not our executive officers. We have not set aside or accrued any amount to provide pension, retirement or other similar benefits to our executive officers and
directors. Our PRC subsidiaries are required by law to make contributions equal to certain percentages of each employee&#146;s salary for his or her pension insurance, medical insurance, unemployment insurance and other statutory benefits and a
housing provident fund. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">240 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Incentive Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amended and Restated 2017 Employee Stock Option Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2017, we adopted an equity incentive plan, as amended and restated in 2019, which we refer to as the 2017 Plan, to secure and retain the
services of valuable employees, directors or consultants, and provide incentives for such persons to exert their best efforts for the success of our business. Pursuant to the 2017 Plan, the maximum aggregate number of ordinary shares which may be
issued pursuant to all awards under the 2017 Plan is 13,376,865, subject to further amendment. As of the date of this prospectus, awards to purchase 9,859,381 ordinary shares under the 2017 Plan have been granted and outstanding, excluding awards
that were forfeited or cancelled after the relevant grant dates. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following paragraphs describe the principal terms of the 2017
Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Types of awards</I>. The 2017 Plan permits the awards of options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan administration</I>. Our board of directors will administer the 2017 Plan. The board of directors will determine, among other things,
the participants to receive options, the number and subscription price of options to be granted to each participant, and the terms and conditions of each option granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Offer letter</I>. Options granted under the 2017 Plan are evidenced by an offer letter that sets forth terms, conditions and limitations
for each option, which may include the term of the option, and the provisions applicable in the event that the grantee&#146;s employment or service terminates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligible participants</I>. We may grant awards to employees, officers, directors, contractors, advisors and consultants of our company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Vesting schedule</I>. Unless otherwise approved by the board of directors and set forth in an offer letter, the vesting schedule shall
be a three-year vesting schedule consisting of a cliff vesting 50% on the second anniversary of the applicable vesting commencement date, and a vesting of the remaining 50% on the third anniversary of the applicable vesting commencement date. Except
as otherwise approved by the board of directors, vested portion of option shall become exercisable upon the earlier of a listing or the occurrence of a change in control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Exercise of options</I>. The board of directors determines the subscription price for each option, which is stated in the offer letter. The
vested portion of each option will expire if not exercised prior to the time as the board of directors determines at the time of its grant. However, the maximum exercisable term is ten years from the applicable vesting commencement date or such
shorter period specified in the award agreement. Further, an option will lapse upon the earliest of, among other circumstances, two years after the date when the option becomes exercisable upon the listing or the occurrence of a change in control,
and a violation in transfer restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transfer restrictions</I>. Options may not be transferred in any manner by the participant
other than in accordance with the exceptions provided in the 2017 Plan or the relevant offer letter or otherwise determined by the board of directors, such as transfers by will or the laws of descent and distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Termination and amendment of the 2017 Plan</I>. Unless terminated earlier, the 2017 Plan has a term of ten years. The board of directors
has the authority to amend, suspend or terminate the plan, subject to the limitations of applicable laws. No amendment, suspension or termination may adversely affect in any material way any awards previously granted pursuant to the 2017 Plan unless
agreed to by the participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">241 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes, as of the date of this prospectus, the number of ordinary
shares under our outstanding options that we granted under the 2017 Plan to several of our directors and executive officers, excluding awards that were forfeited or cancelled after the relevant grant dates. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary Shares<BR>Underlying<BR>Outstanding<BR>Options&nbsp;Granted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise<BR>Price<BR>(US$/Share)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Date of Grant</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Date of Expiration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Zheru Zhang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,505,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;1,&nbsp;2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;1,&nbsp;2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joan Huaqiong Shen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,505,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;1, 2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;1, 2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jielun Zhu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">August 1, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;1, 2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weimin Tang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;2, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;1, 2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yunhan Lin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;1, 2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;1, 2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lili Qian</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;1, 2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;1, 2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other grantees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4,913,377</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;1, 2017<BR>to&nbsp;July 25, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">October&nbsp;1, 2027</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">9,859,381</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Note:
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Less than 1% of our total outstanding shares. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2018 Employee Stock Option Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2019,
we adopted an equity incentive plan, which we refer to as the 2018 Plan, to secure and retain the services of valuable employees, directors or consultants, and provide incentives for such persons to exert their best efforts for the success of our
business. Pursuant to the 2018 Plan, the maximum aggregate number of ordinary shares which may be issued pursuant to all awards under the 2018 Plan is 14,005,745, subject to further amendment. If we successfully list on an internationally recognized
securities exchange for a qualified public offering by December 31, 2019, the maximum aggregate number of ordinary shares which may be issued pursuant to all awards under the 2018 Plan shall be 15,452,620. As of the date of this prospectus, awards
to purchase 13,536,588 ordinary shares under the 2018 Plan have been granted and outstanding, excluding awards that were forfeited or cancelled after the relevant grant dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following paragraphs describe the principal terms of the 2018 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Types of awards</I>. The 2018 Plan permits the awards of options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan administration</I>. Our board of directors will administer the 2018 Plan. The board of directors will determine, among other things,
the participants to receive options, the number and subscription price of options to be granted to each participant, and the terms and conditions of each option granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Offer letter</I>. Options granted under the 2018 Plan are evidenced by an offer letter that sets forth terms, conditions and limitations
for each option, which may include the term of the option, and the provisions applicable in the event that the grantee&#146;s employment or service terminates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligible participants</I>. We may grant awards to employees or if approved by the board, designee of any employee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Vesting schedule</I>. Unless otherwise approved by the board of directors and set forth in an offer letter, the vesting schedule shall be a
two-year vesting schedule consisting of a cliff vesting 50% on the first anniversary of the applicable vesting commencement date, and a vesting of the remaining 50% on the second anniversary of the applicable vesting commencement date.
Notwithstanding the foregoing, if a listing occurs at anytime prior to any option granted under the 2018 Plan becoming full vested, and to the extent such option has been granted and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">242 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outstanding, any such option shall vest in full with immediate effect upon the listing. Except as otherwise approved by the board of directors, vested portion of option shall become exercisable
upon the earlier of six months after a listing or the occurrence of a change in control; provided, however that in each case, no option of an employee shall become exercisable until the third anniversary of such employee&#146;s employment
commencement date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Exercise of options</I>. The board of directors determines the subscription price for each option, which is stated
in the offer letter. The vested portion of each option will expire if not exercised prior to the time as the board of directors determines at the time of its grant. However, the maximum exercisable term is ten years from the applicable vesting
commencement date or such shorter period specified in the award agreement. Further, an option will lapse upon the earliest of, among other circumstances, two years after the date when the option becomes exercisable upon the listing or the occurrence
of a change in control, and a violation in transfer restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transfer restrictions</I>. Options may not be transferred in any
manner by the participant other than in accordance with the exceptions provided in the 2018 Plan or the relevant offer letter or otherwise determined by the board of directors, such as transfers by will or the laws of descent and distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Termination and amendment of the 2018 Plan</I>. Unless terminated earlier, the 2018 Plan has a term of ten years. The board of directors
has the authority to amend, suspend or terminate the plan, subject to the limitations of applicable laws. No amendment, suspension or termination may adversely affect in any material way any awards previously granted pursuant to the 2018 Plan unless
agreed to by the participant. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes, as of the date of this prospectus, the number of ordinary shares
underlying our outstanding options that we granted under the 2018 Plan, excluding awards that were forfeited or cancelled after the relevant grant dates. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Ordinary Shares<BR>Underlying<BR>Outstanding<BR>Options&nbsp;Granted</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Exercise&nbsp;Price<BR>(US$/Share)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Date of Grant</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Date&nbsp;of&nbsp;Expiration</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jingwu Zhang Zang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,438,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">February&nbsp;22,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">February&nbsp;22,&nbsp;2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Zheru Zhang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;25,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">February 22, 2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joan Huaqiong Shen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;25,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">February 22, 2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jielun Zhu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;25,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">February 22, 2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weimin Tang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;25,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">February 22, 2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yunhan Lin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;25,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">February 22, 2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lili Qian</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;25,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">February 22, 2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other grantees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,110,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;25,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">February 22, 2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,536,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Note:
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Less than 1% of our total outstanding shares. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">243 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_18"></A>PRINCIPAL SHAREHOLDERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as specifically noted, the following table sets forth information with respect to the beneficial ownership of our ordinary shares on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> basis as of the date of this prospectus by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors and executive officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person known to us to own beneficially 5% or more of our ordinary shares. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The calculations in the table below are based on 99,942,347 ordinary shares on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis
outstanding as of the date of this prospectus, and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares outstanding immediately after the completion of this offering, assuming the
underwriters do not exercise their over-allotment option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules and regulations
of the SEC. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, we have included shares that the person has the right to acquire within 60 days, including through the exercise of any option,
warrant or other right or the conversion of any other security. These shares, however, are not included in the computation of the percentage ownership of any other person. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary&nbsp;Shares</B><br><B>Beneficially<BR>Owned&nbsp;Prior&nbsp;to&nbsp;This&nbsp;Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary Shares</B><br><B>Beneficially Owned<BR>Immediately After<BR>This Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors and Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jingwu Zhang Zang<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,370,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Zheru Zhang<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,025,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joan Huaqiong Shen </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wei Fu<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,395,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mengjiao Jiang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jie Yu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lin Li</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lili Qian</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jielun Zhu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weimin Tang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yunhan Lin </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Neil Warma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All Directors and Executive Officers as a Group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,491,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Principal Shareholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">C-Bridge</FONT> entities<SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,395,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tasly entities<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,852,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hony entity<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,537,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Genexine<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,261,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes:
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than 1% of our total ordinary shares on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis
outstanding as of the date of this prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as otherwise indicated below, the business address of our directors and executive officers is Suite 802,
West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai, China. The business address of Wei Fu and Mengjiao Jiang is Suite 3306-3307, Two Exchange Square, 8 Connaught Place, Central, Hong Kong. The business address of Jie Yu is Tianshili
Great Health City, No. 2, East Puji River Road, Beichen District, Tianjin, China. The business address of Lin Li is 6F, South Tower C, Raycom Info Tech Park, No.2, Kexueyuan South Road, Haidian District, Beijing, China. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 3,932,113 ordinary shares directly held by Mabcore Limited, a British Virgin Islands company.
Dr.&nbsp;Zang, through himself and The Jingwu Zhang Zang 2018 Retained Annuity Trust, owns a </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">244 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
55.6% equity interest in Mabcore Limited. Lili Qian and two other individuals own the remaining equity interest in Mabcore Limited, and (ii) 10,438,088 ordinary shares issuable upon exercise of
options exercisable within 60 days after the date of this prospectus held by Dr.&nbsp;Zang. Dr.&nbsp;Zang is the sole director of Mabcore Limited. The Jingwu Zhang Zang 2018 Retained Annuity Trust was established under the laws of New York and is
managed by Dr.&nbsp;Zang, as the trustee, the settlor and the sole beneficiary. Pursuant to the currently effective memorandum and articles of association of Mabcore Limited, Dr.&nbsp;Zang, as the sole director, has the power to direct the actions
of Mabcore Limited, including the voting and disposal of Mabcore Limited&#146;s shares in <FONT STYLE="white-space:nowrap">I-Mab.</FONT> Accordingly, Dr.&nbsp;Zang is deemed to indirectly own all of the 3,932,113 ordinary shares held by Mabcore
Limited, while Dr.&nbsp;Qian and the other two individuals are only entitled to their respective <FONT STYLE="white-space:nowrap">pro-rata</FONT> economic interest in Mabcore Limited. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 1,025,232 ordinary shares issuable upon exercise of options exercisable within 60 days after the
date of this prospectus held by Zheru Zhang. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 40,395,989 ordinary shares issuable upon the conversion of (i) 4,629,231 Series <FONT
STYLE="white-space:nowrap">A-1</FONT> preferred shares and 512,356 Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred shares held by IBC Investment Seven Limited, a Hong Kong limited liability company, (ii) 8,361,823 Series <FONT
STYLE="white-space:nowrap">A-3</FONT> preferred shares held by CBC SPVII LIMITED, a Hong&nbsp;Kong limited liability company, (iii) 14,089,714 Series B preferred shares, 2,247,321 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares,
and 1,997,618 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares held by CBC Investment <FONT STYLE="white-space:nowrap">I-Mab</FONT> Limited, a British Virgin Islands limited liability company, and (iv) 1,804,880 Series B preferred
shares, 287,880 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares, and 255,894 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares held by <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited,
a British Virgin Islands limited liability company, and (v) 6,209,272 Series C preferred shares directly held by <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Seven Limited, a British Virgin Islands limited liability company. IBC
Investment Seven Limited, CBC SPVII LIMITED, CBC Investment <FONT STYLE="white-space:nowrap">I-Mab</FONT> Limited, <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited and <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II
Investment Seven Limited are collectively referred to as the <FONT STYLE="white-space:nowrap">C-Bridge</FONT> entities. CBC Investment <FONT STYLE="white-space:nowrap">I-Mab</FONT> Limited, <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II
Investment Ten Limited and <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Seven Limited are controlled by <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Healthcare Fund II, L.P., whose general partner is <FONT
STYLE="white-space:nowrap">C-Bridge</FONT> Healthcare Fund GP II, L.P., and its general partner is <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Capital GP, Ltd. CBC SPVII Limited and IBC Investment Seven Limited are controlled by <FONT
STYLE="white-space:nowrap">I-Bridge</FONT> Healthcare Fund, L.P., whose general partner is <FONT STYLE="white-space:nowrap">I-Bridge</FONT> Healthcare GP, L.P., and its general partner is <FONT STYLE="white-space:nowrap">I-Bridge</FONT> Capital GP,
Ltd., which is indirectly controlled by <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Capital GP, Ltd. Wei Fu is the sole director of <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Capital GP, Ltd. The business address of <FONT
STYLE="white-space:nowrap">C-Bridge</FONT> entities is Suite 3306-3307, Two Exchange Square, 8 Connaught Place, Central, Hong Kong. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 15,852,781 ordinary shares issuable upon the conversion of (i) 8,361,823 Series <FONT
STYLE="white-space:nowrap">A-3</FONT> preferred shares and 5,938,640 Series B preferred shares held by Tasly Biopharm Limited, a British Virgin Islands limited liability company, and (ii) 1,552,318 Series C preferred shares directly held by Tasly
International Capital Limited. Tasly International Capital Limited is wholly-owned by Tasly Holding Group Co., Ltd. Tasly Biopharm Limited&#146;s sole shareholder is Tasly Biopharmaceuticals Co., Ltd., which is controlled by Tasly Pharmaceutical
Group Co., Ltd., which is in turn controlled by Tasly Holding Group Co., Ltd. Tasly Holding Group Co., Ltd. is controlled by Tianjin Tasly Health Industry Investment Group Co., Ltd., which is in turn controlled by Tianjin Fuhuade Science&nbsp;&amp;
Technology Development Co., Ltd. Kaijing Yan is the controlling shareholder of Tianjin Fuhuade Science&nbsp;&amp; Technology Development Co., Ltd. and the ultimate beneficial owner of Tasly Biopharm Limited. We refer to the entities in the preceding
sentence collectively as the Tasly entities. The registered address of Tasly Biopharm Limited and Tasly International Capital Limited is P.O. Box 957, Offshore Incorporation Centre, Road Town, Tortola, British Virgin Islands. </P></TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 8,537,749 ordinary shares issuable upon the conversion of 8,537,749 Series C preferred shares held
by Fortune Eight Jogging Limited, a British Virgin Islands limited liability company. Fortune Eight Jogging Limited is wholly-owned by Hony Hongling (Shanghai) Investment Center, a PRC limited partnership, whose general partner is Hony Capital
(Shanghai) Ltd. The sole shareholder of Hony Capital (Shanghai) Ltd is Beijing Hony Hezhong Management Ltd. Each of Yonggang Cao, Minsheng Xu and Lijie Wang holds 33.3% equity interests in Beijing Hony Hezhong Management Ltd. The registered address
of Fortune Eight Jogging Limited is Kingston Chambers, PO Box 173, Road Town, Tortola, British Virgin Islands. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">245 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 9,261,823 ordinary shares issuable upon the conversion of 8,361,823 Series <FONT
STYLE="white-space:nowrap">A-3</FONT> preferred shares directly held by Genexine, Inc. (Genexine) and 900,000 preferred shares issuable to Genexine upon the full conversion of the US$9.0&nbsp;million interest-free convertible promissory note based
on a conversion price of US$10 per share. Genexine is a Korean public company. The registered address of Genexine is 700 <FONT STYLE="white-space:nowrap">Daewangpangyo-ro,</FONT> Korea Bio Park, Bldg. B4F,
<FONT STYLE="white-space:nowrap">Bundang-gu,</FONT> <FONT STYLE="white-space:nowrap">Seongnam-si,</FONT> <FONT STYLE="white-space:nowrap">Gyeonggi-do,</FONT> Korea. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, none of our ordinary shares outstanding is held by any record holders in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ADSs that we issue in this offering will represent ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not aware of any arrangement that may, at a subsequent date, result in a change of control of our company. See &#147;Description of
Share Capital&#151;History of Securities Issuances&#148; for historical changes in our shareholding structure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">246 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_19"></A>RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;Description
of Share Capital&#151;History of Securities Issuances.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shareholders Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;Description of Share Capital&#151;History of Securities Issuances&#151;Shareholders Agreement.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements and Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;Management&#151;Employment Agreements and Indemnification Agreements.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Incentive Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See
&#147;Management&#151;Share Incentive Plans.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Related Party Transactions with Our Shareholders and Affiliates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;25, 2017, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin and <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai
entered into a loan agreement with each of Qianhai Equity Investment Fund (Limited Partnership) (&#147;Qianhai Fund&#148;), Shanghai Tasly Pharmaceutical Co., Ltd. (&#147;Shanghai Tasly&#148;), and Tianjin Kangshijing Biopharmaceutical Technology
Partnership (Limited Partnership) (&#147;CBC RMB Fund&#148;), pursuant to which each of Qianhai Fund, Shanghai Tasly and CBC RMB Fund made a loan to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin to fund its business operations in an
aggregate principal amount in RMB equivalent to US$1.3&nbsp;million, US$5.1&nbsp;million and US$1.6&nbsp;million, respectively. Each of these loans bears an annual compound interest rate of 8%. Pursuant to these loan agreements, each of Qianhai
Fund, Shanghai Tasly and CBC RMB Fund has the right to contribute its interest in the respective loan to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin in exchange for <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s equity
interests. We fully repaid the loans made by Qianhai Fund and Shanghai Tasly in 2018, and neither of these lenders exercised such right. The loan agreement with CBC RMB Fund was not performed by CBC RMB Fund and was mutually terminated on
September&nbsp;25, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2018, we entered into a collaboration agreement with Everest, an affiliate of <FONT
STYLE="white-space:nowrap">C-Bridge</FONT> Capital Investment Management, Ltd., whereby both parties agreed to collaborate on programs to <FONT STYLE="white-space:nowrap">co-develop</FONT> MorphoSys&#146; proprietary CD38 antibody for all
indications in hematologic oncology and commercialize the CD38 product in China, Hong Kong, Macau and Taiwan. For a detailed description of this collaboration agreement, see &#147;Business&#151;Licensing and Collaboration Arrangements&#151;C.
Collaboration Arrangements.&#148; As of June 30, 2019, we recorded RMB231.4&nbsp;million (US$33.7 million) of research and development funding received from Everest. Everest had paid us prepayments of RMB166.3 million and RMB51.6 million (US$7.5
million) for the six months ended June 30, 2018 and 2019, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2018, we entered into a biologics master services
agreement with CMAB Biopharma (Suzhou) Inc. (&#147;CMAB&#148;), an affiliate of Bridge Capital Partners LLC. In July 2018, we entered into Service Proposal: CMC Development of A Monoclonal Antibody with this entity. Pursuant to these two agreements,
CMAB will provide us with CMC services in connection with the preparation of the IND filings to the FDA and the NMPA in a period of 18 to 22 months for US$3.6&nbsp;million. We had paid CMAB RMB2.8&nbsp;million (US$0.4 million) for the year ended
December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2016, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin entered into a CRO agreement with Tasly
Pharmaceutical Group Co., Ltd. (&#147;Tasly&#148;) and three ancillary agreements to this CRO agreement in November 2016, May 2017 and June 2017, respectively. Pursuant to these agreements, Tasly Pharmaceutical Group Co., Ltd. will provide <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Tianjin with CRO services in connection with <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">G-CSF-HyFc</FONT></FONT> fusion
protein. All of these agreements were terminated on December&nbsp;10, 2018. We had paid Tasly RMB0.8&nbsp;million, nil and RMB5.6 million (US$0.8 million) for the year ended December&nbsp;31, 2017 and 2018 and the six months ended June 30, 2019,
respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">247 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_20"></A>DESCRIPTION OF SHARE CAPITAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a Cayman Islands exempted company with limited liability and our affairs are governed by our memorandum and articles of association,
the Companies Law, Cap. 22 (Law 3 of 1961, as consolidated and revised), as amended, of the Cayman Islands, which is referred to as the Companies Law below, and the common law of the Cayman Islands. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, our authorized share capital is US$50,000 divided into: (i) 402,796,550 voting ordinary shares of a nominal
or par value of US$0.0001 each, (ii) 4,629,231 voting redeemable Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares of a nominal or par value of US$0.0001 each, (iii) 512,356 voting redeemable Series
<FONT STYLE="white-space:nowrap">A-2</FONT> preferred shares of a nominal or par value of US$0.0001 each, (iv) 25,085,469 voting redeemable Series <FONT STYLE="white-space:nowrap">A-3</FONT> preferred shares of a nominal or par value of US$0.0001
each, (v) 23,288,783 voting redeemable Series B preferred shares a nominal or par value of US$0.0001 each, (vi) 3,714,580 voting redeemable Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares of a nominal or par value of US$0.0001
each, (vii) 8,254,622 voting redeemable Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares of a nominal or par value of US$0.0001 each, and (viii) 31,718,409 voting redeemable Series C preferred shares of a nominal or par value of
US$0.0001 each. As of the date of this prospectus, 8,363,719 ordinary shares, 4,629,231 Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares, 512,356 Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred shares, 25,085,469
Series <FONT STYLE="white-space:nowrap">A-3</FONT> preferred shares, 23,288,783 Series B preferred shares, 3,714,580 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares, 3,301,849 Series <FONT STYLE="white-space:nowrap">B-2</FONT>
preferred shares, and 31,046,360 Series C preferred shares are issued and outstanding. All of our issued and outstanding ordinary and preferred shares are fully paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately upon the completion of this offering, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; preferred shares
that are issued and outstanding will be converted into ordinary shares by way of <FONT STYLE="white-space:nowrap">re-designation</FONT> on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, and our
authorized share capital will be US$50,000 divided into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares with a par value of US$0.0001 each. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Post-Offering Memorandum and Articles </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will adopt an amended and restated memorandum and articles of association, which will become effective and replace our current amended and
restated memorandum and articles of association in its entirety immediately prior to the completion of this offering. We refer to this amended and restated memorandum and articles of association as our post-offering memorandum and articles of
association. The following is a summary of the material provisions of the post-offering memorandum and articles of association and of the Companies Law, insofar as they relate to the material terms of our ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Objects of Our Company</I>. Under our post-offering memorandum and articles of association, the objects of our company are unrestricted and
we have the full power and authority to carry out any object not prohibited by the laws of the Cayman Islands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Ordinary Shares</I>.
Our ordinary shares are issued in registered form and are issued when registered in our register of members. We may not issue shares to bearers. Our shareholders who are non-residents of the Cayman Islands may freely hold and vote their shares. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Dividends</I>. Our directors may from time to time declare dividends (including interim dividends) and other distributions on our
shares in issue and authorize payment of the same out of the funds of our company lawfully available therefor. In addition, our shareholders may declare dividends by ordinary resolution, but no dividend shall exceed the amount recommended by our
directors. Our post-offering memorandum and articles of association provide that dividends may be declared and paid out of the funds of our company lawfully available therefor. Under the laws of the Cayman Islands, our company may pay a dividend out
of either profit or the credit standing in our share premium account; provided that in no circumstances may a dividend be paid out of the share premium account if this would result in our company being unable to pay its debts as they fall due in the
ordinary course of business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">248 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Voting Rights</I>. Voting at any meeting of shareholders is by show of hands unless a
poll is demanded. A poll may be demanded by the chairman of such meeting or any one shareholder holding not less than 10% of the votes attaching to the shares present in person or by proxy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An ordinary resolution to be passed at a meeting by the shareholders requires the affirmative vote of a simple majority of the votes attaching
to the ordinary shares cast at a meeting, while a special resolution requires the affirmative vote of not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes attaching to the ordinary shares cast at a meeting. A special
resolution will be required for important matters such as a change of name or making changes to our post-offering memorandum and articles of association. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Alternation of Share Capital </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may from
time to time by ordinary resolution of shareholders: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">increase our share capital by new shares of such amount as it thinks expedient; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">consolidate and divide all or any of our share capital into shares of a larger amount than its existing shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subdivide our shares, or any of them, into shares of an amount smaller than that fixed by the memorandum of
association, provided that in the subdivision the proportion between the amount paid and the amount, if any, unpaid on each reduced share shall be the same as it was in case of the share from which the reduced share is derived; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cancel any shares that, at the date of the passing of the resolution, have not been taken or agreed to be taken
by any person and diminish the amount of its share capital by the amount of the shares so cancelled. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may by special
resolution, subject to any confirmation or consent required by the Companies Law, reduce our share capital and any capital redemption reserve in any manner authorized by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>General Meetings of Shareholders</I>. As a Cayman Islands exempted company, we are not obliged by the Companies Law to call
shareholders&#146; annual general meetings. Our post-offering memorandum and articles of association provide that we may (but are not obliged to) in each year hold a general meeting as our annual general meeting in which case we shall specify the
meeting as such in the notices calling it, and the annual general meeting shall be held at such time and place as may be determined by our directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholders&#146; general meetings may be convened by our directors (acting by a resolution of our board). Advance notice of at least seven
calendar days is required for the convening of our annual general shareholders&#146; meeting (if any) and any other general meeting of our shareholders. A quorum required for any general meeting of shareholders consists of, at the time when the
meeting proceeds to business, one or more of our shareholders holding shares which carry in aggregate (or representing by proxy) not less than <FONT STYLE="white-space:nowrap">one-third</FONT> of all votes attaching to all of our shares in issue and
entitled to vote at such general meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Companies Law does not provide shareholders with any right to requisition a general
meeting, nor any right to put any proposal before a general meeting. However, these rights may be provided in a company&#146;s articles of association. Our post-offering articles of association allow our shareholders holding in aggregate not less
than <FONT STYLE="white-space:nowrap">one-third</FONT> of all votes attaching to the outstanding shares of our company entitled to vote at general meetings to requisition an extraordinary general meeting of our shareholders, in which case our board
is obliged to convene an extraordinary general meeting and to put the resolutions so requisitioned to a vote at such meeting. However, our post-offering memorandum and articles of association do not provide our shareholders with any right to put any
proposals before annual general meetings or extraordinary general meetings not called by such shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">249 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transfer of Ordinary Shares</I>. Subject to the restrictions set out below, any of our
shareholders may transfer all or any of his or her ordinary shares by an instrument of transfer in the usual or common form or any other form approved by our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may, in its absolute discretion, decline to register any transfer of any ordinary share which is not fully paid up or
on which we have a lien. Our board of directors may also decline to register any transfer of any ordinary share unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the instrument of transfer is lodged with us, accompanied by the certificate for the ordinary shares to which it
relates and such other evidence as our board of directors may reasonably require to show the right of the transferor to make the transfer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the instrument of transfer is in respect of only one class of shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the instrument of transfer is properly stamped, if required; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of a transfer to joint holders, the number of joint holders to whom the ordinary share is to be
transferred does not exceed four; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a fee of such maximum sum as the Nasdaq Global Market may determine to be payable or such lesser sum as our
directors may from time to time require is paid to us in respect thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our directors refuse to register a
transfer, they shall, within three calendar months after the date on which the instrument of transfer was lodged, send to each of the transferor and the transferee notice of such refusal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration of transfers may, on ten calendar days&#146; notice being given by advertisement in such one or more newspapers, by
electronic means or by any other means in accordance with the rules of the Nasdaq Global Market be suspended and the register closed at such times and for such periods as our board of directors may from time to time determine; provided, however,
that the registration of transfers shall not be suspended nor the register closed for more than 30 calendar days in any year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Liquidation</I>. On the winding up of our company, if the assets available for distribution amongst our shareholders shall be more than
sufficient to repay the whole of the share capital at the commencement of the winding up, the surplus shall be distributed amongst our shareholders in proportion to the par value of the shares held by them at the commencement of the winding up,
subject to a deduction from those shares in respect of which there are monies due, of all monies payable to our company for unpaid calls or otherwise. If our assets available for distribution are insufficient to repay all of the <FONT
STYLE="white-space:nowrap">paid-up</FONT> capital, such assets will be distributed so that, as nearly as may be, the losses are borne by our shareholders in proportion to the par value of the shares held by them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Calls on Shares and Forfeiture of Shares</I>. Our board of directors may from time to time make calls upon shareholders for any amounts
unpaid on their shares in a notice served to such shareholders at least 14 calendar days prior to the specified time and place of payment. The shares that have been called upon and remain unpaid are subject to forfeiture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Redemption, Repurchase and Surrender of Shares</I>. We may issue shares on terms that such shares are subject to redemption, at our option
or at the option of the holders of these shares, on such terms and in such manner as may be determined, before the issue of such shares, by our board of directors or by our shareholders by an ordinary resolution. Our company may also repurchase any
of our shares on such terms and in such manner as have been approved by our board of directors or by an ordinary resolution of our shareholders. Under Cayman Islands law, any redemption or repurchase of shares by our company may be made out of
profits of our company, out of our company&#146;s share premium account or out of the proceeds of a fresh issue of shares made for the purpose of the repurchase or, if so authorized by the articles of association and subject to provisions of the
Companies Law, out of capital. Any premium payable on a redemption or repurchase over the par value of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">250 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares to be repurchased or redeemed must be provided for out of profits of our company or from sums standing to the credit of the share premium account of our company or, if authorized by the
articles of association and subject to the provisions of the Companies Law, out of capital. At no time may a company redeem or repurchase its shares unless they are fully paid. A company may not redeem or repurchase any of its shares if, as a result
of the redemption or repurchase, there would no longer be any issued shares of the company other than shares held as treasury shares. In addition, our company may accept the surrender of any fully paid share for no consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Variations of Rights of Shares</I>. Whenever the capital of our company is divided into different classes the rights attached to any such
class may, subject to any rights or restrictions for the time being attached to any class, only be varied with the consent in writing of the holders of all of the issued shares of that class or with the sanction of an ordinary resolution passed at a
separate meeting of the holders of the shares of that class. The rights conferred upon the holders of the shares of any class issued with preferred or other rights shall not, subject to any rights or restrictions for the time being attached to the
shares of that class, be deemed to be varied by the creation, allotment or issue of further shares ranking <I>pari passu</I> with such existing class of shares varied by, the creation, allotment or issue of further shares ranking <I>pari passu</I>
with or subsequent to them or the redemption or purchase of any shares of any class by our company. The rights of the holders of shares shall not be deemed to be varied by the creation or issue of shares with preferred or other rights including,
without limitation, the creation of shares with enhanced or weighted voting rights. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Issuance of Additional Shares</I>. Our
post-offering memorandum and articles of association authorize our board of directors to issue additional ordinary shares from time to time as our board of directors shall determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our post-offering memorandum and articles of association also authorize our board of directors to issue from time to time one or more series
of preference shares and to determine, with respect to any series of preference shares, the terms and rights of that series, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dividend rights, dividend rates, conversion rights, voting rights; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rights and terms of redemption and liquidation preferences. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may issue preference shares without action by our shareholders. Issuance of these shares may dilute the voting power of
holders of ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Inspection of Books and Records</I>. Shareholders have no general right under Cayman Islands law to
inspect or obtain copies of our list of shareholders or our corporate records. However, we intend to provide our shareholders with annual audited financial statements. See &#147;Where You Can Find Additional Information.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Anti-Takeover Provisions</I>. Some provisions of our post-offering memorandum and articles of association may discourage, delay or prevent
a change of control of our company or management that shareholders may consider favorable, including provisions that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize our board of directors to issue preference shares in one or more series and to designate the price,
rights, preferences, privileges and restrictions of such preference shares without any further vote or action by our shareholders; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit the ability of shareholders to requisition and convene general meetings of shareholders.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, under Cayman Islands law, our directors may only exercise the rights and powers granted to them under our
post-offering memorandum and articles of association for a proper purpose and for what they believe in good faith to be in the best interests of our company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">251 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Exempted Company. We are an exempted company with limited liability under the Companies Law.
The Companies Law distinguishes between ordinary resident companies and exempted companies. Any company that is registered in the Cayman Islands but conducts business mainly outside of the Cayman Islands may apply to be registered as an exempted
company. The requirements for an exempted company are essentially the same as for an ordinary company except that an exempted company: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">does not have to file an annual return of its shareholders with the Registrar of Companies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">is not required to open its register of members for inspection; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">does not have to hold an annual general meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may issue negotiable or bearer shares or shares with no par value; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may obtain an undertaking against the imposition of any future taxation (such undertakings are usually given for
20 years in the first instance); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may register by way of continuation in another jurisdiction and be deregistered in the Cayman Islands;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may register as a limited duration company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may register as a segregated portfolio company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Limited liability&#148; means that the liability of each shareholder is limited to the amount unpaid by the shareholder on the shares of
the company. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Differences in Corporate Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Companies Law is modeled after that of England but does not follow recent English statutory enactments and differs from laws applicable to
U.S. corporations and their shareholders. Set forth below is a summary of the significant differences between the provisions of the Companies Law applicable to us and the laws applicable to companies incorporated in the United States and their
shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Mergers and Similar Arrangements</I>. The Companies Law permits mergers and consolidations between Cayman Islands
companies and between Cayman Islands companies and <FONT STYLE="white-space:nowrap">non-Cayman</FONT> Islands companies. For these purposes, (a) &#147;merger&#148; means the merging of two or more constituent companies and the vesting of their
undertaking, property and liabilities in one of such companies as the surviving company, and (b)&nbsp;a &#147;consolidation&#148; means the combination of two or more constituent companies into a consolidated company and the vesting of the
undertaking, property and liabilities of such companies to the consolidated company. In order to effect such a merger or consolidation, the directors of each constituent company must approve a written plan of merger or consolidation, which must then
be authorized by (a)&nbsp;a special resolution of the shareholders of each constituent company, and (b)&nbsp;such other authorization, if any, as may be specified in such constituent company&#146;s articles of association. The plan of merger or
consolidation must be filed with the Registrar of Companies of the Cayman Islands together with a declaration as to the solvency of the consolidated or surviving company, a statement of the assets and liabilities of each constituent company and an
undertaking that a copy of the certificate of merger or consolidation will be given to the members and creditors of each constituent company and that notification of the merger or consolidation will be published in the Cayman Islands Gazette. Court
approval is not required for a merger or consolidation which is effected in compliance with these statutory procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A merger between
a Cayman parent company and its Cayman subsidiary or subsidiaries does not require authorization by a resolution of shareholders if a copy of the plan of merger is given to every member of that Cayman subsidiary to be merged unless that member
agrees otherwise. For this purpose a company is a &#147;parent&#148; of a subsidiary if it holds issued shares that together represent at least ninety percent (90%) of the votes at a general meeting of the subsidiary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">252 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consent of each holder of a fixed or floating security interest over a constituent
company is required unless this requirement is waived by a court in the Cayman Islands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Save in certain limited circumstances, a
shareholder of a Cayman constituent company who dissents from the merger or consolidation is entitled to payment of the fair value of his or her shares (which, if not agreed between the parties, will be determined by the Cayman Islands court) upon
dissenting to the merger or consolidation, provided that the dissenting shareholder complies strictly with the procedures set out in the Companies Law. The exercise of dissenter rights will preclude the exercise by the dissenting shareholder of any
other rights to which he or she might otherwise be entitled by virtue of holding shares, save for the right to seek relief on the grounds that the merger or consolidation is void or unlawful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Separate from the statutory provisions relating to mergers and consolidations, the Companies Law also contains statutory provisions that
facilitate the reconstruction and amalgamation of companies by way of schemes of arrangement, provided that the arrangement is approved by a majority in number of each class of shareholders and creditors with whom the arrangement is to be made, and
who must in addition represent three-fourths in value of each such class of shareholders or creditors, as the case may be, that are present and voting either in person or by proxy at a meeting, or meetings, convened for that purpose. The convening
of the meetings and subsequently the arrangement must be sanctioned by the Grand Court of the Cayman Islands. While a dissenting shareholder has the right to express to the court the view that the transaction ought not to be approved, the court can
be expected to approve the arrangement if it determines that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the statutory provisions as to the required majority vote have been met; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the shareholders have been fairly represented at the meeting in question and the statutory majority are acting
bona fide without coercion of the minority to promote interests adverse to those of the class; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the arrangement is such that may be reasonably approved by an intelligent and honest man or woman of that class
acting in respect of his interest; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the arrangement is not one that would more properly be sanctioned under some other provision of the Companies
Law. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When a takeover offer is made and accepted by holders of 90% of the shares within four months, the offeror may,
within a <FONT STYLE="white-space:nowrap">two-month</FONT> period commencing on the expiration of such four-month period, require the holders of the remaining shares to transfer such shares to the offeror on the terms of the offer. An objection can
be made to the Grand Court of the Cayman Islands but this is unlikely to succeed in the case of an offer which has been so approved unless there is evidence of fraud, bad faith or collusion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an arrangement and reconstruction is thus approved, or if a takeover offer is made and accepted, a dissenting shareholder would have no
rights comparable to appraisal rights, which would otherwise ordinarily be available to dissenting shareholders of Delaware corporations, providing rights to receive payment in cash for the judicially determined value of the shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Shareholders&#146; Suits</I>. In principle, we will normally be the proper plaintiff and as a general rule a derivative action may not be
brought by a minority shareholder. However, based on English authorities, which would in all likelihood be of persuasive authority in the Cayman Islands, the Cayman Islands courts can be expected to follow and apply the common law principles (namely
the rule in Foss v. Harbottle and the exceptions thereto) which may permit a minority shareholder to commence a class action against, or derivative actions in the name of, our company to challenge: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an act which is ultra vires or illegal and is therefore incapable of ratification by the shareholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an act which constitutes a fraud against the minority where the wrongdoers are themselves in control of the
company; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">253 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an act which requires a resolution with a qualified (or special) majority (i.e., more than a simple majority)
which has not been obtained. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Indemnification of Directors and Executive Officers and Limitation of
Liability</I>. Cayman Islands law does not limit the extent to which a company&#146;s memorandum and articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman
Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime. Our post-offering memorandum and articles of association permit indemnification of officers and
directors for losses, damages, costs and expenses incurred in their capacities as such unless such losses, damages costs and expenses arise from dishonesty, wilful default or fraud of such directors or officers. This standard of conduct is generally
the same as permitted under the Delaware General Corporation Law for a Delaware corporation. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[In addition, we have entered into
indemnification agreements with our directors and executive officers that provide such persons with additional indemnification beyond that provided in our post-offering memorandum and articles of association.] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers or persons controlling
us under the foregoing provisions, we have been informed that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Directors&#146; Fiduciary Duties</I>. Under Delaware corporate law, a director of a Delaware corporation has a fiduciary duty to the
corporation and its shareholders. This duty has two components: the duty of care and the duty of loyalty. The duty of care requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar
circumstances. Under this duty, a director must inform himself of, and disclose to shareholders, all material information reasonably available regarding a significant transaction. The duty of loyalty requires that a director acts in a manner he or
she reasonably believes to be in the best interests of the corporation. He or she must not use his or her corporate position for personal gain or advantage. This duty prohibits self-dealing by a director and mandates that the best interests of the
corporation and its shareholders take precedence over any interest possessed by a director, officer or controlling shareholder and not shared by the shareholders generally. In general, actions of a director are presumed to have been made on an
informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Should such evidence be
presented concerning a transaction by a director, the director must prove the procedural fairness of the transaction, and that the transaction was of fair value to the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a matter of Cayman Islands law, a director of a Cayman Islands company is in the position of a fiduciary with respect to the company and
therefore it is considered that he or she owes the following duties to the company&#151;a duty to act in good faith in the best interests of the company, a duty not to make a personal profit based on his or her position as director (unless the
company permits him or her to do so), a duty not to put himself or herself in a position where the interests of the company conflict with his or her personal interest or his or her duty to a third party and a duty to exercise powers for the purpose
for which such powers were intended. A director of a Cayman Islands company owes to the company a duty to act with skill and care. It was previously considered that a director need not exhibit in the performance of his or her duties a greater degree
of skill than may reasonably be expected from a person of his or her knowledge and experience. However, English and Commonwealth courts have moved towards an objective standard with regard to the required skill and care and these authorities are
likely to be followed in the Cayman Islands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Shareholder Action by Written Consent</I>. Under the Delaware General Corporation Law, a
corporation may eliminate the right of shareholders to act by written consent by amendment to its certificate of incorporation. Cayman Islands law and our post-offering articles of association provide that shareholders may approve
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">254 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
corporate matters by way of a unanimous written resolution signed by or on behalf of each shareholder who would have been entitled to vote on such matter at a general meeting without a meeting
being held. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Shareholder Proposals</I>. Under the Delaware General Corporation Law, a shareholder has the right to put any proposal
before the annual meeting of shareholders, provided it complies with the notice provisions in the governing documents. A special meeting may be called by the board of directors or any other person authorized to do so in the governing documents, but
shareholders may be precluded from calling special meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Companies Law does not provide shareholders with any right to
requisition a general meeting, nor any right to put any proposal before a general meeting. However, these rights may be provided in a company&#146;s articles of association. Our post-offering articles of association allow our shareholders holding in
aggregate not less than <FONT STYLE="white-space:nowrap">[one-third]</FONT> of all votes attaching to the outstanding shares of our company entitled to vote at general meetings to requisition an extraordinary general meeting of our shareholders, in
which case our board is obliged to convene an extraordinary general meeting and to put the resolutions so requisitioned to a vote at such meeting. Other than this right to requisition a shareholders&#146; meeting, our post-offering articles of
association do not provide our shareholders with any other right to put proposals before annual general meetings or extraordinary general meetings. As an exempted Cayman Islands company, we are not obliged by law to call shareholders&#146; annual
general meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Cumulative Voting</I>. Under the Delaware General Corporation Law, cumulative voting for elections of directors is
not permitted unless the corporation&#146;s certificate of incorporation specifically provides for it. Cumulative voting potentially facilitates the representation of minority shareholders on a board of directors since it permits the minority
shareholder to cast all the votes to which the shareholder is entitled on a single director, which increases the shareholder&#146;s voting power with respect to electing such director. There are no prohibitions in relation to cumulative voting under
the laws of the Cayman Islands but our post-offering articles of association do not provide for cumulative voting. As a result, our shareholders are not afforded any less protections or rights on this issue than shareholders of a Delaware
corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Removal of Directors</I>. Under the Delaware General Corporation Law, a director of a corporation with a classified board
may be removed only for cause with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. Under our post-offering articles of association, subject to certain restrictions as
contained therein, directors may be removed with or without cause, by an ordinary resolution of our shareholders. A director shall hold office until the expiration of his or her term or his or her successor shall have been elected and qualified, or
until his or her office is otherwise vacated. In addition, a director&#146;s office shall be vacated if the director (i)&nbsp;becomes bankrupt or makes any arrangement or composition with his or her creditors; (ii)&nbsp;is found to be or becomes of
unsound mind or dies; (iii)&nbsp;resigns his or her office by notice in writing to the company; (iv)&nbsp;without special leave of absence from our board of directors, is absent from three consecutive meetings of the board and the board resolves
that his or her office be vacated; (v)&nbsp;is prohibited by law from being a director; or (vi)&nbsp;is removed from office pursuant to any other provisions of our post-offering memorandum and articles of association. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transactions with Interested Shareholders</I>. The Delaware General Corporation Law contains a business combination statute applicable to
Delaware corporations whereby, unless the corporation has specifically elected not to be governed by such statute by amendment to its certificate of incorporation, it is prohibited from engaging in certain business combinations with an
&#147;interested shareholder&#148; for three years following the date that such person becomes an interested shareholder. An interested shareholder generally is a person or a group who or which owns or owned 15% or more of the target&#146;s
outstanding voting share within the past three years. This has the effect of limiting the ability of a potential acquirer to make a <FONT STYLE="white-space:nowrap">two-tiered</FONT> bid for the target in which all shareholders would not be treated
equally. The statute does not apply if, among other things, prior to the date on which such shareholder becomes an interested shareholder, the board of directors approves either the business combination or the transaction which resulted in the
person becoming an interested shareholder. This encourages any potential acquirer of a Delaware corporation to negotiate the terms of any acquisition transaction with the target&#146;s board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">255 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cayman Islands law has no comparable statute. As a result, we cannot avail ourselves of the
types of protections afforded by the Delaware business combination statute. However, although Cayman Islands law does not regulate transactions between a company and its significant shareholders, it does provide that such transactions must be
entered into bona fide in the best interests of the company and not with the effect of constituting a fraud on the minority shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Dissolution; Winding up</I>. Under the Delaware General Corporation Law, unless the board of directors approves the proposal to dissolve,
dissolution must be approved by shareholders holding 100% of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors may it be approved by a simple majority of the corporation&#146;s outstanding
shares. Delaware law allows a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Cayman Islands law, a company may be wound up by either an order of the courts of the Cayman Islands or by a special resolution of its
members or, if the company is unable to pay its debts as they fall due, by an ordinary resolution of its members. The court has authority to order winding up in a number of specified circumstances including where it is, in the opinion of the court,
just and equitable to do so. Under the Companies Law and our post-offering articles of association, our company may be dissolved, liquidated or wound up by a special resolution of our shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Variation of Rights of Shares</I>. Under the Delaware General Corporation Law, a corporation may vary the rights of a class of shares with
the approval of a majority of the outstanding shares of such class, unless the certificate of incorporation provides otherwise. Under Cayman Islands law and our post-offering articles of association, if our share capital is divided into more than
one class of shares, we may vary the rights attached to any class with the written consent of the holders of all of the issued shares of that class or with the sanction of an ordinary resolution passed at a general meeting of the holders of the
shares of that class. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment of Governing Documents</I>. Under the Delaware General Corporation Law, a corporation&#146;s
governing documents may be amended with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. As permitted by Cayman Islands law, our post-offering memorandum and articles
of association may only be amended with a special resolution of our shareholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>History of Securities Issuances </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of our securities issuances in the past three years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Ordinary Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;30, 2016, we issued (i) 1 ordinary share to Offshore Incorporations (Cayman) Limited which was immediately transferred to Mabcore
Limited for a purchase price of US$0.0001 and (ii) 4,019,553 ordinary shares to Mabcore Limited for a purchase price of US$401.9553. Dr.&nbsp;Zang, through himself and The Jingwu Zhang Zang 2018 Retained Annuity Trust, owns a 55.6% equity interest
in Mabcore Limited. Lili Qian and two other individuals own the remaining equity interest in Mabcore Limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;18, 2016,
we repurchased and cancelled 87,441 ordinary shares from Mabcore Limited. The remaining 3,932,113 ordinary shares held by Mabcore Limited have been designated as restricted ordinary shares pursuant to the restricted share agreement, dated as of
October&nbsp;18, 2016, by and among <FONT STYLE="white-space:nowrap">I-Mab,</FONT> Mabcore Limited and certain other parties thereto. None of these restricted shares may be sold, transferred, pledged, hypothecated, or otherwise disposed of, directly
or indirectly, by any shareholder of Mabcore Limited or Mabcore Limited prior to the termination of our repurchase right unless consented to by IBC Investment Seven Limited, an affiliate of <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Capital
Investment Management, Ltd. As of the date of this prospectus, our repurchase right with respect to 70% of these restricted shares has already lapsed, and our repurchase right with respect to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">256 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
remaining 30% of the restricted shares shall lapse on October&nbsp;18, 2019. However, such repurchase right may be terminated earlier upon the completion of: (i)&nbsp;a change of control of our
company; (ii)&nbsp;the consummation of a firm underwritten public offering of the ordinary shares of our company on the Shenzhen or Shanghai Stock Exchange, the NEEQ (which is the National Equities Exchange and Quotations Co., Ltd., a Chinese <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> system for trading the shares of a public limited company that is not listed on either the Shenzhen or Shanghai Stock Exchange) or other recognized regional
or national securities exchange, with an offering price that reflects a market capitalization of not less than US$200&nbsp;million (exclusive of underwriting commissions and expenses) and gross proceeds to our company of at least US$40&nbsp;million
(prior to any underwriters&#146; commissions and expenses), or (iii)&nbsp;the termination of employment or consultancy of any of these shareholders of Mabcore Limited with us without cause. Prior to the termination of our repurchase right, we have
the right to repurchase, from Mabcore Limited, all of the restricted shares ultimately held by any of these shareholders of Mabcore Limited, at a repurchase price equal to the equivalent amount of US$ of RMB0.5385 per share, plus a 12% interest
compounded annual interest accruing from October&nbsp;18, 2016, upon (x)&nbsp;the voluntary termination by a shareholder of Mabcore Limited of his/her employment or consultancy with us, or (y)&nbsp;the termination by us of such person&#146;s
employment or consultancy with us for cause. To exercise our repurchase right, we shall deliver a written notice to Mabcore Limited and the applicable shareholder of Mabcore Limited within 60 days after the termination of the employment or
consultancy of such shareholder. We have no obligation to repurchase any restricted shares. We may not assign any repurchase right to any party without the prior written consent of IBC Investment Seven Limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;18, 2016, we issued an aggregate of 4,431,606 ordinary shares to BioScikin Co., Ltd. and Hangzhou Tigermed Consulting Co., Ltd
for an aggregate purchase price of approximately RMB16.0&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;18, 2016, we issued 4,629,231 Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares and 512,356 Series <FONT
STYLE="white-space:nowrap">A-2</FONT> preferred shares to IBC Investment Seven Limited for an aggregate purchase price of approximately US$4.6&nbsp;million and US$8.4&nbsp;million, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;6, 2017, we issued an aggregate of 16,723,646 Series <FONT STYLE="white-space:nowrap">A-3</FONT> preferred shares to CBC
SPVII LIMITED and Genexine for an aggregate purchase price of US$30.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;22, 2017, we issued 14,089,714
Series B preferred shares to CBC Investment <FONT STYLE="white-space:nowrap">I-Mab</FONT> Limited for an aggregate purchase price of US$48.4&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;9, 2018, we issued 1,804,880 Series B preferred shares to <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten
Limited for an aggregate purchase price of US$6.2&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;29, 2018, we issued an aggregate of 2,535,201 Series <FONT
STYLE="white-space:nowrap">B-1</FONT> preferred shares to CBC Investment <FONT STYLE="white-space:nowrap">I-MAB</FONT> Limited and <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited for an aggregate purchase price of
approximately US$13.7&nbsp;million as a result of the conversion by these two entities of the convertible promissory notes issued to them on September&nbsp;25, 2017 and February&nbsp;9, 2018, respectively. On the same date, we issued an aggregate of
2,253,512 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares to CBC Investment <FONT STYLE="white-space:nowrap">I-MAB</FONT> Limited and <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited for an aggregate
purchase price of approximately US$13.7&nbsp;million as a result of the exercise of the warrants granted to them on September&nbsp;25, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;29, 2018, we issued 8,361,823 Series <FONT STYLE="white-space:nowrap">A-3</FONT> preferred shares, 5,938,640 Series B preferred
shares, and 947,218 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares to Tasly Biopharma Limited in exchange for Tasly Biopharma Limited&#146;s equity interests in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2018, Tasly Biopharma Limited transferred to Rainbow Horizon Limited 947,218 Series
<FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares and the warrant in part to purchase 841,971 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares for a total purchase price of US$6.0&nbsp;million. On the same date, we
issued 841,971 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares to Rainbow Horizon Limited as a result of the exercise of the warrant by Rainbow Horizon for an aggregate purchase price of US$5.1&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">257 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2018, we issued to Qianhai Ark (Cayman) Investment Co. Limited
(&#147;Qianhai Ark Cayman&#148;), (i) 1,455,549 Series B preferred shares for a purchase price of approximately US$2.0&nbsp;million, (ii) 232,161 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares for an aggregate purchase price of
US$1.25&nbsp;million as a result of the conversion of a convertible promissory note issued to Qianhai Ark Cayman on July&nbsp;6, 2018, and (iii) 206,366 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares for an aggregate purchase
price of US$1.25&nbsp;million as a result of the exercise of warrant granted to Qianhai Ark Cayman on September&nbsp;25, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
July&nbsp;6, 2018, we issued an aggregate of 31,046,360 Series C preferred shares to Fortune Eight Jogging Limited, <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Seven Limited, HH IMB Holdings Limited, Ally Bridge LB Precision
Limited, Marvey Investment Company Limited, Mab Health Limited, Casiority H Limited, Southern Creation Limited (formerly known as Ally Bridge <FONT STYLE="white-space:nowrap">LB-Sunshine</FONT> Limited), Tasly International Capital Limited, and
Parkway Limited for an aggregate purchase price of US$200.0&nbsp;million. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July 25, 2019, we entered into a share purchase
agreement with Caesar Pro Holdings Limited, WuXi Biologics HealthCare Venture, and Hongkong Tigermed Co., Limited. Pursuant to the share purchase agreement, these investors will subscribe for an aggregate of 3,857,143 Series <FONT
STYLE="white-space:nowrap">C-1</FONT> preferred shares of <FONT STYLE="white-space:nowrap">I-Mab</FONT> for an aggregate purchase price of US$27.0 million. We expect to close this transaction in October 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Promissory Notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;25, 2017, we issued a US$12.1&nbsp;million convertible promissory note due September 2020 to CBC Investment <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Limited. On June&nbsp;29, 2018, CBC Investment <FONT STYLE="white-space:nowrap">I-Mab</FONT> Limited converted this note to 2,247,321 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;5, 2018, we issued a US$9.0&nbsp;million convertible promissory note due February 2021 to Genexine. Genexine can at any time
prior to February&nbsp;5, 2021 convert this note into preferred shares of <FONT STYLE="white-space:nowrap">I-Mab</FONT> at US$10 per share, subject to certain price adjustments. As of the date of this prospectus, Genexine has not converted this
note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;9, 2018, we issued a US$1.6&nbsp;million convertible promissory note due September 2020 to <FONT
STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited. On June&nbsp;29, 2018, <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited converted this note into 287,880 Series
<FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2018, we issued a US$1.3&nbsp;million convertible
promissory note due July 2021 to Qianhai Ark Cayman. On July&nbsp;6, 2018, Qianhai Ark Cayman converted this note into 232,161 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Options and Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;18, 2016, we granted IBC Investment Seven Limited a warrant to purchase up to 2,246,744 Series
<FONT STYLE="white-space:nowrap">A-3</FONT> preferred shares. The warrant was cancelled on September&nbsp;6, 2017 pursuant to a termination agreement between us and IBC Investment Seven Limited, who had not exercised the warrant prior to the
termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;6, 2017, we granted Shanghai Tasly an option to purchase up to 8,361,823 Series <FONT
STYLE="white-space:nowrap">A-3</FONT> preferred shares. On September&nbsp;25, 2017, we granted Shanghai Tasly an additional option to purchase up to 5,938,640 Series B preferred shares and 947,218 Series <FONT STYLE="white-space:nowrap">B-1</FONT>
preferred shares. On June&nbsp;29, 2018, Tasly Biopharma Limited, as Shanghai Tasly&#146;s permitted assign, exercised these options in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;25, 2017, we granted (i)&nbsp;Qianhai Fund an option to purchase up to 1,455,549 Series B preferred shares and up to 232,161
Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares, and (ii)&nbsp;CBC RMB Fund an option to purchase up to 1,804,880 Series B preferred shares and up to 287,880 additional Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred
Shares. The option granted to Qianhai Fund was exercised in full on July&nbsp;6, 2018. The option granted to CMC RMB Fund was terminated on February&nbsp;9, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">258 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;25, 2017, we granted a warrant to each of CBC Investment <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Limited, Shanghai Tasly, Qianhai Fund and <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited to purchase up to 4,994,046 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred
shares, up to 2,104,928 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares, up to 515,914 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares and up to 639,734 Series <FONT STYLE="white-space:nowrap">B-2</FONT>
preferred shares, respectively. On July&nbsp;6, 2018, these investors exercised their warrants in part and purchased 1,997,618 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares, 841,971 Series
<FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares, 206,366 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares and 255,894 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares, for an aggregate purchase
price of US$20.0&nbsp;million. These investors have waived and cancelled their rights under the rest of the warrants. On September&nbsp;25, 2017, we also granted a warrant to CBC RMB Fund to purchase up to 639,734 Series <FONT
STYLE="white-space:nowrap">B-2</FONT> preferred shares, which was terminated on the same date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2018, Tasly Biopharm
Limited, as Shanghai Tasly&#146;s permitted assign, transferred to Rainbow Horizon Limited the warrant in part to purchase 841,971 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares. On the same date, Rainbow Horizon Limited
exercised this warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted options to purchase our ordinary shares to certain of our directors, executive officers
and&nbsp;employees. See &#147;Management&#151;Share Incentive Plans.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Shareholders Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into our shareholders agreement on July&nbsp;6, 2018 with our shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shareholders agreement provides for certain special rights, including right of first refusal,
<FONT STYLE="white-space:nowrap">co-sale</FONT> rights, preemptive rights and contains provisions governing the board of directors and other corporate governance matters. Unless specifically noted, those special rights, as well as the corporate
governance provisions, will automatically terminate upon the completion of a qualified initial public offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>[Registration
Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our shareholders agreement dated July&nbsp;6, 2018, we have granted certain registration rights to our
shareholders. Set forth below is a description of the registration rights granted under the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Demand Registration Rights</I>.
At any time after the earlier of (i)&nbsp;December&nbsp;31, 2020, or (ii)&nbsp;six months following the effectiveness of a registration statement for a firm underwritten public offering of our ordinary shares on The Stock Exchange of Hong Kong
Limited, or other internationally recognized securities exchange, with an offering price (exclusive of underwriting commissions and expenses) that reflects a market capitalization (immediately prior to the public offering) of not less than
US$1.0&nbsp;billion, the holders of a majority of the registrable securities then issued and outstanding may request in writing that we file a registration statement covering the registration of at least 20% of the registrable securities (or any
lesser percentage if the anticipated gross receipts from the offering are to exceed US$5.0 million). Upon such a request, we shall, within ten business days of the receipt of such written request, give written notice of such request to all holders,
and use our best efforts to effect, as soon as practicable, the registration of all registrable securities that the holders request to be registered and included in such registration by written notice given by such holders to us within 20 days after
receipt of the request notice. We have the right to defer filing of a registration statement for a period of not more than 90 days after receipt of the request of the initiating holders if our board of directors determines in good faith that filing
of such registration statement at such time will be materially detrimental to us or our shareholders, but we cannot exercise the deferral right more than once during any twelve-month period and cannot register any other securities during such
twelve-month period. We are not obligated to effect any such registration if we have, within the <FONT STYLE="white-space:nowrap">six-month</FONT> period preceding the date of such request, already effected a registration. We are not obligated to
effect more than three demand registrations. This demand registration right is subject to the customary exclusion right of the underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Registration on Form <FONT STYLE="white-space:nowrap">F-3</FONT></I>. If we qualify for registration on Form
<FONT STYLE="white-space:nowrap">F-3,</FONT> any holder or holders of a majority of all registrable securities then issued and outstanding may request in writing that we effect a registration on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">259 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">Form&nbsp;F-3</FONT> (or an equivalent registration in a jurisdiction outside of the U.S.). We shall promptly give written notice of the proposed registration and
as soon as practicable, effect such registration within 20 days after we provide the aforesaid written notice. The holders are entitled to an unlimited number of registrations on Form <FONT STYLE="white-space:nowrap">F-3</FONT> so long as such
registration offerings are in excess of US$500,000. We are not obligated to effect any such registration if we have, within the <FONT STYLE="white-space:nowrap">six-month</FONT> period preceding the date of such request, already effected a
registration other than a registration from which registrable securities of the holders have been excluded, or if we would be required to qualify to do business or to execute a general consent to service of process in effecting such registration in
any particular jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Piggyback Registration Rights</I>. If we propose to register for a public offering of our securities
(other than registration statements relating to demand registration, Form <FONT STYLE="white-space:nowrap">F-3</FONT> registration, any employee benefit plan or a corporate reorganization), we shall give written notice of such registration to all
holders of registrable securities at least 30 days prior to filing any registration statement and afford each such holder an opportunity to be included in such registration. If a holder decides not to include all of its registrable securities in any
registration statement thereafter filed by us, such holder shall nevertheless continue to have the right to include any registrable securities in any subsequent registration statement or registration statements as may be filed by us, subject to
certain limitations. This piggyback registration right is subject to the customary exclusion right of the underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expenses of
Registration</I>. We will bear all registration expenses. Each holder, however, should bear its proportionate share of all of the underwriting discounts and selling commissions applicable to the sale of registrable securities or other amounts
payable to underwriter(s) or brokers in connection with such offering by the holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Termination of Obligations</I>. Our obligations
to effect any demand, <FONT STYLE="white-space:nowrap">Form&nbsp;F-3</FONT> or piggyback registration shall terminate upon the tenth anniversary of our initial public offering.] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">260 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_21"></A>DESCRIPTION OF AMERICAN DEPOSITARY SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>American Depositary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, as depositary will issue the ADSs which you will be entitled to
receive in this offering. Each ADS will represent an ownership interest in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares which we will deposit with the custodian, as agent of the
depositary, under the deposit agreement among us, the depositary and you as an ADR holder. In the future, each ADS will also represent any securities, cash or other property deposited with the depositary but which they have not distributed directly
to you. Unless specifically requested by you, all ADSs will be issued on the books of our depositary in book-entry form and periodic statements will be mailed to you which reflect your ownership interest in such ADSs. In our description, references
to American depositary receipts or ADRs shall include the statements you will receive which reflect your ownership of ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
depositary&#146;s office is located at &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may hold ADSs either directly or indirectly through your broker or other financial institution. If you hold ADSs directly, by having an
ADS registered in your name on the books of the depositary, you are an ADR holder. This description assumes you hold your ADSs directly. If you hold the ADSs through your broker or financial institution nominee, you must rely on the procedures of
such broker or financial institution to assert the rights of an ADR holder described in this section. You should consult with your broker or financial institution to find out what those procedures are. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an ADR holder, we will not treat you as a shareholder of ours and you will not have any shareholder rights. Cayman Islands law governs
shareholder rights. Because the depositary or its nominee will be the shareholder of record for the shares represented by all outstanding ADSs, shareholder rights rest with such record holder. Your rights are those of an ADR holder. Such rights
derive from the terms of the deposit agreement to be entered into among us, the depositary and all registered holders from time to time of ADSs issued under the deposit agreement. The obligations of the depositary and its agents are also set out in
the deposit agreement. Because the depositary or its nominee will actually be the registered owner of the shares, you must rely on it to exercise the rights of a shareholder on your behalf. The deposit agreement and the ADSs are governed by
New&nbsp;York law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of what we believe to be the material terms of the deposit agreement. Notwithstanding this,
because it is a summary, it may not contain all the information that you may otherwise deem important. For more complete information, you should read the entire deposit agreement and the form of ADR which contains the terms of your ADSs. You can
read a copy of the deposit agreement which is filed as an exhibit to the registration statement of which this prospectus forms apart. You may also obtain a copy of the deposit agreement at the SEC&#146;s Public Reference Room which is located at 100
F Street, NE, Washington, D.C. 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-732-0330.</FONT></FONT></FONT> You may also find the registration statement and the attached deposit agreement on the SEC&#146;s website at
http://www.sec.gov. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Dividends and Other Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>How will I receive dividends and other distributions on the shares underlying my ADSs? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may make various types of distributions with respect to our securities. The depositary has agreed that, to the extent practicable, it will
pay to you the cash dividends or other distributions it or the custodian receives on shares or other deposited securities, after converting any cash received into U.S. dollars and, in all cases, making any necessary deductions provided for in the
deposit agreement. You will receive these distributions in proportion to the number of underlying securities that your ADSs represent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">261 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as stated below, the depositary will deliver such distributions to ADR holders in
proportion to their interests in the following manner: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Cash</I>. The depositary will distribute any U.S. dollars available to it resulting from a cash dividend or
other cash distribution or the net proceeds of sales of any other distribution or portion thereof (to the extent applicable), on an averaged or other practicable basis, subject to (i)&nbsp;appropriate adjustments for taxes withheld, (ii)&nbsp;such
distribution being impermissible or impracticable with respect to certain registered ADR holders, and (iii)&nbsp;deduction of the depositary&#146;s expenses in (1)&nbsp;converting any foreign currency to U.S. dollars to the extent that it determines
that such conversion may be made on a reasonable basis, (2)&nbsp;transferring foreign currency or U.S. dollars to the United States by such means as the depositary may determine to the extent that it determines that such transfer may be made on a
reasonable basis, (3)&nbsp;obtaining any approval or license of any governmental authority required for such conversion or transfer, which is obtainable at a reasonable cost and within a reasonable time and (4)&nbsp;making any sale by public or
private means in any commercially reasonable manner. The depositary will hold any cash amounts it is unable to distribute in a <FONT STYLE="white-space:nowrap">non-interest-bearing</FONT> account for the benefit of the applicable holders and
beneficial owners of ADSs until the distribution can be effected or the funds that the depositary holds must be escheated as unclaimed property in accordance with the laws of the relevant states of the United States. <I>If exchange rates fluctuate
during a time when the depositary cannot convert a foreign currency, you may lose some or all of the value of the distribution</I>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Shares</I>. In the case of a distribution in shares, the depositary will issue additional ADRs to evidence the
number of ADSs representing such shares. Only whole ADSs will be issued. Any shares which would result in fractional ADSs will be sold and the net proceeds will be distributed in the same manner as cash to the ADR holders entitled thereto.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Rights to Receive Additional Shares</I>. In the case of a distribution of rights to subscribe for additional
shares or other rights, if we provide evidence satisfactory to the depositary that it may lawfully distribute such rights, the depositary will distribute warrants or other instruments in the discretion of the depositary representing such rights.
However, if we do not furnish such evidence, the depositary may: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell such rights if practicable and distribute the net proceeds in the same manner as cash to the ADR holders
entitled thereto; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if it is not practicable to sell such rights, do nothing and allow such rights to lapse, in which case ADR
holders will receive nothing. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have no obligation to file a registration statement under the Securities Act in order
to make any rights available to ADR holders. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Other Distributions</I>. In the case of a distribution of securities or property other than those described
above, the depositary may either (i)&nbsp;distribute such securities or property in any manner it deems equitable and practicable or (ii)&nbsp;to the extent the depositary deems distribution of such securities or property not to be equitable and
practicable, sell such securities or property and distribute any net proceeds in the same way it distributes cash. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
the depositary determines that any distribution described above is not practicable with respect to any specific registered ADR holder, the depositary may choose any method of distribution that it deems practicable for such ADR holder, including the
distribution of foreign currency, securities or property, or it may retain such items, without paying interest on or investing them, on behalf of the ADR holder as deposited securities, in which case the ADSs will also represent the retained items.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any U.S. dollars will be distributed by checks drawn on a bank in the United States for whole dollars and cents. Fractional cents will be
withheld without liability and dealt with by the depositary in accordance with its then current practices. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">262 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary is not responsible if it decides that it is unlawful or impractical to make a
distribution available to any ADR holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that the depositary will be able to convert any currency at a
specified exchange rate or sell any property, rights, shares or other securities at a specified price, nor that any of such transactions can be completed within a specified time period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Deposit, Withdrawal and Cancellation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>How does the depositary issue ADSs? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary will issue ADSs if you or your broker deposits shares or evidence of rights to receive shares with the custodian and pays the
fees and expenses owing to the depositary in connection with such issuance. In the case of the ADSs to be issued under this prospectus, we will arrange with the underwriters named herein to deposit such shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares deposited in the future with the custodian must be accompanied by certain delivery documentation and shall, at the time of such
deposit, be registered in the name of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, as depositary for the benefit of holders of ADRs or in such other name as the depositary shall direct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The custodian will hold all deposited shares (including those being deposited by or on our behalf in connection with the offering to which
this prospectus relates) for the account of the depositary. ADR holders thus have no direct ownership interest in the shares and only have such rights as are contained in the deposit agreement. The custodian will also hold any additional securities,
property and cash received on or in substitution for the deposited shares. The deposited shares and any such additional items are referred to as &#147;deposited securities.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon each deposit of shares, receipt of related delivery documentation and compliance with the other provisions of the deposit agreement,
including the payment of the fees and charges of the depositary and any taxes or other fees or charges owing, the depositary will issue an ADR or ADRs in the name or upon the order of the person entitled thereto evidencing the number of ADSs to
which such person is entitled. All of the ADSs issued will, unless specifically requested to the contrary, be part of the depositary&#146;s direct registration system, and a registered holder will receive periodic statements from the depositary
which will show the number of ADSs registered in such holder&#146;s name. An ADR holder can request that the ADSs not be held through the depositary&#146;s direct registration system and that a certificated ADR be issued. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>How do ADR holders cancel an ADS and obtain deposited securities? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When you turn in your ADR certificate at the depositary&#146;s office, or when you provide proper instructions and documentation in the case of
direct registration ADSs, the depositary will, upon payment of certain applicable fees, charges and taxes, deliver the underlying shares to you or upon your written order. At your risk, expense and request, the depositary may deliver deposited
securities at such other place as you may request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary may only restrict the withdrawal of deposited securities in connection
with: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">temporary delays caused by closing our transfer books or those of the depositary or the deposit of shares in
connection with voting at a shareholders&#146; meeting, or the payment of dividends; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the payment of fees, taxes and similar charges; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with any U.S. or foreign laws or governmental regulations relating to the ADRs or to the withdrawal of
deposited securities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This right of withdrawal may not be limited by any other provision of the deposit agreement. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">263 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Record Dates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary may, after consultation with us if practicable, fix record dates for the determination of the registered ADR holders who will be
entitled (or obligated, as the case may be): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to receive any distribution on or in respect of shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to give instructions for the exercise of voting rights at a meeting of holders of shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to pay the fee assessed by the depositary for administration of the ADR program and for any expenses as provided
for in the ADR; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to receive any notice or to act in respect of other matters all subject to the provisions of the deposit
agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>How do I vote? </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
you are an ADR holder and the depositary asks you to provide it with voting instructions, you may instruct the depositary how to exercise the voting rights for the shares which underlie your ADSs. As soon as practicable after receiving notice of any
meeting or solicitation of consents or proxies from us, the depositary will distribute to the registered ADR holders a notice stating such information as is contained in the voting materials received by the depositary and describing how you may
instruct the depositary to exercise the voting rights for the shares which underlie your ADSs. For instructions to be valid, the depositary must receive them in the manner and on or before the date specified. No voting instructions may be deemed
given to the depositary to give a discretionary proxy to a person designated by us if no instructions are received by the depositary from you on or before the response date established by the depositary. The depositary will try, as far as is
practical, subject to the provisions of and governing the underlying shares or other deposited securities, to vote or to have its agents vote the shares or other deposited securities as you instruct. The depositary will only vote or attempt to vote
as you instruct. The depositary will not itself exercise any voting discretion. Furthermore, neither the depositary nor its agents are responsible for any failure to carry out any voting instructions, for the manner in which any vote is cast or for
the effect of any vote. Notwithstanding anything contained in the deposit agreement or any ADR, the depositary may, to the extent not prohibited by law or regulations, or by the requirements of the stock exchange on which the ADSs are listed, in
lieu of distribution of the materials provided to the depositary in connection with any meeting of, or solicitation of consents or proxies from, holders of deposited securities, distribute to the registered holders of ADRs a notice that provides
such holders with, or otherwise publicizes to such holders, instructions on how to retrieve such materials or receive such materials upon request (i.e., by reference to a website containing the materials for retrieval or a contact for requesting
copies of the materials). </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our constituent documents the depositary would be able to provide us with voting instructions without
having to personally attend meetings in person or by proxy. Such voting instructions may be provided to us via facsimile, email, mail, courier or other recognized form of delivery and we agree to accept any such delivery so long as it is timely
received prior to the meeting. We will endeavor to provide the depositary with written notice of each meeting of shareholders promptly after determining the date of such meeting so as to enable it to solicit and receive voting instructions. In
general, the depositary will require that voting instructions be received by the depositary no less than five business days prior to the date of each meeting of shareholders. Under the post-offering memorandum and articles of association that we
expect to adopt, the minimum notice period required to convene a general meeting is seven days. The depositary may not have sufficient time to solicit voting instructions, and it is possible that you, or persons who hold their ADSs through brokers,
dealers or other third parties, will not have the opportunity to exercise a right to vote. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the above, we have
advised the depositary that under the Cayman Islands law and our constituent documents, each as in effect as of the date of the deposit agreement, voting at any meeting of shareholders is by show of hands unless a poll is (before or on the
declaration of the results of the show of hands) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">264 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
demanded. In the event that voting on any resolution or matter is conducted on a show of hands basis in accordance with our constituent documents, the depositary will refrain from voting and the
voting instructions (or the deemed voting instructions, as set out above) received by the depositary from holders shall lapse. The depositary will not demand a poll or join in demanding a poll, whether or not requested to do so by holders of ADSs.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no guarantee that you will receive voting materials in time to instruct the depositary to vote and it is possible that you, or
persons who hold their ADSs through brokers, dealers or other third parties, will not have the opportunity to exercise a right to vote. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reports and
Other Communications </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Will ADR holders be able to view our reports? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary will make available for inspection by ADR holders at the offices of the depositary and the custodian the deposit agreement, the
provisions of or governing deposited securities, and any written communications from us which are both received by the custodian or its nominee as a holder of deposited securities and made generally available to the holders of deposited securities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if we make any written communications generally available to holders of our shares, and we furnish copies thereof (or
English translations or summaries) to the depositary, it will distribute the same to registered ADR holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fees and Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>What fees and expenses will I be responsible for paying? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary may charge each person to whom ADSs are issued, including, without limitation, issuances against deposits of shares, issuances
in respect of share distributions, rights and other distributions, issuances pursuant to a stock dividend or stock split declared by us or issuances pursuant to a merger, exchange of securities or any other transaction or event affecting the ADSs or
deposited securities, and each person surrendering ADSs for withdrawal of deposited securities or whose ADRs are cancelled or reduced for any other reason, US$5.00 for each 100 ADSs (or any portion thereof) issued, delivered, reduced, cancelled or
surrendered, as the case may be. The depositary may sell (by public or private sale) sufficient securities and property received in respect of a share distribution, rights and/or other distribution prior to such deposit to pay such charge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following additional charges shall be incurred by the ADR holders, by any party depositing or withdrawing shares or by any party
surrendering ADSs or to whom ADSs are issued (including, without limitation, issuance pursuant to a stock dividend or stock split declared by us or an exchange of stock regarding the ADRs or the deposited securities or a distribution of ADSs),
whichever is applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a fee of US$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADR or ADRs for
transfers of certificated or direct registration ADRs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a fee of up to US$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS for any cash
distribution made pursuant to the deposit agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a fee of up to US$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS per calendar
year (or portion thereof) for services performed by the depositary in administering the ADRs (which fee may be charged on a periodic basis during each calendar year and shall be assessed against holders of ADRs as of the record date or record dates
set by the depositary during each calendar year and shall be payable in the manner described in the next succeeding provision); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reimbursement of such fees, charges and expenses as are incurred by the depositary and/or any of the
depositary&#146;s agents (including, without limitation, the custodian and expenses incurred on behalf of holders in connection with compliance with foreign exchange control regulations or any law or regulation relating to foreign investment) in
connection with the servicing of the shares or other </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">265 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
deposited securities, the delivery of deposited securities or otherwise in connection with the depositary&#146;s or its custodian&#146;s compliance with applicable law, rule or regulation (which
charge shall be assessed on a proportionate basis against holders as of the record date or dates set by the depositary and shall be payable at the sole discretion of the depositary by billing such holders or by deducting such charge from one or more
cash dividends or other cash distributions); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a fee for the distribution of securities (or the sale of securities in connection with a distribution), such fee
being in an amount equal to the fee for the execution and delivery of ADSs which would have been charged as a result of the deposit of such securities (treating all such securities as if they were shares and there would be a fee of five cents per
ADS outstanding); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stock transfer or other taxes and other governmental charges; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cable, telex and facsimile transmission and delivery charges incurred at your request in connection with the
deposit or delivery of shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfer or registration fees for the registration of transfer of deposited securities on any applicable register
in connection with the deposit or withdrawal of deposited securities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses of the depositary in connection with the conversion of foreign currency into U.S. dollars.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay all other charges and expenses of the depositary and any agent of the depositary (except the custodian)
pursuant to agreements from time to time between us and the depositary. The charges described above may be amended from time to time by agreement between us and the depositary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our depositary has agreed to reimburse us for certain expenses we incur that are related to establishment and maintenance of the ADR program,
including investor relations expenses and exchange application and listing fees. Neither the depositary nor we can determine the exact amount to be made available to us because (i)&nbsp;the number of ADSs that will be issued and outstanding,
(ii)&nbsp;the level of fees to be charged to holders of ADSs and (iii)&nbsp;our reimbursable expenses related to the ADR program are not known at this time. The depositary collects its fees for issuance and cancellation of ADSs directly from
investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by
selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions, or by directly billing investors, or by charging the book-entry system accounts of
participants acting for them. The depositary will generally set off the amounts owing from distributions made to holders of ADSs. If, however, no distribution exists and payment owing is not timely received by the depositary, the depositary may
refuse to provide any further services to holders that have not paid those fees and expenses owing until such fees and expenses have been paid. At the discretion of the depositary, all fees and charges owing under the deposit agreement are due in
advance and/or when declared owing by the depositary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment of Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ADR holders must pay any tax or other governmental charge payable by the custodian or the depositary on any ADS or ADR, deposited security or
distribution. If an ADR holder owes any tax or other governmental charge, the depositary may (i)&nbsp;deduct the amount thereof from any cash distributions, or (ii)&nbsp;sell deposited securities (by public or private sale) and deduct the amount
owing from the net proceeds of such sale. In either case the ADR holder remains liable for any shortfall. Additionally, if any taxes or other governmental charges (including any penalties and/or interest) shall become payable by or on behalf of the
custodian or the depositary with respect to any ADR, any deposited securities represented by the ADSs evidenced thereby or any distribution thereon, including, without limitation, any PRC Enterprise Income Tax owing if the Circular Guoshuifa [2009]
No.&nbsp;82 issued by the SAT or any other circular, edict, order or ruling, as issued and as from time to time amended, is applied or otherwise, such tax or other governmental charge shall be paid by the holder thereof to the depositary. and by
holding or having held an ADR the holder and all prior holders thereof, jointly and severally, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">266 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agree to indemnify, defend and save harmless each of the depositary and its agents in respect thereof. If any tax or governmental charge is unpaid, the depositary may also refuse to effect any
registration, registration of transfer, <FONT STYLE="white-space:nowrap">split-up</FONT> or combination of deposited securities or withdrawal of deposited securities until such payment is made. If any tax or governmental charge is required to be
withheld on any cash distribution, the depositary may deduct the amount required to be withheld from any cash distribution or, in the case of a <FONT STYLE="white-space:nowrap">non-cash</FONT> distribution, sell the distributed property or
securities (by public or private sale) to pay such taxes and distribute any remaining net proceeds to the ADR holders entitled thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By holding an ADR or an interest therein, you will be agreeing to indemnify us, the depositary, its custodian and any of our or their
respective directors, employees, agents and affiliates against, and hold each of them harmless from, any claims by any governmental authority with respect to taxes, additions to tax, penalties or interest arising out of any refund of taxes, reduced
rate of withholding at source or other tax benefit obtained. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reclassifications, Recapitalizations and Mergers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we take certain actions that affect the deposited securities, including (i)&nbsp;any change in par value,
<FONT STYLE="white-space:nowrap">split-up,</FONT> consolidation, cancellation or other reclassification of deposited securities or (ii)&nbsp;any distributions not made to holders of ADRs or (iii)&nbsp;any recapitalization, reorganization, merger,
consolidation, liquidation, receivership, bankruptcy or sale of all or substantially all of our assets, then the depositary may choose to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">amend the form of ADR; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distribute additional or amended ADRs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distribute cash, securities or other property it has received in connection with such actions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell any securities or property received and distribute the proceeds as cash; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">none of the above. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the depositary does not choose any of the above options, any of the cash, securities or other property it receives will constitute part of
the deposited securities and each ADS will then represent a proportionate interest in such property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment and Termination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>How may the deposit agreement be amended? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may agree with the depositary to amend the deposit agreement and the ADSs without your consent for any reason. ADR holders must be given at
least [30] days&#146; notice of any amendment that imposes or increases any fees or charges (other than stock transfer or other taxes and other governmental charges, transfer or registration fees, cable, telex or facsimile transmission costs,
delivery costs or other such expenses), or otherwise prejudices any substantial existing right of ADR holders. Such notice need not describe in detail the specific amendments effectuated thereby, but must give ADR holders a means to access the text
of such amendment. If an ADR holder continues to hold an ADR or ADRs after being so notified, such ADR holder is deemed to agree to such amendment and to be bound by the deposit agreement as so amended. Notwithstanding the foregoing, if any
governmental body or regulatory body should adopt new laws, rules or regulations which would require amendment or supplement of the deposit agreement or the form of ADR to ensure compliance therewith, we and the depositary may amend or supplement
the deposit agreement and the ADR at any time in accordance with such changed laws, rules or regulations, which amendment or supplement may take effect before a notice is given or within any other period of time as required for compliance. No
amendment, however, will impair your right to surrender your ADSs and receive the underlying securities, except in order to comply with mandatory provisions of applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">267 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>How may the deposit agreement be terminated? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary may, and shall at our written direction, terminate the deposit agreement and the ADRs by mailing notice of such termination to
the registered holders of ADRs at least [30] days prior to the date fixed in such notice for such termination; provided, however, if the depositary shall have (i)&nbsp;resigned as depositary under the deposit agreement, notice of such termination by
the depositary shall not be provided to registered holders unless a successor depositary shall not be operating under the deposit agreement within [45] days of the date of such resignation, and (ii)&nbsp;been removed as depositary under the deposit
agreement, notice of such termination by the depositary shall not be provided to registered holders of ADRs unless a successor depositary shall not be operating under the deposit agreement on the [90]th day after our notice of removal was first
provided to the depositary. After termination, the depositary&#146;s only responsibility will be (i)&nbsp;to deliver deposited securities to ADR holders who surrender their ADRs, and (ii)&nbsp;to hold or sell distributions received on deposited
securities. As soon as practicable after the expiration of six months from the termination date, the depositary will sell the deposited securities which remain and hold the net proceeds of such sales (as long as it may lawfully do so), without
liability for interest, in trust for the ADR holders who have not yet surrendered their ADRs. After making such sale, the depositary shall have no obligations except to account for such proceeds and other cash. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Obligations and Liability to ADS Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Limits on our obligations and the obligations of the depositary; limits on liability to ADR holders and holders of ADSs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the issue, registration, registration of transfer, <FONT STYLE="white-space:nowrap">split-up,</FONT> combination, or cancellation of
any ADRs, or the delivery of any distribution in respect thereof, and from time to time, we or the depositary or its custodian may require: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payment with respect thereto of (i)&nbsp;any stock transfer or other tax or other governmental charge,
(ii)&nbsp;any stock transfer or registration fees in effect for the registration of transfers of shares or other deposited securities upon any applicable register and (iii)&nbsp;any applicable fees and expenses described in the deposit agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the production of proof satisfactory to it of (i)&nbsp;the identity of any signatory and genuineness of any
signature and (ii)&nbsp;such other information, including, without limitation, information as to citizenship, residence, exchange control approval, beneficial ownership of any securities, compliance with applicable law, regulations, provisions of or
governing deposited securities and terms of the deposit agreement and the ADRs, as it may deem necessary or proper; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with such regulations as the depositary may establish consistent with the deposit agreement.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance of ADRs, the acceptance of deposits of shares, the registration, registration of transfer, <FONT
STYLE="white-space:nowrap">split-up</FONT> or combination of ADRs or the withdrawal of shares, may be suspended, generally or in particular instances, when the ADR register or any register for deposited securities is closed or when any such action
is deemed advisable by the depositary; provided that the ability to withdraw shares may only be limited under the following circumstances: (i)&nbsp;temporary delays caused by closing transfer books of the depositary or our transfer books or the
deposit of shares in connection with voting at a shareholders&#146; meeting, or the payment of dividends, (ii)&nbsp;the payment of fees, taxes, and similar charges, and (iii)&nbsp;compliance with any laws or governmental regulations relating to ADRs
or to the withdrawal of deposited securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The deposit agreement expressly limits the obligations and liability of the depositary, us
and our and the depositary&#146;s respective agents. Neither we nor the depositary nor any such agent will be liable if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any present or future law, rule, regulation, fiat, order or decree of the United States, the Cayman Islands,
China or any other country, or of any governmental or regulatory authority or securities exchange or market or automated quotation system, the provisions of or governing any deposited
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">268 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
securities, any present or future provision of our charter, any act of God, war, terrorism or other circumstance beyond our, the depositary&#146;s or our respective agents&#146; control shall
prevent or delay, or shall cause any of them to be subject to any civil or criminal penalty in connection with, any act which the deposit agreement or the ADRs provide shall be done or performed by us, the depositary or our respective agents
(including, without limitation, voting); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it exercises or fails to exercise discretion under the deposit agreement or the ADRs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it performs its obligations under the deposit agreement and ADRs without gross negligence or bad faith;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it takes any action or refrains from taking any action in reliance upon the advice of or information from legal
counsel, accountants, any person presenting shares for deposit, any registered holder of ADRs, or any other person believed by it to be competent to give such advice or information; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it relies upon any written notice, request, direction or other document believed by it to be genuine and to have
been signed or presented by the proper party or parties. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the depositary nor its agents have any obligation to
appear in, prosecute or defend any action, suit or other proceeding in respect of any deposited securities or the ADRs. We and our agents shall only be obligated to appear in, prosecute or defend any action, suit or other proceeding in respect of
any deposited securities or the ADRs, which in our opinion may involve us in expense or liability, if indemnity satisfactory to us against all expense (including fees and disbursements of counsel) and liability is furnished as often as may be
required. The depositary and its agents may fully respond to any and all demands or requests for information maintained by or on its behalf in connection with the deposit agreement, any registered holder or holders of ADRs, any ADRs or otherwise
related to the deposit agreement or ADRs to the extent such information is requested or required by or pursuant to any lawful authority, including, without limitation, laws, rules, regulations, administrative or judicial process, banking, securities
or other regulators. The depositary shall not be liable for the acts or omissions made by any securities depository, clearing agency or settlement system in connection with or arising out of book-entry settlement of deposited securities or
otherwise. Furthermore, the depositary shall not be responsible for, and shall incur no liability in connection with or arising from, the insolvency of any custodian that is not a branch or affiliate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The depositary and the custodian(s) may use third-party delivery services and providers of information regarding matters such as pricing, proxy voting,
corporate actions, class action litigation and other services in connection with the ADRs and the deposit agreement, and use local agents to provide extraordinary services such as attendance at annual meetings of issuers of securities. Although the
depositary and the custodian will use reasonable care (and cause their agents to use reasonable care) in the selection and retention of such third-party providers and local agents, they will not be responsible for any errors or omissions made by
them in providing the relevant information or services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, none of us, the depositary or the custodian shall be liable for the
failure by any registered holder of ADRs or beneficial owner therein to obtain the benefits of credits on the basis of <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax paid against such holder&#146;s or beneficial owner&#146;s income tax
liability. Neither we nor the depositary shall incur any liability for any tax consequences that may be incurred by holders or beneficial owners on account of their ownership of ADRs or ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the depositary nor its agents will be responsible for any failure to carry out any instructions to vote any of the deposited
securities, for the manner in which any such vote is cast or for the effect of any such vote. Neither the depositary nor any of its agents shall be liable to registered holders of ADRs or beneficial owners of interests in ADSs for any indirect,
special, punitive or consequential damages (including, without limitation, lost profits) of any form incurred by any person or entity, whether or not foreseeable and regardless of the type of action in which such a claim may be brought. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the deposit agreement each party thereto (including, for avoidance of doubt, each holder and beneficial owner and/or holder of interests in
ADRs) irrevocably waives, to the fullest extent permitted by applicable law, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">269 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any right it may have to a trial by jury in any suit, action or proceeding against the depositary and/or the company directly or indirectly arising out of or relating to the shares or other
deposited securities, the ADSs or the ADRs, the deposit agreement or any transaction contemplated therein, or the breach thereof (whether based on contract, tort, common law or any other theory). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary may own and deal in any class of our securities and in ADSs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Disclosure of Interest in ADSs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the
extent that the provisions of or governing any deposited securities may require disclosure of or impose limits on beneficial or other ownership of deposited securities, other shares and other securities and may provide for blocking transfer, voting
or other rights to enforce such disclosure or limits, you agree to comply with all such disclosure requirements and ownership limitations and to comply with any reasonable instructions we may provide in respect thereof. We reserve the right to
instruct you to deliver your ADSs for cancellation and withdrawal of the deposited securities so as to permit us to deal with you directly as a holder of shares and, by holding an ADS or an interest therein, you will be agreeing to comply with such
instructions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Books of Depositary </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary or its agent will maintain a register for the registration, registration of transfer, combination and <FONT
STYLE="white-space:nowrap">split-up</FONT> of ADRs, which register shall include the depositary&#146;s direct registration system. Registered holders of ADRs may inspect such records at the depositary&#146;s office at all reasonable times, but
solely for the purpose of communicating with other holders in the interest of the business of our company or a matter relating to the deposit agreement. Such register may be closed from time to time, when deemed expedient by the depositary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary will maintain facilities for the delivery and receipt of ADRs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Pre-release</FONT> of ADSs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In its capacity as depositary, the depositary shall not lend shares or ADSs; provided, however, that the depositary may issue ADSs prior to the
receipt of shares (each such transaction, a <FONT STYLE="white-space:nowrap">&#147;pre-release&#148;).</FONT> The depositary may receive ADSs in lieu of shares (which ADSs will promptly be cancelled by the depositary upon receipt by the depositary).
Each such <FONT STYLE="white-space:nowrap">pre-release</FONT> will be subject to a written agreement whereby the person or entity (the &#147;applicant&#148;) to whom ADSs are to be delivered (a)&nbsp;represents that at the time of the <FONT
STYLE="white-space:nowrap">pre-release</FONT> the applicant or its customer owns the shares that are to be delivered by the applicant under such <FONT STYLE="white-space:nowrap">pre-release,</FONT> (b)&nbsp;agrees to indicate the depositary as owner
of such shares in its records and to hold such shares in trust for the depositary until such shares are delivered to the depositary or the custodian, (c)&nbsp;unconditionally guarantees to deliver to the depositary or the custodian, as applicable,
such shares, and (d)&nbsp;agrees to any additional restrictions or requirements that the depositary deems appropriate. Each such <FONT STYLE="white-space:nowrap">pre-release</FONT> will be at all times fully collateralized with cash, U.S. government
securities or such other collateral as the depositary deems appropriate, terminable by the depositary on not more than five (5)&nbsp;business days&#146; notice and subject to such further indemnities and credit regulations as the depositary deems
appropriate. The depositary will normally limit the number of ADSs involved in such <FONT STYLE="white-space:nowrap">pre-release</FONT> at any one time to thirty percent (30%) of the ADSs outstanding (without giving effect to <FONT
STYLE="white-space:nowrap">pre-released</FONT> ADSs outstanding), provided, however, that the depositary reserves the right to change or disregard such limit from time to time as it deems appropriate. The depositary may also set limits with respect
to the number of ADSs involved in <FONT STYLE="white-space:nowrap">pre-release</FONT> with any one person on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis as it deems appropriate. The depositary
may retain for its own account any compensation received by it in conjunction with the foregoing. Collateral provided in connection with <FONT STYLE="white-space:nowrap">pre-release</FONT> transactions, but not the earnings thereon, shall be held
for the benefit of the registered holders of ADRs (other than the applicant). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">270 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Appointment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the deposit agreement, each registered holder of ADRs and each person holding an interest in ADSs, upon acceptance of any ADSs (or any
interest therein) issued in accordance with the terms and conditions of the deposit agreement will be deemed for all purposes to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be a party to and bound by the terms of the deposit agreement and the applicable ADR or ADRs, and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appoint the depositary its
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact,</FONT></FONT> with full power to delegate, to act on its behalf and to take any and all actions contemplated in the deposit agreement and the applicable ADR or ADRs,
to adopt any and all procedures necessary to comply with applicable laws and to take such action as the depositary in its sole discretion may deem necessary or appropriate to carry out the purposes of the deposit agreement and the applicable ADR and
ADRs, the taking of such actions to be the conclusive determinant of the necessity and appropriateness thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The deposit agreement and the ADRs shall be governed by and construed in accordance with the laws of the State of New York. In the
deposit agreement, we have submitted to the jurisdiction of the courts of the State of New York and appointed an agent for service of process on our behalf. Notwithstanding the foregoing, any action based on the deposit agreement or the transactions
contemplated thereby may be instituted by the depositary and holders in any competent court in the Cayman Islands, Hong Kong, China and/or the United States or through the commencement of an English language arbitration either in New York, New York
in accordance with the Commercial Arbitration Rules of the American Arbitration Association or in Hong Kong following the arbitration rules of the United Nations Commission on International Trade Law (UNCITRAL). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">271 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_22"></A>SHARES ELIGIBLE FOR FUTURE SALES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, we will have &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ADSs outstanding,
representing approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding ordinary shares, assuming the underwriters do not exercise their over-allotment option. All of the ADSs sold in this offering will be freely transferable
by persons other than by our &#147;affiliates&#148; without restriction or further registration under the Securities Act. Sales of substantial amounts of our ADSs in the public market could adversely affect prevailing market prices of our ADSs.
Prior to this offering, there has been no public market for our ordinary shares or the ADSs. We intend to apply to list the ADSs on [the Nasdaq Global Market], but we cannot assure you that a regular trading market will develop in the ADSs. We do
not expect that a trading market will develop for our ordinary shares not represented by the ADSs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">[Lock-up</FONT>
Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed, for a period of [180] days after the date of this prospectus, [not to offer, sell, contract to sell,
pledge, grant any option to purchase, make any short sale, lend or otherwise dispose of, except in this offering, any of our ordinary shares or ADSs or securities that are substantially similar to our ordinary shares or ADSs, including, but not
limited to, any options or warrants to purchase our ordinary shares, ADSs or any securities that are convertible into or exchangeable for, or that represent the right to receive, our ordinary shares, ADSs or any such substantially similar securities
(other than pursuant to employee stock option plans existing on, or upon the conversion or exchange of convertible or exchangeable securities outstanding as of, the date such <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement was executed),
without the prior written consent of the representatives of the underwriters.] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, each of our directors and executive officers,
our current shareholders [and certain option holders] has also entered into a similar <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement for a period of [180] days after the date of this prospectus, subject to certain exceptions, with respect
to our ordinary shares, ADSs and securities that are substantially similar to our ordinary shares or ADSs. [These restrictions also apply to any ADSs acquired by our directors and executive officers in the offering pursuant to the directed share
program, if any.] These parties collectively own [all of] our outstanding ordinary shares, without giving effect to this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
restrictions described in the preceding paragraphs will be automatically extended under certain circumstances. See &#147;Underwriting.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than this offering, we are not aware of any plans by any significant shareholders to dispose of significant numbers of our ADSs or
ordinary shares. However, one or more existing shareholders or owners of securities convertible or exchangeable into or exercisable for our ADSs or ordinary shares may dispose of significant numbers of our ADSs or ordinary shares in the future. We
cannot predict what effect, if any, future sales of our ADSs or ordinary shares, or the availability of ADSs or ordinary shares for future sale, will have on the trading price of our ADSs from time to time. Sales of substantial amounts of our ADSs
or ordinary shares in the public market, or the perception that these sales could occur, could adversely affect the trading price of our ADSs.] </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule
144 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our ordinary shares that will be outstanding upon the completion of this offering, other than those ordinary shares
underlying the ADSs sold in this offering, are &#147;restricted securities&#148; as that term is defined in Rule 144 under the Securities Act and may be sold publicly in the United States only if they are subject to an effective registration
statement under the Securities Act or pursuant to an exemption from the registration requirement such as those provided by Rule 144 and Rule 701 promulgated under the Securities Act. In general, beginning 90 days after the date of this prospectus, a
person (or persons whose shares are aggregated) who at the time of a sale is not, and has not been during the three months preceding the sale, an affiliate of ours and has beneficially owned our restricted securities for at least six months will be
entitled to sell the restricted securities without registration under the Securities Act, subject only to the availability of current public information about </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">272 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
us, and will be entitled to sell restricted securities beneficially owned for at least one year without restriction. Persons who are our affiliates and have beneficially owned our restricted
securities for at least six months may sell a number of restricted securities within any three-month period that does not exceed the greater of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the then outstanding ordinary shares of the same class, represented by ADSs or otherwise, which immediately
after this offering will equal &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares, assuming the underwriters do not exercise their option to purchase additional ADSs; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume of our ordinary shares of the same class, represented by ADSs or otherwise,
during the four calendar weeks preceding the date on which notice of the sale is filed with the SEC. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales by our
affiliates under Rule 144 are also subject to certain requirements relating to manner of sale, notice and the availability of current public information about us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule 701 of
the Securities Act as currently in effect, each of our employees, consultants or advisors who purchases our ordinary shares from us in connection with a compensatory stock plan or other written agreement executed prior to the completion of this
offering is eligible to resell those ordinary shares in reliance on Rule 144, but without compliance with some of the restrictions, including the holding period, contained in Rule 144. However, the Rule 701 shares would remain subject to <FONT
STYLE="white-space:nowrap">lock-up</FONT> arrangements and would only become eligible for sale when the <FONT STYLE="white-space:nowrap">lock-up</FONT> period expires. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">273 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_23"></A>TAXATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary of the material Cayman Islands, PRC and U.S. federal income tax consequences of an investment in our ADSs or ordinary
shares is based upon laws and relevant interpretations thereof in effect as of the date of this prospectus, all of which are subject to change. This summary does not deal with all possible tax consequences relating to an investment in our ADSs or
ordinary shares, such as the tax consequences under U.S. state and local tax laws or under the tax laws of jurisdictions other than the Cayman Islands, China and the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cayman Islands Taxation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cayman
Islands currently levies no taxes on individuals or corporations based upon profits, income, gains or appreciation and there is no taxation in the nature of inheritance tax or estate duty. There are no other taxes likely to be material to us levied
by the government of the Cayman Islands except for stamp duties which may be applicable on instruments executed in, or brought within the jurisdiction of the Cayman Islands. The Cayman Islands are a party to a double tax treaty entered into with the
United Kingdom in 2010 but otherwise is not party to any double tax treaties. There are no exchange control regulations or currency restrictions in the Cayman Islands. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments of dividends and capital in respect of our shares will not be subject to taxation in the Cayman Islands and no withholding will be
required on the payment of a dividend or capital to any holder of the shares, nor will gains derived from the disposal of our shares be subject to Cayman Islands income or corporation tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No stamp duty is payable in respect of the issue of shares by our Company and no stamp duty is payable on transfers of shares of our Company
provided our Company does not hold any interest in land in the Cayman Islands. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRC Taxation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the PRC Enterprise Income Tax Law and its implementation rules, an enterprise established outside China with &#147;de facto management
body&#148; within China is considered as a Tax Resident Enterprise for PRC enterprise income tax purposes and is generally subject to a uniform 25% enterprise income tax rate on its worldwide income. The implementation rules define the term &#147;de
facto management body&#148; as the body that exercises full and substantial control and overall management over the business, productions, personnel, accounts and properties of an enterprise. In April 2009, the State Administration of Taxation
issued Circular 82, which provides certain specific criteria for determining whether the &#147;de facto management body&#148; of a <FONT STYLE="white-space:nowrap">PRC-controlled</FONT> enterprise that is incorporated offshore is located in China.
Although this circular only applies to offshore enterprises controlled by PRC enterprises or PRC enterprise groups, not those controlled by PRC individuals or foreigners, the criteria set forth in the circular may reflect the State Administration of
Taxation&#146;s general position on how the &#147;de facto management body&#148; text should be applied in determining the tax resident status of all offshore enterprises. According to Circular 82, an offshore incorporated enterprise controlled by a
PRC enterprise or a PRC enterprise group will be regarded as a PRC tax resident by virtue of having its &#147;de facto management body&#148; in China if all of the following conditions are met: (i)&nbsp;the primary location of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operational management is in China; (ii)&nbsp;decisions relating to the enterprise&#146;s financial and human resource matters are made or are subject to approval
by organizations or personnel located in China; (iii)&nbsp;the enterprise&#146;s primary assets, accounting books and records, company seals, and board and shareholder resolutions, are located or maintained in China; and (iv)&nbsp;at least 50% of
voting board members or senior executives habitually reside in China. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our PRC counsel, JunHe LLP, is of the opinion that, based on
its understanding of the current PRC Laws and Regulations, <FONT STYLE="white-space:nowrap">I-Mab</FONT> should not be considered as a PRC resident enterprise for PRC income tax purposes because I-Mab does not meet all of the above conditions. <FONT
STYLE="white-space:nowrap">I-Mab</FONT> is incorporated outside of China and it is not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">274 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
controlled by a PRC enterprise or PRC enterprise group. We have structured a clear management guideline in place to segregate the policy set up and business operating execution responsibilities
in order to differentiate the effective control from our headquarter office and subsidiaries including record keeping and offshore work location plan. <FONT STYLE="white-space:nowrap">I-Mab</FONT> is a company incorporated outside the PRC. As a
holding company, its key assets are its ownership interests in its subsidiaries, and its key assets are located, and its records (including the resolutions of its board of directors and the resolutions of its shareholders) are maintained, outside
China. However, the tax resident status of an enterprise is subject to determination by the PRC tax authorities and uncertainties remain with respect to the interpretation of the term &#147;de facto management body.&#148; However, we cannot
guarantee you that PRC tax authorities will not take a different view. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the PRC tax authorities determine that <FONT
STYLE="white-space:nowrap">I-Mab</FONT> is a PRC resident enterprise for enterprise income tax purposes, our worldwide income could be subject to 25% enterprise income tax; and any dividends payable to non-resident enterprise holders of our common
shares or ADSs may be treated as income derived from sources within China and therefore, subject to a 10% withholding tax (or 20% in the case of non-resident individual holders) unless an applicable income tax treaty provides otherwise. In addition,
capital gains realized by non-resident enterprise shareholders (including our ADS holders) upon the disposition of our common shares or ADSs may be treated as income derived from sources within PRC and therefore, subject to 10% income tax (or 20% in
the case of non-resident individual shareholders or ADS holders) unless an applicable income tax treaty provides otherwise. See &#147;Risk Factors&#151;Risks Related to Doing Business in China&#151;If we are classified as a PRC resident enterprise
for PRC income tax purposes, such classification could result in unfavorable tax consequences to us and our <FONT STYLE="white-space:nowrap">non-PRC</FONT> shareholders or ADS holders.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>United States Federal Income Tax Considerations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of U.S. federal income tax considerations relating to the ownership and disposition of our ADSs or
ordinary shares by a U.S. Holder (as defined below) that acquires our ADSs in this offering and holds our ADSs as &#147;capital assets&#148; (generally, property held for investment) under the U.S. Internal Revenue Code of 1986, as amended, or the
Code. This discussion is based upon existing U.S. federal tax law, which is subject to differing interpretations or change, possibly with retroactive effect. No ruling has been sought from the U.S. Internal Revenue Service, or the IRS, with respect
to any U.S. federal income tax consequences described below, and there can be no assurance that the IRS or a court will not take a contrary position. This discussion does not address the U.S. federal estate, gift, Medicare, and alternative minimum
tax considerations, certain information reporting requirements pursuant to section 1471 through 1474 of the Code, or any state, local, and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax considerations, relating to the ownership or disposition
of our ADSs or ordinary shares. This discussion, moreover, does not discuss all aspects of U.S. federal income taxation that may be important to particular investors in light of their individual investment circumstances or to investors subject to
special tax situations such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks and other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pension plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cooperatives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">traders in securities that elect to use a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain former U.S. citizens or long-term residents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> entities (including private foundations);
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">275 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investors who are not U.S. Holders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investors who own (directly, indirectly or constructively) 10% or more of our stock (by vote or value);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investors who acquire their ADSs or ordinary shares pursuant to any employee share option or otherwise as
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investors that will hold their ADSs or ordinary shares as part of a straddle, hedge, conversion, constructive
sale or other integrated transaction for U.S. federal income tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investors required to accelerate the recognition of any item of gross income with respect to our ADSs or ordinary
shares as a result of such income being recognized on an applicable financial statement; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investors that have a functional currency other than the U.S. dollar; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">all of whom may be subject to tax rules that differ significantly from those discussed below. Each U.S. Holder is urged to consult its tax advisor regarding
the U.S. federal, state, local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> income and other tax considerations of an investment in our ADSs or ordinary shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
purposes of this discussion, a &#147;U.S. Holder&#148; is a beneficial owner of our ADSs or ordinary shares that is, for U.S. federal income tax purposes, (i)&nbsp;an individual who is a citizen or resident of the United States, (ii)&nbsp;a
corporation (or other entity treated as a corporation for U.S. federal income tax purposes) created in, or organized under the law of, the United States or any state thereof or the District of Columbia, (iii)&nbsp;an estate the income of which is
includible in gross income for U.S. federal income tax purposes regardless of its source, or (iv)&nbsp;a trust (A)&nbsp;the administration of which is subject to the primary supervision of a U.S. court and which has one or more U.S. persons who have
the authority to control all substantial decisions of the trust or (B)&nbsp;that has otherwise validly elected to be treated as a U.S. person under the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership (or other entity treated as a partnership for U.S. federal income tax purposes) is a beneficial owner of our ADSs or ordinary
shares, the tax treatment of a partner in the partnership will generally depend upon the status of the partner and the activities of the partner and the partnership. Partnerships holding our ADSs or ordinary shares and their partners are urged to
consult their tax advisors regarding an investment in our ADSs or ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For U.S. federal income tax purposes, it is generally
expected that a U.S. Holder of ADSs will be treated as the beneficial owner of the underlying shares represented by the ADSs. The remainder of this discussion assumes that a U.S. Holder of our ADSs will be treated as the beneficial owner of the
underlying shares represented by the ADSs. Accordingly, deposits or withdrawals of ordinary shares for ADSs will generally not be subject to U.S. federal income tax. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Passive Foreign Investment Company Considerations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation, such as our company, will be classified as a passive foreign investment
company, or, or PFIC, for U.S. federal income tax purposes for any taxable year if either (i) 75% or more of its gross income for such year consists of certain types of &#147;passive&#148; income or (ii) 50% or more of the value of its assets
(determined on the basis of a quarterly average) during such year is attributable to assets that produce or are held for the production of passive income. For this purpose, cash and assets readily convertible into cash are each categorized as a
passive asset and the company&#146;s goodwill and other unbooked intangibles are taken into account. Passive income generally includes, among other things, dividends, interest, rents, royalties, and gains from the disposition of passive assets. We
will be treated as owning a proportionate share of the assets and earning a proportionate share of the income of any other corporation in which we own, directly or indirectly, 25% or more (by value) of the stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">276 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No assurance can be given with respect to our PFIC status for the current taxable year or
any future taxable year. The determination of whether we are or will become a PFIC is uncertain, because it is a fact-intensive inquiry made on an annual basis that depends, in part, on the composition of our income and assets. Fluctuations in the
market price of our ADSs may cause us to become a PFIC for the current or subsequent taxable years because the value of our assets for the purpose of the asset test may be determined by reference to the market price of our ADSs from time to time
(which may be volatile for biopharmaceutical companies, such as ours, that have not yet achieved commercialization with respect to any of their products). The composition of our income and assets may also be affected by how, and how quickly, we use
our liquid assets and the cash raised in this offering. Under circumstances where our revenue from activities that produce passive income increases relative to our revenue from activities that produce non-passive income, or where we determine not to
deploy cash for active purposes, our risk of becoming classified as a PFIC will substantially increase. In addition, because there are uncertainties in the application of the relevant rules, it is possible that the IRS may challenge our
classification of certain income and assets as non-passive or our valuation of our tangible and intangible assets, each of which may result in our being or becoming a PFIC for the current or subsequent taxable years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discussion below under &#147;&#151;Dividends&#148; and &#147;&#151;Sale or Other Disposition of ADSs or Ordinary Shares&#148; is written
on the basis that we will not be classified as a PFIC for U.S. federal income tax purposes. The U.S. federal income tax rules that apply if we are treated as a PFIC are generally discussed below under &#147;&#151;Passive Foreign Investment Company
Rules.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below under &#147;&#151;Passive Foreign Investment Company Rules,&#148; any cash distributions (including the amount
of any tax withheld) paid on our ADSs or ordinary shares out of our current or accumulated earnings and profits, as determined under U.S. federal income tax principles, will generally be includible in the gross income of a U.S. Holder as dividend
income on the day actually or constructively received by the U.S. Holder. Because we do not intend to determine our earnings and profits on the basis of U.S. federal income tax principles, any distribution we pay will generally be reported as a
&#147;dividend&#148; for U.S. federal income tax purposes. Dividends received on our ADSs or ordinary shares will not be eligible for the dividends received deduction allowed to corporations in respect of dividends received from U.S. corporations.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holder will generally be subject to tax on dividend income from a
&#147;qualified foreign corporation&#148; at a lower applicable capital gains rate rather than the marginal tax rates generally applicable to ordinary income provided that certain conditions are satisfied, including that (1)&nbsp;our ADSs or
ordinary shares on which the dividends are paid are readily tradable on an established securities market in the United States, or in the event that we are deemed to be a PRC resident enterprise under the PRC tax law, we are eligible for the benefits
of the United <FONT STYLE="white-space:nowrap">States-PRC</FONT> income tax treaty (the &#147;Treaty&#148;); (2) we are neither a PFIC nor treated as such with respect to a U.S. Holder for the taxable year in which the dividend is paid and the
preceding taxable year, and (3)&nbsp;certain holding period requirements are met. We intend to list our ADSs on the Nasdaq Global Market. Provided the listing is approved, we believe that the ADSs will be readily tradable on an established
securities market in the United States, and that we will be a qualified foreign corporation with respect to dividends paid on the ADSs. Since we do not expect that our ordinary shares will be listed on an established securities market, we do not
believe that dividends that we pay on our ordinary shares that are not represented by ADSs will meet the conditions required for the reduced tax rate. There can be no assurance, however, that our ADSs will continue to be considered readily tradable
on an established securities market in later years. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that we are deemed to be a PRC resident enterprise under the PRC
Enterprise Income Tax Law, we may be eligible for the benefits of Treaty and in that case we would be treated as a qualified foreign corporation with respect to dividends paid on our ordinary shares or ADSs. Each
<FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holder is advised to consult its tax advisors regarding the availability of the reduced tax rate applicable to qualified dividend income for any dividends we pay with respect to our ADSs or
ordinary shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">277 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends will generally be treated as income from foreign sources for U.S. foreign tax
credit purposes and will generally constitute passive category income. In the event that we are deemed to be a PRC resident enterprise under the PRC Enterprise Income Tax Law, a U.S. Holder may be subject to PRC withholding taxes on dividends paid
on our ADSs or ordinary shares. See &#147;&#151;PRC Taxation&#148; above. In that case, depending on the U.S. Holder&#146;s individual facts and circumstances, a U.S. Holder may be eligible, subject to a number of complex limitations, to claim a
foreign tax credit not in excess of any applicable treaty rate in respect of any foreign withholding taxes imposed on dividends received on our ADSs or ordinary shares. A U.S. Holder who does not elect to claim a foreign tax credit for foreign tax
withheld may instead claim a deduction, for U.S. federal income tax purposes, in respect of such withholding, but only for a year in which such holder elects to do so for all creditable foreign income taxes. The rules governing the foreign tax
credit are complex and their outcome depends in large part on the U.S. Holder&#146;s individual facts and circumstances. Accordingly, U.S. Holders are urged to consult their tax advisors regarding the availability of the foreign tax credit under
their particular circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Sale or Other Disposition of ADSs or Ordinary Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below under &#147;&#150;&#150;Passive Foreign Investment Company Rules,&#148; a U.S. Holder will generally recognize
capital gain or loss upon the sale or other disposition of ADSs or ordinary shares in an amount equal to the difference between the amount realized upon the disposition and the holder&#146;s adjusted tax basis in such ADSs or ordinary shares. Any
capital gain or loss will be long-term if the ADSs or ordinary shares have been held for more than one year and will generally be U.S. source gain or loss for U.S. foreign tax credit purposes. Long-term capital gain of
<FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders is generally eligible for a reduced rate of taxation. The deductibility of a capital loss may be subject to limitations. In the event that we are treated as a PRC resident enterprise
under the Enterprise Income Tax Law and gain from the disposition of the ADSs or ordinary shares is subject to tax in China, a U.S. Holder that is eligible for the benefits of the Treaty may elect to treat the gain as PRC source income. If a U.S.
Holder is not eligible for the benefits of the Treaty or fails to make the election to treat any gain as foreign source, then such U.S. Holder may not be able to use the foreign tax credit arising from any PRC tax imposed on the disposition of the
ADSs or ordinary shares unless such credit can be applied (subject to applicable limitations) against U.S. federal income tax due on other income derived from foreign sources in the same income category (generally, the passive category). U.S.
Holders are urged to consult their tax advisors regarding the tax consequences if a foreign tax is imposed on a disposition of our ADSs or ordinary shares, including the availability of the foreign tax credit under their particular circumstances and
the election to treat any gain as PRC source income. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Passive Foreign Investment Company Rules </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are classified as a PFIC for any taxable year during which a U.S. Holder holds our ADSs or ordinary shares, and unless the U.S. Holder
makes a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election (as described below), the U.S. Holder will generally be subject to special tax rules that have a penalizing effect, regardless of whether
we remain a PFIC, on (i)&nbsp;any excess distribution that we make to the U.S. Holder (which generally means any distribution paid during a taxable year to a U.S. Holder that is greater than 125&nbsp;percent of the average annual distributions paid
in the three preceding taxable years or, if shorter, the U.S. Holder&#146;s holding period for the ADSs or ordinary shares), and (ii)&nbsp;any gain realized on the sale or other disposition (including, under certain circumstances, a pledge) of ADSs
or ordinary shares. Under the PFIC rules: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the excess distribution or gain will be allocated ratably over the U.S. Holder&#146;s holding period for the ADSs
or ordinary shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount allocated to the current taxable year and any taxable years in the U.S. Holder&#146;s holding period
prior to the first taxable year in which we are classified as a PFIC (each, a <FONT STYLE="white-space:nowrap">&#147;pre-PFIC</FONT> year&#148;), will be taxable as ordinary income; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount allocated to each prior taxable year, other than a <FONT STYLE="white-space:nowrap">pre-PFIC</FONT>
year, will be subject to tax at the highest tax rate in effect for individuals or corporations, as appropriate, for that year, increased by an </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">278 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
additional tax equal to the interest on the resulting tax deemed deferred with respect to each such taxable year. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are a PFIC for any taxable year during which a U.S. Holder holds our ADSs or ordinary shares and any of our subsidiaries is also a PFIC,
such U.S. Holder would be treated as owning a proportionate amount (by value) of the shares of the lower-tier PFIC for purposes of the application of these rules. U.S. Holders are urged to consult their tax advisors regarding the application of the
PFIC rules to any of our subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an alternative to the foregoing rules, a U.S. Holder of &#147;marketable stock&#148; (as
defined below) in a PFIC may make a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election with respect to such stock. If a U.S. Holder makes this election, the holder will generally (i)&nbsp;include
as ordinary income for each taxable year that we are a PFIC the excess, if any, of the fair market value of ADSs held at the end of the taxable year over the adjusted tax basis of such ADSs and (ii)&nbsp;deduct as an ordinary loss the excess, if
any, of the adjusted tax basis of the ADSs over the fair market value of such ADSs held at the end of the taxable year, but such deduction will only be allowed to the extent of the amount previously included in income as a result of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election. The U.S. Holder&#146;s adjusted tax basis in the ADSs would be adjusted to reflect any income or loss resulting from the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election. If a U.S. Holder makes a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election in respect of a
corporation classified as a PFIC and such corporation ceases to be classified as a PFIC, the holder will not be required to take into account the gain or loss described above during any period that such corporation is not classified as a PFIC. If a
U.S. Holder makes a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election, any gain such U.S. Holder recognizes upon the sale or other disposition of our ADSs in a year when we are a PFIC will be
treated as ordinary income and any loss will be treated as ordinary loss, but such loss will only be treated as ordinary loss to the extent of the net amount previously included in income as a result of the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election. If a U.S. Holder makes a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election it will be effective for the taxable year for which
the election is made and all subsequent taxable years unless the ADSs are no longer treated as marketable stock or the IRS consents to the revocation of the election. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election is available only for
&#147;marketable stock,&#148; which stock that is regularly traded on a qualified exchange or other market, as defined in applicable United States Treasury Regulations. We expect that our ADSs, but not our ordinary shares, will be treated as
marketable stock upon their listing on the Nasdaq Global Market. However, we cannot guarantee that our listing will be approved and we cannot guarantee that, once listed, our ADSs will continue to be listed and traded on the Nasdaq Global Market.
Furthermore, while we anticipate that our ADSs should qualify as being regularly traded, but no assurances may be given in this regard. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election cannot be made for any
lower-tier PFICs that we may own, a U.S. Holder may continue to be subject to the PFIC rules with respect to such U.S. Holder&#146;s indirect interest in any investments held by us that are treated as an equity interest in a PFIC for U.S. federal
income tax purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not intend to provide information necessary for U.S. Holders to make qualified electing fund elections which,
if available, would result in tax treatment different from the general tax treatment for PFICs described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a U.S. Holder owns our
ADSs or ordinary shares during any taxable year that we are a PFIC, the holder must generally file an annual IRS Form 8621. Each U.S. Holder is urged to consult its tax advisor concerning the U.S. federal income tax consequences of purchasing,
holding and disposing ADSs or ordinary shares if we are or become a PFIC, including the possibility of making a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">279 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_24"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the underwriters named below have entered into an underwriting agreement with respect to the ADSs being offered. Subject to certain
conditions, each underwriter has severally agreed to purchase the number of ADSs indicated in the following table. China International Capital Corporation Hong Kong Securities Limited is acting as the book-running manager of this offering and as the
representative of the underwriters. The address of China International Capital Corporation Hong Kong Securities Limited is 29th Floor, One International Finance Centre, 1 Harbour View Street Central, Hong Kong. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;ADSs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[China International Capital Corporation Hong Kong Securities Limited]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters are offering the ADSs subject to their acceptance of the ADSs from us and subject to prior
sale. The underwriting agreement provides that the obligations of the several underwriters to pay for and accept delivery of the ADSs offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain
other conditions. The underwriters are obligated, severally and not jointly, to take and pay for all of the ADSs offered by this prospectus if any such ADSs are taken, other than the ADSs covered by the underwriters&#146; option to purchase
additional ADSs described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters initially propose to offer part of the ADSs directly to the public at the public
offering price listed on the cover of this prospectus and part of the ADSs to certain dealers at a price that represents a concession not in excess of US$[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] per ADS under the
public offering price. After the initial offering of the ADSs, the offering price and other selling terms may from time to time be varied by the underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[Certain of the underwriters are not broker-dealers registered with the SEC. Therefore, to the extent they intend to make any offers or sales
of ADSs in the United States, they will do so only through one or more registered broker-dealers in compliance with applicable securities law and regulations, and FINRA rules. China International Capital Corporation Hong Kong Securities Limited is
not a broker-dealer registered with the SEC and, to the extent that its conduct may be deemed to involve participation in offers or sales of ADSs in the United States, those offers or sales will be made through one or more <FONT
STYLE="white-space:nowrap">SEC-registered</FONT> broker-dealers in compliance with applicable laws and regulations.] </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional
ADSs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase up to an
aggregate of [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] additional ADSs from us at the offering price listed on the cover of this prospectus, less underwriting discounts and commissions. To the extent the option is
exercised, each underwriter will become severally obligated, subject to certain conditions, to purchase additional ADSs approximately proportionate to each underwriter&#146;s initial amount reflected in the table above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commissions and Expenses </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total
underwriting discounts and commissions to be paid to the underwriters represent [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]% of the total amount of the offering. The following table shows the per ADS and total underwriting discounts and
commissions to be paid to the underwriters by us. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional ADSs. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per ADS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discounts and commissions paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">280 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to pay all fees and expenses that we occur in connection with the offering.
We have agreed to reimburse the underwriters for certain expenses in an amount not to exceed US$[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[We have agreed that, without the prior written consent of the representatives of the underwriters, we will not, during the period ending 180
days after the date of this prospectus, (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or
dispose of directly or indirectly, any ordinary shares or ADSs or any securities convertible into or exercisable or exchangeable for such ordinary shares or ADSs; (ii)&nbsp;enter into any swap, hedge or other arrangement that transfers to another,
in whole or in part, any of the economic consequences of ownership of the ordinary shares or ADSs; (iii)&nbsp;establish or increase a put equivalent position or liquidate or decrease a call equivalent position in the ordinary shares or ADSs within
the meaning of Section&nbsp;16 of the Exchange Act; (iv)&nbsp;file any registration statement with the SEC relating to the offering of any ordinary shares, ADSs or any securities convertible into or exercisable or exchangeable for ordinary shares or
ADSs; or (v)&nbsp;publicly disclose the intention to make any offer, sale, pledge, disposition or filing, in each case regardless of whether any such transaction described above is to be settled by delivery of ordinary shares, ADSs, or such other
securities, in cash or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of our directors, executive officers, existing shareholders [and certain of our option holders]
have agreed that, without the prior written consent of the representatives on behalf of the underwriters, it will not, subject to certain exceptions, during the period ending 180 days after the date of this prospectus, (1)&nbsp;offer, pledge, sell,
contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any ADSs or ordinary shares or any
other securities convertible into or exercisable or exchangeable for ADSs or ordinary shares or (2)&nbsp;enter into any swap, hedge or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of
ADSs or ordinary shares, whether any such transaction described in clause (1)&nbsp;or (2) above is to be settled by delivery of ADSs, ordinary shares or such other securities, in cash or otherwise, or publicly disclose the intention to make any such
offer, sale, pledge or disposition, or to enter into any such transaction, swap, hedge or other arrangement. The foregoing sentence shall not apply to transactions relating to ADSs, ordinary shares or other securities acquired in this offering or in
open market transactions after the completion of this offering and certain other exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, through a letter agreement, we
will instruct [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], as depositary, not to accept any deposit of any ordinary shares or deliver any ADSs until after 180 days following the date of this prospectus unless we
consent to such deposit or issuance. We will not provide such consent without the prior written consent of the representatives of the underwriters. The foregoing does not affect the right of ADS holders to cancel their ADSs and withdraw the
underlying ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representatives of the underwriters, in their sole discretion, on behalf of the underwriters may release
the ADSs and other securities subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above in whole or in part at any time with or without notice.] </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ADSs [have been]
approved for listing on the Nasdaq Global Market under the symbol &#147;IMAB.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stabilization, Short Positions and Penalty Bids </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriters may purchase and sell ADSs in the open market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These transactions may include short sales, stabilizing transactions and purchases to cover positions created by short sales. Short sales
involve the sale by the underwriters of a greater number of ADSs than they are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">281 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required to purchase in the offering. &#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to purchase additional ADSs in the offering. The
underwriter may close out any covered short position by either exercising their option to purchase additional ADSs or purchasing ADSs in the open market. In determining the source of ADSs to close out the covered short position, the underwriters
will consider, among other things, the price of ADSs available for purchase in the open market as compared to the price at which they may purchase additional ADSs pursuant to the option granted to them. &#147;Naked&#148; short sales are any sales in
excess of such option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters must close out any naked short position by purchasing ADSs in the open market. A naked short
position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the ADSs in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing
transactions consist of various bids for, or purchases of, ADSs made by the underwriters in the open market prior to the completion of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the
underwriting discounts received by it because the representatives have repurchased ADSs sold by, or for the account of, such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchases to cover a short position and stabilizing transactions, as well as other purchases by the underwriters for their own accounts, may
have the effect of preventing or retarding a decline in the market price of the ADSs, and together with the imposition of the penalty bid, may stabilize, maintain or otherwise affect the market price of the ADSs. As a result, the price of the ADSs
may be higher than the price that otherwise might exist in the open market. The underwriters are not required to engage in these activities, and if these activities are commenced, they are required to be conducted in accordance with applicable laws
and regulations, and any of these activities may be discontinued at any time. These transactions may be effected on the Nasdaq, the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A
prospectus in electronic format will be made available on the websites maintained by one or more of the underwriters or one or more securities dealers. One or more of the underwriters may distribute prospectuses electronically. The underwriters may
agree to allocate a number of ADSs for sale to their online brokerage account holders. ADSs to be sold pursuant to an internet distribution will be allocated on the same basis as other allocations. In addition, ADSs may be sold by the underwriters
to securities dealers who resell ADSs to online brokerage account holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[<B>Directed ADS Program </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our request, the underwriters have reserved up to [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]% of the ADSs being offered by this
prospectus (assuming no exercise by the underwriters of their option to purchase additional ADSs) for sale at the initial public offering price to certain of our directors, executive officers, employees, business associates and members of their
families. The directed ADS program will be administered by [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]. We do not know if these individuals will choose to purchase all or any portion of these reserved ADSs, but any
purchases they do make will reduce the number of ADSs that are available to the general public. Any reserved ADSs that are not so purchased will be offered by the underwriters to the general public on the same terms as the other ADSs offered by this
prospectus.] </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">282 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include
securities trading, commercial and investment banking, financial advisory, investment management, principal investment, hedging, financing, investment research, market making, brokerage and other financial and
<FONT STYLE="white-space:nowrap">non-financial</FONT> activities and services. Certain of the underwriters and their respective affiliates may have, from time to time, performed, and may in the future perform, various financial advisory, commercial
and investment banking services and other services for us and to persons and entities with relationships with us, for which they received or will receive customary fees and commissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their various business activities, the underwriters and their respective affiliates may make or hold a
broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers and may at any time hold long
and short positions in such securities and instruments. Such investment and securities activities may involve securities and instruments of us and/or persons and entities with relationships with us. The underwriters and their respective affiliates
may also make or communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such assets, securities or instruments and may at any time hold, or recommend to
clients that they should acquire, long and/or short positions in such assets, securities and instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pricing of the Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our ordinary shares or the ADSs. The initial public offering price was determined
by negotiations between us and the representatives of the underwriters. Among the factors to be considered in determining the initial public offering price of the ADSs, in addition to prevailing market conditions, will be our historical performance,
estimates of our business potential and earnings prospects, an assessment of our management and the consideration of the above factors in relation to market valuation of companies in related businesses. An active trading market for the ADSs may not
develop. It is also possible that after the offering the ADSs will not trade in the public market at or above the initial public offering price. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No action has been
taken in any jurisdiction (except in the United States) that would permit a public offering of the ADSs, or the possession, circulation or distribution of this prospectus or any other material relating to us or the ADSs in any jurisdiction where
action for that purpose is required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, the ADSs may not be offered or sold, directly or indirectly, and neither this
prospectus nor any other material or advertisements in connection with the ADSs may be distributed or published, in or from any country or jurisdiction except in compliance with any applicable laws, rules and regulations of any such country or
jurisdiction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Australia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">does not constitute a product disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001
(Cth) (the &#147;Corporations Act&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">has not been, and will not be, lodged with the Australian Securities and Investments Commission
(&#147;ASIC&#148;), as a disclosure document for the purposes of the Corporations Act and does not purport to include the information required of a disclosure document under Chapter 6D.2 of the Corporations Act; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">does not constitute or involve a recommendation to acquire, an offer or invitation for issue or sale, an offer or
invitation to arrange the issue or sale, or an issue or sale, of interests to a &#147;retail client&#148; (as defined in section 761G of the Corporations Act and applicable regulations) in Australia; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">283 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or
more of the categories of investors, or Exempt Investors, available under section 708 of the Corporations Act. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ADSs
may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to subscribe for or buy the ADSs may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to
any ADSs may be distributed in Australia, except where disclosure to investors is not required under Chapter 6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application
for the ADSs, you represent and warrant to us that you are an Exempt Investor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As any offer of ADSs under this prospectus will be made
without disclosure in Australia under Chapter 6D.2 of the Corporations Act, the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if
none of the exemptions in section 708 applies to that resale. By applying for the ADSs you undertake to us that you will not, for a period of 12 months from the date of issue of the ADSs, offer, transfer, assign or otherwise alienate those
securities to investors in Australia except in circumstances where disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains general information only and does not take account of the investment objectives, financial situation or particular
needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate to their
needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Canada </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ADSs may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the ADSs must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus
requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser
with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the
securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with
a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts,
or NI <FONT STYLE="white-space:nowrap">33-105,</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with
this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Cayman Islands </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus does not constitute a public offer of the ADSs or ordinary shares, whether by way of sale or subscription, in the Cayman
Islands. ADSs or ordinary shares have not been offered or sold, and will not be offered or sold, directly or indirectly, in the Cayman Islands. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">284 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Dubai International Finance Center </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to an Exempt Offer in accordance with the Markets Rules 2012 of the Dubai Financial Services Authority (the
&#147;DFSA&#148;). This prospectus is intended for distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing
or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify the information set forth herein and has no responsibility for this prospectus. The securities to which this
prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the contents of this prospectus
you should consult an authorized financial advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to its use in the DIFC, this prospectus is strictly private and
confidential and is being distributed to a limited number of investors and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the securities may not be
offered or sold directly or indirectly to the public in the DIFC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>European Economic Area </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area (each a &#147;Member State&#148;), no ADSs have been offered or will be offered
pursuant to this offering to the public in that Member State prior to the publication of a prospectus in relation to the ADSs which has been approved by the competent authority in that Member State or, where appropriate, approved in another Member
State and notified to the competent authority in that Member State, all in accordance with the Prospectus Regulation, except that offers of ADSs may be made to the public in that Member State at any time under the following exemptions under the
Prospectus Regulation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined under the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus
Regulation), subject to obtaining the prior consent of the representatives of the underwriters for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such offer of ADSs shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or
supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an
&#147;offer to the public&#148; in relation to any ADSs in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any ADSs to be offered so as to enable an investor to decide to
purchase or subscribe for any ADSs, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Hong Kong
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ADSs may not be offered or sold by means of any document other than (i)&nbsp;in circumstances which do not constitute an offer
to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32, Laws of Hong Kong), or (ii)&nbsp;to &#147;professional investors&#148; within the meaning of the Securities and Futures Ordinance (Cap.
571, Laws of Hong Kong) and any rules made thereunder, or (iii)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; within the meaning of the Companies Ordinance (Cap. 32, Laws of Hong Kong), and no
advertisement, invitation or document relating to the ADSs may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely
to be accessed or read by, the public in Hong Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">285 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ADSs which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; within the meaning of the Securities and Futures Ordinance (Cap.
571, Laws of Hong Kong) and any rules made thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Indonesia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus does not, and is not intended to, constitute a public offering in Indonesia under Law Number 8 of 1995 regarding Capital
Market. This prospectus may not be distributed in the Republic of Indonesia and the ADSs may not be offered or sold in the Republic of Indonesia or to Indonesian citizens wherever they are domiciled, or to Indonesia residents, in a manner which
constitutes a public offering under the laws of the Republic of Indonesia. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Israel </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the State of Israel, the ADSs offered hereby may not be offered to any person or entity other than the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a fund for joint investments in trust (i.e., mutual fund), as such term is defined in the Law for Joint
Investments in Trust, 5754-1994, or a management company of such a fund; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a provident fund as defined in Section&nbsp;47(a)(2) of the Income Tax Ordinance of the State of Israel, or a
management company of such a fund; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an insurer, as defined in the Law for Oversight of Insurance Transactions, 5741-1981, a banking entity or
satellite entity, as such terms are defined in the Banking Law (Licensing), 5741-1981, other than a joint services company, acting for their own account or for the account of investors of the type listed in Section&nbsp;15A(b) of the Securities Law
1968; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a company that is licensed as a portfolio manager, as such term is defined in Section&nbsp;8(b) of the Law for
the Regulation of Investment Advisors and Portfolio Managers, 5755-1995, acting on its own account or for the account of investors of the type listed in Section&nbsp;15A(b) of the Securities Law 1968; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a company that is licensed as an investment advisor, as such term is defined in Section&nbsp;7(c) of the Law for
the Regulation of Investment Advisors and Portfolio Managers, 5755-1995, acting on its own account; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a company that is a member of the Tel Aviv Stock Exchange, acting on its own account or for the account of
investors of the type listed in Section&nbsp;15A(b) of the Securities Law 1968; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an underwriter fulfilling the conditions of Section&nbsp;56(c) of the Securities Law, 5728-1968;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a venture capital fund (defined as an entity primarily involved in investments in companies which, at the time of
investment, (i)&nbsp;are primarily engaged in research and development or manufacture of new technological products or processes and (ii)&nbsp;involve above-average risk); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an entity primarily engaged in capital markets activities in which all of the equity owners meet one or more of
the above criteria; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an entity, other than an entity formed for the purpose of purchasing the ADSs in this offering, in which the
shareholders equity (including pursuant to foreign accounting rules, international accounting regulations and U.S. generally accepted accounting rules, as defined in the Securities Law Regulations (Preparation of Annual Financial Statements), 1993)
is in excess of NIS 250&nbsp;million. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any offeree of the ADSs offered hereby in the State of Israel shall be required
to submit written confirmation that it falls within the scope of one of the above criteria. This prospectus will not be distributed or directed to investors in the State of Israel who do not fall within one of the above criteria. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">286 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Japan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ADSs have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as amended)
and, accordingly, will not be offered or sold directly or indirectly in Japan or to, or for the benefit of any Japanese person or to others, for reoffering or <FONT STYLE="white-space:nowrap">re-sale</FONT> directly or indirectly in Japan or to any
Japanese person, except in each case pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Securities and Exchange Law of Japan and any other applicable laws, rules and regulations of Japan. For
purposes of this paragraph, &#147;Japanese person&#148; means any person resident in Japan, including any corporation or other entity organized under the laws of Japan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Korea </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ADSs
may not be offered, sold and delivered directly or indirectly, or offered or sold to any person for reoffering or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea,
including the Korea Securities and Exchange Act and the Foreign Exchange Transaction Law and the decrees and regulations thereunder. The ADSs have not been registered with the Financial Services Commission of Korea for public offering in Korea.
Furthermore, the ADSs may not be resold to Korean residents unless the purchaser of the ADSs complies with all applicable regulatory requirements (including but not limited to government approval requirements under the Foreign Exchange Transaction
Law and its subordinate decrees and regulations) in connection with the purchase of the ADSs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Kuwait </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless all necessary approvals from the Kuwait Ministry of Commerce and Industry required by Law No.&nbsp;31/1990 &#147;Regulating the
Negotiation of Securities and Establishment of Investment Funds,&#148; its Executive Regulations and the various Ministerial Orders issued pursuant thereto or in connection therewith, have been given in relation to the marketing and sale of the
ADSs, these may not be marketed, offered for sale, nor sold in the State of Kuwait. Neither this prospectus (including any related document), nor any of the information contained therein is intended to lead to the conclusion of any contract of
whatsoever nature within Kuwait. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Malaysia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No prospectus or other offering material or document in connection with the offer and sale of the ADSs has been or will be registered with the
Securities Commission of Malaysia (the &#147;Commission&#148;) for the Commission&#146;s approval pursuant to the Capital Markets and Services Act 2007. Accordingly, this prospectus and any other document or material in connection with the offer or
sale, or invitation for subscription or purchase, of the ADSs may not be circulated or distributed, nor may the ADSs be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons
in Malaysia other than (i)&nbsp;a closed end fund approved by the Commission; (ii)&nbsp;a holder of a Capital Markets Services License; (iii)&nbsp;a person who acquires the ADSs, as principal, if the offer is on terms that the ADSs may only be
acquired at a consideration of not less than RM250,000 (or its equivalent in foreign currencies) for each transaction; (iv)&nbsp;an individual whose total net personal assets or total net joint assets with his or her spouse exceeds RM3&nbsp;million
(or its equivalent in foreign currencies), excluding the value of the primary residence of the individual; (v)&nbsp;an individual who has a gross annual income exceeding RM300,000 (or its equivalent in foreign currencies) per annum in the preceding
twelve months; (vi)&nbsp;an individual who, jointly with his or her spouse, has a gross annual income of RM400,000 (or its equivalent in foreign currencies), per annum in the preceding twelve months; (vii)&nbsp;a corporation with total net assets
exceeding RM10&nbsp;million (or its equivalent in a foreign currencies) based on the last audited accounts; (viii)&nbsp;a partnership with total net assets exceeding RM10&nbsp;million (or its equivalent in foreign currencies); (ix) a bank licensee
or insurance licensee as defined in the Labuan Financial Services and Securities Act 2010; (x) an Islamic bank licensee or takaful licensee as defined in the Labuan Financial Services and Securities Act 2010; and (xi)&nbsp;any other person as may be
specified by the Commission; provided that, in the each of the preceding categories (i)&nbsp;to (xi), the distribution of the ADSs is made by a holder of a Capital Markets Services Licence who </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">287 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
carries on the business of dealing in securities. The distribution in Malaysia of this prospectus is subject to Malaysian laws. This prospectus does not constitute and may not be used for the
purpose of public offering or an issue, offer for subscription or purchase, invitation to subscribe for or purchase any securities requiring the registration of a prospectus with the Commission under the Capital Markets and Services Act 2007. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>People&#146;s Republic of China </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus may not be circulated or distributed in the PRC and the ADSs may not be offered or sold, and will not offer or sell to any
person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale directly or indirectly to any resident of the PRC except pursuant to applicable laws, rules and regulations of the PRC. For the purpose of this paragraph only, the PRC does not
include Taiwan and the special administrative regions of Hong Kong and Macau. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Philippines </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE ADSS BEING OFFERED OR SOLD HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE PHILIPPINE SECURITIES AND EXCHANGE COMMISSION UNDER THE
SECURITIES REGULATION CODE OF THE PHILIPPINES, OR THE SRC. ANY FUTURE OFFER OR SALE OF THE ADSS WITHIN THE PHILIPPINES IS SUBJECT TO THE REGISTRATION REQUIREMENTS UNDER THE SRC UNLESS SUCH OFFER OR SALE QUALIFIES AS A TRANSACTION EXEMPT FROM THE
REGISTRATION UNDER THE SRC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, this prospectus, and any other document or material in connection with the offer or sale, or
invitation for subscription or purchase of the ADSs, may not be circulated or distributed in the Philippines, and the ADSs may not be offered or sold, or be made the subject of an invitation for subscription or purchase, to persons in the
Philippines, other than (i)&nbsp;to qualified investors in transactions that are exempt from the registration requirements of the SRC; and (ii)&nbsp;by persons licensed to make such offers or sales in the Philippines. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Qatar </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
State of Qatar, the offer contained herein is made on an exclusive basis to the specifically intended recipient thereof, upon that person&#146;s request and initiative, for personal use only and shall in no way be construed as a general offer for
the sale of securities to the public or an attempt to do business as a bank, an investment company or otherwise in the State of Qatar. This prospectus and the underlying securities have not been approved or licensed by the Qatar Central Bank or the
Qatar Financial Centre Regulatory Authority or any other regulator in the State of Qatar. The information contained in this prospectus shall only be shared with any third parties in Qatar on a need to know basis for the purpose of evaluating the
contained offer. Any distribution of this prospectus by the recipient to third parties in Qatar beyond the terms hereof is not permitted and shall be at the liability of such recipient. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Saudi Arabia </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
prospectus may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities Regulations issued by the Capital Market Authority. The Capital Market Authority does not make any representation
as to the accuracy or completeness of this prospectus, and expressly disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this prospectus. Prospective purchasers of the securities offered hereby
should conduct their own due diligence on the accuracy of the information relating to the securities. If you do not understand the contents of this prospectus you should consult an authorized financial adviser. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Singapore </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each
underwriter has acknowledged that this prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, each underwriter has represented, warranted and agreed that it
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">288 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
has not offered or sold any ADSs or caused the ADSs to be made the subject of an invitation for subscription or purchase and will not offer or sell any ADSs or cause the ADSs to be made the
subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus or any other document or material in connection with the offer or sale, or invitation for subscription
or purchase, of the ADSs, whether directly or indirectly, to any persons in Singapore other than (i) to an institutional investor (as defined in Section 4A of the Securities and Futures Act (Chapter 289 of Singapore), as modified or amended from
time to time (the &#147;SFA&#148;) pursuant to Section 274 of the SFA, (ii) to a relevant person (as defined in Section 275(2) of the SFA) pursuant to Section 275(1) of the SFA, or any person pursuant to Section 275(1A) of the SFA, and in accordance
with the conditions specified in Section 275 of the SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the ADSs are subscribed or purchased under Section 275 of the SFA by a relevant person which is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of
which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each
beneficiary of the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">securities or securities-based derivatives contracts (each
term as defined in Section 2(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the ADSs
pursuant to an offer made under Section 275 of the SFA except: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in
Section 275(1A) or Section 276(4)(i)(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as specified in Section 276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and
Securities-based Derivatives Contracts) Regulations 2018. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Switzerland </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ADSs will not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange
or regulated trading facility in Switzerland. This prospectus has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for
listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this prospectus nor any other offering or marketing material relating to our
company or the ADSs have been or will be filed with or approved by any Swiss regulatory authority. In particular, this prospectus will not be filed with, and the offer of the ADSs will not be supervised by, the Swiss Financial Market Supervisory
Authority, and the offer of the ADSs has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (the &#147;CISA&#148;). The investor protection afforded to acquirers of interests in collective investment
schemes under the CISA does not extend to acquirers of the ADSs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Taiwan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ADSs have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws and
regulations and may not be sold, issued or offered within Taiwan through </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">289 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a public offering or in circumstances which constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or approval of the Financial
Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorized to offer, sell, give advice regarding or otherwise intermediate the offering and sale of the ADSs in Taiwan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Thailand </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
prospectus does not, and is not intended to, constitute a public offering in Thailand. The ADSs may not be offered or sold to persons in Thailand, unless such offering is made under the exemptions from approval and filing requirements under
applicable laws, or under circumstances which do not constitute an offer for sale of the shares to the public for the purposes of the Securities and Exchange Act of 1992 of Thailand, nor require approval from the Office of the Securities and
Exchange Commission of Thailand. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>United Arab Emirates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ADSs have not been offered or sold, and will not be offered or sold, directly or indirectly, in the United Arab Emirates, except:
(i)&nbsp;in compliance with all applicable laws and regulations of the United Arab Emirates; and (ii)&nbsp;through persons or corporate entities authorized and licensed to provide investment advice and/or engage in brokerage activity and/or trade in
respect of foreign securities in the United Arab Emirates. The information contained in this prospectus does not constitute a public offer of securities in the United Arab Emirates in accordance with the Commercial Companies Law (Federal Law
No.&nbsp;8 of 1984 (as amended)) or otherwise and is not intended to be a public offer and is addressed only to persons who are sophisticated investors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>United Kingdom </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has not been approved by an authorized person in the United Kingdom and is for distribution only to persons who (i) have
professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#147;Financial Promotion Order&#148;), (ii) are persons falling
within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Promotion Order, (iii) are outside the United Kingdom or (iv)&nbsp;are persons to whom an invitation or inducement to engage in investment
activity (within the meaning of section 21 of the Financial Services and Markets Act 2000 (the &#147;FSMA&#148;)) in connection with the issue or sale of any ADSs may otherwise lawfully be communicated or caused to be communicated pursuant to the
Financial Promotion Order (all such persons together being referred to as &#147;relevant persons&#148;). This prospectus is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any
investment or investment activity to which this prospectus relates is available only to relevant persons and will be engaged in only with relevant persons. No person may communicate or cause to be communicated any invitation or inducement to engage
in investment activity (within the meaning of section 21 of the FSMA) received by it in connection with the issue or sale of the securities other than in circumstances in which Section 21(1) of the FSMA does not apply to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Vietnam </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ADSs
have not been and will not be registered with the State Securities Commission of Vietnam under the Law on Securities of Vietnam and its guiding decrees and circulars. The ADSs will not be offered or sold in Vietnam through a public offering and will
not be offered or sold to Vietnamese persons other than those who are licensed to invest in offshore securities under the Law on Investment of Vietnam. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">290 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_25"></A>EXPENSES RELATED TO THIS OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below is an itemization of the total expenses, excluding underwriting discounts and commissions, that we expect to incur in
connection with this offering. With the exception of the SEC registration fee, the Financial Industry Regulatory Authority, Inc. (&#147;FINRA&#148;), filing fee, and the [stock exchange application and listing fee], all amounts are&nbsp;estimates.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC Registration Fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA Fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[Stock exchange application and listing fee]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and Engraving Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal Fees and Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting Fees and Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>US$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">291 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_26"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are being represented by Skadden, Arps, Slate, Meagher&nbsp;&amp; Flom LLP with respect to certain legal matters as to United States
federal securities and New York State law. The underwriters are being represented by Davis Polk&nbsp;&amp; Wardwell LLP with respect to certain legal matters as to United States federal securities and New York State law. The validity of the ordinary
shares represented by the ADSs to be sold in this offering will be passed upon for us by Conyers Dill&nbsp;&amp; Pearman. Certain legal matters as to PRC law will be passed upon for us by JunHe LLP and for the underwriters by King&nbsp;&amp; Wood
Mallesons. Skadden, Arps, Slate, Meagher&nbsp;&amp; Flom LLP may rely upon Conyers Dill&nbsp;&amp; Pearman with respect to matters governed by Cayman Islands law and JunHe LLP with respect to matters governed by PRC law. Davis Polk&nbsp;&amp;
Wardwell LLP may rely upon King&nbsp;&amp; Wood Mallesons with respect to matters governed by PRC law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">292 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_27"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements as of December&nbsp;31, 2017 and 2018 and for each of the two years in the period ended December&nbsp;31, 2018
included in this prospectus have been so included in reliance on the report of PricewaterhouseCoopers Zhong Tian LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The office of PricewaterhouseCoopers Zhong Tian LLP is located at 11th Floor, PricewaterhouseCoopers Center, Link Square 2, 202 Hu Bin Road,
Shanghai, the People&#146;s Republic of China. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">293 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom713200_28"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed a registration statement, including relevant exhibits, with the SEC on Form <FONT STYLE="white-space:nowrap">F-1</FONT> under
the Securities Act with respect to the underlying ordinary shares represented by the ADSs to be sold in this offering. We have also filed a related registration statement on Form <FONT STYLE="white-space:nowrap">F-6</FONT> with the SEC to register
the ADSs. This prospectus, which constitutes a part of the registration statement on Form <FONT STYLE="white-space:nowrap">F-1,</FONT> does not contain all of the information contained in the registration statement. You should read our registration
statements and their exhibits and schedules for further information with respect to us and our ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately upon the effectiveness
of the registration statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> of which this prospectus forms a part, we will become subject to periodic reporting and other informational requirements of the Exchange Act as applicable to foreign
private issuers. Accordingly, we will be required to file reports, including annual reports on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> and other information with the SEC. The SEC maintains an internet site at http://www.sec.gov that
contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. We maintain our website at <FONT STYLE="white-space:nowrap">http://www.i-mabbiopharma.com/en/.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a foreign private issuer, we are exempt under the Exchange Act from, among other things, the rules prescribing the furnishing and content
of proxy statements, and our executive officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&nbsp;16 of the Exchange Act. In addition, we will not be required
under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. However, we intend to furnish the depositary with our annual
reports, which will include a review of operations and annual audited consolidated financial statements prepared in conformity with U.S. GAAP, and all notices of shareholders&#146; meetings and other reports and communications that are made
generally available to our shareholders. The depositary will make such notices, reports and communications available to holders of ADSs and, if we so request, will mail to all record holders of ADSs the information contained in any notice of a
shareholders&#146; meeting received by the depositary from us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">294 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A><A NAME="rom713200_29"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Financial Statements for the Years Ended December&nbsp;31, 2017 and
2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin713200_2">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin713200_3">Consolidated Balance Sheets as of December&nbsp;31, 2017 and
2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin713200_4">Consolidated Statements of Comprehensive Loss for the Years Ended December&nbsp;31,
 2017 and 2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin713200_5">Consolidated Statements of Changes in Shareholders&#146; Equity (Deficit) for
 the Years Ended December&nbsp;31, 2017 and 2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin713200_6">Consolidated Statements of Cash Flows for the Years Ended December&nbsp;
31, 2017 and 2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin713200_7">Notes to the Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT>
(Tianjin) Co., Ltd. (previously known as &#147;Tasgen <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd.&#148;) (Note)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Financial Statements for the Period from January&nbsp;1, 2017 to July&nbsp;15,
2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin713200_10">Report of Independent Auditors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin713200_11">Consolidated Balance Sheet as of July&nbsp;15, 2017</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin713200_12">Consolidated Statement of Comprehensive Loss for the Period from January&nbsp;1,
 2017 to July&nbsp;15, 2017</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin713200_13">Consolidated Statement of Changes in Shareholders&#146; Equity for the Period
 from January&nbsp;1, 2017 to July&nbsp;15, 2017</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin713200_14">Consolidated Statement of Cash Flows for the Period from January&nbsp;
1, 2017 to July&nbsp;15, 2017</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin713200_15">Notes to the Consolidated Financial Statements for the Period from January&nbsp;1,
 2017 to July&nbsp;15, 2017</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>I-Mab</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unaudited Interim Condensed Consolidated Financial Statements for the Six Months Ended June 30,
2018 and 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin713200_16">Unaudited Interim Condensed Consolidated Balance Sheets as of December 31, 2018
and June 30, 2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin713200_17">Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for
 the Six Months Ended June 30, 2018 and 2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin713200_18">Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders&#146;
 Equity (Deficit) for the Six Months Ended June 30, 2018 and 2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin713200_19">Unaudited Interim Condensed Consolidated Statements of Cash Flows for the Six
 Months Ended June 30, 2018 and 2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin713200_20">Notes to the Unaudited Interim Condensed Consolidated Financial
Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective
July&nbsp;15, 2017, the registrant acquired 66.67% equity interest of <FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. (referred to as &#147;Tasgen Group&#148;) for approximately
US$63,802,000 by issuance of convertible preferred shares (the &#147;Acquisition&#148;). Under Rule <FONT STYLE="white-space:nowrap">3-05</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X,</FONT> when comparing Tasgen Group&#146;s total
assets with registrant&#146;s total assets, the Acquisition was determined to be greater than 50% to the registrant on the basis of the most recent <FONT STYLE="white-space:nowrap">pre-Acquisition</FONT> annual financial statements (being the year
ended December&nbsp;31, 2016), and the net revenue reported by Tasgen Group in its most recent fiscal year (being the year ended December&nbsp;31, 2018) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
was less than US$100.0&nbsp;million, hence requiring 2 years of audited financial statements for Tasgen Group to be provided in connection with any public offering of securities by the
registrant. To meet the <FONT STYLE="white-space:nowrap">two-year</FONT> audited financial statements requirement, the registrant is filing the <FONT STYLE="white-space:nowrap">pre-Acquisition</FONT> financial statements for Tasgen Group from
January&nbsp;1, 2017 (the first day of Tasgen Group&#146;s fiscal year) through July&nbsp;15, 2017 (the Acquisition&#146;s effective date), so as to provide potential investors with 2 years of financial statements for Tasgen Group. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin713200_2"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Board of Directors and Shareholders of I-Mab </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Opinion on the Financial Statements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
audited the accompanying consolidated balance sheets of I-Mab and its subsidiaries (the &#147;Company&#148;) as of December 31, 2018 and 2017, and the related consolidated statements of comprehensive loss, of changes in shareholders&#146; equity
(deficit) and of cash flows for the years then ended, including the related notes (collectively referred to as the &#147;consolidated financial statements&#148;). In our opinion, the consolidated financial statements present fairly, in all material
respects, the financial position of the Company as of December 31, 2018 and 2017, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of
America. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis for Opinion </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These
consolidated financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s consolidated financial statements based on our audits. We are a public accounting firm
registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the
Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits of these consolidated financial statements in accordance with the standards of
the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are
free of material misstatement, whether due to error or fraud. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of
the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated
financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our
audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers Zhong Tian LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shanghai, the People&#146;s Republic of China </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July 29, 2019 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin713200_3"></A>Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>As of December&nbsp;31, 2017 and 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,588,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Prepayments and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.4,&nbsp;5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">691,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,036,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">296,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,025,345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,375,938</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>346,094</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Liabilities, mezzanine equity and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Short-term borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accruals and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Contract liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Advance from customers</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Research and development funding received</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.4,&nbsp;15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Onshore convertible loans</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred subsidy income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>309,151</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>415,684</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>60,550</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series A convertible preferred shares (US$0.0001 par value, 21,865,233 and 30,227,056 shares
authorized, issued and outstanding as of December&nbsp;31, 2017 and 2018, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series B convertible preferred shares (US$0.0001 par value, 15,894,594 and 30,305,212 shares
authorized, issued and outstanding as of December&nbsp;31, 2017 and 2018, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">921,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series C convertible preferred shares (US$0.0001 par value, 31,046,360 shares authorized, issued
and outstanding as of December&nbsp;31, 2018)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">305,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,015,989</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,915,358</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>424,670</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Balance Sheets&nbsp;(Continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>As of December&nbsp;31, 2017 and 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Ordinary shares (US$0.0001 par value, 500,000,000 shares authorized as of December&nbsp;31, 2017
and 2018, 8,363,719 shares authorized, issued and outstanding as of December&nbsp;31, 2017 and 2018, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">12</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Treasury stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">17</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(357,860</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,014,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(147,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(299,795</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(955,104</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(139,126</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total liabilities, mezzanine equity and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,025,345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,375,938</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>346,094</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:320pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin713200_4"></A>Consolidated Statements of Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Years Ended December&nbsp;31, 2017 and 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenues</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensing and collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(267,075</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(426,028</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,058</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,671</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280,955</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(438,638</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,895</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,704</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expenses), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,444</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,027</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before income tax expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(401,111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58,428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(251</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to <FONT STYLE="white-space:nowrap">I-MAB</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58,679</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustments, net of nil tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss attributable to
<FONT STYLE="white-space:nowrap">I-MAB</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(292,322</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(349,144</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(50,858</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58,679</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of ordinary shares used in calculating net loss per share&#151;basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,742,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss per share attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#151;Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8.99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#151;Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8.99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:240pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin713200_5"></A>Consolidated Statements of Changes in Shareholders&#146; Equity (Deficit) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Years Ended December&nbsp;31, 2017 and 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary&nbsp;share&nbsp;(Note&nbsp;12)<BR>(US$0.001 par value)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Treasury<BR>stock</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">paid-in</FONT><BR>capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>other<BR>comprehensive<BR>income</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>shareholders&#146;<BR>equity&nbsp;(deficit)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,363,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(227</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59,620</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,512</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,363,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(357,860</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(299,795</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction with redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests
(Note 16)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55,889</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(253,796</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(309,685</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,363,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,014,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(955,104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:240pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin713200_6"></A>Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Years Ended December&nbsp;31, 2017 and 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58,679</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Adjustments to reconcile net loss to net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on disposal of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expenses of convertible promissory notes and onshore convertible loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61,405</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,945</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,622</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,984</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from conversion of 2017 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from conversion of onshore convertible loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from issuance of 2018 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,602</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepayments and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(76,276</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accruals and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,803</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Advance from customers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development funding received</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred subsidy income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(252,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,889</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash acquired from acquisition of a subsidiary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,409</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for investments in other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(369,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,370</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash received from disposal of other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash received on income from other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash (used in) generated from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157,665</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible preferred shares, net of issuance cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT>
interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of onshore convertible loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from bank borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of bank borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(99,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,421</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash generated from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">758,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,479,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Cash Flows (Continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Years Ended December&nbsp;31, 2017 and 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Effect of exchange rate changes on cash and cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase in cash and cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,268,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and restricted cash, beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and restricted cash, end of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental cash flow disclosures</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-cash</FONT> activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payables for purchase of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payables for <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred shares issued for business combination (Note&nbsp;3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:240pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral
part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin713200_7"></A>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. PRINCIPAL ACTIVITIES AND ORGANIZATION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">I-Mab</FONT> (the &#147;Company&#148;) was incorporated in the Cayman Islands on June&nbsp;30, 2016 as an exempted company with limited liability under the Companies Law of the Cayman Islands. The Company and its
subsidiaries (together the &#147;Group&#148;) are principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People&#146;s Republic of China (the
&#147;PRC&#148;) and other countries and regions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the incorporation of the Company, the Group carried out its operation in the PRC since
November 2014 mainly through Third Venture Biopharma (Nanjing) Co., Ltd. (&#147;Third Venture&#148;), which was incorporated on November&nbsp;17, 2014 in the PRC. For the purpose of introduction of overseas investors and in preparation for a listing
of the Company&#146;s shares on the overseas capital markets, the Group underwent a reorganization (the &#147;Reorganization&#148;) in 2016. The Reorganization was approved by the Board of Directors and a restructuring framework agreement was
entered into by Third Venture, the Company, and the shareholders of the Company based on Reorganization framework agreement, pursuant to which on July&nbsp;7, 2016, Third Venture transferred all of its assets and operations to the Company&#146;s
wholly owned subsidiary, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Co., Ltd. <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Shanghai&#148;), which was a transaction in which shareholders had identical ownership interests before
and after the transaction and was accounted for in a manner similar to a common control transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Reorganization, as described above has been
accounted for at historical cost. That Reorganization was reverse merger of Third Venture and Third Venture is the predecessor of the Company. As such, the assets and liabilities of Third Venture are consolidated in the Company&#146;s financial
statements at historical cost. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, the Company&#146;s principal subsidiaries are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Subsidiaries</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Place of<BR>incorporation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Date of<BR>incorporation or<BR>acquisition</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Percentage<BR>of direct<BR>or indirect<BR>ownership<BR>by the<BR>Company</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Principal activities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Hong&nbsp;Kong</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;8, 2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Investment&nbsp;holding</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">PRC</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">August&nbsp;24,&nbsp;2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR><BR><BR></TD>
<TD VALIGN="top" ALIGN="right">Research and<BR>development of<BR>innovative<BR>medicines</TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT>
(Tianjin) Co., Ltd. <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Tianjin&#148;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">PRC</P></TD>
<TD NOWRAP VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">July&nbsp;15, 2017</P></TD>
<TD NOWRAP VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">100</P></TD>
<TD NOWRAP VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">%&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;<BR><BR><BR></P></TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Research and<BR>development of<BR>innovative<BR>medicines</P></TD>
<TD NOWRAP VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">U.S.</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">February&nbsp;28,&nbsp;2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR><BR><BR></TD>
<TD VALIGN="top" ALIGN="right">Research and<BR>development of<BR>innovative<BR>medicines</TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. PRINCIPAL ACCOUNTING POLICIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.1 Basis of presentation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying
consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#147;U.S. GAAP&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant accounting policies followed by the Group in the preparation of its accompanying consolidated financial statements are summarized below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.2 Basis of consolidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying
consolidated financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. All inter-company balances and transactions have been eliminated in consolidation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.3 Use of estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of the
consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of
the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations
of assets and liabilities and other intangible assets. Additionally, estimates are used in determining items such as useful lives of property, equipment and software, impairment of contract assets and other receivables, impairment of long-lived
assets and goodwill, share-based compensation, tax valuation allowances and revenues from licensing and collaboration arrangements. Management bases the estimates on historical experience, known trends and various other assumptions that are believed
to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.4 Fair value measurements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial assets and
liabilities of the Group primarily comprise of cash and cash equivalents, restricted cash, other financial assets, contract assets, other receivables, short-term borrowings, accruals and other payables and warrants liabilities. As of
December&nbsp;31, 2017 and 2018, except for other financial assets and warrant liabilities, the carrying values of these financial assets and liabilities approximated their fair values because of their generally short maturities. The Group reports
other financial assets and warrant liabilities at fair value at each balance sheet date and changes in fair value are reflected in the consolidated statements of comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group measures its financial assets and liabilities using inputs from the following three levels of the fair value hierarchy. The three levels are as
follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level&nbsp;1 inputs are unadjusted quoted prices in active markets for identical assets that the management has the ability to access at the
measurement date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level&nbsp;2 inputs include quoted prices for similar assets in active markets, quoted prices for identical or similar assets in
markets that are not active, inputs other than quoted prices that are observable for the asset (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other
means (market corroborated inputs). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. PRINCIPAL ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.4 Fair value measurements&nbsp;(continued) </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level&nbsp;3 includes unobservable inputs that reflect the management&#146;s assumptions about the
assumptions that market participants would use in pricing the asset. The management develops these inputs based on the best information available, including the own data.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Assets and liabilities measured at fair value on a recurring basis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group measured its other financial assets and warrant liabilities at fair value on a recurring basis. As the Group&#146;s other financial assets and
warrants are not traded in an active market with readily observable prices, the Group uses significant unobservable inputs to measure the fair value of other financial assets and warrant liabilities. These instruments are categorized in the
Level&nbsp;3 valuation hierarchy based on the significance of unobservable factors in the overall fair value measurement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes
the Group&#146;s financial assets and liabilities measured and recorded at fair value on a recurring basis as of December&nbsp;31, 2017 and 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Active&nbsp;market<BR>(Level&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Observable&nbsp;input<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-observable&nbsp;input</FONT><BR>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Active&nbsp;market<BR>(Level&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Observable&nbsp;input<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-observable&nbsp;input</FONT><BR>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. PRINCIPAL ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.4 Fair value measurements&nbsp;(continued) </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The roll forward of major Level&nbsp;3 financial asset and financial liability are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Other&nbsp;financial<BR>assets</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Warrant&nbsp;liabilities</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of Level&nbsp;3 financial asset and liability as of December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,931</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Business combination (Note3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment in other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">369,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of warrants to investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposal of other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(133,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,027</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income received from other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Currency translation differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of Level&nbsp;3 financial asset and liability as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(65,832</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment in other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposal of other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income received from other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,909</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Currency translation differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,505</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of Level&nbsp;3 financial assets and financial as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,618</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Refer to Note 15 for additional information about Level&nbsp;3 warrant liabilities measured at fair value on a recurring basis
for the years ended December&nbsp;31, 2017 and 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.5 Foreign currency translation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group uses Chinese Renminbi (&#147;RMB&#148;) as its reporting currency. The United States Dollar (&#147;US$&#148;) is the functional currency of the
Group&#146;s entities incorporated in the Cayman Islands, the United States of America (&#147;U.S.&#148;) and Hong Kong, the Australia Dollar (&#147;AUD&#148;) is the functional currency of the Group&#146;s entity incorporated in Australia and the
RMB is the functional currency of the Company&#146;s PRC subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transactions denominated in other than the functional currencies are translated
into the functional currency of the entity at the exchange rates prevailing on the transaction dates. Assets and liabilities denominated in other than the functional currencies are translated at the balance sheet date exchange rate. The resulting
exchange differences are recorded in the consolidated statements of comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of the Group are translated
from the functional currency to the reporting currency, RMB. Assets and liabilities of the subsidiaries are translated into RMB using the exchange rate in effect at each balance sheet date. Income and expenses are translated at the average exchange
rates prevailing for the year. Foreign currency translation adjustments arising from these are reflected in the accumulated other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. PRINCIPAL ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.5 Foreign currency translation&nbsp;(continued) </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
comprehensive income. The exchange rates used for translation on December&nbsp;31, 2017 and 2018 were US$1.00&nbsp;=&nbsp;RMB6.5342 and RMB6.8632, respectively, representing the index rates
stipulated by the People&#146;s Bank of China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Translations of balances in the consolidated balance sheets, consolidated statements of comprehensive
loss, consolidated statements of changes in shareholders&#146; equity (deficit) and consolidated statements of cash flows from RMB into US$ as of and for the year ended December&nbsp;31, 2018 are solely for the convenience of the readers and were
calculated at the rate of US$1.00=RMB6.8650, representing the noon buying rate in The City of New York for cable transfers of RMB as certified for customs purposes by the Federal Reserve Bank of New York on June 30, 2019. No representation is made
that the RMB amounts could have been, or could be, converted, realized or settled into US$ at that rate on December&nbsp;31, 2018, or at any other rate. The US$ convenience translation is not required under U.S. GAAP and all US$ convenience
translation amounts in the accompanying consolidated financial statements are unaudited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.6 Cash and cash equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents consist of cash on hand and bank deposits, which are unrestricted as to withdrawal and use. The Company considers all highly liquid
investments with an original maturity date of three months or less at the date of purchase to be cash equivalents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.7 Restricted cash </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted cash consists of the guarantee deposits held in a designated bank account as security deposits under bank borrowing agreements. Such restricted cash
will be released when the Group repays the related bank borrowings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.8 Property, equipment and software </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property, equipment and software are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the
straight-line method over the following estimated useful lives, taking into account any estimated residual value: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laboratory equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3 to 5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Software</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2 to 5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Office furniture and equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Leasehold improvements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Lesser of useful life or lease term</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group recognized the gain or loss on the disposal of property, equipment and software in the consolidated statements of
comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.9 Intangible assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intangible assets with definite useful lives are amortized to their estimated residual values over their estimated useful lives and reviewed for impairment if
certain events or changes in circumstances indicate that the carrying </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. PRINCIPAL ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.9 Intangible assets&nbsp;(continued) </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amount of an asset may not be recoverable. Amortization is initiated for <FONT STYLE="white-space:nowrap">in-process</FONT> research and development (IPR&amp;D) intangible assets that are
acquired from business combination when their useful lives have been determined. IPR&amp;D intangible assets which are determined to have an impairment in their fair value are adjusted downward and an expense recognized in research and development
in the consolidated statements of comprehensive loss. These IPR&amp;D intangible assets are tested at least an annual basis on December&nbsp;31 or when a triggering event occurs that could indicate a potential impairment. (see Note 7). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.10 Impairment of <FONT STYLE="white-space:nowrap">long-lived</FONT> assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Long-lived assets are reviewed for impairment in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are
reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable. Long-lived assets are reported at the lower of carrying amount or fair value less cost to sell. For the years ended December&nbsp;31,
2017 and 2018, there was no impairment of the value of the Group&#146;s long-lived assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.11 Goodwill </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually
identified and separately recognized. The Group allocates the cost of an acquired entity to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The excess of the purchase price for
acquisitions over the fair value of the net assets acquired, including other intangible assets, is recorded as goodwill. Goodwill is not amortized, but impairment of goodwill assessment is performed on at least an annual basis on December&nbsp;31 or
whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group has elected to first assess
qualitative factors to determine whether it is more likely than not that the fair value of the Group&#146;s reporting unit is less than its carrying amount, including goodwill. The qualitative assessment includes the Group&#146;s evaluation of
relevant events and circumstances affecting the Group&#146;s single reporting unit, including macroeconomic, industry, market conditions and the Group&#146;s overall financial performance. If qualitative factors indicate that it is more likely than
not that the Group&#146;s reporting unit&#146;s fair value is less than its carrying amount, then the Group will perform the quantitative impairment test by comparing the reporting unit&#146;s carrying amount, including goodwill, to its fair value.
If the carrying amount of the reporting unit exceeds its fair value, an impairment loss will be recognized in an amount equal to that excess. For the years ended December&nbsp;31, 2017 and 2018, the Group determined that there were no indicators of
impairment of the goodwill. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.12 Deferred subsidy income </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred subsidy income consists of deferred income from government grants. Government grants consist of cash subsidies received by the Group&#146;s
subsidiaries in the PRC from local governments as support on expenses relating to certain projects. Grants received with government specified performance obligations are recognized when all the obligations have been fulfilled. If such obligations
are not satisfied, the Group may be required to refund the subsidy. Cash grants of RMB2,500 was recorded in deferred subsidy income as of December&nbsp;31, 2018, which will be recognized when the government specified performance obligation is
satisfied, which is expected to be more than 12 months after December&nbsp;31, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. PRINCIPAL ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.13 Revenue recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group adopted Accounting Standard Codification (&#147;ASC&#148;) 606, <I>Revenue from Contracts with Customers</I> (Topic 606) (&#147;ASC 606&#148;) for
all periods presented. Consistent with the criteria of Topic 606, the Group recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in
exchange for those goods or services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an
amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the
following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction price, including variable consideration, if any; (iv)&nbsp;allocate the
transaction price to the performance obligations in the contract; and (v)&nbsp;recognize revenue when (or as) the entity satisfies a performance obligation. The Group only applies the five-step model to contracts when it is probable that the entity
will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once a contract is determined
to be within the scope of ASC 606 at contract inception, the Group reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Group recognizes as revenue the amount of
the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration revenue </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At contract inception, the Group
analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808,<I>&nbsp;Collaborative Arrangements</I>&nbsp;(&#147;ASC 808&#148;) to determine whether such arrangements involve joint operating activities performed by
parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities.&nbsp;For collaboration arrangements within the scope of ASC 808 that contain multiple
elements, the Group first determines if the collaboration is deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. For the collaboration arrangements
that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group&#146;s collaborative
arrangements may contain more than one unit of account, or performance obligation, including grants of licenses to intellectual property rights, agreement to provide research and development services and other deliverables. The collaborative
arrangements do not include a right of return for any deliverable. As part of the accounting for these arrangements, the Group must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation
identified in the contract.&nbsp;In developing the stand-alone selling price for a performance obligation, the Group considers competitor pricing for a similar or identical product, market awareness of and perception of the product, expected product
life and current market trends. In general, the consideration allocated to each performance obligation is recognized when the respective obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is
not constrained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When the timing of the delivery of product is different from the timing of payments made by the customers, the Group recognizes either a
contract asset (performance precedes the contractual due date) or a contract liability </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. PRINCIPAL ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.13 Revenue recognition&nbsp;(continued) </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(customer payment precedes performance). The Group&#146;s contractual payment terms are typically due in no more than 30 days from invoicing. In limited situations, certain customer contractual
payment terms require the Group to bill in arrears; thus, the Group satisfies some or all of the performance obligations before the Group is contractually entitled to bill the customer. In these situations, billing occurs subsequent to revenue
recognition, which results in a contract asset. For example, certain of the contractual arrangements do not permit the Group to bill until the completion of the production of the samples. In other limited situations, certain customer contractual
payment terms allow the Group to bill in advance; thus, the Group receives customer cash payment before satisfying some or all of its performance obligations. In these situations, billing occurs in advance of revenue recognition, which results in
contract liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Licenses of Intellectual Property</I>: Upfront <FONT STYLE="white-space:nowrap">non-refundable</FONT> payments for licensing the
Group&#146;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, the Group recognizes revenues from <FONT
STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">up-front</FONT> fees allocated to the license at a point in time, when the license is transferred to the licensee and the licensee is able to use and benefit from the
license.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Services</I>: The portion of the transaction price allocated to research and development services performance
obligations is deferred and recognized as collaboration revenue over time as delivery or performance of such services occurs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Milestone Payments</I>:
At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Group evaluates whether the milestones are considered probable of being reached and to the extent that a significant reversal
of cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative
stand-alone selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Group
<FONT STYLE="white-space:nowrap">re-evaluates</FONT> the probability of achieving such development milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price. Any such adjustments are recorded on a
cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> basis, which would affect revenues and earnings in the period of adjustment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Royalties</I>: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to
be the predominant item to which the royalties relate, the Group recognizes revenue at the later of (i)&nbsp;when the related sales occur, or (ii)&nbsp;when the performance obligation to which some or all of the royalty has been allocated has been
satisfied (or partially satisfied). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.14 <FONT STYLE="white-space:nowrap">Value-added-tax</FONT> (&#147;VAT&#148;) recoverable and surcharges
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Value added tax recoverable represent amounts paid by the Group for purchases. The surcharges (i.e., Urban construction and maintenance tax,
educational surtax, local educational surtax), vary from 6% to 17% of the <FONT STYLE="white-space:nowrap">value-added-tax</FONT> depending on the <FONT STYLE="white-space:nowrap">tax-payer&#146;s</FONT> location. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. PRINCIPAL ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.15 Research and development expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Elements of research and development expenses primarily include (1)&nbsp;payroll and other related expenses of personnel engaged in research and development
activities, <FONT STYLE="white-space:nowrap">(2)&nbsp;in-licensed</FONT> patent rights fee of exclusive development rights of drugs granted to the Group, (3)&nbsp;expenses related to preclinical testing of the Group&#146;s technologies and clinical
trials such as payments to contract research organizations (&#147;CRO&#148;), investigators and clinical trial sites that conduct the clinical studies (4)&nbsp;expenses to develop the product candidates, including raw materials and supplies, product
testing, depreciation, and facility related expenses, (5)&nbsp;other research and development expenses. Research and development expenses are charged to expense as incurred when these expenditures relate to the Group&#146;s research and development
services and have no alternative future uses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group has acquired rights to develop and commercialize product candidates. Upfront payments that relate
to the acquisition of a new drug compound, as well as <FONT STYLE="white-space:nowrap">pre-commercial</FONT> milestone payments, are immediately expensed as acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development in the
period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#147;business&#148; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing
and, absent obtaining such approval, has no established alternative future use. Milestone payments made to third parties subsequent to regulatory approval would be capitalized as intangible assets and amortized over the estimated remaining useful
life of the related product. The conditions enabling capitalization of development expenses as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.16 Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leases are classified at the
inception date as either a capital lease or an operating lease. the Group assesses a lease to be a capital lease if any of the following conditions exist: (1)&nbsp;ownership is transferred to the lessee by the end of the lease term, (2)&nbsp;there
is a bargain purchase option, (3)&nbsp;the lease term is at least 75% of the property&#146;s estimated remaining economic life or (4)&nbsp;the present value of the minimum lease payments at the beginning of the lease term is 90% or more of the fair
value of the leased property to the lessor at the inception date. A capital lease is accounted for as if there was an acquisition of an asset and an incurrence of an obligation at the inception of the lease. The Group has no capital leases for the
years presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All other leases are accounted for as operating leases wherein rental payments are expensed on a straight-line basis over the periods of
their respective lease terms. Certain of the lease agreements contain rent holidays. Rent holidays are considered in determining the straight-line rent expense to be recorded over the lease term. The lease term begins on the date of initial
possession of the lease property for purposes of recognizing lease expense on straight-line basis over the term of the lease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.17 Comprehensive
loss </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Comprehensive loss is defined as the changes in equity of the Group during a period from transactions and other events and circumstances
excluding transactions resulting from investments by owners and distributions to owners. Among other disclosures, ASC 220, <I>Comprehensive Income</I>, requires that all items that are required to be recognized under current accounting standards as
components of comprehensive loss be reported in a financial statement that is displayed with the same prominence as other financial statements. For each of the periods presented, the Group&#146;s comprehensive loss includes net loss and foreign
currency translation adjustments, which are presented in the consolidated statements of comprehensive loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. PRINCIPAL ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.18 Share-based compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company grants restricted shares and stock options to eligible employees and accounts for share-based compensation in accordance with ASC 718,
<I>Compensation</I>&#151;<I>Stock Compensation</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Employees&#146; share-based compensation awards are measured at the grant date fair value of the
awards and recognized as expenses a) immediately at the grant date if no vesting conditions are required; or b) for share-based awards granted with only service conditions, using the graded vesting method net of estimated forfeitures over the
vesting period; or c) for share-based awards granted with service conditions and the occurrence of an initial public offering (&#147;IPO&#148;) as performance condition cumulative share-based compensation expenses for the options that have satisfied
the service condition should be recorded upon the completion of the IPO using the graded vesting method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A change in any of the terms or conditions of
share-based awards is accounted for as a modification of the awards. The Group calculates incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the original awards
immediately before its terms are modified at the modification date. For vested awards, the Group recognizes incremental compensation cost in the period when the modification occurs. For awards not being fully vested, the Group recognizes the sum of
the incremental compensation expense and the remaining unrecognized compensation expense for the original awards over the remaining requisite service period after modification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share-based compensation in relation to the restricted shares is measured based on the fair market value of the Group&#146;s ordinary shares at the grant date
of the award. Prior to the listing, estimation of the fair value of the Group&#146;s ordinary shares involves significant assumptions that might not be observable in the market, and a number of complex and subjective variables, including discount
rate, and subjective judgments regarding the Group&#146;s projected financial and operating results, its unique business risks, the liquidity of its ordinary shares and its operating history and prospects at the time the grants are made. Share-based
compensation in relation to the share options is estimated using the Binominal Option Pricing Model. The determination of the fair value of share options is affected by the share price of the Group&#146;s ordinary shares as well as the assumptions
regarding a number of complex and subjective variables, including the expected share price volatility, risk-free interest rate, exercise multiple and expected dividend yield. The fair value of these awards was determined with the assistance from an
independent valuation firm. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.19 Income taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group accounts for income taxes under the liability method. Under the liability method, deferred income tax assets and liabilities are determined based on
the differences between the financial reporting and income tax bases of assets and liabilities and are measured using the tax income rates that will be in effect when the differences are expected to reverse. A valuation allowance is recorded if it
is more likely than not that some portion or all of a deferred income tax assets will not be realized in the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group evaluates its
uncertain tax positions using the provisions of ASC 740-10, <I>Income Taxes</I>, which prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Group recognizes in the
financial statements the benefit of a tax position which is &#145;&#145;more likely than not&#146;&#146; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant
information. Tax positions that meet the recognition threshold are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. PRINCIPAL ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.19 Income taxes&nbsp;(continued) </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. It is the Group&#146;s
policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.20 Borrowings
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost; any
difference between the proceeds (net&nbsp;of transaction costs) and the redemption value is recognized in the consolidated statements of comprehensive loss over the period of the borrowings using the effective interest method. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.21 Business combination </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group accounts for
its business combinations using the acquisition method of accounting in accordance with ASC topic 805, <I>Business Combinations</I> (&#147;ASC 805&#148;). The acquisition method of accounting requires all of the following steps: (i)&nbsp;identifying
the acquirer, (ii)&nbsp;determining the acquisition date, (iii)&nbsp;recognizing and measuring the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree, and (iv)&nbsp;recognizing and measuring
goodwill or a gain from a bargain purchase. The consideration transferred in a business combination is measured as the aggregate of the fair values at the date of exchange of the assets given, liabilities incurred, and equity instruments issued as
well as the contingent considerations and all contractual contingencies as of the acquisition date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group allocates the fair value of purchase
consideration to the tangible assets acquired, liabilities assumed and intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and
liabilities is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets may include, but are not
limited to, future expected cash flows from acquired assets, timing and probability of success of clinical events and regulatory approvals, and assumptions on useful lives of the patents and discount rates. Management&#146;s estimates of fair value
are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Additional information, such as that related to income tax and other
contingencies, existing as of the acquisition date but unknown to us may become known during the remainder of the measurement period, not to exceed one year from the acquisition date, which may result in changes to the amounts and allocations
recorded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acquisitions that do not meet the accounting definition of a business combination are accounted for as asset acquisitions. For transactions
determined to be asset acquisitions, the Group allocates the total cost of the acquisition, including transaction costs, to the net assets acquired based on their relative fair values. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.22 Segment information </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with ASC
280, <I>Segment Reporting</I>, the Group&#146;s chief operating decision maker, the Chief Executive Officer, reviews the consolidated results when making decisions about allocating resources and assessing performance of the Group as a whole and
hence, the Group has only one reportable segment. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. PRINCIPAL ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.22 Segment information&nbsp;(continued) </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Group does not distinguish between markets or segments for the purpose of internal reporting. As the Group&#146;s long-lived assets are substantially located in and derived from the PRC, no
geographical segments are presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.23 Loss per share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic loss per share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding
during the period using the <FONT STYLE="white-space:nowrap">two-class</FONT> method. Under the <FONT STYLE="white-space:nowrap">two-class</FONT> method, the net loss is allocated between ordinary shares and other participating securities based on
their participating rights. Net loss is not allocated to other participating securities if based on their contractual terms they are not obligated to share in the loss. Diluted loss per share is calculated by dividing net loss attributable to
ordinary shareholders by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares consist of shares issuable upon the conversion of the preferred shares using the <FONT
STYLE="white-space:nowrap">if-converted</FONT> method, shares issuable upon the exercise of share options using the treasury stock method, shares issuable upon the conversion of the convertible promissory notes using the <FONT
STYLE="white-space:nowrap">if-converted</FONT> method, and shares issuable upon the exercise of warrants using the treasury stock method. Ordinary equivalent shares are not included in the denominator of the diluted loss per share calculation when
inclusion of such shares would be anti-dilutive. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.24 Recent accounting pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> Leases (Topic 842) (&#147;ASU
<FONT STYLE="white-space:nowrap">2016-02&#148;).</FONT> Under this guidance, an entity is required to recognize <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities on its balance
sheet and disclose key information about leasing arrangements. This guidance offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative
information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. In July 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">2018-11,</FONT>
Leases (Topic 842): Targeted Improvements (&#147;ASU <FONT STYLE="white-space:nowrap">2018-11&#148;),</FONT> which provides entities the option to initially apply ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> at the adoption date and recognize
a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> and ASU <FONT STYLE="white-space:nowrap">2018-11</FONT> are effective for the annual reporting
period beginning after December&nbsp;15, 2018, including interim periods within that reporting period. The Group adopted the new leasing standards on January&nbsp;1, 2019, using a modified retrospective transition approach to be applied to leases
existing as of, or entered into after, January&nbsp;1, 2019. The Group have reviewed the existing lease contracts and the impact of the new leasing standards on the consolidated results of operations, financial position and disclosures. Upon
adoption of the new leasing standards, the Group expect to recognize a lease liability and related <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset on the consolidated balance sheets of approximately
RMB11,333 and RMB13,100, respectively. The impact of adoption of the new leasing standards will have an immaterial impact to the consolidated statements of comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-13,</FONT> Financial Instruments &#150; Credit Losses (Topic 326): Measurement of
Credit Losses on Financial Instruments (&#147;ASU <FONT STYLE="white-space:nowrap">2016-13&#148;).</FONT> This guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The
measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability. In November 2018, the FASB issued ASU
<FONT STYLE="white-space:nowrap">2018-19,</FONT> Codification Improvements to Topic 326, Financial Instruments-Credit Losses (&#147;ASU <FONT STYLE="white-space:nowrap">2018-19&#148;),</FONT> which clarifies certain
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. PRINCIPAL ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.24 Recent accounting pronouncements&nbsp;(continued) </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
topics included within ASU <FONT STYLE="white-space:nowrap">2016-13.</FONT> ASU <FONT STYLE="white-space:nowrap">2016-13</FONT> and ASU <FONT STYLE="white-space:nowrap">2018-19</FONT> are
effective for the annual reporting period beginning after December&nbsp;15, 2019, including interim periods within that reporting period. The Group is currently evaluating the impact on the consolidated financial statements upon the adoption of this
guidance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-15,</FONT> Statement of Cash Flows (Topic 230), Classification of
Certain Cash Receipts and Cash Payments. ASU <FONT STYLE="white-space:nowrap">2016-15</FONT> provides guidance for targeted changes with respect to how cash receipts and cash payments are classified in the statements of cash flows, with the
objective of reducing diversity in practice. The amendments in this update are effective for public business entities for fiscal years beginning after December&nbsp;15, 2017, and interim periods within those fiscal years. Early adoption is
permitted, including adoption in an interim period. The Group elected to early adopt this ASU and applied this guidance retrospectively to all periods presented. The impact of this ASU to the consolidated financial statements is immaterial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-18,</FONT> Statement of Cash Flows (Topic 230) (&#147;ASU <FONT
STYLE="white-space:nowrap">2016-18&#148;).</FONT> This ASU affects all entities that have restricted cash or restricted cash equivalents and are required to present a statement of cash flows under Topic 230. ASU
<FONT STYLE="white-space:nowrap">2016-18</FONT> requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents.
This update was required to be adopted for fiscal years beginning after December&nbsp;15, 2018, and interim periods within fiscal years beginning after December&nbsp;15, 2019, and early adoption is permitted in any interim or annual period. The
Group elected to early adopt this ASU and applied this guidance retrospectively to all periods presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. BUSINESS COMBINATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2017, the Group acquired 66.67% of the equity interests in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin and its subsidiaries including Chengdu
Tasgen <FONT STYLE="white-space:nowrap">Bio-Tech</FONT> Co., Ltd. and Shanghai Tianyunjian <FONT STYLE="white-space:nowrap">Bio-Tech</FONT> Co., Ltd. (together the &#147;Tasgen Group&#148;) by issuing convertible preferred shares to the then equity
holders of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin. The acquisition date was determined as July&nbsp;15, 2017 when the Group controlled the board and business of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin from July&nbsp;15,
2017 accordingly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin and its subsidiaries are principally engaged in the research and development of
innovative medicines. The Group acquired <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin and its subsidiaries for its research team, technical experience, and pipeline assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually
identified and separately recognized. The Company allocates the cost of an acquired entity to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The excess of the purchase price for
acquisitions over the fair value of the net assets acquired, including other intangible assets, is recorded as goodwill. Goodwill is not amortized but is tested for impairment at least annually or more frequently if events or changes in
circumstances would indicate a potential impairment. None of the goodwill recognized is expected to be deductible for income tax purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group
completed the valuations necessary to assess the fair values of the tangible assets acquired and liabilities assumed, resulting from which the amount of goodwill was determined and recognized as of the date of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. BUSINESS COMBINATION&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
acquisition. The following table summarizes the estimated aggregate fair values of the assets acquired and liabilities assumed as of the date of acquisition: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of July&nbsp;15, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred shares to be issued (Note 13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial assets (Note 5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets (*)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepayments and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accruals and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,824</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(266</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of net assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests (Note 16)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The intangible assets acquired in the business combination were IPR&amp;D intangible assets, which represented
the fair value assigned to research and development assets that the Group acquired. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The acquired business did not contribute any
revenues and contributed net loss of RMB14,750 to the Group for the period from July&nbsp;15, 2017 to December&nbsp;31, 2017. Unaudited pro forma operating results for the Group, assuming the acquisition of Tasgen Group occurred on January&nbsp;1,
2017 is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the year ended<BR>December&nbsp;31, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(314,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,810</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summarizes the business combination as presented on the consolidated statement of cash flows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the year ended<BR>December&nbsp;31, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash acquired for acquisition of a subsidiary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred shares issued for business combination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. PREPAYMENTS AND OTHER RECEIVABLES </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepayments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Prepayments to CRO vendors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Prepayments for other services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Value-added tax recoverable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rental deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. OTHER FINANCIAL ASSETS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial asset at fair value through profit or loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Note receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group placed the principal amount for short-term investments through a contractual arrangement with a third party for the
period from June&nbsp;30, 2017 to June&nbsp;30, 2020 (&#147;Principal Amount&#148;). The Principal Amount can be redeemed from the third party at the discretion of the Group from time to time whereby the Group is expecting to earn an income on the
Principal Amount with an average yield in the range from 4.50% to 5.25% per annum. The Group initially records these assets at cost, which approximates its fair value at inception and subsequently records these assets at fair value. Changes in the
fair value are reflected in the consolidated statements of comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to December&nbsp;31, 2018, the Group entered into an agreement
with the relevant party involved for early termination of the contractual arrangement with effect from June&nbsp;22, 2019 (&#147;Termination Agreement&#148;). Pursuant to the Termination Agreement, the Group shall receive cash with an amount of
RMB95,056 and commercial bills with a total face value of RMB160,944 (including those commercial bills redeemed during the year ended December&nbsp;31, 2018 with a face value of RMB40,387). No material gain or loss was arising from such termination.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Up to the issuance of these consolidated financial statements, cash of RMB80,000 was received and an amount of RMB85,374 cash was received upon the
maturities of certain commercial bills. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. PROPERTY, EQUIPMENT AND SOFTWARE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property, equipment and software consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,650</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,390</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,222</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total amounts charged to the consolidated statements of comprehensive loss for depreciation and amortization expenses
amounted to approximately RMB1,634 and RMB6,740 for the years ended December&nbsp;31, 2017 and 2018, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. INTANGIBLE ASSETS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intangible assets as of December&nbsp;31, 2017 and 2018 are summarized as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IPR&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IPR&amp;D represents the fair value assigned to research and development assets that we acquired from business combination of
Tasgen Group in 2017 and had not reached technological feasibility at the date of acquisition. Upon commercialization, the Group will determine the estimated useful life and amortize these amounts based upon an economic consumption method. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. GOODWILL </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The goodwill of RMB162,574 (US$23,682) as of
December&nbsp;31, 2017 and 2018 represented the goodwill generated from the acquisition of Tasgen Group in 2017 (Note 3). The business of Tasgen Group was fully integrated into the Company post acquisition. As of December&nbsp;31, 2017 and 2018, the
Group performed a qualitative assessment by evaluating relevant events and circumstances that would affect the Group&#146;s single reporting unit and did not note any indicator that it is more likely than not that the fair value of the Group&#146;s
reporting unit is less than its carrying amount, and therefore the Group&#146;s goodwill was not impaired. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. SHORT-TERM BORROWINGS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the third quarter of 2017, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Co., Ltd. borrowed loans with the total amount of RMB99,000 from China
Merchant Bank Co., Ltd. for a term of one year and at the interest rate of 4.79% per annum. To facilitate the borrowings, another subsidiary of the Company in Hong Kong placed cash deposits of US$16,015 (equivalent to approximately RMB104,783) with
the bank. The use of such cash deposits and the interest earned thereon are restricted by the bank during the period of the borrowings. The deposits have a <FONT STYLE="white-space:nowrap">one-year</FONT> term and bear interest at 2.00% per annum.
The borrowings were fully repaid in 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2018, <FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT>
(Tianjin) Co., Ltd. borrowed a loan of RMB80,000 from China Merchant Bank Co., Ltd. for a term of one year and at the interest rate of 4.20% per annum. To facilitate these borrowing, another subsidiary of the Company in Hong Kong placed cash
deposits of US$13,500 (equivalent to approximately RMB92,653) with the bank. The use of such cash deposits and the interest earned thereon are restricted by the bank during the period of the borrowing. The deposits have a <FONT
STYLE="white-space:nowrap">one-year</FONT> term and bear interest at 3.26% per annum. The borrowing was fully repaid in 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. ACCRUALS AND OTHER
PAYABLES </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Staff salaries and welfare payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued external research and development activities related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payables for purchase of equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued travelling expenses, office expenses and others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. INCOME TAXES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cayman Islands </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> is incorporated in the Cayman Islands. Under the current laws of the Cayman Islands, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> is not subject to tax on income or capital gain. Additionally, the Cayman Islands does not impose a withholding tax on payments of dividends to shareholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hong Kong </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited is incorporated in Hong Kong. Companies registered in Hong Kong are subject to Hong
Kong profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Hong Kong tax laws. The applicable tax rate in Hong Kong is 16.5%. For the years ended December&nbsp;31,
2017 and 2018, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited did not make any provisions for Hong Kong profit tax as there were no assessable profits derived from or earnings in Hong Kong for any of the periods presented.
Under the Hong Kong tax law, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited is exempted from income tax on its foreign-derived income and there are no withholding taxes in Hong Kong on remittance of dividends. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. INCOME TAXES&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Australia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Australia Pty Ltd is incorporated in Australia. Companies registered in Australia are subject to
Australia profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Australia tax laws. The applicable tax rate in Australia is 30%.
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Australia Pty Ltd has no taxable income for all periods presented, therefore, no provision for income taxes is required. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Ltd. is incorporated in U.S. and is subject to U.S. federal corporate income tax at a rate of 21%. <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Ltd. is also subject to state income tax in Maryland of 8.25%. <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Ltd. has no taxable income for all periods presented, therefore, no
provision for income taxes is required. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>China </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;16, 2007, the National People&#146;s Congress of PRC enacted a new Enterprise Income Tax Law (&#147;new EIT law&#148;), under which Foreign
Investment Enterprises (&#147;FIEs&#148;) and domestic companies would be subject to corporate income tax at a uniform rate of 25%. The new EIT law became effective on January&nbsp;1, 2008. Under the new EIT law, preferential tax treatments will
continue to be granted to entities which conduct businesses in certain encouraged sectors and to entities otherwise classified as &#147;High and New Technology Enterprises&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai has been qualified as &#147;High and New Technology Enterprise&#148; and enjoys a preferential income
tax rate of 15% from 2018 to 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s other PRC subsidiaries are subject to the statutory income tax rate of 25%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No provision for income taxes has been made because the Group and all of its subsidiaries are in cumulative loss positions for all the periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reconciliations of the differences between the PRC statutory income tax rate and the Group&#146;s effective income tax rate for the years ended
December&nbsp;31, 2017 and 2018 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(401,111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58,428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax computed at respective applicable tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,672</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,093</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,171</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-deductible</FONT> expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses plus deduction</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,846</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,762</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(985</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of tax holidays entitled by the PRC subsidiaries on basic loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. INCOME TAXES&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal components of the deferred tax assets and liabilities are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization of property, equipment and software, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrual expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,541</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,511</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,767</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Movement of the valuation allowance is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of January&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,472</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,541</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,216</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Business combination (Note 3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,629</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,036</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease due to the change of tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,541</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,511</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,767</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31 2018, the Group had net operating losses of approximately RMB462,148 which arose from the subsidiaries
established in the PRC. The tax losses carried forward in the PRC will expire during the period from 2019 to 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A valuation allowance is provided to
reduce the amount of deferred tax assets if it is considered more likely than not that some portion or all of the deferred tax assets will not be realized in the foreseeable future. In making such determination, the Group evaluates a variety of
positive and negative factors including the Group&#146;s operating history, accumulated deficit, the existence of taxable temporary differences and reversal periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group has incurred net accumulated operating losses for income tax purposes since its inception. The Group believes that it is more likely than not that
these net accumulated operating losses will not be utilized in the future. Therefore, the Group has provided full valuation allowances for the deferred tax assets as of December&nbsp;31, 2017 and 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and measure the
unrecognized benefits associated with the tax positions. As of December&nbsp;31, 2017 and 2018, the Group did not have any significant unrecognized uncertain tax positions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. ORDINARY SHARES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017 and 2018, 500,000,000 ordinary shares had been authorized by the Company. Each ordinary share is entitled to one vote. The holders
of ordinary shares are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors of the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. CONVERTIBLE PREFERRED SHARES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;18,
2016, the Company issued 5,141,587 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> and <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Shares with a consideration of US$11,282 (equivalent to approximately RMB74,742). In connection
with the Series <FONT STYLE="white-space:nowrap">A-1</FONT> and <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Shares issuance, the Company also issued 2,246,744 warrant to purchase its Series <FONT STYLE="white-space:nowrap">A-3</FONT>
Preferred Shares (Series <FONT STYLE="white-space:nowrap">A-3</FONT> Warrants and see Note 15). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;6, 2017, in connection with the
Group&#146;s acquisition of Tasgen Group (see Note 3), the Company issued 16,723,646 shares of series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares at a price of US$2.55 per share with a total consideration of US$42,645 (equivalent to
approximately RMB289,024). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Shares, Series <FONT STYLE="white-space:nowrap">A-2</FONT>
Preferred Shares and Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares are also referred to as Series A Preferred Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
September&nbsp;22, 2017, the Company issued 15,894,594 shares of Series B Preferred Shares with a consideration of US$52,546 (equivalent to approximately RMB346,515). In connection with the Series B Preferred Shares issuance, the Company also issued
convertible promissory notes that are convertible into Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares (2017 Notes and see Notes 14) and 5,633,780 warrants to purchase its Series <FONT STYLE="white-space:nowrap">B-2</FONT>
Preferred Shares (&#147;Series B Warrant&#148; and see Note 15). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the Company&#146;s issuance of Series B Preferred Shares, the Company
also completed a round of onshore financing with respect to the Group&#146;s subsidiary <FONT STYLE="white-space:nowrap">I-MAB</FONT> Tianjin (&#147;Series B Onshore Financing&#148;). Series B Onshore Financing comprised 1) capital injection to <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Tianjin by a number of investors (&#147;Series B Onshore Investors&#148;) (see Note 14), 2) <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s issuance of convertible loans (&#147;Onshore Convertible
Loans&#148; and see Note 14), and 3) the Company&#146;s issuance of 2,620,842 warrants to purchase its Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares (&#147;Series B Warrants&#148; and see Note 15). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June 29, 2018, the Company issued total 8,361,823 shares of Series A-3 Preferred Shares upon exercise of Series A-3 Option held by its holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;29, 2018, the Company issued 2,535,201 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares upon conversion of 2017
Notes and issued 2,253,512 shares of Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares upon exercise of Series B Warrant by Series B preferred shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;29, 2018, the Company issued total 5,938,640 share of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares upon exercise of Series
B Option held by a Series B Onshore Investor and issued 947,218 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares upon conversion of Onshore Convertible Loans by a Series B Onshore Investor (see Note 14), respectively.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 6, 2018, the Company issued 1,455,549 shares of Series B-1 Preferred Shares upon exercise of Series B Option held by a Series B Option Investor,
issued 232,161 shares of Series B-1 Preferred Shares upon conversion of Onshore Convertible Loans by a Series B Onshore Investor (see Note 14) and issued 1,048,337 shares of Series B-2 Preferred Shares upon exercise of Series B Warrant by Series B
Onshore Investors, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. CONVERTIBLE PREFERRED SHARES&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Series B Preferred Shares, Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares and Series <FONT
STYLE="white-space:nowrap">B-2</FONT> Preferred Shares are also referred to as Series B Preferred Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 6, 2018, the Company issued 31,046,360
shares of Series C Preferred Shares at a price of US$6.4419 per share with a total consideration of US$200,000 (equivalent to approximately RMB1,323,363). In connection with the offering of the Series C Preferred Shares, the Company incurred
issuance costs of RMB16,730. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Series A Preferred Shares, Series B Preferred Shares and Series C Preferred Shares are collectively referred to as Preferred
Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key terms of the Preferred Shares are summarized as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of Preferred Shares are entitled
to receive dividends, out of any assets legally available therefor, prior and in preference to any declaration or payment of any dividend on the ordinary shares or any other class or series of shares of the Group at the rate of eight percent (8%) of
the original issue price per share per annum on each Preferred Share, payable in US$ and annually when, as and if declared by the Board. Such distributions shall not be cumulative. No dividend, whether in cash, in property or in shares of the
capital of the Group, shall be paid on or declared and set aside for any ordinary shares or any other class or series of shares of the Group unless and until all dividends have been paid in full on the Preferred Shares (on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> basis). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conversion </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Preferred Share may be converted at any time into ordinary shares at the option of the preferred shares holders at the then applicable conversion price.
The initial conversion ratio is 1:1, subject to adjustment in the event of (i)&nbsp;share splits, share combinations, share dividends or distribution, other dividends, recapitalizations and similar events, or (ii)&nbsp;issuance of ordinary shares
(excluding certain events such as issuance of ordinary shares pursuant to a public offering) at a price per share less than the conversion price in effect on the date of or immediately prior to such issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Preferred Shares shall be automatically converted into ordinary shares immediately upon the closing of a public offering of the Company&#146;s shares with
an offering price (exclusive of underwriting commissions and expenses) that reflects a market capitalization (immediately prior to the public offering) of not less than US$1,000,000,000 (the &#147;Qualified Public Offering&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group determined that there were no beneficial conversion features (&#147;BCF&#148;) identified for any of the Preferred Shares during any of the periods.
In making this determination, the Company compared the fair value of the ordinary shares into which the Preferred Shares are convertible with the respective effective conversion price at the issuance date. In all instances, the effective conversion
price was greater than the fair value of the ordinary shares. To the extent a conversion price adjustment occurs, as described above, the Group will revaluate whether or not a beneficial conversion feature should be recognized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of any liquidation (unless
waived by the preferred shareholders) including deemed liquidation, dissolution or winding up of the Company, holders of the Preferred Shares shall be entitled to receive a per share amount equal to one hundred percent (100%) of the original issue
price on each Preferred Share, plus an amount </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. CONVERTIBLE PREFERRED SHARES&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
representing an internal rate of return of twelve percent (12%) per annum on the original issue price as adjusted for share dividends, share splits, combinations, recapitalizations or similar
events, plus all accrued and declared but unpaid dividends thereon, in the sequence of Series C Preferred Shares, Series B Preferred Shares and Series A Preferred Shares. After such liquidation amounts have been paid in full, any remaining funds or
assets of the Company legally available for distribution to shareholders shall be distributed on a pro rata basis among the holders of the Preferred Shares, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, together with the holders
of the ordinary shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounting of preferred shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Preferred Shares are redeemable by the holders upon a liquidation event, including a deemed liquidation event (e.g., change in control), and as such are
presented as mezzanine equity on the consolidated balance sheets. In accordance with ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">480-10-S99,</FONT></FONT> each issuance of the convertible preferred shares should be
recognized at the date of issuance after deducting fair value allocated to the detachable warrants and issuance costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company assesses whether an
amendment to the terms of its convertible preferred shares is an extinguishment or a modification using the fair value model. When convertible preferred shares are extinguished, the difference between the fair value of the consideration transferred
to the convertible preferred shareholders and the carrying amount of the convertible preferred shares (net of issuance costs) is treated as deemed dividends to the preferred shareholders. The Company considers that a significant change in fair value
after the change of the terms to be substantive and thus triggers extinguishment. A change in fair value which is not significant immediately after the change of the terms is considered <FONT STYLE="white-space:nowrap">non-substantive</FONT> and
thus is subject to modification accounting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s convertible preferred shares activities for the years ended December&nbsp;31, 2017 and
2018 are summarized below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Series A Preferred Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Series B Preferred Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Series C Preferred Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of January&nbsp;1,&nbsp;2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,141,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series A Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,723,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series B Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,894,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31,&nbsp;2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,865,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,894,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series A Preferred Shares upon exercise of Series
<FONT STYLE="white-space:nowrap">A-3</FONT> Option</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,361,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">323,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series B Preferred Shares upon exercise of Series B Option</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,394,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">291,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. CONVERTIBLE PREFERRED SHARES&nbsp;(CONTINUED) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounting of preferred shares&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Series A Preferred Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Series B Preferred Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Series C Preferred Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series B Preferred Shares upon conversion of 2017 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,535,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series B Preferred Shares upon conversion of Onshore Convertible Loans</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,179,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series B Preferred Shares upon exercise of Tranche I of Series B Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,301,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series C Preferred Shares, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,046,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,227,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,305,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">921,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,046,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. CONVERTIBLE PROMISSORY NOTES AND ONSHORE CONVERTIBLE LOANS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2017 Notes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;25, 2017, the Company issued
US$11,520 convertible promissory notes (&#147;2017 Notes&#148;) to investors of Series B Preferred Shares (see Note 13) at a compound interest rate of 8% per annum, maturing on 36 months after the issuance date. Under the agreement, the holder of
the 2017 Notes may convert the outstanding principal amount into Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares at the conversion price of US$5.38 per share or a lower price as may be agreed by the investors and the Company at
any time from six months prior to the maturity date and prior to the repayment in full of the 2017 Note. No interest shall be accrued if the 2017 Notes have been converted into Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the fair value of the Company&#146;s ordinary shares on September&nbsp;25, 2017 was lower than the effective conversion price of US$5.38, the Company
did not record a BCF. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;29, 2018, the Company&#146;s 2017 Notes were converted into the Company&#146;s 2,535,201 Series <FONT
STYLE="white-space:nowrap">B-1</FONT> Preferred Shares at the nominal conversion price of US$5.38 per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. CONVERTIBLE PROMISSORY NOTES AND ONSHORE CONVERTIBLE LOANS&nbsp;(CONTINUED) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2018 Notes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;3, 2018, the Company issued US$9,000 (equivalent to approximately RMB59,704) convertible promissory notes (&#147;2018 Notes&#148;) to an
investor of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares at an annual interest rate of 0%, maturing on 36 months after the issuance date. Under the agreement, the holder of the 2018 Notes may convert the 2018 Notes outstanding
principal amount into Sereis <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares at the conversion price being lower of US$10 per share and fair market value at any time prior to the maturity date. Alternatively, the 2018 Notes shall be
automatically converted into the Company&#146;s Series B Preferred Shares upon the maturity. As the fair value of the Company&#146;s ordinary shares on February&nbsp;3, 2018 of US$3.96 was equal to the effective conversion price (being lower of
US$10 per share and fair market value), the Company did not record a BCF. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Onshore Convertible Loans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;25, 2017, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin issued US$5,359 convertible loans to Series B Onshore Investors at a compound
interest rate of 8% per annum, maturing on 36 months after the issuance date. Under the agreement, the holder of the Onshore Convertible Loans may convert the outstanding principal amount into <FONT STYLE="white-space:nowrap">I-Mab</FONT>
Tianjin&#146;s equity interest a stipulated conversion price at any time from 6 months prior to the maturity date and prior to the repayment in full of the Onshore Convertible Loans. No interest shall be accrued if the Onshore Convertible Loans have
been converted into <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s equity interest. As the fair value of the <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s ordinary shares on September&nbsp;25, 2017 was lower than the
effective conversion price of US$4.31, the Company did not record a BCF. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June and July 2018, the Company reached agreements with holders of Onshore
Convertible Loans and the principal amount of Onshore Convertible Loans were then effectively converted into 1,179,379 Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares of the Company and the accrued interests were waived,
resulting in an extinguishment loss of RMB8,548. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. WARRANTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the issuance of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> and <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Shares on
October&nbsp;18, 2016, 2,246,744 Series <FONT STYLE="white-space:nowrap">A-3</FONT> Warrants were issued to Series <FONT STYLE="white-space:nowrap">A-1</FONT> and <FONT STYLE="white-space:nowrap">A-2</FONT> preferred shareholder, which provided the
holder the right to purchase Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares. The Series <FONT STYLE="white-space:nowrap">A-3</FONT> Warrants were later terminated on September&nbsp;6, 2017 without being exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the issuance of the Series B Preferred Shares on September&nbsp;22, 2017, 5,633,780 Series B Warrants were issued to Series B preferred
shareholders, which provided the holders the right to purchase <FONT STYLE="white-space:nowrap">Series&nbsp;B-2</FONT> Preferred Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection
with the Company&#146;s Series B Onshore Financing that took place on September&nbsp;25, 2017, 2,620,842 Series B Warrants were issued to Series B Onshore Investors, which provided the holders the right to purchase Series <FONT
STYLE="white-space:nowrap">B-2</FONT> Preferred Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the period from June&nbsp;29, 2018 to July&nbsp;6, 2018, 3,301,849 Series B Warrants
(representing Tranche I of Series B Warrants) were exercised to purchase 3,301,849 Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares with proceeds of US$20,000 (equivalent to approximately RMB132,332). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2018, the Series B Warrants holders agreed that the Series B Warrants shall be divided into two tranches and exercisable in accordance with
different time schedules, such that: (i)&nbsp;the holders have exercised </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. WARRANTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
part of the Series B Warrants in the total consideration of US$20,000 (&#147;Tranche I of Series B Warrants&#148;) and 3,301,849 Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred
Shares of the Company in aggregate have been newly issued to such holders on a pro rata basis; (ii)&nbsp;only when the Company fails to submit a Qualified Public Offering application at an internationally recognized securities exchange by
March&nbsp;31, 2019, the Warrant Holders may exercise the remaining part of Series B Warrants, in the total consideration of US$30,000 (&#147;Tranche II of Series B Warrants&#148;) and 4,952,773 Series <FONT STYLE="white-space:nowrap">B-2</FONT>
Preferred Shares of the Company in aggregate will be issued to such holders on a pro rata basis; (iii)&nbsp;provided that the Company successfully submits a Qualified Public Offering application at an internationally recognized securities exchange
by March&nbsp;31, 2019, the holders shall unconditionally and irrevocably waive and cancel Tranche II of Series B Warrants; and (iv)&nbsp;the Tranche II of Series B Warrants may only be concurrently exercised by all the Warrant Holders in one lump.
This is considered to be a modification to Series B Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to the confirmations issued by the Company&#146;s Series B Warrants holders in
July 2019, the holders of Series B Warrants has unconditionally and irrevocably waived and cancelled the Tranche II of Series B Warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounting
of warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The warrant is a freestanding instrument and is recorded as liability in accordance with ASC 480, <I>Distinguishing Liabilities from
Equity</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the Company&#146;s issuance of warrants were bundled with other instruments (such as convertible preferred shares, convertible promissory
notes, etc.), out of total considerations, the warrants are initially recognized at fair value and the remaining were allocated to other instruments on a relative fair value basis (if applicable). The fair value changes of the warrants (including
the fair value changes arising from modification of warrants) up to the time of exercise or termination were recognized in earnings. Upon exercise, the total carrying value of the associated warrant liabilities was reclassified into the carrying
value of the Preferred Shares into which it was converted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determined the fair value of the warrants with the assistance of an independent
third party valuation firm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group has measured the warrant liabilities at fair values on a recurring basis using significant unobservable inputs
(Level 3) for the years ended December&nbsp;31, 2017 and 2018. The Group used the binomial model to estimate the fair value of warrant liabilities using the following assumptions: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate of return</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.84</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.49</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maturity date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">September&nbsp;25,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">September&nbsp;25,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated volatility rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">US$6.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">US$6.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of underlying convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">US$5.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">US$6.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The model requires the input of highly subjective assumptions including the risk-free rate of return, maturity date, estimated
volatility rate and fair value of underlying preferred shares. The risk-free rate for periods within </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. WARRANTS&nbsp;(CONTINUED) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounting of
warrants&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the contractual life is based on the US treasury strip bond with maturity similar to the maturity of the warrants as of valuation dates plus a China country risk premium. For expected
volatilities, the Group has made reference to the historical daily stock prices volatilities of ordinary shares of several comparable companies in the same industry as the Group. The estimated fair value of the preferred shares was determined with
assistance from an independent third party valuation firm. The Group&#146;s management is ultimately responsible for the determination of the estimated fair value of its preferred shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The significant unobservable inputs used in the fair value measurement of the warrant liabilities include risk-free rate of return, interval between valuation
date and maturity date, estimated volatility rate and fair value of underlying preferred shares. Significant decreases in interval between valuation date and maturity date, estimated volatility rate and fair value of underlying preferred shares
would result in a significantly lower fair value measurement. Significant increases in risk-free rate of return would result in a significantly lower fair value measurement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. REDEEMABLE <FONT STYLE="white-space:nowrap">NON-CONTROLLING</FONT> INTERESTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Company&#146;s acquisition of Tasgen Group (see Note 3), on September&nbsp;6, 2017, the Company also entered into an option agreement
with the third party investor of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin, pursuant to which the Company granted the third party investor an option to subscribe for certain number of Series <FONT STYLE="white-space:nowrap">A-3</FONT>
Preferred Shares of the Company at a price that stipulated in the agreement, and at the same time, the third party investor shall transfer its equity interests in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjian to the Company at the same
price (&#147;Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option&#148;). This Series <FONT STYLE="white-space:nowrap">A-3</FONT> can be exercised at any time at the holder&#146;s own discretion or upon the request of the Company if the
shareholders of the Company approves an initial public offering. In addition, in the event that the exercise of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option has not been completed within 6 months after the option holder delivers the
share purchase option notice, the Company shall purchase the third party investor&#146;s equity interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjian and the Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option at a price that
stipulated in the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the Company&#146;s issuance of Series B Preferred Shares (see Note 13), on September&nbsp;25, 2017, the
Group&#146;s subsidiary <FONT STYLE="white-space:nowrap">I-MAB</FONT> Tianjin entered into a capital increase subscription agreement with Series B Onshore Investors, pursuant to which Series B Onshore Investors subscribed for additional equity in <FONT
STYLE="white-space:nowrap">I-MAB</FONT> Tianjin of US$24,444 (equivalent to approximately RMB161,196). On September&nbsp;25, 2017 and in tandem with the aforementioned <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s capital increase
subscription agreement, the Company also entered into option agreements with Series B Onshore Investors, pursuant to which the Company granted Series B Onshore Investors options to subscribe for certain numbers of Series <FONT
STYLE="white-space:nowrap">B-1</FONT> Preferred Shares of the Company at a price that stipulated in the agreements, and at the same time, the Series B Onshore Investors shall transfer their equity interests in
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjian to the Company at the same price (&#147;Series B Option&#148;). The Series B Option can be exercised at any time at the holders&#146; own discretion or upon the request of the Company if the
shareholders of the Company approve an initial public offering. In addition, in the event that the exercise of Series B Option has not been completed within 6 months after the option holders deliver the share purchase option notice, the Company
shall purchase the third party investor&#146;s equity interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjian and the Series B Option at a price that stipulated in the agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the accounting assessments, the Company considers that the aforementioned Series <FONT STYLE="white-space:nowrap">A-3</FONT> and Series B Options are
embedded features of the <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests that are not required to be bifurcated. Since the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. REDEEMABLE <FONT STYLE="white-space:nowrap">NON-CONTROLLING</FONT> INTERESTS&nbsp;(CONTINUED) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
aforementioned <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin are redeemable at a determinable price, upon occurrence
of an event that is not solely within the control of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjian, the aforementioned <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests in <FONT STYLE="white-space:nowrap">I-Mab</FONT>
Tianjin are accounted for as redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests in the Group&#146;s consolidated balance sheets. Subsequently, the redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests
should be carried at the higher of (1)&nbsp;the carrying amount after the attribution of net income of the Company and (2)&nbsp;the expected redemption value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option and Series B Option were exercised by respective holders on June&nbsp;29, 2018 and July&nbsp;6,
2018 to acquire 8,361,823 Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares and 7,394,189 Series B Preferred Shares, respectively. The transactions were accounted for as equity transactions, and the differences between the carrying
amount of redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests of RMB305,708 and the fair value of convertible preferred shares of RMB615,393 that issued were recognized in additional
<FONT STYLE="white-space:nowrap">paid-in</FONT> capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group&#146;s redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest
activities for the years ended December&nbsp;31, 2017 and 2018 are summarized as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">305,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital injection by Series B Onshore Investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests arising from business
combination (Note 3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(144,512</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,051</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of Series B Option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(161,196</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">305,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. SHARE-BASED COMPENSATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(a) Restricted shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended
December&nbsp;31, 2016, the Company issued 4,019,554 ordinary shares to Mr. Zang Jingwu Zhang, Ms. Qian Lili, Mr. Wang Zhengyi and Mr. Fang Lei (collectively the &#147;Founders&#148;), including the 369,301 shares which represented the equity
interests of Third Venture held by the Founders, and the Company recorded share-based compensation expense of RMB18.7&nbsp;million for issuance and grant of 3,650,253 ordinary shares to the Founders in June 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2016, the Founders entered into an arrangement with other investors of the Company, and the 87,441 ordinary shares issued to the Founders in June
2016 were canceled and out of the remaining 3,932,113 ordinary shares held by the Founders, 70% became restricted and subject to service vesting conditions, that shall vest 20%, 20% and 30% over the next three years, respectively. There shall be no
acceleration of the vesting schedule except that, in case of a change of control of the Company or a Qualified Public Offering, or the termination of the Founder&#146;s employment with the Group without cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred share-based compensation was measured for the restricted shares using the estimated fair value of the Company&#146;s ordinary shares of US$0.77 at
the date of imposition of the restriction in October 2016, and was amortized to the consolidated statements of comprehensive loss by using graded vesting method over the vesting term of 3 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. SHARE-BASED COMPENSATION&nbsp;(CONTINUED) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(a)
Restricted shares&nbsp;(continued) </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the Group&#146;s Founders&#146; restricted shares activities: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Numbers<BR>of&nbsp;shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>average<BR>grant&nbsp;date<BR>fair&nbsp;value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,752,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(786,423</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,966,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(786,423</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,179,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts of shared-based compensation expense in relation to the restricted shares recognized in the years ended
December&nbsp;31, 2017 and 2018 were RMB7,039 and RMB3,520, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shared-based compensation expenses related to restricted shares were included
in: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(b) 2017 Employee Stock Option Plan (&#147;2017 Plan&#148;) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2017, the Company adopted the 2017 Plan. Under the 2017 Plan, a maximum aggregate number of 13,376,865 shares that may be issued pursuant to all
awards granted were approved. Stock options granted to an employee under the 2017 Plan will be exercisable upon the Company completes a listing and the employee renders service to the Company in accordance with a stipulated service schedule starting
from the employee&#146;s date of employment. Employees are generally subject to a three-year service schedule, under which an employee earns an entitlement to vest in 50% of the option grants on the second anniversary of the grant date, a vesting of
the remaining 50% on the third anniversary of the applicable grant date. The stock option under 2017 Plan, to the extent then vested, shall become exercisable only upon the earlier of (i)&nbsp;a listing, and (ii)&nbsp;occurrence of a change in
control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the Company completes a listing, all stock options granted to an employee shall be forfeited at the time the employee terminates his
employment with the Group. After the Company completes a listing, vested options not exercised by an employee shall be exercised until later of: (i) 90 days after the date when the options become exercisable, or (ii) 30 days after the date of
cessation of employment or directorship, or such longer period as the Board of Directors may otherwise determine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. SHARE-BASED COMPENSATION&nbsp;(CONTINUED) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(b)
2017 Employee Stock Option Plan (&#147;2017 Plan&#148;)&nbsp;(continued) </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group granted 11,051,230 and 1,470,000 stock options to employees, all with an exercise price of
US$1, for the years ended December&nbsp;31, 2017 and 2018, respectively. No options are exercisable as of December&nbsp;31, 2017 and 2018 and prior to the Group completes a listing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the stock options activities for the years ended December&nbsp;31, 2017 and 2018: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number&nbsp;of<br>shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Weighted<br>average<br>exercise<br>price<br>US$</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Weighted<br>average<br>remaining<br>contractual<br>term</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Aggregate<br>intrinsic<br>value<br>US$</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,051,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other addition (note)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">710,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,761,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,470,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(226,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,005,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">note:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Other addition represented the modified share options that originally granted to two senior management
employees in October 2016 (see (c) Other share-based compensation) </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock options granted to the employees were measured at fair value
on the dates of grant using the Binomial Option Pricing Model with the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62.34</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">61.32%-62.13</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate (per annum)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.32</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">2.81%-3.06</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise multiple</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contractual term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The expected volatility was estimated based on the historical volatility of comparable peer public companies with a time
horizon close to the expected term of the Group&#146;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of the Group&#146;s
options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As the Group did not
have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as the Group has never declared or paid any cash dividends on its
shares, and the Group does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. SHARE-BASED COMPENSATION&nbsp;(CONTINUED) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(b)
2017 Employee Stock Option Plan (&#147;2017 Plan&#148;)&nbsp;(continued) </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of stock options granted to employees for the years ended December&nbsp;31, 2017 and 2018
amounted to RMB99.0 million and RMB45.2 million, respectively. Since the exercisability is dependent upon the listing, and it is not probable that this performance condition can be achieved until a listing, no share-based compensation expense
relating to the 2017 Plan was recorded for the years ended December&nbsp;31, 2017 and 2018. The Group will recognize compensation expenses relating to options vested cumulatively upon the completion of the Company&#146;s listing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(c) Other share-based compensation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended
December&nbsp;31, 2016, the Group recorded share-based compensation expense of RMB3.3&nbsp;million for issuance and grant of 710,366 stock options to two senior management employees in October 2016, as rewards for their services they had performed
in the past and in exchange for their full-time devotion and professional expertise. Stock options granted to the two employees were exercisable once granted, with an exercise price of US$0.06. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2017, in connection with the adoption of 2017 Plan, the Group amended the stock option agreement with the two aforementioned employees, under which
the stock options would become exercisable only upon the earlier of (i)&nbsp;a listing, and (ii)&nbsp;occurrence of a change in control that defined in the stock option agreements. As the modification of terms and conditions of share-based
compensation were not beneficial to its employees, no further accounting impact was resulting from it. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. LICENSING AND COLLABORATION ARRANGEMENTS
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a description of the Group&#146;s significant licensing and collaboration agreements entered into for the years ended
December&nbsp;31, 2017 and 2018. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with MorphoSys AG (&#147;MorphoSys&#148;) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2017, the Group entered into a license and collaboration agreement with MorphoSys, with respect to the development and commercialization of
MOR202/TJ202, MorphoSys&acute;s proprietary investigational antibody against CD38 (the &#147;CD38 product&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under this agreement, MorphoSys granted
to the Group an exclusive, royalty-bearing, sublicensable license to exploit MOR202/TJ202 for any human therapeutic or diagnostic purpose in the licensed territory, namely mainland China, Hong Kong, Macau and Taiwan (collectively &#147;Greater
China&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to this agreement, the Group granted to MorphoSys an exclusive license to its rights in any inventions that the Group make while
exploiting the CD38 product under this agreement, solely to exploit the CD38 product outside of Greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to this agreement, the Group paid
to MorphoSys an upfront license fee of US$20.0&nbsp;million (equivalent to approximately RMB132.7 million). The Group also agreed to make milestone payments to MorphoSys, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. LICENSING AND COLLABORATION ARRANGEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements&nbsp;(continued)
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conditioned upon the achievement of certain development, regulatory and commercial milestones, in the aggregate amount of US$98.5&nbsp;million (equivalent to approximately RMB653.5 million). Such
milestones include first patient dosed in human clinical trials, marketing approval, and first annual net sales of CD38 products covered by the agreement in excess of a certain amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Group is required to pay tiered <FONT STYLE="white-space:nowrap">low-double-digit</FONT> royalties to MorphoSys on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis during the term, commencing with the first
commercial sale of a relevant licensed product in Greater China. Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect until the expiration of the Group&#146;s last payment obligation under the
agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2017, the Group paid a US$20.0&nbsp;million (equivalent to approximately RMB132.7 million) upfront fee to
MorphoSys, which was recorded as research and development expense in the consolidated statements of comprehensive loss. Due to the uncertainty involved in meeting these development and commercialization based targets, the Group evaluated and
concluded that the remaining milestones are still not probable as of December&nbsp;31, 2017 and 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Summarized financial information related to the
above agreement is presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Years Ended December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">As of<BR>December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Research and Development Expense</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Upfront Fees</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Milestones</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Extension/<BR>Termination<BR>of<BR>agreements</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Amortization<BR>of prepaid<BR>research and<BR>development</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Intangible<BR>asset balance</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with Genexine, Inc. (&#147;Genexine&#148;) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2017, the Group entered into an intellectual property license agreement with Genexine with respect to
<FONT STYLE="white-space:nowrap">GX-I7/TJ107,</FONT> a long-acting <FONT STYLE="white-space:nowrap">IL-7</FONT> cytokine. Under this agreement, the Group obtained an exclusive, sublicensable and transferable license to use and otherwise exploit
certain intellectual property in connection with the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical development, manufacturing, sale and distribution of GX-I7 to treat cancer in Greater China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, the Group made an upfront payment of US$12.0&nbsp;million (equivalent to approximately RMB79.6 million) to Genexine which
was recorded as a research and development expense in 2018. The Group also agreed to make milestone payments in the aggregate amount of US$23.0&nbsp;million (equivalent to approximately RMB152.6 million), conditioned upon the achievement of certain
development milestones, including completion of Phase 2 and Phase 3 clinical studies and new drug application (&#147;NDA&#148;) or biologic license application (&#147;BLA&#148;) approval in Greater China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, the Group agreed to make milestone payments in the aggregate amount of US$525.0&nbsp;million (equivalent to approximately RMB3,482.7 million),
conditioned upon the achievement of certain cumulative net sales of <FONT STYLE="white-space:nowrap">GX-I7</FONT> up to US$2,000 million. The Group also is required to pay Genexine a <FONT STYLE="white-space:nowrap">low-single-digit</FONT>
percentage royalty </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. LICENSING AND COLLABORATION ARRANGEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements&nbsp;(continued)
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in respect of the total annual net sales of <FONT STYLE="white-space:nowrap">GX-I7.</FONT> The aforesaid milestones and royalties (other than the upfront payment) will be reduced by 50% following
the entry of a generic version of GX-I7 in China, Hong Kong, Macau and Taiwan without the consent or authorization of us or any of our sublicensees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect until the later of (i)&nbsp;the expiry of the last to
expire patent of the licensed intellectual property that includes a valid claim for Greater China and that covers the composition of GX-I7; and (ii) 15 years from the date of the first commercial sale of
<FONT STYLE="white-space:nowrap">GX-I7.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2018, the Group paid a US$12.0&nbsp;million (equivalent to
approximately RMB79.6 million) upfront fee to Genexine, which was recorded as research and development expense in the consolidated statements of comprehensive loss. Due to the uncertainty involved in meeting these development and commercialization
based targets, the Group evaluated and concluded that the remaining milestones are still not probable as of December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Summarized financial
information related to the above agreement is presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Years Ended December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">As of<BR>December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Research and Development Expense</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Upfront Fees</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Milestones</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Extension/<BR>Termination<BR>of<BR>agreements</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Amortization<BR>of prepaid<BR>research and<BR>development</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Intangible<BR>asset balance</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with MorphoSys </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2018, the Group entered into a license and collaboration agreement with MorphoSys for MorphoSys&#146;s proprietary antibody (MOR210/TJ210) directed
against C5aR (the &#147;C5aR Agreement&#148;). Under this agreement, the Group obtained an exclusive, royalty-bearing license to explore, develop and commercialize certain anti-C5aR antibodies in Greater China and South Korea. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group will perform and fund all global development activities related to the development of MOR210/TJ210 in Greater China and South Korea, including all
relevant clinical trials (including in the U.S. and China) and all development activities required for IND filing in the US as well as CMC development of manufacturing processes. MorphoSys retains rights in respect of development and
commercialization of MOR210/TJ210 in the rest of the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, the Group also agreed to make milestone payments
conditioned upon the achievement of certain development milestones and certain annual net sales of anti-C5aR antibodies. The Group is also required to pay to MorphoSys tiered <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> royalties on
annual net sales of anti-C5aR antibody products within the licensed territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2018, the Group paid a
US$3.5&nbsp;million (equivalent to approximately RMB23.2 million) upfront fee to MorphoSys, which was recorded as research and development expense in the consolidated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. LICENSING AND COLLABORATION ARRANGEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements&nbsp;(continued)
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statements of comprehensive loss. Due to the uncertainty involved in meeting these development and commercialization based targets, the Group evaluated and concluded that the remaining milestones
are still not probable as of December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Summarized financial information related to the above agreement is presented below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Years Ended December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">As of<BR>December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Research and Development Expense</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Upfront<BR>Fees</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Milestones</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Extension/<BR>Termination<BR>of<BR>agreements</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Amortization<BR>of prepaid<BR>research and<BR>development</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Intangible<BR>asset balance</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">3,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the above arrangements, the Group has entered into other various <FONT STYLE="white-space:nowrap">in-licensing</FONT> and collaboration
agreements with third party licensors to develop and commercialize drug candidates. Based on the terms of these agreements the Group is contingently obligated to make additional material payments upon the achievement of certain contractually defined
milestones. The Group made US$0.6&nbsp;million (equivalent to approximately RMB4.0 million) upfront and US$0.3&nbsp;million (equivalent to approximately RMB2.0 million) milestone payment under these agreements for the year ended December&nbsp;31,
2018. Under the terms of the agreements, the licensors are eligible to receive from the Group up to an aggregate of approximately US$164.4&nbsp;million (equivalent to approximately RMB1,090.6 million) in milestone payments upon the achievement of
contractually specified development milestones, such as regulatory approval for the drug candidates, which may be before the Group has commercialized the drug or received any revenue from sales of such drug candidate, which may never occur. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and collaboration Arrangements
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement among HDYM, <FONT STYLE="white-space:nowrap">I-Mab</FONT> and Hangzhou HealSun Biopharm Co., Ltd.
(&#147;HealSun&#148;) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2017, one of the Company&#146;s subsidiaries, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai, entered into a
technology transfer agreement with HDYM and HealSun with respect to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> humanized monoclonal antibodies. Under the agreement,
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai agreed to grant to HDYM exclusive, worldwide and sublicensable rights to develop, manufacture, have manufactured, use, sell, have sold, import, or otherwise exploit certain <FONT
STYLE="white-space:nowrap">PD-L1</FONT> related patents, patent applications, know-hows, data and information of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai, relevant cell lines as well as any <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> monoclonal antibody arising from such cell lines for the treatment of diseases. Further, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai and its cooperative party, HealSun agreed to provide
subsequent research and development services on such intellectual property to HDYM, including the selection and examination of innovative <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> humanized monoclonal
antibodies, cultivation and selection of stable cell lines, establishment of cell bank, research and development of manufacturing processes and preparation of samples, toxicological and pharmacological testing,
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> pharmaceutical experiment report drafting, and application for and registration of clinical trials. HDYM agreed to make milestone payments conditioned upon achieving certain contractually defined
milestones. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. LICENSING AND COLLABORATION ARRANGEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and collaboration Arrangements&nbsp;(continued)
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group determined that this collaboration is more reflective of a vendor-customer relationship and
therefore within the scope of ASC 606. Under this agreement, due to the early stage nature of the development, the Group determined the license to the intellectual property and research and development services are not distinct and thus were
accounted for as a single performance obligation that is satisfied over time. The Group would receive RMB51.0&nbsp;million (inclusive of VAT) milestone payments under this agreement, and considered that the achievements of milestone II, III, IV are
constrained such that the transaction price shall initially only include the milestones payment which have been achieved (that means when uncertainty associated with the variable consideration is subsequently resolved), the additional milestone
payment shall be included in the total transaction price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group used a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> input method to measure progress as that method
best depicts its performance under the agreement. For the year ended December&nbsp;31, 2017, the Group achieved milestones I and II and received milestone payments totalling of RMB29.0&nbsp;million (inclusive of VAT). The cumulative percentage
complete in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> input method related to this agreement as of December&nbsp;31, 2017 is estimated to approximate 42%, the Group recognized
RMB11.6&nbsp;million (exclusive of VAT of RMB0.7 million) of revenue in the consolidated statements of comprehensive loss, and RMB15.8&nbsp;million (exclusive of VAT of RMB0.9 million) were deferred as contract liability related to this arrangement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2018, the Group achieved milestones III and IV and received milestone III payment of RMB11.0&nbsp;million (inclusive
of VAT) and recognized as contract assets as of December 31, 2018. As of December&nbsp;31, 2018, the cumulative percentage complete in the <FONT STYLE="white-space:nowrap">cost-to</FONT> cost input method related to this arrangement is estimated to
approximate 100%. The Group recognized RMB36.5&nbsp;million (exclusive of VAT of RMB1.3 million) of revenue in the consolidated statements of comprehensive loss for the year ended December&nbsp;31, 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration Agreement with Everest Medicines Limited (&#147;Everest&#148;) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2018, the Group entered into a collaboration agreement with Everest, which is controlled by the ultimate controlling party of a principal
shareholder of the Group. Under the agreement, both parties agreed to collaborate on programs to <FONT STYLE="white-space:nowrap">co-develop</FONT> MorphoSys&#146; proprietary anti-CD38 antibody for all indications in hematologic oncology and
commercialize of MOR202/TJ202 in Greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A joint steering committee with equal representation from each party was established to coordinate and
oversee the development and commercialization of the CD38 product. All decisions of the joint steering committee shall be made by unanimous vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under
the agreement, the Group is primarily responsible for carrying out the development, manufacture and supply of the CD38 product, as well as seeking regulatory approval of the CD38 product. Everest is primarily responsible for sharing the development
costs of the CD38 product, including payments due to MorphoSys under the Licensing Agreement, dated November&nbsp;30, 2017, in the proportion of 75% by Everest and 25% by the Group. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The joint steering committee will decide which party shall be responsible for conducting the commercialization of the CD38 product pursuant to the
commercialization plan approved by the committee. If Everest is selected to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. LICENSING AND COLLABORATION ARRANGEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and collaboration Arrangements&nbsp;(continued)
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be responsible for commercialization, the Group shall grant an exclusive royalty-free license to Everest to commercialize the CD38 product for all indications in hematologic oncology in Greater
China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group and Everest will share the profit and loss and <FONT STYLE="white-space:nowrap">out-license</FONT> revenue derived from the CD 38
product in proportion to the costs that each party incur in developing the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon any termination of this arrangement, the terminating party has
the right to continue the development and commercialization of CD38 product. If Everest is the rightful terminating party, the Group shall (i)&nbsp;assign the MorphoSys license to Everest (subject to the terms and conditions of such license); (ii)
grant to Everest an exclusive license to all intellectual property rights that the Group owns or controls to further develop, manufacture, and commercialize the CD38 product; (iii)&nbsp;transfer the development, manufacture and commercialization of
the CD38 product to Everest. The terminating party shall be solely responsible for the cost and expense of such development and commercialization after termination. In the event that such continuing party successfully develops and commercializes the
CD38 product, it shall pay to the other party a percentage of the product profit and <FONT STYLE="white-space:nowrap">out-license</FONT> revenue generated therefrom in accordance with the terms of this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The US$26.0&nbsp;million (equivalent to approximately RMB178.7 million) in aggregate proceeds from Everest under the agreement represented the full funding
available under the agreement, and was recorded as a research and development funding received liability on the consolidated balance sheet as of December&nbsp;31, 2018, in accordance with ASC 730, Research and Development. Because there is a
significant related party relationship between the Company and Everest, the Company is treating its obligation to make payments under the commercialization stage as an implicit obligation to repay the funds advanced by Everest (see Note 28). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with ABL Bio </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2018, the Group
entered into a license and collaboration agreement with ABL Bio, under which the Group granted to ABL Bio exclusive, worldwide (excluding Greater China), royalty-bearing rights to develop and commercialize a bispecific antibodies
(&#147;BsAbs&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group agreed to share costs fifty-fifty (50:50) with ABL Bio through the completion of in vivo studies, with ABL Bio responsible
for all costs and activities following that time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In consideration of the license, ABL Bio agreed to pay the Group an upfront fee of US$2.5&nbsp;million
(equivalent to approximately RMB17.2 million), and milestone payments in the aggregate amount of US$97.5&nbsp;million (equivalent to approximately RMB646.8 million) conditioned upon achieving certain research, clinical development and sales
milestones. These include research milestones of up to US$2.5 (equivalent to approximately RMB17.2) million, clinical milestones of up to US$30&nbsp;million (equivalent to approximately RMB199.0 million) and sales milestones of up to
US$65&nbsp;million (equivalent to approximately RMB431.2 million). Further, ABL Bio agreed to pay the Group royalties at <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> percentages in respect of the total annual net sales of the licensed
BsAbs product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, ABL Bio granted to the Group an exclusive, royalty-free, sublicensable license to use the BsAbs technology solely to exploit
the licensed BsAbs product for all indications in Greater China. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. LICENSING AND COLLABORATION ARRANGEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and collaboration Arrangements&nbsp;(continued)
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group determined that this collaboration is more reflective of a vendor-customer relationship and
therefore within the scope of ASC 606. Under this agreement, the only one performance obligation was to grant the BsAbs license to ABL, considering that the achievements of milestones are constrained such that the transaction price shall initially
only include upfront payment and subsequently, once another milestone was achieved (that means when uncertainty associated with the variable consideration is subsequently resolved), the additional milestone payment shall be included in the total
transaction price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31,
2018, no milestone has been achieved, and the Group recognized revenue of US$2.5&nbsp;million (equivalent to RMB17.2 million) of revenue in the consolidated statements of comprehensive loss, which was upfront fee related to the grant of the rights
of BsAbs to ABL Bio as mentioned above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration Agreement with ABL Bio </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2018, the Group and ABL Bio entered into a collaboration agreement (the &#147;ABL Bio Collaboration&#148;) whereby both parties agreed to collaborate
to develop three <FONT STYLE="white-space:nowrap">PD-L1</FONT> based bispecific antibodies by using ABL Bio&#146;s proprietary BsAb technology and commercialize them in their respective territories, which, collectively, include Greater China and
South Korea, and other territories throughout the rest of the world if both parties agree to do so in such other territories during the performance of the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At contract inception, as both <FONT STYLE="white-space:nowrap">I-Mab</FONT> and ABL participate actively in the research and development activity. Also, they
share the risk of failure of the <FONT STYLE="white-space:nowrap">bio-sequence</FONT> products and share the income of licensing, so this contract meet the criteria of the definition of a collaborative arrangement, the Group categorized this
agreement within the scope ASC 808. Prior to commercialization, the Group recorded the share of the expenses incurred by the collaboration for the development of three <FONT STYLE="white-space:nowrap">PD-L1</FONT> based bispecific antibodies
products in research and development expense in the consolidated statements of comprehensive loss. For the year ended December&nbsp;31, 2018, RMB1.0&nbsp;million expenses were incurred by the Group and ABL did not incurred any expenses. According to
the terms set out in the agreement, the Group recorded RMB0.5&nbsp;million (50% cost sharing) of expenses in the Group&#146;s consolidated statements of comprehensive loss for the year ended December&nbsp;31, 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration Agreements with Tracon Pharmaceuticals, Inc. (&#147;Tracon&#148;) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2018, the Group entered into collaboration agreements with Tracon, under which both parties agreed to
<FONT STYLE="white-space:nowrap">co-develop</FONT> the Group&#146;s proprietary CD73 antibody, TJD5 (the &#147;TJD5 Agreement&#148;) and <FONT STYLE="white-space:nowrap">co-develop</FONT> up to five BsAbs (the &#147;BsAbs Agreement&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given the early preclinical stage of development of these assets as of December&nbsp;31, 2018, there was no significant financial impact to the Group for the
year ended December&nbsp;31, 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with CSPC Pharmaceutical Group Limited (&#147;CSPC&#148;) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2018, the Group entered into a product development agreement with CSPC. The Group granted to CSPC exclusive,
<FONT STYLE="white-space:nowrap">non-transferable,</FONT> <FONT STYLE="white-space:nowrap">non-irrevocable</FONT> and sublicensable rights in the PRC (excluding Hong Kong, Macau and Taiwan) to develop and commercialize TJ103 for treating type 2
diabetes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. LICENSING AND COLLABORATION ARRANGEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and collaboration Arrangements&nbsp;(continued)
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CSPC is responsible for developing, obtaining market approval and commercializing the licensed products. The
Group is responsible for transferring the manufacturing technology of the licensed products to CSPC and assisting CSPC in the continued optimization of such manufacturing technology thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In consideration of the license, CSPC agreed to pay the Group an upfront fee of RMB15.0&nbsp;million (inclusive of VAT) and milestone payments in an aggregate
amount of RMB135.0&nbsp;million conditioned upon achieving certain clinical development and regulatory approval milestones. In addition, the Group is also entitled to royalties of up to <FONT STYLE="white-space:nowrap">low-double-digit</FONT>
percentages in respect of the total annual net sales of the products after its commercialization in the PRC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group determined that this collaboration
is more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under this agreement, the only one performance obligation was to grant TJ103 license to CSPC. Considering that the achievements of milestones are
constrained such that the transaction price shall initially only include upfront payment and subsequently, once another milestone was achieved (that means when uncertainty associated with the variable consideration is subsequently resolved), the
additional milestone payment shall be included in the total transaction price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. As of December&nbsp;31, 2018, RMB14.2&nbsp;million upfront
fee received and was recorded as advance from customers in the consolidated balance sheets. The license was approved by china intellectual property office subsequently in June 2019, and accordingly, RMB14.2&nbsp;million (inclusive of VAT) was
recognized as revenue in the consolidated statements of comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19. OTHER INCOME (EXPENSES), NET </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes other income (expense) recognized for the years ended December&nbsp;31, 2017 and 2018: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from conversion of 2017 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from conversion of Onshore Convertible Loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,548</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,245</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from issuance of 2018 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,081</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net foreign exchange gains (losses)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,873</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subsidy income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(172</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,444</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20. NET LOSS PER SHARE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share for each of the years presented are calculated as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note 2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center">(in thousands, except for loss per shares)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to ordinary shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58,679</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of ordinary shares outstanding - basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,742,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share - basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8.99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2017 and 2018, the effects of all outstanding convertible preferred shares, convertible
promissory notes and restricted shares have been excluded from the computation of diluted loss per share for the years ended December&nbsp;31, 2017 and 2018 as their effects would be anti-dilutive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2018, the Company also has certain dilutive potential stock options. These stock options which can not be exercised until
the Company completes its listing are not included in the computation of diluted earnings per shares as such contingent event had not taken place. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
potentially dilutive securities that have not been included in the calculation of diluted net loss per share as their inclusion would be anti-dilutive are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,811,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,389,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">673,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,623,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,134,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21. EMPLOYEE BENEFITS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Full time employees of the Group in the PRC participate in a government mandated defined contribution plan, pursuant to which certain pension benefits, medical
care, employee housing fund and other welfare benefits are provided to the employees. Chinese labor regulations require that the PRC subsidiaries of the Group make contributions to the government for these benefits based on certain percentage of the
employees&#146; salaries, up to a maximum amount specified by the government. The Group has no legal obligation for the benefits beyond the contribution made. The total amounts charged to the consolidated statements of comprehensive loss for such
employee benefits amounted to approximately RMB5,120 and RMB9,294 for the years ended December&nbsp;31, 2017 and 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>22. COMMITMENTS AND CONTINGENCIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating lease commitments </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group leases offices
under <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating lease agreements. Future minimum lease payments under <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating lease agreements with initial terms of one year or more
consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total amounts charged to the consolidated statements of comprehensive loss for rental expense amounted to approximately
RMB3,127 and RMB4,659 for the years ended December&nbsp;31, 2017 and 2018, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Capital commitments </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Contingencies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group
is a party to or assignee of license and collaboration agreements that may require it to make future payments relating to milestone fees and royalties on future sales of licensed products (Note 18). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group did not have significant capital and other commitments, long-term obligations, or guarantees as of December&nbsp;31, 2017 and 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23. RELATED PARTY BALANCES AND TRANSACTIONS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table
below sets forth the major related parties and their relationships with the Group as of December&nbsp;31, 2017 and 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name of related parties</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Relationship with the Group</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Everest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Controlled by the ultimate controlling party of a principal shareholder of the
Group</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CMAB Biopharma (Suzhou) Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Controlled by the ultimate controlling party of a principal shareholder of the
Group</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23. RELATED PARTY BALANCES AND TRANSACTIONS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of related party balance as of December&nbsp;31, 2017 and 2018 are as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and development funding received </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Everest (Note 18)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of related party transaction for the years ended December&nbsp;31, 2017 and 2018 are as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Receipt of CRO services - recognized in research and development expenses </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;year&nbsp;ended&nbsp;December&nbsp;31,&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CMAB Biopharma (Suzhou) Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>24. CONCENTRATION OF CREDIT RISK </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that are potentially subject to significant concentration of credit risk consist of cash and cash equivalents, restricted cash, other
financial assets, contract assets and other receivables. The carrying amounts of cash and cash equivalents, restricted cash and other financial assets represent the maximum amount of loss due to credit risk. As of December&nbsp;31, 2017 and 2018,
all of the Group&#146;s cash and cash equivalents and restricted cash were held by major financial institutions located in the PRC and international financial institutions outside of the PRC which management believes are of high credit quality and
continually monitors the credit worthiness of these financial institutions. With respect to the contract assets, other receivables and other financial assets, the Group performs <FONT STYLE="white-space:nowrap">on-going</FONT> credit evaluations of
the financial condition of its customers and counterparties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>25. SUBSEQUENT EVENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group evaluated subsequent events through July 29, 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On February 22, 2019, the Group adopted the 2018 equity incentive plan (&#147;2018 Plan&#148;). Under 2018
Plan, the maximum aggregate number of ordinary shares which may be issued pursuant to all awards is 14,005,745, subject to further amendment. If the Group successfully lists on an internationally recognized securities exchange for a Qualified Public
Offering by December 31, 2019, the maximum aggregate number of ordinary shares which may be issued shall be 15,452,620. Accordingly, 10,893,028 stock options granted to a director of the Group under 2018 Plan were fully vested and exercisable upon
the adoption of 2018 Plan. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On February 22, 2019, the amendment and restated 2017 equity incentive plan was approved by
the Board of Directors of the Company, pursuant to which 3,435,215 stock options held by a director of the Group under the 2017 equity incentive plan became fully vested and exercisable on February 22, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>25. SUBSEQUENT EVENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In addition, the Group repurchased 3,890,155 stock options held by a director of the Group,
including 3,435,215 stock options under the amendment and restated 2017 equity incentive plan and 454,940 stock options under the 2018 equity incentive plan, at the total consideration of US$21,902 (equivalent to approximately RMB148,308). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In July 2019, the Group granted 640,000 stock options and 3,098,500 stock options to the employees under 2017 Plan and 2018 Plan,
respectively. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On July 25, 2019, the Group entered into a share purchase agreement with certain third party investors, under
which these investors will subscribe for an aggregate of 3,857,143 Series C-1 convertible preferred shares of the Company for an aggregate purchase price of US$27.0 million. Up to the issuance of these consolidated financial statements, this
transaction has not been consummated. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">According to the confirmations issued by the Company&#146;s Series B Warrants holders in July 2019, the holders
of Series B Warrants has unconditionally and irrevocably waived and cancelled the Tranche II of Series B Warrants. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In July, 2019, the Group entered into an in-licensing and collaboration agreement with MacroGenics, Inc. for
development and commercialization of an Fc-optimized antibody known as enoblituzumab that targets B7-H3, including in combination with other agents, such as the anti-PD-1 antibody known as MGA012, in Greater China. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26. UNAUDITED PRO FORMA NET LOSS PER SHARE </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited
pro forma net loss per ordinary share is computed using the weighted-average number of ordinary shares outstanding and assumes forfeiture of Tranche II of Series B Warrants and the automatic conversion of all of the Group&#146;s outstanding
mezzanine equity into ordinary shares upon the closing of the Group&#146;s Qualified Public Offering, as if it had occurred on January&nbsp;1, 2018. The Group believes the unaudited pro forma net loss per share provides material information to
investors, as the automatic conversion of the Group&#146;s outstanding mezzanine equity and forfeiture of Tranche II of Series B Warrants. The disclosure of pro forma net loss per ordinary share provides an indication of net loss per ordinary share
that is comparable to what will be reported by the Group as a public company following the closing of the Qualified Public Offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26. UNAUDITED PRO FORMA NET LOSS PER SHARE&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the unaudited pro forma net loss per share attributable to ordinary
shareholders: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the year ended December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note 2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6">(in&nbsp;thousands,&nbsp;except&nbsp;for&nbsp;loss&nbsp;per&nbsp;shares)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to ordinary shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58,679</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Add back fair value change of Tranche II of Series B Warrants (Note 15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,935</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator for <FONT STYLE="white-space:nowrap">pro-forma</FONT> basic and diluted net loss per
share</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(436,714</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,614</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of ordinary shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pro-forma</FONT> effect of the conversion of Series A Preferred
Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,103,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,103,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pro-forma</FONT> effect of the conversion of Series B Preferred
Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,146,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,146,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pro-forma</FONT> effect of the conversion of Series C Preferred
Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,140,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,140,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator for <FONT STYLE="white-space:nowrap">pro-forma</FONT> basic and diluted net loss
per share</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,919,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,919,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pro-forma</FONT> net loss per share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6.16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.90</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6.16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.90</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma loss per share excluded the impacts of the Group&#146;s share-based awards that subject to IPO
conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>27. RESTRICTED NET ASSETS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Group&#146;s ability to pay dividends may depend on the Group receiving distributions of funds from its PRC subsidiary. Relevant PRC statutory laws and regulations permit payments of dividends by the Group&#146;s PRC subsidiary only out of its
retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. The results of operations reflected in the consolidated financial statements prepared in accordance with U.S. GAAP differ from those reflected in
the statutory financial statements of the Group&#146;s PRC subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the Company law of the PRC, a domestic enterprise is required
to provide statutory reserves of at least 10% of its annual <FONT STYLE="white-space:nowrap">after-tax</FONT> profit until such reserve has reached 50% of its respective registered capital based on the enterprise&#146;s PRC statutory accounts. A
domestic enterprise is also required to provide discretionary surplus reserve, at the discretion of the Board of Directors, from the profits determined in accordance with the enterprise&#146;s PRC statutory accounts. The aforementioned reserves can
only be used for specific purposes and are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>27. RESTRICTED NET ASSETS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not distributable as cash dividends. The Group&#146;s PRC subsidiary was established as domestic invested enterprise and therefore is subject to the above mentioned restrictions on distributable
profits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2017 and 2018, no appropriation to statutory reserves was made because the PRC subsidiary had substantial
losses during such periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of these PRC laws and regulations subject to the limit discussed above that require annual appropriations of 10%
of <FONT STYLE="white-space:nowrap">after-tax</FONT> income to be set aside, prior to payment of dividends, as general reserve fund, the Group&#146;s PRC subsidiary is restricted in their ability to transfer a portion of their net assets to the
Group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Foreign exchange and other regulations in the PRC further restrict the Company&#146;s PRC subsidiaries from transferring funds to the Company in
the form of dividends, loans and advances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the Group has a consolidated shareholders&#146; deficit, its net asset base for purposes of calculating
the proportionate share of restricted net assets of consolidated subsidiaries should be zero. Therefore, the restrictions placed on the net assets of the Company&#146;s PRC subsidiaries with positive equity would result in the 25&nbsp;percent
threshold being exceeded and a corresponding requirement to provide parent company financial information (Note 28). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>28. CONDENSED FINANCIAL
INFORMATION OF THE PARENT COMPANY </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company performed a test on the restricted net assets of consolidated subsidiaries in accordance with Securities
and Exchange Commission Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> Rule <FONT STYLE="white-space:nowrap">4-08</FONT> (e)(3), &#147;General Notes to Financial Statements&#148; and concluded that it was applicable for the Company to
disclose the financial statements for the parent company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The subsidiaries did not pay any dividends to the Company for the years presented. For the
purpose of presenting parent company only financial information, the Company records its investments in its subsidiaries under the equity method of accounting. Such investments are presented on the separate condensed balance sheets of the Company as
&#147;Investments (deficit) in subsidiaries&#148; and the loss of the subsidiaries is presented as &#147;share of losses of subsidiaries&#148;. Certain information and footnote disclosures generally included in financial statements prepared in
accordance with U.S. GAAP have been condensed and omitted. The footnote disclosures contain supplemental information relating to the operations of the Company, as such, these statements should be read in conjunction with the notes to the
consolidated financial statements of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company did not have significant capital and other commitments, long-term obligations, other
long-term debt, or guarantees as of December&nbsp;31, 2017 and 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>28. CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Balance sheets </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">603,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">603,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investments in subsidiaries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receivables due from subsidiaries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">371,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,455,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">211,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>554,128</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,058,282</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>299,823</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, mezzanine equity and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deficit in subsidiaries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>143,642</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>98,028</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,279</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A convertible preferred shares (US$0.0001 par value, 21,865,233 and 30,227,056 shares
authorized, issued and outstanding as of December&nbsp;31, 2017 and 2018, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B convertible preferred shares (US$0.0001 par value, 15,894,594 and 30,305,212 shares
authorized, issued and outstanding as of December&nbsp;31, 2017 and 2018, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">921,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C convertible preferred shares (US$0.0001 par value, 31,046,360 shares authorized, issued
and outstanding as of December&nbsp;31, 2018)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>710,281</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,915,358</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>424,670</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>28. CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY&nbsp;(CONTINUED) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Balance sheets&nbsp;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares (US$0.0001 par value, 500,000,000 shares authorized as of December&nbsp;31, 2017
and 2018, 8,363,719 shares authorized, issued and outstanding as of December&nbsp;31, 2017 and 2018, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Treasury stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(357,860</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,014,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(147,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(299,795</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(955,104</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(139,126</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities, mezzanine equity and shareholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>554,128</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,058,282</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>299,823</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Statements of comprehensive loss </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(128,721</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(121,734</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,733</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,373</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,239</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(128,721</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137,107</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,892</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,467</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,088</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share of losses of subsidiaries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(151,600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(319,664</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,564</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,027</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before income tax expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58,679</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58,679</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustments, net of nil tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(292,322</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(349,144</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,858</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>28. CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Statements of cash flows </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash (used in) generated from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(132,732</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(356,635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,032,483</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(150,398</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash generated from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">475,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,498,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Effect of exchange rate changes on cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net (decrease) increase in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,446</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">569,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents at end of the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">603,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin713200_10"></A>Report of Independent Auditors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Board of Directors and Shareholders of I-Mab Bio-tech (Tianjin) Co., Ltd. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying consolidated financial statements of I-Mab Bio-tech (Tianjin) Co., Ltd. and its subsidiaries, which comprise the consolidated
balance sheet as of July 15, 2017 and the related consolidated statement of comprehensive loss, of changes in shareholders&#146; equity and of cash flows for the period from January 1, 2017 to July 15, 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management&#146;s Responsibility for the Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally
accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement,
whether due to fraud or error. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Auditors&#146; Responsibility </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our responsibility is to express an opinion on the consolidated financial statements based on our audits. We conducted our audits in accordance with auditing
standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures
selected depend on our judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the
Company&#146;s preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the
Company&#146;s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as
evaluating the overall presentation of the consolidated financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Opinion </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our opinion, the consolidated
financial statements referred to above present fairly, in all material respects, the financial position of the I-Mab Bio-tech (Tianjin) Co., Ltd. and its subsidiaries as of July 15, 2017 and the results of their operations and their cash flows for
the period from January 1, 2017 to July 15, 2017 in accordance with accounting principles generally accepted in the United States of America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/
PricewaterhouseCoopers Zhong Tian LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shanghai, the People&#146;s Republic of China </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July 29, 2019 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT>
<FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Tianjin&#148;) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin713200_11"></A>CONSOLIDATED BALANCE SHEET </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>As of July&nbsp;15, 2017 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of July&nbsp;15, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepayments and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>123,899</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18,048</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>123,942</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18,054</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accruals and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,824</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>266</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(176,772</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>122,118</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>17,788</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities and shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>123,942</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18,054</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:240pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> TIANJIN </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin713200_12"></A>CONSOLIDATED STATEMENT OF COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Period from January&nbsp;1, 2017 to July&nbsp;15, 2017 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Period&nbsp;from</B><br><B>January&nbsp;1&nbsp;to&nbsp;July&nbsp;15,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,882</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,585</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,745</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,627</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,131</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,622</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(236</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before income tax expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,367</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,367</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,367</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:240pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral
part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> TIANJIN </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin713200_13"></A>CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS&#146; EQUITY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Period from January&nbsp;1, 2017 to July&nbsp;15, 2017 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">paid-in</FONT><BR>capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Shareholders&#146;<BR>Equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balances as of January&nbsp;1, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(160,523</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balances as of July&nbsp;15, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(176,772</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:240pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:240pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral
part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> TIANJIN </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin713200_14"></A>CONSOLIDATED STATEMENT OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Period from January&nbsp;1, 2017 to July&nbsp;15, 2017 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Period from</B><br><B>January&nbsp;1&nbsp;to&nbsp;July&nbsp;15,&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,367</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Adjustments to reconcile net loss to net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from short-term investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(482</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepayments and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accruals and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,304</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,758</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,587</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for investments in other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,370</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash received from disposal of short-term investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash received on income from short-term investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash generated from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash generated from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net decrease in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,276</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(332</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral
part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB TIANJIN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin713200_15"></A>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. PRINCIPAL ACTIVITIES AND ORGANIZATION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. (previously known as Tasgen <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd.) (the &#147;Company&#148;) and its
subsidiaries, Chengdu Tasgen <FONT STYLE="white-space:nowrap">Bio-Tech</FONT> Co., Ltd. and Shanghai Tianyunjian <FONT STYLE="white-space:nowrap">Bio-Tech</FONT> Co., Ltd., (together the &#147;Group&#148;) are principally engaged in the research and
development of innovative medicines in the People&#146;s Republic of China (the &#147;PRC&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of July&nbsp;15, 2017, the Company&#146;s
subsidiaries are as follows </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Subsidiaries</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Place of<BR>incorporation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Date of<BR>incorporation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Percentage<BR>of direct<BR>or&nbsp;indirect<BR>ownership<BR>by&nbsp;the<BR>Company</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Principal&nbsp;activities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chengdu Tasgen <FONT STYLE="white-space:nowrap">Bio-Tech</FONT> Co., Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">PRC</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">May&nbsp;30,&nbsp;2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR><BR></TD>
<TD VALIGN="top" ALIGN="right">Research&nbsp;and<BR>development&nbsp;of<BR>innovative&nbsp;medicines</TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR>&nbsp;<BR>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shanghai Tianyunjian <FONT STYLE="white-space:nowrap">Bio-Tech</FONT> Co., Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">PRC</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">June&nbsp;28,&nbsp;2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR><BR></TD>
<TD VALIGN="top" ALIGN="right">Research and<BR>development of<BR>innovative medicines</TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR>&nbsp;<BR>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. PRINCIPAL ACCOUNTING POLICIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.1 Basis of presentation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying
consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#147;U.S. GAAP&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant accounting policies followed by the Group in the preparation of its accompanying consolidated financial statements are summarized below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.2 Basis of consolidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying
consolidated financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. All inter-company balances and transactions have been eliminated in consolidation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.3 Use of estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of the
consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of
the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used in determining items such as useful lives of equipment and software, impairment of other receivables, impairment
of long-lived assets, taxes on income, tax valuation allowances. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making
judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB TIANJIN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. PRINCIPAL ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.4 Fair value measurements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial assets and liabilities of the Group primarily comprise of cash and cash equivalents, other financial assets, other receivables, accruals and other
payables. As of July 15, 2017, except for other financial assets the carrying values of these financial assets and liabilities approximated their fair values because of their generally short maturities. The Group reports other financial assets at
fair value at each balance sheet date and changes in fair value are reflected in the consolidated statements of comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group measures
its financial assets and liabilities using inputs from the following three levels of the fair value hierarchy. The three levels are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level&nbsp;1 inputs are unadjusted quoted prices in active markets for identical assets that the management has the ability to access at the measurement date.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level&nbsp;2 inputs include quoted prices for similar assets in active markets, quoted prices for identical or similar assets in markets that are not
active, inputs other than quoted prices that are observable for the asset (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market
corroborated inputs). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level&nbsp;3 includes unobservable inputs that reflect the management&#146;s assumptions about the assumptions that market
participants would use in pricing the asset. The management develops these inputs based on the best information available, including the own data.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Assets measured at fair value on a recurring basis </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Group measured its other financial assets at fair value on a recurring basis. As the Group&#146;s other financial assets are not traded in an active market with readily observable prices, the Group uses significant unobservable inputs to measure the
fair value. These instruments are categorized in the Level&nbsp;3 valuation hierarchy based on the significance of unobservable factors in the overall fair value measurement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the Group&#146;s financial assets measured and recorded at fair value on recurring basis as of July&nbsp;15, 2017: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of July&nbsp;15, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Active&nbsp;market<BR>(Level&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Observable&nbsp;input<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-observable&nbsp;input</FONT><BR>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.5 Foreign currency translation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Translations of balances in the consolidated balance sheet, consolidated statement of comprehensive loss, consolidated statement of changes in
shareholders&#146; equity and consolidated statement of cash flows from RMB into US$ as of and for the period ended July&nbsp;15, 2017 are solely for the convenience of the readers and were calculated at the rate of US$1.00=RMB6.8650, representing
the noon buying rate in The City of New York for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB TIANJIN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. PRINCIPAL ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.5 Foreign currency translation&nbsp;(continued) </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cable transfers of RMB as certified for customs purposes by the Federal Reserve Bank of New York on December&nbsp;31, 2018. No representation is made that the RMB amounts could have been, or
could be, converted, realized or settled into US$ at that rate on December&nbsp;31, 2018, or at any other rate. The US$ convenience translation is not required under U.S. GAAP and all US$ convenience translation amounts in the accompanying
consolidated financial statements are unaudited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.6 Cash and cash equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents consist of cash on hand and bank deposits, which are unrestricted as to withdrawal and use. The Company considers all highly liquid
investments with an original maturity date of three months or less at the date of purchase to be cash equivalents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.7 Equipment and software
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equipment and software are stated at cost less accumulated depreciation, amortization and impairment (if any). Depreciation and amortization is
computed using the straight-line method over the following estimated useful lives, taking into account any estimated residual value: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Laboratory equipment</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3&nbsp;to&nbsp;5&nbsp;years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Software</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2 to 5 years</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group recognized the gain or loss on the disposal of equipment and software in the consolidated statement of comprehensive
loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.8 Research and development expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Elements of research and development expenses primarily include (1)&nbsp;payroll and other related expenses of personnel engaged in research and development
activities, <FONT STYLE="white-space:nowrap">(2)&nbsp;in-licensed</FONT> patent rights fee of exclusive development rights of drugs granted to the Group, (3)&nbsp;expenses related to preclinical testing of the Group&#146;s technologies and clinical
trials such as payments to contract research organizations (&#147;CRO&#148;), investigators and clinical trial sites that conduct the clinical studies (4)&nbsp;expenses to develop the product candidates, including raw materials and supplies, product
testing, depreciation, and facility related expenses, (5)&nbsp;other research and development expenses. Research and development expenses are charged to expense as incurred when these expenditures relate to the Group&#146;s research and development
services and have no alternative future uses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group has acquired rights to develop and commercialize product candidates. Upfront payments that relate
to the acquisition of a new drug compound, as well as <FONT STYLE="white-space:nowrap">pre-commercial</FONT> milestone payments, are immediately expensed as acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development in the
period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#147;business&#148; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing
and, absent obtaining such approval, has no established alternative future use. Milestone payments made to third parties subsequent to regulatory approval would be capitalized as intangible assets and amortized over the estimated remaining useful
life of the related product. The conditions enabling capitalization of development expenses as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB TIANJIN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. PRINCIPAL ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.9 Income taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group accounts for income taxes under the liability method. Under the liability method, deferred income tax assets and liabilities are determined based on
the differences between the financial reporting and income tax bases of assets and liabilities and are measured using the tax income rates that will be in effect when the differences are expected to reverse. A valuation allowance is recorded when it
is more likely than not that some portion or all of a deferred income tax asset will not be realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group evaluates its uncertain tax positions
using the provisions of ASC 740, <I>Income Taxes</I>, which prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Group recognizes in the financial statements the benefit
of a tax position which is &#145;&#145;more likely than not&#146;&#146; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that
meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. It is the Group&#146;s policy to recognize
interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. EQUIPMENT AND SOFTWARE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equipment and software, net, consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;July&nbsp;15,&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total amounts charged to the consolidated statement of comprehensive loss for depreciation and amortization expenses
amounted to approximately RMB22 for the period from January&nbsp;1, 2017 to July&nbsp;15, 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. COMMITMENTS AND CONTINGENCIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating lease commitments </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group leases offices
under <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating lease agreements. Future minimum lease payments under <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating lease agreements with initial terms of one year or more
consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;period&nbsp;from&nbsp;January&nbsp;1</B><br><B>to&nbsp;July&nbsp;15,&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Within 1 year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB TIANJIN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. COMMITMENTS AND CONTINGENCIES&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Contingencies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group is a party to or assignee of license and collaboration agreements that may require it to make future payments relating to milestone fees and
royalties on future sales of licensed products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below sets forth the major related party and its relationships with the Group as of December&nbsp;31, 2017 and 2018: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Name of related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Nature of relationship</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tasly Pharmaceutical Group Co., Ltd.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Controlled by the ultimate controlling party of a principal shareholder of the Group</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the period from January&nbsp;1 to July&nbsp;15, 2017, transaction with related party was as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Receipt of CRO services- recognized in research and development expenses </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;period&nbsp;from&nbsp;January&nbsp;1</B><br><B>to July&nbsp;15, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Note 2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tasly Pharmaceutical Group Co., Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin713200_16"></A>Unaudited Interim Condensed Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>As of December&nbsp;31, 2018 and June 30, 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Pro&nbsp;forma)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Pro forma)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Note 26)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,588,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,269,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,269,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Prepayments and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.4,&nbsp;4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,036,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,604,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,604,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,375,938</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,955,338</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>284,827</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,955,338</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>284,827</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Liabilities, mezzanine equity and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Short-term borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accruals and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Advance from customers</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Operating lease liabilities, current</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Research and development funding received</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">23</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.4,&nbsp;15</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>346,158</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>413,443</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>60,225</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>363,292</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>52,920</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Operating lease liabilities, <FONT STYLE="white-space:nowrap">non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Deferred subsidy income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.7</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>415,684</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>491,037</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>71,528</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>440,886</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>64,223</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">22</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Series A convertible preferred shares (US$0.0001 par value, 30,227,056 shares authorized, issued
and outstanding as of December&nbsp;31, 2018 and June 30, 2019, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Series B convertible preferred shares (US$0.0001 par value, 30,305,212 shares authorized, issued
and outstanding as of December&nbsp;31, 2018 and June&nbsp;30, 2019, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">921,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">921,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Series C convertible preferred shares (US$0.0001 par value, 31,046,360 shares authorized, issued
and outstanding as of December&nbsp;31, 2018 and June 30, 2019)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Total mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,915,358</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,915,358</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>424,670</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Unaudited Interim Condensed Consolidated Balance Sheets&nbsp;(Continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>As of December&nbsp;31, 2018 and June 30, 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Pro&nbsp;forma)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Pro forma)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Note 26)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Ordinary shares (US$0.0001 par value, 500,000,000 shares authorized as of December&nbsp;31, 2018
and June 30, 2019, 8,363,719 and 8,363,719 shares authorized, issued and outstanding as of December&nbsp;31, 2018 and June 30, 2019, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Treasury stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,381,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,014,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,871,826</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(272,663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,921,977</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(279,968</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Total shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(955,104</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,451,057</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(211,371</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,514,452</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>220,604</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Total liabilities, mezzanine equity and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,375,938</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,955,338</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>284,827</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,955,338</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>284,827</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:340pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial
statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin713200_17"></A>Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Six months ended June&nbsp;30, 2018 and 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Note 2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenues</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensing and collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(202,693</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(265,084</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,614</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,687</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(574,584</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83,698</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(200,003</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(824,668</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(120,127</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,097</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expenses), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,594</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,854</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before income tax expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(166,720</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(857,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to <FONT STYLE="white-space:nowrap">I-MAB</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(166,720</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(857,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustments, net of nil tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,446</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(724</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss attributable to
<FONT STYLE="white-space:nowrap">I-MAB</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(174,166</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(862,309</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(125,610</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(166,720</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(857,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of ordinary shares used in calculating net loss per share&#151;basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,397,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,184,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,184,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss per share attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#151;Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26.06</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17.38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#151;Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26.06</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17.38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:226pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial
statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin713200_18"></A>Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders&#146; Equity (Deficit) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Six months ended June&nbsp;30, 2018 and 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary&nbsp;share&nbsp;(Note&nbsp;12)<BR>(US$0.001&nbsp;par&nbsp;value)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Treasury<BR>stock</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">paid-in</FONT><BR>capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>other<BR>comprehensive<BR>income</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>shareholders&#146;<BR>equity&nbsp;(deficit)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,363,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(357,860</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(299,795</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Foreign currency translation adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,446</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,446</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(166,720</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(166,720</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Transaction with redeemable <FONT STYLE="white-space:nowrap">non-</FONT> controlling interests
(Note 16)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(54,298</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(229,701</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(283,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance as of June&nbsp;30, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,363,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,755</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(754,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(756,031</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,363,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,014,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(955,104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Foreign currency translation adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(857,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(857,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance as of June&nbsp;30, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,363,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,871,826</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,451,057</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:320pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial
statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin713200_19"></A>Unaudited Interim Condensed Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Six months ended June&nbsp;30, 2018 and 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(166,720</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(857,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Adjustments to reconcile net loss to net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense of convertible promissory notes and onshore convertible loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,527</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from conversion of 2017 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from conversion of onshore convertible loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from issuance of 2018 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of <FONT STYLE="white-space:nowrap">right-of-use</FONT> assets and interest of lease
liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepayments and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,706</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accruals and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,803</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Advance from customers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,061</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development funding received</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred subsidy income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,336</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(486</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,653</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(389,034</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,669</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,127</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,930</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for investments in other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash received from disposal of other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash received on income from other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash generated from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from bank borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of bank borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,653</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash generated from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,370</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Unaudited Interim Condensed Consolidated Statements of Cash Flows&nbsp;(Continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Six months ended June&nbsp;30, 2018 and 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Effect of exchange rate changes on cash and cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,737</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,093</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(451</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase in cash and cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(264,071</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,466</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and restricted cash, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and restricted cash, end of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">504,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,416,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Additional ASC 842 supplemental disclosures</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for fixed operating lease costs included in the measurement of lease obligations in
operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets obtained in exchange for operating lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other supplemental cash flow disclosures</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-cash</FONT> activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payables for purchase of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:420pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial
statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin713200_20"></A>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. PRINCIPAL ACTIVITIES AND ORGANIZATION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">I-Mab</FONT> (the &#147;Company&#148;) was incorporated in the Cayman Islands on June&nbsp;30, 2016 as an exempted company with limited liability under the Companies Law of the Cayman Islands. The Company and its
subsidiaries (together the &#147;Group&#148;) are principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People&#146;s Republic of China (the
&#147;PRC&#148;) and other countries and regions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the incorporation of the Company, the Group carried out its operation in the PRC since
November 2014 mainly through Third Venture Biopharma (Nanjing) Co., Ltd. (&#147;Third Venture&#148;), which was incorporated on November&nbsp;17, 2014 in the PRC. For the purpose of introduction of overseas investors and in preparation for a listing
of the Company&#146;s shares on the overseas capital markets, the Group underwent a reorganization (the &#147;Reorganization&#148;) in 2016. The Reorganization was approved by the Board of Directors and a restructuring framework agreement was
entered into by Third Venture, the Company, and the shareholders of the Company based on Reorganization framework agreement, pursuant to which on July&nbsp;7, 2016, Third Venture transferred all of its assets and operations to the Company&#146;s
wholly owned subsidiary, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Co., Ltd. <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Shanghai&#148;), which was a transaction in which shareholders had identical ownership interests before
and after the transaction and was accounted for in a manner similar to a common control transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Reorganization, as described above has been
accounted for at historical cost. That Reorganization was reverse merger of Third Venture and Third Venture is the predecessor of the Company. As such, the assets and liabilities of Third Venture are consolidated in the Company&#146;s financial
statements at historical cost. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of<B> </B>June&nbsp;30, 2019, the Company&#146;s principal subsidiaries are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Subsidiaries</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Place of<BR>incorporation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Date of<BR>incorporation or<BR>acquisition</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Percentage<BR>of direct<BR>or indirect<BR>ownership<BR>by the<BR>Company</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Principal&nbsp;activities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Hong&nbsp;Kong</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;8, 2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Investment&nbsp;holding</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">PRC</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">August&nbsp;24, 2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR></TD>
<TD VALIGN="top" ALIGN="right">Research&nbsp;and&nbsp;development<BR>of innovative&nbsp;medicines</TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT>
(Tianjin) Co., Ltd. <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Tianjin&#148;)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">PRC</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;15,&nbsp;2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR></TD>
<TD VALIGN="top" ALIGN="right">Research and development<BR>of innovative medicines</TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">U.S.</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">February&nbsp;28,&nbsp;2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR></TD>
<TD VALIGN="top" ALIGN="right">Research and development<BR>of innovative medicines</TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. PRINCIPAL ACCOUNTING POLICIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.1 Basis of presentation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying
unaudited interim condensed consolidated financial statements of the Group have been prepared in accordance with the accounting principles generally accepted in the United States of America (&#147;U.S. GAAP&#148;) for interim financial information.
Accordingly, they do not include all of the information and footnotes normally included in the annual financial statements prepared in accordance with U.S. GAAP. Certain information and footnote disclosures normally included in the annual financial
statements prepared in accordance with U.S. GAAP have been condensed or omitted consistent with Article 10 of Regulation <FONT STYLE="white-space:nowrap">S-X.</FONT> In the opinion of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. PRINCIPAL ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.1 Basis of presentation&nbsp;(continued) </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
management, the Group&#146;s unaudited interim condensed consolidated financial statements and accompanying notes include all adjustments (consisting of normal recurring adjustments) considered
necessary for the fair statement of the Group&#146;s financial position as of June&nbsp;30, 2019, and results of operations and cash flows for the six months ended June&nbsp;30, 2018 and 2019. Interim results of operations are not necessarily
indicative of the results for the full year or for any future period. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended
December&nbsp;31, 2018, and related notes included in the Group&#146;s audited consolidated financial statements. The financial information as of December&nbsp;31, 2018 presented in the unaudited interim condensed consolidated financial statements
is derived from the audited consolidated financial statements as of December&nbsp;31, 2018. Significant accounting policies followed by the Group in the preparation of the accompanying unaudited interim condensed consolidated financial statements
are summarized below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.2 Basis of consolidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is
maintained. All inter-company balances and transactions have been eliminated in consolidation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.3 Use of estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are
used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities and other intangible assets as well as subsequent fair value measurements. Additionally, estimates are
used in determining items such as useful lives of property, equipment and software, impairment of contract assets and other receivables, impairment of long-lived assets and goodwill, share-based compensation, leases, tax valuation allowances and
revenues from licensing and collaboration arrangements. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments
about the carrying values of assets and liabilities. Actual results could differ from those estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.4 Fair value measurements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial assets and liabilities of the Group primarily comprise of cash and cash equivalents, restricted cash, other financial assets, contract assets, other
receivables, short-term borrowings, accruals and other payables and warrants liabilities. As of December&nbsp;31, 2018 and June 30, 2019, except for other financial assets and warrant liabilities, the carrying values of these financial assets and
liabilities approximated their fair values because of their generally short maturities. The Group reports other financial assets and warrant liabilities at fair value at each balance sheet date and changes in fair value are reflected in the
consolidated statements of comprehensive loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. PRINCIPAL ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.4 Fair value measurements&nbsp;(continued) </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group measures its financial assets and liabilities using inputs from the following three levels of the
fair value hierarchy. The three levels are as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level&nbsp;1 inputs are unadjusted quoted prices in active markets for identical assets that the
management has the ability to access at the measurement date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level&nbsp;2 inputs include quoted prices for similar assets in active markets, quoted
prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable for the asset (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by
observable market data by correlation or other means (market corroborated inputs). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level&nbsp;3 includes unobservable inputs that reflect the
management&#146;s assumptions about the assumptions that market participants would use in pricing the asset. The management develops these inputs based on the best information available, including the own data.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Assets and liabilities measured at fair value on a recurring basis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group measured its other financial assets and warrant liabilities at fair value on a recurring basis. As the Group&#146;s other financial assets and
warrants are not traded in an active market with readily observable prices, the Group uses significant unobservable inputs to measure the fair value of other financial assets and warrant liabilities. These instruments are categorized in the
Level&nbsp;3 valuation hierarchy based on the significance of unobservable factors in the overall fair value measurement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes
the Group&#146;s financial assets and liabilities measured and recorded at fair value on a recurring basis as of December&nbsp;31, 2018 and June 30, 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Active&nbsp;market<BR>(Level&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Observable&nbsp;input<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-observable&nbsp;input</FONT><BR>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June 30, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Active&nbsp;market<BR>(Level&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Observable&nbsp;input<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-observable&nbsp;input</FONT><BR>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. PRINCIPAL ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.4 Fair value measurements&nbsp;(continued) </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The roll forward of major Level&nbsp;3 financial asset and financial liability are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Other&nbsp;financial<BR>assets</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Warrant<BR>liabilities</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of Level&nbsp;3 financial asset and liability as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,618</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposal of other financial assets due to Termination Agreement (Note&nbsp;4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(159,974</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reclassified as other receivables due to Termination Agreement (Note 4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,056</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value changes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(508</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,854</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Currency translation differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(679</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of Level&nbsp;3 financial assets and liability as of June 30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>80,420</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(50,151</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Refer to Note 15 for additional information about Level&nbsp;3 warrant liabilities measured at fair value on a recurring basis
for the six months ended June 30, 2018 and 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.5 Foreign currency translation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group uses Chinese Renminbi (&#147;RMB&#148;) as its reporting currency. The United States Dollar (&#147;US$&#148;) is the functional currency of the
Group&#146;s entities incorporated in the Cayman Islands, the United States of America (&#147;U.S.&#148;) and Hong Kong, the Australia Dollar (&#147;AUD&#148;) is the functional currency of the Group&#146;s entity incorporated in Australia and the
RMB is the functional currency of the Company&#146;s PRC subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transactions denominated in other than the functional currencies are translated
into the functional currency of the entity at the exchange rates prevailing on the transaction dates. Assets and liabilities denominated in other than the functional currencies are translated at the balance sheet date exchange rate. The resulting
exchange differences are recorded in the consolidated statements of comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited interim condensed consolidated financial statements
of the Group are translated from the functional currency to the reporting currency, RMB. Assets and liabilities of the subsidiaries are translated into RMB using the exchange rate in effect at each balance sheet date. Income and expenses are
translated at the average exchange rates prevailing for the year. Foreign currency translation adjustments arising from these are reflected in the accumulated other comprehensive income. The exchange rates used for translation on December&nbsp;31,
2018 and June 30, 2019 were US$1.00 = RMB6.8632 and RMB6.8747, respectively, representing the index rates stipulated by the People&#146;s Bank of China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Translations of balances in the consolidated balance sheets, consolidated statements of comprehensive loss, consolidated statements of changes in
shareholders&#146; equity (deficit) and consolidated statements of cash flows from RMB into US$ as of and for the six months ended June 30, 2019 are solely for the convenience of the readers and were calculated at the rate of US$1.00=RMB6.8650,
representing the noon buying rate in The City of New York for cable transfers of RMB as certified for customs purposes by the Federal Reserve Bank of New York on June 30, 2019. No representation is made that the RMB amounts could have been, or could
be, converted, realized or settled into US$ at that rate on June 30, 2019, or at any other rate. The US$ convenience translation is not required under U.S. GAAP and all US$ convenience translation amounts in the accompanying consolidated financial
statements are unaudited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. PRINCIPAL ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.6 Goodwill </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually
identified and separately recognized. The Group allocates the cost of an acquired entity to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The excess of the purchase price for
acquisitions over the fair value of the net assets acquired, including other intangible assets, is recorded as goodwill. Goodwill is not amortized, but impairment of goodwill assessment is performed on at least an annual basis on December&nbsp;31 or
whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group has elected to first assess
qualitative factors to determine whether it is more likely than not that the fair value of the Group&#146;s reporting unit is less than its carrying amount, including goodwill. The qualitative assessment includes the Group&#146;s evaluation of
relevant events and circumstances affecting the Group&#146;s single reporting unit, including macroeconomic, industry, market conditions and the Group&#146;s overall financial performance. If qualitative factors indicate that it is more likely than
not that the Group&#146;s reporting unit&#146;s fair value is less than its carrying amount, then the Group will perform the quantitative impairment test by comparing the reporting unit&#146;s carrying amount, including goodwill, to its fair value.
If the carrying amount of the reporting unit exceeds its fair value, an impairment loss will be recognized in an amount equal to that excess. For the six months ended June 30, 2018 and 2019, the Group determined that there were no indicators of
impairment of the goodwill. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.7 Deferred subsidy income </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred subsidy income consists of deferred income from government grants. Government grants consist of cash subsidies received by the Group&#146;s
subsidiaries in the PRC from local governments as support on expenses relating to certain projects. Grants received with government specified performance obligations are recognized when all the obligations have been fulfilled. If such obligations
are not satisfied, the Group may be required to refund the subsidy. Cash grants of RMB3,920 was recorded in deferred subsidy income as of June 30, 2019, which will be recognized when the government specified performance obligation is satisfied,
which is expected to be more than 12 months after June&nbsp;30, 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.8 Revenue recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group adopted Accounting Standard Codification (&#147;ASC&#148;) 606, <I>Revenue from Contracts with Customers</I> (Topic 606) (&#147;ASC 606&#148;) for
all periods presented. Consistent with the criteria of Topic 606, the Group recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in
exchange for those goods or services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an
amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the
following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction price, including variable consideration, if any; (iv)&nbsp;allocate the
transaction price to the performance obligations in the contract; and (v)&nbsp;recognize revenue when (or as) the entity satisfies a performance obligation. The Group only applies the five-step model to contracts when it is probable that the entity
will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. PRINCIPAL ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.8 Revenue recognition&nbsp;(continued) </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once a contract is determined to be within the scope of ASC 606 at contract inception, the Group reviews the
contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Group recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when
that performance obligation is satisfied or as it is satisfied. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At contract inception, the Group analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808,<I>&nbsp;Collaborative
Arrangements</I>&nbsp;(&#147;ASC 808&#148;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on
the commercial success of such activities.&nbsp;For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Group first determines if the collaboration is deemed to be within the scope of ASC 808 and those that are
more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. For the collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group&#146;s collaborative arrangements may contain more than one unit of account, or performance obligation, including grants of licenses to intellectual
property rights, agreement to provide research and development services and other deliverables. The collaborative arrangements do not include a right of return for any deliverable. As part of the accounting for these arrangements, the Group must
develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&nbsp;In developing the stand-alone selling price for a performance obligation, the Group considers
competitor pricing for a similar or identical product, market awareness of and perception of the product, expected product life and current market trends. In general, the consideration allocated to each performance obligation is recognized when the
respective obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is not constrained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When the
timing of the delivery of product is different from the timing of payments made by the customers, the Group recognizes either a contract asset (performance precedes the contractual due date) or a contract liability (customer payment precedes
performance). The Group&#146;s contractual payment terms are typically due in no more than 30 days from invoicing. In limited situations, certain customer contractual payment terms require the Group to bill in arrears; thus, the Group satisfies some
or all of the performance obligations before the Group is contractually entitled to bill the customer. In these situations, billing occurs subsequent to revenue recognition, which results in a contract asset. For example, certain of the contractual
arrangements do not permit the Group to bill until the completion of the production of the samples. In other limited situations, certain customer contractual payment terms allow the Group to bill in advance; thus, the Group receives customer cash
payment before satisfying some or all of its performance obligations. In these situations, billing occurs in advance of revenue recognition, which results in contract liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Licenses of Intellectual Property</I>: Upfront <FONT STYLE="white-space:nowrap">non-refundable</FONT> payments for licensing the Group&#146;s intellectual
property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, the Group recognizes revenues from
<FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">up-front</FONT> fees allocated to the license at a point in time, when the license is transferred to the licensee and the licensee is able to use and benefit
from the license.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. PRINCIPAL ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.8 Revenue recognition&nbsp;(continued) </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Services</I>: The portion of the transaction price allocated to research and
development services performance obligations is deferred and recognized as collaboration revenue over time as delivery or performance of such services occurs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Milestone Payments</I>: At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Group
evaluates whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the
most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are
satisfied. At the end of each subsequent reporting period, the Group <FONT STYLE="white-space:nowrap">re-evaluates</FONT> the probability of achieving such development milestones and any related constraint, and if necessary, adjust the estimate of
the overall transaction price. Any such adjustments are recorded on a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> basis, which would affect revenues and earnings in the period of adjustment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Royalties</I>: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to
be the predominant item to which the royalties relate, the Group recognizes revenue at the later of (i)&nbsp;when the related sales occur, or (ii)&nbsp;when the performance obligation to which some or all of the royalty has been allocated has been
satisfied (or partially satisfied). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.9 Research and development expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Elements of research and development expenses primarily include (1)&nbsp;payroll and other related expenses of personnel engaged in research and development
activities, <FONT STYLE="white-space:nowrap">(2)&nbsp;in-licensed</FONT> patent rights fee of exclusive development rights of drugs granted to the Group, (3)&nbsp;expenses related to preclinical testing of the Group&#146;s technologies under
development and clinical trials such as payments to contract research organizations (&#147;CRO&#148;), investigators and clinical trial sites that conduct the clinical studies (4)&nbsp;expenses to develop the product candidates, including raw
materials and supplies, product testing, depreciation, and facility related expenses, (5)&nbsp;other research and development expenses. Research and development expenses are charged to expense as incurred when these expenditures relate to the
Group&#146;s research and development services and have no alternative future uses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group has acquired rights to develop and commercialize product
candidates. Upfront payments that relate to the acquisition of a new drug compound, as well as <FONT STYLE="white-space:nowrap">pre-commercial</FONT> milestone payments, are immediately expensed as acquired
<FONT STYLE="white-space:nowrap">in-process</FONT> research and development in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#147;business&#148; as
defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. Milestone payments made to third parties subsequent to regulatory approval would be
capitalized as intangible assets and amortized over the estimated remaining useful life of the related product. The conditions enabling capitalization of development expenses as an asset have not yet been met and, therefore, all development
expenditures are recognized in profit or loss when incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. PRINCIPAL ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.10 Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the adoption of ASC 842 on January&nbsp;1, 2019: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leases, mainly leases of offices, where substantially all the rewards and risks of ownership of assets remain with the lessor are accounted for as operating
leases. Payments made under operating leases are recognized as an expense on a straight-line basis over the lease term. The Group had no capital leases for any of the years stated herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon and hereafter the adoption of ASC 842 on January&nbsp;1, 2019: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> (&#147;ROU&#148;) assets, operating lease liability, and operating lease liability, <FONT STYLE="white-space:nowrap">non-current</FONT> in the Company&#146;s consolidated balance sheets. Please
refer to Note 2(12) for the disclosures regarding the Company&#146;s method of adoption of ASC 842 and the impacts of adoption on its financial position, results of operations and cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ROU assets represent the Company&#146;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#146;s obligation to
make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. When determining the lease term, the Company includes
options to extend or terminate the lease when it is reasonably certain that it will exercise that option, if any. As the Company&#146;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate, which it calculates
based on the credit quality of the Company and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has elected to adopt the following lease policies in conjunction with the adoption of ASU <FONT STYLE="white-space:nowrap">2016-02:</FONT> (i)
elect for each lease not to separate <FONT STYLE="white-space:nowrap">non-lease</FONT> components from lease components and instead to account for each separate lease component and the <FONT STYLE="white-space:nowrap">non-lease</FONT> components
associated with that lease component as a single lease component; (ii)&nbsp;for leases that have lease terms of 12 months or less and does not include a purchase option that is reasonably certain to exercise, the Company elected not to apply ASC 842
recognition requirements; and (iii)&nbsp;the Company elected to apply the package of practical expedients for existing arrangements entered into prior to January&nbsp;1, 2019 to not reassess (a)&nbsp;whether an arrangement is or contains a lease,
(b)&nbsp;the lease classification applied to existing leases, and(c) initial direct costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.11 Share-based compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company grants restricted shares and stock options to eligible employees and accounts for share-based compensation in accordance with ASC 718,
Compensation&#151;Stock Compensation.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Employees&#146; share-based compensation awards are measured at the grant date fair value of the awards and
recognized as expenses a) immediately at the grant date if no vesting conditions are required; or b) for share based awards granted with only service conditions, using the graded vesting method net of estimated forfeitures over the vesting period;
or c) for share-based awards granted with service conditions and the occurrence of an initial public offering (&#147;IPO&#148;) as performance condition cumulative share-based compensation expenses for the options that have satisfied the service
condition should be recorded upon the completion of the IPO using the graded vesting method.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. PRINCIPAL ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.11 Share-based compensation&nbsp;(continued) </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A change in any of the terms or conditions of share-based awards is accounted for as a modification of the
awards. The Group calculates incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are modified at the modification date. For
vested awards, the Group recognizes incremental compensation cost in the period when the modification occurs. For awards not being fully vested, the Group recognizes the sum of the incremental compensation expense and the remaining unrecognized
compensation expense for the original awards over the remaining requisite service period after modification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share-based compensation in relation to the
restricted shares is measured based on the fair market value of the Group&#146;s ordinary shares at the grant date of the award. Prior to the listing, estimation of the fair value of the Group&#146;s ordinary shares involves significant assumptions
that might not be observable in the market, and a number of complex and subjective variables, including discount rate, and subjective judgments regarding the Group&#146;s projected financial and operating results, its unique business risks, the
liquidity of its ordinary shares and its operating history and prospects at the time the grants are made. Share-based compensation in relation to the share options is estimated using the Binominal Option Pricing Model. The determination of the fair
value of share options is affected by the share price of the Group&#146;s ordinary shares as well as the assumptions regarding a number of complex and subjective variables, including the expected share price volatility, risk-free interest rate,
exercise multiple and expected dividend yield. The fair value of these awards was determined with the assistance from an independent valuation firm. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.12 Adopted accounting pronouncements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2016,
the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> Leases (Topic 842). This ASU requires lessees to recognize lease assets and lease liabilities on the balance sheet for the rights and obligations created by all leases with terms
greater than 12 months. As we are not a lessor, other changes in the guidance applicable to lessors do not apply. Additionally, in 2018, the FASB issued codification and targeted improvements to this guidance effective for fiscal years and interim
periods within those years beginning after December&nbsp;15, 2018, with early adoption permitted. The Group adopted the new guidance on January&nbsp;1, 2019, using the alternative transition approach. For additional information, see Note
6&#151;&#147;Leases.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-18,</FONT> Statement of Cash Flows (Topic 230)
(&#147;ASU <FONT STYLE="white-space:nowrap">2016-18&#148;).</FONT> This ASU affects all entities that have restricted cash or restricted cash equivalents and are required to present a statement of cash flows under Topic 230. ASU <FONT
STYLE="white-space:nowrap">2016-18</FONT> requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. This
update was required to be adopted for fiscal years beginning after December&nbsp;15, 2018, and interim periods within fiscal years beginning after December&nbsp;15, 2019, and early adoption is permitted in any interim or annual period. The Group
elected to early adopt this ASU and applied this guidance retrospectively to all periods presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.13 Recent accounting pronouncements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-13,</FONT> Financial Instruments&#151;Credit Losses (Topic 326):
Measurement of Credit Losses on Financial Instruments (&#147;ASU <FONT STYLE="white-space:nowrap">2016-13&#148;).</FONT> This guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected.
The measurement of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. PRINCIPAL ACCOUNTING POLICIES&nbsp;(CONTINUED) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.13 Recent accounting pronouncements&nbsp;(continued) </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability. In November 2018, the FASB issued ASU <FONT
STYLE="white-space:nowrap">2018-19,</FONT> Codification Improvements to Topic 326, Financial Instruments-Credit Losses (&#147;ASU <FONT STYLE="white-space:nowrap">2018-19&#148;),</FONT> which clarifies certain topics included within ASU <FONT
STYLE="white-space:nowrap">2016-13.</FONT> ASU <FONT STYLE="white-space:nowrap">2016-13</FONT> and ASU <FONT STYLE="white-space:nowrap">2018-19</FONT> are effective for the annual reporting period beginning after December&nbsp;15, 2019, including
interim periods within that reporting period. The Group is currently evaluating the impact on the consolidated financial statements upon the adoption of this guidance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. PREPAYMENTS AND OTHER RECEIVABLES </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepayments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#151;Prepayments to CRO vendors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#151;Prepayments for other services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Value-added tax recoverable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rental deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables arising from Termination Agreement (Note 4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. OTHER FINANCIAL ASSETS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial asset at fair value through profit or loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Note receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group placed the principal amount for short-term investments through a contractual arrangement with a third party for the
period from June&nbsp;30, 2017 to June&nbsp;30, 2020 (&#147;Principal Amount&#148;). The Principal Amount can be redeemed from the third party at the discretion of the Group from time to time whereby the Group is expecting to earn an income on the
Principal Amount with an average yield in the range from 4.50% to 5.25% per annum. The Group initially records these assets at cost, which approximates its fair value at inception and subsequently records these assets at fair value. Changes in the
fair value are reflected in the interim condensed consolidated statements of comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;22, 2019, the Group entered into an
agreement with the relevant party involved for early termination of the contractual arrangement (&#147;Termination Agreement&#148;). Pursuant to the Termination Agreement, the Group </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. OTHER FINANCIAL ASSETS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall receive cash with an amount of RMB95,056 and commercial bills with a total face value of RMB160,944 (including those commercial bills redeemed during the year ended December&nbsp;31, 2018
with a face value of RMB40,387). No material gain or loss was arising from such termination. As of June&nbsp;30, 2019, cash of RMB80,000 was received and an amount of RMB79,974 cash was received upon the maturities of certain commercial bills. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to June 30, 2019 and up to the issuance of these interim condensed consolidated financial statements, an amount of RMB11,953 cash was received upon
the maturities of certain commercial bills. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the balance of other receivables of RMB15,056 (Note 3) was fully settled in August 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. PROPERTY, EQUIPMENT AND SOFTWARE </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property, equipment
and software consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,390</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,848</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,871</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Construction-in-progress</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total net book value of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total amounts charged to the interim condensed consolidated statements of comprehensive loss for depreciation and
amortization expenses amounted to approximately RMB1.4&nbsp;million and RMB4.5&nbsp;million for the six months ended June&nbsp;30, 2018 and 2019, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. LEASES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2019, the Company has
operating leases recorded on its balance sheet for certain office spaces and facilities that expire on various dates through 2027. The Group does not plan to cancel the existing lease agreements for its existing facilities prior to their respective
expiration dates. When determining the lease term, the Group includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option, if any. All of the Group&#146;s leases qualify as operating leases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. LEASES&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information related to operating leases as of June&nbsp;30, 2019 and upon adoption of ASC 842 on
January&nbsp;1, 2019 is as follows (in thousands, except for percentages and years). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, <FONT STYLE="white-space:nowrap">non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average remaining lease term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information related to operating lease activity during the six months ended June&nbsp;30, 2019 is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;six&nbsp;months&nbsp;ended</B><br><B>June&nbsp;30, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets obtained in exchange for lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease rental expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expense for short-term leases within 12 months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest of lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future annual minimum lease payments for operating leases as of December&nbsp;31, 2018 under ASC 840 were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Operating&nbsp;Leases</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,935</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,175</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. LEASES&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Maturities of lease liabilities were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>As&nbsp;of&nbsp;June&nbsp;30,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remaining 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total undiscounted lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,807</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(263</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total lease liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,068</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,758</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. INTANGIBLE ASSETS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intangible assets as of December&nbsp;31, 2018 and June 30, 2019 are summarized as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IPR&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IPR&amp;D represents the fair value assigned to research and development assets that the Group acquired from business
combination of Tasgen Group in 2017 and had not reached technological feasibility at the date of acquisition. Upon commercialization, the Group will determine the estimated useful life and amortize these amounts based upon an economic consumption
method. As of December 31, 2018 and June 30, 2019, there was no impairment of the value of the Group&#146;s intangible assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. GOODWILL </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The goodwill of RMB162,574 (US$23,682) as of December&nbsp;31, 2018 and June 30, 2019 represented the goodwill generated from the acquisition of Tasgen Group
in 2017. The business of Tasgen Group was fully integrated into the Company post acquisition. As of December&nbsp;31, 2018 and June 30, 2019, the Group performed a qualitative assessment by evaluating relevant events and circumstances that would
affect the Group&#146;s single reporting unit and did not note any indicator that it is more likely than not that the fair value of the Group&#146;s reporting unit is less than its carrying amount and therefore the Group&#146;s goodwill was not
impaired. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. SHORT-TERM BORROWINGS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2018, <FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. borrowed a loan of RMB80,000
from China Merchant Bank Co., Ltd. for a term of one year and at the interest rate of 4.20% per annum. To facilitate this borrowing, another subsidiary of the Company in Hong Kong placed cash deposits of US$13,500 (equivalent to approximately
RMB92,653) with the bank. The use of such cash deposits and the interest earned thereon are restricted by the bank during the period of the borrowing. The deposits have a <FONT STYLE="white-space:nowrap">one-year</FONT> term and bear interest at
3.26% per annum. The borrowing was fully repaid during the six months ended June&nbsp;30, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2019,
<FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. borrowed a loan of RMB50,000 from China Merchant Bank Co., Ltd. for a term of one year and at the interest rate of 4.15% per annum. To
facilitate this borrowing, another subsidiary of the Company in Hong Kong placed cash deposits of US$8,000 (equivalent to approximately RMB54,998) with the bank. The use of such cash deposits and the interest earned thereon are restricted by the
bank during the period of the borrowing. The deposits have a <FONT STYLE="white-space:nowrap">one-year</FONT> term and bear interest at 2.63% per annum. The borrowing will be fully repaid in 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. ACCRUALS AND OTHER PAYABLES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Staff salaries and welfare payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued external research and development activities related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued travelling expenses, office expenses and others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. INCOME TAXES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Group has incurred net accumulated operating losses for income tax purposes since its inception. The Group believes that it is more likely than not that these net accumulated operating losses will not be utilized in the future. Therefore, the Group
has provided full valuation allowances for the deferred tax assets as of December&nbsp;31, 2018 and June 30, 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. ORDINARY SHARES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018 and June 30, 2019, 500,000,000 ordinary shares had been authorized by the Company. Each ordinary share is entitled to one vote.
The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors of the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. CONVERTIBLE PREFERRED SHARES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;18,
2016, the Company issued 5,141,587 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> and <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Shares with a consideration of US$11,282 (equivalent to approximately RMB74,742). In connection
with the Series <FONT STYLE="white-space:nowrap">A-1</FONT> and <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Shares issuance, the Company also issued 2,246,744 warrant to purchase its Series <FONT STYLE="white-space:nowrap">A-3</FONT>
Preferred Shares (Series <FONT STYLE="white-space:nowrap">A-3</FONT> Warrants and see Note 15). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. CONVERTIBLE PREFERRED SHARES&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;6, 2017, in connection with the Group&#146;s acquisition of Tasgen Group, the Company
issued 16,723,646 shares of series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares at a price of US$2.55 per share with a total consideration of US$42,645 (equivalent to approximately RMB289,024). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Shares, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Shares and Series <FONT
STYLE="white-space:nowrap">A-3</FONT> Preferred Shares are also referred to as Series A Preferred Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;22, 2017, the Company issued
15,894,594 shares of Series B Preferred Shares with a consideration of US$52,546 (equivalent to approximately RMB346,515). In connection with the Series B Preferred Shares issuance, the Company also issued convertible promissory notes that are
convertible into <FONT STYLE="white-space:nowrap">Series&nbsp;B-1</FONT> Preferred Shares (2017 Note and see Notes 14) and 5,633,780 warrants to purchase its Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares (&#147;Series B
Warrant&#148; and see Note 15). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the Company&#146;s issuance of Series B Preferred Shares, the Company also completed a round of onshore
financing with respect to the Group&#146;s subsidiary <FONT STYLE="white-space:nowrap">I-MAB</FONT> Tianjin (&#147;Series B Onshore Financing&#148;). Series&nbsp;B Onshore Financing comprised 1) capital injection to
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin by a number of investors (&#147;Series B Onshore Investors&#148;) (see Note 14), 2) <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s issuance of convertible loans (&#147;Onshore
Convertible Loans&#148; and see Note 14), and 3) the Company&#146;s issuance of 2,620,842 warrants to purchase its Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares (&#147;Series B Warrants&#148; and see Note 15). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June 29, 2018, the Company issued total 8,361,823 shares of Series A-3 Preferred Shares upon exercise of Series A-3 Option held by its holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;29, 2018, the Company issued 2,535,201 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares upon conversion of 2017
Notes and issued 2,253,512 shares of Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares upon exercise of Series B Warrant by Series B preferred shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;29, 2018, the Company issued 5,938,640 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares upon exercise of the Series
B Option held by a Series B Onshore Investor and issued 947,218 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares upon conversion of Onshore Convertible Loans by a Series B Onshore Investor (see Note 14), respectively.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2018, the Company issued 1,455,549 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares upon exercise of the
Series&nbsp;B Option held by a Series B Onshore Investor, issued 232,161 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares upon conversion of Onshore Convertible Loans by a Series B Onshore Investor (see Note 14) and
issued 1,048,337&nbsp;shares of Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares upon exercise of Series B Warrant by Series B Onshore Investors, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Series B Preferred Shares, Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares and Series <FONT STYLE="white-space:nowrap">B-2</FONT>
Preferred Shares are also referred to as Series B Preferred Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 6, 2018, the Company issued 31,046,360 shares of Series C Preferred Shares at
a price of US$6.4419 per share with a total consideration of US$200,000 (equivalent to approximately RMB1,323,363). In connection with the offering of the Series C Preferred Shares, the Company incurred issuance costs of RMB16,730. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Series A Preferred Shares, Series B Preferred Shares and Series C Preferred Shares are collectively referred to as Preferred Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. CONVERTIBLE PREFERRED SHARES&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key terms of the Preferred Shares are summarized as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of Preferred Shares are entitled
to receive dividends, out of any assets legally available therefore, prior and in preference to any declaration or payment of any dividend on the ordinary shares or any other class or series of shares of the Group at the rate of eight percent (8%)
of the original issue price per share per annum on each Preferred Share, payable in US$ and annually when, as and if declared by the Board of Directors. Such distributions shall not be cumulative. No dividend, whether in cash, in property or in
shares of the capital of the Group, shall be paid on or declared and set aside for any ordinary shares or any other class or series of shares of the Group unless and until all dividends have been paid in full on the Preferred Shares (on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> basis). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conversion </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Preferred Share may be converted at any time into ordinary shares at the option of the preferred shares holders at the then applicable conversion price.
The initial conversion ratio is 1:1, subject to adjustment in the event of (i)&nbsp;share splits, share combinations, share dividends or distribution, other dividends, recapitalizations and similar events, or (ii)&nbsp;issuance of ordinary shares
(excluding certain events such as issuance of ordinary shares pursuant to a public offering) at a price per share less than the conversion price in effect on the date of or immediately prior to such issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Preferred Shares shall be automatically converted into ordinary shares immediately upon the closing of a public offering of the Company&#146;s shares with
an offering price (exclusive of underwriting commissions and expenses) that reflects a market capitalization (immediately prior to the public offering) of not less than US$1,000,000,000 (the &#147;Qualified Public Offering&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group determined that there were no beneficial conversion features (&#147;BCF&#148;) identified for any of the Preferred Shares during any of the periods.
In making this determination, the Company compared the fair value of the ordinary shares into which the Preferred Shares are convertible with the respective effective conversion price at the issuance date. In all instances, the effective conversion
price was greater than the fair value of the ordinary shares. To the extent a conversion price adjustment occurs, as described above, the Group will reevaluate whether or not a beneficial conversion feature should be recognized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of any liquidation (unless
waived by the preferred shareholders) including deemed liquidation, dissolution or winding up of the Company, holders of the Preferred Shares shall be entitled to receive a per share amount equal to one hundred percent (100%) of the original issue
price on each Preferred Share, plus an amount representing an internal rate of return of twelve percent (12%) per annum on the original issue price as adjusted for share dividends, share splits, combinations, recapitalizations or similar events,
plus all accrued and declared but unpaid dividends thereon, in the sequence of Series C Preferred Shares, Series B Preferred Shares and Series&nbsp;A Preferred Shares. After such liquidation amounts have been paid in full, any remaining funds or
assets of the Company legally available for distribution to shareholders shall be distributed on a pro rata basis among the holders of the Preferred Shares, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, together with the holders
of the ordinary shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. CONVERTIBLE PREFERRED SHARES&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounting of preferred shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Preferred Shares are redeemable by the holders upon a liquidation event, including a deemed liquidation event (e.g., change in control), and as such are
presented as mezzanine equity on the consolidated balance sheets. In accordance with ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">480-10-S99,</FONT></FONT> each issuance of the convertible preferred shares should be
recognized at the date of issuance after deducting fair value allocated to the detachable warrants and issuance costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company assesses whether an
amendment to the terms of its convertible preferred shares is an extinguishment or a modification using the fair value model. When convertible preferred shares are extinguished, the difference between the fair value of the consideration transferred
to the convertible preferred shareholders and the carrying amount of the convertible preferred shares (net of issuance costs) is treated as deemed dividends to the preferred shareholders. The Company considers that a significant change in fair value
after the change of the terms to be substantive and thus triggers extinguishment. A change in fair value which is not significant immediately after the change of the terms is considered <FONT STYLE="white-space:nowrap">non-substantive</FONT> and
thus is subject to modification accounting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. CONVERTIBLE PREFERRED SHARES&nbsp;(CONTINUED) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounting of preferred shares&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s convertible preferred shares activities for the six months ended June&nbsp;30, 2018 and
2019 are summarized below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Series A Preferred Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Series B Preferred Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Series C Preferred Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Balance as of January&nbsp;1, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,865,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,894,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Issuance of Series A Preferred Shares upon exercise of Series
<FONT STYLE="white-space:nowrap">A-3</FONT> Option</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,361,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">323,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Issuance of Series B Preferred Shares upon exercise of
<FONT STYLE="white-space:nowrap">Series-B</FONT> Option</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,938,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Issuance of Series B Preferred Shares upon conversion of 2017 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,535,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Issuance of Series B Preferred Shares upon conversion of Onshore Convertible Loans</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">947,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Issuance of Series B Preferred Shares upon exercise of Tranche I of Series B Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,253,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Balance as of June&nbsp;30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,227,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,569,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">812,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Balance as of January&nbsp;1, 2019 and as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,227,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,305,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">921,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,046,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. CONVERTIBLE PROMISSORY NOTES AND ONSHORE CONVERTIBLE LOANS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2017 Notes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;25, 2017, the Company issued
US$11,520 convertible promissory notes (&#147;2017 Notes&#148;) to investors of Series B Preferred Shares (see Note 13) at a compound interest rate of 8% per annum, maturing on 36 months after the issuance date. Under the agreement, the holder of
the 2017 Notes may convert the outstanding principal amount into Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares at the conversion price of US$5.38 per share or a lower price as may be agreed by the investors and the Company at
any time from six months prior to the maturity date and prior to the repayment in full of the 2017 Note. No interest shall be accrued if the 2017 Notes have been converted into Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. CONVERTIBLE PROMISSORY NOTES AND ONSHORE CONVERTIBLE LOANS&nbsp;(CONTINUED) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2017 Notes&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the fair value of the Company&#146;s ordinary shares on September&nbsp;25, 2017 was lower than the
effective conversion price of US$5.38, the Company did not record a BCF. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;29, 2018, the Company&#146;s 2017 Notes were converted into the
Company&#146;s 2,535,201 Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares at the nominal conversion price of US$5.38 per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2018 Notes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;3, 2018, the Company issued
US$9,000 (equivalent to approximately RMB59,704) convertible promissory notes (&#147;2018 Notes&#148;) to an investor of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares at an annual interest rate of 0%, maturing on 36 months
after the issuance date. Under the agreement, the holder of the 2018 Notes may convert the 2018 Notes outstanding principal amount into Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares at the conversion price being lower of US$10
per share and fair market value at any time prior to the maturity date. Alternatively, the 2018 Notes shall be automatically converted into the Company&#146;s Series B Preferred Shares upon the maturity. As the fair value of the Company&#146;s
ordinary shares on February&nbsp;3, 2018 of US$3.96 was equal to the effective conversion price (being lower of US$10 per share and fair market value), the Company did not record a BCF. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Onshore Convertible Loans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;25, 2017, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Tianjin issued a US$5,359 convertible loan to Series B Onshore Investors at a compound interest rate of 8% per annum, maturing on 36 months after the issuance date. Under the agreement, the holder of the
Onshore Convertible Loans may convert the outstanding principal amount into <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s equity interest a stipulated conversion price at any time from six months prior to the maturity date and prior
to the repayment in full of the Onshore Convertible Loans. No interest shall be accrued if the Onshore Convertible Loans have been converted into <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s equity interest. As the fair value of the <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s ordinary shares on September&nbsp;25, 2017 was lower than the effective conversion price of US$4.31, the Company did not record a BCF. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June and July 2018, the Company reached agreements with holders of Onshore Convertible Loans and the principal amount of Onshore Convertible Loans were
then effectively converted into 1,179,379 Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares of the Company and the accrued interests were waived, resulting in an extinguishment loss of RMB8,548. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. WARRANTS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the issuance of the
Series <FONT STYLE="white-space:nowrap">A-1</FONT> and <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Shares on October&nbsp;18, 2016, 2,246,744 Series <FONT STYLE="white-space:nowrap">A-3</FONT> Warrants were issued to Series <FONT
STYLE="white-space:nowrap">A-1</FONT> and <FONT STYLE="white-space:nowrap">A-2</FONT> preferred shareholders, which provided the holder the right to purchase Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares. The Series <FONT
STYLE="white-space:nowrap">A-3</FONT> Warrants were later terminated on September&nbsp;6, 2017 without being exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the issuance
of the Series B Preferred Shares on September&nbsp;22, 2017, 5,633,780 Series B Warrants were issued to Series B preferred shareholders, which provided the holders the right to purchase Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred
Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-90 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. WARRANTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Company&#146;s Series B Onshore Financing that took place on September&nbsp;25, 2017,
2,620,842 Series B Warrants were issued to Series B Onshore Investors, which provided the holders the right to purchase Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the period from June&nbsp;29, 2018 to July&nbsp;6, 2018, 3,301,849 Series B Warrants (representing Tranche I of Series B Warrants) were exercised to
purchase 3,301,849 Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares with proceeds of US$20,000 (equivalent to approximately RMB132,332). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2018, the Series B Warrants holders agreed that the Series B Warrants shall be divided into two tranches and exercisable in accordance with
different time schedules, such that: (i)&nbsp;the holders have exercised part of the Series B Warrants in the total consideration of US$20,000 (&#147;Tranche I of Series B Warrants&#148;) and 3,301,849 Series
<FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares of the Company in aggregate have been newly issued to such holders on a pro rata basis; (ii)&nbsp;only when the Company fails to submit a Qualified Public Offering application at an
internationally recognized securities exchange by March&nbsp;31, 2019, the Warrant Holders may exercise the remaining part of Series B Warrants, in the total consideration of US$30,000 (&#147;Tranche II of Series B Warrants&#148;) and 4,952,773
Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares of the Company in aggregate will be issued to such holders on a pro rata basis; (iii)&nbsp;provided that the Company successfully submits a Qualified Public Offering application at
an internationally recognized securities exchange by March&nbsp;31, 2019, the holders shall unconditionally and irrevocably waive and cancel Tranche II of Series B Warrants; and (iv)&nbsp;the Tranche II of Series B Warrants may only be concurrently
exercised by all the Warrant Holders in one lump. This is considered to be a modification to Series B Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to the confirmations issued by
the Company&#146;s Series B Warrants holders in July 2019, the holders of Series B Warrants has unconditionally and irrevocably waived and cancelled the Tranche II of Series B Warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounting of warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The warrant is a freestanding
instrument and is recorded as liability in accordance with ASC 480, <I>Distinguishing Liabilities from Equity</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the Company&#146;s issuance of
warrants were bundled with other instruments (such as convertible preferred shares, convertible promissory notes, etc.), out of total considerations, the warrants are initially recognized at fair value and the remaining were allocated to other
instruments on a relative fair value basis (if applicable). The fair value changes of the warrants (including the fair value changes arising from modification of warrants) up to the time of exercise or termination were recognized in earnings. Upon
exercise, the total carrying value of the associated warrant liabilities was reclassified into the carrying value of the Preferred Shares into which it was converted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determined the fair value of the warrants with the assistance of an independent third party valuation firm. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-91 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. WARRANTS&nbsp;(CONTINUED) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounting of
warrants&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group has measured the warrant liabilities at fair values on a recurring basis using significant
unobservable inputs (Level 3) for the six months ended June&nbsp;30, 2018 and 2019. The Group used the binomial model to estimate the fair value of warrant liabilities using the following assumptions: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate of return</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.49</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.90</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maturity date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">September&nbsp;25,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">September&nbsp;25,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated volatility rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">US$6.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">US$6.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of underlying convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">US$6.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">US$7.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The model requires the input of highly subjective assumptions including the risk-free rate of return, maturity date, estimated
volatility rate and fair value of underlying preferred shares. The risk-free rate for periods within the contractual life is based on the US treasury strip bond with maturity similar to the maturity of the warrants as of valuation dates plus a China
country risk premium. For expected volatilities, the Group has made reference to the historical daily stock prices volatilities of ordinary shares of several comparable companies in the same industry as the Group. The estimated fair value of the
preferred shares was determined with assistance from an independent third party valuation firm. The Group&#146;s management is ultimately responsible for the determination of the estimated fair value of its preferred shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The significant unobservable inputs used in the fair value measurement of the warrant liabilities include risk-free rate of return, interval between valuation
date and maturity date, estimated volatility rate and fair value of underlying preferred shares. Significant decreases in interval between valuation date and maturity date, estimated volatility rate and fair value of underlying preferred shares
would result in a significantly lower fair value measurement. Significant increases in risk-free rate of return would result in a significantly lower fair value measurement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. REDEEMABLE <FONT STYLE="white-space:nowrap">NON-CONTROLLING</FONT> INTERESTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Company&#146;s acquisition of Tasgen Group on September&nbsp;6, 2017, the Company also entered into an option agreement with the third
party investor of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin, pursuant to which the Company granted the third party investor an option to subscribe for certain number of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares
of the Company at a price that stipulated in the agreement, and at the same time, the third party investor transferred its equity interests in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjian to the Company at the same price (&#147;Series <FONT
STYLE="white-space:nowrap">A-3</FONT> Option&#148;). This Series <FONT STYLE="white-space:nowrap">A-3</FONT> can be exercised at any time at the holder&#146;s own discretion or upon the request of the Company if the shareholders of the Company
approves an initial public offering. In addition, in the event that the exercise of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option has not been completed within 6 months after the option holder delivers the share purchase option notice,
the Company shall purchase the third party investor&#146;s equity interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjian and the Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option at a price that stipulated in the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the Company&#146;s issuance of Series B Preferred Shares (see Note 13), on September&nbsp;25, 2017, the Group&#146;s subsidiary <FONT
STYLE="white-space:nowrap">I-MAB</FONT> Tianjin entered into a capital increase subscription agreement with Series B Onshore Investors, pursuant to which Series B Onshore Investors subscribed for additional equity in
<FONT STYLE="white-space:nowrap">I-MAB</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-92 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. REDEEMABLE <FONT STYLE="white-space:nowrap">NON-CONTROLLING</FONT> INTERESTS&nbsp;(CONTINUED) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Tianjin of US$24,444 (equivalent to approximately RMB161,196). On September&nbsp;25, 2017 and in tandem with the aforementioned <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s
capital increase subscription agreement, the Company also entered into option agreements with Series B Onshore Investors, pursuant to which the Company granted Series B Onshore Investors options to subscribe for certain numbers of Series <FONT
STYLE="white-space:nowrap">B-1</FONT> Preferred Shares of the Company at a price that stipulated in the agreements, and at the same time, the Series B Onshore Investors shall transfer their equity interests in
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjian to the Company at the same price (&#147;Series B Option&#148;). The Series B Option can be exercised at any time at the holders&#146; own discretion or upon the request of the Company if the
shareholders of the Company approve an initial public offering. In addition, in the event that the exercise of Series B Option has not been completed within 6 months after the option holders deliver the share purchase option notice, the Company
shall purchase the third party investor&#146;s equity interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjian and the Series B Option at a price that stipulated in the agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the accounting assessments, the Company considers that the aforementioned Series <FONT STYLE="white-space:nowrap">A-3</FONT> and Series B Options are
embedded features of the <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests that are not required to be bifurcated. Since the aforementioned <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests in <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Tianjin are redeemable at a determinable price, upon occurrence of an event that is not solely within the control of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjian, the aforementioned <FONT
STYLE="white-space:nowrap">non-controlling</FONT> interests in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin are accounted for as redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests in the Group&#146;s interim
condensed consolidated balance sheets. Subsequently, the redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests should be carried at the higher of (1)&nbsp;the carrying amount after the attribution of net income of the Company
and (2)&nbsp;the expected redemption value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option and Series B Option were exercised by
respective holders on June&nbsp;29, 2018 and July&nbsp;6, 2018 to acquire 8,361,823 Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares and 7,394,189 Series B Preferred Shares, respectively. The transactions were accounted for as
equity transactions, and the differences between the carrying amount of redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests of RMB305,708 and the fair value of convertible preferred shares of RMB615,393 that issued was
recognized in additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group&#146;s redeemable
<FONT STYLE="white-space:nowrap">non-controlling</FONT> interest activities for the six months ended June&nbsp;30, 2018 and 2019 is summarized as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">305,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(144,512</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of Series B Option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(129,464</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Preferred Shares to be issued (Note)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,732</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">Note:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of June&nbsp;30, 2018, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong had acquired Qianhai
Fund&#146;s equity interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin but had yet to issue 1,455,549 shares to Qianhai Fund in order to complete Qianhai Fund&#146;s exercise of its Series B Option, which was subsequently completed on
July&nbsp;6, 2018 (see Note 13). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-93 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. SHARE-BASED COMPENSATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(a) Restricted shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended
December&nbsp;31, 2016, the Company issued 4,019,554 ordinary shares to Mr.&nbsp;Zang Jingwu Zhang, Ms.&nbsp;Qian Lili, Mr.&nbsp;Wang Zhengyi and Mr.&nbsp;Fang Lei (collectively the &#147;Founders&#148;), including the 369,301 shares which
represented the equity interests of Third Venture held by the Founders, and the Company recorded share-based compensation expense of RMB18.7&nbsp;million for issuance and grant of 3,650,253 ordinary shares to the Founders in June 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2016, the Founders entered into an arrangement with other investors of the Company, and the 87,441 ordinary shares issued to the Founders in June
2016 were canceled and out of the remaining 3,932,113 ordinary shares held by the Founders, 70% became restricted and subject to service vesting conditions, that should vest 20%, 20% and 30% over the next three years, respectively. There shall be no
acceleration of the vesting schedule except that, in case of a change of control of the Company or a Qualified Public Offering, or the termination of the Founder&#146;s employment with the Group without cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred share-based compensation was measured for the restricted shares using the estimated fair value of the Company&#146;s ordinary shares of US$0.77 at
the date of imposition of the restriction in October 2016, and was amortized to the interim condensed consolidated statements of comprehensive loss by using graded vesting method over the vesting term of 3 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the Group&#146;s Founders&#146; restricted shares activities: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Numbers<BR>of&nbsp;shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-average</FONT><BR>grant&nbsp;date<BR>fair&nbsp;value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2017 and June&nbsp;30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,966,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2018 and June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,179,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts of shared-based compensation expense in relation to the restricted shares recognized in the six months ended
June&nbsp;30, 2018 and 2019 were RMB1,929 and RMB1,026, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share-based compensation expenses related to restricted shares were included in:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(b) 2017 Employee Stock Option Plan (&#147;2017 Plan&#148;) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2017, the Company adopted the 2017 Plan. Under the 2017 Plan, a maximum aggregate number of 13,376,865 shares that may be issued pursuant to all
awards granted was approved. Stock options granted to an employee under the 2017 Plan will be exercisable upon the Company completes a listing and the employee </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-94 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. SHARE-BASED COMPENSATION&nbsp;(CONTINUED) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(b)
2017 Employee Stock Option Plan (&#147;2017 Plan&#148;)&nbsp;(continued) </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
renders service to the Company in accordance with a stipulated service schedule starting from the employee&#146;s date of employment. Employees are generally subject to a three-year service
schedule, under which an employee earns an entitlement to vest in 50% of the option grants on the second anniversary of the grant date, a vesting of the remaining 50% on the third anniversary of the applicable grant date. The stock option under 2017
Plan, to the extent then vested, shall become exercisable only upon the earlier of (i)&nbsp;a listing, and (ii)&nbsp;occurrence of a change in control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group granted 305,000 stock options to employees, all with an exercise price of US$1, for the six months ended June&nbsp;30, 2018. The Group did not grant
any stock options to employees for the six months ended June&nbsp;30, 2019. No options are exercisable as of December&nbsp;31, 2018 and June 30, 2019 and prior to the Group completes a listing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the stock options activities of 2017 Plan for the six months ended June&nbsp;30, 2018 and 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number&nbsp;of<br>shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Weighted<br>average<br>exercise<br>price<br>US$</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Weighted<br>average<br>remaining<br>contractual<br>term</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Aggregate<br>intrinsic<br>value<br>US$</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,761,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,470,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(226,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,005,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(266,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repurchased (Note 17(d))</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,435,215</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,304,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock options granted to the employees were measured at fair value on the dates of grant using the Binomial Option Pricing
Model with the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">61.54%-62.13</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate (per annum)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">2.81%-2.92</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise multiple</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contractual term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The expected volatility was estimated based on the historical volatility of comparable peer public companies with a time
horizon close to the expected term of the Group&#146;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-95 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. SHARE-BASED COMPENSATION&nbsp;(CONTINUED) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(b)
2017 Employee Stock Option Plan (&#147;2017 Plan&#148;)&nbsp;(continued) </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the Group&#146;s options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would
decide to voluntarily exercise their vested options. As the Group did not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is
zero as the Group has never declared or paid any cash dividends on its shares, and the Group does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no stock options granted to employees for the six months ended June&nbsp;30, 2019. Since the exercisability is dependent upon the listing, and it
is not probable that this performance condition can be achieved until a listing, no share-based compensation expense relating to the 2017 Plan was recorded for the six&nbsp;months ended June&nbsp;30, 2018 and 2019. The Group will recognize
compensation expenses relating to options vested cumulatively upon the completion of the Company&#146;s listing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2018 and 2019, the
Company concluded that the performance condition described above for the options was not probable of being satisfied at such time. As a result, the Company did not recognize any compensation cost during the six months ended June&nbsp;30, 2018 and
2019 for the options granted under the 2017 plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(c) 2018 Employee Stock Option Plan (&#147;2018 Plan&#148;) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;22, 2019, the Group adopted the 2018 Plan. Under 2018 Plan, the maximum aggregate number of ordinary shares which may be issued pursuant to
all awards is 14,005,745, subject to further amendment. If the Group successfully lists on an internationally recognized securities exchange for a Qualified Public Offering by December&nbsp;31, 2019, the maximum aggregate number of ordinary shares
which may be issued shall be 15,452,620. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock options granted to an employee under the 2018 Plan will be generally exercisable when the Company
completes a listing and the employee renders service to the Company in accordance with a stipulated service schedule starting from the employee&#146;s date of employment. The vesting schedule shall generally be a two-year vesting schedule consisting
of a cliff vesting 50% on the first anniversary of the applicable vesting commencement date, and a vesting of the remaining 50% on the second anniversary of the applicable vesting commencement date. If a listing occurs at anytime prior to any option
granted under the 2018 Plan becoming full vested, and to the extent such option has been granted and outstanding, any such option shall vest in full with immediate effect upon the listing. Except as otherwise approved by the board of directors,
vested portion of option shall become exercisable upon the earlier of six months after a listing or the occurrence of a change in control; provided, however that in each case, no option of an employee shall become exercisable until the third
anniversary of such employee&#146;s employment commencement date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Board of Director&#146;s approval of 2018 Plan on February 22, 2019,
the 10,893,028 stock options granted to a director of the Group under 2018 Plan were fully vested and exercisable upon the adoption of 2018 Plan. Out of aforementioned total 10,893,028 stock options, 454,940 stock options were repurchased by the
Group (see Note 17(d) for further details). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-96 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. SHARE-BASED COMPENSATION&nbsp;(CONTINUED) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(c)
2018 Employee Stock Option Plan (&#147;2018 Plan&#148;)&nbsp;(continued) </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts of shared-based compensation expense in relation to the stock options (except for those
repurchased by the Group as described in Note 17(d)) recognized in the six months ended June 30, 2019 was RMB365,330, included in administrative expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the stock options activities of 2018 plan for the six months ended June&nbsp;30, 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Number&nbsp;of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Weighted</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">average</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">exercise</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">price</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">US$</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Weighted</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">average</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">remaining</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">contractual</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">term</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Aggregate</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">intrinsic</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">value</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">US$</P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of January&nbsp;1, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,893,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repurchased (Note 17 (d))</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(454,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,438,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,438,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock options granted to a director of the Group were measured at fair value on the dates of grant using the Binomial Option
Pricing Model with the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="28%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56.307</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate (per annum)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.752</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise multiple</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contractual term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The expected volatility was estimated based on the historical volatility of comparable peer public companies with a time
horizon close to the expected term of the Group&#146;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of the Group&#146;s
options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As the Group did not
have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as the Group has never declared or paid any cash dividends on its
shares, and the Group does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(d)
Repurchase of share awards held by a director </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;22, 2019, the amendment and restated 2017 equity incentive plan was approved by the
Board of Directors of the Group, pursuant to which only the 3,435,215 stock options held by a director of the Group under the 2017 equity incentive plan became fully vested and exercisable on February&nbsp;22, 2019. As a result of the performance
condition being waived, the shares held by a director of the Group were accounted for as a Type III </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-97 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. SHARE-BASED COMPENSATION&nbsp;(CONTINUED) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(d)
Repurchase of share awards held by a director&nbsp;(continued) </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
modification where a condition that the Group expects will not be satisfied is changed to a condition that the Group expects will be satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, on the same day, the Group repurchased such 3,435,215 stock options under the amendment and restated 2017 equity incentive plan that was held by
a director of the Group along with 454,940 of his stock options under the 2018 equity incentive plan for which the share awards also became fully vested and exercisable, at a total consideration of US$21,902 (equivalent to approximately RMB148,308)
at an average share price of US$5.63 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group recorded the total payment of US$21,902 (equivalent to approximately RMB148,308) as share-based
compensation costs (included in administrative expenses) in the interim condensed statement of comprehensive loss. There was no impact to the overall stockholder&#146;s equity balance as the amended shares vested immediately and were repurchased.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. LICENSING AND COLLABORATION ARRANGEMENTS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following is a description of the Group&#146;s significant licensing and collaboration agreements entered into for the six months ended June&nbsp;30, 2018 and 2019. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with MorphoSys AG (&#147;MorphoSys&#148;) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2017, the Group entered into a license and collaboration agreement with MorphoSys, with respect to the development and commercialization of
MOR202/TJ202, MorphoSys&acute;s proprietary investigational antibody against CD38 (the &#147;CD38 product&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under this agreement, MorphoSys granted
to the Group an exclusive, royalty-bearing, sublicensable license to exploit MOR202/TJ202 for any human therapeutic or diagnostic purpose in the licensed territory, namely mainland China, Hong Kong, Macau and Taiwan (collectively &#147;Greater
China&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to this agreement, the Group granted to MorphoSys an exclusive license to its rights in any inventions that the Group make while
exploiting the CD38 product under this agreement, solely to exploit the CD38 product outside of Greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to this agreement, the Group paid
to MorphoSys an upfront license fee of US$20.0&nbsp;million (equivalent to approximately RMB132.7 million). The Group also agreed to make milestone payments to MorphoSys, conditioned upon the achievement of certain development, regulatory and
commercial milestones, in the aggregate amount of US$98.5&nbsp;million (equivalent to approximately RMB653.5 million). Such milestones include first patient dosed in human clinical trials, marketing approval, and first annual net sales of CD38
products covered by the agreement in excess of a certain amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Group is required to pay tiered
<FONT STYLE="white-space:nowrap">low-double-digit</FONT> royalties to MorphoSys on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis during the term, commencing with the first commercial sale of a relevant licensed product in Greater China. Unless terminated earlier in accordance with the terms thereof, this
agreement will remain in effect until the expiration of the Group&#146;s last payment obligation under the agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-98 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. LICENSING AND COLLABORATION ARRANGEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements&nbsp;(continued)
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2017, the Group paid US$20.0&nbsp;million (equivalent to approximately RMB132.7 million) upfront fee to
MorphoSys, which was recorded as research and development expense in the consolidated statements of comprehensive loss. No additional payments were made in 2018. Due to the uncertainty involved in meeting these development and commercialization
based targets, the Group evaluated and concluded that the remaining milestones are still not probable as of December&nbsp;31, 2018. In March and April 2019, the project achieved the first and second milestone and the Group paid US$8.0&nbsp;million
(equivalent to approximately RMB54.9 million) of milestone fees to MorphoSys, which was recorded as research and development expense in the interim condensed consolidated statements of comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Summarized financial information related to the above agreement is presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Six months ended June&nbsp;30</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">As&nbsp;of&nbsp;June&nbsp;30</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Research and Development Expense</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Upfront&nbsp;Fees</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Milestones</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Extension/<BR>Termination<BR>of<BR>agreements</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Amortization<BR>of prepaid<BR>research and<BR>development</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Intangible<BR>asset balance</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with Genexine, Inc. (&#147;Genexine&#148;) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2017, the Group entered into an intellectual property license agreement with Genexine with respect to
<FONT STYLE="white-space:nowrap">GX-I7/TJ107,</FONT> a long-acting <FONT STYLE="white-space:nowrap">IL-7</FONT> cytokine. Under this agreement, the Group obtained an exclusive, sublicensable and transferable license to use and otherwise exploit
certain intellectual property in connection with the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical development, manufacturing, sale and distribution of GX-I7 to treat cancer in Greater China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, the Group made an upfront payment of US$12.0&nbsp;million (equivalent to approximately RMB79.6 million) to Genexine which
was recorded as a research and development expense in January 2018. The Group also agreed to make milestone payments in the aggregate amount of US$23.0&nbsp;million (equivalent to approximately RMB152.6 million), conditioned upon the achievement of
certain development milestones, including completion of Phase 2 and Phase 3 clinical studies and new drug application (&#147;NDA&#148;) or biologic license application (&#147;BLA&#148;) approval in Greater China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, the Group agreed to make milestone payments in the aggregate amount of US$525.0&nbsp;million (equivalent to approximately RMB3,482.7 million),
conditioned upon the achievement of certain cumulative net sales of GX<I>-I7 </I>up to US$2,000&nbsp;million. The Group also is required to pay Genexine a <FONT STYLE="white-space:nowrap">low-single-digit</FONT> percentage royalty in respect of the
total annual net sales of <FONT STYLE="white-space:nowrap">GX-I7.</FONT> The aforesaid milestones and royalties (other than the upfront payment) will be reduced by 50% following the entry of a generic version of
<FONT STYLE="white-space:nowrap">GX-I7</FONT> in China, Hong Kong, Macau and Taiwan without the consent or authorization of the Group or any of the Group&#146;s sublicensees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect until the later of (i)&nbsp;the expiry of the last to
expire patent of the licensed intellectual property that includes a valid claim for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-99 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. LICENSING AND COLLABORATION ARRANGEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements&nbsp;(continued)
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Greater China and that covers the composition of GX-I7; and (ii) 15 years from the date of the first commercial sale of <FONT STYLE="white-space:nowrap">GX-I7.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No additional payments to Genexine were made in the six months ended June&nbsp;30, 2019. Due to the uncertainty involved in meeting these development and
commercialization based targets, the Group evaluated and concluded that the remaining milestones are still not probable as of December&nbsp;31, 2018 and June&nbsp;30, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Summarized financial information related to the above agreement is presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Six months ended June&nbsp;30</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">As&nbsp;of&nbsp;June&nbsp;30</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Research and Development Expense</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Upfront Fees</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Milestones</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Extension/<BR>Termination<BR>of<BR>agreements</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Amortization<BR>of prepaid<BR>research and<BR>development</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Intangible<BR>asset&nbsp;balance</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with MorphoSys </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2018, the Group entered into a license and collaboration agreement with MorphoSys for MorphoSys&acute;s proprietary antibody (MOR210/TJ210)
directed against C5aR (the &#147;C5aR Agreement&#148;). Under this agreement, the Group obtained an exclusive, royalty-bearing license to explore, develop and commercialize certain anti-C5aR antibodies in Greater China and South Korea. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group will perform and fund all global development activities related to the development of MOR210/TJ210 in Greater China and South Korea, including all
relevant clinical trials (including in the U.S. and China) and all development activities required for IND filing in the US as well as CMC development of manufacturing processes. MorphoSys retains rights in respect of development and
commercialization of MOR210/TJ210 in the rest of the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, the Group also agreed to make milestone payments
conditional upon the achievement of certain development milestones and certain annual net sales of anti-C5aR antibodies. The Group is also required to pay to MorphoSys tiered <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> royalties on
annual net sales of anti-C5aR antibody products within the licensed territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2018 the Group paid US$3.5&nbsp;million (equivalent to approximately
RMB23.2 million) upfront fee to MorphoSys, which was recorded as research and development expense in the interim condensed consolidated statements of comprehensive loss. No additional payments were made in the six months ended in June&nbsp;30, 2019.
Due to the uncertainty involved in meeting these development and commercialization based targets, the Group evaluated and concluded that the remaining milestones are still not probable as of December&nbsp;31, 2018 and as of June&nbsp;30, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-100 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. LICENSING AND COLLABORATION ARRANGEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements&nbsp;(continued)
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the above arrangements, the Group has entered into other various <FONT STYLE="white-space:nowrap">in-licensing</FONT> and collaboration
agreements with third party licensors to develop and commercialize drug candidates. Based on the terms of these agreements the Group is contingently obligated to make additional material payments upon the achievement of certain contractually defined
milestones. The Group did not make any upfront or milestone payment under these agreements for the six months ended June&nbsp;30, 2018, and made US$0.2&nbsp;million (equivalent to approximately RMB1.4 million) during the six months ended
June&nbsp;30, 2019. Under the terms of the agreements, the licensors are eligible to receive from the Group up to an aggregate of approximately US$164.1&nbsp;million (equivalent to approximately RMB1,088.6 million) in milestone payments upon the
achievement of contractually specified development milestones, such as regulatory approval for the drug candidates, which may be before the Group has commercialized the drug or received any revenue from sales of such drug candidate, which may never
occur. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and collaboration Arrangements
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement among HDYM, <FONT STYLE="white-space:nowrap">I-Mab</FONT> and Hangzhou HealSun Biopharm Co., Ltd.
(&#147;HealSun&#148;) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2017, one of the Company&#146;s subsidiaries, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai, entered into a
technology transfer agreement with HDYM and HealSun with respect to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> humanized monoclonal antibodies. Under the agreement,
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai agreed to grant to HDYM exclusive, worldwide and sublicensable rights to develop, manufacture, have manufactured, use, sell, have sold, import, or otherwise exploit certain <FONT
STYLE="white-space:nowrap">PD-L1</FONT> related patents, patent applications, know-hows, data and information of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai, relevant cell lines as well as any <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> monoclonal antibody arising from such cell lines for the treatment of diseases. Further, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai and its cooperative party, HealSun agreed to provide
subsequent research and development services on such intellectual property to HDYM, including the selection and examination of innovative <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> humanized monoclonal
antibodies, cultivation and selection of stable cell lines, establishment of cell bank, research and development of manufacturing processes and preparation of samples, toxicological and pharmacological testing,
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> pharmaceutical experiment report drafting, and application for and registration of clinical trials. HDYM agreed to make milestone payments conditioned upon achieving certain contractually defined
milestones. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group determined that this collaboration is more reflective of a vendor-customer relationship and therefore within the scope of ASC 606.
Under this agreement, due to the early stage nature of the development, the Group determined the license to the intellectual property and research and development services are not distinct and thus were accounted for as a single performance
obligation that is satisfied over time. The Group would receive RMB51.0&nbsp;million (inclusive of VAT) milestone payments under this agreement, and considered that the achievements of milestone II, III, IV are constrained such that the transaction
price shall initially only include the milestones payment which have been achieved (that means when uncertainty associated with the variable consideration is subsequently resolved), the additional milestone payment shall be included in the total
transaction price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group used a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> input method to measure progress as that method best depicts its performance under the agreement. For the year ended December&nbsp;31, 2017, the Group achieved
milestones I and II and received milestone payments totaling of RMB29.0&nbsp;million (inclusive of VAT). The cumulative percentage </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-101 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. LICENSING AND COLLABORATION ARRANGEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and collaboration Arrangements&nbsp;(continued)
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
complete in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> input method related to this agreement as of December&nbsp;31, 2017 is estimated to
approximate 42%, the Group recognized RMB11.6&nbsp;million (exclusive of VAT of RMB0.7 million) of revenue in the consolidated statements of comprehensive loss, and RMB15.8&nbsp;million (exclusive of VAT of RMB0.9 million) were deferred as contract
liability related to this arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2018, the Group achieved milestones III and IV and received milestone III payment of RMB11.0&nbsp;million
(inclusive of VAT), which was recognized as contract assets as of December&nbsp;31, 2018. As of December&nbsp;31, 2018, the cumulative percentage complete in the <FONT STYLE="white-space:nowrap">cost-to</FONT> cost input method related to this
arrangement is estimated to approximate 100%. The Group recognized RMB36.5&nbsp;million (exclusive of VAT of RMB1.3 million) of revenue in the interim condensed consolidated statements of comprehensive loss for the year ended December&nbsp;31, 2018.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration Agreement with Everest (&#147;Everest&#148;) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2018, the Group entered into a collaboration agreement with Everest, which is controlled by the ultimate controlling party of a principal
shareholder of the Group. Under the agreement, both parties agreed to collaborate on programs to <FONT STYLE="white-space:nowrap">co-develop</FONT> MorphoSys&#146; proprietary anti-CD38 antibody for all indications in hematologic oncology and
commercialize of MOR202/TJ202 in Greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A joint steering committee with equal representation from each party was established to coordinate and
oversee the development and commercialization of the CD38 product. All decisions of the joint steering committee shall be made by unanimous vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under
the agreement, the Group is primarily responsible for carrying out the development, manufacture and supply of the CD38 product, as well as seeking regulatory approval of the CD38 product. Everest is primarily responsible for sharing the development
costs of the CD38 product, including payments due to MorphoSys under the Licensing Agreement, dated November&nbsp;30, 2017, in the proportion of 75% by Everest and 25% by the Group. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The joint steering committee will decide which party shall be responsible for conducting the commercialization of the CD38 product pursuant to the
commercialization plan approved by the committee. If Everest is selected to be responsible for commercialization, the Group shall grant an exclusive royalty-free license to Everest to commercialize the CD38 product for all indications in hematologic
oncology in Greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group and Everest will share the profit and loss and <FONT STYLE="white-space:nowrap">out-licensing</FONT> revenue derived
from the CD 38 product in proportion to the costs that each party incur in developing the product. The parties will also split <FONT STYLE="white-space:nowrap">out-license</FONT> revenue according to the proportion of development costs incurred,
with the Group getting an additional five percent (5%) share and Everest receiving five percent (5%) less. Everest cannot share in any profit from the commercialization of CD38 product until it has fulfilled its payment obligations under this
agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon any termination of this arrangement, the terminating party has the right to continue the development and commercialization of CD38
product. If Everest is the rightful terminating party, the Group shall reasonably cooperate with Everest to facilitate the following: (i)&nbsp;assign the MorphoSys license to Everest (subject to the terms and conditions of such license); (ii) grant
to Everest an exclusive license to all intellectual property rights that the Group owns or controls to further develop, manufacture, and commercialize the CD38 product; (iii)&nbsp;transfer the development, manufacture and commercialization of the
CD38 product to Everest. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-102 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. LICENSING AND COLLABORATION ARRANGEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and collaboration Arrangements&nbsp;(continued)
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
terminating party shall be solely responsible for the cost and expense of such development and commercialization after termination. In the event that such continuing party successfully develops
and commercializes the CD38 product, it shall pay to the other party a percentage of the product profit and <FONT STYLE="white-space:nowrap">out-license</FONT> revenue generated therefrom in accordance with the terms of this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The US$26.0&nbsp;million (equivalent to approximately RMB178.7 million) in aggregate proceeds from Everest under the agreement represented the full funding
available under the agreement, and was recorded as a research and development funding received liability on the consolidated balance sheet as of December&nbsp;31, 2018, in accordance with ASC 730, Research and Development. Because there is a
significant related party relationship between the Group and Everest, the Group is treating its obligation to make payments under the commercialization stage as an implicit obligation to repay the funds advanced by Everest (see Note 23). During the
six months ended June&nbsp;30, 2019, an additional US$7.6&nbsp;million (equivalent to approximately RMB51.6 million) of funding was received and recorded as a research and development funding received liability, resulting in a total balance of
US$33.6&nbsp;million (equivalent to approximately RMB 231.4 million) as of June&nbsp;30, 2019. No additional milestone has been achieved in the six months ended June&nbsp;30, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with ABL Bio </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2018, the Group
entered into a license and collaboration agreement with ABL Bio, under which the Group granted to ABL Bio exclusive, worldwide (excluding Greater China), royalty-bearing rights to develop and commercialize a bispecific antibody (&#147;BsAb&#148;).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group agreed to share costs fifty-fifty (50:50) with ABL Bio through the completion of in vivo studies, with ABL Bio responsible for all costs and
activities following that time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In consideration of the license, ABL Bio agreed to pay the Group an upfront fee of US$2.5&nbsp;million (equivalent to
approximately RMB17.2 million), and milestone payments in the aggregate amount of US$97.5&nbsp;million (equivalent to approximately RMB646.8 million) conditioned upon achieving certain research, clinical development and sales milestones. These
include research milestones of up to US$2.5 (equivalent to approximately RMB17.2) million, clinical milestones of up to US$30&nbsp;million (equivalent to approximately RMB199.0 million) and sales milestones of up to US$65&nbsp;million (equivalent to
approximately RMB431.2 million). Further, ABL Bio agreed to pay the Group royalties at <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> percentages in respect of the total annual net sales of the licensed BsAb product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, ABL Bio granted to the Group an exclusive, royalty-free, sublicensable license to use the BsAb technology solely to exploit the licensed BsAb
product for all indications in Greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group determined that this collaboration is more reflective of a vendor-customer relationship and
therefore within the scope of ASC 606. Under this agreement, the only one performance obligation was to grant the BsAb license to ABL Bio, considering that the achievements of milestones are constrained such that the transaction price shall
initially only include upfront payment and subsequently, once another milestone was achieved (that means when uncertainty associated with the variable consideration is subsequently resolved), the additional milestone payment shall be included in the
total transaction price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-103 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. LICENSING AND COLLABORATION ARRANGEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and collaboration Arrangements&nbsp;(continued)
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018 and as of June&nbsp;30, 2019, no milestone has been achieved, and the Group
recognized revenue of US$2.5&nbsp;million (equivalent to RMB17.2 million) in the consolidated statements of comprehensive loss for the year ended December&nbsp;31, 2018, which was the upfront fee related to the grant of the rights of BsAb to ABL Bio
as mentioned above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration Agreement with ABL Bio </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2018, the Group and ABL Bio entered into a collaboration agreement (the &#147;ABL Bio Collaboration&#148;) whereby both parties agreed to collaborate
to develop three <FONT STYLE="white-space:nowrap">PD-L1</FONT> based bispecific antibodies by using ABL Bio&#146;s proprietary BsAb technology and commercialize them in their respective territories, which, collectively, include Greater China and
South Korea, and other territories throughout the rest of the world if both parties agree to do so in such other territories during the performance of the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At contract inception, as both <FONT STYLE="white-space:nowrap">I-Mab</FONT> and ABL Bio participate actively in the research and development activity. Also,
the parties share the risk of failure of the BsAb products and share the income of licensing, so this contract meet the criteria of the definition of a collaborative arrangement, the Group categorized this agreement within the scope ASC 808. Prior
to commercialization, the Group recorded the share of the expenses incurred by the collaboration for the development of three <FONT STYLE="white-space:nowrap">PD-L1</FONT> based bispecific antibodies products in research and development expense in
the interim condensed consolidated statements of comprehensive loss. For the six months ended<B> </B>June&nbsp;30, 2019, RMB3.49&nbsp;million expenses were incurred by the Group and RMB3.41&nbsp;million expenses were incurred by ABL. According to
the terms set out in the agreement, the Group recorded RMB3.45&nbsp;million (50% cost sharing) of expenses in the Group&#146;s interim condensed consolidated statements of comprehensive loss for the six months ended<B> </B>June&nbsp;30, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration Agreements with Tracon Pharmaceuticals, Inc. (&#147;Tracon&#148;) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2018, the Group entered into collaboration agreements with Tracon, under which both parties agreed to
<FONT STYLE="white-space:nowrap">co-develop</FONT> the Group&#146;s proprietary CD73 antibody, TJD5 (the &#147;TJD5 Agreement&#148;) and <FONT STYLE="white-space:nowrap">co-develop</FONT> up to five BsAbs (the &#147;BsAbs Agreement&#148;). As of
June&nbsp;30, 2019, the Group has recorded US$0.6&nbsp;million (equivalent to RMB4.4 million) of research and development costs in the interim condensed consolidated statements of comprehensive loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with CSPC Pharmaceutical Group Limited (&#147;CSPC&#148;) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2018, the Group entered into a product development agreement with CSPC. The Group granted to CSPC exclusive,
<FONT STYLE="white-space:nowrap">non-transferable,</FONT> <FONT STYLE="white-space:nowrap">non-irrevocable</FONT> and sublicensable rights in the PRC (excluding Hong Kong, Macau and Taiwan) to develop and commercialize TJ103 for treating type 2
diabetes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CSPC is responsible for developing, obtaining market approval and commercializing the licensed products. The Group is responsible for
transferring the manufacturing technology of the licensed products to CSPC and assisting CSPC in the continued optimization of such manufacturing technology thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In consideration of the license, CSPC agreed to pay the Group an upfront fee of RMB15.0&nbsp;million and milestone payments in an aggregate amount of
RMB135.0&nbsp;million conditioned upon achieving certain clinical development </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-104 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. LICENSING AND COLLABORATION ARRANGEMENTS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and collaboration Arrangements&nbsp;(continued)
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and regulatory approval milestones. In addition, the Group is also entitled to royalties of up to <FONT STYLE="white-space:nowrap">low-double-digit</FONT> percentages in respect of the total
annual net sales of the products after its commercialization in the PRC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group determined that this collaboration is more reflective of a
vendor-customer relationship and therefore within the scope of ASC 606. Under this agreement, the only one performance obligation was to grant TJ103 license to CSPC. considering that the achievements of milestones are constrained such that the
transaction price shall initially only include upfront payment and subsequently, once another milestone was achieved (that means when uncertainty associated with the variable consideration is subsequently resolved), the additional milestone payment
shall be included in the total transaction price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. As of December&nbsp;31, 2018, the amount received of RMB14.2&nbsp;million (net of VAT)
was recorded as advance from customers in the consolidated balance sheets. In February 2019, an additional amount of RMB0.8&nbsp;million (net of VAT) was received, and the license was also approved by China intellectual property office in May 2019.
Accordingly, total RMB15.0&nbsp;million was recognized as revenue in the interim condensed consolidated statements of comprehensive loss for the six months ended June&nbsp;30, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19. OTHER INCOME (EXPENSES), NET </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table
summarizes other income (expense) recognized for the six months ended June&nbsp;30, 2018 and 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from conversion of 2017 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from conversion of Onshore Convertible Loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,865</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from issuance of 2018 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,893</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net foreign exchange gains (losses)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(759</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subsidy income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(508</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">(21,594)</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-105 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20. NET LOSS PER SHARE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share for each of the periods presented are calculated as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended June&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center">(in&nbsp;thousands,&nbsp;except&nbsp;for&nbsp;loss per&nbsp;shares)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to ordinary shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(166,720</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(857,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of ordinary shares outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,397,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,184,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,184,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26.06</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17.38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the six months ended June&nbsp;30, 2018 and 2019, the effects of all outstanding convertible preferred shares, restricted
shares, warrants and certain stock options have been excluded from the computation of diluted loss per share for the six months ended June&nbsp;30, 2018 and 2019 as their effects would be anti-dilutive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the six months ended June&nbsp;30, 2018 and 2019, the Company also has certain dilutive potential stock options. These stock options which cannot be
exercised until the Company completes its listing are not included in the computation of diluted earnings per shares as such contingent event had not taken place. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The potentially dilutive securities that have not been included in the calculation of diluted net loss per share as their inclusion would be anti-dilutive are
as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended June&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,869,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,578,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,848,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,167,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">252,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,803,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21. EMPLOYEE BENEFITS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Full time employees of the Group in the PRC participate in a government mandated defined contribution plan, pursuant to which certain pension benefits, medical
care, employee housing fund and other welfare benefits are provided to the employees. Chinese labor regulations require that the PRC subsidiaries of the Group make contributions to the government for these benefits based on certain percentage of the
employees&#146; salaries, up to a maximum amount specified by the government. The Group has no legal obligation for the benefits beyond the contribution made. The total amounts charged to the interim condensed consolidated statements of
comprehensive loss for such employee benefits amounted to approximately RMB 3,581 and RMB 5,204 for the six months ended June&nbsp;30, 2018 and 2019, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-106 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>22. COMMITMENTS AND CONTINGENCIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Capital commitments </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Contingencies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group
is a party to or an assignee of license and collaboration agreements that may require it to make future payments relating to milestone fees and royalties on future sales of licensed products (Note 18). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group did not have significant capital and other commitments, long-term obligations, or guarantees as of December&nbsp;31, 2018 and June 30, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23. RELATED PARTY BALANCES AND TRANSACTIONS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table
below sets forth the major related parties and their relationships with the Group as of December&nbsp;31, 2018 and June 30, 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name of related parties</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Relationship with the Group</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Everest Medicines Ltd. (&#147;Everest&#148;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Controlled by the ultimate controlling party of a principal shareholder of the
Group</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tasly Pharmaceutical Group Co., Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Controlled by the ultimate controlling party of a principal shareholder of the
Group</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of related party balance as of December&nbsp;31, 2018 and June 30, 2019 are as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and development funding received </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Everest (Note 18)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of related party transactions for the six months ended June 30, 2018 and 2019 are as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Receipt of CRO services&#151;recognized in research and development expenses </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tasly Pharmaceutical Group Co., Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-107 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23. RELATED PARTY BALANCES AND TRANSACTIONS&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Receipt of research and development funding </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Everest (Note 18)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>24. CONCENTRATION OF CREDIT RISK </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that are potentially subject to significant concentration of credit risk consist of cash and cash equivalents, restricted cash, other
financial assets, contract assets and other receivables. The carrying amounts of cash and cash equivalents, restricted cash and other financial assets represent the maximum amount of loss due to credit risk. As of December&nbsp;31, 2018 and June 30,
2019, all of the Group&#146;s cash and cash equivalents and restricted cash were held by major financial institutions located in the PRC and international financial institutions outside of the PRC which management believes are of high credit quality
and continually monitors the credit worthiness of these financial institutions. With respect to the contract assets, other receivables and other financial assets, the Group performs <FONT STYLE="white-space:nowrap">on-going</FONT> credit evaluations
of the financial condition of its customers and counterparties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>25. SUBSEQUENT EVENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group evaluated subsequent events through September 5, 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In July 2019, the Group granted 640,000 stock options and 3,098,500 stock options to the employees under 2017
Plan and 2018 Plan, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On July&nbsp;25, 2019, the Group entered into a share purchase agreement with certain third party investors,
under which these investors will subscribe for an aggregate of 3,857,143 Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred shares of the Company for an aggregate purchase price of US$27.0&nbsp;million. Up to the issuance of
these interim condensed consolidated financial statements, this transaction has not been consummated. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">According to the confirmations issued by the Company&#146;s Series B Warrants holders in July 2019, the holders
of Series B Warrants have unconditionally and irrevocably waived and cancelled the Tranche II of Series B Warrants. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In July 2019, the Group entered into an <FONT STYLE="white-space:nowrap">in-licensing</FONT> and collaboration
agreement with MacroGenics, Inc. for development and commercialization of an <FONT STYLE="white-space:nowrap">Fc-optimized</FONT> antibody known as enoblituzumab that targets <FONT STYLE="white-space:nowrap">B7-H3,</FONT> including in combination
with other agents, such as the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody known as MGA012, in Greater China. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26. UNAUDITED PRO FORMA BALANCE SHEET AND NET LOSS PER SHARE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma balance sheet information as of June&nbsp;30, 2019 assumes the automatic conversion of all of the outstanding Preferred Shares into
ordinary shares at a conversion ratio of 1:1 and forfeiture of Tranche II of Series B Warrants, as if the conversion and expiry had occurred as of June&nbsp;30, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-108 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(All amounts in thousands, except for share and per share data, unless otherwise noted) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26. UNAUDITED PRO FORMA BALANCE SHEET AND NET LOSS PER SHARE&nbsp;(CONTINUED) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma net loss per ordinary share is computed using the weighted-average number of ordinary
shares outstanding and assumes forfeiture of Tranche II of Series B Warrants and the automatic conversion of all of the Group&#146;s outstanding mezzanine equity into ordinary shares upon the closing of the Group&#146;s Qualified Public Offering, as
if it had occurred on January&nbsp;1, 2019. The Group believes the unaudited pro forma net loss per share provides material information to investors, as the automatic conversion of the Group&#146;s outstanding mezzanine equity and forfeiture of
Tranche II of Series B Warrants and the disclosure of pro forma net loss per ordinary share provides an indication of net loss per ordinary share that is comparable to what will be reported by the Group as a public company following the closing of
the Qualified Public Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the unaudited pro forma net loss per share attributable to ordinary shareholders: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="2" ALIGN="center"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Note 2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">(in&nbsp;thousands,&nbsp;except&nbsp;for&nbsp;loss<BR>per&nbsp;shares)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to ordinary shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(857,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Add back fair value change of Tranche II of Series B Warrants (Note 15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator for <FONT STYLE="white-space:nowrap">pro-forma</FONT> basic and diluted net loss per
share</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(813,483</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(118,498</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of ordinary shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,184,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,184,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pro-forma</FONT> effect of the conversion of Series A Preferred
Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,227,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,227,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pro-forma</FONT> effect of the conversion of Series B Preferred
Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,305,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,305,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pro-forma</FONT> effect of the conversion of Series C Preferred
Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,046,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,046,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator for <FONT STYLE="white-space:nowrap">pro-forma</FONT> basic and diluted net loss
per share</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,762,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,762,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pro-forma</FONT> net loss per share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma balance sheets and loss per share excluded the impacts of the Group&#146;s share-based awards that
subject to IPO conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-109 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Page intentionally left blank for graphics] </P>
<P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;6. INDEMNIFICATION OF DIRECTORS AND OFFICERS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cayman Islands law does not limit the extent to which a company&#146;s articles of association may provide for indemnification of officers and
directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The post-offering memorandum and articles of association that we expect to adopt and to become effective immediately prior to the completion
of this offering provide that we shall indemnify our directors and officers (each, an indemnified person) against all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by such indemnified person,
other than by reason of such person&#146;s own dishonesty, willful default or fraud, in or about the conduct of our company&#146;s business or affairs (including as a result of any mistake of judgment) or in the execution or discharge of his or her
duties, powers, authorities or discretions, including, without prejudice to the generality of the foregoing, any costs, expenses, losses or liabilities incurred by such indemnified person in defending (whether successfully or otherwise) any civil
proceedings concerning our company or its affairs in any court whether in the Cayman Islands or&nbsp;elsewhere. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the
indemnification agreements the form of which is filed as Exhibit 10.3 to this registration statement, we agree to indemnify our directors and executive officers against certain liabilities and expenses incurred by such persons in connection with
claims made by reason of their being such a director or officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriting agreement, the form of which will be filed as
Exhibit&nbsp;1.1 to&nbsp;this registration statement, will also provide indemnification for us and our officers and directors for certain liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us
pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;7. RECENT SALES OF UNREGISTERED SECURITIES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the past three years, we have issued the following securities. We believe that each of the following issuances was exempt from
registration under the Securities Act pursuant to Section&nbsp;4(2) of the Securities Act regarding transactions not involving a public offering or in reliance on Regulation S under the Securities Act regarding sales by an issuer in offshore
transactions. No underwriters were involved in these issuances of securities. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Securities/Purchaser</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Date of Sale or<BR>Issuance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Number&nbsp;of&nbsp;Securities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Consideration</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Ordinary shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offshore Incorporations (Cayman) Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;30, 2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$0.0001</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mabcore Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;30, 2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4,019,553</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$401.9553</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BioScikin Co., Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">October&nbsp;18,&nbsp;2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2,215,803</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">RMB1,000,000</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hangzhou Tigermed Consulting Co., Ltd</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">October&nbsp;18, 2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2,215,803</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">RMB15,000,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Convertible promissory notes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CBC Investment <FONT STYLE="white-space:nowrap">I-Mab</FONT> Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">September&nbsp;25,&nbsp;2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$12,100,000 (due&nbsp;September&nbsp;2020)</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Securities/Purchaser</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Date of Sale or Issuance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Number&nbsp;of&nbsp;Securities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Consideration</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">February&nbsp;9,&nbsp;2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$1,550,000 (due&nbsp;September 2020)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Qianhai Ark (Cayman) Investment Co. Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;6, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$1,250,000 (due&nbsp;July 2021)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Genexine Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">February&nbsp;5,&nbsp;2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$9,000,000 (due&nbsp;February 2021)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IBC Investment Seven Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">October&nbsp;18,&nbsp;2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4,629,231</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$4,629,231</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IBC Investment Seven Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">October&nbsp;18,&nbsp;2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">512,356</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$8,447,692</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Series <FONT STYLE="white-space:nowrap">A-3</FONT> preferred shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CBC SPVII LIMITED</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">September&nbsp;6,&nbsp;2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8,361,823</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$15,000,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Genexine, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">September&nbsp;6,&nbsp;2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8,361,823</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$15,000,000</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tasly Biopharm Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;29, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8,361,823</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Tasly Biopharm Limited&#146;s equity interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Series B preferred shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CBC Investment <FONT STYLE="white-space:nowrap">I-Mab</FONT> Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">September&nbsp;22,&nbsp;2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14,089,714</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$48,400,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">February&nbsp;9,&nbsp;2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,804,880</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$6,200,000</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tasly Biopharm Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;29, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5,938,640</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Tasly Biopharm Limited&#146;s equity interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Qianhai Ark (Cayman) Investment Co. Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;6, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,455,549</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$2,035,667</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CBC Investment <FONT STYLE="white-space:nowrap">I-Mab</FONT> Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;29, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2,247,321</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Conversion of US$12,100,000 convertible promissory note due September 2020</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;29, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">287,880</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Conversion of US$1,550,000 convertible promissory note due September 2020</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tasly Biopharm Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;29, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">947,218</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Tasly Biopharm Limited&#146;s equity interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Qianhai Ark (Cayman) Investment Co. Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;6, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">232,161</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Conversion of US$1,250,000 convertible promissory note due July 2021</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CBC Investment <FONT STYLE="white-space:nowrap">I-Mab</FONT> Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;29, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,997,618</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$12,100,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">June&nbsp;29, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">255,894</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$1,550,000</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rainbow Horizon Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;6, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">841,971</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$5,100,000</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Securities/Purchaser</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Date of Sale or Issuance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Number&nbsp;of&nbsp;Securities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Consideration</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Qianhai Ark (Cayman) Investment Co. Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;6, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">206,366</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$1,250,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Series C preferred shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fortune Eight Jogging Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;6, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8,537,749</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$55,000,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Seven Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;6, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6,209,272</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$40,000,000</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HH IMB Holdings Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;6, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3,104,636</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$20,000,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ally Bridge LB Precision Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;6, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3,104,636</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$20,000,000</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marvey Investment Company Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;6, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3,104,636</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$20,000,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mab Health Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;6, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,862,782</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$12,000,000</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Casiority H Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;6, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,241,854</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$8,000,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Southern Creation Limited (formerly known as Ally Bridge
<FONT STYLE="white-space:nowrap">LB-Sunshine</FONT> Limited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;6, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,552,318</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$10,000,000</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tasly International Capital Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;6, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,552,318</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$10,000,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parkway Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;6, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">776,159</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$5,000,000</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Options and Warrants</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IBC Investment Seven Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">October&nbsp;18, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Warrant to purchase up to 2,246,744 Series <FONT STYLE="white-space:nowrap">A-3</FONT> preferred shares*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">N/A</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shanghai Tasly Pharmaceutical Co., Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">September&nbsp;6, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Option to purchase up to 8,361,823 Series <FONT STYLE="white-space:nowrap">A-3</FONT> preferred shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">N/A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shanghai Tasly Pharmaceutical Co., Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">September&nbsp;25, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Option to purchase up to 5,938,640 Series B preferred shares and 947,218 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">N/A</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Qianhai Equity Investment Fund (Limited Partnership)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">September&nbsp;25, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Option to purchase up to 1,455,549 Series B preferred shares and up to 232,161 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">N/A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tianjin Kangshijing Biopharmaceutical Technology Partnership (Limited Partnership)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">September&nbsp;25, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Option to purchase up to 1,804,880 Series B preferred shares and up to 287,880 additional Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred Shares**</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">N/A</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CBC Investment <FONT STYLE="white-space:nowrap">I-Mab</FONT> Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">September&nbsp;25, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Warrant to purchase up to 4,994,046 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">N/A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shanghai Tasly Pharmaceutical Co., Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">September&nbsp;25, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Warrant to purchase up to 2,104,928 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">N/A</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Qianhai Equity Investment Fund (Limited Partnership)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">September&nbsp;25, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Warrant to purchase up to 515,914 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">N/A</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Securities/Purchaser</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Date of Sale or Issuance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Number&nbsp;of&nbsp;Securities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Consideration</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">September&nbsp;25,<BR>2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Warrant to purchase up to 639,734 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">N/A</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certain directors, officers and employees and consultants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">October 2017<BR>to February<BR>2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Options to purchase 24,934,330 ordinary shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Past and future services to us</TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This warrant was cancelled on September&nbsp;6, 2017. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This option was terminated on February&nbsp;9, 2018. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Exhibits </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See Exhibit Index beginning on page <FONT STYLE="white-space:nowrap">II-4</FONT> of this registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreements included as exhibits to this registration statement contain representations and warranties by each of the parties to the
applicable agreement. These representations and warranties were made solely for the benefit of the other parties to the applicable agreement and (i)&nbsp;were not intended to be treated as categorical statements of fact, but rather as a way of
allocating the risk to one of the parties if those statements prove to be inaccurate; (ii)&nbsp;may have been qualified in such agreement by disclosure that was made to the other party in connection with the negotiation of the applicable agreement;
(iii)&nbsp;may apply contract standards of &#147;materiality&#148; that are different from &#147;materiality&#148; under the applicable securities laws; and (iv)&nbsp;were made only as of the date of the applicable agreement or such other date or
dates as may be specified in the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We acknowledge that, notwithstanding the inclusion of the foregoing cautionary statements, we
are responsible for considering whether additional specific disclosure of material information regarding material contractual provisions is required to make the statements in this registration statement not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Financial Statement Schedules </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the Consolidated
Financial Statements or the Notes thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9. UNDERTAKINGS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes to provide to the underwriter at the closing specified in the underwriting agreements,
certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each&nbsp;purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
the registrant pursuant to the provisions described in Item&nbsp;6, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of
any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such&nbsp;issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For purposes of determining any liability under the Securities Act, the information omitted from the form of
prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of
this registration statement as of the time it was declared effective. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purpose of determining any liability under the Securities Act, each post-effective amendment that
contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Index </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD WIDTH="84%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description of Document</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fourth Amended and Restated Memorandum and Articles of Association of the Registrant, as currently in effect</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Fifth Amended and Restated Memorandum and Articles of Association of the Registrant (effective upon the closing of this offering)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Registrant&#146;s Specimen American Depositary Receipt (included in Exhibit 4.3)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Registrant&#146;s Specimen Certificate for Ordinary Shares</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Deposit Agreement, among the Registrant, the depositary and holder of the American Depositary Receipt</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Third Amended and Restated Shareholders Agreement, dated as of July&nbsp;6, 2018, between the Registrant and other parties thereto</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Conyers Dill&nbsp;&amp; Pearman regarding the validity of the ordinary shares being registered and certain Cayman Islands tax matters</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;8.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Conyers Dill&nbsp;&amp; Pearman regarding certain Cayman Islands tax matters (included in Exhibit 5.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;8.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of JunHe LLP regarding certain PRC tax matters (included in Exhibit 99.2)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated 2017 Employee Stock Option Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated 2018 Employee Stock Option Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement, between the Registrant and its directors and executive officers</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Employment Agreement, between the Registrant and its executive officers</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Series C-1 Share Purchase Agreement, dated as of July 25, 2019, between the Registrant and the other parties thereto</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Series C Share Purchase Agreement, dated as of June&nbsp;28, 2018, between the Registrant and the other parties thereto</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Executed form of warrants to Purchase Series B Preferred Shares of I-Mab between the Registrant and certain investors, and a schedule of all executed warrants adopting the same form in respect of each of the investors</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Framework Agreement, dated as of May&nbsp;26, 2017, among the Registrant and the other parties thereto</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Re-organization</FONT> Framework Agreement, dated as of April&nbsp;18, 2018, among the Registrant and the other parties thereto</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Supplement to the <FONT STYLE="white-space:nowrap">Re-organization</FONT> Framework Agreement, dated as of May&nbsp;31, 2018, among the Registrant and the other parties thereto</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Re-organization</FONT> Framework Agreement, dated April&nbsp;4, 2018, among the Registrant and the other parties thereto</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description of Document</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12**</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Supplement to the <FONT STYLE="white-space:nowrap">Re-organization</FONT> Framework Agreement, dated as of May&nbsp;31, 2018, among the Registrant and the other parties thereto</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13**&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">License and Collaboration Agreement, dated as of November&nbsp;30, 2017, between the Registrant and MorphoSys AG</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Intellectual Property Assignment and License Agreement, dated as of October&nbsp;16, 2015, between Tasgen <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. and Genexine, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Intellectual Property License Agreement, dated as of December&nbsp;22, 2017, between the Registrant and Genexine, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">License and Sublicense Agreement, dated as of November&nbsp;4, 2016, between the Registrant and Ferring International Center SA</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17**&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Collaboration Agreement, dated as of July&nbsp;9, 2019, between <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma, US Limited and MacroGenics, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.18</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">License and Collaboration Agreement, dated as of July&nbsp;26, 2018, between the Registrant and ABL Bio</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.19</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">English translation of Product Development Agreement, dated as of December&nbsp;10, 2018, between <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai and CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.20</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CD38 Product Collaboration Agreement, dated as of January&nbsp;22, 2018, between the Registrant and Everest Medicines Limited</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.21</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Supplemental Agreement to CD38 Product Collaboration Agreement, dated as of November&nbsp;7, 2018, between the Registrant and Everest Medicines Limited</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1**</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Principal Subsidiaries of the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Consent of PricewaterhouseCoopers, an independent registered public accounting firm</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Consent of Conyers Dill&nbsp;&amp; Pearman (included in Exhibit 5.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.3*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Consent of JunHe LLP (included in Exhibit 99.2)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Powers of Attorney (included on signature page)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Code of Business Conduct and Ethics of the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Opinion of JunHe LLP regarding certain PRC law matters</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.3*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Consent of Frost&nbsp;&amp; Sullivan</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed by amendment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Previously filed. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form <FONT STYLE="white-space:nowrap">F-1</FONT> and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Shanghai, China, on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person whose signature appears below constitutes and appoints each of Joan Huaqiong Shen and Jielun Zhu as
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> with full power of substitution for him or her in any and all capacities to do any and all acts and all things and to execute any and all instruments
which said attorney and agent may deem necessary or desirable to enable the registrant to comply with the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), and any rules, regulations and requirements of the Securities and Exchange
Commission thereunder, in connection with the registration under the Securities Act of ordinary shares of the registrant (the &#147;Shares&#148;), including, without limitation, the power and authority to sign the name of each of the undersigned in
the capacities indicated below to the Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (the &#147;Registration Statement&#148;) to be filed with the Securities and Exchange Commission with respect to such Shares, to any and
all amendments or supplements to such Registration Statement, whether such amendments or supplements are filed before or after the effective date of such Registration Statement, to any related Registration Statement filed pursuant to Rule 462(b)
under the Securities Act, and to any and all instruments or documents filed as part of or in connection with such Registration Statement or any and all amendments thereto, whether such amendments are filed before or after the effective date of such
Registration Statement; and each of the undersigned hereby ratifies and confirms all that such attorney and agent shall do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons
in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center">Director</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Jingwu Zhang Zang</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center">Director</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Wei Fu</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center">Director</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Zheru Zhang</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Joan Huaqiong Shen</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director and Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Principal Financial and Accounting Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Jielun Zhu</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center">Director</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Mengjiao Jiang</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center">Director</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Jie Yu</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center">Director</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Lin Li</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Securities Act of 1933, the undersigned, the duly authorized representative in the United States of <FONT
STYLE="white-space:nowrap">I-MAB</FONT> has signed this registration statement or amendment thereto in Newark, Delaware, United States on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Authorized U.S. Representative</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-10 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.14</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.14 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENEXINE, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TASGEN <FONT STYLE="white-space:nowrap">BIO-TECH</FONT> (TIANJIN) CO., LTD. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTELLECTUAL PROPERTY ASSIGNMENT AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE AGREEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">DATED October 16<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>, 2015 </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONTENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>ARTICLE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">1.&#8195;&#8201;DEFINITIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">2.&#8195;&#8201;ASSIGNMENT AND LICENSE OF INTELLECTUAL PROPERTIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">3.&#8195;&#8201;FEES AND ROYALTIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">4.&#8195;&#8201;TRAINING</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">5.&#8195;&#8201;JOINT DEVELOPMENT COMMITTEE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">6.&#8195;&#8201;IMPROVEMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">7.&#8195;&#8201;SALE OFPRODUCTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">8.&#8195;&#8201;BOOKS AND RECORDS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">9.&#8195;&#8201;TAX</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">10.&#8194;&#8201;TECHNICAL DOCUMENTATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">11.&#8194;&#8201;MATERIALS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">12.&#8194;&#8201;CONFIDENTIALITY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">13.&#8194;&#8201;CLAIMS AND INFRINGEMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">14.&#8194;&#8201;REPRESENTATIONS, WARRANTIES AND COVENANTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">15.&#8194;&#8201;TERM AND TERMINATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">16.&#8194;&#8201;INDEPENDENT CONTRACTORS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">17.&#8194;&#8201;FORCE MAJEURE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">18.&#8194;&#8201;LIABILITY FOR BREACH AND INDEMNIFICATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">19.&#8194;&#8201;SETTLEMENT OF DISPUTES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">20.&#8194;&#8201;ASSIGNMENT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">21.&#8194;&#8201;NOTICES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">22.&#8194;&#8201;MISCELLANEOUS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXHIBIT <FONT STYLE="white-space:nowrap">A-1</FONT> LIST OF LICENSED INTELLECTUAL PROPERTIES </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXHIBIT <FONT STYLE="white-space:nowrap">A-2</FONT> LIST OF ASSIGNED INTELLECTUAL PROPERTIES </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXHIBIT B CONSENTS OF TECHNOLOGY TRANSFER </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTELLECTUAL PROPERTY ASSIGNMENT AND </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS INTELLECTUAL
PROPERTY ASSIGNMENT AND LICENSE AGREEMENT</B> (the &#147;<B>Agreement</B>&#148;) is made on October 16<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>, 2015 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BETWEEN </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>GENEXINE, INC.</B>, a limited liability company established in Korea, with its registered address at 700 <FONT
STYLE="white-space:nowrap">Daewangpangyo-ro,</FONT> Korea <FONT STYLE="white-space:nowrap">Bio-Park</FONT> Bldg. B, <FONT STYLE="white-space:nowrap">Bundang-gu,</FONT> <FONT STYLE="white-space:nowrap">Seongnam-si,</FONT> <FONT
STYLE="white-space:nowrap">Gyeonggi-do</FONT> <FONT STYLE="white-space:nowrap">463-400,</FONT> Korea (&#147;<B>Genexine</B>&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TASGEN <FONT STYLE="white-space:nowrap">BIO-TECH</FONT> (TIANJIN) CO., LTD.</B>, a limited liability company
established in Tianjin, the People&#146;s Republic of China (the &#147;<B>PRC</B>&#148;), with its registered address at Chenhuan Building, Tianjin Pharma and Medical Device Zone, Beichen District, Tianjin, the PRC (&#147;<B>Tasgen</B>&#148;).
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Genexine and Tasgen are jointly referred hereinafter as the &#147;<B>Parties</B>&#148; and individually as a
&#147;<B>Party</B>&#148;.) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Genexine and Tasgen will be parties to a Capital Increase Subscription Agreement (the &#147;<B>Subscription
Agreement</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Genexine and Tasgen have agreed to establish a cooperation relationship with each other, under which Genexine,
as the sole and exclusive owner of all the patents, patent applications, know-hows, data and information (the &#147;<B>Licensed Intellectual Properties</B>&#148;), which relate to the Licensed Products (as defined below) and are limited to those
listed on <U>Exhibit <FONT STYLE="white-space:nowrap">A-1</FONT></U> attached hereto and may be updated from time to time during the term of this Agreement upon mutual consents of the Parties, intends to grant the License (as defined below) of the
Licensed Intellectual Properties to Tasgen so that Tasgen can engage in <FONT STYLE="white-space:nowrap">pre-clinical/clinical</FONT> development, manufacturing, sale and distribution of the Licensed Products in the Territory (as defined below).
Tasgen intends to accept the License of the Licensed Intellectual Properties from Genexine in accordance with this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Genexine, as the sole and exclusive owner of all the patents, patent applications, know- hows, data and
information (the &#147;<B>Assigned Intellectual Properties</B>&#148;, together with the Licensed Intellectual Properties, the &#147;<B>Intellectual Properties</B>&#148;), which relate to the Assigned Products (as defined below, together with the
Licensed Products, the &#147;<B>Products</B>&#148;) and are limited to those listed on <U>Exhibit <FONT STYLE="white-space:nowrap">A-2</FONT></U> attached hereto, intends to sell and assign the Assigned Intellectual Properties to Tasgen so that
Tasgen can engage in <FONT STYLE="white-space:nowrap">pre-clinical/clinical</FONT> development, manufacturing, sale and distribution of the Assigned Products in the Territory (as defined below). Tasgen intends to purchase the Assigned Intellectual
Properties from Genexine in accordance with this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 1 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOW IT IS AGREED </B>between the Parties as follows: </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFINITIONS </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The following words and expressions shall have the meanings given to them below when used in this Agreement:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148; means, with regard to a given natural or legal person (a &#147;<B>Person</B>&#148;), a
Person that controls, is controlled by or is under common control with the given Person. For the purposes of this Agreement, except as otherwise expressly provided, when used with respect to any Person, &#147;<B>control</B>&#148; means the power to
direct the management and policies of such Person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Assigned Products</B>&#148; means long-acting <FONT STYLE="white-space:nowrap">GLP-1</FONT> named as
<FONT STYLE="white-space:nowrap">GX-G6</FONT> (&#147;<B><FONT STYLE="white-space:nowrap">GX-G6</FONT></B>&#148;). For the avoidance of doubt, the term &#147;Assigned Products&#148; does not include hyFc Platforms. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>hyFc Platform</B>&#148; means: as defined in the PRC patent 201410851771, through the fusion of Fc fragment of IgG4 with the amino
acid sequence of target protein, the 231st to 240th amino acid will be replaced by CH2 area of IgD, as a result of which a long-acting medicine, the half-life of which is longer than target protein, is formed. Such fusion protein only has FcRn locus
instead of Fcy Rs binding locus, which avoids cytolysis and immunogenicity. HyFc Platform means such Fc structure of IgD/IgG4. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Improvements</B>&#148; means any improvement, modification or alteration to the Licensed Products, Assigned Products, or to the
Intellectual Properties. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Licensed Products</B>&#148; means (i)&nbsp;long-acting human growth hormone named as <FONT
STYLE="white-space:nowrap">GX-H9</FONT> (&#147;<B><FONT STYLE="white-space:nowrap">GX-H9</FONT></B>&#148;), (ii) long-acting human <FONT STYLE="white-space:nowrap">G-CSF</FONT> named as <FONT STYLE="white-space:nowrap">GX-G3</FONT> (&#147;<B><FONT
STYLE="white-space:nowrap">GX-G3</FONT></B>&#148;), (iii) long- acting <FONT STYLE="white-space:nowrap">GLP-2,</FONT> named as <FONT STYLE="white-space:nowrap">GX-G8</FONT> (&#147;<B><FONT STYLE="white-space:nowrap">GX-G8</FONT></B>&#148;), (v) <FONT
STYLE="white-space:nowrap">PD-L1</FONT> HyFc, named as <FONT STYLE="white-space:nowrap">GX-P2</FONT> (&#147;<B><FONT STYLE="white-space:nowrap">GX-</FONT> P2</B>&#148;), and (iv)&nbsp;any other products as agreed by the Parties from time to time
after the execution of this Agreement, including but not limited to one product to be mutually agreed by the Parties in good faith within twelve (12)&nbsp;months after the execution of this Agreement, which are developed by using the hyFc Platform
and manufactured by utilizing or embodying the Licensed Intellectual Properties. For the avoidance of doubt, the term &#147;Licensed Products&#148; does not include hyFc Platforms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Net Sales</B>&#148; means, the gross amount invoiced by Tasgen, and its Affiliates
and <FONT STYLE="white-space:nowrap">sub-</FONT> licensees to unrelated third parties for sales of the Products in the applicable Territory, less the following deductions to the extent included in the gross invoiced sales price for the Products or
otherwise directly paid or incurred by Tasgen, and its Affiliates and <FONT STYLE="white-space:nowrap">sub-</FONT> licensees, with respect to sales of the Products in the applicable Territory: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Trade, quantity and cash discounts allowed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Discounts, refunds, rebates, chargebacks, retroactive price adjustments, and any other similar allowances which
effectively reduce the net selling prices (but excluding sales force commissions) in accordance with the PRC GAAP and the laws of the applicable jurisdictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Product returns and allowances; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any value-added taxes imposed on the Product. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Territory</B>&#148; means with respect to <FONT STYLE="white-space:nowrap">GX-H9,</FONT> <FONT STYLE="white-space:nowrap">GX-G6</FONT>
and <FONT STYLE="white-space:nowrap">GX-G3,</FONT> the PRC, <I>provided</I>, <I>however</I>, that Tasgen shall have the right to conduct clinic trial in Taiwan and Australia; and with respect to <FONT STYLE="white-space:nowrap">GX-G8</FONT> and <FONT
STYLE="white-space:nowrap">GX-P2,</FONT> worldwide. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>PRC</B>&#148; means the People&#146;s Republic of China, for the purposes of
this Agreement, excluding Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Technical
Documentation</B>&#148; means complete, correct and effective documents and electronic media embodying the Intellectual Properties furnished to Tasgen by Genexine in accordance with this Agreement, a list of Contents of Technology Transfer is
attached hereto as <U>Exhibit B</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Therapeutic Indication</B>&#148; means (i)&nbsp;treatment of any disease for <FONT
STYLE="white-space:nowrap">GX-H9,</FONT> (ii) treatment of any disease for <FONT STYLE="white-space:nowrap">GX-G6,</FONT> (iii) treatment of any disease for <FONT STYLE="white-space:nowrap">GX-G3,</FONT> (iv) with respect to <FONT
STYLE="white-space:nowrap">GX-</FONT> G8, treatment of chemically induced diarrhea (CID), and (v)&nbsp;with respect to <FONT STYLE="white-space:nowrap">GX-P2,</FONT> treatment of rheumatoid arthritis (RA) and lupus (not including psoriasis). </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any reference in this Agreement to &#147;writing&#148; includes facsimile transmission, telex, cable or
comparable means of communication. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The headings in this Agreement are for convenience only and shall not affect its interpretation.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ASSIGNMENT AND LICENSE OF INTELLECTUAL PROPERTIES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ASSIGNMENT. </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the terms and conditions hereof, Genexine hereby agrees to sell, transfer and assign to Tasgen, and
Tasgen agrees to acquire from Genexine, the Assigned Intellectual Properties (the &#147;<B>Assignment</B>&#148;). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tasgen shall file the Assignment hereunder with the competent authorities for registration of the change of the
patent applicant within twenty (20)&nbsp;working days after the execution of this Agreement. Genexine shall make commercially reasonable efforts to cooperate with Tasgen in the registration of the change of the patent applicant and the response to
any office action issued to the Assigned Intellectual Properties and shall provide all the documents necessary for the registration. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">From the execution date of this Agreement and prior to the effective date of the Assignment, Genexine shall
grant to Tasgen an exclusive (even as to Genexine and its Affiliates) and <FONT STYLE="white-space:nowrap">non-transferable</FONT> (other than to be transferred to an Affiliate of Tasgen, which has the substantially identical ownership structure as
the then ownership structure of Tasgen) license in the Territory to use and otherwise exploit the Assigned Intellectual Properties and to engage in <FONT STYLE="white-space:nowrap">pre-clinical/clinical</FONT> development, manufacturing, sale and
distribution of the Assigned Products for the Therapeutic Indication in the Territory. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LICENSE. </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the terms and conditions hereof, Genexine hereby grants to Tasgen for the term of this Agreement a <FONT
STYLE="white-space:nowrap">non-transferable</FONT> (other than to be transferred to an Affiliate of Tasgen, which has the substantially identical ownership structure as the then ownership structure of Tasgen) license in the Territory to use and
otherwise exploit the Licensed Intellectual Properties to engage in <FONT STYLE="white-space:nowrap">pre-clinical/clinical</FONT> development, manufacturing, sale and distribution of the Licensed Products for the Therapeutic Indication in the
Territory (the &#147;<B>License</B>&#148;). Genexine hereby grants to Tasgen a right of first negotiation for three (3)&nbsp;years commencing as of the execution of this Agreement, if Genexine decides to grant a license in the PRC to use and
otherwise exploit the relevant Licensed Intellectual Properties of <FONT STYLE="white-space:nowrap">GX-G8</FONT> and <FONT STYLE="white-space:nowrap">GX-P2</FONT> to engage in <FONT STYLE="white-space:nowrap">pre-clinical/clinical</FONT>
development, manufacturing, sale and distribution of <FONT STYLE="white-space:nowrap">GX-G8</FONT> and <FONT STYLE="white-space:nowrap">GX-P2</FONT> for therapeutic indications other than the Therapeutic Indications defined in this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tasgen shall use the Licensed Intellectual Properties only in the Territory for
<FONT STYLE="white-space:nowrap">pre-</FONT> clinical/clinical development, manufacturing, sale, distribution, marketing, and service of the Licensed Products for the Therapeutic Indication only and shall not use the same for any other purpose
without Genexine&#146;s prior written consent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The License hereunder shall be <FONT STYLE="white-space:nowrap">non-exclusive</FONT> with respect to the
Licensed Intellectual Properties and exclusive (even as to Genexine and its Affiliates) with respect to the Licensed Products for the Therapeutic Indication in the Territory. For clarity, Genexine has the right to license the Licensed Intellectual
Properties to a third party in the Territory, <I>provided, however, </I>that Tasgen shall be the sole and exclusive licensee in the Territory to use and otherwise exploit the Licensed Intellectual Properties to engage in <FONT
STYLE="white-space:nowrap">pre-clinical/clinical</FONT> development, manufacturing, sale and distribution of the Licensed Products for the Therapeutic Indication. Use of the Licensed Intellectual Properties by Tasgen shall be limited to use for the
licensed activities expressly stipulated in <U>Article 2.5</U> and further subject to confidentiality restrictions on its use and disclosure as set forth herein. Tasgen shall not perform the licensed activities outside of the Territory. Except as
expressly set forth in this Agreement, nothing in this Agreement shall be deemed to grant, directly or by implication, estoppel or otherwise, any license or rights of any kind to Tasgen. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tasgen hereby covenants and agrees that it and its Affiliate shall not, directly or indirectly, develop,
manufacture or sell any Licensed Products outside the Territory. Tasgen shall take reasonable efforts to prevent export of the Licensed Products outside the Territory and to avoid to sell the Licensed Products to a customer who desires to purchase
the Licensed Products for sale outside of the Territory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Genexine shall not grant any license or rights of any kind in any of the Intellectual Properties to any third
party for the purpose of use, marketing, offer, distribution, sale, research, development or manufacture of the Licensed Products for the Therapeutic Indication in the Territory without Tasgen&#146;s prior written consent. Genexine shall ensure that
neither Genexine nor its Affiliates shall, directly or indirectly, develop, manufacture or sell any Licensed Products or Assigned Products in the Territory. Genexine shall take reasonable efforts to prevent export of the Licensed Products or
Assigned Products from outside the Territory into the Territory and to avoid to sell the Licensed Products or Assigned Products to a customer who desires to purchase the Licensed Products or Assigned Products for sale in the Territory.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The License is sublicensable by Tasgen in the Territory, <I>provided </I>that such sublicense (including
have-made right) shall be conditional upon Genexine&#146;s prior written consent (other than to be sublicensed to an Affiliate of Tasgen, which has the substantially identical ownership structure as the then ownership structure of Tasgen), which
consent cannot be unreasonably withheld, and subject to all of the restrictions and obligations of Tasgen set forth herein. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If all or any part of any Intellectual Properties becomes invalid and such invalidity is not due to a breach of
the relevant representations, warranties and covenants made by Genexine in this Agreement, during the term of this Agreement, this Agreement shall remain effective with respect to any other Intellectual Properties that is not invalid. In this event,
during the term of this Agreement, Tasgen continues to be obliged to pay the fees mutually agreed between the Parties pursuant to <U>Article 3.3</U>, <U>3.4(a)</U> <U>and 3.4(c)</U> of this Agreement in consideration of the License to use the
Intellectual Properties (including know-hows, data and information) as granted hereunder, <I>provided, however, </I>that the royalties pursuant to <U>Article 3.4(b)</U> hereof shall be reduced in accordance with the then market penetration rate of
the relevant Licensed Products in the first year when a biosimilar product is sold in the Territory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tasgen shall file the License hereunder with the competent authorities for registration within twenty
(20)&nbsp;working days from the execution of this Agreement. Genexine shall make commercially reasonable efforts to cooperate with Tasgen in the registration and shall provide all the documents necessary for the registration. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With respect to <FONT STYLE="white-space:nowrap">GX-G8</FONT> and <FONT STYLE="white-space:nowrap">GX-P2</FONT>
related Licensed Products, after completion of first Phase I clinical trial in the Territory, Tasgen will have the right to pursue an <FONT STYLE="white-space:nowrap">out-license</FONT> to grant a <FONT STYLE="white-space:nowrap">sub-license</FONT>
(within the scope of License granted to Tasgen hereunder) to a third party for the development and commercialization of the relevant Licensed Product (the &#147;<B><FONT STYLE="white-space:nowrap">Out-License</FONT></B>&#148;).
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, if Tasgen or its <FONT STYLE="white-space:nowrap">sub-licensee</FONT> fails to submit IND
(investigational new drug) application with respect to <FONT STYLE="white-space:nowrap">GX-G8</FONT> or <FONT STYLE="white-space:nowrap">GX-P2</FONT> related Licensed Products for any Therapeutic Indication in any jurisdiction within thirty
(30)&nbsp;months after Genexine becomes ready to conduct the technology transfer, subject to a unanimous decision made by all members of the Joint Development Committee, Genexine shall have the right to acquire from Tasgen all the relevant assets
(including without limitation to the rights of intellectual properties) with respect to any such failed Therapeutic Indication of <FONT STYLE="white-space:nowrap">GX-G8</FONT> and <FONT STYLE="white-space:nowrap">GX-P2</FONT> related Licensed
Products at the cost that Tasgen will have then expended and the license granted to any such failed Therapeutic Indication of <FONT STYLE="white-space:nowrap">GX-G8</FONT> and <FONT STYLE="white-space:nowrap">GX-P2</FONT> related Licensed Products
will terminate. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FEES AND ROYALTIES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Upfront Payment for License</U>. As soon as practical but in no event later than (A)&nbsp;ten (10) working
days after the completion of (i)&nbsp;the Closing under the Subscription Agreement, and (ii)&nbsp;other governmental procedures reasonably necessary for the payment under this<U> Article 3.1</U>, or (B)&nbsp;the end of calendar year 2015, whichever
is earlier, Tasgen shall pay US$13,000,000 to Genexine as the upfront license fees in connection with the License. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Payment for Assignment</U>. As soon as practical but in no event later than (A)&nbsp;ten (10) working days
after the completion of (i)&nbsp;the Closing under the Subscription Agreement, and (ii)&nbsp;other governmental procedures reasonably necessary for the payment under this<U> Article 3.2</U>, or (B)&nbsp;the end of calendar year 2015, whichever is
earlier, Tasgen shall pay US$7,000,000 to Genexine as the purchase fee in connection with the Assignment. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Milestone Payments for <FONT STYLE="white-space:nowrap">GX-H9,</FONT>
<FONT STYLE="white-space:nowrap">GX-G6</FONT> and <FONT STYLE="white-space:nowrap">GX-G3</FONT></U>. Tasgen shall pay <FONT STYLE="white-space:nowrap">two-time</FONT> milestone fees per Licensed Product/Assigned Product, as follows, to Genexine
conditioned upon that each Licensed Product/Assigned Product below reaches the following net revenue milestones: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Licensed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Product</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>/Assigned</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Product</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net&nbsp;Sales&nbsp;Target<BR>(US$ million)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone<BR>Payment<BR>(US$&nbsp;million)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net&nbsp;Sales&nbsp;Target<BR>(US$ million)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone<BR>Payment<BR>(US$&nbsp;million)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">GX-H9</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">GX-G6</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">GX-G3</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Clinical Milestone Payments, Royalties and Sublicensing Fees for
<FONT STYLE="white-space:nowrap">GX-G8</FONT> and <FONT STYLE="white-space:nowrap">GX-P2</FONT></U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Clinical Milestone Payments.</U> Tasgen shall pay clinical milestone fees , as follows, to Genexine conditioned
upon each Licensed Product below reaching the following clinical development milestones: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Licensed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Product</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Indication</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone&nbsp;A:&nbsp;Initiate<BR>P3 Trials</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone&nbsp;B:&nbsp;approval&nbsp;of<BR>NDA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone Payment<BR>(US$ million)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone Payment</B><br><B>(US$ million)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">GX-P2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">RA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">GX-P2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Lupus</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">GX-G8</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">CID</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, if Tasgen pursue an <FONT STYLE="white-space:nowrap">Out-License</FONT> of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-PRC</FONT></FONT> license in accordance with <U>Article 2.12</U> while reserving the PRC license, <I>provided </I>that the clinical development milestones listed above are achieved
in PRC, the clinical milestone payments shall be reduced to 10% of the total clinical milestone payments indicated above. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;In the absence of an <FONT STYLE="white-space:nowrap">Out-License</FONT> pursuant to <U>Article 2.12</U>, Tasgen
shall pay royalties to Genexine in respect of the sales of <FONT STYLE="white-space:nowrap">GX-G8</FONT> and <FONT STYLE="white-space:nowrap">GX-P2</FONT> related Licensed Products for a term of ten (10)&nbsp;years commencing on the date of first
commercial sale of the relevant Licensed Products, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Annual Net Sales between 0 and US$50,000,000:&nbsp;&nbsp;&nbsp;&nbsp;6.5%
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Annual Net Sales between US$50,000,000 and US$100,000,000&nbsp;&nbsp;&nbsp;&nbsp;7.5% </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Annual Net Sales greater than US$100,000,000: 8.5% </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Sublicensing Fees.</U> If the development and
commercialization of <FONT STYLE="white-space:nowrap">GX-G8</FONT> and <FONT STYLE="white-space:nowrap">GX-</FONT> P2 related Licensed Products is <FONT STYLE="white-space:nowrap">Out-Licensed</FONT> in accordance with <U>Article 2.12</U> hereof,
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Tasgen shall pay Genexine a sublicensing fee determined in accordance with the following formula: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Genexine&#146;s sublicense fee = X% * Sublicense Revenue - any paid clinical milestone payments pursuant to <U>Article
3.4(a)</U> hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purpose of the foregoing formula, &#147;<B>Sublicense Revenue</B>&#148; means any and all licensing
fees, royalty and any other income (minus reimbursements and equity purchase) resulting from or in connection with the <FONT STYLE="white-space:nowrap">Out-License.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purpose of the foregoing formula, &#147;X&#148; shall be determined in accordance with the following events: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;If the <FONT STYLE="white-space:nowrap">Out-License</FONT> occurs after the completion of first
Phase I clinical trial in the Territory, X shall be 40; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;If the
<FONT STYLE="white-space:nowrap">Out-License</FONT> occurs after the start of the first Phase II clinical trial and prior to the start of the first Phase III, X shall be 30; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;If the <FONT STYLE="white-space:nowrap">Out-License</FONT> occurs after the start of the first
Phase III clinical trial and prior to the first NDA filing, X shall be 15; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) If the
<FONT STYLE="white-space:nowrap">Out-License</FONT> occurs after the first NDA filing, X shall be 10. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TRAINING </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties shall jointly formulate a training program for Tasgen and shall specify the qualifications of
personnel suitable for receiving such training. Genexine shall provide Tasgen with adequate training in order to enable the personnel of Tasgen having ordinary skill required in the field to manufacture the Licensed Products and Assigned Products in
compliance with the Technical Documentation. Tasgen shall be responsible for expenses relating to travel and lodging (including food) of the personnel sent by Genexine to Tasgen for conducting any training. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that Tasgen encounters technical difficulties that the Parties recognise that Tasgen cannot solve
by itself, Genexine shall, upon request by and on the cost of Tasgen, as soon as is reasonably practicable, but subject to availability, send experts or technical personnel to assist Tasgen in solving such technical problems and applying the
Intellectual Properties in the manufacturing activities of Tasgen. If Genexine does not have its own experts or technical personnel who can solve the technical difficulties, Genexine shall make reasonable efforts to arrange, at Tasgen&#146;s cost,
outside experts or technical personnel suitable for solving the technical difficulties. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 8 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During the term of this Agreement, each Party shall provide reasonable assistance to the other Party in order
to enable the other Party&#146;s personnel to obtain visas and travel permits necessary for the performance of the Contract. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>JOINT DEVELOPMENT COMMITTEE. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Parties shall establish a joint development committee to oversee the development and commercialization activities under this Agreement. The
operating committee shall be composed of three (3)&nbsp;persons, unless jointly agreed otherwise. Genexine shall be entitled to appoint one (1)&nbsp;member and Tasgen shall be entitled to appoint two (2)&nbsp;members who are with appropriate
seniority and functional expertise. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>IMPROVEMENTS </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During the term of this Agreement, if Genexine develops or acquires any Improvements, it shall provide Tasgen
details of the Improvements and such explanations or trainings as Tasgen may request to be able to legally and effectively use the Improvements and grant to Tasgen an exclusive license to use the Improvements free of charge in the Territory. For the
avoidance of any doubt, the scope of Improvements Genexine may provide to Tasgen under this Article is limited to Improvements to the Licensed Products or Assigned Products (e.g., optimization) and does not include Improvements to the hyFc Platform
technology. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During the term of this Agreement, if Tasgen develops or acquires any Improvements, Tasgen shall be the sole
legal owner of the Improvements and has full power, right and authority to grant the license or transfer of ownership of the Improvements. Tasgen shall promptly notify Genexine in writing giving details of the Improvements and shall provide Genexine
with such explanations or trainings to enable Genexine to legally and effectively use the Improvements free of charge and grant to Genexine an exclusive license to use the Improvements free of charge anywhere outside the Territory.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SALE OF PRODUCTS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Licensed Products and the Assigned Products which are approved for sale by the relevant regulatory
authority(ies) (e.g., China Food and Drug Administration) may be sold in the Territory and Tasgen shall be responsible for obtaining all necessary regulatory approvals and complying with regulations applicable to the Licensed Products and the
Assigned Products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During the term of this Agreement Tasgen shall promptly give prior notice to Genexine of sale of the Licensed
Products and the Assigned Products to any customer within the Territory and provide Genexine with copies of purchase order(s) of the customer promptly after receiving the same from the customer. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 9 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>BOOKS AND RECORDS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tasgen shall keep complete and proper records and books of account showing the Net Sales, quantity and
description of the Licensed Products and the Assigned Products sold by it, including accounting receipts and monthly and quarterly accounting statements in accordance with the relevant regulations of the PRC. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Such records and books of account shall be kept separate from any books and records which are not related to
the Licensed Products and the Assigned Products and shall be open to inspection by Genexine or its duly authorised representatives or agents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tasgen shall permit Genexine (or its representatives) at Genexine&#146;s expense to inspect, audit and
investigate at all reasonable times the books, accounts, records, audit reports, documents and other matters of Tasgen relating to the production and sale of the Licensed Products and Assigned Products. Such inspections, audits and investigations
shall be conducted in such a manner and at such times so as not to adversely affect the operation of Tasgen or the sale of the Licensed Products and the Assigned Products and the results thereof shall be kept confidential. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TAX </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Each Party shall (i)&nbsp;bear the cost of all stamp duty, income taxes and duties are legally required to be paid by it as a result of the
transaction contemplated by this Agreement, and (ii)&nbsp;shall comply with all tax reporting and withholding obligations as applicable to it in connection with transactions contemplated by this Agreement as required by all applicable laws. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TECHNICAL DOCUMENTATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Within thirty (30)&nbsp;days after the date of this Agreement, Genexine shall provide Tasgen free of charge
with one set of all Technical Documentation that are reasonably necessary for Tasgen&#146;s use and exploitation of the Intellectual Properties in order to enable Tasgen to perform the licensed activities herein. A list of Contents of Technology
Transfer is attached hereto as <U>Exhibit B</U>. From time to time, Genexine shall provide Tasgen with such requested written or oral explanations thereof at Tasgen&#146;s cost as Tasgen may reasonably require. Further sets of such documents shall
be supplied by Genexine at Tasgen&#146;s expense. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon receipt of any such Technical Documentation, Tasgen shall promptly deliver to Genexine a written
acknowledgment of receipt thereof and shall comply with the confidentiality provisions in this Agreement to protect the confidentiality of such Technical Documentation. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 10 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Genexine shall use all reasonable endeavours to ensure that the Technical Documentation shall be readable,
complete and accurate. Tasgen shall notify Genexine in writing within three (3)&nbsp;months after receipt thereof if any of the Technical Documentation is not readable, complete or accurate and Genexine shall correct or replace the defective
portions of the Technical Documentation free of charge to Tasgen. In the absence of a written notice from Tasgen to Genexine within the three (3)&nbsp;months period, the Technical Documentation in question shall be deemed to have been approved and
accepted by Tasgen. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Genexine shall have the right to make necessary amendments to the Technical Documentation and shall provide
Tasgen with such amendments from time to time. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MATERIALS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Tasgen may source raw materials, ingredients and other components for the production of the Licensed Products and the Assigned Products by
itself, provided that the manufacturing of the Licensed Products by using these raw materials, ingredients and components shall meet the technical specifications and standards of Genexine. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONFIDENTIALITY </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tasgen shall, during the term of this Agreement and after its termination or expiration for any reason, keep
confidential and not make use of for any purpose other than the performance of its obligations under this Agreement, nor disclose to any other person otherwise than in accordance with <U>Article 12.2</U> or with the prior written consent of
Genexine, anything of the Intellectual Properties, including but not limited to, information contained in the Technical Documentation, Improvements and any other information disclosed (whether in writing, verbally or by other means) by or on behalf
of Genexine. Without prejudice to the generality of this obligation above, Tasgen shall: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">keep any and all of the Intellectual Properties separate from its own information or documentation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">arrange proper and secure storage facilities for the Intellectual Properties and control and supervise access
of its employees and personnel to such facilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">mark and label all information contained in the Intellectual Properties and Technical Documentation relating to
the Intellectual Properties &#147;confidential&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">disclose the Intellectual Properties only to its employees pursuant to <U>Article 12.3</U>;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">prevent unauthorized access to or disclosure of the Intellectual Properties; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not use, reproduce, transform or store any of the Intellectual Properties in any place that is externally
accessible, whether it is in hardcopy or electronic form. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 11 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The foregoing obligations of <FONT STYLE="white-space:nowrap">non-use</FONT> and
<FONT STYLE="white-space:nowrap">non-disclosure</FONT> shall not apply to: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">information available to the public at the time when it is obtained or which subsequently becomes available to
the public through no fault of Tasgen; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">information which Tasgen can demonstrate was in its possession, as evidenced by written documents, at the time
when it obtains such information from Genexine; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">information properly conveyed to Tasgen after the disclosure by an independent and unrelated third party,
which, third party disclosure was not under an obligation of confidentiality at the time of disclosure of the third party information; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">information required to be disclosed by law, provided that Tasgen promptly notifies Genexine of such
requirement to enable Genexine the opportunity to oppose such requirement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During the term of this Agreement Tasgen may disclose information which is confidential under <U>Article
12.1</U> to its officers, directors, managers and employees, but only to the extent necessary for the purposes of this Agreement and provided such person has signed a confidentiality contract, in the form and substance satisfactory to the board of
the directors of Tasgen. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tasgen shall, at its own expense, take such steps as Genexine may require to enforce the terms of any
confidentiality contract executed pursuant to <U>Article 12.3</U> including, but not limited to, the initiation, prosecution and enforcement of any legal proceedings. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CLAIMS AND INFRINGEMENTS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tasgen shall immediately notify Genexine of any claim, or any fact which may lead to a claim, of any nature by
a third party that the use of the Licensed Intellectual Properties by Tasgen is or may be an infringement of a patent or other proprietary right of such third party, but shall take no action relating to such claim or infringement without
Genexine&#146;s written consent. Genexine shall advise Tasgen whether it wishes to conduct a defense of any such claim. Should Genexine elect to conduct such a defense, it shall do so at its own expense, and Genexine shall have sole control of such
defense either in its own name or in the name of Tasgen, as the case may be, and Tasgen shall give all reasonable assistance to Genexine to enable it to do so. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Genexine shall indemnify Tasgen and bear related costs for any claims, losses, damages, proceedings sustained
by Tasgen in relation to any claims that may be made against Tasgen pursuant to <U>Article 13.1</U>, unless such claims, losses, damages, proceedings result from the default by Tasgen of its obligations under this Agreement or the use of Licensed
Intellectual Properties by Tasgen otherwise than in accordance with this Agreement. Notwithstanding the above, the total and aggregate liability of Genexine shall not exceed an amount equal to the sum of (i)&nbsp;the upfront payment received by
Genexine pursuant to <U>Articles 3.1</U> and <U>3.2</U>, (ii) any milestone payments of any corresponding product actually received by Genexine pursuant to <U>Article 3.3</U> and <U>3.4</U>, and (iii)&nbsp;any other payments received by Genexine
pursuant to this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 12 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tasgen shall immediately notify Genexine of any information it obtains that any third party is or may be
infringing the rights of Genexine relating to the Licensed Intellectual Properties, but shall take no action relating to such infringement without Genexine&#146;s written consent. Genexine shall advise Tasgen whether it wishes to take action with
respect to such infringement. Should Genexine elect to take action with respect to such infringement, it shall do so at its own expense, and Genexine shall have sole control of such action and Tasgen shall give Genexine all reasonable assistance to
enable it to do so. All compensation which may be recovered shall be made to Genexine. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that Genexine elects not to take action under <U>Article 13.3</U>, Tasgen may, with the written
consent of Genexine, take action in relation to the relevant infringement at its own cost and expense, and Genexine shall give all reasonable assistance in connection therewith. All compensation which may be recovered shall be made to Tasgen.
Notwithstanding the foregoing, Tasgen shall not enter into any compromise, settlement or agreement with any person or entities relating to the Licensed Intellectual Properties otherwise than with the written consent of Genexine.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as provided in this Agreement, Genexine shall have no responsibility for any claim with respect to
licensed activities performed and the Licensed Products or Assigned Products manufactured or distributed by Tasgen hereunder or arising from the use by Tasgen of the Intellectual Properties furnished by Genexine hereunder. Tasgen shall hold harmless
and indemnify Genexine against any claim, loss or damage arising from claims by any third party with respect to any licensed activities performed and the Licensed Products or Assigned Products manufactured or distributed by Tasgen hereunder unless
such claim, loss or damage arises from or is attributable to the any of the representations, warranties or covenants of Genexine herein. In addition, in the event of technical problems of a Licensed Product or Assigned Products as a consequence of
any breach of warranty by Tasgen (including as a result of any failure by Tasgen to correctly apply any Intellectual Properties utilized by Tasgen for such Licensed Product or Assigned Products), Genexine may require Tasgen to implement any
necessary preventive and corrective measures and Tasgen shall comply with Genexine&#146;s advice as soon as reasonably practicable at Tasgen&#146;s own expense. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything to the contrary in this Article 13 or elsewhere in this Agreement, neither Party shall
have any liability, whether arising in contract, tort (including negligence), strict liability, breach of warranty or any other theory of law, for any special, incidental, indirect or consequential loss or damage of any nature suffered by the other
Party. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 13 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REPRESENTATIONS, WARRANTIES AND COVENANTS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Genexine hereby represents and warrants to Tasgen, that Genexine is the sole legal owner of the Intellectual
Properties and has full power, right and authority to grant the license to or make the assignment to Tasgen pursuant to this Agreement and, to the knowledge of Genexine, any of the Intellectual Properties is free of liens, pledges or any other
encumbrances. To the knowledge of Genexine, there are no claims or investigations pending or threatened against any of the Intellectual Properties. To the knowledge of Genexine, the license and assignment hereunder does not violate the relevant laws
of the respective places of registration of the Parties or infringe any third party rights. To the knowledge of Genexine, the manufacture, use and sale of the Products will not infringe upon the intellectual property rights of any third party in the
Territory. To the knowledge of Genexine, the patents related to <FONT STYLE="white-space:nowrap">GX-G6</FONT> and <FONT STYLE="white-space:nowrap">GX-G8</FONT> in the Territory should be able to provide protection for the relevant products. The
Licensed Intellectual Properties, and the relevant technical assistance, guidance and training, shall be sufficient to enable Tasgen to perform the licensed activities in accordance with all applicable specifications set forth in the Technical
Documentation. During the term of this Agreement, Genexine shall maintain and protect the validity of the Licensed Intellectual Properties to the greatest extent permitted by the applicable laws. EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, THERE
ARE NO EXPRESS OR IMPLIED WARRANTIES, INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, RESPECTING THIS AGREEMENT OR ANY INTELLECTUAL PROPERTIES OR TECHNICAL DOCUMENTATION FURNISHED HEREUNDER BY GENEXINE.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as provided in this Agreement, nothing in this Agreement shall limit the rights of Genexine to use the
Licensed Intellectual Properties anywhere in the world and Tasgen waives and disclaims any right or interest in the Licensed Intellectual Properties which may arise under any law or legal theory out of the permitted use hereunder.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nothing in this Agreement shall: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">constitute a sale, transfer or assignment of the Licensed Intellectual Properties to Tasgen, unless it is
otherwise agreed in other agreements, contracts or arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">give Tasgen any right, title or interest in or to the Licensed Intellectual Properties except the license to
use in accordance with this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">give Tasgen any right to register or apply for registration of any of the Licensed Intellectual Properties
(except this Agreement itself), whether in the PRC or elsewhere; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 14 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">diminish or affect the rights of Genexine to take legal action or obtain any other relief against any infringer
of the Licensed Intellectual Properties in the PRC or elsewhere. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tasgen agrees that it shall: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not register or make any application to register the Licensed Intellectual Properties or any part thereof in
the name of Tasgen in the PRC or elsewhere, whether for copyright, patent right or any other registerable right (for avoidance of doubt, Tasgen is permitted to register the License granted hereunder pursuant to <U>Article 2.11</U>);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">strictly adhere to all instructions or advice from Genexine regarding the use of the Licensed Intellectual
Properties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">comply with intellectual property laws of PRC and each of the jurisdictions where the Licensed Products are
sold by Tasgen with respect to the use of the Licensed Intellectual Properties in such jurisdictions in order to preserve and maintain Genexine&#146;s rights in the Licensed Intellectual Properties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">inform Genexine of the imposition of any new laws or regulations or changes in laws or regulations imposed in
the PRC during the term of this Agreement which affect performance by either Tasgen or Genexine under this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.4.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">maintain and protect the validity of the Assigned Intellectual Properties to the greatest extent permitted by
the applicable laws and shall not assign the Assigned Intellectual Properties to its Affiliate (other than to an Affiliate of Tasgen, which has the substantially identical ownership structure as the then ownership structure of Tasgen) or any third
party without Genexine&#146;s prior written consent; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.4.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not contest, infringe or harm any right which Genexine or any affiliate of Genexine may have in Licensed
Intellectual Properties, whether in the PRC or elsewhere. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERM AND TERMINATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement shall take effect upon execution by the Parties and shall remain in full force and effect for 30
years unless terminated earlier pursuant to this Agreement, except that termination shall not affect: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the accrued rights and obligations of the Parties at the date of termination; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 15 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the continued existence and validity of the rights and obligations of the Parties under those articles which
are designed to survive termination and any provisions of this Agreement necessary for the interpretation or enforcement of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise provided herein, this Agreement may be terminated: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by either Party giving notice to the other Party if the other Party has committed a material breach of this
Agreement and such breach, if capable of remedy, has not been so remedied within sixty (60)&nbsp;days following receipt of such notice, unless otherwise provided herein; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by either Party giving notice to the other Party in the event that an event of Force Majeure continues for a
period of six (6)&nbsp;consecutive months that causes Tasgen to cease the production and sale of the Licensed Products and the Parties have been unable to find an equitable solution pursuant to <U>Article 19</U>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by either Party giving notice to the other Party if at any time during the term of this Agreement, the
Government of the PRC should require any material alteration or modification of the contractual rights or obligations of the Parties pursuant to this Agreement which has the effect of preventing the Parties from achieving their business objectives;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by either Party giving notice to the other Party if the other Party becomes bankrupt, or insolvent, or is the
subject of proceedings or arrangements for liquidation or dissolution, or ceases to carry on business, or becomes unable to pay its debts as they become due; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by Genexine giving notice to Tasgen if Tasgen fails to obtain regulatory approvals or other registrations
necessary for sale or distribution of the Licensed Products in the Territory in accordance with a business plan and timeline approved by the board of the directors of Tasgen from time to time due to a reason attributable to Tasgen or ceases to
pursue clinical development or product registration or to conduct licensed activities in a reasonable scale pursuant to a written resolution made by Tasgen&#146;s board of directors; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">15.2.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by either Party giving notice to the other Party if at any time during the term of this Agreement, the
Subscription Agreement or the Joint Venture Agreement is terminated for any reason. However, if the Subscription Agreement or the Joint Venture Agreement is terminated due to a Party&#146;s material breach, such breaching Party will not have the
terminating right under this <U>Article 15.2.6</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon termination of this Agreement for whatever reason, Tasgen shall immediately cease to use the Licensed
Intellectual Properties as provided by Genexine and shall cease to manufacture the Licensed Products. Tasgen shall cooperate with Genexine in <FONT STYLE="white-space:nowrap">de-</FONT> registration of the License hereunder with the competent
authorities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 16 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon termination of this Agreement for whatever reason, Tasgen shall sell to Genexine at market price all the
Licensed Products or parts thereof (which are in good condition for sale to customers and already approved for sale by the China Food and Drug Administration) which are not subject to delivery under a sale to customers. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon expiration or termination of this Agreement, all amounts then due and unpaid to Genexine by Tasgen
hereunder, as well as all other amounts accrued but not yet payable to Genexine by Tasgen, shall forthwith become due and payable by Tasgen to Genexine. However, in the event that this Agreement is terminated by Tasgen as a result of Genexine&#146;s
material breach of this Agreement and Tasgen has raised claims against Genexine due to such breach, the aforesaid payment will be suspended until settlement of such claims pursuant to <U>Article 19</U> hereof. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All Licensed Intellectual Properties, including the Improvements and the Technical Documentation relating to
the Licensed Intellectual Properties as provided by Genexine, recorded in any material form including but not limited to any written records shall be returned by Tasgen to Genexine forthwith upon the termination or expiration of this Agreement.
Tasgen agrees on behalf of itself and its employees that no copies of the Licensed Intellectual Properties in any material form or of the Technical Documentation relating to the Licensed Intellectual Properties shall be made or retained upon and
after the termination or expiration of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon termination of this Agreement pursuant to Article <B>Error! Reference source not found.</B>, all Assigned
Intellectual Properties, including the Improvements and the Technical Documentation relating to the Assigned Intellectual Properties as provided by Genexine, shall be returned or <FONT STYLE="white-space:nowrap">re-assigned</FONT> by Tasgen to
Genexine forthwith. Tasgen agrees on behalf of itself and its employees that no copies of the Assigned Intellectual Properties in any material form or of the Technical Documentation relating to the Assigned Intellectual Properties shall be made or
retained upon and after the termination of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon termination, Tasgen agrees to permit Genexine and its representatives to inspect the records and accounts
of Tasgen and to investigate generally all business transactions carried on by Tasgen under and pursuant to this Agreement for a period of twelve (12)&nbsp;months following the last sale of the Licensed Products, and Tasgen agrees not to destroy any
of such records prior to the expiration of such twelve (12)&nbsp;month period. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INDEPENDENT CONTRACTORS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Parties are independent contractors, and nothing in this Agreement shall be construed to constitute either Party to be the agent, partner,
legal representative, attorney or employee of the other for any reason whatsoever. Neither Party shall have the power or authority to bind the other except as specifically set out in this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 17 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FORCE MAJEURE </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Force Majeure</B>&#148; means all events which are beyond the control of the Parties to this
Agreement, and which are unforeseen, or if foreseen, unavoidable, and which prevent total or partial performance by either Party. Such events shall include but are not limited to any lockouts, explosions, shipwrecks, acts of nature or the public
enemy, fires, flood, sabotage, accidents, strikes, wars, riots, insurrections, and any other similar contingency. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If an event of Force Majeure occurs, to the extent that any contractual obligation of either Party cannot be
performed as a result of such event, such contractual obligation shall be suspended while the Force Majeure subsists and the due date for performance thereof shall be automatically extended, without penalty, for a period equal to such suspension.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Party encountering Force Majeure shall, within fifteen (15)&nbsp;days of the relevant event, notify the
other Party and furnish valid proof of the occurrence of such Force Majeure. Within a reasonable period thereafter that Party shall provide the other Party with evidence of the Force Majeure issued by a relevant agency. The Party encountering Force
Majeure shall also use all reasonable endeavours to minimize the consequences of such Force Majeure. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event of Force Majeure, the Parties shall immediately consult with each other in order to mutually agree
an equitable solution (which may involve early termination of this Agreement a part thereof or extension of the term of this Agreement) and shall use all reasonable endeavours to minimize the consequences of such Force Majeure.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LIABILITY FOR BREACH AND INDEMNIFICATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tasgen shall indemnify and hold Genexine harmless against all losses, liabilities, costs, claims, actions,
damages, expenses or demands, which Genexine may incur, or which may be made against Genexine as a result of or in relation to any breach by Tasgen of its obligations under this Agreement or arising out of any improper use of the Licensed
Intellectual Properties by Tasgen. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Genexine shall indemnify and hold Tasgen harmless against all losses, liabilities, costs, claims, actions,
damages, expenses or demands, which Tasgen may incur, or which may be made against Tasgen as a result of or in relation to any breach by Genexine of its obligations under this Agreement, including but not limited to any breach of Genexine&#146;s
representations, warranties and covenants made in <U>Article 14.1</U>. Notwithstanding the above, the total and aggregate liability of Genexine under this Agreement shall not exceed an amount equal to the sum of (i)&nbsp;the upfront payment received
by Genexine pursuant to <U>Articles 3.1</U> and <U>3.2</U>, (ii) any payments of any corresponding product actually received by Genexine pursuant to <U>Article 3.3</U> and <U>3.4</U>, and (iii)&nbsp;any other payments received by Genexine pursuant
to this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 18 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SETTLEMENT OF DISPUTES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Dispute resolution mechanism set forth in the Subscription Agreement shall apply <I>mutatis mutandis</I>. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>20.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ASSIGNMENT </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">20.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Neither party may assign or otherwise transfer its rights or obligations under this Agreement without the prior
written consent of the other party, except Genexine shall be entitled to assign or transfer its rights and obligations under this Agreement to any of its Affiliates or to any company which succeeds to the business of Genexine, whether through stock
or asset sale, merger, reorganization or otherwise, provided that Tasgen shall be notified by Genexine of such assignment or transfer in writing and such successor succeeds to Genexine&#146;s rights in the Licensed Intellectual Properties and shall
agree in writing to assume the rights and obligations of Genexine under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">20.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement is binding upon and is made for the benefit of the Parties and their successors and permitted
assignees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">20.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tasgen shall continue to be bound by the rights and obligations under this Agreement regardless of any change
of control in Tasgen whether through stock or asset sale, merger, reorganization or otherwise and promptly notify Genexine of such change of control in writing. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>21.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NOTICES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Any notices to be given under this Agreement shall be in writing and deemed delivered when received by the Party to whom it is addressed, and
receipt shall be evidenced by (i)&nbsp;the written receipt of the receiving Party or the affidavit from the delivering person, if hand delivered, confirming delivery or refusal of delivery by the addressee, (ii)&nbsp;the signed returned receipt or
other written proof of delivery if delivered by registered air or express mail (return receipt requested) or by an internationally recognized courier service, or (iii)&nbsp;electronic proof of transmission if sent by
<FONT STYLE="white-space:nowrap">e-mail,</FONT> fax or telex, provided that any notice sent by <FONT STYLE="white-space:nowrap">e-mail,</FONT> fax or telex shall also be sent by registered air or express mail (return receipt requested) or
internationally recognized courier service. Notices shall be given to the relevant party at the addresses set forth below: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Tasgen</U>:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Chenhuan Building, Tianjin Pharma and Medical Device Zone, Beichen District, Tianjin </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: General Manager </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 19 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Genexine</U>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">700 <FONT STYLE="white-space:nowrap">Daewangpangyo-ro,</FONT> Korea <FONT STYLE="white-space:nowrap">Bio-Park</FONT> Bldg. B, <FONT
STYLE="white-space:nowrap">Bundang-gu,</FONT> <FONT STYLE="white-space:nowrap">Seongnam-si,</FONT> <FONT STYLE="white-space:nowrap">Gyeonggi-do</FONT> <FONT STYLE="white-space:nowrap">463-400,</FONT> Korea </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Hansoo Keyoung (CEO and President) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>22.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MISCELLANEOUS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">22.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tasgen shall observe and comply with all laws, rules and regulations applicable to the manufacture, packaging,
storage, handling, advertising, marketing and sale of the Licensed Products in the Territory. Tasgen shall, at its own cost and expense, secure and maintain all necessary governmental permits, licenses and approvals, and will fulfil all other
requirements and undertakings related to this Agreement which are or may become necessary under any law or regulation, to enable the Parties to exercise, enforce and enjoy all of the rights and obligations contained in this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">22.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Failure or delay on the part of either Party to exercise any right, power or privilege hereunder, or any other
contract relating hereto, shall not operate as a waiver thereof, nor shall the partial exercise of any right, power or privilege preclude any other future full and complete exercise thereof. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">22.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The validity, interpretation and implementation of this Agreement shall be governed by and construed in
accordance with the laws of the PRC. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">22.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement is written in Chinese and English. If there should be any discrepancy between the English and
Chinese versions of the Agreement, the English version shall be controlling in all respects. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">22.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Should any Article or any part of any Article contained in this Agreement be declared invalid or unenforceable
for any reason whatsoever, all other Articles or parts of Articles contained in this Agreement shall remain in full force and effect. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">22.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement and all documentation executed in connection therewith shall constitute the entire agreement
between the Parties with respect to the subject matter and shall automatically cancel and supersede any and all prior or contemporaneous oral or written understandings with respect thereto. In the event of any inconsistency between the Subscription
Agreement, Sino-Foreign Equity Joint Venture Contract dated October 16<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>, 2015 and this Agreement in relation to the subject matter of this Agreement, this Agreement shall prevail.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">22.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement may be amended only by a written instrument signed by the Parties. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 20 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">22.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement shall be executed in three (3)&nbsp;originals in English and three (3)&nbsp;in Chinese.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[The remainder of this page is intentionally left blank] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 21 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF </B>each of the Parties hereto has caused this Agreement to be executed by its duly
authorised representative on the date first set forth above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>TASGEN <FONT STYLE="white-space:nowrap">BIO-TECH</FONT> (TIANJIN) CO., LTD.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>GENEXINE, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>/s/ TASGEN <FONT STYLE="white-space:nowrap">BIO-TECH</FONT> (TIANJIN) CO., LTD.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>/s/ GENEXINE, INC.</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 22 - </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT <FONT STYLE="white-space:nowrap">A-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIST OF LICENSED INTELLECTUAL PROPERTIES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g38965st26.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;23&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT <FONT STYLE="white-space:nowrap">A-2</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIST OF ASSIGNED INTELLECTUAL PROPERTIES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g38965st27.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;24&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONTENTS OF TECHNOLOGY TRANSFER </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Transfer of technical documents </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IND documents submitted to regulatory agencies and all regulatory correspondences, covering both clinical
development and CMC </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Detailed reports of technology and <FONT STYLE="white-space:nowrap">know-how</FONT> related to clinical and <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> projects. Please see the list below. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Category 1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Category 2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="white-space:nowrap">GX-H9</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="white-space:nowrap">GX-G3</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="white-space:nowrap">GX-G6</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="white-space:nowrap">GX-P2</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="white-space:nowrap">GX-G8</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">TBD</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Phase<BR>II</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Phase<BR>II</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Preclinical</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Preclinical</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Research</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Research</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="7"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common technical document summaries</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center">Quality<BR>overall<BR>summary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Drug substance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Drug product</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="3" ALIGN="center">Nonclinical<BR>summary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Pharmacology</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Pharmacokinetics</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Toxicology</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center">Clinical<BR>summary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Clinical Investigator&#146;s Brochure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Phase I clinical overview</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quality</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center">Drug<BR>substance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">general information</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Manufacture (manufacturing process development, manufacturing process and controls of critical steps, process controls, materials control)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;25&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="4" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Control of drug substance (specification, analytical procedure, validation of analytical procedure, batch analyses)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#10003;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#10003;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&#10003;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Reference Standards or Materials</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Container Closure System</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Stability Summary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="7" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">Drug product</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Description and composition</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Pharmaceutical development (compatibility, component,
container closure system, formulation development, manufaturing process development)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Manufacture (manufacturing process and controls,
process controls of critical steps, batch formulation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Excipients summary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Control of drug substance (specification, analytical
procedure, validation of analytical procedure, batch analyses, characterisation of impurities)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Reference Standards or Materials</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Container Closure</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">System</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Stability Summary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="5"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nonclinical study
reports</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD ROWSPAN="2" VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD ROWSPAN="2" VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Pharmacology</P></TD>
<TD ROWSPAN="2" NOWRAP VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Primary-pharmacodynamics</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Safety-pharmacology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Pharmacokinetics</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Analytical methods</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#10003;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD ROWSPAN="2" VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD ROWSPAN="2" VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Toxicology</P></TD>
<TD ROWSPAN="2" NOWRAP VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Single dose, repeat dose,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Other toxicology study</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical study</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;<BR></P></TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Clinical study<BR>reports</P></TD>
<TD NOWRAP VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;<BR>&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phase I</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#10003;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: The IND Packages should be offered about <FONT STYLE="white-space:nowrap">GX-H9,</FONT>
<FONT STYLE="white-space:nowrap">GX-G3</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;26&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Transfer documents of cell line, including that <FONT STYLE="white-space:nowrap">GX-G3,</FONT> <FONT
STYLE="white-space:nowrap">GX-H9,</FONT> <FONT STYLE="white-space:nowrap">GX-G6,</FONT> <FONT STYLE="white-space:nowrap">GX-P2,</FONT> and <FONT STYLE="white-space:nowrap">GX-G8.</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Origin and documents of host cell </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Identification of vector </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Documents for IP protection of host cell and vector </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Development report and primary record of recombinant cell line used for
<FONT STYLE="white-space:nowrap">GX-G3,</FONT> <FONT STYLE="white-space:nowrap">GX-H9,</FONT> <FONT STYLE="white-space:nowrap">GX-G6,</FONT> <FONT STYLE="white-space:nowrap">GX-P2,</FONT> and <FONT STYLE="white-space:nowrap">GX-G8.</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Stability study report of recombinant cell line, including the stability of expression capability, gene
stability and gene copy </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Development reports for <FONT STYLE="white-space:nowrap">GX-G3,</FONT>
<FONT STYLE="white-space:nowrap">GX-H9,</FONT> <FONT STYLE="white-space:nowrap">GX-G6,</FONT> <FONT STYLE="white-space:nowrap">GX-P2,</FONT> and <FONT STYLE="white-space:nowrap">GX-G8.</FONT> (when applicable) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Report of upstream process development Report of downstream process development </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Report of analytical method development and method qualification Report of formulation development
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Report of fill-finish process development </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Report of DS and DP stability studies (with stability study protocol) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Report of specification justification </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;27&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Discovery background report for <FONT STYLE="white-space:nowrap">GX-G3,</FONT>
<FONT STYLE="white-space:nowrap">GX-H9,</FONT> <FONT STYLE="white-space:nowrap">GX-G6,</FONT> <FONT STYLE="white-space:nowrap">GX-P2,</FONT> and <FONT STYLE="white-space:nowrap">GX-G8</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">PoC data <FONT STYLE="white-space:nowrap">(in-vitro</FONT> and <FONT STYLE="white-space:nowrap">in-vivo)</FONT>
for <FONT STYLE="white-space:nowrap">GX-G6,</FONT> <FONT STYLE="white-space:nowrap">GX-P2,</FONT> and <FONT STYLE="white-space:nowrap">GX-G8</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Transfer of cell line for <FONT STYLE="white-space:nowrap">GX-G3,</FONT>
<FONT STYLE="white-space:nowrap">GX-H9,</FONT> <FONT STYLE="white-space:nowrap">GX-G6,</FONT> <FONT STYLE="white-space:nowrap">GX-P2,</FONT> and <FONT STYLE="white-space:nowrap">GX-G8.</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Research cell bank, Master cell bank and Work cell bank </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Transfer of <FONT STYLE="white-space:nowrap">in-house</FONT> reference standard for <FONT
STYLE="white-space:nowrap">GX-G3,</FONT> <FONT STYLE="white-space:nowrap">GX-H9,</FONT> <FONT STYLE="white-space:nowrap">GX-G6,</FONT> <FONT STYLE="white-space:nowrap">GX-P2,</FONT> and <FONT STYLE="white-space:nowrap">GX-G8.</FONT> Transfer of cell
line, <FONT STYLE="white-space:nowrap">in-house</FONT> special reagents for bioassay related to <FONT STYLE="white-space:nowrap">GX-G3,</FONT> <FONT STYLE="white-space:nowrap">GX-H9,</FONT> <FONT STYLE="white-space:nowrap">GX-</FONT> G6, <FONT
STYLE="white-space:nowrap">GX-P2,</FONT> and <FONT STYLE="white-space:nowrap">GX-G8.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nucleotide sequence and amino acid sequence related to <FONT STYLE="white-space:nowrap">GX-G3,</FONT> <FONT
STYLE="white-space:nowrap">GX-H9,</FONT> <FONT STYLE="white-space:nowrap">GX-G6,</FONT> <FONT STYLE="white-space:nowrap">GX-P2,</FONT> and <FONT STYLE="white-space:nowrap">GX-G8.</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;28&nbsp;- </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.15</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.15 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENEXINE, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTELLECTUAL PROPERTY LICENSE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">DATED DECEMBER
22, 2017 </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTELLECTUAL PROPERTY LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS INTELLECTUAL PROPERTY LICENSE AGREEMENT</B> (the &#147;<B>Agreement</B>&#148;) is made on December 22, 2017 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BETWEEN </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)<B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>GENEXINE, INC.</B>, a limited liability company established in Korea, with its registered address at 700 <FONT
STYLE="white-space:nowrap">Daewangpangyo-ro,</FONT> Korea <FONT STYLE="white-space:nowrap">Bio-Park</FONT> Bldg. B, <FONT STYLE="white-space:nowrap">Bundang-gu,</FONT> <FONT STYLE="white-space:nowrap">Seongnam-si,</FONT> <FONT
STYLE="white-space:nowrap">Gyeonggi-do</FONT> 13488, Korea (&#147;<B>Genexine</B>&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)<B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT></B>, a company established in the laws of Cayman Islands, with
its registered address at P. O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, <FONT STYLE="white-space:nowrap">KY1-1205</FONT> Cayman Islands<B> </B>(&#147;<B><FONT STYLE="white-space:nowrap">I-Mab</FONT></B>&#148;).
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Genexine and <FONT STYLE="white-space:nowrap">I-Mab</FONT> are jointly referred hereinafter as the &#147;<B>Parties</B>&#148; and
individually as a &#147;<B>Party</B>&#148;.) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Genexine and <FONT STYLE="white-space:nowrap">I-Mab</FONT> have agreed to establish a cooperation relationship with each other, under which
Genexine, as the sole and exclusive owner of all the patents, patent applications, know-hows, data and information<B> </B>(the &#147;<B>Licensed</B> <B>Intellectual Properties</B>&#148;), which relate to the Licensed Product (as defined below) and
are limited to those listed on <U>Exhibit A</U> attached hereto and may be updated from time to time during the term of this Agreement upon mutual consents of the Parties, intends to grant the License (as defined below) of the Licensed Intellectual
Properties to <FONT STYLE="white-space:nowrap">I-Mab</FONT> so that <FONT STYLE="white-space:nowrap">I-Mab</FONT> can engage in <FONT STYLE="white-space:nowrap">pre-clinical/clinical</FONT> development, manufacturing, sale and distribution of the
Licensed Product in the Territory (as defined below). <FONT STYLE="white-space:nowrap">I-Mab</FONT> intends to accept the License of the Licensed Intellectual Properties from Genexine in accordance with this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOW IT IS AGREED</B> between the Parties as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFINITIONS</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The following words and expressions shall have the meanings given to them below when used in this Agreement:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148; means with regard to a given natural or legal person (a &#147;<B>Person</B>&#148;), a
Person that controls, is controlled by or is under common control with the given Person. For the purposes of this Agreement, except as otherwise expressly provided, when used with respect to any Person, &#147;<B>control</B>&#148; means the power to
direct the management and policies of such Person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;1&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Competing Product&#148; </B>means any pharmaceutical product that contains <FONT
STYLE="white-space:nowrap">GX-I7</FONT> or Hyleukin covered by valid claims of the Hyleukin Patents listed in <U>Exhibit A</U> or any Improvements developed or acquired by Genexine or <FONT STYLE="white-space:nowrap">I-Mab</FONT> during the term of
this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;First Commercial Sale&#148; </B>means the first sale of the Licensed Product by
<FONT STYLE="white-space:nowrap">I-Mab,</FONT> or its Affiliates or <FONT STYLE="white-space:nowrap">sub-licensees</FONT> to unrelated third parties in any country within the Territory which shall be determined by the delivery date to the party
indicated on the respective invoice for the actual first commercial sale. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>hyFc Platform</B>&#148; means the fusion of Fc fragment
which is composed of the human IgD hinge region fused to the <FONT STYLE="white-space:nowrap">N-terminal</FONT> region of CH2 from IgD, which is in turn fused to the <FONT STYLE="white-space:nowrap">C-terminal</FONT> region of CH2 and the entire CH3
region of human IgG4. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Improvements</B>&#148; means any improvement, modification or alteration to the Licensed Product,
<I>i.e.</I>, <FONT STYLE="white-space:nowrap">GX-I7</FONT> or Hyleukin covered by valid claims of the Hyleukin Patents listed in <U>Exhibit A</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Licensed Product</B>&#148; means a long-acting (efineptakin alpha &#150; Source: International
<FONT STYLE="white-space:nowrap">Non-proprietary</FONT> Name) <FONT STYLE="white-space:nowrap">IL-7</FONT> cytokine designated as <FONT STYLE="white-space:nowrap">GX-I7</FONT> or Hyleukin covered by valid claims of the Hyleukin Patents listed in
<U>Exhibit A</U>. For the avoidance of doubt, the term &#147;Licensed Product&#148; does not include hyFc Platforms. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Net
Sales</B>&#148; means the gross amount invoiced by <FONT STYLE="white-space:nowrap">I-Mab,</FONT> and its Affiliates and <FONT STYLE="white-space:nowrap">sub-licensees</FONT> to unrelated third parties for sales of the Licensed Product in the
applicable Territory, less the following deductions to the extent included in the gross invoiced sales price for the Product or otherwise directly paid or incurred by <FONT STYLE="white-space:nowrap">I-Mab,</FONT> and its Affiliates and <FONT
STYLE="white-space:nowrap">sub-licensees,</FONT> with respect to sales of the Licensed Product in the applicable Territory: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">trade, quantity and cash discounts allowed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">discounts, refunds, rebates, chargebacks, retroactive price adjustments, and any other similar allowances which
effectively reduce the net selling prices (but excluding sales force commissions) in accordance with PRC GAAP and the laws of the applicable jurisdictions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">freight expense (actual), including insurance, to the extent it is not charged to or reimbursed by the
customer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">compulsory payments and rebates directly related to the sale of the Product paid to a governmental authority
pursuant to governmental regulations by reason of any national or local health insurance program or similar program; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">product returns and allowances; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">taxes (including, VAT, excise, consumption, sales and similar taxes and customs duties) to the extent actually
incurred, paid or collected and remitted to the relevant tax authority (but specifically excluding, for clarity, any income taxes assessed against the income arising from such sale). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;2&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Product Data&#148; </B>means all research data, pharmacology data, preclinical
data, clinical data and/or all regulatory filings and/or other regulatory documentation, information and submissions pertaining to, or made in association with a CTA, new drug application, or marketing approval, for the Licensed Product, resulting
from the development activities conducted by or under the authority of a Party (including, patient report form and other original source data), in each case to the extent controlled by such Party during the term of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Territory</B>&#148; means the People&#146;s Republic of China (PRC), Taiwan, Hong Kong and Macau. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Technical Documentation</B>&#148; means complete, correct and effective documents and electronic media embodying the Licensed
Intellectual Properties furnished to <FONT STYLE="white-space:nowrap">I-Mab</FONT> by Genexine in accordance with this Agreement, a list of the Technical Documentation is as attached hereto as <U>Exhibit B</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Therapeutic Indication</B>&#148; means treatment of all cancers within the field of Oncology. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any reference in this Agreement to &#147;writing&#148; includes electronic mail, facsimile transmission, telex,
cable or comparable means of communication. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The headings in this Agreement are for convenience only and shall not affect its interpretation.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LICENSE OF INTELLECTUAL PROPERTIES</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the terms and conditions hereof, Genexine hereby grants to
<FONT STYLE="white-space:nowrap">I-Mab</FONT> for the term of this Agreement an exclusive, sublicensable (subject to <U>Article 2.5</U>), transferable (subject to prior written consent of Genexine, such consent shall not be unreasonably withheld)
license in the Territory to use and otherwise exploit the Licensed Intellectual Properties and any Improvements (not including Improvements to the hyFc Platform technology that is not applicable to the Licensed Product) developed or acquired by
Genexine and licensed to <FONT STYLE="white-space:nowrap">I-Mab</FONT> in accordance with <U>Article 5.1</U>, in connection with the Licensed Product for the Therapeutic Indication (the &#147;<B>License</B>&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The License hereunder shall be limited to engaging in
<FONT STYLE="white-space:nowrap">pre-clinical/clinical</FONT> development, manufacturing, sale and distribution of the Licensed Product. For clarity, Genexine has the right to license the Platform Patents to a third party in the Territory,
<I>provided, however, that,</I> <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall be the sole and exclusive licensee in the Territory to use and otherwise exploit the Licensed Intellectual Properties to engage in
<FONT STYLE="white-space:nowrap">pre-clinical/clinical</FONT> development, manufacturing, sale and distribution of the Licensed Product for the Therapeutic Indication. Use of the Licensed Intellectual Properties by
<FONT STYLE="white-space:nowrap">I-Mab</FONT> shall be subject to confidentiality restrictions on its use and disclosure as set forth herein. Other than what is necessary to enable <FONT STYLE="white-space:nowrap">I-Mab</FONT> to perform <FONT
STYLE="white-space:nowrap">pre-clinical/clinical</FONT> development, manufacturing, sale and distribution of the Licensed Product for the Therapeutic Indication within the Territory, <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall not perform
such licensed activities outside of the Territory without Genexine&#146;s prior written consent. Except as expressly set forth in this Agreement, nothing in this Agreement shall be deemed to grant, directly or by implication, estoppel or otherwise,
any license or rights of any kind to <FONT STYLE="white-space:nowrap">I-Mab.</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;3&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">I-Mab</FONT> hereby covenants and agrees that it shall not, directly or
indirectly, develop, manufacture or sell any Licensed Product outside the Territory. <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall take reasonable efforts to prevent export of the Licensed Product outside the Territory and to avoid selling the
Licensed Product to a customer who desires to purchase the Licensed Product for sale outside of the Territory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Genexine hereby covenants and agrees that it shall not grant any license or rights of any kind in any of the
Licensed Intellectual Properties<B> </B>to any third party for the purpose of use, marketing, offer, distribution, sale, research, development or manufacture of the Licensed Product for the Therapeutic Indication in the Territory without prior
consent of <FONT STYLE="white-space:nowrap">I-Mab.</FONT> Genexine shall ensure that neither Genexine nor its Affiliates shall, directly or indirectly, develop, manufacture or sell any Licensed Product in the Territory. Genexine shall take
reasonable efforts to prevent export of the Licensed Product from outside the Territory into the Territory and to avoid selling the Licensed Product to a customer who desires to purchase the Licensed Product for sale in the Territory.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The License is sublicensable by <FONT STYLE="white-space:nowrap">I-Mab</FONT> in the Territory, provided that
such sublicense (including have-made right) shall require written consent of Genexine, which consent cannot be unreasonably withheld, and subject to all of the restrictions and obligations of <FONT STYLE="white-space:nowrap">I-Mab</FONT> set forth
herein. Notwithstanding the foregoing, <FONT STYLE="white-space:nowrap">I-Mab</FONT> may grant sublicenses under the Licensed Intellectual Properties without Genexine&#146;s prior written consent only to
<FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> Affiliates or any third party acting solely as contract manufacturer or contract research organization for <FONT STYLE="white-space:nowrap">I-Mab.</FONT> For clarity, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> shall be entitled to license its rights in Improvement within the Territory as long as it is not inconsistent with an exclusive license granted to Genexine outside of the Territory. <FONT
STYLE="white-space:nowrap">I-Mab</FONT> shall timely provide all major (including financial) terms of the intended sublicense for Genexine&#146;s review and consideration upon request from Genexine. In any case, all sublicenses shall oblige the
sublicensee to comply with all the terms of this Agreement (except those provisions that, by their clear meaning, are not applicable to a sublicensee), and <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall remain liable to Genexine for all acts
and omissions of any such sublicensee. <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall continue to have the payment obligations under this Agreement including milestones and royalties unless the sublicense agreement obliges the sublicensee to
pay milestones and royalties directly to Genexine in which case I-Mab&#146;s milestones and royalties payable under this Agreement will be reduced to the same extent. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;4&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If all or any part of any Licensed Intellectual Properties<B> </B>becomes invalid and such invalidity is not
due to a breach of the relevant representations, warranties and covenants made by Genexine in this Agreement, during the term of this Agreement, this Agreement shall remain effective with respect to any other Licensed Intellectual Properties<B>
</B>that is not invalid. In this event, during the term of this Agreement, <FONT STYLE="white-space:nowrap">I-Mab</FONT> continues to be obliged to pay the licensing fees mutually agreed between the Parties in this Agreement in consideration of the
License to use the Licensed Intellectual Properties (including know-hows, data and information) as granted hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">I-Mab</FONT> hereby grants to Genexine for the term of this Agreement an
exclusive, sublicensable, royalty free license to use and otherwise exploit any Improvement <FONT STYLE="white-space:nowrap">I-Mab</FONT> develops and acquires outside the Territory. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FEES AND ROYALTIES</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Payment for License</U>. Within thirty (30)&nbsp;days after the signing of this Agreement, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> shall pay a sum of <B>US$</B><B>12,000,000</B> to Genexine as the license fees in connection with the License subject to the terms and conditions provided herein. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Development Milestone Payments.</U> <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall pay development
milestone fees, as follows, to Genexine conditioned upon the Licensed Product reaching the following development milestones within sixty (60)&nbsp;days after each milestone event: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Milestone
Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Milestone&nbsp;Payment</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-time</FONT></FONT> completion of Phase II Clinical Study in any country in the Territory (i.e. upon submission of the CSR to the relevant regulatory
authority)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>US$5&nbsp;million</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-time</FONT></FONT> completion of Phase III Clinical Study in any country in the Territory (i.e. upon submission of the CSR to the relevant regulatory
authority)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>US$8&nbsp;million</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-time</FONT></FONT> receiving of the NDA or BLA approval from the relevant regulatory authority of any country in the Territory with respect to Therapeutic
Indications</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>US$10&nbsp;million</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">* (1) If a milestone event described above in the table will not occur due to cancellation or omission of a
clinical study of any phase, such milestone event shall be deemed reached at the same time as the next milestone event, and the corresponding milestone payment shall be payable when the next milestone payment becomes due. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;5&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2) For clarity, if there are several Therapeutic Indications, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> shall only pay development milestone fees for the first Therapeutic Indication, and <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall not pay any development milestone fees for the subsequent Therapeutic
Indications in any country in the Territory. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Sales Milestone Payments and Royalties.</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Sales Milestone Payments.</U> <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall pay five-time milestone fees for the Licensed Product,
as follows, to Genexine conditioned upon the Licensed Product reaching the following sales milestones within sixty (60)&nbsp;days after each milestone event: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Accumulated Net Sales</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Milestone&nbsp;Payment</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>US$100&nbsp;million</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>US$5&nbsp;million</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>US$200&nbsp;million</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>US$20&nbsp;million</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>US$500&nbsp;million</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>US$50&nbsp;million</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>US$1000&nbsp;million</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>US$150&nbsp;million</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>US$2000&nbsp;million</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>US$300&nbsp;million</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Royalties.</U> <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall pay a royalty of three percent (3%)
to Genexine in respect of the total annual Net Sales of the Licensed Product during the term of this Agreement defined in <U>Article 15.1</U>. All royalties shall be paid within sixty (60)&nbsp;days after the end of each financial year for the
respective total annual Net Sales of the Licensed Product. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Late Payment.</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the event that <FONT STYLE="white-space:nowrap">I-Mab</FONT> fails to make payments by the due dates set forth in this <U>Article 3</U>, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> shall pay Genexine a late payment fee amounting to one percent (1%) interest rate per month charged on the amount due for each day of delay. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Generic Entry. </U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Development Milestone Payment, Sales Milestone Payment, and Royalties provided in Articles 3.2 and 3.3 shall be reduced by 50%
following&nbsp;the entry of a generic product with respect to the Licensed Product in the Territory without the consent or authorization of <FONT STYLE="white-space:nowrap">I-MAB</FONT> or any of its sublicensees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;6&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>JOINT DEVELOPMENT COMMITTEE.</B><B> </B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Within thirty (30)&nbsp;days after the effective date of this Agreement, each Party shall appoint (and notify
the other Party of the identity of) an alliance manager. Each Party may, at any time, replace its alliance manager with another suitably qualified individual, on written notice to the other Party. The alliance managers shall be primarily responsible
for facilitating communications between the Parties and coordinating the Parties&#146; activities under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties shall establish a joint development committee to oversee the development and commercialization
activities, including but not limited to discuss and make decisions with respect to the manufacturing of the Licensed Product for clinical supply in accordance with the <FONT STYLE="white-space:nowrap">I-Mab</FONT> development plan, under this
Agreement (the &#147;<B>Joint Development Committee</B>&#148; or <B>&#147;JDC&#148;</B>). The Joint Development Committee shall be composed of four members with the equal number of persons from each Party who are with appropriate seniority and
functional expertise. Any decisions of the JDC shall be determined by a majority vote by the JDC members present at a meeting. The minimum quorum for a JDC meeting shall be <FONT STYLE="white-space:nowrap">two-third</FONT> (2/3) of members who must
be present for the entire meeting. If the JDC cannot reach consensus within two (2)&nbsp;weeks on any issue that comes before the JDC, then the Parties shall immediately refer such matter to the Chief Executive Officers at <FONT
STYLE="white-space:nowrap">I-Mab</FONT> and Genexine for resolution. In the event of a dispute between <FONT STYLE="white-space:nowrap">I-Mab</FONT> and Genexine that cannot be resolved within two (2)&nbsp;weeks by the Chief Executive Officers with
respect to matters concerning the research and development of Licensed Product, <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall have the final decision-making authority. Notwithstanding the foregoing,
<FONT STYLE="white-space:nowrap">I-Mab</FONT> shall have <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operational control over the development, manufacture and commercialization of the Licensed Product,
provided that <FONT STYLE="white-space:nowrap">I-Mab</FONT> conducts such activities in accordance with the terms and conditions of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The JDC shall hold meetings at such times as it elects to do so, but in no event shall such meetings be held
less frequently than once every month. Meetings of the JDC may be held in person, by audio or video teleconference; provided that at least one (1)&nbsp;meeting per year of the JDC shall be held in person.
<FONT STYLE="white-space:nowrap">In-person</FONT> JDC meetings shall be held at locations selected alternatively by the Parties. Each Party shall be responsible for all of its own expenses of participating in the JDC. No action taken at any meeting
of the JDC shall be effective unless representatives of both Parties are participating. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party may from time to time invite a reasonable number of participants, in addition to its
representatives, to attend the JDC meetings in a <FONT STYLE="white-space:nowrap">non-voting</FONT> capacity; provided that such participants shall be bound by confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> obligations
consistent with the terms of this Agreement and that each Party shall provide prior written notice to the other Party if it has invited any third party (including any consultant) to attend such a meeting. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;7&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>IMPROVEMENTS</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During the term of this Agreement, if Genexine develops or acquires any Improvements, it shall own such
Improvements and provide <FONT STYLE="white-space:nowrap">I-Mab</FONT> details of the Improvements, whether patentable or not, and grant to <FONT STYLE="white-space:nowrap">I-Mab</FONT> an exclusive license (with a right to sublicense) to use the
Improvements in the Territory. For the avoidance of any doubt, the scope of Improvements Genexine may license to <FONT STYLE="white-space:nowrap">I-Mab</FONT> under this Article is limited to Improvements to the Licensed Product and does not include
Improvements to the hyFc Platform technology that is not applicable to the Licensed Product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During the term of this Agreement, if <FONT STYLE="white-space:nowrap">I-Mab</FONT> develops or acquires any
Improvements, it shall own such Improvements and provide Genexine details of the Improvements, whether patentable or not, and grant to Genexine an exclusive license (with a right to sublicense) to use the Improvements free of charge anywhere outside
the Territory. For the avoidance of any doubt, the scope of Improvements <FONT STYLE="white-space:nowrap">I-Mab</FONT> may license to Genexine under this Article is limited to Improvements to the Licensed Product and does not include anything that
is not applicable to the Licensed Product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For avoidance of doubt, any use of the Improvements in the Territory by
<FONT STYLE="white-space:nowrap">I-Mab</FONT> based on <U>Articles 5.1</U> above shall be subject to the same payment obligations (Sales Milestones and Royalties) as <FONT STYLE="white-space:nowrap">I-Mab</FONT> is obliged to pay under <U>Article
3.3</U> with respect to the Licensed Product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If any Improvements developed or acquired by either party are partially or completely funded and/or conducted
by a third party strategic partner, or any third party proprietary information is involved in the studies and/or trials including but not limited to a combination study with other product(s), the Improvements from such studies and/or trials shall
only be shared with the other party subject to the prior written consent of such third party. The party who developed or acquired such Improvements shall make good faith efforts to obtain such prior written consent from such third party to share the
Improvements with the other party. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EXCHANGE OF PRODUCT DATA</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties shall, subject always to approval by the JDC, share with each other the Product Data generated or
attained during the term of this Agreement for use in the product development and commercialization of the Licensed Product within the Territory for <FONT STYLE="white-space:nowrap">I-Mab</FONT> or outside the Territory for Genexine in English along
with their original language versions if they are not written in English. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If any such Product Data generated or attained by either party are partially or completely funded and/or
conducted by a third party strategic partner, or any third party proprietary information is involved in the studies and/or trials including but not limited to a combination study with other product(s), the Product Data from such studies and/or
trials shall only be shared with the other party subject to the prior written consent of such third party. The party who generated or attained such Product Data shall make good faith efforts to obtain such prior written consent from such third party
to share the Product Data with the other party. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;8&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SALE OF LICENSED PRODUCT</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Licensed Product which is approved for sale by the relevant regulatory authority(ies) (e.g., China Food and Drug Administration (CFDA)) may
be sold in the Territory and <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall be responsible for obtaining all necessary regulatory approvals and complying with regulations applicable to the Licensed Product. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>BOOKS AND RECORDS</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">I-Mab</FONT> shall keep complete and proper records and books of account
showing the Net Sales, quantity and description of the Licensed Product sold by it, including accounting receipts and monthly and quarterly accounting statements in accordance with the relevant regulations of the Territory. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Such records and books of account shall be kept separate from any books and records which are not related to
the Licensed Product and shall be open to inspection by Genexine or its duly authorised representatives or agents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">I-Mab</FONT> shall permit Genexine (or its representatives) at Genexine&#146;s
expense to inspect, audit and investigate at all reasonable times the books, accounts, records, audit reports, documents and other matters of <FONT STYLE="white-space:nowrap">I-Mab</FONT> relating to the production and sale of the Licensed Product.
Such inspections, audits and investigations shall be conducted in such a manner and at such times so as not to adversely affect the operation of <FONT STYLE="white-space:nowrap">I-Mab</FONT> or the sale of the Licensed Product and the results
thereof shall be kept confidential. Such inspections, audits, and investigations shall be conducted no more often than twice a year, and Genexine should give <FONT STYLE="white-space:nowrap">I-Mab</FONT> reasonable advance notice prior to conducting
such inspections, audits, and investigations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If any inspection under <U>Article 8.3</U> reveals an underpayment by
<FONT STYLE="white-space:nowrap">I-Mab</FONT> of the total amount payable by <FONT STYLE="white-space:nowrap">I-Mab</FONT> to Genexine hereunder with respect to any period in question for more than 10%, then
<FONT STYLE="white-space:nowrap">I-Mab</FONT> shall reimburse Genexine for the cost of such audit and pay the deficiency immediately with interest at one percent (1%) per month. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TAX</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Each Party shall (i)&nbsp;bear the cost of all stamp duty, income taxes and duties are legally required to be paid by it as a result of the
transaction contemplated by this Agreement, and (ii)&nbsp;shall comply with all tax reporting and withholding obligations as applicable to it in connection with transactions contemplated by this Agreement as required by all applicable laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;9&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TECHNICAL DOCUMENTATION</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Within thirty (30)&nbsp;days after the date of this Agreement, Genexine shall provide <FONT
STYLE="white-space:nowrap">I-Mab</FONT> free of charge with one set of all Technical Documentation that are reasonably necessary for <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> use and exploitation of the Licensed Intellectual Properties in
order to enable <FONT STYLE="white-space:nowrap">I-Mab</FONT> to perform the licensed activities herein. A list of the Technical Documentation is attached hereto as <U>Exhibit B</U>. Upon receipt of any such Technical Documentation, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> shall promptly deliver to Genexine a written acknowledgment of receipt thereof and shall comply with the confidentiality provisions in this Agreement to protect the confidentiality of such Technical
Documentation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Genexine shall use all reasonable endeavours to ensure that the Technical Documentation shall be readable,
complete and accurate. <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall notify Genexine in writing within six (6)&nbsp;months after receipt thereof if any of the Technical Documentation is not readable, complete or accurate and Genexine shall
correct or replace the defective portions of the Technical Documentation free of charge to <FONT STYLE="white-space:nowrap">I-Mab.</FONT> In the absence of a written notice from <FONT STYLE="white-space:nowrap">I-Mab</FONT> to Genexine within the
six (6)&nbsp;months period, the Technical Documentation in question shall be deemed to have been approved and accepted by <FONT STYLE="white-space:nowrap">I-Mab.</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MATERIALS</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> may source raw materials, ingredients and other components for the production of the Licensed
Product, provided that the manufacturing of the Licensed Product by using these raw materials, ingredients and components shall meet the technical specifications and standards of Genexine. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONFIDENTIALITY</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">I-Mab</FONT> shall, during the term of this Agreement and after its
termination or expiration for any reason, keep confidential and not make use of for any purpose other than the performance of its obligations under this Agreement, nor disclose to any other person otherwise than in accordance with <U>Article
12.2</U> or with the prior written consent of Genexine, anything of the Licensed Intellectual Properties, including but not limited to, information contained in the Technical Documentation, Improvements, Product Data and any other information
disclosed (whether in writing, verbally or by other means) by or on behalf of Genexine. Without prejudice to the generality of this obligation above, <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">identify any and all of the Licensed Intellectual Properties so that it can be distinguished from its own
information or documentation; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;10&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">arrange proper and secure storage facilities for the Licensed Intellectual Properties and control and supervise
access of its employees and personnel to such facilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">mark and label all information contained in the Licensed Intellectual Properties and Technical Documentation
relating to the Licensed Intellectual Properties &#147;confidential&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">disclose the Licensed Intellectual Properties only to its employees pursuant to <U>Article 12.3</U>;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">prevent unauthorized access to or disclosure of the Licensed Intellectual Properties; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not use, reproduce, transform or store any of the Licensed Intellectual Properties in any place that is
externally accessible, whether it is in hardcopy or electronic form. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The foregoing obligations of <FONT STYLE="white-space:nowrap">non-use</FONT> and
<FONT STYLE="white-space:nowrap">non-disclosure</FONT> shall not apply to: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">information available to the public at the time when it is obtained or which subsequently becomes available to
the public through no fault of <FONT STYLE="white-space:nowrap">I-Mab;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">information which <FONT STYLE="white-space:nowrap">I-Mab</FONT> can demonstrate was in its possession, as
evidenced by written documents, at the time when it obtains such information from Genexine; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">information properly conveyed to <FONT STYLE="white-space:nowrap">I-Mab</FONT> after the disclosure by an
independent and unrelated third party, which, third party disclosure was not under an obligation of confidentiality at the time of disclosure of the third party information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">information required to be disclosed by law, provided that <FONT STYLE="white-space:nowrap">I-Mab</FONT>
promptly notifies Genexine of such requirement to enable Genexine the opportunity to oppose such requirement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During the term of this Agreement <FONT STYLE="white-space:nowrap">I-Mab</FONT> may disclose information which
is confidential under <U>Article 12.1</U> to its officers, directors, managers and employees, but only to the extent necessary for the purposes of this Agreement and provided such person has signed a confidentiality contract, in the form and
substance satisfactory to the board of the directors of <FONT STYLE="white-space:nowrap">I-Mab.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">I-Mab</FONT> shall, at its own expense, take such steps as Genexine may
require to enforce the terms of any confidentiality contract executed pursuant to <U>Article 12.3</U> including, but not limited to, the initiation, prosecution and enforcement of any legal proceedings. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;11&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CLAIMS AND INFRINGEMENTS</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">I-Mab</FONT> shall immediately notify Genexine of any claim, or any fact which
may lead to a claim, of any nature by a third party that the use of the Licensed Intellectual Properties by <FONT STYLE="white-space:nowrap">I-Mab</FONT> is or may be an infringement of a patent or other proprietary right of such third party, but
shall take no action relating to such claim or infringement without Genexine&#146;s written consent. Genexine shall advise <FONT STYLE="white-space:nowrap">I-Mab</FONT> whether it wishes to conduct a defense of any such claim. Should Genexine elect
to conduct such a defense, it shall do so at its own expense, and Genexine shall have sole control of such defense either in its own name or in the name of <FONT STYLE="white-space:nowrap">I-Mab,</FONT> as the case may be, and <FONT
STYLE="white-space:nowrap">I-Mab</FONT> shall give all reasonable assistance to Genexine to enable it to do so. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Genexine shall indemnify <FONT STYLE="white-space:nowrap">I-Mab</FONT> and bear related costs for any claims,
losses, damages, proceedings sustained by <FONT STYLE="white-space:nowrap">I-Mab</FONT> in relation to any claims that may be made against <FONT STYLE="white-space:nowrap">I-Mab</FONT> pursuant to <U>Article 13.1</U>, unless such claims, losses,
damages, proceedings result from the default by <FONT STYLE="white-space:nowrap">I-Mab</FONT> of its obligations under this Agreement or the use of Licensed Intellectual Properties by <FONT STYLE="white-space:nowrap">I-Mab</FONT> otherwise than in
accordance with this Agreement. Notwithstanding the above, the total and aggregate liability of Genexine shall not exceed an amount equal to the sum of (i)&nbsp;the payment received by Genexine pursuant to <U>Article 3.1</U>, (ii) any milestone
payments actually received by Genexine pursuant to <U>Articles 3.2</U> and <U>3.3</U> and (iii)&nbsp;any other payments received by Genexine pursuant to this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">I-Mab</FONT> shall immediately notify Genexine of any information it obtains
that any third party is or may be infringing the Platform Patents, but shall take no action relating to such infringement without Genexine&#146;s written consent. Genexine shall advise <FONT STYLE="white-space:nowrap">I-Mab</FONT> whether it wishes
to take action with respect to such infringement. Should Genexine elect to take action with respect to such infringement, it shall do so at its own expense, and Genexine shall have sole control of such action and
<FONT STYLE="white-space:nowrap">I-Mab</FONT> shall give Genexine all reasonable assistance to enable it to do so. All compensation which may be recovered shall be made to Genexine. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that Genexine elects not to take action under <U>Article 13.3</U>,
<FONT STYLE="white-space:nowrap">I-Mab</FONT> shall be entitled to take action in relation to the relevant infringement at its own cost and expense, and Genexine shall give all reasonable assistance in connection therewith. All compensation which
may be recovered shall be made to <FONT STYLE="white-space:nowrap">I-Mab.</FONT> Notwithstanding the foregoing, <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall not enter into any compromise, settlement or agreement with any person or entities
relating to the Platform Patents otherwise than with the written consent of Genexine. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Genexine shall immediately notify <FONT STYLE="white-space:nowrap">I-Mab</FONT> of any information it obtains
that any third party is or may be infringing the Hyleukin Patents, but shall take no action relating to such infringement without <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> written consent. <FONT STYLE="white-space:nowrap">I-Mab</FONT>
shall advise Genexine whether it wishes to take action with respect to such infringement. Should <FONT STYLE="white-space:nowrap">I-Mab</FONT> elect to take action with respect to such infringement, it shall do so at its own expense, and <FONT
STYLE="white-space:nowrap">I-Mab</FONT> shall have sole control of such action and Genexine shall give <FONT STYLE="white-space:nowrap">I-Mab</FONT> Genexine all reasonable assistance to enable it to do so. All compensation which may be recovered
shall be made to <FONT STYLE="white-space:nowrap">I-Mab.</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;12&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that <FONT STYLE="white-space:nowrap">I-Mab</FONT> elects not to take action under <U>Article
13.5</U>, Genexine shall be entitled to take action in relation to the relevant infringement at its own cost and expense, and <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall give all reasonable assistance in connection therewith. All
compensation which may be recovered shall be made to Genexine. Notwithstanding the foregoing, Genexine shall not enter into any compromise, settlement or agreement with any person or entities relating to the Hyleukin Patents otherwise than with the
written consent of <FONT STYLE="white-space:nowrap">I-Mab.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as provided in this Agreement, Genexine shall have no responsibility for any claim with respect to
licensed activities performed and the Licensed Product manufactured or distributed by <FONT STYLE="white-space:nowrap">I-Mab</FONT> hereunder or arising from the use by <FONT STYLE="white-space:nowrap">I-Mab</FONT> of the Licensed Intellectual
Properties furnished by Genexine hereunder. <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall hold harmless and indemnify Genexine against any claim, loss or damage arising from claims by any third party with respect to any licensed activities
performed and the Licensed Product manufactured or distributed by <FONT STYLE="white-space:nowrap">I-Mab</FONT> hereunder unless such claim, loss or damage arises from or is attributable to the any of the representations, warranties or covenants of
Genexine herein. In addition, in the event of technical problems of the Licensed Product as a consequence of any breach of warranty by <FONT STYLE="white-space:nowrap">I-Mab</FONT> (including as a result of any failure by <FONT
STYLE="white-space:nowrap">I-Mab</FONT> to correctly apply any Licensed Intellectual Properties utilized by <FONT STYLE="white-space:nowrap">I-Mab</FONT> for such Licensed Product), Genexine may require <FONT STYLE="white-space:nowrap">I-Mab</FONT>
to implement any necessary preventive and corrective measures and <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall comply with Genexine&#146;s advice as soon as reasonably practicable at <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> own
expense. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything to the contrary in this <U>Article 13</U> or elsewhere in this Agreement, neither
Party shall have any liability, whether arising in contract, tort (including negligence), strict liability, breach of warranty or any other theory of law, for any special, incidental, indirect or consequential loss or damage of any nature suffered
by the other Party. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RE</B><B>P</B><B>RESENTATIONS, </B><B>WARRANTIES</B><B> AND COVENANTS</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Genexine hereby represents and warrants to <FONT STYLE="white-space:nowrap">I-Mab,</FONT> that Genexine is the
sole legal owner of the Licensed Intellectual Properties and has full power, right and authority to grant the License to <FONT STYLE="white-space:nowrap">I-Mab</FONT> pursuant to this Agreement in the Territory and, to the knowledge of Genexine, any
of the Licensed Intellectual Properties is free of liens, pledges or any other encumbrances in the Territory. To the knowledge of Genexine, there are no claims or investigations pending or threatened against any of the Licensed Intellectual
Properties in the Territory. To the knowledge of Genexine, the license hereunder, the performance of the licensed activities, and the Licensed Product do not violate the relevant laws of the respective places of registration of the Parties or
infringe any third party rights. The Licensed Intellectual Properties, and the relevant technical assistance, guidance and training, shall be sufficient to enable <FONT STYLE="white-space:nowrap">I-Mab</FONT> to perform the licensed activities in
accordance with all applicable specifications set forth in the Technical Documentation. During the term of this Agreement, Genexine shall maintain and protect the validity of the Licensed Intellectual Properties to the greatest extent permitted by
the applicable laws. EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, THERE ARE NO EXPRESS OR IMPLIED WARRANTIES, INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, RESPECTING THIS AGREEMENT OR ANY LICENSED
INTELLECTUAL PROPERTIES OR TECHNICAL DOCUMENTATION FURNISHED HEREUNDER BY GENEXINE. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;13&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as provided in this Agreement, nothing in this Agreement shall limit the rights of Genexine to use the
Licensed Intellectual Properties anywhere in the world and <FONT STYLE="white-space:nowrap">I-Mab</FONT> waives and disclaims any right or interest in the Licensed Intellectual Properties which may arise under any law or legal theory out of the
permitted use hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nothing in this Agreement shall: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">14.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">constitute a sale, transfer or assignment of the Licensed Intellectual Properties to <FONT
STYLE="white-space:nowrap">I-Mab,</FONT> unless it is otherwise agreed in other agreements, contracts or arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">14.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">give <FONT STYLE="white-space:nowrap">I-Mab</FONT> any right, title or interest in or to the Licensed
Intellectual Properties except the license to use in accordance with this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">14.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">give <FONT STYLE="white-space:nowrap">I-Mab</FONT> any right to register or apply for registration of any of
the Licensed Intellectual Properties (except this Agreement itself), whether in the Territory or elsewhere; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">14.3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">diminish or affect the rights of Genexine to take legal action or obtain any other relief against any infringer
of the Licensed Intellectual Properties in the Territory or elsewhere. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">I-Mab</FONT> agrees that it shall: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">14.4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not register or make any application to register the Licensed Intellectual Properties or any part thereof in
the name of <FONT STYLE="white-space:nowrap">I-Mab</FONT> in the Territory or elsewhere, whether for copyright, patent right or any other registerable right (for avoidance of doubt, <FONT STYLE="white-space:nowrap">I-Mab</FONT> is permitted to
register the License granted hereunder pursuant to <U>Article 2.9</U>); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;14&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">14.4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">strictly adhere to all instructions or advice from Genexine regarding the use of the Licensed Intellectual
Properties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">14.4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">comply with intellectual property laws of the Territory and each of the jurisdictions where the Licensed
Products are sold by <FONT STYLE="white-space:nowrap">I-Mab</FONT> with respect to the use of the Licensed Intellectual Properties in such jurisdictions in order to preserve and maintain Genexine&#146;s rights in the Licensed Intellectual
Properties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">14.4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">inform Genexine of the imposition of any new laws or regulations or changes in laws or regulations imposed in
the Territory during the term of this Agreement which affect performance by either <FONT STYLE="white-space:nowrap">I-Mab</FONT> or Genexine under this Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">14.4.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">maintain and protect the validity of the Licensed Intellectual Properties to the greatest extent permitted by
the applicable laws and shall not assign the Licensed Intellectual Properties to its Affiliate or any third party without Genexine&#146;s prior written consent; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">14.4.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not contest, infringe or harm any right which Genexine or any affiliate of Genexine may have in Licensed
Intellectual Properties, whether in the Territory or elsewhere. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERM AND TERMINATION</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement shall take effect upon execution by the Parties and shall, unless otherwise terminated according
to <U>Article 15.2</U> hereof, remain in full force and effect until the later of (i)&nbsp;the expiry of the last to expire patent specified in <U>Exhibit A</U> as of the date of execution of this Agreement that includes a valid claim for the
Territory and that covers the composition of the Licensed Product or (ii)&nbsp;fifteen (15) years after the First Commercial Sale of the Licensed Product unless terminated earlier pursuant to this Agreement, except that termination shall not affect:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the accrued rights and obligations of the Parties at the date of termination; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the continued existence and validity of the rights and obligations of the Parties under those articles which
are designed to survive termination and any provisions of this Agreement necessary for the interpretation or enforcement of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise provided herein, this Agreement may be terminated: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by either Party giving notice to the other Party if the other Party has committed a material breach of this
Agreement and such breach, if capable of remedy, has not been so remedied within sixty (60)&nbsp;days following receipt of such notice, unless otherwise provided herein; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;15&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by either Party giving notice to the other Party in the event that an event of Force Majeure continues for a
period of six (6)&nbsp;consecutive months that causes <FONT STYLE="white-space:nowrap">I-Mab</FONT> to cease the production and sale of the Licensed Product and the Parties have been unable to find an equitable solution pursuant to <U>Article
19</U>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by either Party giving notice to the other Party if at any time during the term of this Agreement, any
government of the Territory should require any material alteration or modification of the contractual rights or obligations of the Parties pursuant to this Agreement which has the effect of preventing the Parties from achieving their business
objectives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by either Party giving notice to the other Party if the other Party becomes bankrupt, or insolvent, or is the
subject of proceedings or arrangements for liquidation or dissolution, or ceases to carry on business, or becomes unable to pay its debts as they become due; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by Genexine giving notice to <FONT STYLE="white-space:nowrap">I-Mab</FONT> if
<FONT STYLE="white-space:nowrap">I-Mab</FONT> fails to use commercial reasonable effort to obtain regulatory approvals or other registrations necessary for sale or distribution of the Licensed Product in the Territory in accordance with a business
plan and timeline approved by the Parties from time to time due to a reason attributable to <FONT STYLE="white-space:nowrap">I-Mab</FONT> (i.e. due to fault or negligence of <FONT STYLE="white-space:nowrap">I-Mab)</FONT> or ceases to pursue clinical
development or product registration or to conduct licensed activities in a reasonable scale pursuant to an agreement by the Parties. It is expressly stated that such termination events shall include, among others, (a)&nbsp;the first Development
Milestone specified in <U>Article&nbsp;3.3(a)</U> fails to be reached within seven (7)&nbsp;years after the signing of this Agreement, (b)&nbsp;the second Development Milestone specified in <U>Article&nbsp;3.2</U> fails to be reached within ten
(10)&nbsp;years after the signing of this Agreement and <FONT STYLE="white-space:nowrap">(c)&nbsp;I-Mab</FONT> fails to commercially launch the Licensed Product in the Territory within twelve (12)&nbsp;years after the signing of this Agreement; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">15.2.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by mutual agreement of the parties. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In case this Agreement is terminated by Genexine pursuant to <U>Articles&nbsp;15.2.1,</U> <U>15.2.2,</U>
<U>15.2.4 or 15.2.5</U>, or by <FONT STYLE="white-space:nowrap">I-Mab</FONT> pursuant to <U>Article&nbsp;15.2.3</U>, <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall not, and shall ensure that its Affiliates shall not, develop, manufacture,
market, promote, sell, offer for sale, distribute or otherwise make available (or contract with a third party to do any of the foregoing) any Competing Product for a period of seven (7)&nbsp;years after any such termination. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon termination of this Agreement for whatever reason, <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall
immediately cease to use the Licensed Intellectual Properties as provided by Genexine and shall cease to manufacture or sell the Licensed Product. <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall cooperate with Genexine in <FONT
STYLE="white-space:nowrap">de-registration</FONT> of the License hereunder with the competent authorities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;16&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon termination of this Agreement for whatever reason, Genexine may, at its sole discretion, choose to buy at
I-Mab&#146;s initial purchase price any quantities of the Licensed Product or parts thereof remaining in <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> inventory (which are in good condition for sale to customers and already approved for sale
by the China Food and Drug Administration which are not subject to delivery under a sale to customers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon expiration or termination of this Agreement, all amounts then due and unpaid to Genexine by <FONT
STYLE="white-space:nowrap">I-Mab</FONT> hereunder, as well as all other amounts accrued but not yet payable to Genexine by <FONT STYLE="white-space:nowrap">I-Mab,</FONT> shall forthwith become due and payable by
<FONT STYLE="white-space:nowrap">I-Mab</FONT> to Genexine. However, in the event that this Agreement is terminated by <FONT STYLE="white-space:nowrap">I-Mab</FONT> as a result of Genexine&#146;s material breach of this Agreement and <FONT
STYLE="white-space:nowrap">I-Mab</FONT> has raised claims against Genexine due to such breach, the aforesaid payment will be suspended until settlement of such claims pursuant to <U>Article&nbsp;19</U> hereof. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All Licensed Intellectual Properties, including the Improvements and the Technical Documentation relating to
the Licensed Intellectual Properties as provided by Genexine, recorded in any material form including but not limited to any written records shall be returned by <FONT STYLE="white-space:nowrap">I-Mab</FONT> to Genexine forthwith upon the
termination or expiration of this Agreement. <FONT STYLE="white-space:nowrap">I-Mab</FONT> agrees on behalf of itself and its employees that no copies of the Licensed Intellectual Properties in any material form or of the Technical Documentation
relating to the Licensed Intellectual Properties shall be made or retained upon and after the termination or expiration of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon termination, <FONT STYLE="white-space:nowrap">I-Mab</FONT> agrees to permit Genexine and its
representatives to inspect the records and accounts of <FONT STYLE="white-space:nowrap">I-Mab</FONT> and to investigate generally all business transactions carried on by <FONT STYLE="white-space:nowrap">I-Mab</FONT> under and pursuant to this
Agreement for a period of twelve (12)&nbsp;months following the last sale of the Licensed Product, and <FONT STYLE="white-space:nowrap">I-Mab</FONT> agrees not to destroy any of such records prior to the expiration of such twelve (12)&nbsp;month
period. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INDEPENDENT CONTRACTORS</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Parties are independent contractors, and nothing in this Agreement shall be construed to constitute either Party to be the agent, partner,
legal representative, attorney or employee of the other for any reason whatsoever. Neither Party shall have the power or authority to bind the other except as specifically set out in this Agreement. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FORCE MAJEURE</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Force Majeure</B>&#148; means all events which are beyond the control of the Parties to this
Agreement, and which are unforeseen, or if foreseen, unavoidable, and which prevent total or partial performance by either Party. Such events shall include but are not limited to any lockouts, explosions, shipwrecks, acts of nature or the public
enemy, fires, flood, sabotage, accidents, strikes, wars, riots, insurrections, and any other similar contingency. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;17&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If an event of Force Majeure occurs, to the extent that any contractual obligation of either Party cannot be
performed as a result of such event, such contractual obligation shall be suspended while the Force Majeure subsists and the due date for performance thereof shall be automatically extended, without penalty, for a period equal to such suspension.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Party encountering Force Majeure shall, within fifteen (15)&nbsp;days of the relevant event, notify the
other Party and furnish valid proof of the occurrence of such Force Majeure. Within a reasonable period thereafter that Party shall provide the other Party with evidence of the Force Majeure issued by a relevant agency. The Party encountering Force
Majeure shall also use all reasonable endeavours to minimize the consequences of such Force Majeure. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event of Force Majeure, the Parties shall immediately consult with each other in order to mutually agree
an equitable solution (which may involve early termination of this Agreement a part thereof or extension of the term of this Agreement) and shall use all reasonable endeavours to minimize the consequences of such Force Majeure.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LIABILITY FOR BREACH</B><B> AND INDEMNIFICATION</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">I-Mab</FONT> shall indemnify and hold Genexine harmless against all losses,
liabilities, costs, claims, actions, damages, expenses or demands, which Genexine may incur, or which may be made against Genexine as a result of or in relation to any breach by <FONT STYLE="white-space:nowrap">I-Mab</FONT> of its obligations under
this Agreement or arising out of any improper use of the Licensed Intellectual Properties by <FONT STYLE="white-space:nowrap">I-Mab.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Genexine shall indemnify and hold <FONT STYLE="white-space:nowrap">I-Mab</FONT> harmless against all losses,
liabilities, costs, claims, actions, damages, expenses or demands, which <FONT STYLE="white-space:nowrap">I-Mab</FONT> may incur, or which may be made against <FONT STYLE="white-space:nowrap">I-Mab</FONT> as a result of or in relation to any breach
by Genexine of its obligations under this Agreement, including but not limited to any breach of Genexine&#146;s representations, warranties and covenants made in <U>Article&nbsp;13.1</U>. Notwithstanding the above, the total and aggregate liability
of Genexine under this Agreement shall not exceed an amount equal to the sum of (i)&nbsp;the payment received by Genexine pursuant to <U>Articles 3.1,</U> (ii) any milestone payments of any corresponding product actually received by Genexine
pursuant to <U>Article 3.2</U> and <U>3.3</U> and (iii)&nbsp;any other payments received by Genexine pursuant to this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SETTLEMENT OF DISPUTES</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All disputes arising out of or in connection with this Agreement shall be submitted to the Singapore Mediation Procedure of the Singapore
Mediation Centre for the time being in force. The Parties agree to participate in the mediation and undertake to abide by the terms of any settlement reached. If contrary to expectation, no amicable settlement can be reached, both Parties hereto
agree to submit to Arbitration under the Rules of the Singapore International Arbitration Centre by one (1)&nbsp;arbitrator appointed in accordance with the said Rules. The arbitrator shall have the authority to grant injunctive relief or other
specific performance. Hearings shall be conducted in English and shall take place in Singapore at Singapore International Arbitration Centre. Notwithstanding any other provision of this Agreement, the Parties may seek an injunctive relief or any
other form of equitable relief in any court of competent jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;18&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ASSIGNMENT</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Neither Party may assign or otherwise transfer its rights or obligations under this Agreement without the prior
written consent of the other Party, except Genexine shall be entitled to assign or transfer its rights and obligations under this Agreement to any of its Affiliates or to any third party which succeeds to the business of Genexine, whether through
stock or asset sale, merger, reorganization or otherwise, provided that <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall be notified by Genexine of such assignment or transfer in writing and such successor succeeds to Genexine&#146;s rights in
the Licensed Intellectual Properties and shall agree in writing to assume the rights and obligations of Genexine under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement is binding upon and is made for the benefit of the Parties and their successors and permitted
assignees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">I-Mab</FONT> shall continue to be bound by the rights and obligations under
this Agreement regardless of any change of control in <FONT STYLE="white-space:nowrap">I-Mab</FONT> whether through stock or asset sale, merger, reorganization or otherwise and promptly notify Genexine of such change of control in writing.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">21.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NOTICES</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Any notices to be given under this Agreement shall be in writing and deemed delivered when received by the Party to whom it is addressed, and
receipt shall be evidenced by (i)&nbsp;the written receipt of the receiving Party or the affidavit from the delivering person, if hand delivered, confirming delivery or refusal of delivery by the addressee, (ii)&nbsp;the signed returned receipt or
other written proof of delivery if delivered by registered air or express mail (return receipt requested) or by an internationally recognized courier service, or (iii)&nbsp;electronic proof of transmission if sent by fax or telex, provided that any
notice sent by fax or telex shall also be sent by registered air or express mail (return receipt requested) or internationally recognized courier service. Notices shall be given to the relevant Party at the addresses set forth below: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">I-Mab</FONT></U>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Address: Suite 802, West Tower, OmniVision Tech Park, 88 Shangke Road, Pudong New District, Shanghai, China 201210. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;19&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Raven Lin </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Telephone: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Fax: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Genexine</U>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Address: 700 <FONT
STYLE="white-space:nowrap">Daewangpangyo-ro,</FONT> Korea <FONT STYLE="white-space:nowrap">Bio-Park</FONT> Bldg. B, <FONT STYLE="white-space:nowrap">Bundang-gu,</FONT> <FONT STYLE="white-space:nowrap">Seongnam-si,</FONT> <FONT
STYLE="white-space:nowrap">Gyeonggi-do</FONT> 13488, Korea </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Telephone: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Fax: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">22.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MISCELLANEOUS</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">I-Mab</FONT> shall observe and comply with all laws, rules and regulations
applicable to the manufacture, packaging, storage, handling, advertising, marketing and sale of the Licensed Product in the Territory. <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall, at its own cost and expense, secure and maintain all
necessary governmental permits, licenses and approvals, and will fulfil all other requirements and undertakings related to this Agreement which are or may become necessary under any law or regulation, to enable the Parties to exercise, enforce and
enjoy all of the rights and obligations contained in this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Failure or delay on the part of either Party to exercise any right, power or privilege hereunder, or any other
contract relating hereto, shall not operate as a waiver thereof, nor shall the partial exercise of any right, power or privilege preclude any other future full and complete exercise thereof. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The validity, interpretation and implementation of this Agreement shall be governed by and construed in
accordance with the laws of Singapore without regard to its conflict of laws provisions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Should any Article or any part of any Article contained in this Agreement be declared invalid or unenforceable
for any reason whatsoever, all other Articles or parts of Articles contained in this Agreement shall remain in full force and effect. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;20&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement and all documentation executed in connection therewith shall constitute the entire agreement
between the Parties with respect to the subject matter and shall automatically cancel and supersede any and all prior oral understandings with respect thereto, unless such understandings are memorialized in writing contemporaneous with the signing
of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement may be amended only by a written instrument signed by the Parties. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement shall be executed in two (2)&nbsp;or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. If any signature is delivered by <FONT STYLE="white-space:nowrap">e-mail</FONT> delivery of a &#147;PDF&#148; format data file, such signature shall create a valid and
binding obligation of the Party executing (or on whose behalf such signature is executed) with the same force and effect as if such &#147;PDF&#148; signature page were an original thereof. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[The remainder of this page is intentionally left blank] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;21&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B> each of the Parties hereto has caused this Agreement to be executed by its duly
authorised representative on the date first set forth above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="50%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>GENEXINE, INC.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">(official chop)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">/s/ <FONT STYLE="white-space:nowrap">I-MAB</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>/s/<B> GENEXINE, INC.</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;22&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIST OF LICENSED INTELLECTUAL PROPERTIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Platform Patents: </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Country</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Filing</B><br><B>number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Filing</B><br><B>date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Patent<BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Patent</B><br><B>date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Remark</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="4"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Immunoglobulin fusion proteins</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">China</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2015106846795</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2015.10.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">hyFc Platform</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">China</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2013105540798</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2013.11.08</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">103641919</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2017.04.05</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">hyFc Platform</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">China</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2013105538393</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2013.11.08</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">103626875</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2016.01.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">hyFc Platform</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">China</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2008800163139</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2009.11.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">101687933</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2015.11.25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">hyFc Platform</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Hyleukin<U> Patents: </U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Country</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Filing</B><br><B>number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Filing</B><br><B>date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Patent<BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Patent</B><br><B>date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Remark</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Modified <FONT STYLE="white-space:nowrap">Interleukin-7</FONT> Protein and Uses Thereof</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">China</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Under&nbsp;filing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Under&nbsp;filing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IL-7-hyFc</FONT></FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;23&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TECHNICAL DOCUMENTATION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>3. Technical (CMC)</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>3.1. Cell line development</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>CHO DG44 License agreement</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>CHO DG44 information</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> cell line development report</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> cell line development report (Long term stability
test)</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> vector development report</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>TSE BSE CoA <FONT STYLE="white-space:nowrap">(GX-I7)</FONT> QA signed</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Production of a CHO master cell bank</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Production of a CHO working cell bank</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>3.2. Cell bank characterization</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>3.2.1. MCB</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Detection of Replication Competent Retrovirus (RCR) by <FONT STYLE="white-space:nowrap">co-cultivation</FONT> with
Mus dunni cells</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Extended in Vitro Assay (incorporating Day 14 Passage) for the Detection of Viral contaminants Six</I></P></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Mouse Antibody Production Test with LCMV Challenge</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Hamster antibody production test</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Test for the Presence of Inapparent Viruses using Suckling mice, Adult mice and embryonated eggs</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Quantitative Transmission Electron Microscopy of Sections for the Detection of Viruses, Fungi,
Yeasts</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Detection of viral contaminants of bovine origin according to Committee for Proprietary Medicinal
P</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><I>Test for the detection of mycoplasmas including qualification of test article in accordance with the EP,
Section&nbsp;2.6.7 mycoplasmas</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Real time Polymerase Chain reaction Assay for the Detection of Bovine polyomavirus (BPyV) in Biological
Samples</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Real time Polymerase Chain reaction Assay for the Detection of Calicivirus 2117 in Biological
Sample</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Sterility testing by direct inoculation method (EP, JP, USP)</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><I>Identification and Characterisation of Cultured Cells by Analysis of Six Isoenzymes using the Authenti kit Isoenzyme
Analysis System</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>3.2.2. WCB</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Sterility testing by direct inoculation method</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Extended in Vitro Assay (incorporating Day 14 Passage) for the Detection of Viral
contaminants</I></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;24&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><I>Test for the detection of mycoplasmas including qualification of test article in accordance with the European
Pharmacopoeia, Section&nbsp;2.6.7 mycoplasmas</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Test for the Presence of Inapparent Viruses using Suckling mice, Adult mice and embryonated eggs</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Identification and Characterisation of Cultured Cells by Analysis of Six Isoenzymes</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Cell Growth and Sample Preparation</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Method suitability test for sterility by direct inoculation</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>3.3. Manufacturing</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>3.3.1. Characterization</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> Gel IEF method development report</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> <FONT STYLE="white-space:nowrap">RP-HPLC</FONT> method development
report</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> <FONT STYLE="white-space:nowrap">SE-HPLC</FONT> method development
report</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> Western blot method development report</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> <FONT STYLE="white-space:nowrap">SDS-PAGE</FONT> method development
report</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> UV Quantitation Test Method Development Report</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Test Method Development report of <FONT STYLE="white-space:nowrap">GX-I7</FONT> in vitro biological
activity</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> HCD method development report</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> Protein A method development report</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> HCP method development report</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> Endotoxin method development report</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> <FONT STYLE="white-space:nowrap">RP-HPLC</FONT> method validation
report</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> Tween80 (Polysorbate80) method development report</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> <FONT STYLE="white-space:nowrap">SE-UPLC</FONT> method development
report</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Validation Report of UV Quantitation Test Method for <FONT STYLE="white-space:nowrap">GX-I7</FONT></I></P></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>3.3.2. Characterization report by Protagen</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Amino Acid Analysis</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>DA_trASA
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PS-G07-2014-006_umg_001_140912_JG</FONT></FONT></FONT></I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Amino Acid Analysis</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Sequence Analysis by <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">LC-ESI-MS</FONT></FONT> and
&#150;MS/MS</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">DA_PS764-G07-02-01</FONT></FONT></FONT> EICs_001_150520_GK
</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">DA_PS764-G07-02-01</FONT></FONT></FONT> Peptide
 Intensities_003_150512_GK</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">REP_PS764-G07-02-01</FONT></FONT></FONT> Protein
 Reports_001_150520_GK</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Disulfide Linkage by <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">LC-ESI-MS</FONT></FONT> and
MS/MS</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">LIS_PS764-G07-02-04</FONT></FONT></FONT> Identified
 Disulfide Linkages_001_150427_HF</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PRE_PS764-G07-02-04</FONT></FONT></FONT> MSMS_001_150428_HF
</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">N-Terminal</FONT> Sequencing by Edman</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">REP_PS764-G07-02-14_Report</FONT></FONT>
</FONT> Subcontractor_001_140427_SF</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">N-Glycosylation</FONT> Site Determination by <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">LC-ESI-MS</FONT></FONT> and <FONT STYLE="white-space:nowrap">-MS/MS</FONT></I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">DA_PS764-G07-02-06</FONT></FONT></FONT> EICs_001_150522_GK
</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">DA_PS764-G07-02-06</FONT></FONT></FONT> Peptide
 Intensities <FONT STYLE="white-space:nowrap">N-Glycosite_003_150527_YJ</FONT></I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>PRE_Workflow and Data Evaluation <FONT STYLE="white-space:nowrap">N-Glycosites</FONT>
_002_141103_Asc</I></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;25&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">O-Glycosylation</FONT> Site Determination by <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">LC-ESI-MS</FONT></FONT> and &#150;MS/MS</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">DA_PS764-G07-02-06O</FONT></FONT></FONT> EICs_001_150608_GK
</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">DA_PS764-G07-02-06O</FONT></FONT></FONT> Peptide
 Intensities_004_150610_GK</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">N-Glycan</FONT> Profiling by <FONT STYLE="white-space:nowrap">MALDI-MS</FONT> <FONT
STYLE="white-space:nowrap">(MALDI-MS)</FONT></I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">N-Glycan</FONT> Profiling by <FONT STYLE="white-space:nowrap">HILIC-UPLS-MS</FONT> <FONT
STYLE="white-space:nowrap">(HILIC-MS)</FONT></I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Monosaccharides after Acidic Hydrolysis</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Sialic Acids</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Molecular weight or size by Mass Spectrometry</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Spectroscopic Profiles by Circular Dichroism (CD)&nbsp;Analysis</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">REP_PS764-G07-02-23_Report</FONT></FONT>
</FONT> Solvias CD_001_150508_Bmu</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Molecular weight or size by Mass Spectrometry</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Determination of Molar Extinction Coefficient By UV Measurement</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>DA_Extinction
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PS-G07-2015-003_umg2_001_150526_JG</FONT></FONT></FONT></I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Determination of Molar Extinction Coefficient By UV Measurement</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>DA_Extinction
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PS-G07-2014-006</FONT></FONT></FONT> umg trASA_002_141022_AD</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Reanalysis of spectroscopic profiles by CD analysis</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">17-01866_20170307_CD_03_Report</FONT></I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>3.3.3. Drug Substance (DS)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GX-I7-P1402</FONT></FONT> release Test
CoA</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">I7-DS-1416</FONT></FONT> release Test
CoA</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> DS purification certificate of analysis</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> DS purification master batch record (batch record)</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Records of <FONT STYLE="white-space:nowrap">GX-I7</FONT> in vitro biological activity (cell based) assay
test</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> in vitro Biological Activity Test Method</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>3.3.4. Drug Product (DP)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GX-I7-V1501</FONT></FONT> Release Test
CoA</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GX-I7F-V1501</FONT></FONT> Release Test
CoA</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GX-I7-V1502</FONT></FONT> Release Test
CoA</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GX-I7F-V1502</FONT></FONT> Release Test
CoA</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> Drug product MBR (Eng/Kor)</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> Vehicle MBR (Eng/Kor)</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> Vehicle packing Master Batch Record</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> Drug product packing Master Batch Record</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>3.3.11. Virus clearance report</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Preliminary study of process material effects on virus and detector cell lines</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Evaluation of the removal/inactivation of virus from spiked test article</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>3.3.12. Release specification DS</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> Drug Substance Specification</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Testing SoPs</I></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;26&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>3.3.13. Release specification DP</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> Drug Product Specification</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Testing SoPs</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>3.3.14. Bulk harvest</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GX-I7-A1401_Detection</FONT></FONT> and
qualification of virus by TEM</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GX-I7-A1401_DI</FONT></FONT> surface spread
Bioburden</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GX-I7-A1401_Direct</FONT></FONT> Bioburden
PSQ</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GX-I7-A1401_In</FONT></FONT> vitro assay for the
presence of Adventitious Viral contaminants</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GX-I7-A1401_Qualification</FONT></FONT> for the
detection of agar-cultivable mycoplasma</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GX-I7-A1401_Real</FONT></FONT> <FONT
STYLE="white-space:nowrap">time-PCR</FONT> Detection of Murine Minute Virus (MMV)</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GX-I7-A1401_Test</FONT></FONT> for the presence of
agar-cultivable and non agar-cultivable mycoplasma</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GX-I7-A1402_Detection</FONT></FONT> and
qualification of virus by TEM</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GX-I7-A1402_DI</FONT></FONT> surface spread
Bioburden</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GX-I7-A1402_In</FONT></FONT> vitro assay for the
presence of Adventitious Viral contaminants</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GX-I7-A1402_Real</FONT></FONT> <FONT
STYLE="white-space:nowrap">time-PCR</FONT> Detection of Murine Minute Virus (MMV)</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GX-I7-A1402_Test</FONT></FONT> for the presence of
agar-cultivable and non agar-cultivable mycoplasma</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>3.4. Stability</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>3.4.1. Drug substance (DS)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> basal formulation buffer Study Report</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> Preliminary Formulation buffer selection Report</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Protocol of Long-term <FONT STYLE="white-space:nowrap">(-20&plusmn;5&deg;C)</FONT> stability test for <FONT
STYLE="white-space:nowrap">GX-I7</FONT> Drug Substance <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(GX-I7-P1402)</FONT></FONT></I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Protocol of Accelerated (5&plusmn;3&deg;C) stability test for <FONT STYLE="white-space:nowrap">GX-I7</FONT> Drug
Substance <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(GX-I7-P1402)</FONT></FONT></I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Result of Long-term <FONT STYLE="white-space:nowrap">(-20&plusmn;5&deg;C)</FONT> stability test for <FONT
STYLE="white-space:nowrap">GX-I7</FONT> Drug Substance <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(GX-I7-P1402)</FONT></FONT> (~12M)</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Result of Long-term <FONT STYLE="white-space:nowrap">(-20&plusmn;5&deg;C)</FONT> stability test for <FONT
STYLE="white-space:nowrap">GX-I7</FONT> Drug Substance <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(GX-I7-P1402)</FONT></FONT> (~24M)</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Result of Long-term <FONT STYLE="white-space:nowrap">(-20&plusmn;5&deg;C)</FONT> stability test for <FONT
STYLE="white-space:nowrap">GX-I7</FONT> Drug Substance <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(GX-I7-P1402)</FONT></FONT> (~36M) and chromatograms</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Result of Accelerated (5&plusmn;3&deg;C) stability test for <FONT STYLE="white-space:nowrap">GX-I7</FONT> Drug
Substance <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(GX-I7-P1402)</FONT></FONT> (~6M) and chromatograms</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>3.4.2. Drug Product (DP)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Protocol of Long-term stability test (5&plusmn;3&deg;C) for <FONT STYLE="white-space:nowrap">GX-I7</FONT> Drug
Product <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(GX-I7-V1501)</FONT></FONT></I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Protocol of Accelerated stability Test (25&plusmn;2&deg;C, 60&plusmn;5% RH) for
<FONT STYLE="white-space:nowrap">GX-I7</FONT> Drug Product <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(GX-I7-V1501)</FONT></FONT></I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Protocol of Long-term stability test (5&plusmn;3&deg;C) for <FONT STYLE="white-space:nowrap">GX-I7</FONT> vehicle <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(GX-I7F-V1501)</FONT></FONT></I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Protocol of Stress Stability Test (40&plusmn;2&deg;C, 75&plusmn;5% RH) for
<FONT STYLE="white-space:nowrap">GX-I7</FONT> Drug Product <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(GX-I7-V1502)</FONT></FONT></I></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;27&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Result of Long-term stability test (5&plusmn;3&deg;C) for <FONT STYLE="white-space:nowrap">GX-I7</FONT> Drug Product
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(GX-I7-V1501)</FONT></FONT> (~12M)</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Result of Long-term stability test (5&plusmn;3&deg;C) for <FONT STYLE="white-space:nowrap">GX-I7</FONT> Drug Product
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(GX-I7F-V1501)</FONT></FONT> (~12M) and chromatograms</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Report of Accelerated Stability Test (25&plusmn;2&deg;C, 60&plusmn;5% RH) for
<FONT STYLE="white-space:nowrap">GX-I7</FONT> Drug Product <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(GX-I7-V1501)</FONT></FONT> and chromatograms</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Report of Stress Stability Test (40&plusmn;2&deg;C, 75&plusmn;5% RH) for
<FONT STYLE="white-space:nowrap">GX-I7</FONT> Drug Product <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(GX-I7-V1502)</FONT></FONT> and chromatograms</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>3.5. QP Audit</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>QP Audit Report - Binex - Feb 2017</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7</FONT> QP Audit (2017.02.01~02) CAPA Report</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Binex Audit Certificate February 2017</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Batch analysis record including accessible chromatograms for DS and DP</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Reference standard: Characterization Data of reference standard and <FONT STYLE="white-space:nowrap">re-test</FONT>
CoAs</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Source, specification and CoAs of primary packaging and secondary packaging materials</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>GMP Certificates from DS/DP manufacturing sites: notarized and legalized, 2 copies; if sites changed, corresponding
certificates shall be provided as well.</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Power of Attorney: signed by DP manufacturing site;</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>4. <FONT STYLE="white-space:nowrap">Pre-clinical</FONT></I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>4.1. Pharmacokinetics and pharmacodynamics</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">T09-RPT-115</FONT></FONT> (1.0) Subcutaneous
Pharmacokinetic study of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">MGM-IL-7-hyFc</FONT></FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IL-7-hyFc</FONT></FONT> in Normal rat</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">T09-RPT-112-T01</FONT></FONT></FONT> (1.0)
 <FONT STYLE="white-space:nowrap">GX-I7</FONT> Single intravenous Pharmacokinetic and Pharmacodynamics study in Normal Monkeys</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">T09-RPT-113-T01</FONT></FONT></FONT> (1.0)
 Comparison of Pharmacokinetic and Pharmacodynamics study of <FONT STYLE="white-space:nowrap">GX-I7</FONT> by administration route (i.v., s.c., i.m.) in Normal Rats</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">T09-RPT-116-T01</FONT></FONT></FONT> (1.0)
 Comparison of Pharmacokinetic and Pharmacodynamics study of <FONT STYLE="white-space:nowrap">GX-I7</FONT> in <FONT STYLE="white-space:nowrap">CPA-induced</FONT> Lymphopenia Rat Model</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">T09-RPT-119-T01</FONT></FONT></FONT> (1.0)
 Pharmacodynamics of <FONT STYLE="white-space:nowrap">GX-I7</FONT> with <FONT STYLE="white-space:nowrap">GX-G3</FONT> in <FONT STYLE="white-space:nowrap">CPA-induced</FONT> Lymphocyte reduction model</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">2207-011</FONT> <FONT STYLE="white-space:nowrap">GX-I7_Validated</FONT> ELISA in
NHP Serum</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">2207-012</FONT> <FONT STYLE="white-space:nowrap">GX-I7_Validated</FONT> ELISA in
Rat Serum</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>4.2. Toxicology</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">2207-006_2wk</FONT> SC DRF in Monkey</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">2207-007_2wk</FONT> SC DRF in Rat</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">2207-008_4wk</FONT> SC repeated in NHP</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">2207-009_4wk</FONT> SC repeated in Rat</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">2207-013_Validated</FONT>
<FONT STYLE="white-space:nowrap">GX-I7_ADA_ELISA_in</FONT> NHP Serum</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>2207-014Validated <FONT STYLE="white-space:nowrap">GX-I7_ADA_ELISA_in</FONT> Rat
Serum</I></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;28&nbsp;- </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>4.3. Therapeutic strategy report incl. anti-tumor effect</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">08.NIT-N01-17-01.Therapeutic</FONT></FONT>
</FONT> Strategy of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IL-7-hyFc</FONT></FONT> with immune-modulating chemotherapy reagent</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">T09-RPT-106-T01</FONT></FONT></FONT> (2.1)
 The report of study of anti-tumor effect of <FONT STYLE="white-space:nowrap">GX-I7</FONT> by single subcutaneous administration in the <FONT STYLE="white-space:nowrap">TC-1</FONT> tumor mice model</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">T09-RPT-109-T01</FONT></FONT></FONT> (2.1)
 The 2nd study of anti-tumor effect of <FONT STYLE="white-space:nowrap">GX-I7</FONT> by single subcutaneous administration in the <FONT STYLE="white-space:nowrap">TC-1</FONT> tumor mice model</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">T09-RPT-118-T01</FONT></FONT></FONT> (1.0)
 The study of anti-tumor effect of <FONT STYLE="white-space:nowrap">GX-I7</FONT> by single subcutaneous or intravenous administration in the <FONT STYLE="white-space:nowrap">TC-1</FONT> tumor mice model</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>5. Clinical</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>5.1. <U>List</U> of clinical studies completed, ongoing and planned</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>Overview of the Clinical Development Program for <FONT STYLE="white-space:nowrap">GX-I7</FONT> for SC and IM
Administration</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>5.2. <U>Study reports</U> (including bioanalytics reports) for completed studies and protocol for ongoing and planned studies</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GX-I7-HV-001_22Mar2017_v3.2_ENG_v1.0
</FONT></FONT></FONT> (Protocol)</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GX-I7_Human</FONT> PBMC Analysis Report (Interim Study Report)</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">GX-I7-HV-001_(CSR)</FONT></FONT></FONT>
</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>5.3. <U>Validation reports</U> for all PK and ADA/Nab assays used in clinical trials</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>5.3.1. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">T09-RPT-092-T01</FONT></FONT></FONT> (2.1) <FONT STYLE="white-space:nowrap">GX-I7</FONT> ADA Validation Report in Human
Serum</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>5.3.2. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">T09-RPT-111-T01</FONT></FONT></FONT> (2.0) Validation Report of <FONT STYLE="white-space:nowrap">GX-I7</FONT> Neutralizing
Antibody Method in Human Serum</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>5.3.3. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">T09-RPT-121</FONT></FONT> (2.0) Clinical Phase 1 ADA Analysis Report in Human Serum</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>5.3.4. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">T09-RPT-126-T01</FONT></FONT></FONT> (1.1) Human <FONT STYLE="white-space:nowrap">IL-7</FONT> ELISA Method Validation
Report in Clinical sample analysis</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>5.4. <U>Investigator brochure</U></I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><I>INVESTIGATOR&#146;S BROCHURE, <FONT STYLE="white-space:nowrap">GX-I7</FONT></I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>IND package to MFDS for FIH study/solid tumor and subsequent supplements; Sharing FDA</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>IND package/Communication with <FONT STYLE="white-space:nowrap">I-Mab</FONT> upon availability</I></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;29&nbsp;- </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.16</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.16 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FERRING INTERNATIONAL CENTER SA </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="white-space:nowrap">I-MAB</FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE AND SUBLICENSE AGREEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="97%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">DEFINITIONS</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">GRANT OF RIGHTS</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">DEVELOPMENT</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">GOVERNANCE; JOINT STEERING COMMITTEE</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">EXCHANGE OF INFORMATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">6.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">COMMERCIALISATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">7.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">PAYMENTS AND FEES</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">8.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">INTELLECTUAL PROPERTY</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">9.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">TERM AND TERMINATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">CONSEQUENCE OF TERMINATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">11.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ACCRUED RIGHTS; SURVIVING OBLIGATIONS</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">12.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">GENERAL PERFORMANCE STANDARDS</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">13.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">MANUFACTURE AND SUPPLY</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">14.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">WARRANTIES, REPRESENTATIONS, INDEMNIFICATION AND INSURANCE</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">15.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ASSIGNMENT</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">16.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">INDEPENDENT CONTRACTORS</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">17.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">NOTICES</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">18.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ENTIRE AGREEMENT; WAIVER</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">19.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">SEVERABILITY</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">20.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">FURTHER ASSURANCE AND REGISTRATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">21.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">GOVERNING LAW; RELIEF</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">22.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">FORCE MAJEURE</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">23.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">DISPUTE RESOLUTION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">24.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">EXECUTION IN COUNTERPARTS</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS LICENSE AND SUBLICENSE AGREEMENT </B>(this &#147;Agreement&#148;) is effective as of 4<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> of November 2016 (the &#147;Effective Date&#148;), and is by and between <B>FERRING INTERNATIONAL CENTER SA, </B>a company organised and existing under the laws of Switzerland and having its
principal place of business at Chemin de la Vergognausaz 50 <FONT STYLE="white-space:nowrap">CH-1162</FONT> Saint-Prex Switzerland (&#147;Ferring&#148;) and <B><FONT STYLE="white-space:nowrap">I-MAB,</FONT> </B>a company organised and existing under
the laws of Cayman Islands and having its principal place of business at Floor 4, Willow House, Cricket Square, P 0 Box 2804, Grand Cayman <FONT STYLE="white-space:nowrap">KY1-1112,</FONT> Cayman Islands,
<FONT STYLE="white-space:nowrap">(&#147;I-MAB&#148;).</FONT> Each party individually may be referred to herein as a &#147;Party&#148; and collectively both parties may be referred to herein as the &#147;Parties.&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PREAMBLE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHEREAS, Ferring has an
exclusive license to certain Sublicensed Intellectual Property (as later defined herein) and has the right to grant sublicenses under the Sublicensed Intellectual Property with respect to the Licensed Compound and the Licensed Product (each as later
defined herein); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHEREAS, Ferring also possesses certain Ferring Intellectual Property and <FONT STYLE="white-space:nowrap">Know-How</FONT> (as later
defined herein) and has the right to grant licenses to the Ferring Intellectual Property and <FONT STYLE="white-space:nowrap">Know-How</FONT> with respect to the Licensed Compound and the Licensed Product; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHEREAS, Ferring wishes to grant to <FONT STYLE="white-space:nowrap">I-MAB,</FONT> and <FONT STYLE="white-space:nowrap">I-MAB</FONT> wishes to accept, a
license or a sublicense to its interests in the Ferring Intellectual Property and Sublicensed Intellectual Property, respectively, and a license to its <FONT STYLE="white-space:nowrap">Know-How</FONT> to research, commercially develop, make, have
made, import, use, sell, dispose of, offer to sell or dispose of the Licensed Product through a diligent program of exploiting the Ferring Intellectual Property and Sublicensed Intellectual Property and
<FONT STYLE="white-space:nowrap">Know-How</FONT> in the Territory and Optional Territory (if applicable) in accordance with the terms and conditions set forth below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOW THEREFORE, </B>in consideration of the covenants and obligations expressed below, and other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFINITIONS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For the purpose of this Agreement, the following words and phrases shall have the following meanings: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">&#147;I-MAB</FONT> Improvements&#148; </B>means any and all changes,
developments, enhancements, modifications, additions, or improvements to the Sublicensed Intellectual Property and/or Licensed Ferring Intellectual Property and <FONT STYLE="white-space:nowrap">Know-How</FONT> made by or on behalf of <FONT
STYLE="white-space:nowrap">I-MAB</FONT> or its Affiliates or <FONT STYLE="white-space:nowrap">Sub-licensees</FONT> or <FONT STYLE="white-space:nowrap">Sub-Sublicensees.</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">&#147;I-MAB</FONT> IP&#148; </B>means
<FONT STYLE="white-space:nowrap">Know-How</FONT> and Intellectual Property that is conceived, discovered, developed or otherwise made by or on behalf of <FONT STYLE="white-space:nowrap">I-MAB</FONT> or its Affiliates or its <FONT
STYLE="white-space:nowrap">Sub-licensees</FONT> or <FONT STYLE="white-space:nowrap">Sub-Sublicensees</FONT> under, or in connection with, this Agreement or otherwise related to the Licensed Compound or Licensed Product. <FONT
STYLE="white-space:nowrap">I-MAB</FONT> IP shall include <FONT STYLE="white-space:nowrap">I-MAB</FONT> Improvements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Adverse Event&#148; </B>means any untoward medical occurrence in a patient or an investigation subject
who has been administered the Licensed Product and which does not necessarily have to have a causal relationship with the exposure or use of the Licensed Product. For purposes of this Agreement, Adverse Event includes all noxious and unintended
response or symptom to the Licensed Product related to any dose of the Licensed Product, and any adverse reaction, the nature or severity of which is inconsistent with the applicable Licensed Product information. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Affiliate&#148; </B>means, with respect to a Person, any other Person that, directly or indirectly,
through one or more intermediaries, controls, is controlled by or is under common control with such Person. For purposes of this definition, <B>&#147;control&#148; </B>and, with correlative meanings, the terms <B>&#147;controlled by&#148; </B>and
<B>&#147;under common control with&#148; </B>means: (a)&nbsp;the possession, directly or indirectly, of the power to direct the management or policies of a business entity, whether through the ownership of voting securities, by contract relating to
voting rights or corporate governance, or otherwise; or (b)&nbsp;the ownership, directly or indirectly, of more than 50% of the voting securities or other ownership interest of a business entity (or, with respect to a limited partnership or other
similar entity, its general partner or controlling entity). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Applicable Law&#148; </B>means any and all applicable laws, statutes, orders, rules, regulations,
directives and guidelines that have legal effect, whether local, national, international or otherwise, existing from time to time, including any rules, regulations, guidelines or other requirements of the Regulatory Authorities.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Business Day&#148; </B>means a day, other than a Saturday, Sunday, or public holiday on which banking
institutions are not authorized or required to close in China. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Calendar Quarter&#148; </B>means each successive period of three calendar months commencing on
January&nbsp;1, April&nbsp;1, July&nbsp;1 and October 1. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Calendar Year&#148; </B>means each successive period of 12 calendar months commencing on
January&nbsp;1 and ending on December 31. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.9</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;CFDA&#148; </B>means the China Food and Drug Administration. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.10</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;China&#148; </B>or &#147;PRC&#148; means the People&#146;s Republic of China, which, for purposes of
this Agreement, excludes the Hong Kong Special Administrative Region <B>(&#147;Hong Kong&#148;), </B>the Macau Special Administrative Region, and Taiwan. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.11</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Clinical Data&#148; </B>means all data, reports and results with respect to the Licensed Compound and
the Licensed Product made, collected or otherwise generated under, or in connection with, the Clinical Studies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.12</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Clinical Studies&#148; </B>or <B>&#147;Clinical Study&#148; </B>means human clinical trials for the
Licensed Product and any other tests and studies for the Licensed Product in human subjects. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.13</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Commercialization&#148; </B>means, with respect to the Licensed Product, any and all activities
(whether before or after Regulatory Approval) directed to the marketing, promotion, distribution and sale of the Licensed Product in the Field in the Territory or the Optional Territory (if applicable) after Regulatory Approval for commercial sale
has been obtained, including <FONT STYLE="white-space:nowrap">pre-launch</FONT> and post-launch marketing, promoting, distributing, offering to commercially sell and commercially selling the Licensed Product, importing, exporting or transporting the
Licensed Product for commercial sale, conducting Clinical Studies that are not required to obtain or maintain Regulatory Approval for the Licensed Product for an indication, which may include epidemiological studies, modeling and pharmacoeconomic
studies, post-marketing surveillance studies, investigator sponsored studies and health economics studies and regulatory affairs (including interacting with Regulatory Authorities) with respect to the foregoing. When used as a verb,
<B>&#147;Commercializing&#148; </B>means to engage in Commercialization and <B>&#147;Commercialize&#148; </B>and <B>&#147;Commercialized&#148; </B>shall have corresponding meanings. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.14</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Development&#148; </B>means, with respect to the Licensed Product and Licensed Compound, all
activities related to research, preclinical and other <FONT STYLE="white-space:nowrap">non-clinical</FONT> testing, test method development and stability testing, toxicology, formulation, Manufacture Process Development, Clinical Studies, including
Manufacturing in support thereof (but excluding any commercial Manufacturing), statistical analysis and report writing, the preparation and submission of Drug Approval Applications, regulatory affairs with respect to the foregoing and all other
activities necessary or reasonably useful or otherwise requested or required by a Regulatory Authority as a condition or in support of obtaining or maintaining a Regulatory Approval for such Licensed Product. When used as a verb,
<B>&#147;Develop&#148; </B>means to engage in Development. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.15</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Development Plan&#148; </B>means the plan for the Development of the Licensed Product as described in
Section&nbsp;3.2, as updated from time to time pursuant to Section&nbsp;3.2. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.16</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Dollars&#148; </B>or &#147;$&#148; means the United States Dollars. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.17</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Drug Approval Application&#148; </B>means: (i)&nbsp;the clinical trial application for new drugs (MA
aWt4.54 EP ii); (ii) the application for new drug certificate (Mg<SUP STYLE="font-size:85%; vertical-align:top">-</SUP>iE T3FIEI ilA); and (iii)&nbsp;the drug approval number application (A A ft <SUP STYLE="font-size:85%; vertical-align:top">s</SUP>
5C<SUP STYLE="font-size:85%; vertical-align:top">-Ir</SUP> EPA), collectively, each as set forth in the PRC Pharmaceutical Administration Law, as may be amended from time to time (including all additions, supplements, extensions and modifications
thereto), or any corresponding foreign application in the Territory or the Optional Territory (if applicable). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.18</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Effective Date&#148; </B>means the date as of which this Agreement is effective which shall be the
date first written above. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.19</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Exploit&#148; </B>means, with respect to the Licensed Compound and/or the Licensed Product, to make,
have made, import, use, sell or offer for sale, including to research, Develop, Commercialize, register, Manufacture, have Manufactured, hold or keep (whether for disposal or otherwise), have used, export within the Territory or Optional Territory
(if applicable), transport, distribute, promote, market or have sold or otherwise dispose of the Licensed Product and <B>&#147;Exploitation&#148; </B>means the act of Exploiting the Licensed Product. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.20</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Ferring Improvements&#148; </B>means any and all changes, developments, enhancements, modifications,
additions, or improvements to the Sublicensed Intellectual Property and/or the Licensed Ferring Intellectual Property and <FONT STYLE="white-space:nowrap">Know-How</FONT> made by or on behalf of Ferring or its Affiliates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.21</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Ferring Intellectual Property&#148; </B>means the patent applications (until such time as such
applications or any of them are denied, abandoned or issued into patents) listed in Schedule B1 hereof and future patents and patent applications covering the Licensed Compound or Licensed Product, along with any future patents and patent
applications including continuations, divisionals and reissues as part of patents and extensions thereof including supplementary protection certificates and their equivalent. Ferring Intellectual Property includes FerringImprovements. Schedule B1
shall be updated from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time</FONT></FONT> to reflect any new Ferring Intellectual Property, including Ferring Improvements. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.22</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Field&#148; </B>means any indication for medicinal use in humans, including rheumatoid arthritis.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.23</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;First Commercial Sale&#148; </B>means, with respect to the Licensed Product, the first sale by <FONT
STYLE="white-space:nowrap">I-MAB,</FONT> its Affiliates, Sublicensees or <FONT STYLE="white-space:nowrap">Sub-sublicensees,</FONT> as applicable, to a Third Party of the Licensed Product in a country in the Territory or Optional Territory (if
applicable) after all required marketing and pricing or reimbursement approvals have been granted by the applicable Regulatory Authority for such country. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.24</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Force Majeure&#148; </B>means any significant unexpected event that is beyond the reasonable control
of a Party for which such Party cannot reasonably have been expected to have taken account as of the Effective Date, which significantly delays the Development Program set out in Appendix <B>B </B>and including, but without prejudice to the
foregoing generality, events resulting from an act of God, lightning, fire, flood, earthquake, accumulation of snow or ice, lack of water arising from weather or environmental problems, strike, <FONT STYLE="white-space:nowrap">lock-out</FONT> or
other industrial disturbance, act of the public enemy, war declared or undeclared; threat of war; terrorist act; blockade, revolution, riot, insurrection, civil commotion, public demonstration, sabotage, act of vandalism, prevention from or
hindrance in obtaining any raw materials, energy or other supplies, explosion, fault or failure of plant or machinery (which could not have been prevented by good industry practice); government restraint, act of legislature or a directive or
requirement of the competent authority affecting a Party or its subcontractor providing that such Party or its subcontractor&#146;s lack of funds shall not be interpreted as a cause beyond such Party&#146;s reasonable control. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.25</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;IND&#148; </B>means an Investigational New Drug Application submitted under the United States Federal
Food, Drug, and Cosmetic Act, as amended, and the rules and regulations promulgated thereunder (the <B>&#147;FD&amp;C Act&#148;), </B>or an analogous application or submission with any analogous agency or Regulatory Authority outside of the United
States for the purposes of obtaining permission to conduct clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.26</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;Information&#148; means any and all </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">information relating to the business affairs, finances or commercial interests of a Party which is disclosed
pursuant to this Agreement in whatever form; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Know-How;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">samples of Materials provided for testing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">results of any tests performed with samples of Materials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such other written information whether provided in printed, hand-written, electronic or any other form, either
Party deems confidential that is provided to the other Party in writing pursuant to this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.27</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Intellectual Property&#148; </B>means, collectively, all intellectual property rights (whether or not
patented or patentable) related to the purpose of this Agreement including, but not limited to, algorithms, approvals, certifications, chemical compounds, conceptual expressions, copyrights, trademarks, data, designs, formulae, inventions, patents,
patent rights, and prototypes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.28</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">&#147;Know-How&#148;</FONT> </B>means technical and other information of
either Party that is not in the public domain, including information comprising or relating to concepts, discoveries, data, designs, formulae, ideas, information relating to Materials, inventions, methods, models, assays, research and/or development
plans, procedures, designs for experiments and tests and results of experimentation and tests (including results of research or development), processes (including manufacturing processes, specifications and techniques), laboratory records, chemical,
pharmacological, toxicological, clinical, analytical and quality control data, trial data, case report forms, data analyses, reports or summaries. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.29</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Korea&#148; </B>means the Republic of Korea. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.30</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Licensed Compound&#148; </B>means FE301, i.e., SGP130Fc fusion protein, an <FONT
STYLE="white-space:nowrap">interleukin-6</FONT> inhibitor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.31</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Licensed <FONT STYLE="white-space:nowrap">Know-How&#148;</FONT> </B>means the <FONT
STYLE="white-space:nowrap">Know-How</FONT> contained or disclosed in the documents set forth on Schedule A, but excluding any <FONT STYLE="white-space:nowrap">Know-How</FONT> to the extent claimed or covered by published patents or patent
applications of the Ferring Intellectual Property and Sublicensed Intellectual Property. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.32</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Licensed Product&#148; </B>means all pharmaceutical formulations in finished packaged form containing
the Licensed Compound covered by any patent or patent application as set out in Schedule <B>B </B>hereto and/or uses any other Ferring Intellectual Property or Sublicensed Intellectual Property or <FONT STYLE="white-space:nowrap">Know-How,</FONT>
for use in the Field. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.33</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Manufacture&#148; </B>and <B>&#147;Manufacturing&#148; </B>mean, with respect to the Licensed Compound
and Licensed Product, all activities related to the production, manufacture, processing, filling, finishing, packaging, labeling, shipping, holding, Manufacture Process Development, stability testing, quality assurance or quality control of the
Licensed Product or any intermediate thereof. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.34</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Manufacturing Process&#148; means </B>the process used to manufacture the Licensed Compound and the
Licensed Product, including but not limited to the cell line that stably expresses the Licensed Compound, the process to grow the cell line in large scale incubators, the large-scale process to purify the Licensed Compound, and other activities
provided in 1.32. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.35</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Manufacture Process Development&#148; </B>means the process development, process qualification and
validation and <FONT STYLE="white-space:nowrap">scale-up</FONT> of the process to manufacture the Licensed Compound and Licensed Product and analytic development and product characterization with respect thereto. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.36</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;NDA&#148; </B>means a New Drug Application (which, for purposes of this Agreement, includes a
Biologics License Application) submitted to the United States Food and Drug Administration or any successor agency thereto <B>(&#147;FDA&#148;) </B>in accordance with the FD&amp;C Act with respect to a pharmaceutical product (including all
additions, supplements, extensions and modifications thereto), or any other analogous application or submission with any Regulatory Authority in the Territory or the Optional Territory (if applicable), including, with respect to China, a Marketing
Authorization Application filed with the CFDA. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.37</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Net Sales&#148; </B>means, for any period, the gross amount invoiced by
<FONT STYLE="white-space:nowrap">I-MAB,</FONT> its Sublicensees or any of its or their respective Affiliates for the sale of the Licensed Product (the <B>&#147;Invoiced Sales&#148;), </B>less deductions for: (a)&nbsp;normal and customary trade,
quantity and cash discounts and sales returns and allowances, including those granted on account of price adjustments, billing errors, rejected goods, damaged goods and returns, and chargebacks; (b)&nbsp;freight, postage, shipping and insurance
expenses to the extent that such items are included in the gross amount invoiced; (c)&nbsp;sales taxes and other governmental charges (including value added tax) to the extent billed separately on the invoice and actually paid in connection with the
sale but only to the extent actually included in gross sales; and (d)&nbsp;rebates and similar payments made with respect to sales paid for by any Regulatory Authority. Any of the deductions listed above that involves a payment by <FONT
STYLE="white-space:nowrap">I-MAB,</FONT> its Sublicensees or any of its or their respective Affiliates shall be taken as a deduction in the Calendar Quarter in which the payment is accrued by such entity. The methodology for calculating (a) &#151;
(d), on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, shall conform to International Financial Reporting Standards consistently applied by <FONT STYLE="white-space:nowrap">I-MAB.</FONT>
For purposes of determining the Net Sales, the Licensed Product shall be deemed to be sold when invoiced and a &#147;sale&#148; shall not include transfers or dispositions of the Licensed Product for
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical purposes or as samples, in each case, whether supplied without charge or not. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the case of pharmacy incentive programs, hospital performance incentive programs,
chargebacks, disease management programs, similar programs or discounts on portfolio product offerings for the Licensed Product, all rebates, discounts and other fauns of reimbursements shall be allocated on the basis on which such rebates,
discounts and other forms of reimbursements were actually granted or, if such basis cannot be determined, in accordance with <FONT STYLE="white-space:nowrap">I-MAB&#146;s,</FONT> its Sublicensees&#146; or its or their respective Affiliates&#146;
existing allocation method. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-MAB&#146;s</FONT> or any of its Sublicensees&#146; or its or their
respective Affiliates&#146; transfer of the Licensed Product to an Affiliate or Sublicensee shall not result in any Net Sales. In addition, Net Sales shall not include the sales of any Licensed Product to be used in clinical trials, for research or
other <FONT STYLE="white-space:nowrap">non-commercial</FONT> purposes, or supplied as commercial samples or as charitable or humanitarian donations (whether supplied without charge, at a substantial discount or otherwise). </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.38</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Optional Territory&#148; </B>means countries of North America (i.e., Canada, the United States and
Mexico) and the European Union and Japan to be mutually agreed in writing by the Parties within thirty (30)&nbsp;days of receipt of notice from <FONT STYLE="white-space:nowrap">I-MAB</FONT> that it wishes to exercize its option right to obtain an
exclusive license to the Optional Territory, cf. Clause 2.2 below. For the purposes of this Agreement, the United Kingdom shall be considered a member state of the European Union, even if it exits the European Union during the Term.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.39</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Person&#148; </B>means an individual, sole proprietorship, partnership, limited partnership, limited
liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or political subdivision, department
or agency of a government. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.40</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Phase IB&#148; </B>means an initial Clinical Study that assesses safety and tolerability, as well as
the pharmacokinetic and pharmacodynamic responses of the Licensed Product at multiple doses in the Asian rheumatoid arthritis patient population, as further described in the Development Plan. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.41</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Phase II Clinical Trial&#148; </B>means that certain Clinical Study, the principal purpose of which is
to determine safety and efficacy of the Licensed Product in the target patient population or a similar clinical study prescribed by the Regulatory Authorities, from time to time, pursuant to Applicable Law or otherwise, including the Phase II
clinical trial referred to in Article 31 of the Provisions for Drug Registration Administration, promulgated by the CFDA and as may be amended from time to time. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.42</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Phase IIA&#148; </B>means that part of the Phase II Clinical Trial designed to assess dosing
requirements and efficacy of the Licensed Product. For the purposes of this Agreement, <B>&#147;completion of Phase IIA&#148; </B>means that stage of the Phase II Clinical Trial when the efficacy of the Licensed Product as specified in the
Development Plan has been observed and properly recorded. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.43</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Reasonable Commercial Efforts&#148; </B>means with respect to the Development and Commercialization of
the Licensed Product, the level of efforts and resources that are consistent to those efforts and resources commonly used by a similarly situated company in the pharmaceutical industry for comparable products with similar commercial and scientific
potential at a similar stage in their lifecycle, taking into consideration their safety, efficacy, their cost to develop, the competitiveness of alternative products in or reasonably anticipated to enter the marketplace, their proprietary position,
the likelihood of regulatory approval with appropriate and adequate labelling, their pricing, reimbursement, cost or productions, sales and marketing, any other reasonable commercial considerations and on a market by market basis.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.44</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Recognised Agent&#148; </B>means a Third Party through which
<FONT STYLE="white-space:nowrap">I-MAB</FONT> regularly distributes and sells its products in the Territory or Optional Territory (as applicable) where <FONT STYLE="white-space:nowrap">I-MAB</FONT> has no Affiliate and where sales of <FONT
STYLE="white-space:nowrap">I-MAB</FONT> products are a very minor proportion of total worldwide <FONT STYLE="white-space:nowrap">I-MAB</FONT> sales. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.45</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Regulatory Approval&#148; </B>means, with respect to the Licensed Product in a country in the
Territory or the Optional Territory (as applicable), any and all approvals, licenses, registrations or authorizations of any Regulatory Authority necessary to commercially market, promote, distribute or sell the Licensed Product in such country,
including, where applicable: (a)&nbsp;pricing or reimbursement approval in such country; <FONT STYLE="white-space:nowrap">(b)&nbsp;pre-</FONT> and post-approval marketing authorizations (including any prerequisite Manufacturing approval or
authorization related thereto); and (c)&nbsp;labeling approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.46</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Regulatory Authority(ies)&#148; </B>means any national, multinational, state, provincial or local
regulatory agency, department, bureau or other governmental entity with authority over the testing, manufacture, use, storage, import, promotion, marketing and sale of a therapeutic product in the Territory and/or Optional Territory (as applicable)
necessary for the commercialization of the Licensed Product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.47</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Regulatory Documentation&#148; </B>means all: (a)&nbsp;applications (including all INDs and Drug
Approval Applications), registrations, licenses, authorizations and approvals (including all Regulatory Approvals); (b) correspondence and reports submitted to or received from Regulatory Authorities (including minutes and official contact reports
relating to any communications with any Regulatory Authority) and all supporting documents with respect thereto, including all regulatory drug lists, advertising and promotion documents, Adverse Event files and complaint files; and (c)&nbsp;Clinical
Data and any other data contained in any of the foregoing, in each of ((a), (b) and (c)), relating to the Licensed Product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.48</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;RMB&#148; </B>means Renminbi, the official currency of the PRC. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.49</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Royalty Term&#148; </B>means the period beginning on the date of First Commercial Sale in any country
of the Territory and/or Optional Territory (as applicable) and expiring on a country by country basis: (i)&nbsp;fifteen (15) years from the date of launch; or (ii)&nbsp;on expiration of the last to expire patent rights of the Ferring Intellectual
Property or Sublicensed Intellectual Property in the Territory and/or Optional Territory (as applicable) that includes a Valid Claim covering the development, making, using or selling of the Licensed Compound or Licensed Product, whichever is later.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.50</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Sublicensed Intellectual Property&#148; </B>means the patents and patent applications (until such time
as such applications or any of them are denied, abandoned or issued into patents) listed in Schedule B2 hereof and any future patents and patent applications including continuations, divisionals and reissues as part of patents and extensions thereof
including supplementary protection certificates and their equivalent and <FONT STYLE="white-space:nowrap">Know-How</FONT> under which Ferring is licensed with the right to sublicense. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.51</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Sublicensee&#148; </B>means an Affiliate of <FONT STYLE="white-space:nowrap">I-MAB</FONT> or a Third
Party that is granted a sublicense to Ferring Intellectual Property and <FONT STYLE="white-space:nowrap">Know-How</FONT> by <FONT STYLE="white-space:nowrap">I-MAB</FONT> in accordance with Section&nbsp;2.3. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.52</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">&#147;Sub-sublicensee&#148;</FONT> </B>means an Affiliate of <FONT
STYLE="white-space:nowrap">I-MAB</FONT> or a Third Party that is granted a <FONT STYLE="white-space:nowrap">sub-sublicense</FONT> to Sublicensed Intellectual Property by <FONT STYLE="white-space:nowrap">I-MAB</FONT> in accordance with
Section&nbsp;2.3 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.53</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Territory&#148; </B>means China (including Hongkong, Macau), Taiwan and Korea. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.54</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Third Party&#148; </B>means any Person other than a Party to this Agreement and such Party&#146;s
Affiliate. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.55</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Trademark&#148; </B>means any word, name, symbol, color, designation or device or any combination
thereof that functions as a source identifier, including any trademark, trade dress, service mark, trade name, brand name, logo or business symbol, whether or not registered, together with any goodwill associated therewith. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.56</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Valid Claim&#148; </B>means with respect to a particular country in the Territory or the Optional
Territory (as applicable): (a) any claim of an issued and unexpired patent in such country that: (i)&nbsp;has not been held permanently revoked, unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction that
is unappealable or unappealed within the time allowed for appeal; and (ii)&nbsp;has not been abandoned, disclaimed, denied or admitted to be invalid or unenforceable through reissue or disclaimer or otherwise in such country; or (b)&nbsp;any claim
of a pending patent application that has not been abandoned or finally disallowed without the possibility of appeal or <FONT STYLE="white-space:nowrap">re-filing</FONT> of the application. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>GRANT OF RIGHTS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Territory. </B>Ferring hereby grants to <FONT STYLE="white-space:nowrap">I-MAB:</FONT> i) an exclusive
(including with regard to Ferring and its Affiliates, but excluding any <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license granted to Conaris by operation of the Development and License Agreement dated November&nbsp;11, 2008)) license,
with the right to grant sublicenses to Sublicensees in accordance with Section&nbsp;2.3 in whole or in part, under Ferring Intellectual Property and <FONT STYLE="white-space:nowrap">Know-How;</FONT> and ii) an exclusive (including with regard to
Ferring and its Affiliates) sublicense, with the right to grant <FONT STYLE="white-space:nowrap">sub-sublicenses</FONT> to <FONT STYLE="white-space:nowrap">Sub-sublicensees</FONT> in accordance with Section&nbsp;2.3 in whole or in part, under
Sublicensed Intellectual Property, to research, develop, make, have made, import, use, sell and offer to sell the Licensed Compound and the Licensed Product in the Field in the Territory. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Option Right of <FONT STYLE="white-space:nowrap">I-MAB</FONT> to the Optional Territory (as applicable).
</B>Ferring hereby grants to <FONT STYLE="white-space:nowrap">I-MAB:</FONT> i) a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> option right to obtain an exclusive license, with the right to grant sublicenses to Sublicensees in accordance
with Section&nbsp;2.3 in whole or in part, under Ferring Intellectual Property and <FONT STYLE="white-space:nowrap">Know-How;</FONT> and ii) a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> option right to obtain an exclusive sublicense, with
the right to grant <FONT STYLE="white-space:nowrap">sub-sublicenses</FONT> to <FONT STYLE="white-space:nowrap">Sub-sublicensees</FONT> in accordance with Section&nbsp;2.3 in whole or in part, under Sublicensed Intellectual Property, to research,
develop, make, have made, import, use, sell and offer to sell the Licensed Product in the Field in the mutually agreed upon countries in the Optional Territory, and for the avoidance of doubt Ferring shall retain the right to research, develop,
make, have made and use the Licensed Compound and/or Licensed Product in the Optional Territory for the purposes of this Agreement, including the right to grant <FONT STYLE="white-space:nowrap">sub-licenses</FONT> to a Third Party. Ferring may
actively pursue to grant license and sublicense rights to one or more Third Party to research, develop, make, have made, import, use, sell and offer to sell the Licensed Compound and the Licensed Product in the Field in any country outside the
Territory, provided however that notwithstanding the aforementioned, Ferring shall not be entitled to grant any rights under the Ferring Intellectual Property and Sublicensed Intellectual Property to a Third Party without first providing written
notice of its intentions to do so of 30 (thirty) days to <FONT STYLE="white-space:nowrap">I-MAB,</FONT> and in such event <FONT STYLE="white-space:nowrap">I-MAB</FONT> shall be entitled to have a first right of refusal to exercise the option right
and to obtain exclusive license rights to the Optional Territory, subject to payment of the Initial Payment Covering the Optional Territory, cf. Clause 7.1.2 of this Agreement. If <FONT STYLE="white-space:nowrap">I-MAB</FONT> notifies that it does
not want to obtain an exclusive license to the Optional Territory, such notice to be received by Ferring in writing within 30 (thirty) days after receipt of Ferring&#146;s notice, cf. above, <FONT STYLE="white-space:nowrap">I-MAB</FONT> foregoes of
the option right and Ferring shall be free to enter into the agreement with any Third Party. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Sublicenses and <FONT STYLE="white-space:nowrap">Sub-sublicenses.</FONT>
</B><FONT STYLE="white-space:nowrap">I-MAB</FONT> shall have the right to grant sublicenses and/or <FONT STYLE="white-space:nowrap">sub-sublicenses</FONT> (as applicable) to an Affiliate or a Third Party to research, develop, make, have made,
import, use, sell and offer to sell the Licensed Product in the Field in the Territory and the mutually agreed upon counties in the Optional Territory (as applicable, cf. Clause 2.2 above). Any sublicenses and/or
<FONT STYLE="white-space:nowrap">sub-sublicenses</FONT> granted by <FONT STYLE="white-space:nowrap">I-MAB</FONT> shall be subject to the terms and conditions of this Agreement. <FONT STYLE="white-space:nowrap">I-MAB</FONT> shall inform Ferring in
writing of: i) the name and location of the Sublicensee and/or <FONT STYLE="white-space:nowrap">Sub-sublicensee;</FONT> ii) the commercial terms in so far as required to provide Ferring with the requisite information for the purposes of section 7.5
below; and iii) the territory and indications included in the sublicense and/or <FONT STYLE="white-space:nowrap">sub-sublicense</FONT> within thirty (30)&nbsp;days of the grant of the sublicense and/or
<FONT STYLE="white-space:nowrap">sub-sublicense.</FONT> Ferring shall be entitled to request a copy of the agreements entered into with the respective sublicensees and/or <FONT STYLE="white-space:nowrap">sub-sublicensees.</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Disclosure and Transfer. </B>Ferring shall share with <FONT STYLE="white-space:nowrap">I-MAB</FONT> or any
of its designees, as reasonably requested by <FONT STYLE="white-space:nowrap">I-MAB,</FONT> the Regulatory Documentation in Ferrings&#146;s control with respect to the Licensed Compound and the Licensed Product within sixty (60)&nbsp;days after the
Effective Date. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> Disclosure and Materials Transfer
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>2.5.1 In General. </B>Ferring shall deliver to <FONT STYLE="white-space:nowrap">I-MAB</FONT> or any of its
designees, as reasonably requested by <FONT STYLE="white-space:nowrap">I-MAB:</FONT> (a)&nbsp;within thirty (30)&nbsp;days after the Effective Date the Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> set forth in Schedule A; and
(b)&nbsp;within thirty (30)&nbsp;days of a request made by <FONT STYLE="white-space:nowrap">I-MAB</FONT> to Ferring, the agreed portion of the amount of Licensed Compound and the Licensed Product in Ferring&#146;s inventory as described in Schedule
C, and all Manufacturing and batch records associated<B> </B>with the Materials in Ferring&#146;s Control. <FONT STYLE="white-space:nowrap">I-MAB</FONT> or its designee may inspect the received Materials, and shall notify Ferring in writing within a
reasonable period of time after the receipt thereof in the event it rejects the Materials. Upon and only upon acceptance of the Materials and subject to Section&nbsp;13.1.2, <FONT STYLE="white-space:nowrap">I-MAB</FONT> shall pay Ferring the book
value plus the Shipping Cost for the amount of Licensed Compound and / or the Licensed Product received. Notwithstanding anything in this Agreement to the contrary, <FONT STYLE="white-space:nowrap">I-MAB</FONT> will have the right, effective upon
the Effective Date, to include Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> in <FONT STYLE="white-space:nowrap">I-MAB&#146;s</FONT> Regulatory Documentation for filing or submission to, or correspondence or discussions with, Regulatory
Authorities, and the right to grant a sublicense under the foregoing right to a Sublicensee to include Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> in the Sublicensee&#146;s Regulatory Documentation for filing or submission to, or
correspondence or discussions with, Regulatory Authorities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>2.5.2 Assistance. </B>During the Term, Ferring shall give
<FONT STYLE="white-space:nowrap">I-MAB</FONT> and all Sublicensees and <FONT STYLE="white-space:nowrap">Sub-sublicensees</FONT> reasonable access to Ferring personnel familiar with the Licensed Compound and the Licensed Product, including without
limitation personnel having knowledge, custody or expertise in connection with the Licensed <FONT STYLE="white-space:nowrap">Know-How,</FONT> Clinical Data, Clinical Studies, formulation development, Regulatory Documentation and Manufacture Process
Development thereof The assistance referred to above will be provided to <FONT STYLE="white-space:nowrap">I-MAB</FONT> and <FONT STYLE="white-space:nowrap">I-MAB&#146;s</FONT> designated experts by Ferring from its St. Prex headquarters and/or other
Ferring locations as determined by Ferring. Subject to advance agreement as to estimated amount, expenses incurred by Ferring in the provision of assistance at sites other than those mentioned above will be reimbursed by <FONT
STYLE="white-space:nowrap">I-MAB</FONT> or the <FONT STYLE="white-space:nowrap">I-MAB</FONT> <FONT STYLE="white-space:nowrap">Sub-licensee,</FONT> subject to provision of documented evidence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>2.5.3 Delivery of Manufacturing Process. </B>Within thirty (30)&nbsp;days of receipt of a written notice from <FONT
STYLE="white-space:nowrap">I-MAB</FONT> of its readiness to initiate <FONT STYLE="white-space:nowrap">IND-enabling</FONT> Clinical Studies, Ferring shall transfer to <FONT STYLE="white-space:nowrap">I-MAB</FONT> or any of its designees at <FONT
STYLE="white-space:nowrap">I-MAB&#146;s</FONT> cost, as directed by <FONT STYLE="white-space:nowrap">I-MAB,</FONT> Ferring&#146;s technology under Ferring&#146;s Control for the commercial-scale Manufacturing process, to the extent the same has not
been delivered to <FONT STYLE="white-space:nowrap">I-MAB</FONT> in its entirety by the time such written notice is received by Ferring. If materials, <FONT STYLE="white-space:nowrap">know-how</FONT> and Intellectual Property concerning the
Manufacturing Process are owned by and/or under the control of the Third Party, <FONT STYLE="white-space:nowrap">I-MAB</FONT> shall be responsible itself for obtaining license rights to such materials,
<FONT STYLE="white-space:nowrap">know-how</FONT> and Intellectual Property from the respective Third Party, and Ferring will use reasonable commercial efforts to assist <FONT STYLE="white-space:nowrap">I-MAB</FONT> and the Third Party in such
negotiations in order for <FONT STYLE="white-space:nowrap">I-MAB</FONT> or its designate to receive such materials, <FONT STYLE="white-space:nowrap">know-how</FONT> and Intellectual Property within China.
<FONT STYLE="white-space:nowrap">I-MAB</FONT> shall not sublicense such material, <FONT STYLE="white-space:nowrap">know-how</FONT> and Intellectual Property without the Third Party&#146;s written approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>2.5.4 License to Clinical Data. </B><FONT STYLE="white-space:nowrap">I-MAB</FONT> hereby
grants to Ferring a nonexclusive and royalty-free right and license to use all <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data and Clinical Data generated by <FONT STYLE="white-space:nowrap">I-MAB</FONT> pursuant to this Agreement through
the Development of the License Compound and Licensed Product for any purpose outside the Territory and the Optional Territory (if applicable). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEVELOPMENT </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>In General. </B><FONT STYLE="white-space:nowrap">I-MAB</FONT> shall use Reasonable Commercial Efforts to
Develop the Licensed Product in the Field in the Territory at its own cost and expense in accordance with the Development Plan and, subject to the exercise of the option right to receive a license in the Optional Territory, cf. Clause 2.2 above, in
the agreed upon countries in the Optional Territory (as applicable), Develop the Licensed Product in the Field in the Optional Territory (as applicable) at its own cost and expense in accordance with a supplemental development plan to be mutually
agreed upon by the Parties upon the completion of Phase IIA in the Territory, which shall be incorporated into and become a part of this Agreement. If, after good faith discussions the parties are not able to agree upon the supplemental development
plan, <FONT STYLE="white-space:nowrap">I-MAB&#146;s</FONT> position shall prevail. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Development Plan. </B>The initial Development Plan, which covers the period from the Effective Date through
completion of Phase IB, shall be jointly developed and agreed upon by the Parties within 45 days after the Effective Date, which shall then be incorporated into and become a part of this Agreement. Starting from the first quarter of 2017 and for
each Calendar Year or partial Calendar Year (as applicable) thereafter during the Term, <FONT STYLE="white-space:nowrap">I-MAB</FONT> shall prepare an update to the Development Plan and submit such updated Development Plan to Ferring for its review.
Each update to the Development Plan shall set forth for the applicable Calendar Year or partial Calendar Year the Development objectives, the planned Clinical Studies and other Development activities and the contemplated timelines for the foregoing.
<FONT STYLE="white-space:nowrap">I-MAB</FONT> shall manage the preparation of each such update so that it is submitted to Ferring for its review at least ninety (90)&nbsp;days prior to the end of the then-current Calendar Year. In addition, <FONT
STYLE="white-space:nowrap">I-MAB</FONT> may propose updates to the Development Plan to Ferring from time to time as appropriate in light of changed circumstances. If Ferring does not approve any element of an update to the Development Plan proposed
by <FONT STYLE="white-space:nowrap">I-MAB,</FONT> then the Parties shall discuss in good faith Ferring&#146;s concerns with respect thereto. If, after good faith discussions the parties are not able to agree upon the supplemental development plan,
I_MAB&#146;s position shall prevail. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.3</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Diligence. </B><FONT STYLE="white-space:nowrap">I-MAB</FONT> shall use Reasonable Commercial Efforts to
Develop, obtain and maintain Regulatory Approvals for, the Licensed Product for use in the Field in the Territory and the Optional Territory (as applicable) in furtherance of the Development of the Licensed Product for the Field in the Territory and
the Optional Territory (as applicable). Ferring shall use Reasonable Commercial Efforts to perform activities assigned to it in the Development Plan and the supplemental development plan(s) (as applicable) in furtherance of the Development Plan of
the Licensed Product in the Field in the Territory and the Optional Territory (as applicable). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Regulatory Matters. <FONT STYLE="white-space:nowrap">I-MAB</FONT> </B>shall have the right and
responsibility for preparing, obtaining and maintaining Drug Approval Applications and any other Regulatory Approvals, and for conducting communications with the Regulatory Authorities, for the Licensed Product in the Territory and the Optional
Territory (as applicable). All Regulatory Approvals relating to the Licensed Product with respect to the Territory and the Optional Territory (as applicable) shall be owned by, and shall be the sole property and held in the name of, <FONT
STYLE="white-space:nowrap">I-MAB</FONT> or its designated Affiliate. Ferring hereby shares with <FONT STYLE="white-space:nowrap">I-MAB</FONT> all Regulatory Documentation in its control for the Licensed Compound and/or Licensed Product (including
any existing Regulatory Approvals) owned by Ferring and held in Ferring&#146;s name in the Territory and Optional Territory (as applicable) as of the Effective Date. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Subcontracting. </B><FONT STYLE="white-space:nowrap">I-MAB</FONT> may freely subcontract the exercise of its
rights and the performance of its obligations under this Article 3; provided that <FONT STYLE="white-space:nowrap">I-MAB</FONT> informs Ferring in writing the name of the third party contractor and provided that
<FONT STYLE="white-space:nowrap">I-MAB</FONT> remains responsible to Ferring and its Affiliates, officers, servants or agents, for all activities <FONT STYLE="white-space:nowrap">sub-contracted</FONT> and shall be responsible to, liable to and
indemnify Ferring in the same terms as according to this Agreement for any loss or damage attributable to any negligent act or omission or misconduct on the part such subcontractor, its Affiliates, its officers, servants or agents.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that <FONT STYLE="white-space:nowrap">I-MAB</FONT> elects for any reason not to continue with the
pre- clinical or clinical development of any Licensed Product in any and all indications or in any other way resolves not to make any further attempts aimed at commercializing any Licensed Product in a particular country of the Territory and/or
Optional Territory (as applicable), such election to be notified to Ferring as soon as practicably possible, the licenses and sublicenses in such country granted under this Agreement will be terminated and Ferring will receive from <FONT
STYLE="white-space:nowrap">I-MAB</FONT> an irrevocable, royalty free, unlimited and exclusive license to use in such country all <FONT STYLE="white-space:nowrap">I-MAB</FONT> IP, Intellectual Property and
<FONT STYLE="white-space:nowrap">Know-How</FONT> related thereto including but not limited to <FONT STYLE="white-space:nowrap">I-MAB</FONT> Improvements and any <FONT STYLE="white-space:nowrap">I-MAB</FONT>
<FONT STYLE="white-space:nowrap">Know-How</FONT> related to the Licensed Compound and Licensed Product generated subsequent to the Effective Date. In addition, in such event, <FONT STYLE="white-space:nowrap">I-MAB</FONT> shall provide to Ferring all
<FONT STYLE="white-space:nowrap">I-MAB</FONT> IP, Intellectual Property, Information and <FONT STYLE="white-space:nowrap">Know-How</FONT> related thereto including but not limited to <FONT STYLE="white-space:nowrap">I-MAB</FONT> Improvements and any
<FONT STYLE="white-space:nowrap">Know-How</FONT> related to the Licensed Product generated subsequent to the Effective Date. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>GOVERNANCE; JOINT STEERING COMMITTEE </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Formation and Role. </B>Within thirty (30)&nbsp;days after the Effective Date, the Parties shall establish a
Joint Steering Committee (the &#147;Joint Steering Committee&#148; or &#147;JSC&#148;) to oversee the Development and Commercialization of the Licensed Product under this Agreement. The JSC shall not have any power to bind either Party or to make
any tactical or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operational decisions with respect to either Party&#146;s activities under this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Members. </B>Each Party shall initially appoint two (2)&nbsp;representatives to the JSC, each of whom shall
be a senior officer of the applicable Party. The JSC may change its size from time to time by mutual written agreement of its members; however, at all times the JSC shall be comprised of equal members from each Party. Each Party may replace its
representatives at any time upon written notice to the other Party specifying the prior representative(s) and their replacement(s). Either Party may designate substitutes for its representatives if one (1)&nbsp;or more of such Party&#146;s
designated representatives are unable to be present at a meeting. The JSC shall have two <FONT STYLE="white-space:nowrap">(2)&nbsp;co-chairpersons,</FONT> and Ferring and <FONT STYLE="white-space:nowrap">I-MAB</FONT> shall each have the right to
appoint one <FONT STYLE="white-space:nowrap">co-chairperson</FONT> on an annual basis. The role of the <FONT STYLE="white-space:nowrap">co-chairpersons</FONT> shall be to convene and preside at the meetings of the JSC and to ensure the preparation
of JSC meeting minutes, but the <FONT STYLE="white-space:nowrap">co-chairpersons</FONT> shall have no additional powers or rights beyond those held by other JSC representatives. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Meetings. </B>The JSC shall meet at least one (1)&nbsp;time per Calendar Quarter during the Term unless the
Parties mutually agree in writing to a different frequency for such meetings. Either Party may also call a special meeting of the JSC (by videoconference or teleconference) by at least ten (10)&nbsp;Business Days prior written notice to the other
Party in the event such Party reasonably believes that a significant matter must be addressed prior to the next regularly scheduled meeting, and such Party shall provide the JSC no later than ten (10)&nbsp;Business Days prior to the special meeting
with materials reasonably adequate to facilitate discussion of the issue. No later than ten (10)&nbsp;Business Days prior to any meeting of the JSC, the <FONT STYLE="white-space:nowrap">co-chairpersons</FONT> of the JSC shall jointly prepare and
circulate an agenda for such meeting; provided, however, that either Party may propose additional topics to be included on such agenda, either prior to or in the course of such meeting, and such additional topic may be covered with the consent of
the other Party. The JSC may meet in person, by videoconference or by teleconference, provided, however, at least one (1)&nbsp;meeting per Calendar Year shall be in person unless the Parties mutually agree in writing to waive such requirement in
lieu of a videoconference or teleconference. <FONT STYLE="white-space:nowrap">In-person</FONT> JSC meetings shall be held at locations in China and Europe alternately selected by <FONT STYLE="white-space:nowrap">I-MAB</FONT> and by Ferring. Each
Party shall bear the expense of its respective JSC members&#146; participation in the JSC meetings. The JSC <FONT STYLE="white-space:nowrap">co-chairpersons</FONT> shall jointly send draft meeting minutes to each member of the JSC for review and
approval within ten (10)&nbsp;Business Days after each JSC meeting. Such minutes shall be deemed approved unless one or more members of the JSC objects to the accuracy of such minutes within ten (10)&nbsp;Business Days of receipt.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EXCHANGE OF INFORMATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Promptly after the Effective Date, <FONT STYLE="white-space:nowrap">I-MAB</FONT> and Ferring shall meet to
discuss the scope and contents of a mutual exchange of <FONT STYLE="white-space:nowrap">Know-How</FONT> relevant to the Development Plan, and shall, upon reaching agreement, promptly exchange such <FONT STYLE="white-space:nowrap">Know-How.</FONT>
Thereafter each of the Parties shall periodically meet to discuss the exchange of any further <FONT STYLE="white-space:nowrap">Know-How</FONT> which may become known to them and <FONT STYLE="white-space:nowrap">I-MAB</FONT> shall inform Ferring by
written reports on a three times a year basis of its progress in preclinical and clinical development, the development of a commercial manufacturing process for the Licensed Compound and the Licensed Product and the progress of applications to the
Regulatory Authorities for clinical trials and commercial sale. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During the term of this Agreement and for 10 (ten) years thereafter, irrespective of any termination earlier
than the expiration of the term of this Agreement neither Party shall reveal or disclose to any Third Party any Information received from the other Party or otherwise developed by either Party in the performance of activities in furtherance of this
Agreement or the existence of this Agreement and the collaboration between <FONT STYLE="white-space:nowrap">I-MAB</FONT> and Ferring as set out herein, without first obtaining the written consent of that other Party, except as may be otherwise
provided herein, or: (a)&nbsp;for securing essential or desirable authorizations, privileges or rights from governmental agencies; (b)&nbsp;as required to be disclosed to a government agency; (c)&nbsp;as necessary to file or procure patent
applications relating to the Licensed Product pursuant to Section&nbsp;8; or (d)&nbsp;to carry out any litigation concerning the Licensed Product. Consent or the reason for refusal shall be provided in a prompt and timely manner. This obligation of
confidentiality shall not apply to <FONT STYLE="white-space:nowrap">Know-How</FONT> disclosed to Ferring in the case of termination by Ferring pursuant to Sections 9.2 or 9.3 or to such information that is or becomes a matter of public knowledge but
only in relation to such <FONT STYLE="white-space:nowrap">Know-How</FONT> and Information that is specifically required by Ferring for the sole purpose of being able to commercialize the Licensed Product where Ferring has acquired such rights
pursuant to sections 9.2 or 9.3, or is already in the possession of the receiving Party, or is disclosed to the receiving Party by a Third Party having the right to do so, or is subsequently independently developed by employees or contractors of the
receiving Party or Affiliates thereof who have no knowledge of the confidential information disclosed. The Parties shall take reasonable measures to ensure that no unauthorized use or disclosure is made by others to whom access to such information
is granted. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Nothing herein shall be construed as preventing either Party from disclosing any Information received
from the other Party to an Affiliate, Sublicensee, <FONT STYLE="white-space:nowrap">Sub-sublicensee,</FONT> Recognised Agent or subcontractor of the receiving Party, provided that such Affiliate, Sublicensee,
<FONT STYLE="white-space:nowrap">Sub-sublicensee,</FONT> Recognised Agent or subcontractor has undertaken a similar obligation of confidentiality with respect to the Information. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that a court or other legal or administrative tribunal directly or through an appointed master,
trustee or receiver assumes partial or complete control over the assets of a Party to this Agreement based on the insolvency or bankruptcy of such Party, the bankrupt or insolvent Party shall promptly notify the court or other tribunal:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that Information received from the other Party under this Agreement remains the property of the other Party;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">of the confidentiality obligations under this Agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In addition, the bankrupt or insolvent Party shall, to the extent permitted by law, take all steps necessary or desirable to maintain the
confidentiality of the other Party&#146;s Information and to ensure that the court, other tribunal or appointee maintains such Information in confidence in accordance with the terms of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No public announcement or other disclosure to Third Parties concerning the structure or terms of this Agreement
or any work being carried out hereunder or the results of such work shall be made either directly or indirectly by any Party to this Agreement, except as may be legally required or as may be required for recording purposes, without first obtaining
the approval of the other Party and agreement upon the nature and text of such announcement or disclosure, which approval and agreement shall not be unreasonably withheld. The Party desiring to make any such public announcement or other disclosure
shall inform the other Party of the proposed announcement or disclosure in reasonably sufficient time prior to public release and shall provide the other Party with a written copy thereof to allow such other Party to comment upon such announcements
or disclosure; provided, however, that the contents of any public announcement, press release or similar publicity which has been reviewed and approved can be subsequently <FONT STYLE="white-space:nowrap">re-released</FONT> by either Party in any
form without a requirement for <FONT STYLE="white-space:nowrap">re-approval</FONT> provided the <FONT STYLE="white-space:nowrap">re-releasing</FONT> Party advises the other Party prior to publication of the
<FONT STYLE="white-space:nowrap">re-release</FONT> and identifies the media in which it is to be published. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party agrees that it shall <FONT STYLE="white-space:nowrap">co-operate</FONT> fully with the other with
respect to all disclosures regarding this Agreement to, or public disclosures as required by any other governmental or regulatory body, provided that the disclosing Party uses commercially reasonable efforts to seek confidential treatment for any
Information of either Party included in any such disclosure. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Publications. </B>Each Party recognizes that the publication of papers regarding Information and activities
under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties, provided that such publications are subject to reasonable controls to protect confidential information. Accordingly, each Party shall have the right
to review and approve any paper proposed for publication by the other Party, including any oral presentation or abstract, that contains Clinical Data or pertains to results of Clinical Studies or includes other Information generated under this
Agreement or that otherwise includes confidential information of the other Party. Before any such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party shall deliver a complete copy of the paper or
materials for oral presentation to the other Party at least sixty (60)&nbsp;days prior to submitting the paper to a publisher or making the presentation. The other Party shall review any such paper and give its comments to the publishing or
presenting Party within sixty (60)&nbsp;days after the delivery of such paper to such other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and
abstracts, and shall return such items as soon as reasonably practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than sixty (60)&nbsp;days after the date of delivery to such other Party. Failure
to respond within such sixty (60)&nbsp;days shall be deemed approval to publish or present. Notwithstanding the foregoing, the publishing or presenting Party shall comply with the other Party&#146;s written request to: (a)&nbsp;delete references to
such other Party&#146;s confidential information in any such paper or presentation; or (b)&nbsp;withhold publication of any such paper or any presentation of same for an additional one hundred twenty (120)&nbsp;days in order to permit the Parties to
obtain patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or
acknowledgement, as may be appropriate. Each Party shall use its respective Reasonable Commercial Efforts to cause investigators and institutions participating in clinical studies for the Licensed Product with which it contracts to agree to terms
substantially similar to those set forth in this Section&nbsp;5.7, which efforts shall satisfy such Party&#146;s obligations under this Section&nbsp;5.7 with respect to such investigators and institutions. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Nothing in this Agreement shall be construed as preventing or in any way inhibiting either Party from
complying with statutory and regulatory requirements governing the development, manufacture, use and sale or other distribution of the Licensed Product in any manner that it reasonably deems appropriate including, for example, by disclosing to
Regulatory Authorities Information or other information received from the other Party or Third Parties. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COMMERCIALISATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>General. </B><FONT STYLE="white-space:nowrap">I-MAB</FONT> shall use Reasonable Commercial Efforts to obtain
approval of the Regulatory Authorities and to promote, market, distribute and sell the Licensed Product in the Field in all countries of the Territory and/or Optional Territory (as applicable, cf. Clause 2.2 above), in each case at its own cost and
expense. Following receipt by <FONT STYLE="white-space:nowrap">I-MAB</FONT> or its Affiliate, Sublicensee or <FONT STYLE="white-space:nowrap">Sub-sublicensee</FONT> of marketing approval for the Licensed Product in a country or region of the
Territory and/or Optional Territory (as applicable), <FONT STYLE="white-space:nowrap">I-MAB</FONT> shall start, and shall ensure that its Affiliate or its Sublicensee and/or its <FONT STYLE="white-space:nowrap">Sub-sublicensee</FONT> start the
marketing and sales of the Licensed Product and to use its Reasonable Commercial Efforts to promote, market, distribute and sell the Licensed Product consistent with accepted pharmaceutical business practice and applicable legal requirements.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Sales and Distribution. </B><FONT STYLE="white-space:nowrap">I-MAB</FONT> shall be responsible for:
(a)&nbsp;invoicing and booking sales; (b)&nbsp;establishing all terms of sale (including pricing and discounts); (c) warehousing and distributing; and (d)&nbsp;handling all returns, recalls and withdrawals, order processing, collection, inventory
and receivables, in each of (a)&nbsp;through (d), with respect to the Licensed Product in the Territory and the Optional Territory (as applicable). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Product Trademarks. </B><FONT STYLE="white-space:nowrap">I-MAB</FONT> shall have the right to determine the
Product Trademarks to be used with respect to the Licensed Product in the Field in the Territory and the Optional Territory (as applicable), and shall own all right, title and interest in and to the Product Trademarks. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Markings. </B>To the extent required by Applicable Law in a country in the Territory or the Optional
Territory (if applicable), the promotional materials, packaging and Product Labeling for the Licensed Product used by <FONT STYLE="white-space:nowrap">I-MAB,</FONT> its Sublicensees, <FONT STYLE="white-space:nowrap">Sub-sublicensees</FONT> or its or
their respective Affiliates in connection with the Licensed Product in such country shall contain the logo and corporate name of the manufacturer. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Subcontracting. </B><FONT STYLE="white-space:nowrap">I-MAB</FONT> may subcontract the Commercialization of
the Licensed Product in the Field in the Territory and the Optional Territory (if applicable); provided that any agreement pursuant to which <FONT STYLE="white-space:nowrap">I-MAB</FONT> engages such subcontractor shall be consistent in all material
respects with this Agreement (where applicable) and provided that <FONT STYLE="white-space:nowrap">I-MAB</FONT> informs Ferring in writing the name of the third party contractor and provided that <FONT STYLE="white-space:nowrap">I-MAB</FONT> remains
responsible to Ferring and its Affiliates, officers, servants or agents, for all activities <FONT STYLE="white-space:nowrap">sub-contracted</FONT> and shall be responsible to, liable to and indemnify Ferring in the same terms as according to this
Agreement for any loss or damage attributable to any negligent act or omission or misconduct on the part such subcontractor, its Affiliates, its officers, servants or agents. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Meetings. </B>At the request of Ferring, the Parties shall meet annually to discuss sales of the Licensed
Product in the Territory and/or Optional Territory (as applicable), and <FONT STYLE="white-space:nowrap">I-MAB</FONT> shall inform Ferring of its marketing strategy for the Licensed Product. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Launch. </B>In the event <FONT STYLE="white-space:nowrap">I-MAB</FONT> shall decide not to launch any
Licensed Product in a particular country in the Territory and/or Optional Territory (as applicable), either by itself or through an Affiliate, a Recognised Agent, a Sublicense or a <FONT STYLE="white-space:nowrap">Sub-sublicensee,</FONT> or <FONT
STYLE="white-space:nowrap">Sub-contractor,</FONT> <FONT STYLE="white-space:nowrap">I-MAB</FONT> will immediately inform Ferring in writing of the reason for its decision and Ferring shall be entitled to unilaterally delete such country from the
Territory and/or Optional Territory (as applicable) without a notice period. In this case, <FONT STYLE="white-space:nowrap">I-MAB</FONT> undertakes to transfer free of charge to Ferring any authorization to market a Licensed Product and its Product
Trademarks for such Licensed Product in such country that <FONT STYLE="white-space:nowrap">I-MAB</FONT> may previously have acquired and to cooperate fully in the transfer of sales of such Licensed Product if any in such country to Ferring or to a
Third Party designated by Ferring and shall supply at cost Licensed Product or have it supplied to Ferring or its designee for such sale. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PAYMENTS AND FEES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Initial Payments. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>7.1.1 Initial Payment Covering Territory. </B>The initial <FONT STYLE="white-space:nowrap">non-refundable</FONT> fee to be paid by <FONT
STYLE="white-space:nowrap">I-MAB</FONT> to Ferring for exclusivity in the Territory shall be Two Million Dollars ($2,000,000), payable within forty five (45)&nbsp;days after the Effective Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>7.1.2 Initial Payment Covering Optional Territory. </B>Within sixty (60)&nbsp;days after
the license grant by Ferring to <FONT STYLE="white-space:nowrap">I-MAB</FONT> and the determination of the countries in the Optional Territory, cf. Clause 2.2 above, <FONT STYLE="white-space:nowrap">I-MAB</FONT> shall pay Ferring Three Million
Dollars ($3,000,000) as the initial <FONT STYLE="white-space:nowrap">non-refundable</FONT> fee. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Milestone Payments. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>7.2.1 Development Milestones in the Territory. </B><FONT STYLE="white-space:nowrap">I-MAB</FONT> shall pay Ferring each of the following <FONT
STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> milestone payments within sixty (60)&nbsp;days after the achievement of the corresponding Milestone Event. For clarity, each of the following
milestone payments shall be made only once and upon the first occurrence of the corresponding Milestone Event, regardless of the number of countries in which the Licensed Product achieves the applicable Milestone Event: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Milestone Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Milestone Payment</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Completion of Phase IB in the</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Territory</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">One Million Five Hundred Thousand</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dollars ($1,500,000)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Completion of Phase IIA study</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">report in the Territory</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Three Million Dollars ($3,000,000)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NDA submission in the</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Territory</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Five Million Dollars ($5,000,000)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">NDA approval in the Territory</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Five Million Dollars ($5,000,000)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>7.2.2 Development Milestones in the Optional Territory. </B><FONT STYLE="white-space:nowrap">I-MAB</FONT>
shall pay Ferring each of the following <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> milestone payments within sixty (60)&nbsp;days after the achievement of the corresponding
Milestone Event. For clarity, each of the following milestone payments shall be made only once and upon the first occurrence of the corresponding Milestone Event, regardless of the number of countries in which the Licensed Product achieves the
applicable Milestone Event: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Milestone Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Milestone Payment</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">NDA submission in the United States</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Ten Million Dollars ($10,000,000)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">NDA submission in the European Union</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Five Million Dollars ($5,000,000)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">NDA approval in the United States</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Ten Million Dollars ($10,000,000)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">NDA approval in the European Union</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Five Million Dollars ($5,000,000)</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>7.2.3 Determination that Milestone Events Have Occurred. </B><FONT
STYLE="white-space:nowrap">I-MAB</FONT> shall notify Ferring promptly of the achievement of each Milestone Event. In the event that, notwithstanding the fact that <FONT STYLE="white-space:nowrap">I-MAB</FONT> has not provided Ferring with such a
notice, Ferring believes that any such Milestone Event has been achieved, it shall so notify <FONT STYLE="white-space:nowrap">I-MAB</FONT> in writing and the Parties shall promptly meet and discuss in good faith whether such Milestone Event has been
achieved. Any dispute under this Section&nbsp;7.2.3 regarding whether or not a Milestone Event has been achieved shall be subject to resolution in accordance with Sections 21 and 23. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Royalties. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>7.3.1 Royalty Rates in the Territory. </B>In connection with the grant of the licenses and sublicenses under the Licensed <FONT
STYLE="white-space:nowrap">Know-How</FONT> and Sublicensed Intellectual Property in the Territory pursuant to Section&nbsp;2.1, during the Royalty Term, <FONT STYLE="white-space:nowrap">I-MAB</FONT> shall pay Ferring a
<FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> royalty on Net Sales of the Licensed Product in the Territory in each Calendar Year (or partial Calendar Year), as follows, as calculated
by multiplying the applicable royalty rate in the table below by the corresponding amount of incremental Net Sales of all Licensed Products: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>That portion of Net Sales of the Licensed Product in
the</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Territory in a Calendar Year that is:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty<BR>Rate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less than or equal to Five Hundred Million RMB (RMB500,000,000)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greater than Five Hundred Million RMB (RMB500,000,000)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>7.3.2 Royalty Rates in the Optional Territory. </B>In connection with the grant of the
licenses and sublicenses under the Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> and Sublicensed Intellectual Property in the Optional Territory pursuant to Section&nbsp;2.2, during the Royalty Term,
<FONT STYLE="white-space:nowrap">I-MAB</FONT> shall pay Ferring a <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> royalty on Net Sales of the Licensed Product in the Optional Territory
in each Calendar Year (or partial Calendar Year), as follows, as calculated by multiplying the applicable royalty rate in the table below by the corresponding amount of incremental Net Sales of all Licensed Products: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>That portion of Net Sales of the Licensed Product in
the</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Optional Territory in a Calendar Year that is:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty<BR>Rate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less than or equal to Five Hundred Million Dollars ($500,000,000)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greater than Five Hundred Million Dollars ($500,000,000)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>7.3.3 Payment Dates and Reports. </B>Royalty payments shall be made by
<FONT STYLE="white-space:nowrap">I-MAB</FONT> within sixty (60)&nbsp;days after the end of each Calendar Quarter commencing with the Calendar Quarter in which the first day of the first Royalty Term for the first Licensed Product occurs. <FONT
STYLE="white-space:nowrap">I-MAB</FONT> shall also provide to Ferring, at the same time each such payment is made, a report showing: (a)&nbsp;the Net Sales of the Licensed Product by country in the Territory and the Optional Territory (as
applicable); (b) the basis for any deductions from Invoiced Sales to determine Net Sales; (c)&nbsp;the applicable royalty rates for the Licensed Product; (d)&nbsp;a calculation of the amount of royalty due to Ferring; and (e)&nbsp;the exchange rates
used in calculating any of the foregoing. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Mode of Payment; Currency Conversion; Taxes. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>7.4.1 Mode of Payment. </B>All payments to Ferring under this Agreement shall be made by wire transfer of Dollars in the requisite amount to
such bank account as Ferring may from time to time designate by notice to <FONT STYLE="white-space:nowrap">I-MAB.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>7.4.2 Currency
Conversion. </B>If any currency conversion shall be required in connection with any payment hereunder, such conversion shall be made by using the arithmetic mean of the exchange rates for the purchase of Dollars as published by the People&#146;s
Bank of China, on the last Business Day of each month in the Calendar Quarter to which such payments relate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>7.4.3 Taxes. </B>The milestone and royalty payments and other amounts payable by <FONT
STYLE="white-space:nowrap">I-MAB</FONT> to Ferring pursuant to this Agreement <B>(&#147;Payments&#148;) </B>shall not be reduced on account of any taxes unless required by Applicable Law. Ferring alone shall be responsible for paying any and all
taxes incurred under this Agreement which it should be liable for under the tax law of the relevant jurisdiction. <FONT STYLE="white-space:nowrap">I-MAB</FONT> shall deduct or withhold from the Payments any taxes that it is required by Applicable
Law to deduct or withhold. For the sake of clarity, any federal, state, county or municipal sales or use tax, excise, customs charges, duties or similar charge, or any other tax assessment (other than that assessed against income), license, fee or
other charge lawfully assessed or charged on the manufacture, sale or transportation of Materials sold pursuant to this Agreement or a separate supply agreement between the Parties, shall be paid by Ferring. If Ferring is entitled under any
applicable tax treaty to a reduction of rate of, or the elimination of, applicable withholding tax, it shall deliver to <FONT STYLE="white-space:nowrap">I-MAB</FONT> or the appropriate governmental authority (with the assistance of <FONT
STYLE="white-space:nowrap">I-MAB</FONT> to the extent that this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve
<FONT STYLE="white-space:nowrap">I-MAB</FONT> of its obligation to withhold tax, and <FONT STYLE="white-space:nowrap">I-MAB</FONT> shall apply the reduced rate of withholding, or dispense with withholding, as the case may be; provided that <FONT
STYLE="white-space:nowrap">I-MAB</FONT> has received evidence, in a form reasonably satisfactory to <FONT STYLE="white-space:nowrap">I-MAB,</FONT> of Ferring&#146;s delivery of all applicable forms (and, if necessary, its receipt of appropriate
governmental authorization) at least fifteen (15)&nbsp;Business Days prior to the time the tax return is due for filing and/or that the Payments are due, whichever is earlier. If, in accordance with the foregoing,
<FONT STYLE="white-space:nowrap">I-MAB</FONT> withholds any amount in connection with any Payment, it shall pay to Ferring the balance when due, make timely payment to the proper taxing authority of the withheld amount and send to Ferring proof of
such payment within fifteen (15)&nbsp;Business Days following such Payment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Sub-License</FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Sub-Sub-License</FONT></FONT> Income </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the event any right granted, license, <FONT
STYLE="white-space:nowrap">sub-license</FONT> or <FONT STYLE="white-space:nowrap">sub-sublicense</FONT> given to, or agreement entered into by <FONT STYLE="white-space:nowrap">I-MAB</FONT> with any Third Party (not being an Affiliate or Recognised
Agent of <FONT STYLE="white-space:nowrap">I-MAB)</FONT> in Sublicensed Intellectual Property or Licensed Ferring Intellectual Property or <FONT STYLE="white-space:nowrap">Know-How</FONT> and where, but for such right granted, license, <FONT
STYLE="white-space:nowrap">sub-license</FONT> or <FONT STYLE="white-space:nowrap">sub-sublicense</FONT> given or agreement entered into by <FONT STYLE="white-space:nowrap">I-MAB,</FONT> Sublicensed Intellectual Property or Licensed Ferring
Intellectual Property or <FONT STYLE="white-space:nowrap">Know-How</FONT> as granted by Ferring to <FONT STYLE="white-space:nowrap">I-MAB</FONT> pursuant to this Agreement would be infringed or used by the commercialisation of a Licensed Product by
such Third Party, <FONT STYLE="white-space:nowrap">I-MAB</FONT> shall be deemed to have <FONT STYLE="white-space:nowrap">sub-licensed</FONT> and/or <FONT STYLE="white-space:nowrap">sub-sublicensed</FONT> its rights in the Licensed Product for the
purposes of this Section&nbsp;7.5 under a Third Party Agreement (&#147;Third Party Agreements&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Third Party Agreements shall also
include any related agreements with a <FONT STYLE="white-space:nowrap">Sub-licensee</FONT> and/or a <FONT STYLE="white-space:nowrap">Sub-sub</FONT> licensee such as for example any agreement on an exchange product for the Licensed Product or other <FONT
STYLE="white-space:nowrap">non-financial</FONT> consideration but shall expressly exclude sales to wholesalers under distribution agreements and sales under any other agreements which are covered by Section&nbsp;7.3 above and where sales of Licensed
Product to an end customer are not booked by <FONT STYLE="white-space:nowrap">I-MAB,</FONT> its Affiliates, Sublicensees, <FONT STYLE="white-space:nowrap">Sub-sublicensees</FONT> or Recognized Agents. For the sake of clarity, this exclusion shall
not apply to agreements covering or related to the supply and manufacture of Licensed Compound or Licensed Product where commercialisation of the Licensed Product accruing therefrom is covered under Sublicensed Intellectual Property and/or Licensed
Ferring Intellectual Property and/or <FONT STYLE="white-space:nowrap">Know-How</FONT> as granted by Ferring to <FONT STYLE="white-space:nowrap">I-MAB</FONT> pursuant to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-MAB</FONT> shall pay to Ferring a sum equivalent to 10% (ten percent) of the annual total consideration
received by <FONT STYLE="white-space:nowrap">I-MAB</FONT> under all Third Party Agreements for as long as <FONT STYLE="white-space:nowrap">I-MAB</FONT> is obliged to make payments to Ferring pursuant to section 7.3 above. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, annual total consideration received by <FONT STYLE="white-space:nowrap">I-MAB</FONT> under Third Party Agreements
shall also include the sales booked by <FONT STYLE="white-space:nowrap">I-MAB</FONT> in respect of any product <FONT STYLE="white-space:nowrap">in-licensed</FONT> and commercialized by <FONT STYLE="white-space:nowrap">I-MAB</FONT> and acquired by <FONT
STYLE="white-space:nowrap">I-MAB</FONT> in consideration of any <FONT STYLE="white-space:nowrap">sub-license</FONT> and/or <FONT STYLE="white-space:nowrap">sub-sublicense</FONT> by <FONT STYLE="white-space:nowrap">I-MAB</FONT> of the Licensed
Product, whereupon the Net Sales of any such product <FONT STYLE="white-space:nowrap">in-licensed</FONT> and commercialised by <FONT STYLE="white-space:nowrap">I-MAB</FONT> shall be deemed annual total consideration received by <FONT
STYLE="white-space:nowrap">I-MAB</FONT> under a Third Party Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B>will disclose to Ferring the terms of
all Third Party Agreements within thirty (30)&nbsp;days of their conclusion in so far as the terms are directly applicable to the financial and/or <FONT STYLE="white-space:nowrap">non-financial</FONT> consideration that <FONT
STYLE="white-space:nowrap">I-MAB</FONT> will receive under such Third Party Agreements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Not later than thirty (30)&nbsp;days from the end
of each calendar year, <FONT STYLE="white-space:nowrap">I-MAB</FONT> will: (i)&nbsp;confirm to Ferring by itemised accounts the annual total consideration received in the previous calendar year by <FONT STYLE="white-space:nowrap">I-MAB</FONT> under
such Third Party Agreements; and (ii)&nbsp;make a payment to Ferring of 10% (ten percent) of such consideration as specified above. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Upon
receipt by Ferring of such valuation, Ferring will have thirty (30)&nbsp;days either to accept in writing the accounts submitted by <FONT STYLE="white-space:nowrap">I-MAB</FONT> or to inform <FONT STYLE="white-space:nowrap">I-MAB</FONT> in writing
that Ferring requires an independent accountant acceptable to both Ferring and <FONT STYLE="white-space:nowrap">I-MAB</FONT> to review all Third Party Agreements and all books and accounts of <FONT STYLE="white-space:nowrap">I-MAB</FONT> relevant
for the purposes of determining the annual total consideration received by <FONT STYLE="white-space:nowrap">I-MAB</FONT> during the same calendar year under such Third Party Agreements. Following such review, the accountant shall inform both Parties
of the amount of such consideration and the amount shall then be binding on both Parties. Ferring may exercise the right during the term of this Agreement and until the end of three (3)&nbsp;years after the expiration or termination of this
Agreement once per calendar year. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the event of the independent accountant confirming an amount of annual total consideration received
in the previous calendar year received by <FONT STYLE="white-space:nowrap">I-MAB</FONT> under such Third Party Agreements equal to or within a margin of 5% (five percent) either above or below the valuation submitted by <FONT
STYLE="white-space:nowrap">I-MAB,</FONT> the costs of the independent accountant for such valuation shall be borne by Ferring. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the
event of the independent accountant confirming an amount of annual total consideration received by <FONT STYLE="white-space:nowrap">I-MAB</FONT> in the previous calendar year under such Third Party Agreements exceeding a margin of 5% (five percent)
either above or below the valuation submitted by <FONT STYLE="white-space:nowrap">I-MAB,</FONT> the costs of the independent accountant for such valuation shall be borne by <FONT STYLE="white-space:nowrap">I-MAB.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-MAB</FONT> shall promptly pay to Ferring the full amount of any underpayment owing to Ferring pursuant to
this Section&nbsp;7.5 under such Third Party Agreements together with interest thereon at the rate of EURIBOR plus 2% (two percent) per year compounded monthly from the date payment was due. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Audit Rights </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-MAB</FONT> shall keep and shall cause its Affiliates, Sublicensees,
<FONT STYLE="white-space:nowrap">Sub-sublicensees</FONT> and Recognized Agents to keep records of the sale of the Licensed Product in sufficient detail to permit Ferring to confirm the accuracy of Net Sales and royalties payable reported. Ferring
shall have the right at its own expense (unless the result of such audit results in a variation or error exceeding 5% (five percent) of the payment made in the previous calendar year, in which case at the expense of
<FONT STYLE="white-space:nowrap">I-MAB),</FONT> to have a certified public accounting firm examine the relevant books and records of <FONT STYLE="white-space:nowrap">I-MAB,</FONT> its Affiliates, Sublicensees,
<FONT STYLE="white-space:nowrap">Sub-sublicensees</FONT> and Recognized Agents. Ferring may exercise this right during the term of this Agreement and until the end of three (3)&nbsp;years after the end of the Royalty Term once per calendar year. <FONT
STYLE="white-space:nowrap">I-MAB</FONT> shall promptly pay to Ferring the full amount of any underpayment, together with interest thereon, at the rate of EURIBOR plus 2% (two percent) per year compounded monthly from the date payment was due. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidentiality. </B>Both Parties shall treat all information subject to review under this Section&nbsp;7 in
accordance with the confidentiality provisions of Section&nbsp;5. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INTELLECTUAL PROPERTY </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ownership of Intellectual Property. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>8.1.1 </B>Except as expressly set out herein, this Agreement does not affect the ownership of any
<FONT STYLE="white-space:nowrap">I-MAB</FONT> IP, Ferring Intellectual Property, Ferring <FONT STYLE="white-space:nowrap">Know-How,</FONT> Ferring Improvements or the Sublicensed Intellectual Property. The Parties acknowledge and agree that, as
between the Parties: (a)&nbsp;subject to the terms and conditions of this Agreement, including Section&nbsp;10.3, <FONT STYLE="white-space:nowrap">I-MAB</FONT> shall own and retain all right, title and interest in and to any and all <FONT
STYLE="white-space:nowrap">I-MAB</FONT> IP including <FONT STYLE="white-space:nowrap">I-MAB</FONT> Improvements; and (b)&nbsp;Ferring shall own and retain all right, title and interest in and to any and all Ferring
<FONT STYLE="white-space:nowrap">Know-How,</FONT> Ferring Intellectual Property and Ferring Improvements; (c)&nbsp;Conaris Research Institute AG shall own and retain all right, title and interest in and to any and all Sublicensed Intellectual
Property and (d)&nbsp;each Party shall own and retain all right, title and interest in and to any and all other <FONT STYLE="white-space:nowrap">Know-How</FONT> and other intellectual property rights that are owned or otherwise Controlled (other
than pursuant to the license grants set forth in Section&nbsp;2.1 and 2.2) by such Party, its Affiliates or any Sublicensees, <FONT STYLE="white-space:nowrap">Sub-sublicensees</FONT> or its or their respective Affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>8.1.2 </B>If an Improvement is made by or on behalf of both <FONT
STYLE="white-space:nowrap">I-MAB</FONT> and Ferring, then such Improvement shall be deemed jointly-owned Intellectual Property and such Intellectual Property shall be licensed by Ferring to <FONT STYLE="white-space:nowrap">I-MAB</FONT> under the
terms of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>8.1.3 </B><FONT STYLE="white-space:nowrap">I-MAB</FONT> hereby grants to Ferring a <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> fully paid, royalty free, world-wide license to any <FONT STYLE="white-space:nowrap">I-MAB</FONT> IP. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>8.1.4 No other right of license. </B>Except as expressly set out herein, no provision in this Agreement shall operate to transfer, assign or
otherwise grant any Party any right or interest in any Intellectual Property or other intellectual property rights of the other Party. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Patent Filing, Prosecution and Maintenance </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>8.2.1 Licensed Patents. </B>Ferring shall prepare, file, prosecute and maintain (including with respect to related interference, <FONT
STYLE="white-space:nowrap">re-issuance,</FONT> <FONT STYLE="white-space:nowrap">re-examination,</FONT> opposition and invalidation proceedings) the patents and patent applications of the Ferring Intellectual Property and Sublicensed Intellectual
Property in the Territory and the Optional Territory (as applicable) at its sole cost and expense, and shall not abandon any such patent or patent application in the Territory or the Optional Territory during the Option Right (as applicable) without
the prior written consent of <FONT STYLE="white-space:nowrap">I-MAB</FONT> which shall not be unreasonably withheld. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>8.2.2
Improvements. </B>The Party owning an Improvement shall have responsibility for the filing, prosecution and maintenance at its sole expense, in the applicable patent offices in the Territory and/or Optional Territory (as applicable), and that Party
shall control all filings and actions in relation to procuring and maintaining such New Intellectual Property. <FONT STYLE="white-space:nowrap">I-MAB</FONT> shall have responsibility for jointly-owned Improvements. The Parties agree to keep each
other regularly informed of the course of patent prosecution or other proceedings with respect to Improvements and shall provide each other with copies of all official documents sent to or received by the respective patent offices in the Territory
and/or Optional Territory (as applicable). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the Party having such responsibility for the filing,
prosecution and maintenance of Improvements shall not be required to file, prosecute or maintain any patent application or patent where that Party does not believe that such activities are commercially justified provided, however, that such Party
shall not cease to file, prosecute and maintain any such patent application or patent without giving the other Party the opportunity to take over the responsibility for filing, prosecution and maintenance at its own expense in which case that Party
shall grant the other Party an irrevocable, <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> fully paid, royalty free, world-wide license, with the right to sublicense to such Improvements. The Parties agree and acknowledge that Conaris has
the opportunity to take over responsibility for any Improvements should both Parties decline to maintain patents or patent applications on Improvements. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Cooperation and Assistance </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Each Party shall make available its authorized attorneys, agents or representatives, its employees, agents or consultants reasonably necessary
or appropriate to enable the other Party to file, prosecute and maintain patent applications and resulting patents with respect to the Improvements, and shall provide access to such documents and other information as may be reasonably required for
such purposes. The Party shall sign or cause to have signed all documents relating to said patent applications or patents at no cost or charge to the other Party. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Patent Term Extensions and Supplementary Protection Certificates. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Each Party shall notify the other Party of the issuance of each patent within the Ferring Intellectual Property or <FONT
STYLE="white-space:nowrap">I-MAB</FONT> IP in any country in the Territory and the Optional Territory (as applicable) giving the date of issue and patent number for each such patent. Ferring shall have the exclusive responsibility and shall use
commercially reasonable efforts to apply for and maintain any such extension, and shall not abandon any such extension in the Territory or the Optional Territory (as applicable) without the prior written consent of
<FONT STYLE="white-space:nowrap">I-MAB</FONT> which shall not be unreasonably withheld. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Parties shall cooperate with each other in gaining such extensions and each Party shall
execute such authorizations and other documents and take such other actions as may be reasonably requested by the other Party to obtain such extensions. If more than one patent is eligible for such extension, Ferring shall have the right to make the
election of which patent for which such extension will be sought. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Patent Enforcement and Infringement </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>8.5.1 Notice. If </B>Ferring or <FONT STYLE="white-space:nowrap">I-MAB</FONT> has knowledge of any suspected infringement of any
Intellectual Property by Third Parties or of any misappropriation or misuse of the Intellectual Property in the Territory and/or Optional Territory (as applicable), the Party having such knowledge shall promptly inform the other Party of such
infringement, misuse or misappropriation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>8.5.2 Course of Action. </B><FONT STYLE="white-space:nowrap">I-MAB</FONT> shall have the
right, but not the obligation, at its cost to bring any legal action in the Territory and/or Optional Territory (as applicable) related to infringement by Third Parties, that impacts adversely on the enjoyment by
<FONT STYLE="white-space:nowrap">I-MAB</FONT> of the rights licensed to it hereunder. Ferring shall join in any infringement proceeding as a party at <FONT STYLE="white-space:nowrap">I-MAB&#146;s</FONT> request and at
<FONT STYLE="white-space:nowrap">I-MAB&#146;s</FONT> expense in the event that an adverse party asserts, or <FONT STYLE="white-space:nowrap">I-MAB</FONT> determines in good faith, that a court or other legal body lacks jurisdiction based on
Ferring&#146;s absence as a party in such proceeding, or with respect to patents where such joinder is necessary or desirable to proceed with such claim. Ferring and Conaris shall each have the right, but not the obligation, to bring any legal
action related to infringement if <FONT STYLE="white-space:nowrap">I-MAB</FONT> declines to do so. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>8.5.3 Infringement of Third Party
Rights. </B>In the event that a Third Party alleges that <FONT STYLE="white-space:nowrap">I-MAB&#146;s</FONT> or its Affiliate&#146;s, Sublicensee&#146;s and/or <FONT STYLE="white-space:nowrap">Sub-sublicensee&#146;s,</FONT> manufacture of the
Licensed Product or use of Improvements infringes its intellectual property in the Territory and/or Optional Territory (as applicable), <FONT STYLE="white-space:nowrap">I-MAB</FONT> shall have the sole right to defend such action at its own expense
and Ferring agrees to assist and cooperate where reasonably necessary with <FONT STYLE="white-space:nowrap">I-MAB,</FONT> at <FONT STYLE="white-space:nowrap">I-MAB&#146;s</FONT> own expense, in the defense of any such action. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-MAB</FONT> has carried out its own analysis of Third
Party patent rights in the Territory and/or Optional Territory (as applicable) which could possibly be infringed or be alleged to be infringed by its exercise of the rights under this Agreement. <FONT STYLE="white-space:nowrap">I-MAB</FONT>
acknowledges that the grant of the license and/or sublicense under this Agreement shall not imply any warranty against infringement of any Third Parties&#146; patent rights or any other rights of Third Parties. Ferring and <FONT
STYLE="white-space:nowrap">I-MABe</FONT> are in agreement that Ferring shall not be liable for any patent infringement claims brought by a Third Party against <FONT STYLE="white-space:nowrap">I-MAB</FONT> with regard to the manufacture or marketing
of the Licensed Product in the Territory and/or Optional Territory (as applicable) and shall be under no duty to indemnify <FONT STYLE="white-space:nowrap">I-MAB</FONT> from claims and damages arising therefrom. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>8.5.4 Settlement of Third Party Claims. </B><FONT STYLE="white-space:nowrap">I-MAB,</FONT> with respect to a particular claim pursuant to
Section&nbsp;8.5.3, also shall have the right to control settlement of such claim; provided that: (a)&nbsp;no settlement shall be entered into without the prior consent of Ferring if such settlement would adversely affect or diminish the rights and
benefits of Ferring under this Agreement, or impose any new obligations or adversely affect any obligations of Ferring under this Agreement; and <FONT STYLE="white-space:nowrap">(b)&nbsp;I-MAB</FONT> shall not be entitled to settle any such claim by
granting a license or covenant not to sue under or with respect to the Sublicensed Intellectual Property or Ferring Intellectual Property without the prior written consent of Ferring, such consent not to be unreasonably conditioned, withheld or
delayed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>8.5.5 Costs. </B>Each Party shall unless otherwise stated in this Section&nbsp;8.5 assume and pay all of its own <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred in connection with any litigation or proceedings described in this Section&nbsp;8.5, including, without limitation, the fees and expenses of such
Party&#146;s counsel. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>8.5.6 Recoveries. </B>Any recovery obtained by either Party as a result of any proceeding described in this
Section&nbsp;8.5 or from any counterclaim or similar claim asserted in a proceeding described in this Section&nbsp;8.5, by settlement or otherwise, shall be applied as follows: first, to reimburse each Party for all
<FONT STYLE="white-space:nowrap">out-of-pocket</FONT> litigation costs incurred in connection with such proceeding paid by that Party (on a pro rata basis based on each Party&#146;s respective litigation costs, to the extent the recovery was less
than all such litigation costs); and second, the remainder of the recovery shall be paid one hundred percent (100%) to the Party which funded the infringement action. Any remainder of the recovery by <FONT STYLE="white-space:nowrap">I-MAB</FONT>
shall be treated as <FONT STYLE="white-space:nowrap">sub-license</FONT> income pursuant to Section&nbsp;7.5. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>8.5.7 Cooperation. </B>In the event that any Party takes action pursuant to this
Section&nbsp;8.5, the other Party shall cooperate fully with the Party so acting to the extent reasonably possible, including the joining of suit as required by this Agreement or as otherwise desirable and, to the extent possible, make available
relevant records, papers, information, samples, specimens, and the like. Each Party shall keep the other informed of developments in any action or proceeding, including the status of any settlement negotiations and the terms of any offer related
thereto. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Validity and Enforceability Challenge by Third Party </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the event that a Third Party attacks the validity or enforceability of any of the Ferring Intellectual Property in the Territory and/or the
Optional Territory (as applicable), then Ferring shall promptly notify <FONT STYLE="white-space:nowrap">I-MAB</FONT> and Ferring, at its own discretion, subject to good business judgement, shall promptly take such legal action as is required and
appropriate to defend the validity thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If Ferring does not take such legal action as is required to defend the validity of the
Ferring Intellectual Property in the Territory and/or Optional Territory (as applicable), Ferring shall provide at least sixty (60)&nbsp;days written notice to <FONT STYLE="white-space:nowrap">I-MAB</FONT> prior to a corresponding deadline, if
applicable, and the Parties shall reasonably determine an appropriate alternative in the best interests of both Parties. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Parties agree
and acknowledge that should a Third Party attack the validity or enforceability of any of the Sublicensed Intellectual Property in the Territory and/or the Optional Territory (as applicable) and Ferring does not take such legal action as is required
to defend the validity of such Sublicensed Intellectual Property, then Conaris at its option shall control defense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Product Trademarks </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>8.7.1 Maintenance and Ownership of Product Trademarks. </B><FONT STYLE="white-space:nowrap">I-MAB,</FONT> at its expense, shall be
responsible for the selection, registration and maintenance of all Trademarks that <FONT STYLE="white-space:nowrap">I-MAB</FONT> employs in connection with the Licensed Product <B>(&#147;Product Trademarks&#148;).
</B><FONT STYLE="white-space:nowrap">I-MAB</FONT> shall own all right, title and interest to such Trademarks, trade dress and copyrights in the Territory and Optional Territory (as applicable) related to the Licensed Product. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>8.7.2 Enforcement of Product Trademarks. </B><FONT STYLE="white-space:nowrap">I-MAB</FONT> may, at its sole discretion, take such action as <FONT
STYLE="white-space:nowrap">I-MAB</FONT> deems necessary against a Third Party based on any alleged, threatened, or actual infringement, dilution, misappropriation, or other violation of, or unfair trade practices or any other like offense relating
to, the Product Trademarks by a Third Party in the Territory or the Optional Territory (as applicable). <FONT STYLE="white-space:nowrap">I-MAB</FONT> shall bear the costs and expenses relating to any enforcement action commenced pursuant to this
Section&nbsp;8.7.2 and any settlements and judgments with respect thereto, and shall retain any damages or other amounts collected in connection therewith. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>8.7.3 Third Party Claims. </B><FONT STYLE="white-space:nowrap">I-MAB</FONT> may, at its sole discretion, defend against any alleged,
threatened, or actual claim by a Third Party that the use or registration of the Product Trademarks in the Territory or the Optional Territory (as applicable) infringes, dilutes, or otherwise violates any trademark or other right of such Third Party
or constitutes unfair trade practices or any other like offense, or any other claims as may be brought by a Third Party against a Party in connection with the use of the Product Trademarks with respect to a Licensed Product in the Territory or the
Optional Territory (as applicable). <FONT STYLE="white-space:nowrap">I-MAB</FONT> shall bear the costs and expenses relating to any defense commenced pursuant to this Section&nbsp;8.7.3 and any settlements and judgments with respect thereto, and
shall retain any damages or other amounts collected in connection therewith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>8.7.4 Notice and Cooperation. </B>Each Party shall provide
to the other Party prompt written notice of any actual or threatened infringement of the Product Trademarks in the Territory and the Optional Territory (as applicable) and of any actual or threatened claim that the use of the Product Trademarks in
the Territory or the Optional Territory (as applicable) violates the rights of any Third Party. Each Party shall cooperate fully with the other Party with respect to any enforcement action or defense commenced pursuant to this Section&nbsp;8.7. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERM AND TERMINATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Term. </B>This Agreement shall commence on the Effective Date and shall, unless earlier terminated in
accordance with this Section&nbsp;9, continue: (a)&nbsp;with respect to the Licensed Product in each country in the Territory and the Optional Territory (as applicable, cf. Clause 2.2), until the expiration of the Royalty Term for the Licensed
Product in such country; and (b)&nbsp;with respect to this Agreement in its entirety, until the later of: (i)&nbsp;the expiration of the Royalty Term for the Licensed Product for which there has been a First Commercial Sale in the Territory or the
Optional Territory (as applicable); or (ii)&nbsp;the first date on which <FONT STYLE="white-space:nowrap">I-MAB</FONT> is not conducting any necessary and outstanding Clinical Study with respect to any Licensed Product or seeking to obtain any
necessary and pending Regulatory Approval for the Licensed Product in the Territory or the Optional Territory (if applicable) (such period, the <B>&#147;Term&#148;).</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination of this Agreement for Material Breach. </B>In the event that either Party materially breaches
this Agreement (such Party, the <B>&#147;Breaching Party&#148;), </B>in addition to any other right and remedy the other Party (the <B>&#147;Complaining Party&#148;) </B>may have, the Complaining Party may terminate this Agreement, in its entirety
upon thirty (30)&nbsp;days&#146; prior written notice (the <B>&#147;Termination Notice Period&#148;) </B>to the Breaching Party, specifying the material breach and its claim of right to terminate, provided that the termination shall not become
effective at the end of the Termination Notice Period if the Breaching Party cures the material breach complained of during the Termination Notice Period. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination Upon Insolvency. </B>Either Party may terminate this Agreement if, at any time, the other Party:
(a)&nbsp;files in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or for reorganization (other than for the purposes of merger or amalgamation) or for an
arrangement or for the appointment of a receiver or trustee of such other Party or of its assets; (b)&nbsp;proposes a written agreement of composition or extension of its debts; (c)&nbsp;is served with an involuntary petition against it, filed in
any insolvency proceeding that is not dismissed within thirty (30) days after the filing thereof; (d)&nbsp;proposes or is a party to any dissolution or liquidation; or (e)&nbsp;makes an assignment for the benefit of its creditors.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination of Sublicensed Intellectual Property. </B>Ferring may terminate this Agreement with respect to
the license grant hereunder to Sublicensed Intellectual Property in the event the main license (Development and License Agreement dated November&nbsp;11, 2008) governing the Sublicensed Intellectual Property is terminated by Conaris AG. The Parties
hereby agree to discuss in good faith how to resolve and mitigate to the satisfaction of both Parties any consequences negatively impacting <FONT STYLE="white-space:nowrap">I-MAB</FONT> and its representatives, including potential participants in
clinical trials, in its continued efforts under the license grants under this Agreement due to such termination, (provided that such termination of Sublicensed Intellectual Property is not due to lack of diligence, negligence or breach of this
Agreement by <FONT STYLE="white-space:nowrap">I-MAB</FONT> or its representatives). The agreed process should this happen shall be made in writing and shall be signed as an Amendment to this Agreement no later than forty five (45)&nbsp;days after
the Effective Date. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONSEQUENCE OF TERMINATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In the event of Ferring&#146;s termination of this Agreement pursuant to Sections 9.2 or 9.3, <FONT
STYLE="white-space:nowrap">I-MAB</FONT> shall within thirty (30)&nbsp;days of such termination pay to Ferring in full all unpaid amounts which otherwise became due and payable to Ferring prior to such termination in accordance with this Agreement.
The licenses, sublicenses, <FONT STYLE="white-space:nowrap">sub-sub</FONT> licenses, if any, and other rights granted to <FONT STYLE="white-space:nowrap">I-MAB</FONT> hereunder shall be terminated as of the effective date of the termination and
Ferring shall have an irrevocable, worldwide, royalty free, <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license with right to sublicense, to all <FONT STYLE="white-space:nowrap">I-MAB</FONT> Intellectual Property. <FONT
STYLE="white-space:nowrap">I-MAB</FONT> shall transfer to Ferring without delay all applications to and approvals of Regulatory Authorities for clinical trials and/or sale of Licensed Product, all data and Information in its possession related to
the Licensed Compound and the Licensed Product including its database on the Licensed Compound and the Licensed Product, any master cell bank and the Manufacturing Process for the Licensed Compound and the Licensed Product, all quantities of
Licensed Compound, Licensed Product, clinical trial samples or Materials in its possession and as reasonably required by Ferring for progressing to the commercialization of a Licensed Product. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In the event of Ferring&#146;s termination pursuant to Section&nbsp;9.2 or 9.3 after First Commercial
Sale, <FONT STYLE="white-space:nowrap">I-MAB</FONT> shall transfer free of charge the ownership of its trademarks, trade dress and/or copyrights for the Licensed Product to Ferring and cooperate with Ferring in the transfer of any sales of Licensed
Product to Ferring or a Third Party designated by Ferring in addition to the consequences under Section&nbsp;10.1. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ACCRUED RIGHTS; SURVIVING OBLIGATIONS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Accrued Rights. </B>Termination or expiration of this Agreement for any reason shall be without prejudice to
any rights that shall have accrued to the benefit of a Party prior to such termination or expiration. Such termination or expiration shall not relieve a Party from obligations that are expressly indicated to survive the termination or expiration of
this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Survival. </B>Without limiting the foregoing, Articles 10, 14, 17, 21 and 23 and Section&nbsp;2.5.4, 5.2
&#151; 5.7, 7.6, and 7.7 shall survive the termination or expiration of this Agreement for any reason. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>GENERAL PERFORMANCE STANDARDS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Each Party shall utilise qualified, skilled and experienced personnel in performing their obligations under this Agreement. Such personnel
shall be familiar with the GMP level relevant to their role in the process. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Each Party shall perform all its obligations under this
Agreement with all due skill and care, in a professional manner and in accordance with all Applicable Laws and regulations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In relation to
development, manufacturing and other work necessary to obtain regulatory approvals of the Licensed Product, each Party shall perform its obligations in accordance with the present scientific state of the art as well as current demands from the
relevant regulatory and other authorities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Should either Party become aware of any incident which will or is likely to cause delay to
or impair the performance of its obligations under this Agreement, such Party shall immediately notify the Joint Committee, and inform the other Party of actions, initiated and planned in order to remedy the delay. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Each Party represents and warrants that it has, and will maintain during the term hereof, the authority and right to perform its obligations
under this Agreement and that it has, and will maintain during the term hereof, any permits, licences, facilities, knowledge, specialists and personnel necessary for performance of its obligations under this Agreement. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MANUFACTURE AND SUPPLY </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Supply by Ferring for Phase IB Clinical Trial </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>13.1.2 </B>Ferring will pay for the continued shelf life stability testing to the end of 2017 for the current Licensed Product. Ferring will
use reasonable efforts to assist <FONT STYLE="white-space:nowrap">I-MAB</FONT> with additional testing at <FONT STYLE="white-space:nowrap">I-MAB&#146;s</FONT> cost in the event that further extensions are required beyond 2017. Stability testing and
payment of costs therefore have been detailed in attached Schedule C. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>13.2 <FONT STYLE="white-space:nowrap">I-MAB&#146;s</FONT>
Manufacture Duty. </B><FONT STYLE="white-space:nowrap">I-MAB</FONT> shall, at its own cost, Manufacture or have Manufactured the Licensed Compound and/or the Licensed Product required for completing the relevant Clinical Studies. <FONT
STYLE="white-space:nowrap">I-MAB</FONT> shall, at its own cost, complete all testing, shipping, labelling and other readiness work required for completing the Phase II Clinical Studies; provided that Ferring shall provide assistance as reasonably
requested by <FONT STYLE="white-space:nowrap">I-MAB.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WARRANTIES, REPRESENTATIONS, INDEMNIFICATION AND INSURANCE </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Mutual Representations and Warranties. </B>Each Party hereby represents and warrants to the other Party as
of the Effective Date as follows: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>14.1.1 Corporate Authority. </B>Such Party: (a)&nbsp;has the power and authority
and the legal right to enter into this Agreement and perform its obligations hereunder; and (b)&nbsp;has taken all necessary action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations
hereunder. This Agreement has been duly executed and delivered by such Party and constitutes a legal, valid and binding obligation of such Party and is enforceable against it in accordance with its terms subject to the effects of bankruptcy,
insolvency or other laws of general application affecting the enforcement of creditor rights and judicial principles affecting the availability of specific performance and general principles of equity, whether enforceability is considered in a
proceeding at law or equity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>14.1.2 Consent and Approvals. </B>To the best of its belief and knowledge, all necessary consents,
approvals and authorizations of all Regulatory Authorities and other Persons required to be obtained by such Party in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder have been obtained.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>14.1.3 Conflicts. </B>To the best of its belief and knowledge, the execution and delivery of this Agreement and the performance of such
Party&#146;s obligations hereunder: (a)&nbsp;do not conflict with or violate any requirement of Applicable Law or any provision of the articles of incorporation or bylaws of such Party in any material way; and (b)&nbsp;do not conflict with, violate
or breach or constitute a default or require any consent under, any contractual obligation or court or administrative order by which such Party is bound. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Representations and Warranties of <FONT STYLE="white-space:nowrap">I-MAB.</FONT> </B><FONT
STYLE="white-space:nowrap">I-MAB</FONT> represents and warrants to Ferring as follows, as of the Effective Date: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>14.2.1 No Debarment. </B>Neither <FONT STYLE="white-space:nowrap">I-MAB</FONT> nor any of its Affiliates has been debarred or is subject to
debarment and neither <FONT STYLE="white-space:nowrap">I-MAB</FONT> nor any of its Affiliates will use in any capacity, in connection with the activities to be performed under this Agreement, any Person who has been debarred under Applicable Law in
the relevant jurisdiction; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>14.2.2 Compliance. </B><FONT STYLE="white-space:nowrap">I-MAB</FONT> shall, at all times,
comply in all material respects with all Applicable Laws, rules and regulations and standards applicable to the Development Plan. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Representations and Warranties of Ferring. </B>Ferring represents and warrants to <FONT
STYLE="white-space:nowrap">I-MAB</FONT> as follows, to the best of its belief and knowledge as of the Effective Date: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>14.3.1 Title; Encumbrances. </B>It has sufficient legal and/or beneficial title, ownership or license, free and clear from any mortgages,
pledges, liens, security interests, conditional and installment sales agreements, encumbrances, charges or claims of any kind, of or to the Sublicensed Intellectual Property to grant the licenses and sublicenses to
<FONT STYLE="white-space:nowrap">I-MAB</FONT> as purported to be granted pursuant to this Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>14.3.2 Notice of Infringement or
Misappropriation. </B>It has not received any written notice from any Third Party asserting or alleging that any use of the Licensed Compound or any development of the Licensed Product would infringe, misappropriate or otherwise violate the
intellectual property rights of such Third Party; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>14.3.3 No Proceeding. </B>There are to the best of its knowledge no pending, and no
threatened, adverse actions, suits or proceedings against Ferring involving the Sublicensed Intellectual Property. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>14.3.4 No Debarment.
</B>Neither Ferring nor any of its Affiliates has been debarred or is subject to debarment and neither Ferring nor any of its Affiliates will use in any capacity, in connection with the activities to be performed under this Agreement, any Person who
has been debarred under Applicable Law in the relevant jurisdiction; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>14.3.5 Compliance. </B>Ferring shall, and shall procure its
Affiliates to, comply with all Applicable Laws when performing its and their respective obligations under this Agreement. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Benefit to Third Parties. </B>The representations, warranties, covenants and agreements set forth in this
Agreement are for the sole benefit of the Parties and their successors and permitted assigns, and they shall not be construed as conferring any rights on any Third Parties. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>14.5.1 Indemnification by the Parties. </B>Each Party (the <B>&#147;Indemnifying Party&#148;) </B>shall indemnify and hold harmless the
other Party&#146;s officers, directors, shareholders, employees, successors and assigns <B>(&#147;Indemnified Party&#148;) </B>from any loss, damage or liability, including reasonable attorney&#146;s fees resulting from any claim, complaint, suit,
proceeding or course of action brought by or on behalf of an injured Third Party or a spouse, relative or companion of an injured Third Party, against any of them, alleging personal or related injury, including death, loss of service or consortium
or a similar such claim, due to such personal injury or death, and arising out of the performance of this Agreement (the <B>&#147;Loss&#148;), </B>save that the Indemnifying Party shall not be obliged to indemnify and hold harmless the Indemnified
Party in accordance with the terms of this Section&nbsp;14.5.1 to the extent that such Loss is attributable to the material breach of this Agreement, failure to adhere to Applicable Laws or regulations, or the negligence or willful misconduct of the
Indemnified Party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>14.5.2 </B>With respect to any claim for indemnification asserted by the Indemnified Party pursuant to
Section&nbsp;14.5.1: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Indemnifying Party shall have no obligation to indemnify the Indemnified Party requesting
indemnification unless: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Indemnified Party gives the Indemnifying Party prompt written notice of any claim or lawsuit or other
action for which it seeks to be indemnified under this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Indemnifying Party is granted full authority and control over the defense including settlement against such
lawsuit or other action; provided, however, that: (i)&nbsp;such settlement involves only the payment of monetary damages and no injunctive relief binding on the Indemnified Party, and such monetary damages are paid by the Indemnifying Party;
(ii)&nbsp;the Indemnified Party is not required under such settlement to admit any liability; and (iii)&nbsp;the Indemnified Party is released from all further liability with respect to such claim; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Indemnified Party <FONT STYLE="white-space:nowrap">co-operates</FONT> fully with the Indemnifying Party and
its agents in defense of the claims or lawsuit or other action. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Indemnified Party shall have the right to participate, at its sole cost and expense, in the defense of any
such claim, complaint, suit proceeding or course of action referred to in this paragraph utilizing legal counsel of its choice, provided however that the Indemnifying Party shall have full authority and control to handle any such claim, complaint,
suit, proceeding or course of action, including any settlement or other disposition thereof, for which indemnification has been sought under this Section. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>14.5.3 No Consequential Damages: </B>In no event shall either Party be liable or responsible to the other Party under this Agreement for any
special, indirect, incidental or consequential loss or damage of any nature whatsoever, including without limitation, any actual or anticipated profits, loss of time, inconvenience, commercial loss, out of pocket expenses reasonably incurred by a
Party hereto or any other similar losses. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Insurance. </B><FONT STYLE="white-space:nowrap">I-MAB</FONT> shall secure and keep in force during the term
of this Agreement, at its sole cost and expense, a commercial product insurance and clinical trial insurance policy and any other insurance policies as customarily used in the pharmaceutical industry in the Territory and/or Optional Territory, as
applicable. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ASSIGNMENT </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>This Agreement and the licenses and sublicenses herein granted shall be binding upon and inure to the
benefit of the successors in interest of the respective Parties. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Without the prior written consent of the other Party, neither Party shall sell, transfer, assign,
delegate, pledge or otherwise dispose of, whether voluntarily, involuntarily, by operation of law or otherwise, this Agreement or any of its rights or duties hereunder; provided that <FONT STYLE="white-space:nowrap">I-MAB</FONT> may, with such
consent, but not to be unreasonably withheld, assign this Agreement and its rights and obligations hereunder to an Affiliate, to the purchaser of substantially all of its assets required for the further Development and Commercialization of the
Licensed Products in the Territory and the Optional Territory (as applicable), or to its successor entity or acquirer in the event of a merger, consolidation or change in control of <FONT STYLE="white-space:nowrap">I-MAB.</FONT> Any attempted
assignment or delegation in violation of the preceding sentence shall be void and of no effect. All validly assigned and delegated rights and obligations of the Parties hereunder shall be binding upon and inure to the benefit of and be enforceable
by and against the successors and permitted assigns of Ferring or <FONT STYLE="white-space:nowrap">I-MAB,</FONT> as the case may be. In the event either Party seeks and obtains the other Party&#146;s consent to assign or delegate its rights or
obligations to another Party, the assignee or transferee shall assume all obligations of its assignor or transferor under this Agreement. Notwithstanding anything herein to the contrary, in no event may Ferring assign or grant a license under any
portion of the Sublicensed Intellectual Property in the Territory or Optional Territory (as applicable), or sell, transfer, assign, delegate, pledge or otherwise dispose of, whether voluntarily, involuntarily, by operation of law or otherwise, this
Agreement or any of its rights or duties hereunder, to a then existing or prospective direct competitor of <FONT STYLE="white-space:nowrap">I-MAB</FONT> for the Licensed Product in the Territory or Optional Territory (as applicable). Any attempted
assignment, license or delegation in violation of the preceding sentence shall be void and of no effect. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INDEPENDENT CONTRACTORS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>It is expressly agreed that Ferring, on the one hand, and <FONT STYLE="white-space:nowrap">I-MAB,</FONT>
on the other hand, shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither Ferring, on the one hand, nor <FONT STYLE="white-space:nowrap">I-MAB,</FONT>
on the other hand, shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other, without the prior written consent of the other Party to do so, such consent
not to be unreasonably conditioned, withheld or delayed. All persons employed by a Party shall be employees of such Party and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for the account and
expense of such Party. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NOTICES </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>17.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notice Requirements. </B>Any notice, request, demand, waiver, consent, approval or other communication
permitted or required under this Agreement shall be in writing, shall refer specifically to this Agreement and shall be deemed given only if delivered by hand or sent by facsimile transmission (with transmission confirmed) or by internationally
recognized overnight delivery service that maintains records of delivery, addressed to the Parties at their respective addresses specified in Section&nbsp;17.2 or to such other address as the Party to whom notice is to be given may have provided to
the other Party in accordance with this Section&nbsp;17. Such notice shall be deemed to have been given as of the date delivered by hand or transmitted by facsimile (with transmission confirmed) or on the third Business Day (at the place of
delivery) after deposit with an internationally recognized overnight delivery service. Any notice delivered by facsimile shall be confirmed by a hard copy delivered as soon as practicable thereafter. This Section&nbsp;17 is not intended to govern
the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> business communications necessary between the Parties in performing their obligations under the terms of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>17.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Address for Notice. </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to <FONT STYLE="white-space:nowrap">I-MAB,</FONT> to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-MAB</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Suite 219, Bldg 6 Chamtime Plz, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2889 Jinke Rd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Pudong New
District, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Shanghai, 201203, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The People&#146;s Republic of China </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: Jingwu Zang </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to
FERRING, to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Ferring International Center SA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">CH. DE LA VERGOGNAUSAZ 50, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1162
Saint-Prex, Switzerland </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: Group General Counsel </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ENTIRE AGREEMENT; WAIVER </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>18.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Entire Agreement; Amendments. </B>This Agreement, together with the Schedules attached hereto, sets forth
and constitutes the entire agreement and understanding between the Parties with respect to the subject matter hereof and all prior agreements, understandings, promises and representations, whether written or oral, with respect thereto are superseded
hereby, including that certain confidential disclosure agreement between Ferring and <B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B>dated September&nbsp;25, 2016. Each Party confirms that it is not relying on any representations or warranties
of the other Party except as specifically set forth herein. No amendment, modification, release or discharge shall be binding upon the Parties unless in writing and duly executed by authorized representatives of both Parties. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>18.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Waiver and <FONT STYLE="white-space:nowrap">Non-Exclusion</FONT> of Remedies. </B>Any term or condition of
this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition.
The waiver by either Party of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by the other Party whether of a similar
nature or otherwise. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>18.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>English Language. </B>This Agreement shall be written and executed in, and all other communications under or
in connection with this Agreement shall be in, the English language. Any translation into any other language shall not be an official version thereof, and in the event of any conflict in interpretation between the English version and such
translation, the English version shall control. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>18.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>References. </B>Unless otherwise specified; (a)&nbsp;references in this Agreement to any Article, Section or
Schedule means references to such Article, Section or Schedule of this Agreement; (b)&nbsp;references in any section to any clause are references to such clause of such section; and (c)&nbsp;references to any agreement, instrument or other document
in this Agreement refer to such agreement, instrument or other document as originally executed or, if subsequently varied, replaced or supplemented from time to time, as so varied, replaced or supplemented and in effect at the relevant time of
reference thereto. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>18.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Construction. </B>Except where the context otherwise requires, wherever used, the singular shall include the
plural, the plural shall include the singular, the use of any gender shall be applicable to all genders and the word &#147;or&#148; is used in the inclusive sense (and/or). The captions of this Agreement are for convenience of reference only and in
no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The term &#147;including&#148; as used herein means including, without limiting the generality of any
description preceding such term. The language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against either Party. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SEVERABILITY </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>19.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>To the fullest extent permitted by Applicable Law, the Parties waive any provision of law that would
render any provision in this Agreement invalid, illegal, or unenforceable in any respect. If any provision of this Agreement is held to be invalid, illegal, or unenforceable, in any respect, then such provision will be given no effect by the Parties
and shall not form part of this Agreement. To the fullest extent permitted by Applicable Law and if the rights or obligations of either Party will not be materially and adversely affected, all other provisions of this Agreement shall remain in full
force and effect, and the Parties shall use their best efforts to negotiate a provision in replacement of the provision held invalid, illegal, or unenforceable that is consistent with Applicable Law and achieves, as nearly as possible, the original
intention of the Parties. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20. FURTHER ASSURANCE AND REGISTRATION </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>20.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Further Assurance. </B>Each Party shall duly execute and deliver, or cause to be duly executed and
delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the other Party may reasonably request in
connection with this Agreement or to carry out more effectively the provisions and purposes hereof, or to better assure and confirm unto such other Party its rights and remedies under this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>20.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Registration. </B>Either Party shall have the right at any time to record, register or otherwise notify
(collectively, &#147;Register&#148;) this Agreement with or to appropriate governmental or regulatory offices after having first given thirty (30)&nbsp;days&#146; written notice to the other Party of its intention so to do; provided however, that if
feasible, such Registration shall be made pursuant to confidentiality protections, if available, and otherwise, except as may be required under law, all financial and other material and sensitive business terms of this Agreement shall be redacted
from any copy of this Agreement that is to Registered. The other Party shall provide reasonable assistance in effecting such Registration. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>21.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>GOVERNING LAW; RELIEF </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>21.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Governing Law. </B>This Agreement shall be governed by, and construed in accordance with Swiss law,
excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The Parties agree to exclude the application to this Agreement of
the United Nations Convention on Contracts for the International Sale of Goods. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>21.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Injunctive Relief. </B>Notwithstanding anything to the contrary in this Agreement, either Party shall be
entitled to seek interim relief from, and bring suit before, any court of competent jurisdiction based on the cause of action of intellectual property infringement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>21.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Equitable Relief. </B>The Parties acknowledge and agree that the restrictions set forth in Section&nbsp;5
are reasonable and necessary to protect the legitimate interests of the Parties and that neither Party would not have entered into this Agreement in the absence of such restrictions imposed on the other Party by these provisions, and that any breach
or threatened breach of any provision of Section&nbsp;5&nbsp;may result in irreparable injury to the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party for which there will be no adequate remedy at law. Notwithstanding anything to the
contrary in this Agreement, in the event of a breach or threatened breach of any provision of Section&nbsp;5, the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party shall be authorized and entitled to obtain from any court of competent
jurisdiction injunctive relief, whether preliminary or permanent, specific performance and an equitable accounting of all earnings,<B> </B>profits and other benefits arising from such breach, which rights shall be cumulative and in addition to any
other rights or remedies to which such <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party may be entitled in law or equity. To the maximum extent permitted under Applicable Law, both Parties agree to waive any requirement that the other
Party: (a)&nbsp;post a bond or other security as a condition for obtaining any such relief; and (b)&nbsp;show irreparable harm, balancing of harms, consideration of the public interest or inadequacy of monetary damages as a remedy. Nothing in this
Section&nbsp;21.3 is intended, or should be construed, to limit either Party&#146;s right to equitable relief or any other remedy for a breach of any other provision of this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>22.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FORCE MAJEURE </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>22.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>If either Party is prevented from complying, either totally or in part, with any of the terms or
provisions of this Agreement, by reason of a Force Majeure, then, upon written notice by the Party liable to perform to the other Party, the requirements of this Agreement or such of its provisions as may be affected (excluding, however, any
obligation to pay money) and to the extent so affected, shall be suspended during the period of such Force Majeure; provided, that the Party asserting a Force Majeure shall bear the burden of establishing the existence of the Force Majeure, shall
use its best efforts to remove the Force Majeure, shall continue performance with dispatch whenever such causes are removed, and shall notify the other Party of the Force Majeure not more than ten (10)&nbsp;calendar days from the time of the event;
provided, however, that the Party not asserting the Force Majeure shall have the right, upon payment of all sums due and owing under this Agreement, to terminate the Agreement upon written notice to the Party asserting the Force Majeure if the Force
Majeure continues for more than three (3)&nbsp;months. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>23.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DISPUTE RESOLUTION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>23.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Dispute Resolution. </B>If a dispute arises between the Parties in connection with the interpretation,
validity or performance of this Agreement or any document or instrument delivered in connection herewith (a <B>&#147;Dispute&#148;), </B>then either Party shall have the right to refer such dispute to the Parties&#146; executive officers for
attempted resolution by good faith negotiations during a period of thirty (30)&nbsp;days. Any final decision mutually agreed to by the executive officers shall be conclusive and binding on the Parties. If such executive officers are unable to
resolve such Dispute within such <FONT STYLE="white-space:nowrap">thirty-day</FONT> period, the Dispute will be settled by the Courts of the city of Lausanne. Either Party may enter such award in a court having competent jurisdiction and any Party
to the Dispute may apply to a court of competent jurisdiction for enforcement of such award. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>23.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Continuing Performance. </B>The Parties agree to continue performing their respective obligations under this
Agreement to the extent practicable while any Dispute is being resolved hereunder unless and until such obligations are terminated or expire in accordance with the provisions hereof </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>24.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EXECUTION IN COUNTERPARTS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>24.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>This Agreement may be executed in any number of counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument. This Agreement may be executed by facsimile or other electronic signatures and such signatures shall be deemed to bind each Party as if they were original signatures.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[SIGNATURE PAGE FOLLOWS] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">This Agreement is executed by the authorized representatives of the Parties as of the
Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>FERRING INTERNATIONAL CENTER SA</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><B>/s/ Ferring International Center SA</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: 04/11/2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><B>/s/ <FONT STYLE="white-space:nowrap">I-Mab</FONT></B></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Regulatory Documentation for filing or submission to Regulatory Authorities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule B1 </U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Licensed Intellectual Property </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="13"><B>FE301 composition</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Application No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Application&nbsp;Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">State</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Patent&nbsp;No.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Grant&nbsp;Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Status</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Owner</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PCT/NL2015/050837</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">01/12/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">WO</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Ferring&nbsp;BV</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="13"><B>FE301 dosing</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Application No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Application&nbsp;Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">State</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Patent&nbsp;No.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Grant&nbsp;Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Status</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Owner</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PCT/IB2015/002459</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">01/12/2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">WO</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Ferring&nbsp;BV</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule B2 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Sublicensed Intellectual Property </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="13"><B>Fusion proteins comprising two soluble gp130 molecules</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Application No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Application&nbsp;Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">State</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Patent&nbsp;No.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Status</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Owner</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">00 108 691.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">21/04/2000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">EP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;148&nbsp;065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">validated</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conaris&nbsp;research&nbsp;institute&nbsp;AG</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="13"><B>Optimized nucleotide sequences encoding sgp130</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Application No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Application&nbsp;Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">State</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Patent&nbsp;No.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Status</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Owner</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">04 020 455.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">27/08/2004</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">EP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;630&nbsp;232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">validated</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conaris&nbsp;research&nbsp;institute&nbsp;AG</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PCT/EP2005/009247</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">26/08/2005</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>WO</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">expired</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conaris research institute AG</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11/660,461</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">26/08/2005</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">US</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8206948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Granted</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conaris research institute AG</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2575800</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">26/08/2005</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">CA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conaris research institute AG</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2007-528753</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">26/08/2005</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">JP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4615061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Granted</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conaris research institute AG</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="17"><B>Improved sgp130Fc dimers</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Application No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Application&nbsp;Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">State</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Patent No.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Status</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Owner</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">06 013 668.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">30/06/2006</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">EP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1873166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Validateed</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conaris research institute AG</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PCT/EP2007/005812</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">29/06/2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>WO</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Expired</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conaris research institute AG</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2007263939</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">29/06/2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">AU</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200763939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Granted</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conaris research institute AG</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">PI0713063-5</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">29/06/2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">BR</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conaris research institute AG</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2656440</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">29/06/2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">CA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Pending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conaris research institute AG</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">200780024879.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">29/06/2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">CN</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200780024879.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Granted</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conaris research institute AG</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">200802396</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">29/06/2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">EA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">015620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Granted</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conaris research institute AG</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10742/DELNP/2007</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">29/06/2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">IN</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">265303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Granted</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conaris research institute AG</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2009-517012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">29/06/2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">JP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5417171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Granted</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conaris research institute AG</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">10-2009-700163</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">29/06/2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">KR</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">10-1474817</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Granted</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conaris research institute AG</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">200814839</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">29/06/2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">UA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Granted</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conaris research institute AG</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12/307,003</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">29/06/2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">US</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8895012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Granted</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conaris research institute AG</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14/109,466</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">29/06/2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">US</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9034817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Granted</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conaris research institute AG</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14/689,635</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">29/06/2007</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">US</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Allowed</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Conaris&nbsp;research&nbsp;institute&nbsp;AG</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 of 60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule C </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Materials as of the Effective Date + additional shelf line testing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">160908 FE 301 Inventory and Shelf-life </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Drug Substance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Drug Product</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Storage</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">-70 degrees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">-20 degrees</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Container</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">polypropylene bottle</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">vial</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Volume</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.8 L</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5 mL</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Concentration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">21.3 g/L</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">15 mg/mL</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Quantity per container</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">59.6g</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">75mg</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Confirmed Shelf Life</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4 years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">18 months (ongoing stability)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shelf life with current testing plan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">6 years (until April 2018)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3 years (until Dec 2017)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Comment on Shelf Life</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Highly stable. Good probability that shelf life can be extended to at least 6 years.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Highly stable. Good probability that shelf life can be extended to 4 years. Issue: Contractor will close facility after end 2017 so transfer of assays required (could be Lonza since assays very similar)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Testing site</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lonza UK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Octoplus NL</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Activity (CBA) testing site</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ferring BTG Israel</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ferring BTG Israel</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cost for 2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;31,000 (Ferring)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;16,000 ( Ferring)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cost for 2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;30,600 (Ferring)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;14,600 (Ferring)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cost for 2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;30,600 <FONT STYLE="white-space:nowrap">(I-MAB</FONT> if requested)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;14,600 <FONT STYLE="white-space:nowrap">(I-MAB)</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Available inventory</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">20 bottles (1.8kg)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5000 vials (375g)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ferring direct costs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128; 100,000 per bottle</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;200 per vial</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cell Line storage is &#128;35,000 per year, (Ferring responsibility and discretion if and when to discontinue). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference standard &#151; ongoing real-time stability costs (Ferring until 2017. If subsequent testing is required,
<FONT STYLE="white-space:nowrap">I-MAB</FONT> to take over. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arising assay transfer costs in case of change in testing site for Drug Product beyond 2017
&#151; Ferring will assist but all costs and responsibility will be taken over by <FONT STYLE="white-space:nowrap">I-MAB.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 of 60 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.18</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.18 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">COLLABORATION AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>between </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABL Bio
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">I-Mab</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated July&nbsp;26, 2018 </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Collaboration Agreement (&#147;<B>Agreement</B>&#148;) is made and entered into as
of the date first written above (the &#147;<B>Effective Date</B>&#148;) by and between ABL Bio having a business address at 16, <FONT STYLE="white-space:nowrap">Daewangpangyo-ro</FONT> <FONT STYLE="white-space:nowrap">712beon-gil,</FONT> <FONT
STYLE="white-space:nowrap">Bundang-gu,</FONT> <FONT STYLE="white-space:nowrap">Seongnam-si,</FONT> <FONT STYLE="white-space:nowrap">Gyeonggi-do,</FONT> 13488, Republic of Korea (&#147;<B>ABL Bio</B>&#148;) and I<B>-</B>Mab, having a business address
at P. O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, <FONT STYLE="white-space:nowrap">KY1-1205</FONT> Cayman Islands (&#147;<B><FONT STYLE="white-space:nowrap">I-Mab</FONT></B> &#148;). For purposes of this Agreement,
ABL Bio and <FONT STYLE="white-space:nowrap">I-Mab</FONT> are each referred to individually as a &#147;<B>Party</B>&#148; and together the &#147;<B>Parties</B>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, ABL Bio has developed expertise in the area of bi-specific antibodies for cancer treatment and has developed proprietary intellectual property
around the technology for BsAb (the &#147;<B>BsAb Technology</B>&#148; as further defined herein). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,
<FONT STYLE="white-space:nowrap">I-Mab</FONT> has developed three antibodies that it desires to incorporate into a <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody using such BsAb Technology and has expertise in developing biologics.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, ABL Bio and <FONT STYLE="white-space:nowrap">I-Mab</FONT> agreed to collaborate to enable the development and commercialization of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1/4-1BB,</FONT></FONT> <FONT STYLE="white-space:nowrap">PD-L1/TIGIT</FONT> and <FONT STYLE="white-space:nowrap">PD-L1/B7H3</FONT> BsAbs (each as defined herein); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, ABL Bio and <FONT STYLE="white-space:nowrap">I-Mab</FONT> entered into five Materials Transfer Agreements for the transfer of certain DNA and
protein sequences of applicable antibodies from <FONT STYLE="white-space:nowrap">I-Mab</FONT> to ABL Bio (the &#147;<B>Materials Transfer Agreement</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, <FONT STYLE="white-space:nowrap">I-Mab</FONT> and ABL Bio agree in this Collaboration Agreement (&#147;<B>Agreement</B>&#148;) as
follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Definitions</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Affiliates</B>&#148; shall mean with respect to a Party, an entity that directly or indirectly through
one (1)&nbsp;or more intermediaries, controls, is controlled by or is under common control with such Party. In this definition, &#147;control&#148; means: (a)&nbsp;in the case of corporate entities, direct or indirect ownership of at least fifty
percent (50%) of the stock or shares having the right to vote for the election of directors; and (b)&nbsp;in the case of <FONT STYLE="white-space:nowrap">non-corporate</FONT> entities, direct or indirect ownership of at least fifty percent (50%) of
the equity interest with the power to direct the management and policies of such entities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>ABL Bio</B> <B>Parental Antibody</B>&#148; shall mean the monoclonal antibody against <FONT
STYLE="white-space:nowrap">4-1BB</FONT> and B7H3, controlled by ABL Bio as described in <U>Appendix 1</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>ABL Bio</B> <B>Parental Antibody Patent Rights</B>&#148; shall mean any and all Patent Rights
Controlled by ABL Bio during the Term that claim or cover the composition, use or manufacture of the Parental Antibodies. Such Patent Rights are listed in <U>Appendix 1</U>, as may be updated from time to time. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Business Day</B>&#148; shall mean any day (other than Saturday or Sunday) when banks are open for
business in both China and the Republic of Korea. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>BsAb</B>&#148; shall mean a <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody molecule
constructed by the combination of two Parental Antibodies using BsAb Technology, wherein one of the Parental Antibodies is <FONT STYLE="white-space:nowrap">PD-L1,</FONT> and the other is TIGIT, <FONT STYLE="white-space:nowrap">4-1BB</FONT> or B7H3.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>BsAb Improvements</B>&#148; shall mean any and all improvements to the BsAb, whether patentable or
not, that have been identified, discovered or made by or on behalf of either Party or its Affiliates during the Term. For avoidance of doubt, any and all improvements to BsAb Technology, ABL Bio Parental Antibody and
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody that are specifically designed for BsAb should be deemed BsAb Improvements. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 1 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>BsAb Technology</B>&#148; shall mean the <FONT STYLE="white-space:nowrap">Know-How</FONT> Controlled
by ABL Bio during the Term that is reasonably necessary or useful for the practice of the bispecific antibody platform technology, which can cause one antibody to bind two different targeted antigens as described in <U>Appendix 1</U>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>BsAb Technology Improvement(s)</B>&#148; shall mean any and all data, results and other <FONT
STYLE="white-space:nowrap">Know-How,</FONT> inventions and developments that constitute improvements to the BsAb Technology, whether patentable or not, that have been identified, discovered or made by or on behalf of either Party or its Affiliates
during the Term and are not specifically designed for BsAb. For the avoidance of doubt, <FONT STYLE="white-space:nowrap">Know-How</FONT> and Patent Rights pertaining solely to the BsAb Technology itself (but not to Parental Antibody Technology)
shall be deemed as BsAb Technology Improvement, and any and all improvements to the BsAb Technology that are specifically designed for BsAb should be deemed BsAb. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Ca</B>&#148; shall mean the percentage value of costs sharing ascribed to ABL Bio in <U>Appendix
5</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Ci</B>&#148; shall mean the percentage value of cost sharing ascribed to <FONT
STYLE="white-space:nowrap">I-Mab</FONT> in <U>Appendix 5</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Clinical Development</B>&#148; shall mean the Research and Development after the fulfilment of
Decision Point II. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Clinical Development Plan</B>&#148; shall mean, subject to <U>Section</U><U></U><U>&nbsp;3</U>, a plan
for the Clinical Development activities to be performed by either Party under this Agreement that may be amended from time to time according to <U>Section</U><U></U><U>&nbsp;6</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Clinical Development Report</B>&#148; shall mean, subject to <U>Section</U><U></U><U>&nbsp;3</U>, the
report provided by a Party to the other Party summarizing the Clinical Development activities it has performed during the past calendar quarter. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Clinical Study Completed</B>&#148; shall mean upon the completion of submission and acceptance of a
clinical study report (CSR) concerning the applicable clinical study phase. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Confidential Information</B>&#148; shall mean all information and data, of a confidential or
proprietary nature, which is obtained directly or indirectly by one Party (the &#147;<B>Receiving Party</B>&#148;) or its Affiliates, from the other Party (the &#147;<B>Disclosing Party</B>&#148;) or its Affiliates at any time before, on, or after
the Effective Date, without regard to the form or manner in which such information is disclosed or obtained (including information disclosed orally or in documentary or electronic form or by way of model, or obtained by observation). The existence
and terms of this Agreement are Confidential Information of both Parties. BsAb Technology, BsAb Technology Improvements, ABL Bio Parental Antibody Technology and ABL Bio Parental Antibody Improvements are the Confidential Information of ABL Bio, and
ABL Bio is deemed as the Disclosing Party with respect to all BsAb Technology, BsAb Technology Improvements, ABL Bio Parental Antibody Technology and ABL Bio Parental Antibody Improvements. <FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental
Antibody Technology and <FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody Improvements are the Confidential Information of <FONT STYLE="white-space:nowrap">I-Mab</FONT> and <FONT STYLE="white-space:nowrap">I-Mab</FONT> is deemed as the
Disclosing Party with respect to all I-Mab Parental Antibody Technology and <FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody Improvements. BsAb Improvements are the Confidential Information of ABL Bio and <FONT
STYLE="white-space:nowrap">I-Mab,</FONT> and ABL Bio and <FONT STYLE="white-space:nowrap">I-Mab</FONT> are deemed as the Disclosing Party with respect to all BsAb Improvements. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 2 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Commercially Reasonable Efforts</B>&#148; shall mean the efforts, time, costs and resources invested
that are comparable with the efforts, time, costs and resources a similarly situated pharmaceutical company would normally invest into a proprietary development candidate or pharmaceutical product of comparable nature, value and development stage.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Control&#148;</B> or <B>&#147;Controlled</B>&#148; shall mean, with respect to an item or right, the
possession, whether by ownership or license (in each case other than pursuant to this Agreement), by a Party of the item or right, or the ability of a Party to grant to the other Party access to or a license to or under each such item or right as
provided in this Agreement without violating any agreement or other arrangement with any Third Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>CRO</B>&#148; or &#147;<B>CMO</B>&#148; shall mean a company or other business entity providing
contract research services by performing research based on orders by customers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Debar</B>&#148;, &#147;<B>Debarred</B>&#148;<B> </B>or &#147;<B>Debarment</B>&#148; shall mean
(a)&nbsp;being debarred, or being subject to a pending debarment, pursuant to section 306 of the FDCA, 21 U.S.C. &#167; 335a or similar laws outside the United States, (b)&nbsp;being listed by any federal and/or state agencies, excluded, debarred,
suspended or otherwise made ineligible to participate in federal or state healthcare programs or federal procurement or <FONT STYLE="white-space:nowrap">non-procurement</FONT> programs (as that term is defined in 42 U.S.C. <FONT
STYLE="white-space:nowrap">1320a-7b(f)</FONT> or similar laws outside the United States), or being subject to any pending process by which any such listing, exclusion, debarment, suspension or other ineligibility could occur, (c)&nbsp;being
disqualified by any government or regulatory agency from performing specific services, or being subject to a pending disqualification proceeding, or (d)&nbsp;being convicted of a criminal offense related to the provision of healthcare items or
services or being subject to any pending criminal action related to the provision of healthcare items or services. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.20</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Decision Point</B>&#148; shall mean any of Decision Point I, Decision Point II, Decision Point III and
Decision Point IV. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.21</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Decision Point I</B>&#148; shall mean immediately after the completion of final candidate selection
via in vivo efficacy test according to study protocols approved by the JC. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.22</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Decision Point II</B>&#148; shall mean immediately after the submission of IND Application for Phase I
Clinical Study to the Food and Drug Administration in the U.S. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.23</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Decision Point III</B>&#148; shall mean immediately after Phase I Clinical Study Completed in the U.S.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.24</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Decision Point IV</B>&#148; shall mean immediately after Phase II Clinical Study Completed in the U.S.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.25</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Disclosing Party</B>&#148; shall have the meaning as described in
<U>Section</U><U></U><U>&nbsp;1.15</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.26</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Early Development</B>&#148; shall mean the Research and Development prior to fulfilment of Decision
Point I. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.27</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;Early Development Plan</B>&#148; shall mean a plan for the Early Development activities to be
performed by <FONT STYLE="white-space:nowrap">I-Mab</FONT> and ABL Bio under this Agreement as attached to this Agreement as <U>Appendix 3</U> that may be amended by approval of the JC. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.28</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Early Development Report</B>&#148; shall mean the report provided by a Party to the other Party
summarizing the Early Development activities it has performed during the past calendar quarter. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 3 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.29</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><FONT STYLE="white-space:nowrap">I-Mab</FONT></B> <B>Parental Antibody</B>&#148; shall mean the
monoclonal antibodies against <FONT STYLE="white-space:nowrap">PD-L1</FONT> and TIGIT, respectively, controlled by <FONT STYLE="white-space:nowrap">I-Mab</FONT> as described in <U>Appendix 2</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.30</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><FONT STYLE="white-space:nowrap">I-Mab</FONT></B> <B>Parental Antibody Patent Rights</B>&#148; shall
mean any and all Patent Rights Controlled by <FONT STYLE="white-space:nowrap">I-Mab</FONT> during the Term that claim or cover the composition, use or manufacture of the Parental Antibodies. Such Patent Rights are listed in <U>Appendix 2</U>, as may
be updated from time to time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.31</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Investigation New Drug&#148;</B> or <B>&#147;IND&#148;</B> shall mean a drug that has not been
approved for general use by the U.S. Food and Drug Administration or similar authority in the jurisdiction but is under investigation in clinical trials regarding its safety and effectiveness by clinical investigators and practicing physicians using
patients.<B> </B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.32</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>IND Application</B>&#148; shall mean an application for approval of a request for authorization by the
U.S. Food and Drug Administration or similar authority in the jurisdiction to administer an IND to humans. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.33</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Joint Committee</B>&#148; or &#147;<B>JC</B>&#148; shall have the meaning ascribed in
<U>Section</U><U></U><U>&nbsp;6.1</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.34</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; shall mean all biological materials and
other tangible materials, inventions, practices, methods, protocols, formulations, knowledge, information, <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, processes, assays, skills, experience, techniques and results of
experimentation and testing, which shall include without limitation all biological, chemical, pharmacological, toxicological, clinical, assay, control and manufacturing data, ideas, concepts, drawings, methods of use or application and any other
information, whether patentable or not. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.35</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Late Development</B>&#148; shall mean the Research and Development activities after the fulfilment of
Decision Point I prior to the fulfilment of Decision Point II. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.36</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Late Development Plan</B>&#148; shall mean, subject to <U>Section</U><U></U><U>&nbsp;3</U>, a plan for
the Late Development activities to be performed by either Party under this Agreement as attached to this Agreement as <U>Appendix 4</U> that may be amended from time to time according to <U>Section</U><U></U><U>&nbsp;6</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.37</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Late Development Report</B>&#148; shall mean, subject to <U>Section</U><U></U><U>&nbsp;3</U>, the
report provided by a Party to the other Party summarizing the Late Development activities it has performed during the past calendar quarter. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.38</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Laws</B>&#148; shall mean all laws, statutes, rules, regulations, ordinances and other pronouncements
having the effect of law of any governmental authority, including without limitation patent offices and any other local or national agency, authority court, tribunal, arbitrator, commission, inspectorate, official or other instrumentality of a
government with application within a country. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.39</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Net Receipts</B>&#148; shall mean (a)&nbsp;all payments the Parties received from their respective
Out-Licensee under the <FONT STYLE="white-space:nowrap">Out-License</FONT> Agreement, which shall include but not be limited to upfront payments, technology access fees, milestone payments, financial development funding, commissions, royalties,
success payments as well as acquisition prices allocated to the Products, less (b)&nbsp;any portion of such amounts paid or payable by the Parties to their respective <FONT STYLE="white-space:nowrap">Out-Licensee</FONT> under the <FONT
STYLE="white-space:nowrap">Out-License</FONT> Agreement that are reasonably allocable to the development, commercialization or manufacture of the Products in or for such portion of licensed territory thereunder and (c)&nbsp;taxes and other
governmental charges occurred in connection with the <FONT STYLE="white-space:nowrap">Out-License</FONT> Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 4 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.40</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Net Sales</B>&#148; shall mean the aggregated gross amounts invoiced by the Parties or their
respective Affiliates in respect of the gross sales of all Products under this Agreement by the Parties or their respective Affiliates to Third Parties at an arm&#146;s length open market price less deductions actually allowed in relation to or
specifically allocated to the Products using generally accepted accounting standards for: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.40.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ordinary and customary quantity, trade and/or cash discounts actually granted and logistics service provider
fees paid and payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.40.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts repaid or credited and allowances including cash or credit, given by reason of retroactive price
reductions, or billing errors or rebates actually allowed or paid; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.40.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts refunded or credited for the Products which were rejected, spoiled, damaged, outdated or returned;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.40.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Distribution, packing, handling, freight, shipment and insurance costs in transporting the Products to
customers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.40.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Taxes and other governmental charges occurred in connection with the sale of Products. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.41</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><FONT STYLE="white-space:nowrap">Non-Royalty</FONT> Income</B>&#148; shall mean the portion of Net
Receipts that is not Royalty Income. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.42</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Oa</B>&#148; shall mean the percentage value of royalty and
<FONT STYLE="white-space:nowrap">non-royalty</FONT> sharing ascribed to ABL Bio in <U>Appendix 5</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.43</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Oi</B>&#148; shall mean the percentage value of royalty and
<FONT STYLE="white-space:nowrap">non-royalty</FONT> sharing ascribed to <FONT STYLE="white-space:nowrap">I-Mab</FONT> in <U>Appendix 5</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.44</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">&#147;Opt-In</FONT> Notice&#148; shall have the meaning ascribed in
Section&nbsp;<U>3.2</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.45</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><FONT STYLE="white-space:nowrap">Opt-In</FONT> Party</B>&#148; shall have the meaning ascribed in
<U>Section</U><U></U><U>&nbsp;4.3.2</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.46</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party</B>&#148; shall have the meaning ascribed in
<U>Section</U><U></U><U>&nbsp;4.3.2</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.47</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Out-Licensor</B>&#148;, &#147;<B>Out-License</B>&#148; &#147;<B>Out-Licensee</B>&#148;,
&#147;<B>Out-License Agreement</B>&#148;<B> and <FONT STYLE="white-space:nowrap">&#147;Out-License</FONT> Notice&#148; </B>shall have the meanings ascribed in <U>Section</U><U></U><U>&nbsp;3.3</U> and <U>Section</U><U></U><U>&nbsp;4</U>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.48</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Parental Antibody</B>&#148; shall mean each of ABL Bio Parental Antibody and <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.49</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Parental Antibody Improvements</B>&#148; shall mean any and all data, results and other <FONT
STYLE="white-space:nowrap">Know-How,</FONT> inventions and developments that constitute improvements to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody Technology or ABL Bio Parental Antibody Technology, whether patentable or not,
that have been identified, discovered or made by or on behalf of either Party or its Affiliates during the Term and are not specifically designed for BsAb (&#147;<B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody
Improvements</B>&#148; and &#147;<B>ABL Bio Parental Antibody Improvements</B>&#148;, respectively). For the avoidance of doubt, <FONT STYLE="white-space:nowrap">Know-How</FONT> and Patent Rights pertaining solely to the Parental Antibody itself
(but not BsAb Technology) shall be deemed a Parental Antibody Improvement, and any and all improvements to Parental Antibody Technology that are specifically designed for BsAb should be deemed BsAb. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 5 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.50</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Parental Antibody <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; shall mean the <FONT
STYLE="white-space:nowrap">Know-How</FONT> Controlled by <FONT STYLE="white-space:nowrap">I-Mab</FONT> or ABL Bio during the Term that is reasonably necessary or useful for the practice of the inventions claimed by
<FONT STYLE="white-space:nowrap">I-Mab</FONT> or ABL Bio under its Parental Antibody Patent Rights (&#147;<B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; and &#147;<B>ABL
Bio Parental Antibody <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148;, respectively). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.51</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Parental Antibody Technology</B>&#148; shall mean the Parental Antibody Patent Rights and the Parental
Antibody <FONT STYLE="white-space:nowrap">Know-How</FONT> (&#147;<B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody Technology</B>&#148; and &#147;<B>ABL Bio Parental Antibody Technology</B>&#148;, respectively).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.52</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Patent Rights</B>&#148; shall mean all patents and patent applications including without limitation
continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> divisions, patents of addition, utility patents, reissues, renewals, <FONT STYLE="white-space:nowrap">re-examinations,</FONT>
requests for continued examination, registrations, patents of importation or patent term extensions thereof including Supplemental Protection Certificates (&#147;<B>SPCs</B>&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.53</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1/4-1BB</FONT></FONT>
BsAb</B>&#148; shall mean the <FONT STYLE="white-space:nowrap">PD-L1</FONT> and <FONT STYLE="white-space:nowrap">4-1BB</FONT> <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody that uses the <FONT STYLE="white-space:nowrap">PD-L1</FONT>
sequence of <FONT STYLE="white-space:nowrap">I-Mab,</FONT> and the <FONT STYLE="white-space:nowrap">4-1BB</FONT> sequence of ABL Bio. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.54</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><FONT STYLE="white-space:nowrap">PD-L1/B7H3</FONT> BsAb</B>&#148; shall mean the <FONT
STYLE="white-space:nowrap">PD-L1</FONT> and B7H3 <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody that uses the <FONT STYLE="white-space:nowrap">PD-L1</FONT> sequence of <FONT STYLE="white-space:nowrap">I-Mab,</FONT> and the B7H3
sequence of ABL Bio. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.55</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><FONT STYLE="white-space:nowrap">PD-L1/TIGIT</FONT> BsAb</B>&#148; shall mean the <FONT
STYLE="white-space:nowrap">PD-L1</FONT> and TIGIT <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody that uses the <FONT STYLE="white-space:nowrap">PD-L1</FONT> and TIGIT sequence of <FONT STYLE="white-space:nowrap">I-Mab.</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.56</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Product</B>&#148; shall mean a finished pharmaceutical formulation packaged and ready for sale
containing the BsAb. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.57</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Product Family</B>&#148; shall mean all Products containing the BsAb. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.58</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Project Lead</B>&#148; or &#147;<B>PL</B>&#148; shall have the meaning ascribed in
<U>Section</U><U></U><U>&nbsp;2.3</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.59</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Receiving Party</B>&#148; shall have the meaning ascribed in <U>Section</U><U></U><U>&nbsp;1.15</U>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.60</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Research and Development</B>&#148; shall mean any research and development performed by <FONT
STYLE="white-space:nowrap">I-Mab</FONT> or ABL Bio pursuant to the Research and Development Plan. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.61</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Research and Development Plan</B>&#148; shall mean the Early Development Plan, the Late Development
Plan, and Clinical Development Plan. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.62</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Royalty Income</B>&#148; shall mean royalty payments, received by either Party or its Affiliates from
a Third Party under the terms and conditions of an <FONT STYLE="white-space:nowrap">Out-License</FONT> Agreement, which, for the purpose of clarification, shall include payments calculated on the basis of Net Sales generated in connection with such <FONT
STYLE="white-space:nowrap">Out-License</FONT> Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.63</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Term</B>&#148; shall mean the period commencing on the Effective Date ending upon fulfilment of the
last payment obligation of either Party to the other Party hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.64</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Territory</B>&#148; shall mean the following: (1) &#147;<B>ABL Bio&#146;s Territory for <FONT
STYLE="white-space:nowrap">PD-L1/TIGIT</FONT> BsAb</B>&#148; or &#147;<B>ABL Bio&#146;s Territory for <FONT STYLE="white-space:nowrap">PD-L1/B7H3</FONT> BsAb</B>&#148; is the Republic of Korea, (2) &#147;<B>ABL Bio&#146;s Territory for <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1/4-1BB</FONT></FONT> BsAb</B>&#148; is the Republic of Korea and Greater China (<I>i.e.</I>, the People&#146;s Republic of China, Hong Kong, Macao and Taiwan), (3) &#147;<B><FONT
STYLE="white-space:nowrap">I-Mab&#146;s</FONT> Territory for <FONT STYLE="white-space:nowrap">PD-L1/TIGIT</FONT> BsAb</B>&#148; or &#147;<B><FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> Territory for
<FONT STYLE="white-space:nowrap">PD-L1/B7H3</FONT> BsAb</B>&#148; is Greater China (<I>i.e.</I>, the People&#146;s Republic of China, Hong Kong, Macao and Taiwan) and (4)&nbsp;the &#147;<B>Rest of the World</B>&#148; is all other territories other
than the Republic of Korea and Greater China. The Parties are entitled to the exclusive rights to the development and commercialization of the Product and the Product Family in their respective Territory as specifically defined in this Agreement.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 6 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.65</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Third Party</B>&#148; shall mean any other entity than a Party and its Affiliates.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.66</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In this Agreement unless it is inconsistent with the context, a reference to a statutory provision includes a
reference to: (i)&nbsp;a statutory amendment, modification, substitution, consolidation or <FONT STYLE="white-space:nowrap">re-enactment</FONT> (whether before or after Effective Date); (ii) statutory instruments or subordinate legislation or orders
made under the statutory provision; and (iii)&nbsp;statutory provisions of which the statutory provision is an amendment, modification, substitution, consolidation or <FONT STYLE="white-space:nowrap">re-enactment.</FONT> Unless the context of this
Agreement otherwise requires, (i)&nbsp;words of one gender includes the other gender; (ii)&nbsp;words using the singular or plural number also include the plural or singular number respectively; (iii)&nbsp;the terms &#147;hereof&#148;,
&#147;herein&#148;, &#147;hereby&#148; and derivative or similar words refer to this entire Agreement; and (iv)&nbsp;the terms &#147;Article&#148;, &#147;Section&#148; and &#147;Appendix&#148; refer to the specified Article, Section and Appendix of
this Agreement. When this Agreement refers to a number of days, unless otherwise specified (e.g. Business Days), such number shall refer to calendar days. When this Agreement refers to a number of years and/or months, unless otherwise specified,
such number shall refer to calendar years and/or months. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Early Development</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties have agreed to share activities according to the Early Development Plan attached hereto as
<U>Appendix 3</U> up to Decision Point I. Such Early Development Plan provides the planned activities of each Party and shall be updated, if required, by mutual agreement between the Parties. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All Early Development shall be performed according to the Early Development Plan by each Party (and/or its
Affiliate or permitted CRO) as assigned to it therein. In principle, the Parties agreed to share the cost and responsibility for Early Development in the Rest of the World equally with Commercially Reasonable Efforts. However, for the purpose of
administrative convenience, the Parties agree to share the costs for Early Development as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party is responsible to bear their respective costs for any and all
<FONT STYLE="white-space:nowrap">in-house</FONT> work to be performed by each Party until the production of selected candidates prior to <I>in vivo</I> proof of concept experiments in accordance with the roles assigned to the Party as outlined in
the Early Development Plan and Exhibit A of the Materials Transfer Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any and all the costs associated with the subsequent <I>in vivo</I> experiments, including without limitation
<I>in vivo</I> experiments performed by <FONT STYLE="white-space:nowrap">I-Mab</FONT> and the permitted CRO, will be split 50%:50% between the Parties </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Within thirty (30)&nbsp;days after the end of each calendar quarter, all parties (excluding <FONT
STYLE="white-space:nowrap">I-Mab</FONT> but including all permitted CROs) shall submit to ABL Bio a reasonably detailed report setting forth the cost and expense (including both in house and external costs and expenses) incurred by such party to
perform the <I>in vivo</I> experiments activities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ABL Bio shall, within thirty (30)&nbsp;days after the receipt of such reports, prepare a consolidated report,
subject to approval by the other Party; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 7 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Party which has borne and expended more than its share of the <I>in vivo</I> experiments costs shall submit
to the other Party an invoice for such exceeded amount so that the total cost can be borne by the Parties (50%:50%). The other Party shall pay such invoice within sixty (60)&nbsp;days after receipt. Each Party shall keep detailed books and records
of the development cost incurred by such Party to <I>in vivo</I> experiments activities and shall make such books and records available to the other Party for inspection and audit upon reasonable advance notice. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Project Lead</U>. Promptly after the Effective Date, the Parties will appoint a Project Lead (the
&#147;<B>PL</B>&#148;) for each project to facilitate the communication of the Early Development activities. Each Party shall appoint its respective PL within thirty (30)&nbsp;days after the Effective Date, and may substitute its PL, in its sole
discretion, effective upon written notice to the other Party of such change. Each Party&#146;s PL shall be a project manager and will have appropriate expertise and ongoing familiarity with the Research and Development Plans. The PLs shall keep each
other informed of all details of the activities under the Early Development Plan and the Late Development Plan, subject to <U>Section</U><U></U><U>&nbsp;3</U>. The PL responsibilities shall include (i)&nbsp;scheduling meetings, including the JC;
(ii)&nbsp;setting the agenda for such meetings with solicited input from other members, including the JC. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party shall provide the other Party with disclosure of any invention made by that Party during the
Research and Development comprising BsAb Technology Improvements, BsAb Improvements, and Parental Antibody Improvements. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Late Development, Clinical Development and Options</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At Decision Point I and, in the event the JC decides to develop and commercialize any Product in the Rest of
the World, at each Decision Point after Decision Point I, if one Party owns more than 50% of the intellectual property rights for a particular project as determined in accordance with <U>Appendix 5</U>, such Party shall be the Lead Party; if neither
party owns more than 50% of the intellectual property rights for the project, the JC shall select a Party as the Lead Party<B> </B>within seven (7)&nbsp;Business Days after the completion of Decision Point I. For the avoidance of doubt, in the case
of <FONT STYLE="white-space:nowrap">PD-L1/TIGIT,</FONT> <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall be the Lead Party, and in the case of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1/4-1BB</FONT></FONT> and <FONT
STYLE="white-space:nowrap">PD-L1/B7H3,</FONT> ABL Bio and <FONT STYLE="white-space:nowrap">I-Mab</FONT> own 50% respectively and the Lead Party shall be determined by the JC within seven (7)&nbsp;Business Days after Decision Point I. Decisions
regarding Late Development, Clinical Development and entering into <FONT STYLE="white-space:nowrap">Out-License</FONT> Agreement will be made in the following manner: in ABL Bio&#146;s Territory by ABL Bio, in
<FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> Territory by <FONT STYLE="white-space:nowrap">I-Mab,</FONT> and in the Rest of the World, by the Lead Party. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties agree to <FONT STYLE="white-space:nowrap">co-develop</FONT> each of the Products containing <FONT
STYLE="white-space:nowrap">PD-L1/TIGIT,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1/4-1BB</FONT></FONT> and <FONT STYLE="white-space:nowrap">PD-L1/B7H3</FONT> up to Decision Point II and share the cost and
responsibilities equally with Commercially Reasonable Efforts in accordance with the Late Development Plan attached hereto as <U>Appendix 4</U>. No later than seven (7)&nbsp;Business Days following each Decision Point II, III or IV, either Party can
notify the other Party that it intends to share the costs of the next development work with the other Party in the Rest of the World (&#147;<B><FONT STYLE="white-space:nowrap">Opt-In</FONT></B><B> Notice</B>&#148;). After an <FONT
STYLE="white-space:nowrap">Opt-In</FONT> Notice from a Party, such Party shall automatically become the Lead Party if the other Party has not given a similar notice. For the avoidance of doubt, if one Party stops development work or sharing the
costs of development work, the other Party who continues development work or bears the cost of such development work shall automatically become the Lead Party. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 8 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ABL Bio in ABL Bio&#146;s Territory, and <FONT STYLE="white-space:nowrap">I-Mab</FONT> in <FONT
STYLE="white-space:nowrap">I-Mab&#146;s</FONT> Territory, has the right to pursue indirect development and commercialization of the Products via an <FONT STYLE="white-space:nowrap">Out-License</FONT> Agreement (&#147;<B><FONT
STYLE="white-space:nowrap">Out-License</FONT> Agreement</B>&#148;) with any Third Party (&#147;<B><FONT STYLE="white-space:nowrap">Out-Licensee</FONT></B>&#148;). The Party who enters into an <FONT STYLE="white-space:nowrap">Out-License</FONT>
Agreement in its Territory shall make a commercially reasonable effort to obtain the consent of such <FONT STYLE="white-space:nowrap">Out-Licensee</FONT> to disclose relevant information (excluding financial terms) regarding such Out-License
Agreement with the other Party after the execution. In the Rest of the World, either Party may pursue <FONT STYLE="white-space:nowrap">out-license</FONT> opportunities, but the final decision to enter into an Out-License Agreement with any <FONT
STYLE="white-space:nowrap">Out-Licensee</FONT> to indirectly develop and commercialize the Product (&#147;<B><FONT STYLE="white-space:nowrap">Out-License</FONT></B>&#148;) in any country in the Rest of the World should be made by the Lead Party (a
Party entering into an <FONT STYLE="white-space:nowrap">Out-License</FONT> Agreement hereinafter referred to as &#147;<B><FONT STYLE="white-space:nowrap">Out-Licensor</FONT></B>&#148;). <FONT STYLE="white-space:nowrap">Out-Licensor</FONT> shall
notify the other Party of the decision (&#147;<B><FONT STYLE="white-space:nowrap">Out-License</FONT> Notice</B>&#148;) and, subject to consent of the <FONT STYLE="white-space:nowrap">Out-Licensee,</FONT> provide the other Party with a complete copy
of each <FONT STYLE="white-space:nowrap">Out-License</FONT> Agreement within thirty (30)&nbsp;days of the execution of such agreement, which shall not be unreasonably withheld or delayed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At Decision Point I and, if both Parties decide to <FONT STYLE="white-space:nowrap">co-develop</FONT> the
Products in the Rest of the World, at each Decision Point after Decision Point I, according to <U>Section</U><U></U><U>&nbsp;3.1</U>, the Lead Party shall, within ninety (90)&nbsp;days of such decision, convene a JC meeting for and agree to an
amended Late Development Plan, the Clinical Development Plan, and the budget. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The PLs shall continue their responsibilities according to <U>Sections 6.4</U> and <U>2.3</U> during the Late
Development and the Clinical Development; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The JC shall discuss and approve any further changes to the Late Development Plan and the Clinical Development
Plan in case of <FONT STYLE="white-space:nowrap">co-development</FONT> and the budget proposed by the Parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All Late Development and Clinical Development shall be performed according to the Late Development Plan and
Clinical Development Plan by each Party (and/or its Affiliate or permitted CMO/CRO) as assigned to it therein. Each Party shall use Commercially Reasonable Efforts to perform the Late Development and Clinical Development activities assigned to it
and shall provide Late Development Report and Clinical Development Report to the other Party. Subject to the terms of this Agreement, the Lead Party may enter into a service agreement or collaboration agreement, without the other Party&#146;s prior
written consent, with (i)&nbsp;its Affiliate and (ii)&nbsp;any Third Party acting solely as contract manufacturer, contract research organization, distributor or wholesaler of the Party or its Affiliates. A Party who enters into a service agreement
or a collaboration agreement with its Affiliate or a Third Party shall, subject to consent of such Affiliate or Third Party, provide the other Party with a complete copy of such an Agreement within thirty (30)&nbsp;days of the execution of such
agreement, which shall not be unreasonably withheld or delayed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Parties shall share the Late Development and Clinical Development cost as follows. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Within fifteen (15)&nbsp;Business Days after the end of each calendar quarter, the other Party (<I>i.e.</I>,
the party that is not the Lead Party) shall submit to the Lead Party a reasonably detailed report, together with evidence, setting forth the cost and expense (including both in house cost and expense at an FTE rate of USD 200,000 per year and
external cost and expense) in such calendar quarter incurred by such Party to perform the Late Development or Clinical Development activities assigned to it under the Late Development Plan or Clinical Development Plan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 9 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If there is any question in the report prepared by the other Party, the Lead Party may request the other Party
to supplement within fifteen (15)&nbsp;Business Days after receiving the detailed report from the other Party. Otherwise, the Lead Party shall prepare a consolidated report (summary of the cost and expense incurred by both the Lead Party and the
other Party) within fifteen (15)&nbsp;Business Days after receiving the detailed report from the other Party, subject to approval by the other Party. The other Party should give the Lead Party a written notice within fifteen (15)&nbsp;Business Days
if there is any question in such consolidated report. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon receipt of such written notice within the required time, the Lead Party may provide a revised consolidated
report to the other Party. If the Lead Party does not receive such a written notice within the required time, the Lead Party shall invoice the other Party according to the Development Costs Sharing (Ca: Ci) as specified in <U>Appendix 5</U>. The
other Party shall pay such invoice within sixty (60)&nbsp;days after the invoice date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The total cost and expense, unless specifically approved by the JC, shall not exceed one hundred and ten
percent (110%) of the amount set forth in the budget for such Late Development activities in the Late Development Plan or Clinical Development activities in the Clinical Development Plan. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party shall keep detailed books and records of the development cost incurred by such Party to perform Late
Development or Clinical Development activities and shall make such books and records available to the other Party for inspection and audit upon reasonable advance notice. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Immediately after the execution of this Agreement, neither Party shall develop independently from the other
Party or with any Third Party a bispecific antibody that uses the same pair of antibodies as the BsAb under this Agreement for bispecific antibody development, even if the latter bispecific antibody contains a different sequence than what was
contained in the particular BsAb. In the event that both Parties agree, by signing an amendment at any time, that such a bispecific antibody that uses such pair of antibodies under this Agreement has no drug developability, such bispecific antibody
that uses such pair of antibodies should not be limited by this <U>Section</U><U></U><U>&nbsp;3.5</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party should share the clinical data generated during its development work with the other Party without
additional charge. Each Party should provide reasonable technical assistance regarding relevant documents, material, and technical transfer as reasonably requested by the other Party in accordance with, and at the FTE rate set forth in
<U>Section</U><U></U><U>&nbsp;3.4.4</U>. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 10 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U><FONT STYLE="white-space:nowrap">Out-License</FONT> Income Sharing</U><U> </U><U>and Royalty Incoming
Sharing</U> </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U><FONT STYLE="white-space:nowrap">Out-License</FONT> Right. </U>The final decision to enter an <FONT
STYLE="white-space:nowrap">Out-License</FONT> Agreement with a Third Party in the Rest of the World should be made by the Lead Party. All other <FONT STYLE="white-space:nowrap">Out-License</FONT> Agreements shall require the prior written consent of
the other Party, which shall not be unreasonably withheld, delayed or conditioned. A Party who enters an <FONT STYLE="white-space:nowrap">Out-License</FONT> Agreement or Sublicense Agreement with a Third Party shall provide the other Party with a
complete copy of each <FONT STYLE="white-space:nowrap">Out-License</FONT> Agreement within thirty (30)&nbsp;days of the execution of such agreement. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Party&#146;s Territory</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">When either Party or its Affiliate Out-Licenses the Products in the Party&#146;s Territory, such Party shall
not pay the other Party royalties or <FONT STYLE="white-space:nowrap">out-licensing</FONT> incoming sharing on Net Sales of all Products in the Party&#146;s Territory. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Rest of the World</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">In the event the JC decides to develop and commercialize the Products at any Decision Point in the Rest of the World, income sharing shall be
done in the following manner. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Non-Royalty</FONT> Income Sharing</B>. After any Decision Point if both
Parties decide to participate in the development of a Product in any country in the Rest of the World and execute an <FONT STYLE="white-space:nowrap">Out-License</FONT> Agreement for the country, ABL Bio shall be entitled to a share (Oa) of the <FONT
STYLE="white-space:nowrap">Non-Royalty</FONT> Income, and <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall be entitled to a share of (Oi) of the <FONT STYLE="white-space:nowrap">Non-Royalty</FONT> Income as specified in <U>Appendix 5</U>;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Non-Royalty</FONT> Income Sharing Adjustment in case of <FONT
STYLE="white-space:nowrap">Opt-Out</FONT></B>. After any Decision Point except Decision Point I, if a Party (&#147;<B>Opt-Out</B> <B>Party</B>&#148;) decides not to participate in the development of the Product(s) in the Rest of the World and the
other Party (&#147;<B>Opt-In</B> <B>Party</B>&#148;) executes an <FONT STYLE="white-space:nowrap">Out-License</FONT> Agreement in the Rest of the World, the <FONT STYLE="white-space:nowrap">Opt-In</FONT> Party shall pay to the <FONT
STYLE="white-space:nowrap">Opt-Out</FONT> Party a percentage of the <FONT STYLE="white-space:nowrap">Out-License</FONT> income, which percentage shall equal to [X/(X+Y*1.5)] where, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">X is the total amount actually incurred (either paid or shared) by the
<FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party to develop the Product under this Agreement before discontinuing the participation; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Y is the total amount actually incurred (either paid or shared) by the
<FONT STYLE="white-space:nowrap">Opt-In</FONT> Party to develop the Product under this Agreement before the execution of such <FONT STYLE="white-space:nowrap">Out-License</FONT> Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Royalty Income Sharing</B>. After any Decision Point if both Parties decide to participate in the
development of a Product in any country in the Rest of the World and execute an <FONT STYLE="white-space:nowrap">Out-License</FONT> Agreement for the country, ABL Bio shall be entitled to a share (Oa) of the Royalty Income, and <FONT
STYLE="white-space:nowrap">I-Mab</FONT> shall be entitled to a share of (Oi) of the Royalty Income as specified in <U>Appendix 5</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Royalty Income Sharing Adjustment in case of <FONT STYLE="white-space:nowrap">Opt-Out</FONT></B>. After any
Decision Point except Decision Point I, if a Party decides not to participate in the development of the Product(s) in the Rest of the World and the other Party executes an <FONT STYLE="white-space:nowrap">Out-License</FONT> Agreement in the Rest of
the World, the <FONT STYLE="white-space:nowrap">Opt-In</FONT> Party shall pay to the <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Party a minimal percentage of the Royalty Income as follows: when <FONT STYLE="white-space:nowrap">I-Mab</FONT> or
its Affiliate <FONT STYLE="white-space:nowrap">out-licenses</FONT> the Products in the Rest of the World, <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall pay ABL Bio a percentage of the royalties, which percentage shall be no less than 5%*Oa;
when ABL Bio or its Affiliate Out-Licenses the Products in the Rest of the World, ABL Bio shall pay <FONT STYLE="white-space:nowrap">I-Mab</FONT> a percentage of the royalties, which percentage shall be no less than 5%*Oi as specified in <U>Appendix
5</U>. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 11 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:16%; font-size:10pt; font-family:Times New Roman">Example: If ABL Bio decides not to participate in the development of
the Product(s) for <FONT STYLE="white-space:nowrap">PD-L1/TIGIT</FONT> BsAb after any Decision Point except Decision Point I, and <FONT STYLE="white-space:nowrap">I-Mab</FONT> Out-Licenses the Product(s) to a Third Party with 10% royalty in any
country in the Rest of World, then <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall pay ABL Bio 1.5% (= 5%*Oa) of the Royalty Income. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Payments</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The payments under <U>Section</U><U></U><U>&nbsp;4</U> above are expressly stated as exclusive of Value Added
Tax or equivalent sales tax applicable (&#147;<B>VAT</B>&#148;). If VAT is or may become lawfully payable or chargeable in respect of a payment, then the Party receiving such Payment will promptly provide a valid VAT invoice to the Party making such
Payment. If the VAT charged to and paid by the Party making such Payment is subsequently refunded by any relevant fiscal authority having oversight of either Party, then such refund shall be promptly forwarded to the Party who paid for the VAT with
a valid VAT credit note. At the request of the other Party, either Party shall give the other Party the assistance as may be required by the relevant tax authority, to claim exemption from or reduction of the VAT. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If any withholding tax applies to any amount due to either Party under this Agreement, such amount of
withholding tax due will be deducted from the amount to be paid to either Party and paid to the appropriate tax authorities in a timely manner. At the request of the other Party, either Party shall give the other Party the assistance as may be
required by the relevant tax authority, to claim exemption from or reduction of such withholding tax imposed on the amount. The other Party will provide either Party written evidence of its payment of any such withholding tax. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Parties and their respective Affiliates shall keep complete and accurate books and records used in the
determination of all Net Sales, payments and deliveries of the Products to Third Parties for a period of ten (10)&nbsp;years. Either Party shall, not more than once a calendar year, have the right to appoint an independent certified public
accountant or like person (the &#147;<B>Auditor</B>&#148;) reasonably acceptable to the other Party, to perform an audit at the other Party&#146;s site upon at least ten (10)&nbsp;Business Days&#146; prior written notice and within normal business
hours. The other Party shall provide all books and records necessary for the Auditor to determine Net Sales, payments and deliveries under this Agreement. The cost of such audit shall not be borne by the other Party, except for the event that the
audit results determine a shortfall of reported Net Sales greater than two percent (2%). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The other Party shall adhere to the payment terms described in <U>Section</U><U></U><U>&nbsp;4</U>. An interest
of 0.1% per day shall accrue on the total amount of late payment from the day when the corresponding payment becomes due and payable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Party shall make all the payments to the other party under this Agreement in US&nbsp;Dollar (USD),
including, but not limited to, Net Sales and Net Receipts in currencies other than USD shall be converted into USD using the average of the respective exchange rate as published by Bloomberg for the respective quarter. All the payments will be made
without deduction of exchange, collection or other charges. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 12 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Contract Governance</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Joint Committee</U>. Promptly after the Effective Date the Parties will establish a joint committee to
facilitate the performance and oversight of the Research and Development Plan (the &#147;<B>JC</B>&#148;). The JC will be comprised of an equal number of representatives from either Party, at least two (2)&nbsp;named representatives of <FONT
STYLE="white-space:nowrap">I-Mab</FONT> and at least two (2)&nbsp;named representatives of ABL Bio. Each Party shall appoint its respective representatives to the JC within thirty (30)&nbsp;days after the Effective Date, and may substitute one or
more of its representatives, in its sole discretion, effective upon notice to the other Party of such change. Each Party shall have a JC representative who is a senior employee (Vice President level or above), and each JC representative will have
appropriate expertise and ongoing familiarity with the Research and Development Plans. Additional representatives may from time to time, by mutual consent of the Parties, be invited to attend JC meetings, subject to such representatives&#146;
written agreement to comply with the requirements of <U>Section</U><U></U><U>&nbsp;8</U>. All proceedings for the JC shall take place in English. Each Party shall bear its own expenses relating to attendance at such meetings by its representatives.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Meetings</U>. The JC shall meet in accordance with a schedule established by agreement of the Parties, but
no less frequently than once per calendar quarter, with the location for such meetings alternating between <FONT STYLE="white-space:nowrap">I-Mab</FONT> and ABL Bio facilities (or such other locations as are determined by the JC). Alternatively, the
JC may meet by means of teleconference, videoconference or other similar communications equipment, but at least one meeting per year shall be conducted in person. Each Party shall nominate a chairperson (each, a &#147;<B>JC Chairperson</B>&#148;)
with equal voting rights on each decision. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>JC Responsibilities</U>. The JC shall (i)&nbsp;monitor progress under the Research and Development Plans,
review relevant data and share information on progress of the Research and Development with the Parties, (ii)&nbsp;review and approve any proposed updates to the Early Development Plan and, subject to <U>Section</U><U></U><U>&nbsp;3</U>, the Late
Development Plan and Clinical Development Plan, (iii)&nbsp;discuss and consult regarding any technical or scientific difficulties encountered under a Research and Development Plan, (iv)&nbsp;perform such other activities as the Parties agree in
writing shall be the responsibility of the JC, (v)&nbsp;decide which Product to develop and commercialize, (vi)&nbsp;review and approve amended Research and Development Plan and the budget, and (vii)&nbsp;select a Party as the Lead Party of each
project in the Rest of the World within seven (7)&nbsp;Business Days after the completion of Decision Point I. For avoid of the doubt, the Lead Party may be changed at any Decision Point by vote in JC or the consent of the Parties.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The PL shall be responsible for (i)&nbsp;scheduling meetings at least once per calendar quarter, but more
frequently as the JC determines it necessary; (ii)&nbsp;setting agenda for meetings with solicited input from other members; (iii)&nbsp;confirming and delivering minutes to the JC for review and final approval; and (iv)&nbsp;conducting effective
meetings, including ensuring that objectives for each meeting are set and achieved. Each Party will provide the members of the JC with written copies of all materials they intend to present at a JC meeting. In the absence of a PL, the tasks assigned
to the PL in this <U>Section</U><U></U><U>&nbsp;6.4</U> shall be assigned to the JC Chairperson. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All decisions of the JC shall be made by consensus, with each Party having collectively one (1)&nbsp;vote in
all decisions. If after reasonable discussion and good faith consideration of both Party&#146;s views on a particular matter before the JC, the JC is still unable after a period of ten (10)&nbsp;days to reach a unanimous decision on such matter,
then either Party may, by written notice to the other, have such matter referred to the CEOs of the Parties for resolution. If the CEOs are able to resolve such matter within the thirty (30)&nbsp;day period, then: (a)&nbsp;with respect to the Early
Development Plan, the status quo (including the existing budget) shall persist until the Parties reach agreement with respect to any amendment thereto; and <FONT STYLE="white-space:nowrap">(b)&nbsp;I-Mab</FONT> in
<FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> Territory, ABL Bio in ABL Bio&#146;s Territory, and the developing Party(ies) in the Rest of the World shall have the right to approve amendments to the Late Development Plan and Clinical
Development Plan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 13 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Diligence and Reports</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party agrees to maintain proper records (the &#147;<B>Records</B>&#148;) in respect of its performance of
the Research and Development, including the procedures, techniques and methodologies used, the progress made, and any inventions conceived and/or reduced to practice or otherwise made as part of the Research and Development. In order to file,
prosecute and defend and Patent Rights claiming any BsAb Improvement, BsAb Technology Improvement, or Parental Antibody Improvement, each Party shall upon request of the other Party, which shall not be unreasonably made, (a)&nbsp;make the Records
available to the other Party or its designee for inspection; and (b)&nbsp;provide copies of the Records or any part(s) thereof to the other Party or its designee. As part of keeping the Records, each Party shall ensure that all of its personnel and
all of its agents that are involved in the Research and Development will keep accurate laboratory notebooks, that: (i)&nbsp;shall be duly signed, dated and witnessed; and (ii)&nbsp;shall be created and maintained in accordance with its standard
operating procedures that would be sufficient to allow for said laboratory notebooks to be used in any proceedings before the relevant governmental authorities in the relevant Territory, in order to establish the date of invention for any inventions
in according with the patent Laws applicable in the relevant Territory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each calendar quarter until expiration of the royalty payment or income sharing obligation under
<U>Section</U><U></U><U>&nbsp;4</U>, each Party shall provide to the other Party reports as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party shall provide to the other Party an Early Development Report within thirty (30)&nbsp;days after the
end of each calendar quarter during Early Development including all the results obtained in the past calendar quarter (including without limitation all raw data). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Regardless of whether a Party participates in Late Development or Clinical Development, each Party shall
provide to the other Party a Late Development Report or Clinical Development Report within thirty (30)&nbsp;days after the end of each calendar quarter during Late Development or Clinical Development including all the results obtained in the past
calendar quarter (including without limitation all raw data). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon and after the launching of the Product or Product Family, <FONT STYLE="white-space:nowrap">I-Mab</FONT>
and ABL Bio shall provide a biannual report to each other providing a high-level overview of all material commercial activities in the respective territories for the Product within thirty (30)&nbsp;days after the end of each <FONT
STYLE="white-space:nowrap">six-month</FONT> period. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Confidentiality Obligations</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In consideration of disclosure of Confidential Information by the Disclosing Party, the Receiving Party
undertakes: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to keep the Confidential Information secret and confidential at all times; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not to disclose or permit the disclosure of any Confidential Information of the Disclosing Party, in whole, in
part, or in summary, to any person, except as expressly permitted by this Agreement; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 14 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not to use the Confidential Information of the Disclosing Party or permit it to be used, in whole or in part,
for any purpose other than the performance of its obligations or exercise of its rights under this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to take all proper and reasonable measures to ensure the confidentiality of the Confidential Information of the
Disclosing Party, including but not limited to applying the same security measures and degree of care to such Confidential Information as the Receiving Party applies to its own confidential information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to inform the Disclosing Party immediately if it becomes aware of the possession, use or knowledge of any of
the Confidential Information of the Disclosing Party by an unauthorised person, and to provide any assistance in relation to such unauthorised possession, use or knowledge that the Disclosing Party may reasonably require. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exceptions to Confidentiality Obligations </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Receiving Party&#146;s obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT>
under this Agreement shall not apply to any Confidential Information of the Disclosing Party that the Receiving Party can prove by means of reasonable written evidence: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">was known to the Receiving Party on a <FONT STYLE="white-space:nowrap">non-confidential</FONT> basis prior to
disclosure by the Disclosing Party; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is or becomes publicly known other than as a result of breach of this Agreement by the Receiving Party or by
anyone to whom the Receiving Party disclosed the Confidential Information of the Disclosing Party; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is received by the Receiving Party without restriction on disclosure or use from a Third Party lawfully
entitled to make the disclosure without such restrictions; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is developed by any of the Receiving Party&#146;s or its Affiliate&#146;s directors, employees, consultants,
advisors or agents (collectively, &#147;<B>Representatives</B>&#148;) who have not had any direct or indirect access to, or use or knowledge of, the Confidential Information of the Disclosing Party; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">except that the above exceptions do not extend to circumstances where the Confidential Information is (i)&nbsp;specific, does not fall within
the above exceptions, and is embraced by more general information which does fall within the above exceptions or (ii)&nbsp;a combination of information in the public domain separated across multiple sources. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Receiving Party will not be in breach of its obligations under this Agreement to the extent that it is
required to disclose Confidential Information of the Disclosing Party by law (provided, in the case of a disclosure under any freedom of information legislation, that the exemptions under that legislation do not apply) or order of a court or other
public body that has jurisdiction over it, provided that, before making such a disclosure, the Receiving Party shall, to the extent it is legally permitted to do so: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">inform the Disclosing Party of the proposed disclosure as soon as possible, and if possible before the court or
other public body orders the disclosure; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 15 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">take into account reasonable requests of the Disclosing Party in relation to such disclosure;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ask the court or other public body to treat such Confidential Information as confidential; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">permit the Disclosing Party to make representations to the court or other public body in respect of the
disclosure and/or confidential treatment of such Confidential Information. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disclosure to Representatives </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Receiving Party shall permit access to the Confidential Information of the Disclosing Party only to those
of its representatives who: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reasonably require such access for performing its obligations or exercising its rights under this Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">have been informed of the confidential nature of such Confidential Information, the Disclosing Party&#146;s
interest in such Confidential Information, and the provisions of this Agreement, and have been instructed to comply with this Agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">have entered into legally binding confidentiality obligations to the Receiving Party on terms that are no less
onerous than those set out in this Agreement, and which extend to such Confidential Information. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Receiving Party shall ensure that all those representatives who have access to the Confidential Information
of the Disclosing Party comply with the provisions of this Agreement, and the Receiving Party shall be liable to the Disclosing Party for any breach of this Agreement by the Receiving Party&#146;s Representatives. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon expiration or termination of this Agreement, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At the Disclosing Party&#146;s written request, the Receiving Party shall; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">immediately return to the Disclosing Party (or, if the Disclosing Party so requests, destroy or erase) all
Confidential Information of the Disclosing Party that the Receiving Party has received under this Agreement including any copies made and permanently delete all electronic copies of any such Confidential Information from the Receiving Party&#146;s
computer systems; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provide to the Disclosing Party a certificate, signed by an officer of the Receiving Party, confirming that the
obligations in this <U>Section</U><U></U><U>&nbsp;8.4</U> have been complied with; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">make no further use of any such Confidential Information. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 16 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">The Receiving Party may, however, keep one copy of the Confidential
Information of the Disclosing Party in its legal advisor&#146;s files solely for the purpose of enabling it to comply with the provisions of this Agreement. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As between the parties, except as otherwise expressly set forth in this Agreement: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Confidential Information of the Disclosing Party is proprietary to the Disclosing Party and the Disclosing
Party reserves all rights in such Confidential Information; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Disclosing Party is the sole owner of all property rights in tangible records of the Confidential
Information of the Disclosing Party; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Disclosing Party is and shall remain the sole owner of all intellectual property rights in the Confidential
Information of the Disclosing Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No rights in respect of the Confidential Information of the Disclosing Party are granted to the Receiving
Party, other than to use it in accordance with the terms of this Agreement, and no obligations are imposed on the Disclosing Party other than those expressly stated in this Agreement. In particular, nothing in this Agreement shall be construed or
implied as obliging the Disclosing Party to disclose any specific type of information under this agreement, whether Confidential Information or not. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Receiving Party agrees that any breach of its obligations of confidentiality and <FONT
STYLE="white-space:nowrap">non-use</FONT> under this Agreement will cause irreparable harm to the Disclosing Party; therefore, the Disclosing Party shall have, in addition to any remedies available at law, the right to obtain equitable relief to
enforce this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The confidentiality obligations under this Section shall, notwithstanding any termination of discussions
between the Parties, continue in force for a period of seven (7)&nbsp;years after the expiration or termination of this Agreement. Notwithstanding the foregoing, the <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT
STYLE="white-space:nowrap">non-use</FONT> obligations imposed by this Agreement with respect to trade secrets included in the Confidential Information of a Party will continue for as long as such Party continues to treat such Confidential
Information as a trade secret. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties agree to make a joint press release according to <U>Appendix 6</U> of this Agreement. Regarding any
other information not expressly contained in such joint press release, except for disclosure required by applicable laws, neither Party shall make, or permit any person to make, any public announcement concerning this Agreement without the prior
written consent of the other Party (such consent not to be unreasonably withheld or delayed). </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Representation and Warranties</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party represents and warrants to the other Party that as of the Effective Date: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Such Party (i)&nbsp;is a company duly organized, validly existing and in good standing under the Laws of the
jurisdiction of its organization; (ii)&nbsp;has the requisite corporate power and authority and the legal right to conduct its business as now conducted and hereafter contemplated to be conducted; and (iii)&nbsp;has or will obtain all necessary
licenses, permits, consents, or approvals from or by, and has made or will make all necessary notices to, all governmental authorities having jurisdiction over such Party, required for the performance of this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 17 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The execution, delivery and performance of this Agreement by such Party (i)&nbsp;are within the corporate power
of such Party; (ii)&nbsp;have been duly authorized by all necessary or proper corporate action; (iii)&nbsp;do not conflict with any provision of the organizational documents of such Party; (iv)&nbsp;will not, to the best of such Party&#146;s
knowledge, violate any Laws or any order or decree of any court or governmental authority; and (v)&nbsp;will not violate or conflict with any terms of any indenture, mortgage, deed of trust, lease, agreement or other instrument to which such Party
is a party, or by which such Party is bound; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement has been duly executed and delivered by such Party and constitutes a legal, valid and binding
obligation of such Party, enforceable against such Party in accordance with its terms, subject to bankruptcy, insolvency, reorganization, arrangement, <FONT STYLE="white-space:nowrap">winding-up,</FONT> moratorium, and similar laws of general
application affecting the enforcement of creditors&#146; rights generally, and subject to general equitable principles, including the fact that the availability of equitable remedies, such as injunctive relief or specific performance, is in the
discretion of the court. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party represents, warrants and covenants that neither it nor any of its Affiliates has been Debarred or is
subject to Debarment and neither it nor any of its Affiliates will use in any capacity, in connection with the Research and Development, any person or entity who has been Debarred. Each Party agrees to inform the other Party in writing immediately
if it or any person or entity who is performing Research and Development under this Agreement is Debarred, or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to such Party&#146;s knowledge, is
threatened, relating to the Debarment of such Party or any person or entity used in any capacity by such Party or any of its Affiliates in connection with the Research and Development. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ABL Bio represents and warrants to <FONT STYLE="white-space:nowrap">I-Mab</FONT> that as of the Effective Date,
ABL Bio is the lawful owner of all right, title and interest in and to the BsAb Technology, the ABL Bio Parental Antibody Patent Rights and ABL Bio Parental Antibody <FONT STYLE="white-space:nowrap">Know-How.</FONT> As of the Effective Date, ABL Bio
has no knowledge of any claim made against it (x)&nbsp;asserting the invalidity, misuse, unregisterability or unenforceability of any of the BsAb Technology and the ABL Bio Parental Antibody Patent Rights or (y)&nbsp;challenging ABL Bio&#146;s
Control of BsAb Technology, ABL Bio Parental Antibody Patent Rights or ABL Bio Parental Antibody <FONT STYLE="white-space:nowrap">Know-How</FONT> or making any adverse claim of ownership of BsAb Technology, ABL Bio Parental Antibody Patent Rights or
ABL Bio Parental Antibody <FONT STYLE="white-space:nowrap">Know-How.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">I-Mab</FONT> represents and warrants to ABL Bio that as of the Effective Date,
<FONT STYLE="white-space:nowrap">I-Mab</FONT> is the lawful owner of all right, title and interest in and to the <FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody Patent Rights and <FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental
Antibody <FONT STYLE="white-space:nowrap">Know-How.</FONT> As of the Effective Date, <FONT STYLE="white-space:nowrap">I-Mab</FONT> has no knowledge of any claim made against it (x)&nbsp;asserting the invalidity, misuse, unregisterability or
unenforceability of any of the <FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody Patent Rights or (y)&nbsp;challenging <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> Control of <FONT STYLE="white-space:nowrap">I-Mab</FONT>
Parental Antibody Patent Rights or <FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody <FONT STYLE="white-space:nowrap">Know-How</FONT> or making any adverse claim of ownership of the <FONT STYLE="white-space:nowrap">I-Mab</FONT>
Parental Antibody Patent Rights or <FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody <FONT STYLE="white-space:nowrap">Know-How.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">THE EXPRESS REPRESENTATIONS AND WARRANTIES OF THE PARTIES STATED IN THIS SECTION 9 ARE IN LIEU OF ALL OTHER
REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED, OR STATUTORY, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, <FONT STYLE="white-space:nowrap">NON-INFRINGEMENT</FONT> OR
<FONT STYLE="white-space:nowrap">NON-MISAPPROPRIATION</FONT> OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 18 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Indemnification</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the other provisions of this Section, ABL Bio shall defend, indemnify and hold harmless <FONT
STYLE="white-space:nowrap">I-Mab,</FONT> its Affiliates, and each of their officers, directors, shareholders, employees, successors and assigns from and against all Third Parties claims, suites, losses, liabilities, damages, costs, fees and expenses
(including reasonable attorney&#146;s fee), to the extent arising out of (i)&nbsp;ABL Bio&#146;s negligence or willful misconduct in performing any of its obligations under this Agreement, or (ii)&nbsp;breach by ABL Bio of any of its
representations, warranties, covenants or agreements under this Agreement, except in each case to the extent such claims arise from a matter for which <FONT STYLE="white-space:nowrap">I-Mab</FONT> is obligated to indemnify ABL Bio under
<U>Section</U><U></U><U>&nbsp;10.2</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the other provisions of this Section, <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall defend,
indemnify and hold harmless ABL Bio, its Affiliates, and each of their officers, directors, shareholders, employees, successors and assigns from and against all Third Parties claims, suites, losses, liabilities, damages, costs, fees and expenses
(including reasonable attorney&#146;s fee), to the extent arising out of <FONT STYLE="white-space:nowrap">(i)&nbsp;I-Mab&#146;s</FONT> negligence or willful misconduct in performing any of its obligations under this Agreement, or (ii)&nbsp;breach by
<FONT STYLE="white-space:nowrap">I-Mab</FONT> of any of its representations, warranties, covenants or agreements under this Agreement, except in each case to the extent such claims arise from a matter for which ABL Bio is obligated to indemnify <FONT
STYLE="white-space:nowrap">I-Mab</FONT> under <U>Section</U><U></U><U>&nbsp;10.1</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party (&#147;<B>Indemnified Party</B>&#148;) will promptly notify the other Party (&#147;<B>Indemnifying
Party</B>&#148;) in writing if it becomes aware of a claim (actual or potential) by any Third Party or any proceeding (including any investigation by a governmental authority) (&#147;<B>Third Party Claim</B>&#148;) for which indemnification may be
sought and will give such related information as the Indemnifying Party shall reasonably request. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be eligible to be indemnified hereunder, the Indemnified Party will provide the Indemnifying Party with
prompt notice of the claim giving rise to the indemnification obligation pursuant to this <U>Section</U><U></U><U>&nbsp;10.4</U> and the exclusive ability to defend (with the reasonable cooperation of the Indemnified Party) or settle any such claim;
<U>provided</U>,<I> </I><U>however</U>, that the Indemnifying Party will not enter into any settlement for damages other than monetary damages without the Indemnified Party&#146;s written consent, such consent not to be unreasonably withheld. The
Indemnified Party has the right to participate, at its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by the Indemnifying Party. If the Parties cannot agree as to the application of <U>Sections
10.1</U> and <U>10.2</U> to any particular Third Party Claim, the Parties may conduct separate defenses of such Third Party Claim. Each Party reserves the right to claim indemnity from the other in accordance with <U>Sections 10.1</U> and
<U>10.2</U> above upon resolution of the underlying claim, notwithstanding the provisions of this <U>Section</U><U></U><U>&nbsp;10.4</U> requiring the Indemnified Party to tender to the Indemnifying Party the exclusive ability to defend such claim
or suit. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NEITHER PARTY WILL BE LIABLE UNDER ANY LEGAL THEORY (WHETHER TORT, CONTRACT OR OTHERWISE) FOR SPECIAL,
INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH
DAMAGES, EXCEPT AS A RESULT OF A MATERIAL BREACH OF THE CONFIDENTIALITY AND <FONT STYLE="white-space:nowrap">NON-USE</FONT> OBLIGATIONS IN SECTION 8. NOTHING IN THIS SECTION&nbsp;10.5 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR
OBLIGATIONS OF EITHER PARTY. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 19 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Intellectual Property Rights, BsAb Technology and BsAb Improvements, Parental Antibody Technology and
Parental Antibody Improvements.</U> </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party shall have and retain sole and exclusive title to their respective intellectual property rights. For
avoidance of doubt, as between the Parties, ABL Bio shall own and retain all rights to the BsAb Technology (including BsAb Technology Improvements) and ABL Bio Parental Antibody Technology (including ABL Bio Parental Antibody Improvements), and <FONT
STYLE="white-space:nowrap">I-Mab</FONT> shall retain all rights to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody Technology (including <FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody Improvements). ABL Bio grants <FONT
STYLE="white-space:nowrap">I-Mab</FONT> right to exploit (including right to grant <FONT STYLE="white-space:nowrap">sub-license</FONT> for the purpose of <FONT STYLE="white-space:nowrap">Out-License)</FONT> the intellectual property rights in the
BsAb Technology (including BsAb Technology Improvements) and ABL Bio Parental Antibody Technology (including ABL Bio Parental Antibody Improvements) within the scope of this Agreement, and <FONT STYLE="white-space:nowrap">I-Mab</FONT> grants ABL Bio
right to exploit (including right to grant <FONT STYLE="white-space:nowrap">sub-license</FONT> for the purpose of <FONT STYLE="white-space:nowrap">Out-License)</FONT> the intellectual property rights in <FONT STYLE="white-space:nowrap">I-Mab</FONT>
Parental Antibody Technology (including <FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody Improvements) within the scope of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All BsAb Improvements shall be (i)&nbsp;jointly owned by ABL Bio and
<FONT STYLE="white-space:nowrap">I-Mab</FONT> (Oa: Oi) in the Rest of World as specified in <U>Appendix 5</U>; (ii) owned solely by ABL Bio in ABL Bio&#146;s Territory; and (iii)&nbsp;owned solely by <FONT STYLE="white-space:nowrap">I-Mab</FONT> in <FONT
STYLE="white-space:nowrap">I-Mab&#146;s</FONT> Territory. The Parties will coordinate the preparation, filing, prosecution and maintenance of any patents covering any BsAb Improvement. All costs and expenses in relation to the prosecution,
settlement and compensation shall be (i)&nbsp;shared by ABL Bio and <FONT STYLE="white-space:nowrap">I-Mab</FONT> (Oa: Oi) in the Rest of World as specified in <U>Appendix 5</U>; (ii) solely born by ABL Bio in ABL Bio&#146;s Territory; and
(iii)&nbsp;solely born by <FONT STYLE="white-space:nowrap">I-Mab</FONT> in <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> Territory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As between the Parties, all BsAb Technology (including BsAb Technology Improvements) and ABL Bio Parental
Antibody (including ABL Bio Parental Antibody Improvements) shall be solely owned by ABL Bio. As between the Parties, ABL Bio has the sole right for the preparation, filing, and maintenance of any patents covering any BsAb Technology (including BsAb
Technology Improvements) and ABL Bio Parental Antibody (including ABL Bio Parental Antibody Improvements). All costs and expenses incurred relation to the preparation, filing, and maintenance shall be solely born by ABL Bio. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All <FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody (including
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody Improvements) shall be solely owned by <FONT STYLE="white-space:nowrap">I-Mab.</FONT> <FONT STYLE="white-space:nowrap">I-Mab</FONT> has the sole right for the preparation, filing, and
maintenance of any patents covering <FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody (including <FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody Improvements). All costs and expenses incurred relation to the
preparation, filing, and maintenance shall be solely born by <FONT STYLE="white-space:nowrap">I-Mab.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During and after the Term, <FONT STYLE="white-space:nowrap">I-Mab</FONT> will, and will cause its Affiliates
and representatives to, (i)&nbsp;cooperate fully in obtaining patent and other proprietary protection for any patentable or protectable BsAb Technology Improvements and ABL Bio Parental Antibody Improvements, all in the name of ABL Bio and at ABL
Bio&#146;s cost and expense; and (ii)&nbsp;execute and deliver all requested applications, assignments and other documents, and take such other measures as ABL Bio reasonably requests, in order to perfect and enforce ABL Bio&#146;s rights in BsAb
Technology Improvements and ABL Bio Parental Antibody Improvements. <FONT STYLE="white-space:nowrap">I-Mab</FONT> appoints ABL Bio as its attorney to execute and deliver any such documents on behalf of <FONT STYLE="white-space:nowrap">I-Mab</FONT>
and its Affiliates and representatives in the event <FONT STYLE="white-space:nowrap">I-Mab,</FONT> its Affiliates or its representatives fail to do so. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 20 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During and after the Term, ABL Bio will, and will cause its Affiliates and representatives to,
(i)&nbsp;cooperate fully in obtaining patents and other proprietary protections for any patentable or protectable <FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody Improvements, all in the name of
<FONT STYLE="white-space:nowrap">I-Mab</FONT> and at <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> cost and expense; and (ii)&nbsp;execute and deliver all requested applications, assignments and other documents, and take such other measures
as <FONT STYLE="white-space:nowrap">I-Mab</FONT> reasonably requests, in order to perfect and enforce <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> rights in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody Improvements. ABL
Bio appoints <FONT STYLE="white-space:nowrap">I-Mab</FONT> as its attorney to execute and deliver any such documents on behalf of ABL Bio and its Affiliates and representatives in the event ABL Bio, its Affiliates or its representatives fail to do
so. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party shall be responsible for the maintenance of its own intellectual property rights during the Term of
this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event of the institution of any suit by a Third Party against a Party or its Affiliates for Patent Right
infringements involving the registration, development, manufacture, use, sale, distribution, or marketing of the Products, the Party being sued shall promptly inform the other Party in writing and shall take appropriate action to defend such suit at
its own expense; provided however that, if such Third Party action affects the BsAb Technology&#146;s or ABL Bio Parental Antibody Technology&#146;s freedom to operation, then ABL Bio shall have the first right, but not the obligation, to take over
and control the defense of such action; and if such Third Party action affects <FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody Technology&#146;s freedom to operation, then <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall have the
first right, but not the obligation, to take over and control the defense of such action. The cost and expense sharing are pursuant to <U>Sections 11.2</U>, <U>11.3</U>, and <U>11.4</U>. ABL Bio and <FONT STYLE="white-space:nowrap">I-Mab</FONT>
shall provide reasonable assistance to one another and reasonably cooperate in any such litigation at the other Party&#146;s request without expense to the requesting Party. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event <FONT STYLE="white-space:nowrap">I-Mab</FONT> becomes aware of actual or threatened infringement
or validity attacks of BsAb Technology, ABL Bio Parental Antibody Patent Rights or ABL Bio Parental Antibody <FONT STYLE="white-space:nowrap">Know-How</FONT> in <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> Territory, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> shall promptly notify ABL Bio in writing of such actual or threatened activity or validity attacks. ABL Bio shall have the first right, but not the obligation, to bring an action against any infringement of
BsAb Technology, ABL Bio Parental Antibody Patent Rights or ABL Bio Parental Antibody <FONT STYLE="white-space:nowrap">Know-How.</FONT> If ABL Bio elects to institute the enforcement action, it shall have full control over such enforcement action,
including settlement thereof. In any event, at ABL Bio&#146;s request, <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall provide reasonable assistance and cooperation to ABL Bio in connection with any such proceeding, provided, however that all
reasonable third-party out of pocket costs shall be borne by ABL Bio and reimbursable to <FONT STYLE="white-space:nowrap">I-Mab</FONT> upon written request. ABL Bio shall bear all of its costs and expenses of such enforcement actions and shall be
entitled to retain all monetary and <FONT STYLE="white-space:nowrap">non-monetary</FONT> recoveries or settlements obtained as a result. In the event ABL Bio elects not to institute the enforcement action in accordance with this
<U>Section</U><U></U><U>&nbsp;11.9</U>, and <FONT STYLE="white-space:nowrap">I-Mab</FONT> reasonably believes such infringement has a significant negative impact on the rights granted to its hereunder, <FONT STYLE="white-space:nowrap">I-Mab</FONT>
shall, upon reasonable advance notice to ABL Bio, be entitled to institute enforcement actions to enjoin such infringement; provided, however, that <FONT STYLE="white-space:nowrap">(a)&nbsp;I-Mab</FONT> shall keep ABL Bio informed of any such
proceedings in a timely manner, and (b)&nbsp;the settlement of any such proceedings instituted by <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall be subject to ABL Bio&#146;s prior written approval, which shall not be unreasonably withheld or
delayed. ABL Bio shall use its best and good faith efforts to assist and cooperate with <FONT STYLE="white-space:nowrap">I-Mab</FONT> and provide <FONT STYLE="white-space:nowrap">I-Mab</FONT> with such assistance and information as may be reasonably
requested by <FONT STYLE="white-space:nowrap">I-Mab</FONT> in respect of any such action; provided, however, that all reasonable third-party out of pocket costs with respect to such enforcement action shall be borne by
<FONT STYLE="white-space:nowrap">I-Mab</FONT> and reimbursable to ABL Bio. <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall bear all of its costs and expenses of such enforcement actions and shall be entitled to retain all monetary and <FONT
STYLE="white-space:nowrap">non-monetary</FONT> recoveries or settlements obtained as a result. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 21 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event ABL Bio becomes aware of actual or threatened infringement or validity attacks of <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody Patent Right or <FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody <FONT STYLE="white-space:nowrap">Know-How</FONT> in ABL Bio&#146;s Territory, ABL Bio shall promptly notify <FONT
STYLE="white-space:nowrap">I-Mab</FONT> in writing of such actual or threatened activity or validity attacks. <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall have the first right, but not the obligation, to bring an action against any
infringement of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody Patent Right or <FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody <FONT STYLE="white-space:nowrap">Know-How.</FONT> If
<FONT STYLE="white-space:nowrap">I-Mab</FONT> elects to institute the enforcement action, it shall have full control over such enforcement action, including settlement thereof. In any event, at <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT>
request, ABL Bio shall provide reasonable assistance and cooperation to <FONT STYLE="white-space:nowrap">I-Mab</FONT> in connection with any such proceeding , provided, however that all reasonable third-party out of pocket costs shall be borne by <FONT
STYLE="white-space:nowrap">I-Mab</FONT> and reimbursable to ABL Bio upon written request. <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall bear all of its costs and expenses of such enforcement actions and shall be entitled to retain all monetary
and <FONT STYLE="white-space:nowrap">non-monetary</FONT> recoveries or settlements obtained as a result. In the event that <FONT STYLE="white-space:nowrap">I-Mab</FONT> elects not to institute the enforcement action in accordance with this
<U>Section</U><U></U><U>&nbsp;11.10</U>, and ABL Bio reasonably believes such infringement has a material negative impact on the rights granted to it hereunder, ABL Bio shall, upon reasonable advance notice to
<FONT STYLE="white-space:nowrap">I-Mab,</FONT> be entitled to institute enforcement actions to enjoin such infringement in its own right upon reasonable advance notice to <FONT STYLE="white-space:nowrap">I-Mab;</FONT> provided, however, that
(a)&nbsp;ABL Bio shall keep <FONT STYLE="white-space:nowrap">I-Mab</FONT> informed of any such proceedings in a timely manner, and (b)&nbsp;the settlement of any such proceedings instituted by ABL Bio shall be subject to <FONT
STYLE="white-space:nowrap">I-Mab&#146;s</FONT> prior written approval, which shall not be unreasonably withheld or delayed. <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall use its best and good faith efforts to assist and cooperate with ABL Bio
and provide ABL Bio with such assistance and information as may be reasonably requested by ABL Bio in respect of any such action; provided, however, that all reasonable third-party out of pocket costs with respect to such enforcement action shall be
borne by ABL Bio and reimbursable to <FONT STYLE="white-space:nowrap">I-Mab.</FONT> ABL Bio shall bear all of its costs and expenses of such enforcement actions and shall be entitled to retain all monetary and
<FONT STYLE="white-space:nowrap">non-monetary</FONT> recoveries or settlements obtained as a result. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties shall keep another informed of the status of their respective activities regarding any litigation
or settlement thereof concerning the Products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties shall coordinate with each other for the assign, transfer, license or grant any of its rights in
BsAb Improvements in the Rest of the World. Neither party shall assign, transfer, license or grant any of its rights in BsAb Improvements in the Rest of the World to a third party without the consent of the other Party, such consent shall not be
unreasonably withheld. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Termination</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement shall continue for the Term, if not terminated earlier as described in this
<U>Section</U><U></U><U>&nbsp;12</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Either Party (the &#147;<B><FONT STYLE="white-space:nowrap">Non-Breaching</FONT> Party</B>&#148;) may, without
prejudice to any other remedies available to it at law or in equity, terminate this Agreement in its entirety in the event the other Party (the &#147;<B>Breaching Party</B>&#148;) has materially breached or defaulted in the performance of any of its
obligations hereunder and such default has continued for sixty (60)&nbsp;days after written notice thereof was provided to the Breaching Party by the <FONT STYLE="white-space:nowrap">Non-Breaching</FONT> Party. Any such termination will become
effective at the end of such <FONT STYLE="white-space:nowrap">60-day</FONT> period unless the Breaching Party has cured any such breach or default prior to the expiration of such <FONT STYLE="white-space:nowrap">60-day</FONT> period. Notwithstanding
the foregoing, in the event and to the extent that any such breach is a payment breach, the applicable notice and cure period as provided above will be ten (10)&nbsp;Business Days. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 22 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">I-Mab</FONT> or any of its Affiliates (the &#147;<B>ABL Bio</B> <B>Challenging
Party</B>&#148;) (i) commence or participate in any action or proceeding (including any patent opposition or <FONT STYLE="white-space:nowrap">re-examination</FONT> proceeding), or otherwise assert in writing any claim, challenging or denying the
validity of any of the BsAb Technology or ABL Bio Parental Antibody Patent Rights (each a &#147;<B>ABL Bio</B> <B>Technology Challenge</B>&#148;) or (ii)&nbsp;actively assist any other person or entity in bringing or prosecuting any ABL Bio
Technology Challenge, then ABL Bio has the right to terminate this Agreement immediately by giving notice to the ABL Bio Challenging Party (and, if the ABL Bio Challenging Party is not <FONT STYLE="white-space:nowrap">I-Mab,</FONT> to give such
notice to <FONT STYLE="white-space:nowrap">I-Mab</FONT> as well). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ABL Bio or any of its Affiliates (the &#147;<B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Challenging
Party</B>&#148;) (i) commence or participate in any action or proceeding (including any patent opposition or <FONT STYLE="white-space:nowrap">re-examination</FONT> proceeding), or otherwise assert in writing any claim, challenging or denying the
validity of any of the <FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody Patent Rights, or any claim thereof (each, a &#147;<B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Patent Challenge</B>&#148;) or (ii)&nbsp;actively assist any
other person or entity in bringing or prosecuting any <FONT STYLE="white-space:nowrap">I-Mab</FONT> Patent Challenge, then <FONT STYLE="white-space:nowrap">I-Mab</FONT> has the right to terminate this Agreement immediately by giving notice to the <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Challenging Party (and, if the <FONT STYLE="white-space:nowrap">I-Mab</FONT> Challenging Party is not ABL Bio, to give such notice to ABL Bio as well). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that there is an early termination of this Agreement in accordance with <U>Sections 12.2</U> or
<U>12.3</U> after completion of Late Development and either Party continues the further development and commercialization of the Products in any Territory, the Party continuing the development and commercialization of the Product shall continue to
be obliged to pay to the other Party the royalty and the <FONT STYLE="white-space:nowrap">Out-License</FONT> income sharing as described under <U>Section</U><U></U><U>&nbsp;4</U> of this Agreement, provided that such rights have accrued hereunder
prior to the effective date of such termination. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The following provisions will survive any expiration or termination of this Agreement for the period of time
specified therein, or if not specified, then they will survive indefinitely: <U>Sections 1</U>, <U>8</U>, <U>10</U>, and <U>13</U>, and <U>Sections 5.3</U>, <U>7.1</U>, <U>11</U>, <U>12.4, 12,5</U> and <U>12.6</U>. Termination of this Agreement will
not relieve the Parties of any liability and/or payment obligation that accrued hereunder prior to the effective date of such termination nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity
with respect to any breach of this Agreement. The remedies provided in this are not exclusive of any other remedies a Party may have in law or equity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties acknowledge and agree that in the event insurmountable technical difficulties and risk factors
(&#147;<B>Risk</B>&#148;) occurs to a Party and such Risk is not resolved by the Party within 90 days thereafter despite all reasonable efforts, the Party shall be entitled to terminate this Agreement by sending a written notice to the other Party.
After termination of this Agreement in accordance with this <U>Section</U><U></U><U>&nbsp;12.6</U>, the losses incurred to the Parties shall be borne by the Parties respectively, and the terminating Party will no longer have the right to continue
developing any Product. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Miscellaneous</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All disputes which arise in connection with this Agreement and its interpretation shall be settled in amicable
way between the Parties. If the dispute cannot be settled in friendly way, it will be settled by arbitration to be held in New York in conformity with the rules of International Chamber of Commerce (ICC). Such arbitration will be held in the English
language. The decision of the arbitrator will be final and binding on the Parties. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 23 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement shall be construed, and the respective rights of the Parties determined, according to the Laws
of the State of New York, without regard to its choice of law principles. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that any legal proceeding is brought to enforce or interpret any of the provisions of this
Agreement, the prevailing Party shall be entitled to recover its reasonable attorney fees, court costs and expenses of litigation whether or not the action or proceeding results in a final judgment. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement may not be assigned or transferred by either Party, in whole or in part, whether voluntarily or
by operation of law, without the prior written consent of the other Party; provided that either Party my assign this Agreement, in whole or in part, to any of its Affiliates if such Party guarantees the performance of this Agreement by such
Affiliate; and provided further that ABL Bio and/or <FONT STYLE="white-space:nowrap">I-Mab</FONT> may assign this Agreement to a successor to all or substantially all of its assets or business to which this Agreement relates, whether by merger, sale
of stock, sale of assets or other similar transaction. Any assignment in violation of this provision is void and without effect. This Agreement shall be binding upon and inure to the benefit of the Parties hereto, their permitted successors, legal
representatives and assigns. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All notices must be in writing in English and sent to the address for the recipient set forth in this Agreement
or at such other address as the recipient may specify in writing under this procedure. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="78%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to ABL Bio:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">ABL Bio</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">16, <FONT STYLE="white-space:nowrap">Daewangpangyo-ro</FONT> <FONT STYLE="white-space:nowrap">712beon-gil,</FONT> <FONT STYLE="white-space:nowrap">Bundang-gu,</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Seongnam-si,</FONT> <FONT STYLE="white-space:nowrap">Gyeonggi-do,</FONT> 13488, Republic of Korea</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Attention:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Email:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Fax:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">with a copy to:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Attention: Mikyung Chang</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Email:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to <FONT STYLE="white-space:nowrap">I-Mab:</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">I-MAB</FONT> Biopharma Co., Ltd.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Suite 802, West Tower, OmniVision Tech Park, 88 Shangke Rd.,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Pudong New District, Shanghai, China 201210</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Attention:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Email:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Fax:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">with a copy to:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Attention:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Email:</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 24 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All notices must be given (a)&nbsp;by personal delivery, with receipt acknowledged; or (b)&nbsp;by prepaid
certified or registered mail, return receipt requested; or (c)&nbsp;by prepaid recognized express delivery service. Notices will be effective upon receipt or at a later date stated in the notice. If any provision of this Agreement is held to be
invalid, illegal or unenforceable in any respect, that provision shall be limited or eliminated to the minimum extent necessary so that this Agreement shall otherwise remain in full force and effect and enforceable. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The headings used in this Agreement have been inserted for convenience of reference only and not define or
limit the provisions hereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No waiver of any term or condition of this Agreement shall be effective unless set forth in this Agreement, all
rights and remedies available to a Party, whether under this Agreement or afforded by Law or otherwise, will be cumulative and not in the alternative to any other righty or remedies that may be available to such Party. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement (including the exhibits and schedules hereto) constitutes the entire agreement between the
Parties hereto with respect to the subject matter hereof and supersedes all previous agreements and understandings between the Parties with respect to such subject matter, whether written or oral, including, but not limited to all proposals,
negotiation, conversations, letters of intent, memoranda of understanding or discussions, between the Parties relating to the subject matter of this Agreement and all past dealing or industry custom. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement may be altered, amended, or changed only by a writing making specific reference to this
Agreement and the clause to be modified, which amendment is signed duly by authorized representatives of ABL Bio and <FONT STYLE="white-space:nowrap">I-Mab.</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nothing in this Agreement shall be deemed to constitute the grant of any license or other right in either
Party, to or in respect of any product, trademark, confidential information, trade secret or other data or any other intellectual property of the other Party except as expressly set forth herein. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">None of the provisions of this Agreement shall be for the benefit of or enforceable by any Third Party,
including, but not limited to, any creditor of either Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement shall be deemed to have been drafted jointly by both Parties; and ambiguities, if any, shall not
be construed against either Party, irrespective of which Party may have actually drafted the ambiguous provision. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">13.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement may be executed in counterparts, each of which, when executed, shall be deemed an original and
all of which together shall constitute one and the same document. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF THE PAGE INTENTIONALLY LEFT BLANK] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 25 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, <FONT STYLE="white-space:nowrap">I-Mab</FONT>
and ABL Bio, by their duly authorized officers, have executed this Collaboration Agreement as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"><B>ABL Bio</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"><B>/s/ ABL Bio</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>/s/ <FONT STYLE="white-space:nowrap">I-Mab</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 26 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Appendix 1 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ABL Bio Parental Antibody and BsAb Technology Description and Patent Rights </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Substance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Patent</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-B7-H3</FONT></FONT>
monoclonal antibody</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">KR10-2018-0059257</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PCT/KR2018/005968</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-4-1BB</FONT></FONT>
monoclonal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">US provisional 62/613,209</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">US provisional 62/689,310</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 27 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Appendix 2 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><FONT STYLE="white-space:nowrap">I-Mab</FONT> Parental Antibody Description and Patent Rights </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Monoclonal antibodies against <FONT STYLE="white-space:nowrap">PD-L1</FONT> <FONT STYLE="white-space:nowrap">(Hu1210-4)</FONT> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Asset</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of Invention</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Country</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Application&nbsp;#</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Publication&nbsp;#</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="5"><B><FONT STYLE="white-space:nowrap">PD-L1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-PD-L1</FONT></FONT> antibodies and uses thereof</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PCT</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(US, EP, KR, CN)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">PCT/CN2017/088033</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">WO2017/215590A1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-PD-L1</FONT></FONT> antibodies and uses thereof</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">US</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">15744737</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(TBD)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-PD-L1</FONT></FONT> antibodies and uses thereof</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">EP</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">EP17812701.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">3325513</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-PD-L1</FONT></FONT> antibodies and uses thereof</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">KR</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">10-2018-7009566</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(TBD)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-PD-L1</FONT></FONT> antibodies and uses thereof (B6)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">PCT</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">PCT/CN2018/081079</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(NA)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>TIGIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Antibodies to T cell immunoreceptor with IG and ITIM domains (TIGIT) and uses thereof</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">PCT</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">PCT/CN2018/075477</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(NA)</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 28 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Appendix 3 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Early Development Plan </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the Early Development Plan in this <U>Appendix 3</U>, including without limitation details of the task and timeline, will be
changeable without both Party&#146;s signature if PLs of both Parties agree on the changes. Any delay in meeting the timeline set forth in this <U>Appendix 3</U> shall not be construed as a breach of the Agreement if the delaying Party made
commercially reasonable efforts with prior notice to the other Parity. <B></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>(1) <FONT STYLE="white-space:nowrap">PD-L1/TIGIT</FONT> BsAb
</U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Work Task (year/ month)</B></P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Responsible<BR>(ABL Bio/ <FONT STYLE="white-space:nowrap">I-Mab)</FONT></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="34" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>4&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>5&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>7&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>8&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>9&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>10&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>11&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>12&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Generate BsAb</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">ABL&nbsp;Bio</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">in vitro characterization</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">ABL&nbsp;Bio</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Developability test</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">ABL&nbsp;Bio</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">In vivo pilot study</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap">I-Mab</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">In vivo characterization (trangenic model)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap">I-Mab</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Final candidate selection (Decision Point I)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap">ABL&nbsp;Bio/&nbsp;I-Mab</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 29 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>(2) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1/4-1BB</FONT></FONT> BsAb
</U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" STYLE="BORDER:1px solid #000000; padding-left:8pt"><B>Work Task (year/ month)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Responsible<BR>(ABL Bio/ <FONT STYLE="white-space:nowrap">I-Mab)</FONT></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="34" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>4&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>5&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>7&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>8&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>9&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>10&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>11&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>12&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Generate BsAb</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">ABL&nbsp;Bio</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">in vitro characterization</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">ABL&nbsp;Bio</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Developability test</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">ABL&nbsp;Bio</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">In vivo characterization</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap">I-Mab</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Final candidate selection (Decision Point I)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap">ABL&nbsp;Bio/I-Mab</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>(3) <FONT STYLE="white-space:nowrap">PD-L1/B7H3</FONT> BsAb </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" STYLE="BORDER:1px solid #000000; padding-left:8pt"><B>Work Task (year/ month)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Responsible<BR><FONT STYLE="white-space:nowrap">(ABL&nbsp;Bio/&nbsp;I-Mab)</FONT></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="34" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="34" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>4&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>5&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>7&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>8&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>9&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>10&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>11&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>12&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>1&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>3&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>4&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>5&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>7&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>8&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>9&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Generate BsAb</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">ABL&nbsp;Bio</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">in vitro characterization</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">ABL&nbsp;Bio</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Developability test</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">ABL&nbsp;Bio</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">in vivo model set up</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">ABL&nbsp;Bio</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">In vivo characterization</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">ABL&nbsp;Bio</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Final candidate selection (Decision Point I)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap">ABL&nbsp;Bio/I-Mab&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#7f7f7f" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#7f7f7f"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 30 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Appendix 4 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Late Development Plan </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the Late Development Plan in this <U>Appendix 4</U>, including without limitation details of the task, timeline and costs, will
be changeable without both Party&#146;s signature if PLs of both Parties agree on the changes. Any delay in meeting the timeline set forth in this <U>Appendix 4</U> shall not be construed as a breach of the Agreement if the delaying Party made
commercially reasonable efforts with prior notice to the other Parity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>(1) <FONT STYLE="white-space:nowrap">PD-L1/TIGIT</FONT> BsAb </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt"><B>Stage</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Work Task</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(year/
month)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="46" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>10&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>11&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>12&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>1&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>3&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>4&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>5&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>7&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>8&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>9&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>10&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>11&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>12&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>1&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>3&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>4&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>5&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CMC</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Cell line development</TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Cell line stability</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">MCB/WCB production&nbsp;&amp; characterization</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Assay development&nbsp;&amp; qualification</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Process (200L) &amp; Formulation dev.</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">ER run (GLP material for Toxicity, DS)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">1 lot of DS/DP GMP</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">DS/DP stability study</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Preclinical&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">PK/PD study</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap">GLP-Toxicity</FONT> study</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Clinical</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">IND dossier preparation</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">IND submission</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 31 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>(2)
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1/4-1BB</FONT></FONT> BsAb </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt"><B>Stage</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Work Task</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(year/
month)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="46" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="34" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>10</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>11</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>12</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>1</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>3</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>4</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>5</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>7</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>8</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>9</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>10</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>11</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>12</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>1</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>3</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>4</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>5</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>7</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>8</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>9</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CMC</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Cell line development</TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Cell line stability</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">MCB/WCB production&nbsp;&amp; characterization</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Assay development&nbsp;&amp; qualification</TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Process (200L) &amp; Formulation dev.</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">ER run (GLP material for Toxicity, DS)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">1 lot of DS/DP GMP</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">DS/DP stability study</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Preclinical&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">PK/PD study</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap">GLP-Toxicity</FONT> study</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Clinical</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">IND dossier preparation</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">IND submission</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 32 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>(3) <FONT STYLE="white-space:nowrap">PD-L1/B7H3</FONT> BsAb </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt"><B>Stage</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Work Task</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(year/
month)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="46" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>7</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>8</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>9</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>10</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>11</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>12</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>1</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>3</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>4</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>5</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>7</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>8</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>9</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>10</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>11</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>12</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>1</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>3</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>4</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>5</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>7</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CMC</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Cell line development</TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Cell line stability</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">MCB/WCB production&nbsp;&amp; characterization</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Assay development&nbsp;&amp; qualification</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Process (200L) &amp; Formulation dev.</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">ER run (GLP material for Toxicity, DS)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">1 lot of DS/DP GMP</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">DS/DP stability study</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Preclinical&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">PK/PD study</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap">GLP-Toxicity</FONT> study</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Clinical</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">IND dossier preparation</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">IND submission</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 33 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Appendix 5 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>IP Ownership, Costs Sharing, Income Sharing, Royalty Sharing, and </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Calculation Examples </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>BsAb</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><SUP STYLE="font-size:85%; vertical-align:top">(1)&nbsp;</SUP>Development&nbsp;Costs&nbsp;Sharing</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Intellectual&nbsp;Property&nbsp;Right/Non-Royalty</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Income Sharing</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty&nbsp;Sharing</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> (Ci)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ABL (Ca)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> (Oi)</B></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>ABL (Oa)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">I-MAB&nbsp;(Oi)</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ABL&nbsp;(Oa)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PD-L1/TIGIT</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>50%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>50%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>70%</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Out-Licensing before</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Decision
Point III) or</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>60% </B>(Out-Licensing</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">after Decision point III)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>30%</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Out-Licensing before</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Decision
Point III) or</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>40% </B>(Out-Licensing after</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Decision point III)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>70%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>30%</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1/4-1BB</FONT></FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>50%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>50%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>50%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>50%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>50%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>50%</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">PD-L1/B7H3</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>50%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>50%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>50%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>50%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>50%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>50%</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The above table only applies on the <FONT STYLE="white-space:nowrap">co-development</FONT> situation (i.e. both
Parties <FONT STYLE="white-space:nowrap">Opt-In)</FONT> in the Rest of World. For Royalty Income and <FONT STYLE="white-space:nowrap">Non-Royalty</FONT> Income sharing in case of <FONT STYLE="white-space:nowrap">Opt-Out</FONT> by a Party, please see
<U>Section</U><U></U><U>&nbsp;4.3.2</U> and <U>4.3.4</U>. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 34 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Appendix 6 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Press Release </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma and ABL Bio Announce Global Collaboration on Innovative Bispecific Antibodies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma <FONT STYLE="white-space:nowrap">(&#147;I-Mab&#148;),</FONT> a company focusing on innovative biologics in immuno-oncology and immuno-inflammation, and ABL Bio Corporation (&#147;ABL Bio&#148;), a
South Korean biotechnology company, today jointly announced that two companies had entered into a strategic partnering agreement for ABL Bio to <FONT STYLE="white-space:nowrap">in-license</FONT> the global rights excluding Greater China to <FONT
STYLE="white-space:nowrap">I-Mab&#146;s</FONT> bispecific antibodies (BsAb) of undisclosed target with licensing payments of approximately US$100&nbsp;million in total. The two companies also agreed on a collaboration to <FONT
STYLE="white-space:nowrap">co-develop</FONT> additional BsAbs as part of the partnership. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, ABL Bio will pay
US$2.5&nbsp;million in upfront payment. <FONT STYLE="white-space:nowrap">I-Mab</FONT> will also receive research&nbsp;&amp; development, regulatory and sales-based milestone payments, which could result in aggregate payments of US$100&nbsp;million
from ABL Bio. In addition, ABL Bio will pay royalties on net sales. The partnership also includes three more collaborative <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody projects. <FONT STYLE="white-space:nowrap">I-Mab</FONT> and ABL
Bio will share the development cost as well as rights in China, South Korea and rest of the world in different configurations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;This partnership
with ABL Bio is a latest addition to our growing portfolio of global partnerships spanning from early stage projects to clinical assets. We are very pleased to work with ABL Bio for their cutting-edge discovery and antibody engineering platform for
novel therapeutic antibodies,&#148; said Jingwu Zang, the founder and CEO of <FONT STYLE="white-space:nowrap">I-Mab.</FONT> <FONT STYLE="white-space:nowrap">&#147;Bi-specific</FONT> antibody truly represents the next wave biologics in cancer
immunotherapy for its unique modality to create target synergy.&#148; Zang added. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are very excited about partnership with <FONT
STYLE="white-space:nowrap">I-Mab</FONT> to develop <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-Class</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Best-in-Class</FONT></FONT> BsAbs
and our collaboration will accelerate the development of innovative immunotherapy,&#148; said Sang Hoon Lee, the founder and CEO of ABL Bio. Lee also mentioned &#147;We look forward to a productive and successful partnership since <FONT
STYLE="white-space:nowrap">I-Mab</FONT> is a leader in the immunology field. Because of the strong synergies between both companies, we believe this collaboration will provide a great example for our industry.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> has successfully completed a string of <FONT STYLE="white-space:nowrap">in-licensing</FONT> deals with global
pharmaceutical companies such as MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) and Genexine, Inc. (KOSDAQ: 095700) to enrich its China portfolio. This <FONT STYLE="white-space:nowrap">out-licensing</FONT> and partnership is the
second such transaction for <FONT STYLE="white-space:nowrap">I-Mab</FONT> and marks the beginning of <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to <FONT STYLE="white-space:nowrap">out-license</FONT> or <FONT
STYLE="white-space:nowrap">co-develop</FONT> its own innovative biologics through global partnerships. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">About
<FONT STYLE="white-space:nowrap">I-Mab:</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Facilitated by a merger between Third Venture Biotech and Tasgen Bio, which was followed by a Series B
financing of USD 150&nbsp;million in 2017, <FONT STYLE="white-space:nowrap">I-Mab</FONT> has rapidly built a highly experienced team with world-class R&amp;D capabilities. On June&nbsp;29, 2018, <FONT STYLE="white-space:nowrap">I-Mab</FONT>
announced that it had successfully raised US$220&nbsp;million in Series C financing with a group of reputable investors led by Hony Capital, representing one of the largest amount ever raised in Series C by an innovative biotech company in China.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 35 - </B></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> focuses on discovery and development of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-Class</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Best-in-Class</FONT></FONT> biologics in the areas of immuno-oncology and
immuno-inflammation. The company has already initiated a Phase 2 clinical trial and is prepared to submit multiple IND applications for additional clinical trials in China and the US, including Phase 2 and Phase 3 studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">www.i-mabbiopharma.com</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contact: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Raven Lin, Vice President of Corporate Development
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">raven.lin@i-mabbiopharma.com</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">About ABL Bio: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABL Bio is a privately held South Korean
biotechnology company developing antibody therapeutics for immuno-oncology and neurodegenerative disease. ABL Bio was founded in 2016 and recently completed series C fund raising of USD 65&nbsp;million in 2018 after successful series A and B
financing in 2016 and 2017. ABL001, a bispecific antibody (BsAb) targeting VEGF and DLL4 is currently in Phase 1 clinical trial for oncology. In the neurodegenerative disorder space, ABL Bio is harnessing its BsAb expertise to develop
next-generation BsAbs designed to maximize blood&#150;brain barrier (BBB) penetrance and therapeutic efficacy. The most advanced molecule is ABL301, an &#945;-synuclein-targeting BsAb that penetrates the BBB via a receptor-mediated transcytosis
(RMT) and is in development for Parkinson&#146;s disease (PD). ABL Bio is also actively developing immune-oncology therapies and has built strong R&amp;D team to develop
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-Class</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Best-in-Class</FONT></FONT> BsAbs. www.ablbio.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contact: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sang Hoon Lee, CEO&nbsp;&amp; Founder </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">sang.lee@ablbio.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>- 36 - </B></P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>6
<FILENAME>filename6.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.19</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.19 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contract Number: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Product Development Agreement of
TG103 Project Between <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Shanghai) Co., Ltd. and CSPC Baike (Shangdong) Biopharmaceutical Co., Ltd. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December 10th, 2018 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Intellectual Property Licensing and Product Development Agreement (&#147;this Agreement&#148;) is
signed by and between the following parties on December 10th, 2018: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Shanghai) Co., Ltd.</B>,
registered address: Room 802, 8th floor, West Tower, 88 Shangke Road, China (Shanghai) Free Trade Pilot Zone (&#147;<B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma</B>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CSPC Baike (Shangdong) Biopharmaceutical Co., Ltd.</B>, registered address: 212 Jinbu Street, Qinshui Korean Industrial Park, Mouping District, Yantai City
(hereinafter referred to as &#147;<B>CSPC Group</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma and CSPC Group may be
hereinafter individually referred to as &#147;one party&#148;, &#147;each party&#148; or &#147;the Parties&#148; and collectively as &#147;both parties&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS, </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma is an innovative biopharmaceutical research and
development company in the fields of autoimmune diseases, oncology immune and immune-mediated inflammatory diseases, who owns the rights of regional development and commercialization of <B>TG103</B> and related intellectual property rights in China.
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma is seeking strategic partners for product development and commercialization in China. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">CSPC Group is one of the leading comprehensive pharmaceutical companies in China, with product pipeline in
innovative drugs and professional product marketing ability, who has synergy with <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma&#146;s development areas. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parties are willing to carry out strategic cooperation on <B>TG103</B> products, and develop and commercialize <B>TG103</B> products for the treatment of type
2 diabetes mellitus and all indications related to this product in the territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THEREFORE, the parties have reached the following agreements, which
shall be abided by both parties. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFINITIONS RELATED TO THIS AGREEMENT </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Affiliate</B>: refers to: (1)&nbsp;Any company or business entity in which one party directly or indirectly
owns fifty percent (50%) or more of its shares; or (2)&nbsp;any company or business entity that directly or indirectly owns fifty percent (50%) or more shares of one party; or (3)&nbsp;any company or business entity directly or indirectly controlled
by the company or business entity as described in (1)&nbsp;or (2); to refer to any company or business entity, as described in (1), (2) and (3), as the &#147;Affiliate&#148; of a party, a relevant written notice shall be issued by the party to the
other party and inform the other party about the Affiliate in the notice. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Certificate of ownership of property
rights of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma and its Affiliates and TG103 Project can be found in Annex 3. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Third-party: </B>refers to parties other than (1)&nbsp;Party A and its Affiliates; and (2)&nbsp;Party B and
its Affiliates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TG103 product</B>: refers to the long-acting recombinant <FONT STYLE="white-space:nowrap">GLP-l</FONT> Fc
fusion protein injection (including related patents) developed by <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma based on the technology of hyFc technology platform. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, the <B>TG103</B> project is the same as the project underlying
&#147;Clinical Approval of <B>TG103</B> for Injection approved by the <B>CDE</B> in China with the approval number of <B>2018L02834</B>&#148;. The clinical approval and product structure and sequence of the project are shown in Annex 1. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Patent</B>: Each party&#146;s patent applications or patents of TG103 and its related patents (including
divisional applications and acquired patent rights). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Proprietary technology</B>: refers to <FONT STYLE="white-space:nowrap">non-public</FONT> technology and
other information owned by the parties, including but not limited to concepts, discoveries, data, designs, molecular formulas, R&amp;D plans, test and detection designs, test and test results, processes, test records, and data of chemistry,
pharmacodynamics, toxicology, clinical, analytical and quality control, data analysis, reports and summaries. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Genexine&#146;s intellectual property</B>: refers to the patented hyFc platform of <B>Genexine, Inc.</B>, a
Korean company, and the patents related to the licensed products granted by Genexine, Inc. to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma to use and sublicense (details of Genexine&#146;s intellectual property rights can be found in
Annex 2 of this Agreement). <B>hyFc </B>platform refers to that a Fc fragment of <B>IgG4</B> fused with the amino acid sequence of the target protein as defined in the Chinese Patent No.&nbsp;201410851771, where amino acids at the position of <FONT
STYLE="white-space:nowrap">231-240</FONT> on <B>IgG4</B> are replaced by the <B>CH2</B> domain of <B>IgD</B>, thereby forming a long-acting protein drug with a longer half-life than the current protein, and the fusion protein formed only has a FcRn
site without Fcy Rs binding sites, avoiding stimulating cell lysis and producing immunogenicity. This <B>Fc</B> structure of <B>IgD/IgG4</B> is the <B>hyFc </B>platform. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Licensed compound</B>: refers to a long-acting recombinant GLP-l Fc fusion protein. The molecular structure
and sequence of the fusion protein are presented in the Annex I. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Licensed intellectual property rights:</B> refers to <FONT STYLE="white-space:nowrap">I-Mab</FONT>
Biopharma&#146;s patents and proprietary technologies related to the licensed compounds and licensed products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>New intellectual property rights:</B> refers to any improvement, enhancement, modification or change of the
patents and proprietary technology related to the development and production of the licensed compounds and licensed products after the date of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Licensed products</B>: refers to one or more pharmaceutical (including diagnostic) products, including or
containing (1)<B>&nbsp;TG103</B>, alone or in combination with one or more of any and all other forms of active ingredients, current and future formulations , dosage forms and dosages, and methods of administration; or (2)&nbsp;any fragment
(including antigen binding regions or sequences or portions), variations, improvements, modifications or derivatives thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Treatment field:</B> refers to type 2 diabetes mellitus, including combination therapy with other
pharmaceuticals for type 2 diabetes mellitus and all potential indications of the product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Territory</B>: refers to the People&#146;s Republic of China, excluding Hong Kong, Macao and Taiwan.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>BLA Approval/Market Approval:</B> refers to the first-time marketing approval of the licensed product in the
treatment area in the territory obtained from the drug regulatory agency. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Reasonable commercial efforts: </B>refers to that the efforts and resources used in the development and
commercialization of the licensed products shall be consistent with the efforts and resources used by companies of similar size in the pharmaceutical industry during similar product development and commercialization phases. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>First commercial sale: </B>refers to the first sale or consumption of a licensed product to a third party
for final use in the territory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Net sales revenue</B>: refers to the total amount of invoices issued by CSPC Group and its Affiliates and <FONT
STYLE="white-space:nowrap">sub-licensees</FONT> to unrelated third parties for the sale of products in the applicable areas, after deducting the following deductions relating to the sale of products in the applicable areas (if included in the total
sales price of the products invoiced or directly paid or assumed by CSPC Group and its Affiliates and <FONT STYLE="white-space:nowrap">sub-licensees):</FONT> (1) allowed discounts of trade, quantity and cash; (2)&nbsp;any discounts, refunds,
rebates, price adjustments or any other similar subsidies (excluding salesperson commissions) that in substance reduced the net sales prices, and are compliant with China&#146;s Generally Accepted Accounting Principles and applicable jurisdiction
laws; (3)&nbsp;recycling and subsidy of licensed products; and (4)&nbsp;any value-added tax levied on licensed products. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PURPOSE AND APPROVAL OF THE AGREEMENT </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma warrants to own the following rights and shall provide
proof for such ownership: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Description of intellectual property rights owned by <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma:
Fusion polypeptide containing glucagon-like <FONT STYLE="white-space:nowrap">peptide-1</FONT> and immunoglobulin hybrid Fc and its application; Patent Application Number CN2010101771.1 and CN2015800643.8 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Description of technology owned by <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma: possession of
patented technology and technology secrets, the licensed products can be produced independently and effectively by the CMO company designated by <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The purposes of this Agreement to be entered into by and between CSPC Group and
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Tianjin) Co., Ltd. are: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The exclusive licensing of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma to CSPC Group for the use of
patented technology owned by <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Transfer of production technology (not inferior to the current technical level of this licensed compound) and
process to the CSPC Group and in coordination with the CSPC group for technical optimization. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subjecting to the terms and conditions of this Agreement, <FONT STYLE="white-space:nowrap">I-Mab</FONT>
Biopharma grants CSPC Group in the territory the exclusive, sole, <FONT STYLE="white-space:nowrap">non-transferable,</FONT> irrevocable and <FONT STYLE="white-space:nowrap">sub-licensable</FONT> license of the intellectual property rights during the
valid term of this Agreement, so as to develop and commercialize the licensed compound(s) and licensed product(s) within the territory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The CSPC Group may grant <FONT STYLE="white-space:nowrap">sub-licenses</FONT> in the territory, but prior
written consent of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma <FONT STYLE="white-space:nowrap">(I-Mab</FONT> Biopharma shall not unreasonably refuse to agree) shall be the condition precedent for such
<FONT STYLE="white-space:nowrap">sub-licenses</FONT> (except for sub-licnesing to the Affiliates of the CSPC Group), and shall be subject to the restrictions on the CSPC Group as well as the obligations the CSPC Group under this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If, during the valid term of this Agreement, part or all of the licensed intellectual property rights become
invalid, and the invalidation is not due to the violation of the relevant statements, guarantees and commitments made by <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma in this Agreement, this Agreement shall continue to be in force with
respect to any other valid intellectual property rights. In this case, during the valid term of this Agreement, the CSPC Group shall continue to be obliged to pay the fees agreed upon by both parties under Article 3 of this Agreement for the
licensing of intellectual property rights (including patents and proprietary technologies) under this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PAYMENTS AND PAYMENT METHOD </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Upfront payment</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The upfront payment is RMB15.0&nbsp;million (capital: RMB fifteen million yuan), and CSPC Group will pay the upfront payment within 30 (thirty)
days after the entry into force of this Agreement. The upfront payment will not be refunded for any reason except for the reasons specified in paragraph 7.3.1 of this Agreement. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Developmental milestone payments</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">CSPC Group will pay milestone payments to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma within 30
(thirty) days after the following milestones are achieved: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Serial<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Milestone Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Milestone Payment (Unit: RMB)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Authorized development changes for clinical approval</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">RMB15&nbsp;million (RMBfifteen million)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Completion of production process transfer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">RMB10&nbsp;million (RMB ten million)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Phase II clinical end point</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">RMB25&nbsp;million yuan (RMB twenty-five million)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Phase III clinical end point</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">RMB35&nbsp;million (RMBthirty-five million)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BLA Approval / Market Approval</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Market
Approval</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">RMB50&nbsp;million yuan (RMBfifty million)</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Determination of milestone event realization </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">CSPC Group shall notify <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma immediately when the above milestone events have been achieved.
If the CSPC Group fails to notify <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma of the achievement of the milestone event, but <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma has reason to believe that the milestone should be
achieved, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma may inform the CSPC Group in writing, and both parties shall immediately meet to discuss the matter about the realization of the milestone event. Disputes over the realization of
milestone events may be resolved by means of dispute resolution under this Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Sales commission</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Percentage of sales commission </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Within the sales commission period, the CSPC Group will pay sales commission to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma in
accordance with the percentage of sales commission agreed in the following table on the basis of the annual net sales revenue of licensed products in the calendar year: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Serial<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Annual Net Sales Revenue of Licensed Product(s) (Unit:
RMB)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of&nbsp;Sales<BR>Commission</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Less than RMB500&nbsp;million (including this number)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">RMB500&nbsp;million to RMB1&nbsp;billion (including these numbers)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">RMB1 to RMB2.5&nbsp;billion (including these numbers)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">More than RMB2.5&nbsp;billion</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The term of commission of the product shall be the following, whichever later: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Later patent expiration date of licensed product patent application No.&nbsp;201410851771.1 and 201580071643.8
(the ultimately authorized <FONT STYLE="white-space:nowrap">GLP-1&#146;s</FONT> claims part) in the territory; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ten (10)&nbsp;years after the first commercial sale of licensed products in the territory.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tax duties </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The above-mentioned upfront payment, milestone payments and sales commission paid/to be paid by CSPC Group do not include value added tax, and
the value-added tax shall be borne by CSPC Group. Other taxes shall be borne by both parties in accordance with the law. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Invoice </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Within 30 (thirty) working days after the receipt of the upfront payment, milestone payment and sales commission payment, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma shall issue a special VAT invoice with a tax rate of 6% or the applicable tax rate in accordance with the laws at that time to the CSPC Group. The CSPC Group shall pay the corresponding tax to <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma 30 (thirty) working days after receipt of the invoice. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Accounting books and records </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The CSPC Group shall keep complete and appropriate accounting records and books, including financial receipts
and monthly and quarterly accounting statements showing the sales, deductions, net sales revenue and other quantities and descriptions of the licensed product it sells, in accordance with relevant laws and regulations of China.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The above accounting records and books shall be kept separately from all other records and books not related to
the licensed product and shall be subject to inspection by <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma or its duly authorized representative or agent. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The CSPC Group shall allow <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (or its representative) to
check, audit and inspect all account books, records, audit reports, documents and other matters related to the production and sale of the licensed product in a reasonable time at most once every year, and the expenses shall be borne by <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma. The manner and time of the above-mentioned checking, auditing and inspection shall not adversely affect the operation of CSPC Group or the sales of the licensed and transferred products, and the
results of such checking, auditing and inspection shall be kept confidential. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RESEARCH AND DEVELOPMENT </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Obligations of CSPC Group </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">General agreement: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">CSPC Group has the final decision on the development of licensed compounds and licensed products in the therapeutic field in the territory,
including related research and development, clinical trials and registration activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Accountability: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The CSPC Group shall make reasonable commercial efforts to develop licensed compounds and licensed products to commercialize them in the
territory as soon as possible. Such development should be carried out according to the research and development plan jointly determined by both parties. The CSPC Group shall make reasonable commercial efforts to implement the R&amp;D plan in order
to obtain marketing license for the licensed products in the field of treatment in the territory as soon as possible. Any change to the R&amp;D plan shall be discussed and agreed by the Joint Development Committee. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Obligations of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma is not allowed to develop for itself or for others the
long-acting recombinant <FONT STYLE="white-space:nowrap">GLP-1</FONT> Fc fusion proteins and products with competitive mechanism at the same targets based on the technology of hyFc technology platform in the territory. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In order to ensure the development of licensed products in the field of treatment in the territory, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma should continue to assist the CSPC Group in completing the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> study of the licensed products required by the Chinese drug approval departments, and
provide all the research records and data. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma shall make reasonable commercial efforts to assist in
the transfer of licensed products to the production technology of CSPC Group. The technical indicators of production technology transfer shall not be lower than the existing technical level. The plan and acceptance criteria of production technology
transfer are listed in Annex 5. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma shall make reasonable commercial efforts to assist or
guide the CSPC Group in continuous optimization of production process of the licensed product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Project leader: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Within 30 (thirty) days from the date of signing this Agreement, each party shall appoint the corresponding project leader and shall notify the
other party in writing in time. Each party shall notify the other party in writing in time when replacing its project leader. The project leaders will be responsible for facilitating the communications and coordinating in actions between the parties
in accordance with the terms of this Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COMMERCIALIZATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">General agreement: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">CSPC Group has the final decision on the commercializtion of the licensed compounds and licensed products in the therapeutic field in the
territory. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Accountability: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">CSPC Group shall make reasonable commercial efforts to start the marketing and sales activities of the licensed products within a reasonable
time after obtaining the sales license from the governmental departments. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reporting: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">CSPC Group shall provide summary report of the commercialization activities of its licensed products for the preceding <FONT
STYLE="white-space:nowrap">six-month</FONT> period on semi-annual basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>JOINT DEVELOPMENT COMMITTEE </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Both parties agree to establish a Joint Development Committee (JDC) to monitor and coordinate the actions of
the parties and promote communications and cooperation between the two parties. The JDC is specifically responsible for: (1)&nbsp;Supervising the progress of development activities; (2)&nbsp;Discussing the issues of safety, scientific and technical
issues arising from the development of licensed products; discussing and proposing solutions for any delays or overdue delays in the development protocol; and (3)&nbsp;Performing other appropriate functions and making other appropriate decisions in
accordance with the written consent of both parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Composition of the JDC: The JDC consists of 4 (four) members, 2 (two) appointed by each Party. Members of the
JDC should have the appropriate technical capabilities, industry experience and knowledge. Within thirty (30)&nbsp;days from the date of signing this Agreement, each party shall appoint the initial members of the JDC and notify the other party in
writing in a timely manner. If one party replaces the appointed member(s) of the JDC, the other party shall be promptly notified in writing. The JDC has two <FONT STYLE="white-space:nowrap">co-chairs,</FONT> one appointed by the CSPC Group and one
by <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The duties of the <FONT STYLE="white-space:nowrap">Co-Chairs</FONT> are responsible for convening and presiding
over the JDC meetings and preparing the minutes of the JDC meetings. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">JDC meetings: The JDC will decide for itself when to convene a JDC meeting, but at least once every quarter.
The JDC Meetings may be convened in the form of meetings by person, teleconferences or videoconferences, but at least one meeting by person shall be held in each calendar year. Each party shall bear the cost of its participation in the JDC meetings.
Members of each party who are not members of the JDC may be invited to participate in the JDC meetings as required. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INTELLECTUAL PROPERTY RIGHTS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Background intellectual property rights </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The licensed intellectual property rights of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma,
Genexine&#146;s intellectual property rights and all intellectual property rights of the CSPS Group on the effective date of this Agreement shall be owned by each party. <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma is responsible for the
preparation, application, implementation and maintenance of the patents for TG103 product. Since the entry into force of this Agreement, all fees incurred in the Territory for the implementation and maintenance of the patents of TG103 product will
be paid by the CSPC Group to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma on the basis of invoices provided by <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma shall grant
<FONT STYLE="white-space:nowrap">sub-licensing</FONT> of Genexine&#146;s intellectual property rights to CSPC Group for the development of TG103 product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New intellectual property rights </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Both parties agree that in the term of this Agreement, both parties shall have the right to continuously improve and optimize the licensed
products or licensed compounds, including, but not limited to, process improvement, quality improvement, extension of the scope of application of the licensed products or licensed compounds, and extension of the mode of application of the licensed
products or licensed compounds. For the new intellectual property rights arising from the implementation of the above-mentioned improvements, the parties agree as follows: <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma will grant the
license of its new intellectual property rights generated by the implementation of the above-mentioned improvements for exclusive and free use to the CSPC Group in the territory, and the CSPC Group is responsible for paying the application and
maintenance fees for the new patents in the territory; the new intellectual property rights generated by the implementation of the above-mentioned improvements by the CSPC Group belong to the CSPC Group. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Claims and infringement </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma shall guarantee that it has the complete rights to the
licensed TG103 project, including license, <FONT STYLE="white-space:nowrap">sub-license,</FONT> patent application right and patent right. After the entry into force of this Agreement, it shall guarantee that the CSPC Group shall acquire and enjoy
the right of free implementation. If a patent authorization for the licensed compound is not obtained from China Intellectual Property Office, or if the CSPC Group fails to exercise its right of free implementation, the CSPC Group has the right to
unilaterally terminate/end this Agreement, or continue to license the product development of the compound, or implement this Agreement and perform all rights and obligations. In case the CSPC Group terminates this Agreement for the above reasons, it
may issue a Contract Termination Letter to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma by entrusted attorney. <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma shall refund the full amount paid by the CSPC Group within 30 natural
days after receiving the Letter. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a third party submits a claim of any nature claiming that the licensed intellectual property rights used by
the CSPC Group infringe or may infringe upon its patent or other proprietary rights, or that there are facts that may lead to such claims, the CSPC Group shall notify <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma immediately when it knows
such claims or facts. However, the CSPC Group shall not take any action related to such claims or infringements without obtaining the written consent of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma.
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma shall notify the CSPC Group within three calendar days whether it intends to defend against such claims. If <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma chooses to make a defense, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma shall, in its own name or in the name of the CSPC Group (as the case may be), exclusively control the defense and bear the expenses, but the CSPC Group shall give all reasonable assistance to <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma for this purpose. If <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma chooses not to make a defense, the CSPC Group shall have exclusive control over the defense and bear the expenses by its
own, but <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma shall give all reasonable assistance to CSPC Group for this purpose. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a third party submits any claim for the licensed intellectual property rights stated in Paragraph 7.3.1 and
the CSPC Group suffers any claim, loss or damage as a result of such claim, unless such claim, loss or damage is caused by the violation of the obligations of this Agreement by the CSPC Group or the failure for CSPC Group to use the licensed
intellectual property rights in accordance with the provisions of this Agreement, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma shall make compensation to the CSPC Group and bear the responsibility of making compensation with and bear the
related expenses for the CSPC Group. Notwithstanding the above provisions, the total amount of the liability of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma shall not exceed the sum of the following items: (1)&nbsp;the upfront payment
actually received by <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma in accordance with the terms of this Agreement; (2)&nbsp;any milestone payments actually received by <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma in accordance
with the terms of this Agreement; and (3)&nbsp;any other payments actually received by <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma in accordance with the terms of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the CSPC Group learns any information about third party infringement or possible infringement of the
licensed intellectual property rights of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma, it shall immediately notify <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma. However, the CSPC Group shall not take any action related to such
infringements without obtaining the prior consent of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma. <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma shall consult with the CSPC Group within three working days after receiving the
notification from the CSPC Group to determine that one party shall take legal action and the other party shall give all reasonable assistance. In the meantime, if negotiations fail, the CSPC Group has the right to unilaterally take measures to
safeguard its rights. If either party takes legal action, the two parties may negotiate the share of expenses and the attribution of compensation. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma decides not to take action under Paragraph 7.3.4
above, the CSPC Group may bring lawsuit against the infringing party at its own expense after obtaining written consent from <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma, and <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma shall
give all reasonable assistance as required by the CSPC Group. All compensation that may be obtained by the CSPC Group for taking action on third-party infringements is owned by the CSPC Group. Notwithstanding the above provisions, the CSPC Group
shall not reach compromise, settlement or agreement with any third party on the licensed intellectual property rights without the written consent of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.3.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a third party makes claims of any nature concerning the new intellectual property rights, the CSPC Group
shall immediately notify <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma of such claims or facts. The CSPC Group has the right to take any action related to such claims or infringements and to inform
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma in a timely manner. If the CSPC Group waives to take action or make defense, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma has the right to decide whether to take action or raise
defense in its own name, but the CSPC Group shall give all reasonable assistance to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma for this purpose. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.3.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">One of the parties to this Agreement shall not be liable for any special, incidental or indirect damages
suffered by the other party as a result of the contract, intellectual property infringement, breach of warranty or other agreements. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INFORMATION EXCHANGE </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Data sharing mechanism between the two parties: <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma will coordinate with Genexine to share
clinical study protocols and data, all clinical trials protocols, trial data and conclusions with the CSPC Group in China and beyond, to support the global clinical development and commercialization of the licensed product(s). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REPRESENTATION AND WARRANTIES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties hereby mutually represent and warrant that: (1)&nbsp;It is a validly existing entity under the
applicable laws of its jurisdiction; (2)&nbsp;It has the necessary authorization to complete the services under this Agreement, including but not limited to the approval of relevant government departments or other institutions, and it has sufficient
capacity, rights and powers to implement and deliver this Agreement and to fulfil its obligations under this Agreement; (3)&nbsp;This agreement, upon its conclusion, shall constitute a legally enforceable, valid and binding agreement; (4)&nbsp;No
violation of applicable laws and regulations occurred during the negotiation and facilitation of the signing of this Agreement by each party or its affiliated companies; (5)&nbsp;Each party warrants compliance and ensures that its affiliates that
may participate in this Agreement comply with applicable laws and regulations in the performance of this Agreement; (6)&nbsp;The execution of this Agreement by each party or its affiliated company shall not conflict with any obligations it may
assume to any other person or the rights and obligations under any other agreement it may sign; and (7)&nbsp;In case of becoming aware of any violation of this Term, the Party shall immediately notify the other party. If one party violates the
representations and warranties, the other party shall be compensated for the loss. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the knowledge of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma, there are no pending or potential
claims or investigations for the licensed intellectual property rights. To the knowledge of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma, the license under this Agreement does not violate the relevant legal provisions or the rights of any
third party. To the knowledge of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma, the production, use and sale of licensed products will not infringe upon the intellectual property rights of any third party in the territory.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERMINATION </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement shall come into force immediately upon signature by both parties and shall have full legal
effect during the validity of this Agreement unless terminated in advance in accordance with this Agreement, provided that such termination shall not affect: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The rights and obligations already enjoyed and assumed by the parties on the date of termination; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the continued existence and validity of the rights and obligations of the parties under the terms and
conditions intended to survive termination and the provisions necessary for the interpretation or execution of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise provided in this Agreement, this Agreement may be terminated in the following circumstances,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise specified, if one party seriously violates this Agreement, the other party may terminate this
Agreement by giving notice to such effect. If such breach could be corrected, but the defaulting party fails to make such correction within 60 (sixty) days after receiving the notification, this Agreement may be terminated. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In case the force majeure lasting for 6 (six) months or other events that render the purpose of this Agreement
unachievable cause the CSPC Group to stop the research, development, production and sale of the licensed products, and the parties fail to find a fair solution, either party may notify the other party to terminate this Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a party becomes bankrupt or insolvent, or is subject to liquidation or dissolution procedures or
arrangements, or ceases to operate, or is unable to pay the debts due, the other party may terminate this Agreement by giving notice; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If, for the reasons of the CSPC Group, the CSPC Group fails to obtain the approval or registration from the
regulatory authority required to sell the Licensed Products in the territory in accordance with the business plan and timetable approved from time to time by its board of directors, or the CSPC Group ceases to engage in the licensed product
development or product registration in accordance with the written resolution of its board of directors, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma may terminate this Agreement by issuing a notice to the CSPC Group.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon the termination/ending of this Agreement for any reason, the CSPC Group shall immediately stop using the
licensed intellectual property rights provided by <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma and stop producing the licensed products. CSPC Group shall promptly transfer to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma all
relevant data, information, cell lines, production processes and clinical samples of the licensed compounds and licensed products owned by the CSPC Group. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Payment by the CSPC Group shall be suspended if this Agreement is terminated/ended by Clause 10.2.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">CSPC Group shall return all the licensed intellectual property rights to
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma upon the early termination of this Agreement, including improved technology and technical documents related to the licensed intellectual property rights provided by <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma that are recorded in any material form (including but not limited to any written records). CSPC Group, on behalf of itself and its employees, agrees that, at the time of termination or expiration of
this Agreement and beyond, copies of the licensed intellectual property rights in any form of materials or technical documents related to the licensed intellectual property rights shall not be made or retained, except for the purpose of archival
retention. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Within 6 months after the signing of the Agreement, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma
will solve all intellectual property issues stated in Annex 6. Otherwise, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma will be deemed to have violated the agreements in Clause 7.3.1, and the CSPC Group has not obtained and enjoyed the
right of free implementation. The CSPC Group will have the right to terminate this Agreement. <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma will assume the liability for breach of contract within 30 days after receipt of the termination
document in accordance with the agreements of Clause 7.3.1 by refunding the contractual amount of money that CSPC Group has paid. CSPC Group shall return all the licensed intellectual property rights to <FONT STYLE="white-space:nowrap">I-Mab</FONT>
Biopharma, including improved technology and technical documents related to the licensed intellectual property rights provided by <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma that are recorded in any material form (including but not
limited to any written records). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FORCE MAJEURE </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Force majeure event means any event that the Parties could not be expected to foresee, or, even that is
predictable, but unavoidable, that is entirely beyond the control of the Parties, and that prevents the obligations of the Agreement from being performed fully or partially by either Party. Such incidents include, but are not limited to, stoppages,
explosions, accidents, acts of natural disasters or public enemies, fires, floods, accidents, war riots, rebellions and any other similar probable events. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event of force majeure, which prevents both parties from fulfilling any contractual obligations under
this Agreement, such contractual obligations shall be suspended during the period of delay in performance due to force majeure, and the time of performance of such contractual obligations shall automatically be extended to the time equivalent to the
suspension of such events without penalty. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The party subject to force majeure shall notify the other party within 15 (fifteen) days of the occurrence of
the event concerned and provide the other party with an effective proof of the occurrence of force majeure. Within a reasonable period thereafter, the party subject to force majeure shall provide the other party with evidence of the occurrence of
force majeure issued by the relevant agency. The party subject to force majeure shall also make every reasonable effort to reduce the impact of such force majeure. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">After occurrence of the event of force majeure, both parties shall consult immediately to agree on a fair
solution (which may include early termination or extension of the term of this Agreement) and shall make every reasonable effort to reduce the consequences of such force majeure. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONFIDENTIALITY AND PUBLICITY </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential information. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Confidential Information means all information and materials disclosed by one party or on behalf of the party or its affiliates or their
related persons (&#147;Disclosing Party&#148;) to the other party or its affiliates or their related persons (&#147;Recipient&#148;). Confidential information includes all the contents agreed upon in this Agreement, the existence, terms and purposes
of this Agreement, the nature of any dispute, the results of any arbitration proceedings arising out of or relating to this Agreement, and all information and materials involved in the implementation of this Agreement, including but not limited to
the nature of the project, test contents and progress, samples, programs, skills, amounts of money, materials, information, products, plans, technologies, data, experiments, market data, marketing, finance, sources of supply, business information,
business plans, forecasts, structures, concepts, methods, methodologies, procedures, experiments, models, tests, original atlas, photographs, proprietary skills, technical <FONT STYLE="white-space:nowrap">know-how,</FONT> inventions, patent
applications, patent applications and any other documents and information, or information concerning third parties that are under the obligation of confidentiality of the Disclosing Party, whether the information is disclosed by the Disclosing Party
to the Recipient in writing, orally or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidentiality obligations. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in this Agreement, the Recipient shall, and shall ensure that its relevant personnel, (1)&nbsp;keep confidential of
the confidential information during the term of this Agreement, and this obligation of confidentiality shall remain valid after the expiration or termination or ending of this Agreement until the confidential information is legally disclosed or the
Disclosing Party notifies the Recipient in writing that it is not bound by this obligation of confidentiality; (2)&nbsp;not use the confidential information except for the purpose of fulfilling this Agreement; (3)&nbsp;not disclose the confidential
information to any third party, except for (1)&nbsp;those persons who need to know the service-related confidential information, provided that the Recipient shall be obliged to oblige the persons concerned to abide by the Agreement and bear
liability for the violation of this confidentiality obligation by the persons concerned; and (2)&nbsp;inspection, disclosure or other activities required by government agencies, judicial procedures (including, but not limited to, the extent to which
litigation, arbitration or responding, arbitration defenses are reasonably necessary), securities exchanges or relevant legal requirements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">To the extent permitted by law, the Recipient shall promptly notify the Disclosing Party in writing, and through reasonable efforts to ensure
that the confidential information is treated confidentially, and cooperate with the Disclosing Party to take reasonable measures to minimize the confidential information that may be disclosed, but the scope of the above disclosure shall be
controlled within the necessary limits. The Recipient agrees to take any feasible measures to protect the confidentiality of confidential information to a level not less than that of its own confidential content or content of the same nature, and to
avoid unauthorized disclosure and use. The obligations under this Clause 12.2 shall continue to be performed after the termination or ending or expiration of this Agreement. Notwithstanding the foregoing, the existence of this Agreement and its <FONT
STYLE="white-space:nowrap">non-technical</FONT> terms may be disclosed in a confidential manner as a result of potential financing or acquisition. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exception to confidentiality. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The obligations provided under Clause 12.2 do not apply to the following circumstances: (1)&nbsp;Confidential information is public knowledge
or the confidential information that is not publicly known as a result of the fault or breach of contract of the Recipient or its related personnel; (2)&nbsp;the Recipient can provide evidence to prove that it or its relevant personnel have legally
known the confidential information before the Disclosing Party disclose it to the Recipient; (3)&nbsp;the Recipient may provide evidence that it or its related personnel legally acquired such confidential information from a third party that has no
obligation to keep confidentiality to the Disclosing Party or its associated personnel, in a manner of not violating the confidentiality obligations of this Agreement; or (4)&nbsp;the Recipient can provide evidence that the it or its related
personnel has not relied on the confidential information and that the confidential information has not been independently developed by the Recipient in violation of this Agreement. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Return of confidential information. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Within 30 days after the termination or ending or expiration of this Agreement, the Recipient shall, at the written request of the Disclosing
Party, return all Confidential Information to the Disclosing Party (including any form of photocopy or reproduction), or immediately destroy it in its entirety, and shall provide the Disclosing Party with proof of its destruction of the information
and materials; However, where prior written consent of the Disclosing Party is obtained and used for the sole purpose of this Agreement and the obligation of confidentiality is assumed, the Recipient has the right to retain the corresponding
confidential information for the purpose of legal archiving. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Publishing. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The parties hereto shall and shall ensure that their relevant personnel strictly keep confidential the confidential information under this
Agreement. Before obtaining the written permission of the other party, neither party shall disclose or permit any third party to contact, know, learn, utilize or use any of the confidential information for any purpose or in any way, nor shall any
content of confidential information under this Agreement be published in articles or otherwise made public. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Publicity. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Without the prior written consent of the other party, neither party shall, and ensure that its relevant personnel will not, use the name,
trademark, trade name, symbol or logo of the other party in any advertisement or propaganda materials. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COMPENSATION </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">One Party hereto shall protect, compensate and ensure that the other Party and its affiliated companies and its
and their directors, personnel, employees, agents, subcontractors and consultants, as well as legal, financial, accounting, consultants and other consulting parties who need to know the information, are not harmed and exempt from liability and
damages (including reasonable attorney&#146;s fees) arising from third party claims, requirements, lawsuits or procedures. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In any case, the liability for damages suffered by either party to this Agreement for the other party does not
include indirect loss, incidental loss and expected loss of profits. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>APPLICATION OF LAW AND DISPUTE RESOLUTION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The validity, interpretation, performance and other related matters of this Agreement shall be governed by the
laws of the People&#146;s Republic of China and the principles of conflict of laws shall not invoke. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties to this Agreement shall negotiate in good faith to resolve any disputes arising from or related to
this Agreement. The negotiation shall begin immediately after one party submits a request for negotiation to the other party. If the dispute cannot be resolved within 30 days from the date of submission of the request for consultation, either party
may submit the dispute to the Beijing Branch of the China International Economic and Trade Arbitration Commission (CIETAC) for arbitration in accordance with the CIETAC Arbitration Rules in force at the time of submission. The place of arbitration
is Beijing. The official language of arbitration is Chinese. The arbitral tribunal shall consist of an arbitrator appointed by CIETAC. The arbitration procedure is confidential, and the arbitrator may issue appropriate protection orders to protect
the confidential information of the parties. The arbitral award shall be final and binding upon the parties. The parties may apply to the court of competent jurisdiction for enforcement of the arbitral award. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INDEPENDENT CONTRACTORS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Both parties are independent contractors, and no provision of this Agreement shall, for any reason, make one party an agent, partner, legal
representative, principal or employee of the other party. Except as otherwise expressly provided in this Agreement, neither party shall have the right to bind the other party. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>THE TERM OF THIS AGREEMENT AND THE RIGHTS OF BOTH PARTIES AFTER THE EXPIRATION OF THIS AGREEMENT:
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The term of this Agreement begins on the date of signature and expires at the end of the product commission period.
After the expiration of this Agreement, both parties shall continue to abide by the confidentiality obligations stipulated in Article 12 of this Agreement. In the event that the CSPC Group fully fulfills its obligations under this Agreement, after
the expiration of this Agreement, the CSPC Group will fully enjoy the full ownership of the Licensed Products and/or Licensed Compounds in the territory, including but not limited to technical data, research results, sales revenue, etc., <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma will no longer enjoy the relevant sales commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>OTHER TERMS </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Transfer. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">This Agreement shall be binding on both parties and their respective successors and permitted transferees. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notice </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>17.2.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Any notice under this Agreement shall be in writing and shall be deemed to have been delivered upon
receipt of the notice by the intended recipient of the notice. The means of proof of receipt include: (1)&nbsp;if the notice is delivered by hand, the recipient&#146;s written receipt or proof of the delivery personnel, confirming that the recipient
has received or refused to receive the relevant notice; (2)&nbsp;if delivered by registered mail or express mail (receipt thereof shall be requested) or by internationally renowned express delivery, a signed receipt or other written proof of
delivery; or (3)&nbsp;if sent by <FONT STYLE="white-space:nowrap">e-mail,</FONT> the electronic certification material of the sent <FONT STYLE="white-space:nowrap">e-mail.</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mailing address and contact person </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Room 802, West Tower, Haowei Software Park, No.&nbsp;88, Shangke Road, Pudong New Area, Shanghai</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Postal Code</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">201210</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Contact Person</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail</FONT> Address</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>CSPC Group: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">226 Yellow River Avenue, Shijiazhuang City, Hebei Province</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Postal Code</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">050035</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Contact Person</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail</FONT> Address</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any change in the address and contact person of either party shall be notified to the other party in a timely
manner. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Complete contract terms. This Agreement covers all the agreements between the Parties concerning the subject
matter of this Agreement and supersedes all oral and written agreements, contracts, understandings, discussions, negotiations and notifications made by the Parties before signing this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amendments. No modification or waiver of any of the provisions contained in this Agreement or any other form of
amendment to this Agreement shall be binding upon the Parties unless expressly specified and signed by both parties in writing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No waiver. Any party&#146;s waiver of its rights to seek relief against breach of any provision of this
Agreement by the other party shall not constitute the waiver of its rights to seek relief against breach of any other provision of this Agreement by the other party. The failure or delay of either party in exercising any right under this Agreement
does not constitute a waiver of that right or other rights, nor does it adversely affect such right or any other rights. The waiver of any right shall be made in writing by the waiver, otherwise it has no legal effect. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Severability If any provision of this Agreement is deemed to be invalid, illegal or unenforceable, then
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The term will be replaced by an effective and enforceable clause that maximizes the intentions of both parties;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All other terms of this Agreement remain in full force and effect. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Annexes to the Agreement </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Annexes to this Agreement are an integral part of this Agreement and have the same legal effect as the body of this Agreement. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement shall come into force on the date of signature and seal by the parties. This Agreement is in
four copies, each party holds two copies and each copy shall has the same legal force. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Relevant Annexes: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annex 1 Molecular Structure and Sequence of TG103 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annex 2 List
of Patents Licensed to CSPC Group Included in This Agreement </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annex 3 Certificate of Ownership Issued by the Relevant Parties of Licensed Products </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annex 4 Notice of Change of Applicant/Patentee </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annex 5
Technical Indicators for Transfer of Production Technology of TG103 Products </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annex 6 List of Intellectual Property Issues Needed to be Solved by <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma within 6 Months of Contract Signing </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(The remainder of this page is intentionally left blank)
</B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(SIGNATURE PAGE <FONT STYLE="font-family:pmingliu; font-size:9pt">&#65289;</FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt"> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Party A </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (seal) </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>/s/
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Party B </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Shanghai) Co., Ltd. (seal) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>/s/ <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Shanghai) Co., Ltd. </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annex 1 <B>TG103</B> Injection Approval and Molecular Structure and Sequence of <B>TG103</B> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g38965g78v87.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>National Medical Products Administration </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clinical Trial Approval </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Original No.: 50170027 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lot No.: JYSB1700161</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Approval No.: 2078002334</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Drug Name</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5">### Injection</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">English Name/</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5">TG103 Injection</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dosage Form</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Solution for injection</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Application item</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Strength</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">25 mg/ml</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Registration Classification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Therapeutical Biologics</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">## Human</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5">Tasgen Biotech Co., Ltd.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">##Conclusions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5">See attached page.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Send to</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5">Tasgen Biotech Co., Ltd.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Copy and send to</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5">###</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Remarks</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5">This clinical trial</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g38965g86y21.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The complete theoretical sequence of <B>TG103</B> contains 286 amino acids (see Figure below
for details). The sequence of <FONT STYLE="white-space:nowrap">GLP-1</FONT> is from amino acid position 1 to position 31. The IgD sequence is from amino acid position 32 to 79 (orange and pink), a total of 48 amino acids, including a N - terminal
hinge region (orange) and <FONT STYLE="white-space:nowrap">CH2-N</FONT> terminal region (Pink); The IgG4 sequence is from amino acid position 80 to position 286, including <FONT STYLE="white-space:nowrap">CH2-C</FONT> terminal (green) and CH3 region
(blue). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Hinge region of IgD and <FONT STYLE="white-space:nowrap">CH2-N</FONT> terminal, IgG4
<FONT STYLE="white-space:nowrap">CH2-C</FONT> terminal and CH3 region are fused to constitute a hybrid Fc ( HyFc) fragment, which is ligated to <FONT STYLE="white-space:nowrap">GLP-1</FONT> to form a TG103 molecular <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">(GLP-1-hyFc).</FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amino acid sequence, structure and functional sites of TG103 molecule: </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g38965178.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Annex 2 List of Patents Licensed (by I-Mab) to CSPC Group Included in This Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patent application number <B>CN 201410851771.1 ; CN 201580071643.8 </B>(involving the claims section of
<B><FONT STYLE="white-space:nowrap">GLP-1</FONT></B>); <B>CN 201310553839.3 ; </B>and <B>CN 201510684679.5 </B>(Platform patents <B>CN201310553839.3 </B>and <B>CN 201510684679.5 </B>involving the implementation of the license in China of the patent
applications <B>CN 201410851771.1 </B>and <B>CN 201580071643.8 </B>(involving the claims section of <B><FONT STYLE="white-space:nowrap">GLP-1</FONT></B>). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Annex 3 Certificate of Ownership Issued by the Relevant Parties of Licensed Products </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annex <FONT STYLE="white-space:nowrap">3-1</FONT> Letter of Confirmation from Genexine </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g38965180.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Letter of Confirmation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;12, 2018 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Via
<FONT STYLE="white-space:nowrap">e-mail</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> <FONT STYLE="white-space:nowrap">BIO-TECH</FONT> (TIANJIN)
CO.<SUB STYLE="font-size:85%; vertical-align:bottom">#</SUB> LTD. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chenhuan Building, Tianjin Pharma and Medical Device Zone, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beicheng District, Tianjin, the PRC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RE: Confirmation of
Assignment of Long-acting <FONT STYLE="white-space:nowrap">GLP-1</FONT> <FONT STYLE="white-space:nowrap">(GX-G6)</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Sir/Madam: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is made to that certain Intellectual Property Assignment and License Agreement executed between <FONT STYLE="white-space:nowrap">I-</FONT> Mab <FONT
STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjian) Co., Ltd. <FONT STYLE="font-family:pmingliu; font-size:9pt">&#65288;</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">&#148;I-Mab&#148;)</FONT> and
Genexlne, Inc. (&#147;Company&#148;)<B><SUP STYLE="font-size:85%; vertical-align:top">,</SUP></B> dated October&nbsp;16, 2015 as amended as of December 22, 2017 (&#147;Agreement&#148;). </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter shall serve as an official statement confirming that, pursuant to Article 2A of the Agreement, the Company assigned to <FONT
STYLE="white-space:nowrap">I-Mab</FONT> the intellectual property specified in the table below as &#145;No.&nbsp;1 Patent Application&#146; (&#145;&#145;Assigned Intellectual Property&#148;) for use in
<FONT STYLE="white-space:nowrap">pre-clinical/clinical</FONT> development<FONT STYLE="font-family:pmingliu; font-size:9pt">, </FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt">manufacturing, sale and distribution of the
biopharmaceutical product, <FONT STYLE="white-space:nowrap">OC-G6</FONT> for treatment of any disease (<SUP STYLE="font-size:85%; vertical-align:top">n</SUP>Authorized Activities<B><SUP STYLE="font-size:85%; vertical-align:top">,)</SUP></B> in the
People&#146;s Republic of China excluding Hong Kong, Macau and Taiwan (&#147;China&#148;). </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the Assigned Intellectual Property,
there is another patent application that has relevance to the assignment of <FONT STYLE="white-space:nowrap">GX-G6,</FONT> which has been filed under the Company&#146;s name. This patent application, specified in the table below as &#145;No.&nbsp;2
Patent Application&#146;, consists of two parts, and the one that covers <FONT STYLE="white-space:nowrap">GLP-1</FONT> related claims is intended to belong to <FONT STYLE="white-space:nowrap">I-Mab</FONT> without any restrictions whatsoever while
the other that covers <FONT STYLE="white-space:nowrap">GLP-2</FONT> related claims remains the sole and exclusive property of the Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">No</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Protect</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Tula of Invention in China</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Country</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Publication a</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Publication<BR>data</P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GX&#151;G6</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">(GPL-1)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fusion Polypeptide Comprising <FONT STYLE="white-space:nowrap">GLP-1</FONT> and Immunoglobulin Hybrid Fc and use thereof</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">CN1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">201410851771</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2018-07-27</FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">GX-G6</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(GPL-1&nbsp;.GLP-2)</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fusion Polypeptide Comprising GLP and Immunoglobulin Hybrid Fc and use thereof</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">CN</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">201580C71643&nbsp;8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2017-06-26</FONT></FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of such assignment, <FONT STYLE="white-space:nowrap">I-Mab</FONT> has the full rights to perform
Authorized Activities with respect to <FONT STYLE="white-space:nowrap">GX-G6</FONT> in China including a right to license to any third party including CSPC Pharmaceutical Group For clarity, any intellectual properties relating to &#145;hyFc Platform<SUP
STYLE="font-size:85%; vertical-align:top">,</SUP> technology that are not specifically applicable to the product itself and hence are separable from those described above shall not be deemed to be part of the assignment made under the Agreement </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>/s/</B> Kyu Don Kim<SUB
STYLE="font-size:85%; vertical-align:bottom">#</SUB> Ph.D. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kyu Don Kim<SUB STYLE="font-size:85%; vertical-align:bottom">#</SUB> Ph.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Annex 3 Certificate of Ownership Issued by the Relevant Parties of Licensed Products </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annex <FONT STYLE="white-space:nowrap">3-2</FONT> Authorization Statement of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Tianjin) Co., Ltd. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHEREAS, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <FONT STYLE="white-space:nowrap">I-Mab</FONT>
Biopharma (Shanghai) Co., Ltd. and CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. reached a Product Development Agreement (hereinafter referred to as the &#147;Development Agreement&#148;) on the <B>TG103</B> project; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. The intellectual property rights listed in Annex 2 of the Development Agreement are all the intellectual property rights of
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Tianjin) Co., Ltd.; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. The intellectual property rights listed in Annex 3 of the Development
Agreement are the related intellectual property rights of Genexine,Inc. licensed to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Tianjin) Co., Ltd.; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Tianjin) Co., Ltd. makes the following statements: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. For the purpose of fulfilling the Development Agreement, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Tianjin) Co., Ltd. grants CSPC Baike
(Shandong) Biopharmaceutical Co., Ltd. in the territory the exclusive, sole, <FONT STYLE="white-space:nowrap">non-transferable,</FONT> irrevocable and <FONT STYLE="white-space:nowrap">sub-licensable</FONT> license of the intellectual property rights
listed in Annex 2 of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Tianjin) Co., Ltd.; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. Except for the fees stipulated in the Development
Agreement, the licensing and <FONT STYLE="white-space:nowrap">sub-licensing</FONT> of the above-mentioned intellectual property rights do not involve any fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Tianjin) Co., Ltd., the parent compnay of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma
(Shanghai) Co., Ltd., fully authorizes <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Shanghai) Co., Ltd. to handle the relevant formalities of intellectual property right licensing and <FONT STYLE="white-space:nowrap">sub-licensing</FONT>
(if necessary). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stated by: <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Tianjin) Co., Ltd. (seal) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Tianjin) Co., Ltd. (seal) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Representative:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (signature) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December 10th, 2018 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Annex 3 Certificate of Ownership Issued by the Relevant Parties of Licensed Products </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annex <FONT STYLE="white-space:nowrap">3-3</FONT> Authorization Statement of Tasgen Biotech Co., Ltd. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHEREAS, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <FONT STYLE="white-space:nowrap">I-Mab</FONT>
Biopharma (Shanghai) Co., Ltd. and CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. reached a Product Development Agreement (hereinafter referred to as the &#147;Development Agreement&#148;) on the <B>TG103</B> project; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. Tasgen Biotech Co., Ltd. is an associate of <FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co.,
Ltd.; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. Tasgen Biotech Co., Ltd. is the owner of the clinical approval of theTG103 injection product (Approval number: 2018L02834). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chengdu Tasgen <FONT STYLE="white-space:nowrap">Bio-tech</FONT> Co., Ltd. makes the following statements: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. The Clinical Approval of TG103 Injection is the clinical approval for the TG103 product as agreed in the Development Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. For the purpose of fulfilling the Development Agreement, Chengdu Tasgen <FONT STYLE="white-space:nowrap">Bio-tech</FONT> Co., Ltd. agrees to transfer the
Clinical Approval of TG103 Injection to CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. Except for the fees stipulated in the Development Agreement,
the above-mentioned transfer of the Clinical Approval of TG103 Injection does not involve any fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. Chengdu Tasgen
<FONT STYLE="white-space:nowrap">Bio-tech</FONT> Co., Ltd. is a related company of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Shanghai) Co., Ltd., and fully authorizes <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Shanghai)
Co., Ltd. to handle the relevant formalities of above-mentioned clinical approval (if needed). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stated by: Tasgen Biotech Co., Ltd. (seal) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Tasgen Biotech Co., Ltd. (seal) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Representative: (signature)
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December 10th, 2018 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Annex 4 Notice of Change of Applicant/Patentee (Copy of Original) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g38965new25.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Annex 4 Notice of Change of Applicant/Patentee (Translation Document) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="5" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Hanol International Patent
Office</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6/F, 163 Liangduichuan Road,<BR>Jiangnan District,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Seoul (Zip code: 06302)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TEL <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">82-2-942-1100</FONT></FONT></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FAX: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">82-2-942-2601</FONT></FONT></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:hanolip@hanollawip.com</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December&nbsp;31, 2015 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn:
Genexine Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cc: Manager ByungKyu Kim </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From: Hanol International Patent Office </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Title: Acceptance Report of Notice of End of Transfer Registration of Chinese Patent Application</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The management number of our Office: <FONT STYLE="white-space:nowrap">OPA14504-CN</FONT> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Country</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CN</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Right</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Patent</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Application Number</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">201410851771.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Filing date</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">December&nbsp;31, 2014</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Applicant</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5">Genexine Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">GLP-1</FONT><FONT STYLE="font-family:pmingliu; font-size:9pt">
&#21644;&#20813;&#30123;&#29699;&#34507;&#30333;&#26434;&#21512;</FONT> Fc<FONT STYLE="font-family:pmingliu; font-size:9pt"> &#21512;&#22810;&#38043;&#21450;&#20854;&#29992;&#36884;</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Fusion Polypeptide Comprising <FONT STYLE="white-space:nowrap">GLP-1</FONT> and Immunoglobulin Hybrid Fc and use thereof</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Inventor</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5">Cheng Yongzhe / Yang Shihuan / Bian Meishan / Yang Shangren</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Priority Number</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Priority Date</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">International Application Number</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">International Application Date</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#151;&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I wish you all the best. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Regarding the above case, the transfer registration notice has been accepted, please be aware.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">And the transfer procedure has been completed and the case is no longer managed by the Office.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you have any questions about this case, please feel free to contact us. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Hanol International Patent Office</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Acting patent attorney</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g38965185.jpg" ALT="LOGO">
</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MS/TGK/hyp </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">


<IMG SRC="g38965186.jpg" ALT="LOGO">
 Annex: 1. Notice of completion of transfer registration, 1 case completed. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note. If the Applicant&#146;s address or name has been
changed, please contact our office so as to avoid the disadvantageous loss caused by the failure to receive documents in future disputes and other situations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>


<IMG SRC="g38965187a.jpg" ALT="LOGO">
State Intellectual Property Office of the People&#146;s Republic of China</B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>100055</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>JEEKAI&nbsp;&amp; PARTNERS, Floor 15A, Building No.&nbsp;5, 9</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Guang&#146;an Road, Fengtai District, Beijing</B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Zhao Rongmin (63509806)&nbsp;Lu
Huizhong(63509806)</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g38965187.jpg" ALT="LOGO">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<IMG SRC="g389651872.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Date of issue:</B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>February 26th,
2018</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Application Number or Patent Number:
201410851771.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Serial No. of Issuance: 2018022200634430</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Applicant of Patentee: <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Tianjin) Co., Ltd.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Name of Invention-creation: Fusion
Polypeptide Comprising <FONT STYLE="white-space:nowrap">GLP-1</FONT> and Immunoglobulin Hybrid Fc and use thereof</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice of Qualification of Procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As for the above-mentioned patent application or patent, the applicant or the patentee filed a request for the change of the descriptive entry
on February&nbsp;22, 2018. After reviewing, the request conforms to the relevant provisions of the Patent Law and its Implementation Rules. The contents of the change are hereby notified as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Items Changed: Applicant </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before Modification: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Applicant 1 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Whether the
applicant represents: Yes </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Applicant&#146; Name: <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biotech (Tianjin) Co., Ltd. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Country of Applicant: China </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Applicant&#146;s Postal Code: 300400 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Applicant&#146; Address: Industrial Park of Tianjin Medicine and Medical Equipment, Chenchen Building, Beichen District, Tianjin </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Type of Applicant: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Province
in which the applicant is located: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After Modification: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Applicant 1 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Whether the
applicant represents: Yes </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Applicant&#146; Name: <FONT STYLE="white-space:nowrap">I-Mab</FONT>
<FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Country of Applicant: China </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Applicant&#146;s Postal Code: 300400 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Applicant&#146; Address: Industrial Park of Tianjin Medicine and Medical Equipment, Chenchen
Building, Beichen District, Tianjin </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Type of Applicant: Industrial and Mining Enterprises </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Province in which the applicant is located: Tianjin City </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200028 &nbsp;&nbsp;&nbsp;&nbsp;For paper application:
In reply, please send to: The Patent Office of the State Intellectual Property Office, No.&nbsp;6 Xitucheng Road, Jimen Bridge, Haidian District, Beijing, 100088 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2016.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For electronic application: Relevant documents shall be submitted in the form of electronic documents through
the electronic patent application system. Unless otherwise specified, documents submitted in paper or other forms are considered unsubmitted. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Annex 5 Technology Transfer, Current Technical Indicators </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Descriptions to the technology transfer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Include but
are not limited to the following content: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1) Cell banks, including RCB (PCB), MCB, WCB; the specific quantity can meet the needs of supporting process
transfer, clinical sample production and commercial production. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: Cell bank identification should be completed in accordance with the Pharmacopoeia
and related guidelines </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2) Measurement of MCB, WCB of living cells; the specific quantity can meet the needs of supporting process transfer, clinical
sample production and commercial production. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3) Physicochemical and active reference substances, 1000 tubes; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4) All pharmacological research data, including production processes of raw materials, stock solution, formulation and process, quality standards, testing
methods and methodology validation, stability, packaging materials, etc. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5) All clinical application data </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Acceptance Criteria for Technology Transfer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1) The
study complies with the Drug Registration Regulations and the CFDA&#146;s current relevant registration review regulations and technical guidelines. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2)
The transfered processes are consistent with those in the application data, with strong operability, stable process, suitable for industrial production, in line with GMP and relevant production regulations and requirements, raw materials and
packaging materials have legal sources. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3) The CSPC Group completed the phase I clinical sample production in WuXi AppTec.
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma has coordinated with the CSPC Group to carry out process optimization, production and transfer in and from WuXi AppTec. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4) Requirements of process parameters: According to the results of the first four batches produced in WuXi AppTec, the range of expression is from 1.6 to 2.0 g
/ L and if the process parameters and production control of WuXi AppTec meet the requirements, the expected expression level should be within this range; The total purified yield should be within the purified yield of the first four batches produced
in WuXi AppTec. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5) It is confirmed that the quality of process transfer product conforms to the quality standards of clinical registration, as shown in
Table 1 and Table 2 below. And the comparability study of different origin samples needs to meet the requirements of drug registration, including process parameters and product quality. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6) After submitting the research and development achievements to the CSPC Group, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma shall provide
technical support to the personnel designated by the CSPC Group according to the process of technology transfer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. The time and plan of technology
transfer are specifically agreed upon by both parties. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma is responsible for the authenticity,
completeness, consistency and traceability of the corresponding application materials, and shall cooperate to complete <FONT STYLE="white-space:nowrap">on-site</FONT> inspection as needed. As for the requirements for supplements (written or <FONT
STYLE="white-space:nowrap">non-written</FONT> supplements) made by CDE for the pharmacological research part of the registration application materials during the review process, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma shall assist
the CSPC Group to reply to the review opinions in a timely manner and to revise and supplement the registration application materials. The two parties shall sign a supplementary agreement on the requirements for data supplement arising from major
changes in registration regulations after the submission of registration application materials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Table 1. Release Quality standards for TG103 Stock Solution </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Assay Method</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Quality Standard</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"><B>Identification and Consistency</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Immunoblotting (Western Blot)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti <FONT STYLE="white-space:nowrap">GLP-1</FONT> <FONT STYLE="white-space:nowrap">(non-reductive):</FONT> The major band should be
consistent with that of the reference</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti <FONT STYLE="white-space:nowrap">GLP-1</FONT> <FONT STYLE="white-space:nowrap">(non-reductive):</FONT>
The major band should be consistent with that of the reference</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-human IgG4 <FONT STYLE="white-space:nowrap">(non-reductive):</FONT> The major
band should be consistent with that of the reference</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Anti-human IgG4 (reductive): The major band should be consistent with that of the
reference</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Isoelectric point (isoelectric focusing electrophoresis)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>The major band should be consistent with that of the reference (pI range 4.5 - 7.4)</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="3" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Electrophoresis (SDS - PAGE)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reductive: The major band should be consistent with that of the reference;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-reductive:</FONT> The major band should be consistent with that of the reference</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Peptide mapping <FONT STYLE="white-space:nowrap">(Lys-C/trypsin</FONT> digestion <FONT STYLE="white-space:nowrap">RP-UPLC</FONT> analysis)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Should be consistent with that of the reference</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Sialic acid content (FLD RP UPLC analysis)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>4.8 - 8.9 mol/mol protein</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="6"><B>Purity and Impurities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B><FONT STYLE="white-space:nowrap">SEC-HPLC</FONT> (purity determination)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B> 95.0%</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B><FONT STYLE="white-space:nowrap">RP-HPLC</FONT> (purity determination)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B> 95.0%</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NR-CE-SDS</FONT></FONT> (purity determination)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B> 90.0%</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Host cells DNA residues (Q - PCR analysis)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT><B></B><B> 4.0 pg/mg</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Host cells protein residues (ELISA)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT><B></B><B>150 ppm</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Protein A residues (ELISA)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT><B></B><B>10.0ppm</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Activity</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>In vitro biological activities</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">(GLP-1R_cAMP/luc</FONT> cell receptor binding method)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>60% - 150%</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Content</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>The protein content <FONT STYLE="white-space:nowrap">(UV-vis</FONT> spectrophotometry)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>25.0<FONT STYLE="font-family:pmingliu; font-size:9pt">~</FONT>35.0 mg/mL</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="5"><B>Other Verification</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Appearance and properties</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>(visual,
turbidity, colorimetry)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The color should not be darker than the No.&nbsp;4 yellow <FONT STYLE="white-space:nowrap">(Y-4)</FONT> standard solution;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Turbidity should be no more than 18.0 NTU</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Visible foreign bodies (lamp inspection)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>There should be no visible foreign body</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Osmotic pressure molar concentration (freezing point depression method)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>280 - 360 mOsmol/kg</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>pH value (potentiometric method)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>6.5<FONT STYLE="font-family:pmingliu; font-size:9pt">~</FONT>7.5</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Content of poloxamer 188 (RID - SEC - HPLC)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>0.06% <FONT STYLE="font-family:pmingliu; font-size:9pt">~</FONT> 0.14%</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="2" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Bacterial endotoxin (dynamic turbidimetric analysis)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT><B></B><B>2.0 EU/mg</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Microbial limit (membrane filtration)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT><B></B><B>1 cfu/ml</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Table 2. Release Quality Standards for TGI03 Finished Products </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Assay Method</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Quality Standard</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"><B>Identification and Consistency</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Isoelectric point (isoelectric focusing electrophoresis)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The major band should be consistent with that of the reference</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>(pi range 4. 5<FONT STYLE="font-family:pmingliu; font-size:9pt">~</FONT>7. 4)</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"><B>Electrophoresis (SDS - PAGE)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reductive: The major band should be consistent with that of the reference;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-reductive:</FONT> The major band should be consistent with that of the reference</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="3"><B>Purity and Impurities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B><FONT STYLE="white-space:nowrap">SEC-HPLC</FONT> purity determination</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B> 93.0%</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B><FONT STYLE="white-space:nowrap">RP-HPLC</FONT> purity determination</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B> 65.0%</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NR-CE-SDS</FONT></FONT> purity assessment</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B> 90.0%</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Activity</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>In vitro biological activities</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>(GLPlR_cAMP/luc cell receptor binding method)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>60% <FONT STYLE="font-family:pmingliu; font-size:9pt">~</FONT> 150%</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="5"><B>Content</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Protein content <FONT STYLE="white-space:nowrap">(UV-vis</FONT> spectrophotometry)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>22. 5<FONT STYLE="font-family:pmingliu; font-size:9pt">~</FONT>27. 5 mg/mL</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"><B>Appearance and properties ((visual, turbidity, colorimetry)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>The color should not be darker than the No.&nbsp;4 yellow <FONT STYLE="white-space:nowrap">(Y-4)</FONT> standard solution; Turbidity should be no more than 18.0 NTU</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Loading (weighing method)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B>1.0 mL</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"><B>Insoluble particles (laser particle counting method)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Report the number of particles </B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B> 2 &micro;m in each bottle (for reference), the
number of particles </B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B> 10 &micro;m should be no more than 6,000 per bottle.</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>the number of
particles </B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B> 25 &micro;m should be no more than 6,00 per bottle.</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Visible foreign bodies (lamp inspection)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Shall comply with the provisions</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="3"><B>Other Verification</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Osmotic pressure molar concentration (freezing point depression method)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>280 - 360 mOsmol/kg</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>pH value (potentiometric method)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>6.5 - 7.5</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Content of poloxamer 188 (R 1 D - SEC - HPLC)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>0.06% - 0.14%</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Assay Method</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Quality Standard</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="3" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Bacterial endotoxin (dynamic turbidimetric analysis)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT><B></B><B>2.0 EU/mg</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Sterilization examination (membrane filtration)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Should be in sterile growth</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Abnormal toxicity (mice, guinea pigs)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>All mice and guinea pigs should survive</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>and without abnormal reactions</B></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Annex 6: List of Intellectual Property Issues Needed to be Solved by
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma within 6 Months of Contract Signing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to further clarify the ownership of the
intellectual property rights of the TG103 project and avoid unnecessary disputes, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma, in consultation with the CSPC Group, undertakes to complete the following processing of the intellectual
property rights related to TG103 product within six months after the signing of this Agreement and to provide a written proof to the CSPC Group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma will arange Ganassini, <FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd., <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma
(Shanghai) Co., Ltd. to sign a quadripartite agreement with the CSPC Group on the following matters: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1). Ganassini will irrevocably grant
the HyFc platform technology involved in the ZL201310553839.3 invention patent to the CSPC Group exclusive licensing (including <FONT STYLE="white-space:nowrap">sub-licensing)</FONT> for the free implementation in the territory of China of the TG103
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(GLP-1-hyFc)</FONT></FONT> project, and perform the relevant filing procedures as appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2). If the 201510684679.5 invention patent application is granted a Chinese patent, and the TG103 (GLP
<FONT STYLE="white-space:nowrap">-1</FONT> - hyFc) project falls into its scope of protection, Ganassini will grant the CSPC Group exclusive licensing (including <FONT STYLE="white-space:nowrap">sub-licensing)</FONT> for the free implementation in
the territory of China of the TG103 project <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(GLP-1-hyFc),</FONT></FONT> and perform the relevant filing procedures as appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3). Ganassini will irrevocably grant the portion of GLP <FONT STYLE="white-space:nowrap">-1</FONT> patent rights involved in the
201580071643.8 invention patent (if <FONT STYLE="white-space:nowrap">GLP-1</FONT> related portion is authorized) to the CSPC Group the exclusive licensing (including <FONT STYLE="white-space:nowrap">sub-licensing)</FONT> for the free implementation
in the territory of China, and perform the relevant filing procedures as appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4). If there occurs the same scope of protection of
TG103 project-related products <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(GLP-1-hyFc)</FONT></FONT> as that of the 201580071643.8 and 201410851771.1 patent applications in the application process, and only one of them can be
retained according to the Chinese Patent Law, the four parties to this Agreement shall actively negotiate the settlement plan and obtain the consent of the CSPC Group in writing before any disposal of the patent rights is made by Ganassini or <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT>
(Tianjin) Co., Ltd. is required to commit to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Shanghai) Co., Ltd. to transfer the 201410851771.1 invention patent application to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma
(Shanghai) Co., Ltd.. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Shanghai) Co., Ltd. promises to the CSPC Group that it can obtain the
corresponding patent rights and implementation licenses of the above patents in China. Otherwise, it should be regarded as a violation of the provisions of 7.3.1 by <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma, and as a result that the
CSPC Group has not obtained and enjoyed the right of free implementation, and <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma shall be liable for breach of contract in accordance with the agreements under Section&nbsp;10.6. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(End of Annexes) </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>7
<FILENAME>filename7.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.20</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.20 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CD38 PRODUCT COLLABORATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>CD38 P<SMALL>RODUCT</SMALL></B><SMALL></SMALL> <B>C<SMALL>OLLABORATION</SMALL> A<SMALL>GREEMENT</SMALL> </B>(the
<B>&#147;Agreement&#148;</B>) is entered into on January 22, 2018 (the <B>&#147;Effective Date&#148;</B>) between <B><FONT STYLE="white-space:nowrap">I-Mab</FONT></B>, a company organized and existing under the laws of Cayman Islands and having its
registered address at P. O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, <FONT STYLE="white-space:nowrap">KY1-1205</FONT> Cayman Islands (<B><FONT STYLE="white-space:nowrap">&#147;I-Mab&#148;</FONT></B>), and
<B>E<SMALL>VEREST</SMALL> M<SMALL>EDICINES</SMALL> L<SMALL>IMITED</SMALL>,</B> a company organized and existing under the laws of Cayman Islands and having its registered address at 4th Floor, Harbour Place, 103 South Church Street, P.O. Box 10240,
Grand Cayman <FONT STYLE="white-space:nowrap">KY1-1002,</FONT> Cayman Islands (<B>&#147;Everest&#148;</B>). Everest and <FONT STYLE="white-space:nowrap">I-Mab</FONT> are sometimes referred to herein individually as a <B>&#147;Party&#148; </B>and
collectively as the <B>&#147;Parties.&#148; </B> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, <FONT STYLE="white-space:nowrap">I-Mab</FONT> is a biopharmaceutical company engaged in the
research, development and commercialization of pharmaceutical products; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> has entered into a License and Collaboration Agreement with MorphoSys AG (<B>MorphoSys</B>), dated November&nbsp;30, 2017 (the &#147;<B>MorphoSys License</B>&#148;), pursuant to which it has obtained a license
from MorphoSys to develop and commercialize MorphoSys&#146; proprietary CD38 antibody in the greater China region; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, Everest wishes to share the cost for the development of such product, and <FONT
STYLE="white-space:nowrap">I-Mab</FONT> is willing to share the economic interest in such product with Everest, all on the terms and conditions set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>N<SMALL>OW</SMALL> T<SMALL>HEREFORE</SMALL></B><SMALL></SMALL>, in consideration of the foregoing premises and the mutual promises,
covenants and conditions contained in this Agreement, the Parties agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in
this Agreement, the following initially capitalized terms, whether used in the singular or plural form, shall have the meanings set forth in this Article 1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Affiliate</B>&#148; means, with respect to a Party, any corporation, firm, partnership or other
entity, which directly or indirectly controls or is controlled by or is under common control with such Party. For the purpose of this definition, &#147;control&#148; (including, with correlative meaning, the terms &#147;controlled by&#148; and
&#147;under the common control&#148;) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such entity, whether by the ownership of more than
fifty percent (50%) of the voting stocking of such entity, by contract or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>CD38
Compound</B>&#148; means MorphoSys&#146; anti-CD38 Antibody designated as MOR03087 or MOR202, as further described in <B>Exhibit A </B>and<B> </B>any fragment (including antigen binding domain or sequence or portion), conjugate, variant,
improvement, modification, progeny or derivative thereof (including CD38 Compound conjugated, bound, expressed as fusion or otherwise fused to a toxin, label, Antibody, cell or any other moiety or entity). </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.3</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>CD38 Product</B>&#148; means any pharmaceutical
(including diagnostic) product which constitutes, incorporates, comprises or contains a CD38 Compound, alone or in combination with one or more other active ingredients in any and all forms, presentations, in current and future formulations, dosage
forms and strengths, and delivery modes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.4</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Commercially Reasonable Efforts</B>&#148; means those
efforts consistent with the exercise of prudent scientific and business judgment in an active and ongoing program as applied by a Party to the development and commercialization of its own products at a similar stage of development and with similar
market potential. Commercially Reasonable Efforts requires that a Party, at a minimum, assign responsibility for such obligations to qualified employees, set annual goals and objectives for carrying out such obligations, and allocate resources
designed to meet such goals and objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.5</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Commercialization</B>&#148; (with a correlative
meaning for &#147;<B>Commercialize</B>&#148;) means all activities directed to marketing, promoting, distributing, detailing or selling the CD38 Product (as well as commercial manufacturing, importing and exporting activities in connection
therewith) in the Field in the Territory, including <FONT STYLE="white-space:nowrap">pre-launch</FONT> activities and Phase 4 Clinical Trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.6</B>&nbsp;&nbsp;&nbsp;&nbsp; &#147;<B>Commercialization Cost</B>&#148; means all costs incurred by or on behalf of the Commercialization
Party and its Affiliates that are reasonably allocable to the Commercialization of CD38 Product in the Field in the Territory, including Distribution Costs, Sales and Marketing Costs, Manufacturing Costs for CD38 Product for commercial sale, costs
for Phase 4 Clinical Trials, and the associated taxes. Commercialization Costs shall include the Commercialization Party and its Affiliates&#146; internal costs related to the Commercialization efforts, which shall be itemized and subject to the
other Party&#146;s annual audit in accordance with Section&nbsp;4.8. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.7</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Commercialization
Party</B>&#148; means the Party responsible for the Commercialization of the CD38 Product in the Field in the Territory, as determined by the JSC pursuant to Section&nbsp;2.1(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.8</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Confidential Information</B>&#148; of a Party means all
<FONT STYLE="white-space:nowrap">know-how,</FONT> data and other information of a financial, commercial, business, operational or technical nature of such Party that is: (a)&nbsp;disclosed by or on behalf of such Party or any of its Affiliates or
otherwise made available to the other Party or any of its Affiliates, whether made available orally, in writing or in electronic form; or (b)&nbsp;learned by the other Party pursuant to this Agreement. The terms and conditions of this Agreement are
the Confidential Information of both Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.9</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Development</B>&#148; (with a correlative
meaning for &#147;<B>Develop</B>&#148;) means all development activities necessary or useful to obtain or maintain Regulatory Approval for the CD38 Product in the Field in the Territory, including all
<FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and clinical trials (other than Phase 4 Clinical Trials) of the CD38 Product, technology transfer, manufacture process development, manufacture and distribution of CD38 Product for use in
clinical trials (including placebos and comparators), statistical analyses, and the preparation and submission of Regulatory Materials and other regulatory activities related to the CD38 Product. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.10</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Development Costs</B>&#148; means all costs
incurred by or on behalf of <FONT STYLE="white-space:nowrap">I-Mab</FONT> or its Affiliates that are reasonably allocable to the Development of CD38 Product in the Field in the Territory, including (a)&nbsp;the costs of all preclinical studies and
clinical trials (other than Phase 4 Clinical Trials); (b) the costs of formulation development, process development and delivery system development; (c)&nbsp;the Manufacturing Costs of CD38 Product for Development use, and the costs of placebos and
comparator drugs for use in clinical trials of CD38 Product (calculated in the same manner as Manufacturing Costs are calculated for CD38 Product); (d) the cost of regulatory activities to obtain and maintain Regulatory Approval of CD38 Product,
including the preparation and submission of all Regulatory Materials for the CD38 Product; (e)&nbsp;the costs in connection with the licensing of any intellectual property rights of any Third Party. Development Costs shall include <FONT
STYLE="white-space:nowrap">I-Mab</FONT> and its Affiliates&#146; internal costs related to the Development efforts, which shall be itemized and subject to annual audit by Everest in accordance with Section&nbsp;4.8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.11</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Distribution Costs</B>&#148; means all costs incurred by or on behalf of Commercialization Party
or its Affiliate that are allocable to the commercial distribution of CD38 Product in the Field in the Territory, including: (a)&nbsp;handling and transportation to fulfill orders with respect to such distribution; (b)&nbsp;customer services,
including order entry, billing and adjustments, inquiry, credit and collection, and product recall; (c)&nbsp;reasonable and customary fees and other amounts payable to wholesalers, specialty pharmacies and distributors with respect to such
distribution; and (d)&nbsp;costs of storage and distribution of CD38 Product for sale in the Territory, but for clarity, excluding in each case ((a) through (d)) any such amounts to the extent included as a deduction in calculating Net Sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.12</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Field</B>&#148; means CD38 Product for all indications in hematologic oncology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.13</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Laws</B>&#148; means all laws, statutes, rules, regulations, ordinances and other pronouncements
having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision, domestic or foreign. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.14</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Manufacturing Costs</B>&#148; means all costs incurred by or on behalf of <FONT
STYLE="white-space:nowrap">I-Mab</FONT> or the Commercialization Party (as applicable) and its Affiliates that are reasonably allocable to the manufacture of CD38 Product for Development or Commercialization use, which product is either supplied to <FONT
STYLE="white-space:nowrap">I-Mab,</FONT> or the Commercialization Party, or its Affiliates by a Third Party, or manufactured directly by <FONT STYLE="white-space:nowrap">I-Mab,</FONT> or the Commercialization Party, or its Affiliate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;For CD38 Product supplied to <FONT STYLE="white-space:nowrap">I-Mab,</FONT> or the Commercialization Party,
or its Affiliates by a Third Party, Manufacturing Costs means: (i)&nbsp;the amount paid by <FONT STYLE="white-space:nowrap">I-Mab,</FONT> or the Commercialization Party, and its Affiliates to the Third Party supplier (expressed in the case of
commercial units on a per unit manufactured basis) for the manufacturing and supply of such CD38 Product, plus (ii)&nbsp;any costs incurred by <FONT STYLE="white-space:nowrap">I-Mab,</FONT> or the Commercialization Party, and its Affiliates for
manufacturing site qualification, quality assurance and control, capital equipment, supply chain management and other manufacturing oversight activities. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;For CD38 Product manufactured directly by <FONT
STYLE="white-space:nowrap">I-Mab,</FONT> or the Commercialization Party, or its Affiliates, Manufacturing Costs means the actual, fully burdened labor cost of manufacturing such CD38 Product, including without limitation the costs of raw materials,
labor, and other identifiable variable costs incurred or accrued by <FONT STYLE="white-space:nowrap">I-Mab,</FONT> or the Commercialization Party, and its Affiliates in connection with the manufacture of such CD38 Product, and the proportionate
share of indirect manufacturing costs and allocable fixed costs. For clarity, the fully-burdened labor costs referenced above shall be calculated on a trailing <FONT STYLE="white-space:nowrap">12-month</FONT> average-capacity basis with the
percentage allocable to Manufacturing Costs of CD38 Product representing the number of units or runs of CD38 Product produced or performed as a percentage of the total number of units or runs, including those of other products, that have been
manufactured in such facility during the applicable time period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.15</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Net Sales</B>&#148; means
the gross amount invoiced by or on behalf of the Commercialization Party or its Affiliates (but not Third Party sublicensees) for sales of a CD38 Product to any Third Party in an arm&#146;s length transaction during the Term, less the following
deductions specifically related to the CD38 Product for: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;customary trade, cash or quantity discounts or
rebates paid or to be paid or granted, to the extent not already reflected in the amount invoiced; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;taxes (including, VAT, excise, consumption, sales and similar taxes and customs duties) to the extent
incurred or to be incurred, paid or to be paid or collected or to be collected and remitted or to be remitted to the relevant tax authority (but specifically excluding, for clarity, any income taxes assessed against the income arising from such
sale); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;amounts paid or to be paid or granted or to be granted on rejections, outdating, recalls or
returns and the actual amount of any write-offs for bad debt (provided that any amount subsequently recovered will be as added back as Net Sales); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;compulsory payments and rebates related to the sale of the CD38 Product paid to a governmental authority
pursuant to governmental regulations by reason of any national or local health insurance program or similar program; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;freight expense and insurance, to the extent it is not charged to or reimbursed by the customer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For clarity, the amount of any discounts, rebates or allowances granted or taken with respect to the total sales to a Third Party for multiple products of the
Commercialization Party or its Affiliates shall only be deducted in a pro rata basis in calculating Net Sales (i.e. only that part of the discount, rebate or allowance amount shall be deducted that relates to sales made with CD38 Products). Any of
the items set forth above that would otherwise be deducted from the invoice price in the calculation of Net Sales but which are separately charged to, and paid by, Third Parties shall not be deducted from the invoice price in the calculation of Net
Sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, amounts billed by the Commercialization Party or its Affiliates for the sale of a CD38 Product among the
Commercialization Party and its Affiliates shall not be included in the computation of Net Sales hereunder. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.16</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><FONT STYLE="white-space:nowrap">Out-license</FONT> Income</B>&#148; means all license payments,
including applicable upfront payment, license maintenance payments, milestone payments, royalty payments, shares, and equity interests, whether in cash or in kind, received by <FONT STYLE="white-space:nowrap">I-Mab</FONT> or its Affiliates from a
Third Party sublicense based on the grant of a sublicense to such Third Party under the MorphoSys License to Develop and Commercialize the CD38 Product in the Field in the Territory, which, for the purpose of clarification, shall not include:
(a)&nbsp;payments to fund bona fide research and development work; (b)&nbsp;payments for the supply of goods and services at cost, including the supply of the CD38 Product; (c)&nbsp;reimbursement of costs and expenses, including for patent
prosecution and enforcement; (d)&nbsp;bona fide loans; (e)&nbsp;payments to purchase <FONT STYLE="white-space:nowrap">I-Mab</FONT> or its Affiliates&#146; equity at fair market value (for clarity, any premium paid by sublicensee in excess of the
fair market value of the equity purchased shall be included in <FONT STYLE="white-space:nowrap">Out-License</FONT> Income and Everest shall have the right to engage a Third Party appraiser to determine such fair market value). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.17</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Phase 4 Clinical Trial</B>&#148; means a clinical trial of the CD38 Product that is initiated
after Regulatory Approval has been obtained and is principally intended to support the Commercialization of the CD38 Product and not to support or maintain Regulatory Approval or otherwise obtain any labelling change approval from Regulatory
Authority. Phase 4 Clinical Trial shall not include any studies that are required by a Regulatory Authority as a condition to receiving Regulatory Approval for the CD38 Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.18</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Product Profit/Loss</B>&#148; means, for a given period of time, (a)&nbsp;the Net Sales of CD38
Product sold by the Commercialization Party and its Affiliates in the Field in the Territory during such time period, less (b)&nbsp;the Commercialization Costs incurred by the Commercialization Party and its Affiliates for the CD38 Product during
such time period. For clarity, Product Profit/Loss shall be determined prior to application of any income taxes, and if such terms are used individually, &#147;<B>Product Profit</B>&#148; means a positive Product Profit/Loss, and &#147;<B>Product
Loss</B>&#148; means a negative Product Profit/Loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.19</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;Regulatory Approval&#148;</B> means all
approvals, including pricing approvals, that are necessary for the commercial sale of CD38 Product in a given country or regulatory jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.20</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Regulatory Authority</B>&#148;<B> </B>means any applicable government authority responsible for
granting Regulatory Approvals for medical and/or pharmaceutical products in a particular country or jurisdiction, including the China&nbsp;Food&nbsp;and&nbsp;Drug&nbsp;Administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.21</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Regulatory Materials</B>&#148; means any regulatory application, submission, notification,
communication, correspondence, registration, approval and other filings made to, received from or otherwise conducted with a Regulatory Authority in order to Develop, manufacture, market, sell or otherwise Commercialize the CD38 Product in a
particular country or jurisdiction, including the Regulatory Approval.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.22</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Sales and
Marketing Costs</B>&#148;<B> </B>means all costs incurred by or on behalf of the Commercialization Party and its Affiliates that are reasonably allocable to the sales and marketing of CD38 Product in the Field in the Territory, including the costs
of: (a)&nbsp;activities directed to the advertising and marketing of CD38 Product, including sales call and detailing; (b)&nbsp;medical affairs and professional education for CD38 Product in the Territory, including launch meetings and continue
medical education; (c)&nbsp;costs of advertising and public relations with respect to CD38 Product in the Territory; (d)&nbsp;promotional speaker programs with respect to CD38 Product in the Territory, including the training of such speakers;
(e)&nbsp;developing, obtaining and providing training with respect to CD38 Product in the Territory, as well as training packages, promotional literature, promotional materials and other selling materials with respect to CD38 Product in the
Territory; (f)&nbsp;developing and performing market research with respect to CD38 Product in the Territory and developing branding and communications plans; (g)&nbsp;conducting promotional symposia with respect to CD38 Product in the Territory;
(h)&nbsp;developing reimbursement programs with respect to CD38 Product in the Territory; and (i)&nbsp;developing information for national accounts, managed care organizations and group purchasing organizations with respect to CD38 Product in the
Territory. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.23</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Shared Product Damages</B>&#148; means damages
or other amounts payable by either Party or its Affiliates to any Third Party claimant, as well as any reasonable attorneys&#146; fees and costs of litigation incurred by either Party or its Affiliates, resulting from Third Party claims that arise
from or are based on the Development, manufacture and/or Commercialization of the CD38 Product in the Field in the Territory, including product liability claims; provided however that &#147;Shared Product Damages&#148; shall exclude any and all
damages and other amounts (including attorneys&#146; fees) for which a Party has an obligation to indemnify the other Party pursuant to Section&nbsp;6.1 or 6.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.24</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Territory</B>&#148; means the territory of the People&#146;s Republic of China (including Macao
and Hong Kong) and Taiwan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.25</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Third Party</B>&#148; means any person or entity other than
Everest or <FONT STYLE="white-space:nowrap">I-Mab</FONT> or an Affiliate of either Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.26</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Interpretations.</B> In this Agreement, unless otherwise specified: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;includes&#148; and &#147;including&#148; shall mean respectively includes and including without
limitation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;words denoting the singular shall include the plural and vice versa and words denoting any
gender shall include all genders; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;words such as &#147;herein&#148;, &#147;hereof&#148;, and
&#147;hereunder&#148; refer to this Agreement as a whole and not merely to the particular provision in which such words appear; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;the Exhibits and other attachments form part of the operative provision of this Agreement and references to
this Agreement shall include references to the Exhibits and attachments. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GOVERNANCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Joint Steering Committee.</B> The Parties shall establish a joint steering committee (the &#147;<B>Joint
Steering Committee</B>&#148; or the &#147;<B>JSC</B>&#148;) to oversee the Development and Commercialization of the CD38 Product in the Field in the Territory. The JSC shall in particular: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;provide a forum for and facilitate communications between the Parties with respect to the Development and
Commercialization of the CD38 Product in the Field in the Territory; </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;discuss and approve amendments to the Development Plan,
including Development Budget; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;evaluate the implementation of the Development Plan, including
recommending necessary actions to remedy or correct any issues in the implementation of the Development Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;discuss and approve <FONT STYLE="white-space:nowrap">out-license</FONT> of the CD38 Product; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;discuss and approve the Commercialization Party, the Commercialization Plan and amendments thereto,
including Commercialization Budget; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp;evaluate the implementation of the Commercialization Plan,
including recommending necessary actions to remedy or correct any issues in the implementation of the Commercialization Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>&nbsp;&nbsp;&nbsp;&nbsp;establish joint subcommittees as it deems necessary or advisable to further the Development and
Commercialization of the CD38 Product in the Field in the Territory; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h)</B>&nbsp;&nbsp;&nbsp;&nbsp;monitor and oversee <FONT
STYLE="white-space:nowrap">I-Mab&#146;s</FONT> activities under the MorphoSys License; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;perform such
other functions as appropriate to further the purposes of this Agreement, as expressly set forth in this Agreement or allocated to it by the Parties in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Limitations of JSC Authority</B>. The JSC shall only have the powers expressly assigned to in this
Article 2 and elsewhere in this Agreement and shall not have the authority to: (a)&nbsp;modify or amend the terms and conditions of this Agreement; (b)&nbsp;waive or determine either Party&#146;s compliance with the terms and conditions of under
this Agreement; or (c)&nbsp;decide any such issue in a manner that would conflict with the express terms and conditions of this Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3&nbsp;&nbsp;&nbsp;&nbsp;JSC Membership and Meetings. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>JSC Members.</B> The JSC shall consist of four (4)&nbsp;members, with two (2)&nbsp;appointed by <FONT
STYLE="white-space:nowrap">I-Mab</FONT> and two (2)&nbsp;appointed by Everest. Within thirty (30)&nbsp;days following the Effective Date, each Party shall designate its initial members to serve on the JSC. Each Party may replace its representatives
on the JSC on written notice to the other Party. Each Party shall appoint one (1)&nbsp;of its representatives on the JSC to act as a <FONT STYLE="white-space:nowrap">co-chairperson</FONT> of the JSC. The
<FONT STYLE="white-space:nowrap">co-chairpersons</FONT> shall jointly prepare and circulate agendas and reasonably detailed minutes for each JSC meeting. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Meetings</B>. The JSC shall hold meetings at such times
as it elects to do so, but in no event shall such meetings be held less frequently than once every quarter. Meetings of the JSC may be held in person, by audio or video teleconference; provided that at least one (1)&nbsp;meeting per year of the JSC
shall be held in person. <FONT STYLE="white-space:nowrap">In-person</FONT> JSC meetings shall be held at locations selected alternatively by the Parties. Each Party shall be responsible for all of its own expenses of participating in the JSC. No
action taken at any meeting of the JSC shall be effective unless representatives of both Parties are participating. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><FONT STYLE="white-space:nowrap">Non-Member</FONT> Attendance</B>. Each Party may from time to time
invite a reasonable number of participants, in addition to its representatives, to attend the JSC meetings in a <FONT STYLE="white-space:nowrap">non-voting</FONT> capacity; provided that such participants shall be bound by confidentiality and <FONT
STYLE="white-space:nowrap">non-use</FONT> obligations consistent with the terms of this Agreement and that each Party shall provide prior written notice to the other Party if it has invited any Third Party (including any consultant) to attend such a
meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Everest Observer</B>. <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall make reasonable
efforts to discuss with Morphosys to appoint an observer designated by Everest to JDC between MorphoSys and <FONT STYLE="white-space:nowrap">I-MAB</FONT> and this observer designated by Everest shall have full access to information from <FONT
STYLE="white-space:nowrap">I-Mab</FONT> from time to time. <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall make reasonable efforts to enable this observer to have full access to information from Morphosys from time to time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.4&nbsp;&nbsp;&nbsp;&nbsp;Decision-Making. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;All decisions of the JSC shall be made by unanimous vote, with each Party&#146;s representatives collectively
having one (1)&nbsp;vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B><FONT STYLE="white-space:nowrap">&nbsp;&nbsp;&nbsp;&nbsp;I-Mab</FONT> shall have final
decision-making authority on matters related to the Development of the CD38 Product; provided however that <FONT STYLE="white-space:nowrap">I-Mab</FONT> exercises its final decision making authority to increase the Development Budget for Development
work within the Field as specified in the initial Development Plan (attached hereto as Exhibit B) or to add new clinical trials not set forth in the initial Development Plan, Everest shall have the right to
<FONT STYLE="white-space:nowrap">opt-out</FONT> Development Cost sharing for such new work or clinical trials by written notice to <FONT STYLE="white-space:nowrap">I-Mab</FONT> within thirty (30)&nbsp;days after the receipt of <FONT
STYLE="white-space:nowrap">I-Mab&#146;s</FONT> final decision. If Everest elects to <FONT STYLE="white-space:nowrap">opt-out</FONT> such new work or clinical trials, then <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall be responsible for paying
one hundred percent (100%) of the Development Cost for such new clinical trials, and the Product Profit/Loss Sharing shall be adjusted in accordance with Section&nbsp;4.4(a). <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall not terminate the
Development or sell its economic interest concerning the Development of CD38 Product without Everest&#146;s prior written consent, which should not be unreasonably withheld. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;For matters related to the Commercialization of the CD38 Product,
<FONT STYLE="white-space:nowrap">I-Mab</FONT> and Everest shall jointly make commercially reasonable decisions. If JSC cannot reach unanimous decision on matters related to the Commercialization of the CD38 Product, then Everest shall have the final
decision-making authority on such matters. Notwithstanding the foregoing, if one Party or any of its Affiliates and/or its related parties is engaged to be a Commercialization Party under this Agreement, then the other Party that is not the
Commercialization Party shall have a veto right relating to related party or connected party transactions related to the Commercialization of the CD38 Product. For clarity, Phase 4 Clinical Trials are Commercialization activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B><FONT STYLE="white-space:nowrap">&nbsp;&nbsp;&nbsp;&nbsp;I-Mab</FONT> shall have <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> operational control over the Development of the CD38 Product and the Commercialization Party shall have <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT>
operational control over the Commercialization of the CD38 Product, provided that such Party conducts such activities in accordance with the terms and conditions of this Agreement. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEVELOPMENT AND COMMERCIALIZATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Overview</B>. Subject to the terms and conditions of this Agreement,
<FONT STYLE="white-space:nowrap">I-Mab</FONT> shall be responsible for, either by itself or through its Affiliates, contractors and sublicensees, and shall use Commercially Reasonable Efforts to carry out, the Development, manufacture and
Commercialization (if <FONT STYLE="white-space:nowrap">I-Mab</FONT> or its Affiliate is designated the Commercialization Party) of the CD38 Product in the Field in the Territory. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2&nbsp;&nbsp;&nbsp;&nbsp;Development. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Development Plan. </B>The Development of the CD38 Product under this Agreement shall be conducted pursuant
to a development plan to be implemented by or on behalf of <FONT STYLE="white-space:nowrap">I-Mab</FONT> or its Affiliates or sublicensees to obtain Regulatory Approval of the CD38 Product in the Field in the Territory (the &#147;Development
Plan&#148;). The Development Plan shall be consistent with <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> obligation under the MorphoSys License with respect to the Development of the CD38 Product. The Development Plan shall also include a
detailed budget (the &#147;Development Budget&#148;) for such Development activities. As of the Effective Date, the Parties have agreed on the initial Development Plan, attached hereto as Exhibit B. From time to time,
<FONT STYLE="white-space:nowrap">I-Mab</FONT> shall prepare amendments and updates to the then-current Development Plan and Development Budget and submit such amendments and updates to the JSC for review and approval. Once approved by the JSC, such
revised Development Plan and Development Budget shall replace or supplement, as appropriate, the prior Development Plan and Development Budget. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Development Reports. </B><FONT STYLE="white-space:nowrap">I-Mab</FONT> shall keep Everest reasonably
informed as to the progress and results of its and its Affiliates&#146; and sublicensees&#146; Development of the CD38 Product under this Agreement. Before each regularly scheduled JSC meeting, <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall
provide the JSC with a written report summarizing the Development activities performed since last JSC meeting and the results thereof, and comparing such activities with the Development Plan for such time period. The JSC shall discuss the progress
and results of the Development of the CD38 Product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3&nbsp;&nbsp;&nbsp;&nbsp;Regulatory. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Regulatory Responsibilities</B>. The Development Plan shall set forth the regulatory strategy for seeking
Regulatory Approval of the CD38 Product in the Field in the Territory. <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall be responsible for the preparation and submission of all Regulatory Materials necessary to obtain and maintain Regulatory
Approval of the CD38 Product in the Field in the Territory in accordance with regulatory strategy set forth in the Development Plan. The Development Budget shall include the costs associated with the communications and interactions with Regulatory
Authorities in the Territory regarding the CD38 Product. <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall own all such Regulatory Materials, including Regulatory Approval of the CD38 Product, and at the request of Everest, shall provide Everest
with copies of all major submissions and material communications with Regulatory Authorities in the Territory regarding the CD38 Product promptly after submission or receipt. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Remedial Actions</B>. Each Party shall notify the other
Party immediately if it obtains information indicating that any CD38 Product may be subject to any recall, corrective action or other regulatory action with respect to any CD38 Product taken by virtue of applicable Laws (a &#147;<B>Remedial
Action</B>&#148;). JSC shall have the right to decide whether to take any Remedial Action and to control and coordinate all efforts necessary to conduct such Remedial Action. <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall make final decision
relating to Remedial Action arises from the Development of the CD38 Product while the Commercialization Party shall make final decision relating to Remedial Action arises from the Commercialization of the CD38 Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Manufacture.</B> <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall, either by itself or through its
Affiliates, sublicensees or Third Party contractor, manufacture and supply all of <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> and its Affiliates&#146; and sublicensees&#146; requirements for CD38 Product for Development use in the Field in
the Territory. The Commercialization Party shall, either by itself or through its Affiliates, sublicensees or Third Party contractor, manufacture and supply all of Commercialization Party&#146;s and its Affiliates&#146; and sublicensees&#146;
requirements for CD38 Product for Commercialization use in the Field in the Territory. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.5&nbsp;&nbsp;&nbsp;&nbsp;Commercialization.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Commercialization Party.</B> The Commercialization Party shall be responsible for the
Commercialization of the CD38 Product in the Field in the Territory. No later than twenty-four (24)&nbsp;months prior to the anticipated date of first Regulatory Approval of the CD38 Product, the JSC shall discuss and select which Party to be the
Commercialization Party. In the event that the JSC selects Everest as the Commercialization Party, <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall grant an exclusive and royalty-free license to Everest under relevant <FONT
STYLE="white-space:nowrap">know-how,</FONT> patent and other intellectual property rights owned or controlled by <FONT STYLE="white-space:nowrap">I-Mab</FONT> that are necessary for the Commercialization of the CD38 Product in the Field in the
Territory and the Parties shall enter into a formal license agreement to document such licensing arrangement, form and substance of which shall be reasonably satisfactory to Everest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Commercialization Plan.</B> The Commercialization of the CD38 Product under this Agreement shall be
conducted pursuant to a written Commercialization plan (the &#147;<B>Commercialization Plan</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp; <B>Commercialization Reports.</B> The Commercialization Party shall keep the JSC reasonably informed as to
the progress and results of its and its Affiliates&#146; and sublicensees&#146; Commercialization of the CD38 Product under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Everest</B><B>&#146;</B><B>s Right of First Negotiation.</B> During the Term, if <FONT
STYLE="white-space:nowrap">I-Mab</FONT> desires to develop any CD38 Product outside the Field in the Territory (a &#147;<B>ROFN </B><B>Transaction</B>&#148;), <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall first provide written notice to
Everest of its intent to conduct any ROFN Transaction, and upon Everest&#146;s receipt of such written notice and at Everest&#146;s election, Everest shall have the right to discuss and negotiate in good faith for Everest to participate in such ROFN
Transaction on terms and conditions to be agreed upon by the Parties in writing (the &#147;<B>Everest ROFN</B>&#148;). To the extent that Everest provides written notice to <FONT STYLE="white-space:nowrap">I-Mab</FONT> of its intent to exercise the
Everest ROFN (the &#147;<B>Everest ROFN Notice</B>&#148;) within thirty (30)&nbsp;Business Days following receipt of the initial written notice from <FONT STYLE="white-space:nowrap">I-Mab</FONT> (the &#147;<B>Everest ROFN Notice Period</B>&#148;),
the Parties shall commence discussion and negotiation in good faith of terms and conditions for Everest&#146;s participation in the ROFN Transactions and during this period, <FONT STYLE="white-space:nowrap">I-Mab</FONT> agrees not to engage in any
discussions or to enter into any agreement to conduct the ROFN Transactions with any Third Party. To the extent that (a)&nbsp;Everest does not provide the Everest ROFN Notice to <FONT STYLE="white-space:nowrap">I-Mab</FONT> within the Everest ROFN
Notice Period or (b)&nbsp;the Parties are unable to reach agreement on terms and conditions for Everest&#146;s participation in the ROFN Transactions within thirty (30)&nbsp;Business Days following
<FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> receipt of the Everest ROFN Notice, <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall have no further obligation to Everest under this Section&nbsp;3.6. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that <FONT STYLE="white-space:nowrap">I-Mab</FONT> wishes to sell or transfer
or undergo any transaction with any Third Party related to CD38 Product in the Field in the Territory, <FONT STYLE="white-space:nowrap">I-Mab</FONT> will discuss and consult with Everest on such transaction and
<FONT STYLE="white-space:nowrap">I-Mab</FONT> will not enter into any legally binding agreement concerning such transaction without first obtaining Everest&#146;s written consents, which should not be unreasonably withheld. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL
PROVISIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Development Cost Sharing. </B>Except as otherwise provided in this Agreement<B>,
</B>the Parties shall share the Development Costs incurred by or on account of <FONT STYLE="white-space:nowrap">I-Mab</FONT> to Develop the CD38 Product in the Field in the Territory (25% <FONT STYLE="white-space:nowrap">I-Mab:</FONT> 75% Everest)
as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;For each calendar quarter in which <FONT STYLE="white-space:nowrap">I-Mab</FONT> is
anticipated to conduct any Development activities under the Development Plan, <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall submit to Everest an invoice setting forth the estimated Development Costs based on the then-current Development Budget
for such calendar quarter, no later than thirty (30)&nbsp;days before the first day of such calendar quarter. Everest shall pay Everest&#146;s share (i.e., 75%) of the estimated Development Costs set forth in the invoice before the first day of such
calendar quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Within thirty (30)&nbsp;days after the end of each calendar quarter in which <FONT
STYLE="white-space:nowrap">I-Mab</FONT> has conducted Development activities under the Development Plan, <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall submit to Everest a reasonably detailed reconciliation report setting forth the actual
Development Costs incurred by or on account of <FONT STYLE="white-space:nowrap">I-Mab</FONT> to Develop the CD38 Product in such calendar quarter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;If the actual Development Costs for such calendar quarter is more than the amount of estimated Development
Costs amount set forth in the invoice, then within thirty (30)&nbsp;days after the receipt of such reconciliation report, Everest shall pay to <FONT STYLE="white-space:nowrap">I-Mab</FONT> (i)&nbsp;seventy-five percent (75%) of the portion of the
actual Development Costs that are in excess of the invoice amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;If the actual Development Costs for
such calendar quarter is less than the amount of estimated Development Costs amount set forth in the invoice, then Everest&#146;s prepayment in excess of Everest&#146;s share (i.e.,75%) of the actual Development cost shall be credited toward the
payment for the estimated Development Costs for the next calendar quarter (or promptly refunded to Everest if no more Development activities are planned). </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the abovementioned, Everest shall not have the obligation to share the
portion of the actual Development Costs that exceeds the total amount set forth in the Development Budget. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Payments to MorphoSys</B>. The Parties shall share all payments due from
<FONT STYLE="white-space:nowrap">I-Mab</FONT> to MorphoSys under the License and Collaboration Agreement (Exhibit C) entered into by and between MorphoSys and <FONT STYLE="white-space:nowrap">I-Mab,</FONT> including upfront payment, milestone
payments, royalty payments and reimbursement for technology transfer and other assistance within the Field (25% <FONT STYLE="white-space:nowrap">I-Mab</FONT> : 75% Everest) as follows: <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall notify
Everest and provide Everest with a statement of Everest&#146;s share (i.e., 75%) of any payments due to MorphoSys thirty (30)&nbsp;days before the due date of such payment to MorphoSys, and Everest shall pay the amount invoiced within twenty five
(25)&nbsp;days after the receipt of the invoice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3&nbsp;&nbsp;&nbsp;&nbsp;[</B>Intentionally left blank<B>] </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Product Profit/Loss Sharing.</B> The Parties shall share the Product Profit/Loss from the
Commercialization of the CD38 Product in the Field in the Territory as follows, but Everest&#146;s right to share the Product Profit from the Commercialization of the CD38 Product in the Field in the Territory shall be suspended until Everest has
fulfilled its payment obligations under this Agreement which constitute material obligations of Everest under this Agreement: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Everest&#146;s share of the Product Profit/Loss shall equal Everest Total Cost / (Everest Total Cost + <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Total Cost) &#150; 5%, and <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> share of the Product Profit/Loss shall equal <FONT STYLE="white-space:nowrap">I-Mab</FONT> Total Cost / (Everest Total Cost + <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Total Cost) + 5%, where </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Everest Total Cost</B>&#148;
is the sum of (A)&nbsp;total Development Cost actually incurred by Everest under Section&nbsp;4.1 (either paid or shared, but excluding payment for cost overrun under Section&nbsp;4.1(c)), and (B)&nbsp;Everest&#146;s share of payments to MorphoSys
under Section&nbsp;4.2, and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Total
Cost</B>&#148; is the sum of (A)&nbsp;total Development Cost actually incurred by <FONT STYLE="white-space:nowrap">I-Mab</FONT> under Section&nbsp;4.1 (either paid or shared, and inclusive of payment for cost overrun under Section&nbsp;4.1), and <FONT
STYLE="white-space:nowrap">(B)&nbsp;I-Mab&#146;s</FONT> share of payments to MorphoSys under Section&nbsp;4.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By way of example, if the Everest Total
Cost is $60&nbsp;million and <FONT STYLE="white-space:nowrap">I-Mab</FONT> Total Cost is $40&nbsp;million, then Everest&#146;s share of Product Profit/Loss shall equal $60M/($60M+40M) &#150; 5% = 55%, and
<FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> share of Product Profit/Loss shall equal $40M/($60M+40M) + 5% = 45%. For clarity, if <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> final decision regarding the Development of the CD38
Product increases the Development Budget and Everest elects to <FONT STYLE="white-space:nowrap">opt-out</FONT> such budget increase as set forth in Section&nbsp;2.4(b), then one hundred percent (100%) of the increase in Development Cost paid by <FONT
STYLE="white-space:nowrap">I-Mab</FONT> shall be included in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Development Cost and not in Everest Development Cost. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Within thirty (30)&nbsp;days after the end of each
calendar quarter in which the Commercialization Party has conducted Commercialization activities for the CD38 Product under the Commercialization Plan, the Commercialization Party shall submit to the other Party a reasonably detailed calculation of
the Product Profit/Loss for such calendar quarter, including the Net Sales of the CD38 Product and the Commercialization Costs incurred by or on account of the Commercialization Party to Commercialize the CD38 Product in such calendar quarter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;If a Product Profit was realized for such calendar quarter, then the Commercialization Party shall pay to
the other Party its share (as calculated in accordance with subsection (a)&nbsp;above) of the Product Profit for such calendar quarter within thirty (30)&nbsp;days after the delivery of the Product Profit/Loss report. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;If a Product Loss was incurred for such calendar quarter, then the other Party shall pay to the
Commercialization Party its share (as calculated in accordance with subsection (a)&nbsp;above) of the Product Loss for such calendar quarter within thirty (30)&nbsp;days after the receipt of the Product Profit/Loss report. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><FONT STYLE="white-space:nowrap">Out-license</FONT> Income Sharing.</B> The Parties shall share all <FONT
STYLE="white-space:nowrap">Out-license</FONT> Income from the <FONT STYLE="white-space:nowrap">out-license</FONT> of the CD38 Product in the Field in the Territory (in the same ratio as Product Profit/Loss sharing) as follows: <FONT
STYLE="white-space:nowrap">I-Mab</FONT> shall promptly notify Everest after the receipt of any <FONT STYLE="white-space:nowrap">Out-license</FONT> Income, shall first apply the <FONT STYLE="white-space:nowrap">Out-license</FONT> Income to reimburse
each Party the reasonable cost and expenses (including internal cost) incurred by such Party and its Affiliates for the negotiation and execution of the <FONT STYLE="white-space:nowrap">out-license</FONT> agreement, and then shall pay to Everest
Everest&#146;s share (as calculated in accordance with Section&nbsp;4.4(a)) of the remaining <FONT STYLE="white-space:nowrap">Out-license</FONT> Income within thirty (30)&nbsp;days after receipt of the
<FONT STYLE="white-space:nowrap">Out-license</FONT> Income by <FONT STYLE="white-space:nowrap">I-Mab.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Currency; Exchange Rate.</B> All payments to be made under this Agreement shall be made in US Dollars by
bank wire transfer in immediately available funds to a bank account designated by written notice from the receiving Party. The rate of exchange to be used in computing the amount of currency equivalent in US Dollars shall be made at the average of
the closing exchange rates reported in The Wall Street Journal (U.S., Eastern Edition) on the due date of the payment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Late Payments.</B> If a Party does not receive payment of any sum due to it on or before the due date
therefor, simple interest shall thereafter accrue on the sum due to such Party from the due date until the date of payment at a <FONT STYLE="white-space:nowrap">per-annum</FONT> rate of prime reported in The Wall Street Journal (U.S., Eastern
Edition) on the due date of the payment plus two percentage point or the maximum rate allowable by applicable law, whichever is less. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.8&nbsp;&nbsp;&nbsp;&nbsp;Financial Records; Audit. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;[Intentionally left blank] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Within sixty (60)&nbsp;days after the end of each calendar year, each Party shall allow an independent
certified public accountant jointly selected by the Parties to audit its records for such calendar year to verify the accuracy of the financial report furnished by such Party and any amounts to be shared or paid under this Agreement for such
calendar year. The cost of such annual audit shall be shared by the Parties (25% <FONT STYLE="white-space:nowrap">I-Mab:</FONT> 75% Everest). </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;Any amounts shown to be owed but unpaid, or overpaid and
in need of refund, shall be paid or refunded (as the case may be) within thirty (30)&nbsp;days after the accountant&#146;s report, plus interest (as set forth in Section&nbsp;4.7) from the original due date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.9&nbsp;&nbsp;&nbsp;&nbsp;Tax. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Taxes on Income.</B> Each Party shall be solely responsible for the payment of all taxes imposed on its
share of income arising directly or indirectly from the collaborative efforts of the Parties under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Tax Cooperation. </B>The Parties agree to cooperate with one another and use reasonable efforts to avoid
or reduce tax withholding or similar obligations in respect of any payments made by a Party to the other Party under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Payment of Tax. </B>To the extent a Party is required by applicable law to deduct and withhold taxes on
any payment to the other Party, the paying Party shall pay the amounts of such taxes to the proper tax authority in a timely manner and promptly transmit to the other Party an official tax certificate or other evidence of such withholding sufficient
to enable such other Party to claim such payment of taxes. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Mutual Representations and Warranties</B>. Each Party hereby represents, warrants, and covenants (as
applicable) to the other Party as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Corporate Existence and Power</B>. It is a company or
corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction in which it is incorporated, and has full corporate power and authority and the legal right to own and operate its property and assets and to carry
on its business as it is now being conducted and as contemplated in this Agreement, including, without limitation, the right to grant the licenses granted by it hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Authority and Binding Agreement</B>. As of the Effective Date, (i)&nbsp;it has the corporate power and
authority and the legal right to enter into this Agreement and perform its obligations hereunder; (ii)&nbsp;it has taken all necessary corporate action on its part required to authorize the execution and delivery of the Agreement and the performance
of its obligations hereunder; and (iii)&nbsp;the Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation of such Party that is enforceable against it in accordance with its
terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>No Conflict; Covenant</B>. It is not a party to any agreement that would materially prevent
it from granting the rights granted to the other Party under this Agreement or performing its obligations under the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Compliance with Law</B>. It shall comply in all material aspects with all applicable Laws in the course
of performing its obligations and exercising its rights under this Agreement. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Additional Representations and Warranties of <FONT
STYLE="white-space:nowrap">I-Mab</FONT></B>. <FONT STYLE="white-space:nowrap">I-Mab</FONT> represents, warrants, and covenants (as applicable) to <FONT STYLE="white-space:nowrap">I-Mab</FONT> that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;the MorphoSys License is in full force and effect and <FONT STYLE="white-space:nowrap">I-Mab</FONT> has
provided a true and complete copy of the MorphoSys License to Everest; <FONT STYLE="white-space:nowrap">I-Mab</FONT> will maintain the MorphoSys License in full force and effect and will not terminate, amend, waive or otherwise modify the MorphoSys
License in any manner that materially affects its rights to Develop, manufacture and/or Commercialize the CD38 Product in the Field in the Territory or Everest&#146;s right and interest in the CD38 Product without Everest&#146;s prior consent (not
to be unreasonably withheld or delayed); in the event of any notice of breach of MorphoSys License by <FONT STYLE="white-space:nowrap">I-Mab,</FONT> <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall immediately notify Everest in writing, and if <FONT
STYLE="white-space:nowrap">I-Mab</FONT> fails to cure such breach, Everest shall have the right, but not the obligation, to cure such breach on behalf of <FONT STYLE="white-space:nowrap">I-Mab</FONT> and to offset any reasonable amounts incurred or
paid by Everest in connection with the cure of such breach against any amounts otherwise payable by Everest to <FONT STYLE="white-space:nowrap">I-Mab</FONT> under this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;as of the Effective Date, <FONT STYLE="white-space:nowrap">I-Mab</FONT> has not granted any sublicense to
any Third Party under the MorphoSys License to Develop or Commercialize the CD38 Product in the Field in the Territory; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;as of the Effective Date, <FONT STYLE="white-space:nowrap">I-Mab</FONT> has not received any written notice
from any Third Party asserting or alleging that the CD38 Product, including the Development, manufacture or Commercialization thereof, infringes or misappropriates the intellectual property rights of such Third Party; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;as of the Effective Date, there are no actual, pending, or to
<FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> knowledge, alleged or threatened, adverse actions, suits, proceedings, or claims against <FONT STYLE="white-space:nowrap">I-Mab</FONT> involving the CD38 Product or the MorphoSys License. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Additional Representations and Warranties of Everest</B>. Everest represents, warrants, and covenants (as
applicable) to <FONT STYLE="white-space:nowrap">I-Mab</FONT> that as of the Effective Date, there are no legal claims, judgments or settlements against or owed by Everest or any of its Affiliates, or pending or, to Everest&#146;s knowledge,
threatened, legal claims or litigation, in each case, relating to antitrust, anti-competition, anti-bribery or corruption violations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Disclaimer</B>. EXCEPT AS EXPRESSLY STATED IN THIS ARTICLE 5, NO REPRESENTATIONS OR WARRANTIES
WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, <FONT STYLE="white-space:nowrap">NON-INFRINGEMENT,</FONT> OR
<FONT STYLE="white-space:nowrap">NON-MISAPPROPRIATION</FONT> OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, IS MADE OR GIVEN BY OR ON BEHALF OF A PARTY. ALL SUCH REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE
HEREBY EXPRESSLY EXCLUDED. Everest understands that the CD38 Product in the Field in the Territory is the subject of ongoing research and development and <FONT STYLE="white-space:nowrap">I-Mab</FONT> cannot assure that the CD38 Product can be
successfully developed and commercialized in the Field in the Territory. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION; LIMITATION OF LIABILITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Indemnification by Everest.</B> Everest hereby agrees to defend, hold harmless and indemnify <FONT
STYLE="white-space:nowrap">I-Mab,</FONT> its Affiliates and their agents, directors, officers and employees (the &#147;<B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Indemnitees</B>&#148;) from and against any and all liabilities, expenses and/or
losses, including without limitation reasonable legal expenses and attorneys&#146; fees (collectively &#147;<B>Losses</B>&#148;) in each case resulting from Third Party suits, claims, actions and demands (each, a &#147;<B>Third Party
Claim</B>&#148;) arising directly or indirectly out of (a)&nbsp;a breach of any of Everest&#146;s obligations under this Agreement, or (b)&nbsp;the negligence or willful misconduct of any Everest Indemnitee. Everest&#146;s obligation to indemnify
the <FONT STYLE="white-space:nowrap">I-Mab</FONT> Indemnitees pursuant to the foregoing sentence shall not apply to the extent that any such Losses arise from any activities set forth in Section&nbsp;6.2 for which
<FONT STYLE="white-space:nowrap">I-Mab</FONT> is obligated to indemnify Everest Indemnitees under Section&nbsp;6.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Indemnification by <FONT STYLE="white-space:nowrap">I-Mab.</FONT></B>
<FONT STYLE="white-space:nowrap">I-Mab</FONT> hereby agrees to defend, hold harmless and indemnify Everest, its Affiliates and their agents, directors, officers and employees (the &#147;<B>Everest Indemnitees</B>&#148;) from and against any and all
Losses resulting from Third Party Claims arising directly or indirectly out of (a)&nbsp;a breach of any of <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> obligations under this Agreement; (b)&nbsp;the negligence or willful misconduct of <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Indemnitees. <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> obligation to indemnify the Everest Indemnitees pursuant to the foregoing sentence shall not apply to the extent that any such Losses arise
from any activities set forth in Section&nbsp;6.1, for which Everest is obligated to indemnify <FONT STYLE="white-space:nowrap">I-Mab</FONT> Indemnitees under Section&nbsp;6.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Procedure.</B> The indemnified Party shall provide the indemnifying Party with prompt notice of the claim
giving rise to the indemnification obligation pursuant to this Article 6 and the exclusive ability to defend (with the reasonable cooperation of the indemnified Party) or settle any such claim; <I>provided, however</I>, that the indemnifying Party
shall not enter into any settlement for damages other than monetary damages without the indemnified Party&#146;s written consent, such consent not to be unreasonably withheld. The indemnified Party shall have the right to participate, at its own
expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by the indemnifying Party. If the Parties cannot agree as to the application of Sections 6.1 and 6.2 to any particular Third Party Claim, the Parties
may conduct separate defenses of such Third Party Claim. Each Party reserves the right to claim indemnity from the other in accordance with Sections 6.1 and 6.2 above upon resolution of the underlying claim, notwithstanding the provisions of this
Section&nbsp;6.3 requiring the indemnified Party to tender to the indemnifying Party the exclusive ability to defend such claim or suit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Shared Product Damages. </B>The Parties shall share all Shared Product Damages as follows: If the Shared
Product Damage arises from the Development of the CD38 Product, including clinical trials, the Parties shall share such Shared Product Damage as Development Cost (i.e., 25% <FONT STYLE="white-space:nowrap">I-Mab</FONT> : 75% Everest). If the Shared
Product Damage arises from the Commercialization of the CD38 Product, the Parties shall share such Shared Product Damage as Commercialization Cost (as calculated in accordance with Section&nbsp;4.). If either Party receives notice of a Third Party
claim that arises from or is based on the Development, manufacture and/or Commercialization of the CD38 Product in the Field in the Territory, such Party shall inform the other Party in writing as soon as reasonably practicable, and the Parties
shall discuss a strategy on how to defend against such Third Party claim. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Limitation of Liability</B>. NEITHER PARTY SHALL BE
LIABLE TO THE OTHER FOR ANY SPECIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES OR LOSS OF PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING,
NOTHING IN THIS SECTION 6.5 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 6.1 OR 6.2, THE OBLIGATION OF ANY PARTY TO SHARE THE SHARED PRODUCT DAMAGES, OR DAMAGES AVAILABLE FOR A
PARTY&#146;S BREACH OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE&nbsp;7. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.6</B>&nbsp;&nbsp;&nbsp;&nbsp;[Intentionally left blank] </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIALITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Confidentiality</B>. Except to the extent expressly authorized by this Agreement or otherwise agreed in
writing by the Parties, each Party agrees that, for the Term and for a period of ten (10)&nbsp;years thereafter, it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in
this Agreement (which includes the exercise of any rights or the performance of any obligations hereunder) any Confidential Information of the other Party pursuant to this Agreement. The foregoing confidentiality and
<FONT STYLE="white-space:nowrap">non-use</FONT> obligations shall not apply to any portion of the Confidential Information that the receiving Party can demonstrate by competent written proof: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;was already known to the receiving Party, other than under an obligation of confidentiality, at the time of
disclosure by the other Party; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;was generally available to the public or otherwise part of the public
domain at the time of its disclosure to the receiving Party; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;became generally available to the public
or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;is subsequently disclosed to the receiving Party by a Third Party who has a legal right to make such
disclosure; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;is subsequently independently discovered or developed by the receiving Party without the
aid, application, or use of the disclosing Party&#146;s Confidential Information, as evidenced by a contemporaneous writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Authorized Disclosure</B>. Notwithstanding the obligations set forth in Section&nbsp;7.1, a Party may
disclose the other Party&#146;s Confidential Information and the terms of this Agreement to the extent: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;such disclosure&nbsp;is reasonably necessary for (i)&nbsp;the Development, manufacture and/or
Commercialization of the CD38 Product, including obtaining and maintaining Regulatory Approval; or (ii)&nbsp;the prosecuting or defending litigation as contemplated by this Agreement; or </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;such disclosure is reasonably necessary: (i)&nbsp;to such
Party&#146;s directors, attorneys, independent accountants or financial advisors for the sole purpose of enabling such directors, attorneys, independent accountants or financial advisors to provide advice to the receiving Party, provided that in
each such case on the condition that such directors, attorneys, independent accountants and financial advisors are bound by confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> obligations consistent with those contained in this
Agreement; or (ii)&nbsp;to actual or potential investors, acquirers, licensors, licensees, collaborators or other business partners solely for the purpose of evaluating or carrying out an actual or potential investment, acquisition, license or
collaboration; provided that in each such case on the condition that such disclosures are bound by confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> obligations consistent with those contained in the Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;such disclosure is required by applicable Laws, including judicial or administrative process, provided that
in such event such Party shall promptly inform the other Party such required disclosure and provide the other Party an opportunity to challenge or limit the disclosure obligations. Confidential Information that is disclosed under this
Section&nbsp;7.2(c) shall remain otherwise subject to the confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> provisions of this Article 7, and the Party disclosing Confidential Information pursuant to applicable Law shall take all
steps reasonably necessary, including seeking of confidential treatment or a protective order to ensure the continued confidential treatment of such Confidential Information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Publicity.</B> Subject to the rest of this Section&nbsp;7.3, no disclosure of the terms of this Agreement
may be made by either Party, and no Party shall use the name, trademark, trade name or logo of the other Party, its Affiliates or their respective employee(s) in any publicity, promotion, news release or disclosure relating to this Agreement or its
subject matter, without the prior express written permission of the other Party, except as may be required by Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Equitable Relief. </B>Each Party acknowledges that a breach of this Article 7 cannot be reasonably or
adequately compensated in damages in an action at law and that such a breach shall cause the other Party irreparable injury and damage. By reason thereof, each Party agrees that the other Party shall be entitled, in addition to any other remedies it
may have under this Agreement or otherwise, to preliminary and permanent injunctive and other equitable relief to prevent or curtail any breach of the obligations relating to Confidential Information set forth herein. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERM AND
TERMINATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Term</B>. This Agreement shall become effective on the Effective Date and, unless
earlier terminated pursuant to this Article 8, shall remain in effect until the Parties cease Development and Commercialization of the CD38 Product in the Field in the Territory (the &#147;<B>Term</B>&#148;). </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination for Breach.</B> Each Party shall have the
right to terminate this Agreement in its entirety immediately upon written notice to the other Party, if the other Party materially breaches its obligations under this Agreement that would (x)&nbsp;lead or cause
<FONT STYLE="white-space:nowrap">I-Mab</FONT> to materially breaches its obligations under the MorphoSys Agreement or (y)&nbsp;lead or cause the essential business purpose of this Agreement could not be acheived and, after receiving written notice
identifying such material breach in reasonable detail, fails to cure such material breach within sixty (60)&nbsp;days from the date of such notice. For the avoidance of doubt, such material breach includes at least the following: on the part of <FONT
STYLE="white-space:nowrap">I-Mab,</FONT> <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> failure to make any payments due or use Commercially Reasonable Efforts to develop the CD38 Product under the MorphoSys Agreement; on the part of Everest,
Everest&#146;s failure to make any payments due or use Commercially Reasonable Efforts to commercialize the CD38 Product if the JSC selects Everest as the Commercialization Party under this Agreement. Such material breach does not include mistakes
or errors in clinical trials that do not constitute material breach under the MorphoSys Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination for Bankruptcy.</B> Each Party shall have the right to terminate this Agreement in its
entirety immediately upon written notice to the other Party, if the other Party shall file in any court or agency pursuant to any statute or regulation of any state or country, a petition in bankruptcy or insolvency or for reorganization or for an
arrangement or for the appointment of a receiver or trustee of such other Party or of substantially all of its assets, or if such other Party proposes a written agreement of composition or extension of substantially all of its debts, or if such
other Party shall be served with an involuntary petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed within ninety (90)&nbsp;calendar days after the filing thereof, or if such other Party shall propose or
be a party to any dissolution or liquidation, or if such other Party shall make an assignment of substantially all of its assets for the benefit of creditors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination for Suspension of Development or Commercialization.</B> The Party acknowledge that under the
MorphoSys Agreement, <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall be deemed to not be using Commercially Reasonable Efforts to develop the CD38 Product if <FONT STYLE="white-space:nowrap">I-Mab</FONT> fails to initiate or conduct any material
development activities in relation to any therapeutic, prophylactic or palliative CD38 Product for a period of six (6)&nbsp;months. Therefore, the Parties agree that if <FONT STYLE="white-space:nowrap">I-Mab</FONT> fails to initiate or conduct any
material development activities in relation to any therapeutic, prophylactic or palliative CD38 Product for a period of three (3)&nbsp;months not as a result of any order or requirement of Regulatory Authority, Everest shall have the right to
terminate this Agreement upon written notice to <FONT STYLE="white-space:nowrap">I-Mab.</FONT> The Parties further agree that if the Commercialization Party fails to initiate or conduct any material commercialization activities after twenty-four
(24)&nbsp;months prior to the anticipated date of first Regulatory Approval of the CD38 Product in relation to the CD38 Product for a period of three (3)&nbsp;months not as a result of any order or requirement of Regulatory Authority, the other
party shall have the right to terminate this Agreement upon written notice to the Commercialization Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.5&nbsp;&nbsp;&nbsp;&nbsp;[Intentionally left blank] </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.6&nbsp;&nbsp;&nbsp;&nbsp;Effect of Termination. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Continuation by <FONT STYLE="white-space:nowrap">I-Mab.</FONT></B> If this Agreement is terminated by <FONT
STYLE="white-space:nowrap">I-Mab</FONT> pursuant to Sections 8.2, 8.3, or 8.4, then <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall have the right to continue the Development and Commercialization of the CD38 Product in the Field in the
Territory. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Continuation by Everest.</B> If this Agreement is
terminated by Everest pursuant to Sections 8.2, 8.3, or 8.4, then Everest shall have the right to continue the Development and Commercialization of the CD38 Product in the Field in the Territory, in which case, upon Everest&#146;s request and at no
additional cost to Everest, <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall reasonably cooperate with Everest to facilitate the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;subject to the terms and conditions of the MorphoSys License regarding assignment, assign the MorphoSys
License to Everest; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;grant to Everest an exclusive license to all
<FONT STYLE="white-space:nowrap">know-how,</FONT> patent and other intellectual property rights owned or controlled by <FONT STYLE="white-space:nowrap">I-Mab</FONT> to further Develop, manufacture and Commercialize the CD38 Product in the Field in
the Territory; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp;transfer and assign to Everest all of Regulatory Materials, including Regulatory
Approval for the CD38 Product in the Field in the Territory, and all data and results from the <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and clinical trials of the CD38 Product conducted by or on behalf of <FONT
STYLE="white-space:nowrap">I-Mab</FONT> in the Field in the Territory; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B>&nbsp;&nbsp;&nbsp;&nbsp;transfer and assign to Everest
all inventory of the CD38 Product in <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> and its Affiliates&#146; possession; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B>&nbsp;&nbsp;&nbsp;&nbsp;transfer the Development, manufacture and Commercialization of the CD38 Product to Everest, including
providing reasonable technical assistance and assigning to Everest any agreement with Third Party vendors pertaining to the Development, manufacture and Commercialization of the CD38 Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Continuation of Profit Sharing.</B> The Party elects to continue the Development and Commercialization of
the CD38 Product under clause (a)&nbsp;or (b) (the &#147;<B>Continuing Party</B>&#148;) shall be solely responsible for the cost and expense of such Development and Commercialization after termination. In the event that the Continuing Party
successfully Develop and Commercialize the CD38 Product, the Continue Party shall pay to the other Party a percentage of the Product Profit and <FONT STYLE="white-space:nowrap">Out-license</FONT> Income generated from the Development and
Commercialization of the CD38 Product in the Field in the Territory, which percentage shall equal X/(X+Y*1.25) where </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;X is the total amount actually incurred (either paid or shared) by the other Party to Develop the Product
under this Agreement before termination, including its share of the Development Costs under Section&nbsp;4.1, payments to MorphoSys under the MorphoSys License under Section&nbsp;4.2, and other Third Party payment under Section&nbsp;4.3; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;Y is (A)&nbsp;the total amount actually incurred (either paid or shared) by the Continuing Party to
Develop the Product under this Agreement before termination, including its share of the Development Costs under Section&nbsp;4.1, payments to MorphoSys under the MorphoSys License under Section&nbsp;4.2, and other Third Party payment under
Section&nbsp;4.3, plus (B)&nbsp;the total amount actually incurred by the Continuing Party to Develop the Product after termination through Regulatory Approval; </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided however that the Continuing Party&#146;s obligation to share Product Profit and <FONT
STYLE="white-space:nowrap">Out-license</FONT> Income with the other Party shall stop once the total payment to the other Party reach two times X. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Survival</B>. Expiration or termination of this Agreement shall not affect the rights or obligations of
the Parties under this Agreement that have accrued prior to the date of expiration or termination. Without limiting the foregoing, the following provisions shall survive any expiration or termination of this Agreement: Sections 5.4, 6.1 - 6.4
(solely with respect to claims arising from activities before expiration or termination), 6.5, 8.6, 8.7,10.11, Article 1, 7 and 9. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 9 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DISPUTE
RESOLUTION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Disputes</B>. The Parties recognize that disputes as to certain matters may from time
to time arise during the Term which relate to either Party&#146;s rights and/or obligations hereunder. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under this Agreement in an expedient
manner by mutual cooperation and without resort to litigation. To accomplish this objective, the Parties agree to follow the procedures set forth in this Article 9 to resolve any controversy or claim arising out of, relating to or in connection with
any provision of this Agreement, if and when a dispute arises under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B> </B><B>Internal
Resolution. </B>With respect to all disputes arising between the Parties under this Agreement, including, without limitation, any alleged breach under this Agreement or any issue relating to the interpretation or application of this Agreement, if
the Parties are unable to resolve such dispute within thirty (30)&nbsp;days after such dispute is first identified by either Party in writing to the other, the Parties shall refer such dispute to the Chief Executive Officers of the Parties for
attempted resolution by good faith negotiations within thirty (30)&nbsp;days after such notice is received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Binding Arbitration. </B>If the Chief Executive Officers of the Parties are not able to resolve any
disputed matter within thirty (30)&nbsp;days and either Party wishes to pursue the matter, each such dispute, controversy or claim shall be finally resolved by binding arbitration administered by Hong Kong International Arbitration Centre
(&#147;<B>HKIAC</B>&#148;) pursuant to its arbitration rules then in effect, and judgment on the arbitration award may be entered in any court having jurisdiction thereof. The Parties agree that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;The arbitration shall be conducted by a single arbitrator jointly selected by the Parties. If the Parties
are unable or fail to agree upon the arbitrator within thirty (30)&nbsp;days after the initiation of the arbitration, the arbitrator shall be appointed by HKIAC. The place of arbitration shall be Hong Kong, and all proceedings and communications
shall be in English. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 10 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Entire Agreement; Amendment</B>. This Agreement, including the Exhibits hereto, sets forth the complete,
final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto with respect to the subject matter hereof and supersedes, as of the Effective Date, all
prior agreements and understandings between the Parties with respect to the subject matter hereof. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties
other than as are set forth herein and therein. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Force Majeure</B>. Each Party shall be excused from
the performance of its obligations under this Agreement to the extent that such performance is prevented by force majeure and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse shall be continued so
long as the condition constituting force majeure continues and the nonperforming Party takes reasonable efforts to remove the condition. For purposes of this Agreement, force majeure<I> </I>shall include conditions beyond the reasonable control of
the nonperforming Party, including without limitation, an act of God or terrorism, involuntary compliance with any regulation, law or order of any government, war, civil commotion, epidemic, failure or default of public utilities or common carriers,
destruction of production facilities or materials by fire, earthquake, storm or like catastrophe. If a force majeure persists for more than ninety (90)&nbsp;days, then the Parties will discuss in good faith the modification of the Parties&#146;
obligations under this Agreement in order to mitigate the delays caused by such force majeure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Notices</B>. Any notice required or permitted to be given under this Agreement shall be in writing,
shall specifically refer to this Agreement, and shall be addressed to the appropriate Party at the address specified below or such other address as may be specified by such Party in writing in accordance with this Section&nbsp;10.3, and shall be
deemed to have been given for all purposes (a)&nbsp;when received, if hand-delivered or sent by confirmed facsimile or a reputable courier service, or (b)&nbsp;five (5) business days after mailing, if mailed by first class certified or registered
airmail, postage prepaid, return receipt requested. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If&nbsp;to&nbsp;Everest:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Everest Medicines Limited</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">800 Boylston Street, 16th Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Boston, MA 02199</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fax:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to <FONT STYLE="white-space:nowrap">I-Mab:</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">I-MAB</FONT> Biopharma Co., Ltd.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 802, West Tower, OmniVision Tech Park</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">88
Shangke Road, Pudong New District,</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Shanghai, China 201210</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Attention:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Fax:</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>No Strict Construction; Headings</B>. This Agreement has been prepared
jointly and shall not be strictly construed against either Party. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision. The headings of
each Article and Section in this Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular Article or Section. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Assignment</B>. Neither Party may assign or transfer
this Agreement or any rights or obligations hereunder without the prior written consent of the other, except that a Party may make such an assignment without the other Party&#146;s consent to an affiliate or to a successor to substantially all of
the business of such Party to which this Agreement relates (whether by merger, sale of stock, sale of assets or other transaction). Any permitted successor or assignee of rights and/or obligations hereunder shall, in writing to the other Party,
expressly assume performance of such rights and/or obligations. Any permitted assignment shall be binding on the successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of the foregoing shall be null,
void and of no legal effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Further Actions</B>. Each Party agrees to execute, acknowledge and
deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Severability</B>. If any one or more of the provisions of this Agreement is held to be invalid or
unenforceable by any court of competent jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall make a
good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.8</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>No Waiver</B>. Any delay in enforcing a Party&#146;s rights under this Agreement or any waiver as to a
particular default or other matter shall not constitute a waiver of such Party&#146;s rights to the future enforcement of its rights under this Agreement, except with respect to an express written and signed waiver relating to a particular matter
for a particular period of time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.9</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Independent Contractors</B>. Each Party shall act solely as an
independent contractor, and nothing in this Agreement shall be construed to give either Party the power or authority to act for, bind, or commit the other Party in any way. Nothing herein shall be construed to create the relationship of partners,
principal and agent, or joint-venture partners between the Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.10</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>English Language. </B>This
Agreement was prepared in the English language, which language shall govern the interpretation of, and any dispute regarding, the terms of this Agreement. To the extent this Agreement requires a Party to provide to the other Party Information,
correspondence, notice and/or other documentation, such Party shall provide such Information, correspondence, notice and/or other documentation in the English language. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.11</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Governing Law</B>. This Agreement and all disputes arising out of or related to this Agreement or any
breach hereof shall be governed by and construed under the laws of Hong Kong, without giving effect to any choice of law principles that would require the application of the laws of a different jurisdiction. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.12</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Counterparts</B>. This Agreement may be executed in
one (1)&nbsp;or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>, </B>the Parties have
executed this CD38 Product Collaboration Agreement in duplicate originals by their duly authorized officers as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>E<SMALL>VEREST</SMALL> M<SMALL>EDICINES</SMALL> L<SMALL>IMITED</SMALL></B><SMALL></SMALL></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>/<SMALL>S</SMALL>/ E<SMALL>VEREST</SMALL>
M<SMALL>EDICINES</SMALL> L<SMALL>IMITED</SMALL></U><SMALL></SMALL></B><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT></B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U><B>/<SMALL>S</SMALL>/ <FONT STYLE="white-space:nowrap">I-M</FONT><SMALL>AB</SMALL></B><SMALL></SMALL></U><SMALL></SMALL></P></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>List of Exhibits </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit A&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CD38 Compound </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Initial Development Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit C&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LICENSE AND COLLABORATION AGREEMENT </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CD38 Compound </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MOR03087: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amino acid sequence of Lead Compound MOR03087 human Ig lambda light chain: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DIELTQPPSVSVAPGQTARISCSGDNLRHYYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSG </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SNSGNTATLTISGTQAEDEADYYCQTYTGGASLVFGGGTKLTVLGQPKAAPSVTLFPPSSEEL </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">QANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSH </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RSYSCQVTHEGSTVEKTVAPTECS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amino acid sequence of Lead Compound
MOR03087 human IgG1 heavy chain: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSGISGDPSNTYYA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLPLVYTGFAYWGQGTLVTVSSASTK </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TQKSLSLSPGK </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Initial Development Plan </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Initial
Development Plan, including the estimated timeline and the estimated Development Budget, are shown as below. It should be modified after receiving China FDA&#146;s opinions in <FONT STYLE="white-space:nowrap">pre-IND</FONT> meeting in the Territory.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g38965456.jpg" ALT="LOGO">
 </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>License and Collaboration Agreement </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>8
<FILENAME>filename8.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.21</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.21 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUPPLEMENTAL AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CD38 PRODUCT
COLLABORATION AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS SUPPLEMENTAL AGREEMENT</B> is made on November 7<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>, 2018 (the
&#147;Amendment Effective Date&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BETWEEN: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">MAB, a company organized and existing under the laws of Cayman Islands and having its registered address at
P.O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, <FONT STYLE="white-space:nowrap">KY1-1205</FONT> Cayman Islands (&#147;<B><FONT STYLE="white-space:nowrap">I-</FONT> Mab</B>&#148;); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">EVEREST MEDICINES LIMITED, a company organized and existing under the laws of Cayman Islands and having its
registered address at 4th Floor, Harbour Place, 103 South Church Street, P.O. Box 10240, Grand Cayman <FONT STYLE="white-space:nowrap">KYI-1002,</FONT> Cayman Islands (&#147;<B>Everest</B>&#148;, together with
<FONT STYLE="white-space:nowrap">I-Mab</FONT> are referred to herein individually as a &#147;<B>Party</B>&#148; and collectively as the &#147;<B>Parties</B>&#148;). </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">I-Mab</FONT> and Everest entered into a collaboration agreement on
January&nbsp;22, 2018 (the &#147;<B>Collaboration Agreement</B>&#148;) in relation to, among others, the development and commercialization of and sharing of economic interest in CD38 Product (as defined in the Collaboration Agreement).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">I-Mab</FONT> may apply for the listing of its shares on internationally
recognized stock exchange (the &#147;<B>Listing</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties agree to amend the Collaboration Agreement to provide more clarity on the development and
commerciliazation cost of CD38 Products. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOW THEREFORE</B>, in consideration of the foregoing recitals and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise defined herein, capitalized terms used herein shall have the same meaning ascribed thereto in
the Collaboration Agreement. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Article 3.2(a) of the Collaboration Agreement shall be amended and now be read as follows:
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;3.2 Development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Development Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Development of the CD38 Product under this Agreement shall be conducted pursuant to a development plan to be
implemented by or on behalf of <FONT STYLE="white-space:nowrap">I-Mab</FONT> or its Affiliates or sublicensees to obtain Regulatory Approval of the CD38 Product in the Field in the Territory (the &#147;Development Plan&#148;). The Development Plan
shall be consistent with <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> obligation under the MorphoSys License with respect to the Development of the CD38 Product. The Development Plan shall also include a detailed budget (the
&#147;Development Budget&#148;) for such Development activities. As of the Effective Date, the Parties have agreed on the initial Development Plan, attached hereto as Exhibit B. Pursuant to the initial Development Plan, the Development of CD38
Product shall be [completed] by December&nbsp;31, 2024 (&#147;Development Complete Date&#148;) with a total budget of US$200,000,000 (the &#147;Initial Development Budget&#148;). Such Initial Development Budget shall be inclusive of all costs and
expenses to be incurred by or on account of <FONT STYLE="white-space:nowrap">I-Mab</FONT> and Everest under the initial Development Plan, but shall not include and shall be in addition to any payments (including upfront payments, development
milestone payments, and any other payments) made by <FONT STYLE="white-space:nowrap">I-Mab</FONT> under the License and Collaboration Agreement by and between <FONT STYLE="white-space:nowrap">I-Mab</FONT> and MorphoSys AG (&#147;Morphosys&#148;),
dated November&nbsp;30, 2017 (the &#147;Morphosys Agreement&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;From time to time, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> shall prepare amendments and updates to the then-current Development Plan and Development Budget and submit such amendments and updates to the JSC for review and approval. Once approved by the JSC, such
revised Development Plan and Development Budget shall replace or supplement, as appropriate, the prior Development Plan and Development Budget. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Upon the Listing of <FONT STYLE="white-space:nowrap">I-Mab,</FONT> if
<FONT STYLE="white-space:nowrap">I-Mab</FONT> proposes to increase the Initial Development Budget or the then applicable Development Budget (as determined in accordance with this Article 3.2(a)(ii) and/or (iii)) (such amendment, &#147;Material
Development Plan Amendment&#148; and such incremental increase of the Initial Development Budget, the &#147;Increased Amount&#148;), in addition to the approval by the JSC as required under Article 3.2(a)(ii),
<FONT STYLE="white-space:nowrap">I-Mab</FONT> shall comply with the applicable rules of the stock exchange on which its securities are listed (&#147;Applicable Listing Rules&#148;) and submit such Material Development Plan Amendment for the approval
of its shareholders who are not otherwise connected with Everest (to be determined by the Applicable Listing Rules) (the &#147;Unconnected Shareholders&#148;). The Material Development Plan Amendment may only become effective after being approved by
the JSC and the shareholders of <FONT STYLE="white-space:nowrap">I-Mab</FONT> in accordance with the Applicable Listing Rules and such approved Material Development Plan Amendment shall replace or supplement, as appropriate, the prior Development
Plan and Development Budget. In the event of a Material Development Plan Amendment, the JSC approves such Material Development Plan Amendment but the Unconnected Shareholders do not approve such Material Development Plan Amendment, then such
Development Plan Amendment may only become effective, and the Parties shall carry out such Material Development Plan Amendment, if Everest agrees to bear one hundred percent (100%) of the Increased Amount without requiring <FONT
STYLE="white-space:nowrap">I-Mab</FONT> to share such Increased Amount under Section&nbsp;4.1 (but for clarity <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall continue to share the then-current Development Budget before such proposed Material
Development Amendment under Section&nbsp;4.1) (the &#147;Everest Sole Development Costs&#148;).&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A new Article 3.5(d) shall be added into Article 3.5 of the Collaboration Agreement: </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;3.5 Commercialization </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) Net Commercialization Cost Budget</B>. The Parties agree and shall procure that the Commercialization Party shall not incur
Commercialization Costs in a manner that would, at any given time, cause the Net Commercialization Costs (as defined below) to exceed US$100,000,000 (&#147;Net Commercialization Cost Cap&#148;) without the prior approval of both Parties. For the
purpose of this Collaboration Agreement, &#147;Net Commercialization Cost&#148; means the cumulative Commercialization Cost incurred by the Commercialization Party from the launch of the CD38 Product in the Field in the Territory (including fully
burdened cost of manufacturing the commercial products, sales and marketing expenses, general and administrative expenses, phase 4 or post-marketing clinical study costs, commercial milestone and royalty payments made to Morphosys under the
Morphosys Agreement, and all related tax) less the cumulative Net Sales of CD38 Product sold in the Field in the Territory during the same time period. It is acknowledged that, upon the Listing of <FONT STYLE="white-space:nowrap">I-Mab,</FONT> in
order for <FONT STYLE="white-space:nowrap">I-Mab</FONT> to approve any additional Commercialization Cost that is higher than the Net Commercialization Cost Budget (&#147;Increased Net Commercialization Cost Budget&#148;), <FONT
STYLE="white-space:nowrap">I-Mab</FONT> shall comply with the Applicable Listing Rules and submit such Increased Net Commercialization Cost Budget for the approval of its shareholders who are not otherwise connected with Everest (to be determined by
the Applicable Listing Rules). The Increased Net Commercialization Cost Budget may only become effective after being approved by the JSC and the shareholders of <FONT STYLE="white-space:nowrap">I-Mab</FONT> in accordance with the Applicable Listing
Rules and such approved Increased Net Commercialization Cost Budget shall replace or supplement, as appropriate, the prior Net Commercialization Cost Budget. In the event the JSC approves the Increased Net Commercialization Cost Budget but the
Unconnected Shareholders do not approve such Increased Net Commercialization Cost Budget, then Everest shall bear one hundred percent (100%) of any Commercialization Costs that would cause the Net Commercialization Cost to exceed Net
Commercialization Costs Cap (the &#147;Everest Sole Commercialization Costs&#148;).&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Article 4.1 of the Collaboration Agreement shall be amended and now be read in its entirety as follows:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;4.1 <B>Development Cost Sharing</B>. Except as otherwise provided in this Agreement and subject to Article 3.2(a)
above, the Parties shall share the Development Costs incurred by or on account of <FONT STYLE="white-space:nowrap">I-Mab</FONT> to Develop the CD38 Product in the Field in the Territory (25% <FONT STYLE="white-space:nowrap">I-Mab:</FONT> 75%
Everest). Within thirty (30)&nbsp;days after the end of each calendar quarter in which <FONT STYLE="white-space:nowrap">I-Mab</FONT> has conducted Development activities under the Development Plan, <FONT STYLE="white-space:nowrap">I-Mab</FONT> shall
submit to Everest a reasonably detailed report setting for the actual Development Costs incurred by or on account of <FONT STYLE="white-space:nowrap">I-Mabto</FONT> Development the CD 38 Product in such calendar quarter and the supporting proof of
payment, and an invoice for seventy-five percent (75%) of such actual Development Costs. Everest shall pay to <FONT STYLE="white-space:nowrap">I-Mab</FONT> such invoiced amount within thirty (30)&nbsp;days after the date of such invoice.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the abovementioned, Everest shall not have the obligation to share the portion of the actual Development Costs that exceeds the
total amount set forth the in the Development Budget. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A new Article 4.4(a)(iii) shall be added into Article 4.4(a) of the Collaboration Agreement:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;If and at the time Everest incurs any Everest Sole Development Costs and/or Everest Sole Commercialization Costs,
such Everest Sole Development Costs and/or Everest Sole Commercialization Costs shall be included in the Everest Total Costs, and Everest shall be deemed to have fulfilled its payment obligation under Section&nbsp;4.4(a) and Everest&#146;s right to
share profits shall not be subject to any suspension notwithstanding the provision of Section&nbsp;4.4(a).&#148; </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Article 8.1 of the Collaboration Agreement shall be amended and now be read as follows: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;8.1 <B>Term</B>. This Agreement shall become effective on the Effective Date and, unless terminated pursuant to this Article 8, shall
remain in effect until the Parties cease Development and Commercialization of the CD38 Product in the Field in the Territory (the &#147;Term&#148;).&#148; </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Miscellaneous </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Incorporation </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">This Amendment shall become effective on the Amendment Effective Date and shall be incorporated in the Collaboration Agreement by reference.
Unless otherwise expressly amended by this Supplemental Agreement, the Collaboration Agreement shall remain in full force and effect in its original form. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Counterparts </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">This Supplemental Agreement may be executed in any number of counterparts, each of which when executed and delivered is an original and all of
which together evidence the same agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed this Supplemental Agreement in duplicate originals by their
duly authorized officers: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EVEREST MEDICINES LIMITED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>/s/ EVEREST MEDICINES LIMITED </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">I-MAB</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>/s/ <FONT STYLE="white-space:nowrap">I-MAB</FONT> </U></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g38965178.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g38965178.jpg
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M(W9;R.ZDB9K<UCB2UN-"00,*K6'=W1O;^86[_EBX ^$XK??0[?S,M=4J=F/
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M@]0\0_S"/AJ!=?,->/+%13HK]&T'_O#\/U+TA=>7($ XX/QWN!0,.^4U.S<
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M.(_""<58]YS2]>5@Q.^4X94H&Z#-1\N(,=RHMD$A665/_ETQ^U,@"(CKL)N
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M;7QV>/SH;^W?%^\T@CX@T76?+7*$H=QN,K("B.P'5RK7"B(B.VPB9H3KOT\
MUFUW!- S'Z=ZK)MG'(0#->PM!( )( ).0%>IZ*(N6>4&^Q^,37;KMY64ZT8V
MX#MX&;[;;_?JCGW#?Q,I\/O6<;+L/[5TRGT[E$.6>38;[\8R!L( .^4*N&PC
MX /[CQ'37.30-Q]WWJHV?CQRNXOC^I1CEODR40*/&PP&'< (&2ZR!AV#<0*(
MH]>T/NU</F2*AF"HW:^-MD#'7L <>FH5^"Z39>Y)[;GXT*G -A^')M4-V@(;
M[CW)!L AX:K2Z!IY9JLWY;Q8G3\_;ZO\X!<4G/F1)C+4=B?(6(UL>.9JJR=J
MAI7\TQLZ1=&(621<H*IQR*0 (J*@'0Y@#</T:RC6  \4>16GTR4;D/#K%O'7
M<CVR=LMK'((Y'M_#&\TTL<[(.<"" :5KA59>H&%3RQW[A!,0/MU$!WZ ;V@.
MKB"&X]2N.M32V\J3"84J#G0]2,\>B]>P^X?U#JQ9%1-X_P";UI_] R__ !4O
MJEW_ ,(/85ELO^?6/^MA_P#,QJQ?#'IQNP$/L'#=  /Y*\S'^WK+;C_P#5W'
MK!_^^?-W?_CT_P#OI5DS,SL3 ,W$A,OFL9'-$#N7DB_<(-&#)NF B9=XZ<*)
MI-T0VV[C" ;CMJUK2?8N)AM9+C",5-:4ZKWMG;=VW;NFRI%VSI%)PW71.51%
M9!<A5$5DE"&,11)1,P"4P"(" [AJAS6)S2QQ8<"TT^"M-G\UX3PUDM7&MF3I
ME];TBS/*G:UHEI/-Z_-1\6N_:2;B%D ,RD$4A:B02*%,&Z@=!U16KYAYCU/\
M[I\,L?6"&YL49[RL?9:<MKC0FF*H-U/)4&P VAH6!?-UJ@6NME:E*H*R2RR*
M?F.6KX$!4$R)3B1;$,@9VYJ9LS?D? _'C-.)\*5_BS2J$WSSGN[UR,D#6O)$
M_"D7EV45&2K=Y%5^&:.FZO11,.TX_B_#HBQKRYR,]1W'>$.1%TF^2>)/J.%;
M_CDE;LF/ZWCBSQ&3,=V.-&ONYB,ABGGI.!9_F9\V<K.'R)#BY25*B)4NTFB+
MU\/N5/-O*N?*&HGR41Y*<=8&PV9IG.Q4C$%>J\-5XMACI_9H%ZM.+5YD_58/
MYHI&9%DNPRKEJJ4>T.T38;@:H'M/5I^Q6OH&$FM*=%)\?<G_ %-^9-2NG*S
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M1LNX[<*8^EKA&2<#"XFJD7"O5)6PNK!Y:Z2CA-=VFF9%DW6W65$Q0+Y9AZ@
M;Z[?N1[_ +&RYV6<^9<3WOF @5.EP:T-'LI5=_Q_T5XAO/&;6XMC1HM?/D)(
M 86@@EP/:1T]I5]<NY-Y08JXYQMVM4SB5G?0?IIS;!&-EI%A*?6CI-:[#0[3
MSO\ /#A^<2F./[L0W$.FM]R[=9MKX,+M]!.R-N':2X8+@_3WA.P\V]1+?CSG
M._+HI7%[A448UKJFIQ&-,_<OGS]7/D!=<H8[X>RF0(F+KF9\8<BY9C/5Q!+N
M;Q\BDM7'L,12-:J'5.B_)V"'EG'<-?0G\NO*;V\X_P"H;<:_(-'_ *DY7FWJ
M'Z86VS<TX/Y-#LK]Q<2X?AI_"%0>PBBVK7;E9S,BX>\1<@KB,%H# '\5Y8JE
M;G#.4H>:8"@A'^2=T=P=\4#"':)1+N =1#7SK><EW>'>X[:)N#-WLC7#)T33
M]I7N.[>FW"G\>GW*%Y\N666-HJ:%S2^O=3PG$K3MZ-^9\^XCXT\@+'BD]!&&
M0Y"5]:RM)^$EW;U>5OY$&37Y99%<C,R#=Z<?,3*7O*'LU[;_ #<\IY/MO+)-
MQLV%TWF[:W(9/D>#FN+]$_3OA?)'[AL-V\ "SNI6T)_%#'JQITI6M?8O;S^S
MSFQSZD7%%#(;FE-+;@^7<.H!Z2*E&=;1>JJIR;U8[=14%I90Y3BB0R?[O8"^
MW?6S]&N:\ELN <UN;YI:T;6_LZ1DKE^4\'XK>[QQ;:=O(=YFXM'7]I]!0'+#
MN^M?1+PGY+Y*R^%MI^6HZ!KUUBXF+ME71C8YTT:S50GTN^/E42N%2JKH&$Y0
M4(!NY,VX"/MU\[^GF^\GY/M[)?- :Z!CFC# $ MZ=B[W^8/TPV_A]Y;[YQPF
M:*%Q9(:ZRV1A(>TGI0@@CHJ05S3S"=9"S15XZ;PA%0F'W@N7:TU$3+11XQ7C
M32K9!L^4?F$14;E[#J>6(%./P[AUU)O-RY#M^ZD7TH?'JP%1@1CE[%6/A7%Y
MN.;3R>ZBDDNKU[F.:T.=IT-;C4?AQ=[*+C*G*7-2V ,1YDQ(SIS![D-\P@GE
M4L4?(O)F5GW2JB -*OY"R"1$NY$R@J;#NF("/7?6PW;E5X;=KF#'J._V*O".
M"\"W?F\ECN;3H9J=J-!1H'[1[1C4Y4Q6@/F]R*MUM]1?T_<PU])BQRI1Z@[B
M[!$R#5RM&Q-\A[!.1ZL>]:,ET'#L"BX\T (;M42 >N_37TIPOF$NY?RF\EN+
M4U<W=XJCO#H5QG)_3WCO'_5*.QNG-$<KAI/^2[(@^PBBS]YP\A.8\]Q"YBP=
M^?8:D:C3ZO 5.]L8:I6-E/*QN0&[5RC*0:P2CYJD#!=PB*H.2D$J9#"'78!\
M\]$-SGWGU+G9>,#3:FW#*?Y=N''W5)P[UN/5GT_XKL?'H)=NEDD9>,+O$0::
M"!0Y9],UG'Z'2@+^F7QU !.;S4[6X[E.T#B52TR!Q\SM  [^O78-=/ZW ?XC
MNR[(Q_\ T5X:ZP;!86L</]D'L^%2M3,E:<JUGU\>01L*.::SR!-4.5A6+B^,
M95[7D(M"D,+!,.' 1"I'*"J2$$0$CB!B"H8"FV >X/2_4:*[L_Y>MJW"U%2V
M"-W=72[]%5O>.1[+=[T+.\)Q< 0W/$@'[SW55L?5VY#\I\F\,<7I9>7QL[H6
M0LA,)^-"IUR1BW[28JKF2CV+=26<3CUJ0%0=*"'[OP-L&O)?Y7?4?S/56TL[
MFT/S_P C.3(&X9,IC7LS7>^L_IUQ&QXA?VT<A?,U]G34:T\P.>:99T'N6T+C
MERKY&1''#!V19QSA5S06<;5ZPYJC/ZBPO<A%I$C8))!@U,]<%!R45.[J  8
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M+H/7+-Y947LT9ZQCG)"Q[D!*F@1$#' X#VZ(KB>GWQPSY@RU<H<T3F'*9@R
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M/3\]X<J]7MF+1LTDP=P5[QO&1S*4L#"04,\>NX>3L<F9R=SY9"+&<G1(!02
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MCQP^Q7[<R%T<L%Y,);N,5;)&W3&\$X -\1JT8$AV)!)6XM9T!$C&5-V%\TI
M,!2[E^,@=P@80 2DW[C>WM =M]8GLIB,J*#:R23M>YV374'L7RH<BN-?*W,W
M+?.^9;YZ>]OR-5;5)UJ*IQ:]E*IU.18M,7RD,UBK1#SKAR^>%2O,#"@#MFHW
M( IJ"EN41WUC4E73R52_4LROP5S#B#(F LC7K)&7\_.7T+'SEXIBCS%.*H]*
MNV:N(QZ2,NBTE(5.89+QI&Y%2^203*B40Z:(L_/3$P9-8@HN8IZR<8)GC5=K
M;,U9T^I$CD.+MD/:@K-.38MY^ 09JN6],2F9E9V1RV567 5![P$ #;1%A5.S
MOJ/..<49S!;>GM/'6JF*YO#;.F$RC33M)2,=3SERA/I2_P ^F*:GRJG?V"D
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M!2N.%.ROLS5%^I35<IPWI6M<=WO%[VLO<;9*K3QK89A[&*JRK.2F9(QHR)2
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MEC9XGX--?<4+7#->7$F"<-X)CI2(PYB^E8RC)M^I*3#2G03*&2DGRACG^8>
MU;D46.4ZIQ*03"1/O'M -QUDJ%2A5W/@WWV+OOOOV]=]A#??;QV'2H2A7G=D
M!1HY2(!>XZ"A"@("!=^P0+W;;#VE'[M1;V::&TDEM@3<-82T#M'MP5KH+>=O
MDWC=5J[!X[6]1AW+YAL0<L/5:Y'V7*+7 <K2[+'8[M#F'EDI*M4>(&-;NW\B
MC")%"8=)&=F4;11Q Y1$P]1, #KSFTWKD^X:Q:1/>8S1U"T$$]I+A5?I'SWT
M=_EN]-N%\>NN86D]EO.Z6L4S6N?*_7%0:GCRGO#14C D'L"[+MRR]4WCUE7"
M];Y"O*9 QF3;Q78EDT1B*6X"5BTK'&LK 3ZC#+K%BU!8RX@GWF[A$FX>.IGY
MYR2QN6,O8M#9" /PFO3H3VJ?:>B?\NW/=@WKD'I-<FYL]KLFOF8X3L="?*JY
MQ\T-U@O:XMTEU%]-X+^5VG43[1, &]^QQ .\.@C[]=\VX> &W#=#C6G6M/95
M?F-(YMI,YIP@<:@]Z[DU"J@8Y2@'@!Q -A-T  [O:;IK,TAWX5DBECF_LS50
M"JD&X=![>[X>P=O[H/P[!O[=9#&\"M,%B=>6['ECG>(&AP/W*$%T1 1[2$
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M[L60/:YGF ^!0BHD4H (@!"[   'P@'@   !L :KY;ST6)MS"XT:ZI]A^Y<
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MK"\V!VBU7*JH0=C$2,!Q#8=;UWJ9R>#^$+Z8@=0X'/VM)6AM-YX8VW:/-@D
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M26D$&N';E[%H9PQ7%:LSP5E3.45%WK!SV=7J-?:(/5DD<:65_)/4(:8MD*8
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M #ZQ_P!;#_YF-6!X8)#_ *-&!4Q !'^$-$'H/L- M1'81*.PB01#PUDMQ_\
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MA]Q4X\O'DB_EW+S$%$<N)24567DGZJL R.H[?+KJ*KK.5S")CG.83&,.XZ\
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M1_;1QQCW$&OV*>ZQJBHJ] /T"R 'B-?EN@>T1CEP_7J-N!(M6X]OV%6VA/\
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M1, *(ZSSRW=@QAFDJQPJ.M">WKU4L<OYIL&\OWW=V:MDGA>6-/X6N<WPBFG
MUIEVJWZW*CU#6/%$.5$C(X794Q5XP=HL5:58U+22HO)M&#;V S-.:%B#%RLN
M58J)C"Y*B<.XVL]LZZ@'G2O!QI0XGX*+M_*?4&]XE%N<D>E]<?WB/AE[U?[)
M.=.9,=D?C+BK'%UP9*VO,F-U+)/F=U.QKLVSV%CEY29N7P2:@L*=)$,1%LF
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ME&MWFW5XLDO.IO6T)23R1GA7J">X&7508_#L4!$VH9WN7YM[:>$##XKF=_\
M4GEEMR)^WPVVF,L;I IG7'HKF-.<_)!I1.+N;K+6<<Q>$LKJMH?*-B.A+M7-
M*E'+UU'E5< Z%(K.*5>-3%*N;;KMX .LWYS+0.+1I/L^M3Y^?\PV"U;>;A;
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MM "GB$68]RHKQ\XHNZ.';Y143 (%]NH_Y<]M-3QHSR_7FOF?;^&[B/4M_(7
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M+%.NU<^6@B(F3_=F42Z[:]BX<^.U])N0<><3YFXW'G!U,(@0P:#7\1 96H(
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M]*LK_ET>TI1 1*42CL)CCOVAL4#"(B)@#QV'IOJU>;Z7]I^*[R$*0H%*&Q0
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MT$Q NP"0I? / /Y-7M;#"S2[ G'M1UU,9--D&B)HH[ #Q?#LIBN\44"D[CE
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M5%=_U[^ ?=JNMG9]05==Q_D4^G<N2D2(!@+VAW&.<?C/OW''N,/V;CJFN/Z
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MMW(3M+MN78?A#8.FJM8*'#(?!6NGVR-_F.8/,E\(\/7/W>Y0G1;E(<2CV]1
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M-B51-N*I6HG35.0JAP_" CMUVVU#MKMCP6,-75Z'/ZE"BYEQ+<(8GQRQN)8
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M(:-AD@G\F4%LC6D$'!>I-.K^73?'C(\CM?\ =,6:$;^)Q_JO[8ZANR"\O_\
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M )Z469UC(5/&$B84\ZL>/;.8Q6T5U- A$T"E.=43#Y92% PZO;)$\L <*4J
MXT! K[,Z$ 5!Z+I=\&T;QQO;[W9#KGT-+63$M:X"N9!&9PH"#T"O-P(_(D%G
M[DM5PQ"?".9UF=)L%XH4--0%DQ['UY5LNR@%:2_@2()MRR+DRCMTW5*44%%1
M*!0\ VMC*'L+6@8$GV"N-/?WKJO3R:0[U*=T:R#<?+;JCC),;6X!NDNJZI%"
M:F@QHMM"_>5(@> "<I3>WQ$/A\!  'WCK9L+=1)[%[!?3>6YKBUKXB:&M>N'
M1:A_5!HF/"1>$[0>CTY[;;)R-Q1#6*14@8M2:L%=3=.Q<0CZ37:*N5F(H)!W
M$4'RQ(&W36BW6UL[F,2/E<VKZ84J?;7HO&/5!VQ6=S!#,QH\Y^)ZY#O^U2KU
M,\68]KG&C'04;&M%16KF:\?QU:C0@(QM'$)89X5)2/.#9,B;&%L+TQ"/ ()
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MW1$[P^W[OVZ(G>'V_=^W1%%OTW^S?1%P!@'H&^B()P =NNB+CO#[?N_;HBB
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M@[9AIRN2&A[%CIBF[%ZXD&EF4*B^!=42IM3>: !TUTTWI]L4'(H;)[)C83M
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MTPE731\0R5D4;." Z(9!!-+O*?OVZ#GM]JX8SB]O>W;+@[K-X2X.=IU5()T
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MG\-YMOD/5Y^L>GQR.P%S@?/H*0)FC$\VZQ_@UG8)9^B]EKO+4YA(EBH].2:
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M,+<XM6X*H\J\2UFL0\; 5NN\=+5%PT+$,T8^+BHQK:H)!FS8,$")I-&R21
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M6;RPVE XZ0,LNU:FYVJ*[?J=19;QL-%Q#%C%1+!I%QD<U39,6$>B1FU9LT"
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M]H 93OV$PB)@']X!@$FROQ_& )CM[.O737-W)51?+%V[=P[>T" 02E,7L+^
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MP@NH7H ;AV[;>  !=NP  G3P^WQU?Y\GF>40*]JKT6(5L+V<QJ,3?<"X$N
M/]R%PA>T/Y Z:V%N"#B:G0?TKTF3_P#YSWW_ /4EK_N8UEBQ_I_R?[;6$_A"
M\Q_]YE_U<7V%3#5BO5*W/_,LY_ZOR_\ \Q<:RM_#\?L*LL?_ ,QV7^MA_P!_
M&K"<.1 G'/ O>(%VP[1BCW?#L8L(U$2COML( /4-7'^Q^'Z5Z3ZR8^MW-*?_
M ']/_OI5E450AR@8AR'*( (&*8#%$#!N40$!$! 0\-8%YRHMP]X?K#1%;;*V
M5L=X9J#J]Y2N<%0Z<P<-FKVQV)X5C%MW+Y0$&3=5R(B9-5TL;M)L4W7V:D6E
ME=7UVR&U#G/J?"*8_'#ZU34UOXS0%6'=\X^(K*D1F27O(W%B5)F;')5*'LBE
MF1+#R-EB62<A+031P1(QW$A&L%2JG $^XI1 PAL.^IHXQOKMW$+(YZZ*^4 *
M^VE??2JN\^,&@=A54T'J1\$E +V<J\- !Q @'"U)E 1V*(]AA;@7O[3 /V .
M^KYN%\BM!^92V<XV^F99X:^VI"M\V/,$*[UQY.\?<?4FOY,N>9\?0./[8HV;
MU>W/[.Q"!L3AT@5R@E"OFZCD'ZAFY@.)4RC\([CMJ!;[/N<SI;5T+VR/Q:T#
M$-(P(!I@3D>O8L4MPQM,: JC&?-_B2]L%6JS'D7BE_8KP,$%4BT;8V65G#61
M;R8$L8"29D%U)-3<I [R&$P" @ @.TBVX7O^WP/GN(KKRZ$U+0  .ZM1\#56
M"Y87#Q-^*GF1^77&?%-O3Q_D?/&,Z+<3L%I<:]8;3&M)A&.;E.*RKMJ(B5IT
M+N4BAR+&_H@/AJR/CV[W$7S, G=!V@"A]E:$COI3O4@RL&%154[:^<G$&@NH
MMG<N0N+:Z^G*S$W")2E[(5LYD:G-,?GH>?3#R5#$CI-ENJW5-MYR8"8 Z:F1
M<;W>^@T10SR1AQ%0 :$=F.-.IR5H?""7 C4X8]X7L=\R.)[3'D/E9YGW%9,:
M6&=5K\-;_P QMS03R?1;JN'$(5VF50?JA6Z)U/+.1,XD+N ;:B2\9WH70AD9
M<?,M%6@@:@.[I[:5HL.FUAB+(PQL9<"1TJ""#UQ! *D<QSFX7UVMU:TS7(O$
M<95;DTF96IRKBS()L)IC7GJT?./HY4J9Q<I1CY,Z2NY2=JI#%\2CMD9QCD E
M<Z-MQYHH#0#J, 3[/@,U<;]QF=<%_P#&<*%U<2,J9=RJZY\I.,..WU,87K-V
M+JC)7MHPEZ:QG[/',G$Y&S**2\/*M!45 [6.?HF*=%94$TE2^!N@B$2#9]^F
M@N([B&29XD<(W$5RPIAG1U0:9&JQ^38/CB;(QA\IH#*_L#/P]R]63>6G&S"4
MA$1V5\X8[H[ZQ0Y)Z$9S]B:MSR4*J<"(2[ &Z:X+1S@?P*]PD-[!U38N.<AO
M[ P7%O+)<1O=6@!( -*&I&67:.JD3SQYU ]O8NO%O+_C1G&QK5'#V;L?Y%M#
M:.7E%Z]59DDE)$CFRA$G#XR?EH@1!LHH &WZ;B'OUFN^,7UFTONXI8F#"KJ"
MAZ9$E1_F6Y-<"5YI?F5Q8KMOE\=3?(K$,3>(&.<2<M!2%SADWL<T:&4*]7>%
M6=D;D59F2.!VX+&6 2" E 0$-9+;CG))&AWRTSF'+P.KW=].]2/,C[0HX'F!
MQEM<_::M7L[XZE[#2H68L-JAHNP).W\!#UTC96=DWR"*8&&/B4G28N%"G$$_
M,V-MMK-=<4W_ ,Z)TD$\;2Z@&G2'DTH*DY]@5PDC/4*>8<Y0X!S^YE6>%<N4
M?)SJ!:L'\VUJ4NG*.(IA(JJI,9!V42H'^4>*)&(0P!L)BB ".PZLO]HOMO %
MW')$3EJH*]U 2FMA_"5>FS6"(JL#+66?DVD+ P$<^F)J9?KIMH^*BXUHL[?2
M#]=00(BT:MTC&.8>A0#<>@:@0V\EW(+>*OFN(  SKW+#.\L;5IHL8(CG%Q-G
M:=:<BPW(;&DI2*6K!(VVS-[(F:'KJMC5%"OI2KD$=VJDPY 4T" 4PJF#;?4Q
MG$]ZAW,VT\<SI71 MC< 32IJYHJ 13K54MIFNCJ]P)KG^CHI*]]0SA2P8Q4@
M\Y08>;L9M)=>*=#:D3IOD&JP-7"J0E0_=@B[_=F ?Z0[>/36.'B6^7#+AEM%
M.9&G, 5CQ]ONPJLKYXFL+B1@%7N+N7O&?-]C/3\29LH.0;0A'.99:%J\R#^0
M3C6BA4'3U5/R"$(V;JG IC".P&Z>.LDNP;I9VM;MDK *#4ZE:G+"I.?<K[>6
M*7(@GZ>]8!>I-R1P)=N*7(C']2RU0K)=HYG"1#NL1=@CGLXE+)V2+%1%5@4Q
ME#^01N?<2 )0$!W\!UQO+^.[K9<+O]T?K%PR1@;,:594Q^$=E03T7OO\KTP/
M\P>RPDC2(933NHY3+@/GK#&(>#7&F(RADVFT:5GX*8/#QUGGV;!=X VJ5304
M2*LH!2(% "%#?X>H!OK=<;X_O%Q9[:^ O,<FV%[S@-;R(SKJ: EM>G;DM5_-
M%\J/5GD4Y #X[ASVG'PN;D<\QT6&N",A45KZOW)RWO+?76]&84FQ/G%F6G&8
M5PC%%E45$W!7Z2Q6JS9-0X[;"/Q"/7V:TMMM6ZQ[Z_SI'O!)J#W]"OH_U"DB
MB_E&XS>- %Y*^,/=U<!6@/Z,EN[)RPXWJ567N2>;L<#5Z_&*2\Y-HV)@JSA8
MM)XDP%](>4=4[1J+M8B0'.4 [S@ ;CTUTDNU\A9O<5HRWD-NYE: $UJ,*4S7
MP1YT6-3C54X;FYQ/0H;7*"G(3&:>.GEF7IC>WFL:00J]L;M!?KU]%Z9+O7D$
M67[XQ03 "I?$/36PGXKR.YW V[8;B/RV!Q:UH!.HD8@G#+!8I+B,4Q%"JFQ/
MRQX\9VEY&NX;S/0<D6")8A)R4+4YQ"4D&4>91- 7RB)OEA%NDLJ4AA#P,8-]
MA';66^V+<MNCK>0RQMRU. ZY9$^WZE@^89^RX$J0S_-KB;57MP867D7BR)?T
M!\TB[C'.;8P(\K\B^759(,WC=(RBRCL[M Z8II H*2A1 P@.L#>/[JT NCFH
MX8$B@.%>OVFB?,LI^(?3W*?..5/'9*>I-;6SCCE"=R-!,[)08Q6T1J#BTU^1
M3648R\6"K@"/&CU-N<4#',F*O:(D VL%YQ[>IK W5NV:.)DFDO PKA@>^AZ*
MHNFC-P(^F/THK9O?44X11KDS1[RJPRFL '.4HV]H<!32[O,$%4$E4S"38=]C
M"/36W/#N12V\,\=K<^74>(-!U]V?57LN(JCQ--575VYD<9,=0]/G[QGG&=;@
M\@19IRCR,E9F:"%MA4E$TU)>",U^<4>LRK'!/X2ANI\.^_36FVK9^07E]/:_
M*R/>QQH VI'M%</>LWFQ]H5_:=;ZU>ZQ"7&H6"+L]8LC!*6@;!#.T7D7+QCG
MJW>L7*)SD604 =@$!Z#T'8>FHC+:^LRZVW$%MVQ[@X' C$T%/9175:[%N2J-
M0VQ?A'KN'X=A';?KL&P[ZMF?)&S5&W6ZH%/:?T)4#$Y+'65Y:\88&7>0,QR%
MQ%&S<;**0K^)>Y!K*4@SETU@:KQ;MF=Z51L];NC>6HF8 .FI\)@ >FMR_9-\
M-I\U':2>66U!TFGQ5OFQ]2%7E]R]C#%,='2>3<CU&AQDFX.VC)"WV6)@4)%9
M),%E$VBK]5L1V*2)@.<""/:3XAV#KK3[58;IN5M<"-KS.Q[@:"NBG3NH?:5<
M9(@<QA]:IB<Y+\?*U*#!6/..+X.92C$9I2+D[S76,B6(<LDI1M*+-'3U-=*/
M7C%B+D5$H)G04*<#"40'6RVO8=[DL@[R99G5(+J5QJ>Q8I;B)K:@C$J%SR9X
M^M:I%WMUG#%C>DST@\BH:U*WNNI0,G)QR8JOXZ.E1?@T=/F211.JD0XG3)U$
M #4:+C_*?G7QNMY#I );I. -:&G8:&ARP6$W4>FM?I\%'%<E./LU+5^ B<Y8
MNDIFV-VSRKQ;*^UIS)SR#I1PFV4BF2;TZS]%TJT5*F9,IN\R1P#<2CM,_+=U
M(+A:24 -?"?I@I/G1Y5"\O\ I3<;1:3<@7/F(Q85MR@RGG8Y#K'RT.\>.EF3
M1"36^>$C([MX@=%'O$/-5(8I=S (:N=LV[AS8Y+24.<*CPG'V)YT8PJ%VN>3
M_')HWKKAWG?$K=.V)H+U@Q\A5I,)])P]6CFZL2 O_,?(JR#91 #$ P"LF8F_
M<40"_P#(][9J!M9:--#X"*&E:? @_!4=*P-K49*52/+SB]#23Z'E>1&&8Z6C
M%UFLE&/<C59!['N6RJB#AN\;J2)%FSA!=$Y#D.4IBF*(" " ZR,X_ODS0Z*T
ME->QI*B&Z;VA5Y YJQ+::C(9!KF3J+-T:(.Z2D[A%VN'?5B/58I@J[3>2[=V
M9BDHV3.!E"F4 2E$!'IK7G;]X;NGY.^SF%T6-</":D.RH*=V:DQS1NCU5%:K
MIALWX@L%,D<CP&4Z),T"%\\9FY1]N@W=9B ;'%-S]6F$7!V<?Y!PV,"JA=AZ
M#JV^L=YLK^/:W6<OS,M:8'"@KEUP5XECH<0J*-RZXO%C&\V;D3AHL.Z<J,6T
MJ.1*N#%9Z@1LJLU*N,@"/GI)/$3F#NW*14AAZ&+O)/'N2Q R2VD@CI^Z:*GF
MQ]H5;6O-^(*+ PUJNN5J#4Z[9$VZ]>FY^W049#S:#M,BC9Q#OGCE%&3072.4
MY#)&.4Q1 =]AWU&AL=XNWN@M;5YE;G0$T]M,O>J^;'3,*627(G!<-7OS;,9D
MQO&U<+"K4BV-Y=*\WA5;*W;$>+09)$[PK,TNFW4 YVX'\TI1 1+L.I,?&]_N
MIS:>1*)VLUD-%'!M:5-<@L4LS&-#J@8T544/*N-LJL7TEC+(-0OK&+=A'R;N
MHV**L",<^,F"I6CX\8Y< T<'2,!BD4[1,7J&HUQMUUMCO+O&R!]/VOU*1#)&
M\:L"KB^ !N/NZC_V>_4>M<50YJC;UD"DXU@5K1D"WURD5MJH1-U.VB9CX.,2
M44'9) SN1600%180'8H&[NG362*VOKI_EV$1E?2IIT':50N:T5<:!4>]SUA9
MA67UQ<Y@QPVJD<,25_95KG7@AF"E@1^:@4GC_P"<^5;&F6_QM0.<IER (D P
M!K-^4[T^5ML;=[9G@T&DU/0D=M*CXCM3S(\ZX+TXYSCA_+*LDCC3*="R XA4
MD59AM4+7"SZT6DY.9-LN]1CG*ZR"#A5,Q4U#@4AC%$ W$!UCO-IW#8?X&Z-E
M;-_ET!0R1DX$*86_+V+J%-0E>NN1Z/4)ZR&.G7X6RVF%A)&:.4![BL&DB[07
M<"7M'M[ 'O-T#<0U6';MXN[-]U9V\DD;74U!I(]E>WJ1T"&2-N!(5-V;D-@N
MG1$%/6W-&-*U"V=%5U6Y28N]=CF5C:M50;NG$,NY>)DD&J#@P$450%0A#CVB
M(#TU?M^U[S>%UL;=YG&'A&(J*^XTQQ3S(NT4*KZEWVE9$@&MJHEMKUQK3U19
M%I/5J98S<0X6;JB@NDC(L%5FRBR*Y1(<H&$2G#8>NH\UK/97!M[@.$G8[,?!
M4UL.1"H.;Y$8'K5GE*=8,RXPA+7#M3/96OS-XKL=+1S9- CE15XP=/DW#9))
ML<%#F, =A!W'8-2Y..[I+:MW&"T>YK\G:30TP_5[E4S,&&H*%;D3@@EE>4TV
M:L9(6R-:N'\C7%KO749MJR:1P3+ETK'*/2."MT(@?FC&[=@;?O/P==8W[)O5
MS:-<R&:,ES?$UI(SI2N.>2LDGC8PY*>T',&+LJHR+G&.1Z7?V\0N@UE5JA9X
MFPA&N')#JMDGX1KIP+0[E-,QDP. =X%'MWV':^XVZZM&>3<M>R6F9&/Q&"S6
M[XY6U%"5<TH%$I1'81$ W'?V[==:OY2#]MH+^I[3VH2033)1!VAX;!_+J^.&
M*(UC: 2J$DYKG</>'ZPUE5$W#WA^L-$3</>'ZPT1-P]X?KT1! !\=6/C9(*/
M (2I&2?"7IT#[-(XV1-T1@!JJ23FFX>\/UAJ]47.X#X#OHB:(N!V]NW\OOT3
M)-R^\/UAH<<T4.Q/[G]>H_REN<= 5=17(=H> @'\NLD<4<5?+ %4))S7.X>\
M/UAK(J)N'O#]8:(FY?>'W:(N/A_N?NTJ56I7.Y?>'ZPU2@KJZJBPYM__ -\F
MC[>'\!;A_P#[A"ZEP?B_] KTN3__ )SWW_\ 4EI_N8UE>Q_I_P G^VU@/X0O
M,?\ WF7_ %<7V%3#5BO5(754A(.>,?\ "2"ETS;] _S:X4$=_P"KVZD1L)%>
MXG[0K+#Q;S#=C".WGMVN[:NGC(IVC'&M%@]Q[R%-U7"_%6+) LWD7;*'C*MH
MI_/*K69PXD8PK>6DHN":I.4#Q-/:%2<O7:XI)%2$=C".P#CD<6,I2H-#AGBO
M6?66QEC]7^871 =\QODSFZ<:-$LA)?6E":B@!/?T5QJ3R%N=IA\KN%:="Q$[
MCF;R@TC:A.#;HA_,0..K)(025G"0DX)&.6C;!'M$'*!F!7;;=VGV*F*(F".'
MDY-<O-!8W-&N<T@.< /:<@LE*!;B72A4JY?)F8C:ZI7K&# I_/\ E FHIK(?
M+E6$B7G$0%QV=XE+W;> >&GF=SE8^V?'(8GEH>TD''(C,*09@QK3LU8\LN,[
MW7(ZR5FVQCN)?1\VR0>L457#=0&4F#=<#!\W&NP(HBH02J)' #%$!#6TV>^?
M8W[+V.H,3@XC*H!Q;[Q@M=N#"QC14&I.17RAQ;A:\X+Q5Z2S2BUF.SW&\MKG
M0KW-O(&.,XBL5UB34L+C)+ ?DR2;5S9:N*+0SP5#NE6\> *#VK?#[Y! [;[A
M_/[B1KMI=;>&,'QZBT@ C\.!';FXYT"U(D<6B,9U6Q/'W'7!2WJOYRQ?)X>Q
M:\QC6>(N,W<=4)*MP#N%CYEN^B(U*9:QSIJ!&,BM&'536<B4RRX?$=3IKDI.
M3<SG]$+&XN1_'?>/K0FKOQG02172.@Z4 "E^2X2.&MA;3O\ CDL![-"UU+A-
MZG^-:BWAK-@O!W*.":<;U7B:$_$UHDK88PT[#56P+"D5E%KLC)D,HW.0&Q%3
M)]PEZ!VH_AW/&-SW&W N)=J>Z5K -3PR0AA() .FM!7M*C2VLTC#22/0#A4G
M[NJR/]/3$K.J\V9. YEXSAWO)1QC"HY#X_V)C^7%,3Q.-HJ.;-FL=CROQS./
M:-+-7@.""3A--9=,A%Q$  GFFTWJ!O3-WVULO&1*S:(W.9+J_&75QJ[430$G
M4#2M10TSHRRF9)61\>K YG+X?#[%;3(&'$9='FWEZI8IP7S;XYY9O-WM-TR5
M&VY*E<A,..XF3E$Y>LP#ZYH/$FR].03 8U=-(K5QN"G[P@"08%A<ZK*UL)'7
M%ON 8=+- \N8:<B<1A2N!!"D""0M<=49;VU."]O*MK5+#=/2'L>#<'0&6"6?
M#4M"5?&N2#P#5]>*W$5:K1\#5[I8E&"#)RXAF1E2>8)"H%44,*).TW2_BTDV
MWMW1M^^6.&-V+X@"8=3=6MNK 8>W$&H5?)D\!#HS\<<<LE9:-Q+&Y.X8^I9;
MIFJX_P 2W>KY!Q_99'C#6V4C HX(7Q/(-DCS)4)!0H.7UTJZZH>8U[4'93"5
M02G'MUM7WS'<DVZ,"8V<C7-$LH:3(XL.DN+/#C^*HH*9"E:1[F*00ODU,PI@
M"<,>]6"G,U3?(2<QQBF4P_3(+%F8,OXHC>)L.EC>MHGI&(HG+TC#Y+@(N7B$
M$9I1O*ST.S4D#.%%BN3'6,;<I]S=E=;-#LEF[<9;B.01M/G$$ZW/T-<USFT#
M:AA! &%"T=%JW22'LH<EM]X3X0XRYY)SBM?*O'N/Y?*M=SYDBAWV,N+ALJ.*
M<1TZ/CVU&C*^W>KIH5&!AX918Z#AF5-,"E#<2GW+KR;E6[[U9/VN?9!7;_EV
MEI#:N>ZI)UBA!)S+2[(D@FF&S@<"S5(YO>*XCZ>_L6O=.!?W?AKQ/<P-&K&3
MI:M^HE8</<?G^3O,>QMWPRW;6!Y7*?.3+UN+AO07$B@*0F6,X03^7!0P%  U
MU^R<@.X<CO;Z>&6&S?M(>^-@ >QX+0Z0-'72#0U)-!@K96ODB;I<RNN@K7'N
M^G:LA\<5\N+*%F',-[3#$7/=[P_Y7! XDIM%B,:0C2F5:URX-<@QJT#"M&0/
MX9H4C:.56-YKY I'("8>TP<WR6Y=>R1QV<+G[8V6,B0D/<YVD$-I4BM:$G5V
MX5*PB*5@),C0^A[J#X*19GJG&_%'!##D=%\*I/.>-,CX,JV0\I<H:;,U5G9Z
M=<IM9HZE))Y;92*E9-Y9W,H_<**IAL@!#"4R0&-N"QW7F#MWU"0-EC-/(- "
MS2/V*8C)P?B:X5I@MAY,@C U1D$9U/W>Y6TR77IF"Y73?)O!>+F=&)A?AYQ[
MS?E+!:[2/<?Q-H&04(^$RG5+(]CD0C)]TC4W?F.G D.B[(AY@I^< D+TVS[I
M<7]F=JY"]QGN+F2*"9M/X<E7NSP+3&]M&4!H13)7>3+KUA\8 :"14XCX=5LO
M]$X<;62A<K,F8YKD;#Q5PY6WI6OK-H="-=-<?KQ-=FJM42@1L0&T;70EE02;
MIG%$B@F[-RB CYWZDPWMC=VT%S(V1XA;4@UJ[ .<< :GV*L43B^NMFDN'4Y5
MRR6ZB>C8NRP\A 3<6A+0LPQ=1LQ%2#<B[*2CGB!T7K%TBH4Z:S=TW.8AR&#8
MQ1$!UYK$^YM[UMS X-8W'O![1AT6TGM#(*!S,^W]2^3W)Y:AQ/HG/#T^6..Z
MC.9#RWF;&BO'%O*P219&V5G,4H!*^[4.4J;11'%KQ!;Z>H8X%;+#N.X#KWG9
MH]QY ^+FK X6%K ^&0 C47L:"<#FTZ\#GAC3KHYHW69,+G,)< 1GV_:K\<XN
M'5)P#CGTW,<8MPUC^[Y(B\JPV/GK:WMXYBUR.]4ISF2F8F]3+=  6BI:>%11
M4Q-R&,0 $Y0UB]/MV.XW.[7=T)X]O;%J):&ZHVG4-3,_%D<>O3MQ2!SP(8W,
MUG#&N>>/V*L>)O$Q:*P7DKE+FX4N)&7G&.<]X-LA$J9$X[J,'79RTKD@<B/&
M\,W82B:T6JJ5JS>$43!TS;IJ&[MP,.DWSDEO<[TVUM(G26K7M<"2"21V5J.P
M@UQ/8I-M$^ >.1@=W5I]BUS<B./Q,%\8<<1V5.,=!BYED^;QF+^6>"\@04ZE
MD^P2#<SN%E\AP,P8DS.ELB7GN%#=RODJ"(=!VUR'JBZ;=.#[GM6W2$7#Y8W:
M'MTM9H(+B2!J!<!2E"#0$%>\_P KC+B;^8S9VL:=/RTGCZ'\7V>Q90>C5QLX
MR\A\?9IM&:X*NY>R-3[6;'+.KWM<\Q_#JG,FR4W'(5V#=.2-HA"1?/57'S1"
M&,;;M[OAVUJMBWV[;P?:GV3)C/:6Y@D+0*$^$$ ]AI7&AP4?^::SNV^J?)2:
M$>:X9XX]?=U6"UJXH49[S2O''W!ULHZM<@[@:5I5=OUH^F5W,)V;]K8IK$$A
M/12JR10<N#&0;$7#]ZFD!#& "AK4\)Y)'N/('Q7]G> -)J2QN0S/XJ_4O>/5
M2ZGL_P"3_BY=%*\!\7X0#^SWD+:EQJQ-@>W\G\J8"S#Q.>\:<KY/X[OX9]C.
M$GH:U80N="5=[2%TK:D4 N(J<BIHB9TB+IE, D ^XB&^O6MVWC==KN[:_MYX
MI[1A&AX \PACOP/&AK:T&AU/=VKX?%A<Z&SO=&T/:':234:A4 X9BN..:P[C
MXVLVS!51]+1*AU)IR!B^;TO0;-(&C8Y2SLL9QRJTZMEQHX5 (PMG=4$@1ZKG
MN WRZ1![1$X@7L[YV["5W.Y9HORB6W&E@=D1^R6AHQKCF14G'HM7>"2-K8M3
M'/U'(FOV!>C.#.9X)\],[YZXWTV)8TS"++&N.IK'-;9.&ZSQEF'$RC.(FDBH
MMWC!98MM9I/G.R7<9R G$ []]3=GL(.7\9@DW5X=.][G.U8$^7)4M%.FDA@'
M9F5#,CVR:HR !3[,/O6++#$LI5^.'J<_QBB6-@R77$..%D>V"<ATVTS V?)5
MF7M%B$"J)_-1<DX5L)DG8(JD3.8I"BF AL&[WQVVON;3Y*"46KV2^&C?$&L&
MFE'D$-_6LHADT.)>S4*=OW+9)CND9%MO/'T\(ODGQRPCCZ%;X/N+/'K2BRI+
M*WM,!7J*U^AOK$R,@B#.4@BJ[I)"0XI&4'J :X2?<;)G"-SM;!MW\RR_+RYX
M9IC/@!:#6H%<A0TZ%7L@E?(T%S*'LKB/TK!?&V"7UZRQEJMM,.4>(XTEY>9O
MI63,QL:)!VJ?Q74(: <G^F+,9.-D6M2J%3CT2OF[U J)C.>Y$5"[ 8>WM=^C
MVO:(H70SOWF.$.BC):V-[@<.M34G2<#A3PJV.*0.!+FZ <3B?T++7FTSXZV;
M /IV\=L15Z:Y&-):'B9%/(E1H:T[EEUQRIDL9"S.*XBF4%XE_:+%WJF3*5(J
M0MR@(E*/=KA^*W7)-NY#?[W/#'' 7.U->0&![F-+2:M H 6@FN66.4LN)#6Z
MP3]=/I59_P#HOY5<LL=YBXHVB-M5:F>/.1)1Y3*U?8Y>$NK?#M_D7=@J;F4B
M'SA5RS(W>KJIF N[=,IB]AA*(;<GZFV=W-NQY*\1"TNFM ##6CHXVAV0#?%0
MEN.('0K9V;FF(,+FZJG[5NN=JF*B)B?"(& W>8W8F4I>IC'. _"4 ]OAKR.X
MN;MUIY^WL!GUM%'=A(U=O19YXZPDZFA?/WF?CE@1;UD./-77P]0E:U>L"95O
MURA#5]B:/LE[0EY5TVL\LEV%!Q8!6;@)5U3 (CML ^(>YV._[]_@&:FIP9)0
M2T:2P?P_"#IR%:5..)Q[-:87ZQXH\LJG'-6Z]4W.6.^36%8N*H5$)8K!@/GE
M6<++,+W%1Z$)/6-)DZ1>Q2"Z:AUV=0LH+"S55,=JJH5+J4X#US>G>R7.S37,
MV]-<8[RT=,T,\1&IP\3M5/$T'L=FL,CJBFIM0ZF:IAOCFQY2]16YL.5?&;"=
M(FV'!:YOXNG5>49Y#A ;PB"D)6YR2E3M@(6Q,VC-=@D4I"'09MDP#N 2B$B?
M<AMG&K:XX[)<2,DW :I7M:TN!-2VFD>%Q-*:0*'L5LD;W2Z7EFH-.%3T!6IR
MJBXQ/P=G&N6*W&VW$W)>N7V7P-.R, WFU<1<D<=32L)+MVR8$[XUW<Z:BHFD
MX0%'H7<4S&UZG;7EWO\ >1ML!'#N-J/XK'4 ?'(PZ0X &H#J.:X8AS2.I4/R
MI0S%S-+LC4YCW+:!EO'BM,Y6>E3_  !PGC2VWU+BU^88:G3JR-0K,S,1E5*^
M;R,C84TC^:ZA#23AXW(43&.X,;<-A$=>7[7N%Y<;)N%S?F1MC\P]KGMT^9&V
MC:M;X2&TK[0#4*:'.#F%I874R[5=+TZ.*F-LX0'J18US+ANBUB9G,\J567A8
M=5.SHXX># N95G&U:;53(+IO5;'(GD6BA! #K'$! -M4]0N1;IM5UL.XVD;G
M6S[5SB:-J\!S!5[: >(=1E6H"NC:9 [Q,!KVG#/!6OX"<-ULI<JINAY^C*+;
M*+Z;*$CAZH,XN$()[Y-SEBDK57)2V.'"8+21X1H[^;23.1,4W0=/,*<PZD<T
MY;?6''F;G:0N8;\"0$4<[PL:"6-)TCPAH-*"IJ<2KVPR$@/>PM;A2IZ]N"E?
M(+@G5L)9SX?L\FP6.[_*<@/4#R!8[(X9Q*YU9'%MM=UB4B*)/C('(,BRB5P<
M*N$=OEB**[EW'KJ'Q_F>\WVT7-S:1.8V&Q Q:W4QU'4?D?%EU.62C"RF!#G/
MC(+NTXCLR542/#MCBSD5Q2X49RFX=MQVR/E'D3GM*O5B2>P5(N\^YDV"U"PM
M(,A*P6%A"QK=N=0IC W7.X% F^_67?\ +G[SLLG(]GAT[U$&P.UM&H^6VOF
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M8\C:\V9E^3D!!-RY01%10O<(=UMYN/*X>90ON/+$,\>D>6,9!@ZA;I TG/\
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MV+I1YC\;@ ?-S;2S#OT_RAML'\B&GO"H>%;W^[+\%VCS%XUG 2ES52A,;X0
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M4H3''2OM!"S<BAV!40_KJ?\ ?!U;+^$>P?8O,+O_ )L[_4L^Q3CO'[/O_;K
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MP;;_ (8"++[O']SUU1/F;G^\D_K.^]=/\.J;_P#XA6/_ *BB_P#P.B?,W/\
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M<)'55.:CE+"5V.6\MV9\Z>PB*_U",B8JM1SF4?/7"239LP1.X4.4FPB18O\
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M^(H#TW*;;J'AW% ?T@&B+D2E-MW% VP[AN #L.PAN&_@.PB&B(
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M!VWV'8>@B&HL+8!N4KB1YU&_9_0O?O4".UMO1+@]Y;1%]^^;<VO(&-/F2&_
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M(4.XQCF,(%(4I0W$1Z &B+DIBG #$,4Q1V$!*(& 0$ , @(;AU 0']&B*(!
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MT!42%.^:D%4Y.H@17<A^?/($>104:P47#9,4I>I;;?3_ %?HSR[+9#<QJW%
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MVV;"M\P8B^F+1$T1-$31$T1-$31$T1-$31$T1-$31$T1>-58B0G$W]'<P[]
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MCBOW&1:O&PJKRU1DN2,<G>EL<:F8TDUF213)194BIBN_E&YE!.**0E(I//\
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M7$&#5) /W29"@14D\XW8"D6M'92&'<=OFV-+NUR9C\CRK1+DU/R.R:&8,[]
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M_P#?NQ;)*_+(_&IVEZZ(JDT1-$31%3EBN-1IX0@VVTURK!9;!%5*N#8IR,A
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:1-$31$T1-$31$T1-$31$T1-$31$T1-$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g38965180.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g38965180.jpg
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# __  !$( !<
M;@,!$0 "$0$#$0'_Q "8   " @$% 0             '"0,(!0 ! @0&"@$
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/?W+2T@=?2@*C/5-4Q__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g38965185.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g38965185.jpg
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# __  !$( '$
M;@,!$0 "$0$#$0'_Q "Z   " @(# 0$            '" 8)! 4" PH  0$
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M9T)G[)1A%D4 YQ4(134J.U]D2&$2%[IN3%[%*!.P^H"'49-S<G15.J2GB 2
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M)5Y% E9>PK(56M:C&; QE4"J2XG323;(JG]Q0_CV 2]1G)<;NX2A7)?"Y?\
M4>SUBVRKM4MI)6KO '(KW2.TTZ*P)L&I6[\;\'X.Q]<MMWG%=,T"(>Z_6K6N
MI--("O62&^66IQ;*3*5U58BMID2)\9,?:!<#'[=Q[C(:'XA#SVFZ)S'KVN\Q
MODIO&;8N-JK+$82ICA(TAT)"KZG0=HV/0LBEZ[JJ4W#PYY_)GLY'(V>NS;:O
MF1B%FT@XFFC2'0D'B2;CQD3(@LU1,F@ F$#@^93&\QDWM9TS6M)TRS6D-J;?
MDLI!D4YS7"IEC4U@=ZFYO^]YU&YI=K'CF*DFG*4;JSASI4(O8A7;@G*23"I,
M"R+H(UR]*B<XD=&!RB0I^X!X]-.T1EZ83;7FF:&W<AM17-:@FG=D29UE4X;8
M9B_9?5-.B,MJ;>6A)FMYQ9JU9(MT>:2D)=28H;Z.2:ME2HC[;A)-DHH+I0%/
M--;P 2F _I'!I**"UUA-NVZ^T)*6-F _;&3$0<#/[C8-0:V,9A>KU)7.'-.A
MQ:O!@I+]6:2CY2P),73IVVFUF:C5=LS%N19-!0#F(83E[A1),]L0DZFMU@ %
M8KT]L;:EZ[(7^O+62I9C;(D64M8X.5A+<$5 R3&7K\HK$D,T(UD)"$E(^=*
M.4EV[PR9V_M]@]T?; @1#EIY2X5_6J4$],S"5<W7^C3\+B-,6R6P! W_ &R'
M@K[3$K#'JLKA5_B?&EX1^ZC7)V+:.FX]PH/NK.6X)D0-Y'3'U$SA.4C/VI&B
MY2TK0_T2\5<N2?"#(2,_Q2,_EVQLHKCNZP?0965Q[C>> Q=P5\^O4+7=<+&6
M6YS_ ,%U'!-I4P4W\#)Q4;&LVJ:95Y1%^<#"<$D3D4^4:$YE98S]DTVEQH-+
M/$ST!F1C'/6;/G,S]>F[V#%ZXSJT?^U;2WF(-=J,8\9V5 R",PUFA,5-5Q,$
M,(=US>8&[=P'\.H>JM3LE2$J'W1V+TM0?]7](#Q*CYA50)5X:Y4V">,5SU(Z
MJ?T1:>(%4^0YF6"HF$IP'S2V7/ \ #OY&)X]B^7?_P!^H ;EI)3O3\Q&CNO_
M +]MO_D*_P MR+'/M?FOV_Q^BGJ/ZHO)(WF'/%QT>B4R4N[6 R M'H@3Q(@4
MIO4P^/I_'J[([D]LXJ/I\4JUYH5=H"%+#?XJR,]VZ)*XT"[Y+#\4[%*N)-/-
M['2ZV&GKL8XSB+KKD]+AT8ULBW8% S!B#KL514_N> B)S&\0'H))09C;',M0
MTG]2UB_%NIT/)N'E !0 \:B379/"L3#4-)H%L<5^7K_+ZC9A"NI6*@R^4K F
M8RLPO-$8QU="6D[37D?FR[Y$K,K<$U'1U#]B&#N4!)4UXF48VX+EDZ ^+@D*
MIWTR^?VQ%F-3XK;%$S^D3&PLM;SW.+T_C;"PFM"5E:A1[UG+M9E/0TLV'VCI
MR=>FT"'.@[*"I#]C?U1*/38:2#F!,NDQK[/7+^\0=$T]H"[4V)9@"9*-#0@#
M;B8(DH^H?*24H<OCF_5Y>+RN_0<_:&F<ST/-.E'2<<JX0JUD;)+**1#63C%D
MEB@<A%3E$! /$0,+Z5$4$-6M_<<M><TW5434JW*%5&T@C?,3A"M6=YO&<IMH
MK3+BKDJ=OCFF0[3M6P6787./0:TA N7$=ED]8)ATFC&V=G6'C[R29NSI-UW!
MS%,!E!3,)\10,C*(E]RK;HY=L]4L;Q!?4[X4YI)[QH!+'?6!=N&*OW%DK2LE
MC?UNZ$M!$MFSO9Z_:G.4V[4'D\X=)IQEB5=R[YTXL54F*W&,VK\1<I'(#4Q2
MD.0A""A2U$2,HJ+O2UL)X3JUJ2%3J<<U2??A.']SFDU6SR682$6KA]9M5>MC
MO45I#-+,>QFN%BNQ"N=E6@U6YU"1%4GYI=-+X8JF]\S<3F*4G@'0I*+&WLF$
MVA0$K*"-LI X]9G[HG'*:XP/%ZG:OR-3;'3(RJ<!!2K+Y1H^ 3<S%M:1(W&P
M?I<<[D57K$)Q(SAX"3IX9J@5-,IA#T(4KC%8UJMC9+%H\V"N>:<MG3 @VOC=
MQ]NF4X)&<BXJ?UZR1$B1?.(RH7JY9Z]L%EL:S:5>2)XBI7*H*V.-CD 3<+G<
ME<G;MTCG*GW4,7HC*)=X[;W@*FTI0);H@5PXCTN_,]#/:^$[J:/=](E+_*?!
MW:X1BUCE&$0W@(N>:.#VJ+=5H9!HX.Y;QC7V6B2K?Y)R_)*4P"']/1:):4U<
M*4A"L0F7W&&"XJX?(X\TG+&YI7_AZN1E-;51OFD78Y>V1L9'U0[]S^OIF6>R
MKF>F')'!CJ.%U%W;DPCW,)NW1H44JS"4X0Z+9#J!;U;1.4\3/833&%UB6<1<
MN$7)J>!_8IV!U.U:3:R.I>LRM,<0D<\8IO6AG5>LK&#F4&)T44P(J5NI[IUB
MB0#$ Q@CZB\M=F<TL/NCH_IUJ3]MZD:/?(R\7BB<P9=Y*DD?'?UF$_J!W*_T
MDZFQ4(4!8VJ.8H>)RB)V"^TYT4ZJ@=A$"@T.82AX@;T'T[^G47_QW\$=.O;)
MI/U,V>F@G@J*EG?/A.G&6%-W;#C?<?,6EMB] K=833!Q==(95YZX>)&.U9MC
MQ+]X#L5R"46P)*HE 3@(>(>O5HH#ACKC,^A 'ZVX:3X>S'';!DL++?\ -,5C
M3Q6A8M'4B,S#"X6&4T%L_P#C.)%FV]O5I&0E4V<B#Q*9@A1)%HI$$XF1.IZ
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M845W(S)2J1"YYIFLI=4NJ%6HE6V/CI3K/'<<)+)=9H+V]-;14J7<+>>M2T-
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<\%3_ /#T!#J/%&6/X!_B?\H]*./9!GQ#JC__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g38965186.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g38965186.jpg
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# __  !$(  P
M# ,!$0 "$0$#$0'_Q !K   # 0                 $!@@) 0$
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FH9,\#H),.U%7J?CYC0+?[,?O=/YQ"#JP9S7QLC69]VO/PC0/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g38965187.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g38965187.jpg
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# __  !$( !\
MI0,!$0 "$0$#$0'_Q "!   # 0$! 0             '" D*!@4" 0$! 0$!
M                 @$$ Q   00" 0,# P$&!@,      P$"! 4&!P@1$@D
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M_P!0U,2VP/B?\6'?[TU!3WC9%1M#1MI-!-QF=F8LGI$*VK(&&2RA01SY) "
MKWG&C@\;@#H&VQ;C_P 5:R=G&E;&PQ3GGM_*H3\:W[I?*JJZ';X2H;6!27-'
ME$L.1WM='D/0E1#*Z5'<U7E"O8TGH%NX"\>L^Q79;;:]R_CI;H_QJ\W8%2##
MN1^G\ARB+7962_\ QE1<8_"SRR61$I;9)19UY#(M'!9(]F02.\!.X EFO&K<
M[O''P\Q_&\QXP'JL?Q;: MDR)W*KC_!@'@VO)S&+;'96'9&[.%H<MD0+>&$,
MQD6?[$<YAA*KCJ,7H&X\@W'79LW5G)*)A.=Z"G2,FY+:\M*L\WD5I3&"8Y:U
M.R>0-\J3RY)ET&-#N)\N:"NA03%'+DR&DZ!11&:T%)W3Q@V!:>-3QJ8?)V'Q
MA%9X_P F.1]O:VYN47'JGPL\*X_A[,B1*/+ESB)B^37D,%>H9\2L-+EQ)1!M
M.U%*CG T&H-);!9Y*N?.?7F0\>V+<\4^9.,PZ'$=]Z.DY<]A]8V-?29!D^!U
MF=DO<2--C,$2T-/$$,$BN+**-JJY EW=<7,UDTG UHL^XNB%539<ZTBU?*CC
M .N@-D;RQ:$^NHK,&R8$/.+M8\AUC)2&IUCM]R.XBE$P;PN+S=TSE=OY<>4V
MQ:K)=.QX+N.G&[%PT>0;OTQ39Y+ _,-(3+&R#K3(LJ!EL*H#'J"#9:2(\4/R
MC1QQG/*<+O0"GQNZ6V_@?%O5U5BE]I>^R:5Y:69-,D8CO[2V85%=A)]*55+D
MR3[FARG(J)^00:GY$M:+]_9FBL1WL#:]AF@.O%9H+.L%YC9W.M<MT+>5<[$/
M(8&M7 .0^B<XM(CLCQS7DX+;JIQ3-IN1Q?B&E^U++)$YE801!G< ;6*\$6YB
M<1MF7^$<-OC[;X4Q9>.\-+>LDDM.67%VDQ^6*/EFWY=7%QGOR7'*?*I!L<CQ
M8R6<*,Z.^].BDD>\A3,"A/+[1F7Y#R7Y:7L3(]+0(MAXI]"8A&@Y)R!TECUP
MEC#I=#D//LJ6WSR-95.(N^(]C+J6,-4=59[1R(42O =;CT3=O\<.[,.A7/':
M2>P\IFMLIQVU@\F=#Q,(IZ]NH+&6>,#-'9G4XO/S%L5"P24TM\6W>I"&^,Y!
M]Z@WN^=59=-\LE_D-#D.KX<Z;MSD7;5[;;;''[\G4N+PPIZ*G_(80W(8&WWS
M'VR>^6OL$DQFPF)($&(%QRE"1'-CCEM.XY$<V943(^,:X[FXM-1;0EMRLXZX
MM>8]/KJ[5 JZ;>5=[LJ/)Q,\UTN=WK8"$CXX2D$TB-8T@;9/T7._I%?P\_+X
M?^2_IS_HS\[^M<;_ $#\[^6K\)^6_B+\W](_I#W_ -]^:^1^.^%_J?<]G[O0
#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g389651872.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g389651872.jpg
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# __  !$( !\
MR ,!$0 "$0$#$0'_Q !Q   # 0 # 0$!           '" D& P0%  $* 0$
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M><KY4H;0\*^5070QO&D.0LG2W+1S3R!N$XKSQ$CJ@51S4:A7]4=U3M!/_(V
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+62!='B[V=7>@_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g38965187a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g38965187a.jpg
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# __  !$( "H
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M"))9T=D_<,B+*Q@K"<A%Q2'8H&G>*;ME>@YB& -Q.7<HIE#83G]H-O8)OON
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M@#I]H= GGFB76J_!OM=VLKA1HUB+1R+DG:Y52IE3;0>9X:4.J/5N'61-B8H
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?^5^&;WOT^C09#/X#?X7PB? ^#[G^/\'T:#-T%:#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g38965456.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g38965456.jpg
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M/"]X.GAM<&UE=&$^(#P_>'!A8VME="!E;F0](G(B/S[_[@ .061O8F4 9,
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M/MHQ;V?(]84_3K93_-ZH'W<6#Q5I^[CAGM*=ZORI]M&+>SY'K"GZ=;*?YO5
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M]79&4<NXZ0:1LZFHD@*JBCIN)5$P$3"0N#1=HN .P^158U54\C$)[0XL:Z\
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MT/']V6]0*VRO>X;'K;$D+DR^JR;ERO:&.-VDK,)0*O:)RD<+&5!1ZJ/2"0
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MV5\775]%Y1"J8PC"1S&.4NU%@+TU.28D9Q!_3++CO%U,@JDM'2SQ!RTVB5S
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M?&_87.C F(R+(Q_':'%<69B%-*T<F6)(#2Z]$23$6W1EW;##?6R<K[X+'/\
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MZ30LDQB^JTW,;Z2E>%BN4:CQV2W%>AK-/Y[@+4[=LL9VA3"I[7-/(Q_!KN)
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M<@PF:(?/SY&%F 8U22O$?BZAXY6J[I@,>1[*XP+(XS@;$C&O%%%1GH9DY,H
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MIG2\(D5% UCP 9E3K8:\MG-B+I-I!'FD9"8 Y;MA9LF134U3-$VMFRZMT6Y
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M'1^,ZVU8PD'BNLQ+=,L@)&$!@ZU/[QB&*0$[\YP:X_MLHX?L-Q$X+JCTHJ$
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M)9X_6FK-'P:=W<6!DV>132NHRSE@O+N'[)VD<$TDS' BA><4-P ;S9C"8.:
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M+=G]JDHRN7"G-XAC(PN1J2WK[(8&^2)C'4;OE.VBMS@/,3415BHES9DP.;"
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M08-L"VEOO$U88;-&(,4L(FHX3;75QD"4E+'Q5)'J25N98[M>.:X6CXG9UNX
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M1,(;BEI+&6,YEW:)"9QMCR9?WB)9P5V?R]%JDF_N<+' AW/B;:^?1"[RRQK
M6R8H(/3KI(F(42%*)2[0*>]9,%B E"8SQFG#.:X3&N.R5Q[ *5-Y7DZ-5TH%
MU5%G[J66J[B&2BB1JM;5EGJSLS$4A:BY644YG/.81JU66F_NJV[9@C#]RI\O
M1I+'=3C8*8QM:,/BI5X"'K$Q#8QNS<[6VTFJS40P;OZM7["@H(.FS$R**Q]C
MF**A2F!JDM(K*+!BRBV$?%1C1!A&14>RBXU@U**;5E'QS9-FQ:-TMQ!)!JT1
M(D0H<A4R%*'( :RE0_S2IB=L$-4L:SELL<NPK]>JS]_8Y^>E'";2.@X2#K,A
M)RTP]=J"!6S6,CVRBZA^J4A!VWZ@ZMX8ZK@_S;GX5DM:YTF#<L1XEK+2\]X
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MGFZ)=,2JI\X>:8-]69DI[GD@6(J$CHI+F"E$Q28I'252%..:$Z)5!9TX051
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MOP$YE_%E=?$NGUJV<^GT7[9+Y$ZFVD^@UO[(_E3\G;B"_ 3F7DY?]6-U'J?
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MUNFZ;>-(',G<"<[SRO@Y[V#36Z;IMXT@<R=P)SO/*^#GO8--;INFWC2!S)W
MG.\\KX.>]@TUNFZ;>-(',G<"<[SRO@Y[V#36Z;IMXT@<R=P)SO/*^#GO8--;
MINFWC2!S)W G.\\KX.>]@TUNFZ;>-(',G<"<[SRO@Y[V#36Z;IMXT@<R=P)S
MO/*^#GO8--;INFWC2!S)W G.\\KX.>]@TUNFZ;>-(',G<"<[SRO@Y[V#36Z;
MIMXT@<RH: G.8;:&EAV*8=@C7HB.P".P?O'5Y-4.J:>ZYU]L"V&5&@A]Z%D%
MZ)5TATX"$(H4Q#DB8XIR'#FF(8K1$#%, \H&*(;"&O/I_P ^^%HO'QKHY)#I
M32,D%H+[ZE(/XK@:S*^C'S^-?('HAD7L8[78ODN?D.JIG!NZ;*)K)"HF8Q1V
M'Y(#" \@B&N_['I--5=H>'T\]LO0N;,+KX#F0$MY@]IL<W.#E"XCM(>^3LC4
MS6!SGWVP#3 QB,ASYEX.5S'U3;9NX?<#V)SFFP!?Z!C;)=SR0PS%;H@TBA=*
M*^ODC7JK (%=1;2!CS 2,1>'6%Z9V@L)CB412#WJ=C=3,V3Q+&AU1*J9<U\A
ME(VAIW%IT[)+)AF%MZV]>A=A=APKR:EHVR,?I\.N53\*:R7/F5#WEHNW8O8&
MB()$0!SHDQR+++?A/A>X]V(_RQE!H_O,_1+7P[SY\BSQF$9@:\Y$Q%4V-RML
M>,@9*P2+M#*BS(@*&0(FO"+F-N!N36U&W=<ZKD3)%!A;11RIE/4L?12 '54B
M5,?-:QUPQ#0QAO;M\#<66=EF4<NHI:V?4F;/J1-E.8Z]"1-F-9+)!(M-XV>]
M7GWG*U>3U\LU-H@Y;IK6B6^WTUXZL^5;;/3%B"NS(QC-_,-%T8QM S1BMSJN
M6K4PM0!PD4B9 3YROJ^R]'35%&W$JJ91U$RIELF!DFEIY4N67L:XM',>70)A
M>,"=W>X'&:ZHES'TDH5$@2GNEB],-YP8XMOD0$+T(P$0,ZPT-^OGN[N_W7V/
MQEKI>I\*-KY$J^<OY*1^A6C;5UET1FS"8>DG?@F@<0 WD\OK[[N[O]U]C\9:
M=381]'E>JD?H5.MU?I)GK)_Z5/+Z^^[N[_=?8_&6G4V$?1Y7JI'Z%-;J_23/
M63_TJ>7U]]W=W^Z^Q^,M.IL(^CRO52/T*:W5^DF>LG_I4\OK[[N[O]U]C\9:
M=381]'E>JD?H4UNK]),]9/\ TJ>7U]]W=W^Z^Q^,M.IL(^CRO52/T*:W5^DF
M>LG_ *5/+Z^^[N[_ '7V/QEIU-A'T>5ZJ1^A36ZOTDSUD_\ 2IY?7WW=W?[K
M['XRTZFPCZ/*]5(_0IK=7Z29ZR?^E3R^OON[N_W7V/QEIU-A'T>5ZJ1^A36Z
MOTDSUD_]*GE[?/=W=_NOL?C+4'",(:"XT\H@#T<C]"FMU@MTC_63OTJ_3/[U
ME,S,EP>03V3F9>3>#DK)J0O)&3?/W8I(O(($DA=.W"RXI) <0*7G;%W';;<=
M?(/:U22*3;ZJD4C)<NE$J2+H:/=,OV'<@=ZU?2W9K,FS-C9<Z:Z\75#MS>*]
M#NW'?JMWZY7^;UYUH).8\?D7<19T1W=Y.W'?JMWZY7^;TT$G,>/R)%G1'=WD
M[<=^JW?KE?YO302<QX_(D6=$=W>3MQWZK=^N5_F]-!)S'C\B19T1W=Y.W'?J
MMWZY7^;TT$G,>/R)%G1'=WD[<=^JW?KE?YO302<QX_(D6=$=W>3MQWZK=^N5
M_F]-!)S'C\B19T1W=Y.W'?JMWZY7^;TT$G,>/R)%G1'=WD[<=^JW?KE?YO30
M2<QX_(D6=$=W>3MQWZK=^N5_F]-!)S'C\B19T1W=Y.W'?JMWZY7^;TT$G,>/
MR)%G1'=WD[<=^JW?KE?YO302<QX_(D6=$=W>3MQWZK=^N5_F]-!)S'C\B19T
M1W=Y.W'?JMWZY7^;TT$G,>/R)%G1'=WD[<=^JW?KE?YO302<QX_(D6=$=W>3
MMQWZK=^N5_F]-!)S'C\B19T1W=Y.W'?JMWZY7^;TT$G,>/R)%G1'=WD[<=^J
MW?KE?YO302<QX_(D6=$=W>3MQWZK=^N5_F]-!)S'C\B19T1W=Y.W'?JMWZY7
M^;TT$G,>/R)%G1'=WD[<=^JW?KE?YO302<QX_(D6=$=W>3MQWZK=^N5_F]-!
M)S'C\B19T1W=Y.W'?JMWZY7^;TT$G,>/R)%G1'=WD[<=^JW?KE?YO302<QX_
M(D6=$=W>4FHY<]R6I^V''/%V^+S^G5Y^P)Q^P<[G<X0#G#Z8ZQG,E2YQYL1
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MXM)DN#(.:8MB +HND!5UN#[-UKF.DS),ZI-53B;,#V2F,:94B);+B 6ET0X
M0!+B;8KN9MQ+A[#N%,S1E(D:XM-V6H80EGL<2S,+*ZC+)&9SR#!3!*FY?N7=
ME;L)*N1K-XNBHH*O:ZI%3$324*0*]D<<VFQ_:2AG8I*J)=,Q]8#&6^6TC02B
MR^(!ECBX-LRY.=%:_:#!L"P?"*R11S)$VI,F26D.8YP-Z9>NF),<EZ%N2.XO
M+D>H'P->X!KPXP! N,X[HCX<J\[;HH^YR#-F"IJN$S?\*J_(^]\":0F;_A3\
MC[WP)I"9O^%/R/O? FD)F_X4_(^]\":0F;_A3\C[WP('5U0\3-&[+YISYD.B
MA[GP+]$'O>']D:D?[0,L[^$H'7R;VFMI?KW6%FCTFCIH0NQ^:YT-W+YT-W*O
MH[LZ#/J;)N0CK#HPX#E6Z6N)7;IHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(KA7^U:'^O5B]BU[^_K$EWM=FY?,9#PJXZ&A]]$JW
MM938W1'+!6F^:(Y8)J5*:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)
MHB:(FB)HB:D1W,JI=&Z8959^<9&;B>&O*TG6;[ 8LLC*)L"\!DJTMBNZY1)<
M*L_+'VF;14;/4PC8AR8JJJAT'":)2BH=)0I!(;7/+Q4/))^:,.-7Q#1#/$>)
M:_<$UJB[1@"()"J6MY&52VW2FMYNTY)9YG;6<\-,&6<V.A9C90583REC&1<O
MS=QI@\>U74(11!4O2-S:R*5Q=(!)).^K96V.LA0FB)HB:(N5 H&52 2<\.D+
MN03@F!P 0'F"H80*F4VVPB/( =7DU:G&## P*-^=WH+PIQYQ8Y*M4!76N6\N
M7W%D39<A5EUQ YHJE]K<G7L')6&H\1;^+PJS;R&'H%OPZ7:&R+C^#B96(<^4
M:ZK)PP!20[8D1.XU=^;TG<96?"7F'@5\8+XG\PN+EC>;SKE.R5FV,'+!7-.'
MYV"BJ_3:WPS,.":)R_+<1\] %K;6:K[USFD% 6F =IMDG"JL$#4#HBBG4V9,
MO"+G0X5%V7'W/@49D7B9S&QN-[5KN8+DU<)Y(S/6<TU%K$0CV-X:.'2O9OPK
M5L6YPJL<K4G"];D9K"UKDYQ"9DEI!O,INEWP-SIQ(E;VW3)FF,'.A#.8*82X
M9&^!=:#XB<S+V]O#-\W7J60B[]0H_A1:N&<*Z1XP,=S?&7><7Y GK4Z0IY#9
M,2J.!8F/7+(QBD<FT9J)V)01(X*X&]+?,OB+G0X2K$T $78+VX5*0JAP3-SB
M 8W,'KEW'FB/P1#6U%H6.OC1$T1-$31$T1-$31$T1-$31$T1-$7R;Y4WPAU0
M;_/NQA<W.^H;#2[\.5>E%;^UV"^L\;[#1UYO4?/OCEO'QKII7S;>!:->^<IU
M=7@NRVG<GEB85H5:.,@[J<;%2]@2VO\ 5^UNT(^;EH.+7Z1T!"J=*Z2YJ8F,
M7<P 4>W[+IM:W;BC&&,9-K+KRQKRX-=S'QO%H+H0W "3D"XOM E4TS9:HUQS
MV2K[;6@%PM]S&R.:-F=?D^[F<+FQB^57$2)3")C%\V^*>:8PCN)A#SL;"(B&
M^_7U]BF?M^UKYAH,'_)AM[\K4Q%XAHLT<3:0+,D;5\P.&S#7%AJ,6B,OY*3#
MCC!.Y?"X)^E\JN(D5 #8%/-MBGG@'4V _G8YVW+J9D_M E/,F;080"UY88S:
MF <# B.BAE&7(KDN1LS-!<VIQ,$ FUE.# 98 N!/>0\5PM'-SCVGB(,;FB7G
M&QMBDP\T>J7<<L"/-'K:J,WM 9S#0X,(')IJCC'Y.T;XL*@2=F'@/;4XFX$9
M0RG/'SLN\53N5PLCO_G3Q#_);\[_ *M<4\O.,!C;_P#6OR\XP;CUQU&GV_\
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MFB)HB:(FB+[)OSR@5+IS[&$B'2 D"RA2F,FB*H\B95CE HF'8"@.X]36%/\
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MVE,CR%:F[E)&I$Q)4QP]E+32REI]W16<0)A:3\6)F4ZSZ)^0QA<"8>+E-:6
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M&TU@@(3W-  L: !(L@(#O15C1;.6EU=/<XDDDRP223$DF_G5/(_AS_#U??\
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M,Z.HX$IU3XLN8_0N=>,0X^)7IDEC2 (BS.M$XCBZX@W&/91*W9PM]6O-4?\
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M 0$H[_\ 79R\@B'PAU5K.UCWPU+"C,F<[]><2Z($7?J<71 $3;$ 6JLRL&+
MQU=B&CA= U-L("T#];R DD#.2J>3'"R(<P^5,Y<SY$0*."J.8NY"\PG(.;0
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MO0U$VNVJF2]%.PK#Q+!L#JQT!PWI(;QD* ,!:XS&XE-!=YSFRWQ[UJH%8X;
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MU]B=;;;"8Z=U%2Z5Q$2:R42;IB(QEV@'<-AW05\RMI< ;+T+<4GB5!P U5\
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M)XU3R,X=?S@+K^(!S_6EJKK?;GV)(_;F?(4ZML_[3F_LCOE)Y&<.OYP%U_$
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MJCT\U*/NG-X <>VM.NIGH!QIJCT\U*/NG-X <>VM.NIGH!QIJCT\U*/NG-X
M<>VM.NIGH!QIJCT\U*/NG-X <>VM.NIGH!QIJCT\U*/NG-X <>VM.NIGH!QI
MJCT\U*/NG-X <>VM.NIGH!QIJCT\U*/NG-X <>VM.NIGH!QIJCT\U*/NG-X
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MJ5O\7E3RVIG?*0\"2'9M1J%7T/#Y$UJ7O]W?3RVIGH24AX%D.S? U/5]5NM
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M4TTHY28@!X%I))#8B)-BVV&XB_#VB;*QB7<<2T7I$TNB+.=%F7?-BBKF]8Y
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M,.NK&(1Q$(-,&"$:NZ54;$1YA6ZBIS) 3GGYUMSZY\UTY^S,L/=&-R=3 F(
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MMV'3JVO]'^,WE36).?P%/+"E=_S>!Y;L.G5M?Z/\9O*FL2<_@*>6%*[_ )O
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MBWSFY.-1K$DN@#;P%;312B:T7'*I&YZ2K)JHD?82\],Z)#$-L8I3!SBB ["
M#KFY@(F$'+%;.7Y@X%YX>^PB)>!'-9BE$YBFH(@0! HF$,C500*!AY"B;J;^
MAKT3L8!/:1AP :3HIMCK6G\D^PPMAG7!]I[VR]BZI[O-#F^->!!^&2NV?(."
M\&U&HEC8'(F+,;7^7XD5DK=./)&5L5)?W6T,8,R4TTQF1H628+UQE'F;@Y3?
M(E,=<53&*/T+1;:U5!A5;M#43@^M94393<.@+C&B8)8F.B"Z(#A,!!A=-@A
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M62G*H\B,:<*RM@A7E>(TI]SF,OT:>D9::IM@/)+NY.QMI6O'<2B'0D0(FO\
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M/PK<EBZQJE!'CD8A3BTHJL2W;=I-XE1GQ#GBD6(/B2@,4XXV+Q9D8A))E<]
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M)K&2G%G1I2,8'!1A&2;7B(D8R/4*@5J51A'O,7K-&2A6I"I 9,A3 D4";\P
M*%4G%Z^1,=.D[.U#)KA"+=58<L<K7 VFT@DB-JL3,.9.D&1-Q>6^63'G&:[@
ML<XBP6"R,+%$>:_'WYR.)ON9SI_5)K)&T>-C_P!#KO62/TBMMPBD:T,&)4L
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M!/*FH>Z9CZTF_%&FKU7HG^#E322^D$\J:A[IF/K2;\4::O5>B?X.5-)+Z07
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M-&(<YKL8I")EK[\]PO;EHER(.LLYT3WEBPN%612E*.=>'DPE*4NX7N8 !V
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M_7Z'<#N)5F0^%CA%1GZ._ 1:_+51##&.&\!,V&/L[ILTM%@8OF\K#MIME"!
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M^8.!>?/OKP__ ,"F:!ZFRE ZO4_UCU/J]37HG8V3,[1,/E$AH+)KKQC81*?
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MT6\/*B\NN(OWQUEA?.MVQ768?&UQB,;X-S):;49]?VT==%L\4&&Q?;:[C)A
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MYDVZQ4VZ"Z+A! '"$+K8]V^EQN^KZQ[QA2%VXSE.%($,5.$*YA2X2MRFZ]=
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M3:307I6DA'S&[F7W*JT]3H]/<=HR8><[*<FZG;\IS!4[I2G1@(AT@/G9D^<
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M^&?FJ#L4VP[=?;5A[:*4[13IDIA/NKC(#P;N17)3JVH;?E,==^$>54[HR8B
M!)R@B;;FE*]>',81Y0 I$U#&,;8=]@#T!U)9(;+=-(EZ!EM^XV#N"Q4-J*E\
MX4K6.TQR<YW*@R$D B'=61$0'8>;(.1V'8!V$05VYP;["'5 0V'EU6R73N8)
MC1+<QPB.8WD5$RHJ&3#+=>:]I@;3EXT[HR??23]?NNRZJT4GT<OXK>14:S/Z
M3N,\J=T9/OI)^OW79=-%)]'+^*WD369_2=QGE6VG X]?J<2]+(K(/U2#6LKB
M)%'CDY=RXENYBFYHJ;<XI@W ?0'EZNO(^W27*9V88E-8Q@F,:P@AH%M\#<&8
ME>H=CE1.?V@T4ESCHYE\.$3:+M[Q@+=--PXZ-/\ ?W'RA?\ C#CK?QNOS_=+
M;+FO8SS0Z X !RK[B)+Y@F.\YTIA/#SA^!??;#CY^X]<N.RZ*4[8<?/W'KEQ
MV71%45UPW_PE<>:'./LY<#T91$  RG[Y^]E'?D$=@'8=$0B[E38"*NCB8IS%
M J[D1,5,!,<2@"G* %#?X6B+Y*Y<'YO-77,)E 2*4KM0QC'$VW-)S5S IU_D
M=]@ZNB+ZZ9SN)06="(&,78%W(CSBF$I@VZ3D$I@$!W]$-$5!<.0$Q3*NR&*.
MPE45=)G#K")%#E.!3!U!$-A]#1$[8<?/W'KEQV71$[8<?/W'KEQV71%=%(76
M&YU$!77'_.BN[;N%QV$9ED&_\+MN&^X?!U?D6U$AQRMG- X";59G@:O.;N.D
MN)X0+%Y+9F?R)<Q9;*22D2%+E#( %*5\Y*4I0MLN %*4%-@* !R!Z&OU P&3
M)&!T0N,_5)/N6^C;O+\X\8J9_6]7SG?K,W=/3*QMW1D^^DGZ_==EUM=%)]'+
M^*WD6NUF?TG<9Y4[HR??23]?NNRZ:*3Z.7\5O(FLS^D[C/*OHCV75,":3^66
M4-U$TGCQ500]$2I)J&5-S>J.Q1U9GF53@/<RFT;C 7KK3'@AD5<J9/J'F6Q\
M_2-;>-UMX0X<Z^>Z,F(\T)*3,(GZ,"D?NS&,<3@0"E*"O.$PFY-MMP]$ Y=5
M/E2)9NU>AD#I76N:> D6J:>HJ*KFT[9AWW$@GA$;$-(R9!,4\G)IG*;F'(=\
M\()#\W<"FYQP #F] -]Q'T-M)3:.;>J&ND"E(LO-: -\F&17'.K6/$@L=I7&
M YQR\:'D9)(YDUI.305( "HDL_=)J)[]3I""KSB /7'D'J=75X2_1TU)-9T@
M\05E\ZNE.T;VNO<)Y5R'>2R8D!61E4A4*"B8'>/ ,HD(")5B$ XG%(VVW.VV
MWZNVJ='3F,!3N(RA@:Z[O&S+F5<QU=)#3.O-O6BTY.-<?=&3[Z2?K]UV7312
M?1R_BMY%:UF?TG<9Y4[HR??23]?NNRZ:*3Z.7\5O(FLS^D[C/*N-62DP16$)
M23_@5>I(.RC_  9MPW*L ["'(/7#4Z"G<Q[7RI3F&6X$%C2+6G<AQ9E4RIJ-
M(VZ][2'BT.(.7/%>W5L<..;1_P#"''R6(\/'-_A"_P D<V-:R<QS;*?)&,=0
MPB(\HB(]?7YA[5P;M)7RF@"6RJ>  ( "*_1C9P7=G:$92ZF:XDVDDY;<JM/M
MAQ\_<>N7'9=<\MRG;#CY^X]<N.RZ(G3N1Y"K.3&$0 "@Y7YQA$=MB%%8!.8.
ML&X_ T15%=R *#TKG]Z,8BH"Y6)T1BCL8%!46(!=A]'?;<-NKHB^A5< (<YP
ML4!("@"9RX* IB(@"@;J;]&/-'8>H.VB*AE79>:)SO" 8H&**BKM/<!Z@['.
M4VP^@.VP^AHBH*[H-MU7/*&_(Y6$0W$0#G%!83%W -PW#E#1%3MAQ\_<>N7'
M9=$3MAQ\_<>N7'9=$3MAQ\_<>N7'9=$7OAP"&,?AMK)SG.<PSMLW,H<ZAM@F
MEB@'..8QM@*4 VZFB+ OOQ?]AN[_ -,<=_Z2H:]H^[__ ,3)7]5F_P  KR/M
MQ_P%-_K$O\*_'IK[X7Q"FB+)&(\BV#$^0J]?:K"U^Q62'5=)P,3:*^WM,,I*
MR+)S&,'(P+D.AD)%JZ=E4:%-SB]L%(/-$0UI-HL'H,=PI^'8Q/FT^%'GNF2G
MECF7+2"]I!:'9B1>WUOMG<3K,'Q)F(44J7/J0;C93VAX>7V1#"#>+=X&"]Y\
MHQ,)E^S>]MX<XFJY2EN)FTWM*WY?C*_7HFNO([&3AK,2415+DWB$B)M'4]V@
MS [,=@Z1!82E*!A,/R_AM1/P;!]K-HMEY]3]4),L2J-TZ8XDS;P;,?+O./-;
M%PO-L)@(V+Z'Q&EH*_%-F-G<=DT[-HYTQTVH;+8UH,D EC7P %XP;$$1RQRK
M$V0\@NN)?!/OD,#D*N4Y%EPUVB%DL&*P-1A*\\H31E:9.M%@(]_%,F;Q=F\8
MQ8 8JPF$3*&ZO)S=]A6%LV/VPV8&&5=1,;B]$=:$R:YS7DRG.#^<XB(<(AW>
M6AKJZ7M1LQM&_$*:FESL*K?Z.9<MC7- > 6FZ(@0)%U8>RE<8')'O441/1F,
MZ!CM. XH8&CQC"EQ(MUUHZ*HZKI:1F9EX=Q+3,U,/WBB[E=538Q^: % I"@&
M[V=PVKP7MJJ,,K:R?44CL.?,-^87- ?-;  1NB[&#0!'A,2=-M!74^,=D5/B
M])3RI%;*K@P$,#'.NL=&V <Z.4^19JX&^*?+#O%F9LHY=1QO(8"X:<2(Q49'
M#BVF-9.S7UZW")I%=[N),"2#Q=,&Q!<" B=4ZI!-\MR<_P!H>R&$2MHL.P79
MZKKCM)BE9?>W3382I <;SBV]S!88$@#-8%N=AMIJR=L[B&.[24E$<!H*6#")
M4HF9-+;&@W><ZT$BTKPLD7Z\M(/Y9R1))S*OGLFY30(5-!-S(.EG:Z:"90 J
M;<BJP@0H   0 #;7U V1)IF-II$='+:&VY26@ G?B03'=RKY\G3#.G.GN$-(
MXNAF#K0-Z ($-Q=/52MKC6_@5_XA?^1/JIGG=X^(J]3?K$OX;?&%[D7_ .KL
M?_0;&/\ NVJ>ORXVB_OVO_K\[QA?H]@7]S4?]5E^)65K2+;)HBRUAJ[7JFVP
M"8T@H><NMF21KL(E)P#6Q.F[MPX*ND>':OA[6:OE3)<TZPA\@AS^4H;F B]*
MIUE0[3Q-5M-]!UF6NN+\&SMGR$C',6@5Z1R+%L&KI@U<M6^[5^,0X=JG$.:(
MD,8I3<I=@(M<+C<U,G<-%-S/D&"KEBM]6S@-=,*<8W@FUGK3F/4DQKTJ6%(T
M558H' I"]&//!)/;<!$QA(NAQ52+>Q5;A:L05F(C3V"@+R+J!K,:G&, !:5C
MBEBV3= .>"96QQ02W$Y_DOUPB.B+;;+4>4F/<T&:MH&7K08HKB]>P(VKU997
M7#SURT1(YM$^9HHI(H(1H(F<F.4ZJPB([AL ")%XQ (&#G (" \H" @(#OZ(
M"')HBKHB:(M7..C^>\/'^Q-__O4ONON#[M?^ :C^ON\07Q[]X'_&,O\ J<M:
M)Z^@%X.FB+)N'LCV/$V0X"]5& KEEL\49XW@8JU5QO;8DTI*LUHMH[+ .@,@
M^DV2[PJC0# 8"N */-$=M:/:+":+'<-U#%:A]-A327S'RYAE/@!DO @P,,^=
M=#LSB%3A&*2ZZ@E2Y^(O.C8R8T/9;;&!!$;<L%[A9UCH?+<[[V_AKB+@J:'$
MY<+]!V/-;.KPD577T1C:?=KKQU5MC:((BBRE9=J1N51J( *9T%Q*4H&^2^8M
MF*K%-GL)VJVEV<GSW;)2F.IZ-TY[R;Y%KV7SE!C!S<L1#(OH/&*?#L7Q+9S9
M[:"3(&TDR;IJH26,#?.-V6ZX+8MA%KN)0.1[Z?B I7OFV,+U6:4UJO#41M,8
M,[BTZ!@'F/0K-EDX)-A%R4>P:O#IR;2+*"@*F.!C+'#D 0#6QPZE^IF.[(XI
M0U4^;5XM).M-FS'/9,#P070>2"03$$6@@ +1UU=+VAP?:P5=+3MD894--.94
MM@F-+2(,-QMX-.ZTV$1)W5@?+MRALC^]75:QP^,J#CCN)Q4-:3%Q=*A^UCGC
MX:ENG!G\O,/#+R\U-2CQRJL[764_?!$I0*!2% .KV3PJLP#MNK\"K:J=4RQA
M&E&DF.? S"'70"8"Z2! "(&7*2=7M/58?B?953XE*D2Y36X@6.?*8&N<V%D'
M-$3;'=X,B]"L#Q-;OTEP^8[QA,\.4YP;VWA^6KN2,>NG5(/D^4R::O2#F;?N
M(5=JM=5K+'RJ)53K 8A$2$4.80 "&'R+':F?A>&5N,8^,69M[+Q,-E3&Z<48
MDF8W1L:X0E<YMX.:#$YHA>G810T>)SI6'4S</?L\["+SF_D34AX9:XM'Y40/
MNB,T2OS(3K-"/GIZ.:G,HUCIV9CVQSB F,V8R3IJW'G%Y#!T*1=A]$/1'JZ^
MU)$]]1);.F$%[F-)AD!NB(' 5\BU8 JYK&VRVS'!OP0;%%ZO+'34'(>!%Z?<
M*7]F.;_V]NO]W\?KXK^\A_BNF_JH7UW]WG_"M3_6CXEE'7SHO?TT1=Z-?]RY
M!C)=JM'PQ[UJ^!F_1!PQ=BS7(X!L\0$2@LU7%/FJ$W #$$0T1>BF0+Q+V3A*
M?2F:X>J1]NOELCD<+L8JNQD#+-*^AVDJYET46:*:J$$W*5?F'. "=,2E-OSB
MB!%F5FX:1N>8+A53@:T?#[C#)#/X<T#''=/IM:J.IE:R+3!T.WCRIW*&X* <
M-M]^KHBQ-PIY!G!AK9'7>"I+3ASQE4IZ-M+]Q58Q!:<EBF4:QR2\L<JCN6LL
MKSCB<I $.;S0V QBZ(H2L6Q7"V%L S]#BH1%SF'*-C5MZTK#L)AR\K;*<2BX
MZIJ+O45CM&Q(Q4"*E)L;I"B(#RZ(M;^*NL0M/X@<E05>:(Q\2E,-WC9@W*4C
M=F>3C6;]R@@0OR*2!7+@_,(&P$#D#J:(M?-$31%#Y._LU<1'U@Q__O-@->W=
M@/\ Q&I/ZK5?P%X_VY?X"/\ 61XEY$F^6-\,?CZ^\&^:.!?$BIJI2J"'. 2\
MO* @/-$2FV'DY!#Y(!Y>00Y0U!\TM>827 @GW43DANQX$;-:Q[0/GKP+8Y+,
MH.XO=OA6SM/6+A9SY9^(^FXGB.%.DXE\VV/HEGCZ$@7EHRD$=W-CFU;DB-QF
M+!87()](^<](<4G:Q3@).:?;YCVNP"51[<X=A6QM;6S]K9M2)U0YT^8Z7*I@
M8N;,B\M8+MC6F$8@ 6A?2&R^-39NQV(XCM=24,K!&4YE4C1*EM?-FD0>YHN@
MN<'6DMB1NE7#BZY..'IO[V)A>EUJDFI_$I$L[%GDDO4("?D,AN+U.-(4S.3E
M)-@[=D;0[61_>4TQ*!>B(41$ Y='BTANT<G;+:NKJJB7B6%5%RDNS7M;+:QT
M ;' -) YQRFV*R\+GTFSM7LKLU1TM-,PO$:43)YF2V.F/<X6^<"X@;@M5C<,
M\YD_''&WDOAGP;4L;H8?JF?+Y/Y2LMGI$!+/(?$\6^3:OXR;N<J156'A(F/;
M"G&H(]$(NCCSA, F#72;:R,%Q/8.CVLQNIK6[45>%2)=-(DS)C=)4.NM9.$I
MI%Z\71<^Z8BTFR*T6R,S&:3:VKV=PNFHW[-TN)S)D^=/EL=<D.C&7?<#" \U
ML?.@ +59F"LNX><>^@RY,58KQQ8:#ES-,;6ZG,ST&HY3J,"DT=#99JBP/.3A
M8]6WR:)U$7*B1SH-P_>BDYXZS-J\"QYO9#+.)5E1(Q'#*$Z=K9I:Y\]QL:\@
MQ==9N1M.=8^R^*X35=J4Z714LJ9AT^OT<J]+!:V2 27 $$ EUD<L(+S?XFDD
MD.(_/S=!-)!!OF;)*"*"*9$D4$DK9)ID1223*5-)-(I>:!2@ % -@ ->U[*S
M&3=E,+G,)-[#Y!)-L7:-MXQW;<ISQC:O)-I63)>T%=*FAH<RLG  9M(Z[DWL
MF]"%BPAK?+2)HBVVX&O[3%+_ *-98_W27C7D7;M_PLQ3X#/X;5ZAV-?\1L/X
M7_P'+=9/^#3_ &!?C:_/^;\_,^'_ /"U?= RL_,L\;U]ZH52?#ZFB+T%X++]
M=S2Z-6[E4QGARG1T]8\K6&8K,8JJI%N$7CE(TO87:2KE1V*P FV03#F= D/.
M+L'*1=MM;XW%>"+CFC$<-"QDG>^(.8@8AY*0S&56BZ(S%=Y'PS-O()N$V2;]
MNEN8"@4W-4#JB&B+M93E+5CWB8=,<&U&JC<,JU"B2I6+BKL)LT/*2K95W*J1
M#%V064:D^7*55XKS=B)%,("7JZ(HSB,R6TK?$E%O,3P=-F;['U./J%@5:5MC
M.Q3C(CQ<"O','%JD,S6G8\G-;%5.7<IC"4W* CHB@>->78+FQ'"3C:ODS-%T
M[MG+3RO,VC!J25E$X]5E$O"LT"HGD6YDU3F(&_1D4  $"B&B+1;1$T1731_M
MSJ/]**[]FF.K]/\ /2OS[%9G_,S/S#UY(YG_ -<F7/\ :CD'_2V7U^HF!?W'
M1?U23_-M7YN8Q_>]7_69O\,K&NMJM<FB+?G@!R3GR&RI$8IX?:M0I6Q9&ME?
M>V:>M%(B[/)0]-@5 \H 6EY)-8:Y44XY=15VHF!%#+ GS#"?8H^4]JV"[*SL
M'./;3U51(U:FGMII<J8YFEJ"&W&EK7"^02("!(M@O4>S3$=HV8@,'P6FD3:.
MHF1G3)DMK]$P 1)<X&XTC.0"O1JQ3V%D<W^^2<3F#*[17TI@7$M+BZ*^&#C9
M*KM,FRB[Z)N5[@X11NK$N#HN6'0$<$*)%3I*&ZB@F'R*DH]H*O"=C=C=IJF?
M+F8E6S[YTCQ,N$#1RGNO7LA$&$[PW5Z?53\!D5FU>TN!RJ6:*.13W!=8Z6'"
MR8]@@6@&!BYL+;28K!N><KVN)HG CQ<5:DT&<XB\LT#(%'FU'&.X66;V*>9S
MS6&A+4A34FZ$2ZMZ!E3%05%$VRBPAMS0*!>IV7P/#ZNJVEV*QBNJ)6S&&8BP
MMF&<YA8P WI9>7 M8;OFDPB8+F=I,9JZ6GV<VHPRAIYN-8EAS@Z4)+7-<XGF
MO:P-(+A'S@(PM7=X_<B(P$SP4-[A$XG#BVIL8UL^<GAZS!^1D2XFE8E:OPV0
M(5@D$6]28..<Z<-CD4!(A#&*'-.4!M=F&',K<*VA>U]<[8FIFAE$U\Q[)I:P
MNTFCF$A\N^8 .!%HLW5=V_JF4N(8)2RFT<O:V5+)JWLE,,B6YPYKIC0VX^[
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M!)8RJ6+K)@JEVV"J)NVT0=V.QQ:<I,B)^FFI)M& DDZ>N04'GBL"NQN4 #D
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M3+8P.,AK!=!87 ML&8QLLM4X)VIC"<*GX;4X;)JG54XNG%[B!-&4%Q!C88.
MA&*L_&/%KC7$^;Y+-M9X4,<@Z06KK_'M5&Y70D9C&:@V3EH]F8)T=95Q*.+
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M'2,0EF7(EZ29S76,R1CN6[Q4)T_O9WYSUI\ //O0UG.[".U,.@,+F#A<WO\
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M.V:7F&KP>(AL(1O#W2L;AI/S^(7"9P$P@.2*N8HF$-^:,JV$HB! *3E*(=0
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M$JDII3I\0+3+82+O!9!=O(M-K<-!X^NM+>3ZE7R)'655O%VE6.<3\#+T^=-
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M :V>S6,NVBPEF+3););WO>TAD;A,MVC<YGO'.8YS>%:S&L'DX+B#\.EN,QK
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M$D8G+:Z7-FL:^%XQ:3E$8[ALR+2XUA)PC&9N'3"V9)8]S/-$' $B.3=61>(
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MN)44V;)F.E1T;GL +7MC;&![UH56.8-3855,U6\:"KI-/+;,AI&M=9!RO"W
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MJK&)SL_-W&0=L8EHD_E&SIG#,&:$8Z7<KJ(KF'F$*4 $X:N8WBN,LQ6BV=P
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MA9%S'G=($#E*BX%OSR@(F$ -MN.VNNPBM9B=!3XE+O"544K7@$FPN;&VW+;
MKF<0HW8?7SL/F!NDDSWM)@+0##-D67>)D^V2F!A$=BXHPJ(["/4+B^MCU $
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M.)[/X-J=0W"&54FJP^>R5.%1 NFE[7$/E^\YOA"CN'SY*4RWOSO[.N:.0W.
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M[1%?=?8<YWV;40C8-+X#9Q;BK[[/_8NNG]+<?_Z1M]9WW:FAW:C2M.0T<_\
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M%!Z\>F9C).2BJ9%,P()";FIE(0 *&?@F!_5W"9>%T<][Y$F#&:0@S+C;&AY
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MD%MUSH1(!$(P $0(#(,EMJUN*5KL1JYN)O@)LV6^(&^T^#-O+*O$7]LV//\
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M#)DB1,EFG=+:^982UEKH9PT.CWU;N"^;Y\<0<P *3SHT7FE+ML4HV>-$I V
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M7RX 7VM;&-[=!M%@C%:L1VP2$>4/0D&74VV_G:74VY-M>EXOSJ"=,'FF6_\
MFWKA:0?TUA_CI?\ .-68>)<HFS]F$NY0$UVF2E$Z9U2@803Y133^3/L #U-<
M_LB[1[$86\VC4V9,N4KH=J1?VRQ!@@#K#LO U90SD_!SA#$T?-2H+W&+M4SN
MQ>7:H7N3DH%_7:XFA+PDA50*2ITMLY;="C$O %8SDYE"J"//VY78[69FV.(O
M+:AN'366&6U], YKG$-?>B)CLI<]OG" ,+%O=I9E'+V9HA+,EU=*(CI#I["
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MM9^#<0+>"GX%/&<E9ZC$>6L_8*X[C4I"9C+!(Q[EQ6:HR<F>G53YZAGI4$D
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M7$ B' J[?WO[G('I:EH<! F+=S>&95<T,:UH@0+3G.<K/&3O]3W#)_13*/\
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M/=)]2<-#70;JUHAEYSET.VT?K;B$,NL'^"U8 *DF0=R$(41ZHE(4HB&^^PB
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MHEALLALH76DB.[%9Z6_LLL?^T))_[LHO7%4W_$*?_LF7_/!=;._P/*_VH_\
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MP467=12*22?/, <X1 H"/*.N.[0]J-EJ[9.NDTN*T#S>;!HFM))B,EJZK8S
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MNVUV.#B!BV'Y?2MY5R[]E=IS LH*T-NC_1'D5!POF, $?-)E#D 1_P!7EQ]
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MMD_%</!?BM<X1FMR&IF$'+D,20NNVQP':"IKY+J7#JYUS#J0'\F<H86YMP-
M6"?,SF3\$F3_ +@;5XJUV?UVV.]K8?ZUO*N/^K6UGLJO]4>17IC?#V7D,B4!
MPXQ1DQ!NA=ZDLNX5H=I31112L$<HJLLH:* B2**91,8P\@% 1'6CVDVQV1.S
MM:UF+X?-F391#98FMC&Z1GB8[BWVSNSFT<O&Z2=,PZN:&S(O&C.2-FY8N[E;
M#V7'64LF.FN*LEN6KG(-T<-G+>@VU=NX;KV2250<(+HPYTED5DC 8ARB)3%$
M! =M7< VRV2DX%12IN*T#9K:22"#-;$$2V@@VY0;"L;&MF-IIN,U<V305NB=
M4S2W\D<A>2-S,K!\R^8_P290_%Y<?$NMM]=MCO:V'^M;RK6?53:KZ#6^J/(L
MY\/>(\KL+M9UGV+\C,D5<,9O9I*O*-:6B1W;W&E@;-&Q%',2D0[ATX5*FFF7
M<ZAS !0$1UQ.W6UNR]50T+*;$Z!]W%J1S@)K;&B8+<N0;IS+K]D-G]HZ2;7.
MG4%;>=AL]H_)G=;;N+!*>%\R<P@>:3*'(0O_ +/+CU@_^XNNV.VVR%][78KA
M[8/<!^5:;(\*Y-^RFTP(;*H*T2PQD/R1Z(WE]^9?,?X),H?B\N/B73Z[;'>U
ML/\ 6MY51]5-JOH-;ZH\BSA4L1Y81P#FMBKB_(R+QY;\/*-&BM&M*3ITFT<V
MX7)VS<\259P1OTY .)"FYO/#?;?7&5>UVS4[;K#ZAN)4 IVTM;>.E; 1T<-W
M=NB'!OKL*39W'I6Q^)4KJ"MTAJ*.[^3.6W>M6#_,OF/\$F4/Q>7'Q+KL_KML
M=[6P_P!:WE7'_53:KZ#6^J/(GF6S(/\ [(\HC\+'EQ\2ZI=MIL:[+BV'^M;R
MJ_)V5VD .DP^N)_-GD6;KOB/*ZN#>'Z/1Q=D99['2&<.Z#-*C6E1TR"0M=6>
M,3.FQ(H7#<CI IC)F.4H' H\T1V'7&X!M7LLS;7'IKL1H&TL^71!DTS1=)$H
MAT+8&!RYETV,X!C[MGL'IY-!77Y;JDO_ "9-AF$C<LL6$?,OF3\$F4/Q>7'Q
M+KM3MGL?+)8<7P\D&$=*VV&[E7)?57:@VLH*VZ<GY(Y.)?"N%\Q]&;_JCR@/
M(( 'F^MY=Q'DVW/#D*'Q1#4?7;9#(S%</+S8!I6[HAG5QFRFTX)<^@K;H$3^
M2.YWEGCB-Q/E:0R*P788NR.\1)B_#;8ZK6C6=PD1PUQM7VSI RR,6=$%FSE(
MR:A.=SBG*("')KB^S[:W9BCV7DT]9B=!+FZ>I-LUMH,]^_WUU.VVS^T-1CLV
M?28;7.9<DCYL[DIN\L#^9G,GX),G_<#:O%6NU^NVQWM;#_6MY5R'U:VL]E5_
MJCR+)^$L0Y:99EQ,\>8LR0S:M<D4IPY=.J-9V[9N@A8HY59===6,*DBDDD03
M&,80* !U=<[MEM=LH=C\2DTN+8?.JYU(]K6":V(:_P X9;28<(72;*[-[24V
MTV'5;\/KFR!-YXT9R\,+%;-WPWF!6Y6]9'$^3%45K795T5DJ':3IJHJ33XR:
MJ9RQ0E,FH78Q1#D$H@/HZV>';:[(##*<'%</!#&Q&E;9S1OK55^RFT[:E\YN
M'UQ>YQLT1MMX%:WF9S)^"3)_W VKQ5K/^NVQWM;#_6MY5@?5K:SV57^J/(LZ
MX%Q-EAE(Y6,\Q;D=J5QP_P"7V3<SFD61N1=X\KZ235FB=>-3(J[<J?(II@(G
M.;D* CKA]M]K=F:@87J>*T!>S&*9YA,:87'$AQMR-B25V.QN!8_3S*]]9AM<
MT'#YH$99MC YLX"P5YF<R!M_U1Y/Z@?^H-J\4Z[J9MOL6Z:XLQ;#[H<1\ZW*
M+#NKCSLMM7+:UK<,KW-+ 0=$?=6YM]/,SF3\$F3_ +@;5XJT9MKL;>$<6P^$
M?2MY52=FMK ">JZ\;^B/(LYP&(\LDX<,HL3XMR,1XXRUBITW9FI%E*[6;MZ_
M>DW"Z+48WMA5! ZQ .<I1(03E 1 3!KB7[7[*OVYI:OK6@,GJR>2=*V <^<P
MPRY3"(&\NT.SV/,V-J*:7AU<9W6,J T9R,DD#<W 3PK!GF9S)^"3)_W VKQ5
MKM/KML=[6P_UK>5<9]6MK/95?ZH\B>9G,GX),G_<#:O%6GUVV.]K8?ZUO*GU
M:VL]E5_JCR+]2/O6D#.UK@]I<39(28KTJE9[XJM%SL6]B)%))>S.5$%%&4@@
MW<$37(.Y#"7FF#E 1U^<O;]7T.)]J%=68;42YM,1(%YA#FN%T9#FC98OO?L7
MH*F@[.Z.GKY;Y522[F.$'-O&T$9]U;XW YTH)91(YDU 61V.F82'#]\$>0Q1
M P<H:\PPX#62WW-W)N9%Z?4@:.$!"(/?6'>WWWJYYZZ7[)K<:.7T1Q+ B5),
MG;L[64,=TY.9)JB9,QEU3&3,+Q HF3,)Q$AA*(AN&P[#K%J); ]A#1$$[G>\
M1(X#!+[H%L3=(M&X;8VY[5'"_?;_ ,^>>NE^R:R1*EP\UO$$B>^J=OOO5SSU
MTOV34Z.7T1Q)$J12>.QC'1Q=N1.5ZV*4XN%1.4HMW B!3"?G  B "(? U!E2
MS,#RUM^Z1& C"(LCF4WG%MTGFQC#<CGX=_*H[M]]ZN>>NE^R:G1R^B.)1$IV
M^^]7//72_9--'+Z(XDB5)N7CP(^*,#MT!C$><XP.%@,;9V< YQ@/N;8 VY=6
MY$N7K#VW1=LW!F"7WC(3DAEW,W HSM]]ZN>>NE^R:NF7+CYHXDB54K]]SB_X
M<\^6#_C2_7_C-1HV $AHC#,H=SA=-K2L/7V5E4[7*IIR<BFF!VP@FF^=)D 1
MCV0B($(J!0$1'K:Y<<V:]C;& V 9!ER#<6T821>.4Y=]6?W8E^^TIX1>=FU7
M$YRJXE3U5EI8]F@$SRLD8BDLP(<AW[LQ#E,Z2 2G(982F*(#L(#R"&J8"!&X
M1 [X.4'>4"PQ%A'X<O&H9>8ENG7*$K)@!%EBAM(O #8%E #8 6Y   V^%J8D
M" R!1!H-Z O9X6KB[L2_?:4\(O.S:F)SE51*N.O2DFHE8NDDI%3F5N0.3GOG
M1^8<JC;FG)SE1YIR^@(<H:I(#B"ZTM,1'<.<9COBU1E!!R.$#OC,<X5N=V)?
MOM*>$7G9M2+! 6!3$IW8E^^TIX1>=FU,2D2KD2DY/R0=K=TI#I0LC)(%>WG7
M2@F,8[.*8*=+S^C$Y0'F[[;@ ZINMOZ2 TD(1W81C".6$;89(VJ!S1=;8V,8
M;D80C#/"R.:Q6WW8E^^TIX1>=FU5$YRIB4[L2_?:4\(O.S:1.<I$K/U=?/?)
M.L'%Z[%19G(J*J"Y7%10P2KM,IE#BISE#%(4  1$1  VZFMK0,9JSW0%XOB3
M"TFP1.<P '  L.K)@#N@0&\,L!FMMX;5)=OOO5SSUTOV36PT<OHCB6+$KD)(
MOB"(B\>#N&VW;2X>CO\ KQZVK,Z6T 76B,=P)$]Y=^7>/"2#DJ;MT0H&1V*1
MPL4H;M&QAV*4X &YA$?ACJFFDRVR[MT!HR" @!O*2YSG%SB2XY2<I[ZC.WWW
MJYYZZ7[)K(T<OHCB41*E(=Z]/),RG>.CE,HH!BF<+&*8 04V 0$X@.V^J9DF
M4YA:YK2T[A @C26&\RQPS6*..^>@/(]=AR=0'*X!U1] #ZN%C"3$#+F"DN<<
MIBOCM]]ZN>>NE^R:IT<OHCB41*DX]X\,5^)G;HPE8@)1,X6,)1[:3#<HB<>:
M.P[<FJ72Y<6FZV(-E@LL.13><06QYI%HW"HP'[\0 1?/!'8/^-+];^,U5HY?
M1'$HO'+NIV^_]7//72_9-4NERP+&CB5N<3HSW;JM._2,@G7XPZ;]\F<TRY*8
MZ;MP0YB@R((%,8J@&,4/0 >36JQ$!M3!M@N[BV%(]YE0),%AONQ+]]I3PB\[
M-K!B<Y65>)RIW8E^^TIX1>=FTB<Y2)5QSTI)D:5@224B05*\BHH)'SHHJ*=T
M)$O2*"54!.?FD -QW'8 #T-4M:UA)8 "XQ,+(G.<YWS:HS>]$!O#,,PWLBMS
MNQ+]]I3PB\[-JJ)SE3$KD1EY85T &5DQ 5D0$!D'@@("H4! 0%;80$-0;<J@
MVY5-6B4E$K%,)I2<BDF5\L!2)OG29"@ AL!2$5 I0^$&H: QH8RQ@$ !8 ,P
M&X%,3$DY28G?.<YSOJ![L2_?:4\(O.S:JB<Y2)5ST^4E%)]B123D5"&+(<XB
MCYT<AMHQX8.<4RHE'8P;AOU!U!MRVJ;SLY5KA,2_-*/=:4W$A-Q[HO.7<H".
M_P"_=?2 !+AYQRG=/"J08 -'FA5[L2_?:4\(O.S:F)SE3$K)&.)*155L JR+
M]44XH@IBH\<J"F89!B BF)U1YAA PAN&P\H]?632@/F"-KFQAND1A&&:.ZL:
MI<0PP.6$=^&2/!N9EDOMV0$VQ7CT1$W-  <N!Y1$>:4  _5';D#6\T<N,+HB
M=X+ ?,#(EY AEC9#A7V5Q*CU'$B("&_\,YZ@\H#\MU!U=ER&1B6"$,R@S67@
MTN%\Q@+(V98#>C;FW5)BM)EBDS L^*<SYV B"JX&,!46PAN;G (ASAY/@ZQI
M4D&:[F<X-&YN1.]DRJJ^2V[$W,VYQ*,Z>6^?R/T9S\WJ]H!T/Q?(EY?15I7G
M%W7D-MPWW6<[;;\N_P GU-2)$+0RW@\B7HV+O/U9, 8<U9^ C'-A/S57 ")Q
M%3G";8W*<1ZN_+JALEG.:Q@A>),!N[N3=51F.)B28PAWLW!O*/Z:6^?R/T9S
M\WJK0#H?B^14WES(+2G3(\Y=_MTR6_.6<"&PG*'+N;;8=]5.DMT+FE@@8[FY
M8@>08@P.7OC(>$;BYY%:3!\Z!-9^! 6.4H$6< 4  =MB@4VP &VVWH:LRJ=N
MC;!ED.CN<2F^3:3:NETTM\_D?HSGYO5S0#H?B^11>7(5:3%"0YZS\0"*E#!S
ME7 @!B,'!RF#<W(8@EW ?0VWUC5<@"3$LW1N;H,1N908$;\(+(IG#26]$^&S
MPBQ:U=T)[8![H3([]9Z_'_\ JZY]DF:)CS==$D;AM68"T>; <2KW0G^^$UZ]
M?]EU=T<W,[B*C32[^CO-TD(PB(PSPRJ>82<L$!9!4DI,%4^X!B"H^=](0JDK
MS1,03*\X@' NVX;;[:LEK \.( >V,#NB.6!RB.[GW5,J8R8'"0YKA'G72#;N
M7H?A5M]V)?OM*>$7G9M5Q.<JN)0)>7$0WEI0>7;ED7G4'J__ $WHZ1.<J(Q5
MQ.965+4X$X2DD!S3%D(8X/W8',0A8?F$,<%N<8I.>.P".P;CMU=4P$2[W3LI
MW3PYT%@#1YK<@S<&96[W8E^^TIX1>=FU47.-I)B@L$!D52S$P [A+RH"&X@(
M2+S<! !$!#]_ZH#J(E3$JX;+*2B;R,*G)R*91K%?4$J;YT0HJ*,DC*'$"J@
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MB_'U!R'@4'<X5AG('VW2W[)M]CV.N4/S\SAY5M&>:K-U4JU<%2^VFN_7B/\
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ME8;^=./K7)^QC:L3\K?A*"HKT"_"#67,W%(35M%*-_J3)?3,?_RK5)\\<!_
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M"&X ;3_W'MFG<T;,5T?Z]1?*3[!9OTZL_8W+C\M7(_\ T=4 ?@7ECM]B]/\
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M+W>]!C;O+<1,!"FO 'D$+0R#8>K]2GNON4V%H=87-#A',<AWN P.\OF%P+2
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MN$E:.$:_3LAD-LTG*NVIV5I/)]CO-?54>*&L=I:N9E_A!=4"HBU(E'O9\XS
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M(<39&'FKPYR?*"TS;FI'G;"EDRV[COL/+)G'?F]3_A;:_H9[)ZS_ /AWA5\
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M8HV;=T4QQ:Y@=$B&7<7E]9@\VBJYM&]S'OE/+2YD"PD&!NG=X5R>4'_I;?#
M 'X@>CJYKDSTA[N^L4T$S< X@G=\!ZIP'X>P?W=-=F=,]W?349N8<2=WP#J&
M /2'?X?6TUV9TSW=]-1FYAQ)W?#YYZ0%'379G3/=WTU";F'$J=W@ZH" ^B(^
MC\/;4Z[,Z:D4,S=AQ*OE!O\ \/;X'-#]34:[,Z9[N^H-!,W (< 5]T:BHY,E
M459<2#5X)5I(O%-ER%=R#18CQHQ Y>: F2<)D,IL.P[; .X#K\4/^;#]^1G8
MYL>>Q#LQJM)VH8Y+O54R5-O/PVC:\DZ1I!#*B>YIT;/-$HAY,2 ?WY_Y,/W
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M?M+]R9Q'850-)MTDS^$5@XSP"D,914"D ACG.<.84J90'GG,8Q@*!"@ [CU
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MYI]OTSV<[UIY4_\ ;]E>V&_$7?>^]A\5K)./5/,U@Q9%D#Y+:!F]P3%PX;@
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MA@$QC"(B(]W+),B63:8KBYP@\PR16_\ Z!?A!K:3-Q4A-6T4HW^I,E],Q_\
MRK5)\\<!_ I47JI0FB*5<?4N*_Z0]E$U;E?K#N >)0>[P**U>=YQX5*H/RI_
MXM3]P;4(5B3)7VXR'TI$_8MIKE'_ *R];*5\V%8FI5Q35<^K\)]>(G[(M=$7
M0D/JC)_7-]_+FT1=31%<]6_AYO\ HM8/80Z(K8T1-$5S-/M1F?KY#^Q)+1%;
M.B)HBW7PG]H$?].R?LQ31%=5T^U]?^.1_=FUG8=^MGX*M5/F=\+"NMVM<I1A
M_,YCZ40]G-]8M1Y[.[,HW>\HL>J.LH9%*:(I)'ZDN_I]K[&<ZCW0X#^!%&ZE
M$T12SCZG17\4^]F'U;D?K+N]X@H7Y>>-%V1OQDYM*!REV"F"/.-S ^T^.';<
M1V$=?AM]^Z4Z;VZUS@UT"QEA!!R"V&6&^OV?^YC.DR^Q*@F.>VXZ8\6&-MXY
M0,G?6EN7*XZR7CBW4>-MCVHO;)!R,4E-1:Z!5DSO&RB":;H%6[H%(\XGV6*0
M"*"3?F& VVOF#L_QFDV0VNHMH*^C;64E/-#G2WM)$.D/?-RA?16VN#SMI=FJ
MG!Z"KU:KFM%U[3;8?-W@5KU-X2NBV3FUJ7M3Z\0;"JPL9%=U[FV@WR+F+K\U
M'3$#-$953II"OVY\_2,X%FJS.)2%$^ZB15#>R8;VJ;.2MDQA,BC9AM6ZL?,F
M"72Z8P=-8^7.E.=,#&39+0\,;,9,:2Z!YI*\WK>SS%9VTTW$ZJJ=7TV@A*+Z
MA\EOF7'R9K6$.,J:2"]S1>:&<WG$*S(GANO\>QHYY6R5^S7NJLLS09,J/IR7
M)96(9+JM>8U:ULD7"3LX/: \B!CTFI%"]*U22<E,58RF^\G]L&QDV=72::EJ
MJ7 :N=AL[4V2)6A.IS)IG2(AK#<GWQ/<YP)$USV EH:5JV=F&/B32"HJ:2?B
MLJEQ&2ZK=,F";&I8T4\YP!@7RX: 7<DL-<[G%RYH_AJLCNK,(:=DP*HUA\@G
M"+6O;UU%,+I,TVO0%5L<.-?B*VFR19S<*:1,!DUETG:@N1,=8YM35=LVSTC&
MM?H9<PTYG4I<YE'+$R9*E3ILR<R8)Q?$OES&R201%K("#8*NE[+<3F8>&5DZ
M5+K-!4  5$TL;,FRY;)=@,+K'L,[A<1E4\KAS*Z[^UG86N,KQ9ZX5FTEL*D^
MXF;4I*1]?M<5+/0D$V#!0E;3=2S-=C$NA=F:*I* FKT0)$#"?VG[ ZG2NJZ*
MHJJ^10ODZ-LEDJFNFHDS0QTNV,XLEN#IS;K7<V-I)53M@=KG39XDU%/)E3:T
MS0]LYYF!SJ:;*,T$F DWG@"3YS8Q L43$<.=D>I,F-C"OQ-53>(N'E&BKM9)
M6+=3+#&-@J"MT7?*)1ZSF2LEKDVLFJW.42I&:$74Z5R'.&JH[9,$HZAU3A3:
MJ?B&C UF?24XF&6ZME5!I0P-+6RY4ECY+7^<0Z (:J:?LQQFM DXFZAD4'._
M(2ZBI,MKQ3/DBH#@;QFNF.;,+3S!")YRW%H@RD!1Z5!3\FC(ST)4:[#SD@5R
M9<KZ7C8ILTD7A7"_[\X!T[2.ISS_ "1A,(CKYUVH%!B.T-;785*<S#IU7.FR
MQ=+2&37E[6%N1NC!N0%D&V6+VW 6/I,'IJ>M>16RZ>7+>'/#Q>E-#+[71-DR
M%\QMB;;5UKMD:/JD0X=.G29#\TA$2E$QU55UE"I((()) =5=9PL<"$*4!,8Y
M@  $=9>R6Q6(;3XM+PV@DOFU,PP:T?AS=]:_:7:S#=F:!^(UT]LFEE^<XQAW
ML_>6XO!5P6S^0;!%9XSU%F;)MER2- H$A^^$@4E$TS-IR;2.50CFPNTN:8B8
MD*FR(82@)E-S:_:;[NWW<\&[*,+;C6+,;/VLFM&8Z($1!#A82(YXK\A>W[[P
M&*]IN).PO!7F1LTQS@0 1I "006D P=OA>]\8P:QM#6:-$DT44K(P(!4B 0O
MU*>B8>:4  -S;CU-?4R^8U":(J<P@\HID$?1$2\H_!'1%L)74TPJ55$$R<K"
M2]#_ .[#S6XH/U5WPEB5?FJ3YI/G9/2_\^MBL1.:3YV3TO\ SZM3F.> &YT4
MG,D2"2=<U-,/DD>H7_[&U^#J)#7-;;NE%&<TGSLGI?\ GU>12<.FF:38@*28
M_OR@_*]9!3X.H=D11QR)@( "9 #;J 7X(CU]5(OGFD^=D]+_ ,^H12T:!.CD
M YA/Y@'_  ?_ +6EK%G2WN?$9$40!2;!^]DZ@>A_Y]9+00T Y45>:3YV3TO_
M #ZA_F]\>-6YWS9[MU6AD)-,U=BMTR?5MU_P?_L)-:C$OUG_ #5GT?S:PMS$
M_G2?[76O66G,3^=)_M=$5RSZ20,ZM^]DY:XB/*'H]TI/J:(K:YB?SI/]KHBY
M4$TNG0_>D_X='_@__6%T13=K32"R37[TG_/UNJ7X(:(K?YB?SI/]KHBNRF?;
M"P_8R'V+>:(K4+\J3]@3]R&B*NB+SGS/'<3ZG&!$2>)6^5G5.9T;$A.TJH?(
M#2LOT'-FR>PR@DXF6,JGBB&,QAY&'>O^[K%=^Z3;-THY1%P)#ZS*3SEC5/F*
M7EKSQBV:(X2[-C7&F=G3/AKHF-+9Q#Q]H"3QK-Y8N<F^KM*R)2E:U:F0268.
MX&/TY^22*W.#8DTLR634.8I=;%LMX>"19%82]G#@F!Q!(_2$VY#["7??E#Y$
MP%,&Y=AV$ $-];"7E[R%2(_4=+ZX//Y!KK%E_./X!XU R**U>4JI?EB_L@^/
MJ"(@C>1:T\;&*\B9UPNPPQ0 KZ3/),Q4X')LC99.5C(QEB9JY7F[BRWKZ[:P
MN'%E+%MXPA61RKI@[,IN4I!'6'H9F92VPQ*\RFK7WQ6%6M\.\>9#BI+!6$X>
M(>6.MVZ$<XBL#."X?,RQKAY7:6NQ<6NV9%O]U95279+I@X/$NP.DOT9@537:
M.<T\P"*N%P65,<8O]\"LU?\ *%SD7*]03+B^^SN.*MD3*%-G[.IE>9QYB%K5
MB90DH>,7:RU?6O*5O?13 YNAAP=-R.TRID3;)SHYSFWG 6;ZB\%>C+'?'XVF
MJR6(MMVC*#8LBV)C9:QDS*=4L63L=8Q@#4B^5R46NL"W?QEAM60+97;!6%3-
MS.E(R!L:"I]^TP3+0V4]PB!E5#K3$9%]<*V*N+XN7ZGDCB0;+I,*O&YPBX%K
M-7Z,NT]6(C)%8P$Y0KA91"4G'\M$IWNKV86IUUN>5H"1^C;)JHMTKC)3VO!(
MLBJRX0@O45/^ D?K1+?8]QJJK^9/"KE-\X?@E:QZYIGGNX0LY?F?_P#%.?V$
ML!?]L['7^@U]U>F?JLS@_ JZ?YP_G6>)>^_OC]NM='X#KA8:58I>K6$'O#Q"
MMI:"NCK',J+.S9@Q?6IR,;WUF .:>C-P,LZ:+2)! S5)8QPZ@B'F%(QU37O?
M-A<9$#O;R]-JYC64T#&))AQKS^I7'%E'"&$\Q54]^CWF6Z3Q,\04!3*MD&2D
M^*IHGCFAXB@\VQE$KV=&=\QQ'72-J]8E$5)B>F) KV',\.P(T=+-BAK(G4DI
MTZTBZ"8Y#X1EX<BPI5<\2K0;T <A%O!N<'&LP6;WSK)U+@K'DBT4.H)UZ5X2
M87B!P;CRO-7=I?Y*L)L0U#(][AIS(,7:.EQ\^Q[(6D16B)6OMC/H!(CYN^,<
MYDRT.H:4D6Y%4W$9\#88]VY^%;@\-7$5FNZXJSA><QT*(.XQ:@[G:5(TX(&,
M5RC7D<<-[LNU3J,)D+*2E:DF4P"\<V.M(F&3;B@Z(BGT@D"U.IZ<U;9<LVW!
MXRK\BJGZLZ8\'SN3E6IEAX_,OU[AKQSE=;+/##-9*S;66V2<?47'=#M%Z"%A
MD<12>5['CVRBXR]6H]NZK;)H0BU@?2$6)T4G',C3KE*GK(U5M\L]T%CSZZY3
MAYO!IWBHNP^^@Y-I\ _R?:*/3FU6L'!L'$1A+'4*R>V>4RK<XK!\+E:]UB4R
M##VQP;'+VDR,DH!XJ5@4QD*\0'[9^90>@"U(H&/GM:^%TN43:N=+E.F,'/ B
M.[\*VLP'GK/>4,)<1,SE:NP=9EZ34GTECJ\U$(.%2M;.7Q4ZLYY#R3BLD90<
M5EW4IXIDFCAQ)<V3;"BZ(DD.Y0E\J7+JC)]P KS*BHFTM]PM(S[L1 =^,#_E
M7BEC3B5SA4>';)Z<OE_(4-)3?"'P YWKDFOQ)O>((S69L?$11*CF?(DM?GSL
M);"\CD!E:T6JM+<"+'M))PLD<0353+LGRI0+7&$+AR<609._P[JUS)\ULK1$
M$/#[;,MAW3E[T<D,ZW\]\BXK+O$90IL7PU6K*4RRX8ZDIQ:Y/;\/L!+Y!JV0
MVK2WMH*O86RG.4\K^-B:?8Z1"6^37([5*F+A@U,(?O9=8-/2!C9@,(.)A;OK
M*?5N?HW"\2&B,0<UNXO9JIVJ"O-7K5VJ[Y*4K-P@(6U5Z20-ST'\'8XUK,Q+
MQ(^X\XCB/>IF#E'JZU#I$QLPC<!SK>L-Z2#;:W=L7EK[_%_[GSCZ_P!BG_ZX
MU;6\P7^\I??\17/X[_=K^%O\(*[O>,__ '3/O?\ _P!EF%_E)C7K,KYB7PKR
MV=\X>%>EWH%^$&MK,W%0$U;12C?ZDR7TS'_\JU2?/' ?P*5%ZJ4)HBE7'U+B
MO^D/91-6Y7ZP[@'B4'N\"BM7G><>%2J#\J?^+4_<&U"%8DR5]N,A]*1/V+::
MY1_ZR];*5\V%8FI5Q35<^K\)]>(G[(M=$70D/JC)_7-]_+FT1=31%<]6_AYO
M^BU@]A#HBMC1$T17,T^U&9^OD/[$DM$5LZ(FB+=?"?V@1_T[)^S%-$5U73[7
MU_XY']V;6=AWZV?@JU4^9WPL*ZW:URE&'\SF/I1#V<WUBU'GL[LRC=[RBQZH
MZRAD4IHBDD?J2[^GVOL9SJ/=#@/X$4;J431%*N1VCHGX*;X/3=GU;D?K+N]X
M@H7A'Q>< >7LM9[NN3:59D6$9;$X4#QZ\*B\%%:)BV\60R+D9!L=8%DT $0$
MH;#R!KY,[5_NE;.=JVV51MGBU?.973X M@2   ("!&X(!?4_9?\ >EVC[,-D
M*?9/"Z&0^5)+HNL =$QL!!(/?6LQ/>ON)#G!O:VX@(@'+5T=@WY-QWG1ZFO-
MG_<%V&8V]UA.^*[Y2[\_?FVS]G2.,<BM2>][IXBH65=Q:EA9KF:=  F-6DD]
MQ6;IK[AM,''D!0 $!]$-:]_W%-AVN@VOG<1Y5E#[[FVI$104_&.10_Z/WB'[
M],?N>+XUU1^XML5[0G?%/*I_?;VU^@4_@Y%WHSWO+B)D)!DP)/LD3/G234#!
M6TU-A6$0 X@:7)R$$/0'<>II^XKL3]/G<1Y4_?<VU^@4_@Y%U%/>^N(E,YR&
MGV2HD443YPUQ(G\&<Q-]BRYN0PEWT_<5V)]H3OBGE3]]S;7Z!3\8Y%\?H_>(
MCOVQVZWD\')\49@2_P!P-/W%=B?I\[XIY4_?<VU^@4_@Y%(,?>[^(EZ5^8L^
MT(#&/</S%"N)"4Y4#)%$IC#+@)=^E]#?J:?N*[$^T)WQ3RI^^YMK] I_!R+,
MO#K[W*^CLBM,BYKDPL9ZX4GDM7Q8ILXJ.>_) K,*M".UA?2!><'0'4-L@(;D
M#<=]>U=D7W=MC.R:LF8E2-%7B)\Q[QYO"#'P07CO:I]X#:_M2D2Z&O)IL-'G
MRV&%[@(A#OQ7L<S9MV#<C1HF5%NGR$3(4I"A\(I   U] DQ,3E7@\ +!D5X)
M?:8[_I.R^Q3W4(K8T1-$6PM>^U*J?2$C]F'NMQ0?JKOA+#J_-"DM;%8J:(I.
M9^J3K]DC[#;:I9YH[MU%&:J12D+]4V/\:K_(*:AWFE%'*=7XG]\=5'*B^-0B
ME(WY20^D ]EI:I=E'"BB@Z@?"#XVJD5=4O\ -[X\:MSOFSW;JM'(/VNQ7U[=
M>P2:U&)?K/\ FK/H_FEA;6O66FB*YK#_ #.J_P!&T/LE)Z(K9T1<J'\.A_'H
M_P J71%.6S[9)KZ?6^/HBM[1%=5,^V%A^QD/L6\T16H7Y4G[ G[D-$5=$63L
M:"/2V+E'ZDI>CZ)9%@!1_P#D[CMUM95";\XLS+&J?,62S&,)A$1$1YV^X\O*
M7F@4>7]:! VZVP=;6_6$J;B(\HB([=41W'TQY=7)?G=Y"I0?J.E]<'G\@UUB
MR_G'\ \:@9%%:O*5]$^7+^R+\<-$4A("(%CMA$/\5M>H/P5-0,IX44?SS;@/
M.'<-A =^7<-MOA[;<FI1<S<QA<(B)C;BX2,([CN(](4=]]]]]5.^9/=F4+L2
M1C!(/=A$-W"F_+U?D^=R]?Y(-_AZM2OFPIW%T.</4W'EY1^#\/KZK1<B?\!(
M_6B6^Q[C6-5_,GA613?.'X)6L>N:9Y[N$+.7YG__ !3G]A+ 7_;.QU_H-?=7
MIGZK,X/P*NG^</YUGB7ZUUJQ7+I1F%6MM<@K=6Y>NPB,K7++$,)^#E$2,6*I
M$I&'E&[N/?)$7(0Y2JIG*!P*(<H .O*)C9C)KG2W0MXUZPULIS/RL(1.7A*M
MQ7!>$W%:A:0MAS%*M/KTHI.U^HK8_IXUF%F5@.1:7B8(\0,5'2:X*F*9PDD1
M0XFV,8=]4Z>:; #'A4&53M!= *)HU0X?Y]Y*W['E.Q/)OET9G%TW;:Q5JFLY
M7;TUT>I3]!DIF/8"NX:5UW%&C5X\YS((]K=") *0H:@U#F",P$9E#62'V!HC
M"VWBXU>]%QOC[&<8XA<;4*FT&)>O32+J*I59B*U'/)%5--$7KAG#LV2#AZJF
M0I.D,43B4 #?8 U3%\XZ27E%FZI=HI8N.'-S6+&<#A?A?M=:=$JV*, V6I/K
MA(3CT(*B8]FJZXO4*Z=0LK*."L8A>,4M<2_*X9.51YSI!4JB)S //)JIDZ=*
M>2^+G9U 93S!![1= L"N0]"P33K3&32E*Q/6+G<8]/&\+)JUNG0\_9XQ"'55
M3H<2Z.R;R4TS2KL2J8(M$52 Q:&'H^A2'FA/GQBT&\K!;(+@PCFE7%2\98UQ
MS#/J[C['](H\!*N%WDG"5&I05;B)-RY(*+A=_'0T>S:/%%40%,14(;=,.;\K
MR:H?.?"_,B'1RK)$@-.0789\B@HO!.#8&NV&GP6%\30M2MQ426RKQ6.*?'5Z
MSIMSE4;)V"&:0R$=,IMU"@9,KE-4$S  EV'59K2X ")@H92RP27 $E3=/QEC
M3'D=(0] QW1*/$RZ::,M&4^HU^M1\HBBDN@DE(LH:/9-7R22+I4A2JD, $5.
M <AS;V75,TGFF 59IY)RM"NF+BHN$CF$-"QS"'AXIHWCXN*BV;=A&QK!JF5%
MJQ8,6B:+5FS;(D B:29"D(4     U6*B-A%JO&QL-Y>4GO\ %_[GSCZ_V*?_
M *XU;6[P7^\I??\ $5S>._W:_A;_  @KN]XS_P#=,^]__P#99A?Y28UZS*^8
ME\*\MG?.'A7I=Z!?A!K:S-Q4!-6T4HW^I,E],Q__ "K5)\\<!_ I47JI0FB*
M5<?4N*_Z0]E$U;E?K#N >)0>[P**U>=YQX5*H/RI_P"+4_<&U"%8DR5]N,A]
M*1/V+::Y1_ZR];*5\V%8FI5Q35<^K\)]>(G[(M=$70D/JC)_7-]_+FT1=31%
M<]6_AYO^BU@]A#HBMC1$T17,T^U&9^OD/[$DM$5LZ(FB+=?"?V@1_P!.R?LQ
M31%=5T^U]?\ CD?W9M9V'?K9^"K53YG?"PKK=K7*48?S.8^E$/9S?6+4>>SN
MS*-WO*+'JCK*&12FB*21^I+OZ?:^QG.H]T. _@11NI1-$4HZ^IT1^P>^S#ZM
MR/UEW>\04*+W$.H(AJZ<JE5#<?D!$=C[$'EY=A$.I\'5#P'-(.100/"L-9!,
M(W"7-ORF4;B.V_5&/8B.N8<XNG.:<@*VK+6A6;N/7'TQT52N"I\MIKP#R_XX
MC^KOR?X6C\'1%"+F_P (<   4"KKA\CN&^RZO5Y>KHBXMQZX^F.B*YJX(BE9
M 'E#R9D>0>I_"-=$5L?W ZP=31$T17.E]ICO^D[+[%/=$5L:(FB+86O?:E5/
MI"1^S#W6XH/U5WPEAU?FA26MBL5-$4G,_5)U^R1]AMM4L\T=VZBC-5(I2%^J
M;'^-5_D%-0[S2BCE.K\3^^.JCE1?&H12D;\I(?2 >RTM4NRCA110=0/A!\;5
M2*NJ7^;WQXU;G?-GNW5:.0?M=BOKVZ]@DUJ,2_6?\U9]'\TL+:UZRU8]JR13
M:2\;,K+*BQ<NV_;*"0-'"Q3)"8Q"F,JB4P%,8Q!  ]'6MJL7HJ*>V54& .5=
MELSV?[6;8RG56S=-K%-+?HW1<&0F&T"\;(0(4=+<1F(G;>!30L:AS,81)FX
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M*)JW*_6'< \2@]W@45J\[SCPJ50?E3_Q:G[@VH0K$F2OMQD/I2)^Q;37*/\
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M[;+"C)]RRR!B='S 1-($%(/DN=S@WVVY=29LLRBV(BA:[,IV5(8L@\$VQ=G
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M9-S?B?P=T%]1=FF$XEC/9%74N'23,GG$P (M$;!:(G)OK:#\J_ I@W\LSCR
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M/YQN: \FXCMJIU1+<TM!<#G@J1V2;? Q.'O(^&SY2I^59@4.?M<A_?!,*H#
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M@X!!HSEW#QJ5J=B\@7BJ@ME68@8Y5! 0,&P=77K.QG8FS:_!'8Q*YEP.+F@
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MT=ZZ,ENYWE]1=DN)UV,;-:]B4PS:K2%MX[V[WUZTAU0^&'Q]>.KU%7&Z^U&
M^O5F_<PNB*V]$50ZOQ!#T>J(;!OL B ?&U2YS6-+W>:,JI=?NG1@%^X%Y=9^
M]]0C\7<2LQ@13!4W/A4;#CG'#VY-KO&,6:J]DC(!5M)%B5X55P0J99C84NE$
M!%(?D^77K^'=D]=B&R;=K!.<VE=*<Z%T91D&6,#;$KS&O[3*.@VH^J[Y0-4'
MM!,3D.4Y(1%EB]11#;D]'T0ZWP/0ZFO)#+F,;&9 .B19O+U NEF86RR2T &T
M0RA2$1]58SZXL/9B&J46R#_^?//IIQ_*GUTLGYEOP1XEK)GSAX5U=7%0I6&_
MG3CZUR?L8VK$_*WX2@J*] OP@UES-Q2$U;12C?ZDR7TS'_\ *M4GSQP'\"E1
M>JE":(I5Q]2XK_I#V435N5^L.X!XE![O HK5YWG'A4J@_*G_ (M3]P;4(5B3
M)7VXR'TI$_8MIKE'_K+ULI7S85B:E7%-5SZOPGUXB?LBUT1="0^J,G]<WW\N
M;1%U-$5SU;^'F_Z+6#V$.B*V-$31%<S3[49GZ^0_L22T16SHB:(MU\)_:!'_
M $[)^S%-$5U73[7U_P".1_=FUG8=^MGX*M5/F=\+"NMVM<I1A_,YCZ40]G-]
M8M1Y[.[,HW>\HL>J.LH9%*:(I)'ZDN_I]K[&<ZCW0X#^!%&ZE%4 $P@ >C_Y
M;_$T16-(Y?Q\@]<UGNTY<S=74,TGV4=!SLF,4Z? G(M6[M:/CG+<BJS)T10
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M[;6$ZQMDW*(=,40*!P+]==FFUFQM!LE44=-.--"3SVO'.>8VAL;6\(X%\O\
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M2+)==+:;[(AKB6CG76Q!A880[R^0=I>R7$\+VC%!AK73**8>8ZZ7- <>;>=
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MY54F3 HJ'.(@4 #8!$>3613[)X_58;68O)IGG#L/,L5#S "49K@QEZ,"+SB
M%2_$<+ESY-*Z:!45-[1-.5]PP==SP\5N11B&7L>.;F^QVC;8@UVC2&.^KIU'
M"#U'F,F<DJF51PBDR<N$(Z00<*)(JJ*)(*E.<I2COK/F]G^V,K 9>T[L/GG
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M5(O):C^^FH65U.JLX#&T(\K%KLE;7AI^PVA.3$8.3=Q2<@(MXLS19M((MA7
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MB\/'$\EQ<T)SF!*NHU@JUHL-63CF[I=VBJVJKE.):29%'::#DG=1NB5<4S$
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M%)2+M<"PA7-BDY!JQ<03Y1YCYB\M]6M+-;&BC-\@RA)]!O7.YIEU""3M10H
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M94]V32#)*F&QML05Z5P\O%3\4PFH20;2D5)MB.F3UHITB2Z"F_,-U $IOD1
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M%]U1Z_Q];?3R\ZS[YWD[JCU_CZ:>7G2^=Y.ZH]?X^FGEYTOG>7T,H<  >=L
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M=H< G39L\T-,)+9TUUZ=,$ "9KP&AQLL(:U?E;55!K*^9B) :^:2;HL: 3&
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MT9Q(4Y]P+SMPY0 =?G!_S,>S_M1[4NPB51[#5=3)P"@G&97T4DW75#;[3+=
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M90R*4T122/U)=_3[7V,YU'NAP'\"*-U**AOE#_L#_N!U1[MWP"H?YC?AA?F
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M%KM".EX?*G<I;T74;X4CO;6JY<^8#YCLF8\BKER67N<X0X?*N^,<L$8FF"S
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JBV[Q"T48TEBU44:K&*ZD3"HR>-GZ \]V<0 KIFHLV,8/1 #"(>CHB__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g38965g78v87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g38965g78v87.jpg
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M;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^T 2%!H;W1O<VAO<" S+C
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M_\0 F0   P # 0              !08'  ,$"@$  @,! 0
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D$-2*QK=ZKJPTBXTC2[[Q?Z*?N=H1U,#?'/\ D?V=6VCV/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g38965g86y21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g38965g86y21.jpg
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M;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^T 2%!H;W1O<VAO<" S+C
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M_\0 L    00# 0$!            !P0%!@@  @,) 0H!   ' 0$
M       ! @,$!08'"!   00! P,#!  #!@4%     @$#! 4& !$'(1(3,10(
M05$B%6%Q,O"!D4(C%M$S)!<)P6*2-"41  $# @0$ P8#!@0#"0    $1 @,
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MIX+4!QVP<EMF_P!R.MB2ODC?51]%2NZ,@E,KG@-(P'AEAC7;;R_$^T1]O[/
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M0;$%$(Q[[^J"/75#"'6=\Z1X+823B<![ZZ/9RQ]Z?:[Z>1'[ILSUU#%TX<H
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M9-ME\R"?YP!\0HJ;Z<J'6AJG:J*NV_X]4W]4^R^NC /"@%<3H^84-LTQ6WM
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MVD7>E6*NGDO.H5CN%S%M\,-G#:-O'0N>'/R#FDC$G@>*GF:&01+RXK[K'ZO
MYT+'<9*Q(;0:&&-S.CMF<N)"?D9"\XK2@V8D:CWNJWMN([[:BF23(-"#W_&M
MK-;[5M,]G=2;E;R[C<AIDC#ECC)S31[L<%H^<5>V6UN&6J^K@C-Q3"+Z5^OA
M,1G';.VB2_V!FK;8J0$L4.T=]F^O;LJKJ;;EQ5?#@E<T[GFNYK1CKB25\+99
M&M7$:6NP1?QSHZMQT'8E7==U5$3?M1.NR(*JNWKO_-=./8"Y1E69UM.+!Z4K
MHC(IOLOUW].J+]/\-U_QT36Z:223G31:#'9@379/B6,TTZKX/D#;!,(V1NB:
ME^ HHIU5>GWTHN#6DNR2DP0.==Q=!Q9*9  G'PKRHGU];,N,EFUC+<S_ '!?
MW=DL60#R&=A<N./1ZYYZ(CA&VBH#37:G8V";#NB[)1=5TTI(  !X5ZIL6W.U
M[-&-X>88"P>L8N PQ]6"T!K3CK-ZB\]_=8[2P;"/1V%.M="KRDQVUODEN-M$
M4YIEU]A>QCW#SS@F:]R[]=9OZ:=E^97.=I\JZ2-^L=XV-NW6-R78#U8+AAEE
M[J]BN(9U=?8!C=C#:B(R59#C.-1&^R'[B,PTQ*5AOT0%D,KOLI;KZJNM[92!
MUMD!7B?O"TO-OWY[WS2/U$X.R0GWT813841/HFE,*M4U2@(*^JJ(NRKUTM#1
M%S04)QJ&9V\ 8]8B"4KLPHDKV<>\D-Q84@Q97W#+LAQ45H2C$2*0_P!*[*O3
M27/Z3=2*M6.VME-VU&2/C)"Z KA^Q_A5:*B)FN/'(BTEF>-ME,Q&H@0W<@>S
M6MA1,AE$,;Q1;"(VHOM-=ZN&TX@?B.R;==,2$]3J %N6&80UN[J?8C;L9/!+
M)*CM1+.FKFYX@X!4&/OHE83:YM*L78E[D-7=1CDV[3;14P5%@<&I>2O>M(:Q
M94EHFOVZ^(FS_-!1"1?5-/ %[=1)S/!*SF_V^P_3 Q0Z':03ZBY''\N/@A6J
MX8%"2R^9?)\L'&__ ,N%3N#ZJ0MC2"TX!.?YO^LD(NWVUF]K;$-]N)%*AIP]
M@KJV]3NL_M!8Q3@![W #WN_<*-7R+C2*L<+S9IM'&<;R.($X!(A(XSST><V/
M8*=QB3L)=^T5)-DZ==6M_P"@MG/RJ![ZQ/VZ2[M]QV!ZB2>QE<TC)6@9\>/
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MXL(D)L&7G@!]]MMZ2,<5)P(K1D)/NIT38=UW71E %.52[3;[R_?T[.-\C_\
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M^-03AV_HJR-=T41+UYQC'0 YU'4RQM9)Q;JW9)UIH6"-F>;$IL]B[B!44>J
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G\NU8Z@5'AE2X=MD[5Z;?V_OT"O'.G8].@:/EK;14NLT*%9H4*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g38965new25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g38965new25.jpg
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M;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^T 2%!H;W1O<VAO<" S+C
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M_\0!!P !   & P$               $"!@<("0,$!0H! 0 # 0$! 0$
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MP??,C1X7/D#/NX"G.(=Q'RM;BEV*B;==S<+ W?"QK+87BZ:1#.!+UF$?84=
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M;;=\/;,3VGP(E3M[P7PU!(T T T T T T T T T T T T T T T T T T T
MT T T T T T T T T T T T T T T T T T T T T T T T T T T T T T
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MQS;&=QWN(3D5-9.FL:1]4B%4$[(XG(BRN:_).%#N7(QL-$M%6IU05?.&J?I
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MPSOG3W$I=G3U7A'4ZRY$X723>-8]OZ[IVVB).\H3PF*0#!Z2C0' G*( F([
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M*ILT1E!C7*C;TP!PF!%1$#]0!J,N97KMJH4RRU*.KEZLVE:YS0: : : : :
M: : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
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MCJU-SO7  Y6<;BDL&Q/AU9WQ45(;KD=DO.6'9MM/6L'+VR[0[N?(7F3,%Z2
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M%:I)+D,ZQG"*2H8^D6&&)A,472%-FX5\LA89%^)C;RC<LL*ATD78*%+N!B;
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MA[NWR?==3U_8>-E_4=KY.!:U4\>2U:62GZ.Z\VET?0LXGS[YSV&[W'%-?O\
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M&P#JTDR.D/=J98ED=00- - 0Z0]VIEDRQTA[M)8ECI#W:2Q+(Z@@: : : :
M: : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M: : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M: : : : : : : : : : : : : \=E8J_(J.$H^<AWZK,ICNTF4FR=*-2%$0,
M=P1!=0R!"B4=Q,  &VD-"2>.G828%8(B8BY46XE*X"-D&CX4#&WZ06!JJJ*0
MFV';JVWVTA@['TG'"U5? _9"R0%<%W@.D!:(BV4,DY!9SU^BF+=4ABG Q@Z#
M (#L(: ZT9/04T*H0\U$RPH 45@C)%F_%$#[](J@U65],#;>&^V^IAKJ)3.T
MI(,$G2#%5ZT2>NB**-6:CA(CMRFE_93MVQC@LL1/]L)2B >W4 Z?UA@ DOH<
M9R("7ZP3^BADF0276*8+ 3Y$5OFNL4A VW1OTCOY:F&)1Z8N$"J B*R0+" B
M"/67U1 I>H1!/?K'8OCY:@'"X?,FC8[QV[;-6B>WJ.G*R:#=/J4*D7U%U3$2
M((JF OB(?$.WGH#L)J)JD*HD<BB9R@8BB9@.0Y1\C%,41*8H^\- 3Z : : :
M : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M : M#GQ&-<X:R.VF,DN</Q2]4E4I')C-5JBYIK,[<Q7,T@J\,1L15LD(["80
M#Q]^K4_$M)UZ$6Z/6#YFY*,9EE,T9*X59%D82NXZPT[I3HDE9G$G=<U22YT&
M=LNC&LR3DHQ,+(-VZRAUT@,8#H=:>W6<"]L]*Y5JW]AS=VZ=$C(/C&.*X;D$
M>$X_Y4L;+$=CXC%E<O6PUU<*M:Q;Q8O'2KZ4GW0N'-=FVDTFF5P"J)%$TQ(4
M@"4^JWW;/K7U;M"U(5OI>D'4Q#8FMT[:6?*4VRW"0LZTRA(DF)NSVQ9XZ8PL
MS.%59.Y"1B7+I:+3FU4C>DZ,)6QQ*<^_2.^ETZYTXT@)SC:G4R,[?.?<74&T
MY.QM9*7B#'05"NU'Z2S90;JK/46Y!\HD"25BM<F\/&!8W2[KU$DD3@9406$2
M@!-]4S4LTK*7/;N6HTI327F>IR6MU8K/= XO.S9"3*64JR[.>B9>T'4A:NXD
M@5:P(Q\.91NQAUYEN)'*8G,<SE8_6!>D0THF\%M!9KU%J8EY7AL&J9N1K-2Y
M(.[=GQAR!C+WDSD9;+"E7(&CUE@[:1:>-(EBR>_1]LE(QRBBT(BW*;H43,FN
M(=(AK2KLJRZ_1$1_$HU7=H_JGJ;7^3%OB,K8T?0F$L^5R,R) N6K5%[!W1!F
M@]DGS/;Z(LZD.D^<LV;MH!E3B/25 H]9A -<D6KU74WE/2355?[*61[8&3EE
MK9<HF8BL\2B+-XM=G:R-Y?2BT585F[)9R*;R4AXTDR*7RR9B[/&2BNP!N =6
M/_G)PH=3&W_+?Q-X7#^>CK'QEPM)QDDUE434.#;K.VDP$\3YQLU*D[14E=S"
MY<(K%$%.KXBFW*/EKER:7?Q-J:U7P,DM4+#0#0#0#0#0#0#0#0#0#0#0#0#0
M#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0
M#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0'CS]?@K5#2-=LT/&6"
M F&JK&6A)IBVDXF39+EZ%FDA'O$EFKMLJ7P,10IBF#S#1-IRNHZZ%KX+CC@&
MKKKN:SA?%]<7=-SM':D#1Z[$"]:*$524:O2Q\>W*\;G36.42* 8NQA#;Q'5G
M:SZMLA52Z)'HUW!&$Z@TFV%3Q'C:LL;,W*TL3. I5<B&T\T*83E;3"+".03D
M6X&'?H5 Y=]'>SZMZ#;5=$C@A>/V"JY%6""K^&\80D);&Z#2TQ$51JTPC;&U
M:G.JV;3C)M&IMI1!NJ<3$*L4Y2F$1#1WL]6W(VU6B2@\UMQGX\-(9:N-L(8J
M2KR\VWLJD$6AUKZ'&?:-%6+27+&C&BT3?M6BZB::A2 9,JIP+MUFWGU+S,N2
M-M>D(]>T8&PE=YUK:+EB3'%JLC%-JDSGK#3*_+R[=)AT?()I2#]@NZ(1CZ9?
M1#JV2$H"78=0K66B;@G:GJTI/#5XO\;UYHED4P/B(U@),'L'TT&/:J634FSN
M%'9Y1=Z6+!PX?&>*BN*AS&-ZVRF_6 #J?4OTEP1MKUA249?>$?%/);0K"VX-
MH+EH24/-@E%0K>NB>65#9>075KX1BKETN'@<ZACF$/#?;PU5V;ZN24DNA<Z7
MP-A>?I#'&\UBZC2E$C%$UXZK/:U%+P[!VDD= C]FS.V%-K(@DH8/F"=*P]0_
M%XCO*M9.4W(A-0UH5Q4ZC5Z)7XVJ4ROQ%7K<.@#:+@X-@WC8QB@ B/IMF;5-
M-%,#&$1'8-Q$=Q\=0VVY?4))*%T*BU!(T 'R';S]F@--?*SN+P,+E&<P'3;^
MIA:<H$X@YL>3;+7)2<AYY5C"J3!:M L8>-E4SQ\DY.FT=NG1VITU! $"JCU;
M=%,+==S4RNAG:^L+0RJX9\Q8?DS%65DH^JR]CJ$@TCG(5=S9G#9\R.V*!998
M]FKM=5*NY< .Y$"+(EW\%!#6>3&Z1UAEJVW&=6LRQ1>1,@U+%5*L>0;U+HP5
M4JL8XEIF25(HL*+5L03B1NV1*HX=NUQV(DBF4RBJA@*4!$=2D[.%U(;C5FCZ
M]\V,WWV.>$;W"XX1O,!FS'UEI-,0HS6/:WKCUD&TPT=6?K3-2"TNA\\\CW&[
MDA :KD.<Y2E$ $Q>E8Z5[2H\>YF[-^3-Y5ML3ZK5":LC6MS=PD8:+7>I5>L)
MM%9R<=MR#O&Q*;]TR9"Z<*@)2>JLF3WF /'7,E+CH:"CV1];JI"622JL_2'T
MNR3=N*K:"L"3\*=3?^TY,D8]D&)7) #Q!-90H;^>C4.$Y)1B%SUY-4KCSBCY
M:=L]TK=IO!G+&H/,? V"Q,7<65-\:2<+NH^5380 NP09NUP;+J%*[ "$$PAK
M3%1WMI$%;V21J(X^<XLG53,M;G\F<G0RGCRQRI8%KCMH^M5@DJZ=ZX^5%W(!
M7</I.)]XF80!LFL=@DH.YP.8/#6]L:=8K6'^WF9JS3U>AL*S=S!R@]SY"XKP
MC V2>Q3"G8T_/F08"HN5)&F6#(K1&&IZM3GY(Z$6$G"2,^S>.#"BNDB9(Q%-
MNA4"Y5QUV;K?B[(NV]T+IW+)\<.6/(*X\%>3%YD;>I:LC8*EKG%0]H6@VZL_
M,Q,*T=.FZCI- C5B[G (4.E5-$"@)=O3'5LF.BRU24)D5LW5^*-;6#^;O+NR
M\BN/].O&7)ETNXN-:CIERT^B17L=3MZL?--HJ>68 I%/4BMGWP%(V0<-@.)#
MG$X"!=KXL:HVEV,U:VY2;H,L\SE1Y:CQ>A[S#T:JSF.[+"$OZ;1%[(H9C?Q[
M@U<A8&9*X<QC&6BE2 *C1ZB!E51*4NXCMKGKC_I^IWG[C5V^K:5/VU>2,YG#
M"J$)D:\%NN6ZD[FOK&]49$;/UH$UHG(B ?2IVJ",>,@X")4 R92D5*D"9S$
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M+&WK",7\PC&L'C SD46;A)(A@ QC*B<QC"-EF<--*&NQ#ITCLRLLX\1\KO\
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M_;9GQ \70:M<JXW<N72Z+9LW;WBM++N'+A0J*#=!(DD*BJRRIP*0I0$QC"
M&^K;+>#(E%R]5)&@/#G[+7JHP^E+-.PU=C 5(@:1G9-E$L2K*B()I&=OUD$
M44$/A+U;C[-0YE)*6R4M)+71_(G#4Q>V&-H+(=6G[C*-%G["*@I,LP59HV1*
MLY$TC')N8I)RDF<#>@9<%1((&Z=AUTTP6O5VZ0I.3-R'BZ*5/B0OG(O#N.8*
M1G[)>H%)I$RQ8"139/22:T;.*L9.00C)<D:#OZ$5<-H9R)5'GH([IB G#7-C
MWY+NL-)-_<X.AVBBOXI/[3EQUR Q=D^B)Y,K5IBRTA1-)4;!*O$(I@@18G60
M7:[XZ"37J\@ Y@'W@'AK?)A=$GW9SXN0\F1XW6(\_P"XJB)RQB^?D6L1 Y'H
M4W+/3G391<3;X"1D79TTCKG(U9-'RSE<Y$4C'$"E$0*41\@'6;K9:M.#IE'M
MV*Y5.H(-G-ML]=J[9XJ9!HXL4U'0J#I<I!5,BW5D7#9-94J91,)2B(@4-]MM
M<SRVW.M:S E=RU49R@P#-Y(:8CA,J5*:R$_;BZ95Z'D/I,[I$&X.S"A(,4UX
MM0Y6X]0D!83AX[AX#K6OJ66YU:KXB:S$ZGLW+/\ AVBQ5DDYW(M-*M5H^2D)
M.$:V>"<6 1BVRCEPP;0X2!7BTF<J?2F@!?4.<0  UHJV?;J)2)<?Y]Q7D?&=
M5R[!VR-84>XD3+#2EE<)5OU7IUU&AHLY)<[4/I CQ$Z0$*)O4,4>@3!L(G6R
MLZ]T$TU/8ZMVY&8:QS?*5C.[W1K7KED55JA2HU['RXMK"X>O$F#5LQF$8]2&
M%TN\733*D9P4XB<OA\0;E2UJNRZ(-I:,O:8.H-O+QU4D%#I#;S\= 1T T T
MT T T T T T T T T T T T T T T T T T T T T T T T T T T T T T
MT T T T T T T T T T T T T T T T T T T T T T! ?(?M#_,T!\\G<YQ
MMDRNY7JV6:IBV6<C+Y:IK.NVEYF69E65HL31@R>0]>C<;IKHL*8Q<IQ#Q-PJ
M(AU=)CE$#*#OUX75UVM]O#^)E=-.?,R3[4L%;EZGE._S%GG&R=FR-8H\V,'A
M6;FOU%U#3BJ3U>,DR=3AV_<#U)CL8403 -O'QU7+&Z%U26OB<.5_UE'7^_H;
MA/$ 3 1ZA ";F$ #<?:.P> ;ZP71GJT_#\BQ_)'(E(QGAVYSU]D:@QA744XA
MD4KV#H]5E)*52,T8Q,PBR(=TX9OUE (=-/8ZA1$"CN(:43=EMZE+-):]#YHX
MJZT.7Y/M+X.4\*U6=Q\E%SF/YV"QA(I<>7RAF1OGJ_(5Y-L:X/;6P<NA.FZ3
M-T@9+J]VNSZMD0X?GK_88Z3*:_@?2%,9)KMVXV/<D1^6B4^#D*:>37RS4XM0
MZ<09LGT2,Q"1,\T<+=!72*@(I+I'. " " CXZY-K5]L:^!M,J45QAT%R8ZJ
MAD9[E1%W%MWK>]3#5FSE+&V<]3CYYPWCT4&B1A(L0"E*0NQ0VU%NO2 NA1W)
MZ8+$XKEP#&3/*SI^5PTC*U,$9A7$Y@&#MS$/[*[?E,V80R4@@FF=00ZA.H4I
M1 3;ZHOQK6"W\KA=C0W@.S6]ZIQK8PE$8T2!NF5+79I![&7^-F72LY6DD5+)
M'1=5;J'D:=&2SA3UCE4V(ND $3^'PU[6!JMFGUV_<>1S*SC=O,J'G[Q)L=!O
MEYRTPLE,?/<YW%"+I6.H^+ML:XE95Q3).(ECR"7SI*1\TW(JZDSO7!0,FH(
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MF_07VCTAN(^'D : F$0* B/@ >8Z @!BF$0*.^VV^WEXAN'CY#X: FT T T
MT T T T T T T T T T T T T T T T T T T T T T T T T T T T T T
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M+%K'?)9.HU/+"W<R<HNY4(O,/2K_ "@P[=-RFL(=*BBNQ1$2ZKC]/;]:^J?
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M9]\D^BEVXNDWD3,G;DBI9/Y<.LWRZR@E+Y@&I>.ZKN:T"LFX[ET)C*F,X('
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M]MVKY%K/(_D.3,;Z%0R)(U&/D[-!UFOLJK#(K2UH%T5TM"QAU&K:73$XHJG
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MB/A]C0$WZ7;MM_ROL/\ ]_3?YSH"4_=W[;P!\'+[#@CO^WGSE#;[8(&\?N:
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MG;;_ )7V'/[^N/WGH"4.\+VVA_\ .^PW_?UQ_/9!H#G)W@NVL(?%R^Q#OO\
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MB(>WV: G']6L[;^WPQV7P-[PR9,G_P"9,H(: A_Q;#MS$\F67"@/L-D*4/\
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MI6J'Q& !WV\@'0=.IE$'8=[6H@)OS<=B@ B)C7"Y 0 #Q$1-],@   >8CX:
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M\?\ 'SRDVMQRUQ357#U29?R23B.E)() J"H2:KQ=0J0Q_P"+$!V*<N_@.PZ
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MK>7Y=.80?8-G>2$0^P(A#% 1^X'VM 0_0/\ %7_'GS _CUDOX(T _0/\5?\
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M; 7U\\R!B[AN(]/17T1W^Z.@!NPEQ#4'J1S/RZ2)ML)4\[2G2)O:/A$!X[:
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M97RUDY42_8**=F*  /V= <1^QEV[3&$1QM;4A';\63+622E#PV\ 4L9CAO\
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M[?\ )#_.UYYU$V@.-7\'Q_IA^\0X_L: T'\4$@#OA]QG=,NQL0X8,'P%V$3
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M)#H*)>BF!TE2]1#%\@Z%S+U25$JQ6)6C<S^)]7UC7MH9WPK(V\C=M92?1?\
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MPW])"QZ8_;*Q8>/[&@*KT T!KT[IA0/VZN79#%.<IL,S8"5, ,H8-VG@0H^
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M]L^.^@"G82X%J%Z?7Y&I^(#U)<A[^0WA[-_FA\!T!P?H"^!G_J[DK_PC+_\
MOC0$/T!/ <1W,YY(F-^Z-R*OXB.WEO\ VS[- 3?H"^!'[5QR/(/[HG(>^E,'
MVC XW\= 3$[!O HN_4YY(*^X%>1-_. ?9#^V0V$= <H=A+@0'@!N1'_"%O\
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M]5.!EDJ>L#6UQ@J.!3<LY&"=#Z2I#$$HJ ( .K6Q6K7<^Q"LFX1FKK,L- -
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M)?Z&@'II_P"5D_J2_P!#0#TT_P#*R?U)?Z&@'II_Y63^I+_0T!'H('D0@?\
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M**[<PE#<?9H#G;*MF2?I,V+)JD(B84VRC9!/J'S'H22(7<??MH#L_2 ^U-(
M]H_-)^ >T?P?9H"8)) P[%.B8?8'K '\TN@)OGB^Y+_-R_UN@.,TD!1VZ41^
MV[3+^P)=] 2_28?N$/\ 3B7];H!]*)A^&"! ]_S)#^/NV(01T!R%DDC!N441
M#W^N ?\ /$ = 1^D"?\ 2?\ 3!/ZW0#Z0)_TG_3!/ZW0#Z0)_P!)_P!,$_K=
M 2#)$ =MD?\ 3)/ZW0 )(@CMLC_IDG];H")I$A=O[".__KDG];H"7Z3)[D?]
M,D_K= <I'Z9A*&Z(=0@'@X(.V^WLV#?0'(9XD4HF,=,-C].PK)^/V=P$WWM
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MI+I' Q3%$2F*("'GJI)0%%[>O";*B4POCW-&:+J2!D31,Z->Y,9*DCQ4D45
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MW-$'RVXO9 N8RUBIEVLUGL5"F(1T7+AVM;@9).,^6F)E SAF";%11L@Z=',
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MZ4TS+* ;\(VK9(IDK9O73["M9=6D:QH6A52EUC)=&D&T]!Y$:V;&M084^[M
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MU9L-8OM[N:E+!1*C)SD]'&C'T](5J%DI840:'9-U$W,DQ> "[- ^R9C%-ML
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MX1FK3$UM;'F6X)%S9TZO,SDI QY8RNOSI/A.G*>F^5<B<BC(Q031(=500'I
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MQV.JH&9*5>)Z\+(3J\Y+TN%BOH%1G$R"K4'":9Y$JWJMTR "Q0 #@8HB8 W
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M(I7;)LDUB7&@&@&@&@/F_P"T0\^;[BG=V*5#T2I9MJ1"@4G0!^B/L!3&#I
M$#&#?[>@,Y>X[Q\R_D&6PID#CI 2PY)AK/+P]MGZY(MHN50H\O"%C7)EE'Q_
MDE"IE,) ,8AC].Q?$/ )K:U&KI*RKK#[OLNC.[AVX[5\&>[QK)"5DIVS^)Q*
MUC22X7'_ +?./\58-O.-920>2TQE.HR%:G+2>'B6%E@8>8(\<%B&4DDBO(*
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MV"\64>9>U7&U1297[-T6XK\6T)99A\#JQSB*DDH^E(^55<'47.N""XF,.P
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MTM[">S_?I=.^4:#Q]8Y16KX_5L1:]7",B0T1"RKNLNC0\>FG&- 5.@4CI0$
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M /53_=E^_H#0Q^L)';EX?XH2$?B>\N<&*]8"'4!XT+,=$A1\ND_S0]6_C[M
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M=M 3AQY_6"=@]3E]QJ$^WQ"A$._2$?>GZF."'Z?M@ Z YAX\?K .VX\QN.!
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MS(/I2=L^6Y9F.1[O65G\^4)PSZ>>MR.%'6T+,W.0.DW2.NQ  .8CSTA4'X1
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MPB.X^.OB<Z5<UZKHK/\ >?08[.V.MGU:156LBXT T T T T T T T T T T
MT T T T T T T T T T T T T T T T T T T!H5_6%O_) Q"?\ <\L\.!M[
M^HM@+Y^S;0&[JB_]R56_^*]:_P"TS?0%8: : PN[AAA3X,\J ('X&%+MT^W_
M *UJ!]WP'0&F/]5F64/P:R40VW27/%A('P[?"A5ZD1/Q_P B8=_?H#Z;= -
M- - 6ZRKB^KYAQU<L8W!%5Q7+O"R,+)^B8H.FZ<@W,@#Q@JH50&SUF<0504
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MJFYQ !'7/GRK-FOF5556LW"Z*7,+R-,=/3QUQRWM24OJX[LJW61<: : : :
MAN'O#[X: COOY: : : : AN >8AH!N'O#[X: ;A[P^^&@&X>\/OAH".@(;A[
MP^^&@([[^6@&@&@&@&@(;A[P^_H!N ^0AH".X!YCMH!H!H!H"&X!YB&@(Z ;
M[>>@&@-"OZPW\'#?%)P\R\KL.& ?9U 6Q"'[(: W:T YCTZH&-MU'J=8,;PV
M\1A&QAV#V>(Z K70#0&&?<'5*AP?Y4K&1.N">$;V844U 1.?^XZVP%5$IP((
M#X[[#H#Y=?U?+N2\+^(/$2\8QY(9YKN.+W*9BFK,Q@YEK)N'!X-S5ZFDBY^=
MBV;ELIUJ>'2)RG#;\'0&^]+O?]K1R7K+R]QX4 \-E23Z1OZD[(@[?9VT!./>
M^[710$1Y;4+I* [F!&>Z-@_; ;Y';IV]ONT!UQ[Y/:S -R\N:&L/A^+;-;$Z
M6'?VE0;1RJQ@#VB!1  \1T +WR.UN;?_ 'V-/)M_ET1;4!'[0+1"8F^YH#B-
MWS^U@0PE-RXI!3%'80&/M'A]WZ+VT! >^CVJP 1#F#CPP[>!2)SRAQ^P4A&(
MG,/V #0$I>^EVKS#M^=U1O[WV</YL:.@)3=];M4D,)3\OJ$4P>8&9V4!#<-P
M\!C/=H#D_3H]JH0W#F%COQ#<-RS@#Y;^)19 (#]C0$4^^?VKE#=)>8&.Q'W=
M,V'\UIH#L?IQNUD/ER^QY]Z:_>>@.L?OH=JXAC$-RZHO44=AZ65F4+O]@Z<8
M8A@^R B&@)B]\OM;''I+RTI8B/L^C+2'[(Q@!H"8>^5VM2'*0_+6DE,??H 8
MZS_%MY^48(>W0$%.^9VLT5?25Y;T<A@$FX#'V<0 # !@$3!&&#;8?<.@-'7;
MO[E_"#!_.GN(Y7RIR"K52H_(/)-8L6))QT654C[-!Q,=8$7KA-%$%WC4HJIB
M.RZ2(B.VP"&PZ W>?IU^U3_+"Q[_ )A/_O+0$?TZ7:L/XEY=T10/+J29650H
M#Y["9./,4!\?+ST _3H]JK^5_CX!#S(*-@!0!_<BD+,% -]C;?0$#]]/M5E+
MNKRZHQ2[@'QLK*B&_L#J4CBE$?L>>@)DN^=VJE0$4>7= V*(=74G/>8^6W]I
MAH#E_3F]K OA^=[CX-O^E3O[ST!(IWSNU<@053<NJ"8"[;@1*<$WB/3X;M-O
M,= =0W?>[5(>?+6E&_R+:</]\"LS;: %[[?:N.&Z?*VHG+Y;D9SH!O[O%H7Q
MT!$_?4[5_I&,IRJIXI].Y@^6F3;E]W0#<3&^UMOH#KE[\/:H*  7E=4P /
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M?_>T^@)@[^O;! /AY#/C%#R$*1->(!]CY$H_L: E)W^>U^)@ .0KX?/SI$V
M??%CMH"<_?X[7X;?[X9X'GY4J9^Q_P"L0T!#]/EVO3_$/(IT C[!I4ON'V]X
MXW\W0'*/?N[8!0$QN3"A2@&XB:FS0  ?9$8L #0'7/W]NUP ;FY,F6#?\%.F
MS"A@']UTA%F'8/Y^@)TN_GVNE"B*?)@R0 .PE4I\LF81]_2:-*.WW- :L.Z_
MW4.%/,?!N+,+\=<LJW^^AR7Q;9EXL]8F4F)X:.&?1?O#OI!,6J(ME3]!2%$-
MCB.Q0 - ?651MBU2K%\A^K%;* ?:AD/#[@!H"L- - 89=PCJ_,?Y3]!@*;\B
MEW\1*!@V^BE>H.D=@'<NX: ^>C]7!XJ<<<X<,+_:,N8.Q;D*Q-<V33!K,V:I
M,I!^G%_5>JJ-6HN' K#^+V'J  VW\AT!]#:/;VX1(E$A.*F"2@([[?D^@U/'
M_)*-A-]S0'+^C\X4!Y<6\&>'D7\GD)M]@/[#MM]S;[&@+.7W ?;#Q7+(0=]Q
M-Q?JE@73:.$X0U9K3:R$8O7*;4DJ>-;(A)MX5(Q]W#HQ"MT4@$RA@* CK?!Q
MLW)OZ>"KM?73QC6%XORZLSRY<>&N_(XJ7<-P)X7+I)N&_'7$!4#I@J5<*="N
M$54CE Y%2*JI'+Z9B#N @.PAXZPAS'<T[3V+=NN*W;F:V>'ICC%?'HUML E"
M)KY*[5595^"B:ZJ9TF:21UO25(U4Z3" %-T" #X:Z:\/E7I?)7';9C2=G'X4
M^D_$PMR>/2]*6O57R-JJGJUU@J"T<->WO3(67L5CXW<?(R(@$DW$T^_)]73C
M%-E%$R Z>%;,SKMVY 5 QU! "D3W,80* CK!4LXA/7IYFSM53+6G4HMCQQ[9
M,Q5$;LWQ/QB95569<P!+"6+I00ZLPV(9<8TDLFH:/6<J,NEP4A3B84C /OUM
MGXO)XUUBY%+4R.JM#4.'T?P9EAY''Y%7?CWK>BLU*<J5U7R.Q5^._;(M$RWJ
MM7Q-QBL]@<*N$VL='UBJ23]Y\ND5RX50!%!87#9!(X *I=TP'PWWU6O&Y%\5
ML]<=_0HX=H<)OS+7S8<>2F&]Z^M=2JRFX7EU14=WX@]N['5>D[9=N.?':!@H
ME$7,@_=X_K(@BD"J:1C^DFS.NITJ*E 0*41#?5*8\F1[<:;?D6M>E%-VDB2H
M\/>WG?*T2UUSC5Q[?0HKNVJKDE!JQ2H/(]3TGK190&Q4RKM5/ X=7PB.VM,W
M&S\?(L6:K61I-+Q3U37Q,\6?#GH\F*RMC3:GS6C7R/'LG&?MHTB;C*O9<)\7
MJ_89EW',V$%)5&I)2CAY,+F:QJ16GH&5 7C@GID$0V$WA[0U;C\/E<M6?&QW
MNJ5=K-)M)+JV1GY7&XVU<B]:.]E52TFV^B@]FP<2^W%5)1"%M&$N,-=F72 N
MV\7+P%/BWR[<!V%P@S= @L=$!_;%+MK&F.^1Q1-OR4FUK5JILTD5R7@APN=H
M$.VXUX2]-<A5$7+2AP(@9,P <ITE2)&*8IR^0^(" ZHTUH^I/74D+P$X<$'I
M-QGPJ[(8?B%W1(4RA/(-DMF@AL(>?EXZ E'M^<+Q4 Y.-.'$2@)1]%*BP8)^
M&V^P&:F$.H?/0&@CM?\ %#C3>.XEW3:M;\&8QM4!CS)5'B:9%V*H1<DSK#9P
MPGEG2,,W63.BU07Z]A*!0T!O^_,!X4?R5\#?Q:5S]ZZ X%>WYPN.8!3XSX7:
ME -O3:8_@$$Q'<1ZQ(5IL)QWV$?< : A^CYX2[?%Q8P8=7;Q<'QY &<&/M_9
M3*BTZA4$?'??ST!%+M^<+B&$5.,^%W11#;TW>/X!=(!W >L"&:;=8;; /N$=
M =DO 7A83P)Q:P.4!\]L:5SQ^\U#0$1X#<+_ .2Y@;[N,Z[_ #?E] 1_,&X7
M#X&XMX(,7VA^32N>/WVHAYZ !P%X5%\N+&"0_P CC>N$^_LR\= !X%<,B^"?
M%K!/3_38[K^^_P!Q@/AH#E)P-X9IF*<G%W!('*(&*/Y-JYX&#V[BS'?Q^QH#
ML?F-</\ ^3'@O^+BN?O'0#\QKA__ "8\%_Q<5S]XZ ?F-</_ .3'@O\ BXKG
M[QT!$.#?#\!W_-CP7]S'%;_GL- 1'@YP_$Q!_-CP6/2(CN..*WU!Y;=/]SQ#
M0'9_,EXB?M>-.#P#W#C:L&'[_P B&@.N7@[Q *<#AQDP8 @.X"&-ZV(@/OV%
MCMH YX6\1&Y"*?FSX/,;U2%3#\FM8 /5,(@03#\B.Q0-Y^ ^'LT!H[Q#QJP,
M[[Y'+JB36(,;R55C./\ CB7@ZNXJ,.XK<8,M!(NECMXP[5)N@NH??K I-MQ\
M!T!O-#A5Q)  $.-F$MP -O\ <ZK8>/L\/D1V_9T!RDX9<4RF ?S;\(DVW^(N
M.ZX(^7N&.*'[.@.?\S?BI_)TPK_%Q6OWEH##/DS>NUIQ#MN-Z%F_&^$:_<LK
M22#"G5R/PZPGY%9J=^TCW4Y+!$03U.#@F!W8&.Y=F23/TB4@F/X:TQ8KY\E<
M.)3DLX2\60VDI?0R[C.*?$B9BF$Y%8"P+(0\HQ;R4=)-L>U55F\8.T2.&SM!
M<L?Z9T%T% ,4V^P@.JVK:EG2Z:NG#7@R>NJZ%FY"I]N^,SE7N-KO%F 2YIM-
M9<7"$I*.+X1PZ<UQL204/)JO4(<\>U34)%.13*HJ4RGHFZ0';5JX<MZ6R5JW
M2BEOPU2_>T1*F.[/;N6-^WOCY2<9VZ@<6826KD=])2L"_@<>,YUN@HV.[9D&
M)<)IO?6D4DQ] O1NJ(AT[[ZS)+8U&1[:]OXQ)\P4,18<A,$?1+Z7>6FQX<CH
MEQ'-XR>6JT@FXB7$$6146;6-N=F )IG]18H@3?0%%8$RUVEN3=I;TS"5.P?=
M; Z^8*@V0P@:/;F5:)^JX;F?2E69LTW**0"84S' X &^VNBG%SWP6Y-%.&CA
MN5H1N2>WN9!W7'7;WQX]D(6UX^XO15G8,CO0J3R!QXRLKP1;?,M&C2)=IHNU
M'DB E*@3IW4,<NV^X:P5;-2DVD2>%BBL]O?,F'BYVJ6',)ML<)C+I2DO9,70
M%<5@WE?<G9S;*8:RL2V69N(YRF)3=0 4W@)1$! =:9\&;C-5S5:LZJR7D^GV
MD)I]"W[BX=LIC)8<3C\<X%E(W.5DL],H=HA<=U>2A5[=64XA92O/56D<JNT>
MR[>7*HT,)/342()Q,!3%$RG'Y5LSPO%:MU16UA?2U,K77^T;JQ,Z29C?FI<<
M/9Q_PK_%Y6P_^"QUD20_-2XX?R?\*_Q>UO\ @O0$!XJ<<2@.V <+EZOQ8F+C
MVM"8"J?BS" #%@ CTFT!K/Y)<=<$1_<!X#133"6)T8FQQ^<D)B,1I$ BQD"L
MZZ@]CU7C8D;Z;A1!4_5\6^QA';<- ;. XL\<U ZCX'PX/B;;_<ZK CL)S&'<
M1C]Q'K,/W- <?YJ?&[JW' .&!#?<3#CNL]0_9V^C=M_NZ G'BKQO$! <"8;-
M]@<=5@ ^WN$<.@(DXJ\;0 ?]P/#9?']KCNLC_-CBZ G_ #5^-O\ B%P[_%S6
M/WAH!^:OQM_Q"X=_BYK'[PT! >*W&[V8&PZ _P#T<UC]X: !Q6XW>W V'1'_
M .CFL?O#0'7'BGQO$P_[@&%A 1'Q''E:W'[8?1FV_P!W0$Z?%3C<41$<!89+
MX;;DQW61'S#P\8TOAH#E'BMQO]F!L.![_P#<YK'[P'0'#^:GQOZM_P @.&!\
M0$3#CNM=7V1V^C1#?[N@)S<5>. E$!P)AHV^W@;'58 /,!\1".$= <7YJ7'#
MV<?\*_Q>5L/_ (+'0$/S4N.'\G_"O\7M;_@O0$!XH<;3@)%./V%1(;P,'Y.Z
MT;P_R(QA0'[^@)0XC\8B^)>/>%M_+PQO6"^'VP8#H"0W$/BZH/4KQXPL<WEN
M..:P/A]L8[0&D_OH8"PCC?BKB>?HN)L?TN:)RKQ$Q+-5*K14!*%8*K3[E5G\
MS&-VISHJKD #%,80$I0^SH#Z#J3\=7JIP\ ^K5=-M_DH5$ #[F^@*PT T!AM
MW R@?A%RF*.X .$[SY?]B%M :8_U6TVW!K(Z6W@&<)<=_;\-3JH!]CVZ ^F7
M0'"X5,@W76(DHN=%%54J"0 *JQDR&.5)(#"4HJ*"&Q=Q -QT!\R_*-Z&2,MV
M87.,,EL&_(R[T^'BZG9\3L"Y(D9.DKC%.F6,[[(6 S:#92 ;]22K44%!, ]0
M#XZ][V=Y</)KR<6JP)VL^M4O&R\#SN=Z=\+PWT]3Z5XM^1G]EW*>85>.ZV*Z
M/@>W<?J7%5>*JYLIY=L#<Z% J%83K,;&K/XV%4D)B3F9M^H6/:I@N<7"9%%U
M#E >G7+>M<G)KR5DKEY.3([.J4?5N;\E#Z]HDU5O3PVQ.KIAK2$WKIMC[48'
M8@C<OPN3N&DQ?$Z#%D7O+ZHU.3@859O.3L"G9F[2*F9^96(1W.PDZK(.$VP"
M!#-OB3ZA$P&U]AARY>1C]V7*KMY/Y?=:B?TII:-:]E\3Y+/BQ8+^V/BO=QOS
M$5NU%G+U3T[OX%M\S81R\]Y!9"PXQCZJ]R QBW=XGWE?N>3589RQF6JED%1Y
M#6&<FXAAZD:\%-%NU11 5DR$(*?B(_.^TS@W>Z4O7_ITHI;^:7$Z0]/N@^C]
MR=,M*^V7I;_J&UO6NU52<:IJ9^U,S#Q[AKEQ8>'=?QIC+'="8,;Q;9"WW1[;
MIF.KEF- (?5\M;"$KKN EHJ,?29X10RIW1#_ !IB/B)S&UI^HN=QN9[E3-@O
M:^%8:UG7\2EV4O5ZOJ<_Z?X>;A<"^+D55,[S6LEI#3B'"T6BZ%M>"&)\SOK1
M?K+1HRP5]M%6TM>NB%RR+&PCBKVB.,E+*Q24+1:Y#2TG6S@Y'U8\C]%J901$
M2"("(QDKD]KP\>G+:OPN1C>15A6A6;3LE:4KO_%$EG>GN>?/?CS7G<>ZQNTQ
M+HE%6ZPW1>$E <M\8(X7M,M?+T:"ISVVFN1HK!$/<[YE:>O;9Z_<*N\E/',W
M,+QE*CD577J-XY-KZ29>HO684QZ?/XO)R8+O)PZ^IDVM2]-M6TG:>DJKGSU2
MZGI9./AY-:XN;?T\&Y/Z5N=KU3M6D=8M9)>6C?0N+/1MR9=O>&R,T^E+-*P%
MZL;]6,JD:+J$K;5W8"?7"7GFT>JSD)%![#E])P@504D%/%$I!\==GO\ 2V+F
MX<7&NZYL5<5EDUEU592B6OGU?>3G_3W(QVQ<C/RL5;X<WK5>)I0KV<3,3U[+
MY08]41O;Y6/H&8+%08IS6Y[,%<B6TX_2L+>2?3#JYGDGJLTYL\A,J,B-VK]-
M1-7U/133>)$4%04@ /?]AXW*PIX<U]KMQL^3;6)K5JNSIJ]Z3>WMM[-GA_J#
MD\3-_4PUW;,_'QS9.+6KN]3KTV-I;N^[P1<?N*UL\AR4A7R>3E9B#F(,CBFL
MV!ZG9FJ<^!!CW=$^DHB1C7]>9(+G()5WWJID(83=([:\+V95K99:SZE;?5.B
MV=W\?)'L\Z75TLOH=?ICKN\/@;MN&]/947#T%!FNSJVV%XUCIRPLGML@K6M6
MGKF,;,#P[1U! 1NC&-U8XP)@8#&]3K 3G, CKS?<\_YCDO)6J6.6DTFIUZZ]
M]3KXF/TL2HVW;JY:<>1EEKSCJ&@/G%[30>GW->[^4/$#Y?H6^_LWA)H_AM]G
M0'T=: : : : : : : : QCY(Y\O>"V->>4CC;ESD6K-+O$7T=B4D"H_KA&R:
M:B+J7).R4<G\L^$QBIBF8QNH@AT^W0%^JO/+62 A9Q:'DH%668H.UH682*C*
MQBJJ15#LWR9#F(1PV.(D. "(;AX#H"HM - - - - - - >;*CLV3,'L>,@_J
MW220_> _W] :$,0G$W?YYA#L'AQGQ.3[B=92V'[8Z ^@ /(/M!_,T!'0$BIC
ME34,F3U5"D.8B?4!/4.!1$I.L0$"=9O#?8=M ?*7W%SS.0,YX_SC=>*G*7$<
M];23?%^97A[#B>P1&4J-*A+/ AXYA;H28^I<P\;L55D)5D5%=-LH)A$%"$4)
MU</'GR9U;CUW7I]4>5=?VC4K9I+ZNC-C-SR!R(G>*$OAZ XTWSC/0X''$G6)
MW(F1IBNY,E:QCFL5R.*[=1]8:(F-/2\I%*+H-_4.'IJ-SFZ2_ 8+TS8\_-?(
MYDM6L[-5[M]O+4AIJFVIKOX@.[1CKD/V])').>Z?D3",G(9-K?&8C&H5RE/(
MJOV7'%K8-7D^NQ!Y:I::E)9JU9')*.% (X?I^F(% 1UZV?-7/CY%?3R?G;I2
MITJJNKT\?I3?D9I0ZZK9^\QW[BG%+D?)\Y<?84@LP<?I/*F<Y.\9C@LHV_C/
MB#&;R"B*=)J/:O"S.6(6LI6"T60K+H1>"HX%-T8N_IE >D/"X_(R<;*LV*/4
M724G$^3TG]QLZJRA]#.3 V(.?UI[=$9A+C=?\;4C*L)F[+56S7-V%\7HM=>D
M;%,2\S*4><KK!JK5T+-.2RJC9RR30=)-S%%%<IRF,.3GKXDF.7$[CQRE7Y$9
M%/B[$V"*=F#".1U:_F>Z-N2_*F3<W8[LR!9^474F,CR(3<I)E#\>=X43F,/0
M?X=BZ]]8[</A8,G(M/&S.82K9)=&X:_&ET;Z&/XKM5_$B[?=&Q>A2,^UCDUE
M:%Q2QO+HD0UP-CJA4.,D9O.UVID'4'UQFLVVF5].;;URNBX5C&A$G)BE9%8@
M!04,J<<_;MCO98=UM+*VYI*M/%/_ !?=Y"\]_P!F5IPBXP91Y =NC,%60S9*
MQ-8R#/9"4KF+6-;K",'7+='2XSSE,MA2CRV9]%R\L=-%=FLZ.W%!,2=(E,;?
MI]YO3@<JB2]3)7%C=;/2*P](4)^,O4C%-JM]%+, ^).69NR2.,<$!@>R0EA>
M\LL>7N??56-H5-Q11)+$T4I6;"A#TZJQ\0SAG%G7=F>.4B="7J[EZ3"0!'GX
M_&R8N1CSYLB_*5X^18Y?U-6<IO752VDH#:M*2UE2?:6 [[_;\/M>P=>$;D=
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MH ':H[=I?P>'''L/?OC:!-_SR CH#F+VL.WJ0H%+P\X^ 4/VH8T@-O$=Q_\
M2_MT!SH]KGM]-U"JH\/>/I5"[[&_)S"#^$ E'P]#;Q = =T>V5P''_S0N/G\
M6T$/\U#0'55[7_ )8W6?B)Q] =@#PQE73> ;CYG:F$//0'8+VR. Q0* <0^/
M@@4  -\:P(#L ;!Y-P /N: G_1F<!P\N(?'S^+>#_P XT!R%[9_ @H;?FA<?
M1\?\7$)_G&@(_HT>! >(<0N/NX>7^YQ">?L_Z!H"(=M7@B [_FC\??XN(3_.
M- 3?HV."7\D?CY_%O"_YSH!^C8X)?R1^/G\6\+_G.@'Z-C@E_)'X^?Q;PO\
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M34KH5;^9/Q+_ ).>&_\  *O_ +RU0DZ*_!KB0LH90W&W!IQ$ #J7QI6EU!
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M%,!W_-WPY]RA0/\ /:: B;AMQ3';_>[X=^[0H#^<ST!QCPSXJ"._YN^&_P#
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M: @/E]T/YH: U9\I_P#R^^W"/_K_ #;^Q2TOZ.@-I*7X'_+'_P"?-H#DT T
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MO5M_D_F.O?[.^_V= <G_ !<CMK?]$KF9W!/:DKFZ]B01]@CTR)1W#ST!(?\
M5Q>VD80%.I9=2V#Q ,SW57?[(BN^5$/N;: G+^KD]MHI0*%<RZ ![!RW9S;?
M8ZC*B8?OZ E_XN+VSP\24_+J9P_!4_+3>%>D??Z2T@HB?[1BB'V- 1#]7'[:
M8_V6JY7<>[ULL68>GW[=*I?/0 ?U<?MK /XNL991)[$T\L64" /M$ ,H8?$=
M 0']7%[9XH^E]3\N=7J=?J?EJO0CU=75ZGIC(^AY^/3T=/LVVT!)_P 7$[:W
M[>LY<5]P#EJR!TF]A@V4+XAH"8_ZN/VUCB JUC+JX@&Q3&RW9/A*'D0-E2>
M#_-T!)_Q<3MH_P"U++?\;EE_S_0')_Q<?ML_[7<N_P ;-D_KM 1_XN-VTA#\
M=5,NN!#\$?RR7)MTA[0V:/&Y3[^\P"(>S0$/^+C]M8/!*L9=1)["?E?M:^P^
MT?5<+K+&W^R8=O9H"7_BX?;/\!&FY4$P;B"GY6;/U[CYF_LWF(Z ["/ZN?VV
MFXF%"KY;2$P !A#+5F'< '< 'J6'VZ @K^KF]MA<W6O5LM*G  *!ARU9@V*
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MEDDC+J@B@510A!66$AU 22 P@*BHIIF-TAN.Q1'V: G$Y"F(0QRE.IU>F03
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MQ+Q=OSD7"\<.)F7Y^YFR8U:15[K]/QK2,K.I N9GUUL$,HF2HV*.FG#ES'6
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M!$ WVU\]R\->/R+8J7K>J?6NJ.S'9WHK--/S+H:YRXT T T T T T T T T
MT T T T T T T T T T T T T T T T T T T T T T T T T T T T T T
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MNXZ-\<YCS1EX]J?S*^630K1M6E6Z"$+6(>%^8.BT9ID*)EEG"[HXJ&'8HAL
M!KHR<N^3BTXMDMM+-I]]>Q18U7(\BZM$.2?&FO\ (N@1N/)"35JL2UMT'97Z
MD(S:)+2#:+,NFYC>L$BG:F7;N3"14@@8BA2^9=P&W"YV?@9O7P1OAK75:C+B
MIFKMOT*_A,,U:OY%D<G,)*X'L,K"L()ZQ>VZ=?U@6<8S18LSLZP[>*PT:Y(B
MB'4HW23$YA$QMQ'?6/K6>)XHK#M,PI^WK'D6VK<K:Z*/(NUK$L- - - - -
M- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
M- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
M- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
M- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
M- - - - - - - - - - - - - - - - - - 0W#?;<-_/;?QV]^@([[^7CH!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!N ^7CH!H!H!O^QX: : : : : : @ @/D(#N.W@(#X^[[?AH".@&@&@&@
M&@&@&@&@&@&@,'\^=QCB-QFR$RQ?F');JNW!TVBGSMJUIURFXZ"8S4JQAXM[
M89R'@WD-#MG;M\&QE5PZ2D-U  B0I[TI?(U6BEMQ\_CT(=DNIF=#3,58HF-G
MH*0:2T-,,FTC%R;%8CAF_8O$BKMG39=,1(JBLD<#%$/8.HO2U+.ETU=.&@FF
MI70QWSGRHQY@BRT^BSQ7L[D')$78G6.:+7Q0<V*U2< #%,(XC98Z*<<WD'TF
M@W2=K'!$%#&$?A3.(:X./DY-W3'$I-N7"A)O^!GES4PUW7F)2T\W!9GCMW"L
M49EI-QN&0/H? 2M!<P\7;83(ESA&SR&GY!-W\[!KJ."QI%GT8\; WV1!3UU3
M@">XB #TYO;\F+!@S5>YYJMPM=NL).&]7X.&9TY-;9LN*RV^FUJ])TF5*6B\
M2ELR]SO!5!3QP]Q:ZB>1$)>KI.4&5G<66^&F6-'L$5&1TLT+8BL"R3DL?)-7
MBG]M$(*"!DR@H8/5(.J<+A9.7FKCUKC=MKM$I-IM)_&"<_(IAQVMH\BKN59A
MM*)C[3-'(>8:WB_%;K+5GC+8_@F<7$2*L32:I.WNT.#S1V:+-G&5VLL7TK(K
M&<O2%,8B0)IEW44,1,IC!R9*^G>U'_*VOL-Z/>DUINC[S6M,]XS#CBPQL3CO
M$69;E&L+6-8R;*35;-CZ1QJ<\>:1;N)*FV<$KE(J.&P=8))L4]D]Q$VY1*'9
MP^!FYN2M*.M:6NJ[F])<POG'D8\CD5X]':RL[*CM"4N%$OX*=>IDSECN#83Q
M RL3N:KV7[$6K4&)R#+N*;BRUSD,C%SD<27CFP6$632&%4\4)W2BXJ@S0005
M%18IR"35/R>6,C^E+%9JTM)Z-K1=7T[!9Z-TJI=KJ5"?[^B^9UN#_.NN<V:W
M)6"!Q_8,?J1+8KA[$V*09/WJ/JR;QBV(*C!$K4_KMVQ5NHASE #]/F&^K9N%
M?!Q:<FUDU>UJPH<;?--H5SJV>V"&MM4Y>G7RZZ'6Y!]R'CEQMN]BQO?SY"4N
M-;JQ;6];P>.;=-PJ;!T0_P!&J.9V)BWS=NT=N""F=R!#H-S>"ABF,0I^3:]C
MOIM3CJO-]/D=%%OOZ=?QOIYZQ]NO0H3 _<QI.6\%9 SI-XJRI7X3'$U!5V8@
MH&HRUVN+R7F4RBHT;5"O-7DLBYCE#E%=/=4$DC <YR;](=.;BK%QL/(5TWE5
MM.]8<:ZOK\O@95NWGO@LHV;=>SE3X=BTMA[S6 7+9J;&]?E;!+M[NK4K-4[V
M]/C2YQ,<-/?6-K9HFKOHN7?S[<9%J#)=L/RBS;8RJ@@'IE5O[?PK<_E4X]6J
MJ]]L]8_;^)7F9OR?'>>RGZ-R4]O/P[_87,SMW?\ @_QG@:JOF'*L6PNUFKWT
MT;'5/60O-CAG!8KZ0^B9I2"66CHA\LN)&R:;E9)7U52=9"%ZC!S9L7HY;8F_
MPV:GQAP:T>_&LBZ-+[U/3J5GQ*[C>)N4^.[!E(&)<8TJM4VN726G+;8XD8Z/
M8SS^:B%6DD\(5LW8OH^7@ED!3,8QSG,0H "AO3#IR<&^/A8>:G*S6M55C5.K
M2^<RC!<FCY63C?\ PZU;?;ZE/RB#L7[N.X-C,=0V4<-R$=R"J;BRRM>LKNA6
M!DV6J'T9 S4D+V49RJ"3PY32T:BQ41*F"R0N@5$HD(.HXG!R\KDX^,HJ\E]L
MOL_-=9\B<W(QX<&3,Y;I3<DEU_;K)D98^1N/:/@N*S[?%9"K5.4K<-/D8+M%
M)&:*ZG8XKZ/@$FL:5P5S+N#F]$@%,"0J>9P+XZRS<>^+DVXM9ODK=U^E-RTX
MT74VXT\FE;TA)UW.6DDO%MZ)+Q,!S]UFL"UPI=?R=.XG&-XN3V@9:D+/,?0-
MGPU.RJWJX[<O()>/.O/H6F+:.E3I)E0]+TC]*IQ*F5?H7MV6<5<CVVSSZ<IQ
M9J9KV:<I5Z1+6I?T[O\ ,>GMLN-17R19.*MU4J)3_%+U3A/23)3,'<"P/AF[
M5VAR[#*%TE[+7F5K9N,68ZF\BL4*]))^I&RC@*X#J15;O!\ ^7;KBG^$J!""
M!M<]^+GQX[9<E6J5M#GL^D?$SI>F2U:4:=K*5KU7B5!6>6*EPP?DC-,/AG)\
M22C1$K/151O,.I39ZTQ4>DZ73<)MY!%5U$J*-V9UE45D#+(I"00*<QND*9,7
MIJKE6W*=-?E\3HQXJWR5QVM6B=H;?2OBW$RHUT,$./?=UL.>;[C.LAQ>2I]4
MR787$!'WV2Y"XH?(H*,RG,\43IJ*K>]N%2"02$34CFXG/X;E#QUI@X_J3ZN^
MB>-VK]+>YKMVT\U,#F8ORM[4I:N39DVV:?TI/HT]>O@X9>;F;W+8OB+E2M8R
ME<,7*TM[''P;YK=&\NPA*\FXEI!TR<(G(Z8O7+]A#-DRKO1; JZ2()O[7V!,
M5>.]U3KT._V_VN_N"C%;^J[[56JW6;B9?1)>#;[,O96.8->R-Q@O')C&-=-?
M$J;#65^6H5^44))2JM6345>M(YR[A4Y J;]-!0[;UH\BJA2_"GXZZ+8;5V.V
ME;U5DWTA]SS+5=,M\5TU:EW5KO*[=>OS,.\4]X:CY6RC0\6UO%+ETO=^A-&R
M$N*"41%/DWHM)2+>IR=9AWJTC&G^(002424 Y.A01,8"UP8[<B[ICAO8[>+:
M7DOXP>ARO;LG"XM>3R=]:N[I^'3<O/=KVU2:[=38?E;EYQJPO81I.2LTX[J%
M[6C224=3)^S,(V?DDW *@P3;L5C^L)Y!=+TTPVW$PAX>6JUK:S5:IMV<+S9Y
MS45WO2OB64X7\YFG+&,R<]E<;N<5NL92T@QDVCFT-;:BNQCG3UJK("]814<F
MB?\ M$QQ2(5;8H^!Q'PUZ7-]LOPN-BY%[:Y-R=8AU=7#7G\=/@<V+DURY[XJ
M*:UAI^*LI7P?EJ6TO_=!QY#-\)V;'=&E,A8\RIFB;PI/6IU,I55]1YB*1^89
MSBE;5C99_+P4VBFJ9LL<S(H]!2F$#J%+J,7MN2V2F+,]ELF/?7294./")C['
M(R9U3=L6[9:+:Q'3^W[=#*&\<V>*..K4^Q[<<^XLK^0V*+3U*1+V^,8V#YN1
M;%7CF!V2JOJ).G8'*'0(=1.KX@#7G*KM?TZZWF(\SH>E5>VE64GPMY8RO+&J
MWFR2^,/R6.*7>)ZEGB#V]"X*OAAIF5C$Y4KUI"1#,K601CBK)"D9PF;U! IS
M 4#FZ^3Q/RV+%=VG)DJVZ]ZM6:AZ]=)[=3.EW=V3354]'VLH3E>/6/D60YJ]
MUK!?!:_0-"S!C//KM.Q)PQF&1:Y0&;C$B"TRMZ96+^\OY^/(E(,4@%1PBDV6
M.F0/(1\-<B4N#0K+@QW"Z'S6J.>[M$PK2FU7!>6KKCMU:5K,TEJS8X"K@M),
M;PTE#LXPC*-DJSZ3Y0IP.1 AQ_&F HCK2^.M<=;JTV<IJ.C7GW40Y^15-NS3
M6A2.*.ZSQUR1E[)&/)ARICJE5RU1U0Q3FBWNE6.-\_2CANB=^;&=@7C6T-*-
MF#I<J '2=K@HH A\(B4#2L-K8O534[U6.^J;GX:#<MVWM$E=<MNY%@WA[=8O
M&-UJV8K_ )/LM#^O]-H6(<>/KY/VV.-,RD"5A#M8]R19213>Q"IUB]'0@WV4
M,;Q HY0WT+%F>,'==JF;,=\BL@9<PAD7CC^;E,U"-M%5MI5INUND;V53ZK&4
MADH>&=Q,E**"D4K9<G27U=S*@4IA#>G&R9:T]%.V6[:VI:Z?M\H*.]:SNTJE
MU+-.N^5A=.#I[8^,K74\RR^6ZKC^R\>LFN7-&RG#U*Y296<'DJ"8/(-S&62
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M.OEU^XK>^Q2_%?>X,T^97>2X9\*;O'8NO<U;K]E!\N\:O*-BZ(B9J3J[AN4
M;C<7,[/5QA!H/W!BII"51PJ(#U^F) WUR==#0N1VX^?T?W!,5VG(K;&+_%CV
MHV]U4I. =65O:T170*)TET9-.(K[@#+)EZ^@[,I>@Y1*<P]0%Z,N!8L6/)N3
M=TY7@TX^?C)2M]UG6.GWR6ZH?=_XPY#Y#'P/"US,;*&6ND]C2!SY/4(\5@6X
MY%KRY49"JU*^J2*C>5=I"FN4X'316(HW,!D@+\>HQ<?)FW*GXE7='=KR_>3:
MZKUZ3!L+0S)C!UE%[A5"Y12F5(ZNI6UY20^9+,(5I=0B24R8IFY6QF2BJ@%
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MM$_<<:MCOCK?@RN//TJTSL6B3?68[^)1G:\PSR%K>:,YQ"]_853'5&S&J5Q
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MKE3,/6D.PB '*)=6MD]!6X^.RO@;JW&B;7]DM20EOB[46U+-=O/CK)8#Y?\
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MN?/'*SS5S>,LH6G(%";Y#R0Q5L5F7-8X&RUX+456?1(,LZAE'Y7+<X])2J
MD$H" ZZ_<;<9\?CUXMG:JK:9[6TE?#P,\*NKWWJ-5'PU,2^7_:PR?$85P; 6
MKDKE'++V#R;C.@5K'M!I<%1Z'&PJ3T(YF\85:LE*X=V5K#-P/\\NJ<Y52&.
M!YC7VVO&RV=,V1X75.V[=$M+2L/2?/J3F=ZJ:K<GI$?>;X>.S.]4 ]@P58:9
M8T*1B>/K<3B_+5@M<?:'N6*\O$MU9%_+IH*'DH2=A9P7#91!T!?4;E243$2B
M.WGY<ELV1Y;?B9M6JJMJZ(R@UF2- - - - - 0$ '8?<.X>?GL(?=\!T! A
M(7I+OL&X_$8QA\1W\S"([: \Z6A8>>8KQDY%Q\Q&N=OF&$FT0?,UND=R^HV<
MD52,)3>(;AX#Y: Y6T9',FR+)HQ:-FC<Q#H-D&Z22*)TQ 4SIID*!2G()0$!
M -P$-);Z@YEVC5T!"N6R#@J2I%TBKI$5*FNGOZ:R8* 8"*I]0])@V$-_#0'-
MTE]W[(_T= 4JXH5'>2GTX[I]8=37JIK_ $NY@HQ>2]=( !)87RK8SD54P*'2
M;JW#;PT!5(IE-MYAL(#\)C%\AW\>D0W#PT!/H#SI*'BIIDO'3$:QE8]UT?,L
M))JB^9./34(LGZS5R15!4"*D*8-RCL8 '0'%$0,'7VGR$##Q<*Q]0ZWR<2P:
MQS7U5!W.KZ#-)%+U#CYCMN.@/+=T6E/Y49U]4*P]FA6;N!EW<%%N)(7#0$P:
MK_/+-3N?6;@B3H-U=1>D-A\ T!56@.%%N@V(*;=!%N0RJRYB()D2(99PH=9=
M4Q4P*4RJRRACG,/B8PB(^(Z Y1 !\P =O+?QT!$ V\M >:I#1*KY"34C&)I)
ML5<K>0%JC\Z@5T*(N2I.@("Y"N!;)]8 ;8_07??8- >CL&^_C]\=OO;[: ;!
MOOX_U0[>_P M]@T!X;*KUJ.E7L['P$,QFI(#!(R[2-9MI)_U& YOG7R*)'+L
M3' !'U#&\0T![1DRF 0'J\?Z8P;>S<NP_ /V0V'0'591L?&(F;1S)K'MS*J+
MF19()M4C+K&ZEEC$0*0IEEC>)S#\1A\1$= 2HQ<:V>.Y%NP9H/WXI&?/46Z2
M;IZ9!$C=$SM<A2J.3(H)E(43B82D* !X!H#N])=Q';Q-MN("(#X>7B ^&@.%
M)HU05<.$6Z*2[LR9G2R:9"JN3))@DF9=0  ZIDTR@4!,([ &VI;;4/HA".4Z
M9%"F*<H&*8  P#Y" #N'VMAU .%-DT15<+HMD$EW?I?-K)I$(JY%!,$D1<*%
M #K&22#I*)A$0+X!X:"3G I0'<  !VV\/#P\/O\ EH#I/8N,DA;FD8]D_%JJ
M"[47C5!S\NL7\%9#UB'])4/88NPZ Y6K%DQ2%!DT;,T3+N7)D6J*;=(SAXNH
MZ=KBFD4A16<N53**&VW.<PF'<1'0'9 I0\0#Q]_]'WZ ;>(#[M_:/M^QY#H"
M04DQ$1$H"(^8CYC]OW[?L: @1%),H%(F0I2EZ0*4H  %]A0#RZ0]WEIU!R
M!Y  ?:_Y/L: CH"'2&^^P;^_V^/V?N: CH" E ?, '[?C^QH#C%!(1$3$*;?
MQ^+XOV!W - <@%*'D !M[@V_F: @8A3;=10-MOMN&X>/GX#X:  0@> %  ]P
M> ?< /#0#I*'CL&_O]OW_,= 1$ 'ST!#I+[O^3[/OT!-H"'2 #OMX_;'0$=
M<:B2:Q>E0@'+[AWV_P"3QT 3122)Z:9 (3]R7_DWT!.  'D&WO\ L_;'0$=
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M.NFF9,AS$(=8PD1(=0I#JG*4QS%2*;8RABD*(B ;B !OH#F =PWT $=@WT!
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M HG(5(S<M.P,"9W17+&Y+U]G"K4-I**HNG0L'C@7K8X@8 #TQ'SZIRWW6O\
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MSXHXOVK)./,%W&&R=5LN5[!$\GGFMSE"J%>L%@B)!R3):+ALW>EM=!;+QYE
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M#LDX[E[< <K<*\E<2#F_&5D64QTFDNL[FK&R/7?H]%JT3?.E7Z;\X U2;ME
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MFK:8:3T?0X;93*E?(<]>NU:@K; JK(.586QQ;*9BEG#8_J-EE8^017:JJ-U
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M8]=1!19C(M$'C14[5PD[;'4;N"*)',W=(D4((A\)R 8/$ T3=7-7##4Z,]$
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M#\-=X/&\KD>I,+Q98EM.U^MN9=NF_F(AXZ78M9"/W-Z#ELY=MCID$IQZCE$
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M/Z^"F7LZ9VY-<2L#V(F*8ILE7WM<Y\2N+[YDO'I'9D(0RN+V]7EIAS--$E%
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MM>A]S_K LG#_ -/O85R-UK+!6'I-ELE.-/&(TZ&V'6)_-@T T T T T T T
MT T T T T T T T T T T T T T T T T T T T T T T T T T T T T T
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M%/"C^>QWEW#V/RN8W+:[&(FJ[%VN4;%!NBFR7^?0*^C%W3<X(N4CBHD8YQ3
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M3#MCAPRABBIQ%HQ9(76/^G:O9EGE>CV[^!M[10JJHLK1$HBV453*91LHIUE
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MM;*M<2K2L]%5VAVA_P W3P@KQ>Z<J6=_9Q$G#X HM"=N#(QSB6LLJ]L#]N4
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MU6'_ $Y_3KQ_S<;'_P"X;K=>@?R4- - - - - - - - - - - - - - - -
M- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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MLNA6F_&Y5K?:<NJ$D!Z=OBVV^SMM^SH"&Y!]I1V\/9][0'"X;M'J0H.D&[M
M%$511<))KI JU63<MU!34*8GJ-W")5"#MN0Y0,&P@ Z Y]P]X: CO_1T _F?
MT= <2R2+A%5!PFDN@NF=%9%8A%$5D52B11)5,X&(HFH0P@8H@(" [#H"5LU;
M,FR#-FW0:-&J*;=JU;))H-FS=$@)I((()%(DBBD0H%*4H 4H!L : X7\;'2S
M51E*,&4DR6%,56C]J@\:JBBH55(5&[A-1(XI*D Q=P'I, "'B&G0=2=PQ9._
M2!TS:N007(Y1!PW26]%RGU"1PEZA#>FN3K'8X;&#<?'QT!V *4OX)2AXB/@
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M.G1>9R9<WHVJKVU=EHE+:<K^S7R/I9UQ'6- - - - - - - - - - - - -
M- - - - - - - - - - - - - - - - - - - - - - - - 8^\B^,6).5-(
M6QSF6*F9ZFO!*22@H^TV* CI=L#MF]%I+-(:29-I%+YE@D<AE2&50,7=(Y!,
M81M2RK:6DUX.?X05LG90FU\/[RG\#\1L5<<)27D\9?3S/Z>8(L9AM+O6DV9_
M\JH LG*DL_8*V$AVJ!02!(CPK<X!UJ)G5W4'T>9[KR>=QZ<;,J^GC258E0DH
MB)V_-J?.#AXOMV#B9KY\3MOR:VF'+GK,3\ICR/-YA<;E^1.$LG4ZHRR5.RC9
MZ%,5*JW@K^<BR1PR!DE"HS P#YDO),"]*A4P6!8&QECG(3XCE/P5RVK2V-1M
MM$Z*=.D/JODU/<[;8ZVLKN=U>FKC7Q71_-,UF]JWMBY4X>VO-:^>(S#,W Y6
MQK7*4]AL?%FI2JRH0[HR+]2=86Y,ZLF_LK-0ZL@)D4VXJ?"0@E$1UZ7(Y7'R
M\%XJPLSS*T*L)55-OBY;?S.#!Q\V/F+):7B6)J6Y;;M/@M$C)YYVT^/<7R5Q
MC;JSQMP$&&X/%UMK5BK#[&=*?MALSB90?PLN[;2D.^4F'P-WJZ:2BO6)"%,!
MC;%2*'+C7#?"R>I/YS=79X1KNG[CHR?FOS=/3C\KMMN\9TC^)F;3.,F$Z M%
MFJU&C6#2#BIB%A8I8R[^(BXV>]8DHS91SY5PV1:*M'*K9) "^@U:+*(H$324
M.4TY/<.5DH\=FDK;9BJK.W\*>U+IU\WJ]2*<+CTNKI-NLQ+;C=U>K?7IY+1:
M%MJIQ_DJ/R4C+O6$6$;B:,Q0>DP%5CB(LHZI*HO$%$V$:P('@V6!,PD NR:*
M72F4H%* :V_-UO[=DQ9+-\B^6KZ:0EU,ORUJ\['EHDL%<=EU[M]#7#E7M.V^
MQWSDM9ZL[Q<G5LS\A,99AC::I#*1[8(2KQ,>C.PSI%)NI$LI0TW&F=%4(W,5
MW\ZJ*@E4^,=>'SN/AQ8,62NM,[O9^4)54=XU,^3Q,^7)FR4MI?"J57G+E^78
MW9P%0AZ=5U*_1X2 J20(/%VC*'B6D?$-YAZF915\>/8)MD#BJ]-ZBNP *GCN
M.XZ\S-ER9LF_+9V?26Y<+HCT,6.F*FRE55>6FO<Z>,V.0(RC5]CE.<@[+?FZ
M#HMBG*W%K0T)(+FD'9VBC",<.':S0B<:=$AP,H;=0IC!X#MJEW5VFBBI:NY+
MZM66XY2<?(3E/@V\X&M%QNU(J^0X\D/99;'[N"8V%Y!F6(J_@P=6&!L;%*-F
M4B>@ZZ6X+BB80343,/4$)PT_,EZJ"B,28"ROBX,&Q3?.AW]&Q-1YC'L_0OJ6
MS3B;S$_+PZ%.GW$F>55F(RZ5LD6)%G*:IX]XFN<",6XB AV<C/QLV2^14NG9
M*/J6EI4MQ52FNVD3U.7#ASXL=,;M6*O7Z7JNR7U.'/?6? N!R@Q#*9\X^Y<P
MY"64U/F,B4B:K,99B(%<##/I!L9-L\%(0$XD35VZA)L<"B(E$!UA@R>EEKD;
MLH?6KA_)FV:GJ8W2*N5TLI3^*-8?;W[>.2,"Y S--YZJV"E49R-H\57)'&M1
M(WB;+)5IB99M>W%>GUY=C&W"(DG"AA>BB*CA8XJ 4GQ=?J9.7@P\)4XEG7EW
MR6=G2:Q1I+:]6W+EM3$?=Y^/BYLG,=N2E;C4I555HM-I;W+1)0HUB9DO38NW
M!8;/?Z'DF5Y89A>6G%#NVHT.4?-*^]6EJY=URNY6'RI&K,_JS>W,(J)THARE
M'QWRS104ETW.Q3%Y,?*P8E3;7*K*K5OK6K;T=?I^F/B]=4T=.3CYLCMNMCVN
MR=?I>B75/ZOJGY?!EVKSQ4RA8.&66N,T+F=*+M]RK<_ TG)$#6ST96I)RSHC
MI(@L:U*!TE*4545#-!;%.@J8G0 "(#'-Y''Y7(6;'2U%"W;K.[;75RTGKW_>
M.)@S<? \5[5LTWMBNQ)=E";6G[(QO[7/!;,_$ZD9*J&?IB@VF)E<F,[KCRJP
M,4O*UZFRT9"-H0ULK)YQP]<UZ2F$V_6J0@B<AMA3.F7<FG*RT]';QKW6>Z:N
MZS6NUQ%-O?I+U@8,5WEG/6KPT:=4XL]VLVE]/+NBK>4W;'Q7E2M9BM50)839
M6N\M(WR*+,3;B<AT+T\5(Z<*QC66=%4BF;Y8GPM4W)6+??<B.WAJ?;L^+%?'
MBY%:>DKK=>&[1,O28?V%>;@R7QY+X;7]3:]M943&G:?O*OY#=O?&O)3B.TP_
M/4RB57+#.CP"]=R#&U>(;2U.RDQB(,)"?92D.VC9!0)!_%>B\ BQ".T!#K >
ME,2.5RO5YULU;6>-9'LF?IKN;JEKHEX=AQN-Z7#KALDKNBWQ&MMJ5F_%N.KZ
MEF.*O$;E#C?,+%QG>)X^S% @\2(4C'<]B&OO(9YBNP1CI.10L<'&WU6YN7<_
M*KH_C'8*H^@N;<I#$^'72^?DMP<N+UMM\F3<ZU33O/TM6::6V-8AZF*X=*\S
M'D]+=6E-J;::K&J=4TWNG296A9+(?8X1N>2[WE4>5V4WEFRA-)R=X-8*YCEV
MC*EAW3IY4#]+>J)-T7T!T-&ZKA%)%T[;%<$]5,JYBAR<7E?ETK4=ZY:V5DTU
M&G31KKJ]9^1T\CC>NVKJML3JU#F=>NL].FD?,V*9(XLW/*7$*T\?,@9)96[(
M[VBV*K5C+S"G1]8EX1S)Q!XED_8MDW,D2'D",U#-EG#)1L95 ^P%)X[Y\B_'
MS<NN;$LE,7\R=E9MOJYVKXQ'S+X:9\7'>/(Z6R=H4))=%$O[9^1A/VS^W#EC
MC"CE<^;%,4N74TK$)8W6JM;2EUJH^B8<D2>W1+FSJ3#V&E)-5 ';E!);Y<[I
M50Y")B8XFZ^9GPOBUQ\?)=9[/ZW6:K9"2I#;G5-SY]&<W$PY%R'DSXZ/#5?2
MK19[Y;=Y24=8CR[&7]DX!T6<JCZ0)8)!//P1EH;1>> 9L0MJP3[)PBG5[2LX
M1>N[ICI)RKUC#S"[],A3G*B9,G04E:<_'BRSCPX_0A+;:7,?S.TI[OA%>GTZ
M%K\/)DQQDRW]:6]RA1/9+51\9?74KKB]QO/CO#N%(3+45 3&3,75I>(^9C%W
M3JLL)%RNN9U(0T6J*$9ZQTU1!%<[;UT"',0AB@(@.O/]SRYN1EM@MMQ9=NZ$
ME,+IXI3VF/$SX?M^/#AQUS5G)CF);<2^OA/G$GG/>,*T%R1X]Y%H+:'A,88K
MIN8J](UQ)>1/(-I7(K^(FFSIE\X\<H&BOG6KO=,@$^7.L $**9MD\US?4PYW
MR+-\C)6JZ)3#76%UA?/JW)=\3T\N%8$E@QVL^KTE/Q[:_(S6UYAZ T T T T
M T!@MR%X5K9NS[@WD?'9JO-1N?'Q^]?4*G*1M9F<7E5G(][#VAY)PZ,5#W![
M)ST0\!N<XSORZ14B]" ")Q/T\7)AQ9-V>MKTVM0K*O51U=;?N^9AR,>7)3;A
MM6MY3EIOHYZ)K]YD5E' 6%LWDKY<PXIQODXU9>?/0HWRBU>X%C7!TQ(X!@2R
MQ<J#-!WO^-(38% * &WVUSII/I*-FFUYF#O%7MEX/PRUD)B_8@PK(Y,A,WWO
M(F.LBT"I)T^Q0E;FWZSBKQYW\*E$.63F)8R#AJHT;F^CQ1Z0!,0\ [[<RN*T
M\&JQIX]MI2M+UEK<K-2M-&F<=>+;)6.6W=K)NK#:A:1,1.NNJ,D.;G&I/EOQ
MCRO@-.585Z5O->^6KEDD8\)1I 6)DX2>PTJZ9"8AW2#1VB F(4Q3&*(@ ZX%
MUD[3 [MN\%\^\0<OYEE\C+8PF:QD:$K+8UDQ^QDZJ,M,U-HW9M99]4E9*49-
M'D@FHH546ZB*)P3 X)D$QBZ]7-EXEO;*TF>9ZFYI5A1$:N?)=$CS<>+DUY[O
M'_2[(EVEMS/3PZ]6S;G3V-PCF3Q*YV.+LTBO)O'#1W$0"E=:LXQ4^[*.%HK*
MRZBZS5,-C+"J'J#X])?+7!R+\>]D^/2U**JE.VYM]W,+KX0=F&N:M7Z]E>TN
M(4:=E$O[2K]8&PT T T T T T T T T T T T T T T T T T T T T T T
MT T T T T T T T T T T T T T T T!#8/<'WM 1T T!#8/<'WM 1T T T
MVW\] -MO+0#0$-@]P?>#0#8/<'W@T!'0#0#;?ST VV\M 0V#W!][0$=M_/0#
M8 \@VT T T T T T T T T T T T T T!#8!\P#0#8/<'W@T V#W!][0$= -
M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
M - - - - - 0W#WA]_0$= - - - - - - - - - - - - - - - - - - -
M- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
M- - - - - - - - - - - - - - - - - - - - - - - - 2 38=]_V/_1T
M!/H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H" CL C[@W_P#0T!X9[+!I+&;JRD<FJ0#>
MH R#'9,Y# 4Z)_[8 Q52B(;E$ '0#ZRP'^O4.'^3E6)!^]ZPCMH"?ZR5W;_5
MZ%W]WTJQ^]_9] 2?6:O!XGG8,H>\9=A_/6#0$/K36 \[' _WWC_WQH"/UFKP
M^)9V#,4?(P2[#8?_ ,,.@'UGK@>)I^#*'M$9>/V#_P##Z A]:JQ_MC@?[\1_
M[XT!'ZTUG_;%!?WWC_WQH" VJL!YV.!#;SWF(_P__2-  M-8$.H+' B'O"7C
M]OO_ #&V@'UJK'^V.!_OQ'_OC0#ZU5C_ &QP/]^(_P#?&@(_6FLAYV."_OO'
M_OC0$/K56/\ ;' _WXC_ -\: A]:ZO\ [9(#^_$=^^- 1^M-8VW^L<#M[_I>
M/V_ZHT ^M58_VQP/]^(_]\: @-KK ?\ ?%!#]J8C?Y[H- /K75_;9($!]WTQ
M';_:_P!$[: A]:ZU[)Z%-[1 LO&"(![Q_MORT!)]<*GY&L]>((>933<6 A]L
M =#MH!]<*G_MHKFWO^G(W]\Z E"Y501$/K+7PV]IIN+ ON\P=B/CH";ZX5,?
M*T5L?_=R-_?&@(?7&HA^%::V ^[Z<C/Y[D- /KE4/]M5;_OY&?OK0$IKI3B;
M":V5HH"(% 33L6&XCY!XNO/PT!-]<:D'G:*X #^"(SD9\0>\/[9T!+]=:=OT
M_6VL]6^W3]/16^X^&VWS6^^@![K34S@12V5HAQWV*:=BRCX>?@+H- 0^NU,_
MVW5C^_\ %?OO0$/KM3?]MM7_ ,((K]]: #=J8 #M;JQ_?^*#]GYK0$H7BG#_
M -]E6_PABA_F.= 3?7:F_P"VVK_X017[YT!Y9\G4-,YTS6F"W(<Q#&"7C!+N
M41*(@;YSQ+X>?NT! <G4,"B?ZTP8I .PJA+Q?I@(^0=7S@>?LT!+^5/'W^VZ
MO!_[LQ?\YX.@/32O=+72(LG;:ST*%ZB=4]%E,(;B'E\U[PT!YPY.H0!N-J@@
M /,1EXP #[8_-Z YV^2*&Z$P)6^M )0 1]2=BR!L/AX"+L=QT!S&R'0B")3W
M:HE,&W44;)#@)0'Q 3 +P! !#0'$IDG':73ZE\II.L0 N]GA0WWVVV_MWR\=
M 0')6.P\KY3!_P#">$_?N@(ER3CPP;_7NF!X[?\ =1"?SWH: D)D[&ZBATB7
M^F&42-TG+]9X7<IO/8=WH!OH ?)F.R%W"]TTX[[=);/";_\ 5N@)E<EXZ02]
M9:^4U),-MS&L\*  (^0?Z-\] 0')F. VWOU+#< $-[1">(& ! ?]&^0@.@/*
M+F/%YUO1"]58!ZS)BH-@AP1 2F$HB)_GO H[>>@.\YRIC=JF14]YJ2A#B( *
M-CAE=M@W$3=+[P#;0'C_ );L5^(C>*T4H"("<T[#E)N'F&XO_9H &<,3B "%
M^J@@/D/UAA?W_H"?\MN*/]O]2_PBA?W]H"(YMQ*4@G/D2G$ # 78]DA@,._M
M /GA\ ]N@(GS7B<AMORA5 _@ ]1+'#&*.X;^?SP>6@)!S=B< W&_U+P]UAAA
M_P#9V@(%S?B@V_3?:J.WGM8(;]_: &S?B<H[&OM5 ?/8;!#>7^GM 3I9KQ6L
M B2]U;I+^$8;!# 4/LB/SWEH"8^:<4D#J'(%1'QVV"Q0PC_U<&@.,,VXI'RO
ME5'[5@AA_F/] 3AFG%8AO]?:H'V[#"@/_5^@(_EIQ7_M]J?^$4+^_P#0'9;9
M?Q<Z$X$R!3B= %$?5LT(F ]6X?"(OO$0V\= =O\ *EC7V9 I9@]Y;/"&#[X/
M=M 1/E'&J9#'-?Z;TD 3#M9H81V#W!\[N(Z ZK;+F,'8F!*_5 !+ON"ECAR>
M0@'AN]V'ST!VARCC8!V^O],^Y9H7]^Z @?*.-B)F4&_4T0(0QQ MEAA,(%*)
MA H?.^)A / - <,1E3'\](-XN(M<$_D'0F!NT;2\:NNL8I1.)$T47:BJA^D!
MV I1$= 5^0X'W$H@( .P&*(& 0\O 0]H" @(>P= 3Z #XAMXA]KST!J,R)V8
M.+V2;[:,BR^1^4$3-VV9DIN2:5G.,Q"PJ+J47*X7281J,<<C5JFH7\63J-T@
M.VXZ HM3L4<2U1ZE,J\NU#>6Y^0<X8=O=N,6.@.O^@>XC=77^57EYOU=6WYP
M<UMY[[;?17EH#G'L2\1CATGR?RV.4?,H\@)S8?=Y1@>0Z ZRO89X?*B CDOE
MJ78/VO(*=#_X,T!RD[$/$5,I2%RCRX I0V*'YP,V.P?=B] =?] QQ#'P-E3E
MZ8!\RFY!S6P_;VB0'0'&/87X=E$H&R?RV 3CTD >0DX F,!3'$I0&,^(0(41
MV#V (Z [2?8<X?)E OY2N6IMM_$W(&=$?$=_];- =7] OPZ6 QBY/Y;&*<3@
M(DY"39B[@8Q3E 0C!#<I@$!]PAITZCKT)R]A;AZ5($@R;RXZ0'?_ ,H*<W]W
M^MF@.0G89X>D#;\I?+8WCON;D%."/D ;?ZF?8T!$W8>X=D !/DOED4!,4H";
MD%-E 3',!2%#>,#<QC"  'M'0'(/8>X?"&PY)Y9_\(&=_@S0'75[#7#LPD V
M3N6J8F$2D+^<'-E$YND3B!0&,W,8"$$?#V .D,2<!.PMPX7*"J64N6RJ9_P3
MI\A9HY#;#L/28L8(#L(:--:/J0FGJNAW@[#O#X"@7\I/+,0  #?\X&=W\/;_
M *F>>A)QG[#/#TX 'Y2^6Q=AW^'D%.!O_P"]F@.HIV#.&JINI7(_+10P!L!C
M\@)P1V#<0#?Z,\MQT!*IV$^&J"1C*Y/Y9HMTR[G%3D)-)HD3#SZC'C *4@![
MQU*3;A=2&TE+Z'74["7"M!5! ^3^5K9=T)R-TQY"RZ:SGH+UJIHD4C>I7I+X
MF H"(!YZ)-IM)P@VDTF]6=IOV#^%R(J$2R%RL%3<AE@#D#.]>X@/0)REC@Z=
MPWVW#QU!).KV$N%8!ZB]_P"50!N4HG4Y"6$@")A I2B/R12[F$0 /?J4F^@;
M2ZG%^@'X2DW.%UY3IB "(G#D#8BB4/:/4++P#;SU )R]@WA5L!BWSE6)3;"4
M0Y!V(0, ^(=(@RV'<- =@G81X4D#8URY2*COOU*\@+,8P!X> "5J4-@T!,;L
M-\)$Q3(>X\G"&4-T)%/R!LQ3*& -^D@&1 3FV#?8-QTALB4NH_0+<)%B[_6W
MDXJ4#& !#/\ 9S !R&$AMA*CMU$, @/N'?0D@/89X4&$2&NG* XI])0(;D#9
M1%+K\2EV!N EZ]O#?STAB4<"_80X,I%,NXM/)A$0$.ITIR#M:0D.8P$3/UF*
M5(I^LP 7PV$=O =2DVX74AM+5]" =AK@R=L3YBY\EWB3A0B:3EQR%LQA55,I
MTD325232(<YU V H;B(^ :;;3$.4-U8F5!'] +P8_P!L')G_ (0%O_H:@D[*
M?8/X.)E @3O)40#VFS];Q'[^@.D3L(<$?4*);-R2.855$RE_.$MANI5$PE62
M  '<QTC (&+YE$/'4P_ B5XG>'L)<&B )AG>210#S,;/UO  ^V(CL'CJ"2;]
M EP=_P!?.2?\?MOT!R!V&.$0;!].\BQ*'[4V;)P^X>XQCLC*&W#S$1$1]^^@
M)1[$7!T0.A]8N0OI@H1,[8,W3'0"I@ R1#$%F)P4$-A*&^XZF&1*\24W8;X,
M(] 'F>0)!5.":8'S9-E%102F,"9 %J'6<2E$=@\=@'W:0WT)E+J3CV%N#PB(
M_3?(\N_L3SS;$B!]@J:0$3('V   U )_T#O"$PF*,[R(/L =9!S7-#X&WVZ@
M!EU;#M]W0 .PQP:_;R7(8_NZ<XV=N(?=:IH&,'V!W#0'52["W !;UE_6SJ_-
M)(^D"ZN=[:Y,=-,O3U-U 6^(2%]OQ &I::ZID)I]&13[!_;Q:E*BYC,R.#^B
M<4S/LY77U@32!,AUB 5\B&R0J%W';I 3!OYAHDWT#:74F-V".WJ(!_<7,X@(
MAL(9NO([[AX;?V_[=02<37L)=NY<JORL;F%P"*QT5O1SE=%?273V!1%3TY _
MIJDW#<H[&#VAJ6FNJ:DA-6Z-,[Y^P;V\C)E*2MY?14 -CN$LUWL%U1_=*&&1
M,43?: -02=-/L(]NTZZK=.+S HX;@F9=N7.5U.LB58HBD*R02 G3!4H")=P#
MJ#RU,-*6G#(E-PGJCM!V)>W4J4%5(C*;ILU/\LJ13.=V.V!<YR)D2<"25+TK
M H(%*43 /4.VVXZG;;I#DC=6)E0#]A?MV)"4B\!ED#J>J9(JV;[R4YB)AZAR
MI@:3*)B()^>WX)?/4)-]"6TNIS#V'>WB^^6<HUW*!VI2%Z"M<OVH6[H@!MU'
M73<F64ZMO$Q5 $1]NC33AZ,)IJ5T.%SV'>WBT#YA6'RNP;=9""5?--M%KU*'
M J:7]T':Q2B<X@ ;"!A$=M$G9Q5-L-JJFSA'<'L,=N]8 ]2FY(7(&Y3%-E>V
M=)C%$0,)NAT7<V_@/VM022$[#';?$YT24&]F41 @J)%RQ;Q.F4X"*8J$!_U$
M X .V^V^WAJ8<3V(E3'<Y#=AGMRD*8YZ#?2$(43'.;*MO*4I2AN8QC"^ "E*
M ;B(^6HZD]-6<1^P[VXSHIB6EY 217.F*1T<MVTI%SG_ +#T&^>$JAC@/P[;
M[[^&IAS$:HB5U[$'/8E[;S8R/SU-O"2C@X(H&>9=M:2CA0.DI4T_4D">J< $
M  "[CY:E5M;\*;@.U:_B:4G(7L,]N)=/J3H5\53,)@ZT\KVXY1$AQ*8 ,5\(
M;E.40'W"&VH::T?4E-/H2F[#';D;$.J-%O[=,A1,JH;*]M(0I"AN)CG.]Z2E
M*'B(CMMHDVX74AM)2^AQG[#G;>,A\XI2;V9N"?J?-&RU;/1]'\(%/6!\"?I[
M#OOOMIMM.V'N&Y1NE;2*/8C[<;L"GCJE?NE+TS&%AEVU*$$#EZTQ.)7RO@H0
M=P\0W#Q#1UM7\2:"M6WX6F=A7L.]NX2&,ZIF1E42 *A@<99MP)$ @"(J&$7I
M0*!"[^(CL :CKHNI/35]#KH=B'MOK@06=,O2A5$BKD^6RW:U041,.Q%BB5\?
MJ2,(; 8/ =2ZM=4T0K5?1IG6=]AGMPMQ*=W5,A-075!-+U\O6I JBIQV(DEZ
MCTH'.8?(H;B.BK:WX4V':M?Q-(*]A3MQMQ2!>IY%1%=4J" *Y=M:8K+G 1(B
MD!W@>HJ<"CL4-Q';1)OHN@;2ZOJ01["G;A=@?Y>K9*6*D?H4%GF:Y$Z%!*4W
M0J+21*/5TF 0*;R =_;HZVKU3033Z-,Y![!?;M#\&K9:3+X!L&:[Z ;B.P;;
MR?F(CJ"3D2["O;R35ZT*YEDJR!@'<,TWA44CB7J+UI*R*B8B)1W #%$!#V:
MBMV'NWL!$V[N%RL)5U_Q*:F9+6V,JXZ3#TI"W=-E5#@3?X0$? -]O#?4I-]%
MT(;2ZLX%.PAV[$^DRM;RPF!SD2*)\VWL@&44,!$TR]4H&YSF$   \1'RT2;Z
M!M+J<GZ _MX%#?ZL9:#I#?<V:;V(!T^.Y@/)"00#;Q 0$!]OAJ"2[V .T?PJ
MX]94J^9L61-X"ZTU1=U"N)3)$S/QB)W[55J*KB-74,W< 9$YA)U>&X;AY:EU
M:ZIHA-/HTS9^W;IMDBI) ($+U#X[")CG,)SG,.P;G.8PB/LU!)SZ @/D/VAT
M!I?YZ<RLD<8\RK,6=B>-:C9JI3*W",FK$\BFQMEFL3H[=UT()G^CGKEA#.DO
MF5A @$. #X]&_P!5[3P>'GX.*_)JO5ORU2KCJMNJ?DM'\3Y?W7F\S!S<E.-;
M^G3BNUE/1JVC7F^GP*A8<T>3MWQIF^4K]!QK V)GA]7(6#R%NS*P.Y6/26^4
M=2MH:L%5E(J21*!Q!BH!5DERAZ@= ZQS>T8L.?TOJ=J<I8VWI2R>JA]O[#;%
M[MDS8?4T5;\9Y$EK>K6D-=_X/J4!E[N:WO!-GP3ADE=A,@7*S8,HV7[A:)%9
MS&?2;2WR4Y'1,3"QR0"=>4].L.2OCCXD7.F(!\0ZOQO:^'SO>LW!2R8\7J6K
M6-56-VMGX2M/)E>1[ER^%[/BYK>/)D].MK3H[3&E5XZZ_ W4PTJE+1\<Z'TT
M7;R+82*['U2F7:@^;)+@11/?U"@45.D!$ WVU\YDHZ7=?Y59J?&#Z''=7HK?
MS-)QX2:2>_7R5Y'<;N+%0D>.\E.5-S<[VM7[WD*%"*!2KU9*'6<'9E<OE2/(
M^1GE#F!JX;E,!#MS%.(=9=\RYA+V@<^YTL50F)BP3N3,A6:MX:L=OM-.&XM[
M':<M2Q(R4&JS,+^.623M+LQTT2M#B15$Q0,)>G7U7(RXLGZ<QTS8J>KCLJTR
M5BVDRZV:_#;R9\Q@Q9,?Z@R6Q9;K%DJ[6QVE:Q"=4_Q5\T8PX;Y 9U?69E"9
MB#+="RS/3DPBO:K!E">L;#+QWDVFWFJ]5728C3Z-)+@";AO$-S[/A546;B)"
MFUV^PY<6!OB^X84J9TKXYK-:M)K=9=5,3X?:<?OF+)GCE<#*W;"W2\6:M96:
M>VKZ.)A]_L-JG*"=//\ +RH8H:9-S"\R-!X8Q1-X^P= R0&KL9+RSN;&7LL\
MR*JDA,R 1%:=K.'W6;T 9;?MB /%[0^-7)DY&^E'6UO4=E]%L=OPUK.B;?1=
M?L.OW5<BU,?'V6LK5KL5=;UNNKM&L)=7T^T[5B?9NC^.?)B?:VV]15IG>0T&
MD=1.]P6-K;=*C!MV[6[PV.)FZO6T9&RDB8JK=$H"4PBEL ;AK#G\CA>EPMM:
MY*4P/=5?XFWI9_8S?@X.9ZO,FUJ6MG6UO_"DM4ON* XYSMH#*> XZ+R3<8VH
M6[)SN</B"XY-CLD9)KRD3!';)2V19N%=N8]Z\FA.Y32$#>F+<H=(")-]>IQL
M_"Y7LN9NCMS<'&VN[4*+6F/E"A_$\WDX.9QO>,,72X6;D;E1.7*KU;\Y<KX&
MVSG'EBBX=XWWNS9%9Y6?UF10;UERUPJ29+D116=4^51^@GL DK)Q9P'?K<IA
MND7QU\52-RW.%/7K!]C=M5;2E^!\^G#//N.I+-.'G;6XYTS9-Y R5,,J%0+8
MOF8AH.%2/%(/;#<CV2/:,I";J:3<2MUI(4A7:M5E4BF,=7;ZK&N!Z5L>"M^.
M_1NJY;)1EB)3\):A1W^)\Q=\[U:Y,[IG_K4;Q5;G%,PT^\)RYZKX&TWD]>^1
M%PR#'3-;9+XNHV)<GLZ_4ZU:/35E\_W=@Y:RT!8J<NU6&*B:L59,&Y74F<C=
M4AU>O80 -</M/H8Z9+;7DRO'??7\*5&H</O;O5+N=GNOK9+XZ[ECQK)79;\3
M=YE)KHJ^+9LTQA8[-:*-!35PC8F'LSI%0)>-A9 LDP;K)KJD2%-7<RJ!W+4I
M%3H*[+-S'%,X=11UY7+QX<6=UX[N\.C6Y1;5=UY/3SZGJ\7)ER8%;.JK-K.U
MRM'V?GU\C0/SS>9#'E!:&"CGDHW>NIN@-,3C6+/9ZUB:..Y70+(.'9&Y2U>R
MIV%F#ADLV%7YMJY42.)=A#7O>Q4]OR6I7+9K.G9W37TWHE*6O5UB6NYX7O=N
M?CK>V))X7M5&G]5+MPW\+3"?8O5R1LV:L/XWX=+84QXY@K9#9+M3F8I=SMLC
M+URPV%C!QQF[R^RU9<.Y95Q+.W+E9L4P!L(F.<H%Z=:XN/DYONF:M,^.^)\>
MTWM5JJIIHE';35=.AGDSTX?MN&U\&2N7UZQ2MD[;M9;;<:ZRGU,J>,G(#F)D
M')<7#9SQSAVO5:4BID?5Q%;WEP0CG$:FFY;OYA64*A,1JCE18K;I42*W4$Q?
M3$3%/K@S\+VS#[?>U,_J<ZMTU"=:VJ](2LM6NK^1W8.;[EEY]:WP[.#:K3EU
MM:MEK+=7HGT7S+9=UY7,\77<06:IV/(M?P= S=G<9U6QG8TJS/\ 0>)0^HIE
M'K8?II2.//%,1842BFB @<^N'V_T;9_2S4=U=0H4NMNUO@NZ.[G^K7#ZN*ZH
MZ.7.B=>Z^+71^)ASVZKYE]:^K(Y*R?8GU;B<?9;FZ4T=@WE)"F,W'T6Z^9DX
MULNLM895BS!(YWK@-Y%TD?I -S!KZOW;AKB>SV>6U;\UVQ;X22K"M%4UUCN?
M*^U\Q\KW:JQ5M3AJN5TEMNTNLVA^>J,"\0YER?7<H\@(;*7(7/UT;91F0+C>
MRVF403@[1&RJ1F:<4U29*?1S-,3&!-1@7I<(% #[= ".M/8^!3 T\N-.U[5M
M6UE-&E68QVZ;D_'KT13WGG7SIK'=JM*VK:M7%DVXG(O!KPT[GT8SB+G\\"E!
M8;/8)&.QYQ]"?I-,^;0=#;K6#N98S4^Q9-C@0; _C$TVXD.(BL*11('2 CKP
M,;V>RY\N*JW9<ZK;_=JM4O@V_N/<NE;WG!BR6^G'@=J_[UG]+?Q27WFI#-G+
M3E6^E[K8U+;4L+0V4S1C%)K%S";Z_8UKD=:F\1&4*[HH'4CX?(=@W.@T%L(K
M+E>"0X 8 UW^U<''R^#6N916N6OI6<+?>S6[&D^J\^S.+W/F9.+S;6Q.7;%;
MU*J7LI5?3=M='/;NCQ>9,WD2/N_'=O:2YT71MW%VAM</6F@W!9I34+ZQ;1KJ
MR.\@1+%<7$Z1NH'KK-G)?[=^;;])OQ)M:\7#CY?NV;AX9Q9*\FUMZ72DM64]
MHT7F9\K-?B^UXN7E_JTMQJUV/O>$ZN.\ZOR+]\>KIDO+'#OFW9,J7F;N]XHM
M.A+&QE8NP*5@RDUC"'MUIKL6LI$*"C#QQW\$V0DVA-BN$/4(J.R@ZQ]WQ8N+
M^2KPUN=<F36%-FKUZ]FS7VK)EY/YRW+;JK8\>DN*ITLM/ IJ[WZ\<A)5LUO6
M4)3'55P_QWK62JH6#FWL+%6BR/H!@],_M,*P.0\MU/W0M&Z*8G 12*;;??4K
M%^4Y>7\O7_J5RJ))K<]MOQ*'U6K(>3\WQ<2Y%G^6?%NVT]OU+\+GL^ALWX3W
M&1N4SF5[*KRBK]NAAQ)R637<+* N;'3?UW $6'H;J/ER&64(0 W,?J-XFUR^
M_P"&F&F&N-+9NS)1_P ?3Y=#I]BS7S7S/(V[[<4SX[-?MZF#_==Y5Y,XRYVX
MPFQU&P4S*76)MS>,+=HNY255KLM!KB]&QMVE306._G"M5@2!+8QR(_&)>G<=
M>-QLV7'7)BQK3)2+>23F?@NY[')PXLEL>3(]<=YKYMZ1\7V*9X\-\]UC >?[
MORHD\@6=N;!ZEU6>8GGOJ-.LJ^-GG+K8&U(D"/B+5^4AXQ51ZJ8W2X.U'<VP
MG NO9]UO@?MN/'CR4RYJY7NM5=5LHE\E^%? \?VRF=>X9,F3'?%AMB6VMGT^
MN\_-Z6?Q,(<8VK(C3)N.E,3W/.U0X[WZR5!%A2\C6M?(UIDEF9"NVLG/WV1=
M*RDKZ;]8JS>/:F40:B(%,80$=>]P?;,7%XV.W(RTRY/1R6K32$G5OOKKW9X?
M-]RR<KDW6#%;'C]7'5WUEM6CMI'@C)?/V:.-M$YR\D5.8ULY3P:=>?4*0Q G
M36^2?J&A1$Z) )6H[![54SQBE.<3DLI\X@[ !1>D>+=0(F3-KY3B*V7CUIPL
M;_.TN[6R1TK]*33[*KF?C)]3RG7'GM;F77Y.]%6M/&WU-J.[>D>9<N6R9DMG
M@'BR? D(ZLA);D6^L5+4L<Y(Q.,YAHR?B-%I][GTC*3C1*1<OD'K84BF2,9J
M(J? )M>_R\-[^[9L=KTK?\G]5MNY/Z?J:CO&J9X/%RUI[5AR5I>U%R_IKNVM
M?5]*;?9/JC+GBGR8YJ9.S!/4G/F#\<4.%K[A>,?*42?FI4[<@13"4C[*J$^B
MVD/HR3<O%&:!P3^77,W,*9A,!M>-GX'MV#A9'ZZOS*WKMVIJMJVJFUKWJ^O@
M>SAYW/S\S&O0=.):EMVYIVK:K:G1]+*(\2Y7<BM%"IG&>;LF3ZKEFW4:/L=;
M1FH_#=L5IEI0&4?DBHYRXF$7C%0L4:4>HI*$ X;G4)[M>1QZ/)GIC4;K624J
M5+T4KN>IR+K'@OD<Q6K;APX7F:<^$-VO<+RJK53E,@9)?XW?RT]E6CT*Y6%U
M-*U:L/"O41;(OG C+7.26;-/1%VX#U'!R;%#?7WG.]LIP?;^2[9?6RK!1=%]
M,/\ EC5)=(9\/PO<;\WG\95Q>EB>:SZOZI75SHV^NAC];.8^%0S_ )0@'D'R
MUS#/WFP2UAAKK8XW+E&B*LVD9&1@V3%QCT&:"TA5:D2002:K%)Z)C)B<X](@
M.OGO;.1QZ/%DQTO7)@UR7VJRB>OC5.=K['O^X\?D667'>]+8\VF.FYU<QT\+
M1&Y=SZH,&2YU,18[--$L,5(JP,6R%M>$OHVR.')$2(D%PT7,"G6YV 4RAN(D
M$->9[A56YN6V+9:CLW]&M8^)Z/M[M7A8UE5ZW54OKTM*T*%YG!:S<6<YGI2)
MW%B:T61D&R*<^%74481JS>0G@2G1,F#%4(!LY$NY@]4VR>_QZQXF3'BY6/)E
MKOQ*RFOBNZ-N7COEXU\>*VS(ZN'X/LS1K@O)58EISC/5\&T'(.,WTIEJ$=NK
MQF&^_E9F)1Q)-?HLC%HJ23<-'5?C578N$DS#LBJ4H;%'PU^@8N%DX_!Y'YV]
M+8:\>UEBI":K,J6M4^B^&A\'EYF//S>/^4I>N:V>E7EM+3MT<)]5U:\X9E[R
MANW+JY9DK=FB$8["F+<.Y.E*E2*[*6.'G)KD-9WT2N]C+(6+CG8MXR)(6%,C
M& ]$A2G=K%/^,W /E?9_RM5DO=6OD6*SO64ELTF'_BEJ/@SZGW5\INE*M4H\
ME=MHE[]8E?X8F2T'=&R_8'>!N-3G,$38:A6[C:9XF2+GBBQ9/--8S<,*NX=,
MGYX+&:+J3F!7<@9LNW7#H:N# <NX &N-K@8>7-JY+<5UE*VEM4X7VQ#Z1J=2
M?/R\72V.O)F)6M=&I?V3*^1Z/9V:0![9DUY6,EY?O=?8H%B8L^0X+*D,DB($
M;N7#%TIEMLRF'K]+U <]3$AV8&7.'5U[@'=S,F/_ "S\OCQ+&J9M59S=35:K
MR?[SBX>._P#F7YC)D]1VQ:6JHH_J>GQ7[C;%RULUDJ.')6?K$Z\@7L=+5]PY
M5BG+=K-R<8G,,QE(:"5="#<):0C_ %2H@H($.8.DP@!M]<7M&+#GYJP9HB];
M)-ZJMG5[;->">IV>[9,V'AO/AF:6JVEHW5-2D_%K0U\T,N2ZYG/!$#-@[J-
M8*Y!=8]H*+]Q)OU7+Y@O*M2V.QI++1TK9)--P JEZA09''TO#;7T&3+CR^V<
MZUHR\U;-V15VUVIPMJ?AW\7J>%BIDQ>Y<)+^EPWOVXW;=:6I>YK37L8]3F5\
M@/&F4W]PDLJV.0/'2-,8S=Z<OZ?6Z/$VBT1R#Z#Z6I$I*5FJ[,1C5VBNF46C
MEJDI\>VV^WM.''_0])TK3)=7V_3>[MCJYA=E9-K7HX,/=<M_Z_K;[6QU=-WU
M4JJY+*)?=U:3TZJ2J.X3S6O7%V/Q%296QYX<RRM0C'#ZVX9KE<BX6TOSQZ0*
MN0>3!]Q2 -NE GQ=7B >.OD\N?#7DY;8L2].UGM5M=NOWL^IQ8,MN-BIER-Y
M*U6YUTW:?<C*KM9949YHQW>,EQ4?DF*C[A,,9AZTRB[03L+NS :2C9V:;PC,
MZK1K'RAXY(PNBB!G3@J@"4 3#?IY_+_-\3CVM6JO1.FB[*(E^.KT[*/$Y^!Q
M5Q.5GK6UG6[5]7W<S"^77N_@6#[P64:+!!0Z);:-GSJ=14U-(9HQTPR*\I&.
M5%U6\81M-M,?)+/IF8<BX!=%)4ORZ22)^H>HQ0UR\%<9Y_\ J=SK&E:J=UNR
M?@GW.KFODK#_ --M5GULW^&O=KS78[W;TRK6ZK#9EE87']]'&%(AGCPO(?)4
M#8*>%MD(UH@\=0L>RM)PE'%?5EG2B++I*)RK$4#R,37N>YUIR,2PXOZ/)KG=
M?R\RDWKNKX*7#D\7VVU^/D>;+_5X]L*M^8B)2TVV\7"E1\S "E\I+KDK+D;B
MAS9PB*PWY#Q5\N-:>T7)43;(N6GI!(S=T7(;MJE5IZJHQ;U(J+ J@N 4$3E*
M/I&U[>'$LO+M?%16KQ^';&[:;7D57I7MY-]X9XV;+Z?%K3)9U?(YE;JL_4J.
MRUMWCNE\#-_+!; IE'(668?($A8;PVY2&QK"TN4MI65:4Q['4M*&D4X^)]<J
MT0VJJK589!1 G]O+*#ZP_#OKR.%3'BKCQ\/;:F7C[LS>KJU?2/!UTVKNSU>9
M:^2V2_,W5MCS[<*6BLG3H_%/67V-BO!>;M<W@"!^L\;(QJ;20DVM=.Z;LD&:
MM>*[4!FE"JM%E59*)9K%4(D[7V66*/C\( .N+]2X\&/W2WHV5FZK=$SNC69Z
M-^"T1V?IW)FR>VU]6K23>V8C;.D>*79O5F@3N&+YLA.Z.Z5-F>^.Z26A5=6I
M8TCD)1U7&$1.1Z"<N(NH<1C8&R,IU,Z[$9 "J+D$#DWUM^F<%;<U<B[BM&TY
M7T0UT;\6^QC^I,UJ\)X*J;6AJ']<I]4O!+N7)YJYER91^W;=<DP7(+,E+G,I
MY=A*C3!AIIM.7ZSUXC66@K-4T8PY3-8M9T @NX=L#"Y6(B0#;%$PZM[^N+CY
M6/BNM*;*IV=*K^;71]6H>B?0K[$^3DXV3E*UK[K-55[/MIJNB<K5KJ4)V1;!
M?T9BI+VR]97O<5/NIM-K:W*5IZY(LJX![!P]\:RI3^BSB4D#$*8W2D4 $Q1V
MUV6XZI^EW5^F[>H[TW0K['W2ZILY5R'?]2IKU$O35+[9==Z[/Q2\3=5W3$LB
MNN%^3&6)Y(D=D!^[K;*N N\0CV;YZO,( 5E(/7:S=FVC^D!66,L<I (B/COL
M _->V+)^>QO"JO+5MI6B&TFUH]'Y+OV/HO<?3_)W6;<L323=9E)M)ZK5:=7V
M[FH[MW5SG;D7*M"L>>,^C;H6F2T&U)C%Y(-(!G M(=\@[G$(^+8JB=^NDA&E
M%LH;K151$ $=C!KZ+)CP<3BY>9S%9\KE8;;4L;6RSZSV4_:?/X\F;E<G%P^&
MZKB\;-66\BL[U7AW<?88R\I,CRF"LFY>:V$A8*Q9&SHR7IK6N9>0S*OC*$AK
M+%I6*.LS*#?NE*Z_O:,RT<@18"$B#&,D;;IVUC[3R?0X==MK89M:;;599&X2
MJEUT_P 7:3;W3C^MR[.U:YFJUBNYU>-*6[3TU[5[P?4+Q".L;C=B]14IO6/$
MRRABG>GD#B<]DFS^+U0QS.!-O^%N(>P/ ->;[^H]WSI?XEY?RH]'V+_])P_\
M+\_YF?'5E/D/?9'E[F5"Y1%KKT>YSW?8N%93LG>Y!A _5JU/HB1I\ZM!J'JP
M%C';$2=;DQ&RQ# 0!UV>U>WTYF3CY,UO1W.*NM7]6VT.;+I;_>9Q^Y\^W$Q\
MBF*OK-*;*UE],J5%7U7DC:_R]RQ)OF?'*OWC)N!F[%SBYG9HK#C#-\+A,]3E
MI4'K2MY.G2SKM UZJX T$IX5L8Y4E(]R@4!!<PZY^=EP</W#/3'6]LBRIJ]_
MQU=;2VO&>S?5'1PL>;E^WX+9714>-S2GX;*U82?A'=+HS8?VV7U<1B\MUNNY
M8CLSH0TK2T7=RKKM:4JK:7:U1LSG:M"R9A,D9&M29#-P2W]0I0 3!XZZOU!R
MZ>X8N/SL5*TI;U%"B7%^K7B^_8Y?8>+?@9,_"R6M>]=CES"FO1>2Z+N4KW3F
MU+1K..'MGH^5+;+3#BR5:I2-#R>[Q]!UBP/6C-1@\L#5F\0<V!VN8QE6J"2:
MAS U4 =BCX^3[7P[<_G8^-6VQMS/A&K?V+OH>K[GRUP>%?D6KO241XSHE]K[
M&%_$/(^8<75OE.K>;+E*7L>+L$3Z\(Y5AG5\M<&7Z6:*0*$?16'K*O',$D;?
MTMA<*D$3J &OH_?<&'%[53)BO7+6W+M%E#E*O1OOK]G1'SWL>?+E]TO3)2V*
MU>+6:O2&[=4NVG3Q[F".%>0]8#+M;QBAB#E[)9+<72G/Y[(]@:V]4+++ 2,M
M18>-QS.F*E3PE%7B:PR<H5$@-5_#P-KCX7(XM,CY]<=L."U?2>DXMUJPYC5=
MG".SFX.3?&N$[US9ZV]5:QDVUM*B='W4LR^Y>3-Y=Y?OU\?VJ1D;W'941HM5
MK\!9YA%E5*Y&P,?85(@M;.HF!9B#EUDFAY1-,6SI9\8$CF NO0]APX5A=<#5
MK6IDKD:JNG\J3?C&C[=#@]\RYGF3S)UK6^-XUN?7^9N/#ND;$NU.MZN+,AG<
MOW$E).[P#M59RZ5=K-VH13-F@U5,NHHJB8RC4ZH$-M\*@&#P-JOZU4<S#"2H
ML4=(UF7^\M^C7_T>5MMV>6?E"12'<ZY6$PO;N.U-A:2ZR&_;WDN3+RU;SS2$
MB*E3ZXS=,FCVS/3.$UVHSTE(^FS24#T7)$' AN=,NOGO:ZYE:^7&J[&O3=K=
M*O)HG\?X2>][E;"ZTQY';>GO5:];*FK7P,8LI9\NDKP\YY98=P%EJEFLZM,D
M(&DM[#(OW<0TMC!@I%,49JIF<.X\SP3@*JK?8B)#;FVV'7;[CQ7QN)Q./=+?
MNR)^;WM=?#P9R>W\JO)Y?*ST;V[<;7DMB^_Q1@KP/M-WA.0>(XV[TR[0CIQ(
MTB:1KMBRC+9&4GF4^_GH].SQZZ;E<X0L7-)/$T5G0%,9-J4AO@0,.O9X_">'
MC\O!DQX<.7'QW+K=6>K5DK>+C1/K&AXW(YBRY^)GI?+FQ9,ZC=1U6B=6ZQVG
M5KI.I6&9^>^6<I\E81M:K-:\:3&+I'*",?5J\C-4[&$:^I3E5Y!A.S]C1;.I
M[($VR0*I'MD2B=50WH 7I$-<'L=>%3)AOFPWVY%>E[O7&]RB([1W?8]#WFW,
MMCS5Q9:3C=+UHM,BVOK/>>R[F;?([F[*89P]@#+G(;-F7L:,+JWL#EY*8MIS
M=Q7'C,'CA=@>>;PZ3I\S*E%-!V.8"J%Z^O;\'7+[GC]OXW)S^U\?%K9UK6\S
M:C[Q/BW]QO[=DY_(XV#W3/D_!6UK4B*W752EKHD9&]N7,=8Y'63(N8L8V@GU
M 09,,?(5-O%2*+$$JX!',)/LWLELN@I)HOU55TC@"IE#B(^&NC]0^W\K@>Q8
ML?(L[\C?:RRNRW.4I5DO):/H>9['[K@YWOF5\>OIX71)XTOI4=&I^)MM)O[1
MW\"_?Z?'[XZ^4QO=BJ^\'V.OJ6_PSH<FK%B ^0_:'0%D\F\=\-YC:2+/)= A
M[:E*NJ^]='D3NRN2.JL]&0@UV+QLY1=1AVCL>HWRYTO6#X5.HOAK6F;-C25+
MVJDY4-J'XKS\S.V'#=MWK5MJ'*3E>#\O(HS&?#GCKA^!O-:QWCI*NQ>2$5VU
MQ ECM,A(2C5?K$[1*7E)IY*QC0#J&,5)JLB0AAW* #XZM;DY[XUAO9O%5MI>
M;ZOX^96O'P4R/+6J62RAOR7;X>1W5.(7'1Q>Z'DIUC&'>7+&E7-3:?*/G<L]
M2CJ^+\94C5W&.I!6*FG+>4.=RBZ?(.'2*ZAU"*%,<PC:O,Y=+7O3)=7NHLTV
MFUX,K;B<6]:TMCHZ4<U32A/Q7GW+P0&/JC6;!:+7#Q!4;'<G*+JPS+AV^D'[
MWY=,$VS1)>0<NC,(ML4OXMHW])JF.XE3 1$=9/+EMC6)V;Q5;:4Z)OJX\6:K
M%C61Y55+)9)-QJTNBGR,9><G!G#7/[#R&&<TKVN,A6%CC[7"V"D2C**LL)-1
MR;A JS)>3C9B+42<-G)R*$7:K$$! 0 ! !#,N63X%]K?$';^3L33&]ZR)=V,
M\BZ(0EZ>Q)W# 90X&F44C5^,A6B[)]Z"!BD41,=-1+J _B !T+E9EQ7PY7H.
MZM$=UI*9SOBX7R5RX?KJNV9[/75%<47MM<=*$Q:U^.;V=_3(R;>2T'39*83/
M%PC-4Z:L77VLDU9M;&\B:ZJ01:&=O7#K8XE564(!"E[,'O7N?&HL>'*U1*%*
M3A>$M,Y,_L_MO(N\F7$G=N7#:E^.C15V7NWSQ1SCD1CEG(6/9MUD>/I\=0$+
M?6,GY2Q_+FJ$0H[6C8-RK0KG6R/&K15^J8HJE.?J/N)MP#;SM]W.OXNOF>CL
MKIITZ>1<"O\ #_C3 TV)H2V':?;JW"20S$:ADYD?+$BWEA2!N$F,]DI6U3BT
M@1N )E6.X,H5/X0$ \-7OGS75:WLW6B^GR^!2N#%1VM6J5K_ (O/XGLT[B]Q
MSQU;$[OC[!>*:):4VJC,)BF46MU==1%0Z1O573@X]B@X>(E2Z4ESD,LDF<Y"
M&*50X&A9\Z5JJ]MMOQ*7K\?'YCT,,ULZ5W5Z.%I\/#Y%]52F,!0)Y@HF(^7X
M)3 )O/[ :R-2W]1QG5ZB^NDK%QYD)*^2JLE8G)G3A51X($51;IE.943(II)+
M'$H%V$HG$ '8"@&V3/ER8J8;O^GC327Q<LQI@QX\M\U5_4R--_)0C#U?M><,
MW*ZSAU0K^\66>OY #O.0/(!U\NYE#+"^%D#C)R@,$EP<'+Z:/0F4ANDI0+X:
MFG)ST_#;6>NC?VLB_'PW_%72/-+[%H9G8ZQM1\35.*I&/:\SK=;AVR#9HR;&
M7<+K>@@DW!W)R;U9S)S,FLDB7UG;M99RL8.I0YC>.JYL^;D6WY[VO>(EMMPN
MVI;#@P\>NS!2M*3,)):^.AB5DKMM\2,MVZ5O&0*5?K!8)N93L$@?\O>>8R*-
M+HF1.@[;UZ*R4P@&7H'0(*9$&R::8E#I*&J*UE$/H7=:N4UU/:M? CC[8<8U
M3%L/$V&D0]*LXVZOR\%8GTM92S*K<C-^M-S%T/:E;6249)$27"5!X)BID$!
MQ0$.JON'-IEIFKDNLE*[:N>E?#X>70YK<#AWQ7PVQT>.]MUE'6WC\?/J7&P_
MQ:Q!@^46L5-@W1K2[COHI_99.07<O7C(5$E!*+!$S>#:JF.D BH@T24$#& 1
MV,(#MRO=_<.;@7&Y.3=AJY2BJU^*29EQO:N!P\[Y''Q[<UE#<MZ?-M%1<@,'
MUCD5C&9QG:7LG$MGRS.3BIR',V"3@+!%G,O#S;-%ZB[CG:L>Y'K]%RBLW4\C
MD$-<.++EP9%EPV=<E7*:<-'9EQ8\V-XLM5;&UJGJF6WXY\/,5<<7CRR5M%_,
MW^9KD+7[/>)DZ0RD^,6V:HNY!1%N4B#529<LTUUDR!Z29R@1(J:92D#MYWO'
M+Y?'6+D.OI5>Y[:JLOQ<+KJ_M9P\/VOB<+/;-@5O4M6-;.T+P4]NGV(QXJG:
M[P_!Y/\ KC/VVR7ZAQ$JG9*-BJUP5(-%TBT#,#,.I)A9XFMQELF4%UC"0B4D
M[=^DF/PFZ@ VJ\7WSEUQ^GCNFE3;64FZ+QJ^S\QG]IX62_J6JTW?=:&TKO\
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M)ZN9;KB)W9<AKNY1XI,3.2<G/FHC,NG+J3:_0*UP-7RQCTSD2': U!MZ!2)
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M/[CMS8<>?&\65;L;ZKX:F(W*KMZ8.Y@.JP_RJXN*3^HM0:PHUZ>4CV""0%Z
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M\6'X\XKK^0H/)D+58^,LE:IXT:%%HW;ILV,&5TN[1%!+TO42=(&>N"%.4P?
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M3B3:QSCXS*<N.,^0L&-+-%4NQ6N.1)6;S*0JDV%2GVRI%6DZR9M7\4]2>MQ
M0(HW<H*IB;<IP'7(=9A7PWX8<N<(OZ)1<J6KCD\PSCEM(JPKR@4&3>91EIA<
M%XT5YBT9#>VIP=G.1"RH/C$,#SI<%136*FF(&[,?-RUK:F5VR4MCV0[6A*4U
MT:E*-$]/(Y,G#Q6=;8DJ7KDWRJUEN&GU3U<ZM:^90S#MDV" S5E^]U%M2:,Z
MOKRSM*NC7ZX#C'$/2)A\R71;1M8</#1E0N)4TUC*.4VJQU%3B*9TRF$->EPO
M<^%BQK'R<-G:(=JV==U5K%THW:]V>=S/;>9ER/)QLU5692M56VVZ31N=NG9:
M&XS'%.:T3'],HJ %4;U>KP]?,82( #DT='(LUW"H-TD$#J.U$S'.)2%*8QA'
M8-]M>5S.0^5RLG)MUO=V^US'R/4XF!<;C8^.NE*)?8H/D*YI=E[F7E7G5?<U
MT.!H+BA2.4Z=/5!E7&,35H<M(7,B>?=R*8"9JA9H=X@ .$E&JYI(BHJBJ7T^
M@U./D6+/3*YBMDW'71E\^-Y<-\:B;5:4]-3=]E'@]R(EJI@5OB_,U=8SM+J@
MXLR@UL;:9/#3-"D)5T\E)&KNHE^RE6=E;,WZS445UE8]ZB5(BZ)RI@&O1Y7N
MCOS\O)XU57!DLFZ-)IQKJHB9[K52X9YW&]L5.%CX_(MNSXTTKIM-3IUF8CL]
M'W,L*!Q!H^*"V5S1GAH4\QC5AC)!DK#PC^"3C(Q03HS;V%,P!N^F'PFV<D$
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M= T T T T T T T T T T T T T T T T T T T T T T T T T T T T T
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8#0#0#0#0#0#0#0#0#0#0#0#0#0#0'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g38965st26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g38965st26.jpg
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M P,# P,#_\  $0@"6@-P P$1  (1 0,1 ?_$ 0$  0  !P$! 0$
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MR/C89M(OGC5%-8CH&;4[I!0BQTB'.8H$6WVB)HB:(FB)HB:(OS0^L9B?.GJ
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M+[?YI^]PS=_H3HB?AJ>"7V_S3][AF[_0G1%*'K3<#P,8X3N9P.<  YPXWYM
MQ@+\D#&"D;F OP;^&B+!SKU&_2T><A(SE&X;9H/FF'Q9*X986CZ ,^%13Q[-
M6-C:Y&%/#A4 BE3KSD:BMYYDA7*!>T#=HB&B*:&]1WTMH#/]YY.QB.:D<RY&
MQ_4,86ZT'P%GY9*2IM%DY.7K,86)5J)XMJI'OY=<_G)I%5/W[&,( &B+. >M
M/P0 3"$]F@!-L)A#C?FT!,(!L F$*1N.P:(OD7UH>!1%!6),9C(J;?N5+QLS
M650V_CN<*.!AW_)T13?AI.!O=W_/>9>\3 <3_P"[;FSN$Y2]H&[ON(W[@+T
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MWDHI&^[.T9!=#YWL+<"%.HS:B90#&\L-S .I5AO#UKFQW+7.VG8ES#L;;/\
MMYW-N+AK ^K2T'9$=0'OH*#=T*B68\R76%>(KK!7?W$6';DKEAN+=KK>W<\L
MHX.(WRB@)C94@G;U"W7KED;6FNP%GBS.0C+)"1<_' [0,V=@QEV*#]J5TV4
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MXZO\WXU_L[E-WQKNF?[4L&\MVD[HVOU;K2FZGY+'X1R;_>/%K7DHB$(N0\[
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M,$C8W.9;O=5S!(&"4AO\@<XM9\"I5_Y0W5]Y,L<E>11Q6S;O[QYC+VM=<,:
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M]M-6A*CB./S,3%MQC7#Q]:I61RNV>,VJ]GA';1)K'?<XB_5!02++BN<P&
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MQZZOR1V[PZ8!I@$H9IJ:N&YHH->AU^"L0ONJL!)$[X3)J"!1IH[4^H=Z>O5
M 1  ZCN(  ?G=Q$H ._0NX@.JI;2"U@%U'VPYTA8*N -6DAVA-: CKT2.:ZO
M)W6SP\L;&UYHTD4<*MU'J0>G52@(>R8-_:'8OLFW^I\ " &VV#5IT4&UQ86]
MRGO+7 FGKMI]7Y*^P7;7-=('=JOLJ"!7I[J_3^:B/3N_0[]WZ';J;??80'<?
MXXZL%MI;P6EVTO<R\@,T?M->V.I>/_#/R=0K+#[JYFN[5P8U]E.(9/<*=P]
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M<UKCNIMZDZZ@!4/9'+MREQ'_ />[8_I@"K26Z5W=->M5 PE'H;H&_01\-Q^
M/'KM\6L^<P6T\K8^V<<V1K("YP#B"T5]I-1[J]5C?K7MY]V[N"ZE89)P&D@.
M;[1J!0^VBB.Y?E )1W -A#J(B'02A^:  ^$.@?'K7N;;SWTUA+L^Y@B[CP'
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MRG?(*._P'1->KQ-$0!^KMO\ "/0/RQ^ -42.C[/W,I/;^-*G^ 5;&2,G^VC
M[GXT'\2F_3X=NHCT'J)AV$.WQ[S"&VVWB&O&['M;+$1W7:-WG;5HU/6FB3.?
M;!HG:_[=T@9^FTO_ %#T!VUIH1J?1-_BZ[B(_& B&^X[@(]0VU7OCLIHW0!A
MN'@DC<-?BO0R:ZFN+*Z[C6VK6EQ+74 <1MUZ'J*_!1W$.HB/4=A\?$0^$?@
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MWWN<:;>E/G75:L<O\PR.(<3)K5JT0M.O%[LT!0Z98YX$#1M?D9QV'OUC=H.
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M/#&%=S0_MT'+5>UR.06K:DP3=IA%1T*1:&M#2**CDKJ>>J=Y 9/#"98A1.8
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M\1O!,EGQB(3$<)XYR#E)'V3%V$##VB&X:X-_MG%9+F=O@<5-*[[C(BV&X!E
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MBV\L9EDS+IL<#9([,0 ?;N'M-R]Q'^IZ-=N_#57[GQ-AGPNM727#HWWAG/\
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M ):+)F+\757$-7/4Z@60,P<S<U8W[V7=_.$O)S=@?*2$I(R3X2)BNNX<*>R
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M=EE_N'W[<?$Q[FCVN?W-Q#334@=1Z4*O9GPLPNQO4?D)#[KBRL5;D;TQCE+
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MQ^@!:"*4/YG^Q<<LN6YRSO+?$6&\VC,7#)K7ZG;J_P!P5C5#ECE]I6G#NW9
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M@DJ(#XZY/Q24_P#F+F+N*>=UY:R9&1T48!;&_O.#6UW#J"2*#H%U?EMM;/\
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M-Y/F! S+2WC1%&]Q!A9W0YS6T:=#2OIKZ+5'EJC"66'K&2ZW8<97Y&S<=/N
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M?Q)M\@7Q6_O@$^IWCI,9F2NMI-W=8\L(%31PH2-*CU'R^"J@CADB%S$&]IS
M\$T%6DD ZT/4'YA?,C)DD9P=O'QZ"CX1%^*3)HG[X&VW<[%) @NS&^'S.X-O
M$!\-6&SGN; 7[V:T(=I3\1177PM# 7; U^@U;K73T/\ >BT;%+MRL5HV.<QQ
M!V1CG+!FLQ1 @?6CD:'0%N @<1'H0!#6:,A,90P$]UPTU_Q_]:QCBXQ$9"&]
MIIUZ4_A_ZEY204&FB5L2%ABM2JE<E:DAXU)H5T78?>BMBH"B5R!O X% 0#X=
M6W&>:8TKW?77_&JJ#88(033M#II\?R54^K_%T_\ D:L-!>PRC5K7;2?G\/C_
M (*\ZD;Q&='.;N ^7]R:\7J:(FB*11--9,Z*R::J*I#)K)*D!1)5(X"51)1,
M>ATU"B(" ]! >NO1-<6Y$UK03MZ?^GX+PPV]P##=:P.&O_I^*L6!Q1BZK/'#
MZM8XHE?>NV;I@Z?1%6B8]TY9O0,#MLX4:M"&70<@<>],PB4V_74A=R?/W%H+
M9CP9 /C_ (DK0Q<4P<=V;@L.RM>G^"^P8QQJ2ONZFCCZE(U5ZZ"0>UHE8B$H
M%[(!\E^[BTFI6R[Q,1W*<P".^L>#/<@<TL#@71#7W#2G6E3_ '=55<83CL4E
M7@CN.H*-)K7T-!_>JA"TJGUF'>UZM5.N5^OR/O'SA!PT2RC(E_[TA[LZ%W&M
M$"-51=(AVJ[A[1-P^'6#>Y;*WEK^Y3R 6T+PTOJ?J?T_XO3K19MEC,-9W7[9
M!&77,S=VW;Z-Z_\ #Z]*U7Q?T*BRH002U(J4K]RY4BUHS^ C'7W. @!?*""*
MNV4".*02AL!.WMV#;KUUE'D&=QSA:/>!*Z,O K4[:==*^GYK&9@<!DQ]U$PN
MC;*&'2GOK0-U ^/7I\U]1HU)/9?NR5I]6/;_ "Q0^ZH\%&C8!0%/RC$&6!I[
MZ0OD^P %-MV]-4.Y!GHRUI> 7BHU.O\ #_%93>-X25KBV,D1FAZ:'\_\%2HS
M%6+H.6-/0>-J-"SIC.C#-Q=:B64L<[[O!\H=^V:I.1.Z ?;W,/?N.^LUG*>2
M.B-GN!9'UJ>E=?4_/T6*SAF FDDO(65(U=T]/QI7\JJZH>&B*]'HQ,#$QL'$
MMA4%K&1#-"/CT!64,LN9)HV3(BD*RYS',)>IC")C=1UJ)KR_O1W+IX=&#\?5
M;&ULK""'O6+:,KM)Z?.E.O\ 915/6,LA-$31$T1-$7P49L5!6.JR:+*.03!R
M95FU4]Z*EMY1')E$A.X22 /D'$2[>&K@O.U<QB&IE;2@U_\ 8K9LQ+;2.F [
M1K4Z?^U8TIV'JC2[G;<@M5I^;N%P*W8O9>RRZDL>,K[18Z[.MUXBB2:4/ -%
MU#'(U(02]=C&-L&I=?\ *,C>6T=NQAVP AVH'U4I\*]/FHQB^'VEO)/?-<"U
MY!!T]*_GZK)J;=JDV,R29-$F0E$HM$6S=)N<%?L_<V(D#8Y3B(B)3$[3;]0U
M$S,^>X$U29 ZO6G]JD43(60.@C'Z6T@^W2G\**A6"J0EEJD]27[4&U=L<')5
M^0:19$H[R(^5;*MG0, 13\ELH*:QA 0)\K8=7L?R&YQF1$C*F0'Y_P!__K5.
M0X[;9/&%CR!%3Y?W+PTVAUBAT^#I%?C6Z<) PD97T =MF;MZ]8Q+9-JR&67]
MW0"17322 1.H CW]?#63GLU/>WLN6N]P[A%:5<1[0!4-J1T^"U^#X];6MI'B
M[7:1&#2M&@^XDZNH#U^*N0D9&$7%W\V1OO1C)*"Y"/9^]]Z!.Q$X.O**N8R1
M>@")@$H>R'3IK CFFE,<;"2Z:NQI)!- 7'VDU&@)]P'\5L6V%LR1S74W,ZD"
MHK6FC@*'\B5$D=')*BNG'1Z2PN#._-08-$%?>E?95=E412*<'1BAU.(B8?C'
M5H7F]T;&N)=,\L;U]SFUJ/RH>M!\%DG'0-K3:"T5]-/F/_4IRLF)7+AZ1@Q3
M=ND_*=O",6A'SQ+;;RG+HJ)E'20!T JIA#;QU<[TIT)-/S5H10C4 5_)1*R9
M%*W &3,@-"J%9E39M"%9%4^R)M2@CLV25_-@GMW:J$DIUW 5^+@/[RJ2R$:;
M2:?!I/\ <$(S9)^4*3%DD* &*W%)HV3]V*I]D*U[$RBU*IO[0$$._P"'7CW2
M%IW.!'_,#7\JJIC8MP+0:CXM(_M(7WU95Y-$31%.G]E2_LJ7]&71%TMT1-$3
M1$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1
M-$31$T1-$31%\U?D#_%\ Z(M#\G_ .?UG_R@'^+H:(K#T1-$5A!DFJ&R2^Q.
M5V[-<HZDM\A.V?N2I6Q*VYD%8M)4CL3>4JY%VD(>6'40VUMSQZ]?@+;,-&D]
MX8A^&YP_P6M'(\0S/W.'?3?;V0E/X[6D_P!ZPR7F'A9S$T:5AG%RM2V1(ZP3
M=9@*G3)B>LRL!5Y56%F[#(0S(AUHR$9R2)DO/5$.X^P% =]3"Z\99.VO[I]"
M+6S9$7?_ *T$C_\ *5"8?)^'N;:R;&1]U>/E#?C^FYH/_P"9;-,G:$@S:/VH
MG%L^;(/&XJ)JHJ"@X2*LEYJ*Q$E4503.'>4Q0,4VX"&H#?[)9]EG39&[W4^7
M5="A#HXFR7OUR#VU^)Z+TZQE>31$T1-$31$T14Z8E$(2(E)ETFY5:Q,>\DG*
M3)NH[>*-V2!W"Y6K5+=1RX%-,>PA>IAZ:KACEGN[>UA^N>YBB_\ YCPT_P!Z
MHGDB@L[B[F^B"VEE_P#Y;"[_  5AXKRU4,QT2$R/35)(E8L1WA(=6PQCBOOW
MOS>X.T='28/^U<R97"9BE$-^X0';4GY'PO(87DM_@ "!;6HEI^+=RC''.:8_
M-<;L,^2";FY,5?P=M61A<HE.HF=PU341()EP4<)$\@0[>JP&.!DB>V'4P%WW
M^/4=AL\J86$0@C:-:?)2*:]Q8E>#-3W'2OS_ !7T!5$1$!52(*92G7*95/O1
M(?HF8Y-P$.XP" [[ &WCJ[]EEO\ X _@K?WV*_\ CG^/_K7Q5>M46AGJCAM[
MN"1U"* Z1%);M364 B*_<""IS^5ML4P[".VLJQP^4R%Y%9.AHV5X;6G2JPLG
MF<5C\?-?=ZO:C+J5ZT_-6+BG)4%F#']=R/6F\BTA+,B]68-Y9%-O()E823N*
M6]X0245*F(N61Q#VNI=AU1E<+<86Y-O/715X/-V^7M?N(/@LAZUK@ Z@Z+;D
MDFIZIJE>)HB:(G\7Q^&K<CNS26;_ $#H/Q]4N6]ZWCBA_P!</)/X+#S_ #QC
M6,S3"8 ?2SQ')=BKB]IB(PT<N$<\BVX+F.F68$PLDY(X-%1*W$>\0+J5.X+R
M!W'Y^6V;"['11G3TJ>BCE]SK -Y-9\2O'M;D93UTK0=5\Z!GO&>3;IDR@T^9
M7D+#B)\UC;QYS!=G&,GKL52)@QDU_P!+R+<BJ)R'.GT(8O75W)\0S]AQ_#9@
M6Y!R4@;6G6I"U^,YA@+[D.9P_?'_ -MC<ZE>E 5F CAL?;M<(& Y?,+VK)&W
M2$.BH"0Q@%,@_*'Y(?'K1S8K-VKW": T!(U'P*DD&4P=TQIAG%7-!T/Q"I<W
M/1U?@I*Q/0=.8Z+:*O'!(IJK*/54T@#ZRQ9-"G5D'2I_93(EOW&U;M8I+NZ;
M:3,V2NZ#X_\ H57=31VELZ[B?OB;U/P/P6 F_+7#3BDS5V&1L;,D#;6E"DJF
M_JDPTOB5TD2 I&5DE1.D,FM*2"!RJID* ]R0B;P#4MD\=9L!MS#7M4K\J*'_
M /F3@V,?!,1W@LIX\RE3<HTY&]TZ06=UXRLFU=&>,74?(Q<A"*JH3,5+QCA,
M'3"3BU4A!1$P";?8 ZB&H]R?C>0XY>6]M.#^O3\ZJ5<8Y'C^5XNXNH*?]/7^
MP+&$?RQPX\/=TI*0L5/<8_K@W";:WBJS56=NJH9X,<WL$&VDVY%9=BZ?@"*7
MD@8ZAS%V#KJ0?^7F7B?%:ACIWWH#H9F_3:@]&O/H1U(U47C\AX=\4EP7M@98
MDLEA=]=T6]7,'J#T'1>9GR\PF]I\Q<BR5E:%A+'%U)Y4I&JS+/(![%.HD=0$
M:UIRK;YT=*3C(3+MA* @=(HCTU>=XOY%!>#CTKS+E']+X?Z3*] 3\NG3U5MG
MD_CMQ:?[AC:(L97M&P-.\_N?ID@?.OQ7PD>8F#HZJ5FW%EK'*-+6>PEC82"J
M<Q+VYI]QP":Y#,UMND5]$DJH;>_&5V! !W'H(:K@\8YV?(CCIJ,@QP+[S_PI
M&@ZL!^+AH--2K<_E# QX\\@!:;&7=;MLQ_JQF(%X>X>@80''7T6P]:L<+<*]
M"6NM/TY2OV.,:S$-)(;^0]CGJ8*M7*6X /:HF;;KX'*8/@U#,GC;K&<EFP,P
MHV&NGX*:8S)VN3XU#GH=734U_%5O6O9*)07#H'$?P-%L7Q&$AIZD _Q%4U6J
M$T16%DG)=3Q174[3<73II#K3,+ IK-6:CU49*P21(J+2,BD(&*19XL0#'\"%
M$1'H&M]@\,_-6SIH>K:_V+0YW,LPMRV&;HZG]JM"Z\AL4XZG+C 7&P*P[VBT
MJ,R#8E%V#@S1M6Y>4-#1QF[E,%"O)1W(I&23:D#S#F$NWCK.PW \YFC++$'=
MJ*39^=*_W%8&9Y[@\*(H9*=Z6/>/XD?X*ZL<Y*@\FP[N9A8>XPJ;-RFV5C[E
M592J2X^>@5RW<I1\LD@=RU<I'#L,01[AZ!K6Y[!NQ3OM)"6RN-*_#4+.P^>M
MLK;F\E8Z6R:*N:.I'I3\Z%8VB.4&/9;(M>Q<>NY3@K5:W4PUKXVC'<Y P\E\
MPI*K2CE"7=D]U,T111$P*[]A@$H;[B&MY/XZ[6"_=^]KMKU*B4'D?CTN>_:?
ML;FFZG3_ -:]F0^3>),7VU"E6R4FD)@&L0^F7$;7927A*DPL,@2*@7UNFF:
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M.WS*0:&?LI5X#<3!&Q3MN "FNKVE/OL&M5C^&<GON-Y?,=AW_P!LN3'6G2A
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M#6/-Y#XS'D^0NMW,9:3=@VK6TVQTW=SM#HW=INV_*JR(O'?)Y<7QYMPU[[R
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M6(15(X>TDJ0JJ1]NNQDS@*9@-X#W 8-O@UD6TOV]/@J70=_353 &P
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M0JP<J3\[4\9W^U5H(PT]6*?8+#&%F4UUHM1S#1KB0(B\2:G3<G3< W[ [!W
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M3F1F,A]UL[D#*E7KU+QW7I>US\E!XYLCR*<381#4AW/N[)BB11VL!@3*8?9
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M<,_E$HFJQZ*WO+MZR!D/O"ZOUDIA H!UU&^.>/>.9#C63R%YE&NOK9_Z9 H
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MB&+R6'!&8<;B2XJXGOL#R(V,:=&&,=2VA--2N,7WE*/!<PRF-S1KB&_;Q6]
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M3;**DWR*:+J3A%U@(Z1Z&3V$=QUI,QXMYGQK#768SC8&LM;[9(UKJN9%(&B
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MV ZCDTU=Q@SJ#RH62)G*+7;D_G2R#UV\DK(P>2 H#7[,\%ZJ)54N]-(QBB4
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M"-SR;I7L#;<2@ CMX:\YAD1E^2R9)AJQ\31^8_QHKW#\0,)QF*P=_J"5QI\
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MV1U!R[1VS85R+M02"KB"AH1!?9%!!/L$VPCON(AVC,>46QPV)M(VAEO0T:
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MV_%U;:9>R;.+61E@R+Q16H;[GH=FEC=FZ5C).<;K>X.?*LS[WJ/*@"Z@E#L
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M)HB:(FB)HB:(OFK\@?XO@'1%H?D__/ZS_P"4 _Q=#1%8>B)HBTU>6ES!<X+
MQFK,I$UMYQ42E(F.DY<T?"K2,7<G2<J]8MW2Z3(\DT:*%!51,/,(D(=W379L
M!@_WO@UO]K#&R]CS,.]]/<^,-=H[X@KBN7S!PG.KO[J:1]C-BI2QI/M;*'-
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M,JUVK0==L1J]FC'&)Z;,LVCZP-VH7*F'L\C+6!C$K^?,*M5DQ;H-VITQ,<P
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MER+J9DT8%I%Q95?=6A6;9,H'=*" BL'>([#MJ007_%<WX_PG9L[>":3D#!.
MVFYL<!8=WK0O =3XK27MCRS ^1,YWKRYF@BX\XP$NKL<^8/]OI4,);^"M?@O
M<K"MF.V4AJ.22U;Z%*19[0VR++.9DQ,JKO%V-DFH)TN[?@2+G%"'.D9-0$G
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M-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$7S5^0/\7P#HBT/R?_G]9_\
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M!L.XK/<6.0CX_K"EWC&K9G'V92/(I*M$6;<K1L*:ZG<G[RDV(4I5?+\PH!L
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M,UU7T ^(^"NVEXPQUC@)7[@:37*B:=<^]S)X2-3:'D5@[]A<FW4,<A?-/V$
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M#O=\:;BZGYJ3.XWQIN%;@I0^;%L^EDNTT^'TAJJ53I]6HD$SK%-@8VMU^/\
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M/%7'VAU -/7JLM:B"F*:(FB*(=>F^V_B8? H?"81^ "AU$? -4/D,3=P)!)
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M\?8LY3=P2SXFX_T96/[+M?4LVOW#\Q^*T)Y7@<QEG<?MKB.WSUL?UHBWNC\
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M<27.#MHV]=214^B^>2Z!E*=Y*3<S&XYO2S:?ROB"TQ%:1AT3XBNM=@V*7O\
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M%EN[<!I;[86;V.H*U+@::#4]1HI!<FRGY1S2VQN*O9(Y<$(;5Q8\AUTZ2.0
MN#:-:8ZG=T:?:3577Q'CBSN78&VU6F3M1JU,XS4_&-T&6K+VK)O,BM),'#N)
M!%XU:C*NX8B*GF.2 <H@</:'NUI_*,CK7!9"RO+QD\MSR'[BU:VA_P"F,<]7
MN()V.JY@V'77Y+?^+(S=<DLKZTQ]Q:VEOQJ*VN'R-<S_ *QKH=[&AP&\>UQW
MC0@:=5TUZ]=QW'<P[_'N81 =OR!U\]+Z*31$T1-$31$T1:B<TJ//Y"QA3Z]
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M6(ANF &$1V#8-Q\-4""R#MW:]P_XW?\ :LAES?1FK)!T]6-]4*<Q1+L8P@4
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M-LFX]7%U1_ A4&6X[K98Y'1[1T:&T/XU!4"G,4  ISDV$1#L44( ;^.P%.
M(_'I#%:V\;F00L8X_P P+JC\*N(_B%3<ON+P@7<TDD7JT[:'Y$AM5'O$![B^
MP( ( )!,00W\>I3 .P]=P\!WU;@9/;3=^&:0.K\5[ (H7>Z-DD/^5PJ% #G#
M?8Y@$0 -]]^GP[=P&ZF^$1W$?CU?EENII#*^:3<XU.JN/-JYY<R")C"=&@:#
MY!0 QBAVD.8H".XB B41Z[[#V=O03  _E:H#0[_ZD=X>@>7:?,4(ZJ@N+?\
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M3"7;;IL.X 7H&K-T+B[MH+5\\H9;DEM#UJ2?\5>M)9K&ZGN;0L8)P 6[ :4
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M;R$1;DXO]MNQ+LB^Z=#(Q\5NUQ80^W/Z@D<\48W^:H-:+F,7EUK["0/QDO\
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MU*^=)H* 0075;M# H<I.XQ2^(:S_ /RXYZ9S:_M%]]P "6]LU <[:TD>@+M
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M?M#-]2:FBR*YX=9YF,XTV^V2ZTN4IU-R+'6ADC\]SQ'9:PE4P@%X5M5$Z\E
MIR+)??\ 39W2BCQ,VR@EVVUH8_+?"[3AMY@\?8WD65N\>Z%SMD);WC-W1(9N
M\92PC38& ,(]M:K?R^(>;7?,[+.Y"_LY<79Y!LP;OF#A"(.UVVPB$1;P==Y>
M2\?41T5ZXXXI9,KD5@*O65;&9X[!V6KS9PD85>34D[%2K.QETF"R[=[!(HMK
M&T=R@=Z7F&;E(F!BJB;IK49_RAQ_(76<O\>S(BXS6+MH=DG;V13PNC+J%LI)
MA<UFCJ;R30M 6XP/BSD-A;8&QOWXTV^$RES/NC[F^6"9D@;4.B $S7/U%=@
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MH&X?4W'X>GQ_#IT%3T3IU4=NH&VW[0 .NXEV^J B(=0T0Z:GHINXVX#OL(=
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M<T?:6=GRT8>O>MFSEL9 _P#"8TQM)^%:#0Z_)=0EO;N\XH,PT,AF?;[I7?\
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M6:4W,C)>TZ"HH#5:[,\YY<^R?CVY)[X8I[@FZ <)YH&0N="UXK7;)( QPJ2
M:D475;#=CD[?B;'%IFY:'G)N>IT%)3$K & T.^DW+(AWSJ.$@]GD*+B(&^$%
M2G#P  #YZY38NPGD&\Q5D ZW:7 FH7TAQ#*LS_#\'F\J2QT4#=VA-'4Z=*G^
MY9(U#(V0LW-@-8^X[Y:UU_M4RF+S*YS^A-1\VGZ3^835Q6TT1-$6I?-.R7.G
MX5+8J)<I>D3S>]T*-&4ADX]5=:/GK(QA7[18LBT=H^4HV?&$H@&X'*&NI>),
M189SDYQEXTN:^SNGOTT#(;>24'73ZVC3K\ERWRWE[_!\7&4LWAKF7EJQGQ+Y
MKB.(B@U^AQUZ*I\=+I;[3;^2T)9)Y[8&./<OMZI6BOD6I5&$.%4B'JK4QFB"
M*9RJO%CJ'$P=PF..VP=-/(/'K''8G 7>/!%M>P7,H?0_ZD4SXZ$#4>T'K16^
M!Y^]RF3Y!9Y!C;BYLI[6(PEP ,<D3)>ITT=0Z5Z*W^7,E>*[6&,Q0,L6BJ7I
M51O"XWQY6HF"E1R+='3M'R6,PW>L'3]6&2;&,*XIBBFV2#O.H&P:>-[3][L;
MB?.6Y?C8*U=_P@>@ZD_+X5^"K\M7]YBLE8NQ%\1>.VTM2"&^FF\';\EKA<LX
MYW8S>0<@ENGS,AA?+.&<32&*6#*-<5NU#;6,)]U[N7=K-0EC/PD9HXLC(G3(
MF5+?VP 1UTFWXMP]MG#88W' W,UM-=B5P(!CDV%C:[:!Q'5M:CU7+KGF_-9\
MG<97)7HAM&74-M]LUP<6/CW->0 ZI8W_ #4 /HL_H2V2F/*Z%JU7RI8\AUA2
M/L<QF*JR4/"IU3&<:Z2(I1V$0^C&**S.S/5BB'NJCE995(#*&(!>NN>9:# W
M?CL7^3QYL8Y9(+>!A!#G2Q/<9*B@H*.;1WTGI71=/P]WR!GD,X_'9%EZ^&.>
MXF?O :V*9C1'0EU":M=5HU'J JCF:QY*J7)#C0SB+Z];4+(EKGZS/4!O$1Z;
M)R$=7G4F+QU,B0\FN91T4@I)E$A4NT=A$!U?XO!Q[)</SL5U&&3X\,E:30@.
M8T.&@J2*CH%A<KN\]BN8X*2VN(WQ9#?$X!X!(>XL(J2 -#H2:*B7R9R5 \C*
M'$4;+$[:QE'DG,9+QH_C(0M$H6,6L.X!&>?R35D5_$RYI1),4#K.A,Z*!C F
M)0$=5\=PO'+GA;_OXIK-]U(U_P!P&EUQ)4@[64^F,C2CB" 3HL7D>8Y+;<U;
M^WW%I>16D19]L96-@80"-TA+O=(/BUI!--5A;B9F_+MXS,QB;Q>YR7A;54+U
M..HVR0T=%U:5E(*VN8^'>X.D6#9)Q/5IE"E*9\<YU1#?<-M]]2CR!PW"6G#:
M<?C9':]R%S6 @'VL;W'O!H0]SJN</4FHJH[XVYGF9^;N?GIC-=]N9KGUW-!<
MX]MC2W<"UK2&M-= !6G1=1!_]>_QZ^<6,VW5W)_(^5I;\P 05])3.[D-J3_J
M,B>'?(ES2/QT'HFKBMIHB:(H#\6P#OTV'< '?IXE]H.OPAUU<B=$UX[SRR,Z
M5 ).N@%!_F)H3Z U5J87!C_Z4-=*"#0F@V@U?J?4-J1\3HN9%JR3G+&&2K@>
M-RPYS(6HT7)UWR[60KS&.Q[C9DRAUWV-XJ*=MT"OT+&L^2*1PW,X7.JD!C'*
M0!#?Z$QO#L;?8+&XS*0&RMC.TNC;[N^TG4N(T%=*=>J^;<KS+D5MR+)9/&W+
M;]P8]O<=5ICC;7M1,#M28R&UZ#VJI8DR5R$5L+NAL[DVR;:KOQ[IN9JV^R S
M91T/4;!9)+W.:B^Z%:M55ZXR:K@HW0'=810V[Q'<=8?-^*<3L,!'>!AAQ+,^
M^!T0%=\#9' %M!TH-*Z_);#@7(^:WW)9,9-(+CD3^.1W7>+@ )GQ-<:EQZU=
MK0KVXJL'(3+/%>/E$\I/DLFM+Y?V<Y,5N*A$[9;656FI5JUJ]#:S1DHB,?O5
MD4RHJN@.4C< [O:'?5GG..XEA/(K[+%69NN#2VEN.T6G<QLF[O&FWTH/Q'17
M>!9GDW+/'$%YG;UMIR6.[NW22[AME=#M[4))<"!)N-7:@4U6'HG/^:\CU6C0
MS+)[^HV*M8-RQD^ZS<'#Q82<W;\<SJD.UIEB)),E&0(L"H@64]U  66W%(X$
M'4Z?Q3AMGR*>5F+W<<N;NQAL&AI+MAD_5>YNW<P-!K[@T_!0B3F',\C@;?&S
M97_[CC+.^N;J4N ;+,(ZV\(.ZCMCF^TM+A5WHKYR3E_/+.E85Y%QM[<0]'L,
M=BE:X4Z,B(@]7J2%B(W&U2^0Q=*+V%^E,KK^3%IL2E,V$Y3G$2EU%..<9X3>
M??<7GQ&_E[1<-CGVNVL:7.VMW%H'0ZZGKZ*6\BY/RN#[#F;<R(^-.[#Y+>M7
MR/:UM7 !W2H]1Z+SXBSMFF9N>([,YM:]MCN0TMFZ)88YDFL<PK%0<4%PO]QG
MS(^0;%E4/,3;^6],X44 Q51-L'35WF?$>-X_A^7L[-GV[;!UHTBA_4WQQ=X
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M*O('DUEFD<6#2U74KB&3\NV)C8)2EY#AZRYLT/6C2CDD0BX*V<KPS%H1@85
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M8]:^2JM;L*PM3LP:2\-VE([C$VIQ(FW$X)I@(B'4PZS;CRURPXR+$0S8FD(
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M3$0$/#6+=<]R\XR62DJU^6$=1TKVZ_\ :J+?QMAX'V$+Y!LQ;Y=GR9)MV_\
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MORC&:BU54A$%")/XU=TT5.F)1W IQ$!UL<SA<GC<BV'+QS6_8&XC:YF[3=0
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MXTJK:B[G3)Q])1L)<*I,R<*4QIF.B;'#2+^((0QBG-*,V3U9S'E3,40,*Q2
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MA4E%'\0W>JR#(B:AP PJ)E N^X[!K>W/&.88JVCN9[.:*TN/H,C',9)_R%P
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M1$T14%G:JQ(6&6J;&<8.[/!-6#^:@$5TU)*+9R@J!&NG[4H^:W;/A2-Y1S
M'[1VUL'8K.163<I/!V<1+4-=3:V;;H:= \C^:E2#U6#:YO%R<CGQ,,D<]_#:
MM.TD.,+G-!'6NPGTZ5]%71[0 PF[2E AC&,?8I02*4_=N8VP 0 *;Z@;#K7V
M=[ ^Y-ICW SS 5;4 @=&T'6AK\-5E18[)7&&CO<O&6MMGR>X FM2#[S3J*:5
MZ:JTH#(% M3MU'56\TVS2# @G>Q]>M$'-/F:951;B=TRC'SIRV(58@D[CE*
M& 0\0'6WRG&LQQQP&2@EAG<26M>US'5&IH" :BHZ?$+58[DF$SM3C[R":-M
M2V1KA0U !()%#K^-%> E'?;K[(@(_" #\8[#T#K^1K5M?:"./WD7 ?1C:ZB0
M^C1_F-1H-5M7LN#+(2QAA,=7O^+!7W.=_E%#J=%1;#88&HPLA8K1+,*_ Q"
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M&GJVO0 =16FGQ5E]B]SS,[;L<W4^A#?[P*_E50,(%#N,/01VW\0 0 !$-PW
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MB[\D6&.9B;#[(Y]H_P#J=*;H_7O+LEUGK:T\;W^1DRU_]Z, X_\ TVOTR?\
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MH-C7N%"6-Z,TZ!H 'HIOJ]=NTI2AN(E*4HF$I2@/0"@(CX:LQW4T5R^[:?\
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MIU&K=0Q$R]H$(03I&$A"]H;  [:\AN;FW#VQW%RULAJYHFE#*_%K0[:TGXM
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MMSNYFO-Y^,<2\0@@D51VJ]8I.#N$4&PF$3F$-BE#?PUS^7CF7MX)+O(XF?\
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MQ,ZJ"J &[2J%,&^LC%^0>!X++V-I8!L\'_4S/=(-0^1Y(;[:>T;C3UT6'FN
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M3RIQF_[4EX&D&2\G#:>V-\ENV%K6#X 1M(K4[B=5%X_%7)\?#+;V3G->([.
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MY2]G@?N'IL/0=^O35N1C9 &/>YC2YM7-ZCW#I57[>:*WD,LS6O8&.]IZ$EI
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MKT;D)@C%63XW(U?LE;?4.NY,O4="3,E9:I.%K=@AA5KBR[F/=*D]W4\ON#O
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M02D\;Q,X+HR8UZ..=B50XG$PB!=$7<8A@,4# (" ^ AX#U_EZ(IM$31$T10
M-M_JCOHBCHB:(M ^7GIZXDYG73%.0K[>\UXXN^#GSR0QM;,(9 /C^PPDB^2=
MIN'BL@6)E"O ,5R ^68AB *9!Z#OHBJ6$_3\X_X!R;=<N4]O:)^\Y,>1LMD&
M<O\ ,M[=(6JPQ=<BZXA87SY_&%>$EW(1ZSU<Q#E14?OW2@$("O:!%O03Y)?
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M&I:]I:YK:$[G ]&Z?5T7G;9KM;Q$CAG-$=-U $4UVRC)=%0 ,8HF(JDW.F<
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M61S"V/\ )YT.JR+B6VMWMA=-"^Y<*B-CPZ3XZL&HTU4OTQ73I_WF<-_A'W4
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MF&Z_;)3_ *+;]:Z(GTPW7[9*?]%M^M=$3Z8;KU_[R4Z (B/:VV  ZB(_I7H
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M<2X5#"6^UG<)W=*;?7XZ+T20G%R9<R1BUB<T.:7 25=)VQ1G4^[^S53CE^[
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M?L:-C>SV9SEER]R#D&*.PK<]7,?,8]PP;1%<:S2R$?.60DB8JJ(OU#-"$[P
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M6+A*8VLK#+'&HF44?H\3?MY#'4FPL$ W5B[$L=Z\(NE,F7/Y:AA0.10@D #
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MVP*B$D"DH\?+H[F$O:F0IMM]PWUYEO&O!8KG/16S[[_HI+1S>Y(QI?)5_<(
M:X!ATVT*LVOD[G<6.X]=3V^*F?D&W;'[8YGF*(B,1M>[NLK(WW;AMH-/<5<&
M".3F9[K;\"(7YCC_ .YG.-2OSMNQJ[233E8":Q^],T6DC/G3@Z#UG/$()A1
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M%$.V.;G;]C8A@$>X"; ?X=](^9<@M+][X9C^_EO9DF!.][8OU',+?30&ON-
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MQW %WX+._P!N8NVQS\+%M9AY:S?!K&N<#0_#8XAA^!T5R]-@_0@  'AL =
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M;>R8Q=K5?1C9<]AC(XWZ08S!C)F.^:,NX13(?<"[]-9O[[DHX(X)+H-="?\
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M]V""9'2?4 -@U^/N51:4*D,"UU-E4J\U)4&[UK52H1;5(M<;220HR#>& J8
MP1>HF$JI4]@.7H.M<[+9R2^N/N[][V3L:"9"0X!E=K7ZGW"I]5GVV#XZ8HVQ
M8^&%EN2YO;H6R/?3=(-![G4%10TH-2D?0*+$*0"\34J_'+55*11K*C..01-
M(S!Q/+)1/:0/<DY$_58"; <?'5IN9REW!<-O;C>)BP%I)J1&:M/Y%46^$Q=M
M(R6"W[<EN7%CJ ?Z@VNI^2NS6"MFFB)HBG3^RI?V5+^C+HBZ6Z(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:
M(FB)HB^:OR!_B^ =$6A^3_\ /ZS_ .4 _P 70T16'HB:(M><I\I,.8;LJE3O
M<Q-M)=M6$[K(A%52P3S*%JBCU2.^?YR0B6+IK$Q:3Q Q%%5C%*3;<>FN@<9\
M7\DY-:.RL$.VRM@8N\7Q".5T]9&0QC?O,H U#FM:"#[ES;E'E#CG%[MF+GEW
MWMR\2=D,D[D38/TWSR>S9VJG3:YSB"*-5[1F9\<3,G=HB+L!7KK'M0@;W9SM
MVKE1JUJMGBWLS!RK9UY8(ODWT9'J*E*D)C 4.H;CK0LX1RBQ; ;^WEC%RVXM
M7-)C)_Z9[(^W[7D;P7=*T^!*D<'-N+Y26ZCQUS'(ZTC@O@_;(T;9VN?O]S X
M TJ#2OQHKIIEP@<@5*N7BK.S/ZW;(AE.P;XZ*S8[N,?D,HU7%NN4JR/F)EW[
M3  A\.L;,X+(X*\;974#VQV@DMP26T:6[:AVM:FN@%>BS,+GL=G\2[+VD['?
M=W(=MHZKBT_4W2FT?$E7/K3+=)HB:(FB)HB:(J?+2C2#B9.:?^>#"'CWDH^%
MJV6>."LV"!W+DR#5N11=RJ5%(PE(0HF,/0-5Q64F1GCL8G[))96M&H!-33:"
M2!5W05(%5;FN6V5O+>.A=.(8GOV 5^EI.[\&TJ?6@5G8LRA3LS4B)R)0WCU_
M4YQ1XA&/WT6_B%G*D>[,R<F(RDD&[GR"N"&*4_;L;M';PU*\UPCDG$LG=8DV
M;WSP-J(B^'?N[0EKI(6@$&@JX:]=%&<)S#&<HQMIE8I3%;SR[3,&O[8&[9ZM
M#S[O;HT^[19! ?C$I>A1'<Y>TO?\@!4W[ $_P=>OP:B%;QD<3[EM))6U#-CR
M:TJYH(:02PU!()!H:$BBEW:MI72LA(VQ.(<XOC%-:-)!<"-VA (!U%0"HD,)
MS=I [Q'N$-AZ]@% W<(>)=OS0"'LZ13MEN8X(R R0&C]DFTO;UC^BN[J>E-"
MJ9K8P6[YYC61A%6;X]P8[I)]=-G3UKJ-%(JJ":*BP[&32146.*8]VX)$,<Q$
MP]GO.;L'M#IW  B'0!U<MV27DPLW-/?+@',#'[@UWTOU&T-=U%2"O)VV]G;F
M_P"XPVS6N(?O9M+V"KHQ0EVYO0BG56'B_)%=RY18'(E3!Z%>L1'JD=\Y( U?
M=K"0=QBWGM@.H*(BX9GV 1WVVZ:V/),)<\5Y#-QR[]T\$C&%P'M)>*@BM#IZ
MZ+3\>S]IRGCT/(L>-EO/&][6GZ@&:$&FE3Z4*O[6K6U:7%H+_J(315)HB:(F
MW\7\7Q:R+9A9*"PC?,X,'R.NI^2L3N?(PB0_]+ W>1\>E:+$SO.&-8_+\1@A
M]/BVR=/5Y>TP\$9FY%)]#MP6\Q5.1 @LR+[-U# D)P4$I!$ '4GQG"\O=<'E
MY78Q]YSKA\;(Q3<7QTW=2 ![A0DJ-9CF>&L^<1<4N7B&-MNR5\I^@-DJ * %
MQ/M-=/P4*/G'&F2+GD6@4NP%FK/BJ1:Q5W:D:ND&T4^>=_DI)OU4P:O0 R9B
MG,D8Q2&#81U:RG%,]C^/8/.MM'$YI\C0T%NX"$5F+JD?Z;?<X=2.@*NXCF."
MON19S!2736MPK(R7'=M)F-(0V@/^H[VM/2O6BRQW>&^P .W43%$ *8QRE,;M
M$PE W9N&M#<-O[4V_=@<6W-=NGTD.+=KOF:;A2NA"WUO=65Y]P(9P#;4KK]0
M<T.W-^0KM-::@JDST]&UJ$D;#+*J)QD2T6>O3M6SB0<E01#J5!BR27=.ESF]
MDB:9#&.;H&LUV*O+G*NQ5M")9VN:TEKFM:7.8)*5D+!4#VG7J/@M;+EK6WQ+
M<G=2F*"1KG@.:YS@ULACK2-KS[C[A0?2?BL'-^56$7%%F,@_=0\;P\#96]-E
M(QY7IQG;FMN=D*HSK)J>X9$L!YI\B8%$$"(&.HE[0!MJ22>*.</S<&"CMG">
MXLG7+2)8"P1M+06EXEVM=[@?<0W3K4@&+P>5.#6_'KK/37<;H;:\;;.;VK@2
M&1P<06L,(<YOMI[07:]* D9.HN2:9DFH-KU3IE.4K+D9$AGHMW;1=BZB%E49
M9A)L7*";V/D(PZ)@714("A! 0$-PU%,GQ/*87)MQ,@D;>N .QSF#<T_S-?O[
M9:?B7^JE.,Y7C,SB3FV&-]@PTWM#SM=_E<S9W-P]0&+&L+RGPC-#==[0]@C4
M"$-9;$G:Z].U=<*Z#@[4L[%HS+%J>8BEER=A%6P* 8XE* ;B :EEUX]\@XJS
MCL6V3)ADMC1[H7OM@PG21S93&"S=5U': Z*+67D/@&7NGY!U\Z 8X/<06S,9
M<F0#6-CH@\A^VC:MU(7F8\LL&/Z/*7Y*TO$8N&FF-;?Q3NN3K6UEL4L5-:(B
M&]468EG73N7;*>:U*1$163*(EUD7?C#GC\C_ +3E@CNKB<LNHKR!\7;<6_4!
M(90W](,J^KA3TJ5CV?D[@QL6\I9.^SAB#[62SG9+W&AWTET;8MWZI?1FUKJ^
MM OE+<N,"P]0K-X5N#E]"6X\V2&1AZ[.RT[O6P.-D-*5YDP5EX9.O=@^_&<I
M)E;?F]M6;7Q/RFYN3QYL#J6DCIY;O?'LJ1M+"[?[MWT-V%U20%7=^5N+V;#F
MWSM+[F(11VFV3<0SW!X;L]NVF\[PV@%5GR GH:TPL59*[(-Y6"GH]K*P\HU,
M)FS^.>HD<-72(B #V*HJ .P@ E'<!ZAJ'7&.N;;,2X:8AC8JT!J#I\E/;>]@
MN,?99"$%\M\P.!;J&@C^8]?X557UKP\O))TH2/X:+*  ) ]":_C75->KU-$0
MQ@(50YAV*0AU#?SJ93&-L'B([%'6+>NJ8W-J6.V]-3[G;?[.I^2O6+FM;(UQ
M >TNZ]/:W<?CU!H/FM8J?S"P+>)<82#LTL1ZHQL[^,/+U.PPT?8$J8"XV4E<
MDY"/183:T6#8XG*W.<=@UU;*^)^18T!I9NC;/!$YP<P-+YVL<Q@#G!U=KVDD
M@,ZC=447*\-Y:X]E6NEWB.8P3RM8X.+FQP.>UTA+&N;M)8X  E__  T60&>=
M<8OH?%4^WGSGBLU2!(O';D(]X S;PS-Q("D=$4P58@5HU.?N5 I1VV =]1^X
MX1R"URF7L,C$^.##-89"'1N[0?MH\[7FK3N ]FXU.HI4C=VWD+CMSC\/?8V0
M2SYA\C8QMD;W3'N!8-S&T(VD^_:T@:$F@5;R7E&I8FAD)RWGG1:N5E446]=K
M<U:) YFZ!G#E06$$T>N"-FJ11,JJ<I2)E 1$>FL+BW"<_P QO);?&U$#=(W/
MDAC$SO1D>^1ON/INVA;;E_,L!Q#'1WN1([S]9&LCFD,+?\\FR-PVC_A)/R6-
M)7E;AF-)1U&TO8;(7(U<5ME3"H4^QVI5[ (.V\>Y?N4(5@[5CTVK]R"2OG 4
M4S /=MJ067B#F#[JYBOK::"XLWM9());<=HNW>UU)CN+=IJ8]S?\I*B=[YAX
M;:LL3:W4$]OD8C)&]D=QM>T%HW5="-H=N%!)M</Y@%<\YG_%]:O==QU/R\G%
M6*TN(^/ACO*]-HP:\Q*H>\L()2PG9A#(S3A'<0;F6[PV$!V$-M48;@.=RN%_
MW98L[T4 >Y\1?%N<QNCFN9OWZTT(:1\5M,[S_!X?DW^Q+UXBNIBQK)PR3MAS
MQ5I8_9M]OK5P/P5,BN36%IJ\R>.F%O!2R18S9%#*1<LG!O7-:336L;&)GQ9C
M%RTA"H* 9=!NHHH380VZ:LS^,.8PP0<D%L[??:&%TD(%N'Z1&0=S<P;M6DMI
M\2%5;>4.(760N.("X:38#<)FQS'[AS/=*(G=O:\ENCFAU3Z KWTKD/B'(%7N
M=VK5M24J6/I*1B[;.RK%]"-8A:,1!TX45+)-T%CMCM3E434*42J 8 +N.K&4
MX'R7%Y&ULHK>1\EPVKF-=&3)2NY['!Y86M(-27#H57B.?<7R_&\AGY;F**WL
M)=GO;(US#IM:YI9N#C44 'J%15.46'4:/](+N6L+*!4G65:CV[VFV=K/3TU)
M(F<QK2M5Y:,)+3I9%L454%$$S$43 1 ? !S[?QGR27*_LC(@S*,:+JCI80WM
MG],.,G<[8IO#2"\.J>BP)_)_%XL0W-RW =82G[8M$4Y>'G]7:(^UW#4,+@0T
MMIZK*./\@U'*-5C[I2)8LS7I3SR-W7D+M%D7#1=1J]8OF;I-)TQ?LW*1B*(J
M% Y1#KJ/\CXMF.)Y(X?+0D3Q#>YX<QS0;C]1H#FN(=N J',W-H-2"I#QSD^,
MY9C!F<6X_:2GMM#FN:X_;_IN.US06[2:$/#37H"*J\]:%;Y-$31$\.O_ *0
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MHS,558 *GVAY@ ;;SA. = #7S=S.XBS_ )"N\E8^VV)=_B?\5]/<,MY,!Q+
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M'.",8SN'K=8;U"9 K=F>Q5%A@?! 5RJW4TRLWG3O7J M)ERT5$Z2*0&24(
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M-VH5ZLH>4E'C(%7 @JD'O0" AN   ZY7C;BWO?).*E=- Z$7SZS!H$ UZEE
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MH/[EJKG X=\XN(XR7UJ>G7J?[5<0= ^+J(C\)A,([B8P] W,/Q:T;6;9'O\
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MZ+ /'KEWD/)EQQ#7KM7<:'8YJH5BN\(;&\[+2<U1@KJQ2G8WV.DO,*S+()G
MJ2A#%#S0VV'4YY[XJP'',5E;_#7&1$V'OHK>3[N-C([GNCZK9[*;MIU<"#IJ
MH+P#ROR#DF5Q-EF;?'=C,V,MQ']I(]\EMVC3;=,?7;NZ-(IJKZRSR-MM'Y 0
M.(F3O%-6K\K7*W,)63)BEO:&G92;FW48O7*^^A6JD(E*(MVX'3*[43 QU"A\
M.M+Q?Q_B\UP:?E4S<G<WT5Q+&8K,0.[;(XVO$LK9")"PDT)8#0 K><I\@9;#
M<Z@XK [%VN/DMX9.]>=]O=?)(YAAB=&#&'@"HWD:D+X0O(Z[3O(ZZX8%WB.M
M,:W85X6 B;.K<FE]NK9*O-9;YUKYR-0K#U!)ZZ\M1,BHJ^6F80+OJN\\?X:R
MX!9\NV96XFN(!)+)"+=UM;DREFR77O-):*@ENVI&JHL_(&;O?(-YQ$NQ5M!;
MW!CB9,9VW-P!$U^^(T[+@'.H0#NH#0)#Y6Y0/,RSN&7$-@5[*P^.%+N\FH9W
M?1BX%](R L*K$3P.TP7$\P*2J@E1 3E23W#QU[=\8\;0\1AY<R;.,M9<@+=L
M<@MM\C6-W3/BVFE(ZM%7:5-%3:<G\F3<OGX@^+!/NHL>;ATD9N=D3GNVPQR[
MA6LE":-%:"J]F,<M\C+[+9OJ_P!SV%G4OC"9@JG$6&*E+@WI[^U/&J<C86TB
MH^04D5$*TP73!0J!0,=8W;N&PCJSR3BW ,':X;)?<9AMIDH9)Y(GL@,[86DM
MB+ TA@,S@:%V@:*^JN\:Y5Y"SEUFL8;?#NN\;-%!'*Q\XMW3. ?*'EP+R(6D
M5VBI=I56PUY?65M@FYWJ6I,-*Y.K]XN>.:K6JK(O'-6R'.U$JR[N=K\@\*1\
M2JLF3=55XL??R00.'=N(:V4GBC'2<VL\):WDT7&Y[*WNYIIF-$UK'/0-CE:W
MV]YSB&QM'U;@:+6Q^6<C%P>\S=U912\EM[VXM(887.,-U)!4NEB<[W"%K0YT
MCC].TBJDR)RMOM.PUA_+S&&Q:H:^5FKS<E2)NQR["V6:4L+F/;JU[&C-)$Z;
MURS*]%3S'1A*(  " >.O<!XQP>6Y=EN*3S9("QN9HV7$<4;H(61-<1+=N)JT
M.VTHS5>9[R?GL5P[$\NMX<8?OK:&1]O)+(V>5\KF@Q6C0"'%NZNYYIZ+?%NH
M=9NW641.W46;H+*-U! 5&YU4B*'04$OLBHB8PE-MTW#7$I&ADCF-(<T.(!'0
M@&E1\CU7<(W%\;7N!:YS02#U!(K0_,=%]=4JM-$31$#ZOAHBTNN_(O(^)<HI
M5W(U3I#RDS5,R-=XDU)F)=_<Z]"T%E[\D]M[9^W2C2LYT-D4U$-BIKJ 3<VP
MZZ]AN <>Y3QLW_'[J]9F8;NUMW_<1QMMY9+EVTM@+27[H_J(=J6@G1<>S7D'
MD7%>3#'\AM;)^&FM+NXC^V?(ZXBCM6[@Z<. 9MD^D%N@<0-51,><E\SVB2>U
M2;QK16UTLF&H_.6+F+"T2B,.[K+]TF@K"7%^\9JJLYR+1=)*J&;$,BKN)2[#
MUUFY_P =<1QENS)V>1O78>WR[L=>.="PR-F:TD20-:X!T;RUP >0YNA*P,!Y
M'YAD[E^+O,=8MS-QAV9*R:V9XC="YP!CG<YI+9&!S22P;7:@*Z*AR@D93BW7
MLZ3]98GNUF))14#0JZX<K)6"X(R<A&1L)$JN]W9D'!V(JK*F^Q(%.<=@#6MR
MWC>WMO)4_"K&Y>,/;%CY;F4 &* L:]\CPWVU =M:!U=0>JV>)\F3W7C"WYQ?
M6S#F;D/9%:Q$D2W >]C(V%WNH=NYQ/TM!/HL6LN8&5K31L7NJ3CRE.,AVC$%
MLS5=8R=F)=K6H:MU!^XCUX:#<M4U7SN:EG+4Y$#J[(IB&Y^@ZDLWBCC&,S62
MBS-_>-P-ME8,?;OCCC=-)+.T.$D@)#6QL!!<&^X] HU!Y:Y1E<'C)L+86;L]
M=8F?(7#)9'MACB@<YACC+:N=)(6D-)]HZE5NW<D<XIU+$F2Z#7L1R-2S5*T&
M%I=4GG=N"_K2-M,D6616,P3"%,G!)E76.H4>WR$MQZCK"Q7CWACLKE>.YRXR
ML>4P\5S)<31-@^U#8*["-WZE9#M:!UW.H%G9;R'S5F,Q7(\';XJ3$YB6VCMX
M)73_ '1?/3>#M_3I%[G$]-K:E?5ORYNA[S&NE*' +89F<RS>!(V69RCXU]6N
MT$P<'5F31JB01/W.OIEHHT1(!_> Z''H.VJ9/%>'&%DC;?3CET.(CR;XW,;]
ML+>1PI'O!W]UL;@]QIMZ@+V+RQF'YN.1UC >(2YB7&,>U[ON3<1-),FPC9VG
M2-+&BN[H2O3QNY87#->29"FS-6IS2/\ N;GK$H2J2\G(6''3F%LZ]=1JN3VS
M]%)LTL,J5 5DBM=R@ " [AUU;\A>+\5P[CL>7M+F[?<?<11#O,8V*Z$D(E,U
MF6DET3*[7%^JN^//*.7YCR*3$7EK:,MS;RR_HO>Z6U,<QB$-X' !LKZ;@&:+
M>W7%%VY-$31$T1-$6D]AY<P>-\_Y4QYD]Z$11:I7<<2$!+1E9F919F]MQW",
MB[M,G'(NFT9#). 2(1=<$DR";J(Z[%8^*[WD'!L9G^-L[N:NKB[9*Q\T; YL
M%"QL+'EI?(14EK=Q-.BXS?\ E>RX]SW*<?Y*_LX2TM[1\3V0R/+73U#W3/8'
M-9&'4 <Z@%>JRZIR5Q(,6_D&L^Y769WTV+B1X0\G\XK7M1D9\SBTV (>\J,G
M+0 7!V4/(%N/F=W;UU%&^/.4BYCMY8&M:^Q^\W=QFP6P=M<\NK0.#O;L/NW>
MVE5+7>1>*&VDGAN'.>R^^RV]M^XW);N:S;2I:YON#Q[=ONK1:_8)YA.+I1K!
ME3+-GPC5Z;",7Z[RO5&7L,KD"ON4+"X@V"%AB7)54Q4E#H@5!)N4RJJJA2E
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M:(GT POVX<?J/]F:(GT POVX<?J/]F:(GT POVX<?J/]F:(GT POVX<?J/\
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MI)HI'+ID3$[E-38B[$\2N:&;^0/I3RF?LM<FZE@VUU)201N?)-W2Z[[N>J,
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M/^1XQVC(:?*)T)<(\WZ)A5U92XWQRXE\EU&^Y$K%=-7[U8E8EC 03NMLIA=
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M >G9*M R58JYD,CNR3$+$R]5<23'(*:K:J[(F8 JFHF0I]A,&_F!VCJ*8?\
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M;#/1RM==D.U9/W $43.\.N<4! P  ZLY_P#I6Q^6SUYR>>]?9XR2\?*;9EN
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MK'MC<1C;,T;0L81<I-Y1JD6L4Z55),O)9JC52K(K.TA?)-73E,L@Y$@ 943
M1='&/%C#0\?"<9+-48JX8D6A?F*7J\RR1+%R[#WLKTK=PP:@BV1;I*ID!-),
M"ID(F4I0  VT18>=>F-P">T<F,7'%##1\<I23683HOW),BU8DHU=E?!(!#E
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MF\+",\8DOT]=G4] WV.8(263']ZQ\Y0BF$*V%8STRG>H)0 5-$67:3QZ]4:
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M;S1<IQ)3J&6V$04]D #8=8W^V?%CY\[''QO #]HN(8HZQ1D2B1K'N<[ITWD
M#X:E9!Y1Y6;;X*5W)<\?W>VFDDI-+^D8WO8T,U-:[-Q)KUTHMK^#7(#E^ZY'
M\$U;SR9SMD&&SK(Y$^D.B7%[*NZQ%1==<24/"ME4G;<6RRST&0.#+")5"J>
MAN(C!/*W$_'47$>66^)P>)L[K$"W,$\+6B5SI@U[S4&M&UVAHTIU4Z\2\O\
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M7?P\:ZA,<P[*?N$@]G'0LH]M#Q$A*0S9ZX7="!"D]X(8QC !=Q$ T1:CX_\
M6>X99&O6+*7$2UPBFN5,9RF46EUM,3$5JGTR)@YA>#F(7(3R6GFTC6+-'OT!
M(HV,U5*4VY!4 _LB19^J_J:< [JLT;U/EAARP*O9>-@&P1=F(Z*:<F$%W49$
M'4(AY:$D]9M%5B(G$J@H(J*;=A#& BIN6/4KXI8SP+-<AH.[+YHID5=8#&S&
M-PLU0N-CLU_L]D6J,)4JVS6=Q3&0E'EC;*M-Q<IH$53,!U"[#HBTLDO7WXG1
M]>CWPXLY#GN:UKR=4YK%ZU=QU'VRL.,1Q;.;M[^6E9+)C6A.&9HEX"\>1E,.
MG,B4A@02,(;:(M^(_F[4;;Q_J/('%.(LZY>C+TBBO6J'3*2R:7Q1%=".? O-
MM+?.UB!JR"47*).5#R+]L4B?<&XG*)=$7/EU^,&<.TJ[#3S#&W(V;<'@KU:;
MU7HNDU(TUB^MXYL1JE:):TG=WUI#2A4[&@NV:(0KR4<OP;G4;IJ$ !T1;#T_
MU=N/-XSK6L#06/<\GF;IBQ#+U*MSFAL$*9<:JJV!90*P[^Z(\S*O$'(&;F[&
M((F6(8"*&* FT196P7ZA- S7GVX<:7N)<TXERM3XF#LB\3DB'IAXZ3K%G93C
MZOSC"9HEWNL<BG)(UQV/NSI1N\1 $Q42("I-$6_VB)HB:(FB+F]R2]2W'W%>
M]PM:RA@CDFG1IW(]5Q&QS;$T:NN,7K9!NG>$!"M57URC[?*-5E4CD6>LXEPS
M;"7=10"COHBUZH/KJ\2<D6U[5*S0.13SWZK72Y8PFD<=1#V-S;!T*==5J>'&
MK2.MSR=5D1F&Q2MVTJSBSKMU"N"_6=S@17S4?6 P[D3C4TY/8\P+R7MM0,-C
M5FZXA5<?P]HJ+&GK/T+*_M*\]DF,J,<2.4C52D1+**N7!P[4TQ$!V(O"V]:#
MC0\GN.,*ACCD.DUY-0A)>FV:4QTPA*S N5*P]N"4!:Y&5LK0Z$Z,"P.L=)BF
M_32W*"AR[AHBL)WZ\_$)A;K37WE%SVWKT&.9VE>R*K3ZN6H9#F\""L7(D%3B
M!=ALAW;95JLFQ6?Q[%H_5;+E26'RC[$5EA^,)\34L+MLYOL49U9T^3LU?JD&
MD"N$W[R7D[.PBWT0/OL9F)[7(=(PS"**X2+]HHV7[R*% Q!#1%GS(7K*<:\7
MX/Q[FBV4?,A762+,G 0V)H.$I]HRDTBRN(II*7V2BZ[=I.OIX\@7$TV!Y*I2
M2J*8+%[0,)@*)%9@^N'QO>7/[D*[A[D994G-YE\40UJ9UK'L35Y_+D)42W-]
MC>+=6?)4%)!-!''*@5VNU1B??A!N+L#Z(J'(>NG@R#LUAH-DXW\HX')4%E"G
MX81H*\-B&1EYK)MUKXV>.JT=*0>7I.K-W$?"@"\@L\?M6[$AR>:<#& NB*FS
M/XP!P^C*]"6!ECW/\^+FJ6BZVV&C*S1$9C'\#2KL&.K5\^(RV18UK.S,1<OT
MF:-@EI5^IL)TTC$V$2+L]CR^0&3J; WNKG>'@K$T,[8_.+)>.?$!-=5JLB[8
MN2D7;+H.$#D,4P>)?BT17GHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+C'&
M^KY0*US7S9QBSNA2,04/&;EQ%US)DK/S"[FSS1%(T&\<YC4XE1I'F61>G,)O
M,$I03ZCUZ?2,W]/.7OO&F,YMQ0W61RUZW?+;,C8!%'1U7!Q>"ZA%*4KJOF:#
M^HW#V/D[*\&Y<+7&XFP>61W+I'DROJRC7-#"&U#B:UH*:E;/7?U.>%E4Q;<\
MHQ>=Z%:V52=R,$E$1DLNC(S5Q9QSB1:51BDNP\\'DD5N)4UQ3,W#?<3[:A&,
M\(>2[_.VV#GQ5W!+<,;)O<T%K(7.#3*XAU*-KJVH=Z44]R?G+QE88&YSL&5M
M;B*W>Z,,:XASYFM+A$T%M:NIHZFWUK1:Y\7_ %=:SR AY;(MPPK+X-P-7XZ8
M<3N;+GD.I/J[&2D49JD6$5A622%C6=OEW0)I&2;G*8W0-]3/G/\ 3U=\2FCQ
M.-RD65Y7,]@990V\S97-?4[P]U8P&@:@N!4)X'_459\PAER^2Q4F*XE"QY??
M37,3HFO80 PL $A+B:"C3KHM_JORYXTW/$5ASU6,S4F7Q#4@=_=/>6\@H2*@
M3,C$*X3E$UT$G[-8#*% J9T0.IW!V ;<-<DR'CWFV+Y##Q/(8VZBY%/3MP%O
MN?7IM():1\2#0>M%U_'^1.$93CLW+,?D[67CMO7NSAQVQTZ[P0'-/P!;4^@*
MTGY(^K=QPQ[A#(&1./F0\:YYOE&;5Z24H+:PR$:9S$3<DV8JOP<EC164(R(Y
M RA42J&3'8% +KIG#/Z?N99;D]GA^86=[B<3=ND:)S&UU'QM)VTW4U(H*D5]
M*KE_,_ZA^%8GC%WE^'7MCELM:B)Q@$CFU9(\-+J[:G;6I#:D?S45QXW]67B-
M)8EHMMR_F''F.,E6#';.\V7&;65D)A_ .'#!61/!(KECP(M)F03 $FZIDW!S
M&*'8&X:PLSX!\APYVYLN/XV\O,)%>F"*Y+6L;)1P;O(W:-J=7 %H^*V&*_J"
M\</P=M>\@R=G9YJ2S;/+;!SGNC);NV5#:%U.C20XU&FJT<RM^,$XE3B*2I@#
M':MHG;%;'\%.LLKS25&;UJ*;"@1G.NAB!L"HL94Z_<FJ82E3(F;O #=-=4X]
M_2+R!UY=1\PO/M[."W$C'6L9G,KS4F-N_MBK::_$D4-%R7D7]87'FV5K+PZS
M^XO)[DQO;=R" 1M%*2.+.Y[75T.E*&HKHNHE8]1?AI..PK;OD9B="\1U;3G+
M+ ,K&9TVCUF\4C)3+2.E#-4V4R>/ QP C<ZBYRDZ$[@$ X3?^'/)%I#]^S#9
M XJ2?MQ2.CH75=M87-J7,W::N :">J[S8>:/&=W+]B_-8\96.'?+&V0D-(8'
M/#7TVOVZZ-)<:=*JWOPJ/IZ>2"_^]9C#RQ2\T/TS,]XD[._8$OFCS!/M^9V[
MM^FV_369_P"1'EZH'[#?5)IT9\:?Y^E?7HL3_P _/#NW=^_V- /B^O2O396O
MRZ^BREB?G-Q&SI<6V/\ $N?*!>+F\BS3+.NQ$BX"1=1Z92G54;$>-6I%UT2'
M 5$2F%<@=3$  '6BS_BWR#Q?&NS&?Q-W:XQDG;=(]HVAWP-"2 ?1Q&T^A6^X
M]Y6\=<KR3</Q[+VEUDWQ[VQL<=Q;U--P%2 =6CW#U"VOU 5T%-$31$T12D^2
M'Y?\L=$4VB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)
MHB:(FB)HB:(FB)HB:(FB)HB:(I2_FOYX=$4VB)HBXE9/]-_E+4.:V0>8O"SD
MACC%TGFIDB?+U,R_BI]DR"EIB$BTX>!F:\$5;*B\B9GYH=.&1Q,NHS.@DW.=
M+S4A,J1:2YO] ?)>7L=9WA8C.T5CB^7C*EHRKCNQP$49VTAG.4:+C?'63:O8
M6SH 5EX>7K])=F6,!T?>%'Y0*1(R":I2+]%''[&LCB/%5;HDL]:2#^)&267<
M,2J%; ,E).I$J!/-]HPMBN03,;P,)1$.@Z(LSZ(FB)HB:(OSCXQ]!N!AQY5V
M7(-AJTKEG,T[F"SXGRA%$LYI#%$EDU%G @V90#V94K2AQK$.+=[()LT7KAM*
M*-^X"H@)B+24/Q>/EXE\Z32_(/"$M<FK; 9JX^=XVD5:R9Q@F9<VJ/2EJH\L
M*[610L+]RDS=E55*1(6YUDO85*D0BR;"?B]V<(Z;I-JEL\XSEK2C=LW7S(+N
M*H[VOP<C.Y3K<536"58A/G"15AHN&@8E)43*N7+MV\%05C@42"4BJ,%Z!N?H
MB0CW<9F/%538'X_.,%9(:UN)O));.T>PP@CCBI-\C>]V=Q46E3J]E8I2#1LQ
MC"229M@%Z*8F(!%:5V_%T,M61%N2#S#BB(&'QCQI@(=M-52T/X]6X\=V+U,C
MJ0-7[-6YTD%;I&8=**-FK]J9FCV%35,)0#1%ZK;^+Z\E%*%+4VAYUX\U6+O&
M YG"F0()IAB<E$2&>VF7M9;#1)2U7J;E:^[D)^SO7;HKMR^(J!"&[4W %,4B
MW0YG\#>0B'&#AA#XDKT9EG(?&6U2"5JJK,Z*"%DK%O86&NR3FM-Y-RS9QTW#
M,[0=V1R94@ +7RA$2'[BD6IV*/1"Y9R6*,>4'(6>\<1^(H;*,KR#+B=AC*5K
M%^5N0VR6R'5L?9 NIK58(I_5H2[RIG3E2/CVSA]Y"28G32[A$BKU9_%Y+13H
M/%>2(OD#*RW*6D\AK9E2S6">F[(?"=CI]_83#:]P$-B=!P=K5Y2>3?HMDG*3
MI4Z"#9,YQ5,7LT1;J^H)PWLV1O\ =2I& N.U58.H7)U9O69+U3JS6*O7:K$5
M<]<F4&S11FXB)=_*3=AJ;9@C[DV="PCSG55\L@% Q%VEJ<']S%5K-:]X]\^Y
MZOPT'[WY?E>]?-,<V8>\>5W'\OS_ '?N[=QVWVWT17!HB:(M!O4IXD6?FUQ<
MF,$5&R1%4F)&\X]M19>;:*O6)6M.LS2<=-O=DCIB=9TFW["B)B@&^^^X!HBX
MC9@_%W,@WK*F5K'4^05:K..\K8WN,4G3753<2OW!9&N5D9W.Q6:#<+O2INX^
MU3T.U^<&9TBI*J'5<"85%% .15^:]"+DM<L=9<<6KDQB2/SM=K)@6SU.T4K#
M:D-2*[*X&+++560=UU_8I23E7[IU;Y0)DRK[LE&X$;D!!(YA*1;@VCT?W*_I
M]8XXLT._PU.RYBK(=.RY5\B&K[:3A'%^ILRQED)"7A%P*1XVEY!B+UPD8QNQ
M9TX(F8 4[P(N<&0/Q;_--WKC%.2SY@VR6>6M^0+ID=O=,/SD[0+%9;A")P<;
M8:_5/NR;.H"6H\;$-$J^X5>.E&RKITHX*I]:[2+K%<N!_,N*]/\ H'#/!/+:
M)JMX$K>O96S[=ZS.S-KF:(#!-*8BH$M:L%=D8V:LX-O=G,@D\3<-TG!Q1-N'
M=HBYLY(] _DI<T:D>N9OX]XX<-,;M\'WR,IF*+,-2GL;LI0)EK-4Z#F;>Y=U
M&XH'<K( +EW)MG!C'67(9503Z(MAHSTE^8-.Y.XLSW2,V\<V]=PQB!O@RM4>
M8QM?'TK8:LY,Y7D;),6DEU09MIQ):0$@)$C10400$H%*8X'*19GX!^E?DOBO
MR?OO)6WW+"E=/?:]&Q4QBWCACF9QMCB5D$"V+WNU6&*F[+9W<M>WQY-L5U(%
M61143:$ J/<8QBD7<C1$T1-$31%POY8>GAS5Y/\ *KZ7K3G;!%DP!CTR[3!W
M'^TT"^H.J:K*Q8M9W(J5KKMZC8=;*;@CY=BU?OXE\1@R)^EP(9501(M0<$>A
M/R#P;=V-W-G'$N0W>)ZI:Z1Q\C)NG6.#CX6!ODR62LPY$<0DVC(6I=LF9-NR
M!F:+'W9H J'%93N*1>FN^B1RTA^'<OPWL^9>'V5*G*WB8MQ9J_\ ':X3<0R+
M:',Q(2"B-7>9046"PU]])*BQ>E>%3$BQ2BB44S&,15FY>BWR^G&G&2OP7)C#
MQJGQ@A$D89*_X^NEHM=TD)RCOJ7<$74W%7:!95M$[%\L+0"-W@$74(H8Q^PQ
M3D5J4+T%,]U/(=8M+KD!BF3JF*I;)ENPS2)?&;R9;0=SR789&P2+F^2*TR@G
M>*W$A99-NQCRM&1E2.#%=K*$ HZ(KWI_HO\ )ZHJ9CO+3)G#-3*.;YN.>VB"
M5XI,0P!!LBPQ8$5*GB4MF41C[!'MI!RNI(F="LLX:M0(4"E$=$5MV7\73A)3
MB=7<?QF9K? <CH.*B:<\NU'N=LQ_C.<HS7+BN2Y"+>8\BGSYCYH'=JD8$%7R
MF@)MB^T+<IA(O'*^@YG17)J5EB\ZXU;8SK.1+9G*DXY^XR7/-IYBMU(CX9RO
M.Y =S+I\\J#*=9B^*3W4TDH_V4%R")C)@17Y+>AK?Y#B2&*WN0,-W/D'-Y<E
M,F7C*^1J5:96+G9*6F)1^YG&"58M-4L\1-I?."(ME$Y'S46T>W;G46*!]R+6
MO('XM?D"3@,50=#SMBN*1Q_5'S-!Y8,62;V:JEYF;^GD.?RIC-6,M\=$5/*3
MN6<JHLY$[=VFQ:())@!A[C'(OU(8+QS)8DQ+1\<2]E=7&2J<.$:\LSXHE>3"
MWO+AP9XZ$?:4<'\_VSCL*A@$P@ CMHBRQHB:(FB)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB+\NW+#T?.4F9LZ\O<GU=QB?YES-(QLA0U)JR/6\FR(SDXMV[/(D+7
MW7S6JHT9*%W2.IW ( /0=?<G OZB.#<;XMQ["7@R N\;&]L^R,%IW-<!M_4&
MX5(Z@+X1Y]_3CSODG+>1YZS_ &XVF3E:^#?*0X;7L<=WZ9V&C3J":]%SRX_\
M#)[D3R>L.,L4S+BPX^H%!"QWV9DH*>AL>L\T1]1<5<:\U5D6#/WP@VA,01=>
M3[;8IC@0Q0Z]?Y=Y3MN&<&@S>?B$.8O;KMP,;)&^X=9.E$O<(8YVW]/JRNCJ
M"H7'.'>*KGFW/9\'Q^5T^'L;7N7#W1R,MVWS83%VP7M;N_5^EX;JVI (Z[X,
M_0@R.;APVK*@8\C.6<9DAQ,+SK>V3SBEV_'9EVZC:IS:XQY441;*I N02,@'
MO)L8X[AKELO]5F)/D7[PNO9/'QL@P1F*,30W%#65@W5-:T-7]#H NK0_TEY9
MGC<V;6V4?D/[TO=()I##-;U%(I#MH*'W"C.HU)6VG)'#63<8>EKRWC,E8?P'
MB^WS$' ))PO':.D5&$]'0;F CF4S9GKEJU6E;"N!#;B1NF5,H>)M]PYUQ#D6
M$SGG/ 383(Y:_P ='*_WY!S=S'/#W.9$T$AD8^;C5=&Y;QG.8#P1R&'-XW#X
M_)RQ,&S'-=MD;&6-:^5Q#2^0Z_R@ ?%<D,&>E%RGY1\?:7E*J-,(4R!?XC6J
M=0C5G,G"V>U*N+0NX>S=U6;P2I6\L3RC;G5%8QDP*4NP:^A>4^>^"\%Y==8&
M_?E+FY;DA-,ZC7QPAL5&L@J\5::C04H:DKYWXIX Y[SWB%IR"Q9B[6W.-[,
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M:VE_>,?4RXRD1\PO[/6XB<=1 .2NR,E))FDZ\M)R4I/.0.50#IF$I3=A@[@
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M:33&'ESNXQ(I%1,D1-!(AS&4$.X '?7W[9^'</Y#\+<<LL<ZPQO()H^YWW0
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MJ;IU3PUE?CI9+]3V&2<=9):Y"CS*R=:A;*@R?JL%J\A'2C9!^H11$#=Y>I!
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MV!C5:M=H6_\ S13I!O7F]BG:TN1_7FUJ\EDL:;K\=+HI.SQZ@@W<JHD!4#$
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M%XJ-MD/* 96">L(UM'I&232$@D40.10AA X#T$.<7/\ 4%S.7R /(5M':P9
MVS;>2%K7&":)M?;(USBXUK6H<"#T72[;^GGA<7CQWCJYDNI\?]RZXCF<6">&
M5U/=&6M#12E*%I!!(-53LA^G*\KW W.G%G#F0+C?+EE0@O4;5FRY/I8RDH:2
MCG )&<)ME6T+'(LV8E*FV;E QMA, CX7,7YBBO?*F+YUR"SM;/&6+J=FQA#
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M;X@\?B\D6''Z_77)UAL\_BVA\@;AE*8=XC+(RAV7G5Z6QT$CYZ[F(8HG.9R
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M\@XC"6O%<$S'#',MQ:1/<V8S-=VP.X9-P95I=H TD$=*4*U D<Y\@<R53CQ
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MR!$S,#=N,>)+1!V.73G['#S56:/HRPS#=JHQ82$XR6[D)5Q$M%!39"L4_N1
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MQL 1 P-B(C!!! )82:@D:D]5R_*^&?&F:O[S*9+%Q2W]^09WE\H,A!!!($@
M((!]H'1:J<</2GA\=9PR7F7-MKJF44IVDO,28WI=?J"M5@J7BU5I\SMXYPI\
MX+O7,S]SGZ247*H902B8_G")M@GG,_/-SF>+V/&^,07%CVKD7=Q-)*)9)KH'
M>7#VAH9W/>&TIT&W10#A7@&VPO*[[D_)Y[:^$ULZTMH8X3$R&U(V!I]Q+G]O
MV%U:TJ=QKINI$\&N*$+A1]QU8X5JHX8D9EQ87-%>FE)*."=<]OF2[9U(R#J3
M92)>T.Q5%<AT_P R(;CKFMQY0Y[<\F9S&7)S_P"Y8XQ&)V[6NV#HPAK0TM^(
M+2#ZKI\'BS@%OQA_#68R \:DD,A@=O>WN'J\.<XO#O@0X$>E%C#*WI]XCDN'
MV7.)^ 8*MX1B,EQRW;(LH]Y*(%G!>-'J<C-J.7BTO*%,+,$Q$ZYS))CL0-@V
MUO,+Y=Y$/(MAS_E\T^4NK.05#G-:=E""U@ #&]:Z- )ZK0YOP_QP^-\AX]X=
M#!B[6]C-"&N>-]00YY+B]_2FKB0.BP]QU](#B3BK"45CO)N+Z=E&]2%>;1&1
MK\=.P1ZUI71D1DQ]R3"9!>):$7*0OU@43K$3#S-PZ:DG,OZBO(6?Y,_+X2_N
M;'$Q3.?;6]8W"(%NW4[*/=2OU;@"=%&>%?TX>.^/<79A\W86U]EY(0RYN/U6
MF4AV[V^^K&@T'MVEP W+*"?I0>GNA+-)IOQFIC9^P=(O69FTC:T&[=PW%,4S
MILDK 5GL I (E$@E,.^X#N.M$_S]Y>DM39RYNY=;EI:06Q$D.Z^[M[O[=/1;
M]G]/GAV*[^]BP=LVX#@:A\P%6]/:)-O]FOJKAK?IE<%JA*P<W7>.]0C92MV=
M&X0KHCVQK"QL"!2D2=D2<S2R*B)2E /(.4S<0\2#K$OO.'E3)6\EK>YFXD@E
MM^RX;8Q6,_RU# :_\0.[YK+L/!?BC%W$=W8X:WCN(KCOM(=*:2#H:&0@C_A(
MV_)>F/\ 33X+1=GGKBRXW4!.P6,LR$D\.C*+HD//@J656C(]>24CH9RN"YP*
MHT21.CW#Y8DU3/YM\JW.-AQ,V;O#80%FQM6C_3IM#G!NYX%!H\N!]057#X-\
M3V^1FRT6#LQ?SAX>ZCR/U*[RUI<6L)J=6-:170A>A7TX>%:R&/6RN":\='%4
M7)PM (,M:-J[&3#MX^DFC8?GWN7(Z=2"QQ%85# )QV$.FK+?,ODMK[R096;?
M?R-?/[(OU', :TGV:4#0/;3HKY\,>,RRSC.*AV6$;F0#?+^FUY<YP'ZFM2XG
MW5.NBKU+X#\1L=V+&ELIF%H""L6'_G,<<RK:1L2CBM?/+APZD?=P<S*Z3GWA
M=VH;Z^57M[QVV#6+E/*_D',VU_:9/)2RV^3V?<M+8P)>V &5HP4H /II\UDX
MKQ'X[PEU87N+QD,-UC-_VS@Z0F+>274J\@U)/U5I71;@:YVNCIHB:(FB*4GR
M0_+_ )8Z(IM$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-
M$31$T1-$31$T1-$31$T1-$31$T12E_-?SPZ(IM$31%1U[%7VTC\SN9V';RP-
MCO!BUY-DE(^YII*KG=>Y*+E<^[$1;J'$_;V@4AAWV =B*D$R#0E$O/)=Z@=
M$@7%8EEAC) @/F[+>8#T2>4/DG]K?;V#?$.B*X8Z3C9=J1]$R#&48JF.5-Y'
M.T'K50R9A(H4CALHJB<R9RB!@ >@AL.B+W:(FB)HB:(FB((@ "(CL =1$>@
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M]G;Y]O&5,CWMD\AOG;)DA&S#:M5U^L8[F K\>TC631O'"W[&Q"'*<$VR8)E
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M3T6[KZ*34=G*BLR@Z4CDTVX_9!%0 )\.VN4RXW(P78Q\]O.R_) $;F.$A)Z
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MWH=UE7,J$8XD%7:AT630Q"[J*%*)%=E']%?G'44L39]?7IE-9<9<D,FSV1\
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M:(J>\B(F14*K(1D<^5(DH@11XR;.5"(*B JHE.LD<Q4E!* F* [#MUT15
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ME(E:5YH=*R;59>C9#JT%=:=8$"M9NL6:,:S$'+-B*IKD0?QSU-5LZ2*LD4P
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M93J6,F%6:,< /YW)4I$WFWU.BR-^]VJ#4[!1B:LA9NZ.E)QJ@HL9\U3-YHE
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MDE.RKARXM%SG4K-6;,A-7JS^]J%7ENQ%RF150J784_:!%F6L>CM@5CG=//\
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MUYHB?@4/7D_Y]=P_\G6+]>:(GX%#UY/^?7</_)UB_7FB)^!0]>3_ )]=P_\
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M,'Y ?0'H^Y4Y#TK%7'^YV:5:,F%IRA3'D35,B_.0N]I2!6>)D<235,H'137
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M,X2I61QR+PJ2 OTLS@J/,!DFIJ1]OF)%NH[CX^M.4Y4Z4VY?-DC*(E;"IYI
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M47Y+)56B22PK&3!RFB4O>(D#1$@.-_IGW!:Q6*LXZXQ697D_*/F<U+0ZE3F
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M,KM\>0^-RQ,G3\0V^+HE)G;Z\O5PK 2+FDRB;4&1$@5.DF4O: B&VB*O\9N
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MJK,M[-'.I&(2NK^DNG@IO2N_,#WE82GV5'N(M]:-BWU8[O7 ,\J_.[&S8B7
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MO[:1K(S#&0^2K0X#_P"74@DD#1='<P<9>86'>'$MQ[S!2<8<H<&T^HR%+Q%
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MC<UI/E_\SXYR3'U6@M,,5EBRXXY!KP-'4>VJ[2O24E!UR(BI,HI*L4F*2BA
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MFZ_NCA1JL9,3I]IA*80WT15YLW09MT&C5%-NU:HI-VS=$A4T4$$"%21123*
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M#ZOW<2WY'VQ^+1$#U9OQBP/#T-F7U/\ QQ+=/R/^\=$3\+-^,5_\C5ET\/\
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M/P,6&P[BHB FRJ[*&ZRFY>[>^!VB5/H<!V[!]H=@V 2* >I'^,S"4#!Z,.'
M[@+L!LJ.P$/,7.1/N ;V7;M(00.'38! P]H#U(IA]2+\9F$1 OHQX;#<#"43
M95>"'MN 12W_ /'1>I.HF#IN3V_9#1% ?4C_ !F;M,8/1BPWX+;!]*CPPALH
M5(@" 7L.XQ3B/Q=Q>H; &XD43>I%^,S!W[>C'AH0#SQ 2Y5>&Z)B"9=A"]^V
M/F]0V^60>G@)M$0WJ1?C,P=W_P &+#?LBMX96=FZ)$3*/;M>Q[OKI]R^/>4!
M N^W=HB&]2+\9F 1_P#@PX;V+YF_;E9V8!\MN!S@40O8[B8X^QMOW#[(;CU
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M_P!:KLO4X'5.)M[X()E,D  (C]C/T'J/;HB$]2+\9F,)0_ QX:W$&W4V57A
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M72#CJU;T96'.@L@:',HAY[M),YR[&W(N_&B)HB:(OBKYA2*G3)YBA2&%-/N
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M*;LOFCW+&#IHBRKQ+](GB7Q'5L+N!:7',4C9X^.A):2S])PF2G*U>KQ$4*?
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M!C"F'QZ[OS_SWR'F]GC<=#')C\?81L8^**XD++C9MVF1M&C3;T.[J5P3Q_X
MXYP:^R>3FDBR&1OY'O9++;QB2WW[]PC<2\Z[M:;>@6IE1]!V#AX]6C6/EKE*
M<PQ*9"0R79L5Q-3KU<86&RLO,*Q=.I?YPE7"9FZ!_+W\HX=HB)2E,/<$YO?Z
MIIYKDYBQX_8Q<G%G]M'=/FDD,<9^H!FU@UZ]1\ZC10+'_P!*-M!#^TWW(;Z;
MB[[P7,EHR&.-LDC=&DOWO.@TZ'3I0ZK9_-7HZ<2+]BNS8_Q14H[ ]@M;B&&5
MO]=:2=EE7#&*D DUV"T9-V L<9.1=E ZAB F)3![(;=-0_B_]2/D3#YZVRV?
MN7Y:RM6O[=O(6QL:Y[=NX.9'N]H.@-?FIKRK^FOQUFL#<XG 6S,3?73HR^XC
M#Y'D,<';2U\FWW$"I%%B?)GI&90S#@RK\>LB\Y;I8L<TZ<92]?C5,.TA@=@W
MBHI.*AH=)6+E61PCHI(#G2*(B/<H.XCK=87^H+!\>Y5<<QQ/%[>+,W,;FR.^
M\G=N+W[GO.YCO<[0'\%H,Y_3MG^2<5M^'YKE=S/AK:4/C:;.!NT-9L8RK7M]
MK!4C\2LR//26P%8\6+PUZ,UMG(!2E!3T.31X1S%7%N+*,&#@9D*NQL05I1_#
M0A2-B[EV5*7N-[0[ZT%M_4'RW'9P38K=!PW[KO.QG<#H75=O>SNNC[H:]]7=
M=.@T4DE_IXXC?8+L9?;<\R%KV6Y,L+911O;8_M"3M%S&4;TUI4ZK3+,?I1HX
M1PYA25JH9"Y/R6 XC(509XKKU9@(A_?VN6EY7WN3DG+N<.G&,*PK(%54*D*J
MBI4P[=A'71N.^>G<KY-DX+\V>"@R\MO,;J261[;<V@;1K0UE7.D#: F@!*YI
MR3^GYG%.,XRXQXO,]-AXKF)MI'%&QUP+LOJYQ,AV-B+JD#<2!\5@OBMZ&-BN
M?'ZN.<\STEA3)RF5BWQ:%:1L9<'XU"+8I,Z_5YLJLNDUCE"&%94Q"'4,3S.T
MY=PU*N<_U2V>+YC-_M2%F4P@QYMP\N?"WO/),DK/:2[T J!6E05%.!_TIW>5
MX9 >62OQ>=.0%P6!K9G"%C0(XG^\!IZG0FE:$:+IMFCTMVERS_7^2>"N0=SX
MQ9)BZHRJ,DOCVGU5[$RC!HQ)'JN"Q;@&+1!U(MR_IGSBN4U3 4W:!B[CQ'C?
MG:7'<0EX1RK$6V<PC[@S-%Q-*U[7$U W#<2&GZ:;2-16A7=.3>!HLER^'F_$
M\O<X+.LMA ]UO#$YKV 4)VG: 7#ZJAP)UI4+J-68I[!5V#A9*<D+-(143'Q[
MZQRQ&J<G.NVC5)!Q+/TV2+=FF[D%2"JH5(A2 8P@4 #7"KV>*ZO);F&)D$,D
MCG-C;4M8"20QI<2:-&@J2=-5WBQMY;6SBMII7SS1QM:Z1]-SR  7NV@"KCJ:
M #715S6*LI-$31$T12D^2'Y?\L=$4VB)HB:(N,WJLX+Y#9JS#Z9BW'E[9*C,
MT#EA8K-9\N0E"9Y$C<1P+G#ETB"6JS0,FJA$FBG;YX1B4SE0B?FN"^([!HBT
MMN7&"0],?D9P0R)3<5\JN6=5K\CS7OG(7(6'L2.\E7>:S%R'1K<HYL4I3J>5
MK&UB(G)E!5-LV0[4&R20!W&$!-HBV!X)<:^>=(I>=,O4AIBSBQ*<L.8]^Y(/
M\%9>J<G=)*@XHL[:'8PU?5:4ZP1$=5\BSJ,>H_E$>Y=)LY7\LP=Y3:(O!PYR
M1>..'-WU%<<Y*XL\LWT?R(Y=/\D8\RO5,"V6QX2E:@GBZNQJLD]R"BH$4Q2<
MR,,N@F0X'[U#$)ON;1%[/2 NEU/G[U'&%NXO\I,'P^;.5EFY 8RL&9<'S^-J
MC+T!]5:946;%&6DA*S;V89&%74". !/[J *;[#HBT RWP8S7BB^^J!R'P=@K
MD$I;O]_CB5E>I-:38,AN;#F/ M7#']MS0UQI N;&+"\*'E4GJ9D$TSK'*D9F
MF8$B@GHB\G(6E\O<X8<YW9 7Q?STQS#W?G1CS)^'<5,L>7ZP3]^QE%X0@&;2
MH7:@TBWP=[@<56"UHG+(?,+]%6*D@*9R ]B@:(J!8\4>IK9(?-LP^PQR:I-5
ME<.^FLIDK#]$O=NE;#.8SJ:$V')K%F$[;+2PR<ED0L8=H24(T<DF5R 9N98R
M_M"15B*XS<J[[ 5.N4'&/-/&7"RZ^J+@6;QIB:^V;)D#G/'?&YOCN<BLY2UU
M6>V.2R+1\63US4!1!M)R"ATDU.\HE Y!T1=%^*&/\UX X)>IWC2[H9;K-6QG
ME+F>AQG?9,F[/*6-'" 5!Y+T.2K-ML3UW89:MM7BZXQSPSE0Y2D]D_LZ(N"F
M!L=<P,M\2(>Z\7<8<\H67E?2AOD+R&ON0K7D67B.1><K,SK(X4=\?E)2S2Z%
MGLL2#9ZY3D()-G[JT4*@N J@81(M[N2_$O+.+W6/ZO8,+\]LXX5E.#T>TP9&
M8#O^5K):L<^H!8S+/[=?,UO(VXQ]@BW+YXM'F;2,HJM 1I6ZZ8-R!N71%BV[
M<'^=5$SMD_)\;C/-4US6S1Z2>.Z?5>2%*F;3,T6+Y74XLPSR]"VNQ-YM.J5B
MU6"D"FUA2N$ :+2A_/:E36.*HD7OXG8!YYP"/%.8;1/*YECM3GE3+#;<:VRA
MYCQ^MC:L1/'JZ0F0YV>;Y%O5QMDSCZV7M=DJLY=N BE94.]JD4I@V(L_< >*
M?*C"N5?2SS!,5[E,RM]^9\T:GS:#(=MR)8J[%5E*4G9?!Z%XJ]DE7T%40*[2
M;A"JI((*JD.!>XX#HBO/\8 K7-/),U2J%QFP/FZX-8O!F1KQ2<K8?3RM,KPF
M=(J78&KU:-'XZN53@ZO.A#-C.V4G8$Y)HY,(M4VQS"("1:W97XL<V;O'<Q>1
M;RL<NS<B*+D[TW[CQL3@;/D:)8OG+6GXT9\BW5<H$9*-ZQ8FA%QDT;$FLS62
M2,FIN4ABF$2*W\F<=.3MVY=UN4R=QOYG7?D%6/5RQEE5?.""ULF.*33A6PE'
M1Z$C6VK::-1&Z-.CCD*[12C2R,<[\Q5PMV' -$7;+U$WF<\<\G_3LY"8[QEG
M/,&)\7Y S96\WTG T9)6BP^[Y/QNVK] GY^E,7S-&;K439VH^>Z7[DHSS 6,
M)0W-HBX,6'#O/AEQK]/.RR.'>:][S/3,A9V>RG'.68Y0^X.1?6_DI+RE>FLL
MY)H]QA+!BVV4^CK)KPLK,^_UQ2-]CR3  !HBVBX>X)]1)'U:;+?,Z2&=*Q\T
MYHS39K/9E*=D2=P3DSCA/UA9IBW&[#)#BZCAYLVK"SAB=DRCX-*<0D62@KJ&
M*8XZ(LS>H-Q"EY#U3HKD;$\?,UY)C<E^G)R(PY!Y!QN%UL-5J7()NS=$I3'(
M$;%324178.;IAU6C4J[<T>^D5""9,[D .!%H-3N%/J$X$P5BFL\/ZOR/Q]DC
M*OHIS$-EM"QV2YO(6%Y752?QB6MU1NVM$HO XTRJ2DKST?%-&!&&Q"@7;N(!
M]$53XY<?.>T+7.+4M#1'+)KCIQS95L,YBVST+,F/9'%M58\5[U7[?)3[/(EY
MN-TE*%;LC.&"OGOW0QRDU[31,H&+L15^A<1<^8KXA^FE/9_Q!SJR[B>=ALF6
M#U$L-8ZMN7K'R+ELMJPIH? <G/U**M\3>?N'IPD<)*1L*Y:)(G40<.B*;=^B
M+*W'3@+R"MV=/1RR7RJQCFZ>FL3(<TW=@L%HNMV>3^'\9(2@VWB+3<RST%.M
MV 72/8.DFCHCDRJD@=+W-Z9P"0D B_6+HB:(FB)HBE+^:_GAT13:(FB)HB:(
MFB)HB:(FB)HB\P/69C=I7;8Q@'82@ND)@'<"[; ???N';\G1%Z=$7S3525#N
M2434#8#;IG*<-C;[#N41#8=AV_(T1?31$T10,8"@)C"!2@&XF,(  !\8B/0
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MYRX209MVJ1!55<KN53E12;IIE$QCF,!0*&XCMKUD4LL@AC:YTSC0- )))T
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MI,62*?05CYR\2)Z%D$C(R,1+Y.ITG&/T4%4U!1=L73E=L[2%4I3 0Q3%/MN
M" :(J0IZI?H]FKBU.4YE\,U*DI[X"M8-?Z&I7E 5,=9V3YG\PT<=-P9P81*"
M8E5[C  #UT16P7U%O1)29#&)\H.!Z4:5R+L(U"QXQ3CRO$FJR(.TV22)6H.B
MM72A"*E+WB!S%*.^X:(L:8VY?>@]B<]U/3N4W#9$<C2?SW?2R^4ZO84[=/\
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9X-M_[<9?WE_?7V9C_>/_ .T_]7_KVB+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g38965st27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g38965st27.jpg
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M P,# P,#_\  $0@ ) -P P$1  (1 0,1 ?_$ +$  0 !!0 # 0$
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MX_)OT\.&@>&-Y5''X1R'X]']4U[/5#CP#XJX[;^G<>&@>&-Y5'#X1R'X=/\
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M4^Y@$LNPKYA.5L(O/)G.5ST,5FG"UNF%Q6!\9TLB45##D;XV'BD2- IS?KU
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M1$JP$:MVZ8Z(DT#E[RO=UDFM MEKM]IW&/H'9&J+IE8$%ETG"EZI(B&XAO4
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M6)#'4K>BND0*96B99I65297[6BI0C]I73U]MAU5)\X]2>/\ D5<&QXK!RO\
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M=6I0UH-Z +#J"-([B/&_&O??C/*>&[SBN2Y6?'/*K[Z;UW6SV,=F3%6?]?\
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MMU>=;7O:;6M/ZS:TS,S_ %EFVVUVVRP5VNSQX\.UI&E:4K%:UC]*UK$1$?\
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M3= \PMWW':;H'F%N^X[3= \PMWW':;H'F%N^X[3= \PMWW':;H'F%N^X[3=
M\PMWW':;H'F%N^X[3= \PMWW':;H'F%N^X[3= \PMWW':;H'F%N^X[3= \PM
MWW':;H'F%N^X[3= \PMWW':;H'F%N^X[3= \PMWW':;H'F%N^X[3= \PMWW'
M:;H'F%N^X[3= \PMWW':;H'F%N^X[3= \PMWW':;H'F%N^X[3= \PMWW':;H
M'F%N^X[3= \PMWW':;H'F%N^X[3= \PMWW':;H'F%N^X[3= \PMWW':;H'F%
MN^X[3= \PMWW':;H'F%N^X[3= \PMWW':;H'F%N^X[3= \PMWW':;H'F%N^X
M[3= \PMWW':;H'F%N^X[3= \PMWW':;H'F%N^X[3= \PMWW':;H'F%N^X[3=
M \PMWW':;H'F%N^X[3= \PMWW':;H'F%N^X[3= \PMWW':;H'F%N^X[3= \P
MMWW':;H'F%N^X[3= \PMWW':;H'F%N^X[3= \PMWW':;H'F%N^X[3= \PMWW
M':;H'F%N^X[3= \PMWW':;H'F%N^X[3= \PMWW':;H'F%N^X[3= \PMWW':;
MH'F%N^X[3= \PMWW':;H'F%N^X[3= \PMWW':;H'F%N^X[3= \PMWW':;H'F
M%N^X[3= \PMWW':;H'F%N^X[3= \PMWW':;H)&L]_P!_#^;EKOMK_P!Z#[&?
GS#AOVN^T/\Q?J#[,?:!O^OOKSWS_ '3ZG^J_:^]>U]3V'6WT'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g713200g00i34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g00i34.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1WB4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             !
M[0   [X          0                         !              .^
M   ![0                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   ![0    !29VAT;&]N9P   [X    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   >T     4F=H=&QO
M;F<   .^     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    $.$))300,     !-3     0   *    !2   !X   F<   !,W !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !2 * # 2(
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MS)NW;<F_?B_^:ZEG[1R=]%VQ)3O=%MR3;U.B^]^2,;,].I]@8'!CJ,;)]/\
M05TLVLLR+-GL^@M-<2/K7=TKZQ9/2[<-K[^HYH+&MN$G]!B5;:#8RNM[O28R
MS],_'_2V_9_\'ZBV+?K)F8N?97G=,OQ\!K6[,LEA&\]KG!_V:JMWT&O^T_\
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M)Z))0JM9=4RVLRRQH>T^3AN:IIJPBC14DD@9V0<;#NO;JZMCG,'BZ/8W^T]
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M?SUGT.?I4_SW_=G_ +D?R_LZ^:$DE/TH[\W_ )/_ )[*Y^%OT?\ NS_Y8_\
M7U8;_3:OZ+_A./Y[Z3_YK_W8_P"$]5?,:22'Z3Q_H4?\G_S3_P";XX=_,?\
M ?Z5'POHXW]$^A7_ #''\V?Z-_P7^A_[K+YE224_1G0_^1\+^A?S+?YOZ'%'
M]'_[K_Z'_@/L2L8/_+F5_1_Z+1_-?SG\]F\_\#_[L>NOFM))3]5)+Y5224_5
M22^54DE/U4DOE5))3__9 #A"24T$(0      50    $!    #P!! &0 ;P!B
M &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '  ( !# %, -@    $ .$))300B      %&34T *@    @
M" $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H  ,    !
M  (   $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I  0
M   !    O    .@ +<;    G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD ,C Q.3HP-SHR,2 Q.3HU-CHP, !R<C4P.3$V-P
M Z !  ,    !__\  * "  0    !   #OJ #  0    !   ![0         &
M 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P    $
M @   @$ !     $   %& @( !     $              $@    !    2
M  $X0DE- _T       @          /_A 4A-30 J    "  ( 1(  P    $
M     1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$  @
M !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $   "\
MZ    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*0 R,#$Y.C W.C(Q(#$Y.C4V.C P ')R-3 Y,38W       #H $  P    '_
M_P  H ( !     $   .^H , !     $   'M          8! P #     0 &
M   !&@ %     0   38!&P %     0   3X!*  #     0 "   " 0 $
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M3Q$\14 _*;U?\RM/4!.#O)O&,2:%QU@LPXRR*ZL/?INR4J^V>ED490/Y[S3
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M=H*[&0,3^+%))Y2#D/XFI^1^D(^DM_ Y'/5& "?:N^H5R_8LZ$?M31S:$4V
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M'19RLM*N;0VBP.)C+R'*U?R?+DHVZU7D-73F"Y+JZ4T<D5>.Q*<D89Y4H2G
M7:...*!W8(A$=50(/J+KM6FA]^9I0,ZIPB0-! +]FXLW;RM(["[]N[D77R[O
M)3M3B^+=N0,)6T[GTJB,1%%%C3L=&8Y6!E0J5QH@D,):DY[!)<8CI$,C@BU:
M/H@2C[ATQ-EF!7<@T7311CO#N86>&7IM&E0JV[4L30C)9L:4+11.Y/+'[=&]
M4BL1S/[9$%N.P(R0Q21-&8N[Y%ZD%Z)HI#(08O)V$(2=W_9^Y8Y'!V^>G!Q?
MHG9W=GZ4>H93=L?'+&6.:Y.3_IGEUOL_<V+618;'%K2J+#X@](D)S2(>'@HZ
M%-P)FV7UTD%("P;=XU_$M(8(LL[<DH\]WUW6R?4*Q(VC!0X[R0Q *&C').V7
MK,$81A1VI;D]B:*\;L_L;,LQ@;.->\S",4X]$4,V8PO <MBL+]G'T+30/Y>7
MNUFB &<!^[P"+.W7E$[OV#P+HJ 46*^7F&2.H;:%&(!:M3R/HFND8(B.9 U7
MLS_K\ ^JURD/<II,F8MK'9')_P!%0<R>MD6K( ^$M7C5P^V\W6O2'1X5S?-Y
M/<.7/I:VUR;-ARVJ/4.KJT,JA=*E([$T$U.Y6TKMFF=<?%QS)!=B$@F?]!+_
M .(^;U._"IR;@<V(.AR'A=+@539V[^A)HG=P)]R2I!R>NTL16@U*FAG8V5H?
M4V#_ (VV%R.9V8JH^D;UB+P>GB)XB>(GB)XB>(GB*(\HSO->T*OCWV_E$TE3
M<UM%_P#37"B:,OM PUKB%[*YSC.$7"<8!6EAOG&=5-D7B_\ ;.FWUQ%+/=WF
M&9!]XL7(NZ<C??JWIS#G4G?^A-5@U&'[/U(7W;[71D=8/H3R[3[\;G/N<X/$
M:_;N)'B\1HR\IW6!F_YD9Z^AQ#W.^Q8X(^NB%V>49P$$DX4O&Y*'%R".R 8^
M"G@)M@U*AC0<HU59$A188^279$1I!FNLT?,7:"S9TV5407242WVUS*U2Z\='
M%_.G:?.7_P 1C8]60DJU&\P0ZD3)!$ >EJ<P8!^&SQN4.Z1KV(;'GY27#%HA
M<[M,4"!ZN6ZL89AR[5'/]#;#6I B]EGB)XB>(M;VM;]:4=#W<^MB8B81$6;E
MLR5,%]U\Z*OGF=_U6#)FS0=$"3]?5)91)D/:.G6R*#A?"/X6ZRFFOU-;.Q:A
MWM2W#2J 0@\TSOTYGWX@ BQ')(3,3L$8D3B)%UT+NTIX=PGE?J!N0\;X;AW=
M_:GBEG"C2&-B&O P^]8GFGDAK5:\;F G8LS0PM))''Y^Y)&)9!"YK$[%BH.<
M08^,E,2DK'0D#/AW&KH>19[[;I_D15U^F==TEDU6[E!75-PT=(K-7*2+A%5+
M3OIW*NA5ANTIX[-6P#20SPDQQR _;=L[?NSLXD+]$!,0DS$+LVLWL'9XQL:'
M'^0YMO(VLJP570SKT3PV:LXLQ>,@/\.)@02Q2 Y130G'-$9Q2 98Q<MN1&BZ
MYD%G3?\ EE0@)0*P0&1X6L;DTDD<J/BXE#8?%@K?;14O*9E+C@.+1L9JHCH]
M-%V*"SALCNHX2R5J5I:-]>Q=H$G!GH: S;CQ" HQ5\5>]%%:R%1(B)F[XH+C
M#P!9D#L&>5B5)/2H=X*?1%*8:34*_4%ZE(ZV:R"/.RI%WY/M+D +B*;&.HN?
MQ2<Z BY3"UB-NP-FWE4:-.S@\3( #AP=30*!2!&-'QK4FS459*D1#]AA;]QO
MNC@BXXCMSCF0%H8!"=3<_%3=BJ,48&(86Y!7)*8+$Y&<AP]".,DC>S@NN\E\
M:/Q1NBR3655DPA\!UUR50W:8(N7OV9R.FO8#;?INAM5ZI_#FRTLVM",;0/1>
M3LX3HK*\?S7_ +&CK,B#&)++D/P(MY*\; G&Z1-;1KL1=!->[N/H$TD6YOHR
MGE3$;K8E;3F(#+$B#V:/X.-@>]G9*B(U_,ID7^7\"U3E8Q'5/39Z <-C*><"
MEM7GB+[P_N7D.;-6&P?HVF-"SNM$;==Q=W9D*3E 2 [1!O/7A\X%3.+.A[(1
M#W*<C+KJ8R@Q!_\ O*JO\5MH\V(M[06S*\L^+#)Q7$VB\[AAO+_ :5Q(V/D$
M=+?Q9)X&([#3 M=RP?:,RH]\/7W;+JZ)NVBZ.=OO3VQ@B\^'S-'.AW]W1$2Q
M!U;'^::HJ^NK0D5HV3P,-[7U%/9K;YVL[-D03!EJ13!NZ?:*4Y(BL-C+-.6R
M&*3"0RM'=T.A:Z"9%<OPE.;'LWC/F"PK?9&!]H3*D:\D4\:'8NPA)-*3E(XQ
M=%=E8B,'!V4<;K.5-UF =(0+V8CU&J"XUBXU5:I$56?S=]&7A36]7 :0M.90
M,KF@.Q;F>CH;.(Q52VA:FH7"2$/L8W+YBS=BK CM<ECCER6YZ%YU.6FF935U
M278Q]?74BC_5G;/14F[D#E0=T3.U)%)^G+:HU'C!-]$8/%BO.<0^/2.=&5I:
M@^#R,>WD%>RF=W"X'J;65*#^H9)"99ASY=(<-_61(K$N&9O9]@=Q?(0?MRDB
ME RW-?\ $K/: F)W"+%=ZCFX;H/],O\ U%7Y F RF1^]3[&6'/[C;\.?V--?
MOT^I%;5XB>(L6FH,Y)8L9!QJ:&:[.D6NJ(V:QX;&#!F/KZKI*Y>,1DS!R2,/
M%-TT]VVZ1<&0;_A74VT2T<:HK)9-.:&O9AGL4X="",G>2G8DLQ0SCXNW@<E.
M>M9!F=V)GBGC+L69W<7=G^3$B A$RC)VZ8Q8'(7_ *LQB8/_ /<+M_DM <P\
MV'.; A2+;7O8EJQ)V4E)\7'9K'*J$MP$AG,WD5A3(RR(P6!14X\6/2>4%WFS
M(L4?BAB3C#,.P8-$6R*.]Y)R*'D4T5G\CS\NT$56"2Q2L:DI3UZ-*OGTX3CO
M7[4(#!6K0AYQ1A+(X^<IF1$[X]6L]47#WY9@<C)AD&%O$I)"E,F>.,'?R,R?
MIW=F^S,S+8UA\\4#;AAI(;5I"H[+/L!Z(AB<GU<Q"7EV8INY=O4!C4E( Y!X
M@/0>$'[M%DDMJV3<O7:^B>JKE;;?7T-_=RHCKY>SJYT$DCS'#1T+=2(Y7$ >
M4HX)HP*1PC 7-Q<G$ %WZ$6;LDKUYG8I8(929F9BDB W9F=W9F<A=V9G=W9O
MZN_]5L\($#1H.*CT=$C ( &/9B @,*Q:BQ <4.;IM& P6-9)(,V ]BU22;-&
M;5%)NV033113T3TUUQK9IIK$LMBQ+)//-(<LTTQE++++(3D<DLAN1R2&3N1F
M3N1$[N[N[KM9F%F$681%F819F9F9FZ9F9OAF9OAF;X9EV?NM<IXB>(O);=/.
MJ/*/S"26VXW.U=]%*\?]N,HNUCJ#/9V$6M!<1:M7_LMGZ:.B#2$![%F \PW8
MYW5'CFP9R.RI^T7]:?J/NR;OX?<W7+/<K/ .78?<[3N;M6RZGMW;S,4;GW8Q
MM2S1DA]QOXLSS,;AU ]A^@D,<GJG?X9/.(4O57A_(N#EYCT$>GLQ#;XR3_/B
M3U^7Y6%8%W;OQ A;I_U+UF-W"#MN@[:JZ+MG2*3ANNEMC=-9!;351)5/;']M
MM%$]M=]-L?VSKG&<?[?56)"8B0NSB3,0NWV<7;MG;_)V?M5_+%)#))#*!1RQ
M&<4L9MT021DXF!,_RQ"3.+L_V=G9?;W*^$\1/$3Q$\1/$3Q%$?F[&978_4UO
M[YPHVE%OHUE&E]=OR)J12BX^SABWX-_KG_Y.;%<V.KG7'TU_.HMMKCZ;?=M%
M>/?WK0Y-K/\ (V=9LVL_W;Z7$@"F3,_]/S$M$OCX[)_W[5T>J3_D_%O2'A+?
MIER.$GRS5C=O$QV/4+2GW0]T>F_B-QB'BP=OV7M@#._;>(RX]*E2ZI;@?_V@
M#H'_ /:[I3__ $7-_$5TGB)XB>(H$WQ\;?+%\ # U_"<020F3^TF<3J![-Q\
MHV+JK.UWJCA4FV+#WC4DH^<[OVKAAMA53;19'=!=%)72#;OIWQC=KRQR4_HK
M$L_U+WJ+C':]UW,C=WE&6,QD<S]P"C=G=_(7$A$F]&>G7XIO5_TZTJ-JMO\
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MSG,;>I'IT?2=:L^A"P36.D[B;Q,2E/WHC5@T$?KN)#JVP]46V#,&(11]G?\
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M6VT20;H(Z;JK+*[ZII)Z;;[[:ZZYS@BJ=LCY%N'.CN4[JR.,6=;=363:T\X
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6)XB>(GB)XB>(GB)XB>(GB)XB>(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g713200g01c14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g01c14.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1=.4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/T
M   2 #4    ! "T    &       !.$))30/W       <  #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             #*@
M!RH          0                         !              <J   #
M*@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #
M*@    !29VAT;&]N9P  !RH    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   RH     4F=H=&QO;F<
M  <J     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MNM:'OV.+ZZJX+W$?SK_6_P# %KJ+&-8"&\$EVI)U<=SN?Y124X_[0^L#F/\
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M300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
M;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
M     0 X0DE-!"(      49-30 J    "  ( 1(  P    $  0   1H !0
M  $   !N 1L !0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(
M @   !0   "< 3L  @    D   "PAVD !     $   "\    Z  MQL   "<0
M "W&P   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C W
M.C(Q(#(P.C P.C(T ')R-3 Y,38W       #H $  P    '__P  H ( !
M  $   <JH , !     $   ,J          8! P #     0 &   !&@ %
M 0   38!&P %     0   3X!*  #     0 "   " 0 $     0   48" @ $
M     0              2     $   !(     3A"24T#_0      "
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M     0   RH         !@$#  ,    !  8   $:  4    !   !-@$;  4
M   !   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
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M05%8=YBXUB0G56%Q@9&A\"4F,D=26=@I-6F'L?_$ !0! 0
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M6L:/2AZ]?F9(1Y5:)E=,FP728# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MQ(\J$)\B#+S\FMOD-O8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MUM7@<4=]MG7*(6*8# 8# 8# 8# 8# 8&C?2EUL//%(6!;;L6ZD1"."D&</B
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M7C49FT:/'T(T1:B7H^0+!Q9-T12"/F9X&[9E>V_+%RV,BET5^TB#3I8-D8#
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MUF[2201.3QTL2AU=U''5FR"":,DMN9P@822018A5RK_\J/5#K>F/R$W)O?!
MO2_C&$OT^/N3BO*WI/T,DU[^S?>DCLC%1*B(!(.-;4X[YZB'H &AWKGI%T^U
MO[^0[8!\?7GC983*[B9S+U7/@KK@@.FGJ>7/KA_2BB7?WI%8K7A5)G3->OTN
M_P"Z17K>M(A^%U_=<Z^_?7>PVUZ;].T7XRI"87W?\U$U[5\!%[</7KC[>GA!
MS]OX0J,18*CO3L[)#3G\(<# C$E'+MRIQSKE)NFLND&B?C<]EE_>?G+OT6_K
M\W6P>16),Q4(CQZ,F8X]4@HE0?\ LX2VX.D%GLI4=(.E4R4H0!Q(0[-MR@T
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M#A(:-];^(?1-^^B)%8\6YIP96[6'U^ ' 2-G6.#.71R/G<%EDYBMW(M*RE+
M5 $!L0T*KZ-Q!^0$-"SZ3RF5!C1&:*)1H(P;^*SVIJ.+AW?H:&GSG3IO^?F1
M*>66T+R^6\MO4"4<]$'DT8:\Z:6M32-RU$)@,<Y>EAYMC1<<<.9K$^Q\69Q\
M+%?/ >R ONSV.A9LXC,]*N//OC%X"(Q> NZ];"HJM8OM_D2 (CGDWG71DP/4
M3>J/9*B^#MR?+I%-*.C?RO7;D+#L!@,!@,!@,#6]OVQ":,K.9VW8I)47#H*%
M6,F%VK58@2=;THFU'!@8IMKIX:D<@*N6(&- 6":I$Z?)#A ]%9Z]02["$E>G
M!7G>,3#V/[&?:C%\^@WH$ Q@#36YA*(1$T7A1>EO)%0Q^-MGA>=3-EP4>EY6
M/B30L\F]NR&9FV??459Q]$,';?L?ZQ]--M&;DECSQK0[CE,KJHJKDO'/I60
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M$?AUF^0*/B#6SVDF V'+2DJ0"5BQDY^502:5U^O2@P]VX%<B&C$>D%_& P&
MP& P& P&!^;WKG6^NMZUK6M[WO>_IK6M?OWO>]_NUK6OW[WO^3 KR,3B<^W"
MY6!TA))16WE4.2) [(]+Q,@R%2J[WPM?L::K/S.8XZ>OQ$1:DDGX2QO02#1@
MXX69/(Q2#YT=5?V/!0G%!8+#:QAT;KZO8R&AL)B AF!C$7C[%$:&""&"6D6K
M%BS;\\II))\<_7KKZ;465Z[66[46444Z"&]T364^C;'.>2*3D92-1Z-<C.O6
M]VQ=_P!LBE=Q\TR3*#:*K@Z/?H/!E[62&7:OS)EJDJK4=7D]2E14?,9=6O:P
M;<M>Q:P\7^?V"X.()-X_#1D;K*EZ;@Z#!@3F,I<(I1ZM:C@ UPLU9<$##E%J
M/;*.%D!@(0V(R0^\8  Q8DU"*_B.RJY[E\N!,90OZ-]*6H>>3+U;>%/!BDF\
M_5Q* XERC&:?8VV05;1)*,UB+X:UO *YBI603SE;M]/IO$PK^6S"1;"T# 8'
MSFV<:N"K/F8&OGL8L'FG;PN"EHT)EHV]3\1A.CC>A6#+H88IV"^H(J&FNUG$
M7)\Z,VIYWE)!9SRV"I%B81K#6K +FO1]S3FG$:_=PZ+0Z8;E4N'1?N-F)46#
MS>5E"9,4V9Q6L0(N-FTC4@4#+R25$RQM^&C,3 Q%^4D[MA'5"LDC80E;?(A;
M(]H33E]+QV.2N*5I)_1D\@I@M* )T#0$:=05KQ^A/7 ,B&F%A23<R(\QS3%X
MPC"Q*%&PQ1V+7?,'288I=WO ?*?(WIC^$Z$FHLVL/R$5L>J?X.(E:MR.^X5>
M,#N\9"QUF-X'7A?J 287_!L_=2PL5_ @(OLNU8<2=14<Z<+A;!57^"^M_P#,
M*'_ZO#L#,U&+)5VV(*LVJC]FBY;M'JC=+MVU;O=M^GB#9SUQM9!%WTT:].4D
MN^>%]MF^U>>]HI_:'N52272407336163[2615XY42524YWPHFHGWK?':??&]
M\]\=:WSUSO?/6MZWO6!T)F(1.1H#VTAB\=/-A*W#@4W,A!I1 8NGQI--<>D^
M;+ILEDT^>>.%&W*??/'.N>>M<ZUK _.(=$4Y O+$XK'$Y2Z0_+.9+P#&<2!P
MV_ 3:_EUS/+71%9#\JBBV_"4<])_@))H_;^'QSSH.W_3A_Y-N/\ R#/\@UTS
MTU8_E4/R;;0Y1%8?INV^S\%'3%5NW59_A\<_EE$$>T/LZ2XWR'$3  4>#":(
M00DG(55ESZ:8UGQP<7<MN&;A8QSRCKDFJNS33:K*/=+]JMN.$.]])<\\Z#6%
MN^?*CO0$VC=F150P):%7!E-(/(I3"W:KUXS68/\ 3PK"#<<*D&))JM^&3%/G
MK@61[09.'K-=R/8+-@S W7$&D,7)0PI&1?4;+ E8V[8,4>A'? 93E?7+4>_$
M=L20E1JHY7=#G@IXR?"W_?Z@.<M7W/#CD.NJNI8!2L10@U; U 4<0?D2O2#H
MP<D1)X3*N-N7Y I(),2,2 N]7[WPEIR4)NU4&:#0>WZ28LVC=$-@KMF[KGCA
MRW1<\)K(.4^%TDUN>'#5;APU<<<J<]:Y6;.$TUT%>=:4163X53ZY[YYZT&+/
MJ^@)1OVT)PB($6JAA>0J-GT:"NV_<@=<_:Z.=HN&2B?1ASSO?*Y/?.WJW/[E
M%^M8'>\!A"910XF*&IFEF*0Q8QPQ:\E%1J"O;A >H0Y2T[[8HKJ*+)-.EMMT
MU>^U.$]=];ZV'I1CT?;HEVZ ,.@WD#AT[/((C&2:)MT^1Y;O7)=+A#G@DX=M
M^.$'2SWE91PCSRDKUWQSKG0:WM>AJJNR/HQBQ(TL1%-RJAI+]"D<I@Y/D@NF
MJD[4Z.P4U&SBC=_PMULBQ4(]L2*J;9=ZV779M%4 R K5==F80XKAW$A*,,<1
MC4-Y"BDE ?+"-<)<)-AH9\$4'DP6A^TD7 IV%>L'PE\W;$1CEH_;-W*8>%6U
M3 Z7A[.!UP$[ QED\*$4VK@N;D#]P1,OUR9,@2/24D8/%GKMXX4[[=%";M;A
M+2+1+M-HV;H)!L/ 8# 8# II^;'T)Z>IGSM5\6\55&*OWTW9%^5H3BU5+")#
M*#7<-IDZUN22SEM%8P0$/WD=CTGAT C<I+OC H0*:S=FW4>\%B@?CH)K^4:!
M(P&/L[AN7IQ*_6EKQ"-.[NG9Y<>4?1Y^NR;F'M,UTJQ2Y'Q&F*_D#LBRB<0C
MV_R+Q=->5R-])IB8,R8D$O\  8# 8# I+X@(5K\OC,V*L8E!VX8:OWNI4O/E
MGI!9TZ-TV[?KOPML1Q%Q0K41V4-'9*<D,K2$W"[F8PG$'2SV+*0=? NTP&!#
M"N_Y_P#ZO_HM>'O]I/NG F?@,!@,!@,#3UTW]3WGB,-I;<<Z$PP62(I!0#1=
M-^6DLOD#A-15K&(-#0#,K+IU*7J:*O;&,Q (:.O.$E>FP]7E/O?(546/Z'F%
M\7O6S9U2<F($J_Y_A$\]^,#4EC["U9Q9:3U!K&O3OK)G'WLGC_FRB*G8.=D:
M_%622<SLG.3'ZGS7W=JQ6#0CH,/FWK;SSY3F)FV[EFSSW![F:N]P/L=40]-6
ML//KZ6<(=<T?5*S]RZB=8N"?Y9OLG&D"4]]?7/QPBON)SMFSC<1CX</]KKXO
MQNG.?=_COV)+8'KG@R-\M5^P\Z1/RZ*'M5>B8U[;/4_])PZS[_,(-N>%B@^W
M@D&K%/\ ";[=>?0L@%=EE [J=_.[YOJS3J#1OS'Z<G<]!-&XD)3E*H>7K6EW
M!#?/#$#'5(=2OI.P9!'&ZR_Y=GQVM'-(CFOU7_*](H?9L*=)!:'RX_*SZ.[K
M">>;2M/UI&"P<QUY\7LT+$(33H[\1(O'I?ZAEK(%81AQ/_[I)5G6AV$#+3=)
M<@IM4$-JA5B3LEN%P7F/X-8A54Q?VG<?H^SYQ.S.B.G(&D44?.,&"-#7*7)@
M8"EL8?'/2RS@PFB@VELR(^@>IM92+9KNR#$G_+-4VP3Y3^,OP2FGQQWY>K-W
MWSSSSVZ),R90@YZUK6NG#XF2)NB!!XMOZJ.7KYTX>.ENNUW*ZJRG:G02>J>F
MJLHJ)Z@U/P6/5[$=$GAC8&-,M,F'94AI'EZ05X^[OM5TXX;-DU%E>^^_PFZ"
M6MZ323YY#9F! _Y)ZX>VYY&G]=,XO;DP2E16&C28>CV,2-6)R*[E0OMZ3%QF
M=NQL2E3,/QQR3+ #)<-RY'-5W \HU+M!^^@WEY8C'$,\[U#%4VUDL^0<,&L/
MR=O,PHRQVO26U=]MY0)CCPA'PSI#OKI-F%"/%Q(89RQ%C^M-6B7/(;^P(4_(
M/_-C(?\ 7=Y'_P"]Q1V!-; 8# 8# 8# 8$?;M]1TCY]5!"K%E^]367]*(P2J
MX@'-3ZWK =)_=KIO"*NAC W-I$FEWS]CTDR#=!1'.]N39,:RX5<IA&LC#?0'
ML!KKCT%&6GFGR<YUT0/44[D;(S>]R@V_XF^([?LIBY%U *MK0ISKEW+*NK^2
MSPS,1/+<!,+$" 7TO@),,E5]U^7HWO=7>?6Y_P!%22%-&D<959Y#@:UF"HNF
M+118,8P4F<?T,HFK.!K=-!H@/L&R(.S8H<)(<_A<<<\:"NSUI\I'IR&RF)>>
M8%4U04]=5RC9/P+9E;&F7J*^*-C;0.Y2U9,S\Z^9ZBGL>*F4#+\$QB$( W'+
M7DB/.?Q7;#<($2V3@0C$)L_Y J5J@)6;3T5Y*^/R#(NB2Z=G^GHU#H-;TUD4
MH(K2.86$SJZ;WYZCG5HSZ72,J;D!7NST*/D)<R22(.(LU0U^AN0V9%JDJVZ7
M4(E_IF7?(K\Q)^#.29*+@U_-"% >4ALC*,50Y(X A$@C_G"H)WVZC1,T'37F
MEDVF$7C),J*3XZ4,MFKX+6:F],2E*TJOH0_Y89^8 TO"R1:$PZ;7!2O=D\A(
MB$)$W3J.4Q0Q.U8\WB[!PR;,2AA_8,=$"NC0=!#M^;>Z \A/S 8'SB&ZA<Q+
MYE(Y*!T0N.3/R5D#">CAQ>T3S\S%)36Y\W(;- V(.JES3D>I"JC'3>DU*KEE
MCL9KUL5VU&N&S9S#@DE"^6P:.J6U3<4DEA04+*3\%T3YB!DAPYX)1],TN(<E
MT1KMHX;K(H$W $*L^0^_I%UV+8[6X[_+I_:&%,/(GET4D,0&T%5+%$+*F\U$
MI-86$03'25GH=IB0:<)M>>44Q^@X?0\?QK0QAR&#\LV2.A0_3<-:>D:EK*K_
M "-[4=5W XM"G$TH6^9#*UHV&9"E#QA>M9DY4>D.FJ2?XW7YE\_=<)?W+=)V
M1(NDDN'#]XHL$F:J_P %];_YA0__ %>'8&>X# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# UA<UOPFAJTE5K6$\>M8Q%&C915L('N#,B/ERC]H%C,0B0!EKLA))I,Y
M(1%16'1D:FJ2D4F+BPP])1V]1XV&A_,-.S1L8EOICT *9M/2%S,F+)['DGS,
MXPH6HQCE9[!_/L3,--=M':8+MRO);.D8Y55">6J7/EVSC<2%P4/'PF/@,!@,
M!@,!@,!@0PKO^?\ ^K_Z+7A[_:3[IP)GX# 8'YO>N=;ZZWK6M:WO>][^FM:U
M^_>][W^[6M:_?O>_Y,"*5Z>ZO&OF9LLO?/IVDJP<(_?K022V%'4I4Z4XVISM
MN-AS5ZZE19WOM)1--F+#.W2JO'22:/:FOMP*GO4_R]6N4BH@OY I:5PZCY4R
MWSQ[I]+"*WI"L_S#S2B+1G4-=^K;B\Q.YV2ZW^(Z1E4I+BHPU_(**#HM8+==
M)#L*1FE^>3XQ8!NW?0WR#4S;5O2QLN%D=@6][4MZU)"W#.R&VSN%AZC^.BAH
M.'!UR^[;K*+U4T]*GJ_^O:3HK'B/';5^N&QR'KDW/J^;TY\>7G>T_3C&0K:T
M[B_EGP[='@;PDH3+<_3<J]%2X7)9-Z4NMBU;?5'N%\36!1B7?4TO.'<F8JM!
MVPD3Y<\'?+459CSQV"1+S7*!X5Y&(_)1!ZBZCE4-ASM?:[N#U/)(_"_7 VE*
M\>=*[Y6CM+>:O.LF/=-$GDRD9DUW^T:P3_C/P_V*:?C#=RG/)EF'6W'"CTYZ
M'KGU'[NE;A_MEVCV\2->E/63.$,U..]-6B?(>I@C1-HU54%,0:;Q,:P"=(7P
M[9R 5.+DO;]Z1:%<H)LE(!Y^K3R]Y]BG0WAJDS48,B$8H\S9(#ERAMVEV\C-
MBA2+'E=!8$\#OF+=Y@3)J>H:RHN#BJWJ.% H%"@W3I9H# -/RZ2S\@OV[*F2
MCM3I4@<D)I\JL1/2(T[?G3I-=P3,$'K]PLX4#8^ P& P& P&!"GY!_YL9#_K
MN\C_ />XH[ FM@,!@,!@,"$OK/Y%_&/B,(D4]%7U!887(*[:1Z!HFF):Q)01
MZX2Z18A8>P<*%.4U>G#7A<V6X%1@3RZ0='C@IAUT[Y"B^T_[(%H&QGK0#QZG
MCOGZ(R)91 ?7_F@#QZB]GR-GPFJX42>3QB%.>1*+Z6:(K=D51\JO-\R8]\N6
MDJBQ%%RZ%A%B;?,.RI6.'WGQJ^;_ ##!BT[?M6TW]7^[/<WFJ47/-GZ2#SA0
MQ-8H!]%3R[YLH._)*+B5)//7K=@WVW9AH3PU=L6'05WR7VC[#NPKV2].^K_!
M\FYZ<H&.FM\PGV]Z$A(+[G3#;-N I6J:09>+2.N6VUUQ9,Y!2IUHR=]M)%-D
MRS?:[8).I3:(>G(JW@/HKYZ/06H@S",QKZI?%?D:<T+#D!2;-%HZ9[1KR(1<
M.]#K/-*:29G( 0:?DGJK1SPX=I#WS()1^:7WPK>,0?=(UA8/R/\ H#BQ))Q+
M"]>Q=.[Q1R;2LFW9!/U W6%%!J-E=@,E$ +9%-,S&9A$A6^54^.V;ERZ34"U
M*+6JZI$$F1\&?!-=FCIU9QI$W*0WD[R5HJXZ7VEP4F,@E]G%;BX_-\IHO%G<
MJ@NRW2/7&GG"3KA5)$/UC:_SQ6AT6T)\T>:_./'8 CTJ-M@Y')-T-5^YM^6U
M7]C59?UP:ET\4Y[=HCFUA457->,-I)$RQ0O]=Q]8)*^+9!2%>RY[6DDK:[ZH
M]?V.V=E+#D'I\1S)+3OEW$FO2S\N%]!Q;9VG+*CX=CTL6!U_5DN'AJ[C[A5%
MA5U?LTW@EJ%G. P*G:H\-62&]>3+T&.O2+TE#&5KS20R/SOY>6GW,7MM>4*N
MC;4MZ996%.9%7'4_D8T\)F<B7K:E:YE>BQ'E?FPCXURD^>A;%@,"-GLS^9]Z
MM_HV7I_+_P!5\IP-K55_@OK?_,*'_P"KP[ SW 8# 8# 8# 8# 8# 8# 8# 8
M# 8# ]:RR+=%5PX530003[6766[Y32112YWVHJJIWO7"::?'/7???>]<\\ZW
MUUO6M;W@5X5,DM[4M4!Z>/)..O,U3EG;GQ_&G?'X;.U97TQ>A"_KLPS4XUVY
M!N!I$K%O-S5QKE']D'LAMW[7BE@0K<4"Q/ 8# 8# 8# 8# BSZJ]:P#R-%HW
M+)^ F4C82$G)$.V\*: 7;P)'X/ 959LYF!7F0R".-^PL6AL.,$'+,6Y)20HZ
MVR' @1-TYZY2"HRY_E[\B>6_=GHU[^T2%Z.)-Y]\I0]NTI>S//"K<-+:_LOV
M3Q+(W)S=G7768$,9"]RD#HH,_471 5R2:K%6C)NLDKV$?K#_ +(/ODTU*-Z!
M\@^6V+I#GCA@;OWY5?"<?1Z561XZX6ZB4,MHLJ]206Y<\+I(S-IUTGRU[TX2
M[=*)M0B](_E ^9ZR2RW,<]8_ UYX$M^>G372WJ:&3!5YQ^.MRF-=/G$YLA15
MWP@X2Z7<( PS13IAM1)=':VVBP1VD5I?-Q:BQ#]H_P"R"?B9K)G]Z?;1C!_1
M=/1Y+KGITX<Z0;/HGY^V;339ZZ3;[[?%E5G;72*3E5UOA3K8:#;>+O3-I'&R
M_K/Y[_CC]"1X<IQ_]Q[.]_\ H&<PHDV>=H;<[+1>)3^D%/\ R;H:R7:-D3?#
M(FLAM(EQOA/[N@G-2?DJM*>101KCYS_BK\O:Z_&9E2?EGS9X\%V&68?EE^&[
MI:Y;)M"5V;P5TNY^G6^C:J#=)FV=,]HDU%GF@EM%/%_PBS(MS/\ WG\E5=_)
M%<>N&R+6<>F?:D+1C,59ME^G'Z-7]8P2QH]%XS'W2O6EGP<EW)4G#C:W?*J2
M;A9'L+(*:F_P/>>?P%*/G'Q?U:\;*)K)EX9+_-8:0;61[[4176D3<GHZY71[
M4[VBLX(JJI?=]$^^=:UK02LY^2;X[];_  ^/='D'6T^>?[WSZ,J+6^.=_77'
M]SJ6_P!SSO[=ZY_=K6_MWK7\F\#S_C)?CS_Z='D3_M%U)_XMP'\9+\>?_3G\
MB?\ :+J3_P 6X#^,E^//_IT>1/\ M%U)_P"+<#QU\D_QX;ZZXU[J\A;ZYUSO
MKG7HRH]]<ZZ^OV[ZU^UOUUKK[=_;O>OW_3?T_DW@>7\9+\>?_3G\B?\ :+J3
M_P 6X#^,E^//_IT>1/\ M%U)_P"+<!_&2_'G_P!.CR)_VBZD_P#%N!NRG_2'
MGOT)S(.Z&O*H[HXB?0OB4]578L2G_,<Z-Z(=!N3FXL6*:%;+:%%-C=/OP-O=
M#GVVWXGY5?[ W3@,!@?/)Z'^3F+73XHG4E?U!9 >3LKE\DF(7$X+#K4N,=)A
M+^<>2_0P$9)9U!*J=16M9VO';&%1<C$98[1WW+6CAA$R<OTNAK8<B:?,=Z[T
MHHVK;XO[9<_B*OT&I6P1_K8,W;\;^W@20?BHOX;D[CI/776URHYF15532XZ0
M8O7:G7*N!H69?)U\R+_:G[ >:_)T6XZ4;[1_:SSS\OLX532Y3^UUPKV*\8P)
M-7M=;>E$.^44--DO[TIPZZ_O^!H&3^L/[("FP[C8^_?*M/N7C3M-5.&?&Y\H
MYM^)575_$TJFM//#T]&NGK)/^\I;VDJP6Y_>LW54W^+H(_601^:9RR6+3OYE
MYA"@CHS'V/+\7\8_M6NV+,Q(# Z,@!S-Z#\,QW[W)TT58 A85R]50*F2K)L@
MU5*+,.T@V<&\^>]SS-JSLWYX/D::M>GW*A%M6WQ7^Y@9#MDCO726F$F2KD*1
M:N%.OWKI]LU&N^-?AJ<..>M_0-E _&R9Q1Z$OOYE?G,M>MRK/;,Y!XUY/]V5
MFL<;]*I]K,"4BW14W7V)>(<*M7[%H.:+ND5ND]ODT]]IJAO6L/CD_L?FKOR[
MAOXGO^?&$MMU71VW?'_R7V>\*.D>6WWNR(Z64\_C2BCI5KI=T@V MF2G2[E'
MEHFS7Z;8$OPRGPIT>P1+BO$<;KAGM<-$^#ZOQ,^B@RSAU*I$+"1\ L??^3>'
M;QW(921"AQ#%P]67)FW@L<T36>+-4>@F4*]J^3@+/D>#@?H0,PXZ[4X8B?CS
M]L#V?'??TVIWRV9^:$4>>^]ZUOKK7&NNOIKZ[W],#O>O?WG3OCI/L+ZB[3ZY
M^SI/KP5[HZXZYWKZ?;OG?G#?.^?I^[>MZ^GT_=O QHQ[+\BR+A!*05U?IU-M
MUWVV3,?';[5)\-^U.>=*=H<O?,R_*/2G////?2>N=]ZYUK>]_;K6@Z_7OCQA
M5PSM[Q'KPKP._, 1"CI/P)[.B@YZ>DYH;%XR-[63\W,6SDL>D!43'PK3?7;L
MD6(,!C+A9VZ;H]AG'\8#YX_]$>I/^P9[I_\ XXX#^,!\\?\ HCU)_P!@SW5_
M_'' ?Q@/GC_T1ZD_[!GNK_\ CC@>;;Y O-2Q2.B7J]]1Q252R(P8,2FWCOV#
M 8SW*9Y)A4-B LC+YK1 "* MGI2<$ V3TZ9&C_SY%JDL[2TIKK FG@?.S9LP
M9PSYJXU&6R[&,R:R)M53I:(-;BM6/#;0@K>C7P]];<E9"_5,;K).<1.21X97
MD<IHWYJE9.:QX,A)$7+],[L_$0M;]8W;+ZG(U.%@$XKH5,Y[(NQ@&O)B$5($
MK!Z:&XDF9<]2#N71D= 8#$(R2.$II,'C8N]1)O(<)C;$S)BHB%S$*\AGR+7N
MY8!G?4GI$@JZ\\Q_T5UP/BQ3C@W9!KFONG'B 1K<]<*)VHWW+'2;4KO\U,M=
ME(M^<@/6VY/DB')L?V=;D[\C>J]%ZO,7;L[Y,(2<H.H9A7XI[Y\+VE#/08J4
M5U;'=FW'%TB2]1)5X%2D[D#MS/.R1QUVI7J#-48EP%R55?X+ZW_S"A_^KP[
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M]+[CXMFE3* ,O:/\);=66@X;V[/," =PX;6J23?I)LPN$JK_  7UO_F%#_\
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MWUUUO>PV)K6M?7>M:UOK?UZWK7T^N_IKGZ[_ .??TUK7UW_R:UK^36L#]P&
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MTZH\%^(9964"D44C4@ED=*Q($N*DC>W;_$<&6W ]NCM[V'=60@[".5%4N]/
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MCLS*F3 NV*/ Z W2SM,,"4^13QBFT7(:O$*N.0(LA_))G')N_'/$7B,]65D
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M6)2C<5D(D_J.RD7,8KT2CAS8IVZ_2CC#E='IX*??@/6VE4]JH<:[Y^H6+X#
M8# 8# 8# 8# 8# 8# 8# 8# 8# U;<5<.+1AJ<?''TXN=$RV!SN,'W C]H&
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MG'7)/ITJTZ[8\,W23OH)8X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M)+HZVC$AB UIN)VM-8N!5#!I5UV?T(>1D0%=,2)'?*I=-7]4Y323=\)\!*_
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MUZ%J6 P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P&!^;UK?\NM;^G\GUU]?I]=?3?\ \=;WK_V;^F!^;YYW_+SS
MO]WV_OUK_P##_P#I_P#9^[^3^3 ?9QO^7CG_ )O_ ,.OY/W_ +OY/_7O_P".
M_P#GP'V\_P#Z>?\ EU_)K^3>_KO7_OW^_?\ S[_EP'V\_7Z_;S]=_77U^FOK
M]-[^N]?^_?[]_P#/O^7 _/PT]<_;KCC[=?OUS]NOM^N_KK>_I]/I^_6]Z_\
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C QN2<P";RN+-BAQ@2<LAAMWPS[05_!52"9. P& P& P/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g713200g02t31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g02t31.jpg
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M  (1 0,1 ?_$ !X  0 " P$! 0$!           '" 4&"00# 0H"_\0 3Q
M 0,$ 0$#" 4&"P8$!P  !0,$!@ ! @<($0D2%!,5%U%4D:33%B%7EM48&3$W
ME-0U055Q='5VL[2VTB(D-E:3E2-387<E-#A2>;&U_\0 '0$!  $% 0$!
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MZ(G6_KO[[T1.M_7?WWHB=;^N_OO1$ZW]=_?>B)UOZ[^^]$3O7]=_?1$[U_\
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M+W:&'4NN+6TW_8NC0W=.TCG%8AO%CI9KZ4KP.42D)IL-MG7\M&&R I4KC'D
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MX\8Z*84P47#DLX4-ES.:&<'(YH<V^CY ,C+D::NTMSV410<)V.>TEW-RY'$
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MANR-FIIANF!%]MLQ4(D242V ,FV@0MTME:P?2B 83HW$G:ZQBZ[,1US58NR
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M@.R%O[)(%]]U#90(G1.9FN[.UV8@M=ERWL-':<A4 )=DA G' %7@L:VU('V
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MC=QAA;/!7'&W3&RZ7>P[]\;?[.*F.>.=L>F.7?QQQQQV2MPV*K.<.X*6ULX
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M$[LRIO$W'&I8AF4LLY7:I^;7SE-HJ_1LU&(652377NIEBHI1A_5=P6+:?:O
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MB\>+S8;M-@U9#@+'RXQ-%70F&@@9PA=43RN<V,4HX*3^E-<ZG.1UI#98&);
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M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B*-BVX=7@B3P08FX
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ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B+B]OW]<FP_P"T*_\
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M7]_MO]%O]N5862<Z]P@)?(V5M1PD@%A>'(T*8&BIL\)NI!*-7FM-)0'&.SE
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/1$HB41*(E$2B)1$HB__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g713200g05c03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g05c03.jpg
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M5G)TT==A<9*WU('_Q  = 0$  @(# 0$              08'" ,$!0()_\0
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MJ/21$0.43']@VJYN6O,0=W@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 6VX]U\/\ %NQ_M.JY.TN=
M-"@N3( P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M3B %ZP]ED[2YTT*079D 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8!UTO&)3,6_BEG,BR2D&JS4[N(D7D1*-@6()>^PD
MV"J#QDZ2Y]:+ANJ10AP >8AS 0,45[A[U%5K2QN<'4465@CW[V;1=^499=!2
MT2;>U,I*ZNV#E\JQ>WB2CKS;XN0N#INK8GT789&-=2*K-1-%,*J9"7*4+A$F
M I0,:MV+J,   FZ9.K '4/MCR#S!S]H/:R=I<Z:%!<V0!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#K9B
M7BZ_%2$Y-/FT9$1+-=_(R#M0$FS-FV3,JNNLH/M$(0HCR !,8>12%,80 0+&
MJNY-57AQ"M*A?ZM8G-BB"SL*A%2S9TI(1IE9-#K2*F<1*Z(M"3B:L:KVY)$\
M'. JT(,/)>%"B[G3HJ%SN/=?#_%NQ_M.JY.TN=-"@N3( P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M+M*%+)/2I( (%#K9) L!&2OL>?=;%3. B8>KF8>;IDZ5XQ3+>M_)F/D(E$/
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M>( @+=8B?KZAYX)VZ\FT40AD 0;M_&2_2V6%<J@R\@*ZAA'GT.%_$=UPB'M
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M=*<0IDO6[ESE,89 47*'C)?I=+%7.<)>0!9(Q3";H;+ X[K9$1'D9% Q$Q*
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P"U)+W3,/BI:?VA5\^V96_3
M9I4A<BYET$6LNI6!@# & 29UU[D8S_SO_P!H.LJUI[,BYH?X;3W9'8S,[_34
MTG.+G\:SB8_K^W#_ /L&PYN_@AW)X+_]NV)_^;+&J>$?=#;O\YM3UZ.1YRQ'
MC# & ;,?J&__ $)[G_K38?X2B\UBU=?[;L3^51/6XIGC4E_LJU?Y@SU9AYD>
MJW_CP;%^+>NO\$PV90U(>X6S?&;2]>CE"U2.ZR>X"1]4A'FGF32B# & >WWJ
M&_\ TU[H_JMC_P#%D9F#=77^PK%_FS_4XQE?4E_M:U/Y<WUF$96]67V_MG6N
MR],,=<[1V)0&4G1; ZDF=*NUEJK60=(SZ:*3E\W@I-@D[<))"*2:RY%%")B)
M"F OFSR=1:Q[(M.R[;B6E95FV@^%/R[(;YV1EIM\-BRZN5K'1X416-5;U:U4
M15O5*GHZJ%IVE(3]ELD;0GI-D23C.>V5FX\NU[DC(B.>V#$8CG(ER*J*J)<>
M,O\ "IXG_P"D?OK^^#87VBS-/N4P6^;=@?<]G?IC%_NAM_Y<MC[SG?ZX_A4\
M3_\ 2/WU_?!L+[18]RF"WS;L#[GL[],/=#;_ ,N6Q]YSO]<?PJ>)_P#I'[Z_
MO@V%]HL>Y3!;YMV!]SV=^F'NAM_Y<MC[SG?ZY/GU,??F];SQGZLK5UW3MFX5
MQ_'[".^K]IV-<+!"/3L]=6EXT,[BI:9=L'!FKQ!!TV,L@<4'**2Z0E53(8,?
MZJ&#]@R.!-K34E8ED2<S#B6<D.8E;-DY>.S'M*48_$BP8+(C<=CG,=BN3&:Y
MS5JBJA<< K9M>;PILZ7FK5M*9@/9.X\&8GIJ-"?BR,P]N-#B17,=BO:US:HM
M'(CDO1%-JW-3C8<8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 1$;;5VPI
MQ/O-=JQ'324K*[A$HWR64O/7".E:U>6^Y_+ I>*,+C<DG,:7"/\ %>25 CC+
MIL2RC5R[4$[2=-OF3ES$A9!9T>W-4"1[@2EK,^DBN*S,$G0+O:R*BB1?$BL0
MK4X%25!PD@8YC@9 %DP,<OTU:47+1S57BKI/E;T5-XQ3]S"S_P#=8_*@_<RP
M=>)?XN-Y&?G/(ZW1>_A_^7Y1]S"S_P#=8_*@_<QUXE_BXWD9^<=;HO?P_P#R
M_*/N86?_ +K'Y4'[F.O$O\7&\C/SCK=%[^'_ .7Y1]S"S_\ =8_*@_<QUXE_
MBXWD9^<=;HO?P_\ R_*9<JK&3@H-I%N6(JK-S.1,H@Y;"D;O.EER](J*IG\Q
M5  >90]D \N8>?/&FXS9B8?%8CD:Y&T1U*]JU&K6BJF5-T]&7A+!A-AN5%5%
M=>E:7JJ[:)NFOMN_U('B%V?NC;>R8:[ZI81&P-F7J[1;&3E+,629QUIL\I.,
MFK\K6L.6Q7K=L^32=%;N7" +D."2ZJ?2<VP]AZLN#]EV)8]F1K,MF)&LZR[/
MD8L2%#DM;?$E)2#+O?#QYUKL1SH:JS&:UV*J5:BU0PO:NIC;,_:EI3T*>LQD
M*<GYR;AMB/FD>UDQ,1(S6O1LJYN,UKT1V*YR51:*J7F+OO)'$O\ ZPM-_.MN
M^R.>IV=,&ODJW/JY#]<=#L3V[\H63]9.?HQ]Y(XE_P#6%IOYUMWV1QV=,&OD
MJW/JY#]<.Q/;ORA9/UDY^C'WDCB7_P!86F_G6W?9''9TP:^2K<^KD/UP[$]N
M_*%D_63GZ,];_4[>$S8W![KZ_5&^2-9LCZV7)M8V+FHO7BS1NT1A&<89!T,R
MPB%@<"LW.H4$4E4NT8HBH!N90Q!JCX8V?AE:%GSEGRTY+0Y22?+1&SC8+7N>
MZ.^*CF:Q&C-Q<5R)VRHM=JEYDG G!J<P9DIR6G(\M'?,S38['2SHKFM:D)L.
MCM=A0EQJHJW(J4VZW$1.-WU,?=_$YQ#VG;].M6N8*!G8FJL&T;99&=2ET58&
MOL(AR=<D7 2;,$UEVAU$!3=G,*1BBH4A^9 N. VJG8N"^#DI8T[(6I'F)>--
MQ'195DHL%4F)F)&:C5BS4)]4:]$=5B)5%HJI>5K"S "U;?MN8M.5F[/A08T.
M78UDP^92*BP8#(3E5(<O$915:JI1RW4K1;B)?WDCB7_UA:;^=;=]D<MW9TP:
M^2K<^KD/UQ6^Q/;ORA9/UDY^C'WDCB7_ -86F_G6W?9''9TP:^2K<^KD/UP[
M$]N_*%D_63GZ,?>2.)?_ %A:;^=;=]D<=G3!KY*MSZN0_7#L3V[\H63]9.?H
MST,]3MX!=N<'NP;];KY/4BR,;93FU<8MZC(2JSMN[0FVDF99T$S$1"(-Q1;G
M(445E5>Z)0%,"\S!CK5'U0[*PRLZSY.SY.T):)*3KIF(Z<;+-8YBP(D+%9K$
MQ&=C8ST6]$2E;ZW%UP)P,M'!F=G)F<F9*.R8E4@,;+.CN<CDC,B5=KL"$F+1
MJI<JK7:H<KU17@-VUQB7/7-DH4[2JTTIM8EH.00M[^41<.7#^5(_259A#1,N
MD9$B11(H*RB*@*<NDAB^RSXU.-4&RL#9*TI:T).T)E\[-0H\-TFV6<UK8<%8
M:H_7YB"N,JWIBHY*;=3ZPWP-M#"::D8\E,R<!LK+Q(+TFG1VN<Y\3'16ZU B
MI1$N6JHM=H\Z?O)'$O\ ZPM-_.MN^R.9([.F#7R5;GU<A^N*1V)[=^4+)^LG
M/T8^\D<2_P#K"TW\ZV[[(X[.F#7R5;GU<A^N'8GMWY0LGZR<_1C[R1Q+_P"L
M+3?SK;OLCCLZ8-?)5N?5R'ZX=B>W?E"R?K)S]&2JX*_4P-Y<-/$;1]R6^UZX
MG("KM+:W>1E;DIY68<&L%0G*\U%L23K\:R$J+J416<=UXD(-TU13!10"IFJ>
M&^JK8F$V#4_8LG9]J0)B;=)N9%F62B06I+SDO,OQEA345_;,A.:VC%[94K1*
MJEAP5U/K5L*W).U)J<L^+!EVS*/AP'S*Q7:]*QH#<5(DM#9<Z(BNJ].U1:56
MB'N*^DY%JB"J,$\>&ZP**2+EF!P 0$>L/PQ@$ $  ?:]L/\ [9@N$QL1V*Z(
MV$E*XSZXN;M45:[EQEJ(YS$JUCHE]*-5$7/?1.4ZGUR37_@Z7^4L?I<['4L+
MPR7_ /9^0X=?B>#1?*S\P]<DU_X.E_E+'Z7'4L+PR7_]GY!K\3P:+Y6?F'KD
MFO\ P=+_ "EC]+CJ6%X9+_\ L_(-?B>#1?*S\Q]$L<P8Y2FJ$N4HF*!C>(8C
MT@(@ FY=X.?(//RYAS_TA[>0LM#1%5)N754151/XE^][S;)2/$JE9:*B;:U8
MM-_WQ9VY]U570FM;'MC8K>594ZJC#A+N8UNC*/4_+L]%UN/[+!LOWE^N4F&2
M:G1_))&.L;V"9L[5B6-/806G+619K8;YV;U[66Q8C83%UB7BS,3&B.N;2%!>
MJ5RJB-RJ=>U+3E+'D(]HSKGLE9?6M==#8L1Z:]&AP&48V]:Q(K$6F1%5<B$#
M_OQ/!KZ5V!^8[[Z?+]V',-_!9#[P@E0[)>"OA$W]BC#[\3P:^E=@?F.^^GQV
M',-_!9#[P@CLEX*^$3?V*,/OQ/!KZ5V!^8[[Z?'8<PW\%D/O"".R7@KX1-_8
MHP^_$\&OI78'YCOOI\=AS#?P60^\(([)>"OA$W]BC'HI,W^,@:)*[&D63\E8
MA:D^NSY=(&RKHD#'0ZLZZ639E7[JC@L>B<Y&Q?PAU !(/9#F.($C,3%H0;,A
MM:LW'G(<C#:KD1BS$6.DNQJO6Y&ZXY$5V1$OR%VBS<&#)Q)YZNZGA2SYMZHU
M5=K+(2QG*C<JNQ$54;E5;CSK^_$\&OI78'YCOOI\R/V',-_!9#[P@E)[)>"O
MA$W]BC#[\3P:^E=@?F.^^GQV',-_!9#[P@CLEX*^$3?V*,/OQ/!KZ5V!^8[[
MZ?'8<PW\%D/O"".R7@KX1-_8HP^_$\&OI78'YCOOI\=AS#?P60^\(([)>"OA
M$W]BC'H%JS:L!N/7U6V;2&DDZJEQCAE(1P_20CWBK0'"[7J79+K]UN?O-U0Z
M#^?I #>T(9CRUK+F[%M&;LN>:QDW)1-:CMAO2(Q'XK7T:]MSDQ7)>A<[/GY>
MU)*7GY17.EYIFN0G/:K'*W&5M58M[;VK<I45VC!HJJ(G:2('24.F< 30$ ,0
MPE-R'O\ G#F ^?\ GPVS)IR(Y&LHY$5.W3(J50E9V71517.JBJB]JN5+BG]U
M6 ]ZR7]DA]/D]:YOO6>>A'5TOWSO-4?=5@/>LE_9(?3XZUS?>L\]!U=+]\[S
M5'W58#WK)?V2'T^.M<WWK//0=72_?.\U2Z8:R)SS0SV.CW9T"K';B*AVJ1NX
MF4AS!TF7Y\NE0O(?:'S_ .C.I'@1)=^MQ$1'8J.N6MRU1+^([$**R,U7,551
M'8MZ4O1$7;WE0Z.1V+$Q3UQ'O&<@5RV,!%2D*W.4#&(4X<C@OR-[$X>U_/YL
MYX5GS,:&V(QK5:Y*I5Z(MRJF3.AQ/FX,-ZL<KD<W+VJKE2N7,IPONJP'O62_
MLD/I\Y.M<WWK//0^.KI?OG>:H^ZK >]9+^R0^GQUKF^]9YZ#JZ7[YWFJ/NJP
M'O62_LD/I\=:YOO6>>@ZNE^^=YJG?P=P:V(701C%ZH+0$16[HMD>7?[O;Z>I
M?V7/LGY\O:Y!S]O.M,2L:6Q-=1J8^-BT<CO>XM<F3WR'-"CPX^-K:JN+2M45
M/?5IES*<>:O4? .R,I%D^(NH@1R4$O#*E[1SJIE'J*OR >I(_F]L  !_GS[@
M24>88KX2-5J.5BU<B7HB+D7><A\Q9F%!<C7JJ*K<:YJK<JJFUOHIU'W58#WK
M)?V2'T^<W6N;[UGGH<?5TOWSO-4?=5@/>LE_9(?3XZUS?>L\]!U=+]\[S5'W
M58#WK)?V2'T^.M<WWK//0=72_?.\U3M8>^1TZ\\#'LGQW':.MR4!LD7MIB4#
M#U&7Y<^9R\@]L?\ _,X8\C'EV:Y$1J-JC;G(JU6M+DS*<D*9A1G8C%55HJWM
M5+DINYS"'$?Q@ZDX5&M2=[?&Q1J-V7F6T",-$#.&65@4XQ61!P5FOS; 0DLR
M[8J?RHF.!?Y,V>[@U@?;6%CIQMC0H$19%L!TQK\PR!BI,+%2%BX_OJK!B5ID
MHE<J'DVYA)9>#J2SK3B18:3:Q4@ZU!?&JL%(:OQL7WM-=92N6_<(K_?B>#7T
MKL#\QWWT^6OL.8;^"R'WA!*]V2\%?")O[%&'WXG@U]*[ _,=]]/CL.8;^"R'
MWA!'9+P5\(F_L48??B>#7TKL#\QWWT^.PYAOX+(?>$$=DO!7PB;^Q1B^]9>J
MA\+FW+]5=:4Q]=G5IN4LC"P;=]4W+!HJ^7*<Z9%WBR_:;IB5,W-0_L0\P?SY
MT+4U+L+;'L^;M.=EY-LI)071X[H<["B/2&VE5:Q+W+?D2\[<AA]@[:4Y+R$K
M'F73$U$2%!:^5BL:KUJJ(KEN:EV52>,Q8B03/QTA'NR-^Z1'J34:JFZU.KI#
MI*OSY>Q'F/\ -E!@P(DP_6X:(KJ*MZT2B9;U+A$B-A-QWUQ:HER5RY+BU?NJ
MP'O62_LD/I\[?6N;[UGGH=?JZ7[YWFJ/NJP'O62_LD/I\=:YOO6>>@ZNE^^=
MYJC[JL![UDO[)#Z?'6N;[UGGH.KI?OG>:I^EVI F$"@TDN9A  _!(>V(\@_Z
M_"V7-I?BL\]HZNE^^=YJEYOI92.9N7SF.<E;M4C++&*LT.8"$#F80*"_,P__
M $#.C#8Z(]L-OOGN1K:K1*KDO.T]Z,:Y[O>M2J[=Q9?W58#WK)?V2'T^=[K7
M-]ZSST.KU=+]\[S5'W58#WK)?V2'T^.M<WWK//0=72_?.\U1]U6 ]ZR7]DA]
M/CK7-]ZSST'5TOWSO-4?=5@/>LE_9(?3XZUS?>L\]!U=+]\[S5+R1F3KQZ<F
MG'.1:*LROB&%5H!Q;F1!<#"3O\P-VQY]/M\_-[>=%T-S8BPEICM>L-;[L9'8
MJWY]L[37M<Q(B>]5N,F[2E<F8\R_OQ/!KZ5V!^8[[Z?,H=AS#?P60^\()0NR
M7@KX1-_8HP^_$\&OI78'YCOOI\=AS#?P60^\(([)>"OA$W]BC#[\3P:^E=@?
MF.^^GQV',-_!9#[P@CLEX*^$3?V*,/OQ/!KZ5V!^8[[Z?'8<PW\%D/O"".R7
M@KX1-_8HQ.C1.]J3Q%:_C-G:X++.*A+/95@T>2[((MT+F&>JQ[TJC!54[@A0
M=(G(F<2\E"\CA[$<HENV%:&#EHQ+*M-D.'-PH<*(]L**V,S%C,2(RCVW*JM5
M*IM+<6VR;6D[;DF6A(.>^6B/B,:Z)#=#=C0G*Q]6.O2CD6B[>4S1GCGI# &
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MIU7)VESIH4%R9 & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M!,'@ _'-X=?ZQXS]7>93M4'N*PD_ED;2TLV!O=18GCT/T7&XWL_W,#\(-/\
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M\_/E'J,4O,'X/ES 7%^W3?)X_P!^F\4AC'@H+H^N"8!19<%4W0)0??:I@/\
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MR)%KQD>=W)$,5N]+(,7[(B*9!CF;!<5%E,NZA,)[YO"&(V8C0FPH=F*^##2
ML*81ZVBUJ1EBP8D9$A+V\/6(L!5<JZXL1M&IC;5:>ULM8S'08<1T1\^C(KUC
M)$@JWJ)56$D.*R$JQ$[5^O0XJ(WWB,=5QK^!9(D)%N^]8E3%N@Q%HI$"YNOD
MYVN)^KRFX.%P"4*^ /P8$:R3:.Z/.+ 3^SS8/J*8UE\+KM:&.^+KB3.MV7KT
M-E*:PQ.MO4^M5OJ^ ^-7_&Q;C#?54#76Q.MTGB-AXBP-<M#6GNK77G+U?KR1
M-JC(S(5/\*MYP0F& 1Z+(:O F<)/P>'EA6L?E!PW!0QQBUB%L!8P&!BF!$3M
MXU"2[9"B$B"O6J;EZFC:\Z+U?-XCH.M)+XDEK+'T1.J&KU'KZQJHKJ/CO@55
M4UG%HU.-(T-(38?4DNKTB(]8ZOF]=>U%^!<B3204AJERJR"V-1*ZZBU5>8-B
MBA>2#H*/52HO696S>.!Q<O!Q2Q2"49"/,:W&?G>''\(8LF]D6('  (R(3F0>
M)).82%!A]=;05T*(L1\9669KLPU5JD&,B6<D)(:)VJ+ A0(M,L55HJ<G5,''
MBOZWR:-B,1C86//XD%R)3782K/:XKURJD:)%AUR0T2XE1P*/F\AQ:\-46UB(
MZ$>-MBQY5;#%GE%)A\)VSSI.[2F)*6@BF3]L@,H1F0>7X0B@<P&JX>0(C,$<
M*HKIN8C,BV9$Q):(V52!+T5GP+H,M"F%QMO7X\;>H6#!"*Q^$=@0VRT&$]D\
MS&CL=,+%C5:[X1(L>) 2FUK,&%OU-OG9;)PG66HFEY%8&SQL18JJ<6!7YC"J
M(*N^U&I&(H0.92@Q,S2Z1'K3.8 ,&G=EWS:7T[1RW;U+KZW+M[>^;,3VQW;=
M[4OSY;J7\F\1Z%NKTJE\<Z 5#@8IP*SZD0 >?;2YM!()!#V(]TJI^0>8X#S$
M;'B+1?XC[Z47M*I3:3M*+7;QD5=^IXN,EW:-NVJOOWU[:OD5$WC[!%3N$/XI
M<2E3 @I"5MVU#<A#NG$&X*@H(CS$"*$3Y@'),"\P&<5:HN.ZB)2G:T5:4JO:
MUKMW*B5VB*I2F*F7+VU4WO?4IG15WRGX9;M GX]WU IU][I9=T2\N7:$/!]G
MM\_9<P2!3GYNYT^QR,1:4UQ]:UQOX=<E*>\HB9D1:[9.,E:XC:4I2KZ9_?UK
MM9:;U2NF@H+@3 [<%!7I(1,H-NAN8>D 51ZFQCBH40$P N=9+J,/-,2\B@<U
M>V7'<E6JB)1E&W94JU5K])52];LE%4HG:M6BU5>VJ[>6CJ4S(B[Y)RVQ[HM6
M? ,Y*'%HQ=G7,9*&ZI0IS <J;[HB"E(1(H"D08TL>H*9C"HHHKTJ%J<GLJ!=
M3^*SBOVOWJ>_,['B[?:*1=\.KR7#QKH.Z8!(/2TYM@ PF$J'-J("40'H'Q +
MFZ0 2F _,PVS%7MOXC[Z4N9VM]>U[2^N1<;&NW[SP,9+NT;=EO?VUVWVVUE[
M7%ORW7'T"*@'1-XMP()$ ATQ*VZ%S<A#N+"#8% .(B!A!$Z*?, Y$ .8#.*M
M47'=<E%3M*.RWKVE:W_W5:ER7"J45,5MZU1>VJF\G;4IG15WSX\,KVC)^/=]
M0J=8+=++NE+RY=HH>#[7;Y^?F*0J<_\ K.7FR,1:4UQ]:UKVE<WO**F=%7?&
M,E:XC:4I2KZ9_?UKM9:;U2IV5.X8_BEP*9/H!+I;=LAN0!W2B+<514 0Y\CJ
M&3YB/X/IY $XJU5<=U%2E.UHBTI5%Q:UV[U5*WT%4I3%;EK7MJYO?4IQ5WR3
M,='NC4>+*6;E$Q1@2+G4*G#"=RF=@4Y6BX*1)TP;IE_!$,W(@Z%/^4<J*?A,
MJ<6Z=B5O_P")>E5V_P"*MZTHE5RK2B;B(>]#OEF;7\%+D^ADOJO'6N_4T0"3
MD<5*'3&HUQ0T6H)WBQU[2"M@*(<NU, G9B)))@/G 8)*%4Y^VH(>;-^5E8ZN
MF5ZXSJ)'2D)J,L_%DU[Z6K(JYR[7_%NFDWJWFH*3$)$@)U%*JL):Q'*^=K-)
MWL>DVC6IXLV77?!YR.,G,$"H5Q,THH!V:Q%[2*E>* <A2AP4LQTE4Q'V0C.I
M32G/VE +['"2L='2R]<9U4@)2*U66?BSB]],TD4<U=K_ (1TJF]6\+,0E2.G
M4,JBQ5K#<CYVLJFY K-JUR>,I,+OE<MBBP=QSD:/53),6AVSE@9Q<?"2ZIDP
M(#^1,6VE>D=IF 52%BGD8R%0P@=F=+I3#Y63F%AQV==9]'1HB/9&1EF:Y+-1
MU5@P$6SEA+#5.U59B''BXN2*CJN/KJF#CPG];Y-6PV*Q\/'G\2.ZE-<BJD\D
M1KT7MD2!$@PZY8:MHAPS3#$T>X9!5X$CA=^9XG+%6L?E!H@*A% BVY#6 T69
M@4I11*=U&N9+MJ'$T@94$U2<B2T9(S(O5\VK&04A.EU9(ZS%?14ZH>J2:1TC
M*JHY4AQX<"K41(*-QFKQZ]"UI\/J271SHF.D;'F]=AMJG\%B+-+!6&B)2KX3
MXU%55BJZBIMI^I6G+.<%M&<QR2=12-;[Z<&-<[B[0A4K,_2.D4UJ4LSWMN#@
M+E83/#*@N80040;]* :AZK$%\##.=AQ)F/..24L]5CS*2[8JUE6*B*DK E8-
M&I<VD)%I[Y7+>;(:GD1D7!>5?#@0I9O5$XFM0%CNAI28?5:S,:8BU=E6L14[
MU$2X]&'$:\6<*K)S\NU34Z.AHW2@S-T.D@%$$C.85PZ'N" J'[SE;D<P@GT$
MZ2!C>N\G+SEWIOKR<QV^02, MMQ[KX?XMV/]IU7)VESIH4%R9 & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M64)X9TJB1J\Z2@(+>$67\.?DFX[:@@49_NKG3VD%V9 & , 8 P!@# & , 8
MP!@# & , 8!TMCGXZJ5^<L\P9T6*KT3(34B+%@]E7PLHQHJ\<E8Q<:@ZD9-Z
M=)$Q&D='M7+Y\X,FU9MUG"J:1@->O;^ZN-B)J_&QJ&WM]X-+;.;'X-N)SADO
M- 1EQ<0FI]D[TTS5=T</T5<M1RLS#F3U(2KVU^[B3S:<_;=/79_=;1"-X%66
M[)=[>TW\A]HC:MR;:+7;I546]=M*<:9B[-B3W$T'J2W$Y(1=@XA_N[,>+O>K
M/73^-L>V&NX_6"EZH7,HTAG5Y:,<GV$>ECHM1H$"6),YAPU5V%V"*E633$ N
MQDR4Q6[E*XB5Y<N^9&L>UN,S@UOFE--1SRT\3L)N'?R5YMUHD-7[MV?&:;TE
MNSBGIM'2UW&;E2E91648Z3US?7LQ!R]X<+S<@TK2\Q-(5VIIP-8D!"(CJK<E
M$WKUHN1,Z;6[NY8XU'C X]*2UUYL:\ZUN]^N9](W@VS1?:SWY7HK7BLMZHMK
M36EE?N]60,S(4^R/];Z EKAL*NKQ&NI/8@5.EK^ F)&G,+>SE8V_+[*=-!-&
MK6BHE]V3O:[=]ZW9:(9Z6XTO5#FN\(76+S6&MI.ON3ZVJTG8Z3I7>3R)=3UY
MX.]^[7E+K7K1;YRMF)5X7>^N-9T]"$L%)8O&[;9#*DS$QZY7\),NI(HVBY;J
M[:7WM]BKNUI7=0RAP+\3G&'=K#PQ:[WQ2'4M7[QP6:RV)=-F_<XLU.ML%OIE
M4*T[V?4-P0%F=P8TU^>5LK%K7Y:N0$Y7+7,Q5H8"2FR$?Y'$'(V_%7;6[>JM
M%1?8J5V[TR>P&#Y& , 8 P!@'FCZJ,]VDQU'H%34DSL:$G%^-KA+:6QUK::V
M'"NS:H<[;A4MJ%N"^LW\?83ZU+2QE%;\*JY(MM7R.G3U1#M)K$'TVE]>]6F?
MI^UY#/AEU)O':^K^#Z:V]?>..O;=@N)K8<!).Y3>F_J+3IC2FIMP;0VZC=K+
M1RS=7F-@ZXVI7H.E:3IJ_$2RL=X<T&WUY10[PJ*\W(B56]?>T5$N1$N6FTJ[
M:;>+ES9/:IU;]AHW,L"WU'(.ZH+]FV->RW*HHM",ETD#NI'UOK/2SPD8J*+(
MF:@W\2N+<3H%,11,1'QQ\5_-3E-??C#F^+UMLSU3(FN+1Q!-:LPXAO4NT=1$
MJ]RWJS=,JQ(3FJ XAD-&-:W(DAB50S!6[?=Q2JPIQ3-FE.'M)$E6:O9'VE+L
MGO7UK3+1<7ER'I1PU#>W7&QQ06^N2^R[;PXWG5.L7%:5M]\W"\@Z=NVE7S;%
M>V37D=<;D8$)0;!9H]U7G1&>L3P=')2ZO491Q5BJV2(GID0M*(FW?Y%1%2_I
MGVB$4W*[TV=H#U*;=KRW<0K':N\^*W1B'%E :_V=N2O5ZMTE]6^(68VW4++4
M*598^$IM*I>QIN#H=A?O6,>$<%8H==G)3OPT2F =\B4WLB[:9%6NUOGR;CRX
M]*5';HHT-I-)\YT="[!KE)EK;I??UF?6EU0>/6+X=Z&^FK')7DCO9$E;.%1[
M&[GFWD/.*2DS)KJ;%-)(51TK$E$T;=?N5\VJ_P#E<=Y5^/CU0<\[+0=@TE6I
M6.+,NX=>UQFEMH5=I2JM!^J+'X8IK:<HA*W>=0L$<?A@<EXB4(EHXCT6\4Q+
M<2N'^OR/USA1N[=2N5.]QJ>7M<Z[ID?5'$UQK[X/=8K;E?KO#3KNK\(-?W/:
MY[[F.R82[R=LL$IQ.U1^C2;U)[(C(77SF C*#H[>"D+,UJZS]6@K>-/M+5P2
MS1\[%B%1$2Y:K5=M%VFJF?*J;],Z%^6_B,V^IP[\&6P9J_U_0/$CM7A_I5\M
MC#:6T=,ZJT(SN4U2*+.W>M[7J>QD9W9\LTC[+*N&T:UTK4V]JBA0=PTS?:8T
MDD5) 1=>FU7CIO;1'O?%VXNGURXT7&I[I=[9X[@_]3PLU4EM6R%[<ZF=S<QN
M_8Q>+2R\.I#R\\WC)%WHQ:)G!)2YJ0MS.)=T:1/(NIAQ$R+D?24HE;NV=7=I
M1M*\=:79:W%R:4USQJRL+P_;KG]\[2B[,TVKO"CTG1=G:6:1@+IK]+:O&'&:
MAN.U'9[&Q3=4\=)WW4>RK%)6ME(6&9B.'[6D%595#8U]:O4Q"TOHFTGENK3=
MOKOT6M5)\\#>]9O=>N+,UG-5;>UJZUE:&%*-(;E=N)"U7UT^I=6NLO8Y!VXB
MH5-"Q,)NU25;NL!%,EJ[5;;#2M=@'ZD?'D81HA4ITZ<6ZE%)KX(& , 8 P!@
M# & , \0/5H]8;*V5!\/:6NM>7F_J1$KLI263I52G[4>+(]9T@K,\B2"CWYF
M1'9FKDK4SD$@<"W7!(3BBITYTU$[5LRS(V$:VE:,A9Z1H=EI!6>G)>42*L-U
MH8Z0UF(D/'5F.S'Q:XN,VM,9*XFU4Y"?GH5B))24W.+"B3ZQ$E9:-,:WCMD\
M3'UEC\3&Q78N-3&Q74K13P5_@M<3?]'/>_\ =%L#[/9GWW5X+?.2P/OBSOU)
MA_W/V]\B6O\ =LY_1'\%KB;_ *.>]_[HM@?9['NKP6^<E@??%G?J1[G[>^1+
M7^[9S^B/X+7$W_1SWO\ W1; ^SV/=7@M\Y+ ^^+._4CW/V]\B6O]VSG]$E7P
M.\/&_P"K\6VA+!9M&[AKL#$W^.=RDW.ZSNL1$1K4B#H#N9"2D(1NR9MR"8H&
M6<+)IE$P )@$0RJ8<X1X/36"&$$O*V]8TS,1K.BLA0(%J2,:-%>JMHV'"AQW
M/>Y=IK6JN\6+!*Q;9E\)+'C1[)M.#!ASC'1(L60FH<.&U&NJY[WPFM:U-M7*
MB&UUL_W,#\(-/]RV:EV5LM.#?[#8N>V.[Z3=)'/+,>&, 8!41_E4O]H3](,A
M<BYET E3;_<Q.?!SC]'*C)[*E^%9I+#,['B_04BEEO*\, 8 P"4T9[BF/Q90
M_9A<J,;9L7QI_P"*I8(6Q6<"GHF@3GZ#&FXP!@# -NWU(O\ $BHGQKV)_BV1
MS3_5A[N)[Q.SO56&R>IKW*2GC,[ZP\],\Q>7TZV9AH>Q1,C V"*C9V#F&;B.
MEX:98M9.)E(]VD9%VPD8YZDNS?,W2)SI.&KE%5!9(QDU"&*80$#@,ZC5(Z09
MRT?6*\PE8Z%2KD?)LX6-:R#&O-U3+H0+-Z@V(Y;0J*QSK)1:*A&*:IS*$0*<
MPB('PX]U\/\ %NQ_M.JY.TN=-"@N3( P!@'6+K2Y53E;Q[%9$!#H45E%D%#!
MR#F)D2Q;@I.1N8  +'Y@ &Y@(]( 4O$3OHJ-^>E_J7 'B)WT5&_/2_U+@#Q$
M[Z*C?GI?ZEP!XB=]%1OSTO\ 4N /$3OHJ-^>E_J7 'B)WT5&_/2_U+@#Q$[Z
M*C?GI?ZEP!XB=]%1OSTO]2X \1.^BHWYZ7^I< >(G?14;\]+_4N /$3OHJ-^
M>E_J7 'B)WT5&_/2_P!2X \1.^BHWYZ7^I< >(G?14;\]+_4N /$3OHJ-^>E
M_J7 'B)WT5&_/2_U+@#Q$[Z*C?GI?ZEP!XB=]%1OSTO]2X \1.^BHWYZ7^I<
M >(G?14;\]+_ %+@#Q$[Z*C?GI?ZEP!XB=]%1OSTO]2X \1.^BHWYZ7^I< >
M(G?14;\]+_4N /$3OHJ-^>E_J7 'B)WT5&_/2_U+@#Q$[Z*C?GI?ZEP!XB=]
M%1OSTO\ 4N /$3OHJ-^>E_J7 'B)WT5&_/2_U+@'7QS!Q#D=IQ-8KL6F_D'T
MN^3CWP,B/)637,ZDI-R1M IE7D)!R<[E\\5 SAVX.==PHHJ<QQ [#Q$[Z*C?
MGI?ZEP!XB=]%1OSTO]2X!U\JQ<3T<[B)RL5Z8B7Z78?1DH^\H1[U'J*<47;)
MW JMG*(F*41263.0P@',HX!6<)2+L2BZK\&Y$G,""XDC+"0#<NH"BI!FZ>KD
M'/ERY\@Y^T& <@BLTF0J:<1%D3(4I"$),+%(0A0 I2E*6% I2E*  4H
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MM?9^N5L[5UXO%.'CSUOJ-TW:3I..7,H9%H)IEWN>F[SDQ\$# & , 8 P!@#
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MK\H2_?P!XYE[\:_*$OW\ >.9>_&ORA+]_ 'CF7OQK\H2_?P#Y,\8G*8HO&X
M8HE$2NB$, &#D/2<BA3D-Y_,8IBF*/G*(" #@&&(#1&F*Q':?BH6)<-6&A9.
M8F-5MU;Y='WK;D9ZNV.IR;ATK(6=TM:.[7;;8HM!&W*3S=@A)JGCTFJR395$
M*Y=_*9I\<R]^-?E"7[^ /',O?C7Y0E^_@#QS+WXU^4)?OX \<R]^-?E"7[^
M/',O?C7Y0E^_@#QS+WXU^4)?OX \<R]^-?E"7[^ /',O?C7Y0E^_@#QS+WXU
M^4)?OX!53706Y]E9)7IY=7;4(IT\^?+GTB/+GR'ES]OD/^C *N , 8 P!@#
M& 6_/5.K6H8,UHK4!8S5FP,+96S3T/'2XU^TQ1'*479809!NX&*GXU-X[383
M##L2+,CIP1NX3*NJ!@+@P!@# & , 8 P"W+?[F)SX.<?HYV9/94OPK-)P3.Q
MXOT%(I9;RO# & , E-&>XIC\64/V87*C&V;%\:?^*I8(6Q6<"GHF@3GZ#&FX
MP!@# -NWU(O\2*B?&O8G^+9'-/\ 5A[N)[Q.SO56&R>IKW*2GC,[ZP\],\Q>
M7TZV9F8>N1$K8+#*QL# 04<]F)N;F7S6+B(>)C6RCR1E)62?*H,H^.8-$5G3
MUZ[61;-6R2BZZJ:1#& "V*ML_6MX+&FI6PZ-<"S,8YFH@U6ML!8"RL.SE'D(
M\EHT8F0=@^C&DU'R$0Y?M>ZU0E&+Q@JJ5VV62(%%W#M7'NOA_BW8_P!IU7)V
MESIH4%R9 & , MZPOZI7(J3LUK>U^"A(IJH_F)^P.(Z,BXUD@4.Z\DI61.@T
M9MD2@'6X=+II$+RZC@'+ ,3RN_\ AI@4BK6#;VFZZ0S^3BA]<5RJ, =*4A:V
MWN4Q&N$IA^R5;2$34';6UR3)P1)RQK3E"==))1:J;HP47<,MHFK+ALV>MA@W
M#1['C+,G3?P"Z#R+!-!49%HJEUD<L>TZ:J>+0,H@)'+<P*<EDQ,!AAAQ(\*L
MI$(V",WGH61@UW]<BT9AAL:@O(U22N /QJ+ KUO+J-_%VD(J4&N-Q4!6<".?
M#&%= T7%,*+N&7:Y(TJXP,3::B_J]IK$^Q;RD%8ZXZB9N!FHQT0%&LC$R\8=
MU'R+%RF('0=LW"R"Q! R:ABCSP#NO)D;Z/8_)&_T> /)D;Z/8_)&_P!'@#R9
M&^CV/R1O]'@#R9&^CV/R1O\ 1X \F1OH]C\D;_1X \F1OH]C\D;_ $> /)D;
MZ/8_)&_T> /)D;Z/8_)&_P!'@'1V:4I%*K\Q;+B_J]4JU>8.)6>LEC<Q4)!0
ML8T(*CF0E9:2.V81[)N0!.LY=+I(IE\YSA@%KN-E:9:UV%M[F[:Z0J5DAXVP
M5ZU*SM>3K<W"33Z%C(25BITS@(I^RG)*QP+"$7;.U22[R8CV\:+I5TD0P4+G
M6E:0WLT=2W#^L(V^8@IJT15757C"6"2K=;D(")L$^QAS&!^ZAH24M59CI621
M0.S8/;!#M7*R:TBT(J!;%GV5IBE/(^/N%VUU5GLM9XJE1C:P3E?AU9"XSAHL
MD/5697[A#Q%BDU)V!28PR0FD'"L_ I)-S*3465V%%W-_BW3L(:ZZJL5NM= @
M+30IR]40D6I=Z;$3,!(VFGIS;8KV&/9X%FX6E($LLS,5U&C*-6H/6P@LV[B8
M]6 8ZK'$GPJ782!3-YZ(MPJ3T%5R>MC8=%G^=CM"KA"MP8C$RKL"RD^NT<H0
MS(W)>271419D65+T8)HNXNZ9<)*4I1^C&$=UTT@XDGT*W: 9AWG$Q&, E)&(
M0+R_#2C*-ZY!S'IB9VBS0=N3H@BS='1$'>^3(WT>Q^2-_H\ >3(WT>Q^2-_H
M\ >3(WT>Q^2-_H\ >3(WT>Q^2-_H\ >3(WT>Q^2-_H\ >3(WT>Q^2-_H\ >3
M(WT>Q^2-_H\ >3(WT>Q^2-_H\ >3(WT>Q^2-_H\ LN9NNJJ[;JIK^?M-"A+W
M>R2BE)I<M,0$?:K>G!MA>3*E9K[IPE+3B<2T SJ2/&-')63<IEG(IIE,8 #:
MZ:L=RDC"-[-1U)J(AW]BEH@).$+*1==BYF1KS^P2,>94KME!-IR(E8H\PY12
MCA?1KYN1R8[1<" <]E/Z_DJG&WR.EJG(4J9AHRQ0]L8.HIY79>!FVS=Y"S$7
M,-C*L)"-F&KQHXBGC-=9"12=-CLSK NEU@=-8-@Z?J?KP]=-SUW6PU[ 0=JO
M@ST[78@M+K-G<S3*N6"U&D'+<M?AYYY7+ UAY&5%JTD7$+*(M%55&+@J8'-=
MW#5["C%V<]LE'::X/ L[2G?'$I!I4]2M2+9!Y'SZ5C.L$0I#OVCELX8R*;LS
M5XBY;G;JJ%63$P4VMLIL[KJR1<SS./LM(?/*O),(>Q-6DE#.7,+*RDT\K49'
MR""*AU6SR0LT;)UIDW4*"CJQQ<I HE/+1KYFW"G3ET%RQYJU+$=*1A8=^5B_
M>1;T6J;186DE'K"@]8.@(43(.VJH="S=4"*DYE,)>DY1$#L/)D;Z/8_)&_T>
M /)D;Z/8_)&_T> /)D;Z/8_)&_T> /)D;Z/8_)&_T> /)D;Z/8_)&_T> /)D
M;Z/8_)&_T> 5T6K9MU>';H(=?+K[**:77T\^GJZ"EZNGJ'ESY\N8\O;' *^
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MC(E(_:P<[-M&E3B!?IINWL?K]M(I^(BWD6^> JW)QZ<F3I4E)@@8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@%N6_P!S$Y\'./T<[,GLJ7X5FDX)G8\7
MZ"D4LMY7A@# & 2FC/<4Q^+*'[,+E1C;-B^-/_%4L$+8K.!3T30)S]!C3<8
MP!@&W;ZD7^)%1/C7L3_%LCFG^K#W<3WB=G>JL-D]37N4E/&9WUAYZ9YB\OHP
M!@%MN/=?#_%NQ_M.JY.TN=-"@N3( P!@'6+I3!E3BV?QB2 B';37B73A4H<@
MY]:R<TU(<1-S$!*@GR 0*("("80*78G_ $G#_,;W[0X [$_Z3A_F-[]H< =B
M?])P_P QO?M#@#L3_I.'^8WOVAP!V)_TG#_,;W[0X [$_P"DX?YC>_:' '8G
M_2</\QO?M#@#L3_I.'^8WOVAP!V)_P!)P_S&]^T. .Q/^DX?YC>_:' '8G_2
M</\ ,;W[0X [$_Z3A_F-[]H< =B?])P_S&]^T. .Q/\ I.'^8WOVAP!V)_TG
M#_,;W[0X [$_Z3A_F-[]H< =B?\ 2</\QO?M#@#L3_I.'^8WOVAP!V)_TG#_
M #&]^T. .Q/^DX?YC>_:' '8G_2</\QO?M#@#L3_ *3A_F-[]H< =B?])P_S
M&]^T. .Q/^DX?YC>_:' '8G_ $G#_,;W[0X [$_Z3A_F-[]H< =B?])P_P Q
MO?M#@#L3_I.'^8WOVAP!V)_TG#_,;W[0X [$_P"DX?YC>_:' '8G_2</\QO?
MM#@#L3_I.'^8WOVAP!V)_P!)P_S&]^T. .Q/^DX?YC>_:' '8G_2</\ ,;W[
M0X [$_Z3A_F-[]H< =B?])P_S&]^T. .Q/\ I.'^8WOVAP!V)_TG#_,;W[0X
M [$_Z3A_F-[]H< =B?\ 2</\QO?M#@',:$D"=SQSIFXY]/:\(Q79='+JZ^YW
MI%_W.KF7IZ>UT<C<^OJ#H YF , 8 P!@# & , 8 P!@# & , 8!;EO\ <Q.?
M!SC]'.S)[*E^%9I."9V/%^@I%++>5X8 P!@$IHSW%,?BRA^S"Y48VS8OC3_Q
M5+!"V*S@4]$T"<_08TW& , 8!MV^I%_B143XU[$_Q;(YI_JP]W$]XG9WJK#9
M/4U[E)3QF=]8>>F>8O+Z82WZEM9]K>YPVJHU)65FM>['8)ST;=%*M>ZW8UJB
M_2I+R@LEZG-04S,KV-5 AW$[9:@V@ 20DT59I7G'D!*;9$W2%3XNV.R*2\V1
M+3CF+;7*6=69\6QRRM$E=1^LK=3 &<;59^3>R\%9)S<DCK&]UV&LA9V\TG5A
MX;7LQL*RN:G8EY$3T3)RK1-KEO)YJ []>[ 5C-Q:C6YWP94R*%<%Y2%6\1XD
MYE#)J=2G(4>TFGTDY@?K-Y\G^ZN=/:079D 8 P",?%IMFSZ=U=!3]5,UC7=H
MW-H?5<K<)!LB\C==5G;6WZ;KNR7]VW=\X\5J[$6)TI"K2Y%H!I8UX9Y9&KVO
MMY-FX$HE5\O'=D(H\9FW]X</0T8*1M'8U]+8IC<2DG!5*C:8G;_',:=PSW#8
M,0Q-'NJ@V:2C:-M52:W%RWAX4+=)U^2E82(B[$Z\A-#"42N]DOXZ;:TOXDS)
M4E)2MP;#E5])04C54+J%\TJ6X6;:.J)*CO-:2UC*UU.5S:-=.[#?V\ZXUZ#B
M[3CY@,E7'LM)1Q(9Q&(2:)'(NQ%,NUO+_P#.FW2X\V:GQ'\;2FC=+;AGK#99
MFG[3>\)L;'.(&MZ&-M:Y7*]V78[/=4!1H@\>WHC&FOZNEK :$I=D(&W-KD>U
MIO9 U?-'%3'U1+]ZN[NHE^_ER7<1-K1G$1M>QZ3X6;3/557:D_M@C@MPL^OP
MID5&H]NK;-G$(%Y%6VYT60K^S(%6HPD9LN+6KK*#AK2A;8!BTCGK=O%QP^:)
M?M;E?V]FBJD7]I\4O$'1H_?T1.6J?JMTC*ON._Z2LM<A=3W?3-XU[3^(+7E(
M9R-4G25I>SU78FJX&\P- V_KG;,:_!]:[">=H,[88V%D'<>)HFUQUK7(J^1=
MI47(EZ)MS:TULJ]ON)'B0T7.6'[HE-U14=%7"O["6BX6/FXFT[5':*=MTY;5
MJNPAJS(3U-B*'2MA,56,'$2[:I;@K3:?:.>45.3@BER+NU\EU^GR$N,$# &
M, 8 P"/>V;Q::MMWA9KL)*@T@-E;+OU2N<6=C'.22T7%Z'VG?XHZ;QPU4D(Y
MS'V*EQ2Q%8YTU*X;*NVKTCA)5,$A*;>;VH8AUCLG:2^P]J:EL-EMDU*QF]Z;
MZRK+9ZQK9MSTP]UI5]A3[R.=:Y%2%E:O*ST'=J3#*S\5#;"J;>XTY6TJOG+V
MOS,L%V]DOSU_=-Z[;(][#XQ]HZ_X>82QG-<IFX.N)O:]$E+]!Z-N^PH9AK?6
M?'/*Z-0@GZ6M*1,UR(O%GH*;"(A#3#>+))"PL4O&E=VA.%BI832_BVU1,J5V
MZ=+B2VZ]O;A)L*]:PTK FD;%0=*ZXVLY9D3A"S-K;;,VQ8J4_95,]I.V@4[%
M1J+K;8=ABXV961CIJZ36OF,RY;0:4JQF!%VGD3VY##6N-R;KV-':<MC/; 0"
MLOOB_P!>CZ79ZUKF/B]N<.M?W9=:@RVA;'9(PT_'RUAU^UJB6II36<K6Z[<+
MR]@YU:%L%+NO@:N)IENVM^Y:5ISUVD7;*^[]Q\5S'<C/7>HF+%139<U9&6F7
MQFU0F]=R6JV/"I;+@ZVM895$SZWP=EJ7$XUJ5*>.GR*VNG-2N&OHSR,_G[JG
M*-!%$IEVLF_5$T7E]T+B!L;JQU#4>Q[DI#;"M\3/UBKS$#6XF29R]G%>_2T7
M:IMP+$L(4["#UE8JXV3@VS6LV"XUS83Q)NE59/5LK)@N][>;I5"1O#GM-UO'
M0.EMR/HA.!?[2U;1;Z_A4%%5FD6_M5:CIEZQ8.%N2KN-;NG:J<:]4 #/6 -W
M8@'>Y "W*J;YF;! P!@# & , 8 P#SDD-[[8->EM>A;/),3/\=%VT2M?DX.L
M"_UYK2!X,[%Q%Q9&Q7\0YKR[M>^5UC5QEK/%22BL!-O&7B2SQX>00$I2_-D\
MB?O^QUM8XEMPWSAATAQ!*&2HDU?[7ZGG7+%4DH1BYC$I/=^R=*0N^(YJ>::/
M)-NW(EN26U\FV%YY6JUBUTLL1ZC(GE6IA-$K3/H6G/QDHM87^SS.T.*ROS\D
MI+06K]ATR+I[!"-CTG<9"S&B]:WF2C2*,&K=S*J+6&PS#IJK(J.GI2.DF15Q
M;H($*/G<(,.>*[B>6JO#?M.$I[ZP1'$%2.$:[T.H5QE4'\59IK<=FM=IXD]>
MS*ZP!=F">DN'E:MWK7MAB4FB4[(5VP/;&YFF99.%CA]42]-RM^;)Y5N7*7GI
MGB.XB-BZ@VBK7TX&_;:5X2="[MU&9=O UJ(F=V[LU'>K?):BC"+*0\2K&5B2
MJ=<L4.C89+RJUK]]8(VZSJ,423A 5$NVKU1<R;>G=2J7''USN[BLMEQ-:8X$
M9C1<)O*\:QK#>T1E4@=B;=81U+?)'2D48.*.Q;NZWN9RYI4=-TM&,BHJH:OO
MUPV$W=-VHJJ"+KN7<3-?EINKO93+-#XL(^XRW#4K5I]Y=X/<5Z>ZBM*CJM)5
MHT59YKA:G.,>D7J+:E(JY9UB6UA$1;1I"OGL@_;,]@U-K87C*Y5^RLWP4R[5
M+^6FG-D7>)W8(& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!;EO]S$Y\
M'./T<[,GLJ7X5FDX)G8\7Z"D4LMY7A@# & 2FC/<4Q^+*'[,+E1C;-B^-/\
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M1$/%-$6$9&1S-O%$0:,6#)N@T:-4"$1;MTDTDR%(0H !VGEQE^0F/S>G_JS
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M3B4)TR\@T;4>[LM;4&J-6K=LM$C9;PX<-K )%H:'*)ITW[JIQ5)YJ+G4N[!
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MKNP:G-OJN:WK7)S!R#"R(UXUPA*W+T1&\Q-@II[5Y=B5FAA*HJ:-/,2RP0,
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MBUD;N_;.;:\CK)+Q2\R>->*M!"J^0S)@# & , 8 P!@# & , 8 P!@# & ,
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M1M=U1HH52L6ZF5&GUX+D\GO"T6KU>]6F%AZZ?O)E9R#8KQR\/"0!XL37+O\
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*!@# & , 8!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g713200g07g87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g07g87.jpg
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M<8&76&*"H34V0U*QP=4F151CAI.6U-?P_\0 '0$!  $% 0$!
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MVC\*O_84 \8\.[/V"P2;W1KYT4EOR2"0Z;8&K93^4KYRRGG5?9>M]DG.E35
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MID\9=GNZ>BQ$L^"S-NQ$W&5\/#!FX&<&+CQ]^'+O[O=@L68FQRPR]/3R'/\
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M7:X?EU"FY"E<_M=B,\:Y;R)M$BNTR\"._5JPY74'-BAAU$EE%HEV)QM?TII
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M!H9S96<NFS>I+O9YI_*XO5F;KZRU/D\Y8P6&I?!]PY3(7,[,^"M9;DZ=Y]3
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MYRR_=+LG48^&K5)Z%9.O%<^+X]"=#!$>LT(5STFQQ5YAC(L\^,HZ9=N>BZ^
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MY^_[N.]GY@^T^Y.Z#YY^P>]/JJ_S*?Y^_P"[CO9^8/M/N3N@^>?L'O3ZJO\
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MPB81,(F$3")A$PB81,(F$3")A%%'_P N]^E<_7WD2_SW?6=^)4K'\G']1O\
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M[E!1(GQ#C%:4YM+(;11@_P U:&[/M1=H&2[GAX.&M$YIR.6LA[:-!CCOO+(
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MM24(0G:E*5O24I2G7JI2E;]-)2G6M[WO>]:UK7KO*$@ DD  $DD[  =223T
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MNMZ(@:?]^MGT%+V75ANTGJ45]\ELF_E /E:.<7>@#J3TWZD[;GJ3ZO1T^A
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M]&:8[,K-C),U;VBW&ZCU,[A?6HNV?AL& >..&K7V$,TL).X(C%:*4NDCCFG
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MC92F%>K+S/PYA_;K+Z'*Z#IN6*X1D-8ZF[2+UG3_ &<%^-P,$AKYC7%B.2,
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M]EB5S#N)X7 I1_%UP^5W<NUSCUSL92TD.1&BGW8QI>OPFVY U7PGY!+'X*$
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M)T,S*[72OD<Z6%[HI&0M+I(GN8X%CB%3%ON'6^Y2<NCQ$XY&4J#F'7F9WO\
M?X,"&:D/:M:7BHL-L1_<N0T\GWH6^FT&:^(GY^#C'/5U'(&:TU5K2S;;V4:1
MK8>G;<YE[7>=I04V3[./%)5A;$\VY&OW<#(,E+Y>\]*L[RQI5C6&J]3104,)
MWTXRK\76OYBQ.^G5;YI[A4E=)$S;;;:*.4\) ?#'Z)ISWPPI<9,IO/8YR5[I
MT9W:'7YBZK<)KX3B=[6AF-KA#Q3#HX^U*;8;EGCQ&DI0X#'QN]:;3+X'L@P]
M:V,UJV[:UMJ%W"]]O,N=)1A<"7!E;'O?)&Z.,DAC;3IXF@-=#!7VX1(8[15&
M*87LS/-GLD=G.FO$NKL=U\F*LYSVEC=]FB8R-&P,<<7FBY333;+;;++:&664
M(::::0EMMIMM.D(;;0C6DH0A.M)0A.M)2G6M:UK6M:SKC6M8UK&-:QC&AK6M
M :UK6C9K6M&P:UH      V"W0 - :T     #8 #H  .@ '0 >"^\]*J81,(F
M$3")A$PB81,(F$3")A$PB81,(F$4D _<C7\9_6KR1K_)#VN_%1MCY9_]W^5J
M[F7U93")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(HH_P#EWOTKGZ^\B7^>
M[ZSOQ*E8_DX_J-_E"XL\KVF$3")A$PBT#Y-\JG^S\B/HM8.$"F?OWY#<6$'S
MDI5PI4?F?7:-TF1KI%FA(>P3%<398ZIEP+4]&PDJ5#D2+,BB.-2,H5WTT\)W
M]H^T$?1Z_6%0^'3UC[B"M \GX'Y!<VOH=X=F*9*24A2&&>IEE=(L\@UV*]CU
M2A52!)D8$GD; 5 ^\F)JVXM%WJT@7(=#&AP#K/28H^Q%;K/HN:1ML?'H-MMA
MN3TZGQW\".GKV"H X>D?3XG?[NGTGK[%5&B[ZYRSH]KXKQ_[QK7U20YCR_C1
M-QJ1\I+1=>@N5W/M]D.ZST8V4K,*#%](M:NR(<L5<%7<(^N6"--=W:K9,3P\
M#&\9UIV@Y&YE#H7L[C9D=43%[<CD]FNQVFX?)9-+/-M)$;4/@X.#XZ\I;$Z.
M>X6U%H^:U%:EMG3^FF-M99X+;-L;&MC& [/DE?LYAF9Q;$$.;$[9A$LQ$*])
M. ^.]8X;$%D))>M/0K)M1=VZ!+>]^8G#GW?F266'2%OOAQ7S>U/)&V^X^6]I
M)<D^45I"VMDT+H#&Z+JRR"1^3SV1)ES.>M;ON79WNYDC&/D<^2*MS27B/C<^
M5^TMA\LH:6S&G].5<%"]W$ZWD;)+[V1F\J>>1QXG!I<7.9%QDNX>(N>[RY'/
M=L18;-^6Q)A$PB81,(F$3")A%G(K\DY^D_LZS.J^8[ZWY!8-KSV_5_,K*9E+
M%3"*(R[%\]5J@92HZUOU^&S+P,RK:/\ 9[R0[&GXO_/216OQ?C^W[(FVS.;D
MT;.) /@RW1N$M'HWDAR(XO\ W3/OZ2]23 [-%^KER1YSZE^D X^GABFQIX/X
MS/\ 'Z.NNI&K]XF_<T[TZHU0=?KI:ZO27S2OA[^S:4.S\P3MI>]?9\5I:%HW
MOW(]/36LU^QC-<7=VNU+BL7&[H3C<*^:7;T[.OW)>$D?O-((/AMT6QULIH*C
MLYNE\OEI!U:,IFV01<7H);CZ<0<T']QX<".CM]RL"%XRU N01,7Z?MO2I9._
M7XEEF'T@(_"]VDL!AK;?;9TK6O\ -5GO"[3I+?P/AZVG>!#V;8B6<7,[>RNH
M[0Z\62MO$ ](#(82U[6 _P"*=.^+;9O!MT4A-VGYB&NZGI_'XC350].'&4XS
M8/0C>2:8.C?)L?E6UV2[[NX^([K?L/"0]?!:C(**CX>/9_)!1@; 0R-^FM;5
MID=MM&UJ]->]S>MK7O[5JWO[<WRI2J4(&UJ-6O4KL\V&M$R&,> WX(VM;Q';
MJXC<^))*Y_<O7,A.ZU?M6+EA_G3VII)Y2/0..1SG<(W\EH/"T=  %E,R5BIA
M$PBUM>.<"6P@>:CI%RNVL$7Y(6;9&2<,8!IUPA$388E;PJ9F*:)==)&0V9'2
MD<\^6J(EHY,C)I-U_,8"/)21W*UAV/RD,?)CN,C$T4T'$Y[:N0JE\8N56R.=
M)&&RP6J[GRFI;KBQ9$V#:I"PYLT<A@LL;P-F#0]KV;EPBGC);S8PXES0'LDC
M+G\J6,22!]<I#C1L=-V"?D>)4VSS]IB=P%EM=18II$K9Z]H=L)47:7;?JJS!
M<<X&PTS] 499@FQFVA$D$):1K>NR0:EJ@1S8AU]K';QRX?(57Q[ ]9)*^5FQ
M<E>1WG<FNZ]P[\(GD=U."6Y"/9KZAG /1]2>(MV^<Z.T^LYA/CP,,VW@'N\5
M&?V(*8N5?F$^-83EA* (BB9+?-J0U)DQID2Y %QC\T2XRTZ 5!N.0I(SLCL-
MZ)<7'NZ4$M36[0MY4CEMPN?)!!$?)A8WBXM^DDEQE<$.\K?F@;]=_2O/-G\!
M2ND_-X(V]>A\YTS8_'TE^VX\5/(KDMD/G&K#'<XI]#FVX5FL??;968"0M(5=
M8?T4/" !TP@]4A L$IT^W#D7:!$9(]K[;"EI^V]'1U+='+CHPXB(NW=-EK4-
MN6-Q'RL6.Q-BQ!:Z>2>;EJ+AN#Y0!:O;8\C-Y+8&5&[]7VI62O:?G,KU9)&2
M>KRK4!'3QZA6*I5%BZ4*7H8@N5F)5QEZ<L$FII4E*.C)6@5K:1VF! 8T!#KR
M(Z* 8'"$^.41\-V0.D33-IQ&&KXB.;@DEM6[3F/NW[/ ;%ET8+8F$1M9%#7@
M#GBO5@8R&+CDDX73SV)II&K495:\ASI9I2#-/)MS)"W<-;LT-:R-@)$<3&M8
MWB<[8R/D>_3?E/Q8?O-'K_/WJ96;$U-7BM@SMEL 4.2=SR@K,2?T6>J9,@VN
M5B[?/U2,.H-7FJNMJ=KEDML/;&W&PJ\8\U,++!V_7C]'O5<JGQ/R$CK3Y?HZ
MK%&VJN^1U6$@0;+R'I@6K+$ZW ]U#<=KL%T8>HP=&.K]3.Y9SJN) ?DQBK!J
M%M-B+DTMW6T#$Z=/OW_W?Q_ALMS\0E!_'?@S+';$U+D$'!V:XMU.**!Y]6)A
MNG/SQQU>19H'E#Y?/2NAR3#S\C-C<U25'2+A#)B1&I5^2':B,WG\+IRD_(YW
M)U,739N.=;E#.8X#?EP1]9;$Q'5L$#))G_NL*Q+M^GCXG6+MF*M$/WY7[<1^
M:QO5\CMO!C YY] 6JR_)_M??2B(#Q+YR\'7OC.!E]OZ0+N-K@GM7MIU^!BGV
MWVS'F%Z2M*7FIN02A>M&58?7[:GBTO:5K'74LE#LLT^^''\3HIM::BB-?'Q;
M$M<^A5>UXF>P@$![+DX#OCL9'YPT]VHLMFG.ATS0+8-RU^7R#>77;UV+H(B"
M'EIZ]1*_;SZP\5-.?>$=1&FT7[N]DEN^])=]CKI]Q6Z[5(US2MN)%BZT\\^P
M0(,I:VF6959$9I"6W X6,5K3:9C ]C.)CNC.ZWR-K7>HG<+G3Y<N=BZY!+A%
M6QKWO9)%&7.:QEITE8-X3#3K$;++HZ0JMF%W,V)<WD#U+[9+JS#XAL=<EP<Q
MNY ;(71[;%D,>VRNPAA@45(PS+0XXX^F6!V&T,L,,M-^QIIEIO26VVFT)2A#
M:$I0A.M)3K6M:UG96L9'&(XV-CCC8&,8QH:QC&MX6L8UH#6M:T -:     -E
MM[ &\+6@-:WA#6@   ;   =  .@ Z *+Y%*83")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(I(!^Y&OXS^M7DC7^2'M=^*C;'RS_P"[_*U=S+ZLIA$PB81,
M(F$3")A$PB81,(F$3")A%$K7?*=1Q?G+98HN$;VG:VFBR$_.$Z3Z^OR<>U\0
MXQ6O3?JD4=Y7V;^S[,BLIG,1A8N;E<A5I-(+FMED'.D \>579Q3S;>D11O/T
M*7Q.!S.<EY.)QMJ\X$-<Z&,\F,GPYUA_#7@!]!FE8/I6-Y[T2*Z5&G3M?"DV
MH(<]R.!DI)A GU=T=.MED!"_$<?2"RM;;"'R=,NND)):V.WL?>UXV U!5U'6
MFO4(;+:+)W5X;%F,1=[=& 99(8N)SQ"PN:P/DX'.D$C.6WEDG)U%IVWIFS!0
MR$]5]^2NVS/6K2.F[FV0D0Q3R\+8S.]K72%D9>UL9B?S'"0;3_)Y:^F$44?_
M "[WZ5S]?>1+_/=]9WXE2L?R<?U&_P H7%GE>TPB81,(F$3"*AW9NQ7SJ=\+
M\</'(QL:9':6CJ?44+6J/H,<I?P"XR-+8_\ V]OU6,^Z,O9@Y>]QT>IB09D#
MX7B&K]6YS4V<E[/>SZ9L=QC"-3:F:7&O@JY/!+6KRL_X^>L;WQNYT<I,%<LL
M,GGIZ#FLS?RM]^FM-O#9VC_PME03R\?'OPOBB<WQL>+7%IXVO^*9PR"22"QO
M$^&TCA-416ZB(ITPK;9-CLIR4+F[-)I2KW&R)&M;VEEM2W= Q[2M"@-.+TVE
M;[Q1)'0=&Z*PNB<6,=BHBZ:7ADR&1F ==R5D [S6)!U#&ESN3 T\J!KG<(+W
MR22;)@\#1P%05J;.)[]G6;4@!GM2[=7R.]#02>7&#P1@G;=SGN=N3-N4TF$3
M")A$PB81,(F$3"+.17Y)S])_9UF=5\QWUOR"P;7GM^K^964S*6*F$3")A$PB
M81,(F$3")A$PBJSY&^3<=X_RE#B2H%$GNUQ]YML_.27W]LUFC<XYFU6MW>XV
M _GW->I20 \6_<JVE14W#0-1!CGI67L-S@F(MEB3*H&_W#^)\%%> ^5TUWR<
M\@*Y%<ZA:]*<>(>%K.Y>]3+<==W'+CURFQ)9Y[_-@U1M8/)Y>P=OH'/Q>M\^
M?^O2U?KEGLUNYW=H&.(1M_']?KT_0%N[@?3Y3L?+8+H<Q6X^K$S,K= APH2Q
M$VZN2T/6;Q8ZK7[K4[297*D18:;T."A(Z^TZ9778Q$C6+)$E,((8=:,((>A4
MQN_0:1S:%=L5\M,+5(9KW:^<F36A=$.I3[OE@6%;V3(&*3]K80#));OXFV5[
M^S(G-9[#:=INR&<R=/%TV[CG6YFQ<;@-^7"PGF6)B/-A@9)*[]UA*Q+EZGCX
M3/=LQ5HA^_*\-XC\UC?.>[U,8'./H!5'Y#RPZMV\PBM>(O,S9,#3K@9O9>@B
M.P],B]Z5\-Q^+"(UK9K[6MZ>;;,4_)(VG>G*F4WZ[SC$_:CJ?6DTF.[*=.36
M8.(Q3:OS\+Z>'K=>%SZT,@!G>T'C:V4NL#;RL7*U:>_4N2R[W5],8Y\C.(L?
ME;S3%4C]!,;#YY'B [>0>FLX'=2>B^$D(9.,] \C;A+=\Z%OVN:;L#CK=&AE
M;5\78<77?<ELL-ES:TH',0/".H]%HK@CGXI'"=C5.:ZS/=H.6M:YS_1P;?<]
MN%IG?BY-;'[ALL+'$@1S-93<-G#'Q.633TC$Z87<]:ES5[H0)R13B.^_!'!O
MLY@/@UP;"1UY#5>(002/%'! %'""$9;'%#$9;&%&':3I#3 X[*4-,LMHUI#;
M3:$H0G6DI3K6M:SM$444$4<,$<<,,3&QQ11,;'%'&P!K61QL :QC0 &M:
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MT+UK&7:V0HS.@MU)6S02M\6O:? CP<QPW9(QP+9&.<QX+7$'Q*O,#&UBW6"
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MTE*=:UK6M:SL#6M8UK&-:QC&AK6M :UK6C9K6M&P:UH      V"VP
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M#C8I6GH^.>Y$]I!#@"-EJCLI3!+8GOLN'3^RQ/G9Q#H6F=C>[L</2U\S2/2
ML(KMNM;]$\QZ,O7[RDO<TUK?_/T<Z.A>O]OIM&M_[=:WZZUBG5SAX::U [Z1
M)IP;_3L[4+2/X@'Z%:^$W?\ V;?/T\6._/( _:%V&.VPJ=Z5,5&_0#._Q/OP
M@%BUZ_[-BT29MLAK[?W]AZ3K\>]Z3K>]>V:OK-.]S$YVBP_XQ].#(#U <O!V
M\K.-_68=AXD@ D>AE&#K+4NPCUF)EC_JTI;3_P#J?<MBURW5BW#O$UN<CIA
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M]J3<5&?.JZ6QHAX0?%D=YC<19;]$CQ,X)\":KN=;^I15;Z8L96#=AZFS 59
M?\YP>?1X*;<_\'.0U2P(N-S-M?:+>WIK;$QU6538Q@W&E*6EP6*6PV*^K3BM
MN-_653"AW?VX13#OJO<S@NQ;2F+OMR^7FRFL,LT-X+>J+0R,<3FDGBBJF-L3
MSN>)O?#;,;O+B+'=5ETM'XNM.+5M]G+6AMM+DI18:P@[[MC+0T]>HYIE+3U:
M0>JN4A"&T);;2E"$)2A"$)TE"$)UI*4I2G6M)2G6M:2G6M:UK6M:UZ9UT -
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M>_>F;NM$3")A$PB810^\76,H4&J>E(ZS2[7S+(8\94:Q-VZ=,*?2ZXAL6'@
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MM>Y24^OXU:U]N4/0$[$[#P&VY^@;D#<_20/60J@;D D $@;G?8?2=@3L/$[
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M<8.DF]:4VH..^:E@N6Z_[2ZNE3%@\-7^']:Y(LAQ>!J\4SXI)A\79R(B/%#
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MY UQ9&0T[:N(ZM9SM[56^?*;%_U2[O8V:VZ^A7VMD"1D'%W$WX>T[TI0TS]
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M1QSB-V[F\<$%0./&*7-:)SZH:6+[#<EJ&R<MD?.9&_\ P&MUW#(H2 UX:=R
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M4L+#;;$B1*Q7&7JT5;*,%^EP\#6&0/L4FDGKCK1XGU96;\1B:34FD:!:KSL
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MS/JT8Y<ATC1^_E(\@"T?5X\Z*:2WN(.%)C'66'A'&6_+ALYP] )V]F_15'4
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M>H6%1:(\E:]=K3R":AJ"%+RTR[9N8G2]?@)P2M3MLY]#=1IDUU>EPLX?,5T
M"6NO+H^X52.<.L5?#=,F&1RIZ&8=<DA2?K]?K[52ZU4#NIGCC6^3_L)=IEK&
M_P!3N!\-9('K?-0;-P[EMLZ1U*RT0J*D9+O=<U9NC<7Y6[2>>P8)$S-UR$NQ
ML!,QDG=ZS6)AU\O73??<?9ON>F_\-]_=X+U(PO*T7Y)UJYV[CED@:&)(2LV1
M+40R1KT3,BUV6N%(A^@U69Z71(J;/DX2/C)2^\YC[53(XJ1FX2.;-G6/J$U$
MA[?D1B?K]>Q4KN7,^T'>+3'%OV">HS4W+]&ODA7Y6"Z5RP.?X5SGHO3NXS%(
M*K1LGVVMC2'1O'GDQ5&K-8AQ)TRGUZ[S- ,I\_:H.DV Z *OIWW_ -__ '_3
MX]=_4O49"MK0A:D*:4I*5*:7M&UM[5K6]H7MI;C>U(WOVJVVXM&]ZW[%J3Z*
MV5%I3R.J=MO/$N@U6CMJ+L4O%"MM1#<FW"N6:*&EHXVR4UJ7>>&'BWKK6QI:
MI-'EE!AB.327S#0Q4.DM%4=#^O'T?>J#]/\ 'SR=M_AU?.#\UJT;1"Y:0[E;
MX&K3E_!K:!*S?+9W6Q\<XS7[%0B;,BK2/+I$GCLS,18;P_-&XA#'+:Y;)2E!
M3:F"KOU!/T;_ ,-OU^2]71-E*%&4<V.T:H=G9C0CKA K96VT[(;&?>9&=>'0
M[[TLNNCCN.-Z2M;+2E;0DO*TOU_F]IMTQS.ZT.8@(JZ<NL4U,1+5K!D#ZY*@
MV:JR]2F8^01$E"2([NA)1!H10[CFD$":9=9V@C;K.E:MT[D\M;TWF<';H5<Q
MIC(W+E5N4@L3X^U!DL7;Q5RO8;5EAL1NY5ILT,L;G;20\#F;2%[-YT=J7%8>
MGJ?"9^GD+>$U5C:5.V_$SUZ^2J3XS*T\O2L5G6XIJTC3-5,,\4C6[QS%[7\4
M? ^!P'#KK4N4"<B$,Y7>*K'5"%$3%]&IDE*1LY<U6XVRVZ1G 6)98FX$U)+2
MZZ"@8DJ'E&&2R7)!MC33L%0T3F<5I6+244NE\WBZ^(I0BMJ'#V;-:]F#EILC
MEK-Z!EMT7<)Q(UV/KB.62G:8R65]AK.!T_D-=8/+ZMEUA-#JS!96SF+TQM:;
MS56K:H848>#&8>M0G?3;-\(0&)S<E8=+%%=J220Q-K.DXV3K@G)R^-T$ZKG2
M48:1)6FU6Q4?7@"(JIUA-ED%GHJU/BRRC" *U#)WIH!AU_W*6LA_X3'QO@HG
M=":5ETA@IL9-9K3/L93*94P8^O)4Q6-&2L.G&+Q%666:2#'4P>"!CG[ESI).
M%G'P-@>T#5T.L\_#E8*MJ".MBL5B!8R-B.WE\H<97%<Y7,VHHH8[&3ND<=B1
MD8 :V./B?P<;L+WWGLIUGB'6^80IL?'R]_YW;JC&E2^B-PNC9Z#-CAV9Q(C3
MY2X(MPA(DV@5A\AR*?+0PRZZI+:I]IX7 [;['=:X1N"%2F]>*/:[GRF3HK _
M-JJ58.ZSW<3&*5U.SUPBH$6!=P%)K/.KB3PJ?%B25Z.@[+.VR7YG+CV@FR=+
MJNZ9 NR,3?FO0<T'<\1Z =0.NQ!ZCB_@!OZ =SX*G"?9UWZ$^/AZO5_W*^_+
M:Q)4GF/.:;,K@W)BI42H5B576 28RM+DH&OQ\4<NO1II!9D?!J*$=W$@EE$D
MB ;'8?(>=;6XKP3N2?62>JJ/ >ST*8GMOO F,B_*[)=%(;'T>RL@'XZV5I9^
M<';<:<?%^)M/S#+;K:W6?>A+B%*TK5%54K#X!Y Q7CM^P?"=;YS#2!+$G&2E
MM H%M9,=@['=)2<M(40XCHB28$^3J\J56H^;&<?DH$YY=BCG4',@MB>^)O%Q
M;';Z2/';IZ/0?1Z5YV.VV_3[]O3[OO5P*M#-URL5RO-"Q0+4% Q$,T%!".@0
M8;<7'C@H%A@7WRG@HH=+&F8X1XDAT8-#++C[RT;<5X/B5Z69?0ZXP\VP]\N\
MMIQ#+_PTN_ =4C>FWOA+]$.?#7O2_AJ_!7[?:K[-[PBJQ#^,9@G';1Q.:ZW;
M)FJ7372V+,\+"5>!E#0NM7TVZW,84Z/C]E1;A(L];:M'E@O-/QL38=',JW.1
M$;)M>R_<AVW4;>GU#8?E]GTJFW0C?QW^\[G\_M5IV&&!6&1166AAAFFV!QV&
MT,L,,,HTVTRRTWI+;333:4H;;0E*$(3I*=:3K6L\*JX) %F3 .C25EMCR 9(
M)#@$@?$GH9+96PZL*4BR0Y.-+2VXI0TA'&"GAO:00&2P0VVZDBT) ^*?!8"C
M07,?O'>L_.*U'E1D+1.DV^\]8J0@I+T 0TI=?Z?9;=%EF1#M;CMUF1-&)D:F
MDF?162HENUVA,QZXG;[[]3Z1L#]HV_CZ_3X!4X1X>CU+;- H50Y91ZCS;G\$
M'6*/0ZY#U*I5X#;ZA(:OP(#$;%1[3I3I!9'RX8[2%E&$$FEN:628202ZZ\NA
M)))/B54#8;*0G/1R!W6I-T) C[3C+[9RV$CO,N)VAUIU!&]-N-.(5M#B%ZVA
M:5;2K6];WK/<<4LAVBCDD/JC8YY^QH)]"M230PC>:6*(>.\DC&#I]+B M$$5
M3Q2@JWNHEUOQ[AJB@&8C-U@B'YO'5M$;8)&'F)^/W"N#,QB09N7KD!*S FQM
M#R4C!0YQK;Q,6$ZQ)0X3.V".[XC+3N/AR:%R4GU;<$3B>A^]1,^I--U0>]9_
M"5@/'GY6A"!Z]^9.W;JN0;O7C!1HB/@(OK7$ZY"0H;,?%0$#<*8(!$@"MZ:&
M!CX6'.TT"(.TE+; HPK3+2$Z0VVG6M:R6AT'K>SUBTCJ1P/@]V%R,;#OZ>.2
MNUI]O$H&QVF]G-3<3ZZTBPCQ8W4.*D>/_5Q6GO\ 3\U1>1\V_%6+]WS/::N[
M[?Q_3F)N8_F_28HWW?\ P^N3$'9-VBV-N7I7(-W_ ,N^I5^WO-F';^*@;/;E
MV3U-^;K;%.V_Y-'>N?9W.I/O_#=9#FWF!X]]=N8U!YY>W+!93 SC11?O7MT4
MP^S&L;),T@R:@HX;2VATN/:2MQ.G$MJ2WM3GM0JSGNS'6VF<7)F<WAVTJ$4D
M,4DGPCC++V.G>(XMXJER>0ASRUN[6GA+@7;#<C(TSVR=G>L<U%I_3F>=D,G-
M#//%#\%9>I&]E:,RS;3W:%:+B9&'/V+AQ!IX>([ V8S05T]20#]R-?QG]:O)
M&O\ )#VN_%1MCY9_]W^5J@DH[UQ,@7J%C^<.1.GE?(.2DO9F)!8_V>S9;0D(
M0,V]^/W)9><1K[/16\OJRM-=5;\SB@8G7)'.!Q)J"R-S*K$7<9#;PNV4_*I"
M]81MEG2'=.[)][;CKGN'^$MM+;VG-MTF[139;O[91YR2(QP]P&%-8;2<3^\=
MYY[V..[>5R>6=A\;QC<L(T37+.T5]?'CL]FTU#.)I_A,ZA;;/%%P1]V%/NT<
MK!L_G=XYK0X_$\MP D!IEU#QU\\NQR%;D[^[XXRA=7#FX@'Z?8^I5P>0KEFD
MJK+V:HV4.N:BA+73K))T>H%S]5L;,G!3'T (:0!("66,3NW.[#O^2ZY_TJ'^
MT+G'=_Z2O_+NS7_0R?\ L:_1O'S[H*-T:I=5^^7C!=TH]5N%+KIDITCMTM&,
M5N^2\5.VH ^O29Q<!,JDY2OUPA)DQ&G' IK=>'CR1!H:/98<[L._Y+KG_2H?
M[0J\C^DKX=^[-?7\GDO]C6RYNH?=)++&D0UC>\2K!#E[845$S<1.RL:2H9]H
MH?9 )]??%>V.4RR2QMQI6VGVFGF_:XVE6G-[#O\ DNN?]*A_M"IW?^DK_P N
M[-?]#)_[&L9(<V^Z%RQP$I*QWAO)R<7)?68R1D*S)FG1TQ[(YOZJ 636G" Y
M+V1$2CYX=QLKV1<<GXOH$-IIS>P[_DNN?]*A_M"=W_I*_P#+NS7_ $,G_L:E
M'T[[J!_O_P 7_P#^C:?_ -"XYO8=_P EUS_I4/\ :$[O_24_Y=V:_P"AD_\
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MWO@/^D@[QUGH"/U\O'V7_P#WF Z_=[OS]C;[I<]^"YY$<0#UO\:Q*6T0M/\
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M/C/4S[7>Y/C=J_W;R[^F[9_A_'Q?K?\ 8WWI\9ZF?:[W)\;M7^[>7?TW;/\
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MA_VY/^T9K7_LW^4'_IT!_B'']3=W_GGH?_7$O^R)_P (+'_]'?:5_P##\/\
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MRUY0?^GR/_\ /Q_4^_\ Y]Z'_P!;'_LD_K\C_P"C+M+_ -0-_P"W3_M#1_\
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MK3/;= L$-)-+W).JWKW-C[:CS'-N[9IVXBX>'KW!^X+/9)%P,!<-PQK2.OH
MW!]!4: \3N*QDK79P*B$-3-88L H$HJW75\^1&MDJ!-6D>VE$65UZ]L621B8
MEZ>:NR[ W+MQ,4(>D@.-!'8IRYO#A.WJ\GU;=/5T]2]<V'IY0Z>'BOJ \4>+
MU5^LF5FB$0$A4#CSX24A[;=(Z7TJ3'I )H$M+BV5J3L<"[%\SYU"(K5C*E:\
M/7Z+4:\/%M0E>B@!:&*8^+2?]'Z?>>OTE.;#\X??^O0/9LM_?)%?F5?RI_ZY
M3D2_,/W>]5Y\7SQ]_N3Y(K\RK^5/_7'(E^8?N]Z<^+YX^_W)\D5^95_*G_KC
MD2_,/W>].?%\\??[D^2*_,J_E3_UQR)?F'[O>G/B^>/O]R?)%?F5?RI_ZXY$
MOS#]WO3GQ?/'W^Y/DBOS*OY4_P#7'(E^8?N]Z<^+YX^_W)\D5^95_*G_ *XY
M$OS#]WO3GQ?/'W^Y/DBOS*OY4_\ 7'(E^8?N]Z<^+YX^_P!R?)%?F5?RI_ZX
MY$OS#]WO3GQ?/'W^Y/DBOS*OY4_]<<B7YA^[WISXOGC[_<GR17YE7\J?^N.1
M+\P_=[TY\7SQ]_N3Y(K\RK^5/_7'(E^8?N]Z<^+YX^_W+3EH\<^6W2USMUM-
M+^LSUII+O-[5\U.6+4)::(Z#98[=6L]59F6JM88AH6XVC0PTQ#&Z$?FSC!5,
MF.:?37E3  !IV'4>'CONJ&6$^+QZO2L)&>*/&H:8B+#$TJ0CIV&B9N#8EQ+M
M?&)"1C[--2=DL2;*4BTZ>MY<[8)B0FY>3M:IF3D95Y!Y9CI(PKC->7/\T_=Z
M/#[/1ZO0G-A^</O]O7U]?6N[$>,?)X&8K=BB*E)@V.K'3<D#9&;K>?OCE#+(
M362YYVXSR[.N7Z B5<IE2:,8O9EC'="K<)';:^0C11FZ&*8[^0>NWS=NGAL/
M >)\$YL/SAT^LK#Q[3C+;FG$[1O:_76M^GVZ]NM?O;WF578YC7!PV)=^06+8
M>U[FEIW ;^960S(6.F$5-_(?QAN/D%92]R?5*_$<W3R^YT^NTHGF<C-352Z!
M=:U:ZN=UR(M373(2(*GAH>= @0XN;HTJR)4U7BOQ\@"KH<K)@%7]'V>KW_P\
M/3'M^)%^)DJU*E]NB0)#5Z[-T#H$K4N92U<FY6=Z_39;GNWN9R+_ %>9;YD[
M4*J='JA"I@/I1+UEB4SYKBVS'HM!-_U_'?\ BMP^,OCZ/XU4&8YZ!>9R]1)=
MZL]LA")V!I5<=K<-.N"?3Z>!'T*NU>!5&P;(FM,$HB!G7GB2-,L QR(^+ (3
MNK$85$PB81,(F$3")A$PB81,(F$3"*D5\\6^EWKJL_U8OLE+^K1T_0I?BXTG
MQR<D]<LC*5+1LF94Y!8W:8D*X05T>W99"W%@1=*M$K.G4\MZQJ@N:U:LME7?
M];_[O7L=OH^E1@3PEG@(V+KJ>F4^7K$)PSFG*(P&=YG=AYIJU\TO(728GIR;
M31N\466BY)B[CKL-?C:INLR-4.'@GHNT*>A?BG$W'J/4^OV_1]*SG!/#,G@?
M16[O$]':LP)_/(VJVF/G(2\OV&8LK5DZ1=)^T@6(KKY\.T-/VSI$B=\A;J;>
MK-'@AM@ZO99)1$EE#X'V%5!\/:#O] VZ>OI[5C^A^*G3NA](M'0Y'K-3T\S)
M<SD.-!'<DEY CE(_.K[0^ADP!1;/8HV.MT!?Y^HF$WU0D%3K/,N/T_35H$"Y
MO6@-X CD VY3O3Q>4WKN"/4=MM^GH'JZDK/YL>^_,;Z/0?0=]OUM^2UTCP/Z
M"IN)#.[37)./IE<JB.:M%\?DDE4N_P 'U.E]WLEMVX-V)B.FX/H'7*-7R['4
MRX@<\#GD-#4&L6^")^^:V6NO!)_DG=?'RAU'"6@>'H!\?7N2#Z'-B],@/\#X
M[[G[3Z/4IWQ7PXLG(.PR765=$A[(Y:H.<8NL1JDVF#679K-U_O/:9R4JCHW7
MS*[!P+EI[J>#&P=IJ%_GHR!KP8K=U>/D"I)NACE(VY9\>G4> #6C?Z=F^((\
M3T02Q [\P'?QZ'\NGW>]7<^2*_,J_E3_ -<\<B7YA^[WKUSXOGC[_<GR17YE
M7\J?^N.1+\P_=[TY\7SQ]_N3Y(K\RK^5/_7'(E^8?N]Z<^+YX^_W)\D5^95_
M*G_KCD2_,/W>].?%\\??[D^2*_,J_E3_ -<<B7YA^[WISXOGC[_<GR17YE7\
MJ?\ KCD2_,/W>].?%\\??[D^2*_,J_E3_P!<<B7YA^[WISXOGC[_ ')\D5^9
M5_*G_KCD2_,/W>].?%\\??[D^2*_,J_E3_UQR)?F'[O>G/B^>/O]R?)%?F5?
MRI_ZXY$OS#]WO3GQ?/'W^Y/DBOS*OY4_]<<B7YA^[WISXOGC[_<GR17YE7\J
M?^N.1+\P_=[TY\7SQ]_N5.>Y>*]][?=):9D^GU^/IS7/3*OS^ID\RD)62H%R
M.(;E3.B,6!KJ$1%6$^4E8JL@2<=+4_XS%'B9>HU>:JSEVN,[,>Q%(!\F[??<
MG<=1ZMOM_CU] 7DRQD[\P?0-CT/K^WW**@^'/2-3T2=8NH\[N-9&?[5;96CV
M'B$V[ '=8[@7T8:QW8%L3N0JA(:-I%ZUS>)J,PBQN:JI-[<+LA$Y>!Y>JN7)
M_DW#P \IO@-MAX>L;GPW/H3FQ?Y0'Q/@?$_K[SZUQ\V\)[?SSI-!Z-^RG&3"
MZB/=HPFKN4^_B5R/@+=9(R<'KO-A7.\'NU"$A!XUP<.(NCO5H@<^3//A8Z!!
MT!"@#'*01RSUVZ[MWZ=.IVZ[_1MX#??KN$D0._&/^M^O'J=]UZ(!H6V,VA>O
M:K7O]=;_ 'O5Q6]?B_Y;UO,J!I;& X;'<]/XK#F<'2.<T[@[;'^Z JP=Z\H8
MGQ^N%-B[9 LD5&S5V[2;\^)/B?? F?JU?E+-&U6,JRQM,(W.P\!8Y#=PN-@I
M?/H8:"/;F+6&>J."D+RM[?KZ/7^"A41YZ\EGWB8R%K'09*TBVE5073AM<Z^O
M/2;71N!\M(,#?<Z*W7CZXW;/(>I-#VD*=?KTO'P%ND(&2E6AJ_JQDV_@/7Z/
MN7>IOG'S.]6*JUF!IO273+=SN#Z@#(.#T!5>C*K9T7%VMJLED$Z$5!UR7F&*
M--.-PDN>))1SCL6%-#QDC),!X3;T]/M]GV^/H7Y;/,(;GUMZ[%W#FEH>J?-N
MA"T*/L=3<9DBI9(GC0=Y-6ZRR8=G;ID()%UNK0\S#[CJI9;Q9"Y1N(VY"AHF
M-(#)MX=1U_7Z]'TK&B>=U"E;/3JC$T"^N2]LLHU?6N1D>:"1$:VWU6=X]83V
M9X'H$O"V3=6M<3'.2PE7/E][C[;4T#/NS,MJ'9)MX]1T_7Z^_9<5-\T0K?U[
MR7Y$'7(3Z]Q:M6*RT$1^VZAG>FAT4R0K5[?-DIN)#AJ7#0E]9CZ;]?F"OEER
M>[*0.,=7ZO\ ?#+DV\/I\>GA[^G519W[H32'ZG$KBH9)?1CIZKPAM7^?]D2(
MH[JE7YA;B&##V8JQ&BU>5FY**5)L5?<$=9X0L",EI.&6%/GE3;[/7^OP719^
MZ5<IA^?$VV[U"]A3,53K)>Y. KH=>D?FJQ7.ERG*G9. +E[/"-2"C;9$280<
M4^L.;6W%2D@J.1$C-R#Y -UN\#R\ILK'WLZ-H/33':3;:74!HU U!9.NI=^[
MS;O'&O25465T >.'BG.CT:Q(+5<CZC)"P8K,JN-W\TP,LG\?QZ?=^"U+(?=*
M.'Q<1'V&0IO8 H.3=NRQ#SJY4XX@B(HQG'(X^PQ\#)7D2SSL8?(=PIP8@]=A
M)><CEBV-ZT0]=$B/F"2]<)_7O\/UTW4RB/-RK6.SU>LP'+^B$[FK=5:C.3ID
MQR1FN54NW73KM"CE.R\;TR8%LSK<WQJQONMT]4X&Z$;& BR1%M6356"IM^O^
M]78PJ)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(ND1&QYCK9!8 13[0Y0C3Q K#[K8IR6TFC-N.
MH4M YB6FDE,IWILA+3>G4KTA/H1<34-$,+;=8BHUEQH4,%IQH$5M;84<[I^/
M#;6AK2D"@O:T\&.G>F1G=:<80A?VX1?"8*$0MMQ$-%)<:T:EIQ,>(E;>I,G1
MLEIM6F=*1J0,2DLW2=ZT62G3[_Q'=:7A%WMC#;7MS8[&U[>V1M>VF_?M_8_R
MFW]J]OK\;8O^;;<]??\ +_M/N^'^#A%CVJ_ LI;0S"1#*&6 !F4M1H;:6AHL
MKYZ,';2AG6D,1QN]F -)UIL0K?S Z6W?P\(NPF*BT$$EIC0$E&[WLPE(8^B"
M]J8:%5LE[3>G']J&88'WMU2_5AEIG?[6VA.B+A:@H1GX'P8>*:^5%& &^%'B
M-_+@A.;=##8]K.OA"B.J4Z,.W[66'%;6TA"M[WA%]NPT.^PH9Z*C7AEZ1I0[
MH(KC"M-%?/-:4TMK;>]-F_YXC6T[T@K_ #A/H]^'A%V$A!)]WM$%3[E-K5[1
MVM>Y;)+AK2U>B/M4T8\Z6VK?VH)=<?3O3JU+V15B[E9YKF=CIEFH?C*;V2>^
M6N36K!7B(^)+J?WP/UQZ=;^(B#F2U$VM</%NGE;8&V2B%9;641OXC2-#UIJK
M4.FW8\8/1&2U<VVVP;+Z%ME9M$Q&(1MD'=;DCW3A[RTED;&B,@.>XD-A,QD[
M^., I8:QE1*)#(8)1&(2S@X0[XJ4DOXG;=&@<)V)Z[:8:\F.Y,CLB,^!-V:$
M'^2^7%:L [8['TTGYR/^"RF@:;:^0,W\T%[$I^5)_;V/8[^%FC_UI:__ .A?
M47^M?_\ BJ%_:7._\S[_ /\ S7_^FN:8\L/))JJWV2C_  KOH4S7^<=%M-=2
M=.D2PLI9ZM2IVPUFNN1@E8B9 _=FGHV/KS0L67]4==DFT@,$$^QE4YIO7VL,
MSF:>.R?9?F\!2L&7GY:UD62P5!'!)(QTD;\=4XQ)(QD(#9N,&0.:QY'"<W'9
MS+7+D->SINY0@D+@^W)8:]D(:QS@7-->+<.< SH\'=VX#CT.A1O..R0$BDBM
MWU7=ZM7+'(0UHNAK/+:[S22<GXKGC<=8_OTYBBXO47E_.G[69<[TW9XMWH5
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M5^4SA)#SQ@E^Y'#L-MO$GJ JV?Y1?F!_[%YO_J1%_P#Z-SG?]8/:Q_T/3_\
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1A$PB81,(F$3")A$PB81?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g713200g11b01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g11b01.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[19*4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             !
M\0  !T,          0                         !              =#
M   !\0                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !\0    !29VAT;&]N9P  !T,    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   ?$     4F=H=&QO
M;F<   =#     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    $.$))300,      N[     0   *     K   !X   4*    N? !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  K * # 2(
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MMI)*?__9 #A"24T$(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O
M '  ( !# %, -@    $ .$))300B      %&34T *@    @ " $2  ,    !
M  $   $:  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (
M   >    ?@$R  (    4    G $[  (    )    L(=I  0    !    O
M .@ +<;    G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD ,C Q.3HP-SHR,2 Q.3HS.3HR, !R<C4P.3$V-P       Z !  ,    !
M__\  * "  0    !   '0Z #  0    !   !\0         & 0,  P    $
M!@   1H !0    $   $V 1L !0    $   $^ 2@  P    $  @   @$ !
M  $   %& @( !     $              $@    !    2     $X0DE- _T
M      @          /_A 4A-30 J    "  ( 1(  P    $      1H !0
M  $   !N 1L !0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(
M @   !0   "< 3L  @    D   "PAVD !     $   "\    Z    \     !
M   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C W
M.C(Q(#$Y.C,Y.C(P ')R-3 Y,38W       #H $  P    '__P  H ( !
M  $   =#H , !     $   'Q          8! P #     0 &   !&@ %
M 0   38!&P %     0   3X!*  #     0 "   " 0 $     0   48" @ $
M     0             #P     $   /      ?_A0 !H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-
M,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^/'@Z>&UP;65T82!X;6QN<SIX/2)A
M9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-2XS+6,P
M,3$@-C8N,30U-C8Q+" R,#$R+S R+S V+3$T.C4V.C(W(" @(" @(" B/@H@
M(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO
M,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"\B/@H@(" @(" @(" \>&UP.D-R96%T941A
M=&4^,C Q.2TP-RTR,50Q,3HT-3HS-RLP-3HS,#PO>&UP.D-R96%T941A=&4^
M"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I-
M;V1I9GE$871E/C(P,3DM,#<M,C%4,3DZ,SDZ,C K,#4Z,S \+WAM<#I-;V1I
M9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#$Y+3 W+3(Q
M5#$Y.C,Y.C(P*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N
M8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!8W)O8F%T
M($1I<W1I;&QE<B Q,"XQ+C$V("A7:6YD;W=S*3PO<&1F.E!R;V1U8V5R/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P
M=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.G1I=&QE
M/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL
M:2!X;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9" M($=E;F5S
M:7,@1BTQ+F1O8W@\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@
M(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @
M(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^<G(U
M,#DQ-C<\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @
M(" \+V1C.F-R96%T;W(^"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S
M9CPO9&,Z9F]R;6%T/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @
M(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS
M.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S
M;W5R8V52968C(CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI
M9#HS03A!-C(Q04,Q04)%.3$Q.#9&03E",D,T,T,V0C=#,SPO>&UP34TZ26YS
M=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#I%
M-4,W0D-%.#@X04)%.3$Q.#DW.4-%-D(P139!,#=&0SPO>&UP34TZ1&]C=6UE
M;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N
M9&ED.D4U0S="0T4X.#A!0D4Y,3$X.3<Y0T4V0C!%-D$P-T9#/"]X;7!-33I/
M<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@
M(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I%-4,W0D-%.#@X04)%
M.3$Q.#DW.4-%-D(P139!,#=&0SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C Q.2TP-RTR,50Q,CHU.3HR,RLP
M-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C,Y.$$V,C%!0S%!0D4Y,3$X-D9!.4(R0S0S0S9"
M-T,S/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#$Y+3 W+3(Q5#$Y.C,Y.C(P*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T
M:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M
M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S
M9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M
M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H
M;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HS03A!-C(Q04,Q04)%
M.3$Q.#9&03E",D,T,T,V0C=#,SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C Q.2TP-RTR,50Q.3HS.3HR,"LP
M-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ
M2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E
M240^>&UP+FEI9#HS.3A!-C(Q04,Q04)%.3$Q.#9&03E",D,T,T,V0C=#,SPO
M<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT
M240^>&UP+F1I9#I%-4,W0D-%.#@X04)%.3$Q.#DW.4-%-D(P139!,#=&0SPO
M<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L
M1&]C=6UE;G1)1#YX;7 N9&ED.D4U0S="0T4X.#A!0D4Y,3$X.3<Y0T4V0C!%
M-D$P-T9#/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#PO
M>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S
M:&]P+S$N,"\B/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P
M:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( )\"
M4P,!$0 "$0$#$0'_Q  >  $  @(" P$             !P@&"00% @,* ?_$
M $\0  $$ @$# P$$!P4#!PD) 0,! @0%!@< "!$2$Q0A"14B,4$6&"-15Y;5
M%R0R87&!D? S.4)XH;'1)4-'2%)8M\'8)BDT-5-G<H*7R/_$ !P! 0 !!0$!
M               $ 0(#!08'"/_$ $41  $"! 0#!@0% @4"!@$%  $"$0 #
M(3$$$D%1!6%Q$R*!D:'P!K'!T0<4,N'Q(T(5,U)B<E.""!8D-)*R-4-$8W/"
M_]H # ,!  (1 Q$ /P#[^.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B
M$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA$&[%W]AVLLSC8/?0+^3:R=-[:W<,]9
M%@FA)BNFY6%1,FA.))L8IDNYA,ZJ5IHZ 6'(:"<LN="484.^L(I?FGU&K>%&
MR#,M9Z#E; U)@65=.>#;)RZVV35X7E./93U(1M5W=%&I<'7&LB#DE9AV*[CP
MBWR^Q?E-,7WE@:KQZ#>) GS8R$=<SK%W;!V/DM/A&LX>YQ;8V%U)FTS67>?U
M>L,8PK6_23#UOK/,BV-X'"<LM[4F>;7_ +0K:EEMK[,B,G4$?M%HGFL:Y"(@
MS7ZD6Q\]T<F1XSK2PT=9;,TCH?J8T=EB9ECN=6UEJ[.-\ZDP#(JO-<??C(JG
M#\L=5Y["8RN@V.:5YZBY))'>5US )# A&[+B$.(0XA#B$.(0XA#B$.(0XA#B
M$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$0EL+J*T[J[-L/UQFV9 JLUSI8KL
M?H05MO;2TASKF)CD&XN%J($X..T,S(["!C\6]OR5U0>ZFQJP<QTLJ"XA$UHJ
M(GR[OV^%553NBK^2_N7Y^$_T1.(1Y<0AWXA#NG?M^?$(<0AQ"'$(<0AQ"'$(
M<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ
M"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"*;[_P"CS&NHO;^N,^S7
M+,NKL1PO5>W]:7>'89EF88)-S.'M>WUK,F1+K),.R&DG2,72MP6=76V.':4=
MH2UARQR89:QOKH13?8OTQ,AR+/:FCQ/,Z^FT.R]Z;;R?[K8>Y19VX'3C;8I9
M4]9EN(Q;L^OMS9!/B8=745%LC-)=/=8I1$KJZPI,T;AN*$@H1L2QGIEU!B*Z
MN=1T,Z._3N!YOKG""EO;>46+C>Q2X_(S+[4+(ED?=VUY+QFLG2KJT=)LEF^\
ME-D(:=)<1"([?T(]-I,2P3"'8E;KCVM],XCH+$XOZ69$A8.LL'S'!L\QRG/*
M2P]Q-F1,EUSBDPMO*>6RE"@GB2)#XTV4,J$7"XA#B$.(0XA#B$.(0XA#B$.(
M0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA&I[JWZ&]Q[?ZKL Z@]39Q1XOZ
M6(ZMP3(+:QRG+:#(=>PM;[OA;4L<DPJHQ^NF5F:SLXQ4V1Z]MZ#(IM%7AB60
MI19DZ(Z5"<AO[]^PV\\50<[P3KBQO"';>V-F.";+T%O'9$W"LRE8O.H,:R/$
M]HZ/JL?=BBU>+4]Q A5]5G-_7-AS[:T::,6,IWD/':944;SI[HVEHLCM+<&)
MZCK(5KE$;-)D>Q-)#&%AV 9IGDIKXP''*LN-AU)='K@JQ.PI$YD8!2]A#(XG
M=J2L#PZ?Q">)$B;(EK64C-B<1(PTOO*8 S<0M$L=20PK2**5E25%Z#8D^27/
ME&I?HX^MSI_JNV!L["GZ@VMA0</3[3QJUI\;R+9Y\@QMMG]D,F9'38)C=G88
M5;+)<)[H$MDZ @GJQ+ATD;@\]-^+OPEQWPOPW <2/%^'XQ.*"4XF69DK"&5.
M*,^60J;./YQ("5 F6E*QE"^SRYBG7X;B2<3,FRQ)F),HL206-JBEJ_/:-Q^2
MUUUE6*2XN+95.PFVM8L<M7D\>D@V-A4M(X$A7I39!&?#(4@4< @)\;R"I7^0
MFE8B)Y.R@5)4SI)'=!8-2A+@]12-C337J/6_MHU]=%&V]U9STG6N\=L;>%FN
M7W<7=,7'*@N'8GB];63]99GL''JX]=&HP1I=L:568Q"F6,:04R(]DH@FB8KN
MU8<M/O0?7K3G$5=+V].JKJZULN0P=O8QI6\UKIOI^MKXTW7-)?QL]V+LW2&(
M;DR7(\GCV\F(N+X$#]*!XU'I\>6)8"=77EDZY0@X<.&BM/?O?W6)4S+K+O4Z
MH.EW3F'Y/K>7B^29XN#[ON(%K7V7VSEUSH//=HT>-8(X\M)D>MJWT&.7<ZV(
M%Y9X,JQVJC/0I+!KT4;>WEYU8QLWXBL.(0XA#B$.(0XA#B$.(0XA#B$.(0XA
M#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$='D.,XYEU86DRJAILEIS$"8U5
M?5L.VKBECO0H"$A3PGC/($B(03W#5PWHCF*BIWXA$>_J_:(_@QJO^0,5_I7$
M(?J_:(_@QJO^0,5_I7$(?J_:(_@QJO\ D#%?Z5Q"'ZOVB/X,:K_D#%?Z5Q"'
MZOVB/X,:K_D#%?Z5Q"'ZOVB/X,:K_D#%?Z5Q"'ZOVB/X,:K_ ) Q7^E<0A^K
M]HC^#&J_Y Q7^E<0A^K]HC^#&J_Y Q7^E<0A^K]HC^#&J_Y Q7^E<0A^K]HC
M^#&J_P"0,5_I7$(?J_:(_@QJO^0,5_I7$(?J_:(_@QJO^0,5_I7$(?J_:(_@
MQJO^0,5_I7$(?J_:(_@QJO\ D#%?Z5Q"'ZOVB/X,:K_D#%?Z5Q"'ZOVB/X,:
MK_D#%?Z5Q"'ZOVB/X,:K_D#%?Z5Q"'ZOVB/X,:K_ ) Q7^E<0A^K]HC^#&J_
MY Q7^E<0A^K]HC^#&J_Y Q7^E<0A^K]HC^#&J_Y Q7^E<0A^K]HC^#&J_P"0
M,5_I7$(?J_:(_@QJO^0,5_I7$(?J_:(_@QJO^0,5_I7$(Q^IU7TO7UI?4='K
M[1=S=8K)CP\GJ*G&L$L;3')DL*R(L2^KX<,TNGDR0-4\<%@*.4P44@VN8BNX
MA&0?J_:(_@QJO^0,5_I7$(?J_:(_@QJO^0,5_I7$(XTC1/3[#]!9>HM11?=2
M!0XRR,'Q$'N)9U5 10>K6M]6094<@@#\BD5%\&KV7B$<G]7[1'\&-5_R!BO]
M*XA#]7[1'\&-5_R!BO\ 2N(0_5^T1_!C5?\ (&*_TKB$5ZWM?]%G3D*L+LO5
M&'C6QJ;[)Y <5T:F;2:#!\3-4 R_863QL5Q:U/C^"8D2_I4R');%@8,#[2C=
MW$57HQ"+ AT)H*0(9X^G-3F 9C2",+ \4(,HWHCF/&]M6K7-<U45KFJJ*B]T
MXA'L_5^T1_!C5?\ (&*_TKB$2!C>*XQAU:E-B6.T>,5"'+*2KQ^J@T]>DD_C
MZ\A(=>"/']8W@SU2^GYD\6^3E\4[(1WW$(<0AQ"'$(AN'U#:-L+"EJ8.VM>R
M[;(LYO-9TE3&RNG/:V>P<8=,;DF&Q*P<ITXF1T'L93[BI]!)=:(?K2QB$YCG
MHHYVV.V_K$QHO?YXBL4RRG_G!M)?]4/J3_\ B_TO\0BX1G>*L:]JO4B^+E1O
MDGBJKV1?S1/GO^[X5?P3OP06H2/GX<^=A%CD,D@J<7 ) ZW\_2(NU]IG3VL+
MG*[S66ML'P>YS>S^U,SLL3QVHI;#(;-S>ZRKF1  $THO?N54,JM]8A#>/J/>
M]VPQO&.*<3E2)./XEB\;+P2>SPTO$3YDY&'33NRT*/=!#58J9DYLH#.R[,)(
MEY KO'NY0JE\S * -V?>)/GV$"GKYEI:S8M=65L4\VPL)T@42%"AQ1.-*F2Y
M4APP1HT<3'E,<I&"$-KGO>UJ+VUP+[^-#%V[#I:OKYQ0+!=>=!^\\$KM'ZXL
MZ.^QW5=UD6<55+BV99;CN1XZ7.)F1KDM_5VHK&IR2;B^5ORW):V?8P9<O&;2
M%:R*MIRA4865A7S]O:]J?O$RYITD=.N;)6_:F)K6Q!XE4X 6NQ++,DPRIR?
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M650TE!M>TT^;/L>S_36(YIC60W.8Z=S2XS3$C+CN09;CF,2,KQS%,HBX;/\
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M)1Z5H[418^8R$(O7CN-8[B%1&Q_%*&GQFBADFFB4M!6PZBJBEL9TFSL"1Z^
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M'%A;^R:LQRFFRUK]5DQND!C;<@I+!X<SR#'9N9Q4LWT46*,5>2R11MM;_?\
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M3Z8R"/H*38!R7,]O8"FWL<RV'EV/MM[/(M8CH]>[C%3Y$"FL 7$$ZG!5WRP
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ME<ULMMR-JT=;CEUEMW@LN;"UWZ^64.,86=D* D=UB1[]^^<(^K).W9.WX?\
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M+BEZ$&S>_6/L=Z7BJ?INT(96(-2:=UP]6(O=&*[$:ARM_P#ZJO;M_ESN,/\
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MQ"'$(<0AQ"'$(<0C"]BYYC>L,$R_8F73OL[%\)QZVR;()S1O.Z)4TT,LZ>=
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M1KP.)QAF85*42P%!@&  -J4]0+[1*FR]>W&*1\)NZX=S<8ID]%EA:+(+.!'
M&794T]X+:#7()YA./7Q/2DC()47U"'>)O@/S788PJ"3DJXJ1Z'UU_G2X$253
M@->[2P>POH3??K%)M\4^TLPB8V/ WD'&BR"/G B3W0I3RJK?0,8SG-0X ^+_
M ":Q/GR^4=XJU><F2YAL:O4"Y]+^N\>G?#6)X5A)&-'$D2YE%]CVC. HD@!P
M]BPZN:1.FO<ES7#F@2--DP[:?0_8M]]FM,@),>?%6'.:YO@]W@7R*CO_ .;G
M)XHJ\VV![4,6:C7-]6IX?(VC@^,S,+.FS52 $([0Y4@9:,-!R]WB3MB83=XU
M0X=E48%S9X=?BO@4^06U:.&UF35-B+]((4!P7G%*''AOCE;)8YJ.>28)&^41
MZ),Q!4P)METUN&;?^ U8U^$"%JREGS ZU:C;7-Q:HWBCN^,5VOF-UC<_!93A
M5D=GC,CQ[!\1(QF2%(V1+12,0XO1=X,1>WE_A5/W\],EJ49A26 H14>_"PY-
M'IGP[C>%2\)/DXF7+[9$M60D!U$EZ.*FU-2_6)]PW)+W$[%TB/92*<EC2V-'
M;'@I)"$L2SA/#)B%<QI7( QFL]-'.?X$<QO_ $U3DSA06ZLP+/0<V'TW<N^C
M1P?%U22J>0 D=J5(8,R22#KLPY:/6)GV7K6UQW7V)Y[61[BTQ:XE6<=M[:P$
MAC';P)K8]M7UIPOD,L@AC/C$D2$](@3.-&5G]W\EVN+2TLY=M=WU<GPT\1&G
MP&4SA4#4 TI6UW^NA-8UW;&PG;&0;%H+K&;!\7'(RP5<@IKXXHCPR/5E^YC*
M[^]M*SL)51'=V.[?DG.:F)F',4FFNU:-7F1]K/ZOP?B7!,-PG%2L5*EJQ*@0
MDJ2%*?NL;4+:"XK6L6AJLGD8[=Q'P)IJF1,K;:ODR8HR-1*V=$6-81B,&BJH
M9?F((VO7LYY6(SY[(FVX8)@S:C<5W!<FQKHPK81YQQ(R\JPL!9G+S2B?_P!-
M#NR1JX%15G/.)EV;KJQQK L-V/6Q[>QQ+(+NRIC7TT8!PQ9#"C1#2:6&4#WO
M(K&N(28\C!D$5"HOGX/\9F)2H))9]/%CYZ!_G1]?@LBIH068 I ?4TUMX[TC
M7ED^'[5MMOU>34MEWQ0$BN+Z+9BH"+$8K5E1#P7N:DE#KYHY_BOFUS>_^'FA
MFI50Z:>%]MC2NCM'J>'Q_"I7 URBE'YA 4%%0&8FM;6J .\]-7,6>!DDRCMX
MJ@EEKB3&38DEX$3TW0I,=S)(G-5>[P*A!C]-._9SD[?+>;;A>8K2X9)3Y,YK
MS-A?UCSCB79S94M; "I %F.FXK<'Y1,>:Z]LJ_6^)[(@ N+#&K&\)06]O+&!
M8<7(_LJ',=5AEQR.<XJB85",(P91,$)'*OF[QFXY!*2S53:@((8M2]M--]8O
M#C+$XI-&-"?F?EK>-?Y,.VRNZ Y&.>I<,9.]TQC9ZK'2M:+LM>2"UR.0RN[?
MM%:CG=O/S3NWG-*0M*B*FK:,*_-@S;F\>G3,?PG_  >3(R2SB<IS=T$DT %=
M'J[MHVL666_D0[*M6/*]L:0^<$BM<]B^Q/%-'F#>[Y\1.&5!]G*]7^3>WRC>
MVUP0*2"?=&^OB*QPF-[-4J;D"4J6I*DC8)!/-N5?WE[(L'LX&K<:V("/;V-2
M^[90W\R0&*L2EO3Q#S8M463&7]G,?7,[#C&:A617!<\CE+V;,Q8691R:C30A
MV#FNGSTC2X&=+DXV49Z 98(S$U N-FJ]PS5\:#T&,;>C;F+D4^6:5AC9\F3Z
M#IKGP9$!4\H\%D9'M>/P<C6/7Q:]O9_9WSSF2)@/>"G)W(8:DT/T\6CUS%<1
MX(OADJ7+ERLY!=(0,SD=VM&J[NX+UBPEM<O9-J48]@3OL3O8P0W>X:Q0=GO:
M_NKVB1Y&":G=4(]43\6KVW&%)RI%ZN.0(J/&O\M'F\]$LB:ILHS%@VF[G_=Z
M>0FQ^!E#I2NV!5_:MM60\G^RKYLL0E%2R+*PO7U@V.%Y'C FA:I8*/:G["2Y
M>S45$Y+Q"9B91RZ@@$4;J? [MXQKL)/E2<;([=+H"TER Q:FC4Y>%Q%$<+QK
M<$#;LZ\N9Q96))+F$:)TSU8<R&]?.&"/%;]YGHM08WO1&*Q6.3Y7G/@+S]Y^
M=S^]"S;QZSC\;P:;PB0A")(F,:4S$GH!M<EK-%ALCO&.=C\1PQLF/N3FC*-C
MW']L\(V':XC?)?;L(R,SQ=W\BO=V3NBJDV2E=*'W;D?I2K.(\[GR0E*E!60*
M(8:-RI3H[4#B)KJL&EIIW(\JJ"RYK*F^EDR"%+]J-L*OFV->$-C7$4JR71)%
MNZ6POIL[-($C6_\ 23FQFA9DDU<%O.U-'U_F-=@YLB3CI9Q(S2G<E0<.?'5Z
M&M#O%"M=8QN"KVQ87602Y$K'GOG$?ZDWUHDYIW=XK(P$<GH-&SQ_P-3P1%^%
M<JJFG0)IS&OZC<TU]7)VH][1ZCC<=P:9PV6F7+E"9V;!@,Y4-S<5N][EHLAF
M5HBUU'#<5!&_2$I8D<+7++<U:XC9)!E3NOM&E2.UZ$7Q4[V.;W=R3+$P .+6
MO6M[:>%_+AI<JBE$Y$5 !8 I#N&Y^%#IK.F%TERW#\^F4YY/O+&(5\N%+C0C
M5\J)$@^O82HJG(TXI49@H?NGQVN>HV>*]T5RIM2I1E.!I3[.U6I9_._.IF2Y
M/%)?:C-(,Q+FI#!5[4!%'WK%*-2X?NFCV/<V^72I$K&2CD-:PMBLF-9%<=I(
MI(,=KW$C!:SS]1C6C1C51G94:BKIQF[56?57(ZO=BW.F[1ZEQC&\%7PN6B3+
MDYRD;441?^UW.]-*:VZ9*@(R+)(5/>B=,:V&C/-ZP7 %W>Y?)KV,2<P0@HK5
M1[G/>B]D7OLY7^:CJG[_ "OTZOY>I"F60"A!S-T)H .1(VZO'W8=- O0Z=M%
MA[H[T=1Z\'Y-3LU?#%*I.[47Y[?'Y_/[_GGHN'_R)/\ _6CY"//\3_[B</\
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MP8D)# Z7<FAW^7EI+1/4ELY#!@.]MON/8UC%18G=R)L>^NSQ91B^I]CQ6&C
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MA&+^"HO_ ,OW=_\ )?\ P_?RA)! ;QOKR_BL 0;1Y-=W5R=V_"_@B_/;_/\
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MS%*5*58&C5I;YQ1ZMZZ=/&/>GRB+^_EX)(!,5A\_N3_>O_ARG>'^GUA'@4C
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ML;(F8>8626!:S5%&4W/?EX=[L9E92QZROB2(Y9$FN9);(B2EDQ;])C?<U\A
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MFG4\RXS^_CTY:R+^DZY/*I==STO:>KI)/F(J,*BOC[]_./IE9W[+W3MV^/\
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ML2G+6T/39=]..0XM;["S>;9YW8V1:[(YV54UK[,-:&5"@8\VGK:MWN(UY/\
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MP[(Q<DISOO-3TQA:\A$<OCZ;7>2>/?FOXH_Y&>PT36FX<^'AY7W7 /\ \MA
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MBA:,3PO:YBC[^:I(GE2I;W=[/MKXO$7#*"5L3E[M[D$"GF?2HC75ENL<]O\
M:53E\"W;%HQ'AG41)!1D"*&K5+%9&^&F:5K.SE>C>ZN<C_/X[<_,03,4JX#%
MMK'FVS$CJ[QZ7@^/\,D<$5A%RT]H4E*U4J5 ZY@[/M1G%6$6.=9&#, K))(B
MS7$ 9L9K_2(!4<20%S!.:K@,5!HP?Y.5J?Z;7 )[R<PM9WY'7V#:/..*2PE
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MP"(*4\@9,=33)H0%C]T(\SU<Y60%<.1,<J32[./L#1W]:1TR.-)35$TYB.\
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M4)/9*2@J+]]JN;$<P& IOK?WTU7:UDJ7+FR0.EF"Z*43?;G",)?3,K M$XS
MH14'YJ)RN16N&4G=R,Y)E24A(#$$6(I\J/K4T>U(A8B;VH$MW0BF7Y4#4/2F
MSWS<UODA,1EXL^PD'QR59CO15I"JD6%;":YB6$=%1&@*YCE&3Q[(1O;R3NB+
MR^:D+24*J*@FS^+..O(>,-".S45C]3N:_P  CK;QC!98\E'5EE1:V&V/%:R
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MKVZRMM&;;@;==F678ED&;X;7BU@?$$S&1!R_'<7NI6/7L6J-1S3P)D%]@"9
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MH=W?1M: 4U#5BPV>ZPN<5CXE.QFXFWN+YO29C'IY\JN-6'+;8W-:R91,"XY
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MIKN?'4?+>GF^.5*6E,R4P2I2E,U;[6-QSLXB>\XUI?U&K<,V="DOM\7R"Q=
MERQP?:BI[X-<V7(J2O8<K2'0+7$9W],A *TSQM<[MR=BT94NG:WO2C4TZB(N
M$6CMDI67=GZ:,[]0_P!*T(GZ.S"9MT&?"R*,RF2>":Z*A)+)B#8C4=6M9W4+
MP*O=7N\OO"5&J-7-\EY]065*40ST#FS':YH-69X]-/'^'R^$2,$H@S)2"D@
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g713200g11t09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g11t09.jpg
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M 0$! 0$! 0'_P  1" $  E$# 1$  A$! Q$!_\0 '@   @,! 0$! 0$
M      H'" D&!0,$ @'_Q !2$   !00  @(+# @& 0(%!0 #! 4&!P ! @@)
M.'>V$A,4%18W6'5VM+41%QDA-E=QEI>8M]88,355<K'7V"(S<[*SU2-!E211
M4E;3,F&3TM3_Q  = 0$! 0 #  ,!            " <!!08"! D#_\0 5A$
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M@FF&QQPR!L<M6)D3C:X$VLJ)R]?Y(;ST/@% % % % % % % % % % % % %
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M[EB62J@JN .*F@*V9$@(J(IL@H"$".9G(J".#IJ * * * * * * * * * *
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M +(<&PF5K87%#M?L[ 62H H H H H H H H H H H H H H H H H H H H
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MGBUU1K.-NXN)')R<;>J/@WS(X5-NS@7\,EBFD]#@* * * * * * * * * *
M* * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
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M (2C0%1=W9Z>.ML"*THL5/;BFX"#A;22"4=1-2/)&198/]RFLQ"Z4K(ARXV
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M(N&5\! Q,<L,\;WQRQO:][4!^ 5!0QT\%)'1DD9*+A @ )@J<3$3P 2X@(H
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M/EBAHF.>&>*.EXYAY YX9XIY2V>&1>W8E\L,K ^[CD!C_A!O:]KA6^+"^-J
M^ETE*O86UTQ/O8<YWQ&M<F6O890[#$/NX6UP_P#R'.UX8!]U9^Z/V&../9]C
MC:U@ NE)904,<HFIY48($0L$,7)EP10RXPN XI<,0,/'/ $48/ 80+&]@\Q<
M,!,L;YXVO8#T* * * * * * * * * * * * * * * * * * * * * * * *
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MY12C"(QR AU'9)!O(ZFID#@YM_+@3@]_+PD[DR9-.)E4]/*EB) B6 )D2),
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M\!>@I?VBH5#E8U]Z28BWHG96U"+IR+,6.VV6XKQ1ZH* * * * * * * * *
M* * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
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MC>_>SCXU4B-KO]@HS46U=;D9,9YHJ\"BN=3@TXZV78M"F  D5:0C.)W$R@E
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MU"+IR+,6.VV6XKQ1ZH* * * * * * * * * * * * * * * * * * * * *
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M'$H?M#DU0L5T9L<6#D\<?IJQ?:]ZU6IJ_,)F$QT!G=:-THG/('3"KU6&3&%
M.(:&\G\!>@I?VBH5#E8U]Z28BWHG96U"+IR+,6.VV6XKQ1ZH* * * * * *
M* * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
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M9U[GC3])FY:.!)5VRU^]+.#)9M<R\N2WAVK.3)DX[2]5#@* * * * * * *
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MI7#(SMPXT+4B%*F&W&O^3FO7GN1_4&;5"5!;JI-F\KTD<8M7)N:0]/,-'"F
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MQE^6J/\ IR0.H,CUM=1-ZYG]7HGO*5&4UO7=@,:<:C,!:FJM)U"@'7-:>7*
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MXIUT;'90BO9+EVGOH6E+J,NUW%%;ST<QZ3]X0YU=(=X)Y@\SU)^)05?1&X4
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MC0M2(4J8;<:_Y.:]>>Y']09M4)4%NJDV;RO21QBU<FYI#T\PT<*8 52AA 4
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M5HT6-JM2;@H!S[4/E8UUZ%XXZJ)=0?3:^%*,>FNN/BP*)W8H_@\OU5T6)O\
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M^*==&QV4(KV2Y=I[Z%I2ZC+M=Q16\]',>D_>$.=72'>">8/,]2?B4%7T1N%
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M(B^P>FH9>J0XE#]H<FJ%BNC-CBP<GCC]-6+[7O6JU-7YA,PF.@,[K1NE$YY
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MB]=,>#=O(^*?1CQV[55:V##<0V\:88V2JUL651+55;+5.P@Y; 2]AMW 0<-
MNWC6S;8@X=S#,-MV(SLVV7+##+36Q1$V2HJV(B6V(=C^CXPOWW,_WCMA/ZGU
M]&U>3J3U'V]C^\UUD6.G0K59\K SB>T<JCQ<!D(  PNNF398<*P. 5"Q!*@C
M*:L^#9T4(L#CB$ 'F/E@"%CB&';'"UK5W$'2*D$N<,PLOGDW@89EIIIF'@YC
M&0SAEIM=DVTRY</F':--M*K32HS:TN5;5.LBI')HU\L1&2J71;]I&66G\5 P
MK]\TC*;%E%>/7+;:HRB(C**U8B9$R'._!M:4_,@1^N4B_F^OM>.%+?I12'SS
M,?:3Z_BQ1SYADWFN ]G/9;_#]U*:2R1<35BXVV7 EB9C)BZWY&E-&64X80(0
MN(*14TU[%CI03, 84'/,N.'ED$*('>]\,\L;_P (FDU(XUP\A8R?SJ+AGR(R
M]AXF:1K]P]91I&D1XY>OVW;:(TRRTB-,JB-(B[:(?V<2"1PKYB(A91+(9^Z5
M5=OW$O@W+YVJHK*JP\=N66V%5E59566D5454VE4ES]'QA?ON9_O';"?U/KI+
M5Y.I/4=KL?WFNLY9WZAP9(*5@AOU*?SW1 C@2B$CN^;IN<J4&H%PQP0#V">L
MR(=*8' 03)D((SB#88,,P.'AGCB*);+[D#,IA+'RQ$MCHN7Q"NVG2OX&(>PC
MY732LM-.U>N&W;:NVFF&&FF%:V*JRRJI:REGU8N @X]TCB.A8>-<HVCQ',6Y
M=1#I'C*-(RVCM\PVPC:(TTB-66HC32(MBJ1G\&UI3\R!'ZY2+^;Z[;QPI;]*
M*0^>9C[2==XL4<^89-YK@/9P^#:TI^9 C]<I%_-]/'"EOTHI#YYF/M(\6*.?
M,,F\UP'LY,B1K+%B EIR&@CRLB(J02+)J2CI&P,]IJ6EIY,+$ H03D\G)0)0
MD2*@88 EBI8$(  +#$,+#'#&UK=$_B'\2^>Q$2]>1$0_>-/7S]^TKU\^>MJK
M3;QZ]>*TV\>-M*K33;;2M-*JJJJJG;NG#IPZ=N7##+ERZ89=NG+IEEVZ=.V$
M1EAAV[81&&&&641&6641EE$1$1$/1_1\87[[F?[QVPG]3Z_E:O)U)ZC^FQ_>
M:ZR"[\-O2J][WO")*][WO>][O.1;WO>_QWO>]W?[M[WO^N]>B\<*6_2>D/GF
M8^TG2>+%'/F&3>:X'V<_SX-K2GYD"/URD7\WT\<*6_2BD/GF8^TCQ8HY\PR;
MS7 >SG=,K2O7:-N^7O=-5V,'OSW'WX\"I@F5K=]>]_=7<'?+O$_R'=W</=IS
MN/NKMO<W=9KM/8=O%[/KH^<S>:^"_P"*3283+P&S\!^GQD1&>!\+L/">"_2'
MCSP?A/!N]GL+-GL&-E;L4L^[!RJ6R[PG_#X&#@?#;#POZ'#.(7PO@]EL/">
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MBO$2A9'9N#D<1O$!5-%D<4LDG! PL6Q5X$YRWMO=]RWN^Y:_N?':U_=M:_\
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MD55]!8A#E1PF2TB#N>)GFV<X_1R*OB7)J+2>([M$-IZJI"H#9 :J\H&,W03
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MD9\/9S=UV(Q2CK<;$%4IB0[NR,J"L]UMZ)\;%D,8(F!FD*Y1U* :]WX1<T@
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M+9Y,J9$V^/\ /R$-M[4>4VQ*6XTG&M>H3D%WR_M4U]@($=CED09'-LP-B11
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MVQ4=R;%<1,%'D^)9:AF-9D)S6N/A>CMHKP-E!H]RQ9:'FX5".O%\-]@.J6K
MR*)@>(MA*;Q8PIA-E!-Y#A%1+-O;15][>K(=RY8OVC+2M+>S["8K!O+$@0WK
M[KJW6&M2AWB36JU8X=LQR#)4B>&84=ODB=6U5?EL="C=(.L\^4"(-=$=;M3@
M!5I;8B<"*F1%Y5]^3WY3X.5C;-Y0G'L.-W5:"LX_-$7 E2M%8^TCH+)QEKES
MX822T3;]/:^+2C(922\<U5>E\^M-I&.K0*H;:ZF;=&2\XE\<,G&O!9D_ODLX
M/R(P4=2I,<&QFU$UR9KE#,JD9MB?6AJLQ+,RCFD'FP[8A;LAX/.P#B,QX<5F
MZAJ3C>:9BVW C F5L0DA8JJBA$#G:$W$<[+(B6JEEMMG+Y2SFPJ5LX\FDPF,
MC0M#\LMEP-L$38)#7)J7(H1%]7"!3,AV&C!91-*1M;C9>/V5;.DHK][S"XVP
MRC540U!*6W"!D.,F7;Y,G]TR]9 BIIC*"Z0DN-U2[8+,F;-WM?=UW8X4U<,&
M1&KC%BOK_)SXBQ.)FTTDI+:BOR] 14DUW%8)+3@X\?1\VJ9);@9Q)(=XYMX?
MW59VN-%2W;XE_ EIBA;<@/B2Y+?>M$+9NM4; R.W5!*V65UHZ>:J$XA##1BI
M)3#T!H2<SRI@DN+SM=3N.+:X,XGF7!3#A,NVAFM:.AQDR95ZO[E7I/X?[Q-H
M+>3(TCYC8L11XAD:;C+$#N%W6*LAC,=LQRF-Y_M)OA9(K@1L7)(S\"7)"5&X
MB$RC$+KSG7# :EF=%-JJ\.4:Y[=C9;REV6*UI<BN-9B(Q3 L0L=0[['UR&XR
M#DE6LW5YT.(/%1<KC?#A(,[N1EI)UPGA!<&NUT%=$#+HYY0P6.Z'.73&Z/CS
M^4@!K:\3B.](%F]T1:PV<^H1EJ6'4Z6RVI?'DM>F9)G*+59IO]ZGG@KQI$R&
ME/8JZO 85MM<=-!;24Q6><::0KH:3=K(Z(.55.?GR69=I,JY+/?CYMN:_;11
M/&C"AU#AV&9J9X\A2IL7*P3BGQ?C-.49NEK8Q\;%@M F %!L@&ER+XS=;M+F
M"1P8!OJCY/(B#DK(R6B$5UO.P<JJ*MN5,B(F3@1$3C3;1,O =X<TUF)'VCB"
M>$C8J0'8UF<I;".YY,U=2(1(CFU:5,&6(E,UOJ1*&BKD4&J.4;0+.L<=+V,N
M1J,YMLY(0'"7 )#YW'%J6;67)ERD;:):AR=K%'FLS578$A%-D^.T9VLR4)M0
MI .'#&;.=2P<=2W@@HQ%D(:B]%5>4$5FHH5G.=0BZ!E8RXL1U3%+N@+HY5;;
M<J\B>ZY+.2VWDVR899BJ?YYD=^,^0(;B\"%UUH25$;)DX*<E<V\&(QY+9)IK
MO1^$HCQAS!.4)+=((PK?(&!Y-+ -5J&KD4TR!BK/H!WCC(EBIMIEVO[_ )?V
MX5O:_P"SS+58WEY#:\:K<OP'I.3U*8S<5GV?1&8]'<[7G%:U*,CG%LDU5U01
MV0ED899BBQ$@VBY.AP'S[A0EX@T"I<@OJ(YMVTMR*MJY.*VSBXUMX.(D)$C:
M556'A(9D[3^#7(RI .R@%(K:69V]\A.4%)U8E'%X;OP=>@AHEW28DY\.%\''
MS=!0RI]CADTE0;"0Z,%SO(SQQPY%7W\OYE9PN'Z[D^7D@R_HQ8.S,6MSAQP/
MI5BKOQY8(3V=#PC):D,Z[GP8!.MYQ#H1)V)3S)@Y*Y5PF'&&L@*(V17,((D?
M-<6>A$ZK?6<[+)DM1;57)Z/?B3CR7.FHIM.Z8@8;.0X@BAW*CW1!B&P[:RG-
MQ1ND)"*=1P@U2/V$]<8H>RPN$UDP<--M8>8S>::L(VB*@>04]LN!QIAYG<G"
M66^C)_?UE9I!TIE60&UM4R\TABM-%WF;.N9602K><8Y]&@TVPVT@1G+3=0A1
MF\WS3M208F:C=)Q4JI;?1++;X"4O"9!C]NYDSU#E%LLY+?QMR^O\SIIN@79+
M:/'8V-I(BZ*V(T)<@[8#7%A30ES<MNQV1M&TI-%01@5!.BNT/(!/-ROIQD66
MNR):\E=QETMOI" 1%5<6[@;7P1;%1<MJ*BV69,GE_(KQ._#XEJ3&I)PK BZ'
MHU,2:W^'RVW3#J.X"*+&K@<6IVSV<YR@_P ^*B-/-/.EW R0$Z+8X-FVT ZU
MM*)D@WVG-A+3TQ/3@9:L5-O)LK/*EB9.?+MFB\1,AZ1=:;,F5K]%T:(:_@GO
MMJ-1!D(QD-(,N9-4-IJ^3D')- - CENV06/&B,5.HR<ZC9T8=>6SB47'3PRR
M\..+*O+D_OEX>(JYAKSLC(IU@R1)<510Q93BC9N-MF39UJS,K2*-,ZLG1^_8
M4>3:MFI11'1&.4=F1 ^5 C$R",:<Q-67BR5@[7 BGQW4_7 .;;-K*BI9E3FR
M[:Y;4_(#&O\ LFSVE)38;T219+3?V;GR9IQGUI.B;E.,R@#>>)A 0&3$!<Z2
MB.2 G&D*\?-A$)3 )<JGIRB:LO-='$6$!?&5@0MY5R(B)D3UIP[7]BY*G'[^
M>DKZ_O5WDFXGMR)62^G6JH",KFE+ .?G8@H3$1#* 8-):6(;;C28"]-B#@I'
MRZ<95/#=*,=[".1(T%8<<?OD]["B^L&HTIPI8JJK6OL)GY3RW)V(G0K+7OB&
M+'FW'6PTW2FXE7$0),9)59<SN0(8E5;;!1M'3H+9&=8)(;OWBG$RYS$<JMO'
M98SDY491./DV_P "TC\2-CG3L,U30T'Q,Y(58:^EFV0[EN=%I'<B HK:&9;S
MXDTU&1.&UDLL.I%;3A=+58:%A(B23L04%8^HJY0ZY2_@@.,EG#;S9.;;_+T9
M:S1?I].,/M;45&04IEN@]P_8)F2,8E#5W@90DV9W2XT-KQK$BHM*1) 6#[+;
MI"+T-0.R78RC**D6>ZP$G-0FXD9&P<*L.56W9?O+;Z57AY<GY'H.C628YNBO
M"/YX@B)LF0Z9U3I$V6CA'F ]("_LPWA8Z=R(:."O,_&L3!,UPLV02\&.)BHQ
M,^G!%6=#Q)A@/)#0L4\B("*B9;5M1,BV66+:G+S]=N4CUOZ13>G2OJPZI2:#
M%V-:$$ZN;'0:H@R*^PU-UYFI3FF)WA$0(JFO,\Y@[U"-HFC HP7A(*GFE+CL
M< XK@"(C]\5 2@V6142U+597)DVD6WAXUR%S5%)V99VM3#8D2Q/&!%\IEP6*
M,T2\U+S;0X\B!$%54AL8M>1E",'FHKK_ ";&3VHD7/GV872RKE.*[BPP.DT<
MDBK0XR6Y;?[]?OR%8E/3V9!$*;QF@PXOC$]LMHRV--34?H+Z4W8SH(-1<LSR
MF1>[2[B4FDTE-^M>[%GQ:-NLD00$9<"<;204%/)JI)PJ[T0QS:F3;R-6]=EO
MH3A)F18OG,I)[$9ZY \2NK7Z(T$E&L9.]QS>HG7&DLR[&*LQW/12B'WF!D=6
MD-V(.*LR25QI&+E$1GK2H2 -E0'0]"2P.,EFVMJ[>1+/3M>3R9"G4W\,5WO*
M"-F6Q%Q LW%=W:C'],=5XN?$NOAXHD41>NKZ6Y' =>+S<H[P%2LE$VW6,CI[
M+995Q)+1;4<HQ0JY'297C.: .=EE2W+_ (MDJV;?DX>';V^&PT5B".5Z/Y =
MZVV]>8PB)L.1A)X2]FUWKW8N.][-=2-9LU.#0DML)#7045.2UYX8*KA&&.K"
ML:44 OW"4)(@F1L<>5;??^Q51S:];0SLCN-5E.)87C>4"<H:TSDA/!"G1Q20
M&ZES5N>6E+\?0R.4'A1CB,N,L4I-?"+95#-N4X2=,@+3WP01CZDJ@"A;9M*O
M#R;:6<9(EM;'(IK^TJK)$(LR76=NK(J<<?,=.-[D$XO'\?L*#8ZB6/R"^%WD
M5B#D4W"K,Y><[P46LKV.,8-P)))K@O@TA9*1H+=K@5$ZUV2KZ%_ @,]PZ95(
M0O/NOOAR#(2=M=K)K- $DRNYUH[X1M];BM@F(7EY]*("A@=5G'D[(MLF++%Q
MP.*"P=D0F>)O4\E):ID[@!S;E1;-I;43RVHG'M\-IT4>ZD2HQWMM _#^O4)O
M1^REN4J;%0T_5V11TX\R42[8BINM@1TCI;*%<69Q"46*KN!19Z&IF$Q<(J7@
:_=PDKJ)Q0*ALMK*MB)8J>K+[[9KS0^)__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g713200g19d04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g19d04.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[19B4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
M3   !.<          0                         !              3G
M   "3                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "3     !29VAT;&]N9P  !.<    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   DP     4F=H=&QO
M;F<   3G     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    &.$))300,      O3     0   *    !+   !X   C*    NW !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !+ * # 2(
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ME2KZG8;/2;96^T<T7!U-OR:/5>_^QCI*=1,J@Z@0=MU%C2.=D6_]"HNO_P#
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M)25!R,<W^G^ELJ]-P?\ HS&Z#.Q_[U?\A&224__9 #A"24T$(0      50
M  $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D
M &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B
M      %&34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;  4
M   !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4    G $[
M  (    )    L(=I  0    !    O    .@ +<;    G$  MQL   "<0061O
M8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR,2 Q.3HU,#HR
M.0!R<C4P.3$V-P       Z !  ,    !__\  * "  0    !   $YZ #  0
M   !   "3          & 0,  P    $ !@   1H !0    $   $V 1L !0
M  $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
M     $@    !    2     $X0DE- _T       @          /_A 4A-30 J
M    "  ( 1(  P    $      1H !0    $   !N 1L !0    $   !V 2@
M P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "P
MAVD !     $   "\    Z    \     !   #P     %!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*0 R,#$Y.C W.C(Q(#$Y.C4P.C(Y ')R-3 Y,38W
M       #H $  P    '__P  H ( !     $   3GH , !     $   ),
M      8! P #     0 &   !&@ %     0   38!&P %     0   3X!*  #
M     0 "   " 0 $     0   48" @ $     0             #P     $
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M]2F-E=4IM?)2M@GKTZMOLFULHS[,(P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@''XC^X/YC@'. , 8!%FVQI05H/KO%3DM'BJX!HC!0=OG7";ST+GA59O
M3F;Q\BB"7D**SHA6H',4@F\IB ($1]"@HCT<=-7IRG(W_(_2_ 10BJ:A$?A*
M'C*=-<"K)G*3M Q%B@J4P"50 , X(7]W_4M?@D8 P!@# & , 8 P!@# & ,
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MR&6E/?==T^Z:]SQYQ<6XR34HMQDGM-2B]--/NFFFFGW3]3O@@8 P!@# & ,
M8 P!@# & , 8 P!@# & _P#']1@# ./Q']P?S' .< C#9>VJQJD]""T-IY5+
M8>PJYK2&=0T,YE&C"PVI19O#K3[E'A*(B5W:1&0R#@PE!VY;(E(<RGV0*TQ?
MTAO3C+R\9"M).U>LE748= 5:L]212K4Y.U*L0=W<*&/PG5Y>P7JJ1;50H'EB
M+2Q%G42W:-7KAN!<.5GH)%I(HK342DLFU=D424D6::A#E1. D.0RP&*8!]A*
M8 $!]A# *\]#QBFZ0>G(Q1 Q3:EJ E, \@8!C$A 0$/80$/<!#V$/</;!"_N
M_P"K+48)& , 8 P!@# & , 8 P!@# & , 8 P!@&*4^\4_C-_4. 97 & 5]M
M_2UHV^R]MG;?3G4[)WAQ$.K&X=VZZD(X7@X*8J\>>/;-[$BU@0"KV*Q5EX2!
M1C22==L$["217<9+R#9P!Z&G=/\ IF@JV=2IZ\KL62X+)*3K0S=20C5DD9N>
MLR,>QBY-9Y&PL.E9;5:+(G"PK6/B26"R3LR5D$E+/G*X'\YOTLNLDY38="KD
M8XC6S&P;9V+#Q4"T?2Z*3-\XZ?-HG@VD?$GAV\(P<N)U*.:,RQ[IP7U+LA>P
MR2BX!S.;X*WQ!PG+X5*A*^G MSJ(6;Z9WXDZYT1>N_2[7#KUW4.II]N_JGY&
MO$$/"WCOC>?NG;7A<?7-<K.AZMCPN;;1QW,2K[->97QV9DVU]7P>97'KW'9M
M$^C:ZO";4U#":XV)))!L;6;.)J4H_7.8JLE&IM4D*M*R?E(F8B\HP2*R7>F#
M@D^R?PLL#.:(DF_Y7AWE89/&<?YDFXV8U,:;I_>;A%5SIO\ 1PR*;$ZK5*,9
M1G'IFDY5SNZWY5_ N1QGBOQ/;AT1A;C\KF6Y_&TJ34(9%D\JGD.-6O\ 4<;G
M8TX9N*Z96QGC3=]#\NK+QN.VGY:#Q48 P!@# & , 8 P!@# & , 8 P!@# &
M , 8!Q^(_N#^8X!S@$;[*U54]KLZVPMP3)V]3M\#>H4(>=E((Z-FK#H'T$^<
M*1;EL=X2/>%*Y3:.A5:'5(4545 #C (3C^ASIDBY*.EV6N2)/XN5:R3189ZQ
M* #6/DZ_-QE8634E#)N*7%354K4M&5!<JD QD(..<H,2'1^T!@>K#7E/-4$)
M-E%4VNR[Z:<JR$TJWK$(]DA4CGJBI'$G(RM=,\455X6.F9\X5.<OE,B/:*A0
M,QT"D\?15TO$ 2F FE*&4#$$IB& L&V !(8AU""40 !*)%%"B'':<P<&$/\
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M.$3\_C^'XX!6;H?]^D+IS]^?_5-4??\ ^FIX(7]W_7^_J6HP2, 8 P!@# &
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MTZL.ESJEJ01JDM!+MY0J"$M2=CL6+44) 5?S4:N+\SFOO)(BZ8+,TF$DY=F
MJ+UN0H"FH%<Y3A\G!G+&Y'%U&7>,IPZZ+5OX9U6-=,O9K34XOU49)I57D.)\
M1>$,].Z&7Q]\&U1G8L[%1?"44WY&77J%L)P>K*F^I1;KOKB^J)6GJ)Z$#.GK
MBZ:^;REC;^,YG#>&DT8K;L,D<P**&B[*_!:&V_ D3* *TC:C5[..6X&:Q%];
M(%:P^4C.\/5.?VC$G?CVJ2GY^)+63&26NJZJ>Z>2C%:Z5D1^UUQ7Z#(<NB*]
M.\,?E8S(X\>*YNGC.2PW5]G_ #=S54Y</=0VY2Q\'+Q^G/\ "5ETF^O\V3EX
M=RK)1_.7#PJ\_(E7G3DWMS1QE/ACQQMS7C%4J3V+:O)'7^Q=?"W5\9B$"0.X
MDJQ#Q[A%1.6I]G2G-8+22HLJR_AU2/D%]*.1R6'TV9=4<^A=,%R6'.S&OBDV
MM9'4W*'1K])3F=<%.6G<Y;BK4^)\'>()78GA_-M\*\E-69$_!?B3$Q^8XO(E
M<H_I.(C7T49'VER;Q>3\->1>Z(*VO JIU;.V5:^D>T^PE&=<OUQ/K^<>D!5K
M ;W@U-729V_D$@.&^PV*<GJ>83<CVECO+(5GU)>#'6Y$39U<7FJ[.E+(A.4D
MFJ,R*P\E*3EI*Y=6+<WK4%'HZDM]3WLH/.?DYR<)V2NXC+PX5SLA+D/#MDO$
M?#2=23DY8%DJ^>XVJM)NZR^6:X2?0JHM=+O+6-Q4.T,V#UM,M6:4FFD>/<.W
M3!2)D17#E).(L\<[?U6=4.'N4L).2!A#W$I0YX[$<VG:C;U8TY:U'(2@I-^B
MA:G*FQOV5=DF_D4"[PYR*A9?@.CF<6OJ<[^)LEE3KA#[UF3@N%?)X=:[;GF8
M6/#?929* "!@ 2B @(<@(#R @/R$!#V$,VS@-:[/LUV:?L<X P!@# & , 8
MP!@# & , X_$?W!_,< T?!K&8O?TK*[I:S1#MEKJ4-L=@FG)U"9L,"FRJL!'
M*PCIK5]I*WJJ1<DE87S1E%WB@MZ?+^K>2Q&Q[ C OS@;PL J*MT3:2?3"<[,
M$N4W(DOM@V$=23M3LR;F5M%JIUYG(MTBT1:$7KCVWZ^I=@-#G#QIOJ\R(DJ1
MHH[;.0,#U4ZWIJ%73FXV(K<#-2<VY4DYD[:DM74@*T>]55(NYN%JJ#18ZBP%
M6,"#YTZ,8G=Z44P.H0P9_H'+V]%?2\4! W;I2AE[B^(2F[8-L'<44%%D!*/'
M("BLJD(" IJ')P81"_N_ZLMS@D8 P!@# & , 8 P!@# & , 8 P!@# & 8I3
M[Q3^,W]0X!#/4[#UB4T7L5Y:JA0;LUK%;D[=%PNRXI&6JP3U>9.'T2[71434
M7;OD5RB2.=QYD)%)TL0K-PBHIW8!X'HJ"LR&F"6^M:4C=#)72U6B66HR5&DJ
M'96[9G*KPT*I>H^8C(U_(VI.$CV+5U+ #J.=M46@Q+HT>5!--^'R!;G & :[
M-K55U'=8?2?85$@*WD]P;1(DH&X-CV83"?IRVN;WUG.?[AJI[)&_/U\?*A]R
MB'C>NN0?^/ZE$>K+HAN^I=\SO4/TNJ.ZM:)@'%QBHR&1;MXV9F065D;34O @
M5%1"9%TFK8JW*)&='/%RTY5Y:/5ID8:0K'HOA'QCC86'/PWXCI6;X?R9S=5D
MU.VSC++G^EZ814YV85DF[;:*H^95;U96/&5W5&S4OHDY^=5I6I)->BFEZ>Z7
M4EV3?9^DNWI?/HEZ[JQU*U>)AK>9E5]IIB^BW#,XBSC+-+P2GIIUA&D==AXJ
MXPZ@%4L=!?F+.1S99O.1Z,C5Y"/EUN?XH\)3XB<LSCIO-XBQ0NA;"4;98U5_
M>F<IUMQR,*WO'&Y&INBV<9T62KRJ[*H_=-ZL24_AL[K3[;:]4M]U);75!ZDO
M772TW?*R5JOW"$D*W:8:-L$#*H^GD8B79H/F#M(#%4("S9P0Z9C)*D(LBIV@
MH@NFFLD8BJ9#EI1L&JW?'T>!$G2USTTW.]E$&;AOXF<P6J[-;HK"IR5*V'36
MK6SV"21RD6@]H1!K7*$3]]JH'(V;E[F%S^=BU?9;G'/P7TIX>9NV"2:_Z4V_
M,JTONJ,NA/NX2VRX\/XVY?C*(X&5*/,<0W'KXSDO]12H1U\./99&<\?27PP7
M7C;_ .ICV1<HN#J/UB;7Z:I%&J;);2DI7FAF2*C"R0DO!+-E'9TRC&IQKD)"
M6ILN0%0,TBHY>TU95HW,$695TY B.2>/Q/(M2P+EQ^1/>L/+DHU=7=I0R'TU
MN+;23DX3<GI4I=S?MX_PEX@EU<-F_F#D+6]<=RTE# G-IM0IS]^37U271&4Y
M4J4VHPQ*TG(O+6;CTX]8;9.=H%P"F[12;\J+QKEM&7%HN5!(BB;A%)9+XR#1
M,$VXR<.\;6"+:B9FA*0I73ANIP>0X?)P[_T]5V%DZ_ZL8Q<+H^BZNJ,Z;XM)
M:>G.,?A4X;:.?E0YOPTH\3XAXB.5@[<\;'Y!7.F+>Y._B>2Q+J[:E/;G..+D
MRQ;I.,LK&NE"'3%FW>FC;S6/424UW0NHRMJE5^(LX=W!:XOW<X.873]&N7*.
MGM3W!X5'M(12T.F=G6-WBC;T%%!RLY?$^:MSQXN;<D[\!PI?Q+<K+,'(Z\:V
M7SL5DKFM^7TMZ+IP?Y09X>H8_,Y$:(QKZ.*\70OY7'2I?Z+&Q?$W$K'YK$QU
MO=>'+%KX[J47E>;%=2H&\UQIC7EI5@(%39/3/<Y$2KO(RN_6?I_DG0$(D)"#
M3;*XF-%[$1**1223BM6'8CF3Y432@$@7$H\B%6?A2\K&L>17K4L:N#JO5:CK
MOQ6:YJ4.WQVXT[96M[A7\K[=E^%/$,/MG+X:X;-4U*CF;;8\AQL\J<EN57C?
MPTJITW+:^SX/+4<;CX>U]IR7WW..O=G]6='3.YUYM77N\H1L9P96OS3!/6%H
M;-VX"5LW=1@J/J*Q*8"D*I)/HS7*\BJ<3IH=Y@4/M8O)KO%=6-8OOQI;K\OI
M32=O'Y<E&B#UJ6YXMDW]R'5V.7SG@:Z5:OL^S\SB61C/%OY%1RLC*ZVI.O!\
M6< O.Y7([R\M2Q>;QL>/2KK%&,G&S<!](RI6UDXW?>C]B:\52\'J;)&Q#J<K
M9D%DB":0]2R*Z9),TEQ.D=1*8>$.!06;G5(8 #MT\C.;C'IJO;]J9JF]1U]]
MXN2X-QW_ /'=;OUCO>CS#DO!^/C*VQW9O$QAZ2Y#'?*<4K&]*C\_<%#*K5NM
M-PS.-P95[Z;E6]LN%K3J@T%MU!-6A;2J4PL<1(,>>4;L),BH>QD18OSMUU%2
M"( <J!5>T1#WS;AFXTI*$INFQ[2KR(3HF]?[5:HJ:^3@Y)^S*_?X:YBJN=].
M-#DL6"ZI9?$9%'+8]<?G?+ LOEBOL]PRHT6+]:"9/)3%, "4Q3 (<@)1 0$!
M^0@(>P@/ZPS;WONNZ.$TTVFFFGII]FFO5->S1VP0, 8 P!@# & , 8!UXY$0
M'Y"4 '_;W8!K5UQ"ZDC.L2;UE'!N0MUJ!9F\!$V#J!V+/49I"+Q\&I!S["GR
MEG<1TP61?V"98DK;LDDWJA&;5Z#)JFM'^D#Z^OY&RS & 1%N:.FI*KD2A(^U
M2+A-==19*I+Z^0>D1!BY**CD^Q&SJ,%KWB4!*Q(5_P"02"4WA!4! BSH3*<G
M1OTTD4!4JA=.THIRKBB98IPB$ ,546P W%0#<@<6X @)N?$ )]H8(7]W_5EL
M,$C & , 8 P!@# & , 8 P!@# & , 8 P#%*?>*?QF_J' (2ZHSP[O1UZJ<S
M(044GLB+6UG'R%J(U&JH35Z25@8<EC</V[R/91;I^Z19'=O6$D@1RY;)%B9=
M=5&+> O1:]/8C_H7KJ=/Z?HJHI2,#*?5>W7J$57K<]'6Z)1<L[,_]6P2N</5
M:-$VYS&N3JL9";84RL%&0;NHYW$(R4>]46 N%@# *";?;02?5CTB+L]6.*]+
MJ;BV>#W81X*H-$+,4>G#;8F13EXV5<65[YC FKVRL<V3-Z03*&*=- #A_P %
MXI^!C++%N(B61,JU7\9RG24.W=LW2"A5FDA'NT1*NQD6+@B;IB];G3<-7*2:
MR1RF* X!I@ZU.CQVNK8ME:N5;Z_W8[125E'Z,4FTU3U$*1W8M R5NCXPK1M7
M-W5\Z7BA;!%OJW:GRQCJU.8>"Y5@VUU\*>*GPUU>)R,9Y/$R=BBD]W<;*_7F
MW8K:FI8]VE]OX^<+,7,A\<Z99%=5D=:ZGK75'M->NEVFDNR>_22]837Q0?9;
M6]YCHC^D/?/I6O:(ZI +3=A2:)6M/MLC,C*5NW.&Q6Z"S!*Q.F;!9M*INE0:
M/H>P%)+Q[\43"X<L)9FC%];Q%X3IR:;^7\/QC.-,(7Y_&5QBK:*;(]4<S$A"
M<H97'S]:LK%^"4=UW549-5L+/FO(TU7;VD^T9Z^%OWC+_;->DHOW[QW%[6Z#
MGGW#W#/-#;/"WK6="V9&'B;S5HFQ-#)F2(=ZV*#UL0YBF.#*11%)^R[Q*'E!
MJY2*L7E-8%$S&(8#3WO[Z)^41G7VQNF:]OHN;[0<%HEAEE8=NH\35\I%X2TQ
M[<PQQT1,<S6.!G#"=4$R!:(M+R*#V,+F\S#K^SS<,W#?KAYD5?3K>]5]?4ZM
M?JJ*<$WU.#:[VKB?&'+<71]AG*GE.)>E/BN4K6;A=/OY4+NO[/+6^EU:A&6I
MN$FM..:GU2]:_3!,I5#;+-];(]LH@BVK6XV2K":E6XHE%<*=M:'&1C9UV"Q1
M3:L$GNQ@10$32,HQ.4Y2=6,/#?*ZUYO#94_935F+U?/IL:CI^GPW8VFO@HEM
M:[]=7@/Q%I163X4Y"R3W&%L,KCI2?ITU94ZXQBVTGTYF)K6JL::?:_= ZW^F
M#?<>G4MG,(VESRY@(^I^TV,5(P O$OO#QUG$CNLO$$3\ @^77C5A.( FD54I
MBEYG(^%\NN+W53R.,OB4ZH]<DGM1<L><?-KFUZ:4NW=2UK>O;X0\4\'99F\'
MESS81CMY/"Y5].4J9=XQR,"7DYT%8M2=3IMA*.GN<>YZ"X=&>LK.5A:M5KUR
M+D6_Z1%+/$7<U%+HG2%,$XVX5F:@-A11%"B4&QVESD(5F(>0E==!^;&FYG!U
M7? W.$Z^T(Y"G;*K2UTUV2E#,H_!5Y$8Q_V/T-CA_P H?,\'?;#(QG4[')9L
M<%0XBS)E)J3^W\;]GOX'/>U\;S^$NR)IZ61!ZD5_<ZWV9KPCA*\PUZ;0C=RX
M,247KB6_Z:*)^0\PSVIT-<[PCD^ !0'MSJEK1CDA_/OW/;WCPY\-ET2;\VZ5
M*;:4J8YT.Z3WU8TL'D>IM:^-9JCW:]=GHN-^4CAN2KCTT8E'(60U)UY\O#%_
M4IOIK4.9J\3^$'5TM-^2_#GF=X.,.TB$[)T[4[:YU)F%UM4MD-&(BBO;]27F
MOW2U1A%>XBH/TV8Z2WM77B &,88EG?9ERT5*408K+?=XXOEZMPQ7]KQHI*5:
MOIY*$5_MNP,N&#GT:7?HAEVR79>6V;DUX#S^C(YRF'A[F+7.>+FOC>1\&WVV
M=U&W"\3<!D>)?"^?&?K]IR.$PJY.4GY\$MSBY.Q;(T=,)QFI>I[;]&,R$AE]
M;[OKH[-8G,D'C$$ZG= UCLB,:J)E3+ZD+YL-P<O8=-LZ54*HKD7**J33P,ZI
MK4I_FYMSBX^LI<9D+HJBDMZCYLY):2>]FK=X&?(4=</%/AGDJYORL=^,(41H
MMC)[A5B^-.,MAFYEO5+2E8L.B+]7%1E%64HWTB&]H0AT]BZ:J>U(ILD C9]*
M7$L;/&,4_!AD]=[)84Z<2=G()3!'5PEA4!4W@3463[79]_&YVFY/R\O'NDO_
M &<J,^-R$W^K/S8RKZEWTNFI-KUT]E7YC\E?)X35F5X>YGCJ)=UG\#D87C/B
M+8]+:NQXX5]&?#%;7>;LS9QCMM.47%VTH_TA?3);S)M)>V2NLI<?&5:*VI6I
MNCJ(+F .]$[^89I18"D?DACF>D*8 \A>4Q V==9]:75;7=3'M^D<%;3W_P#O
MQY6TQ7==[)P//K/"N9*<J\#,X[D;(MIXL<G\W\DFMZ@N+Y>''Y]UK2_Z>)1D
MOY.2[EPX*RURTL4I.LS\+88Y<H'1?PDHRE6:I#>X&(Y8KKHF ?P$#CFU7;5<
MNJJRNR/SKG&:_C%LX>7@9_'V>3GX65A6^OEY>/=CSU\U&Z$)-?)I::[F;S(:
M@P!@# & , X_$?W!_P!^ :U-4UJXLNNB_;"2^+AJK9D#.K5AP9]'GJ$Q*Q,;
M3F#R5@7(6AW+/YM=6(D&TG K4J!91#://*-)Z9!V<I@-EF , BG;QZ,2LE&^
M2TQ$1WF7]&M"S=N@W"K[T3GM25<4]VS?*HBEY#"BY.9IW%*<2^0I! ")NA3P
M_P"1QTU>G,8[?\C]+\!SG54.='X2CXCG47$RQSF3[3&.L(JF,(F4$3B. O\
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M$#]3M CF-:";K83<;-2DP[-)NV%E=I"X36CWJRA/3S4F>-12,N!3]C)! Y!
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MR7W^T8]<I8=CT^]N+6G/'DWKX\12K^6+'O)UDLO1CTX315F!+1N#4)UUCG&
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M$3-QD6*#E9J<0X\K-R<@N&:P<_96:JI*E'W*<!]\ A.Q=,U0E%#O8.=M5:E
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M'$<J<JE8,6+(#>F9MDD@-?6Q8Y-#KEZ8WH0[UJHXV]M,II-6ER<2U=@/3KM
M>U&TN-05EA,B;M 03;;,M1E (*A6[@$#+L0-GV , 8 P!@# & , 8 P!@# &
M , \1;-=5"Z"1>;B2_%$4A0:6",7<0]C8I"(B*+2=C%6LFFU,)A%9B9P=@Y
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M9W3_ *;ZF:XB4 6F=86%"F691,!X.J.M]JIOX-1P).XWA8[#$#'$"D H"(E
MPU2WUTU1ULA8J?B-N=,]P6DFB+2L;&@[]K>K2SY58J:,<D^26>:GGDG*QRI
M1C+. 5$Q>PQ1$. -@P"!@ Q1 Q3  E, @(" AR @(>P@(>X"'L(8!S@&*4^\
M4_C-_4. 97 & , 8!KHW-$%;]6O2=(P[ZB'F'6XMG%4;HRL\\GD2#TY[7,I\
M8C#3BS%L7A,H',SC68E5,@'<!3G*H!?+MN/O^=K7S+V_H\I\N [^?TKY]W/;
MQ^''/O@#MN'_  M:^1O\WE/GW?9_SGY=O'=[<]WR'C ';<.0X5K7' <_H\IS
MSQ]KC]*^7=\OV?,.<#O]?+W_ +G %N/XJUGG[7R;RGZQ[?\ .OU<=W[>>/;
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M_ B'<  / B'/ X!6WH=*!.D'IR*4H%*74M0*4I0 "E*$8D!0* >P  <  !P
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MFXX#CN$>. X^6 ?"<I0.< *4  Q@       1    ]@  ^08!E\ 8 P!@# &
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MR:AG+Y1XH4/KZ_D7+P!@# & , 8 P!@# '[?_/X__G & , 8 P!@# & , 8
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# .! ! 0$ $!#@0'W 0'Y@(?B X!U\:?(#V$Y#@ 'M+R': @''M^ &, ?
MJ 1 /F. =3(HF*)3))&*/;R4R9!*/8'!.0$./L '!?\ 1#Y<8!YF7HM.G[-4
M[G,UJ'DK912SI*=8G;))67KB=G8)1EB1BGHE\[5O-L$&[:3;D-X79&S85DS'
M;(&3 ]/X4?L_FD_L?V/S9?L\@ #V^WV>0*4/;CV*'Z@P"*(#0NFJNI6EH#6U
M3C%J=<[YL6KKH1:1EX.^;/7GG.P;?'K+>15&Q6U6T6()F5[Q>.4IJ1;^4K=T
1HD($MX P!@# & , 8 P#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g713200g21v73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g21v73.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[25P4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %X< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(R-C0V,3<< @4
M-4UI8W)O<V]F="!0;W=E<E!O:6YT("T@25!/('!R;V1U8W0@9&EA9W)A;7,@
M,#<R,BYP<'1M.$))300E       0*]X2)5P^CK[\D2Y'K/^1]CA"24T$.@
M    Y0   !     !       +<')I;G1/=71P=70    %     %!S=%-B;V]L
M 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N
M0FET8F]O;      +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O
M;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R
M;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP
M<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U='!U
M=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S
M36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M     $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C
M:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M    1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R
M9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !0
M9U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M        5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M           08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T
M=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E
M8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M       0 \     !  $#P     $  3A"24T$)@      #@             _
M@   .$))30/R       *  #_______\  #A"24T$#0      !    !XX0DE-
M!!D       0    >.$))30/S       )           ! #A"24TG$
M"@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F
M  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M      $X0DE- _@      '   /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z   .$))300(
M       0     0   D    )      #A"24T$'@      !      X0DE-!!H
M     S4    &              -%   #>          !
M          $              W@   -%                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   -%     %)G:'1L;VYG   #>     9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   #10    !29VAT;&]N9P   W@    #=7)L5$585     $
M  !N=6QL5$585     $       !-<V=E5$585     $       9A;'1486=4
M15A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'14
M15A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI
M9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#
M;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T
M3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG
M:'1/=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-
M!!$       $! #A"24T$%       !     0X0DE-! P     &LX    !
MH    )<   '@  $;(   &K( &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B
M90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.
M#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,
M# P,# P,#/_  !$( )< H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$!
M 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'
M" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"
M(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#
MTW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W
M$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P
M,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S
M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
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M69&)914_TWO$!VOCJTQ^]]%8F?T?[)B->"ZYQ,6P!L#8/^#]SE+"=;J>.5C
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MOZ"V[WLM%OTE\Q))*?_9.$))300A      !5     0$    / $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T
M &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      49-30 J    "  (
M 1(  P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $
M @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !
M  $   "\    Z  MQL   "<0 "W&P   )Q!!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#$Y.C W.C(R(#$S.C$V.C(W ')R,C8T-C$W       #
MH $  P    '__P  H ( !     $   -XH , !     $   -%          8!
M P #     0 &   !&@ %     0   38!&P %     0   3X!*  #     0 "
M   " 0 $     0   48" @ $     0              2     $   !(
M 3A"24T#_0      "           _^$!2$U- "H    (  @!$@ #     0
M   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M'@   'X!,@ "    %    )P!.P "    "0   +"':0 $     0   +P   #H
M   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M #(P,3DZ,#<Z,C(@,3,Z,38Z,C< <G(R-C0V,3<       .@ 0 #     ?__
M  "@ @ $     0   WB@ P $     0   T4         !@$#  ,    !  8
M  $:  4    !   !-@$;  4    !   !/@$H  ,    !  (   (!  0    !
M   !1@("  0    !              /      0   \     !_^% %&AT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B
M(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX\>#IX;7!M971A('AM
M;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R
M92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @
M(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO
M<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @(" @(" @(#QX;7 Z
M0W)E871E1&%T93XR,#$Y+3 W+3(R5#$R.C0W.C,W*S U.C,P/"]X;7 Z0W)E
M871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @
M(" \>&UP.DUO9&EF>41A=&4^,C Q.2TP-RTR,E0Q,SHQ-CHR-RLP-3HS,#PO
M>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P
M,3DM,#<M,C)4,3,Z,38Z,C<K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @
M(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N
M<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R
M/D%C<F]B870@1&ES=&EL;&5R(#$P+C$N,38@*%=I;F1O=W,I/"]P9&8Z4')O
M9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB
M:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @(" \
M9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @
M(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/DUI8W)O<V]F="!0;W=E
M<E!O:6YT("T@25!/('!R;V1U8W0@9&EA9W)A;7,@,#<R,BYP<'1M/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L
M93X*(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q
M/@H@(" @(" @(" @(" @(" \<F1F.FQI/G)R,C8T-C$W/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@
M(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS
M=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U
M<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B @(" @
M(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z,4,W,3A&-T(U,D%#13DQ
M,4$T0D%$.30U048T0CE$.4$\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @
M(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z,4$W,3A&-T(U,D%#13DQ,4$T
M0D%$.30U048T0CE$.4$\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX
M;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HQ03<Q.$8W0C4R04-%
M.3$Q031"040Y-#5!1C1".40Y03PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$
M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI3
M97$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z,4$W,3A&-T(U,D%#13DQ,4$T0D%$.30U048T0CE$
M.4$\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,3DM,#<M,C)4,3,Z,38Z,3<K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HQ
M0C<Q.$8W0C4R04-%.3$Q031"040Y-#5!1C1".40Y03PO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C Q.2TP-RTR
M,E0Q,SHQ-CHR-RLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N
M861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E
M<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F
M<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O
M97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z,4,W,3A&-T(U,D%#13DQ,4$T0D%$.30U048T0CE$
M.4$\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,3DM,#<M,C)4,3,Z,38Z,C<K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @
M(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z,4(W,3A&
M-T(U,D%#13DQ,4$T0D%$.30U048T0CE$.4$\+W-T4F5F.FEN<W1A;F-E240^
M"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z,4$W,3A&
M-T(U,D%#13DQ,4$T0D%$.30U048T0CE$.4$\+W-T4F5F.F1O8W5M96YT240^
M"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I
M9#HQ03<Q.$8W0C4R04-%.3$Q031"040Y-#5!1C1".40Y03PO<W12968Z;W)I
M9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P
M/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @
M(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D
M93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X
M.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_
M>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!#
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $, 1P# 1$  A$! Q$!_\0 '@ !
M  (" @,!              <(!@D$!0$#"@+_Q !*$  !!0 " 0,# 00&!0<*
M!P $ 0(#!08 !P@1$A,)%"$5%B(Q02,R46&1T1<D)4)#"C-2<8'2\!E$4U58
M8I66H=,F-#=VDK*V_\0 ' $!  (# 0$!              $" P0%!@<(_\0
M21$  @$"! ,%!@4"! 0$ PD  0(1  ,$$B$Q!4%1$R)A<? &,H&1H=$40E*Q
MP2/A8G*2\0<5,Z*"D\+2%E3B)#1#4V-S@Z/3_]H # ,!  (1 Q$ /P#[^.*4
MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7A51$555$1$5555]$1$_BJJO\
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M7MC84X=*;I,9U]:/DH<K\CLK2%?J-MI;@&*:1S /N58GSEJL0[?Z\\J1K/\
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MZF^BATA]1TIGL_\ L[7D/&@U6L%L3R[U(G*QYH%0.95LK )7HJBH;(67./\
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M(@/O,6/3NB//\WE(/05NWYRZYE.*4XI3BE.*55OO3Q7Q?<DQ.AAGFS&Y<+'
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M$STC<URPHC7R21-DF9&V9^C@+F.N62W$+-NQ>%QP%MMF4VQ&1I#, 3W@1FF
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M5Q6.P^'Q%O"7+H1[]UQ8M93WV!((E5(7WE S%1) !,Q5@KLI@2JP3'+E4C6
MQ%17@6]K!-655J0@E99V$;PP+$MTS1FC F$)&.40XAS8&0P2/D?,Y(VM5Z^G
M)6_9>X]E+J/=M0;EM6#/;!$C.HDK(U$@2-MZB" #!@[&-#&\'G6-B[C2:G7:
M')EY7LB6IP-!1SLW=S5&NZ_D'M988A:'.WY)$D$Q8LA#(I*\>*-L4L!L:(GV
M:J_&HP>'N!+;8:W?Q3/<:S;*+>=@"6N.B@$Z G.^IUC4D58ARN8R5'=UDQOI
MX;?45E5?7GVQP=75ADV%C8$PA@@APO(*+*(D;% ./!&CI)999'-8QC455<J<
MSLRHI=V"JH)9F,  "223T%4K:AXU^'YN&O*OL/LDD.6^KXU)I,J&J%04Y\K/
M9&?:GM=]N78!QOD^W%$9,((5["V&D30PK%Y;B/%AB$;#X<,+;'OW&T+CFJ@;
M(>9/>8:$ $SE58U._P"U;!.<*KTXI5//)SR:T/0.@PH5?BZ"[S%U4:/0;37Z
M'2W=/58NMS]WCJ]GZU^S>/V4V8I[.LT&@LW=D[:+.=79X_+AY[5:JG*UU28/
M=4S F3,@  3)@GJ.D0)8SMI2J!G?5\T(55:7B^/@4@$&D-QE9&FP["5Q.@%\
M9V>1[99;V'I(C$%1/"83EURE%J[?L^1&MU(.%.H8#Y!,W8"0,_+,?=VS9=LT
M_&,O*9JP$^O"=IGU\*OKU'YB9G876.ZZ[,H;7J_N/>:+34^2PQ&?['EAT%14
M1=CVF?UC2M5U[B;O)5.WS?4G9-UF!>R,WB[.Y;@]8E$-=5U>%:V>)K9$E=5&
MYE=-M-"02,RSE)&N]1'V]>HJY7,=16!=I]<YWN#K7>]5:Y#5R_8N1T&+OUK2
M5"LHZK1U9-49-7&(R3[4^"$ITP9"QR)"3'%(Z.1K58Z02I##<$$>8,TJ@'D%
MU%I.M\R3W?V?Y3]I6=\#FM+TZ0[(]==>??WN9[GL^JL_!B^O<E9Q$9S.[6\T
MF'ICG:XQQ[9K:[LB#H0LU5TU325O8E,/:9V20&2%&K-<+94420#F+Y0"0!S/
M.MG"86YC+ZV+64,P=BSDA+=NVC7+CN0&.5$5F,!F,0 20*H[N\GBNDC.PVS]
M#]J]!UOD!U8/U':U&W\K^AJ9MWFZ^\&)T!%1%NNV2R%**R#@NNH)1IGP8_*(
M%5YY*V"$49NF_$KUK)VN%R=XE.TOX5,T #0&XLQN=]3K76L<%LXD-^'XBN(R
M92_X?A_$;P7-,9BN'\- 1KRTDU5SS,\IY.Q>W(KXC)4M-1A8_/U6=IZ7N7I?
M9!U=2&ABR11&X_96%+$K[&0Z7[*(AA,$#ATF@8QT+G;6%XRMJT9PR&7)9CCN
M'CXY7Q"'8[[;P23%=;"\"RIE7$7"V8R6X=Q*WKI'OX63IT'QJ'LY>AZ>DKKZ
MO81&'9P+/#&5&D4[$;))"]LC6ND8OI)$]&R12212L]LL4CXWM<O?PV*M8JQ:
MQ%M#DNKF =0K#6""->8.H)!$%200:T<3AWPM^YA[A4O;,$J94Z2") .H(T(!
M!T(!!%=US/F'Z1]/M6"M;'GWV::+'FNJ*PB2 >Q$;J]/\4BM^\%:9,)05TJ-
M5/<.PP ^Q)AD]6OG@JIFIZP\NO,P!.D1\S/7IT!\:PWF@!1N9)/AT]?Q6L;E
MJU:<4IQ2MH'TS_('5]9=FLH*BUD%*K9OVYQCGO<K!KJL?#'>U*-]?5]??T\L
MC[ /_F'P!'_N>X\ETE+J+<ME6V@@]8WD>((WY:5FMPZM;;4$'^.<Z1X=!IN:
M^_3KG;UG9.#R.]IT5M=K*&NNQX7.1T@JFCLDG!G5OX^X (64,E$_"3P2(G\.
M><=2CLAW5B#\#7+=2C,IW4D?+G\:S3E:K3BE.*4XI5'?-KN.QPN2J\-FSY0+
M_:H3)8FBR/B+!S(BI"2R"6-S9!YK8J1H;9V.1R"#V+&>V1S7L[/!L&N(O->N
M &W8B 1(:X?=D;$* 6@Z3EF1(-':-!N?7^U:K*;15]70:6F)S57:EWL(L0=T
M8B*=1N'D>]\@*K#(]'2^Y%7X9Q55[&?.XB+UAYZ'$82[>Q.%Q"8N]93#LS7+
M">YB)  #PPT$;%7$$Y0IUJH8!6!4,6B&.ZZZQY_#XC2M7/=FPFUFZLHVS>^K
MS\LU)61M=ZQ*HLGL/+;Z+[7.+-9*J2HB>\:,5OY2-J\]QPZP+.%0D?U+T77/
M, CN(?\ *IVZD]:UF,GP&U1%S>JM.*5L#\=._KN>HLL&5=S!6UA5NK)I7+"Y
M=/20L>W[>66=DDGZH)!+/'++ ^,HH)\LWR/=]ZY?)\9X-AWNV<6UD.EFZ+J:
M$?A[Q_,,I [-F"D!@45@ 1JM9[=Q@&4'WA!YR-?7D:S^TZYQEUM<SV)9TD96
MQQX=G7YVY4HZ-]<+;P2C'QH+"3&"2LD!!$<;RQIY!T(F4=T3I%=S4#,%*@PI
MC-MK&HU.WC5I.TUF5IVD-CJ87(7.Q H*?;WX8 -18&!"-T&A=\3@P@EG1"9R
MY7"C^T4:5&SR0C-?&^1(475;!X>YB$QC60^(LVV5+FI*HT@P)RG1V$D$C,8.
MM2&;*5!.4ZD>7.NE[=P 8'3&P[%5^9EL+S#[B@]1OMW:F (*CN9VCG2I A*5
MR$0R3M&4A\,+R!)UC1YB*V,-CA<XF<"+5Y38-JX;K+_1?,5T1I][6-M<KB>X
M9DJ0@>1!)&6=1',CX?MUK!,9WS65O2F2SU;TKY"-U4E=0PW5Q7U](W-7M"+4
M1H+&@7[>0QE1.E4>87[FJCE:C7D*0GSJ,U<P.)?BCW[F)P#X1$;\/:9";]G$
M%E#NMPV"5'O3%PZ0N30-3,N2 &#DZF>Z5Y")_CX\JQ#LOL.'N#)YG#=B=(=Z
M:+*X[0":G.5+Z2B CKKL%2?MRON*O<A&%-;&:9!]L800,D!,L38FM5OMV+.
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M1ZRJ41TUUW),^1RJYTDKW9U5F>YRJYSI?>JJOJJ^O-L<1X@H@8_&@#0 8J^
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MHJO-]U9P$BP=E*V3-[. 6-TTPV>4LBQJ;OXF?O?9UAYMD/:2M:]T,-@(3*C
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MGK0]]D-=HJ+45172E'I,I@-#7&0'N&9I1,;K;_$WUL2&5)L<4?)D];'=4*-
M2.T:(F5[VA ([VX\I&8=#K2NQJO"7I>@DL9*$_M2F_:'."9C9-"[<WOIO@1[
MS:Z4HO</)NB)M+<W5]V-MK.^N#Y'GVQ&@,^ZF=&T>.&3<8[Y3T[HTT TTT@
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MN5<$F(DQTG3Y5CGERKNVM:QJ-8UK6I^$:U$:U/\ J1/1$Y%*XIM=7V4$@UB
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MB00HY9M5QLW(?$U2')[#2X:]#TN4N#*6Y"E26(L63T^5/<CGP&0N]T!HD_\
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MK+(P"8V]T.D[)[$GV=_;Z6:O.M4+N;<R>:XF0,F"X/:S)S@ =!#*1(F  JP
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M3BE.*4XI3BE.*4XI7A4]45$54545/5/3U3^]/5%3U3^*>J*G]J*G%*^>:O\
MIF^3?77U7.H_+:P[+G[[ZAN]UMM'K]%:04&7V&!-,ZEV6:H8M'E*,6GS-L"Q
M%H,Z#J,A6"3SO^!EOG:B&-IA70_$VFPC6<O9N%4 "2&AE)@ZD3J2K&!!(.H
MS=H#;*Q! $>/>'/?J8/P/*KL?4 \K)L+6S=*]>6BP;"\":_:7(,R-(S-";$J
MQ4XT\;T<->7L#DDG?ZMGKJ9[98VMGM R18P>'[1A<<2@/=!_,0=_)3\S(Y5G
MPEC.>U<=Q3W1U;KY CXGR@Z.O1?[O\4_SYU\J]/X_:NG3T7^[_%/\^,B]/J?
MO2GHO]W^*?Y\9%Z?4_>E/1?[O\4_SXR+T^I^]*>B_P!W^*?Y\9%Z?4_>E;*O
MIAXN*Z[FU.Q(B;+'B,;+&(]?RH]OJ3&5X\S53\(KJ@.^@_CZ^V9R>GI^><_'
ML%MJ@'O-J?\ *)CYE3_M6GC6BVJ_J;Z+_<CY5O=YR:Y=>'.:UJN<J-:U%<YS
ME1&M:B>JJJK^$1$_*JOX1/RO%*TK>9V_R^][:B=EBAK,3-9X7.FVXCHY13[&
M&PLCB8Q"8U5A0P2',%0ACG1O)82V)71,9(_V'!K%VSA2;H*]I<+JAW"Y5"DC
MD3!,;QE-8G,G3I]ZTT=F5F!Z;N]"_K2DAHMUV#'*7J+D4LN1];5%EO)F$J()
M29!Z9]L>CBI(ZZ$9D,<$<D<;%2O>-['A]BYBLMS$'M+%@A;:%0%>XH&K1[P0
M=3J=#(# X',0!\=]O[_/>JT*JJJJJJJJJJJJJJJJJ^JJJK^555_*JOY5?RO.
M_6.LMQ6RM\+>C7E1(OJQ6QG!.>YHUD$KD640E$]4]'(GNAE]KGCS(R9B*K5:
M[#B+%O$VC:N;'56W9&Y,O\B1F$B1H1()!D5MS\?;7 ]B7N=L;8J!^>L("7M'
M,G:-'^KPQ>L55:/;*Q('QS>]'1K*V,F:.")KI1RF?+\[]H?Q^#P>(7#*WXA"
MH)09F%IC#7;0@YM"-8)49CHRR-NQD9QG]TSN8&;E)T_O4F=\TF*I-)70Y!H(
M\DU>^2X K)6R!BSMF]HKDCC>^,6>>+Y/E&C^-J,BAF6)KIE?+SO9O$8_$86Z
MV.-Q@MP"Q<N@AW6)<9B)95,96),R1)C3)B%17 2)CO ;#:-N9YC[U43MOL03
MJCKO3;TP-UDVA%@</7,F093CSSA:RO%<0L<WP0R&FP?<3I#,Z$=)960RN8V-
MWI[5LW;BVP8+<X)@ $DP/ &!SK7K%/'WN<?O+!KK$J4H[ *W,H[>L84ID$)H
ML(I<<PI+HH))!B0CA9426%CX9EG'596PMGEMB+)L7,A8,"H93$&"2-1RU'4]
M?"E6$K*>WNYW"TU786I+(UF?!6AD&S,B:J(LKXQHY',C151%>Y$;ZJB>OJO-
M.]B+&'4-?NV[*DA0UQU0$GD"Q )T)@:^%2 3L"?($_M407/2G7EGV17=G6^7
M8[>4+8QA["68X?XB FS0#3FU:31A$65>V1T0I1@LA0JQ#>Q[7A"+!LKB'-GL
MTN3:<3W2K J==&U[K<X,$'H3,'QY?Q]J[[L#2S8S"[+7#BQ'3Y?+WN@A"FD?
M#"7+45A)[!I96->^..9T"1O>QKG-:Y7(BJGIR$7,Z+,9G528F Q )B1M,[TK
M-,D#;[%^> IZZ8^ZT;:Z,"L#3Y)9C+&.)\8\2N]J>UKI/WI9%9''&UTLKF1M
M<Y,5QUM([W&"H@8LQV $ZD;GR$DG04$GSK;QXY^(0_6-K7[O<V(USL!1WNK*
M@*-74^=*)B=%*2XJ1?DMK.(>22"*9(1PQ'RS201E3,%-B\IQ'BQQ2FS94I9)
M[S-[]P R! T120"1J3 !($BLJK&O/]O[_2KQ\XM7IQ2G%*<4JLWDEY+TOCD/
MUPEGF#=)8=G[*;%T"/T>3Q&<#L1:"TT3VWNUW-M29BG+LQJJ6LS%<:?&1HK\
MD2K&6%CB"QM[!8)\:;V5P@L6Q=?N7+KE2ZIW+5I7N,%+!KA A$!8SH#!,?$Q
M5<.S?J6=>]8DW$%AUMK[+]GMGWEE+9L.CZ_IRI(^A9NOHM,500:335$>FN+I
M>PZY,KD:@F;0W<P)HP@TDRP-DW+'!+U\*1>MKGM86XO<O./_ +6+QMAS;ML;
M:KV+=I<89$!!)B349A^XY<OCXUE(WU$.IA.UM3UUL\_HL'0YJU["I7]CWY^9
M6B^^ZPPN>[$U:V^>$N9=MG08\[HPFUME89U0;*Z:[/Q3LN9A R*'@^(.'MWK
M;I=>XMAA91;F>,1=>S;RN4%IVSH<RAY5>^1E!(F1/KI/GMX5:?JGO#J_NT30
MF=9Z5VA9DK>//:@>>CT>>L<[H'@CV3Z*ZJM-44UG770H98\EA5E"1G5KY6P'
MP#$>L2:&(PM_"E!?3)VBY[9#(ZNDE<ZLC,K*2" P)#1H2*G>I8YKTIQ2G%*<
M4IQ2J_>2O?-)X]]:6.P.2$R_-<ZIQU%)(K77&@GB>Z%)$;ZO96UT;76%I/\
MNHP:'[>-_P!X6)%+FL63>N!!H-V/19$GZZ>-9;-HWG"C0;L>@^YV%?,CH-!<
M:J\MM)H+ BUN[RP*M+2Q+=\A!9QLKIR)I%7\)[GO5&1L1L<4:,BB:R-C&-]
MJA%"J(    \!'Q\Z[0  "C0 0!T KI_5?[O\$_RY:IK\OD9&Q\DKXXXHVNDD
MDD]C&1QL:KGR/>[T:UC&HKGN<J-:U%551$5>*5K[[?\ .RFSIY=!U74!ZHH5
MTD$^IMGS,SJ$QN5CTJ@@WP&74#5140YQM<*]S4>)]^+(PAS<:R)Y<Q^\?N.E
M87O!3"]XCY?WJK+_ #:[_<5]PV_HHH5>C_L(\K2J(C4]/6)))1I;#XW?GU53
MEF3U7VRM]$]$#_%/^:?H:Q&\_A\JL5U5Y[P'&"5';5 )51SN;%^UF9C*>$.]
MWHUC[2A(>:7'!Z^JS&5QI+F*J(VK2/W2,1TY;S_'4\_G65;P)[PCQ&T^OEX[
M5]07TG=A0$VW:]*,>"41IJ#%:>B)%(AGBM*BHGOH#" IHE=&0,Q='53,DA>]
MCV$)(U59^]SE\1!/9M!@%E.G,Q_[8K6QP)6VW(%A_J@C]C6Z?G+KG50OSB[5
ML,]GZ+K#/G.!L]Q\A-Z3'*L#XLW#,@C W3-5'PPVYZN83(U4]X5>8+)[H29&
MKVN#X97>YBKBYDPXE5B<UR"=N>4"1_B*F1%4<Z1,3^U4H[&Z& Q.+?I ] 28
M;6N";9P%PCQ"EH63"&KJYL:)- Z*:=CVPS2EK)"V1?>QS41SA?M)=Q^/&%?#
M(EN[VAM%2Q=2BEXN$]TY@IDA5ACS&V6[AQ;3,&DB)G0&=-.>_P!*T0;Z\ET>
MTTUQ*Y7(5<&L']5]WL"%E40"-%_@OQ!001JJ?A5:JI_'GU_#6A9P]BV.5I">
MN9AF>?-F)\JYLR2>ID> Z5B/,]*<4J5^J.S3.N[G^F^4K.63V,N*]B^YT:_A
MC;()BN1J&#M_#V>K6ECHL$BH]H\L&CCL&N+MZ0MY-;3_ +HW,J>7Z3J-S-E.
M7RZ?SYUL5KK &U!%LJTF$P V%A(I,#D?%-#*GN:]JI_;Z^CFJB.8Y'->C7M5
M$\NRLC%74JRF&4[@C<>MZS R)'.L%[9Z["[7Z]TN"/,?717PL#8+&.%"7 '
MG"V=>7]NLD/W$<1H<#IQTFA6>#Y86S0N>DC;6KAM7$N  E3L=)!!!'@8)@P8
M/*E8MT!TP)T;A%R45LMZ<9;F7EO:_:?8Q$&E0BB,C%$6<I\ XX0(D*)(1,^6
M9LQ"K&DR0Q6Q%XW[F<J%&4*%F8 DZF!,DGD(&G*E7JZ3[1H>O5O!;T$M\%K]
MI-$?70PD$QR").Q!9XI9AU4>1)UDC>R1WQRHY'QJV3Y(_*>T'!\5Q/L'PUQ
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MP3V$LW>Q-^VZ%BG<NI%M\TF267O2 1F[HBL]RT+65@9!,&=]CJ(Y>&^VM;@
MM3FK(,2Q OZ8L$X: P,J"R#DA)%)C;-!/$]LRH^.6-[7L<GX5JHO.4;=Q259
M&!4D$%3((,$'3D:BN5^N4O\ ZXJ__B G_P![D9'_ $M_I/VI3]<I?_7%7_\
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MBI7+QN+X8,@Q2"'0JEV![R$PIT_,I,=2"!K$5=#!CKMZ\OVJZ?.!66K>]/\
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M0"JY!U-=/C?^3P=7 68\^^\D=UJ:F.9KR*[*82BQ!A$35570I9VM_O&0^_\
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M7R_%%))[&N]C'.]$721@KHQDA75C&\!@3$Q^]*L%T5T/NNV2*W/9X5D0%0(
M)?Z<IDK:.I;"/#$]5E]K7EF2M:KPZP=%*G16OE085LQ4.CC<?9P:EKAEVDI:
M4C.V_P ED:LT <I;NU*J3_)K=1TST7B^E*1P&>@<=<G1Q?KFG.CC_5+61B(O
MQM]ON:#6QR(KA:T=RQ1?\Y/(46LI4OCL7C+V,N9[AA03DMJ3E0?^ICS8[\@
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MY/:0/4Q$RS1+_06PK_WDC,!L#\0?H(WT,3OS@UD6P-V/*8&OSZ1MK/E7TR>
MGA;/<6>;[+V.99G>LLA]H1A\R17H#'IC@4:M43#6NCB2++5+FQEQ3+$V"W+B
M'A'0@%AJOYV+Q0"FU;,LPAC/NCI.V8[:'0;ZQ&#%7U13:MD9CHQ4Z(/TB.?+
MP_?>USE5S*<4JLO<WBYC>Z=92:R[N+JG*K@(ZFQAJ$"_VO7#DSE"Q+,5!/\
M9D0R%DL4EL1'O@D;'\3711R-Z.#XE?P=I[5M48,V92^8Y&( ) ! ,@#0\QXF
M:E9YGU/WKE;+IC*9'I;<YKK+K^AEMILI;#5T$M<-8VMD;*))$D\QY[9S+&T8
MQ[Y0/N2'JI;!X8OC9[&MK:Q=V[B[-W$7W@74).8A57-,  @*O6(T))FD0" .
MM:-B!IPR)Q"X"!2AI7P$C$PO@('GC<K9(9X)49+%+&Y%:^.1K7M5%1R(O/<
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M<LVM1M\=FZK0Z1L-K88O0AU=H<!FK2P%R7LSL7C*BBW;63,*B(B:@">Z%9B
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M[_@O&%NJ2Q_T:. ")VC3.@C-$ 0 PRD#X:"F]=)GO!3H#-KE60!;>U!Z];B
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K[TQEC:EVL$#"G3VMHC7MC.G8ZI8L "!I&PUTTB>E23/K;R^=6!Y6HK__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g713200g22d25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g22d25.jpg
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MYV9<0ZH9K2,%@M-6DP M+]K$UO4 XQ9<LESJ/-5&1JJ+EDSU&846<VDTRW)
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M9S*PB<BAT87#0:/93D.K[_Q@@$%AR\6/0.O(>/ZN?FF'$O2#]D;%J7HIV8G
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M$6AO8UI1:Q)5,RAUW'*"VKS=W+2TGQ,C1'2(V2J=E(!PS:OF"891D\_&_0#
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M4>#\[Z+HYQ[4BE_E4\9^/?7&43=!,4O0^@Y= NUT4--F10L#>.!--Q(D@T-
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M6_T@-?TV_*=QOPX^JK_?+9P?P)?66>T22G(B2DI\N?Y5I_\ 2<G^?SR^</\
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M-F@AB(:-=WKHJ\).%4V;8<V9I[NW#Y9;1LBVTW745U2UVWQN$@ L2  ,DDX
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MCXQB\"BH=;\B8BFS%F,?:KC(^\($2*S4CDJC/U\O9_"9:XB.(E378KY9IO\
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ME/EKD(.Z'[CKS^,R?\T"Y8^Y_KJ_13[;9 \<_,TWRK/8D@=RRRNS]I_Y1/\
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M( ))P ,DGQ =3.!_"S5_XPH9_P 2"?\ J^;/P'6?HNH_P;/],U_AFD_2:/\
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MG_I^;'XMUWZ-9_\ C_&='XPT7Z17])_A'PZU%_GX$_\ K<_]/Q^+==^C6?\
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M.4N6Z0Y[D_@G$/I$Y^S5>3_ /C]1ZI??D)QSXBGUI]PRDNE[ZE%BRB/L)"
MC -FU_+;2K14.Y(K%F$7A\T!11V,F>KW7#54T183&'R!NX$ZM6C1=Z<C^[9U
M@&W.F;#5<SLH95 L1[*\$Y"HZJ0^?Z1#HW+ES9<=Z&:%OH2M6*LQ:JQ*K=P&
M"SHS@ICHH*.I!))PK \R!LW7#LJ=NN7S&/F(Z-#,AP%I*XXY:-)(/]I&.YM-
MXCEFP(R%FU$V<+2;184<TLVM%B$"=YDC<4W7SLBQ(&>-&H-K.I4  !EP&&07
M=>18 6#"JW:5YK.[ /(%LZG3+0B,&+$L48':<$(C\PI+5'+,O9VA;.]W8ZA>
MSZ _>(+^21WZ&CRB6?&6?+;WC+C7\77\A?=$VF>_@--/HG(_L=YSMTGA6F_6
M*?M%G&_XB[U5GN&40S&!L9D6K@L\>NVBM;SK,\')-M4=DR#[,*F<)]B>Y5TV
MVU:>Q31Z\\R&=%O:F;77S^JV5TVOK(&-9)/Y-]XQXSL=,'S=^3\TI"6%!8
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M8XQR'CYF>7;SZ5E-CB)Z ?W,MV8H%KTNB761S;4*1[ $K4N&3,*C4,(ZS9V
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M+]UKXUV["=0-=MO)KFGIYC;?PSMY=<S=CC.WACX\^7'Q^&/CSX>&.>@_@K\
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M.=-E&^72&CS*K?VA/7;='UNNGK=-=MM/-C&<\WOQ+K?)5RZ_E!R^J:?XXT@
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M,9,VK9JU27>/R!%\Y;#A8Q@W<D2A)TU'#VKEZY004N?"65.&TLQPH-N2?7.
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M4H$DV$W);'C M^.&Z;Z!90J7C+<H3;N:S:(:--BZ\<;O;SJ*G=FVIO#T/4C
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MB?C%\03,D>%LJZVMF8* MF2Q 'YC>,\I=&**BSHL:;"$F!@*88,RH@N*>-R
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M0:F]JJ#?;7I#50+[]U5)N:L6.K*FXJV*A8;M4UFH9%);.<';DUH"P12^6VH
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MZ0WS85S42 <2,FYUIJ@6]7L$A-6*,W;+9&#G"^@V&UX#K=KA#;!BJT]UF[,
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MZDI8VGL-VGLM0V[;+*+6[2MW!966LY/95[,"YP"!M .X<D0$!AM<*<9 9>3
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M>!!P0P26M)Q9#=[+P F2JMO;='N'O2>%: YSK;2;=WPP]KI<Z]6U!U.S4XH
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M4?.[MSGIC:,9S.S6</36=GFPU]GO_-7=G?MSU/+&P2L?_LCU0?/1LGZHXO\
MKCRU_P#U5U7_ +/I_P#[NS_LS2_$=?Z0_P"PO^J/^R/5!\]&R?JCB_ZX\?\
MU5U7_L^G_P#N[/\ LQ^(Z_TA_P!A?]4DAU%^YGZ7ZL=C*QOYWV+E%M-ZY)ER
M*M=RNK8VRC\FP5C)N.X;$G*<D([I)M-C&I)+.&2_F<LD=,ZZXVSOK&<9_"%J
M>,<,U7#6X;3IUU2HAN34N[($MKMY*:E!SLV]1@'/BG=I^$I1<EPN9]A)VE
M<J5ZYY=<R[0KT;ZOR@)846G%.0"916PB:CE['RT8')LQ@=4&!$J1P8JSU0=-
MA>[L,N:SJ@LWWP1+D-\>'GSMM0M/JM1I+ZM3IK7IOI8/5:A[Y'&<,,Y&<''/
M,DVJ1U974,K<BIZ$>0R/?^!@]%K\R:F/]W&?[:Y.?RO[IO\ WG6?M)_HFO\
MB_1?H]?T'^,?X&#T6OS)J8_W<9_MKC^5_=-_[SK/VD_T1^+]%^CU_0?XQ_@8
M/1:_,FIC_=QG^VN/Y7]TW_O.L_:3_1'XOT7Z/7]!_C))M.E_6\1O FD=J6!@
M(W A:X5E%F,6%;"B0K4,@%$,B/KTE%G"8)!LDL/W7W75]=KZQ13.^=M\P%M]
MMUEMUKM9;=8UMCL>^:QV+NY\[,23C YGEY-D5HH55 "J  !GD , #GR G+'7
M5?K8]QIJ]HFJ7>J><[::NH/'W&-,YQX9SIA5COC7.<8QC.<>&<X_;YP#NOYK
MLN?(Q'L,SL4]1[9H_O1NKGS>Z=^KV,_V=SEVUO\ :V?MM_&8[-/ZHC[T;JY\
MWNG?J]C/]G<=M;_:V?MM_&.S3^J)\9/U.H$_&I"!95; XZ[-@RPAH?$1(*D5
M!.23!PR0,#%,-M/5D!BJVCUEOC;7R.4$MO-KX>..(8@@Y/+SS.Q?)[?XS==>
MKW7;+;5LO2M9N=,H806]?#0:GM&OJ_5J>NUV9[:[^MQX^LUVQG&WFSC/CC/&
MY@<AB#UR"1@^;'2-B^3VS0?>C=7/F]T[]7L9_L[G+MK?[6S]MOXS'9I_5$?>
MC=7/F]T[]7L9_L[CMK?[6S]MOXQV:?U1-<VZM=;V:?JFE&56U2SMG?*3:$@$
M$\[YQC&=O(DRUU\V<:XQG;P\<XQC&<_%CG$N['+,Q/E+$GZS,[%\GMFS@NI=
M!AUI"JYK""F=3<@<FFB1&)A5$P35=@.9Z QF,MMO5C4%6*SU)/'EQAP_=;>7
M'F\<BQ..9Z8Z_7&P>GZ?HZS7+=3.L3A3=9>@*A764SYE%5H#&U%-\^&,>.ZF
MX_;;;/AC&/';.<^&,<R+; ,"QP!X@[ >V8[-/ZHGS^]&ZN?-[IWZO8S_ &=S
M/;6_VMG[;?QCLT_JB?=OU0ZRLU/7-*#J1JKY<Z^M;P..(*>7;P\VOG28:[>7
M/ACQQX^&?#'C^US!LL88:QR/(68CZS&Q!T43;7W4J@W<D '4ZQ@S-F%8GF;H
M WB8746;5,Y$Y:O22?LV/6. ON:O@=MY=O5^Z;WX]?/^RX[CY3,[%\GUF;NZ
MZK=:WV-,/:(JEYA/S93PZ@T?<83SMX>;.F%6._E\WEU\WE\/'RX\?VL<R'=?
MS79<^1B/88V*>H]LT?WHW5SYO=._5[&?[.YR[:W^UL_;;^,QV:?U1'WH_5SY
MO=._5]&?[.X[:W^UL_;;^,=FG]432ROJ70<CC)X QK""QEX9$OAK60AHF%2+
M!5W;?=%,F.5PVTRF\9[[X7;[^?7RJ::Y\<<XAB#U/TS.Q?1],WU7K!UT63W2
M6I&L%4E-<Z*)*PP&HFIIMCPVUWTV9YUVUVQ\6==L9QG'Q9QP&8'(9@1T()!C
M8OD^LS;/O1NKGS>Z=^KV,_V=SEVUO]K9^VW\9CLT_JB/O1NKGS>Z=^KV,_V=
MQVUO]K9^VW\8[-/ZHFO;]6^N#1/"+2C*L:HXSG;"3>$@44\;;?\ BVQHFRUU
M\<_^O/AXY_\ 7SB78G)9B?*22?K,SL7R>V;+'NI5!A-3.KNL8,<R4D)4VWV)
MQ,*ID2T(JZ*( V/BVV\@P9KKE-FG^QQKIMMCRZ_M<%B<<STQU^N-B_?,UZO4
MSK"NINLOU_J%953;.RBJL C:BF^V?V]M]]Q^=MML_P#KSMG.<\Y"VT# LL '
M0!V ]LQV:?U1/G]Z-U<^;W3OU>QG^SN.VM_M;/VV_C'9I_5$U#;JCUF9*959
MT)4K17.N=,J-H)'4%,Z9SKMG3.Z3#7;.N=M=<YUSGPSG77.<>.,<P;+&Y,[D
M=<%F/M,;$'11,/W)T3K&RO>Y[S'Z](^XONO[I?!H'&B??/[H^Y?L?NU[/EI[
M1[B^P.O<WS^L]5[K/_+Y/6;>8KE<]&S_ %LG'HYS.Q?1]_/F3>W\^--LIXUV
M4QKMY-=]LZ:;;^&?+C;;77?;77.WAC;;&F^=<>.<:[9QX9X3E*E(WV)[0'IM
M$ZT86/74HCUH6Y#J:8]BXQ5;II#P5I Z7[3W+V$BE5!BLM<M+*A<+WHROH%'
MIH4<N6XJ33B;!2QF8RB#%PD?3E@>0\ATSYQ@].6<])S.$=PK6=*=7IU9:591
M:F)]UMM^S[8.AF\K(2%>8U(%"E)(:CP?=!TC&ZU:C\D#P)JD5G<GDK4RV:*J
MB?>[HXF",#OO*/HZX/IZ^:<_Z'=N7/;-#L>3?'JT?ZUY> <#$ ->20/)W,9K
M"74135DQ-C-RH4R:&OYLW.RZ: I8]$NE(ZA+([(HV =DV,:]TG28(QCT?O,G
MWQ,2 M]79<]=7?'P<$/1*;,]6;&5&J*"PU\1DPZFA022N[!M>Q+#R:21@2JQ
MT8VC=0#DPSEO-) .?1] ?(E7AXK7"9'3]^?W8Y^?[YC6:[:]LH[UP[)R\:2I
MF9V17G1BG>ZL>DA*/'HQ$8RUM>(=AS4CAK6.B24C<S=O$'U#:*P?)([&G)IC
M+M$92>4W 9='DS@<OE$'ZNGTR1<EO:Z(UV[:Q:2,B@'KB\G4*J"-'@T:K*3C
M)!9$JK!S.<,I<9UMI&U(7LZ)$!@49HWJ)Z-36:#'C\CH#DNYD6F,<NO/[^;'
MU_7+ ^)B1V[.3<W7E<MI0+LN.52,:R4<VD\G+0XA84H>"W[$JT#1.JH,.6U5
MEEHS&<JQ"-QN/X8G'9=L1*L 0$I)7 1#B9'^WBY^?S#K[>4A97':#M*_D,.>
MVJ/@\1<1^X>O'6ZV:<8QE7<N^FUP]<8%<$KFXB4IR\W@$I$I=9P0,A&6FTM!
MM $&GK5:121Z3$26/IG ^HG/H)]'B'TXZ3C9KMMVSRT$5\E$!3VX91V9O>MU
M$*3CL>F[>.PNHZS;SMB"C2]U6!2<8/&U'I(6V*S&8EXMI( XR3>X$)!'#4?9
M1]&!R.>7+KZ3Y ?)_P"99G2D_;6O3526DS),3#.RJR@4_:EQ@DD &E6TQBHJ
M1($AX(R[?EPK%\D1U=-!)5\])#4%4V;YVY=(JK;IQ,R*\R[PT=98:M]WV&Z^
M66KS=5-IL[PEM[-JZ41T56T;Y6\F%]TDU%=4L[;)Z;[8QKE$J:B/8;L_+I?#
MJW#6;7LABUG6<+KV/=G ]2+LHJ]E\4I2]K.N^.U/&'\T<#Y[! $DKFO8Y#)\
M\).T7[4Q; +8G(CL"0D7$Y8]@./-D>/SY\G\)DJG.R5_W')^J&CQK6D)A79#
MHU.+NR]#MSLCDC*X!*?7/.C]L/*Y&BA]>@\VZ6W"",E9$5E[?9F[)EX[JQU:
MDWF^_B_C&!SZ\FQXNG/Z^7H]/BS)TXF-PV-#IU.K,G &<1(M94I"TJ5%05"#
MD2M>0E^M#EYD9:M#QQDY;SR6AI%(X7EHKIKM73B(E':GNF9?CQB8/B]'/[^C
M'SYDO^)B5N=FNQEVTO99Y>$%X;8XV'PN5V;)*,"P\@X,1JDXA3\RDKRR+*LO
MW:UUALFE=N1YO"*NCK8*]1F8EN32&!"ZHZ;2VMDR!_X]/+]TQ[,^RO:NOJB[
M'8:&J?L&P*=KVF;?^$!]'#<3CC*'VC%984D@(7#A!&2Z2>3 )#!GB403)2:.
M,THC-XZ4DS^0DXF[;V CE[?_ !Y.7\#.;LNTMQK]WUJH49LO@)<743HH9(,Q
M)#2-N#8GJ>SOIR';S;64J2U>Z$IFVD;5R+7@+:F,U<,6;-Y]\+S!2+D$SCEG
MQ]?KQ]_'U\6)9=Q.,JV[-]G;^I.9V^1@1RN[*&5E6EHV7+JV0A9? FF:^CE&
M'9%6LGM"RV\C;JXL"=7>-%-$H V:,MBE*$I')0XULM W\M,IR R!XL\L^?/I
MZ8\?EY>/EJ97V$[-02/V> :E*QFQFF.X?6:F)98YH"6C2Y:K[LWZT%3&!D%"
M."@A>PFFUW%HXU76D@(,'CZ$?EB[ ^6]H#$48'T@GZ,_PF ^Q?>_LG3A"[$$
MQ#EL4:-NU(^"1QU14O2B\284Q$WDKJ2P0]QE2+6 V\[L,.(7=3"'AR&<Q@[*
M!$2)9B!2%'=9>@ ''S>3Q]?./-_YEDG6<W;!T%)G=KK63L^2+-&XA"RZUKVM
MB2;35GZQPL.9U[-ILR)L5UE=--G)!XR=(.&ZB2;;=';"N4X^C[_4)Q3N/9-F
MUE# Y>LIO&(S("/OC%1*(N(&[LJP;CM=01AS6-5P**)2".-56!MVV.%+",JD
M&JL;B(5R<<FH?&V,FFT<3(^_DQX_W8]AZ2-"'9[LDZ,Z$'\EIB#L9K8W8^B6
M$?E0 DXC5+R6@ZYDTH4MV731.4!WTHB"ABN)H\.BW+6*L7,9E=>I,C,<<"C9
MJ4)G ^?D>7CR>GUCQ=<^:8W/]O\ M ,AL[/"CT4VC5?4EVI[15W8$SJQY'2?
M8BJ: 84Q[U&I.([21E[Q(_-)),[)8K2P:U;E"\&&558 (0);2IZP>H &0/..
MG3GY^?WSZ9G#K;=_86W;HF69%M8K2M(_>O8& ,DF=0UPVK/$<K67S2*1MH_L
M12P5;#U-8P$'IDUTX5ZI>3ZJCM<)"5LOM$P<#Z >OE'DQ+ K"=R)A YH^B):
M)@)2SBI]U'3T]T=J0<&:0%.E1IF8),'HQZO&1;O5)^=0:$QCA<8W<HI$Q^^^
M'B*8E3#OMEV>6#R+2-3*%+1D;5_;3L54MTRRJG(E.\:KZUQ?K$B&U?0W65CD
MP<-G-GW78C-G/Q61CJ35? HA*X@QU8S-I,"*<L#V#&?+GZ^A]/D\4BH1=W86
M87:5 1$C7=A",5Y,9;)X)[A&XG&:,,D@T8,]>H%.;E;^^@@XLV>L2KLQ9$79
M00X]B\5<M98U A!B</3M9,??^/W^;GS(CC]]7VME&.J (:J56DEG5%VLG-G*
M4=4,/FBRDAI:[J=K:.[" UH6-&T $-P/GAO#C;<T;.N'V0F%]]M=7J^R9( S
MUY$#J/&"?)SZ2W^,[$MXW']C"SMP7V!B=BJ[]@T%OER66#?+Y9Z,'N7C <[4
M=>MW<L&3QTT9K;;MVSE=%/179.,K-OGLWV$JJ<W+B%2*N+(%P&%S@Q*8XT@I
M?$5H#9^QC;6AU)_8"4H:.I'8$G)&5)C.*S:HC'&M9;;G6KF%L6<<D%BIR !Q
MXL].?7R_^/.?'XMAL'L3V?C(^W87';'KH[:E0VY)Z:K,'I5CHC-^TEH&*(Z_
MWO4\52B;&6LQ,.A@9E;DK!7C-!SYHVC\?BK"QEB]?@!\GUXC Y>3&2<CES(/
MB\W(=?3-)V%[/=G*R>W^M!97!I^TKB(2I_*&T1KA9\(HZ4%+&K@31$$TEAF4
M,FE@6[,*UDDCE4_@;]!J@"<:QLXZ<0.-&X<WL5  /WQXCGR\@1U]/S3IZU&;
M3.Q4\^M5:Q-BND@RU&(637,!K<RF/2&LEMEF0ROIE-1C\8NY<*Z)OGI%J^PZ
M;NV^66K=)%=9./H^_P!0F/.YMF6[648 OZ?F,1%3 PREXN UP]@[R?SR[[G]
MA&.ZOK>-"$I#'FHZ$.M&\K*6Y*E';%6'Q9@VE;N30Z+A93(&R9&/'_L/&?X2
M/NW9[L"Z/NR>\RIN$1F;3OMW4@5E-8Z^]PJ1=]7'YX9FW9C+<2@*XE$9(H5]
M-I%(!A!O%!VS"4UTU:&(VB*/%9.F<?N/ISXOOYSSZ#C4P[,]IHIU\/WPT/QL
MG$:])3V9CG1FIM0DTL^@H^0B*@J[;!A+Z>!3==5*%"Z66_E9.#1F161((TG7
M4ZB, ;+NRD -(QXL\^7^P\I^?'MF3>LMT]A;:MZ8KRE>P-*V 7WVFKICAA4=
M<,ZK<1RH;>M*LH@CBR/A <6(J5PVB8=4HYVA22+V5(OQVN$0ZVCS&!^\_4<3
M!Q]0]@^OY\8\\GA:!$^(KF;E8M(H7#SXR,&7XV76-HX5@<569L5G&\EEZ+4D
M&67CX%%-4J3;ZF0VCAJT405,"DE-W[?,Q*F)!W [0"H9/9 +.Q3,:KND.T_:
M2O9],ZL>1PKV)JF@V5.YB;4G$=Y&R]X8&:2"7V0Q6E8UJ@4+0EA55@@PXAM*
M7PQ\G+ )QCJ0.N<$GETZ\O/Y?FR],>X,[IJQ+7/SB6PB>U)7T<EBLX' 8[[S
M E1V)*)] H_U9I\C;9X^L'<V/8,7E;LO=#8ZUU!U@CL)G,@(5[!G\;3FZ8P.
M77GC_P G'IZ??$<J^[P=C[J2HYI")2UE[R25SV%D-AE^K];U_:@=64U=V%:U
M@$P-^$6RXV@)BBL8=MWK;;!$F:(*/!SUUHBDXSME,X &2#UQCIRQZ)> ']LP
M(%^Z"RSA_P"YS'VY=PU09.%WGLR7M*R[)JJNV:+*K>?=5JW760;[[;)(JJ)Z
M:[Y3C*O+L[,]BJVL.S1L+D];V$+CR#@/*&3* ELQ#KF6L">UK!^O_OQF^DI9
MN9G8),1-2%DV76*.@U5K#F;4KH0@(9U$2UDID#R_5]?^_P!1YXVJ8=C.S@9K
M,H?&K KF0VO7-OS:FJZB3>LGC^4]HYXA%:GL>%MW@EE*$!];5M$(E8KX)?EB
M"E-V<9?"<SA)>)BF6T-.(Y?OZ]!X_I\7S3']M]R.T%;_  N:GF1:,F#\MF W
MKB,'U_4LQC4E@T/[C510CN0 9$ NPV<*SA>O[(CAYM%+,BU;,59%+%V&SE/>
M(D6VZ9 !Z'T^G!/DZ<O/+)>MQ>S3<)*O[36G^YWWS.VS%&QZ^@U<'4120P3N
MEEN'@$NF@=X+5=K/,MR3@JB04<ZO&JK%)NU;+N$XG'B^_P!0F+.YEG7'68*.
MN:8ET.9S<X/EHRN:L(0I[.9M>=SZMQ#FNX&+:('@2$=K5)LE*"5Q33*K=:&Q
MO1C+G4DB<=C\@>O4R,>/VXQY3_ 2/J7:.^'ITD0=3^FX'#IJ<[P1<8\FT8=I
M :)%=,^P*%1/;,D,DS*Q?OL%'(:$F4M/M#FD<$LI84@HEN3# &AMR91C_+X^
M?,>+[_3,0E>[_9X"LU0+A33*&0F!RF^I#:2U*!&[Z14"C<#^(0R>6774MM^O
M9' !'P?QJ1RJ5 X ,D]KDVAB)2@97T17'G:T()G /U<L^7Q=#]>,'RR1G4VZ
M>PUP6/,"$V7L%.OP]V=K(&.T1J.N!-7. -0WQ:=40Q!E83>P7]@NRF@J("5R
M*[N&M$B,A0*(9PV'*(*[)@@#TX!Z^4 ^3S^7ZY.6WBYR/UE-CD<EL&@!0.!>
M$_?U9>BBL$A8YCC5R;E<F13)A,+CH\$3(%\H.#0=BNLT12(E1S#=R\13$JH,
M=P.T@B$6%+,/8ZV"TS1MW=HP!27U40CDJ[)517TI:-($*>0]S(V+FK74SCXB
M7Z[O4&.#CM2059+]HS$T7)ROR*<MO/R<P.N<9'T]?81GQS.)"Z[P1GG8!BYN
MRO&=75)7MHS6T+3!5.X*Q+KN?B$UC$@@5:H%",K;I6;+WU!:3PU=H[;.KV!2
M4?$S.C>,#)F B[Q,8Y#RG&.G/KD^;GC'SS!;.^.]"<EJJ 2UU+5)=(^O"-X2
M\94%#5O(C\8>3"S)(PB\/F#">6F %#2<2A2 2/R1W'7Q%F8FS"0OF23(1N/2
MXF>7,\\<AU]//IYNF)<PUU6T:MM'*V7#C1NCJNXREHAE=;5/7"JV4$\[)HY5
MWQMOE+3;;1/.WDUSG7&,\3C*K[4[+=CH/9$] 1&65O/PC63QBN)*1&5\4]Y_
M7*9W9V5I&G:!%%93M*FZMB6 WJ^SY':MPU]XM<B-X^ >K$:]C<KA[>;IRY>C
MY^O(Y^O '[STT9;L?V912TC("=5Q(+/C5U3RF8A!!];/GTE[&EH?.8[N]DIE
MNWE*3"JJS@E72!NG;4^&J+#@<[\Y5M@<BM&ZOEB,>7ICR]/'])QR'GF Y7WY
M[0LV\[48M$6;68S@ QHPBRK$,]VE<-_PB]1=32Y6E$GT_P!OA PA5=LQ<@>4
MN!I5;GX3I5$S,+9FJX..<QM&WV?02I(S\XZ>;GB6S=="MCF8"Y?6@M.E9$I(
MR.C?2PX'"J[D#<2FS&:-D< H'*YB$78[.L/7#8EN7U?N-EUFZ[1%)HWW53C]
M_OTF(.VUG7-7C^#-*=ED+]]\HU=#Z_IMW#'TOF=T3M(R"]<R?/$#@E* 4[$H
MRX($;+L9-%;>)8)B#3H@CJP:1>;ID>CR9\TCLQ[47D0)N'Q6RJ>KR'6$"[@2
M@>>FL2<M1/7^)=1NU%;4L9+FB6TK;:2LF=K"8G3A320["A(BV1@%AIZN)/GX
MQ-,X'D/B^?(/3E]'68VE'<[MG7<?"R^:QDPUC8X"TEL4VTZXV [)7F -=C)9
M!1+*T,B"#QCU6D"]#CX'-Q#:=[ 71Z;6 OX F3J"2FGT48'/^.,<OKYY'[^>
M9(#IG='8:Z)$_D-B+V#I#<R>[!3+7>HZXC]8.&D)M.5P>-HA9V/L M/7[S4:
M&:K[[$HDP3(/4"65MFJ6&^JJ8./9]8SY/WR;5U'3,8JZ82('-X)6CD(/0)D+
M"LM'9Q"X3&F9!FM,)26;X)AD7"P.)Z&B(=!^6'"%CC<:D9=HB=GN^$Q*OM^W
M/:=A&I;(2:D?#L*7K'X>?42ZK24;F'8:K))?$\@]>,WL5=R-L]J*3'*LKIX9
M6989*G$Y?/8"4-16(HLSU6.4Y8'ISR&#TZ>89ZX\GD)Y&<HGW:/L9 KC6IY[
M)H,\TN!]6^U.V(C FVT1&B)9V,B%63AS!5Q<_/[3O-70JQ8*%DF]C)P=YO=$
MDCA$"&D\ //@$61@8SZ1CYL@_3GYA]./8]VO[7V':A>M0[F6JZ5]%Y2+D!NF
MJ3KV8X/2:$=O^VG6UQ+Y TL:S8[K%6$G ]?0$B; 0"YU,>;(2IE[3EFS&>M0
M0HQU^GS ^0],RZK7&<:ZXVV\VV-<8VV\,:^;.,?'MX8^+'CGX_#'Q8_:XG&?
M-PW1=MUVKC3"C=RBJW73SG;7"B*VFR:NF=M<Z[8QOIMMKXZ[8VQX^.,XS\?$
M2,4>Z4]58G$74"C-(0L'#W6T9WU C$'[5F-5AF'>L47 >J?:K1IP 2?O6PMS
M'E1B[5F[<,TU,-5MT=DSD^7Z>?G]LS:-K: !?>+@-#8X(TK$"O%J[0%B68]M
M"8VY'#!"P&,-6B2+8.(V%AA([ ]DDBV39CFC=-/1)#37"8F\!XO'8^0E18(&
M'BR4X/-Y1+WS-OHBYD<B:1>-PIL9+*:XQL[((1.'Q>/)N%/'?44"&-<9]6VT
MQA$W[B)@]_UKHHG:N]WO:TCJULK+@7+B=8T>(FW2T8:881[9XH@[20>8#L\9
M;L-'2"J:">RF-=?\8IG9&3TSR\D_L:ZV4)#X9.:[C%30D+!K+$O(].XLR#(:
M!I+&WH1>-;Q<@TV\^GO5:QUTZ!"HPW]2!""'"XX./8M%5$MD3=W%%4\ZLUO<
MKBN8JM:#7=%=&9[C$LEM2#8$[BK4WMG]S*21I%'[Z)M),HWWD#2*O7<:;DD@
M;A9ANF<G&,\IECB8F*[8I&I[S% 0EMP4'.Q<7D24NCC4VDOO@))T1!<"D=&*
MMUVZ[,FF%/FQ6KM%757# J_;>;U3I779&<=)LP;K=1,?E<4G0BKHFSE\'#,@
M,4D.K#*I,,.&"C $7E!PX45RJ1%@)#(0 PTZPN9' I >#,GZ PR2:ND9FJEW
M7RE)V'? 9;6L6-"R,R>V$Z178>I7S."8IP *2IN_:;MR#,V5C[Q]'BKYFZ;K
M$X^1)@WVS@22?LW",G]WS3*@H4+ BQH,&-8!@H9@S%"! IFW'C!0L<W39CQH
MY@T31:L6#%HBDU9LVR23=LW23113T3TUUPB?TF-8F1I .4;)O1A5B[&D6:WC
MZIVQ?-U&KMLKY<Z[>K7;JJ);^7;7/EWSX9QGX^(D:PW2KJM'H>M 0=(PP7#U
M',?>H@F2#Y%H,=Q4:7"Q]P!WU?>T1U48#/G0*&P%<=G8"9*!%O6"G[IHJF<G
MKDS.3&OX.+?1$D+B4?&/8#%B<'A"HT4T8:Q.'&<QC).+QY!HDB@)!//>7$]5
M!C-)%IC2.B4]$M$V:.NJ8FXQ2*QR#1B/PR'A1\<BD4##8]&P EOHT&!0@AHD
MQ&#&#9/&-$&C)F@DW03U^+5-/7'CG/CGB)O_ !$P2ZZR4(]M$I=3JKHPM:9M
MR.=FIGL@YP4,N!,>:Q,:H6TU<ZLB664:9- B&KQJMIH/03;^7.FO$9/3/+R3
M61?KE1<+@LGK.+59#@L"FF<XE<6:"DO<J0)8$CP#=J315RILY8#H\($QT0/W
MW]A"QX2+!"6[(2.9LT$3<4Z)IU*SE+F3KF+:6@JMN\WF6HU/W5R54CB<-4D&
M,>/LNLI5AB*4,5E6K;$C5AR2<54*;1_34=A&3TF6>(D?,]4NN>\YEEDJU!#7
M$UGBIM:;F73!1UB7J22*X@Q_,F&N5U1!S4O#M4XP^T)L'*;@(B@.WURV013T
M3.3Y3.3QVA:;BD-5KX!74:80]Q)P\U>!?8LNDB,OCY<"= R8JY>J.7Q4X&)Q
M:,KBR1)TZ=,$HZ"9M54F0A@V;IB;"8ZN]>9 4L$T;I^#%"=J CL9L!T\#(K9
MDH.5)BDI8/=);9]0W3ENH$#M+%6"31Q)U@0-P=5(+AQRC9$Y-6%(U73")EO6
M$-'1!&0*LEC*8]<@MA^J.T<Z,MU<OWCS.N6^CQUC3"64\9]=MYL;9\O@C.>L
MVVU^O-*WD]BQ*V:[ 3@C"-3ND1?E]'6'L>TD^@M.0:#'3-RU7;:F$PHK1_KJ
MIX+Z,&^N^/#3PRC)'0XG&CW4;K/*'$O=2*E($97GT86ALRW(!]'&)#'';".B
M2(\CIOOE-3)@3#XD).O=-="!X7%HX-,NWS(&+0:HR?+]_N3/CCJ!UER%#1U:
MF(6\"Q\T4/B6!%DX)IMGYU(&B>1WW(.G*SL,?TC$;]WHX]4<1XWN #*E!;M4
M8RW13.3Y9NH?JYU_C]A.;6!U;'!-@O)&9E[N2C\/VKIS)Y$J[7.G%VR+W4>J
M1+N'[UR0<;M,[N7+I9PKYEM\[\1D],G$RC.H-$+,ALGKR?QX9+(1-09&-2R+
MFD,.A$@CYALHR*ARC7;.-'0\BS55:O&RGBFX;JJ(JZ[)[[:Y3$PIMTYZP*1I
MI#W%*PI]&6)LA(&X<DS<DVN"!D6Q"'$E?=!TY5<AY '&#Q<BCKE16/R!@S;M
M3(Q\BEKIA,Y/E/W_ -YR:(=:Z*@%@'[3AE:1V-S^4EY&?D4E%Z/&[PP;ESK9
M[)2KY'#O+)9^:=[[+OG66N%55,^/FQC&,83&?%XIM,MZG]<ITA$6TIJ&(%$H
M&UEC*'8PT<,5(ZRG9@;()DS&+#7+-9!I)3@826+MO691>/QS-RKIE5NGMJF<
MGRGZ9G$$$%1D(&C8)FF."1\4/"!AZ.RFR3 4*:(L![-+9;=179-JT;HH:;*J
M**9UTQG??;;QVRF)@M#J5UL;R6<R[2FX3N>LWWW_  AN7([=XTFN)^R7&S76
M3"':ZX<QI*!SE=B93>L%M'K-39LKKE'PTPC)\LV(ETEZI%T(X@2H^&.]HEK*
MM0#U1$A@NRS.7X<I,EE#>C_4P_<RA_'8^Y.NR+YVY)[@0N'2JF@IAJW1D_[<
MI]L=+.J^%ITO\",*SM9JLE<3]+9L\V:RMU,3FLFE+PNRV>Y9N'QV0ZX-$7N$
M-7:Y+Q=Y6PMMMME,Y/E/WY>R91K&F*PIED5'5C$!\09&W2#TJW'K$%M'CIJE
MN@@LIE^\>;:[)I;[Z8PGMIKG&?CQG/AGB8SGK-CM7KE2%WEHR>M>MX_-C<,8
MGAD5+%='>I$ .E"P5Q(V0QXR=-5VS4VO' "I-#3?U;Q0,-V6UWRS0SHC)'0_
M?[DS89%U)ZU2YW-G\EI:!FG=CA%8Y-UGX9-;,B#.MHUL19OM?/A/&3.89#L2
M!RWU0=R'2)QE,XN03 BM6B9R?+]_O^_RS1;].NL"HL&&=4I"'XR./B[X0S)L
M%BB:/O@5 N#XYSL0<N5"4?.N8K&'9J,$]WD<+/(Z#>/Q;AR*8JH(R?+U_=TF
M] .KG7^*V XM.-U=' D^=R.22]U(QN'[5PO)Y@Z*/I2<5:I/=1VY$^^-%GQ1
MQLSSN[?$7;Q7S.5ME<HR>F3B9,L"OX5:L+D==6-&A<Q@TO&JAI/%S;?VL0<%
M+[:;+CR+;.=<.&BV=-<+([9\BFN/)OC;3.=<IC..8Y&8?QU!ZS9#!8\K3,,>
M!H\:)GQ#$BS<$DVK\YH"3.H[[D'3E9V&/8B\:V/1QZHXCQM2/A5B@MVJ+9;H
M)G)\I^F<@@G6RBZQFL@L2 5I'HI-)42E!B1G1&KQNX,%IJ;4DDM)O4,N]V2A
M"1'UEC!5Y[-AP[(++.55,J+*9V3&3Y9LDJZD=;9MN!4DU/0\DK&$I0@ 6U:N
M6"XM";2/>7RU!LN-=,U<(2"4*;GRB.^^Z;DIMEYOKZW]EQ,Y(Z$S/8D4/!BA
M@02VT9"@X]F*&,TL[[)M!X]LFT9MD]E-MU,Z(-D4TM,J;[[YUTQG;;;;QSE,
M3 *'4/K.V.3R1)TQ"=BMH[3+:Q5' ]1VSF>UA;K[S?:0B73A822VD^[E?8ML
MX9;;.<J;>.<?%X)G)\IFU/\ I3U5)YC6[ZD88NXB+20LH^_]2_3*LD):>2E,
MKRH62?IDR#F3R5!N>D3TD[>/#99NW?DUW+E!)31&3Y9O)+J1UH,*SE8G2D!>
M*63L\WF>5@J>=2VY.7#[!,J))Z[:IB5)!/A J=210+J.WD<S&L)2=V('6B#]
M-,9/W^_S>CE,@5E3]:TV+(A:RB;"(BRS_!0BS8+/EDW3_5NDTPYWV?NW:F-\
M-T4DO#3?73RZ8SY?-XYRC.>LXW:?6^C;M-QV26K6T>FD@B(PV%C)HIH\T)@Q
M$D=!WL@&CGC)VU7;LC+N/@G))MKOZIXL&&*+Z[[,6V4T9(Z'[_<F;#(^HW6>
M7+SES):4@1A:RFVC2;[O ^F_N\A@]')2YU5UUWUT:;%I-#XG(9 J.U9K20W&
M !0^H2?"!Z[=&3Y8UZC=:O8HJ.5IJ%NV<)(/B492(,52.1JQ0F&-D6V57[AR
ML^$OC<<CIMV"(J.PC@S'P154?L0#CG#9,Y/EFX1/JYU_@L]<6=#JNCD<G3L_
M+I4YD K#]JLO(YZ[,D)F94::/?<[+^2D)$<?EE_8_,Z?%'CS?_O*VRO$9/3)
MQ,C6+7$%MR%G:ZLN+B9I!Y,BV;GXP<0RZ%%D&;]J3:I/$,;:>LT0(,6CO3'F
MQX+-T]OC\/#*8F*4^H_6O1C%1N]-PQRRA)=^<C"+]DN2]RWQ1_'RI/355^Y<
MK.AI M$XJ7?!'RCH*Z+QB.E5Q^Y &+<M4SD^7K/F#ZA=9XWF?X"4U#6"%J"9
MP"L5DFT<J#9B)LPJL<L%D<%KNE1SQ.9%W+LE(MMFN%2CMX\6=;J;NW.549/E
M,WZS>M5$W)(!TKLVM(]+9*)#[1X<=?ZO4"C8'N]4)9$ZO![MFMNPP_55>:ME
M=MTM'"BBNFNN^^V<IC)'0XF9V#%H,8LQK!'5LQ'M&[%FWTSMG1!HT1T0;HZY
MWVVWSJDBGIIKG;;;;.-<>;;.?'/$2/#'I]UC'/IV1:4M"4W-G;2]2?Z;L%G#
M*5KSXVI))D[+C7#E4<X?2*0JJ'"3_#71XJ6WV(:KZ.MLJ\3.3Y3],T3CI=U9
M=.XN06I*&>Z,-'OQ<<)(MWK8DP9EI0^FYG50@W>I/"#@Y,B9&5'GI-=X].2%
M\Z,%G#Q^NHOLC)\O6:\CU ZQ%DYFB1I& .DK >-G\K34#:8T?NVLZ86AJLTU
MTWUU"97LL6.L-_J!P,T)SABVEA'5T>1T?X1D^69+K2I:ZIT*]CM:19C$@I H
MJ:>CV"SU9)P46:,V*KS?9^Z=JX4W:,&:.==5-4_*AKG&F-L[;;)C.>LXI9'6
MRB[=E8.<V16D>EDPC8A4 "DA#1XF6&!'!)$PX$M7;)VU4U8."C=L_7:[9V26
M<MFZJNNVR"7D3.2.A(^>;#(NH?626[3C:1TG B^;(?-"4TPZ#ZYT-$&<P&V'
MJ\SHFIIH/<.[ #B9T75%ZL=CDS&,)29R_.-$'^B,GRGETFI8]4.N0]:&.&U0
M0[*]>N]7T06<LEGR@ETC(4)<QWVW?.'&2.HB6MFTK (E<OD(])V[>0 TQY=%
M-YJC)\IY]9J8/U<Z_P!:S%6?P.K8Y%9<L^D)-0N'P_;;9(2QR^>21WAEA[L.
MT7,NR9!T^WT::Y5<O'"_Q*J;;<3&3Y9D&RJR@%Q0LM7=H103-H0=5$+EXT<0
MV<#'ZX$T.D859=+7=/;*HPZ)&%F>^N^NR+UBV7TSC9/7/$3&B'4[K@W3A:6M
M/PY;6O":Y>&Y>,EB"@5\X.")0IE-5\X<*NVNLHCT>D[<>0W=CVDD  C[5JB7
M#C7C9&3Y9^\=4.MVOOW\M+P'7-BJ86ENVH-#79\MB6>_["S'?7.-H^KK8&-;
M!U5CN1.^L^TTFV-L2E/0MJB;,8Z8]6CON!DE2,)VVB\9:PT&JS9NA:S*,LRQ
MD^@(V7%NV:SMO@](Y <4W>[N5US!TP4765?$WJZR9R?+]'*26;H(M4$&K?3"
M2#9%-!!/7QSA-%'35-/3&=LYSG&FFNNN/'.<^&/CSG/$Q/MQ$<1'$1Q$<1'$
M1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$H#]']Z>Z
MN>_7:E'JU&^N\VKHNL!G!W$N-S@$<&ZIPE'USAOD8P",G6=W^/V*._M/E1S\
M>^N_+UQWN&U' ^%GB=G$*=0@>A.R2AT;\L< [F=AWOCY<Y&:7B::J[L14R'#
M'<6!'>^8 =9R"FO21WC(#<#<3XS$G,?L7[YMN\$XZ;]BZ<9P;:EHK:DIC;R
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M62TLQE62-76-+>N,,*O')&L$;>:2C%@G;Z9T>PC.T-6PFKDK:C"08DVN(PW
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M/0)!V\EG8:L#$<E2%BQANL+TF ]W',NP;%Z93.,].7I]!.<_-Y)F1/O16(X
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MHFMC_HZZ/"I!19&575,8C$G]@&8%7\NLT@_@D"/V4#G,9D4@CD='LA;=<N@
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M_;;;J)ZN&CM+=!PCE1'=-;3"B6^VF=TE-%-?'QTWUVQC..2.U;K8AVNC!E.
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7B.(CB(XB.(CB(XB.(CB(XB.(CB)__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g713200g27e81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g27e81.jpg
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M 0$! 0$! 0$! ?_  !$( 3L"/0,!$0 "$0$#$0'_Q  ?  $  @(# 0$! 0
M        !@<%" ,$"@D" 0O_Q !:$   !@(  P(%#0D-!@8!!0 ! @,$!08
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MU0^TE6K(_).G?H*JFUH_4K<G'HHMXAZFVCW@1Z+Z.9N$0JOU=[&:Z6O@)O\
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MZLUVN3$Y!Q],A6,94VS>?G)%M#HV"3=3"@57U1#D@>!C0$'5:303Q5FLFO\
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MVT<*M;=3D^,UNIWRWL&!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & <:RH((JK&*H<J*:BHD13.LL<$RB<2I(I@9150P!R33(4QSF$"E 3"
M8!IQK+C-J6QK14:>:G6FM3MGF&M:>QLVS?1LK4[/(L=_RK*OV:%G(J#F8^0;
M1W#E=C376P[NU<S%/-#+V&'EW<U%C-/7P>DVZ1EHYQ(NXE%VF>28)HK.F?KB
MK)(KAS25 #E*"B9N8 *B0G*0P@0XE.(%$8,C@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M32#LA9*7='UG7-:US!5-KKF!$P*UQX#N0^/'[^P\_P"%]M_UE5__ !;G[C[
MC/WJ=]")_=C\E]F%_P"[S?I5?[</W]AY_P +[;_K*K_^+<>P(S]ZG?0B?W8>
MS"_]WF_2J_VX[3'U<]X]>LV?[F)LGWMTW;=I]V-4_9]NJ1+KZ/N7EZNGJZNG
MJ+U<N74'/GGR_H#,8QSORI<N"USJ=)42M$5:5Z:K0^F=%][WM;^3[4PG-;7I
MHJTJJ)6G2]*GH+SG<_;!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M'H?=>NIOWS@Z''E]6G6K;G<$72T\;>=OG)PP#*0?LU#^E(_Y6CFN-N47-O\
M)4V0=UA9QGE(?Z F?SS.U!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M\25,WF@VC & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MIYF !'RX!QFJ]<,B^;&@XLS>4<%=R*(LD!3?.2*"J1=T02=*ZQ53&4!10#&
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M%#:B-HUD-D5K&M3@:B(:K_NH.);_ (A]Y_\ 5J_?Z@SUGY*ZF/W<L'Z'L_\
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ME:+2J77(36N1[6O3$YJ.2N.CDJE?"=C/D^A@# & , 8 P!@# & , 8 P!@#
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M5%14HJ7*>V?.'3K08 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MQ'VR'#AU5C&-5<=&HE?$4':>##A9N]BE[;;M'T6Q6:?>*2$U-RL:H[D9-\J
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M[3D9>7;!6"D1BN<]'?GHKJT1M.J>ZF-<1.DIB+&6)KCD=@HVFT8E*X5>I:G
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M&1:K%9@W8 G*)IG(T,@T0<F*N8!65[ZY>'!41!$Z*/)(!@G& , 8 P!@# &
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M07DCD[>V=I+!RN)@P!@$1'S\+^B)OGDF 2[ & , 8 P!@# & , 8 P!@# &
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M( .$6=D[LZ(6<C =*.0.S<# +"DV:@(]3=9MX; SI80Y #DKAL4! 1[N//D
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MO,@[:J'E&)F:;,J;QJ$2H59R^ AP,[1=^%#%:H&4%,X,S-G)BE(8G>S"<#D
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M:B8!*W0;^&Q%HJ!>91<F7=%,(@;NY>7(0.4[:=$TD))>/(1<I0BRC#*G&/,
M^N,[-X7+X2 Q?(!2%C^D?+S'\& ?TC:<!6.,>68'112Z9-(L.H0[];D;[ZU5
M&6.$<3F)1[(Z3\?6B':^NYE ZXL[+W1=,)R+!Z=T"C=T-?6%!!GR\K91IX<
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M921>FR:JF#K/_6KL6C:HN%LFJKA74P3*Q)+_ *BDK,)ATV+6;8NL41<+7O\
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ML[26#E<3!@# (B/GX7]$3?/), EV , 8 P!@# & , 8 P!@# & , 8 P!@#
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MNZ(/.-/<WMGV'C/20_)5LX0L?=XN:\]IV!:.Y,SGFN*%ST)3C )IKWSOB?\
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M=7_)R#^"F/T& /%.K_DY!_!3'Z# 'BG5_P G(/X*8_08 \4ZO^3D'\%,?H,
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MWENO+LKS"5TOQ)<,]&M.RI)V%9X >)9[M"?D;!+*UV:OL'LSA*D'FR9:O/9
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M_M%UKO8*M? %MGZG$RUDA>[+B9=OX*F7;UCV"QC*H]AV:@B<HC@PN-2T< 8
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M&HSDA"'E"OFK 9-DS%511*%EG\6/(I)R)8.)F$-(1).^B!., 8 P!@# & ,
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M +\D?J. .NU>UZ_[\D?J. .NU>UZ_P"_)'ZC@#KM7M>O^_)'ZC@#KM7M>O\
MOR1^HX Z[5[7K_OR1^HX Z[5[7K_ +\D?J. .NU>UZ_[\D?J. .NU>UZ_P"_
M)'ZC@#KM7M>O^_)'ZC@#KM7M>O\ OR1^HX Z[5[7K_OR1^HX Z[5[7K_ +\D
M?J. .NU>UZ_[\D?J. .NU>UZ_P"_)'ZC@#KM7M>O^_)'ZC@#KM7M>O\ OR1^
MHX Z[5[7K_OR1^HX Z[5[7K_ +\D?J. .NU>UZ_[\D?J. .NU>UZ_P"_)'ZC
M@'(B:R"JEWA"#*AVA>V%%T_,J"74'6*13LR$,IT\^D#&*43<N8@& 9S & ,
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M , _)CD*) ,8I14-T$ Q@ 3GZ3'Z2 (\S&Z"'/TAS'I*8W+D41 #]8 P!@#
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M1D=(2_L@\8,W+A1NF,&>P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M-2C20R4>Q2B$V18Q.*3:($C4XXB -21Y&)4P:D9%; #<K0J0(%0 $03!,.G
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FX..N\?<C!\C & , 8 P!@# & , 8 P!@# & , 8 P!@# & ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g713200g27s64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g27s64.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1HF4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
M3   !#P          0                         !              0\
M   "3                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "3     !29VAT;&]N9P  !#P    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   DP     4F=H=&QO
M;F<   0\     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    ).$))300,      ^7     0   *    !7   !X   HR    ][ !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !7 * # 2(
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M0_Z3FM]3V?G+(ZCU'HS>KV4YF VZRFME=N66,<6UV]GS^D;C[;/^W'^DRO\
M2)&NBEAG?56QAWXS6LH+R-U#MOIUN<+K_:S^C5V[_M+G_P U=_2?TBG;?T>V
M@9/[/L?71ELESF"MS'EE5+<W;:ZNSTVTV55/=]/9_.?X1-^T_JJ^EMAHK]*M
M[6-G',"SWN=2W]'_ #M#?4MM8WZ#/>I8O4OJ[GNHJ..T6VO9<*[*?H6EGZM8
MY^WTV66T5?JMN[]+75^C02__T>NZ9D5W?7#+<ZRM]P9=6VEC6MLJ;6[%KW9+
M6O?9^M?3Q[[F?IZ:OT?Z+T5TZYSI^3F_\[,O&MOM.,*WNKHL<QS=TT.VU^E]
M'TZW^MZ;W^OZ67^FJKK^SV6SOJ^M0MVTV;F?;C8VP^D ,4[/3I>S;N=55^E]
M3;^M6?H_UA)3:^KWT.H?^'\G_JU>S,['PVL=>7 6.V,VM+B7$%S6PR?I;?8L
M+I#.KOJS*ZKL>MOVRX9-NUQ+7SON=6RQVST[/]&_^;]3^=L0\NFK(R,+ IR+
M7873;F/LOKW/<;' NKINM8YNW;3ZEMN1_P +4CMN/L4GQ,D6]2SVV90KR'FI
MN2R0/08&DLQL>S\^ZS=^FLK=^CL]6S_0K3P^I].MJ/V8D5U/=3M##S6=CMK6
MA/C7]*HWT8>S=7M#JZ6RXR-S/H?3]OYZGCOZB6.]6M@.]VS<_79/Z.6UUEN[
M9_+3#QDV2/L_Q5T>  V#(])7P_\ -];&_JM%-E#-ECOM%GI@BNS0[762?9_(
M1OM8)AM5KO[!;_Y\V*+ZLY[JR+VU!KI>UK-VX0?8YSW?O?N*?I9/>_[F#^.Y
M*I=_P23"A43XW+?_ )J#&S[K*B_(Q+<=V]S0T@/T:=K7_H_W_I(WVW''TM[/
MZU;VC_IL"'CX3Z*RQN0\@N<^=M<^]Q?VK_-W(OH6_P#<BS[J_P#TFD!(=;\P
MHR@23P\/A$_]]QK#-PSH+ZY\-PG\JFZO'N$N8RP>) <H''>X0Z^PCP(K_P#2
M2$>F4$R3)\=E4_?Z2/J\#^"/0>X_YW_>,ST_![4,8?%@V'[Z]J?[#4/H/M;\
M+7G_ *+W.:A_LVJ(;;<S^K86_P#4J7V)P9M;DWMC\[<''_P1CTJ\!]$5'H?M
M'_HR_3\,X.(S&-]F26%Q]6XASSN<7^YP#?H[E957IN$<'#9C&PW%A<?4< "=
MSG/[?UE:2&PZ(H#0&P-+_P#1E(5F+BVML;;36]MT>JUS00_;&WU)'OV[?SD5
M)%35;TKIC9VXE(F)BMNNT^HS\W\VQV]/5TWIU+V/IQ::WUEQK<RMK2TO_G"P
MM'M]3\]64DE/_]+T'!Z1DXW5<G/NR*LAMX+:P: VYC"]US*?MOJ.=92S?M])
MU7^A_P!'^DNG/P0 3D5 &W[.#O;_ #TQ]GY_G_\ @?YQ'6&SZI83&-K;?<*V
MY(RV@>F"'M'IM:RT5>M7^A_0^HRS[0]GJ;[OTB2FCTWJ>+@,^L1OL%9JR[K]
M=3#PREL-_P"-K6K]6,"_I_1,;'R6AN3!?D:@DO<2=SG-^D[;M7*5?5[)SNHW
M8]-=O[,.5=5=D-L;NJ#'V.]CK[7Y%[WNV[_5KL^G_(7?CA+7K7?3]O\ 6^=)
M(-5Q#3U7\O%_56;6QKG.:T!SXW. @F-!N4DDDD*22224I))))2DDDDE*2222
M4I))))2DDDDE*22224__T_55A-^M_3G5-M].W:[*^RCZ$\-?Z^WU-WI[;&?H
M?Z9_W66Z@?8<+=O^SU;M_J;MC9WSO]7C^<WG=O24\_T3ZP=*H9FBRU\V9N0]
ML4W'0NTG;3]):/\ SHZ+_I;/_8>__P!(I^@'J7IY?[0H9CN.2\UAC6LW P7/
M_1N?ZGO^C>_]+=_A*UJI*<@?6KH9<YHO>7,C>T47$B1N;O;Z/MW-4O\ G1T7
M_2V?^P]__I%5L%_U@'68R,>MN+8;O6N96UN]K++68MCW^J^WU6T-Q&55[?TE
M5M]OL]+TUO)*<C_G5T/?L]=^^-VST+MVV=N_;Z.[9N_.3_\ .CHO^EL_]A[_
M /TBJ#<CZQ.ZZXLQ?U09'HFY]+&N-(@_SXN+OLFUUUM#]OK?;*OTM=-.56NE
M24Y!^M70@YK3>\.?.UIHND[=7;6^C[MJ?_G1T7_2V?\ L/?_ .D53ZQ=]8F]
M4GIV,+J:VU[+'UUG:YQ][:K77-L]+(]E>8[9OQJJ_5]/Z'J=$DIR'?6KH;8W
M7O;N(:V:+A+CPQLT^Y_\E/\ \Z.B_P"EL_\ 8>__ -(JM]8KOK W)I9TW#;=
MBL8ZRS(VUV/9;]%CJ*+K:?TM57J[/],^WT_T?^$VL9U[L:IV2UK,@L:;F-,M
M#R/TC6']UKTE.:_ZU]"8TOLO>QHY<ZBX 2=H]SJ?WE+_ )S]&_TMO_L/?_Z1
M0_K&[K&W&9TVAN4USW&^I[6N:[:W=1O=:YK:F,M_3?\ ">CZ++:;+5=Z39FV
M=.H?GMVY);[P0&N(D^FZRMCGLKM?7L?;4Q_Z.SV)*:COK5T-C7/?=8UK07.<
M:+P !JYQ_0K58]EC&O80YCP'-<-00=00LWZPOZJS!8.F4-R7OM8R^MX!FDSZ
MC=MA#/TCME+]W\W599;_ (-2Z _J;L".I5"FUCW-8QK0R&"(;Z=;[6;*W^I5
M3[_TN/75=_A$E.DDDDDI22222G__U/54E\JI)*?JI)?*J22GZJ27RJDDI^JD
M#.9D68617BN%>2^I[:'GAMA:16[AWT7KY<224_0(K^NN)2ST-EE;9BFZSU[9
M>ZNME5E_IT;FU?ILAU^[V4_HOTGH^_;Z.WJ[,,LZN^NS*;8\"RK0.KG]$]S-
MK?3>YOYGO7S&DDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J2
M2G__V0 X0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
M "  0P!3 #8    ! #A"24T$(@     !1DU- "H    (  @!$@ #     0 !
M   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M'@   'X!,@ "    %    )P!.P "    "0   +"':0 $     0   +P   #H
M "W&P   )Q  +<;    G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M #(P,3DZ,#<Z,C$@,3@Z,C,Z-#D <G(U,#DQ-C<       .@ 0 #     ?__
M  "@ @ $     0  !#R@ P $     0   DP         !@$#  ,    !  8
M  $:  4    !   !-@$;  4    !   !/@$H  ,    !  (   (!  0    !
M   !1@("  0    !              !(     0   $@    !.$))30/]
M   (          #_X0%(34T *@    @ " $2  ,    !      $:  4    !
M    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (
M   4    G $[  (    )    L(=I  0    !    O    .@   /      0
M \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR
M,2 Q.#HR,SHT.0!R<C4P.3$V-P       Z !  ,    !__\  * "  0    !
M   $/* #  0    !   "3          & 0,  P    $ !@   1H !0    $
M  $V 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !
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MY;^]=KFJ)Y#_ !XV/FBXU5D4""HNJFB0 $1.JH5,@ 4/481,<0  * "(B(^
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M)Z^:SQ-HU1;I-$FZ!&J"::*+8B*94$44BE(DDDB4H)D32(4I4R%*!2%*4I0
M   ^_*T -Y1RC0#=#0 &@ /( #R Z!3 UH:&AH#0  T <H \@!Y #70>BCF<
MQ/&K, A8\ES.? 0* _6J'593R4J@K% ?GHI?R!5A%4H?W*C[@>#??D:2A1F&
MI:=24'722O"\=.HZ.8?(]1\E!FQ6+L=)\=0F&M$2TZ\@(WO1YXW=-G>OGU6*
M&ZR8@F0"1-)"I 4J14S4&Q6O.U$2H"/M>PM19VO*H>D@BAY1.F)F@_)F$6G]
M#SX?1&/\F0.A_P#&GL5=:.QKNTL6M=0-?JG7DHQP&)\HZG=M: [E/9HZUY<O
M<YH.7IX>FO!X/L]%P)]>HV/,0U>U??*^9/T>V'Z7;+;DB>@#$_\ ;:0>[-5"
MF1-[(IK(*)AZ2+D(1V4'/,?1C6Z[.[DH]:T.^23#I]UD3^G3\_/JM?H1C-&'
M)YJ'7E_:<UD?+[-[O8/3IHC7KKFZKE4R_6&1 ^A]C[LN<I42D)<:/E5@:_T9
MA*;WBP%/I4@J"J(^#"6336]\I%Q5,3W$%1I76Z,>6L'RZ3UZ<@.O/?905W'8
M^;SU&_+8+Z.R3/T6?N.\M"U3QLS>GS[&I4>1KS^LYB='F\P>)"#[/1HD\:-B
M]J1(! %"2RFX5=ZN!?)#>J4C-6G6:*ARB58ZQ*^HF94IDDVJ":H*(NSR["-6
MZ$K1YB2E-&X^F^>.Z6@^I^J(.B &[&@AX@C\K^*LM'I+C;-=Y\QUDBR,K ?(
MDB#1.P&M!'+YJV/LM&^D%\JR6RI%*G[J\'L%DA79S>HQ%#(Q<YE"K4/4'MK^
MTK8"@BF91('#I1,AE\F;+,UNE3G'J8KTD3OV1RU"WKYZ,W0>KCYY,^>CUS8[
M&SC0V8<I/$XGR/+'-C2W_NT9QH;&W$#F\4=8U%J/IGNM.CI^GVO<<5BWX_8V
MA0,8R:IB ^T*MRRQ4S "A 2AS*J-S H=%!0#H$"[<&NTQ-H>6S%/1E ZZ.@;
M,;W#UZ,WH[('4# R60:/KL#?'ES&O9Q<[1LZ) =>@E< >HU%OE():#MH_#=B
M*^P,)+'G>Z5LY?0!_=Q:_P!G03,90R2@'?Y]#W*-\)*@4IE"/#HJD.1=JHX;
M^M4F/I2)OZ6KD8?/?-C[,@\]?:KLF'G]YWL$=.J?3D#/T]',P?/FQ%Z=HZZ.
MWTH;3//IL.(=L%I<WJN=+L]@OV"3TF%JIOV/4E?6\MG:R8G.*7I60O4?75D3
M)JA[*Y%4R';+F(@Y*DL<A#!F,;HE]IL('F;+):H'X]X9%R]?"=ZT[PGKT66\
M0X8_;O1U_GWUDU'7X]\C@UH]' ZY7>%VG=%G<!JV7VOT?A?1Z'9/=]OVOH%O
MK\Q[GO%,='T?3I!SZ_=(4QTO3Y]92B8OD 'Q)BNTY]=C;K3;UKLIXI-[\OL/
M=YZ.OGHZ\E-AR./L'5>]3G\B.QLPR [!(UR/=O8!(UZ K.TU$U2%42.50A@\
ME.0P&*8/\0, B A_U#DK>^HZA3 01L'8/D1U"J+N235+7,/:#KETIZ=QN4G!
MV*O0M^) 1RD-%YEHMEC%RQ0AX14>6:"B4EWP@87X%^F&,8BH)!P<D +V/;WZ
MQ +%A\<T4=D1M$;*=N9A#-;'--%&"[KL'D\BJQEPWZ3Q3?I2Y5%JS)#/!#<$
M$?8QX^]88X1ZV"ZQ#$"\[Y^L>R#H6\#\@^_G[!]Q_,?^H\[RLZ_>$3A%@=F@
M[])2":]7OD;68\K5-)2/=TM"PJJ.BJ+&4= ^4G8TQ"J)G13*V]@Q4Q1,I[AA
M5$I"*K5#ZR:Y3-?T+2 WEX\:6=(H0T3)0DG,Q#!267)(6$4:V]M98V(]J0:H
MIQ(M%70),'#A A6P!Z#$5OZRPL<='J(6BQ-;-(F=**IR#2"3KR2;0R2)4V@L
M4Y"3*<Z:I%U1<BX**@+%3]HH) 8Y%0+O+FNPZ-LW0PN-6F>SF:KNW:Q*2^J1
M6<,]+C*!%.>LVNQ8/+%#S!2UUHQL+QZWJC)]..6J)96:9I,3JR1VB"A/?YCW
MZJIO9'K1J'7Z'JMVI*^X=F-EN^E=FMEUJ]T:-;46X25QF.D]IQVLJU0F<522
MC<P0CX"J4JKT\(B&F+*[FVB!HM:P7669D<$5>*4PW1O>KBR?1/8U]U'6MO56
MVZA&T#)>[&>J2]*3C^T,-I2=)K&N6FX]A;8HG?F_7=QM)*,SK+^YU!DX?+4!
MW"*34Q9'OYI[_+WZ?O4V[A%:N\K?6(:E']B*OU39M.R:#^,UG..VFV:.%F<W
MZ#/A+[0*'U[OU [(1M56HWX^4R@NBN)8U&CU*BPT>(C+\E67\0_A[]_Y^C_3
MW[_>J]AGNS1+797-Q@.ZMD[8V3JUUL@^KND1%)W&JQ3[;X1GJ(UMSI#NC6FZ
MYI6+-5W$E1DM0EMSODHR_"*ECC[%,KJRMRAW+W[]_@G3[NA._P O85N(^)UD
M-GBD7D/V>-VY3[N+RTY;4FFUEZWGZ<FT)VJ#%O9%S&ZYFSP>N)F42VHZ+T=
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MZ<(G")PB<(G")PB<(G")PB<(G")PBU3]GXW7\<[HTKMQ7>K6@=N*6TZ^KXW
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MB>3D/P+ RZ$S9IG1W+AXZ!)W08(KR]\8V,9PA/FJD-2EAK4EG(42Z.Q8D-+
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M(E*H $5+Z5B$7+X6(50.?_5KA\$EF'Q\#COQ5:\=1_7S\=81.'7Q=#]K3OM
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M7B#F,>FG?*TC+YNB=@U$B%K6_0+%4J21!-8,<B9GW52G_I5CFC+572E!1+[
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M+\CKN=S*FC=?DINB1%X3T@*0Q:5323+M&#4**H1G3X]*"'W),@RW,=?R_/\
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MX%/8))GV?[#J-G=Y^6\S2B1ZOKC&N' %Q]!C0K5&-$Y3"T R7I.8BL)^IZZ
M?NJT/^)SM+_.?A$_4]= /W5:'_$YVE_G/PB?J>N@'[JM#_B<[2_SGX15PVOX
M-."/M-ZNKXY0+M&YS&ZW8'O91!WV?[#E4ELK_1-H#>$CF9)767DFHZ'4%J*X
M*%;49212('.[=EB"R":A%8_]3UT _=5H?\3G:7^<_")^IZZ ?NJT/^)SM+_.
M?A$_4]= /W5:'_$YVE_G/PB?J>N@'[JM#_B<[2_SGX15OP/X-&",;5V67W*@
MW:1K$GOTF]ZZM6O9_L.=:'PP,]SQM'L'OT366JY' WU"^NP)/KOYT$7*8KN2
ML31Z"1%9#]3UT _=5H?\3G:7^<_")^IZZ ?NJT/^)SM+_.?A$_4]= /W5:'_
M !.=I?YS\(JY=N/@TX#+=<-8C>JV?W>$["/*\BAETL_[/]ATV4?/FEXP57+D
M]HUN1@2I)Q82 G^HL728A]DT%%Q2*)%8I+X//0,$DP5RO0A4!,@*"'9SM+X$
MX%#UB'_SF#[";R(?8/\ (/RX1>?ZGKH!^ZK0_P")SM+_ #GX1/U/70#]U6A_
MQ.=I?YS\(GZGKH!^ZK0_XG.TO\Y^$7K>OO0AAU9[QRFB8=#3]8ZV3_5)W2[!
M$3NQZ-H1W^X*Z]#3C&20@]%N-MD&A&="C'#895JHS9)B[%F@15=V^,7'K]VO
M)/3RZ_/^2VD\RB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+5-\1BYW136^EN
M$1^PWS!\TVNQ]B'^EZ+FUM)G]L][)<&L-YH];:W<4S+0K%[8"'L$FT;*(GG&
ME7-&NA5BSR+=8BL=\._6="W;HSU3V'5U3.M&T/$*)9;=)'9HQQYN7?0R'NV(
MS%LD@U:FL:9$IT46:"#,HR/_  B"+;VDRD5R^$3A%A^@,[U(4NR,,RG:W5[\
M\BW#:JV.WUY_;*W!2RX FA+2U8C)VL/I]LP*8[D(E"Q0WSRR:;=21;)'44 B
M^9/.]U[$:'@'2;-].[5:]5TM%M7Q2IW4-ZKEP3H=ZM=BZR6W2_T5U\;0 +A
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g713200g29v69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g29v69.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2QJ4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
ME0   T<          0                         !              -'
M   "E0                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "E0    !29VAT;&]N9P   T<    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   I4     4F=H=&QO
M;F<   -'     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    &.$))300,     "';     0   *    !^   !X   [$   "&_ !@
M ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@
M!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(               $
M /;6  $     TRU(4" @
M                       18W!R=    5     S9&5S8P   80   !L=W1P
M=    ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    4
M8EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP
M  "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:
M!#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X
M=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A
M;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2
M<U)'0B!)14,V,3DV-BTR+C$
M                             %A96B        #S40 !     1;,6%E:
M(                     !865H@        ;Z(  #CU   #D%A96B
M  !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)
M14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@
M            9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'
M0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N
M,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M             &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I
M=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M              !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@
M  %865H@      !,"58 4    %<?YVUE87,          0
M          */     G-I9R      0U)4(&-U<G8        $      4 "@ /
M !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P
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M8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]
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MP  1" !^ * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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MW_92*Z]FV_Z7^D56SI?6P,<V=:M(%C34/LY(+FV6/V6"MC'^G?C_ *+](_\
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M #A"24T$(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
M<P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !#
M %, -@    $ .$))300B      %&34T *@    @ " $2  ,    !  $   $:
M  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >
M?@$R  (    4    G $[  (    )    L(=I  0    !    O    .@ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q
M.3HP-SHR,2 Q.3HT-3HU-P!R<C4P.3$V-P       Z !  ,    !__\  * "
M  0    !   #1Z #  0    !   "E0         & 0,  P    $ !@   1H
M!0    $   $V 1L !0    $   $^ 2@  P    $  @   @$ !     $   %&
M @( !     $              $@    !    2     $X0DE- _T       @
M         /_A 4A-30 J    "  ( 1(  P    $      1H !0    $   !N
M 1L !0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0
M  "< 3L  @    D   "PAVD !     $   "\    Z    \     !   #P
M  %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C W.C(Q(#$Y
M.C0U.C4W ')R-3 Y,38W       #H $  P    '__P  H ( !     $   -'
MH , !     $   *5          8! P #     0 &   !&@ %     0   38!
M&P %     0   3X!*  #     0 "   " 0 $     0   48" @ $     0
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M$0$#$0'_Q  ?   " @$% 0$             "0<(!@$#!0H+! +_Q !D$
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MQ3JJ"Z"R9C)JHK)'*HDJF8Q%"&*<AA*("(#$- &@#0!H T : - &@#0!H T
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M-UJ:QQC]S$6&*D825;$<6MN9Q&RK-9@^0*NA.$71,JU753!5%0BB8F Z9R'
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M[P^R?2+/]M#OC\?2:6K=><KJ.G$%#KN5E 56<+1C-5=50$P2!114Z)E#G!(
M3 QC"8$P @#U0X:B0L8?,6GU(G4ZE8KQ>S A2=6&C@Z@)MRLTP)P;_2@1H0C
M8@!P K<A40X)@!=  T^I&  -6*\8 #J@!H:.$ +X.1IU0 6X@ >"))MN <O!
MTR(_R92E !=F]-HU8VJF,V39NS:(5U<J#9LBD@W1)XQ5.)$D4BD33*)A$1*0
M@!Q'K=X\^'X4^%6;9(?KO?\ $M-\G[Q/P@^M)'W2#XE+=<N6"-0[P]8?GUK%
MWL7DOL,/!\S&6;.8V.E<86)I*,6<BU/;W)C-7S5%VW,<L5% 4QD5R'3$0 Y@
M PE$0 P@'?PUWO!?P*;](BZ?F2_<5'X^VUPLL%/ZBD::.G=ENK[-'PMVI4ZL
MJ8QE:W J&.50IS*1# XG*L9 RQ3B9N(F!4S5J90#<0.+= 3<123ZO2D('X\C
MZD)C&&KU[K'%4QS>)H[B<RSA)TL8P^#\3&5=((.5!'B)UT4EC"*B93 !&F:Z
M] 1V&<PO(^$B6+LN*\CD*Y:1S1LX*1W6)-5T0%D42* 5PJF11<H&X*J$(<X&
M,4! #IF%[@]0:&CP?.W=L=]=-VM5P7,:Z&<;J8U6S3LNTK72F.BP6T[ZYW /
MPMT;]?LOR>G[V@6.O&_JI70WJ:T'<%5KE?674<K0<0JX6517574CF9UE5FRZ
MSENLHJ9$3G50<N'"Z*AC"9-9=94@E.H<PC8V"5*K)@F!*W D!$6ID0+$,"@D
M9B50C(R8 W^D,S(LJ1J)> H%54*D) .8! T)4:JD*1DZU IF0[#L1)$,"BCX
M*BJV:]D)6X"3P=NNL@AU>'9(JJ))]4AS%$#FV[=NT01:M$$6S9ND1%NW;I$1
M0012*!$TD4DRE3333(4"$(0H%*4 *4   #0% ND0P1EC.&)FD=A[<1";>K,"
M%LHB\E<7%E:TRTLLR0!\;MXER]J5MJ$Y$7-O-2\2KCV:8NY-TA/KFC&<.X>S
M#9RS#??VF9;#,-S6!,$'QC8<G5K)<O"9!O;EXE3)2V2U1QLI+2_C(,45QS?[
MI?[V6+IA7()I-[?9G4PBJ^6 K2+CA8QK4"Z.@-E<0[%8.(<>R4Y?ZAM +\Z*
M3['?M5^#I7Y33^BWH!A.@#0"7NE<_G;"_P#=UT_2:]J7.*]K,RO=_/LNEK^;
M.?P*T?* =+1P:K_0Y1]:S=8HC4K/'T-N[#KQ6BF-RU%=5Z=>%>?\+@ULL:::
M[*Z,=>-]&KE5JM1LW]/7T/4QWW14>UWE'W]1?R=#4)\9?C:Q?05]I%SEH^(+
MQ-ESZSL_1^HR^D:UJ-R?@T!A>2/:[OOO+M/ZC?:V@[^'RH>U'C:/!Y_F9OJ1
M'F$(_4A^;S#]+\P#4OQ=\^:#[. K;I?E1>LS? .?'U\.\>' 0Y<._ESX</<[
MM8!-VV/ZY3;R/G]G'$WQ^7T!W#[H#YO3R'AW>5I\#M2_V$[U-1]F3E_&%D^D
MV?1_MH??O4]+;42%C T : 6EO>_IE4?>^M^GJ</C^?'CKA^%/A5G\R_79:;Y
M/WB?A!]9R/ND&^[*2:Y<L$:AWAZP_/K6+O8O)?8'@QG6R@...+!R_K<[^/Q5
M$A_@/F#_ !UWO!=_J4Y:5:&^ARX*;XE1N/NOYV9.I_4<B_\ MEMNV<^S N;K
MI2$ T!%.=_:0S%\%M_\ DI+: Z6@=P>H/S:&E7?I^<UCA1Z=2]F-51&NAFBO
MUN_3H?.M/;3!%@]IOUSN ?A;HOZ_9:#3IP>B[%5Z=\3N.Z&P: - &@*)=(MM
MR7W/;;W6/HC&M%R=;VF0\66*GQ^16LA(UFKR,?D"O(3-\<Q$;;J*O8%*=47E
MCFR5H]HCF]B(U4AURO4W@L'0' ]&)C7*6)MK$53<P8BI.%;DUNMR>KU&AU*O
M4J'<M9!Z@Y"><05;O6261)"0>G?(GD7-QE)":9,F,PY1BP?)Q+$-(PH>8" =
M_ >[0"/=O.%.D1:9^WGSDED*UXL@[[/2;_%%HRXHXSK1X1DTS9D208141C@,
MO1<4]4F,3OZD2%GZ>WQ3$U& 1BZ;8ZO;[=#R=J?C&K3M>.!;'HETW*71Q[2D
MGKA-V\3QB1-V[20%JDZ<DL,X5=PFU%5<6R:RH'4(@*ZPHE,"?:J=7KB,C$M
M&@$O]*Y_.V%_[NNGK_\ >:[J7.*_O,K^79;KW7YLY=5+[M6LK1\H#PC@U?\
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MDV?I_2PW'I:ZB0L8&@#0"T][P?QRJ//^KZX?]_4$?C_)YM</PI\*L_F8KO\
MC+3?)^\3\(/K21]T@*1ZY<L$:AWAZP_/K6+O7S/L88SK9080QQ8.[G;W0_\
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MX/*A[4>-H\'G^9F^I$>80C]0'/EQ#U]W_G]_AJ7XN^?-!]G 5MTORHO69O
M\1]' ./'W>''S\A'GQ'\WFP";]L?+<IMY'ERSCB;\E]@/BY\OO"&O*U>!VE:
MY$[U#[,G>,+)])L_VT/O[=*/2VU$A8P- &@%I[WOZ95'WO+_ *>I][S>OU>?
MA^%/A5F\P_7>^/QM-\G[Q/E_ZTD?=("D>N7+!&H=X>L-:Q=[%JS7V,/!C.=E
M/+'%@\W\;G7+_LJ(#AW_ #_+KO>"_@,[Z3%]G+*B\??\K,GU5?XCD<WA=NWK
MM+G:Z4A$- 13G?VD,Q?!;?\ Y*2V@.EH'<'J#0TOVMNM%5JZNJ[KT5K2B-=#
M.-VV]77]G/KHK\2P6TWZY[ 'PMT;]?LOGY] EIT.M:TPT7JJI3;AS47<>T-@
MT : - 4#Z1.M;74L%NLL[F<(^S)&XVEJY'59*%D(^IWB'F,D7"LT-F2 R0]M
MV/DZ'$OIF9A5+3-R%YKE?91+$\G-N^PC4^J!S&P>CX-KF'G=EPI@5A@=O;[
M^\HXL^0*/ENSV!Y J'8,I.RY/H^0LJ-+,<B"BI8]L_O$D]ADE5FZC5@=91(X
M:=]^G=7C$.("'I#AH!8%6Z+_ !M$Y3W'WR]Y(R#D^I;BHRL+V*FRC_R'G6%I
MK.2LGY)2FSY+Q2K1+G,,FQ\BDK$!%23U16)K$#'03N2EX=E"1\(!EW1,-$(_
MHY-I;!J4Q&S+&)6C<AU55SD0;6&<11*99PHJNL8J9"@95951500$ZBASB)A
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M%_9H [%+[4G^ 7]F@/V!2E#@4 *'H   /B#0&N@#0!H T : - &@-! # )3
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M4UIAU)6*8<LH=5Z1J88]NW8-JT,AH T!^3%*<HE.4IBF 0,4P 8I@'O 0'B
M@/G >6@$SU+HW,N5.K8DK(W3#=C:87V69VVW5]K-UVS'96:^9XO^/K1)VRQH
MCX2DUK-2C<<1)H-LR;.9EY-O5E5U&3=@V56;_B#%,?\ 1?YKK-EP=,63(6%[
M%%XOI^W@U@AC5VW*>45XVO[?LR[?*5!-G+U59)/&60(7)["RWQJ]9JR48^CI
MZ%BV$NSL0/X\!A^QO!-[VS[9\?X.R',4R?G*&K9VS>7H;:99P3N)FK3,69D
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g713200g30a67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g30a67.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1/F4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <T[QL
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             !
ME   !YP          0                         !              ><
M   !E                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !E     !29VAT;&]N9P  !YP    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   90     4F=H=&QO
M;F<   ><     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    %.$))300,      E8     0   *     A   !X   />    D\ !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  A * # 2(
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M(:UH)<3P .2@T9^%D"HT7-L%[0^HM,AS2)WL/R61TKZQ.ZEDOQ;&>BZ]@=C
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M)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?_V3A"24T$(0      50    $!
M#P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E
M "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %&
M34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !
M=@$H  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (    )
M    L(=I  0    !    O    .@ +R.\   G$  O([P  "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR,2 Q.#HT-SHP,@!R<C4P
M.3$V-P       Z !  ,    !__\  * "  0    !   'G* #  0    !   !
ME          & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^
M 2@  P    $  @   @$ !     $   %& @( !     $              $@
M   !    2     $X0DE- _T       @          /_A 4A-30 J    "  (
M 1(  P    $      1H !0    $   !N 1L !0    $   !V 2@  P    $
M @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !
M  $   "\    Z    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#$Y.C W.C(Q(#$X.C0W.C R ')R-3 Y,38W       #
MH $  P    '__P  H ( !     $   ><H , !     $   &4          8!
M P #     0 &   !&@ %     0   38!&P %     0   3X!*  #     0 "
M   " 0 $     0   48" @ $     0             #P     $   /
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M 0$! 0$! 0$! ?_  !$( 'X"70,!$0 "$0$#$0'_Q  >  $  @(" P$
M        !P@&"00% @,* ?_$ %@0  $$ @( ! (#" P("P<%  4" P0& 0<
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M$6EZ?J\$K<=YV 8:VO7]AO5BND:T^S7J.;TN;"[!"K*B'[5,)E:LDW8</!Q
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M)H0?*5)4G.,I5C.,9QG&<9QG'GCGQ]J0[9O/$=",IE""/1_I<ZZ!C6AQH-<
MYKC5:X$;@@]V""#X@CH0OG(\*W>.Y]C[LWD'V!M?8MV$S^NNRK-.&6JY6 ]
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M?5SZ @]_*Y^ S?3M_P!^J_#Z[+6'>YR+[^/3\3UX]D_Q)OA[^7_USW;]7_\
MI-E_O_Q<:=]^37WR+A?HV.Z?B5UW[ 8K[M-_:G_0L![N_BZ/"8_F;V>_)_\
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M\LKWRRRN<^261SGR2/<2YSWO<2Y[G.)+G.)))))W*EP      -@!T  \ !Z
M%"'5+\&3K[_0WKG]4Q7E_F_OCDSJ;W1YWY7R'Q?]ZEW7E7_>(?N4?Q_R1LI_
MY!KV57]P7"I!]Z=8 9>S !AJ;;KPN$)(%X$,G+01UK:PP]<6#(?;DOIFEY#
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MN/&C/<-VD?>>*^<N?'^U6]O?\8[V*/RSK7Z+@U^=6_Q9/B'?QF=*?YK:+_\
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M*GH#;F%2YF59SF=S,QO-T\RAO%5K.KY3,L99)IU(:G?-%#&W81#*(0Y@?*)
M[F./ ,DDBM/7=93T>>5P&/I3BQ..ZGRW=3&/D'!_=TZ61@XN>Z3@3:#W, Y1
MM/G/L-?;/V+'TRURZ5J[7!"VQ:Z8D5B++V4:(PY1]J!(6)C2ARJ'6<S6'IR8
MZ'(N+ %]PA66?FL#*_=-8SKN<A#I9,'3LQQ-,CJ]3.O99L!O4PP/L81L+)9
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MT?=@"21"&-%7.N$EM#I,F,6A>V6^@BPCP\ZCLFC=7*C6MK@2M=MT"S[(_P
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M+NN^QGLYS=+B[5.;TSHYCANZ#*9:&WE8NO6.S@L'%G=1U7G?;C9PM, [@R-
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MP FQA\FD#OH-9&L3UB\3/?)A9<6AO$K+'H96I*<.?$K&.=[@NTQVVVYS;K"
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MYG%3UJF8UFZW8AR%26"JU]7"\'6)63.CA#N+N)D<T'B=O K\ZQ[*US#\-GQ
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M/%HV7U@[(,<;?@$XODM&%KC2F8LU$>1AZ'F?!'3U1U3!T%^.14D[(U/I/J"
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M;ILR[;XS$+;-0M'7;4FGXENBF*!:A<D8"9CA)X;9+#!\ZD+6"!"+7LT^<Y;
MU2)V!J;96X6"+9)0;F(V-1*5L*OK]0#>ZE7+F$<]:+)]01: \,V-7[B"_*A2
M/CA3F5>M#DR(KOG\<=]YE2'%$66\(G")PB<(G")PB<(G"+$;]1JYLRF66@6^
M)(FUJV"908Q'AD)PF;F)*1\.78!47(B$AD^,YA$F"1'RH\R#+99DQGFWFD+P
M1:ZNRFONHE$LW0S26QM#C]BBJS=GQ^GDG6:]:6:PRJ%7-"+C'F[TV8-7Z&0(
M[[KA\\"Q(=DNMUN=L\K)DR]?1H\UMZ^OKX? $^$?$K:?><]1/X*_7#^H_67]
MF.$3[SGJ)_!7ZX?U'ZR_LQPBKM6.N/54KV=VM14]-M!_+JMJW5\^99VJ3K<E
M6FG3!J\2 0C-">H$)BO7$CA5GE&B8\H8>GUH-2UF506Y("-DBL3]YSU$_@K]
M</ZC]9?V8X18AL#K+U'H=&M]V1TWT1:U5.MF;%]&Z_I/3+)LY@/ ?GJ&BWK"
M,!@VILI+&6F72I@;!;4K"Y$MEO"E8(JJ]4 /A[;RM.S]:4'JWIB40UV UUM.
MS3K9K'5)V4T1['3M@7IZH#/B!/%&A6O) UZMQDO1XH@=$S KH!"QX-#BR*[/
MWG/43^"OUP_J/UE_9CA%5?M1I[ICK$)0*61Z=:6-*[ 7H?I&&NCT33%-O8EZ
M[,NC))VEJF!X1D@;K0U^=;)#X3,;%<K]?.6:<8&Y%0V")%(^A-+].=\ZGJVU
M873+15.8LSEA956+%I;3<HX%DURT&JK-A$Y $,4"N2T30DA3F19,C!Q\>$QI
MTMO"9#A%,/WG/43^"OUP_J/UE_9CA%JV[G'NA/7G94*):^E6MS3FC HO='_Z
M=UK2PN"=S<FRVHH]9V72X89TC- S!=XLMNI0ZTPOE9"T:R(6^4W7A%#C7#)%
MN-U[IS3VJL$G=4ZJUKK7Y^B#DRO7U&J].R91 ]RH=\T56Q8[YBF#[Z9F%[K+
MV(WNY.6/@]P[E9%)?")PB<(G")PB<(G")PB<(L-V)(O$2A725K."$)[%CU8\
M_11MD=>8K\^VM#)*Z_#-/1GXK[8R04Q%:FJ:EPU^@I>,2XO_ +]LBUX:-ZAP
MMH[59[@=AM9KJFU#4=EPAK4U@!.'L7RFG @"O;2Q"C)L)6M2G:UK2H&ZK3%[
M-OP2GNV6SL#Y[TDB7,6,BE[3?44O7+%$L.^K^GL 4U[9C1+2UCMPS!"VUP<:
M>K1-^2>LAG)$_)(-G*R/.Q:]!,II FS^[L $&)'1-<5+59%,(WK#IX3O,QV'
MAUYW&Q3@B0,FN/S790%$N8NN^[L<())2[&'V21'J@2)DC#4RAAMLK)B1HY*S
M6B<:(K!<(NC56*VJQ,V]0$/FU1Q,X"Q9/EL3YZT$)R1<T@(05]+WN!LV6%$2
MI,+UO;O/C(+JV\KC-*23U]?RK6?N#KYM#M_MLOKO?^OH-=U?J^WR;!K;9M;=
M%.#['KVQM*C%J5."V)Z[-V6P6&(,KK1PRV&UM+ (Q=JA)CV#7Y++.XR*7+3T
MUG%=@@AP&\LA>L"ZJ/K]LZ_K&+(!/< RA:T0R%8A%G"U6&FS-V?KUK(7Q(")
MLT42"&7(=R(O680]1"*8=C]3](;.#:J G*LZ*'Z4<"M:V35"4RMNUP&"EU:=
M&JD9T>XC*JPY*H]-F9&JQ\4$M4JM8@\@99:R ,C2*P8X</#CX(D3!ABQ0N'&
M'#!@Z,S"'CA\)E$:'!@PXR&H\2'$CM-QXT:.VVRPRVAII"$(2G!%UU@J];MD
M) ZT  ]B@-31A)J$;&PR<9HB%*P3@>>TS,9>;;F"C0P:7'2D)2_#)#X4Z.MN
M3%8<015&[?Q]Y61BJZOH^K!>S-,[>@6+6FZ$QS'R"VUN%;UB04.QPST@JW"
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M6>K&V(V].M^CMO1JF0H.-@ZPIUCE44H%EUV?2B<P+$P7J+X2=&AR1_T:*MS
MK;*HS366H3;D;"HRV5J(I\X1=+9, \UT_BS18DVMY"E<6&%/A))098/,%_YM
M%FCELR$3XDB![AJ3"5'?3*96MA3+N',H41:V?"C[4@.X^B=C;GCZ'8T#<7=_
M;7J-RKN=>NZ_*6*)5K%(BZ\LIM$N''GV UC6[]8KUE+2GI*8]S 6D1&3"CCD
M08Y/7Q6T#A$X18*-U?K4-9D741KVD"KBW -BD6P=5 4*RH%V6QS+A8AJ#L:
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M44*$(36"9Y%G'21$:9%=2]DBRD1W%ZH6!@3*!]D-)EXQYTPR%?&[*J<QHJX
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?B<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g713200g31j43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g31j43.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2*R4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             !
MQP   ^@          0                         !              /H
M   !QP                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !QP    !29VAT;&]N9P   ^@    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   <<     4F=H=&QO
M;F<   /H     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    (.$))300,     !@D     0   *    !)   !X   B.   !@( !@
M ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@
M!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(               $
M /;6  $     TRU(4" @
M                       18W!R=    5     S9&5S8P   80   !L=W1P
M=    ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    4
M8EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP
M  "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:
M!#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X
M=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A
M;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2
M<U)'0B!)14,V,3DV-BTR+C$
M                             %A96B        #S40 !     1;,6%E:
M(                     !865H@        ;Z(  #CU   #D%A96B
M  !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)
M14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@
M            9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'
M0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N
M,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M             &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I
M=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M              !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@
M  %865H@      !,"58 4    %<?YVUE87,          0
M          */     G-I9R      0U)4(&-U<G8        $      4 "@ /
M !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P
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M8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]
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MP  1" !) * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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MCW6.D'>,=KCL_-_H57_HS?\ HTYC=-))))2DDDDE*22224I))))2DDDDE/\
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MF:-_\#_T;$E/_]/U5))))3Q%%E8Z#UX%[9^TVZ2/WRB]">W]JN&X?\EXW?\
MX)BZ*W^D#XG\J5_TQ_5;^1'5?W:/U*(/1)!D>O=Q_7*WD'$_F1\3^5&0[K3N
M5))))(4DDDDI22222E))))*4DDDDI22222E))))*?__9.$))300A      !5
M     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!!
M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-
M!"(      49-30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L
M!0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "<
M 3L  @    D   "PAVD !     $   "\    Z  MQL   "<0 "W&P   )Q!!
M9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C W.C(Q(#$X.C0T
M.C W ')R-3 Y,38W       #H $  P    '__P  H ( !     $   /HH ,
M!     $   ''          8! P #     0 &   !&@ %     0   38!&P %
M     0   3X!*  #     0 "   " 0 $     0   48" @ $     0
M        2     $   !(     3A"24T#_0      "           _^$!2$U-
M "H    (  @!$@ #     0     !&@ %     0   &X!&P %     0   '8!
M*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    "0
M +"':0 $     0   +P   #H   #P     $   /      4%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#<Z,C$@,3@Z-#0Z,#< <G(U,#DQ
M-C<       .@ 0 #     ?__  "@ @ $     0   ^B@ P $     0   <<
M        !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H
M  ,    !  (   (!  0    !   !1@("  0    !              /
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M @,! 0$            '" 8)! 4* 0(#_\0 5!    8" 0(# P,-"0P+
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MNS(W[0KHZJY-:LVR=&/B98\+9%.WU,V(B<=)JG#U!B?S5&<ET#J8",W*JX$
M3J()AU -_:*Z8M%:W?'245<^VW=^WP-=FLI*QS\;MIB7N@K,<PVGE?+P@N=$
MT XF*:OIJK C?AY_LW^*_P!@Y.[_ !2=MU8/-J+-3")A$PB81?A11-%,ZJRA
M$DDRB=110Q2)D(4.IC'.80*4I0#J(B(  =QSB][(V.DD<UC&-+GO>YK6M:-R
MYSG$-:T#<DD !%3G<_,2H:Z5<053:!=+:GXDQ:H*BG%L%>G89!RF!E \(_\
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M)\LCN!C6X'SW.:-MOT!1'5\<O5MW+B&C';EV!GGL/4?;LMWVAH)Y6M-ZYAI
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MM-VNEM%K@9!2TL;6-#6M:7EK6LXW<( R0T #DUH#1L K:QC8VM8P!K6C  V
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MRSE914U,OVF[!J>L?<=06:VW:NE(,E764<$M0[ PUIE+.LX&# CCXN",>*P
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M[G<;&OWP.,!X&YY!V0-E5[D2U;+>R)X/$5;H*$+M*: I%$B'(0#2&VRB!2'
M2E#P]NW3MT#T],*C@@=<Q$Z&(QBIO&(S&W@;BIG(PS'",'E@;;X2"**2ZU3'
MQ1O8UKBV-S&N8TM,;00UP(;@$@8&P) VV5_>,^G]4R?#)_,R.M:(^EB0RQBR
M3NJ0;A^!P;G,!@=+,3K@8!_R@/U^CIZYW5%NM_AC3X%2YQG>GBYG'^7[>79Z
M.F>.-M4&-CC:SB X UH:1X@W:!CD3V>A5+]C@Q9,.8V^46+-LS1#5,J4$FJ"
M3=,"%O=/$A0(D4A?"7J/A#IT#KVSG<Z:G@J:+J((HOZ/6 ]6QK"?'H-CP@9
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4A$PB81,(F$3")A$PB81,(F$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g713200g31m68.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g31m68.jpg
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M,3(T-7)TL;*SM!E!)$)1<24F,U5A8G.#D]7_Q  < 0$  04! 0
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M'6ZFNQ_9*ZK0J*U[U\0"3T"%KJ'0Q641:-DXMV*E,#B/44_"6D>*)1_>9PN
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M5)!5C3;OF4K&20#,PKR]&9:716+5?%H7.G<P3CK&M[-1F)$$Y$K"61<2V*@
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M5:BB;E#;T%VX]ZNCOZ.NWH*HME5$]O1WQMIMZ.^N,^CMKG7/F\VV,X\^.?3
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MM>Q* B7$M1FUA,BMA!HRR?AA _(0M)),?=@"J-AV>L<M^6_$L9995$^==?\
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M>3^%KVDUK-HQS7#F1V9\0=R)@8ND3;[SXK7T\?B^P768?2W2P6=4,A,VA#:
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MNY:.FVCM)+9#9=LX1U4RHBIKJ1><2'M702( VM%.P'6\E*$A)%2.#I#>4+"
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M\YVVVSC777&/_KG.<8Q__/'Y/K?^5F_<*J*ZC) %1$2= ,W&5Z;RS5TL3N]
MR#'NI-Y1NS##$# )9#\0^6E21EG'FK4)+RXN-/,9-/U$F@YPYT*^RLG"N_X'
MJ[?5/7=7;33;)81":C$((&L?(96SLR,!<\@TTU\H:";@7.@TM?B5EB#W1TDD
MC.ZC="]MQ<7;/$1<<FFOB4>9<9UU-Q.S8K->V,+EV+F;E6-FE7$XIL8]/#W4
M!85\%:#T1S=-B ^+;$8V/L%![;SNI0L0>O\ 1<8[T#MIP<)K"V5KJ:L=OUQ(
M33/!(WL1BUH@&Y0,PL.Z).PY1%A4EKXWLC8S>2#$T%Y#2)#(ZY+KOS$EIN>X
ML!J+GI1VN>M\D<R,\7[@P]Q-IPQGP&<2G,JHQ1(Y%;(AU7P.1!V<:=L74?#.
MTH[3T)P+-(,W#UN_2-;OM20LOL';_#L'K'9B:>MS/$C7N^C.[9LC(XW-#3%E
M;VL3+&U[@WN#9?;:PMRM$3!&PQN8S-)VKHWRO:2X.S.&:9]VW M:UB+F4MUR
M6!+T/4:D8)-3$=^(4<3"%&)/0RT?C$1R*+-R@637<Z$M%4$]-O;<.%\N<^=7
M97?;;.V8+B+'1U]6QS7,<R9[2UX(<T@VLX.[8$<=]>52JC.:EIR=IB83SD:^
MU<S=_P"\M;WS7S_ZJ%N?%#PVC\ZI_BL7M)WN3R'=4JG'YULH$G"*PU\E<]V[
M.?I8V;]G%,\T'V3?"*'T73?,5:E."\$?T[^I&I*?-=K+IPBQ7[(60M7$IZS"
MVL.ATG^[AV $4>5>29CNX=1P40KFSK'W.BMT\9]K<-\5RX$IBG/J6RBI[4EE
MXE\&[LB95Y?$/Y@+'Z]NR+.B"!AQ,8%5L=K<9?>M5'+H-1(VYKRK8X[H^,6M
M'9)<+H(T>*PX9*)9*6%7[SHBJ/@,.6W:RR2$L[$6,36*MMG-?VVT]]N/8N0C
M?8;5YV/KJ@IG5M10$C-:V:S,7@PZRLVM);,4@AZ1NJ%G.@!*&6'K!BYZ6!3L
M):;J3/<!%=K&(:1F,%8QI*"I;2_X'/\ CUZV]5E-ZT/ +$ET&F3('[<(-5;%
M@L?B]06!*)4YDUG@)M( (URF#@Y(423.,H*>4#/ #EXQ:*BW8PZ[8%W ]DX)
M;\7'$NE7KV%KZ%=>:=[$U3':WE4(N*R.LD8!G)/&7HD=I".RED0> C)LHPV8
M#3K->.,9TRE+B/%&+$@ZT'.0#WX$?+[.V1 -2.2_L!/\ET&%]M(C-($UDR4"
MJL69>3CM) 8VRT&GSP&S'G7()+2FI^)GF4,9IQ<>>0BRY-\(GZ(<@W:-RK*,
MNI:DV&G2Y+>RU_MMQ+ZJ][21R4%@K*60.KX4T.MNH2PMUO'SYW!(AV:A,BDC
MB.:[AHX[;AB TF"R/"&3ZC"-J(*><P1:.U6R"I"+?CQD+UA7M7T_30!+8=-7
M.98RK(M#&PZG9J6?3<!<A$L(K*2P]B+A+QU(HW+281^Q9G!J2PYFOL+P57'Z
MR&/;%26/OTX]-MQQ+N];W1UIMU]&QU>8"2-Y*8/%;%8-D:_)M'#")S=O*G$6
M(25L0CS1U$U"N8/+66K22HBG3,N#< B"30VY'CWA+$>LC[1M]Z]Z^)L0_@K&
M_P QC/\ "\*B?$V(?P5C?YC&?X7A$^)L0_@K&_S&,_PO")\38A_!6-_F,9_A
M>$3XFQ#^"L;_ #&,_P +PB?$V(?P5C?YC&?X7A$^)L0_@K&_S&,_PO")\38A
M_!6-_F,9_A>$3XFQ#^"L;_,8S_"\(GQ-B'\%8W^8QG^%X1/B;$/X*QO\QC/\
M+PB?$V(?P5C?YC&?X7A$^)L0_@K&_P QC/\ "\(GQ-B'\%8W^8QG^%X1/B;$
M/X*QO\QC/\+PB?$V(?P5C?YC&?X7A$^)L0_@K&_S&,_PO")\38A_!6-_F,9_
MA>$3XFQ#^"L;_,8S_"\(GQ-B'\%8W^8QG^%X1/B;$/X*QO\ ,8S_  O")\38
MA_!6-_F,9_A>$3XFQ#^"L;_,8S_"\(GQ-B'\%8W^8QG^%X1/B;$/X*QO\QC/
M\+PB?$V(?P5C?YC&?X7A$^)L0_@K&_S&,_PO")\38A_!6-_F,9_A>$3XFQ#^
M"L;_ #&,_P +PBYUJU:LD$VK)L@T:HZ^BBV:HIMT$M<YSMG5-%+71-/7.V<[
M>;77&//G.?\ /G/"+]^$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1>#=H*;<
M=@J M*G&1O,;)3F,JCQ!O*Q-NB.-LG;0P$6>KA'@XVB-V+#F:1-0,_8EM!RC
MK8:[;/<(+:%4&Q!6)>G4NXG77J]:03Q5,.CUW')7(&E=!IG.Y/ ZK N 52 4
MZ7B!HA!XX87@=KJ1*T9+8,H&1^&&:^D%K$',"C)MVR2*<)?9;B]NI-SMYOL6
M1?4VDY#14"ET=/I1T1B56G,[$$0F*2:33P'7X^6?!B[R.-;%FP>/3*?."<C;
M'IR3D,D!BW3<K,'L<&LTX\!#><J+*+A%K)\3V526.UY2XN+%=HX1GUWQBOUY
M6FQ'$7,8&'4':Y(D/9F&SX,H8=MAVX$$H88$AK8V9'NG8HLFC\&.\U@SG-DE
M#3E+]YCS6!+0YYN0""VY RMS @.(-G=R<3BK6NCC+AF$8EDR7(#BU@L"6D.R
M@G,[*0<H-B-HTYF[QM7:DZO5"INRL^G5^RZA7,GC3"*-'[AC Y;;0+,[$LY>
MKB$BW<U'56V<HK$VY0('5EF7@R/R'+,;'R$B=-+O4=M7OJ'P%S<NR-\K2\9N
MT!>(M+W:"[1KM&G"-@BW^4.[6..G;4!CBXB\C(G"-Q99Y##+Q$.<&6+FW+A\
M$5O.R5W?7F:)SW8]'#=@U]5EH@=HA  Z<1.'I28@3I[9+89+93+M)7*9XK&X
MW!%:RVWKU%ZS+2 [E6%E&9(7\[\_+$_.7-+FQ2M+&-R.)='>0![GYG29&L,?
MZ,$.<Z\9#F^K:>,221[WE<W-+&[/(<[6Y9 (KL:S*V,.=)OOZ35K6]L#>6CR
M"J6+3;Y0+[H7N#_)],?VBZAY+MPGA7A/E5G\/JU88GP&?F9\5BK">=)*')PB
MM=O"1]V7T;^C?6OZ#0YR_NK\),:](5'74VHN!TW0Q]4+,*[_ -Y:WOFOG_U4
M+<Q-#PVC\ZI_BL7O)WN3R'=4JG'YULH$G"*PU\E<]V[.?I8V;]G%,\T'V3?"
M*'T73?,5:E."\$?T[^I&I*?-=K+IPB\BN&F8U= N(-#A.0QTS7L_C]GP&7Q-
MP*0D41FL=;DQS4N-T/AY%'GNCT"=D$;*CCP P-?!#Q-ONTU<;MW38BZN4Z\L
MB3-RGI:%H,"II&9(S,ZW4KMXM8&)L(C$??;R^-G*[+P%VH) PV-A8]D7#Q.H
ML8/6:8U62*FL$2?CCTYET4!TKJJ-.:+8#"DR4K_KF%BXFJZT*%VI:/1I6"16
MOH="'S(P]'J3)/X"%5V(>+L=I(HQ,'5WQ4BBIDF<;F"7.OCVKGY5U/@4NM=>
MX7\FGC23K3&HIMAD/?1?0$B5I8//@L2;I-7<2>O\CW+:R9(L<26)K.7CG+#9
MH['H-<H*D^Q<8]Z>5^YZ_P!*]<FTNL45#*%.TA(H,;8OH>I+E"/7N41V95ID
MX\)PHB"((,#\3 .B:2$>9?"R;#V9WMENZ>)N"K?4GEO[5P"'1:J&ZZI/2465
MM(B=B7!:\JDRA:*;E9E/[JJW:FI/(#C;,,^ 67P77N@\+&145"QL&/R('.WH
MPFYP\4>$OXAQ#[+WY>/CXT8=%ZK8*A%-959#I("[ZZNFS1X0ABS5SIUD"DP=
M?LGR>L&3W79DFA=XI+=-5$EBCC;3X/7#M]<M\DO[?ONOR$=#:9",ZM9,3%@Y
MTI5O3X.L%G9H"]=Q2"47(GTFKRN6[MW%U5R$78O7+!N5?&-R,U/L8\ 2,2YV
MNQW<."7.OCN?M.TKG:WZ65+69FFY",?RTV:H<08!5V7D"T4W,L TA#2,(>"O
MCP2) SQ"-&$9%J3(PY4GK#7,GCT4EZD?S*0+0QPESKX]JRZX5$X1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X189=S;0M: C*%B%.MCGQLO6^D*G6+QG>!-Y#'A
M#.FKEMYV1#D+1'G*^$N'SFJ&4=<DY+&I5HV%G"&0<9-2G8"Q5*HX_$+^T:+J
MC:T[!L[JA1DSA5K'05E3L*P<Y:!HM1T=M^X)(%@4N*FJ_KP1:DMD%*1>8NS4
M;<2J0$M5[#B^L#B,WVB>&[!^+FT;)L)V'FO;GY;>WW+(;K'9!2X>N-#6J>=B
M7T@L2GZYF,C> 6#\6"<2.01(22D"H0>5\Y%F'V,N'WP6@\W4738^HQNLMG_*
M[E0[2O<N$7A=G7Y&:L.LP!H0<?N7@E NFL,T'[(:HN'CYEHEOEV^;*>NPHP4
MVSC73.GH[Z>;;.WI8QDJ/#)JV)TL<D;0V0QD/S7N&M=?M6D6L\<?*K"KQ&*D
MD;'(R1Q<P/!8&D6+G-L<SFZ]JO.?OQH'_!F7?_Z@W_\ UN7?Y J?UT'KD_\
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M3A$X1.$3A%Q+<\"=&B<;:FA+F1!1X@L9 -R+-8T)%2!8NV DR8I-;9\P'FW
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M.< >0D KX=)&RV=[&7V9G!M^:Y"^#XY1#^%4;_/@S_%<^OH]1^HF_P#U/_\
MJOG?X/UT7_[&?>OV;RF,/%TFS21@73E??":+=N7'KKK*;?YM$DDW&RBF^?\
MVUTUSG/_ +8Y0P3-!<Z&5K1J28W@#G)%@JB:)Q ;+&XG8 ]I)Y@#=<]SR7HM
M5?B^'(_'^M,%*2&2Q "@)['T;*FX^93.(05I,,U_,$+")14.9G)N.QK>3.@<
M5*D8^P)F![)V4%M]'Y 8/P[)L\W@5-4553*RF@EJ)&1,E,<,;I'ED=53N<;#
M0<@+BUN8M!<+W6-Q-[60LS'*'.DC#K$Y#)33L:XY076NX!U@2&DD G0Z(!]Q
MUJ8IHU6C+L5UQKMU.;)LRQI#I)KIJ8\';P2Q+HFTW>5$[4A5KZ$V,C.1LR/:
MS$G'U2$>9-C$E&1B4KD/@XVUEXPG%C$Z,8?6,+Y))'9Z69PR23/>8CDU#BUP
M#RV[0"X-<39PCYEA$PE)WP,BCC;EN';Y' Q@F&^,REK7 E@=9Q(:7, N#XY7
M]NUT$C/6*I9U(J%VCT+KWKUI:<^K"\NK&KDM)J8E.3U<0$TYE5[A)0.@E2F&
M;*92)]$Q,P<RXF0*B(<T$"URS:1>3,)Q<,IHI,)K;,C@WQ\=*[5T+LT<9S97
MAL3@'N+0_,20P-%P[VDEA<^IF9.,SY*C>8Y!-9K9FY9)&Y8BTR2CM&AY8& !
MSR3;+.-9[ZJ,VN^FVN^F[9#?3?3.-M=]=DM<Z[:[8SG&VNV,XSC.,YQG&<9Q
MGS<UV[NCSGWJ5C8.8>Y:OO&P]U9W4^:=/ZVQKDEW&^$^#^='X4BL\1X%4>0.
MLU58/.FE#$X16E_@>^ZDZ7_-L8^T&8\YGW:>%&,><,^7A4SP[@5/Y!ZSEM.?
M_P"HO?\ A'/_ &=^1@;1SCWJ]5,)O_I[?[VW_//.OUK]?SPBGV^2<?(B["_2
MI*_9)5?-%]E'ZZH/1;/FZI2;!.#R]-_0Q2F^:S6:55=XS7O2.[7SUE_T6)YT
MYN0\&<&\S;UWJ%XAPVHZ0^X+61R2*S4J[R3/Y8G93Z-./M1@W-8=E+ZIP[TC
M_MIEFL$X1+T/];%/:YHY295^/E7OO!J5^AS!?MJOSF]^Q=]0UGI>?Y.@48QO
MA,70#XDBC"\V2L,MMG@3^]EZ:?EM,_LFL#D5W;>"V+]##\W3J^PWAU/Y3OAO
M5HYSFE3)1+/*UODU]3OGQEOU"6YM/L6?6.*>91?'"P>.=Z@Z1W54$KF[5&UW
M"O/W?P?\L(S^FF7/*?O$W12=0KZ9W;?*;[PKECG(BGRTV^4"^Z%[@_R?3']H
MNH>2[<)X5X3Y59_#ZM6&)\!GYF?%8JPGG22AR<(K7;PD?=E]&_HWUK^@T.<O
M[J_"3&O2%1UU-J+@=-T,?5"S"N_]Y:WOFOG_ -5"W,30\-H_.J?XK%[R=[D\
MAW5*IQ^=;*!)PBL-?)7/=NSGZ6-F_9Q3/-!]DWPBA]%TWS%6I3@O!']._J1J
M2GS7:RZ<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"
M)PB<(G"+7)XBMIR6J:X?2R!W<I74\A%8VC: * Z'X=&\SAE!5H4L:F.B<MC!
MO6R'%;-22;)C2K<W"AEED9\R$G)=&U] 4E!E4"^GX_[>,ZVVV78.U[V23LG0
M\.IB\K%KJ;6C;&U;J/*[,1+89%X[%0QBRK>D$N"G8M)5<R8%#(63@\<9.-VR
M(:Q9M$?C()?#='[-0@X]+Z>/FXCXUGWPJ)PB<(ND#ZSK<2R=#A5?0@:/?0B/
MUF]8#XH!9LGE;Q-(ZA%:_=-6[!-!Q"(RA*9,C'XHKIN!#)2,ZF.8-M"Y##@E
M_O7<&K5LR;-V;-N@T9M$$FK1HU230;-6R">J2#=N@EKHDB@BEIJFDDGKJFFG
MKKIIKC7&,8(OWX1:'_%^:,W-@TEM, 4KD]9)5O<290+$0,IE!#6RW3%CI5I;
M</#F9 RBX9()3AO&SV[71F"F3Z.ND'S ]L"<Z2#"&ET#RYDCX]\D!$;7O.^F
M)F]FT8)N 'Y3;M7EI%G92,/B#K3,R.8V4LBL7N8T&(2O,HN_37M,S1JY@<+%
MN8'7/V 75E'7H!%Y:VG3VZ@=8D(]K*AU;V7/ (2Z-JWAA)Z_&#X4Z&X<S@DJ
M9<I59;PUG(XK!I@TDK+0LE)V;R)ELW.Q[H U[)3,V,MSB&:1HFWMA) 9:[SF
M.]2@.:QX< <UV.Q-/9M0Y[3&V$RA^0RQ1N,.^O !+P>T%OTD1+7R,+2 6D/'
M?^GC&QL=^JM=;@WS%9:R9U([0E15M.<&B,-DD*9K1&N"TA? VM92$+ 9>ZCP
MJ JPV621R4'!CA+2/PE^/G")JRK8YA%4DL<+1SOE>6R ECXQDC+BT1N;&XM$
M>1[B0'.RL(DS7E,Z+-3C,T]O V)C3'E#VR'/(UH<9&ND9F,@<P97.:,SP699
M7/(BI$HO/E8/R!Z*^E]$?L8O'FRNQ=]>UOHF7YRB6&QO@T73CX<BK_>;V483
MA%<X1[_8 /\ D<9_X2'.0I.^2>6[K%3\;!S#W+6;XV'NK.ZGS3I_6V-<D>XW
MPGP?SH_"D5GB/ JCR!UFJK!YTTH8G"*TO\#WW4G2_P";8Q]H,QYS/NT\*,8\
MX9\O"IGAW J?R#UG+:<__P!1>_\ ".?^SOR,#:.<>]7JIA-_]/;_ 'MO^>>=
M?K7Z_GA%/M\DX^1%V%^E25^R2J^:+[*/UU0>BV?-U2DV"<'EZ;^ABE-\UFLT
MJJ[QFO>D=VOGK+_HL3SIS<AX,X-YFWKO4+Q#AM1TA]P6LCDD5FI5WDF?RQ.R
MGT:<?:C!N:P[*7U3AWI'_;3+-8)PB7H?ZV*>US1RDRK\?*O?>#4K]#F"_;5?
MG-[]B[ZAK/2\_P G0*,8WPF+H!\211A>;)6&6VSP)_>R]-/RVF?V36!R*[MO
M!;%^AA^;IU?8;PZG\IWPWJT<YS2IDHEGE:WR:^IWSXRWZA+<VGV+/K'%/,HO
MCA8/'.]0=([JJ"5S=JC:[A7G[OX/^6$9_33+GE/WB;HI.H5],[MOE-]X5RQS
MD13Y:;?*!?="]P?Y/IC^T74/)=N$\*\)\JL_A]6K#$^ S\S/BL583SI)0Y.$
M5KMX2/NR^C?T;ZU_0:'.7]U?A)C7I"HZZFU%P.FZ&/JA>,^-]VZM#I9T,EUK
MU*.AQ.2GYE&JM>MYP**&!&D<G["0#3:[=J(.Q]SH61;HZ;#G*CU5L@KG;9=D
MZUSC3%WN,PJFQC'(J6J=,V..&2J:8',8_?('1N8"7LD&4D]L,MR-A"\\1G?3
MTQ>P-)+@PY@2+.!!V$&_)JJS.*U':<ZC4JF4+KF;RR)P9LJ[F,DCL8,F D9;
M(#GQAPL;)L&:[0=HU##"AIWERJG[*&&$BSCU0Y@[<H]&RU5-!)%%-40Q2SD-
MACDE8Q\I+FL 8UQ!==[FL%AJ]S6#MG-!A[6/<'.:QSFM[H@$@:$ZD;- 3S G
M8%_$<J:T9A$Y1/(I7<UDD)A.FRDOE@.,F"D=C6FC;+U78T79,UF([#=CKL_=
M9<KI^RL-=GKCU377*V$E5312QP2U$,<TW>HGR,;))<Y1D:2"Z[NU%AJ[M1<Z
M(&/<USFL<6M[H@$@<>I&RPU/(-5++\E2[=6@O9EF=&=Q\.Q3C.O[)[,)%-11
M3$]S8.TFHJNLL=S63N0V8O\  3I1; [$<U(_"6-''PO[/C+3;5W9.PFF%-3X
MWFF^EF>FPXLS,WC>-[K9\V3)GWW.+9M\RY=,E]5G,%G?G?36;O>5\U['-FO&
MVU[VRVXK7OQJ;YS3"D2<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")P
MB<(G")PB<(L-[>NNW:KOZDH\[809:EK<GX^M-5M(K/7DB#OWD.DY;,HE-J8)
MCZW@:A":MXA H)6S^-R,W8K\RJN)E0UYLJ(%%7B\>W\>^_LXTLJZ[=K;LC2T
M**,(.I35QSIW7H]PWBL]6D 11K4\MFB4KE%K+$F%;QTN;L$$,KB)4]B,FCLI
M8$\3)C.4%TWL1&$XCRC7VV_!]G&LR.%1.$7EZTHI>=3=Y6Z\BJ^8V172@Z6O
MX$L7BDAF\%6V3:J"9,\BV[AX>C"FR11EN.,K,6.V4R+79LY]%VEE0G\_:N/^
MZK0+ S.1_P!TBGV<AJIJ^DUE,?CA"VYFMV9!OHZ)R"<MOA'1]#VKYKLFX?%C
M^@Y)RWSHLX<;IYUVX1=ZA\TAUAQT=,(!+(S.8D7PXV$RB'GA<FCI35F[78.\
MCC85T]&/<-7S5RR<9;.5<(.VZ[=7T5DE--2+LW"*.-WHORVX;W+GD<CUS32'
MZQ@ATV1KBM!4H^#0\Z;6[;A"&6^HN!SYUY)Z,19Z(;;-L[8@/P?F7)X8;OG+
MMQ)J*.(T].7,B+K4Y:TQQDR;[5RQREQ<TE_Z, :WWNP<+;5@JI\@FE ?)D)J
M<[FOD&\[U2QR16RN 9VY+K6_27+3?8O';X[-V,!LBNCE;]C91('"TMJ8 5K$
M1:&/1=1N?R<Y%V9>/0O4<MM9B<P,J;L)-(,2]A]RV/08M+@#9\Z#28&;OYHJ
M5LD99' >VB:8PR+5LCG-!:S>_P!)F.CCG&]M87M!LYKK*"2H=%(V5]0WM97"
M4OET=&UKLKG[Y^BR#5K<AWUTC6NL"UPR0\&^_;<MV>RAE:EC22=D7_7.HK4?
M(KVEK8\:#2&?%#R!IHL/S#8FO6TTT=@E6YNN$7,ACL;'-A*<?>I/5I(Y*86O
M#/HC'!D8>Y],]SHQ':\D53F;VD49C.9@+HKN8VS<NMR<M2E_TIXSR%C14QAK
M\X)WN2GRN =+()&V><LMFO=F=FTR@2"^81910./*T?E5]7/H^&/M'/\ -W]B
MSZKQ/S]GR\:C6.=_AZ(]<J)]S:*PBV2^#U[S_I!\_L/_ .MQR.[K?!K&?,9?
MY*[H.&4W2M5K'SF%351>?*P?D#T5]+Z(_8Q>/-E=B[Z]K?1,OSE$L-C?!HNG
M'PY%7^\WLHPG"*YPCW^P ?\ (XS_ ,)#G(4G?)/+=UBI^-@YA[EK-\;#W5G=
M3YIT_K;&N2/<;X3X/YT?A2*SQ'@51Y ZS55@\Z:4,3A%:7^![[J3I?\ -L8^
MT&8\YGW:>%&,><,^7A4SP[@5/Y!ZSEM.?_ZB]_X1S_V=^1@;1SCWJ]5,)O\
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MQU\V8FUQE-SERGX*?NFEJ[JR-!",\=.S=0ONW<@' FT/D&J-K+]KNK5;5"*
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M%#%G)YK]UV(BA? 'P.='-+!#ON^1,_2U$S88HH8W.SU$UW&5\; "V%CWM+G
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M\4;;/A,+\K(X^$0]OEOGE<,XL]PR]H+@&XSD6*C<N)2.ODGG:7222'M&=H'
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M.C0B>6&0 90"3VS<U@0TG+?-8%P!-K:^(V_5GUXMA]5+FYVP$9M!VPIY(O\
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MN: .#8J R11U3I\LKFV9)'&*5@>^SH\S"YC7.REV7-FL#8C(UUNVE <Y@;<
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M&&M)8/+,JV0*'ZVK^)%FQ>7&QK@Y*WT5E%G2@BF.1T<AS-:)A,"<(R)N4]Z
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M&+PRLJ0;.F>YKHHW/:V)SLDC<"R1C(WML_-(TL<.U+#VP+7WT<TL_P"$7#B
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M29YRQL;'F<Y[M-2YQ TI))).Y@(!<&AC0QH!=J>)H%R2=@',%:5^'+'ST3Z
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MC:ZX\2^JYH-)4$@$B)Y%P#8Y3J.0\RJF.=/*%)PBLR/)VXI%A?A/]9)0,C8
M=)I1I<FDFD3 ..9G9%H'[%W$S$:'2[=LF0+ZBV?_ ,*.U(.'&&+;_(-L))?M
M><Y[OY97;J<2B=)(Z.+Z'O<;GN+(\^'4;GY&$Y69CJ[*!F.IN5+\*:!0PN
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MZR"IMK7_ 'TK*_+^8_6(CSKFEX-3]!%\-J@+^[=Y3O>5T#GNOE3IO))?D_\
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M)0XA+3TT9>61,;&6M,CR]Y!>QSNV<XDW/'IHK:2BII7E\D8>\VNXWN;"P]0
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M=E]-J\Y8(YFY)07MN#9QTN+V/M*P>_8[GA;_ (FI#_/<I_=<S7YZ[I_VM/\
MN0?VE;_DVB_4-]OWI^QW/"W_ !-2'^>Y3^ZX_/7=/^UI_P!R#^TGY-HOU#?;
M]ZVBA*$Q' HB/!+?N8>% BV 40P1D$6V28BQ;1)BP9I;*PQ179-LT021TRHI
MNIG73&=]]MO/MF,OD=(]\C[.>]SGO=J+N<2YQL"!J23H %=A@  !<   !?8!
MH NO61U8CEO0&85=9%EV_*X#/H\4BDPC3^1QU)D=CQIJHR*"W2C&(M7FB#QJ
MJHBILV<H+8UVSZ"NFWFSSTIZF:DGAJ:=V]3P2-EAD;J62,-VN =<7!%]01XE
M1\;7M<Q]W-<"' G0@[05K;_8[GA;_B:D/\]RG]UR1?GKNG_:T_[D']I6OY-H
MOU#?;]Z?L=SPM_Q-2'^>Y3^ZX_/7=/\ M:?]R#^TGY-HOU#?;]ZV!TCTMKOK
MA6$9IBD)O;%>UA#OACXLQ 1)0;@<(^,!\I*#'LZQ6*D'^_MY\T4)*^O=J^BL
M\4U2]!'":>F!K:ZIQ&IDK*V4U%3-DWR9X <_>XVQ,N&Y6]K&QK18#1H5S'"R
M)@CCNQC;V:#H+DN/K))^U>K?<>)?CKNK\_Q/]2>6MQR#V_>OO+_F=ZUJS)>3
MV^&(8(ORQ*HI([(E'KHB_=*38EA1R]>KJ.73C?&B&FF-UEU5%-L::ZZXSMGT
M=<8\V,2=N[/=,QK6-Q:<-:T-:,D.@:+ =ZX@%9G#J,ZF%MSS_>OB_8[GA;_B
M:D/\]RG]UROYZ[I_VM/^Y!_:3\FT7ZAOM^]9@]:/#7Z\=.@LGCO6A_952!9F
M49&I./C\J'NT3!0<TW8LGCC8Y'RRNBC=HINAIA!1%/.NV<[Z;;>;;&)Q+&,1
MQ=\4F)5+JI\+7,B<\-!8UQS. R!@U(OK=>\5-# "(F[V'&Y#3M(TNLF/N/$O
MQUW5^?XG^I/,;<<@]OWKUR_YG>M:];F\$/H-V%LR4W'<\)F4^LR:KCW,IEQ:
M8JH$#*XH./ #U'*0P>P8Z;-0XH>QTPW:(XRDUTVWQLIG??;/T>ZG'J"FBI*/
M$98*:$.$436Q%K Y[I'6+F.=J]SG:DZE6TE#2RO,DD0<]UKN-[FP 'L "\P_
M8[GA;_B:D/\ /<I_=<N?SUW3_M:?]R#^TOC\FT7ZAOM^]>_=<?"!Z;=1IT1L
MSK@&GE4SHM%W\+(R,#+M'3QU%R9,,9?AU$S0@HTPV<E(\&>;[Z-]5\*,$L:+
M:Z;*Z*6&(;HL9Q6!M-B%=)50-D;,V-[8P!*UKV-?=C&FX;(\;;6<=%Z14=/"
M[/%'D<6EMVDWL2"1ZP%FW]QXE^.NZOS_ !/]2>8:XY![?O5QE_S.]:PW[*^$
MUU)[A2..R[LLRL"VI'$PBL<CI4_+4&C@6$6?K$U1Z&H,**0V1W?N%G.=EDE5
M?34SC"F-/-KC+X=C^+X3')%AU9)2QRO$DC6-80YX:&AQSM>;Y0!H0%X2TD$Y
M#I6;X0+ N)T%[V]:QN_8[GA;_B:D/\]RG]US(_GKNG_:T_[D']I>7Y-HOU#?
M;]Z[Y5_@5^'G2]A1&UJNKZ70^PH&::R*(R@=,W*SX&:99VRU(-4G[)VSW51S
MMMZ.KELNEGS_ +9///"IW6;H*RGEI:G$IIJ>=ACEB<R(->P[6DMC!U\1!7TR
M@I8W->R(-<TW:X7N#RA;'?N/$OQUW5^?XG^I/(]<<@]OWJZR_P"9WK6/79+P
M\*+[?0P/7G9(W9UL0P!)VTS#@#\H&-6C"3LQ1<&V,);A(X*<[.$11XNRUT57
MW0RD^5SLCE3">^E_AV*U^$S/J,.J'4LTD9A?(P-)=$7,>6=N'BQ<QAT%[M&J
M\I:>*=H;*W?&@Y@''8;$7]1*PK_8[GA;_B:D/\]RG]US,_GKNG_:T_[D']I>
M'Y-HOU#?;]Z?L=SPM_Q-2'^>Y3^ZX_/7=/\ M:?]R#^TGY-HOU#?;]ZVJ(4N
M];((MD+HNE-!NDF@BG@_%,XT22TPFGIC.85G/FUTUQKCSYSGS8_#G.>1@NN2
M2 23<[=I^U7F7_,[UKH%L]18;>E<RRI+:L*W)M7,Y&X#RR*DY''T6!H;ARW>
M8:.51T39/=$_:6K=;SMW2._I):X]/T<YQGWI:N>BJ(JNE>8:B!V>*5NKF.L1
M<!V9NPD:@[5\OB9(US'W<QPLYI.A"UU?L=SPM_Q-2'^>Y3^ZY(/SUW3_ +6G
M_<@_M*U_)M%^H;[?O3]CN>%O^)J0_P ]RG]UQ^>NZ?\ :T_[D']I/R;1?J&^
MW[UL2J+J#"J&K>*5%45@6W!ZW@[!47%(H+D@!=@%8+O71%5LV5(Q-Z]WTW>O
M73C.7#I;?TUML8VQIC77$?JZRHKJB6KJY#-43.#I97:.>X-#02&Y6]RT#0#8
MKID3(V!C+M8W1K0= -NB]%WIL@IINGO=5U;:;Z[:;ZY/Q/S;:[8SKMC/FA/G
M_#C.<<M[^(>W[U]9?\SO6M5.?)W?"WSG.<TU(?/G\.?_ ,[E/_?_ /Q<E'YZ
M[I_VM/\ N0?VE9_DVB_4-]OWK_/V.YX6_P")J0_SW*?W7'YZ[I_VM/\ N0?V
MD_)M%^H;[?O69_6SPZJ'Z@1(Y!.MABS:FB,DD:DM. P$I&.FI&1JC!P90JMN
M<CI5QJXW&"1S3.J2R:/JVJ><)8WSOOMA\1Q:OQ:5D^(U#JJ6./>F/>&@MC#G
M/#.T#!;,]QU!-R5[Q4\4#2V)N]M)S$-.TV OZ@%D5]QXE^.NZOS_ !/]2>8^
MXY![?O7KE_S.]:US6KX&'A[W=8DMMBU8#+IG8D[+*G9;*24R<(OC999-)%5Z
MZ2'L6;+17=-%+7.&[5%/S:8\VF,^?.9#2[J]T%%3Q4M+B4T-/ W)%$UL1:Q@
M)-@71EVTG:2K5]!2R.<]\0<YQNYQ)N3RE>?_ +'<\+?\34A_GN4_NN>_YZ[I
M_P!K3_N0?VE\_DVB_4-]OWK(WK7X2G47I]*3\UZUCY_4TIE #XKGS "6HNG!
M(!\(LRWP8OH<#%6^J/PB/9NO21136]8AKCUGH9VUVQV(X_B^+11PXC6R5444
MF^QL>U@#9,I;F&1K#?*XC4D:KUBI(("71,WMQ%B6DZB][>L!9F?<>)?CKNK\
M_P 3_4GF(N.0>W[U[Y?\SO6L*>R'A#=.NWDV$V/V1$SVUYN#BS.%"9"?ER;5
MVRBP\L:.,PR2800*:Y;(%I$:>Z[J-]W&57ZN-EMD]4M$\SAVZ'&,)A=3X=6R
M4L+Y3,^-C8R'2N:QA>2]CC<MC8W;:S1HO"6CIYW!TK-\<!E!<3H+DV]9*Q\_
M8[GA;_B:D/\ /<I_=<O_ ,]=T_[6G_<@_M+R_)M%^H;[?O7I=/>!]T"H"RHK
M<%.P>8P2RH0[=/XK+!4R67(!G;T:]#NEVR1)@^8[[+#2+UIOAPU6U]6XWSKK
MC?&NVMM5[JL?KZ>6DJ\1EGII@&RQ.9$&O <'@$MC:[1S6G0C4+[90TL;P^.(
M->WN7 FXN+>XK8=]QXE^.NZOS_$_U)Y@+CD'M^]7.7_,[UK&KLMX;?7ON&!C
M47[+D;*MH!#R[D]&AL@E(]H@)+O&61[E\WV!QX4MNJLRVRWVU7453QIGSZZ8
MV_;<R.'8OB.$222X=4NI9)6".1S TE[ <P:<X>-#KH 5Y2TT,X E;O@:;@..
MPG2ZP[_8[GA;_B:D/\]RG]US+_GKNG_:T_[D']I>'Y-HOU#?;]Z^ICY/3X8(
MUZS(L:@D;=ZP=-WK-QI-B6=T'3571=NMKC=';7.R2J>F^N-M=M<YUQY\9QY\
M<H=VFZ9P+3BTY#@01DAU!%B.]<B##J,:B%MQS_>MI_W'B7XZ[J_/\3_4GD8N
M.0>W[U>9?\SO6O++KZ8U]V+K&44S=<YMBP*QFF@I.41 O)03<>8T!G1DE%:N
M%A<58/\ 3#(Z&%D4_4.T<[+,T]5/32RHGO=4=;4X?4Q5E'(8*F'-O4K0"YF=
MCHW6#\S=6/<W4'0Z:ZKXDA9*PQR7<QUKM)T-B"/: 5KY_8[GA;_B:D/\]RG]
MUS/?GKNG_:T_[D']I6WY-HOU#?;]Z?L=SPM_Q-2'^>Y3^ZX_/7=/^UI_W(/[
M2?DVB_4-]OWK9!6?52,TY7\0JRL[)MZ(U_ @+",1",CY''560,"+1P@P&M57
MT1=O-T6R.N$]-G+E=7.,?MU-L_AY'JFIFK)Y:JI?OL\[W22R.T<][C=SB&V%
MR>0 >)73(VL:UC+M:T - .@ V +M!>B-CPDH#+W#<[X29'/1)1DK((MJF\'$
M6RK-ZU4V3A>BFNCALLJEOE/?3?&N^<Z;:[>;./)CS&]KV=J]CFO:X7N'-(+2
M->(@%?18"""7$'0B_$5JW_8[GA;_ (FI#_/<I_=<DWYZ[I_VM/\ N0?VE9_D
MVB_4-]OWI^QW/"W_ !-2'^>Y3^ZX_/7=/^UI_P!R#^TGY-HOU#?;]ZS>ZZ>'
M]2W4J!O*QZYR&T*K@;^2$)@\C8*3BG3)>2E6 H80+;J&HT4=X<.F 04VWTU<
MZH8T9)YT2UWRIMOA<0Q.NQ6<5.(3NJIVQMA$CPT$1M<YS6V8&BP<]QV7UV[%
M<14\4+2R(%C22XAITN0 3Z@/4O>_N/$OQUW5^?XG^I/+&XY![?O7IE_S.]:[
M-;A54'5EC&D;#!5'N)A$G)?=4DXY@7CU<:L0SQRI.#(LL2$"GXZ+)I[FG+8H
M2:#54V6=7ZF6F5M-J+Z6H.3=@NT0>,RQYF[IQ#X</I3N;V?I>=V37M,B[5GL
M+Z]1;J\V@,?NV)XK /'(U%I/-;'M^5/HY'X76EP;U5FK6Q@W"9JPF[55^/Q^
M/4OO333D!U-KDG9Q[+?;?;HLG97V4NJK+4OPU,!CJ<PN/]:*(LBK*.KJN)(1
MF J:V)8<^@#IE+"X!G-)A(57TB8!LR<Z'BS(!7\'&N#.\4>+!9"=,E\VT'+<
M[3IH!;F7JW0:XYC>?7%C,["DKB7S<?:W8.#'Y&I6YVIVI+6 7Q8T1CVPR$R$
M2))B1S6(B8^R20>:D"C19LX'24L0EK$^MPAT/J\?$%F;PJ+1")[$$97)2*U?
M]P#4HZ_&K8J>J+1M$I8$!:298Z^G\R0G5@5B*%(:OJ/ITZ=;PCK]'Y"YU&,I
M:ZD.T@K9$=NSC]IV(7W;Q6.T<G+8\IM<[?$>09"U;:=XG7O0N2D+A>'*ZF]P
M]D:S(CT8V&V?W3"X1"NUQ&H[<DDP8:^8PWE,&K*LIJ%81 )'0Q4F:*RATL?;
M$HRQC)4T[;36P^S47'K7(^'1:\[F#J6Q2QK($7/*MZAHNVR=DP"Z']N5?LZL
ME>QV;R/"!92LZT?5B63(Q1Z72BJS0JLM%7T>2=[L'P1SDB0\7%MXK'[>5;2.
M%\K2]V=[$S&-W)?S#KIV&?2:V:7J^[9W,JL+FX6M# SD+U+E1ZI:!KZJ]F^\
MFL.V'MH:PZ_I))AK4@^CL,2,Q"42)J(DL2AFQ?31>UQH2!?7EU]B^R06?:3>
MINQ&:2[-EYA7U37MUO1CUM/-XS9TDD\<FP.G"=@UB(L!MEN%2;/"LN:R(@?4
M$R,J(!38O#HWO&D48P]B1+;.8Z<U_N]>I\?9ZHONUC'>&012;2-WH+(WI=U.
MA:W!VF(?O8[#X!5S.<PR33.AG%8I/(U!3HD>SD[2X6UGN)0]F]E1*+O63J!R
M^."HV0C0<U_;;;RZ;+;/6=MW"^5K3[MVRC%;*JJNXIV.>5I=$Q8M'U?P966P
MN%5^"%L)N#TEUSW$_DZ?K)9%V0C"D+B]8:JN'L].DB+","-7K8Q/*X*HYMFW
MEYN3[;:>H+S3K[:-R6;8>(L!OQ_O,[$J?M'(K@'%6,>G;'K79=:]F(+758@
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M+I\C&"JJSW?<A'DGKQ,*[V6&Z.G&K;"NY?*PD[HVRE&+:J:N(GV.>5S<TN;
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M]NPUBQ\_NM9/<-G')2SG5A5E;AL$K"7%>UY0D3\/0M<Z?:.-5\^%O&;4?M<
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MT>!J[R#+78]NH)8;[&]F.NNC+)?;9OG)++/3771KE[E;+?7775+T,8QCA%]
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MG>=6UT:&]D[:CMR&+>*(5;9,RU2!-W,1\UD@D)2D6<S=H19P,0@*$#">HF0
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B<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g713200g34g52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g34g52.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
MCP$B P$1  (1 0,1 ?_$ !X  0 # 0 # 0$!           '" D& P4*! $"
M_\0 1!   00# 0 ! 00&!@<$"P  !0,$!@<  0(("1$2$Q07%198=YC8(2(Q
M.;6V&",W.$%A@20R47$E,S0V4F)V>(.1L__$ !T! 0 " @,! 0
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M$3")A$PB81,(HWN3_9#:O[MYS_E@IG2R7^CK_P#0K7ZB16G0WY;:/_M3I_\
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M["A,(F$3")A$PB81,(F$67$_(^MFWO> 5" ]4)!:HGT*EMR\P_=%UR26#1^
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M5.U?I5[<S28JTUNNR=\;I6 V%_.:Z[P_[+YQ@FH3!W/]3KT%>H R)'.VO?\
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M5U#""??-9"'.BQ%'4_(K<QCOU*T^:LPY7(Q/AI5W];AL9,TM<';?,RN0C/\
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M=-.O^O+J0H[U_P _KK^C_CE0.A-:@;_)+4A'FW"Y%W_QKE989O#G_:F/^FY
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M(B2#UZBV>/FQ>UII (8B@(;**$7B3Z3-7;AL@HB-;O7O:+50GT[??T;JKOE
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M]=6T]O\ CU\K/$&OIJD55JOB^YI827YC1GA2(1;C8CAP;-\J$.-LV;%Q( #
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*B81,(F$3"+__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g713200g36d33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g36d33.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[19"4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
M%   !SH          0                         !              <Z
M   "%                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "%     !29VAT;&]N9P  !SH    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   A0     4F=H=&QO
M;F<   <Z     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    %.$))300,      NT     0   *     N   !X   5D    N8 !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  N * # 2(
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M0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ',
M: !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3
M #8    ! #A"24T$(@     !1DU- "H    (  @!$@ #     0 !   !&@ %
M     0   &X!&P %     0   '8!*  #     0 "   !,0 "    '@   'X!
M,@ "    %    )P!.P "    "0   +"':0 $     0   +P   #H "W&P
M)Q  +<;    G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ
M,#<Z,C$@,3,Z-34Z-30 <G(U,#DQ-C<       .@ 0 #     ?__  "@ @ $
M     0  !SJ@ P $     0   A0         !@$#  ,    !  8   $:  4
M   !   !-@$;  4    !   !/@$H  ,    !  (   (!  0    !   !1@("
M  0    !              !(     0   $@    !.$))30/]       (
M      #_X0%(34T *@    @ " $2  ,    !      $:  4    !    ;@$;
M  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
MG $[  (    )    L(=I  0    !    O    .@   /      0   \     !
M061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR,2 Q,SHU
M-3HU- !R<C4P.3$V-P       Z !  ,    !__\  * "  0    !   '.J #
M  0    !   "%          & 0,  P    $ !@   1H !0    $   $V 1L
M!0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
M         \     !   #P     '_X4  :'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(CX*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,3DM
M,#<M,C%4,3$Z-#4Z,S<K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @
M(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T
M93XR,#$Y+3 W+3(Q5#$S.C4U.C4T*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*
M(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C Q.2TP-RTR,50Q,SHU-3HU
M-"LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O
M,2XS+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^06-R;V)A="!$:7-T:6QL
M97(@,3 N,2XQ-B H5VEN9&]W<RD\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @
M(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA
M;F<](G@M9&5F875L="(^36EC<F]S;V9T(%=O<F0@+2!'96YE<VES($8M,2YD
M;V-X/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @
M/"]D8SIT:71L93X*(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/G)R-3 Y,38W/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC
M<F5A=&]R/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O
M<FUA=#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @
M("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4
M>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F
M(R(^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z-D(X04)"
M,#<Y,4%"13DQ,3@Y-SE#139",$4V03 W1D,\+WAM<$U-.DEN<W1A;F-E240^
M"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z-#1&-$(S134X
M,D%"13DQ,4)!13 X,$0P,4,U03=%-T4\+WAM<$U-.D1O8W5M96YT240^"B @
M(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HT-$8T
M0C-%-3@R04)%.3$Q0D%%,#@P1# Q0S5!-T4W13PO>&UP34TZ3W)I9VEN86Q$
M;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @
M(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-#1&-$(S134X,D%"13DQ,4)!13 X
M,$0P,4,U03=%-T4\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IW:&5N/C(P,3DM,#<M,C%4,3(Z,38Z,3$K,#4Z,S \+W-T
M179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G
M96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T
M=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO
M/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#HV03A!0D(P-SDQ04)%.3$Q.#DW.4-%-D(P139!,#=&0SPO<W1%
M=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^
M,C Q.2TP-RTR,50Q,SHU-3HU-"LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A
M=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T
M.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O
M;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @
M=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-D(X04)",#<Y,4%"13DQ,3@Y-SE#
M139",$4V03 W1D,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IW:&5N/C(P,3DM,#<M,C%4,3,Z-34Z-30K,#4Z,S \+W-T
M179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G
M96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T
M=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO
M/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^
M"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI
M:60Z-D$X04)",#<Y,4%"13DQ,3@Y-SE#139",$4V03 W1D,\+W-T4F5F.FEN
M<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD
M:60Z-#1&-$(S134X,D%"13DQ,4)!13 X,$0P,4,U03=%-T4\+W-T4F5F.F1O
M8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT
M240^>&UP+F1I9#HT-$8T0C-%-3@R04)%.3$Q0D%%,#@P1# Q0S5!-T4W13PO
M<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \+WAM<$U-.D1E
M<FEV961&<F]M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z
M<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O
M(CX*(" @(" @(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P
M.D-O;&]R36]D93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F
M.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "J E # 1$  A$!
M Q$!_\0 'P !  $$ P$! 0            <%!@@) P0* @$+_\0 <A   00"
M 0("! ,/"A %$08'! (#!08!!P ($1(3"105(3%!4187(C<X.59Q=G=X@;6V
M\ HU89&6H;&WP=<9(R0E)R@I,C98<W1UE]'6&"9"X?$T0T5&1TA29F=R>862
ME;.TQ517:(2ELC-$8V6'E,/_Q  < 0$  04! 0               0($!08'
M PC_Q !A$0 ! P("!0,-"0L&"P@# 0 !  (#!!$%(082,4'P!Q-1%"(R-39A
M<76!L;/!T30W<G-TD:&TX146%R,D)S-VLK7Q)29"18/""$-$1E)4559D99-3
M8F."E*.DPV:$E:+_V@ , P$  A$#$0 _ /?QPBB+<VRY'5<!5I\&O#6)B:VE
MJW7\JR_+N1#D7&[(O4'1U3H6$1DEB4+B2YX0I,0YF/08RE[O)#*;2EPBP0A/
M2/R$PJ%Q\Z,-C$K6ZIM-?:[/.Y:U+<B:$+%,C_\ %="2]O#+OX"I'7Z,I 3@
M)Q UE?4<'W(MC,EL.DP]KAZ-*V6, MM@1YD)!E/*9,E,9:->PD/QHPT\ZIF-
M/=2PEWSE-B/K2WE*,YX17GPBH#EKJS1JXUVRP#<BU+#0+@#DS'(-;G#([VP'
M#+%43A]$L7$_UT&CE-X,?COZM:94-_3>$5$%VCK,[$+D+8E%,Q9).0A:[D6W
M0!&)Z8B591*1,+Y,@OVI)QJ\91(  ^>4&K&4D--Y]W"*LM6ZJ/L"E,6>O/#&
MCR!01+4U&N,%BQ&<XE217D$Y;('C,I5B0>:4ML+*<X)4UVSPBJX1P4F&-(QQ
M@LA'FL-E!G!$-%!EC/)PMD@8EA;C+[#J,X6VZTM;:TYPI*LXSC/"+Z$,$/80
M4"4.:,YEQ+9(C[1#"U-.+9=PAYE2VU9;=;6TYA*LY0XA:%=E)SC!%QR,C'PX
M!LK+'AQ<7&BOG2,E(E,!  !#-J>)+-,)6T.**.RA;KY#[C;33:5+<6E*<YP1
M=>%G(6R18<Y79B+GX61:\^/F(60$E8L]C*LIP\'( O/B%-94E2?,8>6CQ)SC
MOWQGA%5.$5/$EHH\J3!!DH\TV$)9"F0Q#!R2HDP@(:2'$DQV7%N@$OQQ@A[+
M!2&G70RABD)4P^TM1%W\JQC.$YSC"E=\XQG..^>W;OVQ\.>W?'?M\'?'?A%^
M\(G")PB<(G")PB<(G")PB<(G")PB<(L6NIGJ/+Z<F:7,/TK%LK=@8VJ[-/AS
M;@4]&.ZXTU?=OBC1,-[&-'F53HU D8=QQZ5C,QCQ0I*69!*G&FR?3QP5 ]"Z
MZ++9]PBZ@F=95^./@[K7*#?YJ+NYAX.9F\XV"]5)'7+)56!<M\*&/07T7%XU
M<(_"&G$"BHD/8Q:WB+.$'9] DKS(ZT"M$:]?(H%^3.K&<OM2;<>-[,]9,;0\
MRVT4P-[:B<$N"NOX'S("X>\&74XR3R\="OSA%8)>UM71[93Q^R:"$T"JUH-=
M+N%>&;#50W$,WE)2WI%"6%4QUQ#5KP[E&:ZXM#<O@-:L8R14,;?NBC<QB0]T
MZF+5-54B]PZ1MC4]_,M2!%&(*N,;AN85DZK"KCI!)%@%\V)84"8ETM.17\((
MJL9M[4\>,LT_9^NP0VH&)M3A9EUK0PS=7GBD@P=D6^])H:1 S1RDAQ,PI>(^
M1*4D<,AY[.$<(K[?,#%$=D"2AAP&!UEOFOOM,B,B-MY><*>)<4EEH=MK&75O
M+6EM#>,K4K"<9SPB_1"Q) 04\ H<T$T=DL,T1YLD0L4EM+PY(I#*ELOCOLK0
MZR\TM;;K:TK0I258SDBH=MN50H,"9:;U:JW2ZQ'*'3(6.V3D97((%19#0@B3
M)>8*#CQE$EOLBCX>(1EXAYIEOQ..)3DBM9W=>FQY*:AG]M:S8EZW!1UHL44]
M?*LW(P%9EU"HB;%-!+E4DQ<%)J.!3'RQS3 !JC1,#$.9)9\9%S6#<6HZG'2<
MQ:=IZYK41"S3U;F)2?N]9AXZ)L0XXQ1$#)FR,F.,!-,"F"$O193K1S3!0SRV
M$MOM*417U&R4=,QX4M$'A2L5)BL'QTG'%,'1\@"4TE\4P(P9;HY0I+*T.L$,
M..-/-+2XVM258SDB[O"*EQ4W#3K11$)+1LPP#)R4*:]%G"GM!S$,8['R\44X
M*ZZ@>2BSV'PI$%W*"0BV71R6FWFU(P15+Q)\64>)/CPG"LH[X\6$YSG&%93\
M/ASG&<8SV[9SC./AQGA%]<(G")PB<(G")PB<(G")PB<(L2>J>Q;_ *MG7LIH
M=F2F3'4;>&G*H/6P)F*F3PM%[&L>NW)J3>!>/@V$[,@*G%"K$D8H>4*F419K
MK_K3#>"+$O4^XNK>9W/48*7<VG)ZK+N,8-2)VRZ5^9IW9>OR';KC8T]M8I5!
M@5:UE:(\%7F*.,XQ1';4*N/(Q'V3,RX\T4<<>L^K9LB5L)X?9 .O)"GV"/1,
M1,W+0%L=+K1$!,(KR8/,H,T,'/$6,(AI4\PAK,E!B,/9&*RA[P^1E\I4D<(M
M?5D])[T?U2PS-2F+U-(L\'L'<.KC8$2H3LC++N^DE0[%IA!  1B"BWID^>B8
MJC*9:4BXRI?J,1EUY@K#,D$"^6P')P)SON!N#EF#F,K[0O1T3FM#B8[%K7 -
MEB<ZSBX %C7ES7 M.LP@/8"USVM:]I//'^DHZ;S]@P&J%,;4"V7.8GQ'J(3K
M*P/VJ!LM=<N""J7-PL8F0.19S44:>+B&(QF4BY./]DR(TLH*>AGSI+'-#7.:
M0'7+21;6 WCI&>W8<P#D55)3SPQQ2RQ21QSASH7/:6B5K-76?'K6UF7< 'CK
M";@.):X"I07I&>F:TJR/5Y'8ECDTUZ6FUPL/JJ]ERZ).OD&MV&AK$Q"IPG8U
M?"C9&?F:;ESVJ#5P2K,ZCV&WZ]FE>*F0?JRZ="6-?Y:VU4O:VU:#%;-UO4%'
M91?[M39R!DK+#25;H*F\7"6)EH:%FRXR)$A798_,+,LB!//Q1[8Y%\4#JUZ<
M=E0-*GJQMZE83L"'JTW6(2;FA*[;2A;H'2SZT,549MP&Q1TI)L;&HF&HDZ.8
MD$O6V 86.EZ3%0Y-C:]C8$ G<";V%^DV-NFQZ%4&/+'2!CC&Q[(WR!I+&/D:
M]T;'/MJM>]L4CF-)!<V-Y:"&.M>$WO#6T#<*E1"I])5FN5_D-8QH$:PZ?ZE<
MXS6,ON J)FG6<91%*^8*%(F&G2<X;=R0 ,G/GEMIY"I6&5,]+%T;79VLL W"
MQ1K]VAY6<IC,Q7%,KLX</8ZY6C!HS()T@A,WZU96)%%:/4%8TP<58)A^*9#A
M35HFV1.5@0-HOG?8+W(R-R!89 D$B]082QTEVZK7,807L#R7A[FEL1<)'M C
M=KO8QS(R6-D<UTL0?)('I"^F8J\S%*D+'8:R'"VF9I!6Q[75Y*!U-FWP=5G;
MX5 ?/",PF"%*)HM;F+A%%R3H,5+08F78^0(*<:$7"I4W074ST[6=F8(K^\=5
M2[-=K,E<[$X#>ZV^FO5*&&C#)>RSWAD>\-!Q0TS%N2,G)8%$"]=902ZVO.4X
M(HZN'77TFTH!N0E-Y:]+1@RA,'"Q-GA3I"&C]CV2K5>NV.: P>T3&UQ!]UJQ
M$K)D-I3&QL]#G/M^5*QGK9%<9G6/TG@//CE=1VET$CY@DJ%;V+5R"G5V>.5+
M5YH08>2=?.>F8U&38YD)M]TIC*%M(5AQOQ-ODS/>'2I#7.UM5KG:K=9U@3JM
MN!K&PR ) ).0)'2%?&H]\Z<WU")L6G=C5;8</F*K<R\56I)H[((%NA1[%7%2
M8^/"5%DRD&6+*,@2+(QZ R6'7AFDO-^(H4M\(G")PB<(G"+H2,7&2[#0TM'
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M&#5?*]S-6$/; T,<2UH@;)*V( =8)9 VP<0;J_H4LP)L1S=,/O:$%VBHV\6
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M322:0;?,1F =H(.W?GD=H-B"" 5Y->6$N&KV+V'78Q[;2,<PY2-<T. <2QX
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MX1.$3A$X1.$3A$X1.$3A$X1.$3A%J4ZS<6*W=0U)ITU<&Z1JRM1$?<"TRI3
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M*BGR!TH(3$20F52#2B<<<>==K8X)C^S]=R+.6,MP[X"FD^L1C4@EV2E\@%K
M9?DP2C!U1SC[4LV\/*-CCK')BP?:"7"AB+CW@&<0;5'@VA7L#ID<O,.K@T%E
MI</@48$CFY8T)1A#J<N8>$7DD!0627W0C3F(\5TH/F\/JV_,5R]0<4N7@($=
MO*$N(F'7&E.E"A,^;Z@^C&'B'I:)=4VEM3COJ6,R $DMI$?*QI(A.5-..-BG
MCCCP*I[H#?-J,&T/@=*TS#:EY-5$#L8'779U@IAQXZ0BT,.%#NNALM@'C**)
M?: *=1#$R*L$7Q:@GW-.5\(1H&/=1&TQM#,P]'1H0;;6([#HY;Z"!A@\)82X
M-WBRF7$N*2V&\EM7BX1=&196YT^C#FK8CG'*S",ONR;\6",.XX8"VH@TN/+]
M1#:4I7G/%Q)ZRQTJR_$FNR"!B%$XW^'C@+ZB1/[ $H TAM[**Q;@FT.>QC&7
MO+(EV$^-91TQ%',N^'&<OR$C)+,:5YT@646Z\ZLHW<;_  V\GFW+NZI;+9U#
M_7!@$0E8<\^\)'JCGH\3#^"'TC#/..+;);90O"'5S:L%^?AYN20VE&4)*53>
MGL9 53G1&GQ2T-SV%I+!/'E0R?6(&&>RL62S)2AAC&%*4A'M0EIX7*51[ 0,
M<((,V1=?IU%,&@; DH.-!3F70A@>,:BVFU-L-.,9)*1'Y3D<TA3>5O!I99BV
M&\,+A,. O^:LG''M70T< 4/<=J$DC-CH>FW&1<H(")4^TW*RSZGW&VRW78K/
MC*\C$;'"B0#BAW)$;SY$N0<P17-08YX;8]]*\T1+)!$CG+#*JUDEUUR6PXE\
MMN+GI*29RTG"VFO6(J%40ES+TLV3)]EH*/F[V_CZ5T*Z$:SNVQE*0*H,H>3\
MOR7(91;&6A:]A*CV!Y#)H[;KKA*@',1:7R4O%9DCTY;$'>*>/FXXLND0/(9Z
MBPWD! HCL0R''Y%/L;,JX[[$D&&@5-/+;+5&Y5W(4:*A^>')'9$<\FNF*RHH
MX\WKXVK([A2G"+6#Z1CJ1E='(UM!1]HTD.S;27))^E74*U3&V+"35IV#EHL_
M6\-"W&@0)D;'R(XR+%\UUSJL*K#PPQ<TD9]\9XBV,4N4?G*=4YHI;#A,Q6H*
M4(<&'&$'6_(18I;JF!0YBPAC,J<=5EH<2?FQF492VQ+R324F/$6+O5)M?;^N
M;#JV/UG'+?"GB#WCO!5#;/BTV .U:_B8C6RR!4J35T62NV*Y3JK(YE"H[YD_
M6LN>HC2+!!%?6X;&>SL+1E:33[,1'D[0BSW+DQB!^9<)]-2OB<19?G3K-@P>
MO#25)]6@20_"^QW+PKS<-D[_ !N]B\PGI9O1$=<75;UV[$WEI?7U9GM=6&(U
MT+%RLCL"IP1;K]>I\+$2B'(R4D!SF?)."?0A3C.,/(PEQK*DJQSZ(T!Y0-%\
M"T7P_#,2KI(:RG?6.EB;25,HM+63S,M)'$YAUF/;_2R.16G8KA5=4UE5+##K
MQRM8&NYR,;(6L-PYX.1!W+;+Z3/6OI1K'"]/,?Z/2WOU-<!7[ #MUL6ST6!2
M4:D6JLUO'CN##WKB1\C3R4+C\I2C#G=_&<.-=M#T(KM!H7XR[2V".<S5$+\.
M=+354^K'KU)GL*<$,+M:$GG,\LMA64Q.+%'=2B@<]K&QN$PCDC8=;K-3LR+B
MP>,LNG:%G)T>5SJ+B>D;6=8ZLY.1GNH/$#. [,E 9:OG23YQECG,Q[[,M$>K
MP3CK->>BD)=$3A"/+PA25O(<[ZKI*_!:G2#$'X#S=/@[W1&C'-SQQM IHA+:
M-[72MUIQ*;.&TWR:0KVCZKBH8NJF235(U@]H=&7D&5Q;USGL8=5A:#UU[#>5
MDQ7(T:NP6(R,B) 02.0^H0$@D-\E[*U.$9:9>]=<93XG5Y;;P0^RVC*DXRI+
M>,JQ@G1M:]C1/$X.(!>T2ZC+FUW:T0>0-IU6N-ADV]@;ALKRQ[C3S,<T$MC)
M@UI#:X:PB4L!<<AKO8+G-P&8MFC IBY"50U4+7"9F'')(^2GI&NF,$&^:K/A
M2W%6"2?;><P^OME(B&LMM8PX[A2485<U%)!!&'QXC1U;M8-YN!E:'V(-WDU%
M) RPM8@.OF+ YVMJ2MJ*B0QRX57430S6$M1)A[XR1:S!U+6U$FL;DB[ VPS<
M"0#R(4:FVNGYJEY5YA6!L&*F*XFM-M880%F11%-V5)2D+91AU3CL:[(]L^'#
M>/"EI,]1T_,<[]U*$OYO7ZGU*_GM:U^:)ZBYG7W7Y[FR?Z=C=4"OJNJ#!]R,
M1YOG>;%7SF&F#5O;GM7J_J@1_P!*Q@U[?XL')4K8!\HF8 ''UQLBVAB"^?ZY
M4IRE1<.0X^0TXH*1'GKI7I Q8^0FEY:<#< 4@CW+><\6&::>EAF87R8A24IU
MBWFYF5;GD"QUKP4TS-4WL!K7R-P%?22/8ZS:>649=<PP@7\#Y6NR\%E '6=U
ML].G1S1J/9>I.R7&B1.P)Q45 9K,)*S<TB8BP&Y@V/*=J^#\@X:%7EDA]@G+
M+W=QH<E:587G+Z/:*8OI1/5T^#L@G=1,;),Z6=M.S4>\L8YAEU7'6() U0X#
M: <E;5F(T]"R)]1S@YTD-$;.<-V@%U]4D6 (N<QGETKOZQZVNG':G2R]U04:
MU60C2 7M"#58RZ_.!6%EZ+EVJN2M,4:QF7<?:DWVDMDY:7ESO@GNI.,\N3H3
MCXTD@T3YB XS4M#X8A4Q&%S3 ^HOU1?FQ^+C>2"0;BV\+%XKI5A&"X%5Z1XA
M)/%AE#J]4O;3R23,UYHX&V@8"]WXR5@ZT'K3?<5</3GU,:'W)#6UG4%AL$V!
M16VI2Q.3D9-#$#IE_7RL.-+E6T+)R^N/.(<;'[]GE+<4GQO]U>FD^@FD>B#J
M!N.4T$!Q)\K*7F:J&HUG0F(/UC$XA@!F98G(W)V K$Z'\HFC&G/5XT?J:FH.
M&-@=5]44<])JBHYSFRSGFMU[\T^X;V-A?:%AWTG>E!Z!>HKJ!5JK1.P-@3VU
MMC)L9^8ZP4VVQ<28FO!'6,]6#98-J.!Q' !GI!0C+/F-KR/_ $U66,-W.-<G
M.D^ 8=/BF(T]*RDIS$V5T59#,]IFE9"RT;#K$%[VW(N #<K8J3&J*KFC@A,V
MO(#J:\+F-.JTO)UCT@$Y[;>5=O:'I:^@G6O4L=H2\[%V )M^KW6'UZ571*5<
M2ZRQ:Y!UH,!/K(8>8DO*USK*%2*UNMLIRG*%MX;7E55%R;:4XAA46,TU-2NH
MIZ5U9&75L+)70-:YY/-N-PXAALTV)R42XY0PSNIWF;78_FW%L+RP/UM4W<-U
M]X%K9[%(?6SZ1KH[Z/;C4=>=2-ZO%6G[-6R+9$1]4K%GF!I*!>/*A7/:1D ,
MZCRU&1Y+>8]YY/F)1AQUI:,MYY9:.Z#8_I12S5N$PTTD$$_4SW3U44#N=$;)
M2&M>;N 9(PW&6>5[&WM6XK24,C8I^=+W,UP(XG/ :26BY&0)(( VY;KYW/O+
MTA?2GJ+IDU?U,;&NMN@],;N<K+5#L$#5["_8#LV&',M40EV+CQ5RT/ZS$PQB
MGW'VF5L=O(RMMYQ&<48?H5CV)XUB6 4D-.<1PH2NK6254,<3!#/'3OU)G.U)
M/QDC0-0FXN[8%,V*4D%-!5O,G-5&KS6K&YSSK-+Q=@S&33?OJ0>ECK)Z?NJS
M2TON+1UHL=BUW59R5JDG+V*%G(N9;EH@&-DSD*'FVDR)>&Q9D%;979:',KRV
ME7=I6,6V,:*8Q@>*4N#U\4+:VLBBF@;%41S1N9+))$PF5IU6G7B>"'6L #O"
MH&,41H:K$"Z1M-1AYG<Z)X>T1L;(ZT=BYUFN:18&]U+6JK#KXQN1AJ0=)&+:
MS[6DER*"LOO//9;8=+6Z0AM"GB'$I6[AI*<97E2_"G&>W+/$L#Q'"61R5L;&
M-E>6,+9627<!K$68386WE6N$Z283C<DL6'S22/AC$D@?!)%9A<6@WD:+YWR6
MOO2OI:.@S=?4?%Z-UUL38,SMZVV*P5.'A9>EV\&OLRD0*47,#BE&B-Q$>SEJ
MNDNX*SE.27$83EQ?FMIQLN(\F^E&%85-C-93TC:*G@BJ)2RMA?*V.5T;6VB!
MUG.O(W6:+D"_05[0XW0SU#*=G/<Y(\QM<Z%P87 '^GT'5R)[WDI_5%Z4?H!Z
M?NHE>K-VW_8$+MS6SE=[QL'3;?)PH+D\*!8059*BA'(P]4A&R8K)F5J>PTPX
MMC'E/(4K#!^3C2C'<-I\5P^GI'TE2)#"Z2MABD<(I7Q/O&\ZS?QD;@-:VMD1
M<*:G&Z*EFD@EY_7B(#RR%SVB[ \6<,CDX;CT+87MN5UP5$PL7?3I5F,D7FY<
M0>-5(#Y-PPRM"$%. >!_#&,%87EGS&\Y7A&<Y[HQVUK#L#Q'%>?ZCB:_J=P9
M*7RLCLYU[ :Y%]AV+QQ?2+"\$,+<0FDB=4->Z(,ADENUA:UQ/-M<!8N&1-S?
M8J'M+=>JM9:53?;Y8)P.@F- 5W,X''EFS3KI^7(YAY0X@SCR'WW1G<N/^KX;
M2O.5^%*5)QR_P?1'&\=QM^C^'0128G'%+,^*2HBAC#(6L>\\[(X,)#7ML ;F
M^6Q8[&]-]']']'X])\2J)V81++#"R:*EFFE,D[WLC',,:9 "Z-P)M86S5I:R
MZLM VO36Q]M4RQS\CKO3T;/S-UE9*'FU2H04#!OVF5<:%/:S)2CC,4TXXRVP
MEU;F4H&:QE6$IQ=8YH)I%H[BN&8-BE-!%78N8NH6,JX98W\]4"F9KRL<61WE
M(!UB &YG)>6BFGNCFF=!B&)8%45$U+ADQ@JW34DU,YD@BY\AK)&ASQJ&]V[\
MECWT8^DRZ+.KG8\SJKIZOMZMEY&JY=QD&+;5+3$-(@(>0" ?4,?-"L!-)'+G
M14M1PWEX\#JUM-=D.9Y7I!H%I%HS1-Q#%8:9E,^H93!T-7%.[G9&2/8"QAU@
MTMB?UUK C/,A9^CQ>DK9C!#SPDU'/M)$Z-I:TM!()WC6'1>ZV<<TQ91:F.LK
M=VV:5U(ZJJ50L3Y]:&DJ;/FUQG6_S,*ICLJY8JW)7-&\KY@S5EL<>B)$T96M
MFA@;  UA1J"""S(O#)-ZVS\(L*-JW[><1U3:LJ-6^:-C6<B%3G"P(VCL3=9M
MZIB5V"+LUVVW1R#.(IKNNJ_#4><K38L]74S$A/O@%M3Z2F10"*]Y.QS$AU6Z
M^@2Z+9X6+AM8[D7'W*2*J+E=M*GY72ZW6H,>*M$E9V%AJ<6T1\T%=A$*6R[D
M99#?EK<(M.=D]&KU0R?7>7U B1E+5KE[J1#V:A]RX#HELU5B\C3SCV8K(N7/
M7?9S2UX"\>5J=[-87WSC//FFJY,-+)>4&32)L5']S#I,S%=<UL8E-(*YE07&
M'5UM?FP>MO?6R-U]$4W*3HQ%H&S1]\E9]T6Z-OPPM%)(8NJG4+J<#G 2TMYP
MCK\P!F2!FL^MP^D#Z2J%O4K5EVEMG";)J%BK->?1!0<BN#]?62', C*>9/0&
M:"8J6$Q(J>&7A:6F<8\MX-EU'3\5Y4]%,'QB? JR2N;7TU1'3R!E&Y\7.2M8
MYEI0\7:><;<ZMMH7-\-Y,]*,6PB#&Z2*B=0U$$M1$9*MK)3'"Z5CR8]0D.)B
M> "<Q:VU57J*](#TIZ/V\K7.U)3: UWJ(\49D:JB6?$"IN>% F05%(AYZ-CI
MA66<CI6W(B%(92M\;MEIUY*Z\?Y3]%]&L5FP?$WUS:R%D+WB&D,L=IXVRQ@/
M$C026/%\LC<*G N3?2;2+#8<6PV.B=23OE9&9JL12%T,CHGW86.L-=I#<\^A
M9#;:W-J6MRL1"74VZC&8C1Y\--9-L<2VX')^:TS@U^OR\4LK']2KSZF6IYA&
M>R\(RI7?FR8CI-AF&3LIZITPDDA9.W4BUVZCRX-ZX.&9U3EM"U^@T<Q/$H7S
MTS8=2.9\#N<F;&[G(PTN%B";#6&>7MACJAZY.FC1I5&K>WY39(#URK@E_K_S
M$BV 5Q^')R;&LID9&OS,2:WE2E/*=CEOJ:4M#+SF%J;1VP>D?*-HWHO-10XJ
M^L:_$*-E?3\Q2NE'4\CG,:7V<"UUV&[;&RS& <G^D.DD5;-AD=(Z.@JWT-09
MZIL1$[&AS@P:KBYFJ0=?9GTJ4)OJ'TK,ZNUI;) NYHINT(".M=2<C/;T3-.Q
M;" 2AO:),3*A2@CF4E#8(&6:YZQW6A_+N/%WRITNP<8?AF)Z]1U+BU.*JC/,
M'7=$0P@O87#4<0]O6W)6-&BN+.K\2PT-I^J<*J#358,[0P2ASVD1N(Z]MV.S
ML%:.\>L/I[T=J.@VG8)]_$I&Q7B(*LD5X>>(L:EP.$/.X+DA)<:<#6I(V$J-
MS)J*+2I>'7E9=7E5ECFGN :/8=AV*XB^K;28F^6.E,5,9)"Z$7?SC X:@L#8
MW-U=X-H/CN/5]?AM RE=4X;''+4B6I$3 V4@,U'%IUR21D!DK/E>O?I?@NF2
MM[N*D]F,ZCNUHE]:0T@P#/O73VTTU..FK<)<FESXF4IB9%0TO[544VXD?++B
M,Y;RFSFY2]&8-':32>1];]RZRN?A\+A2.Y[JB-LSW:T6M<1V@?9]SG86%S:[
MAY.M(Y\>JM'&1T?W2HZ-F(3--6T0]3O="UI;*&G6?>:.[-4$"_1GS0G7KTQX
MZ9YW?L?)[(=U+$7%6O) V3 GI6W)GI5L-?A8Q+S!\LZ*E,J/Y169#*1?HDLH
M0EG&.3'RE:,R:.SZ4MDK/N53UK</D<:5PGZI<(W!HB+P2RTC;OUK;>]>'\GF
MD;-((=&7,HQBD]&ZO8!5-YCJ=ID!+I2RP=^+=UNJ;Y6.:ZVK>N3I=(T1MG?E
M.D=AKUEKZSQ -NQ+PL@_+1\G,#5R'"&@(THYXE<;V,CG<M-DI9%=>*4PAME*
M6D*+E)T9KL!Q/2."2L.'81-%!5EU*6SA\SXFQZD6N2YMYF7.L+"^60"BJY/-
M(Z+',-T>G91_='%8)9Z0"J:82R!LSWB274:&.M"^PU3>P%\U</3;UF].6X*C
MLRQZJE-D'PVLF(F0N#UU393SVTRK9Z0O96;#-R[SF%)C2<O#!K%80K"%Y:RI
M>,XN, Y0='M)*7$ZS#7UA@PED3ZLS4QB<&S<X6<VW6=KFT3K@'++,KQQO0/'
M]'JG#J3$64HFQ626.EYFI;(TNAYO7YQVHW4'XQNJ2#?,#8 I&I6]=-YBMF7&
M!.O! =/K,O>[<J:*L<KY,/%HD98WV)'2\P<*.XAMLG# ,6R$TI"6!\=FVFDH
MR<&E>$U-/B%3$ZH,6&4<M=5$PD$4\+'2/+!K'7=JL=9HL2198V?1C%*:HH::
M1D DQ&KBHJ?5F:YIGF>UC ]P'6MUG"[C>PS4.]-_77TO]05ZN<=JF4V8;8XF
MH35ZGFK4/96H=B!CCXY!_LB.DYPZ("(22<(E@2-!#SEK"TI5AO"L*PFCO*5H
MSI/55-)A;ZTS4E%+7S">E,+>IX71L>6N+W:SP96];87SL<L\SI!R>:1:-4U/
M5XFRC$535Q4,1@JA*[GYFR/8'#4;JLM$Z[KY&V713>GGKVZ4^HG=&:OJ^2V<
M7L&;A):0PU8@[*#6VXN%"%>.;'CBITF!!6EL9MUK#$6TZLE9#B7$N$OJ<HT=
MY3=&-)\39A.%R5KJN2*:9HGI'0QZD#-=Y+R]UCJC(9W)M?8J\?Y.-)=&\.?B
MF)Q43:6.6*%QAJVRR:\[M1EF!HN">R(/6C:NMJ3TAG2=O'>\!KRD2FT7=CSQ
M,K$Q@LF%9HNJ>=!Q$J8;ZQ'8GEUY.?4@3%((=BG''24CK\>'L-.(\\&Y4M%<
M=Q>#!*%]<:^HDFCC;+1NCC+X(Y)9 9"\@69$^QWFP&U58MR:Z38)A4V-5T="
M**".&21T56V234G?'''JL# 3=TK+B^5SO%ES1?I!^E.X]1D9IH.7VGC:3%X+
MU@("@6S1E.59(F6DHTC!HP<\S!GCY-;)3[0D(LK+K"!\]O TWA$P<J&BU3CX
MT;BDK3B3L1?A@:ZD<(>JHYG0._&ZY'-\XPV?;9G8; GY-M)Z? W:0R1T7W.;
MA[,2);6,,W4TD396D1:M]?4<+LULCE==:[^D'Z3&=^!:0L4IM%&R*]L0+7HP
M<2%98VMYMILX#&"Y,<B9T "3#2>XPWZU("%,H$=)1Y667GVUQ/RI:*T^.G1V
M22N^Z+<19AA:VC<815/F; T<[KYLYQPN_5&68!WS!R:Z3U."MQ^..B^Y[Z!V
M)-<ZL:)>I60NG),>ID_4:;,+@2[*ZR$V3N_30=O33;:3<D3=;D6&\-P3]ABA
M,&2(XCC2G2(.7C?7V\,$-)\)6'FFL./IPW]$YWV.KTIPJBK)*&=T_/Q/9&X,
MA+FZSPTML=87%GMSMMN-RP%+HQBE;1QUT+(#!(Q\C=>9C7ZK'.:[K;&QNPV%
M\Q903U3=>_2MI2^JU'N*1V.)9H0./L?@J,+)K&0W.19C0!")2.D0W%D#L$.O
MM)QV]5,;9>QE2F^W,!I'RFZ,:+XG)A.*/K6U<<4,SA!2&6/5G ='9^NW,@W.
M62SF <G&DFDN',Q3#&43J2266%IGJVQ2:\)U7_BRQQ N<COWK)+:=[U;4:54
MXB].V1ZO6 $/V8F.]>]=+&C PW&L21()(9*5*;?'==3YB?-?3E6>V4<VC$<>
MH,+BIIJHS:E6W6BYN(R&VJUW7 $:N3AM[_0M:P_!*[$Y:F&E;$7TIU9=>0,%
M]9S.M)!ULVF]E)6K[#7+/1:_*U)V2>KWJJP(QV60M$@IF*?=C<X(PM2EY4E8
MJD)4K/T2$ISC&,9QCE]05T&)4L=93%YAEU]37;J.ZQ[HW7;<VZYIMGLS5G74
M4^'U,E)4!HFBU-;4=KMZ]C7MLX;>M<%?W+Q6BU&=86L^H&X=46N9C6U2ZABZ
M%%MU)^V6$+=<T#I!A(TB5@W-?TWKW9VM[\1>DQI! $M8#;3 5=0)32BH6WH:
M) <*;Y 6&5\[9F_2=X&Z^RZVY\*%A+MS6VZI_J@U7<ZNY.N:^AQ*2G,A'W'$
M/ TUR&L5S.VJW9JC[:!7;U;-J,I4:Q7\IA;"W#'PK\B^J#R.P66129.+N6>I
M/6J91BLHJ2:;M;YGWP"Y5VQND9QKGUG$P*0$S&#LI7Y^&%!&$K6G#.7$HSE>
M$D6.UHZZ Z[O([5>=4L&%A7D.B_-1FR-,ON(<E&X]!OJN:\XZE#.3'7DA^O*
M3W4XA+V/-4KDV-K[EFF8/KTC:KG[:T)FU.;N!9A=;6UP3LM?4V=.Q:].M'TZ
M,=TE]7E[Z;7>EUB^G40^DQ#=]5LMB!(.:MM8K=K3E$6J@S#H:(YRQJ'PUB7>
M2\L;).,LY?RVW(:2+A9W"M#CB>&0XCU>(1*V8F+F-?5YJ1[.S$K>R#+]CD;C
M.RNKTBOIKH_H4ZB4Z1*Z:6-ID!T*M7-BUN;%8K+C*+3DU;L8S'N46P+:P.N)
M94LA$AC!*O*SEAM3*>X-+MFY>>!Z('&:'JSJX0?CI8>;-/SGZ/5Z[6YUE];6
M.5A:WE79Z]_34 ]&=CT7!&=-;.S,[=T54MVCEO[%8@,UM5L)E U0#;3M&G<F
MK$1'YRJ40X#DE+V49":PGNJ +W[V>_V*,&T1.+QUC^KA#U+62TEC3Z_.<V&G
MG/TS=6^MV%G6MV1685AZ]PAM(=-&X#-0C22-]:TAMH#U\FS,KQ3WI2$B#\1[
M4@[7'L23H[4^X)B1;#CEK;0YGU="7U(2:TNV?2L2W!=:LKZ3JCW%4/I]?F;\
MYJ/>W6U>=&KFS9=VW:H0ZX/2P!](G3]T][G*T(SL1C>4W8XQ%6=O+4$U6%U5
MO!+).#W*?-(DU.J0G+24@ 9%6E*D+7G&,X $FV_V*\PC1HXK6UM&*OFNHVQO
MYSF-?G \VMJB1NK:X S=X>F^M,>DM$W-T5T/JQ<TJU"C7+8T[14:^7<6I)N,
M55Y&::'EL3F:N&A]2WZ^V0R+B'8R*XZVI!"E,84M8WMOS^A>-9H^:3%I<,ZI
M#^:@9/SPAM?7:PZO-\YM!?:^N+VO;.RZNZ?200^E>B"[]4C6B@9J*J^Q(B@N
MZS:M0T6#)XM4A&(,DG)5-4+'93EZ=>))#5"/X+=2YEPC"B%*3.J;@;SFIHM'
MS5XM%A8JM0RP/GYXQ7MJAQU0SG<[EMKZPM>]C90!I'TTPFX.B?JJZL4]-S5?
M$Z;9>GPKFO,;&:/:N2;D9% N.9F\4<-N&2)B5RM;*H:3P5AK*,J:\SQ)@C5-
MB>CIWFPW*_J]$NI<6PW"S7:_W0;*[GA!;FN:#C;4YWKM;5_TA:^]?/1_Z9F*
MZD=+=9^Y([II$U^KI@UDC:TA!C;!8E%;#*3!61Y(!,DS1XCV0^D2G# 8DG0Y
MA?D.,I\C"!$-K$6-M]K_ #W]BIQ/1,X=5X72=7<Z<2J.8#^8U.9ZZ)NM;G7:
M^<E[=;L58]''Z8V/ZY+GMFB1W3D/J1C5>H)3:*2A;^Q8F9=$/*1<2F#P$Q2:
M\D#"TR.'$FX=*PTEC#6!587XD""#91CVBIP2&EEZMZH-34BGU>8YO4NTNU[F
M5U\Q;5L.FX6:?3IUHA;HO9-*#U:/4,_,]-V-R1&L#)V'EQCC+JQUC-0,=E2B
M737'%/J>SE+GC7EM2G,]EC8'<5B*S">HX1+SX>.<8RW-ZG97N>S=L(Z!=:Z.
MAWTYX'5[U84KIH%Z86M=.WLF\X>NK6RV9U0CE3JEDMKKKT,W0H51BY-R!4*M
M2I1O+*R\DJ4_EORW!! !Z?83ZEGL7T..%X;+B/5XFYH0_BA3%A//2QQ]ESSK
M!NO>]C<@;-W0U)Z=>/V-UN0_22/TMCP)=EWG+Z>)V(ULQ@I[#L7.'U_-C>A$
M4 1PI3[<.T[[/<FDY0G+3&3E882O,ZIM?=Y?8JJG0PT^$OQ3J\/U*-M7S/4Y
M%PYK7!@?SO\ WK7U/(NQ;/3I 57KL.Z/\=+S!9K74/$:%7LK&S&!WWO:%P I
MJ+,N#^8%QW.!VS<%IB53F?$AKU7!Z$J\U, 7&MN!MW]ME3%H<9<&&+=7@7H7
M5O,]3WMJQ&34U^>%]A;K:HZ;;EZ(.0M)3A%@SUT;"M=&HM6^8EJ95)&VP-%E
M(K>OH6]V<2FN1LTE]ZN,6ZO6*FL'+L#4$R8F8CRG%0[D@H1EHGR2FB++F@%.
MFT2E&/Y-R^74JX2]F2"!C9'S7X<-USU^.C!@HT SQKSZT%'AB BO^-@09AA#
M;22*[>$4-[:_7;2_WXHC\S[MPHWCP'U*9.%*<(G")PB<(G")PBP/Z[O1Z:4]
M(54Z'3MUS%\AXO7EBDK+!N4.7BX@MX^4C$19*#W)2$FVWA\#HPIM#33"TN?1
M9<5CZ'FUZ*Z7XEHC/65&'0T<SZV**&45;)7M#8GN>TL$4T)#KN-[DBVY6%=A
M\.(-C;*^1G-.<YIB+027  WUF/%LNA<.K?1X:9T_T?G=%M/G[Y\[$X^3DE3,
MO)Q!]N;(E;(/:"<)-;A1(W+>#AD--HS%]TC94G*E.9\S%^.4#%QI?2Z9.IJ
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MOX^A2MZ4+ZP]Z-?_ #S2/\2MYY;:&>^IIW\7B/[VH?8IKQ_(N$7_ -)AZ/\
M$2^WR^%9E_J?#ZV#N?[]^QOS)UYS"<IOO@:._(*']X5RL7]RFDEO^QJ_+^11
M=&>W/+/);@^EC_""U?Z&9^7_ .VM=_T_8^+'PZWR@^Y:#Y3)Z(<>=:QR8=L,
M2^21>E/&W[/#UZ+7Z\GICY/G[;7_ &_8.P>WZ?M<[CIU[W^+[.U-'Z:CV=Y;
M+AW;&C^5>J15/TYGUUW=W^7T_P#B_L<4OY/?RGDR[A<$^+KOWC6*K&>V%?\
M"9]7A_AWE[=.I//]1:]^//LAS_X87;W_ &^</T$_K?HZH9YIKK7^4_\ 381\
MGJ?20+%[K]^MYQOW5T[\N2?-RY+_ 'W:WQ?B'U>E\/G6A\K8_,AAWC+#!_\
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MY"0)"0R/&(:4YZV1; >$3A%"]K^GCIW[D]N_PZ^X1:G-A:.W#(=6<Q; =:W
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MWD<-R_K+#=H_XJKR]H6(_1Q];2](/][[;O\ $I(\V'E?]\C0#X>'_OEJLO\
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M>+#!>Y^]6?/POK3ZUS=.N/[D]UOX[_\ =-UY]KWRFO/@^7][E>C)_-!I\?\
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M *@%W[^K-=\YSGOX?CSE6<_MY4K/X\\)9/9X7?OZLSW]_O\ #\N>_P##PH
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M;_U-$VVYU[71"T)6G'3M=%XQG'?'B;N.OEH5]M*DI5C]G&/DY/+*!]Z$-O\
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MJ,JRRAMMIOJ_JR4-H1A*4(3L.#2A"4X^APE.,)QC&,=L8[8QCY/+%O?<FO\
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MJ* V)3WK2[&DV>-Z<9T&L)G*S*UR<S=((:ION#*DTS)H]92,E_!S;S$F-AX
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'1.$3A%__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g713200g37e21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g37e21.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1_84&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/T
M   2 #4    ! "T    &       !.$))30/W       <  #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             "B
M L@          0                         !              +(   "
MB                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
MB     !29VAT;&]N9P   L@    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   H@     4F=H=&QO;F<
M  +(     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MM%EA.YSW!H;ZKW_G>HP-?_Y@DIF[.>.KBCW>AL-9U9M]7V6M_1_TC^;?]/\
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MTG?S;4-Y:<^JP6,VULLI>W<-WJ6&BRIFW^I6])31_P">/U3_ /+C"_[?K_\
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M22^54DE/U4DOE5))3]5)+Y5224__V0 X0DE-!"$      %4    ! 0    \
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @
M %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !1DU-
M "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %     0   '8!
M*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    "0
M +"':0 $     0   +P   #H "W&P   )Q  +<;    G$$%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#<Z,C$@,C Z,#4Z,S@ <G(U,#DQ
M-C<       .@ 0 #     ?__  "@ @ $     0   LB@ P $     0   H@
M        !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H
M  ,    !  (   (!  0    !   !1@("  0    !              !(
M 0   $@    !.$))30/]       (          #_X0%(34T *@    @ " $2
M  ,    !      $:  4    !    ;@$;  4    !    =@$H  ,    !  (
M  $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I  0    !
M    O    .@   /      0   \     !061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD ,C Q.3HP-SHR,2 R,#HP-3HS. !R<C4P.3$V-P       Z !
M  ,    !__\  * "  0    !   "R* #  0    !   "B          & 0,
M P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P    $  @
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M 0$! 0$! 0'_P  1" #/ .0# 1$  A$! Q$!_\0 '@ !  (" P$! 0
M      @)!@<#! 4* @'_Q ! $  !! ("  4# 0,* P@#   $ @,%!@$'  @)
M$1(3%!46(2(7(S(8)#$V-SAW>+:X,W:U&24U.5%A=;=!M,'_Q  4 0$
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M&%S,UH':\*$U,R141&IS+4N8CGB"CPHF<):2(,2\6VVU&$9*>8;$4L5#ZBV
MR.O/.5SL;:(4H1(.-H:AJEX'8#6L@$BTZUG3J=L YPI3 JGRL0-RT_%L$.C#
MNE 1+/FRU@?VT!M785B@JC1+A9K-*@P=?@ZW,R,O+R3Z!@@ A@'UO/OO+SC"
M4IQCR2G'FXZXI#32%N+0A05W^$#LUF[=%M'5.1<9#MFL:<U3)"!7 W"LGL5J
MMV"R4VHS^8V[0L'(FQ\^/49!#4S$L&U[,O%SE?'DG)>NS8806@<!P' <!P'
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M]$,59K3NN2Z4;*R=:GJM&VZ.EYU]HB=G%71O-M/GIUYA@494W.R4T9+R^!!
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MA4GX>^-?)[_^*1C6.OB=8U+Z=T;^)4BM82FH'A"OV4;&^:5FD2\!6C0L'/\
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M5&QLGC*OEWM=TGS4B$^IE +\\^Q&XQ\45@9I&&L!<UP' <!P' <!P' <!P'
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M%27DD%X8QI@AH,GV3X+'2PJJ.-:ZU_MP&TYL%*<003W,[D^UB!8NE??N3/\
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M2!$=S.Y/R!)9A-C^\G7_ &=^H-])2G:]['S"2&OW#GQ&V,>_[H2'ZG]9=/\
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,@. X#@. X#@.!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g713200g43c34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g43c34.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $- CL# 1$
M A$! Q$!_\0 '@ !  (" P$! 0            D*!P@$!08# 0+_Q !.$
M!@$" 00+#P(% P('     P0%!@<" 0@)%#AWMA$2$Q47&3=7EK75%A@T-E98
M675VEYBST];8=+<A(B.TU%6'UR1!)3(S46&AL?_$ !T! 0$! 0$! 0$! 0
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MQ6'/+^RIY1,I&Y(UKZR)W$K%RR08Z8(4:,DH<:1+&;-EFU?#=-)C7$24@?(
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MR*MY*:-D#BHB(SC6U5787%]Z7[?N)E /D
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M1Z9$Z]@C4_0\S_2+S ?>B\/]4,U@<
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MJK0F.*(J:-,A1IG9S+3:*S!\F;@
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M>^XE'OAN)E]&S5'X_8]_' !8SWW$H]\-Q,OHV:H_'['OXX +&>^XE/-%6GQ
M2&L]D(X5M!DLJE<<YJ6@K?!"BVM0Y*#>[GN!Z##;-HD-7'G:ZG'*S"LCS#=>
MZ9F99_X@+&>^XE/Y4VAO_6M^C2LX5= JVO0I*1HVJ=[T)/;]"4*W-R1$Z(S=
MLV:?N2-Q-,7I2^Y]HG6F9JBM,#\\L]0L9[[B4]#E?W$JSS),SX:-19F)]#,4
MYF6_B-Y9D8FX:8&XDY:[;]<BM#,--,#-,-<=,\--,<NSIIV %C/?<2GXFOWB
M4HDY*1'PT:A2)$Q6!"=,FW\1LA.G)+QTP+)))*VWX%E%%XZ:8X%EXXX8XZ::
M8Z::: +&>^XE/O[X;B9?1LU1^/V/?QP 6,]]Q*/?#<3+Z-FJ/Q^Q[^. "QGO
MN)1[X;B9?1LU1^/V/?QP 6,]]Q*/?#<3+Z-FJ/Q^Q[^. "QGON)1[X;B9?1L
MU1^/V/?QP 6,]]Q*/?#<3+Z-FJ/Q^Q[^. "QGON)3(%673OPDT_C;%:VQBNZ
MLKYP5*"I+/V?>.S6.Y1M*6@5GIE22$IJ/BY[_FH<"DB#),6_-VI!:O-;J:9B
MFU(-!438:MW+%-YP/D
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M(,FA,Z.:9.]9N=661$YHW1]F5+YLJ;%#VGPBNCI#YBWL 6>_$;?
M
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MHTU9WEGCU,0#1JD4>,:)*Q.;:O>(Z\,[B]O"A:%JWMS_ -Z? ;>@<
M
M          QS<-9LEU5':=.290M21NVJYF]9R!4VYEEN*9DGD9<XL[*&\P[
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MU645RVJHRK;32HBK?L0F8$)*\
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M#$B*4   %8KC!<ZMEZ'HCUBF@UM4?@:_RY&YK &;JVL)W&2(7.8TBL%B)@
M   6%>"MY/[T^V,2]2.8S+7WKE1W>,;G#DOE3NM\ZWY"\R\)LQ 2R
M
M                          !76XTGE:IOHZ=NLJ@:@J&UEGN5'.:,&?ZX
M==91D][G+1# +P1\     G&X*/QGW!?4-=^L)<,^5^=QT:WS,^:@BTU-]TS[
MR$OYR*+ 0S47<   *Q7&"YU;+T/1'K%-!K:H_ U_ER-S6 ,W5M83N,D0N<QI
M%8+$3      L*\%;R?WI]L8EZD<QF6OO7*CN\8W.')?*G=;YUOR%YEX39B E
MD
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MRH[O&-SAR7RIW6^=;\A>9>$V8@)9
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M7*CN\8W.')?*G=;YUOR%YEX39B ED
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MHEA0@   KK<:3RM4WT=.W650-05#:RSW*CG-&#/]<.NLHR>]SEHA@%X(^
M  3C<%'XS[@OJ&N_6$N&?*_.XZ-;YF?-01::F^Z9]Y"7\Y%%@(9J+N   %8K
MC!<ZMEZ'HCUBF@UM4?@:_P N1N:P!FZMK"=QDB%SF-(K!8B8     %A7@K>3
M^]/MC$O4CF,RU]ZY4=WC&YPY+Y4[K?.M^0O,O";,0$L@
M
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MJ.[QC<X<E\J=UOG6_(7F7A-F("60
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MZWY"\R\)LQ 2R
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M$P     +"O!6\G]Z?;&)>I',9EK[URH[O&-SAR7RIW6^=;\A>9>$V8@)9
M
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M5X*WD_O3[8Q+U(YC,M?>N5'=XQN<.2^5.ZWSK?D+S+PFS$!+(
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MR
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M9TS*O5!A#,,C/L^@2RB,IFB0   KK<:3RM4WT=.W650-05#:RSW*CG-&#/\
M7#KK*,GO<Y:(8!>"/@    $XW!1^,^X+ZAKOUA+AGROSN.C6^9GS4$6FIONF
M?>0E_.118"&:B[@  !6*XP7.K9>AZ(]8IH-;5'X&O\N1N:P!FZMK"=QDB%SF
M-(K!8B8     %A7@K>3^]/MC$O4CF,RU]ZY4=WC&YPY+Y4[K?.M^0O,O";,0
M$L@
M      0X<9_R(51TJY]47\7.H?"&<Y&_70Q(ZX-997E3])$%<8:E,]@    $
MEG";YX#']A9SZN($HKGP(B,HR_G6BC5686.=XQO(9+3@Q\::   ""3C:? ]M
MG]3;GY5:#1-0/SE*O$DO*FI$:Y>TH[XTU]4N($AH\AH    !+OP9^<=8G0D\
M]>Z_$3KVP5EGV@A_9TS*O5!A#,,C/L^@2RB,IFB0   KK<:3RM4WT=.W650-
M05#:RSW*CG-&#/\ 7#KK*,GO<Y:(8!>"/@    $XW!1^,^X+ZAKOUA+AGROS
MN.C6^9GS4$6FIONF?>0E_.118"&:B[@  !6*XP7.K9>AZ(]8IH-;5'X&O\N1
MN:P!FZMK"=QDB%SF-(K!8B8     %A7@K>3^]/MC$O4CF,RU]ZY4=WC&YPY+
MY4[K?.M^0O,O";,0$L@
M                      0X<9_R(51TJY]47\7.H?"&<Y&_70Q(ZX-997E3
M])$%<8:E,]@    $EG";YX#']A9SZN($HKGP(B,HR_G6BC5686.=XQO(9+3@
MQ\::   ""3C:? ]MG]3;GY5:#1-0/SE*O$DO*FI$:Y>TH[XTU]4N($AH\AH
M   !+OP9^<=8G0D\]>Z_$3KVP5EGV@A_9TS*O5!A#,,C/L^@2RB,IFB0   K
MK<:3RM4WT=.W650-05#:RSW*CG-&#/\ 7#KK*,GO<Y:(8!>"/@    $XW!1^
M,^X+ZAKOUA+AGROSN.C6^9GS4$6FIONF?>0E_.118"&:B[@  !6*XP7.K9>A
MZ(]8IH-;5'X&O\N1N:P!FZMK"=QDB%SF-(K!8B8     %A7@K>3^]/MC$O4C
MF,RU]ZY4=WC&YPY+Y4[K?.M^0O,O";,0$L@
M                          '"*<F\]:K;"5Z(YR0%)CES>4J(,6HR5FAF
MJ0U6DPSU/3E*M"3=4QAQ>&!^A1G<M<NTR[ 'Q[]LW*'-)WW;.5,A)2EY3<O2
M\H:$YY.:@A0YD]U[H@).3EF'E&JL2BS"2\S<,M<,<LM .2B6HG)(F7MRM*O0
M+"<%"1:B4%*DBI.;CID4>F4D9F$GDF8ZZ98&E9Y89XZZ:XY:Z:@#E      "
M'#C/^1"J.E7/JB_BYU#X0SG(WZZ&)'7!K+*\J?I(@KC#4IGL     DLX3?/
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M(7F7A-F("60
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M$?     )QN"C\9]P7U#7?K"7#/E?G<=&M\S/FH(M-3?=,^\A+^<BBP$,U%W
M  "L5Q@N=6R]#T1ZQ30:VJ/P-?Y<C<U@#-U;6$[C)$+G,:16"Q$P     +"O
M!6\G]Z?;&)>I',9EK[URH[O&-SAR7RIW6^=;\A>9>$V8@)9
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MB8     %A7@K>3^]/MC$O4CF,RU]ZY4=WC&YPY+Y4[K?.M^0O,O";,0$L@
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M?     )QN"C\9]P7U#7?K"7#/E?G<=&M\S/FH(M-3?=,^\A+^<BBP$,U%W
M "L5Q@N=6R]#T1ZQ30:VJ/P-?Y<C<U@#-U;6$[C)$+G,:16"Q$P     +"O!
M6\G]Z?;&)>I',9EK[URH[O&-SAR7RIW6^=;\A>9>$V8@)9
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M+U(YC,M?>N5'=XQN<.2^5.ZWSK?D+S+PFS$!+(
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MC30   02<;3X'ML_J;<_*K0:)J!^<I5XDEY4U(C7+VE'?&FOJEQ D-'D-
M  )=^#/SCK$Z$GGKW7XB=>V"LL^T$/[.F95ZH,(9AD9]GT"641E,T2   %=;
MC2>5JF^CIVZRJ!J"H;66>Y4<YHP9_KAUUE&3WN<M$, O!'P    "<;@H_&?<
M%]0UWZPEPSY7YW'1K?,SYJ"+34WW3/O(2_G(HL!#-1=P   K%<8+G5LO0]$>
ML4T&MJC\#7^7(W-8 S=6UA.XR1"YS&D5@L1,     "PKP5O)_>GVQB7J1S&9
M:^]<J.[QC<X<E\J=UOG6_(7F7A-F("60
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M(HPLW'',PK+4O/'/3$PK/4LTO+7'7733,O/'+ S#7_-AGIKCEIIKIKH /H
M    -#>)MS'[M_[;?W=@(HU4O^X,@_%?8DR/#UD8%SG\.]JP)4I&TC*X
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M(F     !85X*WD_O3[8Q+U(YC,M?>N5'=XQN<.2^5.ZWSK?D+S+PFS$!+(
M                   !%+9U4RMPW?+))A6,C=[#7WSMLFM37<EB"E>RP+;I
M!X44W77!3K-P2YH8?BZ+B;<;%=>J71 Y3)7<S*O:VA[1YOBY@'UL;B(OA5;?
M\?<F,PK?=4W%9MAVG)ZHK*=L.X>QIU&[$VZW>]PERCQM640?L?2PA= )%8Z]
M(457RY->>MCI'2G'%T2/^,JLYOFF,=4H"WJ0L(8L2:J(NJMO1LZEZPV<X=%<
MN]:LUFM), =H;!UI53JVM9)J>;J'DKC/TT#+:K-838$S-; W.\<A*AOC;)&;
M+/:7)ZF96:]N<;!LY)%6J9N(-<=_46U/NX[UO!:24 ?(    !H;Q-N8_=O\
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M3-$@  !76XTGE:IOHZ=NLJ@:@J&UEGN5'.:,&?ZX==91D][G+1# +P1\
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M.X[6,)DU@RY0>DC,1:53V]J4J4Y<H(;T>.F1YA*1/CF>HSQTU_P**QUSR_\
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M     )QN"C\9]P7U#7?K"7#/E?G<=&M\S/FH(M-3?=,^\A+^<BBP$,U%W
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M:E,]@    $EG";YX#']A9SZN($HKGP(B,HR_G6BC5686.=XQO(9+3@Q\::
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M:0    #=WAQ<]2C/K66?V^EHG]:> 5(?(P7M."/:5>8927RD7[/BRW6,3FK
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MD/GU9O0]=[6'L=/B?[2R?SHWK!YC2?DVV<SX87JP\2K(?/JS>AZ[VL&GQ/\
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M1#B[+6PMBN+12Z5ZD([Z3I4J2H5IF0*EEMZ^EO\ ])_E?NO+L;DLP'R
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MHK=LSOC-0<=,<LIBI(;#)'&41B5$F:N^+1WP>4J;(<L2S_U,>+5]\1)T!P
M    #4?=]<-ITC ])Q7FM8%I6UKD1YB&>(I9(Y)8M@8XM":K**K&'Q!S8W-?
M,KA>5CHSH)*2MD*F+*VQ!BFK:<=^SM6(=2RV_P"^[]WNI@UKW97[))&3@PPN
MJ4C/8TSW+4_5C!)G"1-[S#K(VT/;K&I!(;/EK>X.;/(82_.$(LQS*;8Q&8XO
M9T#)$D6,B>S)@K<8N%B??>78U%Q:OOL7CRZO=)NC?ZUA4HK1QV_/[U/;\643
M4[FNK&RM(EN-3F&:O!%O5^23<:=P@];1V#L%HR]\6JW&S291$JN=9Q7;M(6.
M211*Z#J(FS;J6KN>&]X$V+ZV:I[?;INAMFY[CE<?>'!K:H='+LW,UGA&&_9U
MNC)3'LU(VK9U7L#ACN[<909MR5.[OI"FN1O*1$RF=JO5N=>I$J63IM5"4<5+
M$X-E-F_J:I(V!P      #3O=#=%NTZOA2V"(ZR=&Q]>(Y&V>"OY,F>;1NN=2
M"3)$9E=5HA8G1H1P[)BAA+Y-WZQ'M%/&5C:&]<Z22-QZ)1V02U,.I[^_^-C5
MU#!L?W<WE*UR4MN04?'VBU(/?%H5<_3(V3LS34U<[<=PE7U#8,CN5>9(\4TW
M6JH!:;=:[6T1[.KD"!W8'>M7B2%(3T]FDCMFXMZQ%\*VV)N:G];-@Q9AQ#KB
M3O-.(7*"Q7%LDRR!*Y*]I('9F;-+:\LS=K)=O$*MCOWWX-:]K4/E581W'<+7
MYEZFR5-:1*Y?4\+>%,BBSM(C7O\ =;JG+$O^]_%NXKVXNH9NV9[H;9W%.V+E
M+G!K0L2E).56,5;MG6Z.O6]#I'9DIC#=BW;F[!E"ZD+ -T*)+4')8@V9*G[0
MU6L92R$#.Y9E@MFQZT7B0D; X      !IM?=W6U5EJU<QQY'6CS%9U*ZZBS;
M7YB>3O-T3Y*\R_)#=DV8,VMS0,D#A>W>ME""SGMX>F":HYIVJN%&+( ]+XHL
MDHZB6HNY:MNQN)X56\:[0;>5>,PA2*1OBK;Q63=*]OU%[M2K%F)$NRAM-4O<
M2.R%CG'ILQ>[1K46;-86JAT48TS\T3.J627G3ER=B&)@Q@V#/,QVQ$QZJIX5
M2S@U=T\BDXB%L-#_ %RFL^OHC6:V3^ "/J:>?V2>$6O+5=Z,A>F=MQ%8N4MR
M.-UI YNYL\.D\4E,47R1L=$[ZSRF3P^4:1AADX68K^SX$Z?=+3/6P_<E:NY6
M%QF>6"YMVB>551!)]I'&[9SNBV_(F)UF;4V/.:)IM6\).\0FV6MNP5*4!2J!
M(\='(K%)(R5)30J(*4 J(G#C1>)+Y(,!\@      1];E=U%H[>)]DI.9*ZEL
M"3,,VEFM8L&,D7W6X5C7%02&PIW=SE(BW$J*P*'QR9MC76)# ]0YX3R%T>60
MQ%8*.2R9D@^8ZB6^'B\'OP67SQ3SN:W4LD2ME&='JD=K!I^(UW;<B7PRN;HL
M%*[0.SX/,7.-P>&U%#'IWG$HGI5CPMQA#G)L9:V,:.'JDEIGQ4G'!="$@6(O
MWWKZ^#5783WW3&DRXC%F-5?2>[XY%*M<JR[E8T,A;(0XNTB>5<_A&PN3[UDL
MX4SUE?2(S(JV=5L1>*Q2L,?C:9P<&S-HLM#/.1.9L6;AU$MQ\&ZB?UX;QN;M
M3MFQK9;I.YSQ_*>"T2:+FMA&FSG<WM-,0FNI#JH7:8F;C9&]^$5.9B0DP+50
MLE*G8,B,LGDU1W^:<"!Q?>^B^HVX X      !C^UJNA5V5Q,ZELAN<'B!6$P
M+HM+V=KDLHB"QWC[H7W!S:])%#'F/R9O3.*;7-&N[UO"$Q6A.4H5&9B-4H(-
M!+U_$8*7[(-O#NP,D8>VBS)&T,*23LR;&5;A-PDN<7"(37"*82^MI$^RFT7A
M]E-3272#Q75ZJ>1N3I7*_5IQU.C&7+7+E@[:ONB='&?-!L:VZ-A]E'(FBTBR
MK;E#W.IPV';D-R*V/JYV_2UJG1\Z8XPNME3'(9-FJ5L3&[1*6PMJC\@A&3.U
MHX:XL3<@2I"@M7W1/=3X9[%-N?*VAU1-UNQ^0M"26(\I;#-S>YF!3*083F2D
M2^5'3>70>WH[(Y^L=9$E2K]%LU<GY4W%I$C<TFH&I(F0E!;X.!.@VR:VY.SM
MC<TI#%QR5K0I&Y,:Z.CF^.9J=$G+3$F.+T]*W!Y>%V996.2MT=EZUS<%&IBM
M>K4JCC3LQPYP      Q7=-+5UN$KE[J:UVIW>X'(U#&J>FICF<V@2Y:9''YM
MDS3A[I*]D46E"=,4\M#>H5HDKR0C=$Y)C:ZD+6Q2J1G@8Q-V<4.K5Q)>Z-=B
M2!;#LVCDJV67M>LQ7R1+')MI8\6:K)<)79#TOM=CB$X[I(8>Q66IE;1%%*IQ
M21]$W-CJZ(5@[:ONB<6+[C^:QV8[>*D1.S3%(I*G2/O;F[OBZ*69;]S75"\)
M!('YPD[[)&V%W)8$\BC))GA^=G5R<Y(RLZ!\7'NCEBI7F%+E19H72_X1$]5A
MYY)L+VSL^D5PB+!9];%0RIJ^HYB3U#N1W*4XEUK"JUTQ<X!'7M+5EN1!-*E,
M=<; FJXF22DIYE2U5)74]T>UQBC7+0+I>-5U$U5LMV-Q#<3'33'33'3L]C'3
M333MLM<M>QIIV/\ '++77++7_P"^66NNNNO^.NNNH'#]      &'KNH:L]Q,
M2;81:S=)72.M$NC4\;B(M8MCUBY)I7#ENKI%W;20U?+(;(C=6-WT(>4",YU,
M;R7I U//)-7-H;%:0=1;/\(OK/!&;/:)/?8])5K38#H]1M#'D2=<]WA>#\<]
MG0Y9(G&$ODVS>K%7YV#+8,XRIZ<(5,IQE()5%%^30N8GA"KC$6.90M][$W.@
M\K$=A>W"!0AEKN'H+C98K%G-E>(4ETW1;H'-PK]Q86:5QU*HKE]>[A<WRO>7
ML$XE3+)"88XLB>7-CP:DE13R4G18I@NE]T3H.S9]D&W>,/:)^AK3:4 4H6N"
ML^+96^Y#<C7$47-];LB"-P\I\A$&MJ/PV1FMS$V(FQ:K?V%R6/Z8K+&1'NV1
MY^1H6K[HEO#JFVH'       ,'77MTJO<)A!<;.1312;6DK,G$'6PFV[;J1T8
M);FR.D;T?2'>I)Q!W14N(9'MX;D>;@K5X(27-=DCP(-4G&9 BV>]IX-ZV4;=
MY&N=G%[CDX<5;['EK [FGW9=^ABY4Y5%E0:^>''%V)@HTN1931AE=J+RP.PN
M(R.FFDY3C50:8IR';5]T3P\&YJ;AU:?8EMQ20MB@"=JM?&.19.X-L8U/W*;D
MU[_&HV[QQ'$GF#QR7N5M+):PUV\1YN;4+G7;0]HH2K.:VAVS8N_3.U.*,+5U
M?Z(>ECFS^C8=.%5@0U':,.=ETD:9:MCT1W#[AHO5ZQ\9&%@C#><KI=BM-OI]
M2AQC\68&E6RG0;-D<D;826Y-ROMSM30M][$MX=4V< X      !@&Y-LE1WS(
MJ]EMB)K"QDU5>ZG* O=?W;=M-N,?-FB)O;)(IP44]8<$R<5B]L;26LM:[\O5
MMS8J=V]K.1(WY\(<1U%5/OW$7UG@I=L5VRSO&?$RN&RMT0V8QRB/2MJPN*Z&
MUIS0SS6/ZV"I8&UHL% DA[Y8>D7:<9_(XB4QO\TQ,?L9&Y.6DOE_?X+5]7%J
M&2HAMTJR%>X3-M23A[4UD]2&0P1QL*WK?M9WCCI*8P;#7@Q&\V?.I>ZFI,XP
MH6-#<UK%BEK8T[@YYL:-N4.;@<I"W5W=Q#HX7M4J"NYNMGT-SMQD='&:3VPE
ML>*W';BE=7GR^SG^12N=.N5+N%J*Z@QP?Y1*Y!(S6W"#8M*)]<<G9L0(EZ=(
M>0%J^Z)Z]4V- X      !KS8^URH+5LZ*W'+"+)36-"HRLAL;D,&O>]JLP0Q
MAR>T4B=F<YDJ^R8?'G1*].[8TJ'W5V:EQSX2SLJ!W-6M[.V)4@[:J7KW B^M
M#'\KV#[7)LAF;9)(3+%;9.EZAP=6]%<]VL*5GS<+,;KE>T4$+CUB-6M:LTGM
M)G9YM+V*OLHRRR]X9V;W2H'1$SM:1(%J\&XG@XMC%L'?'[,*"6K6!Q=&JQG]
M:PI8VWGJI3?5\RY5,6J%SIXLN%,UHJY193PJMQDADWD+Z]1)FLX^6-D<P>G9
MG:$J1A<EK6>%J[G G1>.[JG:I4%)O!+Q7&=N-):;)\R1Q=WW';BYG7*#W1K5
M3BZ8MM63:U9%6K=ADN6JE* M#%$^#,8=EWFQ0::8Z8A;;BX$3U(;&@<
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MZTB1.V:G\DQ9$=S65/DD<S["C/!4='R6PYP*P3%+S%):-)@0.6V_X1/49C
%  !__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>g713200g49s71.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g49s71.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X=R*:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^9S0Y<S<Q/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@
M3F%M93H@(" @(" @(" @(" @(" Q,C9B+F%I)B-X03M5<V5R;F%M93H@(" @
M(" @(" @(" @(')R,3DV-C Q)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @
M(" R,2U*=6PM,C Q.2 Q.#HP-CHU-28C>$$[15-4(%1I;64Z(" @(" @(" @
M(" @(" R,2U*=6PM,C Q.2 P.#HS-CHU-28C>$$[4V-R:7!T(%9E<G-I;VXZ
M(" @(" @(" @,BXU)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP
M+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @0F%R($-H87)T)B-X03LF
M(WA!.^* HB X,"!#35E+(&)L86-K(&-H87)A8W1E<G,@8VAA;F=E9"!T;R!G
M<F%Y<V-A;&4N)B-X03LF(WA!.^* HB Q.#4@8FQA8VL@=&5X="!C:&%R86-T
M97)S(&-H86YG960@=&\@;W9E<G!R:6YT+B8C>$$[)B-X03M4:&4@9F]L;&]W
M:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R8C
M>$$[5&EM97,M4F]M86XF(WA!.U1I;65S+4)O;&0F(WA!.R8C>$$[+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X
M03M&:6QE($YA;64Z(" @(" @(" @(" @(" @9S0Y<S<Q+F%I)B-X03M5<V5R
M;F%M93H@(" @(" @(" @(" @(')R,S(S.38R)B-X03M,;V-A;"!4:6UE.B @
M(" @(" @(" @(" R,BU*=6PM,C Q.2 Q-3HP-3HU,B8C>$$[15-4(%1I;64Z
M(" @(" @(" @(" @(" R,BU*=6PM,C Q.2 P-3HS-3HU,B8C>$$[4V-R:7!T
M(%9E<G-I;VXZ(" @(" @(" @,BXU)B-X03M);&QU<W1R871O<B!697)S:6]N
M.B @(" Q-BXP+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @0F%R($-H
M87)T)B-X03LF(WA!.RHJ*E1H92!P<F5F;&EG:'0@8VAE8VL@:7,@8V]M<&QE
M=&4N(%!L96%S92!E;G-U<F4@;6%N=6%L(&-H96-K<R!A<F4@8V]M<&QE=&5D
M('!E<B!P<F]C97-S+BHJ*B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S
M(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R8C>$$[5&EM97,M
M4F]M86XF(WA!.U1I;65S+4)O;&0F(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03L\+W)D9CIL
M:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.F1E<V-R
M:7!T:6]N/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X
M;6QN<SIX;7!'26UG/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I
M;6<O(CX*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C Q.2TP-RTR,E0Q
M-3HP-3HU-2LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'AM
M<#I-;V1I9GE$871E/C(P,3DM,#<M,C)4,34Z,#4Z-34K,#4Z,S \+WAM<#I-
M;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C Q.2TP-RTR
M,E0Q-3HP-3HU-2LP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX
M;7 Z0W)E871O<E1O;VP^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S
M*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^
M"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z=VED=&@^,C4V/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @
M(" @(" @(" \>&UP1TEM9SIH96EG:'0^,3 X/"]X;7!'26UG.FAE:6=H=#X*
M(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=)
M;6<Z9F]R;6%T/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO
M.6HO-$%!45-K6DI29T%"06=%05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$
M375-04$T46ML3D$K,$%!04%!04)!05-!04%!045!)B-X03M!44))04%!04%1
M04(O*S1!1&M&:V(R2FQ!1U1!04%!04%F+V)!25%!0F=114)!545"9U5&0F=K
M1T)164I#=V='0F=G3$1!;TM#=V]+)B-X03M$0D%-1$%W341!=U%$031014$X
M3T1"351&0E%417AW8D=X<V-(>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%9
M1VA54D92;V9(>#AF)B-X03M(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&8O.$%!15%G06)!14%!
M=T52)B-X03M!04E205%-4D%F+T5!84E!04%!2$%114)!445!04%!04%!04%!
M05%&07=)1T%104A#06M+0W=%04%G241!445"05%%04%!04%!04%!)B-X03M!
M44%#07=11D)G8TE#46],14%!0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!
M049)4DEX459%1T4R16EC645537!':$)X5WA1:5!")B-X03M5=$AH37A::3A#
M4GEG=D5L47I25&MQ2WE9,U!#3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG
M6FA*4D92<5,P5G1.5DM"<GDT+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:
M,FAP86UT<V)7-799,U(Q9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO
M*T-K-5-6;'!E66U:)B-X03MQ8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]2
M04%)0T%1241"455%0E%914-!341B445!06A%1$)#15--545&55).:$EG6GAG
M6D5Y)B-X03MO8DAW1DU(4C133D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-"
M,U!33F5*16=X9%5K=V=*0VAG6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP
M*U!Z:$I3:W1-5%4U4%)L9%E75G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q
M9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:
M;7!U8VY:-F9K<4]K<&%A;G%+;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X
M03E/,T]R,G1T35EP23=L;49+;4LQ)B-X03MU2E8S1F1N:FI:5#DK2W%8-F9S
M9CDY6&XO4T9E9CE5<U9D*VXW2"]F5C4O,&A8;B]!1E-X5C,V9G-F.$%F5C4O
M,&A8;B]63$98;69N)B-X03MN5"]Z4'903DUU=&544$U-=6Q7>'19<E9D4'4W
M4%5*;T=91U(U6G9393)M:6IE;VE11E5*2VQJ555O>7%&=#E0+T]!86QP.&1Z
M-6=E)B-X03MB4F].5%<Y=6TY0RM3-FMT:W905CE"=E0P.4$O2T5L6%5-:69:
M5E9655!Q1EAQ,S9F<V8Y.5AN+T%%:%AN+U9,07)V,"]9+S<V=E K)B-X03MK
M2S@O-G!9<3<Y4#)0*RMR>B]P0W90.$%Q;&ER=C O62]W0RMR>B]P0W90*W%7
M2W4O5#EJ+W9Q."]W0VM+."\V<%EQ-SE0,E K*W)Z)B-X03LO<$-V4"MQ5TMU
M+U0Y:B]V<3@O-E%R>B]!2W!9<6=.9C%2-WI1.5)T3DUK=DQ,56)I,FUI<S=Z
M-FIE2#!P;E%R2$HO9&9S<U%C5F5B)B-X03LV<G O-6DK<&-F5CE397HP4FQ8
M:%IY6$=U1UI#;VU013,U=%)-3V,Q,7E,9%%S8V%B:F]66D8U06HX,&%0<3-M
M2V9Z1F4S3V]75V]8)B-X03M2;C!M3EDY56XY0TUY>E!W-%0R-$58=U-2<GA2
M>79W.4]P64MZ6#E0,E X079Q."\V47)Z+W%L:7)V,"]9+S<V=E X07!#=E K
M<5=+)B-X03MU+U0Y:B]V<3@O-E%R>B]Q;&EQ2G,W*T,W1$=*6FPT57(V,$US
M2%AW.595<CE'2V]J1EA9<3=&6%EQ-T9867$W1EA9<6PO;417671%)B-X03LP
M5S@Q85<S;75O<DM->E-W5WEQ,'I)=C)U0W5Y2V%$9G)I<G)05S=3-S%3-S R
M2E@Y83!H=#=H<$1X36)X,UAQ0TUO>7,Q9#17<E5$)B-X03M&574X-7).2F)A
M9DA"<4U7;7I*9E<Y=S!S=# Y<GEH9V-02VQ%2#<U6$AW3D=3;TE.86EG>559
M4VQY1G-:4T$U;%$X<%-85&%R<D5L)B-X03MZ93(P>3-C:V,Q<&)7*V]Y6#1J
M4E9P265%:V-8;VIM,U)0:'!464=P67EX>4A-14M*9SAI;FQZ9C-537AJ:C R
M-75&1DM3>$YB:%15)B-X03MD=E5M:F(X36=Y578P<F9F.5=A."]W0T1S+SA!
M<V]X5C,V5G9V*W).968X04(R9B]!1U59<6Q(;7)53%<U,%,T,"]6-T\T<V)4
M55(Y)B-X03M413!K=6UQ4SAU>7%N,6E:-#)C+W-G<69L:7)"8F9Y<C5+94(W
M4WEV.5)4.4PX;%@V=F9A3C9K>'57:6Y(06AY6'%,6#12=4]*8EDY)B-X03MI
M<3-53D4O3'DO=EHY46$O=6ML;45V1C!V.4=B,"]6:&$S6F<X:VMJ=31&=34U
M>4UZ8VQ9:VYJ<W%Y>GE(9F%$6C9B8S)0;'A*.59G)B-X03M7-6UU8F@T-W)4
M8FAK:W5:1V1G>&AN055C=S-%161Q9'-66E K;&(W+W%Z6&XO0C)F+UI29U8S
M-E9V=BMR3F5F.$A:+SEL1TMU+U-T)B-X03LY+S%:<GHO9S=0.$$W2TU69"ML
M8C<O<7I8;B]",F8X03)567$W.4LS,R]6;790.$%G-U O04Q+359D*VQB-R]Q
M>EAN+T%!9&XO=T)L)B-X03M'2W%&.7%-.&QL8U(S1VLS8V-$>$]S<VAE>&]Q
M1E-'63@U>75W+VU&359E8U%A1"M8,71A2EE"<G-7149X<&=E3C=V4VQI931T
M;S$K)B-X03MP4FU8,48O979'9V)I:FAY0T0P2S166D8K5TYH;VYL-WET2%IE
M5F]B+U9D1F5A5V$R=5=U-T,V449M*TY)<$EP=VY&6$(R2&5T9#A#)B-X03MS
M<R]3=#DO,5IR>B]!24]Z+W=#>6I&6&9P5RLO-G,Q-2]W04A:+SA!6E)I<G8P
M<F9F.5=A."\T3WHO-TM-5E).;F14>FAJ3%IZ5VY')B-X03ML0DU9:GER-&5L
M2DPP.3A64D=+=7A6,DMU>%8R2W5X5E)V9E<K<'HK:'HY8C S.4PP=VAF;'A0
M2&=*0TDK5F5N23 X8U995C5B;B]-)B-X03MU5%AD3%A6235).4Q7>6(Y2TQD
M0S!%;C%J;$E63F)54$<W2&Q';TM32TM)>&%-8VMX5DXO4#)T-F1P3VAR2G%/
M;E(V<&%81391=F%3)B-X03LX4VA)1%-Q>$1Q-FYI,%%),C8U:V%B5"M,2W)R
M6G!Z-79$1C!K4&LW>C-O,G K651A,F5H>#)&,69Q5&,S8UI4;2]P0C5&.5%Q
M:6PO)B-X03MI9'E+;G%X.&-Y32MG3T](1F1T3TA6:6-U1VMV+U!$+T%+578O
M4C$O>DIY+W-R*TPT9G!A93!F-&9J*VA++WE9+W=#56]U=BM91U0O)B-X03M!
M2E!26F(R;B]D:BMT*V=T5V<K<RLW.50P>E@Y675T2E%836IW<%IV3$9"1WI2
M,T5R*W!-=VI11EE68S!,=%-T2T1V;6ID=7AI,B].)B-X03MB5')O5$<P=6]*
M>$%T=S!N*VHS8U)"<RM(<D%#6EEY94AR3%4O6CA4,'=Q:4Y5+TUV5'1/83!7
M5%5R0V1R*T\U;'-487)08TI-3$U%)B-X03LS05=A34Y&>6HT;FM'8V1-5E-X
M=D](;#-Z8F](<6%V9#)&;G!Q,T)*9S%#-6MS=E5E,C1Y5EE,2V]K:EAM<D97
M2EAP55EQ:DQ0>4)O)B-X03M.-F)E+W1R6%0W.4QD:DA$3#EA=3=M3&Y!,#!4
M:&<P<F\W8W!P;&LU5DQ%;FQ5-'%U:R]+>E-:02]R861B5$=2;F52<&)Q+VM:
M;FM9)B-X03MU-W-Z>6ML;4QB=#%.1B]L5VEQ62M79DIF*T=28VI23%<Q=%)E
M37)806%A.&U$1D-X5VYR4$IX<'I0,F%F9TU#<#,O>G-N+TQN+WE6)B-X03MX
M5C,O041S;B],;B]!36QC5F0O>G-N+TQN+WE6>%8S+T%$<VXO3&XO04UL8U9D
M+WIS;B],;B]Y5GA6,R]!1'-N+TQN+T%-;&-65WEX)B-X03ME65I9;FEF-G!W
M:U5Q,41-<&]243!);U(Y1TMP1EDK4DEB1S(K<3(Y;F%F5G%W<S!5:SDU2W)M
M,T-#2#%"23<X*TAP3%1L6#EE1E9F)B-X03MY=#514&Q85&XP-U%,2WAS8DM3
M5G S:%9R:'=:2&]'3EI'8SEH=%=G=TMN2"]/>68X=68O04-6>%8S+T]Y9CA!
M3&XO>59X5C,O3WEF)B-X03LX=68O04-6>%9&5V8V4F\S,3,P83=C4%(U9E18
M;&EQ27A6,DMU>%9)<FIZ=C5:=#1*<#=I-F5'3T,Y:C!Y5&Y"3W)F5W!G:&E2
M5DUF)B-X03M*=S1L57$V9W%A.6-65&4X=DQA>G1:8G$U9C W9493.'-H0DY&
M2%4W5D]3:D5Y3D1M:55G0EIE5S902#5$9W5,0C=Z5F1/=4AS3E-M)B-X03LQ
M2WHK<C9D3$%5861(47AQ6&MN-&9%63)*5&IY2U9A<$I/6D@U4$PO0417:C@Q
M:C<R6B]M4E!08BM3.5)M9VMA2U9F4C1Y27A6:%=E)B-X03M-1VA'+U1(4D%(
M2T%F4#=L,5I)>&UV>'4X;#AO-GIR179M:E-O-6(V-&5.-W%)3VI3=59)3$19
M9VY.>G%-55)J;'-/5'$X1U-2;4YZ)B-X03MZ96AF;E X03AO=F$O=T1-9$@O
M>5IL>E<Y;68S:"]Q+W!$;F$O=T-G92\X05=W8CAQ+SA!;$YB4"]5;2\U3DYM
M=S$O.3!F9S1E:2]V)B-X03M!>50X.% X07!3+SE(6"]-;DU8<W(K3#1F<&-J
M=$@K2#0O;U-V.&U0*U5O=78K64=4+VLY1FQV868Y,E V,S9#,6%$-GHW=C%0
M6#<R)B-X03MX<V(K,F4Q=G)E2S9T6D]*:V=N4EI),C1S1U=Q<T-$4F=#4&9.
M1S=D3%0U2SAN1C5(3VAA95=M5U-/62]6669J4V)J-FEV.$%$.%%F)B-X03MG
M3U9E=$U686)Y4C5-94Y),C!$5&UJ:D5Q>&]B4T%Q<7IM<W=!-&)#4W9X+WID
M.%95,"],+W=!:'!".5A4>3-P4W=%<U1%=&QB:$MU)B-X03M!<FYI17 X455!
M*TY-5E1E>7-,1WAT>&(R5G9&83(T6C-%34M,1VY+4FDW='A5059:,DQ%.7EA
M-'%R-'$W1EA9<3=&6%EQ-T9867$W)B-X03M&6%EQ-T9867$W1EA9<3=&6%EQ
M-T971"M94'I/=&1(;3AW475.3TUU:7@R-U)*3G%+=TY,2F-#4G91:T)I67=Y
M56I5;T)Z-6-H6&IV)B-X03M25FUJ6$-#,DYW<$1X.%!557%145)3=7A',D5#
M>7!E3VYZ=C5.26Y$851F=DAD6$189'I%*V]83%)Y4W94;'IJ855O52M%55%J
M9T]W)B-X03MZ6B]Y6$PK8S8O.$%L0U!C.44X>C-A,VYK4RMU,55O='A9;55+
M9'E!-F-Q9FIM2F=J=S5G3S94:S5J94UN>65!,C,K.4U8*W5V-C@V)B-X03M/
M6$HP8V5B,V8X>B]!4&Q"=%,O-31F.$%54DAN4&%$*RM(>"LU,U=S+W5J*T]R
M>#-Y8B]Y;&UK9CAX8U@O17AM-S%0.3-,,T]P,"\Y)B-X03LT4&4Y3R]/9B]L
M1C=8+VU/:B\U37DU<75Z4#=W+W="6#E)9&IR+V](=B]7=V(X<2\K53%S+W=$
M56TO-4Y.;7<Q+W=$9$@T3TAO=C=W)B-X03M-:R]01"]P4R]W1%(Q+WI*>D8W
M2R]I*T@V6$DW4B]H*U V17(O2FHO04I3:38O-6=:4#A!:SE&;'9A9CDR4#8S
M-D,Q840V>C=V,5!:)B-X03MS,&)T,UEQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&5THK62]-=FU$5'16=3=E>',S=31).4QN
M=6)D)B-X03M%<V)Y6&QE:#%7,VHK<W@Q:%E0.&9+3V=904)U5D1I<60K6&(S
M56(S4G)A-C%'2#9V95-"=E5J-%!&<TA+<3-P>45U;DY11S1S87)7)B-X03MH
M>%8U=G%8-7=A-V$V:F17<5=D<7E15%-22WA%;%-%67%#85 W6G599&UW35%B
M3')*-C912D9"-D)O,G%487(U5FDQ1UI&4U<U=#-D)B-X03LP4W9%1VA',5-4
M,GI7-6-9:&LT4C!,;EDU.%5,-S-Z<&Y44%!V9615+W=$2EI0.$$Y<W10*U1)
M>FYS9BM-9C4S-EAE5"]U9C@Q-%9B)B-X03MF-S!X9C8V+W)Z;TIC;E-X-79D
M+WI0.$$K54<Q3"]N:"]W0E)%96,Y;U W-&9(-VYD87HK-E T-G9(9DIV+TM7
M85(O>D9X9CA41V)V)B-X03M5+S-C=F,V;E0O,V<Y-S W.#4O*U58=&8K6390
M+VMZ3&UQ-TTO=D0O049F,&@R3W8K9V4O.6)"=GER+S545WHO04Y38B]K,#)B
M1%@O)B-X03M!3C!F9S1E:2]V07E4.#A0*VQ,+T%.2%@O36Y-6'-R*TPT9G!C
M:G1(*T@T+V]3=CAM4#A!;$M,<B]M0FLO=T-4,%=7.7 O,UDO<F9O)B-X03M,
M5F]0<E!U+U4Y;7I2=3-D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D
M:7)S5F1I<G-64U!Z2'%U<C)D-7!6=' X6$I.46UM)B-X03MT-3=G,G,Y,&QU
M9G$X:G=Y>65I>6-5.5I55G521E%F=$PQ>%9&95<W:E8W;E%,0S4Q:$5I,4]E
M0DIB<4M/3F]64C-(3&@V8G9+>6Q1)B-X03MA34-X,WA6-7 U>"]-3'I6<&YM
M82]S8D\V5DQA0C%73D1&1WA!2TME<%5N<6,S5VTP94]7345J9#%E9E94:DUG
M8VUB+T%*96$S<4]S)B-X03LK6%9V9%%K171W6G!%3$)64557;$YL04=91W-X
M4FA/;SAN33 R47IH6F5(-CDO>#-.4B\U:7!V*U1H>F99=F](=41P<W8Q2#-V
M8U!*)B-X03MV+TM!,E X07I#="]X=&UH,5 X069(,W4U=V8S43EZ=TA/:61%
M.34Q5"]Y5U0O.$%B3%0O04I-:D]E>"\T>"]N9G!D-5 K-2]Z6&A6)B-X03MT
M+W941B]R<BMV3V=L>61,2&TY,R]-+R]!2E%B578X06YH+S%%4C5Z,F<O=F@X
M9G5D,7)0-V\O:G$X9#AM+SA!2U=A4B]W07AC6"]%)B-X03MX;3<Q4#DS3#-/
M<# O=T1E1#-V5'9Z;B]!3U58=&8X06U/:B]!3U1-=6%R<WHK.% Y6#E)9&IR
M+T%+0C<O=T)B0G9Y<B]W0U4Q<R\Y)B-X03M38B]K,#)B1%@O,U(K1&@V3"LX
M1$I0>G<O=T-L3"\P9&8X>6-X97EV-'9H*VQY3S!F-&9J*VA++WE9+S53:38O
M-6=:4"M4,%=7.7 O)B-X03LS62]R9F],5F]0<E!U+U4Y;7I2=3-D:7)S5F1I
M<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5E-J>D),<G--=6QY-E9$2F-X
M3&1N)B-X03LY2G=21T%-,70Y6&UP47IT1U W+T%.3#=,5BMI=4MR4$Q).'A$
M.4MN5VY:,6)52FTP=U-*06I,6FM,-F%59V%114LS24)M8FUW,UE,)B-X03LY
M:TMV4%!Z2S@P*UED3S@P>3(Q:F9Y,CEU26\R16%'9W%6,T]B<E)925-X,E):
M9%AQ.# T>F]&:U U5#8Q<75Q,D=O4'%.,#EY.%5Q)B-X03M,1S!H<5%#<$I!
M>D<W47A29U)W:6TO4EI*4T)S,C@V+TU4+VQ.3E4O-'E,+T%-;3%Z6C90*S9I
M-$=Q+W9#.4XO2U X0351.5 K66E8)B-X03LK1V%R=$@K.2M$<V1&+V1V2&1E
M+S0W;6\O=T1-5DXO>6-/8G)&.4$Y=V14;"MO*SDW:#5.+W=#54)S9BM95G8K
M3G,P3W O=FHW,V,T)B-X03M0-V]E-31$;E)/:64X-G O-4Q*+RLR5VXO2FM:
M>C)0+T%":B]!1'8P=3AN+T%(4"MA.$MT=CDV678Y9&8Q-3!%=51P63@S=2\U
M;B\X)B-X03MO3G%8+U!$+T%+:4DX-3=19C-W*U S3S8Q;CDP9G@Q94\K5&8K
M57,P:B]M3&DO-&U-,V5P+W4U934Q3VXO=D(W,W S-7HO.$%+3#)V)B-X03LO
M361(+W=!;5IC,5A:;CDT9C9V-E$W2%@O45!F*W1G,S56+SAP<EHO-FLS+T%#
M86).:'(O04\V4'=C4%)F,V=:2BME2"]3;"\V3W8K)B-X03M:3UEV6E@X6'<O
M4S5(85 X4'@O46QF-4UF.'!29&8X04U$2B]Y96EY,W10*S=(.6(Y0F%T0CE:
M.3,V;G,R84XR-W-69&ER<U9D:7)S)B-X03M69&ER<U9D:7)S5F1I<G-69&EQ
M5BM:8DQ68GI3>$1P57=G=E9U3%=66&%6-%9-8U9Z2$I-:&5.6&(T-%9D855O
M83!/,DMO6%)D4#$K)B-X03M(>D1Q;#EF.$9S<GE+,E<S9U,Y=4QL56MI1&U5
M:4=72T]/2W!K-#%J4'A"5DQ#=4MS22]/3%5D471D53 Y8E<V;&=6;T=,3$9)
M>4%N)B-X03MN,5!%:DYX,F)#2FEB2%8Q=75M45)29"M4=6\V:&1A<'%#,U8Q
M3$]Q=TM65U=2;D%04'%/4D]0855):4EO9%8P37E38DM29FTQ+WEM)B-X03M5
M,R]'1TPO:4]8.6XO=T(P,&$W*SA:5"M39CA!>'ID5"]W0TTP9CA!>$4U:61Q
M9E9&>65Z+W!,0B]W07A0*U4P,50O:DEV.$%Y8EA.)B-X03MH;R\W<4QH-G(K
M.$PP,SAO+W=$;$0P+S5I2F8T6G%U,&8W,S1/>#!8.3(X9#$W+VIU86HO04UX
M53,O2G<U=7-8,$0S0C%/6#9J-S-U)B-X03M(:S,O04I11W@O-6A7+S0R>E$V
M;BLK4'9D>F<O=6@W;F=/9$4V2C=Z<6XO:W-N+S=:868X;5)N4%DO.$%'4#A!
M3R]3-WEF.$%C+S5R)B-X03MW<3(O,W!I+S$Q+UAN45,U3VQJ>F4W+VUF+WEG
M,G!F.#A0.$%Q26IZ;G1"+V9$-"]C-W)79C-2+TA6-#<U3B\U4WI34"M9=4PO
M:5EZ)B-X03MD-FXK-VPW;E4V9BLX2'9E;F9N4"]W06]V82\X>#!F+T%#6FQZ
M5F1M9C-H+W$O<$1S9&8Y03DO-C)$9FQ8+WEM=&XO<51F.$%*<',R)B-X03M'
M=CA!-V\O0G<Y1B]E0FMN-31F.4M8+V\V+S5K-6DY;&9X9D0Y3&MD;R]W+T@Y
M0U8O:W@O>6Q&,2]W07=-;B]*-DQ,93 O-W-F,78P)B-X03M&<3!(,6XS9G%E
M>EIO,V)U>%8R2W5X5C)+=7A6,DMU>%8R2W%D>F-15S%V3&-4=4DT255A4U=2
M=6EO9W%Z2#5!67%L3G(U>CAT,U4K)B-X03MM5SA&,E=N,6<S23 K3F]P:UIZ
M6F)805E-9SE->&YR>G W67$Q-3!7=VTX<F%N6E@Q,FQH1&8R,'1M3'521$ES
M8GIX<VET=T)8;'A*)B-X03MR4V\K67EC36-P1V]I>7AL35)&;&IF;# V02]N
M5#E,2G(Y=F4S,7IB3EIP87A14$54+V1%55IP2E!H5F)E=D@K6FUA=3E"6E!4
M6DEI)B-X03MY3FU%8SA#84)1=C4R9CA!2$XP>B]J3DHO=T%21UIV6F8Q4V-4
M=$0V47AZ.&XO.$%L3%0O04UW<W8O16QZ2S=3+W4O:30K:"]V4&=J)B-X03LO
M=T$V+W=$:G)A9"]Z1'0O>%!+*WDO<%!V8D\P3UED*U-N+TA7,4@O04IH,2]W
M0THT.7%F4U!E=EHO37!6*V)8+TM:5&8X65EV*TDU)B-X03MB,F8O04A45G)V
M-WAL4#5*+W=$2$XQ4"]!27I2+W=$151M2C)P.5582C=0*VMS2"]!1$4O-514
M5E K36DO=T1*=&,R1VHO=6]U2'%V)B-X03LW=W949GEJ+T%/55!4+VU);"]H
M;7$W4B]V9F<W2%)F,V)X,UAV*T\U<5 X07I&5&8X;D1M-GAF45!C2%4U9G%0
M=F4T951F.$%L06)()B-X03LO;49B+VIB3D1Q9C<T*SDS3T0K-DAU94$U,%1O
M;G9/<68K4WEF+W1L<"]Y6D=C.6HO=T%9+W=!-SE,=DHO=T)Z+VUV0W)B+V5M
M3"]8)B-X03M8.65D0DQK-E=03C=V*UHO+TM$86PO>G<O=T-O:5!/93!(.3A0
M:CEZ=71:+V1(.&18:G9K,R]L3$Y)+S5I-'8K2FI.,W%F-W58=614)B-X03MP
M+S=W93DV9"MC+R]!0VDY<B]Z2%(O.$%*;5A.5C):+V5(*W(K:T]X,2\P1#,O
M<EE.*U9F+TMA,F8K<$XO=T%M;7I982]W1'5J.$A$)B-X03LP6#DT1U-F;F@O
M,'!F*VIR+VU4;4PR5B]&.% P=5(R:B]$.&8P2E@K5$@O2U586"]!1$%Y9CAN
M;W-T-U0O=7@O5R]15W)19E=F9"MP)B-X03LW3FUJ9'4W1EA9<3=&6%EQ-T98
M67$W1EAN,7 K8C%P4$YA5S=A955N=714:C Q:U=94#934W)'5FMK*T%-2D]C
M=G K:T90>$LO=T%8)B-X03M&1UE&5U@K63<O5#=$43=Y-3%'2G W1EDK1GA#
M9T1&,&M):DLP67%.*UAJ:SA737IK26IM5T=366I%:W9/.4@X>2]L;75Q85(Y
M53!Z)B-X03M50F0R33AX,#)385(U0D9,9F=2>G-E9'DY969E;T\U2D<U3F-Y
M6%HR44%M>"M09S0P9&1!;7%,279Z8R\U43DO*UEI3"M/1',W*SDK)B-X03M#
M9&(O04AB>DPX=2\K53 P=B]J23,O2G1S,G5S+W5P3W4P=CDT1V-F;EHO>'ID
M32\T>E-F.%)'82]S=C9P3UHR:#E)634K5"]!4'EL)B-X03MP+S5H6F8X06E3
M-6QD<&8S9GAC9E$O,VYW4B\U,2\X04A7,#<O;4AB+VEE5CEL+U-F93)D;V-W
M-SAL4"M/='%0+TU/=B]%.&4Q4'!()B-X03MV6',O;55Q+TYR+VQ-<'8K34U8
M+T%"2$QE>B\W<'$Q,SDT>6XX:R\K3V)Q9B]'85 O:4IZ13=5*W%,:SEN+U-7
M1"]M2B]W07!P<6XO)B-X03M!0FM8+VLR=6)$4B\S55A$,5@Y-%AP=C52+SA!
M2TAP+WI%4R]W>E9D;R\S=G=D:F]V-W0T-W(S+T%",TY2+S5I<'8X06LT8S-7
M3#9")B-X03LW9S9N3#E2.3<S1'EB+WEG3FHO>D-T+WAT;6@Q4#DX9F4W;D(O
M9$0S4$%C-DHP5#-N5E O04-75"]W1&),5"]K>4TU-T@O:D@K9"ML)B-X03LS
M:R\W;B].9497,RLY35@K=78V.#9#6$HP<V5B,V8X04TO.$$U46)5=BME2"]5
M4DAN4&%$*RM(>"LU,U=S+W5J*T]R>#-Y8B]!37!:)B-X03MP2"]-6$8O>$U:
M=3E4+V1Y.7IQ9% O940S=E1V>FXO-5)E,2\U:F\O*U1-=6%R<WHK.% Y6#E)
M9&IR+V](=CA!,7-'+TMV.$$U5%=Z)B-X03LO=T)38B]K,#)B1%@O=T(P9F<T
M96DO=D%Y5#@X4"ML3"]W0DA8+TUN35AS<BM,-&9P8VIT2"M(-"]O4W8X;5 K
M56]U=BM91U0O:SE&)B-X03ML=F%F.3)0-C,V0S%A1#9Z-W8Q4%AR:E5,0S-U
M3&4R=4QM2T<T=7EY,G--:G%R>6Q25FA'<$E,54(S<&UJ9'4V=S%,5'11:$TY
M:&11)B-X03LS:T-U,&)3=U-,2V=D1%)L3$E32W%E;WA60U@O04IK,%A4.5%H
M,"LV=4-L-4]J>7A1<DA)-4MO:G5D,%9G0U9I9FE#871X3DLT<6ED)B-X03M,
M,5-Y,5-W:78W2GI*8E16-$UY4$<Q5EEQ=UI*06IQ47EK14U!8U99>G)0-6AX
M-F)R,2]O-U<P2WE7;&TY,4)*8S-3,C1M94Y9,SE-)B-X03M":V)I2%=5.%AQ
M87-J0VTQ8U9:3G!.*TY1,'%Z=GA'66AE45)4:4IQ,5@Q540X5%5+9'$Y=TU6
M960V>C5.,&Y50C5I:%AZ:$99>&$O)B-X03MX37!T>D-S-G9(23AQ0U-2<$<Y
M4D%:4W!52W!+2W$X<4$X<F9";B].4'E994I(=D0P2%4W,'AA3&0S,7$V=5DW
M85-E0U%56E1337-P)B-X03M&3FE-1T].>D%097-P5D5K9'IX<B]L8EAN3"]F
M,% X07E+6$XS+THK2C%0-3=).4HX+T\P;FM'+VMB-U1W>$UF;5I%3V%V4T-S
M=V1J)B-X03MQ9C=O=D5T0B]W0T\U<#,O041&42]W1$IW6G9S=C!(,T8P,DPV
M:#<S<U@U=68X;V4O=T1Z15)F>'I3.6YF,W9W9'1R9C=T-6PK6&8O)B-X03M!
M0VUM;"\X04=2=BM48EIT9%HO9%-D9'!F-W=--"]/>B]J;39:+WAM:R\T:4TQ
M+UIF,5-C>G1$-E%X>CAN+SA!;$Q4+T%-=W-V+T5L)B-X03MZ2S=3+W4O:30K
M:"]V4&=J+W=!-B]W1&IR860O>D1T+WA02RMY+W!0=F)/,$]99"M3;B](5S%(
M+T%*:#$O=T-*-#EQ9E-0979:+TUP)B-X03M6*V)8+TM:5&8X65EV*TDU8C)F
M+T%(5%9R=C=X;% U2B]W1$A.,5 O04EZ4B]W1$54;4HR<#E56$HW4"MK<T@O
M041%+S545%90*TUI)B-X03LO=T1*=&,R1VHO=6]U2'%V-W=V5&9Y:B]!3U50
M5"]M26PO:&UQ-U(O=F9G-TA29C-B>#-8=BM/-7%0.$%Z1E1F.&Y$;39X9E%0
M8TA5)B-X03LU9G%0=F4T951F.$%L06)(+VU&8B]J8DY$<68W-"LY,T]$*S9(
M=65!-3!4;VYV3W%F*U-Y9B]T;' O>5I'8SEJ+W=!62]W03<Y3'9*)B-X03LO
M=T)Z+VUV0W)B+V5M3"]86#EE9$),:S974$XW=BM:+R]+1&%L+WIW+W=#;VE0
M3V4P2#DX4&HY>G5T6B]D2#AD6&IV:S,O;$Q.22\U)B-X03MI-'8K2FI.,W%F
M-W58=614<"\W=V4Y-F0K8R\O04-I.7(O>DA2+SA!2FU83E8R6B]E2"MR*VM/
M>#$O,$0S+W)93BM69B]+83)F*W!.)B-X03LO=T%M;7I982]W1'5J.$A$,%@Y
M-$=39FYH+S!P9BMJ<B]M5&U,,E8O1CA0,'52,FHO1#AF,$I8*U1(+TM56%@O
M041!>68X;F]S=#=4)B-X03LO=7@O5R]15W)19E=F9"MP;&9N-B]W1$MK1W5A
M83)R6$XU8C,Q;$4P,7-B5EDR57)*2W)+6#5Q*S93,GES2V5'.5%A6G)-3VQN
M:T9X)B-X03MD:&PQ15E':6IV>3@Q2%),;3(Q0T13-WDV=E-T=V)M-&UV2319
M,S581F%+4%%J:%5Q;VIO=%)50V=R44-K8RMN;&IR:39P>%HT>G5U)B-X03MI
M4F5E9DTS;&DQ.'I+;6]A6F-4-FA926YO,VQV9%,R>D%/:$DO=6Y1-T-69TLY
M2VUN535K64Y#8VME249Q>F%S46Q21$I0>3<Q4%,W)B-X03LW>3)K96PR,#%R
M63)-:'1965HU<$QH=T966$@W,E9N8V=C-D-R8F9,2TY29T]+5D4S<S(T37=Y
M0W=W;GI$*V%0;6)4.61V-T=!5R]O)B-X03LR,#AK569+36QU2W-12VYL;7EW
M-D1(2T%*=F-/1&PQ:S1Y2490469*97-897,K5V)057)Z:CE9;CE4;G=(1F9G
M;&1"45906F,Q=7%X)B-X03MI1U%X2$IZ=%!K331!;#@Y6% X07943"]!2S=F
M<GIP23AN4E,U=F9,8B]Y5SA8+V)(6"]Q1GIN6F8S+RMF*VPS8V8W<B].+U$K
M9CA!)B-X03M/:F1%.34X.68K4RMV4#A!:D)$+T%-5%1/93!N.2M095AE86XK
M-DQX5%%F*T\U<#,O359$+W=!;D)M.7DO469C6%0T=G%(=F5X9FTU)B-X03LO
M=T%O92\X07I%4F9X>E,Y;F8S=G=D=')F-W0U;"M89B]+86%8+WAK8B]K,C)B
M6%=F,U5N6&%8*SA$3U!Z<R\T-75M9CA:<% K26I.)B-X03MF,E@Y56Y--U$K
M:TUC+THO+VQ,5"]W07=S=CA!>$IC>74P=C=V-'50;V8W>C1)+S@V+SA!:G)A
M9"]W07<W9CA!13AR-TPK:RLY<S=1)B-X03LU:#,U2V8X04A7,4@O;4A8+VEE
M4&%N,&HS<C)F>DM69FTQ+WEM53,O04)H:2]W0TDU8C)F+V1.5W4O=D=5+VMN
M+W=!8S-5+RM-,&8O)B-X03M!0D4U:61Q9E9&>65Z+W!,0B]Z12]W0U4P,50O
M04EY3"]W06TQ>EEA4"LV:31E<2]V0SE.+TM0+T%*43E0*UEI6"M'87)T2"LY
M*T1S)B-X03MD1B]D=DAD92]W0T\U<5 O041&5&8X;D1M-GAF45!C2%4U9G%0
M=F4T951F*U5"<V8K659V*TYS,$]P+W9J-S-C-% W;V4U-$1N4D]I)B-X03ME
M.#9P+W=#4WEF.$$W6F%F.&U2;E!9+SA9+WIV,'4X;B]C+S5R=W$R+W="-EEV
M.$%86#EE9$),:S974$XW=CA!;68X03AO3G%8+U!$)B-X03LO<4EJ>FYT0B]F
M1#0O8S=R5V8S4B](5C0W-4XO-5-Z4U K675,+VE9>F0V;BLW;#=N539F*SA(
M=F5N9FY0+WEI.7(O>DA2+SAM6F,Q)B-X03M86FXY-&8V=C91-TA8+U%09BMT
M9S,U5B\X<'):+W=#<$XO>6%B3FAR+W=#-E!W8U!29C-G6DHK94@O4VPO=T-J
M<B]M5&U,,E8O1CA0)B-X03LP=5(R:B]$.&8P2E@K5$@O04-L1C$O>D%Y9CA!
M2C9,3&4P+S=S9C%V,$9Q,$@Q;C-F<5I:-6TX=BM2.5(Q54189&5#-FQ#:V-0
M;WE8)B-X03M.<D1)<75784U'34EP*TEL=4\R*V%V1G%:-'A55',W2$IP-%1.
M>4-/.',K5U!,=6Q%:E$Y5VMR<4U3,T-H2F)E8C%967I26D5R1S%5)B-X03M(
M<2]A6&)C6DA.<4HU2S1U:6-E1TU0<%-N6&9,+W=#6%8O<6QX8V%T-6A4-BMP
M361Y1W4W5TYL849!5U9K0W)X2TI1='1S3CAN:C%E)B-X03M307%*,EEZ,#!*
M1WE.,#@X<S9&;W5N=UA6:&]7<GE-:TTQ8G5'3U,R;6%/6FM86C9X<U9*5419
M-5AL>E-Y1S5-.&5+34)55T\S9FQB)B-X03LX<V12=DQM.&TX=U)Y,T5H:VYU
M2%<Y=&1Q4'AK66A6;T%(*T4K0C)Y-D]T>7A&03="<FQP8V-J6D1+3D@P=E1D
M3C!T<EA4=%EK5W<P)B-X03LU<$5M;SES-&A917E33$EX:5!%<GEQ47@R>DAY
M6D1/6$5E8F)#06E+2$IH-V554'EN94M3-E!M1TEW<49K;&TK=E=V0E))3U--
M5W!1)B-X03M":'502$UN."]L-R]!3$=K-E!(,TUR:FDP3"]#>7EX*UE+*UA"
M8F5K=#9*8E$R+S%C3#98.2\V9D=L3G583$UB>$1X8UA7-V(K0598)B-X03M2
M:D,K4E!Y=5I86F1B5FQJ.5%/=W9,8VA40VAK:W)T='=18VTX0G5C>79Z*UAV
M.$%S8V8X;FHW;5)A=W9L<693;V)(52]-87!986I$)B-X03MZ=&A*4%IX:65'
M3E),>FEB,#%,<7%,>4Q+96TO5$UA1U%X;'A$;35%;T-1;SAM4$PU4B]+-G=E
M2SA/=GAW1TEI5T]6-S(R0V=X;W,O)B-X03M,-&A39VID6% K4U%E:'DX-C=+
M4E)0,DY!,&U-1W=%-3%U6'E:<3%K3$Q5+TY-56QS-FDU5E!R5FML55=4,'95
M0E9&4$@Q1'=R,#5B)B-X03MD8V]X6EI13G@U=# X66U+4$I+3$11=GEU,'$V
M5%5R8GI,1$1.86MS2FUV<E%Q;G@K9U-E44LO,VIC3B\R='5U6%0Q;5-1;VY:
M<6AP)B-X03MO4DYG8G!J<F-F:U18-#19=%(X,%$S0U)E;DI%1G4W2F8Y-E5,
M4DXX0VEO;%)3>69Z1&-:6&EZ>7@O4S):355:+U5H3DPP>CAT=DPW)B-X03M$
M5TQ4>DY$86]Y<D=,=5,Y<WI%4DUR3V\U3W!4-#%I6FPX47 X1&MS=7%Y5$93
M3WI(2' T44YG2R]M6%1F24=Q6%I/="M:22]R3FM()B-X03MI9%AU-U-&;RM!
M1'5R<497:%5-0V$Y34=,57IX:6]R:W=2;CE3,U$W2#AV3D,Q1#!T33AZ=W<S
M,31Y,GEW;3AS,VMK8VQ/36%O-FML)B-X03MI6D4R07(X43AC8W5P;FM&4TLT
M.$599E-O83-P6#5:-G!D4S9J<69M848U5E0Y-TUB,GIJ5E5I8C!Y5'A65D%6
M=FA*.&1S;&HQ95-!)B-X03MQ2C)2:S X2FUY3C!B-65I.&DV3S,Q4%(O3D53
M4&5Q,#91:3=S-4AK4T@Q03=O1U9I5E0P6D]21W<T=%AO8VAL>GEY9E5Z>#1O
M=TAP)B-X03M11CDU92],3%8Y44XU4#5I:6YU-S)32E9+6'1R*SAK;D%71E56
M5F]42BMW0CER=&QK3EIK:4M",F$U-E=%:EI'-F%A3F-E4W1(=#=N)B-X03M4
M3D\X,5%X2EDX-3=Y03-6:S=19T969#5E4T9K05HQ0C5D2VIX>6Y,;&Q-,TQM
M,C0X66=+2$I*3'IY=BM61#-%<SDQ-6IH5V%A4U9P)B-X03M#,3EA<E8P0FQL
M,F]0<W(X5&5!>DE'=7EG540Y:E-D2FI*=6LO=T)/=G9*.71P>F%F6F5A-&9Q
M9&MY,FMQ0S5S6#E*-5=:16ID:6A+)B-X03MU-TEW54AC:TAW>D=L:TUP8U(U
M=#A904-H>5DO2#5++TMI46M2-CE'-5=->G1X=G)9,&E6>$5:1%%F6D5J0F$Y
M2VUN6$UR."]L-R]S)B-X03MC9CA!2C0K-5!F<C-K=3@P2F)29DYK13)K>7%B
M3D=3-G-3:F5N14AA35-"3C)726AJ=E=M*UEW>453-'5R:T=!365(;WAT+TQV
M-4XR)B-X03LP-G)*-6]T;W!G;VQ#4'%.;T<T8V5996@O6C1J;%AW>DDO4#5E
M+S='9V%02#--;3%7.3AN87)P4G1R-WI81$QP.31H:U5I-G-65U)))B-X03M:
M9W)-<G%G<45L6&E31#ER8DUB2&M-2F-1-70P-$-1;SAK:6<X=CA!-54V5F-1
M,S8K6EE,95,S=4-K57-L.6%"4F-28T=A4#1H5&UV)B-X03MQ25-V*U5015IK
M4S%U5U%)2C),5DA3-#1M=T4V,7AF2F5T,C!.;G%F;65+849J1&-W24QQ>5%T
M-GE.-D1Q5E%%<DEJ17 R8G1L3TQ.)B-X03M,1V)I,EI-55II<$I8<$]K+VQH
M<$9Z1G%L:#5N9VEK54@P-7IF5V),4C--0BLP0W K3W%F-C(S6$Q-;7)Y5$9%
M-TU)86%%5%E'-DXQ)B-X03MY,3AH*UE':%A5=DTP5G<Q<C9N<$)B=7I1<E9&
M:VMR=U5D14-S83E"=FMC5V]N:G9H-G-S;4=-+W%1*VE72#5B-D9D9EA.3SAZ
M=W=4)B-X03M4;TE1-79B3G=Y>6=42T%(56HT;%1K2V1T*VU(3'%:-4)5:G-J
M2' T44YG2EHU+R]!34YF-'98.4XO<&(K-U0P9G$O-DXK<2MN-DUV)B-X03MR
M.$]8*VUF,UA0,78Y:%1F,#AO8FQB.'4O=T1!=BM)=$DO4F8V52]4=BM',#1F
M<$-T4#!:-G-0;S@K2"MJ8RM8,F91,BLS>2M,07%1)B-X03LK978X1V9P;EAV
M,#DK;E!5.4LU.5@P9C!6=RMR.%EQ9E8K4#<W:#9V<"MN-G8K-T]83"]D;497
M9BM1+S!,.6$Q>C9H.5DK=697:R]3)B-X03M8<B]64#<S,'AX+S-I+V1C+U1P
M>34O=DMC969B07)Z;3DO=UIZ,3,Y269P+S8S.5AU=G)L9C!2-FY(:F,O63E$
M-$]8;V5V-EAQ8F5N)B-X03MX+S1R=W%Z;CAU+SA/+S19,7(O1#,Q-S9L.6)U
M82]74'$O4#%F4U1N.5@U9G5A5C8K<G8V;DPQ9FDU64998C5F+W=!1BMT1'<O
M5'8Q)B-X03MZ-CEP+U V>"MJ3V9R+U=R4"LY.40T4#<S-G8Y62]B-C K4&YH
M5FXX+W=#:G8K5EE**VHO04LO*VHO,&1(-D@Q6#9V*VMF5#1,.6XV)B-X03MX
M*S4Y96XR<3<X<3 K2VU"6&Y39CAQ*R]28W8O04(R9G$Q3E(Y6&HK:D]01#9H
M<4AQ8V93+V,X2V97=E,T8F,V5B]D.&-+<V<X=V8T)B-X03MC+W<U-4PY8CE-
M+V]R-G1"*VIF4RMO8R]7*W)$-FXY8BMS9D@V.4]81# O9S5C=69W-'%X1%<O
M*U9A*VEN<69P>C!0<6,S;RMH.5@K)B-X03MS8U P1&)E<#964#-D4'%F2&XV
M=2]R53E0-&$T<6UM=&8T5"MO-F(K;% X0458,5@Y2%A8,4PQ4#!:>C0X,BMT
M.'$O=F98.4-N4&QT)B-X03MW-"\W<WA63#EA+W=4>G9V,&@O:6(Y269764LO
M5B\P5CEA*W-F5S,K<F5L.5<O82]V4%0U8BML4VXK-G-64C=F-%8K=E=0,7(O
M15 Q)B-X03MV-G)P9C9/.6(Y158K<F,P.4=L3S,Q<FHV=G%F-W-R5#1/5TMO
M5%90.$IF;VE0-G@O:6XQ=CE!+S-M+U)F,78K-S%3;E P4&=R5#9X)B-X03LY
M67)V6&I8+T%(6FEQ6F599C!,+T%);C%0-C$O:6(Y2V-M-&5H*VE/1F9Q:S-(
M-G)8=C98<E4U8C@V,2M+;4MO5G8X041N*TUD27(O)B-X03M!26PK=BMR0CE4
M*W(O;U@V=#968E1H-FXQ6"]J,C4K;C$K1&YZ-"]&:7%N9F8T5RMS87(V+W=$
M:5 Y255K*W5C4#!*-FY#='AY*WHK)B-X03LV-"]6+UAP-FXK-F8K965+;S-2
M+SA-9C1R<U P9"]I4#8O.$%6<FYN>"]2=C%,;C8R;V5P-B\X07@W*W(V;G(X
M94AW9CAL35911FPO)B-X03MH2&=05"]X3C9V,6E$-C=W+U)8<3@V,B],,691
M,S5E<CE7.50P+S-V<54T+TAZ>%9$95-0.$)C4$U(*T0O=T1&4#9/*W)89$](
M,4PV)B-X03MV=S5W8R]Q4#%V-"]6+W4K2'%F2%-N*U)I<7),+V=0-FU++W!R
M.4=E<% X05=F52]12#%0<&-F8CEB.7AX+S-Q.5 P+SAQ;3-P-'%J)B-X03MT
M32]W,RMJ+T%$1#E2+WA0.5$K=E)F5R]R4#9--%4K=#-(3#!0<G8O04(W*W V
M;G)C.2M.95<O4$95<G90*U9E9F\V,RMS+S1J*V]F)B-X03M6>#E2+W=#3V(O
M92]U3U!P52]E978V4#%F:C(K>%0Y.51&55):9C14+W=!05$X=CA59C1F*W-0
M-FXQ>CE%*W)X*V]P>#5E<G8V4'!C)B-X03MF4SE0.79J>"]9>%9(>2\T4"MO
M-G0Y92]4+S%8-G9,6#%V,%HO=T%S96\K<#90<#<Q.50V,50Q4&<Y86Y(-&%9
M<71U9C!"*VAT0RMT)B-X03LO=T-*=G%V2U@V;CE:+U)(,6HV>CEE1E!7.6(Y
M-S8S<F99+WE/5F1U94MP2#5K+W=&=S!R-C,O:7(Q9G)S;C9)*W O;WHV>%@P
M<DPP)B-X03MU4$0Y-39F;R]6+U,U+T@T+T9X>%909%8O=T%+*W)P4#95+U0O
M;R]O*S(K<&5P*VE0-VHV<DHV;DQJ*R\U*VAY.65N*U)49C X5E-3)B-X03LY
M+W=6-FQZ*VM0.$%%=C%Z:U!6*W(O5E!R;G(O04M49SEB,2]1+S!8,2]R4&\Q
M.4PT+U0V-'%N8F8T62]482]7+W="4"]P1#!K*W(K)B-X03MR*VAF<V-B9C!Q
M96XK>C8O<&-F52M$,4]69F@Y5$95;70O.$%L5R]O86(K:E X5&5L-CA(,40V
M=#E3-BMN93AA.#DO4S5F5TLQ*T1P)B-X03M4.3%X>%8O+S)1/3T\+WAM<$=)
M;6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB;F%I;',^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12
M968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C
M95)E9B,B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B/@H@(" @(" @
M(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C9#-$8U0S0X-3A!0T4Y,3%"
M,C(Q.$4T,S8R-S$P-#(P/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \
M>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C9#-$8U0S0X-3A!0T4Y,3%",C(Q
M.$4T,S8R-S$P-#(P/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP
M34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ
M-$$X-3DP1#,Q-3 X0S@\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @
M(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E
M;F1I=&EO;D-L87-S/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C9"-$8U0S0X-3A!0T4Y,3%",C(Q.$4T,S8R-S$P
M-#(P/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C
M=6UE;G1)1#YX;7 N9&ED.C9"-$8U0S0X-3A!0T4Y,3%",C(Q.$4T,S8R-S$P
M-#(P/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I
M9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP
M1#,Q-3 X0S@\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @
M(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I
M=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @
M(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z1C(U1#=#1#5",T%"13DQ,3@R,$1$1D5%-3-%-T5%1# \+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,3DM,#<M,C%4,3@Z,#0Z,#@K,#4Z,S \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S
M=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG
M960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C9#-$8U
M0S0X-3A!0T4Y,3%",C(Q.$4T,S8R-S$P-#(P/"]S=$5V=#II;G-T86YC94E$
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$Y+3 W+3(R5#$U
M.C U.C4U*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I
M;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @
M(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SII;&QU<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU
M<W1R871O<B\Q+C O(CX*(" @(" @(" @/&EL;'5S=')A=&]R.E-T87)T=7!0
M<F]F:6QE/E!R:6YT/"]I;&QU<W1R871O<CI3=&%R='5P4')O9FEL93X*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<%109STB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W0O<&<O(@H@(" @(" @(" @("!X;6QN
M<SIS=$1I;3TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T1I
M;65N<VEO;G,C(@H@(" @(" @(" @("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @(" @(" @("!X
M;6QN<SIX;7!'/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B/@H@
M(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^5')U93PO>&UP
M5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^"B @(" @(" @(#QX;7!44&<Z2&%S
M5FES:6)L951R86YS<&%R96YC>3Y&86QS93PO>&UP5%!G.DAA<U9I<VEB;&54
M<F%N<W!A<F5N8WD^"B @(" @(" @(#QX;7!44&<Z3E!A9V5S/C$\+WAM<%10
M9SI.4&%G97,^"B @(" @(" @(#QX;7!44&<Z36%X4&%G95-I>F4@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W1$:6TZ=SXV,3(N
M,# P,# P/"]S=$1I;3IW/@H@(" @(" @(" @(" \<W1$:6TZ:#XW.3(N,# P
M,# P/"]S=$1I;3IH/@H@(" @(" @(" @(" \<W1$:6TZ=6YI=#Y0;VEN=',\
M+W-T1&EM.G5N:70^"B @(" @(" @(#PO>&UP5%!G.DUA>%!A9V53:7IE/@H@
M(" @(" @(" \>&UP5%!G.D9O;G1S/@H@(" @(" @(" @(" \<F1F.D)A9SX*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y4:6UE<RU2
M;VUA;CPO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IF;VYT1F%M:6QY/E1I;65S/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^4F]M86X\+W-T1FYT.F9O;G1&
M86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^5'EP92 Q
M/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E
M<G-I;VY3=')I;F<^,# Q+C P,#PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z
M8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.
M86UE/E1)4E]?7S N4$9".R!425)?7U\P+E!&33PO<W1&;G0Z9F]N=$9I;&5.
M86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IF;VYT3F%M93Y4:6UE<RU";VQD/"]S=$9N=#IF;VYT
M3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^5&EM
M97,\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IF;VYT1F%C93Y";VQD/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.F9O;G14>7!E/E1Y<&4@,3PO<W1&;G0Z9F]N=%1Y<&4^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG/C P,2XP
M,# \+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93Y424)?7U\P+E!&0CL@
M5$E"7U]?,"Y01DT\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D)A9SX*(" @(" @(" @
M/"]X;7!44&<Z1F]N=',^"B @(" @(" @(#QX;7!44&<Z4&QA=&5.86UE<SX*
M(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^
M0WEA;CPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/DUA9V5N=&$\
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y";&%C:SPO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E!L
M871E3F%M97,^"B @(" @(" @(#QX;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @
M(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'
M.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'<F]U<#PO>&UP1SIG<F]U<$YA
M;64^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XP/"]X;7!'
M.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z0V]L;W)A;G1S
M/@H@(" @(" @(" @(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^
M5VAI=&4\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P
M,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'
M.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA
M8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y";&%C:SPO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P
M,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXQ,# N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0TU92R!2960\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T53
M4SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 P+C P,# P,#PO>&UP1SIM86=E
M;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^
M,3 P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0TU9
M2R!996QL;W<\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N
M,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \
M+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D--64L@1W)E96X\+WAM
M<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C$P,"XP,# P,# \+WAM
M<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G
M96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP1SIY96QL
M;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N
M,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G-W871C:$YA;64^0TU92R!#>6%N/"]X;7!'.G-W871C:$YA
M;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU9
M2SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8WEA;CXQ,# N,# P,# P/"]X;7!'.F-Y86X^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P
M,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z
M8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A
M=&-H3F%M93Y#35E+($)L=64\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T53
M4SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIC>6%N/C$P,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,# N,# P,# P/"]X;7!'.FUA
M9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO
M=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0TU9
M2R!-86=E;G1A/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z
M='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP
M+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM86=E;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P
M/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3$U($T],3 P(%D]
M.3 @2STQ,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y
M<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,30N
M.3DY.3DX/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUA9V5N=&$^,3 P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^.3 N,# P,# P
M/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8FQA8VL^,3 N,# P,# R/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T].3 @63TX
M-2!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P
M,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUA9V5N=&$^.3 N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXX-2XP,# P,# \+WAM
M<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB
M;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3@P(%D].34@2STP
M/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO
M>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M86=E;G1A/C@P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^.34N,# P,# P/"]X;7!'.GEE
M;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^
M,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TU,"!9/3$P,"!+/3 \+WAM
M<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'
M.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N
M=&$^-3 N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO
M=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP
M,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TS-2!9/3@U($L],#PO>&UP1SIS
M=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA
M;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XS
M-2XP,# P,#0\+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z>65L;&]W/C@U+C P,# P,#PO>&UP1SIY96QL;W<^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P
M/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G-W871C:$YA;64^0STU($T],"!9/3DP($L],#PO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F-Y86X^-2XP,# P,#$\+WAM<$<Z8WEA;CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P
M,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIY96QL;W<^.3 N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z
M8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A
M=&-H3F%M93Y#/3(P($T],"!9/3$P,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X
M;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y
M<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIC>6%N/C$Y+CDY.3DY.#PO>&UP1SIC>6%N/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X
M;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA
M8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H
M3F%M93Y#/34P($T],"!9/3$P,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIC>6%N/C4P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'
M.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE
M;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^
M"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M
M93Y#/3<U($T],"!9/3$P,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIC>6%N/C<U+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA
M9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO
M=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @
M(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#
M/3@U($T],3 @63TQ,# @2STQ,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#
M15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F-Y86X^.#4N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 N,# P,# R/"]X;7!'.FUA
M9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO
M=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8FQA8VL^,3 N,# P,# R/"]X;7!'.F)L86-K/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^
M0STY,"!-/3,P(%D].34@2STS,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#
M15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F-Y86X^.3 N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,S N,# P,# R/"]X;7!'.FUA
M9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO
M=SXY-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXS,"XP,# P,#(\+WAM<$<Z8FQA8VL^"B @
M(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#
M/3<U($T],"!9/3<U($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3
M/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F-Y86X^-S4N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C<U
M+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STX,"!-
M/3$P(%D]-#4@2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM
M<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA
M;CXX,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6%G96YT83XQ,"XP,# P,#(\+WAM<$<Z;6%G96YT83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C0U+C P
M,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STW,"!-/3$U
M(%D],"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C<P
M+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM86=E;G1A/C$T+CDY.3DY.#PO>&UP1SIM86=E;G1A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \
M+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,].#4@33TU,"!9/3 @
M2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXX-2XP,# P
M,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6%G96YT83XU,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'
M.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA
M8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3$P,"!-/3DU(%D]-2!+/3 \
M+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C$P,"XP,# P,# \
M+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6%G96YT83XY-2XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C4N,# P,# Q/"]X;7!'.GEE
M;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^
M,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3$P,"!-/3$P,"!9/3(U($L],C4\
M+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C$P,"XP,# P,# \
M+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6%G96YT83XQ,# N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXR-2XP,# P,# \+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXR-2XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3<U($T],3 P(%D],"!+/3 \
M+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C<U+C P,# P,#PO
M>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M86=E;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE
M;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^
M,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/34P($T],3 P(%D],"!+/3 \+WAM
M<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C4P+C P,# P,#PO>&UP
M1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E
M;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO
M=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP
M,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3,U($T],3 P(%D],S4@2STQ,#PO>&UP
M1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,S4N,# P,# T/"]X;7!'
M.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N
M=&$^,3 P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIY96QL;W<^,S4N,# P,# T/"]X;7!'.GEE;&QO
M=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,3 N
M,# P,# R/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G-W871C:$YA;64^0STQ,"!-/3$P,"!9/34P($L],#PO>&UP
M1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,3 N,# P,# R/"]X;7!'
M.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N
M=&$^,3 P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIY96QL;W<^-3 N,# P,# P/"]X;7!'.GEE;&QO
M=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP
M,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TY-2!9/3(P($L],#PO>&UP1SIS
M=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA
M;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XY
M-2XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z>65L;&]W/C$Y+CDY.3DY.#PO>&UP1SIY96QL;W<^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P
M/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G-W871C:$YA;64^0STR-2!-/3(U(%D]-# @2STP/"]X;7!'.G-W871C
M:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8WEA;CXR-2XP,# P,# \+WAM<$<Z8WEA;CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XR-2XP
M,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z>65L;&]W/C,Y+CDY.3DY-CPO>&UP1SIY96QL;W<^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X
M;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G-W871C:$YA;64^0STT,"!-/30U(%D]-3 @2STU/"]X;7!'.G-W871C:$YA
M;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU9
M2SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8WEA;CXS.2XY.3DY.38\+WAM<$<Z8WEA;CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XT-2XP,# P
M,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z>65L;&]W/C4P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C4N,# P,# Q/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0STU,"!-/34P(%D]-C @2STR-3PO>&UP1SIS=V%T8VA.86UE
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\
M+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F-Y86X^-3 N,# P,# P/"]X;7!'.F-Y86X^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^-3 N,# P,# P
M/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.GEE;&QO=SXV,"XP,# P,#0\+WAM<$<Z>65L;&]W/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXR-2XP,# P,# \+WAM<$<Z
M8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A
M=&-H3F%M93Y#/34U($T]-C @63TV-2!+/30P/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8WEA;CXU-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XV,"XP,# P,#0\
M+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z>65L;&]W/C8U+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C,Y+CDY.3DY-CPO>&UP1SIB
M;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T
M8VA.86UE/D,],C4@33TT,"!9/38U($L],#PO>&UP1SIS=V%T8VA.86UE/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM
M<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP
M93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F-Y86X^,C4N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,SDN.3DY.3DV/"]X
M;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.GEE;&QO=SXV-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C
M:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.
M86UE/D,],S @33TU,"!9/3<U($L],3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIC>6%N/C,P+C P,# P,CPO>&UP1SIC>6%N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C4P+C P,# P,#PO>&UP
M1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY
M96QL;W<^-S4N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,3 N,# P,# R/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STS-2!-/38P(%D].# @2STR-3PO>&UP1SIS=V%T8VA.86UE/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z
M;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F-Y86X^,S4N,# P,# T/"]X;7!'.F-Y86X^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^-C N,# P,# T/"]X;7!'
M.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE
M;&QO=SXX,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIB;&%C:SXR-2XP,# P,# \+WAM<$<Z8FQA8VL^
M"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M
M93Y#/30P($T]-C4@63TY,"!+/3,U/"]X;7!'.G-W871C:$YA;64^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM
M;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8WEA;CXS.2XY.3DY.38\+WAM<$<Z8WEA;CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XV-2XP,# P,# \+WAM<$<Z
M;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L
M;&]W/CDP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F)L86-K/C,U+C P,# P-#PO>&UP1SIB;&%C:SX*
M(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE
M/D,]-# @33TW,"!9/3$P,"!+/34P/"]X;7!'.G-W871C:$YA;64^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM
M;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8WEA;CXS.2XY.3DY.38\+WAM<$<Z8WEA;CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XW,"XP,# P,# \+WAM<$<Z
M;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L
M;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIB;&%C:SXU,"XP,# P,# \+WAM<$<Z8FQA8VL^
M"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M
M93Y#/34P($T]-S @63TX,"!+/3<P/"]X;7!'.G-W871C:$YA;64^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM
M;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8WEA;CXU,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XW,"XP,# P,# \+WAM<$<Z
M;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L
M;&]W/C@P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F)L86-K/C<P+C P,# P,#PO>&UP1SIB;&%C:SX*
M(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @(" @(" @(" @/"]X;7!'
M.D-O;&]R86YT<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \>&UP1SIG<F]U<$YA;64^1W)A>7,\+WAM<$<Z9W)O
M=7!.86UE/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<%1Y<&4^,3PO
M>&UP1SIG<F]U<%1Y<&4^"B @(" @(" @(" @(" @(" @(#QX;7!'.D-O;&]R
M86YT<SX*(" @(" @(" @(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.
M86UE/D,],"!-/3 @63TP($L],3 P/"]X;7!'.G-W871C:$YA;64^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM
M;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA
M9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO
M=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F)L86-K/C$P,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @
M(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#
M/3 @33TP(%D],"!+/3DP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\
M+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P
M,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L86-K/C@Y+CDY.30P-3PO>&UP1SIB;&%C:SX*(" @(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @
M63TP($L].# \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N
M,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X
M;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8FQA8VL^-SDN.3DX-SDU/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STW
M,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \
M+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L
M;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXV
M.2XY.3DW,#(\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+/38P/"]X;7!'
M.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC
M>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A
M/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C4Y+CDY.3$P
M-#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L]-3 \+WAM<$<Z<W=A=&-H
M3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#
M35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P
M,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^-3 N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0STP($T],"!9/3 @2STT,#PO>&UP1SIS=V%T8VA.86UE/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM
M<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP
M93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP
M1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY
M96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIB;&%C:SXS.2XY.3DT,#$\+WAM<$<Z8FQA8VL^
M"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M
M93Y#/3 @33TP(%D],"!+/3,P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%
M4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N
M=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP
M+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F)L86-K/C(Y+CDY.#@P,CPO>&UP1SIB;&%C:SX*(" @(" @
M(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-
M/3 @63TP($L],C \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N
M/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P
M/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8FQA8VL^,3DN.3DY-S Q/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @
M2STQ,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P
M,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXY+CDY.3$P,SPO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L]-3PO>&UP
M1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z
M8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT
M83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXT+CDY.#@P
M,SPO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @
M(" @(" @(" @/"]X;7!'.D-O;&]R86YT<SX*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<$YA;64^
M0G)I9VAT<SPO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX
M;7!'.F=R;W5P5'EP93XQ/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @
M(" @(" @/'AM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" @(" @(" \
M<F1F.E-E<3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],3 P(%D],3 P($L],#PO>&UP
M1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z
M8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT
M83XQ,# N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO
M=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP
M,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TW-2!9/3$P,"!+/3 \+WAM<$<Z
M<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y
M86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^
M-S4N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P
M,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TQ,"!9/3DU($L],#PO>&UP1SIS=V%T
M8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E
M/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,"XP
M,# P,#(\+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z>65L;&]W/CDU+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X
M;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G-W871C:$YA;64^0STX-2!-/3$P(%D],3 P($L],#PO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F-Y86X^.#4N,# P,# P/"]X;7!'.F-Y86X^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 N,# P
M,# R/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM
M<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M<W=A=&-H3F%M93Y#/3$P,"!-/3DP(%D],"!+/3 \+WAM<$<Z<W=A=&-H3F%M
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+
M/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIC>6%N/C$P,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XY,"XP,# P
M,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z
M8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A
M=&-H3F%M93Y#/38P($T].3 @63TP($L],#PO>&UP1SIS=V%T8VA.86UE/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM
M<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP
M93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F-Y86X^-C N,# P,# T/"]X;7!'.F-Y86X^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^.3 N,# P,# P/"]X
M;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.GEE;&QO=SXP+C P,S Y.3PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# S,#DY/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" \+WAM
M<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI3=V%T8VA'<F]U
M<',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT
M=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R
M;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$P+C Q/"]P9&8Z4')O9'5C97(^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX
M;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0]
M(G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0'_P  1" #[ E$# 1$  A$! Q$!_\0 '@ !  ,  @,! 0
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, @'6=D6(R<Y)U0TTMF?2U@=^/Z6UXK'I_5,;B$<521DGZ-@L ^A9G$X+'1O
ML(@J&90!IFT?L&66!+6I?+X(J;)$O)/DB]6.=ZM,U:<>?17>X:41-\]O:I7(
MZ.\C^/[G!KG=7F,SJSGQEL+CV;"JZ-KIGH9GKV4K'>S/A6"'EW$US=CFQ,!1
M@>3;%/@B]ZFK3"?@(#OY,@ "4HM4]2\=>;17O)RX.!@'RDTF\8KUA42>8.>V
MAC2G)DYZW2%Q<.H<L."0G!W5K2+E@NT-$$'6 G$ 'EZQ@@AUO> =,>EWQY^4
M 7\(SK[LX.:+Q<Z=X]+OCS\H OX1G7W9P*+Q<Z=X]+OCS\H OX1G7W9P*+Q<
MZ=X]+OCS\H OX1G7W9P*+Q<Z=X]+OCS\H OX1G7W9P*+Q<Z=X]+OCS\H OX1
MG7W9P*+Q<Z=X]+OCS\H OX1G7W9P*+Q<Z=X]+OCS\H OX1G7W9P*+Q<Z=YX%
M7+7CZH3*2"K*4H33R#B2EJ6'S :E&886( %28"V(+$8CTXA:-)"K2*DPC !T
M>F/*V,H047BYT[RNQCX_]'XR<#D?1Z;NJVW:F69P+>HS*G5M/W:<7?D-LANY
M@>VI[;*;;(JH6QNQ@%O#84]PIW;U24OS._(GII,/1FCZJUE*UFJM=]-]*+OG
M8C#%>'#':#M;^^0=I.,U?>,:SBJZFFPUA9V51!ELWDUA&R8B/12@X\T-LX!)
MI:[*"CVM*CB04VTZ4</, 4+9@XSYM&9:IG3BX^)"/L6X7=&!&&2$18=CVC(X
ME$4'&-.[1J1)78QOL1RX@1J71*B9#.%#/4[,ZB=XTRRPHIQ#$G")M4@.BD4.
M=6P_:5Y"^#E5:7?3?7,J;^G?_',=S\4:UX3<0I67+8)R#N&8JT?'ZJN,;.W6
M*RDKVMDJ.DG>5NE9M"'43I*'.:ASCA$Q>&<3R[.;FL=FSNHG?:YS3A<1 JJN
MG)TJNE-*Z=_B0GCZ7?'GY0!?PC.ONS@^:+Q<Z=X]+OCS\H OX1G7W9P*+Q<Z
M=X]+OCS\H OX1G7W9P*+Q<Z=X]+OCS\H OX1G7W9P*+Q<Z=X]+OCS\H OX1G
M7W9P*+Q<Z=X]+OCS\H OX1G7W9P*+Q<Z=X]+OCS\H OX1G7W9P*+Q<Z=X]+O
MCS\H OX1G7W9P*+Q<Z=X]+OCS\H OX1G7W9P*+Q<Z=X]+OCS\H OX1G7W9P*
M+Q<Z=X]+OCS\H OX1G7W9P*+Q<Z=X]+OCS\H OX1G7W9P*+Q<Z=X]+OCS\H
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M@DL\D?5$'KE' "86+JCT$8>L 6M]400BUY?(+6M^76#@\V , 8 P!@# & ,
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M<Q(61,L41DI0!4YKV';MIO=W5XD2YU*6'2-]VX!7-2B>NF?G)18.!@# & ,
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M<C_PHP!Z6%._L[?^K9R/_"C 'I84[^SM_P"K9R/_  HP!Z6%._L[?^K9R/\
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M48 ]+"G?V=O_ %;.1_X48 ]+"G?V=O\ U;.1_P"%& /2PIW]G;_U;.1_X48
M]+"G?V=O_5LY'_A1@#TL*=_9V_\ 5LY'_A1@#TL*=_9V_P#5LY'_ (48 ]+"
MG?V=O_5LY'_A1@#TL*=_9V_]6SD?^%& 2+3GEJ2"5)7:=DH)+/+[4HU.;V9H
M F [0@\!1Y)G5%KKE'%EFEB\H#  &'8= >; & , 8 P!@# & , 8 P!@# &
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M6F;U#C+(22)G-6R0)JO;8%C<1QFWZTYN^GSD.8MSGN-5'VV33JKHW"541G7
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M9@\.LK<W!W?URK2,Q*&?A3ATL\7'Q(2V!ROJLL 2P1/DJ   A   >%G,0(0
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M]88H.2$/;>@\X-[B@$I1'CE/J7YD53K'D-=]]UFY3IR@T<<9]"XA-*G#,&V
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M<VY[8']I;7AH7HW%$F4E@?'F\?:S/1MB8Q/--JFF7BG:20!M:U"I@*4"A[C
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M/06Y.SN(CX^L>FEU!,WX7ZJ'J=U5>A$<3-R'E%(AR-/%R&TR1/-5U@XI7"6
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MPR8Q@&Q#@;X/Z"^@J?VBX9#EXV-[2:Q;V3LK:Q&$Y%R%CIMDN,\4>J& , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M6(PG(N0L=-LEQGBCU0P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M1ZH8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M@OH*G]HN&0Y>-C>TFL6]D[*VL1A.1<A8Z;9+C/%'JA@# & , 8 P!@# & ,
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M)<9XH]4, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M)MXW;I_PKK^5,&RT;I?B_D/KFO;,Q)7O'QG./X#LR#(&9HYX<GIT9'C<I?\
MRV+_ "JF^9Q>U\7\^]<J[9EQ[F[;&<G]4Q[+C36ID7%3E1O3+^&JO_7DP>X-
MCYM=Q.*YG^[T3VE*C*;WL.P&NG'49@9J<JTG48!M<XT^'*@/4G57N*PY UJ\
M4VDU_..T8DL>SF'I%J:5]1<':4D^+K_\RNGV$_.GA?*8?V[K:,G:/_@'WLGG
M04PHY^B)$@P#0'T*/Q6Y!?/]>^SI9DU7^>66:Y-,]K!&\7.>2SWE$#LXDO%R
M?#:#,#TO?BP1>J>'^UI5E<7(X,>ZZCMA!$UWKXI8U7";6)*M<V S,E%PG\6G
M'SUH1G[9K/(6_P %VFU1%] ]-8S%4AUE#](V39"Q716QTL'@\D?TU@OM?>:K
M<UCF$Y!,=@9W>CA*)Y9 [8RO989,8P#8AP-\']!?05/[1<,AR\;&]I-8M[)V
M5M8C"<BY"QTVR7&>*/5# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MY%R%CIMDN,\4>J& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M"2%<6JJM]TA49; &A5.$;8;]DEC1HMI:-;3L)11L5;B$*5I1HB!SI5GCT_\
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MY5KF/^]L1_@./?\ E\H[Q-6&_N<=[QB.\PWQH6N_O4)_0N.X?E6N8_[VQ'^
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M ,\.71=_@JS.J8;HJ2+;/%4^UE$=(BSGL#S):'T1/BT'ZKIE]MCN9%?9@O\
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MF%^\4)_@5I_^K-]\3-A_[M,/>+[N,;\:5K?^_@OZ)WWC\K#S"_>*$_P*T_\
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M(B=3:=U+:BZ<3&53):BL5(D1K)7(7>1*DB44:;3A)DJAW5K#DZ?9PQF[)*&
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M:/$VQZ0->[$^WEM_'>N.1U TS!JA+BU*2H$+1.2,+^.UYRRC<?.+ZZ/7:;;
MTDZ:2=CMSVFZNEZCKZ)[7K [3LP8K:>>?G)/9A.UA_ UCWCIXL,CW=T=;E#N
M7%$>JPYR\K<LNNYLTRLG/2JZK9^4_D*3P4I1_P"%)!L/&-W5C<5>;H_>OJ[G
ME/<FFZ9/PC5:5S5HG=/GKDE\FU(_[USO\ LZ'-PKS)WG<9^!.=>XI3GW1'\@
MYS.II-13JG&P4PEDCE(FT+W-5FF_<@>%CMM#I7N!)MJM)-J^PTHVF3[/T7VO
M8%=;LP[W+;\6Y=+H"7I9IEZD#!0L&CU9LK"O4A7#MPCQ6/R<UD9>1E9.4UDU
MIE+2ICD==(S&QL9&?EUIWX7%1$3N?Y.1O<]W?-O<C+\-9RLG+R<K)9RJ5R4K
M0^3_ ",W(+Y2*=_U*:?<G/[?'Z\]%F/?#7W:?R^)MCT@:]V)]O)B<-.#7(CB
M)-97,2%E,3X4HBX(UMO-F\WC.D6@NR%T[YI4"JW[:C>]HNP[OM.3KR&=IVWZ
M'4%X>W5Y+5MH"#@6I.DM\#C%BT>LQRQ>Z5<O'.YY"PL/D_"965E-:*9.>J>M
MLA81+*1D5%LS-8[PF&2&W-83P;(H]8>Y>4D0_P K]3)R<E--<K-1;%//7)+Y
M-J1_WKG?X!9E^;A7F3O- S\"<Z]Q7WS/X4\B>7[_  =]//IB ;A;.[-(4I4Z
MF\GTXZ=%J99L_9PZI8.Z;([MV>B]%*.TZ_6[0'5ZN]+L'>*MB(:80[,I29>'
MOW+Y6VHU83<MQ=ML9*,I"Q.7E9=:U9I2E%TG@[86(2UC^"?M3+P#P-R]=(RD
M+X3NFZMLMY64L0XR:9-*4:K6M4T$*_R,W(+Y2*=_U*:?<G/>^/UYZ+,>^&ON
MT\=XFV/2!KW8GV\]U&^A^Y!QV1,$@U8%.*]L3TU/&DNW>:D:4[;%Q"W2?9VH
M*;LG1VR.SV;V1G9];K]F/R=7?\\7?LW%0L3#+9EAA(B'?.%;2;JUD;L[:=Y6
M3^3DKDY5:52M*50_VAKH&8>(<1'Y?:;W!\Z?9/Y-1G*W)MEO)KX<M*Y-*T6E
M:T4N^\]<DODVI'_>N=_@%D_YN%>9.\V?/P)SKW'5-Y0GD?=-1SZJC(C2<<!.
M8^I8A/@+;G3J)LTH,*'WH+<*CV[2S8.R\G8[7)NMUO+VNO)^?N;/3?\ (,ZE
MLX1QX4LNB6(E(=6]Q1[DHJ9"O49>Y%:_K;FW3@.KG4M6<2J.E:O?!TC7#3A7
MZ,;JKO*5%RMSRG>72FC+9]93[^1FY!?*13O^I33[DYM_C]>>BS'OAK[M,F\3
M;'I U[L3[>/R,W(+Y2*=_P!2FGW)QX_7GHLQ[X:^[1XFV/2!KW8GV\M%XHTE
MR-XOU$BJDECI6:@1OKX]^?3+0G,>$9MY4%G[3>;0TP]:!I/U.KHWOPNU\OE[
M,OR>3>0VRM-^=T[>3EJ#\ 5Y#P[CP='_ (2B;@PK&5NJNG%<K3D[GFX5-+LO
M(/S:E3$K2*\,1A^^?;NKKP=5W947)W-'C[]6FG+S\"$D_/7)+Y-J1_WKG?X!
M9Y7-PKS)WGHL_ G.O<4\79T6'(6X[9G]I&2^FX\.=25PD0F0$BFKH%LVO'H?
M= N(J];]K-%>3R=OM$FZ_P#;V(/[,W&07T-R*2RV3I9UF)270CJ%2(6:*Y5]
MN:4RU=) /,BO^SNC=/\ :4R2<W6,S>:1\S6=M0ZQT2\B%<I+T>H[W1:Y&Z>&
M.\NG^UD,UX$.KOR,W(+Y2*=_U*:?<G.W\?KST68]\-?=IUOB;8](&O=B?;R3
MW$GH]^0_%>V!6B2[TS.!BB[S&_,ALPFT=#K3N<WG;6>< 5B][\J?N&@Z([EY
M#>U\O;%]3R"\E;2]1JV$F_)#4D9EZ>%N(KPAF8+%+_8,O$R-R6#A_P!;=/UM
MTS4_56N;TEE;O$LQ-%F;,U6-589]#;BL&D.G]JT[:R]T2)??J[G3)R,]=*4S
MV=>>N27R;4C_ +USO\ LR3-PKS)WFDY^!.=>XA!S2XE\BN83=7S>>52]?Z@:
MV1K FE6#.)1YT^$!#.1LL0!U&P=S[IYIT+0M"5=OV^]=4KLO*9H%@K=K8=[,
MWK,L29?E%W"NU1J+\$W'P9I^U6J0\3NF7NU*?H9.3_I5S>,MA9#\[7< [:C_
M  #P%N(;JD-X3NN[LNF:45\XR,G<O][*RMZF> WY&;D%\I%._P"I33[DYI'C
M]>>BS'OAK[M/"^)MCT@:]V)]O'Y&;D%\I%._ZE-/N3CQ^O/19CWPU]VCQ-L>
MD#7NQ/MY><A<.2*)$C1ZKFD3-)$J=-HS=TSL/:=@4 KK]7^@,75ZW4ZW5ZPO
M)Y?)Y=_VY/3QI'CQX\SIEMM-THBTRFE6E:I6E:5HE> VMAE6&&6<RY+++-:J
ME:(B5I1:5IHJOK/EK':N2%@UY/("*#4DTAF\,E$0$Z!N*=+1-H9*QKF7;@%'
MNBDNE>T>EO>-)=JDVC]E]EM03U^T#_9*XU)9,Y=,D=J^67Q\)&HY5K<]U\$B
M';_<]THWD;IN>3EY#>36N2U2B_RS"$6/@(Z!RT=>&P<3";K3+W/PARVYW3(_
M0R\C+RLG*9RJ4RDK5*6OR,W(+Y2*=_U*:?<G-Y\?KST68]\-?=ICWB;8](&O
M=B?;Q^1FY!?*13O^I33[DX\?KST68]\-?=H\3;'I U[L3[>60<..-_(OB/7<
MB@!#=2T]"_S17,-NIMDSB-"2B5,;"R^;](@4Z_:.T#3'I3WK:HK8MJ=E=W#V
M/:&Y9;FV*VUFD+,FH!)<L- ,0.XLQ/A>7D1$3$;KNBN8?)KX1D9&0M,C*RER
MJ)H=D;,?FI+XB 9C/#D?QC<7NJN/!LG*<.'.YY"/7]:;CE964GZU,G-59<>>
MN27R;4C_ +USO\ L\5FX5YD[SU6?@3G7N*G>2_1I\AN1=V3.XS9'341,E_P=
MZT>+E,V? -_F"*L<8UY'05;M.U7>M,VEN_*WI^QVIVG_ *W17;&;-9.]YJRT
M@@)$S(68U('PJD2LR6'5YX3&1$6O]BD$^1C(5_N?PC64C.5FKDIEMH[M&;03
MF,FZSA818O</^SI H^1WN$,YA_A5BW65E;CE_!LTRLG/2J]$_D9N07RD4[_J
M4T^Y.>B\?KST68]\-?=ITGB;8](&O=B?;SO?C/T:?(;CG=D,N,J1TU+AQ#4B
MT&/&2F;,0'#S_%7N,[\KH&MW?:7NNGG:W7D;U';[3Z3_ -5VO;E^=M9>\U:F
M01\B:D+,$D=X+6)29+$*[\&C(>+3^Q6"<HWEJXW/X1G)1K*STR5[RSEVB6>G
M,'-TG"Q:PGA'_9U@4<H\W>%?0R_VJ1;W)R4?9?P;5<G)S5JEL/GKDE\FU(_[
MUSO\ LQG-PKS)WFHY^!.=>XB7S&XY\B^6];,%>'MM+0(+%.$$ST[%65.)*)4
M)"PR-C\W;0CIUAT3HW4@VI[WI6;L&TFB>[#[?M2O:6&M@MBIK$S-F _**Q$O
M>0&XM1'@B,(\B86(W7=$<Q&53P;(R,A*Y>5E)DT7RMKK,_G5+G$ U&> [A&L
M1FZHY\)RLAQ$.=SR%>N*5W?*RLM:9-,E<JJ5M_D9N07RD4[_ *E-/N3FJ>/U
MYZ+,>^&ONTSSQ-L>D#7NQ/MX_(S<@OE(IW_4II]R<>/UYZ+,>^&ONT>)MCT@
M:]V)]O+HZV:.2%>5U 8 &#4D[!@T*BT."ZBN&=(1.88RQ(&73AM%JBE>D>UN
MD7>=I=*E.D^S.RTH.ZG:"P::QR3.:3*9*[5RLPCXR.5RC6Z;EX7$/(C<MTHQ
ME[GNF1EY#&53*R6:T389="++Y? P&6CWP*#A83=:9&Z>#.&'.Z9%6\C+R,K)
MRFLFM,I:57ZAR7<D7!O7H-UU2)6ER)4CV;JZ9V/LN\D#)[3J?T" Z_4Z_6ZO
M6#UO)Y.MKR^77\;IM';UV\SM;F\8;IF2N2TC5*U6E:4K1:<!_2VRK;#;&9,M
MEIFM56F4BI6E$K2NBJ%&GY&;D%\I%._ZE-/N3E"^/UYZ+,>^&ONTQ7Q-L>D#
M7NQ/MX_(S<@OE(IW_4II]R<>/UYZ+,>^&ONT>)MCT@:]V)]O)]\+>)O(KA\U
MS]M(*I>P-3I?'UPCC;"G$8\V>84[LGT4$L%1O_?.]>=-CV/8TW8]AH/5-[3R
M@S>WENUMP^EKUJ6)+?R<[B7:,LQ?A>[>$M.6JJJP\-D9&XTI1O*RM*4S^ZL?
M9'\TG4<Z9C_#_#7CAY58?P;<]P9>LTHCY_EY6Z5K^CDY._7--WSUR2^3:D?]
MZYW^ 69_FX5YD[SV>?@3G7N*R.7/1]<A^5=K$V><[4S!ADQ1GB_F4J8S>1A%
MII5NBK2WS@.L6/>MG^<]@VG[EO1?8Z%VQG:=4&LV*O2:L=)FI0S)&9@C48_C
M/"&H]8545\PY8W/<D@XC]7<:Y6Z9\K]5*9\WM7=ZEIYHDR:FJP2I"N8;<4@T
MB$_LFGK67NBQ+G];=*9.1FII6N:+WY&;D%\I%._ZE-/N3GK_ !^O/19CWPU]
MVGFO$VQZ0->[$^WG9]+=%=R%IZV*_M$N84W(!P23MDD"R#D,U:PNFVX[1O<Q
M. :]<-H]'>3J]OI$J[/^WL1_V9U$^OH;GDFF4H6SK,,DQA'L*L0DT5ZKG=6:
M9:.E@'>7DZ<G=&*_[2'92>ZQF432 F:3M7ZP,2[B-Q67H[1[N:UR-T\,;R*_
M[60U3@4N)\]<DODVI'_>N=_@%F'9N%>9.\UO/P)SKW$;^5=*<C>3U0.-3G,5
M*PL#@],;QY]+M"<R 16V59WO2?S:*EV70]*?^KV;WX'9?\79F?\ #GJ;'6F_
M-&=NIRS!^'JZ<1#CP=7_ (,B^$,9&5NJ.G],G33<UKHJAYZU$A_.24O)6L3X
M&CQ\X>[NCK=U3<6\O)W-7CFN5HKEI3@4JW_(S<@OE(IW_4II]R<U_P ?KST6
M8]\-?=IF?B;8](&O=B?;Q^1FY!?*13O^I33[DX\?KST68]\-?=H\3;'I U[L
M3[>6_43!N1])5# JI+B5)R0$'8RV4+Z.VITTB<] 4*%'>1-H:0<M)-[[?J=E
MI<I_X.MVGZ75UB-HIQ^7YW,IRKCP59A$+$+#H\W9'5666<E'N0ZR_P!6M=S9
MTTIFJ:Q))8LFE,#*T?>$)!.$<H_5C<E>4::7*W/*>9&FE,MK1I.VO/7)+Y-J
M1_WKG?X!9TN;A7F3O.US\"<Z]QW,M7(FQ&J<')8E;T"(@U4M7+5!21&D3$ V
M8<H5*3QEDIR"2PB&:<:,!98-;$,6@ZWO.#DX:A_8DB-O<%3TTIF]V.0IFM<H
M<49*-R4.?5\VIV]28<$E8<X=8/<2DXS#%?6#W<)GEU@'LA'% ,+)$:6$T[0]
ME%"&'1ANBM!V9LL&]Z$/1>A!V/8=;T#0@];R>76 ?GO*?O'<^\$][V3M3I+V
MI?>.[Z,T5M1V'6[7L=&[T7LWJ]GVF] ZW6WY, \V >O2.[4O5.*%"YMZU<SF
MDD.R-(M3*%36>H)TH()<4Y)HSD1IZ<6CR2U("AF$[T:#0@;T+ /PA>F9T;O.
M[8[-CBT^13OSHA7I5;=Y$9AI*O??4YIB;R)323BE.^U_J#"C0&]418M: _3B
M[M+00%2[.C<UIABV$"AQ6ID1 Q: (S80FJ32BQ"T6$0]ZT+>^H$0O^'6]X![
M#6];UK>MZWK>O+K>OSZWK?\ 9O6_^W6\ X"UW:FTYO3.+FWH%#LJ[@U$+5J9
M*<YKNS&=W-O*/,+&M5=B68;W=,$P[LRQF=3JA%O0#SLU^=/,GG)O\];0^<_-
M'?$_G3S;V_=O.'F_M.]]Q[S_ -'[WV7=^W_JNT[3]' .8 XHP1P"S2S!IS-$
MG@ ,(A$&B**/T4<$.][+,V0>2=H ]!%LHXHS6NH8#>P.,C<FYP&M+0+T2XQM
M6#;W$"-40I&@7EEE'&(5H23!B2K"RCB31IC]%G +.*&(&@F WL#DG'$IB35"
M@TLA.068<>><8$HDDDH.QFFFFCV$!998 B&88,6@@#K8A;UK6]X!Z@<FC93,
M1(S) R%QY2!*8F?1NR #,H N-+(1#(=!*-(C0+#C2B4HBSQ:4&F%EE;&,8=;
M ]N,XHL1(##2RQJ#-DD &,(1'FA*-/V42$6];,,T00<=L -"%HHDTS>NH6/>
M@/6@?F(U?MJ+>FDQTT,PK;:!Q1C7Z,) (PTO:,)VU&AE  ,9@.SZP  $(6M:
M#O>@/;8!Z\IV:CW)6SD.;><[MY"94O:BEJ8QR1)EG7[HH5H0&;4IB%79F=V-
M.* 6?V8^R$+J"\@!O=FMW I,:G)O<RT:U2VK#&]8G6@2N*,>@+$"D28PT)"U
M*/>@*4INPGD#WH)I8=[\F >)<^L;8C2N#D\M3>WK3DB9$N7.*-(C5J'#>@H$
MZ52H.+)4'+1""%(44,9BG8M:)"/>]8![7 /6I'AH<#'$I ZMJTUG5"0NQ:1<
MF4F-:T!0#QI'$!)HQ(50"3"SA)U.BC0E# 9L&@"#O8!$\L[DV%O;<ZMJ]F-(
M,4E.Z)<E5-AJ8G8]'*"UY!IB49!6RS-&&A-V6#98]"%KJ"\@'Z5.S4A5MS>M
M<V]&O=S#R6E$J6IDZMT.2D[4*2FY,<8 Y:8G3ZV>>6F :(HG6S3-!!KK8!P-
MRN+:4=TW)6#2K1W=]IMO#=WC2CK]GV'8]Y[3MNT_J^RZO7Z_Z/5ZWYL YZMW
M:D"MN;USFWHU[P:>0THE:U,G5NAR8G:A22W)CC '+34Z?6SSRTP#1E$ZV:9H
M(-;%@ #LUF.9S*6Y-XWE.D*<%#2!8G$YD(#S1DD+3D 3-JBDAQQ9A12D9023
M#2QE@'L01:T!XDCZR+TZ]6A>&I:D:E*Q$Z*DC@D4)VU8W:\K@D7G$G#+1J4.
MOSK"% BS4NO^O # .+N5Q8*1"O%)6#2%T3A5MBW;RW:2.*46@["I0J=J>Q5I
MQ:&'83DXS"]Z$'>A?GUY0.:6\-!S><[%.K::U)RCSE#F6N2C;R"4H1#4FG+0
MF[3%%)@ &(\P9@0$A"(1FPZ#O>@/ ;(X\0UI'P]^9B65PVBT@=S71"6UK=N8
MRRVW21P&?I(IVX&&E 1=B:/O8S2PD=IL8=; Y)SNU)G%$T*'-O(=G(I4>W-9
MRU,4XN!"((!+3D2(9@5*HI($PL2HP@HP"<(P;-V#0@^4#RJ%Z!(%0-6M2)0)
M"2E"H:A222%,G.&:62>H$8,.B233"#@%&F;" P9)H0BV(L>M <)!(6!U.VF;
M'QG<E 2Q&B3H'-$L.T4$00B-V4G/,'HL(A@"(>P]70AAUO?E%KR@<A.[-2M>
MX-:1S;U3FTZ2[=6Y.M3'+VS2XH1R+;@C+,$H1:6$A$:E[R67W@H(C"NN'6]X
M!Q 2:.&-2Q]!(&0;&W"6 <'D#J@$U(1-Y@R7 *QQT?M(F$A.+,*6:..!M,8
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M\ Y8'9J,<SF0#FWC>4Z,IP/: +4PG,AO/-$02N.0:,VK+1G' &24I&4$DPT
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MWO00!WO\W]F <X3NU ="F0;FW@>CT9CB0T"6I@NAS>2:$@U>4W[,TK,1E'C
M28J 5L@!HPEB'H8M:V 3.[4L5.2%&YMZI<SC(*=T:9:F/5-1BDC2E,6Y)RC1
M'(1J$V]*" *@%"-(WHTO0B]]; .#J4QC;&.3ZD;#N-%EF'#D.G=OVQ@**/$F
M--&[:4=P"66I").8/:C00'A$4+>C-;#@'Z52>-(A%@6R%C2#.)*4E 5.R!.(
MU.=KK$J"PFJ ;&2:'6Q%&AULLS7YPBWK /.J?61"U&/RUY:D;&42%0:\JG!(
MG:BR!C"6 \QQ-. C 2,P8 !,$=H AB"'0MB%K6P/(K>&A -N+7.C<C&\*@(F
MD"M<F3C=%IA0SRTC<$XT&UJHP@LPX"=-HTT118S @V (MZ _NG=J$Z#8PN;>
M)Z+0@<S&?2U-MT+;1G;3 <!M^C.]A0C4!$0!6(G1 C@[*T9L>MAP#B:DT<$2
MO4!D#)LAJ<!M+H=IU0;);70K0-F-J\S1_41N!>C"]C1J!%J :,!UB]=8/E \
M[>]LKN(T+4[M;F(C01'!;W!(M$2$>Q:!LW28TW9>A["+0=C\FA;"+6O+Y-X!
M_4CTS. ' Q [-BTMI5J4#J8D7I5(&Q>B"$:Q$X")-&%$K2 &$2E,IV6<0$01
M&@!K>M[ XHY1&2V8B1&2)B!'U7=MI7T;NWA9E.EAP$Z39#H)1I$=WI08 A-V
M9XNW.& HKK#%H.P.:I=6M$L;FY8Y-Z1P=QJ"VE"I6)R%CH8D)[PK+;DQI@#U
MHTJ?^O4!3 -$23_6F:"#]+ . "5Q8Q0%("2L U0SM)P)@/#<)0-0(>BPD!)T
MIV8(X1F]%Z*T'8]CWH.@];\V >_P"/G)M[X^1BJUDEY-FP;=5LCRSJ5+99"N
M/E0U_D:HXQJBK(Z-TN6(HD^*E3TXI36)!)3-M*&0IFF1C-;U+$F=F\/44ZTG
M$:=A<JC<0<)S6$ZXJH>%G/\ D;!\")*RRZBH#)[)Y$L%HW!4<%?&XXZ,J&RF
M:BG,8K:'Z2Z1JTM?1^5%M;4QMPI4S(1]*J_+F3CS(E.?2O'0[JX_ZG*:XNB$
M<;H2J!<@%G1<<@2;7$\@(+G;E-42'H^U4B0R U<,A:>\$R0Z0&+B5IX2$[T>
M\&:$5HQ29L%_TJ:,I*?_ "H?0<<)Y9DBZ1:7.5ET+=5=2R;\0XBLD&YLZ4ZX
MQV%(V^W;%4L+"UCA%PS549&42?88ZB7MS6!=(IB&0RUVCT91O^M$/D_' %T:
M4S5X:_1^*%P>#Y,YG)]#QA=$W)R>\0)_2S9,HMQCG-$V-$Z<F,3<;8NB,J[G
MK26<B[&L=FBCDIF;UNH:]@\^8H_8LI+525[DEIVFI[X62OCCQ,1]HBYD:3@I
M6M-"T3Y<W,=C\P420ZING=(:DK.=2"?@)%ES$6F(0&1%/?R7C5?I\M4,X"P[
M:B9(EK5/Q;4EFHM!5D$AB!Q @CTA%@,TJ[X<KYJI3Y\H[VZ1>O6.;LL<L^-6
M#4TXMSC76"NT8MP\MROJ3N6&W@VR!U;@-:(B'2N-KK8B4ZLMZAG]%]3V?7TE
M;0(I2K.:B&>1]X>FE:.&5WJ9EWT54I\NC-I5*%NV#Y*L^DA8^'<W8P57>4ZH
M:OKBLV--J""6);TT@\4D5*0^-2XEW=[BKAWF3H@5Q271IQ4;5P]5$AHW>76
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M 5Y.3YWD]:T^8^5Z-/4+9ZGX &NDCXNJWN0\)Z\9X0VU]$BF.\=/9M45E()
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M9TU_2T+QI0EGSZ3\)[4I!N@=HS"@H])N05..,4H2;WA(8M'!5=$GIM2''W;
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=[72@)^DFC='Z-UVFC="[31GZ>A=;\^ ?38!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>g713200g53f99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g53f99.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[19@4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %8< 5H  QLE1QP"   " 0$< E  "')R,C8T-C$W' (% #5-:6-R;W-O
M9G0@4&]W97)0;VEN=" M($E03R!P<F]D=6-T(&1I86=R86US(# W,C(N<'!T
M;3A"24T$)0      $!AXZ)PG9:$FP@U%<#"ZD0DX0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /
M     0 ! \     !  $X0DE-!"8       X             /X   #A"24T$
M#0      !    !XX0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              )8   %AP
M   !                          $             !8<   )8
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   )8     %)G
M:'1L;VYG   %AP    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   "6     !29VAT;&]N9P  !8<    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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M9#LK'BRLM>'5$;F^D?3V._==]/<M7J->7;BFO#L%5[BW:XF._N]WTOH_N_\
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MP&7"1;]&?Y-EG^>N;SOH]3_].59/_@ZZT>K_ *-_!_-$S#O_ "2Y+.XZF?\
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M &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@
M   !1DU- "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %
M 0   '8!*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "
M    "0   +"':0 $     0   +P   #H "W&P   )Q  +<;    G$$%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#<Z,C(@,3,Z,34Z,C$
M<G(R-C0V,3<       .@ 0 #     ?__  "@ @ $     0  !8>@ P $
M 0   E@         !@$#  ,    !  8   $:  4    !   !-@$;  4    !
M   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
M  !(     0   $@    !.$))30/]       (          #_X0%(34T *@
M  @ " $2  ,    !      $:  4    !    ;@$;  4    !    =@$H  ,
M   !  (   $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I
M  0    !    O    .@   /      0   \     !061O8F4@4&AO=&]S:&]P
M($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR,B Q,SHQ-3HR,0!R<C(V-#8Q-P
M     Z !  ,    !__\  * "  0    !   %AZ #  0    !   "6
M   & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P
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MH-DM/F9LCP+$+TV88]&=#H,J-;8_7SRY'20WJKXE1=DD.LZZ*]?./#DA"_\
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M9$3^'\HO[?C_ $?[>5J%6WC%&^DCVWN0/RK7([VYD$%W7VLG6!OMWL<O9SC
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MK>"H_+O\-<3Q7XW;_>=TITD^/_'\GR_^;FL_V^\4;[>?CQ_!Y.TT_E_@[?\
MU9_6NG?_ ,??A9TNE^ W(;'^/^,\QU<_?O>]+/UQTL?IBMC=5_44LOGQ:W;^
M-5[JXSV!?D^(@E D0?)R-^1/HI4J:V:%J*KY#ZV5&.-C7+'KY1%:%=GXCXER
M]18N:M8^DQ -U9JZM'D@;20.[[J.Y8Q,K ?+&Q[5R_QA^S#:^6FN_!/+7(NH
MU9UXGFGADBN,*3TK;D(HH#!(Q&L2W44L;,P$MS"H,@ZET]Q5Y!55]Y23XMI4
M6T,$^ML816GBS(<D;2@D *Q51S",<BI^RHO=KD1R*B=:@GAN88[B"1)89D62
M*5"&1T895E(]P0?^![U\A7UC><;>7/'W]M-9WMG-);W5K.ACF@GB8I)'(C=P
MRL"/L?<$@@UC[<^[=3=.^N<BVWN[/L<UKKK%8R2;K*<GG-AP0J]5;&@Q!-0D
MRUN+ W:+4T=3&FW%O->*%609<LHPNNUBURR\>K'ZH:?S&[&Z(OI^V;>WJ52X
MCU@=5F/E8B.0O99!NGK3.2 *YO@B_P!*&6U _+RIJ*_;Z7O2NE.C.F'I[Z9J
M7]/Z"T_@>IZQ]#CN-3&8;0Q*N7;U.*&O)-"R_LF-=99#-A2\FR"8ZWO)=A;S
M)ES82YTZ3(DD(JE9WXI3BE.*5RHVQBW5?T69_G/4%HB3L'JRZ<<WR2QS?=/2
MCD%[*R;;FLY-F=9N29STEW]W*61:UJ.=(L[+I]O)RUTDOM;KJ=329*52OZ_K
M^O\ NJO;^7_&M\=!=0>H.I_6%!N'1^:UF<X)D33#!8P?;'G5=I#?Z;3'<DII
M@P6N-Y/22O*)<X_<Q(=I726^$B,UKAO>JE9FXI3BE.*4XI3BE.*4XI3BE.*4
MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI6.MO7%WC^JMCWN-H3[
M_3X/E%E3N$Q2%%80Z:8>,<0T_)"1RL:<8T15>\:-[+W[+YG,S3VW$<G<6N?,
M0V%U+"5&2)$A=E8#ZE2-@/J1BMG\%6-AR7C#POQ_*:_AU[X@XFUO0[!4>VGO
MH(Y8W8]E65&,;-VU5B<C&:^:I$/+D(B>R1*E&1$\G*\QY!W_ .9[U[O(4COR
MY[N[GN[N7NJKSY< >1P.[O(V.YRS.Q^I/N6)]R>Y/>OU5)B@B).L4,,>>PU2
M.*-?HJC 5$'8*.P& *VUR76FL,9J;V= %!RIE%@UF&5-!EL@PEV+B>3XU27*
ML;6FCHVLNZK+(=Q!@$8X@"P3C!(( 4E';G=<5Q-K#<21JEV+>PF#.MXQ!Y*R
MNK:"?_"(Q'<0W:SQQD;(48!F56KBW%>*_%W*WO'V]R]QPYY#Q!:2102<-$CC
MPOS/$\M?V.YNTE;S?'WG#36-Q<JRI(EQ&SQI*\1&+=VX_KS%LA#1X+)+(DUQ
M;"->HR5838 _!T3[4ULJSAQ"DMU8LY;E("RZ1O\ 8/MLLCUF,'X_/6W&6ERM
MOQ[EVC:5;C#2O&,%.B TJ(3,1U.MTR\'^'TG.7QN/@#D_$_+\8_(>(8ECBND
MM9>.+0VL%PY99O.$PVD\Z+9!A;BQ\R(>0/\ >3=PJ.BS;I?3:N[W[YLK&T(8
MF,I55-V03O)T>'>NF.@"(+_*,UE7M,T_;LXXZJ/Y=TCM[;S\+[BXZ_*6N6-J
M(8;@C]U+@OTP1]FEC#9^XB7^&N#_ +4_'\=Y#PKRI6->6-Y><>KC EGXX0BY
M=7^KQVMR4,?;$;7DN,=0YW%ZE=Q[ZU%$Q$^C.DS+NJB1>2+@61PL4VGJO6+\
M,# %7OK94TVS[NE#<-NR2IH@#IW2"PUK2.F-&V3'5W8J^,ZU/_KH_4!_X(;<
M'_2PZ3?_ !UQ2G]='Z@/_!#;@_Z6'2;_ ..N*4_KH_4!_P""&W!_TL.DW_QU
MQ2J5T<=:O7)O7J)V_J_>WT],ST-JG#KI\/']MS\WQ:7"J2CH:RP_3-PK+:54
M;/FFGR9 OU=IZQN*2J(\5+?U5?8U]C*15>WW_P!G]?U]JO[ZDC[Q,*UNR/[D
MQQV3VRVOAY^E;AM6/[&A^W\/E\-U\H4=_BA53\M3MR_XH&X\AQ@7;RQNYNMC
M.O6$0Z&WT^0W&N?UQ7U/^RRO'GG_ !0TNGXHO$V8LML;^2:[;\0,>>^.L..$
MA ^J#/?OSNTM1:ZMK>XD;.MZJKH PH53#^X3;6,5;?(+$,)ME&#1QY=@=:"F
M'=W G' VE2UBU$6[D!A37(3FG!6_&333ORLT,5LJ1PIU))4/6N95CZJB!6D;
MR\ GF&5Z(F2%9V$;D'Z<\>\CXGLK*RB\)65Y=\E)/<7L_EK>SF06/&6SW#6L
MKW\L-M'^)7SV%BXCD-\;.:]EL(I+B :Y9I\*U$ F)0LG;@H1"7#!3+:OSPDR
M9D%L4UB'-(5[7P\N,E=1PP@;+!:0X&.>!V08D>PE)9(Q/9AL.&4V<=T./ !L
M5>:+D"[W$Q:5;V.XB2\/3@55#K*D=OZ@B+(XEP-*O>?\:R+S5QQ+>(G9QSKP
MV=SX=2"#C;)$M9.!N./N9N$C-SR$[R-!)9SW'*;1-//);0^5).M.:R<6EY',
MD89!-74#XU4@8IFRAM;/'401WA8@9UG<SHU;)O&6,FKBSK:QF1ZXT8,F4\S'
MHW5;]K1[IVL8VCMBL.J'<#J"&,3LBR232+$TXD:)'ED=8RJLY(-=8X"+F(.*
M@BYZX2ZY)9;PR3(87)MFO;AN/2:2WM+&WENH>/-K%=S6]E:P2W*2O%"J,">]
MO2:^[)T[:L?D"G6?]AD- LCR4JTS+>R9CB]W_E1+CS:M8Z_LL?U*GX[<^A_!
MYG/AGB#<[=3R[:[9ST.M+Y;W^GENEK_U<8[5^<OQE6P7XG>,!QHC%M^)1EQ%
MC07S65JW*?+V#?B9N^H/I)L#WK5;,OJ71<-R[*,1)T&?4QR;]+Y#<X\N38;T
MCV^0XCD*TUC(KENL7NHV5,^\8]9K'6;36C8P6SZXT>6P3&E1J;*>WZ_R_EG^
M?;V[?7VR.]<T( . RMV4Y&0 64$KZ@IRA.K8&NRDJS)AC;[?JIU'_P 3Z?\
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M;Q7B5M/."2]:$6\$4LS)-N4FD5"((2D9$D@>=H^HD?JZ(D8$!2:^V_%K\O\
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M6VQ[*K.S'.%1?=FU!( R .Q)8JHRS '$O;R&QA,TNQRRQQ1( 99YG[1PQ*2
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M_'ZRS@H,@FI.?)<4 J  #   ^P&!W.3[?<]_YU)BS$LQ)/L2QR3@  =R2<#
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M+N[L%1$499F9B JJ 222 !W-21'D=8XT:21V"(B*7=V8X555069F)   ))[
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M, NQX.1.I8U';9'4LEW4>(%T84J9'0(1V! .5>TJ:!S#'*G;W]QD=Y/\B/\
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MQJKVE5J@5(JA&A!O42,)^4A'Q7',EZQN2PAD=5?=0(5"J07&/7ZB5+?*VNJ
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MGOZ,B-X)DQ_=_/,Z;E&%6WE9>E*0RQK&A>,.2%\C)(MPF?WL%Q(C?\[Y<(V
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M/2@N !HGDKB6,0KEHX"+*8')U9NLO4"DZ2K=%F9761:>O>2,DY;KQ(W4/9I
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MPP')"HT)CL(8U&$,71;L)F8T5E,4Y7Y3) >R]_)RLCNXP,L'VN'9N[!]P,E
M*Y2?50F6TG4>H4E :!'[!R.3D2" !GKS8D&X9;5\MXOXVK5PV0@4Y'JY+*H,
M.6PL@0A%YOW@5(5Y'DM&+8M;9+79F.; !##(@;L1,Y=IP,=*=2A"EB*V_P &
M-(;RXV&N;61I@%&/,FZ0.K$>VBA1%G/4C.V2!DR_T@%$C=I"E@%]NGWV(A)(
M?$"?V7-?#N;7'J\DAXWDB#5T:UM0/8HFOL*F$)QD*0()$?B-MI9,C-U(XKA@
MH=EQ!(4AN9 @(5R \4+9V(BFD.N S+E>+\><XW8#1HK@$E0<R(\,D2YP=1Z9
M'![>M%&<D \FM4JUN\=9N<\XVMVUA3G$C!=(DC1,RK%5\:.QKWR)#$3R"!K'
MN,5&C1CE=XKT"]_Y+N\!2?P^XP'8(A_N[]F<D!5/[S$@*,G(Q6W7_P#R9>=V
M']QN.Z@LP_N[]U !)8?0 $D]@*^MQT\#:@S:J-%*V1DEQ'+&!$$L.3/KZOV:
MW@R7-<T(*ZSJ8>*'@RV&&&:5:JO>1$M"Q7_/HC)F'6=@5M8&#LYW6.6;'*2+
MG):2*9[Q9$P3&O6E _)##CA8:'0 YFD!4*-694_NBM]D=%@*MD!B40G+ZU/V
M\JG;#JB17*2JG4:3P'CQRG255W5_4&S.Q[MCN>.1]IFOFRGME_-6/,LI0HSU
MBF?RU"DYDF5QB:.?ILK,%*306\ZV,7=P"O6C"*"FFZ1(6&ZBIR&/6,K\C1[
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M;-A0[MSG1)%7&O+J:]&/C2#P[@C?J7++CK^8G4*KY'Y4*3<;&F&(DC<I(]N
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M\XK2AT5LMZC:"V92IS(GEPI(93449-#J%*[VH[J >@0A#$8'83&4,#V5A*2
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M!UZ$<UVHVSMHL<15QKZ6U"@$95<L"#V-4,.PI;*6X@EA,-.MPQX$B5Y&;#?
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M.,Y1"[%$/W52<+_D!011*[R+'&KR#$CA%#./L[ 9;_,FH8,'Q./72:D5)#;
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MK'*]B#,XBF T;E5PV@(-K%_NHB<D;B<NDAFF,D8Q&YD<N@^R,6)4?H"!41!
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2*4XI3BE.*4XI3BE.*4XI7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>g713200g57c81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g57c81.jpg
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M>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF(WA!.^*
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( ;,!/@,!$0 "$0$#$0'_Q  >  $
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MBU)N/3T;M_):EW9X2#H_>O7J7TA<5H57$A/;/NEVUNR?QR?B -SQ:>=HJJ6
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M08HUYX<#3L<D(L5( ;]/C?AH6&,UE$7"6BB"A0"0=1WK2,AX5,(D< 'Q"?\
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M.I_PP[O\=VWU_KJJO7[:=BNPP&D)\:*UY%>S2'0;Q?@J]^0^"E6TB&'NL]S
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MN[H'T\G<HJ1M&YK.8%XCO:&MK"Z=BR9FUZ\XC3BC%+-$QSJ7:@\S+I,\JFB
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M\#S2-2.W6>T+"R-J!H856X>(U@W+(1F#O;!4(%YF/8-!JAZ9FI.[>-WY08W
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MVZ6[L@_60:-M5%UDD$]EEM.-UE4T]>>=]]=><<LT->-TT\L<,3-"^65[8XV
MD-!<]Y:UNKB -2-20.\K=QV,R.8NP8W$8^[E,C:<YM:ACJD]Z[8<R-\KVP5:
MT<L\SF11OD<(XW%L;'O.C6DC6>/]SJ'D-*G;P;S .S 1]I*EWT>?R6'(RW[N
M,NI8W;!TQVDD59\&):E#2S^'L%B*2AIAPDY3^GKJY^WX$/%6&FQ4V6;:B;#
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MS0?]+939?E#!<XCP](T!)=K2#(66UH716JKF,#H[+_:97.F:&U6NJR0NE;O
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M6O&B:22>G&NB::>FNNFFFFO&NFO'&NO'''''&6    &@'0 =  .X *0
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MY_%W'.6XN9C8;KW-KX^ACZYB/L[N=>IU!5L9#?%5KOC]K)?)[-J^*#=L87
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M:KIPEINBZ*%!H]!77;E-1X09M]=N57*.N^2*M8F<60P32N!<"V.-[R"QCY'
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MPV8^9'<]EGFB8V":>FR1TL;-)'2;FB)[P9(F1RL8\QO?M.GF?[RUYF.$->[
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M<LZ\D!@L*(NXD&!N9(J1*N'SB++NW;[A4JAX(+=W0Q-&G_GU'=ZZ:^/YJA/
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>$PB81,(F$3")A$PB81,(F$3")A$PKL[_ ,OYA?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>g713200g59k87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g59k87.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2%L4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             #
MS0   _,          0                         !              /S
M   #S0                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   #S0    !29VAT;&]N9P   _,    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   \T     4F=H=&QO
M;F<   /S     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    $.$))300,     !;=     0   *    ":   !X  !(,   !;! !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" ": * # 2(
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MB)CXF159OLS;\AL$>G8*0W7\[]!CTV?]-*A^\/\ G*OP;2I]5Z?^T<-V-O\
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MGH_I-59O1K[KCG^J\O\ 3S+:Z]WYK &;6-_DM6DC(4:4#>JD.^AE]3JW$MW
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MN$G:]VX R=WTF!W^8FZ?CY^0;\F\;=U9JJ&TLW207%C'^]E3=GL]3WV_I/\
M!^FE6BJT;K\R\D.I:QS#K#B059Q\AF17O:"""6N:>0X<M*QK^HNH!;Z(#F\^
MH\,:(YWR-_\ FI-OZMA](MS,;$.3DW6%[:3+2&Q'K.I_G7>YN_[.W]-Z?_"(
M\-T._?11T%N\N5^W?76C*S+/LK,G%-V0,6EP#7BNAESZ-KJ]FW[:\8M-7K.N
M_P -;^C_ $=*U/VCUS_RH)_]"*DOVEUS_P IS_[$5)>W+O'_ !X?]\MXAX_8
M7"=U+Z]66&VK$<&;VV-JV5L#ZZZVO]%OJ[K<;[=8S_#OMNP_7^R_SM7KJR>M
M?7)S*MO3&;KG-K!#7[6S2RQ^3;ZME+ZF?:+]K:'T_P#:7)I]?^8M6I^TNN?^
M4Y_]B*DOVEUS_P IS_[$5)>W+O'_ !X?]\KB'8_87)Q^L_7,[&GIH<ZX-/J6
MM+&MW[6V6;&/WTU8EG_:.WULK)9=ZE>1^J6+H^FW95_3\:[,J^SY5E3'7T_N
M6$#U&?V7JE^TNN?^4Y_]B*D_VGZQW"*L+'Q3^_?<;(_ZSCUMW?\ L0Q+VSWC
M_C15Q#L?L+HWWTX]+[\BQM5-8W/L>0UH'BYSEEXS;>L9E74;F.KZ?C$NP*;
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M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %&34T
M*@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H
M  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (    )
ML(=I  0    !    O    .@ +<;    G$  MQL   "<0061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR,2 Q,SHU-CHP- !R<C4P.3$V
M-P       Z !  ,    !__\  * "  0    !   #\Z #  0    !   #S0
M       & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@
M P    $  @   @$ !     $   %& @( !     $              $@    !
M    2     $X0DE- _T       @          /_A 4A-30 J    "  ( 1(
M P    $      1H !0    $   !N 1L !0    $   !V 2@  P    $  @
M 3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $
M  "\    Z    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7
M:6YD;W=S*0 R,#$Y.C W.C(Q(#$S.C4V.C T ')R-3 Y,38W       #H $
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M 0$! 0$! ?_  !$( 3<!1 ,!$0 "$0$#$0'_Q  >  $  @(# 0$!
M    !P@&"0$$!0,""O_$ %40   & @(! @,"!@T(!P4)  $" P0%!@ '"!$2
M$R$)%#$5(A88(S)!41<9)#A566%Q=9:7MM8T-W9W@;&TU24V0U)XD;4S1V)R
M\$)38X*AIK?1X?_$ !T! 0 " P$! 0$            %!@,$!P$"" G_Q !9
M$0 " 0,# @(%!081"0<#!0 ! @, !!$%$B$&,1-!!Q0B46$6,G&!D14C0G.A
M\#,T-3924U97=).4E;&SM-/4%R1B=;*UP=+50V-R=H+1\0C"X414@Y*C_]H
M# ,!  (1 Q$ /P#^_C%*8I76>.VL>U</GJZ;9HT14<.7"I@*FBBD43J*',/T
M*4H"(_41^@ (B 9XS*JEF("J"23V '<GX"E0Q*[SA8M\JR/6K<Y%+Q$1:0KQ
MV<2G ITQ,1DBZ30,H0P'(BY71<@'LJ@D<#E+$RZS:PRO"Z7&],;@('XR 0 2
M I<AA[ 8NIRK*K K6$3H>P8_' &?HW$9^K^GBO2@MXZ\FW0,%)16"D1\0,QL
M#<8U9,QOH5<YS'0:F'Z$*\5;G4'V(4P^V>0Z]I<T@A-TL$Y[0W2M;2-COM$P
M3</BN<CD5]"5"<$[2>P;V2?HSP?A@U+H" @ @(" @ @(#V @/N @(>P@(?0<
MF*R5C5EL[2MH)B=LZD7S@CA1I&,$_5=KI-$P4=.!*'8D:MBF("RH%4.*BJ*"
M"2[A9)$^">=85R0S-M9@B LQ5!EFP,G:.![V=EC0-(Z*WRS!!DY^  R3] %1
M%^SXW2[4<4BU"W(<Y5CL8^3=KI 0WB8YV:D2T73* AWYK%13$OWP.)/O9$?*
M"VY/@7+ 9)"Q$R #S,.?%7GR9%/PSQ6(3Y_[-_CV)'?RSGRK/Z?M2D7A0&T'
M,)C(^)S#%O"_*OOR0B"@)D,)D7)D^A%4K5=<R( /K GT/6W9:QINH,8[6ZC>
M9<[K=LQW"[>^89 LG&1DA2/C619$?@-S^Q/!'U'GR/YBI$R3K[IBE,4IBE,4
MIBE?QH<-^5GQ%:?H>P<[F5BY)[5U+J[C%SSV+R%=<IKC7Y_0.Q-DZSO-H0XY
M0/'.)9S [,A31"-9?QVRY)FC#0!F+%[&)*A(&9'44K9_?/B,\YJR--UTAK+B
M+";J7X4[3^(1?G-INNSAU<PTS4K'$QE6U'5)!-G%3,CM)RTE^KC=Y S>F00Q
MXR;6ONV<H@W:*56^N?%UY5PTCSRY26>$U[-\:]0\*N%W)36?'=VUE8K8U<G>
M2U(GWU>BT;BQADUY*/5M8&)M68FF4PW9P\7 .J)&1)U9IJ]4J>X[XH/--:/U
M[J^;XXTFC;MW?RCJ>@]+[7VU3-V:=T)9*Q.Z8LNXIZ].-?W@B&UE)&K+U&5U
MXSK[>>0;6^;>Q,_%S+-FJI#"'/YG_CBE5[Y)<Q^=L+(_%HA-CWC3SG5O'K@_
MQWVC"5+2ULV-1[/7[ELJI7AS(2^H=R5,U6OAHV4M-9E#6.:DY(SEK#-:BVJQ
M(5PYLI7ZE636^*MO*.VJ96(U?J5WQLI7/#2GPZ;-&S=ON2_)6=V!L^ I2CC;
M5?3%%:KK56#EKFS%"KR+21L=I@8J:L7X01H@""*E>UP=^)YR:Y"[AXM5_<FH
MM(575O,"A<L9W5\AKFRWB0O==G.)VQ(BFS[B[L[&T) EB+FVE1<0T9"N'KV+
M5;%7?3#DK@S%NI6]S%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*KUN>PR(2$+4X]4Z/V@>/5,*?CY*.W:\DX;*#YE,D/V;'5V;?-TU
MB*H?:@13E=(Z34R:D'J]S)%LCCSN!C<8/'B.9#$6!X(1;>=U)]D3> S!@FUM
M:=CE(QV?)/."0/(>[X_97GM6ADQ(LZ6.]>%130!PN8Z@H()$ B;9KZACF2;I
M$#Q /(3JCY*+&.<P]0RQL6\6=S-.PY=^0F?P(@<A$'S1MP3C)Y-?.=N1\YO(
MG/'T#(P,>[/V"L$VG#Q<E5UUWR:!';0BWR#Y0A/4:*G15$H K['^7,J5,[IN
M!P(Y2(9(X=& 0CM9M[:YM!#<A2CRK$N0,H90R!U)QAH]V\<CL1V8Y\< QKY[
MFQW(P=V 1[B#]/PKVN'NPY"ZT*S0<FY6?N-<721IR+]<XJ++1H,F$S%-UE3B
M)UEX]A*(,55CCV8R'CT42"4LAT%JEQJ6B,MRS/+I]Y-8>*Q+&2.-(IHBS-EF
M:..9(F8DEC'N/)-?=JY>+GG8Q3/O  (/<^1%?$9:3MMQE9('[ILU:$\4Q05.
MDH5!P\D"QK1,2&**1&\*DS= 4/)(S^9DGJ@&<I,#-\]W/-<7#JDKQID^*R<,
M LC[(D.=R PF&0<C#SSL<L(-F,G?(Y)QM+*.X( QG'Q.3GOY^1K,$$46R144
M$RI)%#HI"AT ?RC^DQA^ICF$3&-]XPB;WS'&BQHJ(-H7D8]_<G/?)/<]S7I?
MG@9\@?/X=OCY<YJH7)V:0H$>XV%#.RQ=EK3->RD=MSBBJL>O1KZ7 RXI^)U
M,2,:QBAC )A:2JR(^7J(@2D=53>H%=3M6,>H6#07,,B\.<"3="V,;HW C5E.
M1M=D(PY!PSL5.]?G(5(.?>.1]!['\GGG9;6)8\]6Z_-JHBW5F(6+E%$! 0]$
M[]D@Z.ET/N'@942AW[]![YV2WE\>W@F(VF6&.0J>ZET#%3\03@_14B.0#\*]
MS,U>UY9YR&3FD*X>5CB6!U&NIEM"&>MBRSB(9.6C-Y*(QPJ_-J1[5X_9-7#P
MJ(MTG+MNB=0JBR9391!,86N1#(;=)4@:<(W@K,ZNZ1&3&P2.D;NJ$[BJ,P&
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M*J)F(FY23<IK-E%$#F!4A'"*R!C% %4E"")1^U(5E9E#JK*Q1BP#@')4E2K
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M3^]II?\ +(_^GT^3^O\ [J+G^)D_Q-/Q&.9G\9#LO^ICK_'N/EYT3^]II?\
M+(_^GT^3^O\ [J+G^)D_Q5/Q&.9G\9#LO^ICK_'N/EYT3^]II?\ +(_^GT^3
M^O\ [J+G^)D_Q-/Q&>9G\9#LO^I;G_'N/EYT3^]II?\ +(_^GUY\GM?_ '47
M/\3)_BJ?B,<S/XR'9?\ 4MS_ (]Q\O.B?WM-+_ED?_3Z]^3VO_NHN?XF3_$T
M_$8YF?QD.R_ZF.O\>X^7G1/[VFE_RR/_ *?3Y/Z_^ZBY_B9/\37Z+P?YIH 8
M[?XC^Q#*"7H <4=95/OL!#LJEX6 /I^<!!-UV'T$<\/7?1#8W>C730,\[;U
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MKW)R+9<>N27+F/HFH=E[PTFXY.P?&;=VAVFOM0.-V;,_"F/UI<9^K7UO)OK
MZ:V.S6.*J\M&J=23I@I',%*Z7![X36S9RV:,C^<^FI-Q3==_#2B],'^T=E1T
MU&5OD.^Y ;]=32[2,J]Q=DE;7$ZBV,486Y.XQ]'1T;9Y".82*,@YD6*2E1EK
M/X>GQ(+%JTDUOZE2,AN'3&WOAX<:-/MVNR:<Z-8>)7$WD%%[#V1NUPY;VP8Y
M)?8K9XUF)6%E72=S=-*,W:'B'"ZR"+A2O5<?#YY_U%WR9I4?I*M[=TWQ2I'(
M.L?#WIU_OT0\KF[6G+G>]4V+:_P@@F6PZL_*OI+4\=9=?0T%?9^GQ-I<R2$
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MU';7=E=+JUN'>V6-HKM  Q6)Y#+O5<Y+12O--'Y,)IXW9#X0;!,C(YE495@
MPSV/;<>>1V\C]E119]Z+MX@$:G&,YN?<%#TSKR)XE@S(<1 B[XAF4A,H"?\
M-(5E$2(E-X*.OD6JI7J5<N^H72V<P>JM(5R9VN$2!5]X0++,7_[J*&27ON1!
MBL;2X!QL#=]Q( /EQW;GGR/GWQ5)B0-OY+[@@]-O)A&QOI)VPF-W24(U,E7-
M>:LBGX2@TX#?,R HS]_?H-(HZ$G)K3,G!C-/W ,HX8*,:5G3;2YZGU:&S:9K
MF+Q$GU.X1&BBCM8'WI!%[<C)O+;0\CF:61LR*B(B1X8U,T@7<6 ]IVP0!@C@
M \Y)\S@D^=;ZFC5NQ:MF31(B#1FW1:MD$P J:+=NF5)%(A0]BD33(4A0#V
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ME,4IBE,4IBE,4IBE,4IBE,4IBE,4K6'\7G]Y9:?].-?_ /KI,ZCZ'_UZVW\
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M3MNS04<NET6Z")#**K+JD22(0@=F.=102D*4OZ3&, !^D<QR2QQ(TLDD<<:
MM)([!41!RQ+=A@<\U](CR.L<:-([L%1$4LS,>RJHR22> /,U5^^;U^T)>,IF
MMCIO9IW(M#KRRJIT8QNV:KD<NA45(*9OD$T4E%'SLYR-CM2*(IE= L)<YSJ7
M6IO[^#1^F)%EG>8&XU26,-I\$$88R99B"6+!1G 7&>3Y]%TOHA[33[C7.IXI
M;2PBA98;)#F^N;N3"V\:1INQN8\CE@/:*8!Q92'>DD&+9VD\;/TED4S%>-1*
M9NX/X_E%$1)]T4S& 1+T(]![#[@.=#MY4EB219HY1M"M)&08WD7B1D/N+ X
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M;O=0%EFL[6YG2&YN8F7VHW2-RJR+AHR^]2"H(M?15E9W_4FGV]\%:'=)((G
M*32Q1L\43J>&5G )4@AL;2""17\WNMMD;$J&P8"TU*>FBVDDTR52%%XZ55EW
M"CI,!8/DO4$9%!^8PMW#5<%"N2*F3,41-WG\^]#US6]&UFRU71[R\75([N%X
MC'-*[W<C3*?5YEW-ZQ'<$^')&X=75B""":_1M_IUA>V,]I>00&U:%U;=&BK"
MBH?OD> HC:)1N5E*E=O?&:_KD9*++,FBSE/TG"K9!1=+_P"Z642*95/_ /(<
M3%#OW]O?WS^J$#.\$+R+LD:*-G3]@Y4%EY_8G(K\DN%5W53E59@I]Z@D \<<
MCGBNUF6OFN!#L!#]8=>WM]?Y<'GC^BE5IF^,%1L$L\DI.QV]RFY<JNBLUGS!
MP"1E3B<42.GD>Y<F03[!-,JQSG*DFDF*I@3+U3[WH?0M1GDGO!J$YDE\8QOJ
M5UX D/[&$-@# 'G]N:M]CUUU%ID$=OI\UE:"*(0B6*P@\=HQGY[D%=W)]I44
M_::PB2H^F]96-G'6:ES8QRJ2!V5OD'+V4A7KE3S!5A(M68H-VYT#^/BD9DX]
M<@^LHB"8&..F^G],=/3+'+TW!':K[<&I&U2ZC\9\L_K#,C^KX)QXK@ G)&.Y
MVEU/JKJ&#>G4MQ+<Q%C)I?KCVK3+SM,$"LD4Q('S% (SCVC@5$VE)^O;IN6X
M("\:6J=3@Z5-@QI<M#E/&.K*P!U(H 3U4G+8DTNLT;,I1-_$E(S*232;JI H
M4ASU7H_J)>M-8ZKL];Z9TA-/T>\2'2+A[6"7UR EU(>23*2S$*I1K=512V.^
MTG9U>PU7IBRT2?3M;URWFU" R7T EN8(+60[2!L5O":/V_;)0@ '.>144;>B
MM5)M4Y35:MYKUF1D$D5(&32C)&$2*W<$.Y7>)2I9.2:.$_$2-4&<DS\'1A.Y
M3(1(PF@^JINBH;:0V.DWVE:K'=&%&A@ELHXW0X,D@&%\(@95QMP3G)[5T?I"
M+K:[E1=2UC3=0T&:#,P,T%Y-,".(XO8#^)G!92O 4C%82SVALM@JP/(*5VSI
ML%D#$1M$*M*HMD .0CPC="3=3Z#8RS7U4Q&.-$B!C"8JA$A,4*SI76FMV3*J
MWOKP4A((M1\*[B.<*J%Y6$T1;L"LB*,^V"N15EU#H'0KV.8BVDLG969I[ /:
MN"/:+D1Q^')CS#1NQ\N<$55N7(_1^RKA(Z]OT16&1I"9,#)E:*PVJ=>=/6SP
M2LR1[:99(U9T\9O2%*V6&?).^J0/3C >%4(-SU'2.MW@75KBTTZ"&[M3.T^F
MVUMXL%N2 R2_<YI)G@C7,KO.74>&&.6" 4[3M9Z*LYAIEO<WUW+8OX#6FI7=
MUX-W> A4,9U+PX(IR24C%LL;D2-&"%+"K@Q6MK\I&-'T(RFY6-61!-%U%)?:
MR8&$A1(@N2-%VLU.(?=!)XDB8AA #@4X=A4TZ UZXA6YL/4-5AN TD,MKJ$)
MCD\7_M)(KB2"3:64KQG:5?<H!&;2?2+TO:NT&HI>6$T+1QR)=V#+/'G=NAC:
M/Q8]L0V[G'SU=2">0*H;9V%RXT==SSU %FZC&*+15U4I6"E6<NDW!,OS!W#N
M*<-+$Q*[72441?N(Z;K9RG!-\FV(W*9U>NGM'TW2X5M+^ZU?I77PWAB274$^
MYMY(1P]HT:7FGW$Y)V&TE5)L(&+B,H6I'5&HZAJ<[WVEV>B=5=/N@66&ULS)
MJ.G1@Y:6Z/CV]["@!SXZ.T*D\1F0'.QWBIST3W3K!:QVRMR=6L\+99"K3L0_
MC7CD4G[".B)$56DG"LEHN99+(2R!T9)JC'"H;U&[F+8.VSA M_M[[6;97M[P
M6E_)$X5+N!H8?%B,4;J9HDNIUCN S,LH!C&0"(8P<5S6XT_29W6:Q:]LX9%)
M,%Q!-,4D61XW,4IMK8O VP-'E),9*F:0@FMEXAW[#[@/L(#^G+15:JNNP..-
M<MSDTK7)V:U_.CY_NZO&2,T'U"B53N,7Z03]0O1#@W.BF*7F3TORJAAHVN=!
MZ=JL[7UE=WNA:DRLK76FM%X<P;YRW-G<136LZM^$K1C=DY)R<W;1.N-0TJ%;
M.\L[+7-.5@RVNHK*'A8=FM[RWEANH77\%EE..!C: !7:4X/7&UE4A[9OZT(U
M-UY)2L94HR/KK^;8&$ 4CWTFT23=().4^R.%V"S9X4!_(.$S?>&GIZ)]1FD\
M/4>L)I=.;B:TTW0].T::Y0DEHI[VS/BM$X]F2-%2*125>,KD&Y'TKZ;;1B73
M.B[6/4X\-;WNJZUJ>MQ6LH'LRP6-Z? $B'VT>3Q&#X8$,-U7=UUKJG:IIT)0
MZ'",Z_6*^T39QT<R2*F0I"  &66,4 %=RL8/-==3M14XB)A^@!UG2]+L=&L+
M?3=-MTMK2V0)%$@^UW;N\CGVG=LLQY)KD^JZK?ZU?W.IZG<275[=.9)II#DD
M^2J.R(H]E$4!5   KWIV B++'+14TR2?,E@'M-3R*=,XE,4%6ZQ!*JW6*4QB
ME61.10"F,7R\3F*.>[M+:^@>VNX4G@D!#1R#(Y&,@]U;GAE(8>1K7M;NXLIT
MN+69X)HV#))&<$$$$9\F&0,JP(/F*J#;.*]K(NLMK79XPK55918D+;(%K8HU
MLHI[G61,'I*?,']B"L!$C^BFDB8YR$#KENH^C*[]I="ZB]4M2[.FFZQI5OK=
MG;L_SO5)&FM;NV4\>RL[#&0<Y&.GZ;Z2;/V6U[IXWEQL6-]0T?5+C1;N=4QM
M%S&L5S:SD<X8PJ0>>_?"JWP9=3EP@[9OK9"VR&%5E$)NNZ^AXLE<H*,VU[,T
MFY**2,964D&:GY1J1VJJS14!-RFW(]00=)_&C>BUTN[>\ZFUE-:6TF\>UTVS
MTV'2M)29?F326D+N+B1>VZX,LFTM&93$[HV?5_2E&;*YL>E=#;0C>PFVO-5O
M-3GU?69;9@-]O%=SQQK:PO@;H[:.-&(5V4R*KC820A$B$33(5--,I2)ID*!2
M$(0 *4A"E  *4I0 "E       .LZ\!C@< < #RKD)))))R3R2>22>Y)J%-FZ
M6B[X0[^,D%*U8RG*NE)-D2JH+.4Q Z2SE IDE4W '(3IZU627*)2*F!59%N=
M&H]1=(VFN[+B&=]-U.!@]MJ$"*[1N#D%X25$@SC=AXV8##,<"K7T]U9=Z'OM
MY8(]1TR<%+BPG8HKHPP1'( Q0XSMW(Z@]@,G-3)W3?*=HNNVB&.M;$50#=S*
MLY+P)55!^BQXI Q4 ,(_>5#T2^J;R,H*IQ,<_+[[HCKQ97\"UZ4U NP)N_NA
MK6F(Y)&99=-A5HA(?:9TM[J)&9BQ/G73K'K/H-H5-S=]66&P#%FNGZ+J;J!V
MBBU&=HW\,?-5Y[>1T48 QP,ZX\<3)>D7=WNG<]H9WS;"\:I!U]",8_9M1U[7
M5ER.E8FL10J+%([=N"E7E90YSJOG*97! 0 2HIW+H[H*31+MM:URZM]0UIH3
M! MI#X&G:9 W+16,!4;68YW2D"1]TC2/+([2&I]9=?QZU8IH.@V<^EZ"DPN+
MDW4_K&IZO<J-J7&HW"X5O#&!##&%AB4!8HXU&TWFSIE<RIBE,4IBE5%Y3\+M
M6\MWNH)J]6?;E%MFB;7/W+6-XTML>7UC<ZW-VBKOJ;.J-K!#$.[!&1KDD]C5
MTR>F84'*R8* FLL112H6M'PL>-5YO5.VS>YO==XW'K<=$&UMN&V[3E)W9-!'
MC_)3<Q7?P:LCYFHHB%VDK+8'6V0?H2 ;$-*JIS0"@UCDF2E5,XO_  -](T;5
MHU_DY8+MN>XNZ_ROI00;7;&PU]-T:M<J;A<AN\KJ6ER9XT-?W:RZRG8FJVJ;
MA46J9WZ,P]8(BYDG<F^4JRM%^$=Q5HQ@=%E-U6Z:/MGB]NAU8KSL][8YI[=.
M'JDF72 *KJQS=LW@8./DQAI&!CVC*/DHQDQ(*:#LKEXY4KN;(^$[Q?VG7KQ2
MK+-[P0UWM/=>P=[[7UO![8EX>C;-N&RYRIV&Q,K=!MV@E7A&\E38HT",6O%6
M"#:N)=BPL";26>HJ*5]+3\*#B]8':T_"2^[]8W[]FO=V]([:.I=NV"@[&@[+
MR+8P<=N&N1-CATRBG0[>TK, 5Q6G;5X5DM$LG<>\:O$O7%2OTK\)3A@37^P=
M70M/M-8HVR>+E+X@3T' 7&113;:?HEGM%RARQCM^G(/D[:[L=PG).<M+YS(/
MIETY%=Z51<ZZJZE;)F;5%BT:L6X&!!FV0:H@8WD8$6Z144P,8?<Q@(0O9OTC
M[XI79Q2F*4Q2F*5T)2+CIN.>Q$NQ:R<7)-5V4A'OD$W+-XT<IF27;N6ZQ3I+
M(JIF,0Z9RF*8!]PS!<VUO>V\]I=P17-K<Q/!<6\Z+)#-#(I22.2-P5='4D,I
M!!!K)%++!)'-#(\4L3J\<D;%71U.596'(((X(YJMU*X:\<M?VY.\5G73)O/M
MG)GD>J]?2<HSBW8G]0CF-CI!VX9M%T#?Y*J1'U&O0>@9,0 0YUH_H?\ 1[H6
MK+K6G=/Q)?12>+;F>YNKJ"UEW;EDMK:XFD@A=&&8V5,QG!CVD BR7O6?4>H6
M9L;G47:W9=D@CCBADF3&"DLL2(\BM^&&;V_P\U9\1 H"8P@   B(B/0  >XB
M(C[  ![B(_3.F$XY/ '))\JJ]4?L?Q"^-59NJM,=6.7?':O#Q[^PQ4,H^KC-
MTFKZ*I1>%7([=)(J=E.YCV+MN( )DE5"AWG%=0]/WH[T_5Y-)DOKZ<0S&WN-
M1M+%Y].AE5MK_?PXDECC8$/+;PS1Y!(8@ F\6_H]ZEN;(7JV\$>]!)';2SJE
MRZ, RD1X*HQ!!"2.C>\ \5=&)EHR>BX^:AGS:3B95FWD(Z09JE7:O&3I(JS=
MR@J01*HDJF<IRF ?H/Z_;.Q6EW;7UM;WMG/%<VEU#'/;7$+AXIH95#QR1NN0
MRNI!!%4N:&6"62"9&BFB=HY(W&&1T)5E8>1!!!KT,V*QU63:Z6\3/)EI5(NO
M3U8?M/!FDJR9N)%@J=(A%@6;R*Q6KM0JH*JMSF1>-_%4A%&I3(^1Z?KJ=7M)
M.NBMH\MG-"$V728N%;&""'D\)N?FMP><[15PZ??HK;;?=T:Y;WD4Q<SV3J;8
MKGV3G9XZ-@#<H4CR#50-;6NU(%)-)Y"6$B22@E SN(?"F0_9A33*J5 6_L ^
M!#)G'R+T!!Z I"\0NNB^LX)C*VDW$C$EI'LY4EXSDL192._&,C'M$=N>_>X.
MN.AKF%(EU.UC$?">MH]NY'DA]9@5=I['G;COD54O=&U]UZ7L2<TPUC7+96R(
MI*RC>2*^@)P5 Z^8!]-*-Y**9>8F3^62GX$&*W9!(^67.=!O;NE^G R&*[UG
M4-#ZE9O:L-52R.ERVHRP*I?[Q<R% -UNLR3#E@K,H4TSJS6_#99=+T.RUCI@
M@NNH:5=7(OH;PXW'.G\V2<D":6%8V/L!_;S5N.,G(_C7R-A71Y>ER-8L4/\
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M@/):?;"V5$HE,="0(R[%)43%*1BL"!2_-.O4SP+X@G@/*2VT^1Y QQ^(I [
MAHUP>,9[UO" &P\1N&:>6$>YD6!) 3Y91_,<^T,]AG:N ]@ _K !_P#/*Q4-
M7.*4Q2G0>P]?3Z?R?H]O]F*5QT'??0=]==_IZ_5W^K%*X\"_>^Z7[P]F]@^\
M/ZS>WN/\^*5SXE[[Z#OOOOH.^^NN_P"?KV[^O7MBE<>!/O#XE[-^</B'WO\
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M !>5G9AX=60EI)?H/5>/5U53_K#L>X:ZN[B]E,US(TCGMG 5!^Q1!A44>2J
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MU(Z][JRL/.+Z^J41.3=IJC*=1C#WV,2C5&*E&_"(\PYCX@CZ0:J5HVXV<O\
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&Q2F*5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>g713200g61j34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g61j34.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2*$4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M             %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I
M;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!2
M96-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC
M<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /      0 ! \     !
M  $X0DE-!"8       X             /X   #A"24T#\@      "@  ____
M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
M?0   I,          0                         !              *3
M   "?0                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "?0    !29VAT;&]N9P   I,    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   GT     4F=H=&QO
M;F<   *3     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    *.$))300,     !?V     0   *    ";   !X  !(J   !?: !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" "; * # 2(
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MJGS_ %O:JF1?B]9Z <IK0YI82^LZP1K;4[_-W,_ZVMI DQ(.THG_ **Z<A(
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MK&.QQ_XQO\W:W^NU2"4)?.*/[P0W@S'R6C(H>/>);=409']8;F6-_K(K0X-
M<=SAR0(GY+ Q<3JN#U&HY-#<AECX=G89]$NG=[NHX/\ ,V\_S]7\VNA3)QJJ
M-A-DO__5]56=UNWJM6,QW2V"RXO(<" ?S+#4#N+?T=F3Z%=S_P#!TOLL6BDD
MISJ+^HNS\UI878X92[$%C?3;N.]N2SU@+'/^C6_^;_/5;[39=]8L.NRMK'54
M90.U^^3NQ/Y+%M+"+ZV_6;'ET?H<J9<W][$[->YW^>QB2G=20_7H_P!(W[PE
MZ]/^D;]X24D20_7H_P!(W_."7KT_Z1OWA)21)#]>C_2-_P X)>O3_I&_>$E)
M$D/UZ?\ 2-^\)>O3_I&_>$E)$D/UZ?\ 2-^\)>O3_I&_>$E)$D/UZ?\ 2-^\
M)>O1_I&_>$E)$D/UZ?\ 2-^\)>O3_I&_>$E)$E#UJ?WV_>$[;&.,-<''G0RD
MI__6]5225*SK/3:[+ZGW /QANM$.TC9N#=/TCF^M3[*_]+6DINK(M:?^<6'+
MF/!IRH:UL.&N)_..W.W?YJNX?4L+-?97C6%[JFL<\%KFP+-WIZO:UKOYM[?9
M_-O9Z=BJY%=;/K!@N:UK7.HRBX@ $^[$Y_>24Z6QG[H^Y+8S]T?<GD>*4CQ2
M4ML9^Z/N2V,_='W)Y'BE(\4E+;&?NC[DMC/W1]R>1XI2/%)2VQG[H^Y+8S]T
M?<GD>*4CQ24ML9^Z/N2V,_='W)Y'BE(24ML9^Z/N2V,_='W)Y'BE(\4E+;&?
MNC[DMC/W1]R>1XI2/%)30?T_)<; ;VFMY,-+7: O]5K26VM^CN]/V[/9Z:-@
MXEN*+!9=Z^X@M)!#N '&P[G[['N]S]GI5_\ !*S(\4I"2G__U_551MZ+TVZV
MVVRF7W_SIW.$_1GAWMW>E4YVS_0U?Z-7DDE-.CI.!07[*I%K&5O8\E[2VLN=
M6-EA<WZ=EC_Y;WJKG]$Z?E7,J=ATECJ;F[S4UP8YWI-:[Z/M?]):RSK\+.?U
MBC,9?MQ:V@/JW.$P,AKV^G_-O]5]V,_>[^;^Q_\ ")*1?\V.B^MZGV/&CU!9
ML]!D0&>ELX_>_2(8^J?1Q66?9<>2QK-WHLY:XV;_ .UNVK:224X5?U9Z5<'E
MV%1419>!-#-0^6L=Q^;])B+_ ,UNC;P[[)CZ&LQZ+/S 0>W^$W*YT[$NQ67^
ML_>ZZ]]K6@N+6,/LIKK]3Z/Z)C'V?\/ZRN)*<+(^K'2:\:YS,*BQXJL:UHH9
M)+G&QI$#Z3?H(Q^J_1B_=]CQH]0V1Z#.#6:?3X^CN_2JSU#%S+LC"MQ7BO[/
M8]ULO< 6NJMI -+/9D;+;*KMMO\ HDNC8>5A=/9C9=WVFYC[";B7.):ZRRRK
M<ZTN?[:GL:DIJ-^JO1P&@XF.=K:6SZ#-?2<7N=Q_AYVO47_5GI!L]$8./MLK
MR/TGH,]IL>QU?YO^#:[]&MM8N7TOJ=V<[(IM%=8OQ[&5BZP LJ.[)=:T-V^I
M<UWH>C_1_3_EI*9_\U^C>KZGV/&C>U^WT61#6&O9Q^=.]#'U2Z0*RS[-CR6!
MD^@SD/-F_P#Z6Q;:%DL>_&M96 ZQS'!C7.+&DD>T/LKW/8W^4Q)3D5_5KI-N
M\NP<>O;;;$T,U#AL8>/S?S40?5;HP+3]DQ]/2_P+-?3G=V_PLI^D]+ZEB9CK
M<G*-])I:P,+W.]X#-QAWMV[Q=L_D6?\ &>KKI*<+)^K'2:\:][,*A[Q3<UK!
M0R2Y[O59M@?2K_FV(_\ S8Z+ZF_['C1ZILV^@R(-?H^GQ]'=^E5CJ>)DY/H?
M9W^FZNUKWOWN8=@(]2N&-.[U6>S^0I]+Q\G&P:L?)>'V5RT.!+B6@_H_5L=M
M]6[9_/6[*_4M_P &DII-^JW1FM:TXF.=K:6D^@S7TG;W.X_PWT'HN'TC#Z?G
M,?B8]=6]EV^RJMK/I/JLKK>Y@_-]WIK36)?TGJK\^^X94T7VX[V /L8ZEE)M
M]9M-?Z2G=<Q]53OH>I^ELL_P:2G_T/54DDDE*22224I))))2DDDDE*22224X
MMGULZ51DY%&6+<7[*]U3[+6C:YS12_\ 1"MUEMFZO,QK&_HO\*BU?6CH-TBK
M,8]PILR-@D.].HN;:[:X-^CL?[/I_P"$_FUC]5]']I6[OV5/VBR?7]7U9]#I
MOT]GL^T?1]7_ +K?L_\ X9#Q/L_VG/\ ^2Y^QW?S'KSMW7;_ +=^9Z6[_P!"
M/Z1Z'Z-)3K,^M_1"U[K;'4,J;2;76-.UK[Q;LQW/K]1OK5?9[*[]OZ.N[]!Z
MGK>Q7<'J^%GY%]&*XO\ LX8XV""Q[7NMJW4O!.]K;L:^IW\NM<7B?9?M.+'[
M(W?:,7^>^T?:)]_I[MWL^V;/^L_M#[1]I_3K7^HGH_9F>GZ,_L_!_F/5C;^M
M[/3]?_ ?^#_;?M_VC_!)*>K22224I))))2DDDDE/_]DX0DE-!"$      %4
M   ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$
M9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$
M(@     !1DU- "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %
M     0   '8!*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!
M.P "    "0   +"':0 $     0   +P   #H "W&P   )Q  +<;    G$$%D
M;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#<Z,C$@,C Z,3(Z
M,C4 <G(U,#DQ-C<       .@ 0 #     ?__  "@ @ $     0   I.@ P $
M     0   GT         !@$#  ,    !  8   $:  4    !   !-@$;  4
M   !   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
M      !(     0   $@    !.$))30/]       (          #_X0%(34T
M*@    @ " $2  ,    !      $:  4    !    ;@$;  4    !    =@$H
M  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (    )
ML(=I  0    !    O    .@   /      0   \     !061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR,2 R,#HQ,CHR-0!R<C4P.3$V
M-P       Z !  ,    !__\  * "  0    !   "DZ #  0    !   "?0
M       & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@
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M*7T4LL<L*XMU$XN:\2AVYE5O#58H;E5U:T4B"YD9;F(X/V:[[LIQV27'B1G
M&25&,8%TZRLK'5(8^M=#B>/3]4N'BU6T."VEZP<O(C!!@0WB_?POV+,RKZ*)
M\XY<JFCVEUEA?6<I')G;>D;/W:#QQ+0PM2 *T7/M1247D6D4D)>RRQ:C\$XP
M6JUD;1:W<\=PE<]K?:-DXV98MI2(?LY2->I%7:/X]RB\9ND3AU*J@Y;G415(
M/X&(<0_#[\4K[L4IBE,4IBE,4IBE,4IBE=>GF](2''SD^PGZ%#$NNQ BH&Z4
M2P[UI]2W!7X64?V:;=K5^'LZVO)'=VO*M#"A(+1#ZMWF1C(FR2T/$-(>,0?'
M6!_=_M2NP/%.5GL7&O'*)F[AVP9N7"!B&3,@LNW3551,F<3'(9-0YB"0PB8H
ME[3"(@(XI6E')K3NS;YNS0%XUK$OT#TJ*W' V6Y)74(9O 1^P]:V"JP:R%:/
M*(EEW,5;7D'8G3IM'&D$6L83T;I1P@BU.IS_ (?[UP/$'1&_-.ZUM\'.R];J
M<W,SU$<PT6_7?[%BH]*MZGI%-NLL!6TM7RI.[]>Z_/W8QTWGJ%#3)W\R@,R^
M?)HJ57#\6#:>YF=5U?!2AH^0)K7E%KB^H3$/37%?0=KZYAK7<SK-'Z]UGE2E
M!I%N3 B:-,=0R8E!1/Y=UOZ#,1ZLTJWG_FKX7^FL2,@'4=-O+*//YRSQKR<<
MYYQ6I>DK:RN.#'LE_P#Q2)(1V]0I_/TJZ7=6JJQR5TR]K#I9 [:QPS:<J\RG
M]J5C(N8\5XB30.3YF2,1T &,0>HHJB<GURD$(&TN9])O]^&$EO*\4T9X)"/M
MDC8'L<J1@^HP>,U;.ENH;CIK6+75+<ED4A+B('B>V9E+ISP3P&7/!(P>":I]
MUHQL#)];(^28KMMC0[U"M;?JQ)8E=?3%OJ8@G3]C5N=<$+'5_8"S-%F\J-P?
M';14M*H+5RPOC,[<U68;6MV<<4R7EJ-UE?*)H67X59N7C.>Q5L^7N,$>E6']
MH.A6]G?0ZYI05]"U^,7UG)$,QQ2RC?-;G'8ABQ"GD$.N/(,V9\5>3C?;B,C0
M+>Z30VE40<I._41ZT"XMD5'K)M%IH:^\*FY@K!'K*H-;A6#>8822536:K.8=
M_'.E82N>UH%$<<F^_JC\0YM'QZ#ZZ5[G+MB8JZ!A*B:92_1AJAK,U-=R)1,D
MC86)%6[581$&,L6-D"AW-1[KATAU V@:M"\DA2RN1'%<GDB$[@T-T%[%H'PS
MC\<)DC/Q<>=Y$)4 QEA$I&> >^5)^8XSZ>4^E;-_#4WZ]O\ K%_I>[2"SG8V
ME"M(I)T_!1%_:M<.P,6FV8R"_1<'31)):L3Z)^]6/G(=RT>'!V"I"RW[1M"2
MPU)-8LT"Z=K6^4JF#':Z@@'VNVW+Y=K96Y@/ D@E5T\F#6K8S%T:)S]Y#@9/
M!:,C[M\'GMY6SV<,I[8J".9M#=<?=UQ/(6MPQI*EV5;IL6NH)B#63CG*:L9:
M&BB1/JBH_B'SD"&-T 5'A%>I CRG+$Z6R:OITFE3,/M$0S:2.<;7Y\($G\).
M$;V7. <UW?IR2/K;I"YZ8NG4ZII8,VDS.?-N12T,98Y.R15:%N>-NX#<V:@?
M8C>PZ>VUK:/JIW5KTCR3Y'<6YQ^^:'!5&(OS78]6L-,VH0B?5).)VG281S7[
M0LGV$#8%8564+Y)5 %*S;1M]H:-@RLL=UN!!RK1V\I(8<%2"",>XYKCT,;+.
MT<BLKQK<*Z$%2KQQR;E(.,$,N.?7C'-3WS2B)?A_RJUESKI;-P-!NKJ,UAR-
MAXY,_B<(."@UB+6X13#QF<*1R";$%S@7K*1$,F8PG>G$>K='31=6]+ZET1>N
MOVZR634^GI9",J5.Z6U5CSM65M^!D^%-+CA.(&Z5K6ZCO4_FY,0W( _/PY"!
MWP?*??R\BK6[C6*?N[6$Q6WYVTU3MAU<R23QL<BR2\?,,RN(Z58+%'H"R J-
MI!BX3,!DUTD52"!BAG*8WN-.O0VUHKFSG(9&&&22)L/&X^>"CCU!(JS:3J=S
MI&HV.JV3[9[.>*XB(/E<*061N^Z.5-R.I!#(Q!X-4DTIM)4J\3M,O#AJWGF$
M^GK6]'ENH1QK8@T63H]]62ZE,:M[#J_5G8#%Z% A;@[[O5S*)LG=;@2X2WOK
M5,QRPF5=H.?"#'Q(F[YDM)6*>_@-&O:*N@=?Z?!='3^H-+B!L=6LS=PL@^!
MW\HM9,<";3YF:/GG[*T8X$%<1\-Z\R-=^(YSBJELE7 FW#*1KFN>[HJ-9%Q8
M=,5.C5V8KCTRINUY8X:&EA-*.D0\<H#-64;=4%0R=NX1??LTTBYB3=)H6OZA
M;7>W#&.#5(X[B&5@!E4:2,1 DXW\?B%<B.8=2VOP+JQCEB[X)AFFC<9/KAU.
M.V.:M8Y=Z7L.Q:E"WK69S1^YM220VJAR34_IWSU-,G^6:UYP^1T9EH40(U<
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M)=2MV#@6T38UFYG*4>1^B_C9ELD/:K(U692*FWGHXAODN"9$).-./IY>-CW
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MXXO8%PL<4C!+@*$W!F(I5-H5M]/MV$C[EINR@L9RV:K"T?#1Y.1/YUGL"_*
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M,I,WI9\&11*HJZ;NGY![XI(AZKI.HRBPU&U+922PN$=<!OAC)ADY#;2I)CW
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M^Y9BOH,C&X#Y-E9%]@^WN#6XW&8?X\<P/V<G9 /_ &?U"/\ U_Z_CE0ZC_\
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M_=F:5YQ2F*54[R?;1)>2/%5PD:)]Q-S(I8*@CH6>@9'YZ\V.!_-N%=((><_
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M$PJ%,.9I0/A^U'T92C);Q]5^F(SXQOUI]_?Z+O>3G*TZAL_MZ>U]I/3?Y_\
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=6/7\@/[S_M5UF*S3%*8I3%*8I3%*8I3%*8I7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>g713200g61p76.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g61p76.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2JV4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             #
MI   !?0          0                         !              7T
M   #I                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   #I     !29VAT;&]N9P  !?0    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   Z0     4F=H=&QO
M;F<   7T     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    $.$))300,     " H     0   *    !B   !X   M\   " , !@
M ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@
M!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(               $
M /;6  $     TRU(4" @
M                       18W!R=    5     S9&5S8P   80   !L=W1P
M=    ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    4
M8EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP
M  "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:
M!#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X
M=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A
M;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2
M<U)'0B!)14,V,3DV-BTR+C$
M                             %A96B        #S40 !     1;,6%E:
M(                     !865H@        ;Z(  #CU   #D%A96B
M  !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)
M14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@
M            9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'
M0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N
M,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M             &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I
M=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M              !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@
M  %865H@      !,"58 4    %<?YVUE87,          0
M          */     G-I9R      0U)4(&-U<G8        $      4 "@ /
M !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P
M@0"& (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .4 ZP#P
M /8 ^P$! 0<!#0$3 1D!'P$E 2L!,@$X 3X!10%, 5(!60%@ 6<!;@%U 7P!
M@P&+ 9(!F@&A :D!L0&Y <$!R0'1 =D!X0'I ?(!^@(# @P"% (= B8"+P(X
M D$"2P)4 ET"9P)Q GH"A *. I@"H@*L K8"P0++ M4"X +K O4#  ,+ Q8#
M(0,M S@#0P-/ UH#9@-R WX#B@.6 Z(#K@.Z \<#TP/@ ^P#^00&!!,$( 0M
M!#L$2 15!&,$<01^!(P$F@2H!+8$Q 33!.$$\ 3^!0T%' 4K!3H%2058!6<%
M=P6&!98%I@6U!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L &T0;C
M!O4'!P<9!RL'/0=/!V$'= >&!YD'K >_!]('Y0?X" L('P@R"$8(6@AN"(((
ME@BJ"+X(T@CG"/L)$ DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5 IJ
M"H$*F JN"L4*W KS"PL+(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,
MC@RG#, ,V0SS#0T-)@U #5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2
M#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1
M;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G
M%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT7
M01=E%XD7KA?2%_<8&QA &&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW
M&IX:Q1KL&Q0;.QMC&XH;LAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>
M%AY 'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/ A'"%((74AH2'.
M(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E
M]R8G)E<FAR:W)N@G&"=))WHGJR?<* TH/RAQ**(HU"D&*3@I:RF=*= J BHU
M*F@JFRK/*P(K-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N
M[B\D+UHOD2_'+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X
M,_$T*S1E-)XTV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V WG#?7.!0X4#B,.,@Y
M!3E".7\YO#GY.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/> ^(#Y@
M/J ^X#\A/V$_HC_B0"- 9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/ 1 -$
M1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T? 2 5(2TB12-=)'4EC2:E)\$HW
M2GU*Q$L,2U-+FDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/ $])3Y-/W5 G4'%0
MNU$&45!1FU'F4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$
M5Y)7X%@O6'U8RUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>
M;%Z]7P]?85^S8 5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/662
M9>=F/6:29NAG/6>39^EH/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM
M8&VY;A)N:V[$;QYO>&_1<"MPAG#@<3IQE7'P<DMRIG,!<UUSN'04='!TS'4H
M=85UX78^=IMV^'=6=[-X$7AN>,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]
MH7X!?F)^PG\C?X1_Y8!'@*B!"H%K@<V",(*2@O2#5X.ZA!V$@(3CA4>%JX8.
MAG*&UX<[AY^(!(AIB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/
M-H^>D :0;I#6D3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,
MF+B9))F0F?R::)K5FT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B
M)J*6HP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OI
MK%RLT*U$K;BN+:ZAKQ:OB[  L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V
M>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7 <,#L
MP6?!X\)?PMO#6,/4Q%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,
M-<RUS37-M<XVSK;/-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<
MU^#89-CHV6S9\=IVVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC
M8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]
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MP  1" !B * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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M5XJ079>(PV!UU;33'J@N V;OH>IK[-_YNY&6*1A#.ZF:O0;D?JYR'-Q2'_\
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M^54DE/U4DOE5))3_ /_9.$))300A      !5     0$    / $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T
M &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      49-30 J    "  (
M 1(  P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $
M @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !
M  $   "\    Z  MQL   "<0 "W&P   )Q!!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#$Y.C W.C(Q(#$Y.C0U.C,Q ')R-3 Y,38W       #
MH $  P    '__P  H ( !     $   7TH , !     $   .D          8!
M P #     0 &   !&@ %     0   38!&P %     0   3X!*  #     0 "
M   " 0 $     0   48" @ $     0              2     $   !(
M 3A"24T#_0      "           _^$!2$U- "H    (  @!$@ #     0
M   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M'@   'X!,@ "    %    )P!.P "    "0   +"':0 $     0   +P   #H
M   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M #(P,3DZ,#<Z,C$@,3DZ-#4Z,S$ <G(U,#DQ-C<       .@ 0 #     ?__
M  "@ @ $     0  !?2@ P $     0   Z0         !@$#  ,    !  8
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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MB<(L=/VZIU3X'VIL]>K6"DC,09D^:&A\$9>/1YQ8.2,F-\N1CW&_-B/[CO\
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MQ#]:?ES<S[Q9J?7(\8>QE<N4J:=BK]AI>(Z)#WH97J7K3TJLMEJ\UEHFY%%
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MX<-Z/*CO1FU\K!Z8U)&1 >GLV!@[B0EBKS.SM_\ 06TUNJ[;M9K[?/K1[?\
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MR093'EPLV*W![  ##/O7ZI0[.XPRPGR?GLT)_P ;^RA%"31<_JT@7OETN-$
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M6'EQ;Q*7(?8KMBSD=,02V;<QY? U@*2:<^(Y;&5P$B>21]QCRM>(6;F;=*^
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MY5);MJW0$N?#E7R%5Z,]0R<F<8+XW1E )&BG"0=GULM:R%"N!QS1&[FPL3
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MVGKO"O\ K]R^ZUK^E0.]H=TH)F_+V2;.FM<4.TN5ZSB]BTC[)3D$BMA*8.3
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MG?5HQLT.)KCQZ_6"DS#HV'.R\_B/";1EY[.459;:P"7V@#OV4S2:=KN^7VZ
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M20W\S8PM_0^EX-:T8^SO.5>4,7J.*#=AKUJNH[H[%-/U;(,9\\8SC\F<>?\
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MG=Y9;5S+2$,39I0NPM/M9QBBV:&8UAM5Q$C.=;7^,@.:)?#3E4R5327N+ [
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M:!"Y<:@VD4-G2QM8DA656 D[\"+';ER?8=>4-?2YR_6NH@TEK_ Z>RE:/JC
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M>(=BA7\0/(Z>R33$UOQ%Q&$?(YV]#Y5X:L>I\/4O8K'Y-QM-%-<U!#%;U"\
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MU'!$Z+MG7D"L9H([8 .YRHDZ6$L6$TJ/77R5B*P6R[L"!?\ 660T?A8\UH[
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ME<'LPQ,4]29GBLQ"[R02L\<H@;.RR?FPHM.$3A$X1.$3A$X1.$3A%"SQ#=E
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M;JM;H;X:<+80TCZ42-GK=- 5 */LLYU FL,3#_VALA9+XJOUXJ395"Y;]0Z
MRVD(BN:MNXC3^-"!IWR%J[UPE=RXO5IU*4=F]=NL7 .A7K$/.6$7E'JAOL:9
MK6]8Y>A@M-U)\GE<E9:K7K1BT0@^SG)8M6)WCKU*5>$9+-NY8E""K5AGLS$$
M,,IC7GXBW3_N[VQTB9WCL4CK37;HGX=G$:1C'[%(GZRHHB$MU(D]<TPI@BT6
MPI*G2IED& *M7(JR\<(N3:3$&N!Q<'=T)JW07AUE,GJ_(0ZCRDSX@JPVYJ-*
M*6G1.2*>2E0PS9*2&K+)+%%)<OSY*>Q:XM7Z%:*.,6N=RCG-9M@/!_2\N#J5
M9M0,5B_!;LRU=3:C(9:D68OY4L56O28NI7.6MA,<-#H489;%H>O;OVK,MH^@
MNI&^*-HO6U)LW<'L#6K=4Z4,K<L:!D=>;Q5Q\P-%^G0UC2]OZV8MA<0MJ/'E
M-1CA5\K'CN?3)!F8['^I/:V=U3A+V:R-RMI/ V*ENY+8 YPSU*S($Q=0VDBJ
M:B>K#*SD0.4$31$3=4808NFW-J]6>.O%&5RPQA&(/MY:0=Q;;L1U6,F[;^\_
M+;LY._=>'8K0?:XYHK:P6J]H+5=+*4HMB@ ZI^"'4 YTZ4ECWF((^(6@/T66
M%G.R'&LP3C%I%J"3$,%?[\3#S DYP&=TO!F\5-:TS6J5XKU<YK7M?+FT$0R,
M\DAQ&-X9@86?G 5:7K Y1;QN?,5BO:*&80M$1%&;"#PP]W<7V9G;INSN_H_,
M=GV=^S;* ?A8:^\1/K5K_9WX6=+XVJ@]:19)F79>Q8>=>9 R##4/6/I+BY=U
MIQ1H=*04=FC3UHH:D3Y24MDI_K6W"O'B5D_#W4]W&'A\V./:"M+$7E,!+Y!I
M"DY<[;@-.U&\@],1D@KWF88WY11NVYQ^)AR=2*5K,/5(I&+<[+%([<=FX.[F
M!;;/NQ''W=GW+OM:X+[HZ;C34!=KIMW72QN2F83(K?U;>U\,G3'T>IN.#V [
M((:NLKJ_2O"6ZY>"KJO;7GV_2G.><QDTAF"!YL7Y34-=A<WEP-AK\L8B[[E/
M09H\G6;;B^]BE$W=N_RE?.0B^TW*L3OMM8'IB[_)I-WA)_EQD+?X+=@#<VH[
M7<RVN:QLZ@V*_ 1L<P:I82W@"MH%"I648CD2 .#/?)18;F7&?*0]&2UCY$;*
ME8Q)8RY#SXG*U:D60LXR_7HSR%%#<GJ3Q5I91W<HXYSC&,C9F=^+%OV+M[I;
M>XS1&;QA+&1BW(@$Q(A9_BXL[NS?>[?+YK97(]>B<(O!QM#J%MN(0XAQ"D+0
MM.%(6A6,X4E:58SA258SY93G&<9Q]V<<P[,[;.S.S]G9^[=^S_UMV61)Q=B%
MW$A=B$A=V<79]V=G;NSL_=G;NSJN#KMX?%-Z^=I=I]@*SL@H01=89QJ+K5L;
M"'P*NQ<#C1N0U,EQR$ETG!AK'H8KK61PI,5G#R<YD^PC/*!@?#ZOI_4F1U%!
M>LE%D1LA%1> 8H(?,3A/*+2L1-,,+B Q",<72$N^_NK].^)GZ3F9\3?";2/A
M?D]-8^O/IJ;%RV]3/>EMW<F^(QTN/K2A5.O%Y&>V,TDF0D>S;>S(S./3Y&RL
MBYT!?F%.$3A$X1.$3A$X1.$3A%I??&B:;V'I$:B7:?;1 ^!:JO=11BCV.75+
M,(LE/*-%P1$::A)6]'7&F-)RXC+:VWF\J;6G.,_<1?/U\T)6.MVN1>K*7:-B
MV2I@&1T"MM;(N,VZ3ZX"$!AH$36@D^>TT]"KXP>*CXACL86EMYR2]EQ2WU<(
MMX<(G"*%WB$?X)>Q?]X]-?UX:WX131X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$5=FRO#HJ6P>QZ.S4'?6[Z%<(]Q@[ '
M5JM!NNM@IPBXQM<5;4\VP"&=H:#V%9AY(O1J>($2Y,:S(=@^J?) *#R)\EQ9
M%8GPBU?N/;U.T9026QKRHRL+ )5H#%'5H&1LUE/V6Z6433JA6:W7A++Y$R>L
MMI.B @J!&;\WIDYKW5LL)=>;(H;]WMJ43;'A8]I=J4@\P2I.S.E>YK132DIM
MX4Z4%V'3UC(#<9'DD19T6>MAY*9 R5':GQ)"'8TAAM]IQ"2+8/>JEF=[=1-V
MZGU:<IK^P;A4&(=58-VN.%'NE(1@270VX28?RF/(6R.>3 3-RD5(GYBQC*TB
M7IN<;V-J:<O9"G4U=5ENZ:GL1AF:L,UF YJ;DSF#G4DALO%R87GCBE IH6.'
M?:1V4QI_4F=TAF*6I=,70QVH<04UK#WCHT<BU6^U>6.O.-7)13TWDC.1GBGE
MAD*G+PN0 ]B")=4BH>&AWWKUHZZX,:XUO.AFKM%(WF1)V$!)QA(ID]"?>'[?
M>&V-*8 AL ,EJ9>HKT@H_"G9@?4UV%P/!C7ZYX9_HIVI-2W(\-8@FAKPOBHJ
M^2U'6BCGAB%VDP-1[80@<MMQ>:.X)PF;'*\85RF)^LQ_I=_I/Q4*6/+7,,X3
M!;AR\UG3.DYK5^.P,E=FRMXL7)/<>*F;1P2,T)PA'#%O(\0.]P$7P7=9?68E
M@#=@*EH^6ER=)E1^O8J\ ",U<M_*VQ9FV["WYL*;8*^PWE"W@_T<- G$XT$J
M[$:D0FDYY_!2T=1)BH8S5<K,T8LV5UK:OPNP"3.;5CQV\9FY,SAYJ2%@9FX$
M3,;4F]XBY?+PR19?3OAS:,RD)[5'0>'TW<%I" B%YM+>Q&/<@<^M)&5D7,Q&
M88R>-<N7\'6O2G(TN-WRW1/DPV9668IG8%O!P/F+5&<COH>U/M;6)1*FEL*:
M_P#%)IYAAE]:XT1N3CW7/>[F[>Q#B,%HVB/)^)7L5GLS8*,6=H@EEMZJ" 29
MMGFEK4X.J;,0Q1@S1-H8FWH,29]0Z>U?><FBYE@]:8G"Q1&Y.]B2"O;T1FY"
MB?\ XK7FN$<0LP36IR=Y&V_;.F!"P,0A]\DJW./'LOC43U^)!W1H9B9!FP&V
MYBY8.;9;>(:R]*9PU-:9//,36E)D,PH/GF&UJ_KOXAUB?RV/T6(]7FQ8K&X[
M"R[,SN&X-I^Z3O"6XBYW9"V?FSB79IML+X)7XV)M1>)F!G>)MX<A@<-J>H,@
MR[.PWJFJM/S2--"[2,WLB 89&>%RE%AE*,MAZ&]8]?42Z1'-,]GJ.,>JI9R1
M*JNW=*;[C@42H)+Y"HEGV"?M&WB\89.D2ID5)!Z?*BPGFU--BX+"80_4L^)F
MN*\?F+K:P'RT?7<Z.5@MP@0MN?%H,E'8/@X,_)JG+I\3(!9B$=W'^%&D<[?J
MT,!XH: G._=:C5@SN-U1IZY*\DD8P<AMZ=L8J,Y!D%F \PT?F6*O%/*[Q22P
M.\#_ *@[(E53<A%[N*7J\VK[1U]9Z["GZRUZ9KCQ$95+<+&%R &UIE0YYT6D
MO(D0)3,_T#YZ62JH*B;8PC#J=#Q+S7C/?',ZCEL20:::*OCZ,SUSA\W*TI>>
MD>O5JQG-%"P-&#@[C,9V)"DD&L<78?&CP@']%G$5-)XC+5<QFO$>G>/,:EKU
M9<;;IZ<I24!ETY0JEDKIP5LMD.<V4OOPDNTJU?%Q/%5/*06["O%#N7B4ZWZU
M1!.O]Z=7-K#K->JM7]CDZOK ?JC9+.M'QQ;-I?&B=A;UV743"72L4$T6=K@Q
MNPQQY>;*%#1<4:]/1L:PLUZ^G<HUBQ# \U2:.%II8XGED8>7"+F0N9[-OP'<
MMOALN3^!6*R^3\4M'28K&9#(M0SE"S=.E2LVPI0.9"UBV5>*1JT'+W6FF<(^
M7N\MU,30A;Q%-D:,UB9V5V=Z6:YO9;6X'[9.5'39G;Y!J[R!K;%A=^O#^Q]*
MU^V5#$VY#;Z ( W5UFD2F(T=X5$91,L,,\-F()Z\T4\,F[A+#($L1LSN+N$D
M;D!,Q,[/L[[.SL_=G9<NOX^_BK<V/RE&YC;]9Q&Q2OUIJ=N C 90::M8".:)
MSC,)!8P%R Q-MQ)G?(]D]5]Q[=UYL6@W7Q.-S"HM]I5@I"TZTHG56C#(D&PA
MB(F5,DN2=3V6]Y(+P05[TRL[#J$QN(PRT)E!R*5&%>JTU"OPX?"7V1X>VC['
MK&H>)QL1)6Q[&(7UV!6J%HJ5J=I3\<2+2S)J.TJSLFZ*(DAHGUG9U8V33(DN
M4_#_ /#%O"5D"Q-V^:L!G5'N'&%N!7^T?43< *1F9$EBMK];300@2'2''GXK
MALS2NPV:P3F1/[A#=8A:U!P)T=.9"FF)+>?D?<4LL,@RPR20R@[$$D1E'(#M
MZ.)@[$+M\V=E\NPDSL[,3?%GV=G^;.S_ (KK1=<>IO>*!XJ^_P"98>G>CZOJ
M3$'8!0+9D;JVUJ7KM)4<G@G1/X-MG40*3N!#$YSZF]$JJJ1$8AL.3(Y(;7FA
MT!.>GWO%O4U[3>/T](-/G2>%I,I-"%RY;CKB80M-'=&Q7ZG$AZL_3>65PY;B
M1FY146&J16Y;0\V>3=ND).$8.3L[\>#B7?X"[[-N^S>FUVZ>OW:.*PN,(%:8
M"QD^_F$/&>+5XAT(..]Y;CJ688J%K2)'C0F7%Y]N%%S&:0WCVFLM8\LXJCZM
MRA/RDJZ=E-]N4DND],2RF[,S<CD/$$9D^WO$3N[OW=]W6\U2(>S%8;X[>;M?
MN_;>G]GX+F4=4^R^4(R[V2UZAS*$Y<2CLOXACB$K\L94E#BNX32G$)5YX2M3
M;>58QA66T9SZ<8_6S(_^HZ9__1^E?_\ '6?*Q_ZUC_\ +M?_ -R^N+UA[NR/
M9BJ\1*DTX;!B)CLICUW9>R9\U>,MH:^3/.]@Z9+8Q&8:SA4F5(.3R3SRGI4A
MMQM:Y/R6I.;N3X#36Y.[OQQ? 7=WW?8!G8 ;=^P@(@+=A%A9F;#5V^%BP_XS
M;_)OEW_%^^_XNHH>';TA[C=>_$(WSO3L1MO7UUUL>K5P""]C#]F29Y[<4NPV
M4$5KDR=02!(K/IT>NC!\GY\"PV,Y])(HBC:[,-#UK,LV_4_B-5U%H[$:8CTY
M4QDV.FKS'9JD#5A>O#-"7DZW2:2#S/5YS<IY'9V=G>3?D.C4Q95;UBX]N289
MA<6C-MW;D8E[Q\MBX;<0V!O5=AG[45G](@7\[C_WCG+%+KZHAL-/>^/!+C)K
M_I4OV(D^+(>]"?+"E^VRZM?I3G./4KT^6//'GGA%R?")PB<(G")PB<(G")PB
M<(G"+2F^]_:]ZWT5N_['<L#@R6>$U8,'J-:+W"V6.Q&<R'(8BO5H%&E$RLQ,
M&$2+2D,->F*)%D9[ZT,1',\(HX=YKK5+9TF.7$"='3JW=7M#66K%??3'8,@S
M.WM7EQQ"&F3[+JVI V5'E^G+:7&VG,9=0C.,XP13>^T]:_2$'_.T#]XX6-V^
M;+\^U%9_2(%_.X_]XX64^U%9_2(%_.X_]XX1/M16?TB!?SN/_>.$3[45G](@
M7\[C_P!XX1/M16?TB!?SN/\ WCA$^U%9_2(%_.X_]XX1/M16?TB!?SN/_>.$
M3[45G](@7\[C_P!XX1/M16?TB!?SN/\ WCA$^U%9_2(%_.X_]XX1/M16?TB!
M?SN/_>.$3[45K](@7\[0/WCA-T^U%9_2(%_.X_\ >.$3[45G](@7\[C_ -XX
M1?OVGK7Z0@_YV@?O'"QNWS9?GVHK/Z1 OYW'_O'"ROW[45K/Y+$#S_\ NT#]
MXX3=F]7V7TQ#8:>[[$$L,FO^G*_9B3XLEWT)\L*7[;+JU^E.<X\U>7ECSQYY
MX1<GPB<(G")PB<(G")PB<(G"+3N]],!=]ZYEZ^,V"R5%Q-DHUUKEQIZP:;13
MKOK6Z =A4:TA&[,$LM:E305KK0@A@?8:\;!D6678!47-A27F%D4:]S]+^MA#
MHR3ZJW:JXL6K*'HRRT>J$RU;K-]V37,0=>F *[M2$GPTJ)G:R(#\\B-)"Q\.
M0^;D*3&:CL/>RDGU\OK^_P#!:JZ>4CP[NYVF(6Z]>=(^O8.NRK <K2(U@T5U
M\*J?F '([<J4+/T:-;:D>&JS)0PJ:%/SFX96.4!S\12X@C#8(I0N]'ND3+:W
M7NH/5=IIM.5..NZ!U*VVA./RJ6M=3PE*<?Y<JSC&.$4,M!:$\.&;O_L5UBJW
M6+3=[MVM2+.XKM:['H'4$VGA9.Z;5;)4/5E-+?9S+\A&O8P)J)-&,Q5P 34^
M$.R044;)"Q9%-'\1GI/_ *'O5O\ H_ZG_LEPBK_QIOP\HOB$2]5*ZDZP=*E=
M9U_5.$JT'HG\"\#8P\-;]^-#&H*H^+3C8)75TB03F&VZCFMY"B1H=RP9*^@>
M@BL _$9Z3_Z'W5O'^SK_ *G_ +)<)N[=V=V?MW9]O1]V]/O4-.[NAO#RU) Z
M]W#8_6_5C!+\9/5-?I]8U[HG5$XO?2UM>(ZR: VZ)-KT=M_5]>BWS-NM3TB9
M'BBWJ^#?8Q+)9&""?E#!!7%P@ABA!R(W&*,(Q<R?<B<09FY$_<GVW=^[]UN7
M<CD,G*,^2OW<A-'%' $MZU/;E""$>$,(G.<AC%$#<(HQ=@ 6XBS,S*:D;I+T
MSAJ4N'U(ZRQ%+3Z%*C:'U8QE2?/S\E9:JJ,YQY_?Y9SG[\>?$L$,S,TT,4S,
M^[-+&$C,^VV[,3/L^WQ]?R6*F0OX\R.A>N4C,6$SJ69ZQ&+/NPF\)@Y"S]V9
M]VWV?U9EH/M#U[Z%:-T%MS<-RZ>: F J93R90RY6]":5Q84,RO;&?/BS[ '"
MA1V(#TYJ?--G30L.$@1I)<L1ACX,B0W]B  +  B "VPB#,(BWR%AV9F_#9>,
M\\]F4Y[,TMB>4N4L\\AS32%Z<I)9"(S+9F]XB=_O6/\ 3KJST*VCU8T%>:UU
M+T64!&-6U)D<8O\ H/2LBXG60HQD"JP'YP80="EIIYX8X8P<#&RX@ZQ-:,"R
M4Z!.CR7/I>2W3>.HW1JA4^R7,CTJZ^FH59#S3$@14>K^NK39R:(3*G?@ J\&
MI<HD7)RE82S$AQ65*6ZO&7%-,I<=015W];JOX?%@OFL1H[H:!E!.]8V/V.UI
M:-@=?^NDFM4=HYID#8YVKAX\>[-M$,)50U+P1/&!5<(4:O7:]"*W+L[AFSCT
MR"*SK\1GI/\ Z'O5O^C_ *G_ +)<(J>]FWSPL*EN(==#?3*J!)NLMO[*Z=N:
M_-]?NO&LZS;3=EIFA-TE]P%Q^SUTUC "EUAX+!IA$NZ,L!"-<#\D0%E!BS!)
MPGULKA,=&ND^<8S^)[U;^_[_ /!_U/\ V2X15C=W:[X?&ICL34ERZ(5JN--R
M:+M6N[(USUXZZIA7HIJ:]4[9DW58:/.F![.X(NGTD1K"X6LB$@:Y@RM@P*@;
ML[!$XQ$<(ILZ&Z_="M_ZLKVTZ]TEZ[UV&:F6D-/KEEZ^Z3P>KEEHUN/4.X5X
MJL(%,AGY8.V5DT+7+$EB(V;B*F7!F/QGVG%$6"]L=6]%.JFIR&V#WA\:?V'7
M13DY5D1KOKYU[1*JP <!,'2=E,3;FW4A#$1#(GZ,&'QR,H[9;<8KE6 "IY4S
M&:P1>KH-4.E%.LMMTAUWTS5X=\ZB4/5&MK1OIS45!J=FV [8@1P.2RQ= (J$
M<L1F 6U^9!;0D*1%@,WX>; +S()!"K$(GU];*T7A$X1.$3A$X1.$3A$X1.$3
MA%'SLGUUK79BA#J2?M-QHDZOVT->:C>:"_7V;94[0&CD1K9(6W;:];*O+^8#
M-G04R,<K9:+F 8E/1V8Y)F#/B$4>>XO7/JTWTQ+5?;&N(%FUKUMU.T<J#"*9
M4]@7^O5;30L)8GQM&:N4.2VHB;"42 $.);E#?K(U3L<@0BMJQ*CD7#=8=0>'
M[VHTI4]XTGI5UR#URV2K1!APC&C-"%'L2*C;#E-)R()NG#[-4["$F% $R4!L
M5;/E@QP.]")09:VI.$I(M\.]'^D3"%//]0^J[+:/+UNNZ"U*VA/JSA./4M=4
MPE/FK.$X\\X\\YQC'WYQPBAGU/Z^>'/9;1O[K_2NL6GK\1Z[[ GNVW8MVT!I
M^4*L1K<5SV+>9=<I)ENNNO&0.K"[)O5ZLYBQXH)^J?91A^;* $%M$4T?Q&NE
M'^A]U<_H_P"I_P"R?"*!&N]4>'6=[V;ITY Z?:S6>53!52;EF]#:&5I[%HT.
M-J-\OP^CP8\)^TPK4]6^W>K'+02*5J '/-A6(8PG+?J\MO!%/?\ $:Z4?Z'W
M5S^C_J?^R7"*%7;3KYX<NLKUT^"VOK)I^#9KEV:JXJHU/6^@]/J5:%'ZY9]8
MORMGL/UZ+AK3E=-[.K! _.5[V$W9>O!T6.^4)CVE$4U?Q&NE'^A]U<_H_P"I
M_P"R7"*,7='JKT$UOU1W];;?U.TH'K<;65D#E3FM=(Z0"7JO,6R)FI(LE:L%
MB"!Z]62%=?.-&\6H^5' ZNS >L!>;&'#9+J2+,NN'77H1OC1&J=P53IKU\AU
MV_TP.>$,VGK[IA)W,-UGV$/SG1(0P(F_+4PJ5&)B"Q,26AO1R8R?+@RX[[A%
MS&[NN?0[1.I=@;@L72'1=F"Z]K)&S$0%"ZO:TM-M+,#FO<S$#!852PIY]S/I
M]Z7,>A"147#Y4V1&B(4V?'(H@]>-6]"YN])^GU=&:>\]O\ 8[2T.X7_K[U[=
MJ,2K3:9I645I55ACW2UN@U>L*O8(?'/S*P/IDZ\+N-<$FIA06XB216(_B-=*
M/]#[JY__  !JC^R?"*G:[7GPL:;O!=Z+=-ZJ*GA]EV3I>YKBU=?^O.MZH1*0
M!NJMP%MVY%;-73&X X.#O($0-GEG(MF/BS/K#U_(Q6)\DBN)_$:Z4?Z'W5S^
MC_J?^R7"*LKN?7_#WU=:8FG[IT*KX),6=0-JU:_:YZ_]<(D38YO5FQ-<7O.K
M ;9.0.LCE?N9-VLZNN]J+@1FN6G+SFEE[9"(F&4*(IJZ%T!T'[ ZJK&V*STJ
MZZ@A]A=L(^4 L?7W2J3U>L-0LYJEVROELA@A<0[-!VBO&!3LD45(#9>8F)4&
M9(BO-.J(L"[9ZPZ*=4M4S=K'_#XU%L.M#'9JK-C7/7KKYF950, &5,S[&3?N
M+54&J0K QL%7PP^9/L=KN)FNU:NAR)0NPU@B\N@U7Z556R7;2O77354@7CJ#
M3]6ZDM>^4ZDU_4[%L606K4X:5=BW.O"X1NQ$XA>CE0NRY+K<2#B^CC(C/RI@
MF<F,16@<(G")PB<(G")PB<(G")PB<(M=['U'K#;XEH)M"@U.]CHJ"V!J+,$@
M%)(5XX%GUPK.KT^2RLA7BLP$5)"EEPDJ 41"FR6&I;:'5XR18GH#KMJOK+1Y
M&OM2"3(P!./S;04?LENM=ZL)@]/A#1CI$O:+H8.V BZR)#!Q$-$DBMF$+%0(
M,5MIB.A/"+:5HJM8N]>+U&Z5P#;ZI88+PP_6+0('GZ\;&R,>F0/+A2L>6-)0
M7T_<]$F1GF',?<MM6.$6A=9].^M>FMO73>NJ]35JA[,V%7DUBWFZVB6-B%Q>
M;*1M\CU@6)*04:=//E)$X@1ACH\V;EN(S(>6Q#CMMD4F.$6@5]8],N;];[,J
MK4[\+C09(A)3%HM":[EUL/*K3=C71DF,4MRZ-U2;+J3=S<!*LR*J^L!@G@9Z
M8Z2+?W"*.787J5UX[50:Q WWK$'L%-+*QC-4ED5SX9.OS8YVNV)W PH+EPIT
M:*2)50#DQ"0_\4M$@(A3VGXJUM*(I&)3A*<)3CR2G&$IQC\F,8QY8QC_ &8^
M[A%!KMMOGHDTM/4OMCO36-$,[A$U^8,H-IV6YK>UF(4BTX35#M?-0"P,P'E-
M7&N)4"-#RL"0R;$I^/(PZUZ<D4F=0ZOU]H_7=7U/K2"L13:=&?@AQ\PX5L)+
MW"$Z8:(2R9P^0)G#!8L4GD"Q$B5GRYTZ;+DRGGEJ7G."+8SJ&)D=YE64NL2&
MW6'/0O[E(6E33J<+1GS3GRRI.<ISA2<^?WXSCA%$/671;K]I[8U"VCKZ#L('
M9-;:@K&AZI#SMO94^J1=5TZ!,@@*K-IY"SR:V5CQ7)SI9^21&R9A ^W#/$'Y
M)6!!E1R*8?"*'VR>A_6/;<VWD+U1RY&7?=EXVM;WAU^OU=6>LKVLJGIPL/(Y
MKMD%9D4NRZWI%;K5JH;F55"QL#\2RP:40<<EY?7]WULBF!C&,8QC&/+&,8QC
M&/R8QC[L8Q_LX10\V=T3Z];AV;=]LW\=L O:MAZWB:FM4:-MS9H6L3*,-^9(
M%"H54"VD>!#/B#4YZUBB@>#!)P+DW$ML:6@_!ASV"*0&J-64K2FOZ]K+7@Z8
M,J59;(8'L$C)BQE9,LP6GGS98S8;#.)G3ILZ>*DS9HP7(3"!(H0ES)4AQYY2
MN$6!]A>M&L>SH&H5O:2KQ@;1KT'V17%4;8UWUQ.BW&O,36@):20HYP%,(_1W
M9SI 9$(/28<(PS!,QV&R@Z!+C$7%Z:Z@]<^OE[V#LK3NL0]%N6TX(F#?"HF0
M3RFP8#F+'8&YDB#*FR(#)(@<MAPL;)18S$PW/EXDDWI+K+*D$4E.$3A$X1.$
M3A$X1.$3A$X1.$3A%I_<>@-,]@*]-K.X=<U>\P)=:N-18FEAK6+&#!; !NUJ
MYQJI:XN(]FJ#]B!.J&$I]8+"9\B+AMM4GR:;])%]FF-,4'0- 'ZUUM!+0:S
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MLV@"]96UF+M_9X:MR*B!4]*KT,75@UJ@ Z_,KYQ]=M"%@4(<3&71+-NBRV[
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K$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>g713200g61w04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g61w04.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X5^E:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^='@Q-C4\+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @
M(" \9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @
M(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+7)E<&%I<B(^1FEL92!.
M86UE.B @(" @(" @(" @(" @('1X,38U+F%I)B-X03M5<V5R;F%M93H@(" @
M(" @(" @(" @(')R-3 V,C,X)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @
M(" S,"U!=6<M,C Q.2 Q,CHQ-CHR,28C>$$[15-4(%1I;64Z(" @(" @(" @
M(" @(" S,"U!=6<M,C Q.2 P,CHT-CHR,28C>$$[4V-R:7!T(%9E<G-I;VXZ
M(" @(" @(" @,BXU)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP
M+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @3&EN92!#:&%R="8C>$$[
M)B-X03OB@*(@,S8@:&%I<FQI;F4@<G5L97,@8VAA;F=E9"!T;R P+C(U+B8C
M>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H
M92!D;V-U;65N=#HF(WA!.R8C>$$[0V%L:6)R:28C>$$[0V%L:6)R:2U";VQD
M)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<V
M,7<P-"YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C(Q,S@P-28C
M>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,S M075G+3(P,3D@,3(Z-34Z
M,C@F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,S M075G+3(P,3D@,#,Z
M,C4Z,C@F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-28C>$$[26QL
M=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z
M(" @(" @(" @($QI;F4@0VAA<G0F(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H
M="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE
M8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H
M92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT
M.B8C>$$[)B-X03M#86QI8G)I)B-X03M#86QI8G)I+4)O;&0F(WA!.R8C>$$[
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM)B-X03L\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @
M(" @(" \+V1C.F1E<V-R:7!T:6]N/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @
M(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C Q.2TP."TS,%0Q,CHU-3HS.2LP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,3DM,#@M,S!4,3(Z-34Z
M,SDK,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R96%T
M941A=&4^,C Q.2TP."TS,%0Q,CHU-3HS."LP-3HS,#PO>&UP.D-R96%T941A
M=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^061O8F4@26QL=7-T<F%T
M;W(@0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \
M>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V/"]X;7!'26UG.G=I
M9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH96EG:'0^,30T/"]X
M;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z9F]R
M;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @(" @(" @(" @(" \
M>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%05-!0DE!040O-U%!
M<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!04)!05-!04%!045!
M)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!1U1!04%!04%F+V)!25%!
M0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#=V]+)B-X03M$0D%-
M1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(>#AF2'@X9DAX.&9(
M=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&8O.$%!15%G06M!14%!=T52)B-X03M!04E205%-4D%F+T5!84E!04%!2$%1
M14)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%04%G241!445"05%%
M04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!0T%1341!9U%#0F=C
M1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC645537!':$)X5WA1:5!"
M)B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#3E51;FLV3WI.:&15
M6DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT+U!%)B-X03LQ3U0P
M6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD-&58<#=F2#$K9C-/
M16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ8FY*,F5N-4MJ<$M7
M;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!341B445!06A%1$)#
M15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C133D-&5DII8W9%>DI$
M4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG6DIJ6D9':61K9$95
M,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E75G!B6$8Q95@Q4FQ:
M;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO
M)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+;7%Q-GET<G$K=B]A
M04%W1$%104-%44U2040X03E5-'$W1E=.,W(V;S-N4WAT8E15)B-X03LW9U<O
M<%!D-FI91DQ9=TI!<2ML14%X:#EC3DQ-95$O93E%8C)X5D9,-6EN2&UX3D%M
M,#971EIR5S1V3&$O85-*;S56=%I,94YW<4MZ)B-X03M/=3DR=C)G3VU+<#%I
M<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5EE$
M<3,U<'9:95EB5%1%,&DU354S)B-X03M!4T-61VIU0UI$>$AP4D5F1B](<&AP
M5U=8=6]8-S9"8U@R;3(U1CAS36ML=&$S4TUP6C!"25(P0D1$;%-M0E=,1#@Q
M8D53=U-,63-E)B-X03MO,G5P>DUM:TIP='4Q>$LP34UC4G5*-5%'*W=K<S-$
M-%)88D-Q<&(O04IJ9DA,8C-T=DIA5%)A:%!B<&,K:7-K13%V1'%,5V19=TIX
M)B-X03M)1U91;V1M1WI62W%W,GA64W4O>E9T<F%,5'13:S R-U13=%)T2C=I
M,6DY3T]7-W5713%N1F)E9VM5>G)35#8T,W=Y56%O2%1U1EIJ)B-X03MP3V]J
M571.=#<T5S Y<#E945 X059B=4UW>G@Q+UIK:DYE3$1&55AI<G-69&ER<U9D
M:7)S5F1I<D=R+R]!36U4;U@O8D<Q:B]!2VET)B-X03M->%9K=4MU>%8R2W5X
M5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2V],5F1C,&)325!8,5,K9W-O
M=#9.4$ES9&%D95!):7 K5T5!)B-X03MK,$9E1E<S-6M8,G!F;DQB439D9EA5
M,FA83C5(1D1%<W0P23)6;$$U*VE:46Y'=2\R86-D*TYC>FIO9TU81V(T=F4S
M9FMO.%!I2&DT)B-X03MU-VE.9DHY0EIG3DM486AR,VQ3,C%Y>C V*W5B6DY:
M;7 Y5&EK04UV>$=G-&UN=SAJ,#,S>4IM06%A-5IO0U%I4T])<'!D,U56<&)3
M)B-X03M837%Y3DA%3U1,1$A*3DE2+VMX>$LW<V9:46-K,DU28E=V>7AV3DES
M,W5,83(O4F%R4&1A970S<#=X>&A947)Z4W=P3D-T4#<P55I2)B-X03LX4D\Q
M5%A&561(<2]K859B2V(P;U5E-W4R=#=.2F)2-'!V<E1Y974T36-K87E2<S!L
M2D-Z069%43%A:UEQ;S9L2"M7=6DR;#E(93)/)B-X03MN,G1R07%M*VE&;6A1
M:3=92&E64TTX>35T;%IL1E0X2W-D9T1I<5E71W4K5C=B53$X<S),2F(S3G5$
M2$A:=W=V2$%P5D)+66MD545()B-X03M.63-$1D$S2VTY3594=D960RMV-U-W
M=%AU<G54,#1%-&AM;U<S9&=Q9T)14U-764%!1$985T8O86%H6E$S=&\O<3(Q
M=V]E1U-H5W%N)B-X03MO84U!4CE)>%8Q;F97=#1K:C(W.'A&3$I"2G-62WE2
M355D4T=!4%5F4TYX=&EQ0S%Z>E(U93!&23,Q9E5)8E Q:5)%:VIF1SE/=D9"
M)B-X03M6;7 S;TU66#9*-6HP3%A91VXP:2MI=EDT>GAK.4IQ;$-E9V14.%,Q
M<#-'2W-6=EI03DLO;61">&IU6G1)26AJ:6I!=6MT:VE-37AM)B-X03MM85=/
M4DQ5=7-G4F5%>4UX<4].2UE64FLQ>&939FUP<&M5.7 V1G9&;RMQ+U9R:C%&
M9C%G,7IP;DDX0G5N12M06$%R0E!Z+S@U95ET)B-X03M$,4Q33&)3<G53,FEK
M:65:+U1*5W)H=T)5<6%M;$\K6D=N,$U-.3A:27)U3D]Z-T]Y4FIX8E)*.'AE
M>5HS6#4S>%=(;$-#*VUS6FPQ)B-X03MC4GA5:'9)<#19<FMK04\X37E2<VA0
M96AO4&9(5#9A535C2C5D-$E0-F(K>')/;&I+5GAK1$4Y,U)M;C5F96)4-7(X
M<U<K<W-K54UK)B-X03MR3VMK151--&I:1W!X67-Q2&Q3:#9:2%59=D1M675,
M;7@X17%:2&Q,53=&6%EQ-T9867$W1EA9<3=&6%EQ;$]T*V)F3$]H2U1Q,G!7
M)B-X03LY;S%!4D4W9WES0V%$:D5T6D<K:&-L1T5P8VAA44-E5$=,+S@P<$=3
M=6HV3%!,1S(V6'5P3VUM,GI+9G-V2#8S-S952'=73W5$26-E)B-X03M0*SAN
M1U R;'E-5VMY6D0V4F9U,RLW8C=5;G5D4S@U87)56#)S=F%W34XT3DAI5WAI
M;TXK6#$W54-S;B]!045E569N64@K-VA+9FUD)B-X03MH*VHY3&LO:V]W+W9*
M4FHX8E!Y:F8R;%I984@U4W1,:C9X2F5A4D1E36546%4P<#%I*TQ$=C9K-31)
M,RMR2&EC=7%M2W5/3U!D2&8Y)B-X03M1*SE(:39E06]#52]L069)5U0X,E R
M;&YO53,U=3(Q,TA,8UAK:'59,D8T-SA795AI1'E)0TI22R]S.&5N96U1:DA/
M4%1X,T,K5D,O)B-X03MN6#0W,6YR25-I44%1839F5#=Q-2]'+V<Y-'I*9&,X
M.3%B.&MV2S)O95EB6%9H2DY"1$1W33EI<D9K;#E-,4AX<V5A,3<P4'EP;$IW
M)B-X03MI,T)Y9&XT-35"33-S>G5Y<W)7>'19-U<Q5# T26=1:59,57%A.5=*
M4%4U84)4;6=5=WDV+TQ'4S8P-U1.4&PQ44-$4W1097IT5U,S)B-X03MO-6YD
M-#,Y9&DP:DM66#!&<$AX.&9I.$I7;$8S=FM85712=G)$53<O048V6#E)5U5K
M8E5T-V5#3S--8V-G:TM*2$M*-45,1E)Y8C%4)B-X03M79S(R04%6,G0K53E6
M,59F36QH2%!(6C(K<R]6;5,Y95 Q>'A73#!P27A'<W-,0FPY24Y5;6YX9#DV
M1E8Q:#5&=6]036ME<C-'<$Q.)B-X03M$2&-Y86=,4DQC>"\V6E!A3&%3<TI$
M2R\W<FE#5E1J558S63!W2V=R9CAQ9$UT=%%J,4M'4TE8,&,V6$IN5S-!:UHQ
M=E=U;5!0;E=R)B-X03MX3C9&9C5F8C1C3G%L6#5D*U$Y63 K2TM(54Y-=#E/
M9U<U:79B-6<Q6C=U-&AI4$1L4V4X46]K>F5O1T12+T50-W1A;D950G(O=T-6
M)B-X03M/;U<Y;G Q<&%7:UAM2T=+6C4S4S514F=3:4].27A+=W5R6FI&.$15
M*S-W1S-".7%.<3E(.'4V9&,R9C949650,'9R;"].4$9%0T13)B-X03M/:7A)
M9FA*2'AI3&Y4,S-O9'-#<$@U*S$W5DY);G,U8D9%=&=68C$Y5W5,1U<X9VI1
M;6Y";70S5U-09F5P2$4T5E)N-69S:W5K5%AB)B-X03LV<F$V>F0S8SAK,#DW
M845L04A9=6M)1$TW<7-986EQ>"M(07)*.%99,68X02]K>61#+S=9,G-F.5)7
M;5EQ;'8U:69L9F$K8S=M>6YK)B-X03MV9G%B,F%S;%)&-FAD5TE.0V5A8EI%
M.%@X2G!O>C143W%K62LV,D-F;7 K5C9A4C54175J,T9X3D5*66QN<T=(<4M4
M46HQ27HY<U4X)B-X03M'3%5(4VU-37-S2C1H=C<R=DI02G T.&5-.%)(43)F
M,#,Y<58O;').-7,P1%0T,S!Q9FQC179,4#5:=D9E4#9Z17!O6F)9:V)U04M.
M)B-X03LV931P.%-T;&MT8THW-4(O<&59+U=0=#=N33!7<2]-9U)Y,41)9F50
M=B]!-W<Y2G-0>FLX=%A&:F-3>GA4,E8W87A'5V%Z;EAB-&9#)B-X03M23U,X
M83=":E%94D1I04U4>%)026HX8R]*=7IA865/6$1)8F]J>3$K82]L,UA)<#)J
M1')*17=664EL835K8W-$,%=&5T]'94M595EP)B-X03MQ;$%X-6EM32M4+WI"
M=DQJ>F9F,CEX.69U8E)"2C9D;W%T4$I&4FA1>5)O;DPW=6U-<U5G3$E5=TE&
M;&TR<&9M0C5C<SE0=4QL8G!$)B-X03M.06Y-5W,O3S)D<4AC05-O1W%"+VLU
M04%L:6AT02]->GDQ<5=K9G!'-W9,6%1W5TMI1C=H2&)I041Y<%)$,7%/;5--
M2D$Q5S9E13-6)B-X03MB=E!V>DTO4%-A>#%#>F@X;E@Q=F17+T)J95-M27E,
M>C550W%Z8V$W94@S-6TV6%(X9#A927(X9'IM64Y.9#A15&964'IB,4=F>7))
M)B-X03LQ=C5F,49P2C=-<DIQ1#(W4G=,23A8>%-*5EI%6E%4>4%9-VI-5&=!
M3SAO:C1U3TU:2C(S64(K5FYN3#AW:3)O,BMI=U(S>GET13!S)B-X03MS,%1-
M27%C-E4Y0F8R<2]T8F9,3"LP0FEW,7HS-E)"2E R-V9J;35P,$E*,DU9:GI.
M9F5F=4)E:FYY="MA;792,#%F6$I,1T)H6#!B)B-X03M9<&%5-41D4TQF,5I(
M2"MT2W5A-SAX:U P67A(>FUB4'E'>4]$5%$U>4UJ+T%%4BMM5F8W:W!J;U U
M3V%(<%1,36)U-&$W1F56>$%2)B-X03MB=3-)56)L279+53$O=T)F3$],2DEE
M=58K-%50;'4T,E1.12]31%AM8BLV:#EI9E$O;"\U4VE9=4Q(;3=B<SAK<S!H
M2CA4>F1S15E2)B-X03MJ>4%$5DQ*2UA-:V\R,SAQ*U=B96YO-E1:;U(P65%2
M.'5T979'=5-92FI$8G=1<GAH:E=.9D)&0VIB-5EQ;TA39$Q/;T155&%1+W!!
M)B-X03M,>$8S=U@Q855P5&Y3=E1B-5EQ:7-695 K63=4.#E8.#<V63EN3D-,
M2#1/4G1#>3)!05EM5#9Y:VI&>G0K2#)D.#)/339F=WIF4#=F)B-X03MG-6M$
M:31$9DXV:D)A6'0Q<$ET=%AD4F13<59U6'-(;70Q-FUN<'5R3$MM,4YW,6-W
M2E9E,TIX1%8W4$TU679/54=G-E!"<#4Q9S9J)B-X03LK:3=M-3%D<$=U-5@Y
M4U5W2496-V=S=G)H16M-8UE.5D\T07)U14IN8WHK66QU=$944G)06$ID0VEV
M235*6G)H>4HS-7E"5U-96%5S)B-X03MD,39#2GE0-WA456YQ1E9A<6]R>EA.
M<4YZ2#5N:&AU-W5#94$R<U9G='!(9E1S=BMJ;55-<V1H2D9)<&52,D)C;FIS
M3U%)04=+;T1Y)B-X03MW+VY'5'I:671F>#9N135C+UAO-VAP5W-L<VIP,%IJ
M05E!5WI4+U<V.&EO-3$U5BM(1E5Z="]-2#5H+W!'23-&;&(O;S4U,$1O=&YC
M)B-X03MR2W-,,W)7<'))6FU7<7A!5&QU1D]086YX67%L,VQZ>FPU:3AY5VM6
M;&1Z,C!&-W%.>$$X359J1&57,'-';CAF<D5S:VHS4$AN-FE,)B-X03LV4W9$
M5F%T54TS6E9!9C0S.#DV5F\R;C(Y>DA$6EA13&TU=4Y6=&(K9FIA47AX<S@W
M=F)L;5DQ:RM)<T962U5C:EEL5FXO;&4T=5IF)B-X03LP=$A.23!Y5RMO>GAW
M3WA*4$%H6D-O3$5N:6IU>6=D9TM$65E&62\K6FMU<E<X9G(R56PO141A5&]K
M=')00D)!:VI51EI05VQJ-756)B-X03M.1D%5<U!T2G5$:$-S>'-B4%,T:DID
M5TU-0T<W;SAS.$-O4%9P,%IM6#=86')G5FDY-DY7:2]-87IK=&UU-W5Z;5AH
M9%<U4RMI=&)6)B-X03M&:&8Y-DIF55=X;$Q0>$)1>&PV-S%&3598>E1A:2\U
M<6%:2&-7>5$R<V5J-G(Y56Y76&TP;TYZ<&Y0;$AW6# K2C9F13%C5EIF:7)S
M)B-X03M644=T849P97179C%455E"3$=#2&I917)*1S0V4$<V,%I'2%EG-$I2
M0C5S2C1X2558:V8U:RM43E8P,U1,=2ML2G9R94M.,F@Q:%%&)B-X03MU66EY
M.&8X05-L47!Z<G-$36TU+S-9<F1C<'=W;&EY:55B24HY42]N9D1V.#--,#)S
M;D5$1FPO95DK45 X568K2VHK04=+9FQ(<D]V)B-X03M7.6AQ3G99,S)O1U9P
M1F-7=6U78T8U2S)X*TM35V175TYA.4LK+V9.<'(Y4D-%+S=S;F)N+UIU,F%Q
M8T%24752-E52.7!Q4'I+5"M2)B-X03LY2#@S4RMC<G!.3RMV45@X:7I#4U5&
M;S-0>&9&-FIH-% R<58K25I4<4\Q<V-S8UDT*T=C+W=#8C-F3W9T8DI2>5-G
M05(T9&1:47EC)B-X03M0=U!$-G9G9C%V4F18+TMZ.'ET6#!3-G0W-U=23'E8
M;$9:>5A.,F5B2U%W5F<P,'-08F)K1'8T6E)H,6UC4S1J0T$X=78S9G!C57E-
M)B-X03M$8UIX:V8X06AF0U Y3GA%+W=#>%)8-60O:U)P9'!P<7HK8F)56$]P
M*W%Z4C)Y>D5X4G!10F$K;GAQ>$E*4'A%57 S<FPR8E94>6UZ)B-X03MC4C-8
M.3E.5U1,4$EB;#9F244Q*VDR839P*U9N:T15,70Q=71(:D-7;TMW<$$X='-O
M<6%K;%E(:D)9+WI(9DDT<W-S9#A05D=-.$@P)B-X03LP4&=Y139B6DA49C!9
M,&9/>$U0,5IO6$Q05TQH=S1S>D5S87)S4U1825AV845V.$%,;FLW>3$U8D9W
M3D5S;',O<EI5,TA&-4@U1D]8)B-X03M(-V).,#5N<&AL37DU;3)Z2FQL4&XY
M=T@S2GIK5W0R2W5X5C)+=7A6,DMU>%9H96]F;6QO.7!R149G='102D9*>$5T
M=U5E3FLU;6=P)B-X03M#-D-2=G4K5F,Q3U1T845::4Y'=2]L.6Y.,W5(<TA,
M4$5:,T5%9$Q"*S!'9WEN-GA,939C6G1.;%='5U94-D5T>D1)5E5G,'$X2F%#
M)B-X03M1.4]N2F,R:TII47-C;E,U35IH27A0369(-VYN."\U:F5:3$AY+V\K
M;S-35U9X3G$Q;F,S9D=/2U=#3TEO8F1)9WAA85DX5F%C;5)U)B-X03LT-F-E
M<&UW4BMP968W<E-D53!V4G(V.3!U6%5,:3528C)A3FI%9W0U2$-)16EE5FY7
M56QQ+V%904Q5+V%!>%9%*UIV375P86)"-6PQ)B-X03M$5&)7,$TK:W@R<UIL
M;E9U5"]#6FTU;$-#-G%S=T-,5F%%<V$Y<U939GI**UHR=&%6<4XX25EB4C=/
M1S9N,#9#1GA)2FQM:'1%=5)C)B-X03M3=4@T*VQ75&E60T$Y1'DS>'!5*W-0
M3V0S2'!6>DIQ3G%B*SET.51K,&Q5,#5&451Y2S%&6D5U2G5+9&%-1VQ.0T1V
M9U9+=$XX*RM6)B-X03M.3C!Z,3E'.',S<U Q=6%)<' K;C)D=4HU=G)%3%-P
M4#9C36Q#=D-),4Q';S=J0W)F;3-Z4' V-G!9='%E:U<Q-7!D=&5X5VHO5UE)
M)B-X03LU-VE/.&QS-3=R:$-Z4#958DE9-$9,13 K23%)07)I<4\O>'9'<39M
M;6TV3&0R<T=L,U%&,65814-2,FLW3F1I2S8K<GE*2BLX:S5')B-X03M2:65.
M3U$K3')U<6@O=T$Q64Y,:V@P;')T<'9R4U1Y+U5O-#E0+U-K8G-9:GI%;'-1
M45-%,U4Y<4A&55@K5E17;BM&5U,R.55*2&4S)B-X03MA=C8P271J>CE::3-'
M,U5!47)5-U(Y<T-S=WA6:E8O+T%/5$HP3"]T:F%X+S%&85II<DIC5F1I<G-6
M54PV>'1,*WEN<W)Y2517='EJ)B-X03M25'A.,%I(1D-.=#A"1F]L15-&2&M5
M;SAO*U-D0CAQ5V,Q<G!%5&]T=R]Q5%-335AD:4YL<61T;$A40D=!:GEA8T=N
M:&E&4D-B>%=&)B-X03MJ1&-36$5.=D9(8U1F,S!Y27%U+V8T;4%Q9G!W4GAX
M0DI!1FQY-5I:>4%I4U-">49Q*U1A,UEQ-T9867$W1EA9<3=&6%EQ-T9867$W
M)B-X03M&6%EQ:$HY23!U-'99<C)E,&EK=DE0-VUD:U5U=F-566IT,CA-<6QH
M:$M1:U%/2617-D=O>5)I64-2151Z0TQY,7!3.69,,F=+,TID)B-X03M-=$$S
M,68V;E514F<O5FEA*V@Y;BLW<69S9$U65DQB4G1)=&)72S!T<D<S9W1)2$5K
M1G9(16E2;S1.47E);T-Q=T\Y4FEQ1W5F2RMH)B-X03LS;'AE4S,Q<DAE>%@S
M;W1083--8V,P2'%10FQ744DV;C0K3$%%*W=P5&5Q<3AE5V9,66MA56%46FE6
M-%)A=31T-'5444)19VA*-#=X)B-X03MH44)X-E5X5EAT=$DP;3%T66)3,G-O
M24Q7,UE35SA%8U-*2$<T2DE:1E5!2V0K;WA62F9-9C5F95AD9',T3%-71F)3
M2S-91E)B43(Q)B-X03M#1FIA2E9+5%)42E)%8SA0:'%V-TI'2W!P0C5D,%-'
M>E=Z*W%2>E%+.&MV1S1(<FMY5$MY4TU43'I.5U-2;"\Q5'@V8EEQ:V1N*U=8
M)B-X03ML*S!V8C(W:FMM<F93<DQ.14)B;W1&=5)D8T-9-&MD,4UG02]E37A#
M+T-P07A62&5A=%!M:U-#*VDQ*U11:F).=SE5<F)Y44U:5'=8)B-X03MM;'=R
M1&M3,T930T1V5'9I<EAK>4---F,Y+TAR<F$O2&5S5T8R0D-K3E9:9S-P<$%Q
M<4MT6&Q7<$IX5DPY46XX,&XX=W1/07,W=V%$)B-X03M'<GA#848T=G%Z;#13
M>GE4<4I1.59F:7%H:S)O94YE5TMT>E-A;S,U<399;#%B=U)786%0<78Q1V%+
M9#5*6D%B;E1/9G%X3D9'<UA%)B-X03LP-#A8979T:7),.%9D:7)S5F1I<G-6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-6
M9&ER<U9D:7)S)B-X03M69&ER0R]Z9&AU<&9*<V]H;'0T-%)C5WAU;'596F)J
M;D@V>3!J:E=(-"]56BM)5VTO9U90>$)#;VXX<W)6<F9Y<6Y.5U-3831U2FY2
M)B-X03MR5U-Y0VU35FTT<$1,5G=O<E)A;D975C1Q>'$O+W=$2FLV1B\R>'19
M+W=#;W)4359:3&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I)B-X03MR<U9D
M:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-667@K6E9U
M3&IY6G%%4FDY6E0V5$UG:"MS9D-S<7-4-F9Q)B-X03LR.5%!2R]B1D]U2W%(
M-597.#A(:S(S13%S='%(;&UE1D914FAO:DEE1&Q"2E!X3')V5&UC4W%N<78V
M5D@U:F%1.6TY-4I:;$I%,4<S)B-X03M23'A,5E9-36A35C5863)4+TAX05)%
M16QD>7A',DMR-6TQ42]M<'!G=6\T1G-X;RMQ+U5N:60R:UEF5V1--2MQ<DMQ
M<E$P<'A9-'%Y)B-X03LO1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ>% X>$@P
M)B-X03LK-G-,6%%R*V-754]R4S!&+TM5.4=*-V%L=VEY3$HX16=D;W=V<&XW
M47)I<G9Y>&ET669+-6ET<&98:E,X=D9--DMI45--3&AW>C(V)B-X03MX+T%S
M2E R07941E=767%X<2\X02]*:S9&+S)X=%DO-FET37A6:W5+=7A6,DMU>%8R
M2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU)B-X03MX5C)+=7A6,DMU>%8R
M2W5X5C)+=7A6,DMU>%8R2W5X5FIF;E16.4\P.6)"3EET27!T0W5:6%156C=I
M17IX>&-9>3!82D%'<'IF8FM2)B-X03M19E1I<4LX;C9M3E(P4DQM3S%7,'1"
M3$Y(67%I1TI(=&\U1U='5EEM05I!-D%%02]Q>%9+-S-3-W5B.'A,2%5F,$MY
M5W1N0WEJ5UE4)B-X03MA:'!8;%)L36,U37%4*VQ%1'-O4G%U83=C9#%7<'8P
M<"]W07)5,'HV,39(,5 Y1#9R.5,Y3&XV=%!R3VUC+U8U9D0Q<%1J:7),.%9D
M)B-X03MI<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D
M:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER>D@X.#1L;# S)B-X03M41F$V
M83-54$\W:%EP2F=%5TPT-7E)-4EQ96ET5%AF<C!W:%=19FQB85A.<C52:6IN
M4C1G,#@X:T5,4DYB<6M5:VA:5FII9#574TU6)B-X03LK14UA*S)!<7DW1E=.
M6"\O04I-;E%V.$%T:F%X+W="4E=M67%Y6$9867$W1E=L9$A"2W-'04I5:T=U
M-$Y#4&]X5GIU:4M79&=Q:G%X)B-X03M.05!V>%9V1E=I-D)W:%E",D)+<EAC
M9V1A1#)R:7)E2W1",%IM5E="6D129T1U0U)89C9-5F-Z2W%L;4E#9U9*3W=!
M1TMT9V=I;S-")B-X03MX5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R2W!:<G9L:GDO<C!C55=S,D5..4A!>&%&6FPU0E-W;U--
M)B-X03M65G1),%A3=$=S;'-D3'19-T]Z46QL9VE&1D)9,4IP-S1Q:TXS<'5O
M9CAR2C O5DET3VYE>5-W=4Q3-3%$,5E414=L94M334-*<'95)B-X03M!2'!-
M1S1X.5-/=35#<6Y-=7%$.#%.34XQ2D$Q;61(,5@V:VM33W-I:C9Z<&Y0,5=:
M;59Q;6Q/2VI&5U@T<3=&6%EQ>$@X<R\K3U)Q)B-X03LO=T0R,SEB+T%/-FQ0
M:7$O.#%F+T%#6#)T9CA!1T9F*U1Q66A75C1Q>$A7=B]*;V569CA!=&UA>B]W
M06Y,1$976%EQ>$AY9B]!37!H)B-X03LU-R\W861P+S-38E!&53 X-V8X04M'
M82\O=T)S-C<O-4U0:7%9-EHO>'IB5"]J1$@O=T%21TMO;D9867$W1EA9<3=&
M6%EQ-T9867$W)B-X03M&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<7AQ
M+R]W1$IK-D8O,GAT62]W0V]R5$U66DQI<G-644]U-F9C86IO;"]95S%Z2EI8
M)B-X03M.,6)Y=W=8:TQ-:VM-:F]64U)756=G;WAR:7)Y3"]N1U12+TXP1VLV
M-W%(;4LX=35(;'8U8F%+>G5:6D=#5%%Y36)U8FEX<'IK;F-H)B-X03MM-CAL
M3F-62UDO.$%/5$]M-CE0*UAB86AO.35C,C=A9$]J6#%V8GE/:7HR,'!%8D(P
M5#=:4U%O=W(P2$Q&5V5E43E+,6)3=DHR:S)/)B-X03MS6&,Q.7$P5G5R6#EZ
M8U-.3DE:-5 S:VEM4FE3=U)M2W(W05EQ.&LX*V574$]T>"]Z:THU8RMP-G1F
M439,<4U:=5 S8SAQ4G=25W=1)B-X03LS,$5F12]!<S-P4F-Q8D9N1F-693AK
M5D)"-S=B8F9Q>%8T4"M32&QN>G19+VUF-7DO5&5R6#$Q6F%62TQE;'A02S1U
M-7!L6#9V3S1*)B-X03M+=7DR:V%F83-!6F9$1E=A9FXW<'5U6&XU66%R3&]T
M-6-7;#-93#EB;$9T23!:;70P5FQU27!#<%=Q96LW359057%-5E1(.&YD3S%U
M)B-X03MX+TQN4FAR9#509F%P9%%I-VYL=5I(;&124#A!2$A&5U%K<C9C6E93
M4$=U2W-Z>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU)B-X03MX5C)+
M=7A6,DMU>%8R2W5X5F=&.35:,7E8.'A9.553>')#3'$S;6DQ:C%):#96;DAA
M4U)45VY(;#8S-WE:=5A%3'A.86LQ1T969GI8)B-X03MO+VXY9DU.;'(R:#-L
M:$M92S9D1%I45TUR;4\Q,4,T=%1D5'E3:3EH16I1:3)$<49686EQ.6%(07%:
M+U50>DHO-G9U:F8Y=V4V+S=Y)B-X03ME2V]-4B]M=BMM1W-Z<4]J:7=&=7-W
M,40Y1EA.1$U82VU(,"\P;%A:44<U5C<T<6I0<4@U:R\X058Y,&(O=40S6"]E
M5'A60C968F9M)B-X03ML3F%U.7AQ3VI736=U3&Q&9R]23GDO2TY,:5))-7%R
M<5$O=C!54S W8W%(9D96=757+S5P46%48WDR=#EO,G!Z<79W5T(P;3114S%)
M)B-X03M"6&LR<$UO,C,S1TMO-S9H*UI0+T%&9F1'+S=G.3$O,VLX5E%.>$(K
M87%A,5I7.&0Y;S!T<$Q$8TY0<5 V2W5"-D1),%AP>&-$<5A*)B-X03MV5S5-
M86<W8TXK;WA62&954'I*+S9V=6IF.7=E-B\W>65+;U-W='9Z4FML=F97,4A2
M<E52,T)32U0Y13-,975G:E-K,C)P0VTU2U50)B-X03LX=4MR=%1S=GI.5%1B
M=#1T53!A.6Q71U%P6DA33&Q237=1,&E*8E5Y0GI0=S=J1E9E2WDO37@T:UHY
M8C!A3C)51FLO4D8P94I),T9F)B-X03LP;C)X5D-8<V8U<U$S,FY15RMO85!C
M,CDQ2SAD-V-J4S=L0F)2<D,X:7E&5'%23#AP15=/9R]M<C)X5D<O55!Z2B\V
M=G5J9CEW938O)B-X03LW>65+;T\P:B].95A53#8S;3%(4C1,83)A35=L,&1+
M=5=&=TA1335#:E5G531..$\O6$955DQ:9FU9:U1S;70V3DDV<5-Q9F]I-DA)
M)B-X03MG8D-V-E0W-'%H.4IH+TY7-C!U>G5R,U4Y2'-B>65#3U<U<U1P5GI)
M64I844TX4F-A;4$S0FE6-4%B-'%T,4]0.#$W6F)9,FUO-E!E)B-X03MM5S1I
M:&Y!,'$U:CE+1C)O.#(K<$AL-EDS-#DX5E1/>',O4&%88U18*W-A6%!:9R]V
M;UE.375)2D=8=U=2.5%M5E0W;$1I<699<3=&)B-X03M867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ>&I54$YD,FUR849&6G=H9$\Q0SAM<S=X-W5'-'0U
M,6%/,FQN0FEJ;%-,-&8S6#(Y)B-X03MW93-J:7%J-48X.%(K84QN5FI&3&%V
M8E=S:UIS,70S1'EI0U9+<3 Y1UE">59/,4)X*WED=V-65F16.'=A<SDQ<'8V
M1VQJ4T\W=3%S)B-X03LS<S<V=W5O-3(T17E4>6\X:VQT>%))5EEH=E-:4S%"
M6&9&5U%A;&5F571/=7)Z:#9N,6%'4V)H,#5E;7!A;C P>%9J=FMB>DYQ;7,O
M)B-X03M7-&13*W)03F)X5V1W:W1M<G!(=W9B8U1#36@S;%!*4#5Q+T5+1V=X
M5DU03BMO87!P,FE46"MN5'=24W=B.$QI,V4U.59M*T-/1D93)B-X03ME,C1V
M2DEY<4-74%AP:7%A,FXQ<C9R1#EB-&97=4,K=C99250Q2T1L>$)*4$=V5&9&
M5T-A=BM9=6]A5G S;4(W-%=-1C=9-F@K:CE,)B-X03M$=7EW3GET175L37IU
M,%I9:%=B6F5.5%)2=6$T5EI04')18GEO;7-2,VQT8F5P8E(S079*16$T9TA-
M2S(P85-2<R]+=$9#=E5M;EAP)B-X03MG5DLY3SAX*V%',6)Y-UHV;EHR.7%.
M5G-*-VDX:DA->E(S14%J2E5!;FEI,&M'>$Q'=3(Q3C%59#5G,6968E!6.4AT
M3E!E,VU.-T]%)B-X03MU8D8T;F%9,C1).6$T4U9:1E=.66Q/+TM-.&E1=%%3
M3593,SAV4$]'<&59+S!H.65&=7!T>D4Y=4E%9$MX5$=123E8955327=J*T-1
M)B-X03MC95<O=VEM-G%(,5AZ4#4R9S$O571*<V)/1U=224DW=E1&949F56MH
M1G=K5G=W<F5O:V=J4C8O1SA*<BMY4FEQ8S(S;39X2&MM4'I0)B-X03M02TI,
M8C9O3&@S0V96=WI5<'A#3SAG:G$O=T%/.&A!+VUP=FEQ4F%0-30Q;E4W6%%P
M8E=F5')Q-G9B>64R=C=+,5=36#EX0F--:VQX)B-X03M&37-X16%2>$)7*TY$
M>4Q+0E1K34MP:"M92&YI4'EX1%I):W1R2&0S:V=)3C0T4TU14G5I>DU0:5%S
M+S=W0E%$-'0P531&569+=FY$)B-X03M89%,X,%@R:V%N84QB2D9&3&-124E*
M-&U33T\U84=0;$Q)5$A/2EDV4T(T<4%B:D952C5M.#EA+V]'<&%P2&17,&8Q
M8U<P<S)G>"MK)B-X03M0.4E-4W=H;65D8FQI=D(U5%979U-O-E!H5FMV;$A7
M<#E8,%E81C%T95)45%<Q,F=I14%784-6;S-89TIR=&1U4%9:5T(V*S)"535X
M)B-X03M6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A60EAU:&%*9C-6
M=F0S,FXR,3-D5W!$5W,X.$UC:VM20D1!>'5W2EAC5C)X5D5P)B-X03MB,CAC
M<VLP8U-*3$Y1>E-+;T1/5DA&95)'-6].:%A&6%!B5WIZ>#-$>$DQ>$-'5TM9
M<4,V2SE/659U;T1C4E=N5VU+<6A!24E)<41S)B-X03M18U91=6YA5'!7;5%T
M0G!T;$)9=W5X9&]R84I);$Q(<7A606]R-S1Q<E0R,71C0D)016MO:F1:67<V
M:'5,;V%Q-'(P6E0P3TMQ;4MP)B-X03MF8658=$%S>F1'>C!Y,'1J9E9&-EE9
M230O5W)7=G$X5DA0-U(K,30T<6@T8G)Y9C5I=%IT3FAM,"]73%-(:7,Y:VI1
M6$UA8U0X065-)B-X03M&,49#=3%2:7%P1#56.')W6$9T8U%A4%EX6$9M=D,P
M;5,R:%8T5G%4>&I93%9"5C)/,VEC5E9B-U%.0S%#-FAU-R]48E<W=7)A;C%E
M)B-X03LT;FAJ:VMJ;V51-$\V;&QO,BLR2W(Y3S!84CE-.5@Y1S)&=EIF5T<U
M>B]6;VMI.5)V-6XT0F52,S9N1E5.3C54.')4=&-T3F\Q:DLQ)B-X03LV=V4X
M6C=A1FI-=U!)1U=Q+T=1,B]W05=+<&Y$1$9$16M-2TQ&1$5O4T].04965E55
M0W%"<T%":7%8>BM74$Q6>$Y$4&-A5%I45%<W)B-X03M&-V574S-I6F\R6GI+
M>DEX5W%K>45U4T\K+UA&56108C(Y>$598FE*2F]M;U=J:U5-<$MK34MG,4=X
M1F-654Q,4TY*<UIR:65Y<V],)B-X03M783=F,4QU5T=*23)L97!02U)L04QM
M<$\U>%94+W=!4&%!8FDV=51P='(Y6G9K360W3C9%9D]D1%%&6E<T,61D=6I9
M<6EB2WAS<D<Q)B-X03MJ=$Q',VIT8E=)56ET-%573TY15%=I;V]#:F,T<7)9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M)B-X03MQ-T9867$X;T@U865D=G%-36-6-6$R1C%:5UIS24HW2S9U27!P;S5B
M,4QQ471C3$%R46M*2'A10DI"56MM;S)W<7)7+VQJ.'=).5)S)B-X03M.2W5.
M5W9*;WAP3%,S.7EL>F-*16(V1DI,9495=6U2:79Q975S:D%X;F5-359047%S
M-3AO861Q*VTK6&)3>3%E65A';U$X+U=M5V%A)B-X03LT-6-P1UIA>3-".59Z
M>$EQ5%0R049"9U9/359D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D
M:7)S5F1I<G-69&ER+R\R43T]/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @
M(" \+WAM<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M
M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X
M;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E
M+U)E<V]U<F-E179E;G0C(CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^
M>&UP+FEI9#HT.3-&0S(V,T5&0T%%.3$Q04,S.$5&0C$P1#DR.#9#.3PO>&UP
M34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP
M+F1I9#HT.3-&0S(V,T5&0T%%.3$Q04,S.$5&0C$P1#DR.#9#.3PO>&UP34TZ
M1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)
M1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]X;7!-
M33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I296YD:71I
M;VY#;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @
M(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HT.#-&
M0S(V,T5&0T%%.3$Q04,S.$5&0C$P1#DR.#9#.3PO<W12968Z:6YS=&%N8V5)
M1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HT.#-&
M0S(V,T5&0T%%.3$Q04,S.$5&0C$P1#DR.#9#.3PO<W12968Z9&]C=6UE;G1)
M1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED
M.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]S=%)E9CIO<FEG
M:6YA;$1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#
M;&%S<SYD969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @
M/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^
M"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D%!0C<Y-T5#13=#
M044Y,3%"045%.$4S.3E!-#(P-3DU/"]S=$5V=#II;G-T86YC94E$/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$Y+3 X+3,P5#$R.C$U.C0T
M*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I
M/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.FEN<W1A;F-E240^>&UP+FEI9#HT.3-&0S(V,T5&0T%%.3$Q04,S.$5&0C$P
M1#DR.#9#.3PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.G=H96X^,C Q.2TP."TS,%0Q,CHU-3HS.2LP-3HS,#PO<W1%=G0Z
M=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^
M061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z:6QL=7-T<F%T;W(]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO:6QL=7-T<F%T;W(O,2XP+R(^"B @(" @
M(" @(#QI;&QU<W1R871O<CI3=&%R='5P4')O9FEL93Y0<FEN=#PO:6QL=7-T
M<F%T;W(Z4W1A<G1U<%!R;V9I;&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @(" @
M(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%109SI(87-6
M:7-I8FQE3W9E<G!R:6YT/E1R=64\+WAM<%109SI(87-6:7-I8FQE3W9E<G!R
M:6YT/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^
M1F%L<V4\+WAM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@(" @(" @
M(" \>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@(" @(" @(" \
M>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @/'-T1&EM.G<^-C$R+C P,# P,#PO<W1$:6TZ=SX*(" @
M(" @(" @(" @/'-T1&EM.F@^-SDR+C P,# P,#PO<W1$:6TZ:#X*(" @(" @
M(" @(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @(" @
M(" \+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%109SI&;VYT
M<SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z9F]N=$YA;64^0V%L:6)R:3PO<W1&;G0Z9F]N=$YA;64^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D-A;&EB<FD\+W-T
M1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT
M1F%C93Y296=U;&%R/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N=%1Y<&4^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG/E9E<G-I
M;VX@-2XW,CPO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/F-A;&EB<FE?
M,BYT=&8\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^
M0V%L:6)R:2U";VQD/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F9O;G1&86UI;'D^0V%L:6)R:3PO<W1&;G0Z9F]N=$9A;6EL
M>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/D)O;&0\+W-T
M1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y
M<&4^3W!E;B!4>7!E/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^5F5R<VEO;B U+C<R/"]S=$9N=#IV
M97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S
M:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @
M(#QS=$9N=#IF;VYT1FEL94YA;64^8V%L:6)R:6)?,BYT=&8\+W-T1FYT.F9O
M;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.D)A9SX*(" @(" @(" @/"]X;7!44&<Z1F]N=',^"B @(" @
M(" @(#QX;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @(" @/')D9CI397$^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:3Y996QL;W<\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @
M(" @(" @(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX;7!44&<Z
M4W=A=&-H1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'
M<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'
M.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @
M(" @/'AM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" @(" @(" \<F1F
M.E-E<3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G-W871C:$YA;64^5VAI=&4\+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z
M;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L
M;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @
M(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y"
M;&%C:SPO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P
M,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXQ,# N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z4V5Q
M/@H@(" @(" @(" @(" @(" @(" \+WAM<$<Z0V]L;W)A;G1S/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'
M.F=R;W5P3F%M93Y'<F%Y<SPO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @
M(" @(" @(#QX;7!'.F=R;W5P5'EP93XQ/"]X;7!'.F=R;W5P5'EP93X*(" @
M(" @(" @(" @(" @(" @/'AM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @
M(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STQ
M,# \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P
M/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE
M;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^
M,3 P+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(#PO<F1F.E-E<3X*
M(" @(" @(" @(" @(" @(" @/"]X;7!'.D-O;&]R86YT<SX*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @
M(" @/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q
M+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R
M>2 Q,"XP,3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ C@#^ P$1  (1
M 0,1 ?_$ !X  0 " P # 0$            &" 4'"0$#! H"_\0 /A   @("
M P  !0("" ,%"0  ! 4#!@('  $("1$3%!42%A@B%R$Y6'B5M]@C,3,9)3(X
M=B0U-T)#27&VN/_$ !P! 0$  @,! 0             !! 4"!@<#"/_$ #P1
M  $$ 0(#! @$! 4%      $  @,$!081$A,A!S%!L105(E%Q@:'10F&1\",R
M4L$(%C.BX313=(+Q_]H # ,!  (1 Q$ /P#]_'")PBK"_!M['U%1@JU;[\#6
M:_47&P-H*.RAY*":&Q!8T+75,' )5=Y8L+"][M%^-/6M>S5<VL0Q#8H@;9#C
M,19!7OMO/Z9.\YO]4V*LQD:SL^TJ3LDFQU!G7;RAIUAUU5[#"(D4-B[,A,";
M;(50X86-<N^[C#,F%ZEB^GGV_+]^'W5VZ;_O]]%8[A1.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$6*>-?P:ABW[7-6_2X64K\8C#[8MSOI8_J^W7 XYQ
M]E%2?\HH>I,>\\OZNN^N$[ER^HWQ*V5M]57/S[-Y]V! GKV#N (Q:&6QV%$4
M@AAF(.L%+[&@A7*&'4G>(N<;2243J9;)+(7^0[P%Y\'3?<;_ $_7_A<=^X['
MX>/Z*^FXMC--9U:MWD<$&:M07JC*]A_E,"(3$M&N+D:I'V06:,F$9?G36SY)
M:;&4RP*"'IR6T8_2C,R$,%X+DJE?QRMB*^SQ"U=<FKHO7]@V<HM%=IMA:T6K
M4ZV"[.L^ASKP7'W/T%,XH=-K;*_9DL%$"=W:P 5<!0V#J2N$65!]NY#QH8+1
M0+"CL?645<<TWH>M,3GEULBGSB?08DEI#OG5>0+7!?HNKK&GY8=K O-P;Y$.
M %5?A;68B]]F]FNM?W:Z5*RZAO\ :; #.$37]?:SKT]WMXR=/KFNVZ[R%2UN
M5N*Z,_*6%:KJL0T*Z)D4X5BM)TD6+(X BOSAGU)AA)CUEUUGCCGUUGAG'GUU
MEUUEUUG')UCG'EUUW\LL,\<<\>_GCEUUWUWUPB_KA$X1.$3A$X1.$3A%3&Q?
MVANGO\&/I+_6_P I\GB/@?,*^!^(\BKG<JB<(G")PB<(G")PB<(G")PB<(G"
M)PB<(G"+1.WO3WGS0OV\6W=OT:D-#?I]+*RQ=0%71WG+_P!**O497]_<+#/+
M_P#3'2(SY\^^^NL8^_GU\\RGCK^1>YE"E:N.8-Y/1H))A$W^N9T;7-AC ZND
ME+&-'5S@$C#YI'0UXIK4S '205()K<\;"-^9)#69+*R(#JZ5[1&T=7. ZK@'
M\)/VGMGT)\0WTW0[41L4J@KZKLY]45-HO&^W,5,'3[,I:)<O;TS9>T[/6JJR
M+"(GFG'QJHSQ*XG9(4Q".NY3HL/2M9=G>'TOIG#9RG:M2W\C+5BMQS99URK_
M !Z<EB3U?%RVLDC;+&.*;B/"TMY8$<A:WLF5[-<;I3'5-15;N>GNY1T4=VMD
MM49G+8VH;=<6N7C*%Z9]5C2^NYQG+!-$'.CJ<FG*^!GZ<N>4KK:KE6?1?F.R
M[[MVDJKL?7C+T'7UOSMU379C_N[ %9C#).O)8]"X1M"$F!$4C%(*Q-/1X]YY
M'A!]12]X8S;E5]A]1D\;K$8W=$'>T.[?\B1N.( ES?$!=?K:JTY<SEK3E;,4
M9L[2C+[..9+O8C:WA,C>[@?)$'-,T,;WRP@[RL9L=ICO.Z:YHFKK>[VZC,L6
MLLT3H&]JX*&WV.MGJ4Z5E+8\;-5TZ=[F95Y4L!P[K[]=,LE'GZ!+QS^\CAER
M5V!:>M5Z\L8/U1%LUVO.V$/5:6@KM?/T:W:[,DKFP8-JC5BF(D'=0*LG8TRC
M7FV3F5<&@P%K565V1V_@4UXHHV<BD$;CS);[\NU$72:J;>[_ *F:[+(J5DU*
M0 <1K7/JC4-EU<!K#5A,4Q1HH-*K<U0M'V3\E55@094_8%6PP!(HY'-Y&<E4
M:@D:HHTT%PVA?M>4-<1ID$^LFWS2B:ZK+5W@>'6SJ_6\T:NBWJNJ#+&4CG<C
MI&RI!@>%)UC.1;8U[Z"U5LZ.PD5:P$]!UJMH;N<PL*%_4EA5!M/=BZK.P4S&
MSK5(3JC6#JI6615:%LY*DH9,29B1T'((0012('<.I&F)N:S:6N6."Q*RLC+,
M&[UDO%?74["90W?FY#LY.A$JIJ.0L9-9^XP06$$P14\1,6<6)%"KEZ4U13U=
M1>1O<;DENG;V=4WH$ZJUK(DU9)$5/K(4<"SZ%S1*K,WKE/-)72L"1[-9T@$H
MF$,AQ0!%([7O#5=0"8S'7>LL&X5=LUF!IZ6PH6%TL@-2'=3.H*M6NF<3!Z?!
M-772[H8/#OK%FM-"FDAF$)ZA(MF+F +=>"U6%P'K688K!><+)C*,8";!@2(6
M/+CWWC+ 0/+'-%)CWWCG'GCEUW\N^$6I]N>A-):&@32[?V=4J%-8\S(ZVL=L
MX^G]DR7=#Y,?VY6Q>B7[[%;B6)DRS4+3,%^)0V1F4.)$7>;9%]>I=[Z;WNL:
M-]/[(J>P1$1<*^P15UK 4RKC F+*<8"RI<^XG%=.)'PR(&#=  D$#]=SPQYP
M_P _"*MDUKVS![*S3-$%P;TB9TF05&)>3M!144%"(TR[LKS9#7)*)AJ.T$=[
M2#/U^:KO!Q5G7S'U$^NQI<QP8[<187IO?SOB:U9?:*6CKU34>/=]14"RK;M+
M8FEU")W%Y8F=%O:SG54F%)F4GXQ!!B1/K7TV@DR-R)6]Q_:YSQ'P/F%?PGXC
M^ZX__'\]=>@//&W/,]?TYLFT45>74K+<6(U?/Q B.=!V0$  R?Z/7U"2!1AY
M88,6&!(,,9$W4 ^79)^.??M&]DVE.TF"];U)>S4$FGYH)L?'B,]F,&V"65DL
MCKMYN+O4V9"(&%C8XIP3"&3ALD;;+N+W?L=S5'%8_5$<N+TUD9+4<$=U^>PV
M.R\D.+=#8#FP'(03&E#(\2NEEJNB?*^*,RN)KP%EQM[_ !C(M(^90=OM?/\
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MSW'HUI*RZ--^0N5J44M2"2U*R%DUZW7H4XW/.P?9N6Y(:U:(?CFGE9&P=7.
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M?2RM&UC<C6CMT;L+Z]JM,"8YH9!LYCMB'#WM<TM>QP#V.:YH(@6@O.FEO+U
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M:42O4FM8O(9P69OY*'I81$11BTT+T"?[+UIL?);7V.F4 5JK2^=;L>P!%UU
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3")PB<(G")PB<(G")PB<(G"+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>g713200g63r89.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g63r89.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1\J4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %8< 5H  QLE1QP"   "   < E  "')R,C8T-C$W' (% #5-:6-R;W-O
M9G0@4&]W97)0;VEN=" M($E03R!P<F]D=6-T(&1I86=R86US(# W,C(N<'!T
M;3A"24T$)0      $&9H976%ALX6Y+ 3M]'"\MPX0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /
M     0 ! \     !  $X0DE-!"8       X             /X   #A"24T$
M#0      !    !XX0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              *U   #,
M   !                          $              S    *U
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   *U     %)G
M:'1L;VYG   #,     9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   "M0    !29VAT;&]N9P   S     #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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MAC^ED_K%OI*SB=3?U7I^-:ZD4G(OV@->+6.92\N=?1<UK/5HL;3^CL]-F_\
MXO98C#YAYW]B9_*?$5]K_]/U#*QZ\K&NQK9].]CJWQSM>"QT?YRPNJ?57I9H
MLO+++"QV]K=P 8"?4>*PQK?;O?;;[_\ 2?Z/TO3Z),0"(.H/(24^>UX.';8[
M96\.])];P7@S4\;"6;65^YE>UO\ I/S_ -+^F5YG2L2P/<;+0ZV2]P-8DN%,
MZ>CL;[L3'L]O_GOV+7R^D-Q+G9&/7+'<D22T<D;?W?Y?^>LK*+Z&^I206?G
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M1@XWN97N?W>[4JQD45Y%1KLF#J'#0M(^B]COS7-0*\M]+QCYL->=*[^&6?\
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M &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@
M   !1DU- "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %
M 0   '8!*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "
M    "0   +"':0 $     0   +P   #H "W&P   )Q  +<;    G$$%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#<Z,C(@,3(Z-3DZ-3@
M<G(R-C0V,3<       .@ 0 #     ?__  "@ @ $     0   S"@ P $
M 0   K4         !@$#  ,    !  8   $:  4    !   !-@$;  4    !
M   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
M  !(     0   $@    !.$))30/]       (          #_X0%(34T *@
M  @ " $2  ,    !      $:  4    !    ;@$;  4    !    =@$H  ,
M   !  (   $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I
M  0    !    O    .@   /      0   \     !061O8F4@4&AO=&]S:&]P
M($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR,B Q,CHU.3HU. !R<C(V-#8Q-P
M     Z !  ,    !__\  * "  0    !   #,* #  0    !   "M0
M   & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P
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M,I&A!R-"4K'!T15#8G+A\18S@J(D)5-CDC1SLP@U5++2_]H # ,!  (1 Q$
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M=,;[A 4A#JV+5Q3"(P$2)U-<Q"B<HBRY*B1\PS'*]48@VLM\FGO'8O9:?/\
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MT^^JDFE<12NDM(8EBKB$7ZWN)(C"<]7<.5>I%3SKT#LF\5Q>JZ A8K>XV+@
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MP?>1)^YH^C(/4!7U&/@%FV1+A/J+I*_*8MA8.LSLR3,:/<ADH0+ <O#84Z7
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M!D6CMX<6XMA3K')H0:^751989$ET:N'UV4X$32LX_E[_ )]*R -^=II,O'X
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M>_O[LX"P0+DD!F\(DD"L$SG: \K I$]5[M'KL>AV0=4[^_NG^SZ?:#):>=L
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M:4KYD*(+%(8@Q,1417D>UC$5RHC45SE1.5541$Y\JJ(GG2E:GE>:0,56MB+
MMK^^NR2ATF,8\"+*O+1L *2;*6-L^;6UL&MK0.$LZVN+*MJ@RI=;6>\=;7%1
M GL4^LU4N@V^!@T'&/[M]FMU,'R+'[&ZFV&35V.["DFY@W)U5,B7+@,W!BBM
M[.9TQ)42\>YEE#L:V"0Q9U:2TJ;3..GB'Y_TK./<?]W]*]>8T^9YKNBF4S]L
MMWJ_"RXCAM+:X_7,V??89#88AGEAFT6-/DSMP)7L:(AB0@2OPR2&QG@?/AJ2
M&U02M,?XA^?]*8'J/S_I7SVYVH_",GVY)-Q#>H0-O&8OC^%3\A%M+'JL>PS#
M,8W QO'J2^)C^:V5K</!#W L63+P%>MA.=5T'5%$0=Q+MF/<?G_2GKR#GX_S
M%2J3T\51*^!!7,,D8['B947$)@XU DG'29!N-@>ZE61&OJB1;9V+9;M]3DKD
MM(QV6%::7!NV6#GMD)BL?7XU_ >GFC&EM/M\INI]M>3<2N<@LT!55\>39XAN
MS-WA$>+!'%(.!!D74Q:9T1QY1 8]%C#?-D6R2;>2H3QR< <^@'')_*J([G9L
MS?7=238J29(P2M')H,>#6J])TK"!60Z_(+2EX<Y?VAW7R(;,.QPXQI(!C@IM
M@6,^-!E/2S:7ITMP\=K%L21LS3RR@"*!44NTD[<8AM(<S2 D R%%'B9<^0ZW
MJD>J:B\S]X^GVGZF&.+/>W"&0(5@')-SJ-QB"$J,K!^L==L;D7'VI]+^(XYC
MXOVJK5F6$IKI$6B?:65C5XBAA1ALC0)$^9+DV=P$$6,"=D$X\@\M\=K0]($<
MX\C4^TTH9K31G:VLX_U;W01([S4MA;,EPZJIBMV+,8K.,*D:G#[F)"VO3NRT
M,J"[UR,7%W(N8K(.S66EHP4K#;(68/.@55ENG+-(5 3"C+87>7:ZQP_"LBRS
M%SV-^ZCKW2@TJUYK&Q#$8]B2Y$8<)7EGI C*6:L*+7]^0R/V1B*]WGG:?>1R
MW$<,D<41F;#2J5C5F.<!RP 7<>-[/@%L\"I5]HLBQ[X[F::.%?##)EW1.,]V
M0=IP.<",<+T/ KF3AEY&M\BQ$HK8SS7%]4\ELP%=:V<%UN$%P5E?-2'*FDEP
MV3Q(]HV#<1RO:K6L5&VMF"K,Z;#W*.?U+C;&X1C'XDW=WM<+@GI@?/@)]GO4
M[B.6-UDVQG $A +;3NC)!;D'@XW'/-=1K+8V-MH .8XU')EP*ISY>4X7,"QD
M*XKD1JRYF-PQ.Z85Q!"QT@<$Q)D6T:QT=1L/VNYS;?71K>--U1UMI9 ([#5@
M29K>;D1PWTA&9[21B%,AQ);D[PQ7=MV7'9:/0P-3T^-K^.#=)?Z5(OZJXAX[
MR6QB4XBNHE!=8F,D<P'=X#;0V^[B[IX[AFU0,FQ E>C\GAC!A[80!1Q./.CJ
M]TY8PV,[;:H'6>0,@VJR6,,(Z,(9$U5Y+.XCO9K6[5UFMY&2X5SEE9&P1N.=
MP8\JP)#*0ZDKS5L^WV:Z9#=Z?W7<74:O:=T@13WBY#%0!M*#.]6 *NO=MAN*
MR.P^Y/\ >+A,8DXR/R.B[=7>HY4[D@C!\Q+14^>FQ WK([AK?>BF,8U&#;K1
M<1=U(0!X6Y7X>8^1X^&#YU)TZZ^U6ZECF6/"2^I/[+_]8&?3<& Z5-FM%3Z:
M4II2FE*^,B0")'/*DE&"-&"21(.5R,&$(6.(4I'N5&M8-C7.<Y51&M155>$U
M](C2.L:*7=V5$51EF9B J@#DDD@ >9KY=TC1Y)&5$C5G=V("JB@LS,3P%4 D
MD\ #-51VFA&W=W NM[;T)'4=3(D8]MI7R6*@P18CG,D7/:=RWW#NX1.M>OHL
M),YJ.1U?#<.]Z_*O9_2;;LQ:L!<SHMYK<T9Y>23!2UW8SL&T$CPYB2(XQ-*&
M\_[/1-VBUBZ[4W:M]DMW>RT."08"1QDA[K:?[SQ-SR!-), <PQE;::H5>A4T
MI32E-*4TI32E4S]8?J(%L_A_[-8[*$NX.6QR!KFL>CBT-2_N"E9 8:<HA$>U
M8M6,W#)$QQ"]$@$&8+4ZQM3/)N;B).2<?>;R0>7NQ\A[D55>U.NC2;7N(&4W
M]RI$8SS!$<AKAE^16(' 9\MX@C \P=H\1AP(D_>'/7D_"JIQI]5[U7&/9V??
M5'6KT,JOE&6:] 5W6YSY5J19"N10">7K7$A8BWB^\W#?X5Q]WX8Z^BC&.:\G
M@3[US,2<98%LEF8G)<D\L22<9ZL<U]=ML'RSU5;R,BO>>!4#5DZ]L!+UAQ;%
M(A^!1(KW\,?8RGO6- 8UO5)LI$BQ>!(H)K@YDD2RM\CENB@_WDAZD^P'+9/"
MC;G[HJ?I&FSZ[J*PKN2%,27$H_N8%/13P.\<^%!SEB7(VJV._-?!!6P(5;&4
MSHU?#C00+(D&ER%!%"P E/*DD+(DF48V]V1(*0QG]1"D>]SG+6R222>I))QQ
MR>>GE7N*((T1%SM151=S%FPH &68EF.!RS$DGDDFJHV@DV(WDA747B+MKNO*
M;7W0/X(5%ECE>\$T3&](P"D$>IE5W2QL61;*B=N!%8R_0'_BGLY+;2?K-:T"
M,S6S]9;O3P%#Q,QRSLB@J/\ &EL,@S2$^>7"_P#"?::*ZC_5Z'VAD[FZ3.(;
M342<K*HX6-78[^3@1O<X&V&-5MUJ@5Z+32E5QR2SP"LILQW$W-#39)(K<GO,
M<I:?(!5IXU0:O-)J*+%Z*/=HVNJ[/+ "%;R[26L<UBN0"6;9+CD.H%"V1(\C
MA4SGJ2,^%1U8XYP!SQR>@!.*B7U]!IUM)=7#A40849"F20C*1*6(4,[#:I8A
M<\D@<UA=BLFVWR?-<LG;=Q/9A7$<52XHIXI$6WV_L66V2@)B25,EQ!8Y3SE
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M TGVFV ^Z(+C]8JK_AC8O"/>,CRK5V4U,ZMH5C<NV^=(S;7)/WC/;GNV9O\
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M[JM37L#NG,V93-L:D58JV]L7BC2+-L,+L@K!0D>A(<$[GLXBSGN&]SQO<-A
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M-<3/T2*),LQ)&>%7+,H,K5-2M]*LY+RXW,%PD,,8W37-PYVPVT"#)>65\*H
M.!EVPBL1K^UF,6>/X_)GY%T+EN76DO*LI[:M<.-9V2#:*K ].>8M-7AAU@41
MY&=48I!O<PJ+J5KE[!=W:16>?[/T^".PL-V0SP0;BUPX./'<S/+.V0&Q(JL
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M8E:1LGMZ?:;0+B0#<PS&#SM7]\^A(SCT7GSX\O[8Z^9I&TBS?]3&P^V2(?\
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M-W^T.R]IGU-NO8[A1\E]]9QK;*J60&^Q],;B08>(RP?AYG6A&606?F/H?Q^
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MQ(W X\)Z#G[U=:/2]3DM&OH["^>P0E7ODM+A[2,KC>'N5C,";<C=F12."0.
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MFZ@-&;>XR6$9P0>Y=FV <]WW3?MBJUIEY-V@[)7-L7ECU2PA:TN4#,D_VFS
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MM8QC4:QC41K6M:G"-:B<(B(B<(B>$35 )))).2>23R23U)->B@      8 '
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MR@EH]PX)WR3;?")D3,=;]/[)/-=+JG::[_MC4!AH[<C_ ,OM//9'"559 IY
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M(FJR[O([22.TDCG+N[%G8GS9F)9C[DDU9XXXXD6.)$CC0!42-51% Z!54!5
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(2E-*4TI7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>g713200g67b87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g67b87.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X6?0:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^9S8W8C@W/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@
M3F%M93H@(" @(" @(" @(" @(" Q,C)B+F%I)B-X03M5<V5R;F%M93H@(" @
M(" @(" @(" @(')R,3DV-C Q)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @
M(" R,2U*=6PM,C Q.2 Q-#HT-3HS,"8C>$$[15-4(%1I;64Z(" @(" @(" @
M(" @(" R,2U*=6PM,C Q.2 P-3HQ-3HS,"8C>$$[4V-R:7!T(%9E<G-I;VXZ
M(" @(" @(" @,BXU)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP
M+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @0F%R($-H87)T)B-X03LF
M(WA!.^* HB Q-C8@0TU92R!B;&%C:R!C:&%R86-T97)S(&-H86YG960@=&\@
M9W)A>7-C86QE+B8C>$$[)B-X03OB@*(@,CDX(&)L86-K('1E>'0@8VAA<F%C
M=&5R<R!C:&%N9V5D('1O(&]V97)P<FEN="XF(WA!.R8C>$$[5&AE(&9O;&QO
M=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03LF
M(WA!.U1I;65S+5)O;6%N)B-X03M4:6UE<RU";VQD)B-X03M!<FEA;$U4)B-X
M03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<V-V(X
M-RYA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C$Y-C8P,28C>$$[
M3&]C86P@5&EM93H@(" @(" @(" @(" @,C$M2G5L+3(P,3D@,C Z,#0Z,3<F
M(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,C$M2G5L+3(P,3D@,3 Z,S0Z
M,3<F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-28C>$$[26QL=7-T
M<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @
M(" @(" @($)A<B!#:&%R="8C>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H
M96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@
M87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O
M;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X
M03LF(WA!.U1I;65S+5)O;6%N)B-X03M4:6UE<RU";VQD)B-X03M!<FEA;$U4
M)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+28C>$$[/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.D%L=#X*(" @(" @(" @/"]D8SID97-C<FEP=&EO;CX*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX;7 Z
M365T861A=&%$871E/C(P,3DM,#<M,C)4,#4Z,#$Z,#DK,#4Z,S \+WAM<#I-
M971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#$Y+3 W
M+3(R5# U.C Q.C Y*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @
M/'AM<#I#<F5A=&5$871E/C(P,3DM,#<M,C)4,#4Z,#$Z,#@K,#4Z,S \+WAM
M<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E
M($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*
M(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F.D%L
M=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U-CPO
M>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z:&5I
M9VAT/C$R-#PO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @(#QX
M;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @(" @
M(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G14%3
M04))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!04%"
M04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=404%!
M04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+0W=O
M2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C2'@X
M9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF
M2'@X9DAX.&9(>#AF+SA!04519T%F045!07=%4B8C>$$[04%)4D%135)!9B]%
M06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W14%!
M9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!04-!
M44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%54UP
M1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-00TY5
M46YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]0
M128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N9#1E
M6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[<6)N
M2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#04U$
M8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T4TY#
M1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H9UI*
M:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&195U9P
M8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H66%(
M:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ2VUQ
M<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y531Q:$Y9,6)4.4@P=38Q6%5:
M1"8C>$$[1%E75514,U5W4C5/16%#<DYX:D1-841W1TMP2W8U;"M11W-R5S@O
M5#EK<TXT<V)10G!L5U%R345:4S!456M3:7I)>CAL2$%'<E5'2R8C>$$[<&AP
M2&UV>35R3CEE5T]K-FA$9EA';G!"2F1I0G955D9U;%IO5#9I+T%E86]4<U0W
M.5)I<6$T<3=&6%EQ>&TT+TUV>4YB87I0;SDS<28C>$$[,&1P9C(P:&AN5S53
M5T-.6$59;' V,&E,1CEH,4YE9$YW3W!'2W1V*UIF:T=/,6YU6F1E<S1L='!*
M24HT<$I1:S9Y=W4P8E(K9S%*:28C>$$[+TM.9W%H870K>EA&53 P:GI(-64Q
M:WIR;RMQ5VUP3F%K3&-I,&YI;DU:879%4#9B3GAR>$Y+*T=+<&II<G-663E,
M*UE0:S9'-U<Q;B8C>$$[,4I)1V$W8E0P;6U34T]"<G!/9DM&8F@Q5T5U1$,V
M:T(O=$1J.6]G67%W=GI29"]L+W=#6619;&UT=D]M:TQ.9C)2<V%O.$XS4&%X
M428C>$$[>#--='A087I2>G%,571B>7EC-4A5<CA+:SE+1E9I6&U$>6(U6#%B
M4CE6=')Z>G1A86Y-;'1P,79D-FIB85I*9E1X;5-A,G1)55)R5R8C>$$[85%K
M5%1A9%%W<6%Q-W,R,TQD5C8Y6F9M3#5#;G-93&Q033)L=D9+:$EK*W1W>&=M
M3D9E5#189FMP4EA"6E<S5W4K2W Q<'5Q-EAQ;"8C>$$[=CE:,#(X9W9R8FM5
M.64R:U-:3U$V<GE1<TMI=4MO5'I*-6XP8GDS<#8V:'$X<VM.;SAQ5S9V1D)0
M8VXQ2E1X:E5P8G!+-#5..$E.2R8C>$$[5DE(56I&549E+VU.-45S;THU-VY8
M<DI)-V%->E,P;59M-'(V;%965DI:,R]!2$5N=TM#,W=N8D9746]Y=6EU<'%R
M045(,D]+=#1Q-R8C>$$[1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867%X
M3'HS-6<P0T-*=DPK=3)&,V171W)7<V]M84%Q<V)206A::TQI5TM51EDR3&YJ
M,28C>$$[54=L5V]P5EE:3&\O-4LV<3)O,W(V13<V:G%&:D1Q5B]A0V-W>E-P
M9$U,;U$W6$M28S!.:TI745!X541L5VI'<%9%*UAF378U6"M4=B8C>$$[5F92
M.4AU.4Y854I,93%9.&A)<FA:23%H2V@W:5%)=&111&YO5'E9=#A72W96.$-U
M>%8R2W909D\O=T-72#5:4W)Q6&UR5SE#;3%+-B8C>$$[:D0S9'E)2C=K>7E&
M63%1.$EH4$=H4'!X9T)2-&)B-'%W;&9,4#5#*V%.5W,O4V=V3%=85W12=3=C
M;W1Y-E(S,#A2835M.59J3$DS1"8C>$$[-$9)0VQ4*SE5535F64MV5W9++VM8
M>70U6&MU<$Y$<S)T<$PQ24DW<#-M;FY:,'162U%,5V0U0T)':D96<#(R-D%9
M1E0W1EA9<7A05R8C>$$[=GER.&EA,T,X1W V8SEX8G9D='%"="]R3C!K475N
M3$8U5FI35E56;DUJ1G%$8VUP>%9J,3$K56XU5C94<3)J=U(K5S=L,W9H9&%B
M8B8C>$$[6%5.-6-E;&)P3$)03$Q'-&4V4C%74TYP<65M:E5.96TR2W!8;S%P
M*U0V*UEP=DQD=G!.-UDV<C5K;&4T=B]7=EI5:V$T,#8X;&1'9"8C>$$[+W)J
M4RMP-CEU,&E'2W99=%-U2W-K,7(X:G9Y-#%84F)B4T<P*U,Q=')%,T)S1W0U
M-59A1#8R-&4T15ED<$5P259P47%1;W)X<&ER2R8C>$$[9DQF;&Y2=DQM;6I4
M9$EH84<Q-71+=V534UIM:VM.6&1N;%HR3$UD>G8Q>%9#*V-Z<' P=3-I,4MW
M=4Y1=$IR*WEJ2U=S:7A.2$UB;"8C>$$[4'$X>G-:8F,X175"2%AI4V8X:VEU
M2W9-=DU79R]K96US=V58.5HP0S93-'5T45=W5EAU-5EO;65+3D=H;5 X07!I
M8V]K4SDT4F)&;"8C>$$[2$I654M-5F4P>'AR2$=K858T24%Q,4I*;T)18FUP
M3TMR<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&EQ5S,K;F%T4&-'4S$Q
M828C>$$[4WII;T%)5FAH8T%J<654<5<S>%8U=C5O,5!38DA76G Y85<U;G9B
M3F923W!0<'5L>6M2479&3$=&:UDK<'@Y85I'5F5O86IC44-'2B8C>$$[5D-0
M<4AL1TA39&-N=&@V.$]M6$QA2'%T;F(V6G!0<4Y&0DIW<5EJ>#57=VM.1C5D
M-B]$:7%$;3%Z>6IA>D=0-FQ+<SA"5C5&1VTV2"8C>$$[1UEG,#!C66Q:;FM2
M5E54;T)Y<C%J2B]:0GA1.5 P*WHQ,BMS3&$Y:C$R-&IJ=6]K;5)(=')4;6]K
M54U!,T975V]R=E%K67!14&U7-"8C>$$[,7)13D]454QJ5G)Y-71Z4$1"2V)E
M,G-A>$-D>$=S:FE5>%913WEG.&%T=C V-'%X82\X07I1=')(4V10,6%F5G16
M*V\V;EIP9C)S>28C>$$[,D9M=UI(;E-!>#%R5#%6.55-54)*<#!Q>$-L5DU.
M5CAW<DI:24I.5'5D5G-,<%E!>&IT=$YM:%IR;4PQ-%EZ>EI68W-V1VA8:W9X
M028C>$$[,6]'2W%'33,O;D1Y:%E01%!,-G=U2EI%=4DO.7@R:TQ*-C!J45A#
M>4%U>59B;$I(25A"*T9L1E-'-&-L3$MT5S@R6&5N86EL:615,28C>$$[0S=K
M:VUI=&QL=&)B5'!)+U=L6C Y36YM<%9K84UQ=UE$971+,&%I:$M,8C@P9G)5
M,7!&8C,R<E-.97AI5T0O4G1,56UR:4UP>&%:5R8C>$$[3'$O2E-O0E!W<V5M
M*TM793)U;C8Q9%<P5GIB*UEP6&=N4EI9;D9T8FIK:FIK<#-3=31/0E94.41E
M65 K<&=M+S92<F(O;6I&57 Q;28C>$$[,#%32%5D2W-R<2]U8G=A;$Q.8E)8
M271D4&%/1FA!.&I#5#%/36Q*26\S2'=+,U-H<%562W-3,&YZ0C5B=E!.1VQA
M1&(S5#(K<$@Q8B8C>$$[:E1:2DQ$4S1X1'E6,C5X8BMO1VU3<F9U,4IO,4@T
M:S!X5C9(*VAV34@O57=49CA!4TYB9C@P649D*VAV34@O57=49CE),70O>E)I
M<28C>$$[5F$W2'$Q:3%K='AQ5C-E:31M-'A'2S!S6$5C:4M:1EEI5&=F,F1I
M;TI(53!516=Q=V)Z0C5M.'4V2'!O=3E1:G50<4@K9V%H8D].4"8C>$$[,&-*
M2SDU2$I,0DMN3C!#>5(O5E="3#A45E)X<CA/2W93-TMX,64U:&=U-&9-5#-&
M=$MQ>7AS:TYQ>4]J04U#2%)30T=(8TA!<699<28C>$$[-T9867$W1EA9<3=&
M6%EQ-T9867$W1E5S.'=W-GI.6E)P<$UN<%A0<GA&,S5+=$EG-$UL95-38W9H
M+UHR<C0P>%9R44ED9&II=D1R128C>$$[:5!*2F134U=I;W=C4C(W0F5%6EE*
M1E5G.'4S,#1Q>$AZ>C4T=CE$,64T=&]I=T55545Y4G)C,C!*84]73S5,3T9M
M=%IJ4EI,5E4K,R8C>$$[46QX,V]R1E=',V9N3'E%3DLQ2'I"<3EI5S1A:F17
M1C5W=#E*=4HU-5ER5EI88V,W85 Q3V-B54E99V=#:E50=S1Q=3%F>EHU56PQ
M9B8C>$$[579,;6]7='1D5SAE<E=I>"MS3DYE1V4W=C!,1S1K4U-W-&E92EAK
M4GI067--5E%-2#5G9FQB9#9.83-D.7 P>DLW:4U14E=7:EA5828C>$$[4W)#
M,#-&5SE&9G-I1&=#5D97*WI52U-&6'(S;#(S5R\X=C9:939B<60U8C9F9%=S
M13%N8BML67 V8TUK871';D9)1U)E2VM#:6UG-R8C>$$[6492;'IO16PQ2#96
M>G%D>%!(54YW:VES;E=O-D=J5S5X5D%295%T2&E&26U%63E.64M,86%C4#-5
M8D)K:C)T9G-Q>4M1=E%%1$96<R8C>$$[+W=#6'5I6$%H5S1);5,R4DDW6DI,
M5%0S4TI);$M)<V%T86M)1E)I;S0Y='5M2W)8+TQJ44AI14QQ:E%G.&A#8E14
M:DAY2$%C=4@Q6"8C>$$[:GDO8W@W,'(X2RM!>%9F8V9L+V]T>F-#-75E33%Y
M1E)"4$I:-F,W:%EQ:4YE4G1384I8-&9$1E9'9CA!3%1Y,U!)<W-S8V)Z26]2
M2B8C>$$[:EHV8C9I<6]!54LO,5AK=D5+2U5/,4)I<61,<$8V<6A6,64W5E9&
M04%L;4%!4#A!;S-X5G8Y1E@S+U8U=E X06=,4"]!3$HX5E5:+R8C>$$[3#AL
M>%0V>'%6>$YX1$)F56ES;6](6&EW1F)F.7!442LR2V]74'E4<#!C<T4P8WA3
M5S)K:VUT<$9T=%!$4GEY,3E34D-,87%S+TYU4B8C>$$[1S5Q831Q;4@V2W9V
M*W)Z968X0EHO=T1:4&ER=C!69F8Y6&TX+W=#07,O.$%S;GA60C9H-5-T.5)-
M3&%H9'E8:'1M36QU8FDS<TI41R8C>$$[-4A%<VY/,E!%,#)Q35955#5&,',R
M1&%C6DLV939,1SEN.58P+W="1FM7=D942#E6-&Q2>4Y"5$95=W0Y1G5,94]+
M2TQ63&Q)25%Q>"8C>$$[=W)(6G%G4F1G;T,R-&]+8F)9<6UE2W5X5C)+=7A6
M,DMU>%8R2W5X5D)A,7%S3VLV5F1A;$UV2TLQ:DUJ<GE22V=F-51L5D@S+TMP
M,B8C>$$[>%9"-D@U<'-D6G9R*WIT;S5%:S T46U9>6-A2#$Q66=$:7IB<55)
M64A&57 X*S-D<F%T6G9C>DI#:CAK5FY92T-Z155!<C-Y+T,P-28C>$$[5DAY
M2&4R;#-E,U17,'E43$5(:&M:0T=#>5)U1F1$5'5P,D](3'E82'I:<FU/,TY"
M5D)*04%,1W)%9'I3;2\P1$97.%9D:7)S5F1I<B8C>$$[<U9D:7)S5F1I<G-6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5E=I5TEY
M96U(57EC969#;W)X-E9P-%EQ;"8C>$$[=FU$551:5VE.-DM43$LS0FMK,U=L
M0V5N,%I/16)95&Q30S!B>D9*95@V5WAT-#0Q:T),371A+T-T9C1:3V5/:&%)
M>G-P6BM9=6PR5R8C>$$[;VUX:74P-7!%>E-P46QA35!H+UI)-G%X0CEJ:'A"
M1U)3+TQZ4S=05#=Y.%,Q57%**U4X<%IM66U2:6]*<7A06E)H>6I:1U!M>FY-
M9"8C>$$[=61I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER
M<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<4@Q0S9T<F$Q95<U0B8C>$$[35 R
M6$%&86AT=6U'27-O2G!J6&QY2'DS63-L;6QO.'-K,$9L0G!D;UI%46-)24]G
M<7%R=3%">2M1<%1*;D=11TEM0S,K6E57;WDV028C>$$[13 V45)8:&Q8,#-A
M9S)'-V=%:'%%<E5!,#)/2$9Z4FM9.2M8.79R<UAM5V0Y4VY384=252MQ;VXW
M0E=%<DQS1E=G6FAY,W(S-U5Y>B8C>$$[2GE9435S32\U>6(X-65:9DPK<39&
M2&\Y-C%Q;'A"3S!Y:$DS-49854$O1W)5-CES=3!C05%B6EI51B]Z:E8U,S@P
M-B\U=S%+,C%E+R8C>$$[839G:3 Y<$DP2U)O02]R>$Q8-$98<U1H,6M!26EU
M.4=*.4<U<C(U,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R
M2R8C>$$[=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%9J.7!E*V-$<4YJ0F,R35 Q
M2C5B-%@Y,FI"4VE*2S1S=4-&,E W>4U+6$\K+UED;%94>G)02B8C>$$[0C5A
M=DHT-&UN:VE8;6M#9F%D;#-#1')U,U1,369.:%!K=U!Y8G)L-64K63=+,VTP
M-E<S47=R8T<V64@P:35C<C9A,4-M=D=J9D91,"8C>$$[4'IY-EHR86]J9$<O
M;G U-U!K+U$Y3W4O<5@Q-%A.,%EV5#E8,&5.27DQ83A*2SE01$A3-"M);'-Y
M.&U$+VQ**V-P.'DK93=$4B\P4B8C>$$[.54K<TI/9E@K<V5R5# T6&8W4'!*
M,30K3UAA:D1W=TIT<G@X,' O-7DV+S0W4&QZ+VU'=5 K2G!H,%!)<W-Q6&8X
M-&UF.'!Z<3,O8B8C>$$[36(O<4EH>5=U*VME.6-4-G%Z5TYZ<U9D:7)S5F1I
M<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I
M<28C>$$[4W9R;7!*9%119F\Q:7-D+T9A2DE'8VAR85-+2C)U9C=U;G=V2U5+
M,7!S9FDW67%J.5=D,#!Y-61'2W5S8D9753!)3D]X1U-H>E),:R8C>$$[.#(P
M=GIZ8EAT-UI1439P2SAT-'IF5C1I,&=:,6DT<S=54#=01C%.93EC>4-!,$%L
M;$@U;V5:9% X=6553&I63#E:1W1K:VE2:$-O6B8C>$$[<74T03)*6#EE5C1)
M;55Q1&)K-5!-4$IF-7IE5717.#$V6'!T<D9D:31U-VA);VDX84)E5&)#<$5H
M,GI+>31326MT34]A<B]Z;'0O>28C>$$[:65I9CAX-V8X;5=Y1V@K;W1U6&LX
M;R\U>'<O.&TW<$@O1T\W+W=#;V%437)6+S-:83AF3FUN+T]86"](6CAU9CAW
M,7@O=T%45$MD1"8C>$$[>4Q,2VPS+T]*;B]+8S9T+S)Z1R\V:4EC;')V<$AV
M6$4K<7,Q:F,W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6"8C>$$[67$W1EA9<3=&6%EQ>$QZ1#5Z,6I3<&144S,P2V4Y5WA703)X:C5K
M,T)L2T$X94UB1#ES9U5*,U4Q<&ER2S5'2WAS=S9G16HW<U%R028C>$$[:#4Y
M;EHR45AL=5A355%-=G<Q17 V2C$K,3=::RM(1F\X47-T,6$T4F9,.7A0339O
M=F]C;F1I1E566'A/57A(<6):8VYM5VYN>7)"928C>$$[5WIW=%I2=D1*5TIL
M35%+1GHX6$5J<%=U.4UY:D9O1F]Z+VY*9B]Y5D8Y+WI%,G8O04-D1U8V5"LX
M8G-N2C@P+VLY+S5.1'EZ+W=!>"8C>$$[.%@V.#)/;RMG=$U/8C-0+T%*>3(O
M=T-55#!4+T%*:C(O=T-43%IH84@V:3(U951Y:B]N2$0O>6)U:V8X63=V+T%+
M:'!->718+V1L<B8C>$$[>#@R5V8X-6%8.7!.-6PP4WEI:S585G)A>71C4F='
M<6E6=U5.854S-&YP;%=H2'!*6EI5=B]W0V-68C8Q=&9Z0G4W960O5&UV=%!K
M:B8C>$$[=%5)4'AU<VE3:T-G+VMJ63<U3%=I-&9&8UA..5DU<3(U,DMU>%8R
M2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=28C>$$[>%9)
M3F)V4$YC5V]V2'!L;W,Q:CE4:V1*9FA,+T%&<C1U2R]%-D19.$MB54Y7,S)X
M5D]B35A3,F-!=3)6-W-2;TQH-'AX47EC4GI+9R8C>$$[:S!"8G!I<GIR5B]Z
M16HP+U5,*S-N,4EW+U4U07-G6DYG6D=655%(:G4S-WA.:#1J36M2:E116D9N
M;6Y4>51A4$A.33-*,FI*9&IT-"8C>$$[-51)5DIT:61N;%1E5G1$8357-6$S
M<DUL>CEC:EEU+W=Z,4HU3'9T=3=B9%!I3UI63U!B3"]W03%#1"M5;79K8F<V
M63E$+W-";$](*R8C>$$[.$AV8V<O4RM+3D4O-#=6:"]W07A-4#A!>6-'8F58
M27502&TK=68X06Y*9B]!36Q29F8X04U482\X;E)M<3!N.30S-4]4-7 O2C<O
M>28C>$$[84AL;B]M4&DO6&UX,4@P1G!H>F4P9CA!3U5C,3%Q3V\K5E!+.%)I
M:5,O;F%28FE8;CA-:%I95C5C47@T+W9.-DM4;4IO.6=:3G54;R8C>$$[2&PO
M-5)X,R]!2F4X+V543E=1>%-R<DYW,7-)>4AR1W-R9E8S-69:*TQH3'I7;%)U
M4&-::UIY2E)K3S5H0551>78O;DIH3E,P9CAX3"8C>$$[9E8T>6YP86QP8VQN
M1TMM=D9O-4E*=5%&4#):.70X<C!L1T9D>%1K,DM'+TE#-#%,>D@K83)M,S5J
M:&EH,$Q46DEN5D]1+V-R1S!#2"8C>$$[8W1Y8FY-2S1D54)'0DAE5F=B3#9V
M>E9T>G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&EQ0S%85V1/
M,'!,9#<V6#!L=28C>$$[<#%T;U1X6G%Y3T-W2'=G,$9%2G%C5F(P;E=D33%A
M,VMU9$]N5S5G:FUL=#)K4W9(,4E(36-G0E!7:DPQ1WAX5DQ0365N5#-L+UEZ
M428C>$$[87@K:G9Q:51I4T1K44I$36=61TE$<#EJ:6%6.&1Q65%#9VQ&*U=,
M3#9H;VQT64<X1B]*8DM5830U1FEA<U-!4U=D:E%';%-A;G)I428C>$$[;UE,
M-7@X-$QP;FU/-W-N96-'3T$S5E9C2VY&5DHT:7),=6944'-.=DA-:495,'EU
M,EDK4V(X-F@U9'1R-G)L8FM#5E!53E=#=6]9028C>$$[-VYX.&-Q>6,R>4A*
M-5)R9FTS.'1',6)51G9,-GAA9#57:G5224%72FI99T(V:F9J-S5L>'AM=513
M96(Q1%1.47-T43AH;3AS<%9N="8C>$$[6G)/67A42CEL9T995D@P:DU747%B
M9DAK*T-S,V)J4'-B.'AT5W1T3B])1C-N5C)&,7!6<F%2.$%$4C4T:U)386QF
M:$(V-7%-36)Y+R8C>$$[1GE:2%HX;#)6:G%.:F526'1X6GIR0EI35S@Y>51'
M=S1X>6Q:26EA,' V:6M&2SEA:DYO4T-+8V-#;C!F+W=!-5!Y4'%N-69E6#E7
M="8C>$$[;TI(<VUU63=M47-0<U)Z=VYH-FY%:TQ5<T(Q-C5G85!A6D1D:S50
M030P,&)5<C!7;6@R17@Q1S8Q579944ER<WDR:D4X25(K.&M,328C>$$[3G5X
M4"M6;6)U0G9Y<')&9$AU;B]!1&QV<'1O9$@P2%9/2BMU2F-35WEV53 Y3FM,
M:U4V9F%58C5H-D4W:TTX=DHU5"M15VY7,G!F;28C>$$[=F]53C)'94]"<$QM
M24)I2U-7.%13>&YB<TA18EIK-F\Q07--9DYN=B]/6%@O2%HX=68X04U.8V8X
M5%1+3D1Y3$Q+;#,O3TIN+TMC-B8C>$$[="\R>D<O-FE)8VQR=G!(=EA%*VYD
M5#%R5'1-93!3.&M-8E@P-E<Q=4%R3E=343!52&E$445K0W R>E=.>3=49%5T
M3E)H96$R-3A9-28C>$$[6&AC4TDX8D(T>E)H>&-+8U913W-E86)$4W15<W1/
M=45C>3-Y5%-2>4%X<6<Y0TUY14TP:DE">4,P0C96<%=L8U92;6DV<D9Q,FLR
M=28C>$$[<%%O56EU;WA):7-62F]F9%-14C1(1E5T,5!Z;G!U;F%P9#9D36I#
M83!S5S%"-4=A3T]->&]W57)Y9&QO9#8W-V1F1$95-7-B<&)U>28C>$$[=#=P
M56%.8FE.2E%J,#5+2%5.4G%%:6]R:7)(9%8X,C9N6EAE<5%*<%1U;&DQ<W1R
M3696-#-";C0X=5!#3C9C5V9J6&]+17-2:%9L1R8C>$$[0E=,<#5T,4YR>C9U
M*VQ01EA5,C Y0R]Q+T9#0V8S-$EJ-&=C5C5B;6Y103%/1E=56499=F]M;RMD
M2G!T3%168DIB9C%6;D]P8T5"4B8C>$$[0W8X061"6$5R149I9'9H24E"<5%A
M6594+U9)-S945$QU4%0U1FEV,VAK5S!L9F16;4M%4G-D;3)$55!407%5-D9A
M96))<CE8,5<U:B8C>$$[:W-X6GAX=$=R0FEB;%=Q,&TP854K2%DW*R]S<7%)
M.#$R>'4Y1FUS:S%$.4=45&Q05'5G4T-/16EU>2]#>4@T;%AI84AO8TE"2T-A
M528C>$$[4$QS0FAV.$%52D@Q55@U=D1'.%5!3$52:4Y/1$5";F8W5S%A54@V
M9U1%:%%1;RMB.5HP=7AE>FDQ1S-G;E(U5F4R*W-%04-C5D-C3R8C>$$[45!X
M9&%:2T5,67EL5%AK,U=.2W95;F<P=3)T-V4R:61M:T9R>#0K<GEO+TE+0CA8
M:FI/1DQ'5G-C."\S1W-X95I,6F)',U=A,&%.>B8C>$$[94YS5U5Q;SE-3%8P
M-FUV.6U7-"M46&LU<'HK5VMM;WDV27HV;$=S5C934%=296=/.4\W9%)1.6-R
M>3E'94XU3C4K+T\W44Y-.#,V;B8C>$$[<#=716PS.5=K.5 V>$4X8E)T.$MK
M.%0K=DUZ1F=*:4,Q>C5V4W9Y<3@X,DAM2'E28V%X8E%T171P2DU(=&U:5$E"
M1V]A<#0Y3UAB328C>$$[8E!J26Q48FHU4&MA-C!85TYF,6%857)3,D-2-GAC
M6$YX87$X:4$X955K:$)Q4B])>7(O35)18C5T0DE21F1Z5'=K-W9O5'ED-6EM
M;28C>$$[+W=#8UI,-F%Y36QR8V%86C-6<7-Y=%)U84AL>E5J<"]E6F=4:"LK
M,S9T=U!P9D]R,B]L84\P5U):-4IP:EIC;6IQ5DEU,C1G069"5"8C>$$[:7)&
M<6EU-FIR535N,TLR<EHY16%R6EA/=B\X04],9'9*8S-B971B5U,S8E-U1$EZ
M:3%L2E9+:VEN=W%&<C)Z06EE2$\R2&5,-7ET9"8C>$$[63%A.6(Y1G1C0EED
M4DYR8E1T=U%N:$1W:FDW02]#23$V2&5M*V)!>$$S-VUO16Y:.5-F.#5!5T@V
M3R]*239F-FYQ+U5Z67=E<E1J>28C>$$[.4IL5&QX<6%6<#!R;70P<'9*8F1K
M-5!N5#AN=B]*;V579CA!;5!I+UAM9G%0;TQ41&TY>B]W0V-T=CA!;$4Y12]W
M0UDY=CA!:WDR628C>$$[5V@K;W1U6&LX;R\U>'<O.&TW<$@O1T\W+W=#;V%4
M37)6+S-:83AF3FUN+T]86"](6CAU9CAW,7@O=T%45$MD1'E,3$ML,R]/2FXO
M2R8C>$$[8S9T+S)Z1R\V:4EC;')V<$AV6$4K:69-.3E:>'HR.$XQ67A89VIP
M4$5:84AH24-11U=O3D-02$U#14Q:>FY3-WEP9#)B4E,R;&Y:4B8C>$$[,E5%
M4DUG:FDK>5=L67-X<%%D5'9J3T9,0U9Q5W0K64HW4R]E,E=#2U)%06]80DHK
M24%N=FMO67=28D=5-DM995AT4F4K=$A:;S!I128C>$$[5&-%4TU554-G4%1)
M5&I26E%L85,V;C5H=EDW,C1G.4]&-#!:;R]J5&M3;TI&1'9L<V-925E3;5%5
M+S!/.&QU.4YJ;6Q#:&E71D5&0B8C>$$[4E1154=65$9&<VEB1$=:+TTR<TQ.
M27%Z04MR14%C1C9!+TQ,:&I$56-H6E)A,TTP;6IP8TTS-S5O95I9040T=4YA
M,'EG:F5M,$A::"8C>$$[+W=$:4A79BM7<'9U6"MM6E!H>&%E37$O;C<X>71(
M.')*8E=&,G0S2G%';U%03F)#,&E-<$%I<'I*;U%2,7EV1FE-="MJ9$DW349S
M=B8C>$$[>G-T2&MG;$57<U-W<U5K*T<R:UE.1S(T23,S1$%B6F5C2'5A:'A*
M-S5X+TXS>6A0-4)S.59T.5%E=V)85G5F,$TP,$5R35AT1TU4<R8C>$$[>7A*
M349#4T5(9G%-<6AG;'A%9'I/8VA40V9+;C5Y959R5%AB4S0Q8EAY8DM/,E53
M:U%83$)P<6M&=4LR-FYA;E=U.65G<&PP<T5Y3R8C>$$[5%A%-W-X+T\W>B]A
M-E%O,%,S3G=U<TQB<G%0<7A1;5-/3S)-<%(R6F='-#=23U!S-UI49WAK:7<R
M6D=/+VPO*V$Q:$0U<T9T<6DS:28C>$$[<G%K.79:86%R5S565FUU3TMG37A#
M541%:'4Y4#$R6DU-:D5S63=&12]N0C4K<T4X,DYO175I>3,W-DQ$2'%,4W!/
M<U%!23))0F]4+R8C>$$[04AV1VYE=41$:75.,FUE-5=F:S,K62MN6%!M=V58
M64Y+;71*3E1H82LY9#=H6G=E4T-B:U-/5S=,5&%U>#8W,7<U.$Y2=3%H>EEF
M*R8C>$$[64@U;&5B-"]/2&UM1U!6-$Q74%-B<$QE>71':&A:-4EY>%4P3&M%
M.$]0-#ES=7A9>'=J8FUI47-L;68U1&5D9DUM<2MB.64P5%5R,B8C>$$[3SET
M3$\S4U=.,&II6#DU>597*TM%<W)!8VE+:&E$,4=5-FU!15%754YI43A&,5,X
M:3!,5W(O5&18,%9*<G4S,4YR;6%/9C13>6-G-"8C>$$[:65G-4)30C)B;W@Y
M<WI13TE!9SE'0DY08W8X06Y'2W=K=2],;FUQ-"MR=&$R1W%86$,Q3WA!6&<T
M6E9.041W-6=D37=T66%).&UE4"8C>$$[:RMD=%-U9%,P8E9R<E1B5RMN5U!4
M8FUE1S-:6$MK8UA+1F=!9FA,53-P;7=!0D8Y-U5342MQ+WE7,%='>"]*0U T
M=E=854E,<3=K5B8C>$$[=TM+6$1,>#EX.$=A>E53=DLS=T=Z-#EZ8D]-*S!V
M3C9);C5",VEO;U9F,$9(<T)18G=+8S K4"LY*TQK>350:G)24"M/,5EF.'A-
M4"8C>$$[+TIW6G1P8VDT.&5B-C4O-7E8+SAL4F9F.'A.<B]W06Y2;7$P;CDT
M,S5/5#5P+THW+W=!;6@U6B\U:C1V,35S9%(Y0F%98S-U9B]/5R8C>$$[,R]+
M2C9*+WI(="]Y6F)-3%$O55<S3'EE568X04]/2"]!2DXS4U X06I(9"\Y43!M
M6E=R+T%,<W1E4&UZ5"]N3'(O:G,K6% K66$T+R8C>$$[-&UM539(:U=75DQV
M*V-44"M5-3%B+W1M3B\Q15$U3%AF4U!E=4HW:C5N,4AY>&\K<%=.:'%6=F0S
M;'AC>#%365A435%!,41Y5G!L8R8C>$$[5F]34&AO5'-.*VUU0DQA449B>7AE
M95=.675D4G,Y36AV8D<V<S!I3GIZ;6U1:C%J244T.%I71&-F4TYE,V)X>$I0
M5E%!:%!-1W(K5B8C>$$[3E Q<5=X=DQ'-W5R:%!21%-2,TQ316U92&=T1$]'
M0C)'>E4R*TPW3RM):U5%0DU02VMU:6$U6EA-=6Y26&QG:T9Z-F)Q8FU51G5(
M1B8C>$$[<3!74FQO-#(X865"=T5L24-4-FAR+VLV,S%7-G1*.4]V2G T6G!)
M;FQJ=51)1V%.43=';W500W9+=38Y1'5A65));S11;G9L6G1',28C>$$[>E-O
M-S=4;'9B3S%385)0464T;55T>'%.=W-R54(U0G9'=4%L241(-&9-4&MU-'9J
M84IP=#(X-6MA4&MT,7I4:W-V<$5S-'5#04]26"8C>$$[9C4K0D]3-&HS;S11
M>694<F)4-W)1<EA646PU8E=S;' V+S%&-W5684DV:#%$17EH45%O<#EO1&9F
M23)M;4A.-78X:4Q9;3A/;#-R4B8C>$$[9WAR>6IN6C$U4WA34W%+:69V-D0Y
M0EAO931Y6$5E.4A#16@O3S-Y:'%&,2MH4$TK:V%I8E-+1TPP0D1/>'5*87I%
M4W$P87EU,5-G5"8C>$$[:U%L4TM6<'-4;#)(34EG9VDQ26585#92-70P;S(P
M6C%E24Y)<5=T=GAT27!!56I337%!4GEQ<3%55DA5<4M6,G)C9%)$=4Q':C-S
M;B8C>$$[.'=E4G9-4&QV>7(U0E=X=7)A-W9,3F11:UE837)R149V;6IK:C12
M:C1L4F$O=D=O1C5(-&I1-45A:4IL26TY-EAH27!G,G K6&9.="8C>$$[>$9&
M;WAK,#A1=D=L<VI1>51/<$9U4GA9,%9Y<$A$:3%6-CAQ,$YC<T=P9T1E-D1%
M,50P+S@V=DM7<%,K9')D.5 Q4#!6=71,*W%4+R8C>$$[049K:35923@X>D5.
M-FIS-DM5:S1P=#A60T)6<352:'II36%)-G-P4EEX;VYL8GI03C5V.'(R*W V
M<W1X85!F,G5R>$I&17%O-$9X-B8C>$$[8GEP3$-A9WEE;69I<4%D:C1:6612
M1VI1-6A(0V4Y;'8U;&539DM6>#4R=DIB>E9T571,>')+3DQM5T=E,TUB4DQ'
M2VE2-5A-:3AI1B8C>$$[2E9U,WAF6D9C<7@V9WAJ5DI-8E5V>3(X:2M5.5 O
M34-(-G!F871,<4-7-WAQ.#!K259&:VA*034R-T5Q>6=%8T]7>#))-C0U3E%:
M4B8C>$$[<6Q%84MD*UE.2"]*;6)Z1G%A-FXU8F$V,4M/86QZ8VTV2CEA5C)#
M:6@K<V)U5%A9-S%O<"M),'E%8S!W2T)3444P+TQN5&9Y,FLQ928C>$$[*W0O
M2S)J>C908U)O4')&,4A02U!54T]20U5$3$LV;%<U9&HO04%/4FYK;$QM56="
M2SE38CAN3E)U-W953E,X<TYD,V9R:4LV=4=K5R8C>$$[95-2<3A3-FQ:,V%7
M:6=(-$LQ2$MM>6LT4FQM0E%+2T1)=GDO=E!*5C5O5C%.-6)S8FY33DLP.&TU
M93)7-&5"2D]A4%5N.39),2MX6"8C>$$[;'EP='5E=5%L26YC<$1%<G!0>5=N
M:"]33"M4>E!.8WEU6D]4;UI#,U8U1W)0>4LX<3%A;CAP+V%7<WAL;C-L1D)M
M96HS=FQ24$M&,R8C>$$[9E=&;F,R96DV5C9T<BMJ0F-V0VI,5F9S:#55569A
M3D%$=EAA<'!K0U-485=&5%<S-4=2+U9$+V<P=4QW9TIX2T9K<511>4M*-G)6
M4B8C>$$[.31+.5%C<SAA9F558TE:=$QE959B:GE68C9H9%=D,4IO;6]#3WE8
M4UAU6&]%-71(>$5C:W%C<6=F64A99$M63U9G;3<V<%E9='(K4R8C>$$[.%%A
M-6<X;6<O5G9J95-.,%EO-CAZ<T5M9'9T4B]C>70P65I0>' Y-5)16FXU;VLX
M<'DV1EI(6$Q+-#%/=S%K0V5/>&YU:7EP=VE7428C>$$[07!,2W110TML<4AJ
M6&5M=WE%6D5(6DQ$8DLV+TIM=W99-W94=DMK:T8U8FU/5S%U26UO=TQS;U9L
M84M6>7)+5V]W-G%1461W8VUC<R8C>$$[>G-3:6=Y,WHU1C5':3E#=SAY-F10
M<E53;SDW14IB:C%F5$A0:G1'.'=)259U2VUN>&1!4V$U1TUY3U)P2D1(+T%#
M-THK571N<C%L*R8C>$$[:'9,5%=/<'E43&)X6&-%:$)15$8T*V%Y=WEV5D=6
M5%)G845(<FAL:VM24DLP13 X*TPK5S8V:71P-6TP:5173&EX:6HT5%14:59G
M<R8C>$$[.5)S<GI";'%Y:75W-VUL0F=J3U$U1VQ)0T@X;"]W1$MS>')53G8U
M83!+8E-B=E5O<%DO<FM-:E)-16I53U$S<'E.*S!.9S-79T\K1R8C>$$[5U-2
M-6Q103E784=&;CE2;S%-9T%!8V=%,$(U058K67)L858T04A157A664E94DE:
M0D=V<4=H3#!(26M!9V(K=TI'2W)L4D9R>%5,6"8C>$$[8S!&3CA65W)"07!:
M;&I65UEK<U%!0U,Q3U9F;E%6>%9C<7%O;V]!1E-A1&)C;7 O2$96<V-%161F
M5&I62SEE24$W:SEV8S1Q=4MQ5B8C>$$[-&M!<5)1:G141E9Q,CA#;UDQ:E52
M;EEO1D%(5&HP*U<R2W1V2$<O2&UG8F=1>6-G1%)H,$ER,WA683%T8DUO4F]K
M6D%/255Q0TMB8B8C>$$[53A.:&ER;70W9&=O84I#14)62W%$4E-+141W0D=+
M<E1:,EI"57=2;%-E4D)2844Q<EAP-#1Q;"]M9E<Y13AV85!D83=Q-#179&]Q
M928C>$$[=DMS9G%/1DUI<6]!04I0>'--;$-*:V%#0U=+2BMC6#5C9EA93%-2
M,F="1G,Y<DY*0T%N*VPR<3-K26I!<2])>'EO3TE7=DIQ0W4Y1R8C>$$[55-$
M4U52+WET;CAS-71+=617+U-%36QT1U-K>D--=5=+.#%8-&=#<$)#1V@U54%)
M<E-U4E9/3D,X,2M3.5@Q0F)B4TQQ,VYV:D%B="8C>$$[56I3:D=%=C92:U9U
M3D-P8F]19'AU2VEH>%901&%7<')71TTX:5=A<6ID:E%K;F)R.$EX5DE,+WIH
M-64P,C5J55%Y4S-->7I-,S%E228C>$$[1FQH=#)J17-J:VQF9U8U-'@X,BME
M4TU314$R;&-0-7(O;%EW=#!85DQD6C5!<GA7=G!/6FQB:S1O63%1<W))>79Y
M2#=/.6-I;%)F."8C>$$[-69Y<V@P838Q9CA!4V-0,5)8:VEK-$E36G!)=S5#
M3'A(1FUD22M3<517:%=T2S1Q:C=J.'=02F1P<FIA3F9!,F1Z2$I*8C)S:W-)
M.28C>$$[3V%32TM.-6MH2V-Z*S=J;&HU5D$R*U=+<6UM+VU$*UAE<#-S3VQ7
M1W!7,#EX<49*24QD56)J3GI1>4)G4V]6<6E--S$V9VIQ2UEQ>28C>$$[9C9T
M8F,K9G!*>C9C=4ER,35D9FUA-'$T5W1S<V%2:4I"2$=E56%"4E)70G)51'-A
M-'$P3%<Q05E#1DM/07)J:5!I049!1'1U2UEQ,B8C>$$[8F$S25)416A%64MX
M9W%+2T-/2D$X0E1B1E9R5V1M=UI79VI:6$I:=U559VMM<$HR.&-66'1$0WHK
M;S!A;5%!04]10V%!.&=++TU6>"8C>$$[5EE,2WI(1VM%631%1DM)=7A7<$)'
M,C%+-'%V3G9!6$QM3D,U,DQ&4E4W161F:U1I<E@Q93,Y45,K:VYQ3#EL*TDU
M0V]P<V9K2UEQ<28C>$$[67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67%H9%0O0458.5)L+U-N;V952T0Q+W)81#!A5D9/9E T9G15-C129#=+=S-6
M4"8C>$$[*U9*+UAP4#!L*V<O<G1)=5AQ+U8K9%!Q=SE,:%@O;#(T.&50-TA(
M=%1%,G%395IF*VAF2U=V-E$O4G8Q9C8W0GDK<"\W>BMT>&8P=B8C>$$[<F8Q
M9CDQ-EA(;"]E+T)4,GA6;&YL,R]L5U V5VHO=SDK:78P<C9%,W!F5792.6(V
M=C8S-S-J-F4O<"MR,7!T9U9L94MP1'(O05!G9B8C>$$[+U)0,#DK:B]!3RLO
M,$PV,S98.3E19EDU+W1D3VYT-UED,$I&1B]Y<%0Y2DHV6#9#+U-02G94-"]6
M=E8U8S4K9$MB.'58<F-U+W="<28C>$$[=4)+06(O;UAN.4AB+W=#1R]W0DAC
M,#9F5E!2-2]V3T9A9D18-V5+<'1Q,R]!0W%0.4M8+T%/;&8P4BMK*V8X07 O
M,6HP9E<Y5#9S+R8C>$$[6&QV>2MR.'$P,S0T<6MV;$PO;%)N*TIP+W="0B]5
M9C!X-CEV.5<U,7!Z.4(O42MO97(X2$0P*V9(,&9H+T1&6' R2W5X5C)+=7A6
M,B8C>$$[2W5X5C)+=7A6,DMV+SEK/3PO>&UP1TEM9SII;6%G93X*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @
M(" @(" @/"]X;7 Z5&AU;6)N86EL<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @
M(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @
M(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C945V96YT(R(^"B @(" @(" @(#QX;7!-33I);G-T86YC
M94E$/GAM<"YI:60Z0D8T,3,P1C!%04%"13DQ,3DR1#8X-S%%-T8S-T0U-D0\
M+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$
M/GAM<"YD:60Z0D8T,3,P1C!%04%"13DQ,3DR1#8X-S%%-T8S-T0U-D0\+WAM
M<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M
M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO
M>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ4F5N
M9&ET:6]N0VQA<W,^9&5F875L=#PO>&UP34TZ4F5N9&ET:6]N0VQA<W,^"B @
M(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z
M0D4T,3,P1C!%04%"13DQ,3DR1#8X-S%%-T8S-T0U-D0\+W-T4F5F.FEN<W1A
M;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z
M0D4T,3,P1C!%04%"13DQ,3DR1#8X-S%%-T8S-T0U-D0\+W-T4F5F.F1O8W5M
M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^
M=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO<W12968Z
M;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z<F5N9&ET
M:6]N0VQA<W,^9&5F875L=#PO<W12968Z<F5N9&ET:6]N0VQA<W,^"B @(" @
M(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QX;7!-33I(:7-T
M;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I%03 T,T)$
M.#DV04)%.3$Q.#(P1$1&144U,T4W145$,#PO<W1%=G0Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C Q.2TP-RTR,50Q-#HT
M-#HT.2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD
M;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z0D8T,3,P1C!%04%"13DQ,3DR1#8X
M-S%%-T8S-T0U-D0\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IW:&5N/C(P,3DM,#<M,C)4,#4Z,#$Z,#DK,#4Z,S \+W-T
M179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G
M96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O
M9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D
M/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R
M>3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.FEL;'5S=')A
M=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S=')A=&]R+S$N,"\B/@H@
M(" @(" @(" \:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^4')I;G0\+VEL
M;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z>&UP5%!G/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O="]P9R\B"B @(" @(" @(" @('AM;&YS.G-T1&EM/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS:6]N<R,B"B @(" @
M(" @(" @('AM;&YS.G-T1FYT/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O1F]N=",B"B @(" @(" @(" @('AM;&YS.GAM<$<](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+R(^"B @(" @(" @(#QX;7!44&<Z
M2&%S5FES:6)L94]V97)P<FEN=#Y4<G5E/"]X;7!44&<Z2&%S5FES:6)L94]V
M97)P<FEN=#X*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P87)E
M;F-Y/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*(" @
M(" @(" @/'AM<%109SI.4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @
M(" @/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(#QS=$1I;3IW/C8Q,BXP,# P,# \+W-T1&EM.G<^
M"B @(" @(" @(" @(#QS=$1I;3IH/C<Y,BXP,# P,# \+W-T1&EM.F@^"B @
M(" @(" @(" @(#QS=$1I;3IU;FET/E!O:6YT<SPO<W1$:6TZ=6YI=#X*(" @
M(" @(" @/"]X;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @(#QX;7!44&<Z
M1F]N=',^"B @(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.F9O;G1.86UE/D%R:6%L350\+W-T1FYT.F9O;G1.86UE
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y!<FEA;#PO
M<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G1&86-E/E)E9W5L87(\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=%1Y<&4^3W!E;B!4>7!E/"]S=$9N=#IF;VYT5'EP
M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^5F5R
M<VEO;B U+C$P/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^87)I86Q?
M,3,N='1F/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE
M/E1I;65S+5)O;6%N/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F9O;G1&86UI;'D^5&EM97,\+W-T1FYT.F9O;G1&86UI;'D^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y2;VUA;CPO<W1&
M;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP
M93Y4>7!E(#$\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z=F5R<VEO;E-T<FEN9SXP,#$N,# P/"]S=$9N=#IV97)S:6]N4W1R
M:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E
M/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT1FEL94YA;64^5$E27U\N4$9".R!425)?7RY01DT\+W-T1FYT.F9O;G1&
M:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^5&EM97,M0F]L9#PO<W1&;G0Z
M9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY
M/E1I;65S/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=$9A8V4^0F]L9#PO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y4>7!E(#$\+W-T1FYT.F9O;G14
M>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SXP
M,#$N,# P/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^5$E"7U\N4$9"
M.R!424)?7RY01DT\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D)A9SX*(" @(" @(" @
M/"]X;7!44&<Z1F]N=',^"B @(" @(" @(#QX;7!44&<Z4&QA=&5.86UE<SX*
M(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^
M0WEA;CPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/DUA9V5N=&$\
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y996QL;W<\+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E!L871E3F%M
M97,^"B @(" @(" @(#QX;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" @(" @
M(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P
M3F%M93Y$969A=6QT(%-W871C:"!'<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @
M(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P
M5'EP93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z0V]L;W)A;G1S/@H@(" @
M(" @(" @(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^5VAI=&4\
M+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X
M;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA
M9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO
M=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP
M,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y";&%C:SPO>&UP1SIS=V%T8VA.86UE/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM
M<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP
M93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP
M1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY
M96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIB;&%C:SXQ,# N,# P,# P/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" \+WAM
M<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y'<F%Y<SPO>&UP1SIG
M<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XQ
M/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z0V]L
M;W)A;G1S/@H@(" @(" @(" @(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @
M(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C
M:$YA;64^0STP($T],"!9/3 @2STQ,# \+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z
M;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L
M;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8FQA8VL^,3 P+C P,# P,#PO>&UP1SIB;&%C:SX*
M(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @(" @(" @(" @/"]X;7!'
M.D-O;&]R86YT<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4W=A=&-H1W)O=7!S
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P
M.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D
M=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP,3PO<&1F.E!R;V1U8V5R/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP
M;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W
M(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$!_\  $0@!#@(V P$1  (1 0,1 ?_$ !\  0 !! ,! 0$
M   (!PD*"P0%!@,! O_$ &(0  $$ @(  08%# X%" 0/  4#! 8' 0( "!$)
M$A,4%1@*%B$YEQ<W.%97=7=XM;:WU1DB,39155AVE)BTU-;7-4&5L[@:)#1S
M=+&RQ&%QDJ4C)B<H,C-24W*3EJ'1TN3_Q  < 0$  04! 0
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M&S)K%L7;<\SLSKH0Z\RP6>?N*=TCK\\/D%MR5B<AK(LX&A4T8W*3X9@<'O\
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MH*J5U)(::+H[[*MM-=54\YQO@@T(/,K82/7OL<3\E 2Z(E:!&MK>AO1*:=7
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M&,9SK[XO;;QQC;Q\,YQ]6[QQC/AGP\?W?#/A^YPB>ZO66/#QE?8_'CGPQ_\
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M_CX?N>/A]6WQ\/'_ %\(OWW5JS^VKLA_7$[;_P"=O")[JU9_;5V0_KB=M_\
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M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(K>'<?\ ?G%/YL;_ )5><E6
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M5-=LZ;+IZJH.&ZZ6VZ2R"R6^JB2J>VR:B>VN^FV=<XSDB^_"*U3V9^O1+/\
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MX-9?Q-./]F O\2<O]@:S\I3?IR_R59[-4G]R?]!G\Q59K*W8U:VAE2.,S;3
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M8K'^N'//YYRC\N/N= I.2TWYO#Z-J@U5RFH\/+Z1R\9S(7@IW]+_ /HUB?\
M7Q;_ '<@Y&^J'^R?_<?Y*D.!;JGNP_5(IP\C:WZM4]F?KT2S_J8]^;0CDVPC
M\74_ROIY5#\5Y?/\EZ&-4%YLEKU*3J+]=%]_,\M^4@G--CO(F^'9YLBV^"\K
M?X!_GQJY9R(*4K O^%G_ &6_6/\ %S>_I,EG.X]:W\4XC\8_Z:%1G&^41>!_
M?>L4?G3UI5=0\B1\ZMTL_"D\_,J5<C'5G[V,8_-F^GB6;AW+:?OSYKEM..?,
MRF:<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<
M(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")
MPB<(G")PB<(H>]C(%(SMU]*IL#>V,Z90SL"<3DP".$3*<$9QPSUWOQFO*IX&
M#):-'Z;:0;1@(()RQ=R%#E"[) 4W:'#"2[@JCCW/M"C;V,?=D9]V6ZGRJ#5G
M8)?KY"+LBRF%PI,E"7+LX1"VQ%;#E]NP:2# DK3B,(')"FT!P18IQ$JL:,R1
M14Z_,UF\!DX'=ZGAP5U3A43A%C3=XYK( %MN@#2R7U11U^S[,39_-A_Q9274
ME%<ZAGT3CBSF6B#0K+!9F:E,R(#4VFCHJV@N[=9;8)H::.YLQ[FTU&T2;)IH
M\Y?VOMHX8RUO;@C<72$:$B,ZY<P,2R-=/6.,0F<*MK PYS9DDTH>ZS"#>[6L
M!X%]QVV4J.'9+LQ8<2HF$%8VPE4?FIZ* )38DHBM9S*PQ]</&0^%FC$#?I1N
M-REI&9;*W$G:CQVDPT8-V$3TD)=-WJ=2C+<IZ5-1(R!KFAS7N:'/<V-\@CL&
M.+#E:X-<[-89[ -#G7N&AUM-2QOG>'%CF->YD;'RLC,@)>!(,SFES&AMSDO=
MV4>US$9 /29?1T.GKI+5;5)SF(KIZN6SAFXUT60/*::KLWB2#MJMC7;&%6SI
M!%PAOYR2Z2:NNVF-3U0:]AGGV^\6_(<#J.X5L,#T%4.8Q;C?\IQ&A[H4Y^1M
M;]8+_EH/*N]H>L7E&KWI6MV56K0Z)#ZE6%*26)EBAG;>14Y I*0]:>M9.-06
MUP1+N\-\:,TO1ML));94VTRIOW#J-ZG</Q#J=H:JHV^UD=5AV24-;9E9.QMA
MD/!HOJ=5$,5Y=-W(O1,5K3]G:[M_Q;2'_P"@SO\ C;DH_HCA/_S7SS?Y:URO
M>^0%\IGV-[?=W)/5EL,ZW0C+#K[.YBAO$XP3#D_:XF95L,:Z[NWDC*I;-,MC
M;W*J.&V-]U,([85TPGMKO">KW :'#,$BJ*;;;1V(01':2![<KH:EQT#&ZW8-
M;\ZV^"\K?X!_GQK,NYQU2E8%_P +/^RWZQ_BYO?TF2SG<>M;^*<1^,?]-"HS
MC?*(O _OO6*/SIZTJNH>1(^=6Z6?A2>?F5*N1CJS][&,?FS?3Q+-P[EM/WY\
MURVG'/F93-.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1?)=9)LBLX6V\Q%!)197?PVV\Q)+3.ZFWFZXVVV\W77.?
M#77.V?#PQC.?DY4 D@#>2 .Z= A-@2=PU/B5%/>0I;[=4_\ 84G_ %+S8^Q&
M(_!__P L'\U8'LG0_EQ^A+_ GO(4M]NJ?^PI/^I>/8C$?@__ .6#^:GLG0_E
MQ^A+_ JEQ281R;BO;<7)8*B_65F?K6K5ZTQZRWPGLLGZ%^V:K_M,*Z9\[T7F
M;>=^UVSX9\,.>GFIG[.9F1^4.RYFNT-[&['.' \;K*AFBG9M(G9V7+;V<-1:
MXLX \>9>EYXKU5DNX  &1SJ;,Y"$$'6;:P#Y)NU,C691L@09'WZC-^B@^172
M2>M%,Y4:NM-=5T-\YV2WTV^7D_I6M=24H< X"" @$ ZB-MCKQ' J#U#G-JJ@
MM<6G;3"[20;&1UQIP*\EN($J)D$=Q8[=(LOAT42W9-MDR3K5!LUU<D-,I9U>
M+ZMF3-OA9QA13"#1LCC;T:"6NF38:Z;]_3H!KX@!W %X9G:&YNW0:G0:FPYM
MYW<Y5P#I?_T:Q/\ KXM_NY!R-]4/]D_^X_R5(,"W5/=A^J13AY&UOUK+_A%/
MSNW9[[TT/_P^5=SZ-ZW_ +U,.[^N_;JE1#%>73=R+T3%9'Y,UKEDG_!7_G)9
MI^*E9WZ0J>YSOKF^]V'XTIOV>K6WP7E;_ /\^-;#GG U*5@7_"S_ ++?K'^+
MF]_29+.=QZUOXIQ'XQ_TT*C.-\HB\#^^]8H_.GK2JZAY$CYU;I9^%)Y^94JY
M&.K/WL8Q^;-]/$LW#N6T_?GS7+:<<^9E,TX1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%1K%]5UO?37K<W>E75GKUK)[6<-T
M 1/,=&QF*'J]CY!J^E*C=,)F2K.;.BK]&,LG;PPV"NTC!=L+8$@"Q@EM+^+U
M&]&U\UT]O9SUS9/2KNRQ]?$[**H) B>L=%@A96'"5&#F4+-T@KB3*9G<<)[1
ML:Z?E1H0@P+'$!+,W'%#)5MI?U]=%67A475G/]"F/O60_LBW+X_=(^_;YP5K
M_:.[UWU%60^=%4!3A%<VZF?6HS_.8Q_NF'(?CG+?D8_K<I7@_(_E7_NJ37-.
MMJL="X.Y'4F.VU:,?/\ 9NA AT%8LV#&@Q6VH*P*""XN2DV1(828NCB3ED_8
M/$%FKQHX337;.$E$5M-%--M<=/H<*Q*2BHWLH*Q['TM.]CFT\I:YKHF%KFD-
ML00001H0;J#U0_ZFHW>[R\1^4=TJG7OP],_Y5W77Z9:^_7_,KV(Q7_#JW]6F
M_@7A8]'E'WJZ)Y.6[*<N5E;BM1VI7EG)1YU"$SRD!F,?EN@;<FE*]ANA38$_
M?88;/]6#[9GAUE++G#-SE'S_ $"OFQ+JHI*JE-"*FGFIR\5)9MHGQY@W87RY
MP+VN+VW7%]X4@P/=4]V'B#^5YE<PY$UOUK+_ (13\[MV>^]-#_\ #Y5W/HWK
M?^]3#N_KOVZI40Q7ETW<B]$Q61^3-:Y9)_P5_P"<EFGXJ5G?I"I[G.^N;[W8
M?C2F_9ZM;?!>5O\  /\ /C6PYYP-2E8%_P +/^RWZQ_BYO?TF2SG<>M;^*<1
M^,?]-"HSC?*(O _OO6*/SIZTJNH>1(^=6Z6?A2>?F5*N1CJS][&,?FS?3Q+-
MP[EM/WY\URVG'/F93-.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X143EU4%3ES0BZ DG'B2\#I.^*H$B"L=<FQKHK<<JH.5C
MI.0W:2$"Z4'Q9U1VC5['6RC5S(4))OE"0Q]05C8@XW[OTV^Y5Z.D?1?[U]-Z
MI?O+L@-TDY(S5(0^E[#JDB$8@EF;,P_L&6U)+'4D9.7!Q^N(9CEZO5:( E]"
MZRR1U-10YKN+VP2)SCI^J_WJM'"HNK.?Z%,?>LA_9%N7Q^Z1]^WS@K7^T=WK
MOJ*Q5[\LZ=1JUCC$).GT9;P>)=:I!#X<U2COJ=HR"V+ZFE>SB.EDBXE^7+Z)
M1^.Q0(+2CCX8XCY":8++;JOG(11K.9I'ME(:XC(VF<Q@RVD,L[XWM-P7'M6L
M:W*1E+[FY+;1"GBC?$W-&'9WU+7ONZ\38H&21N%B WMW.)S Y@S+NO?\NWL-
M)PEZT-!XIB8CX&1L6.CI?*0M73:7QRP5I.*G ]O"Q4Y#14W$A+.)/@B)F;*;
M%V1I)XN$30<-@P.;XU2SN;-"QN8,,@#W"-[VOS-D&0/#2UN0M#GZAU[:@->J
M04[703O?D,@C<6-=+&QT>4L.<L<X/.<.+6:6L"3<N8LB/J9]:C/\YC'^Z8<C
M>.<M^1C^MRWN#\C^5?\ NJ37-.MJM1?W_P#L\.['XW'9'],DSY]5X%^),&^*
ML/\ V2%0:JY34>'E](Y1'YM5X+-?^"(_O<[Z_?OK;_8+QYQSKK>Z8'WF(^=1
M*08%_:OD/\Y9E/.1*0+67_"*?G=NSWWIH?\ X?*NY]&];_WJ8=W]=^W5*B&*
M\NF[D7HF*R/R9K7+)/\ @K_SDLT_%2L[](5/<YWUS?>[#\:4W[/5K;X+RM_@
M'^?&MASS@:E*P+_A9_V6_6/\7-[^DR6<[CUK?Q3B/QC_ *:%1G&^41>!_?>L
M4?G3UI5=0\B1\ZMTL_"D\_,J5<C'5G[V,8_-F^GB6;AW+:?OSYKEM..?,RF:
M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"
M)PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"*/M:]F:PM:;
ME8'%E)*F4:M9F2CQ(W&B8:/6$%K>:I5Q89VOC#M/5"2!X9.78V/&7FFK;"F3
M<>-BM"49D0,V0*MN/J.[Z_4OG4G9ZK;ID#J.PU23HN5 I.5Q1](XL5CPFQX2
M%DF8@6G%>/R*2>DCB[&1Y:,%GNNK5QLU,1H\BS5C4LBYDP2WKS=WU^D%2&X5
M%X>RI,^AL%DLG&HM'#X,/]:;(OM%E&BBGIT4O-7T;KMEMM/-4SGP373V\<8_
M;>'CC.31PMJ*F&%Y<&R.(<6V#@ TG0D$<.(*\*J5T%/+*T NC;F =>QU&^Q!
M^E08]\.R/X@A'] /?XBY)/8&C_*5/Z<7\E1_V;J?R4'DD_F)[X=D?Q!"/Z >
M_P 1<>P-'^4J?TXOY*>S=3^2@\DG\Q3LKN1O9="(S)B*35!\:%H/G*++15-H
MFJKG;&VJ&BZSA;5/'FX\,*+J[?P[9Y&JN)L%3-"PN+8WEK2X@N('.0 +]P!2
M"FE=-!%*X .D8'$-O8$\UR3Y25WYS_0IC[UD/[(MSRC]TC[]OG!>K_:.[UWU
M%6+'\? %" @N3""")4 JY6!$WXUD[(!5GB6$':HAZX14<C572&NJ+E1FJCNN
MEKA-7.VF,8YT0@$@D EMRTD EI(L2.:XT-N"@0<X @.(#M' $@.MNN./C7V3
M#B446K=(6.2;L76[]D@FR;:(LWRNSC=1XU2U2QHW=*;NW6^[A'71;?9RXVVW
MSE93.RPYAIJ--QYTS.U-S<BQ-SJ.8\XT&G0KH_4SZU&?YS&/]TPY$,<Y;\C'
M];E*L'Y'\J_]U2:YIUM5J+^__P!GAW8_&X[(_IDF?/JO OQ)@WQ5A_[)"H-5
M<IJ/#R^D<HC\VJ\%FO\ P1'][G?7[]];?[!>/..==;W3 ^\Q'SJ)2# O[5\A
M_G+,IYR)2!:R_P"$4_.[=GOO30__  ^5=SZ-ZW_O4P[OZ[]NJ5$,5Y=-W(O1
M,5D?DS6N62?\%?\ G)9I^*E9WZ0J>YSOKF^]V'XTIOV>K6WP7E;_  #_ #XU
ML.><#4I6!?\ "S_LM^L?XN;W])DLYW'K6_BG$?C'_30J,XWRB+P/[[UBC\Z>
MM*KJ'D2/G5NEGX4GGYE2KD8ZL_>QC'YLWT\2S<.Y;3]^?-<MIQSYF4S3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X10,J?JG9-63:.R)M
M8,%*"*HC-MUS38Y:&GT7J5>7U>]<VW8*=@.M)=E(K* ,;K&,0>$D :0L?N3;
M$)D?8NDB^L4%E6^ENY] _P"5_'77I?O2UUR*WB<A"N]4(C.J\K^-Q=:S= H:
M*V%9@^RCZFP.>V3.X[#--7$<B P9"ZJ$PR#"W0Z2GF@O5.5L8_$27TMXSZ\>
MZ?\ F>W"HJ27O]:&=_>;_P XUYGX7R^F[\^8Y8>(<BJ/!GZPK%N+P@&;)^I9
MAT8^,7MS:)8?YCY?$7VF^L'Q9FT'UDWJOLK:5:UYGXXY'87]'['U4QASE^DJ
MRTFNU9M-G<YKY?:NRY\FUR9K6S;/M[7]KQOHHCL)-GM;#+ESVS#-DS[+/EO?
M)M.TO_>Z-5W:]I0AO:8NE]C&-[%+04W9" %%LY6RVAX$X!CCHH1>)I;,Q_K9
M>0M&PEJ[62=%L,S"S%)9(0_W0KM&;017_"%CI W7VC7-:23N%RX6O:]G6OE*
MMV3]D9LOX,/;'FYWN:YU@-YL&ZD;KB^]7OZ1^M- OYO-/^]3D'Q'EU3X5WV*
M8T'(Z;P35[&7D6@>)R@N_4RBP%QTV1>JZI[JY2:,1KERY4PDEKNHIG1%+?;"
M:>FV^^<>;IKMMG&,X\+2^:)C1=SI8VM&ZY<\ "YTWE9+_:/[UWU%8A/[,OY/
M;[LAKZ*[2_PCSLG]%L:^#,_6*?\ F* I^S+^3V^[(:^BNTO\(\?T6QKX,S]8
MI_YB+(2\F?V'JCLYUK^J93,A<R:&_5 E4>]IN@9N/J^U1+<,H^;^SS[ :_\
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MR3%)LWYHW#7(]DK"UUG @EC>>[=V^ZAK'.C<'#VPN-1S@M.GC*J%5'852I7
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M*>=Z7TVOH^@=0N"/QCV4+:AL'8_85\T9DS;7LNUK/;:VS-]][A1_'?[+\O\
MY*L!?\H7@?\ )CEWTE!O\)<Z!_0J7_$(_P!7=_-4?4@NI?ETH5;W:?K95#7K
MO* ;JS;ZJ*OVQIQ8(EZ@)7F,^ 1Y$FNS3C#=1VBQ4(:NE&R;A#=?1+*>JJ>V
MV-\:_%^I&6EPK$ZDUT;Q3X?63%@@<TN$5/(\M!VIM>UKV-N99%)RJF_.(?2-
M6;YSAZG"P_/A4'<VMT*WA?0G:.S?-K/#M8]E$Y3JR _4]UA>NMPP3(;<AF08
MDF)1[4:J.L-M8QL*]G[:*>U_6,[-M>L=;+"*@U$V.;2'L5K*G#C%F?V1MO\
MI)\X;L]GLLI OM<^;^I;5:+&JAF1M+9V<EDV;3+E[=MKWO>_1;I6#USM"CB<
M(MM%Y.KN;6_>[J_%+RJR.S>+Q=$B1K[898#("P/Y+PEN/'DW>J$<D$F'>SG*
MRNN[%3)+#G=/&<N&K;;PTS\LX_@]1@>)2T-3)#++E;/F@+W1Y)KN:+R1QNS
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M'=;OU<$$4F*+U371/#9\USC;.T#ZF\7J,%Q6&JIHX9))1V(6SM>Y@CGDC#W
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M:*-V&=T6V^62.^,IM<[-T-LH:Z><BEGQTU*U<WA%1F[ZG=6S'8RW"R5"'3*
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M;)3D&H^64GYS!Z5JV<GN<G>.\TK3?<^MU DX1;%_X+[\V-C\8>V/R?"^?/\
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MX;E3#WL[6_\ LQC_ &.O^L.9GL'1?^;YP?PK%]F:SFA_0=_&JWT#><WLF:O
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M%\H-KZ/S;TZ?:^AV\]'PG-VX]%MYV-O.3\*&_:;>=C&WCKX9\[&,^/CCE?\
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M:ZSAPJHJIOOG;1]4..Q1LBBQC$HXHV-CCC96U#&1L8 UC&-;(&M:UH#6M
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MYU#9\R0PJ&)IYV9+V*Y6(H_;$<DP%&6.NR5G13JI,2%RF8\/%=KK,F5HUC/
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MM53WGI7 Z%O&7BNQ\'BQ69.8G*;E(#(0[?N*%E.E8]>*FZZ8*CHM:<IG\J?
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MQ6TWD[];;AK=>@CD;5O>LJ2!1F[K@6>77V8E; .3J3NE?4G=]<:-"1A2U)E
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MKL2;3.NH."AA5]*)C73MPPGHD1IIKHYUASYBR?DV4D)XWP(#NPZ"9QN^?HK
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MO[R5O;/8&4==H_#YX,EL0;J*'74F=5J%?"EDXU'Y2G@Y5RUBJ7O&!)%E(4V
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M5^A6UFTZG&2VDL*H//NTX [N@_[[S<&ZK*%\GK3X 6,W!2NTXC/6C1FQ?VA
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BG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>g713200g69u35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g69u35.jpg
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M ?_$ !X  0 " @,! 0$            '" 4& P0) @H!_\0 4!   00" @
M" H'!0(-! , !0 #! 8"!P$("1$5%QA8E]<2$Q095E>6F-76%B$W>)FXV#AS
ME+:W,34*(B,E,SE!471U>;&S)"8GD3(T4__$ !@! 0$! 0$
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M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$%8]H_VDNJ_]SO3_ "2'1=4]\<I6<1!
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M6.Q_VS-.?NQ]E/\ 53J@BZI[XY2LXB" @(" @(" @(*->#\_9!MW]^7PB/\
M/+O]!>5 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M''G<N,?&XZYFYGSSGEESR'.@(""L=C_MF:<_=C[*?ZJ=4$75/?'*5G$00$!
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M>#\_9!MW]^7PB/\ /+O]!>5 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M(RT%$#PU@%VZUTP@)G$IYQF&_)8*4PX^WF)>)QIT+&!R.?F3"@^%((LD@("
M@(" @(" @(" @(" @(" @(" @(" @(" @(/,^_\ =ZZ:T ']G'JF')U.M]@.
MPVHS>J1 Z:UM4=4-$:YVS>&KWB9GV1H,]+MHG5\#8T0?.KH@4UJ[8M8EME<Y
MT-HA92Q%X=WG,9\>+8KSWE>'Q!HFL426+NI#:59U_&CVW%R=6RLF)V]QZV;
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M* @(" @K'VT_9I2OWG.FW\VFED6,_">4K.(@@(" @(" @(" @(" @(" @("
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M GYY28V,#CYY4@Y'BN8PAL&9.D\MQ8SSN!8B8SB8PGE+T,1D0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 04:\'Y^R#;O[\OA$?YY=_H+RH" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(""C7@_/V0;=_?E\(C_/+O\ 0:CN/8?=$2'N[VGJ;(L-A&F-
MFQZ,.+5:(T-/.#MG:I'5>$6E28PW&,$:U>7V8>!&6R$/"Q%PL5B26E/Q6!9P
ML5>,X?ZQ\]S;QMN[4Q;-6Y1 +//4\K=;N&8A,@X-?+L5&O7C8&56L5X?D52:
MX(E7.IQ:- '-B8$1KGEZ5*/Q*1S/S/#">_?]KR(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @("#3]A'K%5:)<K-4:?)V#::[5SIRO4.$4BA)US,"ALF= JP\O/
M9?@#B!Z2PV+@2Y[?R%F9*9RF.,QN'7FP\5/ 4=V3/<C5'8V;'Z_WC4U-JG:C
ML99V[7<S4%_@Y;=[;WV7O(AKP<'CC8LMHOJP!>Z^*NDZ8ZRSR5(P&X,;/XZ6
MV/-:>AV)B+B;B)P][;KT>[:,B @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(*L[WF7XILW0F
MMZ;M6X:E'WB3LR;93M$#:Q+6&>S4:K$("AN&6U->;*!PX.4V;E(EYPP3!%[E
MAAO @RQ\<T\6,IG/*.-[.YVO,)M3UV.SGV4Z9_TD(7&R//J>83:GKL=G/LIT
MS_I(0N-D>?4\PFU/78[.?93IG_20A<;(\^IYA-J>NQV<^RG3/^DA"XV1Y]3S
M";4]=CLY]E.F?])"%QLCSZGF$VIZ['9S[*=,_P"DA"XV1Y]3S";4]=CLY]E.
MF?\ 20A<;(\^IYA-J>NQV<^RG3/^DA"XV1Y]3S";4]=CLY]E.F?])"%QLCSZ
MM2IO4@_KL:1#T3M=OZH"R]GM5T*P*]0.E J*1MMXL!"U6^QS68?4-K&28L=B
M*D3!:>]QG(F39;KKF?/_ !>,1>Z//JVWS";4]=CLY]E.F?\ 20A<;(\^IYA-
MJ>NQV<^RG3/^DA"XV1Y]3S";4]=CLY]E.F?])"%QLCSZGF$VIZ['9S[*=,_Z
M2$+C9'GU/,)M3UV.SGV4Z9_TD(7&R//J>83:GKL=G/LITS_I(0N-D>?4\PFU
M/78[.?93IG_20A<;(\^IYA-J>NQV<^RG3/\ I(0N-D>?5&NT*QN'30RD76'V
MNWC=\'=X]>*45JEWJG5W&M&Z[LW>NO-;V:'/=I/7"E6J.YS7[62<'RPUG%28
MA)N))R=>9:=BOC"=41A.W5%[5YD00$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M)!6/MI^S2E?O.=-OYM-+(L9^$\I6<1! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MZ^:J-IM%JVEV)(AJ&(F$*\0#&2CFT^R^P1M7 X9S2W%G%TL7 Q=,@.<)Y?\
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MSKS8:-#MQ/BE/6879IE:U/JLM=8\BRRH6Q1,^N&L@%6@CJS#CEN>?=C?67T
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M"Q>63)@7?OWG_5+?HBL?;3]FE*_><Z;?S::618S\)Y2LXB" @(" @(" @("
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M,5-)^1! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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4(" @(" @(" @(" @(" @(" @_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>g713200g75i90.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g75i90.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1C<4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %8< 5H  QLE1QP"   "   < E  "')R,C8T-C$W' (% #5-:6-R;W-O
M9G0@4&]W97)0;VEN=" M($E03R!P<F]D=6-T(&1I86=R86US(# W,C(N<'!T
M;3A"24T$)0      $&9H976%ALX6Y+ 3M]'"\MPX0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /
M     0 ! \     !  $X0DE-!"8       X             /X   #A"24T$
M#0      !    !XX0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              )[   #80
M   !                          $              V$   )[
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   )[     %)G
M:'1L;VYG   #80    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   ">P    !29VAT;&]N9P   V$    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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MYO-#B9?4+,AK,BCTZW&T3M.FWTO2W/W.9^=<W=_A=GL6@LW.LS,?*&0PN=1
MW-&K0!]/<!]'_C%8HZCCWV>DW<UQG;N$ QX) UH3]JIP) G$#AK7A_1_O-I)
M)).8E))))*?_T/54EAV9F7[FMSJ&$[I<YVHUV@^ZG;5_.,:QC]_^#_G_ -)Z
MKCJ&0X7!^;CM>-OI02T0TL?8??6=U=C'?SE?_J1.X"BW;26$.H9NVQPS,8-K
M@,<\^T@A@%CW-#MOO=^=_.6>I_8M.KZY6&EME=DN:'-[ALMWOW.#/S?]?42X
M?$*MTT$W.>2V@!T:&P_0'P_TCOZO^>F?-[S6TQ2TQ8X<N/\ HV_R?])_VVC
M!H#6B - !P ALE%]G#OYYQL/@=&_YC?;_GH#J'Y%3OL[_L];_:W8T EOY[_[
M?^"1\@DM;4.;3M/]7Z5G_0">^^C%H==>]M5-8ESW: !([4>JD'[.8RRI]#C7
MZ8VO:?<'L\'M/YW\M'.-3,M;L=^\SVG_ *$(?[2Z?O<P9%;GL#B]K7 EH;OW
M[]OT-OI6?2_<4V9F)9Z6RYCC?N]$2)?M_G-@_.V?G(#3;15*_3U:G],SY!X_
M(RS_ *"K]2(NP'/K<"UI#G#B0#[F0?SOY"MUVUVL#ZG![#PYID:(.5BML:YS
M6[BZ/4KF \#C7\VQO^#>D=01LN@>&43V(+6Z4[&+0#6UE[/:':2[3\W\[Z/T
MUI+ MH?CVLMJAWJ.<ZG8TDB-&B'?X5N[Z"V<2PV8];GN#GEH+B/'\Y-B>AZ,
MN>(TR1-QDE) !+HB-9XA8>9Z%F2RK&K;6 X 6-@ N=L+'C;^:U7>JVVAK:ZG
M2UP<+6 ;CMB-SOW:T+IW3FO ON <UP:Y@U!D&9<A+4T$X@(1]R1W^6+JI*AG
MUY%?J9-62:&[6-@C<T'<6[MCO;^>SZ'[BI_;[ '[<XN);N8WT3ND$NLANS^Q
M_P!;_P"#L1,JW8A D6#^!=M)8(SKX?'4 WEM,UETP/=O]CO?6YCO\);_ ."(
MM5V3:]M>+FBRPD.V%I V!^RU_J6-?_5_[<K_ .$0XQ_*D^T1U_"3_]'T\X6(
MZ)HKT,CVCF=W_5>Y(X>(3)IKG;L^B/HQMV_U=J,DE94@.#AF)HK,"/HCL=W_
M %0W*=[W-8 S^<>=K/(G\[^PWWHB#]/)/A4W3XO_ /,6?]-$>/122MC:V!C=
M T0%)))!2+Z64?\ @V:?%Y_]1I9.+CY51HR:VW5.(+JWB6G:=[=S3[7>YJ57
M\[<?Y0'W-:?^_(J)4\[E=+S*[WLP^G8UF,-C*O4<9+6AOJE^Y[F^HZOUL:E_
MI^HQ]E=F_P!/U$3#KP<7#IS<^BNO-QW/#-AW'<\O KK_ $ES?<UW\QZME6/_
M ,&M9H^T^]_\Q^8S]X?OV?R7?F5_Y_\ P9'T4O=6YS&DU&:R1]'M[4J W4"Y
M_2<FK'I^PW.V7T@N(?(EKR7[V[OS6[MKEI@AP!:9!U!'"BZFIUK+G,!LK!#'
MQJ)^E"&^ES";,?1W+J^&N_\ (O\ Y?\ GI:%)/5<?HKX'T+I(\G@>[_MQG_4
M+)L8/MCQM?\ 3<8;_._%CO\ 7]&M6UPMQO59J6^]H[RWW;?^^(?4R'=.N(U!
M;(^\*/-CXP-:X3^2[%*I5^]HT^F #*X.C3]$0!_QJUTDDL6/@CPW>J)RXC=4
MLYK7"' $>!U4/0I!)%;9/)@(B2>M8>C3_HV\[N!R9]W_ $G)-IJ8XN:QK7'D
M@ '6/_(J:22K?__2]2L<6UN<.0%6^T6^(^Y6+OYIWP5-)<$GVBWQ'W*%61;-
MCN"7F9$3M#6:?R?:F0VW[KG51H) =YM^DB.JB0*OJ:#8^T6^(^Y+[1;XC[D-
M)!-!>O(LW6QI[^2(GVM^BE?D6^BX&2'0T[1)AQ##^5,DC>MHI(;[1H" !Q 5
MMIEH/B)5 J\SZ#?@$$%9[RTP%'U3X!*SZ7R44$@"F%-D6W5[2 ' ZB![Q+MA
M_.]RKW/=9TES0QP(9M#2#N]IV?0^EV5M)$FP1W3'0@]BS-A!(@)V/+C!0U*O
MZ7R000*2I))(K5))))*?_]/U&_\ FG?!4U<O_FG?!4RYH^DX-GB2!^5)=%C8
M\5L<\B=HX_!!QFN<]]SN^@(T$GZ>U&<:G-<PO;#@0?<WO\T#$<&FQI>S:TQ]
M(?2'=NO[J<-BLD#QP_=U_P 9LIQR%'?7^^S_ #F_WJ&5/H.CQ&[X3J$T"]%\
MC0)["T6*Y[K;"3(_.,R-TZ?]%64'$#?3,?2)]X\#V_Z*G8^UK@&5EX(F0?P3
MCJ5F,U $Z]?WOF9J\SZ#?@%GL<]S27LV&8CR\5H,^@WX!-7$V PL^E\E%2L^
ME\E%!<-E*EGNL%M+6$@\M .NZ1V17WY#;'-;CE[0='3R/N57&]V9-\MLW$@'
M]\<-=_9^@GQ%:L625U$6+(%_*Z1Y4J_I?)14J_I?),93LE22216*22224__4
M]1O_ )IWP6-U/'?>*MN,W)V[IW&L;9V_Z<CZ7\A;-_\ -.^"IGA"6Q7P-.+^
MS[O_ "MK^_'_ /)*+<&QTQTYGM.TZT<C^TM7+;E.QW-PWMKR#&QS]6\^[\VS
M\W^2J[J^LG*8]CZ*L;?6^VMHEY$N^T5;W-=O<YKF?I?T?\W^C])1T%_'+P:G
M[/NT_P FU\^./_Y);;O<2/I S(\05'NJN=@VY>T,RK,9K6N:6L!(<7%KF6.]
M]?\ -[4^ JT2).[9KI;6#L!@ZF=>%*%1LZ;?;F5Y5F=:16]EGH-:&URS?N9#
M7>VJSU'>SZ?^FMR$?)Q7W646UW.I-#BZ -S7AVV6O;N9]%K/T:<L  % 4G/"
MO,^@WX!9>+CV8[+&V7OR#98^P/LB6A\?HO;^:S_6NM:C/H-^ 25)A9]+Y*,'
MLI6?2^2J9^&<REM;;74.K>+&O:)DM#MK7MENZOW>[W()&S9@H;L:MUPM+3ZC
M8.G>/H[@J-O2+K;[+3GW0]S7M;I[2W8PAFTL;Z;ZFV5^EM_PO^D0[>@OMQ68
MC\_(;4P6-AD N;9N^GNW[K&;_P"<_P# TD$ [BW64J_I?)#J9Z=;&$[MC0W<
M>3 V[N7(E?TODDD[)4DDD5BDDDDE/__5]1O_ )IWP5,J\]N]I;Q*#]D_E_@D
MN!IKPE"*ZNEMC:G7-;8\2UA(#B!^ZV5(XS00#9!<8:#W,;H']EJ'"$\2"$D1
M[,>N?4O:R"&G<0-2-VW4_NJ;L9K07.?  DD\ (@ *M DCLQV/:',L#FGAP@A
M/]D_E?@DBPURKS/H-^ 0?LG\O\$<" !X)()1V?2^2BBN8'&4WI#Q*"012-)$
M](>)2](>*5)L(U*OZ7R4O2'BG:P-,I()#))))%:I))))3__6]527RJDDI^C>
MN_LOUKOMGKSZ#/6]&(VSD>CS[_4V?;OH>ST_Y[_ *@S_ )N28^T[I;]+C=ZC
M]N_=^B_GO5W?:?T'\[ZO^%7@*227Z"I_8/V(;?M7H_:C,SZGJ;+_ %/^']/T
M?6];T?\ !?\  ^NJM0^K8H/JG)-OK'<0(?M]7]%N%9=^@]3]_P#3^IZOK_I_
M77@Z22GZ I'0OVE@_93>+_6&\1,GTW^GZYM/M_D^C^F]/_NKZRZI?*J22B_5
M22^54DD/U4N<ZD*CG9?V9V8W*FKU?LC6G7]7V<O;_@MW\[_@_M2^>$DE!^A&
M"WT[=C^J;=U.W<W4>\[OYU^[8YO\_P"I^A]+^<5>MN1Z;]MG5-7--'I,$"F6
M>WW6>B]WT-[Z]GL_F:]GK+P-))+] 8S7^IA_9'YXK%M1>2R:37N'M_16-K;N
M]WJ/_P".]=G\RNJ7RJDDHOU4DOE5))#]5)+Y5224_P#_V0 X0DE-!"$
M %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3
M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"
M24T$(@     !1DU- "H    (  @!$@ #     0 !   !&@ %     0   &X!
M&P %     0   '8!*  #     0 "   !,0 "    '@   'X!,@ "    %
M )P!.P "    "0   +"':0 $     0   +P   #H "W&P   )Q  +<;    G
M$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#<Z,C(@,3,Z
M,#DZ-3$ <G(R-C0V,3<       .@ 0 #     ?__  "@ @ $     0   V&@
M P $     0   GL         !@$#  ,    !  8   $:  4    !   !-@$;
M  4    !   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
M          !(     0   $@    !.$))30/]       (          #_X0%(
M34T *@    @ " $2  ,    !      $:  4    !    ;@$;  4    !
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M 2@  P    $  @   @$ !     $   %& @( !     $              \
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M[59.AOF6&^W<&[\E1:?R3I=61N^K\//&J-+UC4]OU'>*NHK3J7>M?LJIMOK
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M+#..&L7PHX6P@)\:7G.Z2:K<_P!ET7@X>7NF#%4C-XPA5T:12<N/FU=US/\
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MVUNLUPAZX$T<0SVBL//5OHE>7TH $_?<HA'V2WJK<XCE$WJZ"OTG7(53JU;
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MBQMDUNBV^CL=;V6L%N*2V'<,?7EL5T,T:JCVN:YJMDAGAE:R<8F!\9(I$<1
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MHD[N-2ZU3#:=;QE<D:'"AQ&')C"LW-$+Z1KUX1SNS(%.-B:\87M4\.GWFLU
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MSS(B%D[0?,E Z!P.WZKCRE_:7*G&OE3CS9N;+JMV+6B*NL?1UK=;V77-F-*
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M<<:M;,]['V#(^LF0G$.(P&.YM(IFCN NA7 95U@J3&)!YK$93)PH)\[:O5_
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MU^-W7JU,D;?,%C=W.VJ<I80GM <<ZZ=?2(DCA/[-R:P/Y<L:;X7,K8Z>3Y*
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MYC3XP^!)+*"=)97F#B4JY!=1)K<NBL$9F+%=6].1%DMH&2JJ>N"JXT@C.#C
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M>'DE3#R3_>2!@W.[P05.V]=CX,^$B>$D%U.EG)9BUF2$K)*)2Y="^H$1QX
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MK7& >9GEJ "0!_&N?C/M9Z1RKRV9Q3JU?*?,-J5?M\=_7W5):"K66&G<;;E
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MBE5PGL3\B?5F@>I]9^-=!6N4I6"H/(_/5'VFMWI+ZEWFUXM.L>4J7C6#WO\
M89=,(NHN/NQ>?QS'<[UJ6A;&3J^MD;7?=H@9VX[ Z6D&(9M$)TIJZO65];D
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M:GIE50V-4V2,$VO<9$1'%-J^L::1!)(I3G%#%:[I>I!F#%^/ 81KE/;%1S7
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M&4J<@#'3';7/DG6"F*4Q2F*4Q2F*5+M%_&BN_--^PDY8_3V_<:UKOZ!O6O\
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$%*__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>g713200g78p43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g78p43.jpg
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M P$1  (1 0,1 ?_$ !X  0 " @,! 0$            '" 4& P0) 0(*_\0
M4Q   00" @ "! <+"0<!!@<!!0(#! 8!!P ($1()$Q07%18A,52DTR(V<7)S
M=):QLK34&#(T-T%55K.U(S-1=925T5,D)5)ADM(*&29#9G;5XO_$ !P! 0 !
M!0$!               ! P0%!@<""/_$ %,1  $# @$&!@P*!P@" @,!  $
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M9GR6H\V8TM,-0H>-%0Q\*%$2RJ!04X;*W^T=P[6-E<Z1SG.S#<$N-S>^OP:
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M>^C597C<6JVQMC A.9 :82&%IE,!:6B(R:\UM[BUC< DG3?![E]#ETNWK?\
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M''=/S4WF==.YVIY^#TG53W;E/I\#ZQ]CQQW3\U-YG73N=J>?@])U4]VY3Z?
M^L?8\<=T_-3>9UT[G:GGX/2=5/=N4^GP/K'V/''=/S4WF==.YVIY^#TG53W;
ME/I\#ZQ]CQQW3\U-YG73N=J>?@])U4]VY3Z? ^L?8\<=T_-3>9UT[G:GGX/2
M=5/=N4^GP/K'V/''=/S4WF==.YVIY^#TG53W;E/I\#ZQ]CQQW3\U-YG73N=J
M>?@])U4]VY3Z? ^L?8\<=T_-3>9UT[G:GGX/2=5/=N4^GP/K'V/''=/S4WF=
M=.YVIY^#TG53W;E/I\#ZQ]CQQW3\U-YG73N=J>?@])U4]VY3Z? ^L?8\<=T_
M-3>9UT[G:GGX/2=5/=N4^GP/K'V/''=/S4WF==.YVIY^#TG53W;E/I\#ZQ]C
MQQW3\U-YG73N=J>?@])U4]VY3Z? ^L?8\<=T_-3>9UT[G:GGX/2=5/=N4^GP
M/K'V/''=/S4WF==.YVIY^#TG53W;E/I\#ZQ]CQQW3\U-YG73N=J>?@])U4]V
MY3Z? ^L?8\<=T_-3>9UT[G:GGX/2=5/=N4^GP/K'V/''=/S4WF==.YVIY^#T
MG53W;E/I\#ZQ]CQQW3\U-YG73N=J>?@])U4]VY3Z? ^L?8\<=T_-3>9UT[G:
MGGX/2=5/=N4^GP/K'V/''=/S4WF==.YVIY^#TG53W;E/I\#ZQ]CQQW3\U-YG
M73N=J>?@])U4]VY3Z? ^L?8\<=T_-3>9UT[G:GGX/2=5/=N4^GP/K'V/''=/
MS4WF==.YVIY^#TG53W;E/I\#ZQ]CQQW3\U-YG73N=J>?@])U4]VY3Z? ^L?8
M\<=T_-3>9UT[G:GGX/2=5/=N4^GP/K'V/''=/S4WF==.YVIY^#TG53W;E/I\
M#ZQ]CQQW3\U-YG73N=J>?@])U4]VY3Z? ^L?8\<=T_-3>9UT[G:GGX/2=5/=
MN4^GP/K'V/''=/S4WF==.YVIY^#TG53W;E/I\#ZQ]CQQW3\U-YG73N=J>?@]
M)U4]VY3Z? ^L?8\<=T_-3>9UT[G:GGX/2=5/=N4^GP/K'V/''=/S4WF==.YV
MIY^#TG53W;E/I\#ZQ]CQQW3\U-YG73N=J>?@])U4]VY3Z? ^L?8\<=T_-3>9
MUT[G:GGX/2=5/=N4^GP/K'V/''=/S4WF==.YVIY^#TG53W;E/I\#ZQ]CQQW3
M\U-YG73N=J>?@])U4]VY3Z? ^L?8\<=T_-3>9UT[G:GGX/2=5/=N4^GP/K'V
M/''=/S4WF==.YVIY^#TG53W;E/I\#ZQ]CQQW3\U-YG73N=J>?@])U4]VY3Z?
M ^L?8\<=T_-3>9UT[G:GGX/2=5/=N4^GP/K'V/''=/S4WF==.YVIY^#TG53W
M;E/I\#ZQ]CQQW3\U-YG73N=J>?@])U4]VY3Z? ^L?8\<=T_-3>9UT[G:GGX/
M2=5/=N4^GP/K'V/''=/S4WF==.YVIY^#TG53W;E/I\#ZQ]CQQW3\U-YG73N=
MJ>?@])U4]VY3Z? ^L?8\<=T_-3>9UT[G:GGX/2=5/=N4^GP/K'V/''=/S4WF
M==.YVIY^#TG53W;E/I\#ZQ]CQQW3\U-YG73N=J>?@])U4]VY3Z? ^L?8\<=T
M_-3>9UT[G:GGX/2=5/=N4^GP/K'V/''=/S4WF==.YVIY^#TG53W;E/I\#ZQ]
MCQQW3\U-YG73N=J>?@])U4]VY3Z? ^L?8\<=T_-3>9UT[G:GGX/2=5/=N4^G
MP/K'V/''=/S4WF==.YVIY^#TG53W;E/I\#ZQ]CQQW3\U-YG73N=J>?@])U4]
MVY3Z? ^L?8\<=T_-3>9UT[G:GGX/2=5/=N4^GP/K'V/''=/S4WF==.YVIY^#
MTG53W;E/I\#ZQ]CQQW3\U-YG73N=J>?@])U4]VY3Z? ^L?8\<=T_-3>9UT[G
M:GGX/2=5/=N4^GP/K'V/''=/S4WF==.YVIY^#TG53W;E/I\#ZQ]CQQW3\U-Y
MG73N=J>?@])U4]VY3Z? ^L?8\<=T_-3>9UT[G:GGX/2=5/=N4^GP/K'V/''=
M/S4WF==.YVIY^#TG57/'UM*RYCVLE'0UC/BKV=IQQQ6/[<8]9ZI*<Y_^+/G\
M/G\BOFYX?CD>:>#@>7<F>YK6CIS<XGHT7VA5(\G),X<+4L#>7@VN<X]!=F@=
M-G="DT:-B"8C<*$WZME'CG.<Y\SCKBO#S.NK\,>=Q?ACQSX8QC&,(0E*$I3C
M!3SR5$AEE-W'1HT!H&IK1R >TDDDE;)3T\5+$V&%N:QNG:YSCK<X\KC;2=@
M    [_**KIPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB
M<(G"*ME4[<:&NEJ@TD'9[(BRD;M(UPQ /ZLVQ4&F[U%US8]MR*O-(VZC@Q8X
MNUK:JF;@N+/FQE8#I&O?SSH)LB4V/Y\G0K'Y=:PO+>7&\.);];EO*TX7AKQR
MGUF4^/FPWYL93Y\X\OCC./'QQPH7W+K>%)1EQ&%K5E"$Y6G"EK2C+BDI3G/B
MI6&\97E.,9SA&,JSCPQX\(OQB0QE*%X?9RAQ7D;5AQ&4K7Y_5^5"O-X*5ZS.
M&_+C.<^?/E\/-\G"+657BK(N\;7&2J?CG+K!&Y,!DQ9JE*K@HH(#3R"YR8V1
MK2F")T2Q[$],00=3,3(9BN1FWGFR+2=1[^U#O81)-ZKN<6S0(D<!.?PZ-.5Z
M>D5;1R2]1.(#V@8%+O5VW"U?"%3L3,%P'9H;;\@&0GMQWU-DU*7DNM+PK*76
MU83EQ*LI6G.$J95Y'4JSC.?#+2\92YC/RH5]RKPS\G"+53][JE8+T8";+(AE
MMD6Z;1*9$1%FR_A>UCJ-<=D3!*GH4:1'&+8I= MIG,HL[!A*P*Q ;DJ)SQL*
M81;3A]A24*2\UE+N?*VK#B,I<5XYQY49QGP7GQQG'@GQSXXSCY^$3+S*?-E3
MK2<)<0RK.7$8\KSF48;:5XY^1QS+K>$(S]TK+B/+C/G3XD6/+&H 1N"[/]M\
MA$J-"QO8A10JKV\K)1$A^TH%0YJX,+UZTXE%9J8XL<UXR"$R+'2IW!%^#9\3
M709BQEI?J X =.*E93#$F>Y&A#HRYDM:(0YF5.EO(CMJ4W#AQI$R0O*&8T=Y
MYQMM1% \;MUUVEHIJFMD14*O9F77@S$JO6Z%,&&X5Z9U=(%WJ#-K\>9K&8G9
MDF/KMIK9#%4S(O3[-1C^M/NH'J*;'WMLOZEW9O:KK_"KA*UM[(&F@@O8!+5C
M[U4%V*YSI>P U7?O!BLA0U2#FS5AF"*5$GW$H\ 'DH0ZJBR]AF2F1 @E,BE%
MCL]]7KT*;A!T,?$ACP0J/+!;$/@E@)4?+8E0#(PE#01'SQDIE:F9L2; <1,C
M/QU.-O1EI?;4IO/FX19#U['@M7KFO*VI"%Y]8CP0MS",MH7GQ\$J7AUO*$Y\
M,JPXC.,9\Z?$B@TCV8TF)H.M-HD;FN+K[;@6N66D6M58N#@J16[9"#$ =CL3
MK(!Q=$KS\:Q _;#E[;K8H/(*PH9B7 F/H8R1=/':?13DVZC85SEF"= ?DQCP
MNO4R^6,I,=@6J71B^*<- U@C.V*W7KK GU"TO:]8M#-6L\&8"L3@PI%?BMD6
M+>[C=9F<"WL[>KCHXU1&MDBST5@S-JTNIR=>EMMPY"+9$%OUI!HAJL$:V0,J
M+I5NW$Z(*(6R "D@HCTY!38ZO$IDI%^KFPJZW::Y\/M!G7WV$.6FG7"A$,JC
MX1E;OP)>P5;-XB+2XE4><H=B%*3YE19#V$+RDH6VYD,8PYG+S.,-93AW.7$8
MPUE:4J1AS.5?<96E:%)PKPRI*TYQXX5CQ(OUEYG&7,9=;QEI&''<96G&6V\Y
M7C#CF/'[A&<M.8PI7@GQ;7CQ^X5X$6'L-FKM2 F+3:#HBNUJO!B5B/'S9&(,
M#A@ >(N>6-$R,QUF)!%#(3:Y<^?(=;BQ8R%//NH;QE7"+D&'1I=XPQ!7*RX!
M*9#D<RAI,<U[;@>/)^,!\C$BL&(/LA2)X%1#DX4J5[4/3-R0'D(L4BQ)J^52
MO'J76"Y=$4WL(P7 5&&F--DX*EP-=+VLM"5*B1GX@]<0""*S5.$WX;+JHOL;
M#CDYZ/&=(HA[1[C,Z4U6[8ZJ.@EKE8++7Z+38A/+GP4FR6>6J/%DD\,N-.KB
MPHS,N7EE#C>9#[+,=;C3;JW$<[[)^6%;D5DL[$<+IH*K&<0Q+#\#P:*JSNU1
MB.)S&.*6IS'->Z*&-DTV8US>$>QD9<UKBX=&[%N1M%EME4W#<5JIZ3!</PW$
M,=QJ:DS>VSAN%Q"26*ESVN8)IY'PQ9[FNX-CWR!CW,:QU<]_SNSVDNNVT[G8
M=Y"+83BPJ"X%* =?CJ:9JYJ?L:J##$2 Y$E$()@',#D)T/#I&"R3PK+:\83Z
MQ>$\[R_G[)N1/8[RHQFORWI,6JHH<!=1U5#D_38/6896SY0X52UD4#HI:B"L
MH9J.>>$/J((ZH$@BV<0WHW8_@[&&6_9%R5P7#\AJS"::6;'FUM+7Y05.,T6*
M44&3N*U-'-4-EBIYZ.NAK*>"8LIIGTI <#G9K2=VM':X8?HF]H,<1M;3%SUK
M18EQ2[8*A6Y-GQ73*LI%V0$ )''!4IWSHPS)%G)8UZ(N2AI:DRVI#<3-8IV5
M:6OP++J".DRJR-QG)K XL7#L0P?#I,3&'5A(I<2H*"IKG4DSB1F24U;-3.B=
M(&N(E9(V+"X7V)ZK#\>R$GDJ\E,M,&REQV7!RS#\8Q*/#.,:(7JL-KZ^FH6U
M<3+$OBJJ&&I9,(W.#3"^)TV1L'<&NT7.:RNC[8V/8*YJNI[,L1*MURO^K^*I
M42Y-)64KE)V&/%.06XV'R,%O"6U2IS<81B7&8E/Q;C$.R]AV!EV&.P3*O*/$
M,-R7PG*3$:C#<-P_-XJJJ1T]3B54>WX:>E= V(/J(&V:99VQTG"QLEDBM\/[
M#N)8[_\ DVXYDEDWAV(Y58MDQAU-B6)X@'<:TM8(*7#*3.H)JBK;.Z0LIIWD
MO$4#I*PQ2R11R[I<>SHRMU +L 'K#:%[HQ/7X_9\ZU5L;78X@'4Y\61/S[:[
M8+(&=EGH0^*[.G@A;,Z3#BY:>DN-)?:\^9QCLFTV&X11Y04.3&4^.X'4Y/P9
M3SXKAM/AT='0X3/#)4'AWXAB5&Z6OA@B=/44-*R>6&(L?(YH>S.PF#=C"JQ+
M&*W)ZNRHR7P''*;**HR6@PK$JG$9:NNQ>":.G' ,P[#:UD6'S5$K(*>OJGP1
M32YS(FO+'YM@:Q8A=PK5>MH-U<@+: 8FQ!WW&U,N/"S<".3'NN,K^[:6Y$DL
MK4VK[I"E92KY<9YO^&8C2XOAN'XM0O=)18I0TF(TCW-+'/I:VGCJ:=[F'2QS
MHI6$M.EI-CI"Y]BF'56#XGB.$5S&QUN%UU7AU9&UP>UE50U$E-4,:]NA[6S1
M/:'#0X"XT%9SE\K%.$3A$X1.$3A$X15LKG;C0UIMR***L]D:LZKKC7+D [JS
M;-48B7E5&G;,15YY6TT<,''%W=?CW;@U%G3XZG:_)%$V_-%-"')Q38_GR="L
M?EUK"_5Y<;PYAO+N496G"\-8SY<N>7.?-ZO"ODROP\N,_)G/CPH7W+C:5)0I
MQ&%K5E"$Y4G"EKPC+F4I3G/BI6&\9<RG&,YPC&59QY<>/"+\8D,92E>'F<H4
MOU:58<1E*G,.X9RA*O-X97Z[.&O+C/CZW.&_#SY\.$6LOWBK1KP)UN\50FZ&
MZO9+F,"IBS7%/UNHE*B&L)%<YN,H;&S (WJJL8A2IC)"6DJF1"BR8T6<]&(M
M)U/O[4.\(,TAK"YQ;(P/A5XK);=&G*_.^ [A&E3*=98PNS# Q*;5+C%@SY%1
MM<*)(KEH:'D5@2A#$"9ZDEK>_ON4O)=:7A64NMJPG+B592M.<)4TKRNI5G&?
MDRTK[ES&?E0KY%>&>$6JV"]U2KEZ.!.%D0RNQ[=+HE-B)BSIF2UK@T>W['E"
M5O0HTF.,6U2Z':C7M19V#!6D8F"B2HE/&PYA%M.'V,I0O#S64N*\K:L.(REQ
M7F\GE1G&?!2O/]QX)SG/F^Y^?Y.$3+[*?-E3S2?(XAE?BXC'D==\F&VE>.?N
M7',NM>1&?!2_6(\N,^=/B18\P:@@H\:40]M]3+*APK/L(HH7<]N.DXH@=ZY@
M3#G/Q869TUC$XK*;9%B8F72):9!'1I,MHB^%S@H"&,6 I+3'$ !T\L6EMMOR
M\Q( R&X0FO9CPFI$IY3,-M;V(\9AZ2[CRI99<6M"5$4 M=ONNCL>IR,[(CQO
MCD:)UT;%GUNXC20<P&N O7Q6)?!)"O1BFL,0+V<!TZ3)V1#JD1NS&@X3+_PB
M4@1Y!38[/#[^^W8LO*[1:&CASIR/L. =A5W8TG41%FHBK%=2[^RX-48O<^FA
M*_40YL]9C0ZDO*MQ%BMC2R!];AE34UQ@<&+2(1+'\]BF(!9*_:@%?M-;,C3E
M<M8D8=K)L9+9EC#P8R/:*B28J6TM3,Z$1&O-3X;["EH?B.)?;SEO/FX4++>O
M8\%Y]<UX-*2ES/K$>#:E82I*5Y\?!"E)6C*<*\,YPM.<?(K'B10:5[,:3":X
MH&W2ER<B:WV8"!VFIVW-8N#PQ56L(L>9'VFR9C@'I%&K#0PJ.E%['>&*Z%KR
M9C#9^<,=7AOA+<BZCG:71:2ER"1[G**F:(X09-B:_3;W9"4YX+:FZ+8F:9!
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MM%FX;/USK.G? M9+TR*!Z^6H;2ZTB,X,AP7A&^^O(FQ,$B065!(:]V!LZN3
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M5QIEVE6<P]-)?5X!;;RWU'=Y5F]O]+-D[*K/4*L8VC1I"NN@S6R;392>J*Q
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MY*U4N3V-Y,8!D=AV%4F+\#58;@F!SE\;WX@^E?VQ79LDM3$XTXA[9X.*9DL
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ML<%.&1$/+,YUOB_9HH\3Q+&JX8-B9&*=B>?L;,=78M'7UW;$E4^9F,UU::2
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MX1.$3A$X1.$3A$X1.$3A$X1.$48;+_W C\K,_8C\P&.ZJ;IF]4:LZO\ P_\
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M<3XY\JT^"D^.?#./'A%R<(G")PB<(M1V!6H]TH=VITL>P6BVRHV2M21<HM+
MQB4<Z&FBWA\DY 'EIX9B8W*5'>+0A9*6.;<5,C#YCS*([A%YW%^L?8,QIZIZ
M57%H;(W7U_QLX3A%T"C:J8%2RNR(%>U)((P= 2VRDK739*K;.<OY[2#"BMI'
MUD4Q!)GXA?8PPIN->T>7;MT[#Y=2C^/T+W2Q:]>7"PM]?]FE-;G=J'K6Q8G2
M]7$]J7]OD6BD:+N(/ U;9AM+&Z#D):1I\7%C;8@.1@X6+"8UW'8PVP4W&RWE
MMT:=-^75XUZ*4&$/T!I34E&NEI>,/T2@T37,NTN0R+[UC+U6IP0\DPZPW\(S
M&G"ZQ$DBOVEY]:%O90[)==SYUWM#A]7B4KH:.+A9&1F5S>$CCLP.:PNO*]C3
MWSVBP-]-[6!6-Q+%:'"8FU%?,8(I)1$UPCEEO(YKWAN;$Q[AWK'&Y ;HM>Y
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M&%PO8C1<:=(Z5Y><UKG#6&DB_@!*B#WAGO\ TAW_ $[W\3S6^.JO]2#]Q_\
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MQ?Y.JOJL_%C5?^;BM!3A%\S\V?P9_5PBJQSH"X^G")PB] =,_P!6E8_)$O\
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M)_\ ]"E_&:O27G$E]$)PB<(G"+33E,9.SLSEV2Y"U99;9]E!V6<*@XPWYO\
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MOI.:&\^U,=8-:X^7$N\>./\ ^;'?XCCN=P3Z-I]S^LG%])S0WN]JD#W9QO\
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MTL-2UK9V"1K3G-#N0VM?1;D6,]Q%4_O_ &#^FYG[7E?C&M^</W-ZJMN*</\
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M,&LMQ26')X>+(L[41R1$HSQ1$&P$V\09TQHEO?W\FU:<(](;J&9&>(& UJ
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M/"+;>$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$42WK1>I]EGQ]GO%-A6
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'$X1.$7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>g713200g83v20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g83v20.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X53%:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^,3(P83PO<F1F.FQI/@H@(" @(" @
M(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @
M(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE($YA
M;64Z(" @(" @(" @(" @(" @,3(P82YA:28C>$$[57-E<FYA;64Z(" @(" @
M(" @(" @("!R<C$Y-C8P,28C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @
M,C$M2G5L+3(P,3D@,3,Z-#@Z,S,F(WA!.T535"!4:6UE.B @(" @(" @(" @
M(" @,C$M2G5L+3(P,3D@,#0Z,3@Z,S,F(WA!.U-C<FEP="!697)S:6]N.B @
M(" @(" @(#(N-28C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP
M)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($)A<B!#:&%R="8C>$$[)B-X
M03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@
M96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S
M<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N
M="!I;B!T:&4@9&]C=6UE;G0Z)B-X03LF(WA!.U1I;65S+5)O;6%N)B-X03M4
M:6UE<RU";VQD)B-X03M!<FEA;$U4)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.
M86UE.B @(" @(" @(" @(" @(&<X,W8R,"YA:28C>$$[57-E<FYA;64Z(" @
M(" @(" @(" @("!R<C(Y-C,T-R8C>$$[3&]C86P@5&EM93H@(" @(" @(" @
M(" @,C(M2G5L+3(P,3D@,#4Z,34Z,S@F(WA!.T535"!4:6UE.B @(" @(" @
M(" @(" @,C$M2G5L+3(P,3D@,3DZ-#4Z,S@F(WA!.U-C<FEP="!697)S:6]N
M.B @(" @(" @(#(N-28C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N
M,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($)A<B!#:&%R="8C>$$[
M)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A
M<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O
M8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E
M<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03LF(WA!.U1I;65S+5)O;6%N)B-X
M03M4:6UE<RU";VQD)B-X03M!<FEA;$U4)B-X03LF(WA!.RTM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SID
M97-C<FEP=&EO;CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS
M.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @
M(" @>&UL;G,Z>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+V<O:6UG+R(^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,3DM,#<M
M,C)4,#4Z,34Z-#$K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @
M(#QX;7 Z36]D:69Y1&%T93XR,#$Y+3 W+3(R5# U.C$U.C0Q*S U.C,P/"]X
M;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,3DM
M,#<M,C)4,#4Z,34Z-#$K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @
M(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN
M9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I4:'5M8FYA
M:6QS/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QX;7!'26UG.G=I9'1H/C(U-CPO>&UP1TEM9SIW:61T:#X*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z:&5I9VAT/C$Q,CPO>&UP1TEM9SIH96EG
M:'0^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X
M;7!'26UG.F9O<FUA=#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z:6UA
M9V4^+SEJ+S1!05%3:UI*4F=!0D%G14%304))04%$+S=107-51VAV9$<Y>F%'
M.7=)1$UU34%!-%%K;$Y!*S!!04%!04%"04%304%!04%%028C>$$[05%"24%!
M04%!44%"+RLT041K1FMB,DIL04=404%!04%!9B]B04E104)G445"055%0F=5
M1D)G:T="45E*0W=G1T)G9TQ$06]+0W=O2R8C>$$[1$)!341!=TU$07=11$$T
M4$5!.$]$0DU41D)15$5X=V)'>'-C2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!9
M14)!64=H55)&4F]F2'@X9B8C>$$[2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF+SA!04519T%C
M045!07=%4B8C>$$[04%)4D%135)!9B]%06%)04%!04A!445"05%%04%!04%!
M04%!04%11D%W24=!44%(0T%K2T-W14%!9TE$05%%0D%114%!04%!04%!028C
M>$$[05%!0T%W449"9V-)0U%O3$5!04-!44U$06=10T)G8T1"04E'06Y-0D%G
M35)"04%&25))>%%614=%,D5I8UE%54UP1VA">%=X46E00B8C>$$[571(:$UX
M6FDX0U)Y9W9%;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD55I(5$0P=4E)2F]-
M2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]0128C>$$[,4]4,%I85T9L85<Q>&18
M;#E76C)H<&%M='-B5S5V63-2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT
M>4YJ;RM#:S535FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A
M-G9O4D%!24-!44E$0E%514)1645#04U$8E%%04%H141"0T53355%1E523FA)
M9UIX9UI%>28C>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9
M-TQ#0C-04TYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C
M>$$[,"M0>FA*4VMT3515-5!2;&195U9P8EA&,658,5)L6FUD;V%7<')B1S%U
M8C)2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7
M;#5I6FUP=6-N6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-
M4D%$.$$Y4%AD-V-W4T))<D-E-E5I<&MH828C>$$[04M$52]$*SEL:F%V,%EQ
M;R]P5RLO=T-R3F5F.$A:+SEL1TMO92LX>69O*S!K=DPO044K93!T25%$3&-4
M>E=-56%!;6=,3SEY1D<U<"8C>$$[=FER0G9Z1&TX<65C24Y,,#-5<FQ,94-Z
M=G9R8W-0,7)49E9M0TQ,6G1%:F981DU:.5=B:GE!2D1I;C)S2W-7=%!+1W-R
M8C9F<E(X*R8C>$$[86QC;SEB3S$Q4G)M,5I*:DU,9%)&134Q3F]U6'%7<G5!
M=3=S44I05593<DMS=#AG-C=O+VQ,>7)"<%8Y<38V<DUJ,T8S3G%K=#%P,"8C
M>$$[5%1F5TAA.&52*U8Y3%@T6G5:8FQU1'DW-$9:>F(V-TYC=U(S1G1P9'I0
M8GEQ2&EM:FMS;E(Q659$2WDS0D)".7-65E P<F9F.5=A."8C>$$[+W=#1',O
M.$%S;WA6,S96=G8K<DYE9CA!0C)F+T%'55EQ-SE+,S,O5FUV4"M$<R\K>6I&
M6&9P5RLO=T-R3F5F.$A:+SEL1TMP4#5S:28C>$$[=3E9,$]7>694-VTQ45-1
M6$1Y4R]5-4E3='1/:S5384TS569/2U%2.$I&-4-Q:S1Q.'IN.')2,S!.,CAE
M=#(W-EID>E))3E!%5VYY828C>$$[9DA,83).>$(V16-2,4DP55=R97(V6EEK
M3D@V;GE+<W8O2WEW5%)D33%A-#!W3G)6:')E<5A7<5)83FXY4T5+3D]1<GA+
M>5AS-D]%328C>$$[9D=O<#AS0W,Q+U-T.2\Q6G)Z+V<W4#A!-TM-5F0K;&(W
M+W%Z6&XO0C)F.$$R55EQ<E=T.6-Z>3A*9%!U3%9A5CE35G)C<EAW+V13>28C
M>$$[3BM'2V]V1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867%H-S=53%-X
M:FEK=5=+2DY.1F)O47).*SAN8U)X9SA184%S=T94=&EQ;B8C>$$[<$]S-EIQ
M,79*8S9D3W1Z0DA.3&)T26QE4'%13UDU04-E=$=8<4YJ:7%->%9)9&8X>B]O
M;3=306EZ;SAA>59U<C9/,68T<%)#2TDV<R8C>$$[4T]B;W9,*UIG3W5+;V$P
M.#(V:F5*-FQN85=.>6Q52$M(56]P0E=46D)667HY<CEN>'=Q;&YM9E=R;E4W
M3%503'0Q.54P*S5K9T18828C>$$[>&%L84,U:70R64%U63=I0UI65B]S.&U4
M=G11,$]+<$9B95)B;3<Y1S1S+U=M=$4T;$DT8BMX94TO2$901U)+3$IP4GA7
M0T5+5FM(=R8C>$$[<40Q3$UY:%AG+TQZ56]F3'-'9VE#*VMS-'!);F1P9%5J
M;&%226IY15)74S)A2TY78F1M:5)(+WES56]7*R]+;31V635L;71B=TYC=R8C
M>$$[;4-D,#%',U5T53AZ2E%7;D98.50T*U-G8C!(,D%&0W).9$MB>E)P,FTR
M,6=M;$Q02&%X<D-K<S$X:&M+;T]+.&ES0V=M9S8P>%9&9B8C>$$[<$QZ5B]W
M0E=32"]P3D@O5DQ!<G8P;#5Q+W=#<DI$+S!M:B]Q;&ER=C!L-7$O=T-R2D0O
M,&UJ+W%L:7)V,&PU<2]W0W)*1"\P;6HO<28C>$$[;&EQ03$K,SAW835O,3-P
M3C%P06IT<C)->%-V0F9H2D%P-CA7.44O<7=Q>'%,.'4W-6)&<DME>G5R=4M3
M47E43F-A:D,X:VET1F-23R8C>$$[:G5,5E=)9C8U27AA=D]V-U=+<'8U3C!,
M6%!+96M.<%9J<#@Q,V)'85-D1W9T5$4W<#9P-49%8C!6;V=/.5!%:VUP3TMP
M-RMK=DY8+R8C>$$[049:268K:S!F.55S0W4O4UAM<B]!2W-K4"]385 K<5=+
M;W)4-WI82G K1C=P<V1R1'A*.59,9U-N;#)(2&=N-CA65$A&6%EQ-T98628C
M>$$[<3=&6%EQ-T9867%H-S=53%-X:FEK=5=+2DY.1F)O47).*SAN8U)X9SA1
M84%S=T94=&EQ>E1.5W-T4VIM:W1'6FAB>E-7,'=:1U%R3"8C>$$[16%-=$=!
M3TMO=D952')'<$IP;6PS5V]/:&M3,6IA5FM5,$I#:71!5&LX8T]/46HS<UIY
M-%EK.7IZ-F8X-4Y';E%2>C922DMG6DA#=28C>$$[>4U/56)",&%H2%97545E
M*V)(*U,U9GIN0B]L0U!C<#)0-75E6')#17<R5VE.8E%L:3=2=VU.1DQ.,5EH
M44YZ-#0O>5A,*V-V.&]2-R8C>$$[;F]U:C9K;7 V6&$V9VE'3DQQ3EI64FI5
M9TU+,$I'83=*1&=K63EZ;E%L>%)"-S!V.'AE56)$6%IO6F)M-&YH34UB4D99
M9E,T=7)3>"8C>$$[5&IM2EDU4'-Y5S9-2U4X1%5B6D)K>&LO:VXU9$]N-G99
M3G%.*V)F5U!Q9G)I='%39W-&2W@X3U5$3%9G84U31#A.1D9!0FER5C<K4R8C
M>$$[6&PK-VIJ:F)69%1I5TA4;TY*:45B,F]#,CEU-GE+47!T>79-;%%#861.
M:%1&55!,*U%F;$]A55-Z86IQ5'5S36-#2&YA:FES56%O<B8C>$$[2T9T>'AE
M<3@K63-$+T5+1VQ&5V1E6$Y"<SE!,$]Z,&%Y85(W5WAJ155,>D5.259(.'I!
M2T-F96U+<&II<G-69&ER<U9D:7)S5F1I<B8C>$$[<U9D:7)S5F1I<G-69&ER
M<U9D:7)S5F1I<G-69&EQ1#%N56AP;6Q896]'4#%287A.2UEW95!,:4LP<E$P
M>7I&1&IK23DW0V-U1TI08R8C>$$[.#9N+T%$;3 K9$)(4&]H;%%-:FA8;%9H
M>6I93VI536965U5%92MB3"M3>B]!1'9S8T@K54(S2V1J*V(R:U=%4FAS=$)&
M=D5Z1C)33R8C>$$[5E9"6G5P3DDK=5 X;&XK9#EI+WEG3S4V5&\R<$15.4MT
M3E%%9G!#-FE755)K.'50259P5V=R;71Y=S1*1U!C-3!*8U5193E!*V1V*R8C
M>$$[55,Q8B]M1FLO=T-)-5!3+S-K9F5W,4@Y,F9C*V1C-EHP1'-69E)8:VXO
M;$5T2B\U:%DO*TDU>D]Q+W9*93DS*VXO=7@W:S9Y:'5D:28C>$$[<G-69&ER
M<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-657)I
M-W1B64EB:5I)4DQ)<U5::UE,>6MK3D52828C>$$[.5=9.4)I<3)Z=C=+.6IA
M4WIN:G5),&1O,V%.9W=$<CEP5%1U3596.%936'IT+WEI5W)F.'=S;B]!0DA,
M.4PO95(Y-U1Q4#=S*S4X-B8C>$$[-3!Z;TA9<2MI=DI0+TM*850O>D-X+SA!
M16,U;E9F,VMV93<O044O.3)08S=Z="]Y:5=R9CAW<VXO16-D3"]E4CDV-FHK
M-U!U9D]U9"8C>$$[339",DMV;W)Y5"]Y:5=K+SAW<V8O16,U;E9F,VMV93<O
M5"\S63EY9%I1,T]X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5B8C
M>$$[,DMU>%8R2W5X5C)+=7A60V%T<4U7;39:8S9H2W)02&%X=$LV3%1K46]R
M459Y94](1DE2-S)--6-)2C=N;CDW*V)N;&TY:%='-3 R-B8C>$$[94Y:27!L
M1E57:VM%:7EX;6]92%HP0GI99GE:4'9$:&9Y:$1U2VAO+S5N955D2'0U3&5W
M,'DW:FIL:TUS;DHQ8VQY;U1Q>FLW2VEQ4"8C>$$[65DO>5I0=D,O;C1D>&5J
M-E1Q35=P85IB86A%<DI(9%)R2VE.5&M!=W)1,'I8-4EC36I(=6,R175)03DV
M03@W9CAO;'$S+TU,2B]X2"8C>$$[3$Y,+T%(:V9E,39J*S=0=69/=61--D(R
M2W9O<GE4+WEI5VLO.'=S9B]%8S5N5F8S:W9E-R]4+S-9.7IV3S,O2TIA="]Z
M0WEF.%)X,"8C>$$[=CDU2#-R<5 W<RLU.#8U,'IO2%EQ*VEV2E X07EI5VLO
M=T1-3$@O>$A/6C%8.35,,W4O,"]W1&1J,THQ;$1C-T9867$W1EA9<3=&6"8C
M>$$[67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E5L.#=F.&]L
M<3,O34Q*+W=!4GDO4R\S:V9E,#9J*S=0=69/=61--D(R2R8C>$$[=F]R>50O
M>6E7:R\X=W-F+T%"2$]:,5@Y-4PS=2]W0E O9&HS3S@W9CAO;'$S+TU,2B]X
M2$A3+S-K9F5U;R]U>C=N>G)N5$]G9&ER-B8C>$$[2SAK+SAO;'!0+TU,2"]X
M2$]:,5@Y-4PS=2\P+SDR4&,W>G0O>6E7<F8X=W-N+T5C9$PO95(Y-C9J*S=0
M=69/=61--D(R2W9O<GE4+R8C>$$[04UO;'!0.$%Z0W@O.%)Z;616+V53.3=V
M.5 X03-9.7ED6E$S3WA6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6
M,DMU>%8R2R8C>$$[<%8U9W0Y96UI<WAO,#914TID4G9D;5-L2'1W1S5O4&AF
M9FM64&)B=FEQ<F]L<G%6=F%33'%--6YU2DHU<$9Q47=32G!$-E-!:%4K>B8C
M>$$[2'AR=#%R,GA634U64UAZ="]W06]L<3,O041#>68X4GDO4R\S:V9E,#9J
M*S=0=69/=61--D(R2W9O<GE4+W=!;VQP4"]!1$-X+W=$128C>$$[8S5N5F8S
M:W9E-R]4+W=",E!C-WIT+WEI5W)F.'=S;B]!0DA(4R\S:V9E=6\O=7HW;GIR
M;E1/9V1I<C9+.&LO.&]L<% O34Q(+W=!4B8C>$$[>FUD5B]E4SDW=CA!5"\S
M63EZ=D\S+TM*870O>D-Y9CA2>#!V.35(,W)Q4#=S*S4X-C4P>F](67$K:79*
M4"]+2F%4+WI#>"\X4GIM9"8C>$$[5B]E4SDW=CE0+V1J,THQ;$1C-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E5M.#5U-F563E9D1TMU
M='1)5EI4428C>$$[9S W15IF<&@K.&HW,G)/9E%F8RMF9C!N<5@O3%A.+WE-
M8BMU9$IW4C=N4F-C=3DS-E0Q3"]L<FTO=T-2:F8Q>#1).7DX8W4Y.4)E5"8C
M>$$[2&0O2VUL3S=&;F$R:DQ->'%3861Y8S5V56HY-4PS=3EW2#!$,TYE9'8K
M55,Q8B]M1FLO-&IJ<&8W>5!V4G%0-W,K-3@V-3!Z;TA9<28C>$$[*VEV2E O
M2TIA5"]Z0W@O.%)Z;616+V53.3=V.5 O9&HS3S@W9CAO;'$S+TU,2B]X2$A3
M+S-K9F5U;R]U>C=N>G)N5$]G9&ER-DLX:R8C>$$[+W=$2TIA5"]!37=S9B]%
M8S5N5F8S:W9E-R]4+T%.,E!C-WIT+W=!;VQQ,R]!1$-Y9CA2>#!V.$%E4CDV
M-FHK-U!U9D]U9$TV0C)+=B8C>$$[;W)Y5"]W06]L<% O041#>"]W1$5C-6Y6
M9C-K=F4W+U0O=T(R4&-N5U5.>G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<58V+R8C>$$[-6=T3D5J<S5,;$AD8GDV4S!J.4U!,&525V)K,5-.9T50
M5$9895AF365N-B]:4S-T:'HY0TLT;71I6D8T171!-5%S0C$T=%-Q,3=9<28C
M>$$[;6U+<$PU,B\U4DQ6=BM95U0O:4]8-E@K.&HW,FY59C-:.7HU,7IP;E%/
M>%8Y1F539BM54S!N+VU&:B\T:FY--G(K.&PW,V8V9BLW2"8C>$$[=60U,B]W
M0U53,6(O04IH6E K230V6"LX:C<Q,4@Y,F9C*V1C-EHP1'-69E)8:VXO04I2
M3%-F.$%M1FHO04])-7I/<2]V2F4Y,RMN+R8C>$$[04QS934S;F(O;$5T5R\U
M:%I0.$%I3T]L+W9)*SED4B]D;C-0;EA/;61!-T98,%8U2B\U4DQ39BM95U O
M04EJ;DTV<BLX;#<S9C9F*R8C>$$[-TAU9#4R+S523%9V*UE75"]I3T]L+W9)
M*SED4B]D;C-0;EA/;61!-T98,%8U2B\U4DQ39BM95U O:4]C>G%V-WE8=F0O
M<"\W<V4U3R8C>$$[<V]B;EEQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<6PS
M;5!52CE/,$<O=G)F:C8Y=$,X:V9)5EAK;W%+:F),8T5"2UE"-FQR>7E-628C
M>$$[:VIO.&IB.#-V3F)5-4IA;6AQ2WA(<5 Y;&TU+VLS2#5U<B]05#AN1#@S
M+TYG1D%T<4(T0TDO.$%.5U X;30O3F9Z,"]*-C4U8S%#9B8C>$$[561"<TPV
M-#0K=F-W<$I*>$9&-4U+;6<S>E1:-$-->4(P3'1-56I+24HV;V)Z="]Y:5=R
M9CAW<VXO16-L<&8W>5!V639J*S=0=69/=28C>$$[9$TV0C)+=F]R>50O04UO
M;'!0.$%Z0W@O.%)Z;616+V53.3=V.5 X03-9.7IV3S,O04-I5W)F.$%-3$HO
M>$A(4R]W0C5(,W)Q4#=S*R8C>$$[-3@V-3!Z;TA9<2MI=DI0+T%#:5=K+SA!
M34Q(+T%-4GIM9%8O95,Y-W8Y4"]!2%DY>G9/,R]+2F%T+WI#>68X045C9$PO
M95(Y-C9J*R8C>$$[-U!U9D]U9$TV0C)+=F]R>50O>6E7:R\X=W-F+T%"2$]:
M,5@Y-4PS=2]W0E O9&HS3S@W9CAO;'$S+TU,2B]X2$A3+S-K9F5U;R]U>B8C
M>$$[-VYZ<FY43V=D:7(V2SAK+SAO;'!0+TU,2"]X2$]:,5@Y-4PS=2\P+SDR
M4&-N5U5.>G-69&ER<U9D:7)S5F1I<G-685IL5E-Z14MO,R8C>$$[2D]W1TMP
M3#5G;#%+84MZ1VI8.$5%:5A58C-::V1A4&)G3GI18E!V>4MN='0S>5A#935&
M:&1O33DU2$)D9G!7-VIE4C=M5G)C97)'+R8C>$$[1T%K0TUC;%=,=S55<'17
M;3E-944Y>3)%-%9L6E%Y:TUP,T)'-$]24VLS;F(O;$5T5R\U:%I0.$%I3U@V
M6"LX:C<R;E5F,UHY>C4Q>B8C>$$[<&Y13WA6.49E4V8K55,P;B]M1FHO=T-)
M-7I/<2]V2F4Y,RMN+W5X-VYE9'8K55,Q8B]M1FLO-&IJ<&8W>5!V6%5F,UHY
M>C4Q>G!N428C>$$[3WA6.49E4V8K55,P;B]M1FHO-&IN339R*SAL-S-F-F8K
M-TAU9#4R+S523%9V*UE75"]I3T]L+W9)*SED4B]D;C-0;EA/;61!-T98,"8C
M>$$[5C5*+S523%-F*UE74"]I3V-Z<78W>5AV9"]P+S=S934S;F(O04I23%9V
M.$%M1FLO-&IJ<&8W>5!V6%5F,UHY>C4Q>G!N44]X5CE&928C>$$[4V8X06Q%
M=$HO=T-95U X031J;DTV<BLX;#<S9C9F.$%U>#=N961V*U53,6(O;49K+W=#
M230V6"LX:C<Q,4@Y,F9C*V1C-EHP1'-69B8C>$$[4EAK;B]L171*+S5H62\X
M06E/8WIQ=C=Y6'9D+W O-W-E-4]S;V)K1G%U<S9D<%-7-S,P=G!,9%1R8E%N
M:7I6:V-&9U!H0F]+2515-"8C>$$[<7%73V\R;#E(2SES>%I96EI,951K<DE2
M2D-X4GA29T0Q2%AO8U923TMT37EQ<%II1E5B:VY91$95;#AW4S9L3D9::E)R
M*T-#4DQQ3B8C>$$[-W-Y3W1(='='-6].;C,U1E0R,C<U3&A08VEW<C924&-2
M451$56(R2V%6<#58:$ED4&AH6GE9-'E65DLX1C(V63A*-VQS2FUR2WEH;"8C
M>$$[25I4=4-.=V-I;$IV3S,O2TIA="]Z0WEF.%)Y+U,O,VMF93 V:BLW4'5F
M3W5D339",DMV;W)Y5"]!36]L<% X07I#>"\X4GIM9%8O928C>$$[4SDW=CE0
M.$$S63EZ=D\S+T%#:5=R9CA!34Q*+WA(2%,O=T(U2#-R<5 W<RLU.#8U,'IO
M2%EQ*VEV2E O04-I5VLO.$%-3$@O04U2>B8C>$$[;616+V53.3=V.5 O04A9
M.7IV3S,O2TIA="]Z0WEF.$%%8V1,+V52.38V:BLW4'5F3W5D339",DMV;W)Y
M5"]Y:5=K+SAW<V8O04)(3R8C>$$[6C%8.35,,W4O=T)0+V1J,T\X-V8X;VQQ
M,R]-3$HO>$A(4R\S:V9E=6\O=7HW;GIR;E1/9V1I<C9+.&LO.&]L<% O34Q(
M+WA(3UHQ6"8C>$$[.35,,W4O,"\Y,E!C-WIT+WEI5W)F.'=S;B]%8V1,+V52
M.38V:BLW4'5F3W5D339",DMV;W)Y5"]!36]L<% X07I#>"\X4GIM9%8O928C
M>$$[4SDW=CE0.$$S63EZ=D\S+T%#:5=R9CA!34Q*+WA(2%,O=T(U2#-R<5 W
M<RLU.#8U,'IO2%EQ*VEV2E O04-I5VLO.$%-3$@O04U2>B8C>$$[;616+V53
M.3=V.5 O04A9.7DW5F9-=&QA-F1C,TYS-C-.>$9'>GA7-$I"9&=.;#9(<FQE
M3TE-9T1S1WEC:4%31T)89C5K86QE3$=T,R8C>$$[-5E3-%='4EIO:$E764Q)
M=&5,:7%B159Z4"]+678U-V@O;6-N.'AF8B]M8G$Q<VAJ="],87A)5TQ&55IL
M0EIT>5123W!X+TM9=C4V+R8C>$$[;6-N.'AN5VQE6F)+-C V,G5B;#%T<FE7
M3EAL='E34VI%8G(P2%1-1$I%0U)!,T1M46M305-G+TYU<5=&>C5:,4]#0UI:
M2G!,95)9-"8C>$$[,7%34U)S0FQM;DE'4TI097=Z0S1%1'5E1F9O;E4O.$%L
M;&PO-$$U,$@U;D@O3T1P9GDX*S4S-DHQ4#A!-5I:9BM!3U U;D@O041G=B8C
M>$$[-65F8SDQ.'!A<%E7,VQN5$E*-6QJ;6IT-#%K:F%O24E'-$]C+W%#1&MK
M4C-U-G=I;T%(=60U=#%3=W5F3$]P=U%43$I.2F)Y3$A'="8C>$$[4U-33F=-
M9$]136M393EC=W5"03=N:%@V2C%0+T%*6EIF*T%/9$(K6G@O>F<V6#AV4'5D
M*VED5"]!3U=76"]G1&HK6G@O=T$T3"M8;B8C>$$[,U!D9DM7<5=&=#5:,'E#
M95I9-6\W94Y:23)Q0T-"=41N4#9G9S5*160W=7-)<4%"-VYE8F15<TQN>7IQ
M8T5%>7E44U<X:7AX<E5K:R8C>$$[:EE$2%1K1$I%;G9834QG44\U-%8K:614
M+W=#5U=8+V=$;E%F;6-F.#1/;"],>C=N9F]N52]W1&QL;"\T030O;6-F.$%/
M0R]L-3EZ,R8C>$$[6'EL<6QH8F579$UG;FU73V%/,VI74TYQ9V=G8F<U>BMO
M24]34DAE-W)#2V=!934S;3-63$,U.',V;D)"37-K,&QV27-C83%*2DDR028C
M>$$[># U07E22C<Q>D,T141U949F;VY5+SA!;&QL+S1!-3!(-6Y(+T]$<&9Y
M."LU,S9*,5 X035:6F8K04]0-6Y(+T%$9W8U969C.3$X<"8C>$$[87!95S-L
M;E1)2C5L:FUJ=#0Q:VIA;TE)1S1/8R]Q0T1K:U(S=39W:6]!2'5D-70Q4W=U
M9DQ/<'=15$Q*3DIB>4Q(1W134U-.9TUD3R8C>$$[44UK4V4Y8W=U0D$W;FA8
M-DHQ4"]!2EI:9BM!3V1"*UIX+WIG-E@X=E!U9"MI9%0O04]75U@O9T1J*UIX
M+W=!-$PK6&XS4&1F2U=Q5R8C>$$[1G0U6C!Y0V5:635O-V5.6DDR<4-#0G5$
M;E V9V<U2D5D-W5S27%!0C=N96)D57-,;GEZ<6-%17EY5%-7.&EX>')5:VMJ
M641(5&M$2B8C>$$[16YV6$U,9U%/-316*VED5"]W0U=76"]G1&Y19FUC9C@T
M3VPO3'HW;F9O;E4O=T1L;&PO-$$T+VUC9CA!3T,O;#4Y>C-8>6QQ;&AB928C
M>$$[5V1-9VYM5T]A3S-J5U-.<6=G9V)G-7HK;TE/4U)(93=R0TMG064U,VTS
M5DQ#-3AS-FY"0DUS:S!L=DES8V$Q2DI),D%X,#5!>5)*-R8C>$$[,7I#-$5$
M=65&9F]N52\X06QL;"\T034P2#5N2"]/1'!F>3@K-3,V2C%0.$$U6EIF*T%/
M4#5N2"]!1&=V-65F8SDQ.'!A<%E7,VQN5"8C>$$[24HU;&IM:G0T,6MJ86])
M24<T3V,O<4-$:VM2,W4V=VEO04AU6DIL1&%W-WI"669M1$QR3GA0;SEY:6%A
M26=S5G,X<4M7;#1'<D$K9R8C>$$[-TE/,C5/.4<V1&IH5EIO5VPO;4Q$-6IJ
M;C%B54DW:E)W<$)I57)Y-6-#05<T<$=.,F]A8C X9D96;6U"6%EQ=S=Z0EEF
M;41,<DYX4"8C>$$[;SEY:6%A26=S5G,X<4M7;#1'<D$K9S=)3S(U3SE'-D1J
M:%93,$13+WI,:#AY0V97.5-G=71'04E32T5"1W V6D$U<498-'5F5VQF128C
M>$$[5399<7IB07)S5EED-6=S4'I";#%M-&XP93523DY%45=+,F561DQ3.$16
M9V919&M(8F-N96ID0GAW<7!E6'1)+TUA,CAW<$YQ*W!P9"8C>$$[-E)2>3!9
M2VAQ;%<T,4-P1TYJ>#(S+W%Q>F)!<G-6660U9W-0>D)L,6TT;C!E-5).3D51
M5TLR959&3%,X1%9G9E%D:TAB8VYE:F1">"8C>$$[=W%O95<Y22]-=3(X=TQ.
M<FUQ4C-M;%9K+V1P=U5G14U%0D-O;E0T83ED-CE/-G)/34-U>%9H,VU#=R]-
M1UA78FEF4C=L13 P4D)9<B8C>$$[6C55571,=TY70CE",E%D='ED-DXP2$A#
M<E=I85(U*W1V355-*V\V:TQR4T-H37-&5C5#5&=Y+W-P2'-7-'1496XV,5=:
M649D:7)$=B8C>$$[349H*UE-=7,S12MJ,TM*<&]I0WA7>GEO<&%89V%S1#9$
M<V<W8FLW,&)O3T]&5DQY.7!8-6MW95E5;3%R56\W<E-12"]!2&%C43(V="8C
M>$$[>#5"55%F>2M0.5978EE&9&ER1'9-1F@K64UU<S-%*VHS2TIP;VE#>%=Z
M>6]P85AG87-$-D1S9S=B:S<P8F]/3T954#5C,'(X>EE0328C>$$[9VXQ>E5O
M8G)244=#47AH42]W0FQQ1BM+;T]P6%E$=#%X5FY/0EA9<7<O>D)P,S5G>C9Z
M8U-A4&5P8F%A65%K56)U:%!Q;$-#-FHP4R8C>$$[5D$V54QF86\Q84-G2W%0
M;"]3=GI,:#AY3%!R97!16$]K8UAR1$112&ME9$1S:V4R-F)5-T4Q>%9M,D)8
M+SEK/3PO>&UP1TEM9SII;6%G93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]X;7 Z5&AU;6)N
M86EL<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @
M("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4
M>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT
M(R(^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z13DT1#0Y
M.3$Q,4%#13DQ,4(T0D1"13DV03 P,C0P-38\+WAM<$U-.DEN<W1A;F-E240^
M"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z13DT1#0Y.3$Q
M,4%#13DQ,4(T0D1"13DV03 P,C0P-38\+WAM<$U-.D1O8W5M96YT240^"B @
M(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR
M-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO>&UP34TZ3W)I9VEN86Q$;V-U
M;65N=$E$/@H@(" @(" @(" \>&UP34TZ4F5N9&ET:6]N0VQA<W,^9&5F875L
M=#PO>&UP34TZ4F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#QX;7!-33I$97)I
M=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z13@T1#0Y.3$Q,4%#13DQ,4(T
M0D1"13DV03 P,C0P-38\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @
M(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z13@T1#0Y.3$Q,4%#13DQ,4(T
M0D1"13DV03 P,C0P-38\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @
M(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS0D9$
M0C$Q.3$T03@U.3!$,S$U,#A#.#PO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$
M/@H@(" @(" @(" @(" \<W12968Z<F5N9&ET:6]N0VQA<W,^9&5F875L=#PO
M<W12968Z<F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#PO>&UP34TZ1&5R:79E
M9$9R;VT^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \
M<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.FEN<W1A;F-E240^>&UP+FEI9#I&0T)$130Y-CA#04)%.3$Q.#(P1$1&144U
M,T4W145$,#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.G=H96X^,C Q.2TP-RTR,50Q,SHT-3HS,BLP-3HS,#PO<W1%=G0Z
M=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^
M061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM
M<"YI:60Z13DT1#0Y.3$Q,4%#13DQ,4(T0D1"13DV03 P,C0P-38\+W-T179T
M.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P
M,3DM,#<M,C)4,#4Z,34Z-#$K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A
M=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI3
M97$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B
M"B @(" @(" @(" @('AM;&YS.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N861O
M8F4N8V]M+VEL;'5S=')A=&]R+S$N,"\B/@H@(" @(" @(" \:6QL=7-T<F%T
M;W(Z4W1A<G1U<%!R;V9I;&4^4')I;G0\+VEL;'5S=')A=&]R.E-T87)T=7!0
M<F]F:6QE/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP
M5%!G/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O="]P9R\B"B @(" @
M(" @(" @('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O1&EM96YS:6]N<R,B"B @(" @(" @(" @('AM;&YS.G-T1FYT
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1F]N=",B"B @
M(" @(" @(" @('AM;&YS.GAM<$<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]G+R(^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L94]V97)P<FEN
M=#Y4<G5E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#X*(" @(" @(" @
M/'AM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/D9A;'-E/"]X;7!44&<Z
M2&%S5FES:6)L951R86YS<&%R96YC>3X*(" @(" @(" @/'AM<%109SI.4&%G
M97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @(" @/'AM<%109SI-87A086=E
M4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS
M=$1I;3IW/C@N-3 P,# P/"]S=$1I;3IW/@H@(" @(" @(" @(" \<W1$:6TZ
M:#XQ,2XP,# P,# \+W-T1&EM.F@^"B @(" @(" @(" @(#QS=$1I;3IU;FET
M/DEN8VAE<SPO<W1$:6TZ=6YI=#X*(" @(" @(" @/"]X;7!44&<Z36%X4&%G
M95-I>F4^"B @(" @(" @(#QX;7!44&<Z1F]N=',^"B @(" @(" @(" @(#QR
M9&8Z0F%G/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE
M/E1I;65S+5)O;6%N/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F9O;G1&86UI;'D^5&EM97,\+W-T1FYT.F9O;G1&86UI;'D^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y2;VUA;CPO<W1&
M;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP
M93Y4>7!E(#$\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z=F5R<VEO;E-T<FEN9SXP,#$N,# P/"]S=$9N=#IV97)S:6]N4W1R
M:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E
M/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT1FEL94YA;64^5$E27U\N4$9".R!425)?7RY01DT\+W-T1FYT.F9O;G1&
M:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^5&EM97,M0F]L9#PO<W1&;G0Z
M9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY
M/E1I;65S/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=$9A8V4^0F]L9#PO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y4>7!E(#$\+W-T1FYT.F9O;G14
M>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SXP
M,#$N,# P/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^5$E"7U\N4$9"
M.R!424)?7RY01DT\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N
M=$YA;64^07)I86Q-5#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IF;VYT1F%M:6QY/D%R:6%L/"]S=$9N=#IF;VYT1F%M:6QY
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^4F5G=6QA<CPO
M<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT
M5'EP93Y/<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S:6]N(#4N,3 \+W-T1FYT
M.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP
M;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F9O;G1&:6QE3F%M93YA<FEA;%\Q,BYT=&8\+W-T1FYT.F9O
M;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.D)A9SX*(" @(" @(" @/"]X;7!44&<Z1F]N=',^"B @(" @
M(" @(#QX;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @(" @/')D9CI397$^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI3
M97$^"B @(" @(" @(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX
M;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W
M871C:"!'<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @
M(#QX;7!'.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @
M(" @(" @(" @/'AM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" @(" @
M(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G-W871C:$YA;64^5VAI=&4\+WAM<$<Z<W=A=&-H3F%M
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+
M/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \
M+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA
M8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H
M3F%M93Y";&%C:SPO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'
M.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^
M,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \
M+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIB;&%C:SXQ,# N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @/"]R
M9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" \+WAM<$<Z0V]L;W)A;G1S/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QX;7!'.F=R;W5P3F%M93Y'<F%Y<SPO>&UP1SIG<F]U<$YA;64^"B @(" @
M(" @(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XQ/"]X;7!'.F=R;W5P5'EP
M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z0V]L;W)A;G1S/@H@(" @(" @
M(" @(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9
M/3 @2STQ,# \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N
M,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X
M;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8FQA8VL^,3 P+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(#PO<F1F
M.E-E<3X*(" @(" @(" @(" @(" @(" @/"]X;7!'.D-O;&]R86YT<SX*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*
M(" @(" @(" @/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M
M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@
M;&EB<F%R>2 Q,"XP,3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C
M<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ ]@(Y
M P$1  (1 0,1 ?_$ !X  0 # 0 # 0$!           ("0H'! 4& P(!_\0
M2A    8" 0$!"P@) 0<$ P$   ,$!08' 0(("3@1$A,6%QEWEI>VUA055%=8
M=K75(38W6729L[?8UR(C45-55I48)4'4)C$R0O_$ !P! 0$! 0$! 0$!
M       (!P8!!0($ __$ $X1  $!! 4%"0X#!P,% 0$    ! @,$!08'$2$V
M$A=1=+0Q05)UD92AL]$3-#555F%Q<H&RM=/4\';!U10B4U25L>$CD](5)#)S
M\19"_]H # ,!  (1 Q$ /P#?P             S3UUR@YQ-DBYFWPCG4NF5
M<&>?7/!#>+1)E$"<6Q[XDT50D=F\.I.O&75 9.U-KHYFX?+HY,M_F9+JW*SR
M9E,9(E)*CV!^[&;DWU92STJNZMN]]V$TBNI5>S\NXTQ.%</F%=.>4ZJT?)<7
M-.09\(ACVQU_QWA/(5KE;:_)*6EK\:P2M))GR I#7R)1I:1)XGL[EHUD/?V]
M^('F2E]]R;MB7[MFE/3N[GGN(XQKK *:JCE\)Y/6=@V0XTR^<Y;@GJZ565'5
MBA!5W'[FDP\=]X?5JZ.4S"T<A6E[3,]RA,2D36WK&&-QQCCDEG[\X2,B0H![
MD6V;B6Y/*K.5?:O^-^Q-PZE6G/2S^0?/[C1'(H@5UU0<C>^I?4SO%E,DR\/5
MF/?$"3T_!VN92^*N$,:]JW5()2^3-3'VEFDSPO=6%V1;R[9*K0H6Q&&2B,JN
MZMC*[ER95^[Z+-[T;A>$!^                      *A>'EG7)RWBG*VQ)
M[<TII::5ASOM:DHS'&;6/I8]6584I,HHU-=<R.+/J YID#I:L>R<Z2F;OFIL
MSTVGY"NN7^*MJ&-I$H_32(EEG!2_2JI;T6V;VY>FZ>Q9.:M@M?4X3T5,<*->
M./(.I)=&>-2Y1%'ICTWY#<89-)%%RLI<E=6M&SR,VPHJ^+G1F4M#XZ-NK+5#
M3A,D;E[D[&+@L3)MWT6^_>7<7S7[VZ<"XC\SWVR>+?#CD=R/NVSZVNKECRSE
M]9IH!$X6?(8)I(V*X+-8FCB4XQ!/'EQ<!(;X56ZTI983F='YV8_L+LYRJ<N#
M*M51-Q'JLV*TB):B);HNL2_IMLO(Q\0^<')N8<X(10L@NB7(&!7SQZD5>N+G
M;J"++*UMFC^/;OB-UY056.J!L4R3R^P%2J:YL>K7GP[=T@I3NXO<AL!7E-'=
M1ZTRB):B?_RPN[>BK9?9H6]/38:@@/\ ,
M                                         / =3UZ5K<E+4@T=7-,@
M6'MK68LT;BW)>2G,,1H-W PH\M#HL4:EI]EAA!VB7!F3]RC-=,Z9 CQY2>2O
MV9&7V\Q[X. #RD\E?LR,OMYCWP< 'E)Y*_9D9?;S'O@X /*3R5^S(R^WF/?!
MP >4GDK]F1E]O,>^#@ \I/)7[,C+[>8]\' !Y2>2OV9&7V\Q[X. '.(DS3B
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MC8XY*T3N(&)B9/&S%)A)9"E<QJ5121PW0F*4I"W!Z+91\K2JB20LL]MYT$
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M=5+%.DKL"/V=(8ZW;0U3'G18//O[W">P
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M OT)RKV"[2O(G:/+IU0_W>G&_P#F&.W^& 7Z$Y5[!=I7D3M'ETZH?[O3C?\
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MU."AH=,-J]*NRVNJ3O,JFQ?A*:;\C<$V#"\J$2CP:DGO]/"%:]]KW0/9@
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MHTV \/JP
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M(V(3%VR1J0H&XA*C('A]R
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M(235WVUQ!-$<$=@
M                                                &1_J5=MJ\/XJ
M"?VOA(M6JG %'_4F/Q>/)5K%QG.O6@?AD$07&AG$@    &I/I*=D1O\ 2'-O
MZK<) KIQL]XLE_NO"F:J\)N]?C?>8+-1DQHX   8N^6O:DY%^FZT/?-Y%Y4+
MPA1?\/RC8'!'U*L34@XYF6UO2/8Z8^      :]^GAV,:)^[SW[XR01)6?CRD
M6LPVP0A6% <(235WVUQ!-$<$=@
M                                                           &
M1_J5=MJ\/XJ"?VOA(M6JG %'_4F/Q>/)5K%QG.O6@?AD$07&AG$@    &I/I
M*=D1O](<V_JMPD"NG&SWBR7^Z\*9JKPF[U^-]Y@LU&3&C@  !B[Y:]J3D7Z;
MK0]\WD7E0O"%%_P_*-@<$?4JQ-2#CF9;6](]CICX     !KWZ>'8QHG[O/?O
MC)!$E9^/*1:S#;!"%84!PA)-7?;7$$T1P1V
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MCICX     !KWZ>'8QHG[O/?OC)!$E9^/*1:S#;!"%84!PA)-7?;7$$T1P1V
M
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M@FB.".P
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MGOWQD@B2L_'E(M9AM@A"L* X0DFKOMKB":(X([
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MUF&V"$*PH#A"2:N^VN()HC@CL
M                                            S&=83M5,?H<B7O+-
MQ6M1^#HGCV-V27DW5M8G<<40NTQI54-C,P     -$G1:_97='I 8_=S43!7U
MX9D/%C_:E-_J>\%SC7W.SH72#!C80   R/\ 4J[;5X?Q4$_M?"1:M5. */\
MJ3'XO'DJUBXSG7K0/PR"(+C0SB0    #4GTE.R(W^D.;?U6X2!73C9[Q9+_=
M>%,U5X3=Z_&^\P6:C)C1P   Q=\M>U)R+]-UH>^;R+RH7A"B_P"'Y1L#@CZE
M6)J0<<S+:WI'L=,?      ->_3P[&-$_=Y[]\9((DK/QY2+68;8(0K"@.$))
MJ[[:X@FB.".P
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M()HC@CL
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M'"$DU=]M<031'!'8
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ML8T3]WGOWQD@B2L_'E(M9AM@A"L* X0DFKOMKB":(X([
M                                                ,_76M_6OC_\
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M31'!'8
M         !GZZUOZU\?_ +O6!^)184K4'WG27699U4:8/7'WU(M7CNLABCP4
M&8N     7;]%7]>[W^Z4-_&'D8!7WX.H[KL=U#@V6IWOZ=ZI"=<]-"(F8WL
M  ,QG6$[53'Z'(E[RS<5K4?@Z)X]C=DEY-U;6)W'%$+M,:55#8S,     #1)
MT6OV5W1Z0&/W<U$P5]>&9#Q8_P!J4W^I[P7.-?<[.A=(,&-A   #(_U*NVU>
M'\5!/[7PD6K53@"C_J3'XO'DJUBXSG7K0/PR"(+C0SB0    #4GTE.R(W^D.
M;?U6X2!73C9[Q9+_ '7A3-5>$W>OQOO,%FHR8T<   ,7?+7M2<B_3=:'OF\B
M\J%X0HO^'Y1L#@CZE6)J0<<S+:WI'L=,?      ->_3P[&-$_=Y[]\9((DK/
MQY2+68;8(0K"@.$))J[[:X@FB.".P
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M@  !B[Y:]J3D7Z;K0]\WD7E0O"%%_P /RC8'!'U*L34@XYF6UO2/8Z8^
M  :]^GAV,:)^[SW[XR01)6?CRD6LPVP0A6% <(235WVUQ!-$<$=@
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MAG$@    &I/I*=D1O](<V_JMPD"NG&SWBR7^Z\*9JKPF[U^-]Y@LU&3&C@
M!B[Y:]J3D7Z;K0]\WD7E0O"%%_P_*-@<$?4JQ-2#CF9;6](]CICX     !KW
MZ>'8QHG[O/?OC)!$E9^/*1:S#;!"%84!PA)-7?;7$$T1P1V
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M;8(0K"@.$))J[[:X@FB.".P
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M 8      6E=(3M8+?1/,/Q:*C'Z[L&.N.H'J(TTRJC%+?%<7UL,:?A(Y2@
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MO%DO]UX4S57A-WK\;[S!9J,F-'   #%WRU[4G(OTW6A[YO(O*A>$*+_A^4;
MX(^I5B:D'',RVMZ1['3'P     #7OT\.QC1/W>>_?&2")*S\>4BUF&V"$*PH
M#A"2:N^VN()HC@CL                                     (<<FN*;
MER 7.1[)8Z* (YQ2-E<;[83+H0=,E$GJ&TUC >_EQ%:3,XCB$3]J2MCRCC,L
M<$LT8D7C,N4.T(?34+9\F'J+9[%M3T^=-\]7=O'.^;>F]<O>EY5*E@%>2%VE
M&E1R_CU-9;$9-(4\J2O-;223Y8>3-?G/K]5K0A2E1\AZ*=(4=.=MK.\2$<C9
MX,5# MW>WEWM_P#Q:3; \       I>ZTG[)Z:](;Q[MG#>*AO#4]XK<[6P8]
M7#X+D^OOMG4SL"H#      "TKI"=K!;Z)YA^+148_7=@QUQU ]1&FF548I;X
MKB^MAC3\)'*4   #/UUK?UKX_P#W>L#\2BPI6H/O.DNLRSJHTP>N/OJ1:O'=
M9#%'@H,Q<     NWZ*OZ]WO]TH;^,/(P"OOP=1W78[J'!LM3O?T[U2$ZYZ:$
M1,QO8   9C.L)VJF/T.1+WEFXK6H_!T3Q[&[)+R;JVL3N.*(7:8TJJ&QF8
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MJ @HL0   *R^K5V0W'TA0C^LX#6:EL;.N+)A[KLSBM3";S7X+WFS+6*_)F
M   )R]-CMLT?_&S?^V<S&>UJX I#_P"N ^+0!VU76,Y+ZT=\,C37&(I*J
M"E[K2?LGIKTAO'NV<-XJ&\-3WBMSM;!CU</@N3Z^^V=3.P*@,      +2ND)
MVL%OHGF'XM%1C]=V#'7'4#U$::951BEOBN+ZV&-/PD<I0   ,_76M_6OC_\
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MU>PDRK94JL!P8/F[YL/.2N;/AT>5J!O3ITVRC!NH676W\EW+:6@ >
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M&EI;U6-"5I-W-Y:&)C+:"U#Y+'1"M3KERIT;ESK\A<$0*MN\G3VDI0/
M  (:3'A?')Y=4_N*47#<+L@LF FU1(JC<$U*.5:I:N<8Y\PR: 15>ZTROMN%
MQZ;+MC);-L1.TV=SDTHPWJ')R-:8]&&=E'MMUG3?;_<YW).G>Q2Q&V8>^2_)
M!4^I)="I6[R4XOCJZ'S0NKXSO'*LC,XBTCX]/M=R2,UZL4ND[8$2J&:J=[.=
MSITY+%SLT1/Q;"WS)OZ=_P!OL]!["<=/&NK(TF:"96Q=#NP3O:?OKXPZGU2W
MD>4VS^-KWQ6FELI')LJA&]DRISJ^2R(TB/;N1M8MLG>#G-! 2&]O869H"U4L
M\W;;_<DY5%7RZM\.9<EY 6[=:98E;4K:EL]FH9J*C>K?\HU,-9]Z:I.I%*DU
MQ+.)+7>,*A]*TU0ILMQ2 S=;NK!?0B>BW\U4[&!X      !!-;P/CSM*KVE#
M[?E]/_E^<M'9_:G<JA#]8@K875,^561 )430Z>R&EBH]Z1)'BK(D\3B01% \
MX<GF4,4K=I)*5SX/;=RY+O3?Z;]_S6'JW+@"U.$JA\ZTY+<B6Z7Q68S*REKF
MG1<;GAMEUGS,IE:C;(?XI-..\LB:2912%QUGKB /4698XJAL'(7M[3OHZR*4
M/+V/<KS)T[FC=TW^D_&5].6IY?*+'FZ^?66VS*>.6'5LES"V4JVR6"*_+17-
M[>%:G?:GE)T[-3S"I:]:&D^[-;3.CT%C9$1C^[8B<7PUU'EN]VW]/G7<LW27
MM9063P-J<&Z4W+9%TJUCA\M3OMEM50-+HTIODQ)'S2WDTY553,AC?X4K=9X5
MT9W)U^4*#M/G/Y)JG2D#SV6??G.D@       ("1?@*T1EMEJ4SDAR&D[O*+.
M;+J(ETI1\<U,P8;99I*E?FZ:$21DX],#M)C4C0E\G*-@L%7,8JTU:87!V%C:
M&QL8MFD?K*\R:-_<T;OM]-Y] 3P<B!2*(Q\VWKM7P9CET/LF60!R>8*MB]G6
MI#;Q>.2)%ER@LVOOG2-R>2W0\F3*;E52YUU'I1EM9F-6QEQY!EJ/'EOF3_%E
MEG)I/CD?3I@K6UQ5(RWA?3*\5N73S-4<M1&TLM?ZL@5$I; 0UQ7<=32*EWZ+
MO; WHK+D:1W>9[&Y?.I&42Q;O4M6*61&HP%OF3?TWVZ;_P"Q-6OHH_0R-DL<
MCLR;6TYE*E:C>8V WUPV2-02H,QN2A.2U57]9Q'5*AUQDI+NGBQ"W<O.<KEB
-PWN&8'A]N    #__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>g713200g84s38.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g84s38.jpg
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M 0 ! P4         !08#! $"!P@4 !,5$1(6(2?_Q  6 0$! 0
M         0+_Q  B$0 ! P,$ P$            ! !$A,4%A E&1H;'!\''_
MV@ , P$  A$#$0 _ .JIG<G"ZRJ*N\4NS7"UCTMV%8Z132^\+J?&"YQ:0>\=
MEY4M?Y[Z!2[*J8I\W&<J.V[9Z*I8D#5".,V)YB<$EDM1N)&8I@YIG\30[LS.
M=7SFOZH:UVQ*HDM1Z+4'4FSF+6S6P3$SC$5<LZO59WZ2U2MAP7;JLO,F%/8R
M978B0&0-I9:+3;$EPH!-1&"7ZY2;\S.?HFQWBK1Z?5] _?8QEIG80#(#Y:)&
MD8*(H*F56(AFU968%E$2I98?N+7-JQEH='%JJ,=H6-HK#)(XE2 SANWWY/'H
MPM6Z0G=_XT58V!U*MC6X>D'VV%W06QSI*?YE( 5 ?/DF_9.P+]D2KJ8M?6Y9
MUO4(N%6*H==+-> @SE[,Q2QC;WR>?",]G6^ATE_SA<K.S[$:H'N4R_B\I%S&
MK6XWNU\-L1M71I145/CR051*PJ[BF/92DPPP5<C-18"9G$TXK9(F.\'[S53W
M[%U/VQQ#EAL;QOLS(O3P]A@UCS/SCE$Y*RR.E[M74^RX,T6)"/W-3%V%SX0Y
MLM7YMS"1T!W>^99(VY4Z;$9: <V-;EH8 WS\RIPS6YUKVMY$Y0%WQ30[J5W/
MLU\/F..U:(]/U 75[9P)'[FEAC(DIQ'0F^M<TNEYZ5[<MBW<JSW1PJQ1*"1J
M-PS(GV^O@^4>5K Y%$CQ0K'?>/'] UZK$R!(R#-Z&56@SI"%9]3(J$78.D+=
MZN"BIZ QN9<5A@ZG4BBKQDTSJ#_0DYXB92#1Z*:=R51<J;5>)6X8_P"-J"FF
MXWTL/('.^;6J@$!ZW9-,QZ_'EN8GEJ?NEQ5WAQ--B0FL,6%*JBMSA?/2!< ?
MO:O%LVKZD]%\I8ZUUF6Z)U,U8Z17XD^[MG?3)"I#%!:VSG;:733&-L_K_?T6
M5C!R]/V3@*99A/D@=#H"RUU<F75V-FXSX]\K/ ^_LU%V&ZTS? 98X;M&K.9D
MI4ZT%<17K1AJ\(^,BT57SWR")^KM&REM:NA$>15#"B+"TE$P6.86+)YBO#^>
>DC=M"J-3$7""[K"\0+>CJ<DK9U*G[<4]F.8F%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>g713200g85v78.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g85v78.jpg
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MM?_:  P# 0 "$0,1 #\ [^. . . . . . . . . . . . . . . . . . .
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MF6UZ[Z]KX3)3@H. . . . . . . . . . . . . . . . . . . . . . .
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M+:N!*VNVW;=> RK[F>+_  "KZ'[!&:'U>9MV"1WLPI4!RPXH@1JJR9ET^GD
MA-\Q\>B$F3*5+(Q@K-TF"+@RSB3<^BQ+&(N0+CQZ2[P4C&\DGPV\.M-KU:_K
M+[61XMW4^JG5C)RS[I6PRMR_92*.)$&B+ N*EL\ZE0V+3>[X-$6C619D2IR-
MB9,X20?2,%'(H]=Q26;:R1(>-:$"(IHOF]>PM=/O%MJB(6*!=R#$XJZJH*^[
MN1^ZFTRK6+R@F8/]18% 9A(M(;+H+=A1(,D+Q+T4AVB$-G7W0"#_ $CJ"D/?
M"UW;D%%OOMVMP;7;A7\_49+:^(;5#&V:NHZ95[<-8V?<10P.@,;LT97D-UDJ
M(.11  ^)Q4R2LK &P6^&\Q;RA,969.:R;:*A9$2V Z.!R;%V*:+M?;QVUV\/
M$9\<%!P!P!P!P#%SNSV21Z?=3+^[-JQE>9[TQ6QZ9L8JBXV9X/EVB6C8(,=O
MM$7"@X6Y+NF.A<DFV<JCA7KCY-LYW;ZH*"J5VEQM(PL[7]B>X_6SI44[7C9;
M2LO7"T-$)E)8^\K<^W2;W#,[%I(:P9P[#&>)Y<U1B'R2SF>@H\^>31D?1AY1
M2:&V*Q(6V%4DW;6M?\GWMI5SCQ<NLXY^YCAF+7*'GHJP[^KF0UNM&X64F@,A
MUJ-P )9YC#6.6$;$2H8AM9\,(QP97YF7S.4#B#W8/$W#P$=9#0T7S>O8O#J?
M>U;2C9=XS?7J&;V%DG3799RSK=GVX?&"(Z/TVJT(H='9T"@G8S(71S>#1\KM
M$G$B&GQ?QBS&:2H#LKK'=R$A3^(-@T'QK7HK_,KK@YSW(_XFD*:6[>5:$F%@
M6I*!UMD(E2E35?4PMC81F/13J!#.T$IPP?&K><BK!6< 2^7PARJVKL^J9E\;
M@C>'/WZ:Y!,-'9P75[O9M:XM6RW#Q[-E,]M_%6B=3P+LC%JZC$UC/8FL>O/9
M>XZ\96Y TF<1.$^MD6@LF/-3$>0F Z>( BJ%B1M4 7(AXX$EXU*0K1:1NEQ'
MF5%8QO;B;BG;:M)M>#@?\RXW:GM3=58F/#;%U\]A(W7MW?$7J2RUC\3?2#(L
M3(Z@E5B*%8CHC)@WQ<2:%(OJR2U)[F&B@\@MA1'UE!%?@I%7TN]%OUI?S++T
MWXMBY!W(ZIL^A[(L2_HSVM[@=5!8OK5'HRZC]GF.HH&-3V12^.B+0M2.N8MB
M0UW+AQ!M%7LKE"K>2!I!'$#[XAN&:D!71X4U:R>OOZK>GP<=DBYQCQA.K\>'
M2DJ=B5X#640B';68%E/D?%"._P !TPMD/3%O"6Z :?$EMR;B8'Q*L4<K)H1Y
M\!=*&#9Z/(L2&C04T7[/\2NO45<&\4WKT3LJ*U(0C5FQ*;S.\;4Z]QUE,M:K
MCXHO8U-3&N89.!H:2N;5VCLD<MW=D,BPB.Q<H;G!\'&I@X$Q-T]$-AY$-%ZW
MQ6?#P_5SVX.-&RK@^1P#_,^?S9]'S>EYL^;S_P"[S^;\'G__ &\_^_@&F.ON
MWG9P'V0[HUE>MET<QKKH?3_5:Z[9E0.J):.3DD4LFN[/FU];BE/EZ<(!DHHV
M@6Q2O-LB3#MPT;+AS[=VY*I%PX^]%6BU?LG)):N"VCP=_65XMXKU=2&PJ'K"
MN*LL,G,;9NZE:RE .6;PP"3@,4O7K?*>SD!G6V@^9F1)M*0PF*%AK<8V.(NQ
M18))]"Z23H< &2P4T=3=UJ5^'7KT=7WXBWMR^+( <,F "B(_(H]9L?OCI)%Y
M]&KJA*+)36K>T?9)_0QGX,0%FFQV)3H*K&Y7MN"FS8!(8^_0!/B,6(BR7H;"
MNCQO5:6SCC'2_FC='P? X X X X X X X X X X X X X X X X!\!5A\:BR
M0SUQ^.^,6#QA\8"G.691CZXW4;^N#7>-=\M7[7X3X=FYQIOE!QHFKC7;T?-D
M#4PCUQE;?J16\+1#W%J9JSQ'49W'HTK*["=&3%>L_%@6EC&83]5X6<2"RHVT
MI1=>P\$IX^D MX)W1L,GZ\28##C*GAXWSZO4?5]?!\WO?W3)KMI#GEO1&N2$
M7'6DY-U/V^ZIE, A>DYBXLFSCO:2CG\YE)<$AJ+:6'"XM7^LH-)%""1R#CD6
MQ63(Z[&(XQ*!JE%_)\S,W."AX4ED@>(!'TB/NMF0@;JAL\<ZMW#K9+5PY19H
MYP@T26<*>DX<):?^&EMG7&WI[>;37;;'K1HU,14C1I1TJD[Z,;J-]&+D]<FD
MK1BWK?K/.K5A1IRJU'HPC;2=F[7:BM23;UM;$6A^^:IC^M2__+TC_P"U<OOD
M?,/S"_:T?MEE\JX'\\_V57[ ^^:IC^M2_P#R](_^U<?(^8?F%^UH_;'RK@?S
MS_95?L%Z I@?(1(XX)7RY&%6B#YBXV260RLU<:8414RBOHFLEG;3.,^@JGIO
MK_NVUQG\',?4ISI5)TZBT9PDXR5T[-;5=-I_4R^ISC4A&I!WA.*E%V:NGK3L
M[-?6C\9'_P"GCO\ @Q3]B7Y6C]+2Y2'M(5/HZGB2]EG/S;EOQNF(NWE<I:R<
MBS>'@D<:,XL!('W^Y X^39(+._5=,,0XEGKNH[)&SCT8):((Y1R\W(.1[)YL
M"K4C2CIR4FM*,>QBY.\G97X$MK<FTEQW:3@]&C.O)P@XIJ,I-RDHJT5?PMO8
MHQ3;VVLFU\EMV]I4@G)EQ!;!FK%J#E$H..(8SCN&,9C,.8MGYTP?-3"41"/M
M,Z(.T?BP(@6=28[\&07"A'[(*<=C:5:O6EI=;J32C*4M!1[&,$G)MSE"/#JC
M=REK<8M1DU6C1Z\[*I3@]*$8J;E><IMJ*C&$)R>S7*RC'4I23E%/;UTS(MC%
M.X+,E-UF1.1.R#-51)9!11H]# 7+??=!QHFNAMNDKIMLBLFFJGG.=%---\;:
MXBN>-/%TVMCPU-KP.=4DN3IK"23VJO437$TH7]9EAS#&5' ' ' /X53U5342
MVSOC533=/;*2BB*F-=]<ZYRFLEMHJEOC&?/HHEOHIIMYMM-M=L8S@#$6/]#N
MJD9ZW3GJ*-J]5?KS8[R9$9?7I^=V3+-"!&?GUY7*7[232J8&9B$>OI4Y6DS1
MR"D U8+(=_CH)L.(ZZN-172=T^%6X%P:EWMFHJN.=3*3C-D0>X6HR<E;4KRL
M)13D;GLKN*WYA(?N?34V(DDH$&UI/.BK:3NRIR/@7^#LC:E#P[(0.T$$A[ 6
MP:MPN[-<#=[=_P#EMX"TL0\-+I3 V$($Q6ETAXB (0-J%%NYQ8QYF0;U79L@
MN6L4IAB12XLM.M*]L^52"81#$Q6.?$K\ENV:^B+0:L$ TGQ\?K23]*5GWBKZ
M/Z(]7^N4X96)3T *Q23"8))*O 9WL:S3H",UO*[!=VF8@T9A\AF!6(@8U\NW
MK@X,'# ;?0'Z6HX)L/$IZ,=0<F]K[^Q&7O!0< < < < < < IJ9Q$#/XC)X+
M*6SI[&9B!+1B0LV18N"=O AQBN-*-$#(%\,-#-W+)RLAAZ*(LGR&%,[MG**N
M-=\ 80Z^%KT6Q!EZY4I1VZBZM15]0:.I"U[I(R 52]631E8L&K./3-_8KF91
MF("9P-'29T(CQX8@>)L&2LBP6U:H:)CZTG>]]=V]BVO;WCV)UX:?2JRVD]'3
M:F$C(NR&UJMI(,2F]C!6:/W=9/$9G=+J,XC\N%+0PA:LH@D6,3DC$E@KXZY8
M/-7"_P  >D2)8%)JUGLV?5>WHN[<1X5U>&[0%E1>UT8<(7K:Q[+$VVDTL-B<
MG1#>(2F]X[$HA<$]CH-K-@C89-;#BT)!B))(QCI@1>[_ !R_<[NEI=.4I4*7
M?A^^SP??@5J)KOPLZ20CB$?["&)MV79QY*WP%:C;/G$O(,:XKB^Z]C,!MZNT
M\BC )K.!DRP =GOC67AW)&-$3&<Q#4"['IDW0KI/;L>KZVG=,R.9=*.OS<;7
M <B%G$N'5.8K60P=M8-OVU8N!)^GCN\FK(WLI.)J?5<EX><RF^&$E]]WN^B&
M@]ZN[%J.&*XI=Z^_Q)+O<6KZC+#@H. . . . 4W,8?%;"B4F@<YCPB6PN9@2
MT7ED7/L4"8.0QTZQ7&&0I<<ZT4;O1Q(>Y<-'C9;39-9!7?3;&<9X!B^:Z'];
MY331#K[, 5@3"GWT7!P=*'22[KI(IB(9&C0"0 HT#-YGR4D%,AQ2+1_;#QL9
MU-/6(ID&)%'H9!,?J*W:U_ \I#P[^IC&:M;'$0*4@9\TM>U+HUF0"Y+J#R1>
M<W@PCPVW,N3#"PD7RT3G[6)1?X^K[9;Y![N  QXTCC5XVPOD-)VM?59+ZD[K
MT<>W@V%,&O"[Z/R)&2MS-1&WR,P1[*-I&GO=%[)ZDV_;\L).=CT5/@+,2^ 3
ML\L#%OB.K7X# 99IC,7^(]55]5!72>K7LT>!?DZH^A?]GL[>&]U UE*<[85W
M* L]0L<!;#.>@KFNT/-ADXCU7L*40(!I4QL1$V$'E:F&,(%*(\(>LH]+0;1K
MF2"R9!JV?(BEWZK;%L;OS^C@*6D7A5]'I::GAZ1U;*BKRS,WS\M$5;QOA <6
M3[.#(F(O1!(<SLILS%(V$TA$:R5T$),/@'(U%T.RR<:)J:"NE+5KV6X%P:UP
M:[=\O]974BAK=UHO$]B\A)J=:I"PEE*N1MG6G%GL,DPR.+Q%@=R^B<T!O)&3
M:QUV\&)NY8N=5^#?/EML[.7KE9443:O;A5GX#R(]TFZQQ.24W+XU6?Q')*$D
M5JR^M"PV8SYLX9R^\6R[2W);+,:2G"5FRFP$G+E222*SDY@9>NW"S_+W1\KN
MXV"[U]^WJV>@QVM+PK>M4JC]L*5LQE-5699H:]1"$^'V9<Y)G$4NS4N#S:^=
M8S"D;0$1D,C8\A#I%7[88T:L!I;?1XS8;L4E0[L5TGPZ]G%P*ROQV14%/>';
M HA#4H;<,ZL6_P ,$LN,V-7X6QIG("8N _(TI"YC%P&F&SP8WF.@2T8DYL,>
M<D8OXR:.)$6BC?1*)NRPPT*-_5JL^_M^^KP[38EP4' ' ,;&G43KVTLN_+<V
M@:Q&;]H88!KR^7!Z8SN1QVQ85& Q:.@8X3@AZ3DH(/'#01XX)1T!1L5ONQ,$
MT%U%='SGX05N[)<"O;O7_P#1;<?X=G486M$7S&M2C8W!K"K>SXS*4+)L]"7L
MI34-4NZ.K;5Q+&\Q2D)./16I7Y"$-8F4(O(T_'DBQ R*)'C)<L^"[]*MP;+W
MYRW<6\)?HA#6HQB"J>5HLPJ=3)"6SJ][_?)CTZ*M&17/4B3?+NSU=\-X/8TJ
M,R 2UWWW:;Y<88/4'8[7+785TI<?'P+A23X.%*QL?X/D< < < < < < < <
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MBU?].< ??-QS\E?9']7BU?\ 3G /\SV:C><9QFJNR/FS^#/_ /#S:O\ \?\
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M![A?#\'K("PV*ZQ8!IH2).F-HUSO(]XJ7,$08<+??[_?4S,;@H. . . . .
M. . . . 8S]<NT]9]H1Y^0U<=C):-#E4UP_JLP!DYB5C3LB8& IT5A I1X0B
M$-G6X$F3KEZ?>(%I2 0^-%P@;;TF>@JU8MJOW(* )5.('/:0D\2F(A>@%($.
M3E $X-F8OLE,I]"(.J?-M$6[6 F8D2K.8%K6#N4SS>-QH<B1B1BP'SYH)5"V
MJ_A]5OB7QIJ[A]PI%EFP7Y.9':L-6;5^?"D2)SS,&>\A*"F0M9?=2,@) \6A
MFYAQNW=*2P')@A(0%?A5&ZXH7QX X X X X!X<E*$@P(D2#@7<G+-F__ +,
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M7K\BP>&A;]\BZ3>GW HVX'HD8T&70%+/O>E?$^.UG=%VG*(Y+GS'LJQ*Q0_
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M&BN*Q_&37OY\1/\ ?S#GCB-[U^1J^Q(^H?/CXT>=$RASD4GQIW\?GV1?</\
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MWS*_(6,_OX?_ #U/^(QORS@^*M_DC]L??=5=_P#H9A_^)&_][X^0L9_?P_\
MGJ?\0^6<'Q5O\D?MF0<4DPZ8QT5)A.CI,<7;Y<M='J::+K5/551'.%DTE5T]
M-O32V_!JKOCS>;/G_#YL8JO1GAZLZ,W%SINTG%MQV)ZFTGL?$C)4:L:]*%6%
M]&:NM)6=KM:TF^+C/2*_T62_N#S]G4Y\0^?'QH\Z/0AAN=?&OQP#OW\D[^8K
M?OULY#[GJ=YHKJH]N\#YJI^]XPD^2;VJ\N^CIG4CS6AF2*H\9/VHO=OZ<3_[
M&-YT[N1[FLF\BI\\B%YAOW$<H^9&L[DC+,ZLO),OG?\ 9?ZMJ/O/A?-8=5+M
M3EWG'_;5C-9)OBKR/^N!WK<T<28C[?*O/:&4Q]36 >^SL%S?'4O[08SSQB/<
MLO(OG>^J?D\.DJG,3S9!AS;[X"?M;NG/YRV5[C[-Y$]W/<KF_)X;WW#%]EN_
ML/XTNCF2A?.:R9')CY6K\V7JE].TG]W[WFTNI9VRS3R&G[Q$PF>?04>5?L,X
M1>;N(T5Q6/XR:]_/B)_OYASQQ&]Z_(U?8D?4/GQ\:/.B90YR*3XT[^/S[(ON
M'_@M2^_ZJ>2W<+W5Y3X^*]QQ1C\UWA7_ %734R+_ .=)D/' )8'PGO9H]&/J
MR5-]E&'.7=U'='G?G+%]+(FV"WGAN1I^RC*^^OQ&7/\ 1/8OV/,<Q>!W[@_*
ML/TL#WJ?1U/$E[+(<_G6Q AP"0[\EA]FS,?K5V?]@*@YH+JF=T5+S9ANFQ1*
M<EWI/EY^Q3.DWFO#+C@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#
M@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@%I;V_%%._\ !<_M3;E]
MEN_L-RG^EEGF&\L1R;YT<U[JU[#2OETS^56VD49=DA= ZUQD3',#WL;?]66%
MXN)KDML)VF&LM9R1^X7RHE(M8GB#!W+)6,?'6RTA0E_7*G7[*3T575#K=HV:
M>%5?3O9STU)_WE'K:MH*79$95&FZ">AV3PLL1UR\KZ2Q3H*%M+0T-%)?-T]-
MW4K=B_(4N2U1O: -#'CLX_B4GNQ_6K,&R"PMQ78Z -^M1FV6<DTEK1'>::VC
MM-@6S8K'BAG1DTB#_5?$*0:/8W,R].NU%B5!MZ,JKII6AUM06&E6TM+Y_77.
M-G%RMH._6[.,Y5ZS2>&E.T5.-!5=)RFJCJ?A*I..A\SK6@]34;N:^?JE%=,=
M"?B@@O\ A*G[P><B6:;_ ,3XZ]B)),NWEA_$?M2+GE?Z+)?W!Y^SJ<LH?/CX
MT>=%Z0PW.OC7XX!W[^2=_,5OWZV<A]SU.\T5U4>W>!\U4_>\82?)-[5>7?1T
MSJ1YK0S)%4>,G[47NW].)_\ 8QO.G=R/<UDWD5/GD0O,-^XCE'S(UG<D99G5
MEY)E\[_LO]6U'WGPOFL.JEVIR[SC_MJQFLDWQ5Y'_7 [UN:.),1]OE7GM#*8
M^IK /?9V"YOCJ7]H,9YXQ'N67D7SO?5/R>'253F)YL@PYM]\!/VMW3G\Y;*]
MQ]F\B>[GN5S?D\-[[AB^RW?V'\:71S)0OG-9,CDQ\K5^;+U2^G:3^[][S:74
ML[99IY#3]XB83//H*/*OV&<(O-W$:*XK'\9->_GQ$_W\PYXXC>]?D:OL2/J'
MSX^-'G1,H<Y%)\:=_'Y]D7W#_P %J7W_ %4\ENX7NKRGQ\5[CBC'YKO"O^JZ
M:F1?_.DR'C@$L#X3WLT>C'U9*F^RC#G+NZCNCSOSEB^ED3;!;SPW(T_91E??
M7XC+G^B>Q?L>8YB\#OW!^58?I8'O4^CJ>)+V60Y_.MB!#@$AWY+#[-F8_6KL
M_P"P%0<T%U3.Z*EYLPW38HE.2[TGR\_8IG2;S7AEQP!P!P!P!P!P!P!P!P!P
M!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P#"
MOK3VW>=@I]942?0V+P-G$BDVUAK1W+[%5L:;Q*(V9(:Z;V!O#9?1==Q76)&]
M@C4G\;5W9MKCP+PX,C4@>CS2F4LBK6S[KP;?@5/1]X6[8]LW16\[J:N8F&IO
MY*""$YKRZ9-9PY_/)2*3E>U?.!LEHJH5QQZ.0(I#IA(UVCLV,:-I[%AS1V^?
M[&] H:K?]?\ 9E;P4,)?$>N=]UXZ/=D+K&@FDF?5W -SS8"^>+#VA-34R)9^
MKKO6Z+A9OIZ+K._PB:"FWGTQCT?-G.<9K<YA5C<[RW"2FZ:KXC0<TE)Q[";N
MDVD]G&BSS#>6(Y-\Z.$1[XYRQ&2+3(ATOI9_+W 5>-N)4],;NI(O'7*:J3D
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M-YKPRXX X X X X X X X X X X X X X X X X X X X X X X X X X X
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M];R*>YF[N;*ZEW;W&^::OOF",-G>]J7+KHZA'_\ -[$8' )GL;_1S#^Y-?\
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M<?!+7J6"XTD[_P#DZ[I).]]22V)&'E6JR;<JDFWHK6^"+O%<22>M)<+;VLV
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M<4B*!%)^7;D) <!\'?\ BT93<%!P##*(U.^J7M-V<N.-5H6)1VW*HZMM5GH
MM'W1^;65&;*[/ISUTY^5LL%KIZPR&3RM%L[$WH\:A$6S&-P=$@I'THZU%>!+
MOOUV_P"RUW5Z%SAYV#G=ASSK1+^O8R+QVRZ[I@2AO2JL#S I7:PN:RR3R$U
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M;=GW3YQY3'H*1,\NWEA_$?M2-H97^BR7]P>?LZG(U#Y\?&CSHO2&&YU\:_'
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M]G,&D-%Q@;)71Q>*'!57X%?6O3P?S[Q:;N'6-$2:'TO6TM.6/.8Q,6LH94[
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MY*I*G4JPAUFEHN%*3C*\[)J3T9M+0:[&S?9*WE;^)-;ZO8=]2+$PUR.!2T3
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M<8YC<RP$,"Z*A4E/KJJ7TDE;0T+6MQZ7J+_+\;+&*JY0C#K;@EHMN^DI;;^
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M<'CZN)QCI:494NM7[&&C><8P4Y1OV2BYZ3BG9J+2:3U&SSF!,T:Z?$&9'9?
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M+_AZG[Q6^V8&SXWZO@9;=!O%D[Q6;WBZ?5S,;/!D8G.^S-(1"3#T:XK]@J]
MR*R(X)+-4GS&.H/6:B[%VNEHY:+HN$-ML*(J:*:Z[8Q6>[F\IP^29O7I4)JI
M1RW'5*;=>K)*<,-4E%M.=G9I:GJ?"7.#7_EX;6_IZ7%P3CWB2$YSL3@YN_*E
M_9J1KZT57?8NU.;"ZF?='/S;B>EPQB,ZWI#EX>Q4([OF_B+#@$QM1OXE*?\
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MKC)6:U*^M/@UFJ[^3;>%Q^3RR/TE$/\ (<D_X];JOTK/]VP?].67R7@?S/\
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M!MVBDKMMOA;98RRS!2;E*E=R;;>G/6V[M_.XRG_Y-MX7'Y/+(_240_R'/O\
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M ,=1?PDY@[KB7K^)<V?&_5\#"+M'X0?5'NG*8W->SI"V+6D\1 *1>.%2,L!
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M[//?1]<-E_BQJU^,B[OT-/6B3WX9XOZ.OPJV_HX\P%2\ H'6JJOTEVT_TK>
MZ3S=59?>;:P^/:R[=9PQW&+K;23 [!G95<:HH/64R]SNHQWW:;YV0VV3R%WL
MOJXCT@L"@L;CVD2CL+B8"*).MGR<9"QP.+CR;W=_@KN\T"L6: W1UN4UU);.
M-6V%=G^,/,[Y<8PIP#Z4(=$6TH>SAM%HXWFA,6@#)2] &,2E! *U5U7;"'I]
M-KJ6=BVRVFBR ]=VHT15TU432UWUQG %1\ H*3U76$W*L3LSKB!2XX+12;C#
M,GA\>/E1S=NY4>((,2)4<[=M$47:RSI))NLGHFY547TUPKOMMD+OC/;$0^)
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M-_@T_@8ZKMN(2^#T^#9Z^CKY@O\ $\UO2%+,Q34$TJ"KVH1E(6TN9!F\ BB
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MCHZ\ZT^3\@/J,T'<]!)>"R3;OQM;%;OKAX'QZJ:G/?&X(7/W0<J?HWLSBF[
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MWHJ#-K&E$B/S8])1BMF!9!((I(8*,N&%-+Q@S2397#D\""\H$8LRBO?6N"7
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M2F<&EY2,3B^ZC!S[XWM"/R4!,1Z<A $RC ^50DK)VX8O'>KA[C153.0_*?\
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MC&,8QC'FX*']< < < < < < < < < < < < < < < < < < < < < < < <
%< < _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>g713200g86o18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g86o18.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X7C0:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^9S@V;S$X/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@
M3F%M93H@(" @(" @(" @(" @("!S=&UP7S$Q-F$N86DF(WA!.U5S97)N86UE
M.B @(" @(" @(" @(" @<G(R.38T,3DF(WA!.TQO8V%L(%1I;64Z(" @(" @
M(" @(" @(#(Q+4IU;"TR,#$Y(#$R.C4U.C$W)B-X03M%4U0@5&EM93H@(" @
M(" @(" @(" @(#(Q+4IU;"TR,#$Y(# S.C(U.C$W)B-X03M38W)I<'0@5F5R
M<VEO;CH@(" @(" @(" R+C4F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @
M(#$V+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!"87(@0VAA<G0F
M(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@
M4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R
M('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E
M('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[)B-X03M4:6UE<RU2;VUA
M;B8C>$$[5&EM97,M0F]L9"8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M93H@
M(" @(" @(" @(" @("!S=&UP7S$Q.&$N86DF(WA!.U5S97)N86UE.B @(" @
M(" @(" @(" @<G(R.38T,3DF(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @
M(#(Q+4IU;"TR,#$Y(#$S.C,P.C X)B-X03M%4U0@5&EM93H@(" @(" @(" @
M(" @(#(Q+4IU;"TR,#$Y(# T.C P.C X)B-X03M38W)I<'0@5F5R<VEO;CH@
M(" @(" @(" R+C4F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N
M,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!"87(@0VAA<G0F(WA!.R8C
M>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E
M(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E
M<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E
M;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[)B-X03M4:6UE<RU2;VUA;B8C>$$[
M5&EM97,M0F]L9"8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M93H@(" @(" @
M(" @(" @("!S=&UP7S$Q.&$N86DF(WA!.U5S97)N86UE.B @(" @(" @(" @
M(" @<G(R.38T,3DF(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @(#(Q+4IU
M;"TR,#$Y(#$S.C,Q.C4S)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @(#(Q
M+4IU;"TR,#$Y(# T.C Q.C4S)B-X03M38W)I<'0@5F5R<VEO;CH@(" @(" @
M(" R+C4F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N,"8C>$$[
M1W)A<&AI8R!T>7!E.B @(" @(" @("!"87(@0VAA<G0F(WA!.R8C>$$[*BHJ
M5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R
M92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ
M)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@
M=&AE(&1O8W5M96YT.B8C>$$[)B-X03M4:6UE<RU2;VUA;B8C>$$[5&EM97,M
M0F]L9"8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M93H@(" @(" @(" @(" @
M("!S=&UP7S$Q.&$N86DF(WA!.U5S97)N86UE.B @(" @(" @(" @(" @<G(R
M.38T,3DF(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @(#(Q+4IU;"TR,#$Y
M(#$S.C,X.C4X)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @(#(Q+4IU;"TR
M,#$Y(# T.C X.C4X)B-X03M38W)I<'0@5F5R<VEO;CH@(" @(" @(" R+C4F
M(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N,"8C>$$[1W)A<&AI
M8R!T>7!E.B @(" @(" @("!"87(@0VAA<G0F(WA!.R8C>$$[*BHJ5&AE('!R
M969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU
M86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF
M(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O
M8W5M96YT.B8C>$$[)B-X03M4:6UE<RU2;VUA;B8C>$$[5&EM97,M0F]L9"8C
M>$$[07)I86Q-5"8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M93H@(" @(" @
M(" @(" @("!S=&UP7S$Q.&(N86DF(WA!.U5S97)N86UE.B @(" @(" @(" @
M(" @<G(R.38T,3DF(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @(#(Q+4IU
M;"TR,#$Y(#$S.C0W.C0S)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @(#(Q
M+4IU;"TR,#$Y(# T.C$W.C0S)B-X03M38W)I<'0@5F5R<VEO;CH@(" @(" @
M(" R+C4F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N,"8C>$$[
M1W)A<&AI8R!T>7!E.B @(" @(" @("!"87(@0VAA<G0F(WA!.R8C>$$[*BHJ
M5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R
M92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ
M)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@
M=&AE(&1O8W5M96YT.B8C>$$[)B-X03M!<FEA;$U4)B-X03M4:6UE<RU2;VUA
M;B8C>$$[5&EM97,M0F]L9"8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M93H@
M(" @(" @(" @(" @("!G.#9O,3@N86DF(WA!.U5S97)N86UE.B @(" @(" @
M(" @(" @<G(R.34U-C0F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @(#(Q
M+4IU;"TR,#$Y(#$X.C$V.C(Y)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @
M(#(Q+4IU;"TR,#$Y(# X.C0V.C(Y)B-X03M38W)I<'0@5F5R<VEO;CH@(" @
M(" @(" R+C4F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N,"8C
M>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!"87(@0VAA<G0F(WA!.R8C>$$[
M*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N
M<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N
M*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@
M:6X@=&AE(&1O8W5M96YT.B8C>$$[)B-X03M!<FEA;$U4)B-X03M4:6UE<RU2
M;VUA;B8C>$$[5&EM97,M0F]L9"8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M
M93H@(" @(" @(" @(" @("!G.#9O,3@N86DF(WA!.U5S97)N86UE.B @(" @
M(" @(" @(" @<G(R.38S-#<F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @
M(#(R+4IU;"TR,#$Y(# U.C$T.C4Y)B-X03M%4U0@5&EM93H@(" @(" @(" @
M(" @(#(Q+4IU;"TR,#$Y(#$Y.C0T.C4Y)B-X03M38W)I<'0@5F5R<VEO;CH@
M(" @(" @(" R+C4F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N
M,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!"87(@0VAA<G0F(WA!.R8C
M>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E
M(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E
M<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E
M;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[)B-X03M!<FEA;$U4)B-X03M4:6UE
M<RU2;VUA;B8C>$$[5&EM97,M0F]L9"8C>$$[)B-X03LM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.SPO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z9&5S
M8W)I<'1I;VX^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX
M;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @
M('AM;&YS.GAM<$=);6<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G
M+VEM9R\B/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#$Y+3 W+3(R
M5# U.C$U.C W*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @(" @(" \
M>&UP.DUO9&EF>41A=&4^,C Q.2TP-RTR,E0P-3HQ-3HP-RLP-3HS,#PO>&UP
M.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#$Y+3 W
M+3(R5# U.C$U.C V*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @
M/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O
M=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z5&AU;6)N86EL
M<SX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \>&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z=VED=&@^"B @(" @(" @
M(" @(" @(" @(#QX;7!'26UG.FAE:6=H=#XQ,38\+WAM<$=);6<Z:&5I9VAT
M/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIF;W)M870^2E!%1SPO>&UP
M1TEM9SIF;W)M870^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FEM86=E
M/B\Y:B\T04%14VM:2E)G04)!9T5!4T%"24%!1"\W44%S54=H=F1'.7IA1SEW
M241-=4U!0311:VQ.02LP04%!04%!0D%!4T%!04%!14$F(WA!.T%10DE!04%!
M05%!0B\K-$%$:T9K8C)*;$%'5$%!04%!068O8D%)44%"9U%%0D%514)G549"
M9VM'0E%92D-W9T="9V=,1$%O2T-W;TLF(WA!.T1"04U$07=-1$%W441!-%!%
M03A/1$)-5$9"451%>'=B1WAS8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P645"
M05E':%521E)O9DAX.&8F(WA!.TAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9B\X04%%46=!9$%%
M04%W15(F(WA!.T%!25)!44U2068O14%A24%!04%(05%%0D%114%!04%!04%!
M04%!449!=TE'05%!2$-!:TM#=T5!06=)1$%114)!445!04%!04%!04$F(WA!
M.T%104-!=U%&0F=C24-1;TQ%04%#05%-1$%G44-"9V-$0D%)1T%N34)!9TU2
M0D%!1DE227A15D5'13)%:6-9155-<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II
M.$-2>6=V16Q1>E)4:W%+>5DS4$-.55%N:S9/>DYH9%5:2%1$,'5)24IO34I#
M:&=::$I21E)Q4S!6=$Y62T)R>30O4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY
M5UHR:'!A;71S8E<U=EDS4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.
M:F\K0VLU4U9L<&59;5HF(WA!.W%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R839V
M;U)!04E#05%)1$)1545"45E%0T%-1&)114%!:$5$0D-%4TU514954DYH26=:
M>&=:17DF(WA!.V]B2'=&34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,
M0T(S4%-.94I%9WAD56MW9TI#:&=:2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!
M.S K4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D<Q=6(R
M4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\F(WA!.RM$;$I75VPU
M:5IM<'5C;EHV9FMQ3VMP86%N<4MM<7$V>71R<2MV+V%!07=$05%!0T5135)!
M1#A!.54T<6=T53%V4G1):6IM,5<O='0F(WA!.U!I;6-24E-853!C2W9)45-%
M57E&45=O<$Y":7%+831G5V1,9'!%13AI<SAC2EE",E9#;V1L6'%1<&1A;G15
M94]+<F)A-W1B<$=K=' F(WA!.V\U,%-2-%AE3F<T16M4;4]20U9*;WE/<%9H
M,DEP:7%R:7%$,5!7=$<P<4]+5%9,*S-S234U0D1!.3%+:TMV2W=*5TY#-5AK
M>&]A06(F(WA!.S1Q=F@Q4%1:-4E9;V)U1U=7-6@K=%<V2DER3DI"5E(V<4%'
M<DI6,2M)8F)J>'A65VEU24I8;%-+4DI(9V8P-6Q69U-J.%$O1F=0<VXF(WA!
M.VDV=%$Y:4U66#1Q9TY..'=A1'%K,#A';39L83,P.7)X*W-X5S X8WIX8W$X
M9E561UER6&EA5CA-5EE4969L<&-F<&%#4WHQ-D-X=F8F(WA!.S!K*W-O-C)T
M8GDU5DQL-51$8WE'8V5V0D5L-#!3,%)E24MB+T%!,$MR1U4O3$11=$LQ;E),
M*S8X-#9B0DQO,31K6$8W94='4S5U55<F(WA!.S!D:W5*1&,X,G584S)$<W=O
M>#4W9W)53U9E,31&9&EQ0S%F6$Y&,&$R5S8Q:E5,8E1B5FY%87HS8S!C15IC
M9VM+1VM+:FM1<$Y-5E8F(WA!.TQN53E.=%E:<')M-VAG:'0T>$YC4U-32VEX
M>$Y53$DU66=+<#1M:$\R,DMO;D9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T8F(WA!.UA9<6AT43%',# K,DXQ9'-59T1X>&QG<E!2<%A%83=+1TY/
M5$1F=&EQ;'!M=#9B<6-L-4A:5&5Q.6A/,7)D3%%Q5FQ4-U,W9U8K94LF(WA!
M.V\W1E=!969.42],;E=*8F)44$UL,TUI851D;3=K=&91;455:DI#,$)76FI#
M>71#>3-*6#1705IV:'%30TU665<S-5-F:S5O5VYZ6#<F(WA!.S9Z<5IT.5!U
M-4Q#.'9%26YK5S1C46,T<%AH=&UE:4=%8U0P:F1M2VQ8-&Q65V$O;'IE95%F
M3&UM-F0U3C!053=I-EIP8FQB3DQY3U$F(WA!.U1.245&-4]R34E954A"8F=6
M<4)1+T0Y;T59<7HW1E=.969025=K*V1D371T3S%/-75R84,Q=4)D23%M-DDU
M8U)343!9=6MN=SA*;38F(WA!.UEQ.'5K+TM,.'$Y43 R0SES+TU'<E9T27)A
M3S-U>4,T:FMV:$-L<5HP1G9'>&M*36)-1TMU15EC:7-95&E64F8U869L2"M8
M;'I%3E8F(WA!.S!N5W(W535,3%5)6EI:>F)X,G-0<C)K<5AA2D-K='5(5THO
M9TPK:R]&*V\W54-V87E!45%E:#)/2W9,.5DO-7@V.&]A=CE51C-Q3W F(WA!
M.SAB1S)T<D<R150R:V),83)F35)1*V]T<TI#=$I+3E9Q=%)A;7%J1E5R,&XX
M:E!Y,SAU*UHY26ET.5@Q3F14=$4K<U=L=DEB9&]85TLF(WA!.V(V>%=C:3%%
M8DYY5W$X,C554W$O,V165G1B-5 O3&XX<615,$XO2S)H-C=Q3V\R;')C2%9,
M:FMY8VU3+W-"6G%P;$YS:2MK.7-X0S@F(WA!.TM%2&QV5F%+<7(V=B]W030P
M955,=3!J=$Q'+W5R0S-E4W=A*U5,0R]Q<G Q<DIA<7E54TU2>E-,35AE4VI$
M;G9X,WA7,W)&:%IX5U8F(WA!.VIB,F-22FET;VMH:DQ5<GAJ54M+,$%&841W
M>%9)9E!Q95AR;E-)<DA7-VEE,V=L=4ER:44R,%144TY*67E,9'%Q<7-5.6$K
M:G5V1W(F(WA!.T-O1TMV3'(O05!,+T%02F%X=F),5' Y9C%'2S8K<$Q:47A+
M1FQ-:U=Q3&5R0WI/3%8O:F1B<595,T<T4456235+=F1S5F1I<G-69&DF(WA!
M.W)S5F1I<G-69&ER<U9D:7)S5F1I<6IE,VM&;%IZ,VQW4W1V8E)T3$UY<7IK
M26=,35%Q9W-D:#!!>%91<SE9<W)Y.'5,4T1M6DQE3T<F(WA!.U8R6D=60VQW
M0WE&5TDS*WEA*T=+<4]U-FQ9,FMC8U8U0CE9:FU*4$-I<W19>7)#;V(S;V-N
M0T9S6E-P0RM88GI2;6UN=#E.<VA:;54F(WA!.W1C5&Q65E$W:VA3>F-E<DAB
M1$M"0TEZ=$XU64I89FMT>$I%2V9:45)K9CA!1$EX>71M.$EM.'=E53ED,5I6
M=C=5,U$Q5U<Y13@X5W0F(WA!.U!.1WAG:DDU5S9*17-B2DE,84U*=S0P66)#
M<4-P5C$Y<5AK:51Y>F%4=' X<TME630R,64V=%@Q2V5Z=4=M5E9C<#9Q=W$X
M<T%%;7<F(WA!.U9V5#E864QY-4UQ<G1/.'<K5G),>F9P56EA5#9';VI56DQ+
M1R]F56UL5TEY<6)E4S1!83-D2%=A2S-5:&HY<&<Y4T=1;&Q8=6XQ4V8F(WA!
M.R]L=&TK-D@O04MP-$9D.55N+S5B6G9U:"]W0W%E2W9!.4LQ;GE21G!M=5@Q
M<' V.#=/4S)J85-Z,6QP,75'<W!963=F;&-#245!2T8F(WA!.V50-UA,9V$Y
M2S166F0K4V-N;&TY8GI(2F]U;5-E6&114SA23E1S;$Q-5"LW-5)-=VUT;U5I
M4'A/1$A(56)6<6%G-$9E;F962B]W1&PF(WA!.W1M*S9(+W%N:7)V<6LO.$%Y
M,GIF9$0O,51X5C5Z-7DQ5%$Q.#-W,D]P=R]72C1)-&)5-F<Q>$9!,%9V<6-N
M0U)0:&AR>5!P5C1&=FDF(WA!.U%.=4YW4W%195%T53AK5W9N<3)S=$8P;38P
M*U,U:&YS8F96-4AK:UHO4VMA27=/<VM$+T55,#E$>5IT=4I&9G,K;W$Y;"MQ
M5"]W1$PF(WA!.V)..3!0+U9007)V<6LO.$%Y,GIF9$0O,51X5FA(-6]Z-DI9
M,F1K*W509#-53"]7,6E3,W5$8GEG+U4U4R]&6491=4=J-4E46#1E5F,F(WA!
M.TMS13@U-G0U3&U7,6LQ4%-P9DU&9S!&<58Q1#8W3F,O5C1B=4<T33EE5G4P
M,%AP:4PT:%%--FUT3V%Q:%9E,U<Y;S-O4BMJ951#3&DF(WA!.W9P:FI%2TQ4
M8EEX,3991E)536)X<5$P<E-M=&54:%%F;#A#<4U66#1Q-T9867$W1EA9<3=&
M6%EQ-T982' T*S)+<V0P:GIV<#)Q870F(WA!.V)A6D1B>GAZ,T9I3E%,4T)/
M36%S-5%24'AD=C-N=VLW5D9+8C<T<6UE=#,Q=EHR4F$T:#EE1UDK:3A7,4-'
M53%"<C)O36Q#3FQJ2U8F(WA!.TIF;W5S85I,96TS=$Q)5WIZ,6%2,4-I<%9D
M<3!'*S-42E-X,$Q21V1L02MF3'DP9VLP,DMA6DDU2GI+<TM-=T)C9TE4>$(V
M-4Q$,5DF(WA!.S55=B]!0R\Q:E-T43%/5#9J9'A83F)8,5(V8FAQ;WIQ03(S
M635,2V1K67AU:5!Z07-04$4W<69,3GAC=VU3,613,74Q='AJ;E,T9V0F(WA!
M.UA:3&AO*UA/151)0413=EAJ<W=X,C5)8E0O;&(X3VE85'994S-E<E).1W1P
M1%!00W%V5%1'6B]584LU:58Q3CA&57-V1')S;UA91E8F(WA!.T15-V8X-5<Q
M2RMA,'0W=4]Y;G19:F%P1&175&5H8R]50S!I>&5T2GE)*W0P56U5<T0R;V]Q
M5E9S9#DK96-/;C)H+W<X;'IC06HV,FLF(WA!.W0S1TI3=G)566=X,S!56$PP
M<3A13G5L5W%3;U9E:F%(85@P,FDR175R;SEV<3!L=D4R;U%25'EM3DQG;T1+
M:55L:RM%4%5$-&HX>F<F(WA!.U9'+V\K1"ME8B]K9DXO>EAI<G8P9D(O4$XO
M>5!M+S5R>%8S-E!G+VYM+S5(>F8X04YE2W4O4CA(.#@S+T%#4&TO=T-A.%9D
M*VHT4#4F(WA!.S5V.$%K9DXO>EAI<G8P9D(O4$XO>5!M+S5R>%8S-E!G+VYM
M+S5(>F8X,31Q-SE(=V9Z>F8X:C5V*V$X5F0K:C10-35V*U(X,R].94LF(WA!
M.W4O4CA(.#@S+TDK8B]M=D989F\K1"ME8B]K9DXO=T$Q-'$W.4AW9GIZ9CA!
M22MB+T%*<GA65VAH4TI3<6QI0V$O1S=/9G9C<V-66#0F(WA!.W$W1EA9<3=&
M6%EQ-T9867%X-C X>F%L3'%D:EE485!01CEA:W96;G5H>6%'1F)75U-/07,U
M4F%M-%=0;79994IQ2W%P=G%L-F)+=VPF(WA!.W5G;DUX.&9H2G!8:W=8<CE/
M4VE,3DEK84-35U!M:WHS<TU0,5)%37)#4&U',T%*03A-<T]+9S%J2EI7+VU&
M<6QL<#)J,CAT,B]"2F(F(WA!.W!):V]#,5=-8VIF<V<Y1E5K*W=W66IU;DIY
M67HU33AZ84AE96%O=%!T8FM46%$K<TM654U25T%&6D)Y<%0T5S)Y>DED;4=-
M8G Q*UDF(WA!.VUK5T8Y3'!K,7EH85,S.68P;41-<$A0,#9J-%-+-W%P*UE'
M47=J;7EY;$%F;'HU9C S4SE7;6%Z5C%R86U-2S!J=6]54V@O:$1%,'$F(WA!
M.WIK;DI:4G-J1V0S;U=9-V,W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ>"LX=F8F(WA!.TXP9#9)-$Q3
M3U<S8E4T;S%L5E9O3D]-35)L9"M5;U!-4W1)05%V8C=0:7%N1V]81#(Y;%!/
M9T)E2D-Y:'5L44\Y2UE9:7EG;6=X:% F(WA!.T]'<&QG1$9$46M$-TPO.$%.
M5U@K14=N>$-M2&XR.6YS9DMD.61144<U;&HY3&I#=&0K57E+5U!%36%+1'E.
M0C!'5EDK8F)0:S@W.'8F(WA!.V5:.5)M.#1A9G!Z84QD43(X:S!982MC2#!L
M<D-:5'5"+T]05"MF,%9V:V1M;4DS96=E97)3,75T2F=3-6A36D5U56169%%W
M1$MR,$DF(WA!.W(S>7)&>F)-;DIJ,VLO4CE*='9-14TY=EIW=WI"6D(V:V-A
M<3-X2G9U0C=:6FM'>D1(>E-Z.#DO>D5I.&YF;U Q3$9R,S8Y.6%P>&LF(WA!
M.T5F2#!F4CA6871F57E7;'@X5G-S<54O:VHK87-(;3=Z6&0V8DAP>E=::'-*
M3&HQ5VQ%9TE784I/3D%Q+S<X>65P>&--8C@R3U!M.70F(WA!.WI"8C-9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M56PQ4%%B,C=N=C5)3E)L=#%V64QE1D4F(WA!.U9P4#-,,C=Y=5I)*TQQ05I0
M5597;TYW=3EE>7%C4VMI2GE.:49.4'5X0W905')M;V=63C=*5&8O04A993)X
M-SES>2M!9'IJ8U):6'(F(WA!.T5T-2]H1S9L=#%%,34Y4UIO5F,P1'DK;E91
M>#(V=#%Z2$@Q3C4U4$MR5RLX-4YD,G%V67A,8CA91$Y+4T]:6G)G3$U/068T
M3TU"-6HF(WA!.S=7.5(T6FLW=$=Z,69Z8E!"8BM8-W%A95)9;VPY4&Q)-T)6
M1EI&07%4=#%Z2'AF53-4-4U(,%!7=$AL,6UY:FIV-V0U2&U255):54HF(WA!
M.TI,0V=!0GI);41285EJ9%$O=T-C:V9-=71E6'9),6IE-E!C+U9B;515-&]8
M:S12>59J83-N66EK:75/<41T:V1*14=7+V,R-654>3,F(WA!.SAI=GI(.#4V
M,2M:;6UA9'%E;R]73$]63&MY4F5J06Q3;'4W3#A34G$S565/6E=P>'A%0U$Q
M-"MA9"\X04]92"]!17E8+V)W+S=&8W(F(WA!.S!06#1-<W92:FXO3THS+VMX
M9%(O-UI%,R]55F):6G)F;TAV4FDU=G)$3E<S=7A6,DMU>%8R2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+=7@F(WA!.U8R2W5X5C)+;V4U,4Q4-U=72T<U=5DT2EIW
M-6A34G=P8U)J:S5513<X4C%X5F1A6&QR95<P9'IA5$I08GEI<V-S6D1+4E=M
M>$AV:7$F(WA!.U,K66).8G5D>D1R07-:4'%D>&%.1#9P0S@U,FE:6E-O9$M-
M9VE903!R4FI1:DI#2E%313 P85 P9$IT3&,S6#$U-V5'3T=3-W)Y36HF(WA!
M.WAO1EIY871U>$94=F=)4T,X<S%F>EIO9'9C,S!S:WIC24QU83)K2WAY3E-7
M37-76%I46#="03AC>6=D;D=),V5K95<W<4<W.'-79#$F(WA!.T-A=WHR+W%2
M:S=':D%K8EIJ>2MP=FIY94\S4#5D-E9C5V1V85!C>FE+,EHR:G V9DMR.%)U
M94AG9RMF6')M5'=T2$4Y6#$O53=84G8F(WA!.TEL,7%&>4=.=%HR26MK0T%&
M=4MO3V<K15I205A/=DYU4#!V14E0>C,X;%!01V=I=F%S=T$O9$HS4"]'5$TT
M-$I.065L+W=$3U$O.$$F(WA!.S5*,WI"+S!:+W=$56)";4IP9C=W9FIO,S5/
M5#56+TMV+W=!;58U6"]!3S)N82\X04HU8S)E9C9$-VUM2$XY1"]!4$]74"]K
M=71/+S<F(WA!.V$X4"]!1D,S3UE':2MS*S5T>3AN:F8X07IJ:"\U3C-34"M-
M9#,O,4136FPV=BLW3%AJ-7914#A!;DU$+T%+6DPO=#1F.6EU56%(<C@F(WA!
M.T=76&]X>B]N13<O>5EU;R\Y<VEB+W%+='-S,78P1#-O>&,S,6AM<F(S67$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E4F(WA!.W$X=V%V96%:
M1EIV83),,WAU8G%/,VQ74&Q73TYW>$UH-'$R=TMG8C!&5#%X5E8P4RMV<C(P
M:VYU-V-7>D-E84]&0GIQ,%55:&I2>4@F(WA!.U933V9(:U!A:'A62W9-:F58
M6G12="\P;&)Z4S-.;6MG9V5.:6]68FA12$=Z<E@W22M637-J:DI$0U5W16(U
M5B]215=L4C)/;%%V0EHF(WA!.S)9.4]/3U1C:7!,9&549'IK6E))5$=6=E!F
M3B]M+U0W3'I$<3A%:U5H97AK9U=3;D%C=EA25RM#<D-V1E=Q9G X379G9&UM
M63-:>C4F(WA!.T-V;S<W>35&9%)O,&%V2DE/1# U07%X53$T;&@Q6'AY<DQZ
M8F-F2F=M<#)F;&AT474O5FIS>7AU2EI(1&5N=DDW14UX<C-09DUI360F(WA!
M.VUK,V)0=$YE2S,X;4LY;'=73T<P:TU(0VA18T9A;$MB9'-X-40Q3CAE5#0X
M+W=#5C!F;48O=T%T.&8X07E):"\U<'IB94)&>')F5%@F(WA!.VY#-VYV4'E#
M=3=U-&)L4&,V1$9,2W=!1EAE0D=9,$=W,T]A,T=0,W9X8VLX;GAN6F8W,E%F
M.%I%+W=#2D1.=654:FIM*WIF*V-H+R\F(WA!.T%#5'9M1"]O>B\V:EE-,4=L
M+W9"*T]J9FLU4&Q8.'$O+TIL958O.$%T<#)V+THU8S)E9C9$-VUM2$XY1"]W
M1$]74#A!-4QR5'8K,G8F(WA!.T0O,4,S3UE':2MS*S5T>3AN:F8O041J:"]W
M0U1D,&HO04EX,V8O54Y*;5AQ+W=#-TQ8:C5S*R\U>2ML:6%4>7)'<G%:12MV
M;#!"0EHF(WA!.U$S,6%L4C)R5$M.1#$K1$Q,,%DU+W=!-'!3>%(O;4YF:5(Q
M479P37E*>4E(2FIC,C5O2SE4=&QM="MJ-&]X8S,Q;&UR8C-9<3=&6%DF(WA!
M.W$W1EA9<3=&6%EQ-T9867$W1E9'.79,97ES-3<R-6)H8E<P8GI44%%N:6MA
M;&U.0E4W05EQ9TY-.#!A4'%D-SE4<S5796-7-EA7-DTF(WA!.V\Y3U$P1S=!
M9D50,F@R<4LT<74X>6%D8V%L;S Y:F)8<'-*-6I(=W5L2D)8:$ER<U!H6D0X
M4W%63D0S>%9$*U@Y1W9.4'9D4VYU9%0F(WA!.V4O1C@X8VM55&MK4F-&-&YI
M0WI!5C(V061-2E9$*V%0334P:3AT8F-447AV8V\W4G!+4GEB:'4S2&-D0C%Y
M>DA!2&TQ>FM1<&54+T\F(WA!.T5(;4,T=6\T8G$S=69Q>7%:0D%W2E%S9&<Q
M0V%6;V-:>$$U3$-24$YJ2&XK1'I%,VU7-&MS6FPK<4=X0U)18V=J9E=A<U$S
M26\Y05(F(WA!.WA&9"]L:SAD,'=Y8S S+TMI,S$K1%,Y4517-VA,;6,S4DYU
M-E5Q24]!0VAU2V]/5E%X,DAF25I794XU,RM92#5X*U9.1C@T-G!P9#,F(WA!
M.UHS<VQZ87EQ:W)X4G=S:$E25T9#,'%N=C1:;#1S2DU15W5F3C96*U4O;7)4
M=DTO;$UA;G X8S!6=CE9;&DT>G%Q=GE7:$IO:D]+9D8F(WA!.S0U:F%I2FI+
M;3-(>69&,VTO=T0U4WI7=BM9*S8O=T-4>EIT;V931VE83CEE+VQ4+T%/4U P
M=CA!-UHP+S8U33%78BLY4'9C:5!*.%<F(WA!.UIU2$=F6FYM4"\Q;F54+W=(
M65 K;UI-,450-S,T=5-E5#0U<W8Y-TE0*TUI9CA31V)9.&Y(2$XY9"\X04]3
M3W4R.$AK4G9,4W=4,T<F(WA!.W$K635)-'1.:6=4,4]4,C%Z0DMY<T%E5E=8
M6F5)3E1M<3!K9E9F44XK5&LK679),# R:F5:9$@X>5A6<&-.<%=M,V-&,V-4
M4E)L=C,F(WA!.V-5=T1C4V5+;F-5-CEC,D]48T=0571-9'0S=&8O3U17<V%H
M<3!M:2M8<F532TQ42G)/6%A+>7%W:TUL=$1-,T5-=DQR1GE!1DMC=7 F(WA!
M.T%Z1#!C44Q06&LR6DAL=FQ#,CAY951.63!F>E9A3D%885='05)3<2].4F5R
M26I";VU#34M)4'1D1'E5:75:3U%I64U735%2=7EZ+VXF(WA!.TDK=T9R*UE6
M+V4V;%I30S(Q3WIT-#E*=F%(:4I92&A--TQ2,$1C66EY:T=V,F@X>%AP1&-.
M=6EC;DY+=GEX:# W5G9Z3C!"9DQE;5,F(WA!.V-,0SDK=5AK=U9U4S)Q<D-N
M2G=:2DM+<W!9,2]Y:&MS,6E"-&ES84HR9EEU86QU9&ER<U9D:7)S5F1I<G-6
M9&EQ5%<O;D113&EA2T<F(WA!.T=D;65A-VLP.5 S8V=8-GA&2#9R3'E+,"MX
M=40S-V0X5E1N1E=,8419*V8T8G)4:G$Q.6)45VM55G=U;W%G+V53>D]Y;48Q
M25)2>%4F(WA!.T$W9D0Q,W)I<60V,60R9'1P.&I8:U%M='!"-E5S4D%+<W-G
M-&Q71&)%2'!K;WAS;VMA4V929%,X=2]P0T]+>'-&=#=H:T9U2D96058F(WA!
M.U)2>4-61SE/;3-Y>6-S6D%90UE*45 U;#9N8S)%1VQE:F%08W)C6%%H;5I/
M4CE.1T<W;FER9EHV-#1L>4I(*U<O;4,K,41Z3$QB5&$F(WA!.V1*8G=*8GEU
M;#1E9G!/56TY4&=/84EW3D)8-&=+:F-:4$ED;4]-8G0O;7AR2&LW5#EB,' Y
M8W9%=&(R1T=2-U1K>G%E3'-!>"M(63<F(WA!.V]/=FAH=U%*1WEC:6HK5%8W
M-4EK,4Q5;W9,=#1T,6-V1$<Y,F5C:VIL67IX5FU-;BMT,3<T-31'25A'.'DO
M4'HX>&9/5V@O;5!D-F8F(WA!.W!E;V96-TY)3&1K:3E'0C9&;W=4.%1O>F1F
M9DUR4S0T;49L:FLU<S8O=T-C6B].=FU$>DAP5W5387ID+U=N=#4T5FA0<'AX
M.%%Y350F(WA!.R]D<6QE;F9+3EI!4DEP;FDU4$(O>G@O.&UV-6HO=T-9;&8X
M06LP;5IU;B]U=S%Z-79E=BMC8V12=#E.+THR-C%'-7(Y5W-R:3AU2G4F(WA!
M.TEQ,T-+3EAA9S=M:35G-G-8:W!T:'EF3D]T861Q97%E64Y1=3=+>75*23<R
M85,X=#$Y3G5B451Y:WAU1B]W07)K3VUB1TUG04QA4T,F(WA!.U,K:%!,;FYM
M5%1F*V-D.5$O4C!B4F%X-6)I1FAE>%A56D%785=C2S8X86=M:5,O9FU"4$AE
M55AY3&-$-EAH;&XK5V5T6%9Z9#(V6$XF(WA!.W-R5UEJ37)->F=(,4]8,F9H
M,W V6C,V9$0P3UIP>D)R.$UV53EE,7)53F,O-7@R,$,V,4="<FE'=S%31S-U
M-#=25U4O57).6EEJ>6\F(WA!.V1V9U5!<V4K63!9:4]5,3-->6)I.'5T-R]W
M1$QV.4@S>5,R1GDK;WEV2CE194]Q;V=-64-B1U$Y6DXK:&]02$UM<#-Z65A&
M-C,K668F(WA!.VQR5B\K5DEE5"]-9VY.;F4K5DQE1UHW96%-;59P3&E70TI.
M;C9&1S-)66(U:31P:GA:1"MC>6PY3G9&9DMY-FIR;7!74&QA2V%+0TPF(WA!
M.U9P-').6FUI5FI(-G-Q8F=G0G%&;$)903<U;51Q231U-7)"2C)E*V8X-5(V
M0G Y=#5$,%,O84I8,4\R=31.4$8T2VAV42MR>G-Y57(F(WA!.U-H9$%C=V1(
M26U22%)T>3AN:V8U1F%6<"MT+VUF<$YJ<7-)=DQ1<D\U:6M*2351=T\X9E%J
M-TQ+0TUY=%-41T))83AF3C98+T%--6<F(WA!.V8Y36PO=T)V1"]S5GI(,%!8
M-$US=E)J;B]/2C,O:WAD4B\W6D4S+U568EI:<F9O2'92:35V<')88G)8-$HY
M4"]!159A<F-W4$U"9C$F(WA!.W!Y5TMO-6-A=6Q$>#5%9&9I04AF3E<S<79L
M*S0Q5S0P>$ID56HY2S=A4U5&0V=J4$%334EY541Y9T5O069T2$953')6-S5K
M9S%3>%0F(WA!.U1R4EHY3F1*:F5Y,$1/:FA$-EA&5$I&6#0V8F1X6&-9<6I.
M0FTQ2V)2-U-8530O4W8S:D18161!=D9J,DE$3T%F1VAX5DMD9'103VHF(WA!
M.S,Y-4IP;'=N,4=3>$U6=$)Z5TXQ=2M126LU3D9,='A"0C,W-U5)<FER26):
M6FQT-&QN8FY-1553=G-+<T(X4C)!1S5X5F=7;U-A9DPF(WA!.V1A:&1P-79T
M5G1B,C9G84]*<FAG669Q5E=M4TQH36\U379B:E1:5%%N9DI555='8U!Q1G(K
M:FTQ0TM26G)546UD2E591D=13'E$2W<F(WA!.W%+160X04<V,C@T+S573"M8
M.78Y5C%"3DM26DQI4U<U=#56:&)L-F=L5T=:>694*T9G-VIL6'=R,GEZ=R].
M:#1N:WIB>F1C,SA8;&$F(WA!.R]U3D]7=#9S46$S5W10:7%+1'%V-GAK641D
M;$QK.#(P+U=V4#=A>'!#=D50<6MZ5VXQ.$9Z>5(R3&DU05!Q;6]&130W9"LO
M5$QY3G4F(WA!.U130WEZ.#0U3D)4>59+=7588E=6:$I016AN545N;%5K0V=6
M*W101$MS351),$<R9DHU-S5!.'<K44QR>C=:>E=7<FDV,5<V;&Q%2T,F(WA!
M.T5X,3E324)L<4DP2"LV*U<U-C5K6DU215-7=4A.35 K8VM04"MO95=B8E)R
M9E-,=4)B*UHU2DQI,F9H2DE)84%)+T%N:T9,2W=$56\F(WA!.U-$9S!M4&EU
M,E=2:#,U1B]M,7)E<2MF27)$6'(V,6AT3&E",&@U0T]%=F-->4Q&1VI%:FMZ
M13!#:F,U9'%C245,1$A'9#!Q+S5Y9S$F(WA!.TYD5C@X+U9,4S)N4"M(-V%+
M1%5*>6<Y24YC9U1X;%=5='-6:T$K241E=5,P67%0=E1K,U90*V-:-W5B469Z
M06949%1S<FU#9E<W96$F(WA!.S)S,F%0:6]K=&%Z>6@K6E5I:7AK8D$W,'=A
M<V-58DA28V5X63DK6FQJ<E!M<CAW3EHQ1S5N=#19-'19;C!72G%/3TUD;WA6
M2&-+2'(F(WA!.U-/;&%B:SES<WA%46="-5=P0FM79B\X04].86%Z;U!N1%5V
M3$9Y67IA,VUM+W!29T993TI)-3!G445T5',W,7 W8C52<39L15,X-EHF(WA!
M.U%&1VYJ.$HX=#9D8U=T<#5K,'$X5%5B6EIK,65'5EAJ;4QU4UEJ>&0P6499
M>71!86(W;6]Z2U!%9G!/>E=+-G9:=GE!,&%(5CE*+TTF(WA!.T-$4UE,:7<P
M4%8T24Q45$IB<%=:5EIO8FA*4GIR>&M-8E-$;'A08V1+-6EA;59'3CAW,E$V
M=D1T4C$S6#E*,6E7,%<W0FXP<#%S;W F(WA!.S%J44AJ6E1+,%I',61N9U$K
M3S%$;6%)9VDK.7%-:4@P6BM56&MY3V8X;W17=3EA95!525!--&LQ1U-!;U5#
M;4U506%H,RM/3&QT;78F(WA!.WHU4#-G039.,%)S*U9056LO;5!B=64R=WI:
M=4\K=CA!561+,#=44"MC8V)I1W=G5S-I;#!*3&E21G)1>7IW<DI)*SED,EII
M8S%56D4F(WA!.S5T*SEY5#E,-45S=CDW25 K36EF.%-'8E4X;DA(3CEM+W=$
M3U$O.$$U2C-Z0B\P6B]W1%5B0FUO,'8X065$.&1'+TIY9DMV-58O.$$F(WA!
M.VMY=DLO=T0R,#=8+T%*4$QM>GHO045(,TY-3V(V2"\U>7@O.&PQ<#,O8EAH
M+W=#;U<U>D$P6#%N,TYU6&LX8B]!3V-C4"]*=392+W@F(WA!.VIU+RMO851-
M=E8O,UIA.&9.-D(O>FU"+S!Y6"]!1SA0*WA82TY$,2M$3$PP634O>FED+S5-
M6%5F*S)23B]W0E)6=&QM="MG93E'3&TF(WA!.WIF>C$K858V9E!-,$=M>&%G
M<T]J>2]O>39G9VQ33DIP6E@Y3&MV-S%+071.2#A21WA#-6HT.$=W2C9S-44Y
M13 O2U X=TQS-CAN;&XF(WA!.U9&=G)I-S%/25A6<F0S57E427$R='5S36Q+
M4WEK8S-H3&)D>64Y8VIL=S%'=VU*3C=S2CAW9FUF<D]T-CEQ3C%P,7)E=U=T
M-FMU;G<F(WA!.U)P9$MG:FMH4FE*:%(P-# K<GE-3FA8-&A83%DT2TA.:61Y
M>C,X;V90;#=)9&$P2%4W0V5++S V3V)62&%78C%163-A9VE5;'!33TXF(WA!
M.TYZ>4\Y8W!Y-'%O,WI:4659,V8U<65B3E-U-W$T=&)A.&A45TI0<G1J1VPO
M47A,87-*<$589%%A=W-">&]0:#1M;5@O04IC1'%W3G8F(WA!.U)V25 U<6%L
M1BM8;FU+5S=S1V954$M506Y:<')J,5)C0S4Y4V5)0G='25)9*TE5.&UQ2UI4
M4$(V9TPK<&U$<SAP9GIT<4E35S(O=S4F(WA!.T9!<$%V1V-A9WE&0F-6<W5A
M=%=O<#9N<&)F6G W1$UN=UDY-U9296UW9FUZ<D5F-4LS;7,R*VU7,79E861E
M3&]I,G-R=$Y$>$%J:DPF(WA!.T9L368K+T]X<&Q(9T1X2W9Z8DPY3'IX4$U8
M;78Q<FY4,C O>2]'=6YT1VEX;3)U<4XY6FAA-5@P,35D1TYU1F)L5#1Q5C)"
M278T258F(WA!.S%98T)T;#,U9R]M0C5I,78X;W9+9#DY8E12,CAX,V)7*W!T
M8D%+;VII9'=V1G!#5U1E2E153U!C,'EV1FI%8V@V,'I*<T(U3$=D5G,F(WA!
M.VMN,4-,>E9-2G)#861R4FI/<G!+8E5H;VU#97,U26LR07%V53EW0V-Y<D(R
M<&AW*V(P:C@V<GAT5G,O254O;4,X=4DY3'9T2T9X<6,F(WA!.SA65FIA-&5/
M3G=Z2VES;DQK5%%C9F)B3694:75+=61S-61,95)25W5I,BML4EA';5AS+RM*
M44EZ06QQ.&A)8FTV>61):UE(:'9S,C,F(WA!.W9M5EIV9C97=6A7,TXW1B]Z
M:S-$2G O;7$R,6DW,#E,<E1R+T%%9S988GI->6-K=59L;6M:9W)",D)26E99
M1V<S-SEC>$Y*=D=R,W4F(WA!.S)C.6U$+VPP>2MA4%!0;#8P,&)226],;E0Y
M4G-T4G4W;U-2<35T8E P:VQ"2$=.5%1H>BM(8VMN8F]"9&PY351:-DU18DME
M+S@U27<F(WA!.U@O;"]Z.6-8;&YE17 U:FAT-W%E17AR*S=A>E%7.&9&:GE*
M*W=7-V1A6D135DM.2&]M97A69CA!;DAL=%8X,2]M46UR-FYE.'!D0VDF(WA!
M.W5B>%9%4T%Z4&5Q,$5N2FPT8B]V3U946'!42%961T9$<6U"<W-9+S5Y1S K
M>C S.# Y5&IS67AB<$]S5C-+<44O1E!/=G%34T=P-G,F(WA!.S=%-5IP5&-"
M8DA*>F5J9C@T:V%B679"<C)Q4$5',4-*;W)73S1.95%H:TA.:S8P;U=J52]2
M;5!R:61G>7AC;FLO=T-E4"]K,2]-9B\F(WA!.T%$17(O=T%M:WI+,"]W1&1H
M:%!M*VA0*V-8=B]!0U8T+W=#62LT+U5M64=S*W1T>#AN>7@U=CA!*U5S,7(O
M;5!U=CA!:S@R8D](,&@F(WA!.V]L>F98=C55+W=$:VHY3"]!3S)D4"MU5$Y6
M;2]V5#<S26IY9D9M8FAX;C):-6HO.5HS:R\X0C)$+W%'5$Y21"LY*TQK;FLK
M3V),+V4F(WA!.WE$+VI);B]%:&TR4$IX>'IF6G8O041K4"]W0U-D.'=F.4=F
M+T%&1W=:<4Y,+V5$.&1'+TIY9DMV-58O*U1+.'(O=T1B5'1F*U1Y-7,F(WA!
M.S@O,$@S3DU/8C9(+T%/8W-F+TID860O,C$T9BMO5S5Z03!8,6XS3G58:SAB
M+W=#8V-0.$%Y8G5K9CA9-W8O<4=K>DPQ9CDR5W9(>F4F(WA!.V=F.$%/64@O
M045Y6"]B=R\W1F-O,%!8-$US=E)J;B]/2C,O:WAD4B\W6D4S+U568EI:<F9O
M2'92:35S<2]-1#AS3DIG.#8S37(K64XF(WA!.U-T-719;$8X,&1Q<TQ,1S5C
M9V,V>6\T4'=K;U-V>$556&-::E$Q3D%#=51967!P*U5N-65A5"]I;#EC9S$W
M53<R-S!Q15%Y45AS4W@F(WA!.VQF<F-:86EU2DI+.&5H<'188G1K8VUO-&\Q
M5DI%5TPV+W=$;%9P1VIE66)R5#$X>#9Q<W%E<&5Q;'%T=59";%5S>6AF6%9G
M-7%"4F<F(WA!.TMG;'9S-S50.#,U0DA#>F8X<&9Y-'-,5S8Q,B]85TPK.&QL
M4G1*;"MS<6EU231W=D9L2W9*.$Y/9WEV3&XT9T)62D5A65!0*U90;$<F(WA!
M.S$Q3S4P<CE/831Z-E1Z:E9O6'1'54MW2W1W-'9S3TQ-2$A51%DW;6U7+VUZ
M,T)J=TTK+TQ8.'-V3&0S-4\Q9&\Y43%397HX,'%)-W,F(WA!.S-::5,T0W<X
M-'@Y:T].=S-F<&Q5.5%346$U36A&:59N-4<O3&AR:5-A0S<X>$,T<VY70EIL
M=F)1<5!48TUL2D9"6#!W-DE1,U1L,"LF(WA!.WE4:W9Z374T2311.4(P:CAR
M4$I52#5D>6%:8WA8;'AO=#4O=5=U8E,X=59345-L1FMO,'-F;TMT3T$V<T(T
M;6U6;E!,:31U<65%57<F(WA!.TXO2VXU17!B3F-V-6$Q0V=737-29'ES2U1$
M-%%33&IQ9FDR.$XK-'E8-6Y*,R]C:F=$4&9.=FQB.'4Y13AJ5V5M-FAP5#-M
M9U<W:&(F(WA!.U-X.5)8;&I-:&%6;6EA5GA*>2LP5'=A=D=V-TYC<CA76$9D
M-W-Q1$%D5#!8.&E.2&MT2&LX<3-B4WIV1CE86#%(:U)I-GA/0U8Y5BLF(WA!
M.U-J,6=$5F4S43%&6B]M36YE:FA$4'90+T%09W!03&UL-F1R=&A096%29&E.
M-V%W:&QJ:E=,,#%54B]!<GA-151M1G%V=W)T6'%-<FHF(WA!.TUG,D]A4T=(
M5TYT*U1N;#=Z1&)Z-EHU974T3E9T<&Y7,G5)-VHQ07),>5)I851354DS56=R
M<V$K1F-N3$Y-:6E50TE:9BM:5G0U178F(WA!.V(K>#!J>E99,T=P:$9-.75Y
M>D%,15A01G595U-.,35+:#0Q1D=);W4K4FAK;$AK:VA)=DM.;BM6=6EE671/
M:SAV-DID5T]O-FMP:&@F(WA!.W4Q;DUI96Q)>7%71$-35E-R16EH;TLO9%5Z
M>7EK2TI104%J=GI&<W9Y,#%$>D0Y5C@P-F).<48U63(O2T\V835615--9W9X
M8FI+:%@F(WA!.S1I4'1$<%9V<VEU34US;SAI:V=&8BM8,7 K6$]L*V%P3D\X
M=&%28S9:9EA-25=E9C$O55AH=TUO4G%35$M'0EAD9&E$.4Y'95=5=5HF(WA!
M.U5!0D)E8V1/+TMN5F9-5W!Z83=O='AF-G!:05)Z6% Q<$%*06Q&4E4T>DM/
M6%5C859R4F9T34)J1$Y/26]&0D%+9&9L8D@U16AV9%(F(WA!.S!V>7!P.7IP
M868S=# U;$QP23!:0VII>&%12&%4<V8T64HU2E,U;$E&35HQ<7<O2G)73E)V
M=%<Q6%%B;35V6'5"2&1Z:31$=$DS,E,F(WA!.SAA=WHO=D%&05!W03%(2VQE
M2D]3:FUM0E%+1$5-="],2SDX;F8T8G9F.$U7;'IP;6LR5F)K=WE3:&528TU7
M8FQ)>%5F,V95=G@Y>'8F(WA!.VM*>DUJ6E-!=U159$@O2D]A85,X;CAS6%4Y
M,V-K6$4S*VMG35105GDU550Q<'ER>6]U,58O;5A,0FYM3W%/15!1+TPR;V57
M<F9Y2F4F(WA!.U-A9&(S3G!O96LK=&),6E!-<69!=3=F1DMW,E!0*V(U5GEO
M>4I.;FUL-3%*-6(O261*:$503$8P-4PK;E9B9W11:W)1<T)/4V]+=%4F(WA!
M.T4Y=WDY46-U+TU:3SE(0TAO:S$U-5AN+T%#-'0U3&TR=68X040Q,4A(669O
M-7!G<D-(;#9+<#AB4G-D;#)!4$PY955I4G4K<5AN<#@F(WA!.W0O:VI&0S$S
M1C57=5=30G=R=6PP6$MY8TI806]K>FYR064S4FQ04FAL=C5J2C-O-%$Y1S@U
M,V9L<3@X<3)K3W916$8U<&UU2VI'>F$F(WA!.V1)-FQ&1G=G87)X='-Y0W!(
M5'8T1W%-:D4R16PU.5HV9BM3,FLV;F(S,FYE6$QU3RMT2&EU3%-D6C)F:3E9
M,E%K3$Q,>%I42G5R1&$F(WA!.VTO96QP>GI);VQ(0T=C+VUC;FLR87IH,#=Z
M4EHS3W%74TPK:T5H5V1!5F%.:$%'-&E33GIT3U(T8C!&5#!R:$UX3FA*1G-3
M.'57,S4F(WA!.U-A2#5J=%HY13!+-G1.5U<T1FY$8W!/6E98,7A+:&--<W-Y
M1D-S6DA,<#<W5GEC<S U0VE504%*+W=$;5AB+VPY9E@X3FXU<C K-#$F(WA!
M.TTV955&=31U1552;3ER5V]%<UI52#!".7)W<C S35E:2E(U1DI!2U9E46@K
M5G5L*V-93$QY>&\Q,W K<5@Y<E(W=C%72T-#46AY:D8F(WA!.VYK06)N1C!)
M0C)(.'=W>GEY:TM*44%!.6MA1T9N.5)O,4UL04]:07)12&M"6#)/*U9-;#1!
M2%%5-V9D:7%Z,$E/6FLY3F5B5350458F(WA!.TY!44MN-45J1E9W5E)79T%Q
M86UN8S1Q=%=#0E-Z3$=Q<WA*66=!16QQ8W$O3V=R:7$U5E924E%!4$%B9&-6
M5W!B=U)R>%-.55AP4E8F(WA!.T%&2VLY=F-K-'%U6E9:4W)!37)#:$(S0D)X
M5F%)24%N05)Q13(K14%5,DA%8F9)57A6=5-+2U1J-FE++T4X;#5!1VA(8U8W
M-'%T93(F(WA!.W1P1C1V16IR4VY&;$)&3G1T+VM-5F)A,V=B:GEJ4G5!25-Q
M9SA19&E"-%EQ=WI6=GI-+TPS5'A-:E-P9$YB-F=.3G99;TEG-6AU:7,F(WA!
M.S!H.5%.>#9#,FM0=S%.4G15-4M50TMV<6A3="]Z:B]+*S=L=#)/<5%+.7IB
M*W5*2D8R5TY71E$W04554FEA<T-50E9V:3)Y2U97,2\F(WA!.TY4.'-R:C%X
M2'%-0W)P<W%1=GEI665M.&I+<69$>#5)5$I*=V]W0G%',F]+-'%Y>3A/;E%)
M,#$P<V%R25%R=39G.&I19T$W8C=%-%$F(WA!.T-513!X=38X*RM49$XQ1# W
M=%1:4FDU93!457!);%=!>G%E16EI469%2T]/0DQ!0W1-56]#8C@T4'EM1G0V
M+S98=%I92EI9,&%127<F(WA!.U%V3590>$\V<6Q65VIS2SAQ1'!G5D9J.'IV
M25EU3#%B2V8V,60R3G!095AI5SA216E2,C5H-6\S35(O1U1C<%)4-S%P5$96
M<U U;2\F(WA!.VPQ.5A6-3=U3WAK:G5M<VUT8FE&:VQJ=DEM8TY">%970FM6
M9W=(06UP-D4Q>%90=DPK=657.65T3&DW,%=E1S=T>$LQ=F-Y4G%14%4F(WA!
M.U%$:W)C9W!.03)+<&HY571F:"]C>"]#2TPX23)&074R,V=!359B1G)B0TXT
M>$5N<'E%=$EN1559;G%33RM+=2MQ,C%E6'!*>7!3=D4F(WA!.U9P>35F.%,S
M*V5+=49R8D-.66A%9VE1.&M12T])3F$Q039D8U9A*W$R=$=8,%5O-$%C8U)1
M9T1I061T-D1B1E<R='):;%)7:5%R1TLF(WA!.TEP545+2U5O4$1B8D96<E=D
M;S193D)'=V-L;4)25%5M;%-D=2]%67%V84-&,T1V1W)/0E%-44-A5G)3=GIX
M5EE,2WI!0VE#3VEK36\F(WA!.S1,445624DR-B]%8U98;4-!=5I$1W!C,'$Q
M0E4P-F(O044T<3$Y5W1U878V4V,P,U)U27%.9TYJ,C)!1TMQ;4MU>%8R2W5X
M5C)+=7@F(WA!.U8R2W5X5C)+=7A6,DMU>%9G578O04-P9C%T5#EF.44K<BMK
M:"ML9E8Y4#A!-#9.2G8W,VYT-FY(,79O-61Q-5I0:6]8.$5#:TAC9C@F(WA!
M.W%!+U(W8W8P1#E5-#=E:C9&86-"5# O4RM,-U R95!V5&5U5G!19FQJ+V]8
M<B]$<"MO9F]N-FIW4#%Z-C=W*W-5.6%0;#EA*W-F=F4F(WA!.UAR8U W>C(W
M67$Y3G8O<4AO1#8Y=SE(:TME<%-N3'0Q>55B-DE.9%=.86HO04UQ<R]35C4K
M:V8P4BMK4%=G*W8K=CA!5B]5.6)K4%$F(WA!.SE8;"LQ>G!X<C-Y2U5P6"]!
M2E5,*VHT868T92MO979(-DYF<79P+U=04TAP,')T-FYP57 S<&EQ='!F+T%#
M<$PP.5$O4F8V1#1F534F(WA!.W8P;#E8*W(O04\X9C=V,796-"]S5CE0;EAV
M4W4K2W!6-6\O-55&*V=F.5 O045B.59O,S%F-FA4-C%Y;VY,,%!Q,S<W,4MC
M95A(96PF(WA!.V$W8W-+<W@X;"\T2"]2.#,K169Q;C%4,5(Y82MP.&$K=#9A
M+S,Q4&DY5&AX<GHS.&-#<VAX5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DLF(WA!
M.W5X5B\O.6L]/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM<#I4
M:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z
M>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @
M(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN<SIS=$5V
M=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E
M179E;G0C(CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#I%
M-C1$-#DY,3$Q04-%.3$Q0C1"1$)%.39!,# R-# U-CPO>&UP34TZ26YS=&%N
M8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#I%-C1$
M-#DY,3$Q04-%.3$Q0C1"1$)%.39!,# R-# U-CPO>&UP34TZ1&]C=6UE;G1)
M1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$
M,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]X;7!-33I/<FEG:6YA
M;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I296YD:71I;VY#;&%S<SYD
M969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-
M.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#I%-31$-#DY,3$Q04-%
M.3$Q0C1"1$)%.39!,# R-# U-CPO<W12968Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#I%-31$-#DY,3$Q04-%
M.3$Q0C1"1$)%.39!,# R-# U-CPO<W12968Z9&]C=6UE;G1)1#X*(" @(" @
M(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T
M.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]S=%)E9CIO<FEG:6YA;$1O8W5M
M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYD969A
M=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @/"]X;7!-33I$
M97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @
M(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C4V,$5$-S)$.#)!0D4Y,3%".40Y
M0T8Q,D(P.3,X0S,Q/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z=VAE;CXR,#$Y+3 W+3(Q5#$R.C0R.C,U*S U.C,P/"]S
M=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!
M9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS
M;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E
M9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T
M179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E
M240^>&UP+FEI9#I%-C1$-#DY,3$Q04-%.3$Q0C1"1$)%.39!,# R-# U-CPO
M<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H
M96X^,C Q.2TP-RTR,E0P-3HQ-3HP-RLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL
M=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA
M;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z:6QL=7-T<F%T;W(](FAT=' Z+R]N
M<RYA9&]B92YC;VTO:6QL=7-T<F%T;W(O,2XP+R(^"B @(" @(" @(#QI;&QU
M<W1R871O<CI3=&%R='5P4')O9FEL93Y0<FEN=#PO:6QL=7-T<F%T;W(Z4W1A
M<G1U<%!R;V9I;&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G+R(*
M(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @(" @(" @>&UL;G,Z
M<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]&;VYT
M(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE3W9E
M<G!R:6YT/E1R=64\+WAM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/@H@(" @
M(" @(" \>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^1F%L<V4\+WAM
M<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@(" @(" @(" \>&UP5%!G
M.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@(" @(" @(" \>&UP5%!G.DUA
M>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @/'-T1&EM.G<^-C$R+C P,# P,#PO<W1$:6TZ=SX*(" @(" @(" @(" @
M/'-T1&EM.F@^-SDR+C P,# P,#PO<W1$:6TZ:#X*(" @(" @(" @(" @/'-T
M1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @(" @(" \+WAM<%10
M9SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%109SI&;VYT<SX*(" @(" @
M(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=$YA;64^5&EM97,M4F]M86X\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y4:6UE<SPO<W1&;G0Z9F]N
M=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/E)O
M;6%N/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.F9O;G14>7!E/E1Y<&4@,3PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG/C P,2XP,# \+W-T1FYT.G9E
M<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I
M=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F9O;G1&:6QE3F%M93Y425)?7RY01D([(%1)4E]?+E!&33PO<W1&
M;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y4:6UE<RU";VQD
M/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G1&86UI;'D^5&EM97,\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IF;VYT1F%C93Y";VQD/"]S=$9N=#IF;VYT1F%C93X*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/E1Y<&4@,3PO<W1&
M;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N
M4W1R:6YG/C P,2XP,# \+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O
M<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93Y4
M24)?7RY01D([(%1)0E]?+E!&33PO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IF;VYT3F%M93Y!<FEA;$U4/"]S=$9N=#IF;VYT3F%M93X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^07)I86P\+W-T1FYT.F9O
M;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y2
M96=U;&%R/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F9O;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG/E9E<G-I;VX@-2XQ
M,#PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/F%R:6%L7S$R+G1T9CPO
M<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z0F%G/@H@(" @(" @(" \+WAM<%109SI&;VYT
M<SX*(" @(" @(" @/'AM<%109SI0;&%T94YA;65S/@H@(" @(" @(" @(" \
M<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y#>6%N/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D^36%G96YT83PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @
M/'AM<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@
M4W=A=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @
M(" @/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @
M(" @(" @(" @(" \>&UP1SI#;VQO<F%N=',^"B @(" @(" @(" @(" @(" @
M(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y7:&ET93PO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P
M,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB
M;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T
M8VA.86UE/D)L86-K/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM
M<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA
M;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P
M,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F)L86-K/C$P,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" \
M+W)D9CI397$^"B @(" @(" @(" @(" @(" @(#PO>&UP1SI#;VQO<F%N=',^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'AM<$<Z9W)O=7!.86UE/D=R87ES/"]X;7!'.F=R;W5P3F%M93X*(" @
M(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C$\+WAM<$<Z9W)O=7!4
M>7!E/@H@(" @(" @(" @(" @(" @(" \>&UP1SI#;VQO<F%N=',^"B @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP
M(%D],"!+/3$P,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'
M.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^
M,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \
M+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIB;&%C:SXQ,# N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @/"]R
M9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" \+WAM<$<Z0V]L;W)A;G1S/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q
M/@H@(" @(" @(" \+WAM<%109SI3=V%T8VA'<F]U<',^"B @(" @(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC
M;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%D;V)E(%!$
M1B!L:6)R87)Y(#$P+C Q/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $
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M(S(U-E-T=:&TP='P%D)58I+3)%23M<+Q4F2#E*3$TM3AXZ,7)4."1*+#_]H
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MI7"\IPB<(G"*$WQ6IU,8MV%\-2-0RRWL&VL6X;ZCLG#.;TGM'P:6AV77&=&
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MG]N)7?\ U>FG_P &#_7W-W[0U7RM/_%)_*6G]NZ;Y*?R1_S$^W$KO_J]-/\
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M3H:EB48+U<$:\PL.LDD_5?Z@OK9[2_+.[0]7)V#K@^C4JAV8XB,]:%I)'C4
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M98X(W2RG*QMLQL3;,X-&C02=2!H%2#[9RF?^M#G\7Y#^K.9_M-B'R3?[6/\
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MED&:A!87%IE')"118(K(-UGRK(22=N4V:2[ILBHYW2PCHLY03VWQNLGKL15
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M>TWUT:[]:P\)$NREDR]>>#L12(PTV'=%BT?$V2ULRO<L:O#SPE'"=HGR<QB
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M8/\ BF!_H'")]C&MOJ]@_P"*8'^@<(GV,:V^KV#_ (I@?Z!PB?8QK;ZO8/\
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M-E#TX13"4S^]3 /Y+BO]7UY \0Y;5>&?YU-J+D=-X&/T0O;'_P#$1K^*2/\
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MWWW<.W2@%DP!IJNU5]FP8>.%MLHL6#-NA,VQQLME8UMB3H.<@-)ZSE ;KN:
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MD<02T@.%FDZ$APYN<%8]5*Z"GEE8&ES&Y@'7+2;C> 0?(0K%?MP;-_Z&@_\
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M'$%_:V35VSLNU'&PA%VTTSLZ:#C0<@Y129E&"[C#KY(S253 ]I>(7DM#AFT
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M"9':, *AX5>9&0.[I*SCL(B#J.M)A%6+J$L'H*H:B%VBE%I45CH<):1I&.3
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M(S$.(O9@L2YP5,Z:ZLV#=6A3X.8AT2=-K$A=-@!TY?G!;^;7)8GSB^9E7QM
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M "J.N'Y<*R_K/R2>UF)?L^N_W2H_EK2*M77+M)UEEUYU=&8IV+HF3R0U+AK
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M0LB;%44NE,\R"DJ&0L=&V053#M (CK(V6ED<8W2T;W0L*N0U&Q)<&N)+F/\
M?@-SL+B#ER'2Y%K$/ ! D <5TEF=T#-@==F%#H@)&S6>[5-\^)1()R.E#<ZW
MIR.R$#%F($:G @$G%L%5)"H1W9S6?V8C%DV#*,5=K7D&R[BSGU38.RGQ!U=M
M(R![*V,4<+HBPUDD<DID=MWQ.(V8:##!3&3,9:KV1/:44?4%\0BL[]3,2X.O
MLP0T-&4$#7<YSPVP#,K=%L0/ I^B;Z9_R'F'Z5Y_S@?#;XTXOX:'[)3J4X;R
M&G[UWK'J!+Y45U1ZY4U7--7/5U00V$6G<O8"?E+1G )BHW.S<@8CSZ2DW9QS
MNNIHX6>GG3@JOG1-/&SM7??V8QGV8G'8TQ3$*RHK*.IJYIJ6CH(&TT+W LA:
MR1L;0P6T#8P&C7<%K,9ABC;'(R-K7R2/+W :N)%S?IUU6&=SKRT"]/"6;8A,
MXBP>HZ.6;Z3@&;MNKCVIKMG)5HBNBICVX]NBJ6^^F^/;CVZ[9^[RW,2V*5P-
MB(WD$<Q#20?$5Z;JYH.XN'G6WEZ^]6^O75.-FX?UTJ6(5#&)&<^<AP+#F2K%
MB3.^X-!?Q1TFJNOG=U\/8LVGGQMC'HMT]?+[<>W/RC7XG7XI(R7$*J6KDC9L
MV/F<'%K,Q=E%@-,SB>Z5.HH8H06Q,;&";D-%@3:U_(%'3\H%^B%[@_Q?3'^T
M74/)!P$^->$]]6?W?5K$Q/D,_<9ZUBUA//I)0Y.$6UV\)'Z,OHW^#?6OYC0Y
M\O\ "OXR8U](5'IJ;47(Z;P,?HA7A7?^\M;WWKY__-0MS4T/+:/YU3^M8K\G
M:Y.\=Z)6G'Y];*!)PBV&OR5SZ-V<_A8V;^CBF><#[)OQBA^BZ;[15J4X+R1_
MAW^A&LE/G.UMTX1.$3A$X1.$7&=/&;+5+=Z[;--%G"#1'=TNDWU5=.E,(MFR
M6RNVF%'#A7;5)!'3.5%E-L:)Z[;9QCA%_'3YDPPAL^>-6>KITBR;9=.$6^'#
MQSMG5NT0RMOIA9TOMC.J*"?F55VQG&FFV<<(N5PB<(NK-G L9$$I!(S N/@0
MS-<B8-FR#04(%#VJ>573\D2?K(,F+-LEKLHNZ=+)((IZYW4WUUQG/"+J'<[@
MX^'YL)_,HHR@.!3<]F<.Y"(;0_ -WHDJU,YDJSS0+@4Y3714;D???<UM%DMT
MUMM5-,Y(N[$EA1\6/-@B8\T%+LFQ(47$O6Q$63'O$M'#-^/(,U%FCUDZ04T6
M;.FRJJ"Z6^BB6^VFV-LD78<(J<W#8S"GJDM*W"K!R5&597,WL8D+9;ZI/"3"
M$1DG)GC!HKOHIHFY>-QBC=#??3?71533;;3;&,XR0:Z*@U37-=,BTNV"S&(U
MZ7NBKXA"9K'!\.+G([ Y:G9T,,&HE&'Y8^G(R<?>C9A&9'$#4APW)M7P9L(F
MS<$+4,+Q$05=/%^?SO\ Q/>]8KAF]M-[6;S#$'.H5S9"L"#696#0\/KNPEF,
M9CQ*6)QIK(R1QVX4KV9DCU:R$L-/FPC^1Q8HBFN(.L9#$XX2V[K^I71<*B<(
MK$ZZZG3^M[ :2T7:,-?"($V[!"Z<"/ZU-[.0HCLU>T-NJPD)\1;64VTECV,H
M0]"$5X[!,X>FT8O7!R5-I,^QHTU*M]/)]0L/SYEZRL^MTRBW8N2]@9I/86?+
M$X+**XUVA56IUW))['BLX RB$$KR-LY47&6))Z<CL?U@-:DF$=C*(@9*;(*:
MMDL3?(4&2^EK?FVOE_!7@<*B\W,)#\TXM()-[I[_ / A+TI[EZ_NOO7N:.RW
MH>\>BX]'U/+Y?4]!7R>WV^GM_<Y>@BV\T4.;+M9&LS6S9<QM>UQ>W1<=U6IY
M=C#)+ES;-CGY;VOE%[7L;7Z;'N*SW[=+3ZM]OQOQ_5CF^_1[_6_^'_\ <M)[
M>_ZK_P#/_P"E/MTM/JWV_&_']6./T>_UO_A__<GM[_JO_P __I5UM;33[(<+
M#3# WX1@O\0_XO\ ?/?_ '?W$H]&_P"%^ZLO5]7W/UO\&3\GJ>G^W\GJ;:2L
MI_8M1)3Y]IL\G'RY;YF-?[W,ZULUMYO:_4MQ2S^R8(Y\F3/FXN;-;*]S/?6;
M>^6^X6O;K7N>8RR%BTQBV;"+7BA\7DWOL;FUL]I:[WKO80!;-8.-HR8$0$:E
MS JU&H2A9:0M0&C^1ZR(P4%KJV!'O@;4(W9(Z%)W#)(71W==KS.S9V:!&(79
M6N!MG.8-N[,2+R-RY0+&'U$,;6S6;QF""027==YG&9S""2VS2ZS<K0?<SF))
M-OM'Y-<1FX9V&AE@,IW'@8BQ&DA5-1 4+JZO)[N<"9J>#1TJ#;MIE+)*&C*A
ME:Y$',L/LT2*3/*&:^>%QT<;^PZ5TKPQX>UHD#[M C9(2W9,:19[W!N8S<=P
M!MVO,UHMN;"(8W/88W.,>4-<72R,RG;2.#CD8USK;$Y6Z$]L#2Y2K^%-+)1.
M>M :6S8DU,2TZQ!/9"48C$0S-^4RT=).7302@JND.;J[I^9%GJX<9;IYU3W<
MN-]=EMXWC#G/%$YYNYT+BX@6!.87L.;N+?X8QD;JQC!E8V8!H)N0,G.3O[JD
MYYI5M5$SV)_?FF_^="OS )Y.,*^#Z;O7^L>H;B7+JCOF^K8J*\V"P5=5U _?
M.+_R)*?GJ.\TF/<CC^<L]5,MQ@G*I/F[_61*2;D24H6!Q\K1_A5]7/P?#'Z1
MS_.W]BSX+Q/Y^S[/&HUCG;X?!'TRL3[G45I%)+X/7TG_ $@^_P"P_P#\[CD=
MX6_%K&?F,OW++H.64WA6K:Q\^85-5B\_*P?X ]%?A?1']#%X\Z5V+OAVM^B9
M?ME$M-C?)HO#CU<BU_O.[*,)PBW.$>_Q #_B<9_J2'/D*3MDG?N](J?C<.X/
M,L.SY2GXC'8NH[-(=!H4T@3FE+WZS0N1S#XC%R!&=[&#]FV"*<I 3C<XV;-$
MMT8&!U;-]PKU3"V[W/G4]Y3U1ZUV.^#^'U5,W'9G3BLH<2FCBRRM;!DCIH'
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M=K<N;)[Z^M\KMUMUO&K:_MT6_P!72WXU:?U>YN/T>_UO_A__ '+5>WO^J_\
MS_\ I3[=%O\ 5TM^-6G]7N/T>_UO_A__ ')[>_ZK_P#/_P"E7JC7GQ$<P(83
M]'#YDU>82SMY_2]Z037]/S^73S^3S^7S>77S>SV^77V^S$=>W(]S;WRN<V^Z
M]B1>VMEOFG,UKMV9H-NBXNJ7=@'KT;1]M$1K+)(BPKV6/1X[7&V=G[UJ&=KM
M66N-/V^<NETTT,8T_;9RI^U^[[.9%$2*NF(%R)F$#I(<+#QJQ6 &EG!-@8G
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M0EIR%EO?QK J::M]=C$??[-,ID5\K,\MUM\([J;(I_,V+874X-7S8=5F(U$
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MD,;M8"7%K2YU@)-P:"2XV T%[D V6XA2/9)(V4ED0!D=LILK<S@UMR8]Y<0
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ME=H[#*0T;)FP-9(88Y''/.X"[ YP:#* #<V!-P-]G+7,KZD5KX'RN=&)9(V
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MJI*MYEBC<QD9VSBUCW!S[1L<;-!).@U-EN\)JH80^*1Q#Y96!@RN=>_%&H!
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M22F,MP<[3")2%)W%"61CU=;2/EC8W#=PMCU&N='^ZN4_^533V_:\Y/CF#5&
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MXV$1DQF.-DIEE#H'YGO<7E:ZHB8VX:T-R3RP@C,<[&!MGNN2+@&[BVS3F%@
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M>X7O9MF-.46MI8<RR:'#JF"J9++E#0'W+7W==S2/'<G53.>+_P"&5=?>[JR
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M/4%/'24>(S04T(<(HF"/*P.>Y[@,S"=7N<[4G4K&DH:65YDDB#GNM=QO<V
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M:U:C605XL\FK1F:8E!+PA'4-=R8YH0%%6KI\W;H*BB>JGN+CRO2A$-=CIO\
M,21R4?V@DD3JEY6'="Y>OCIQ:4,F%CB9S4D,ZKHTC5-KRIKL=UE4R,F95=%P
MH4$?*GY$0B<VCD-E8YZI7+P*++W;7=<Z \PY[V\EK^/K5\4JN3L'6=R=@3#A
M.1VQLUZMT!-JVH&(PITLRA<VFME6- RR[M".:R*=2M!L39M#]BGQ^"#]G!8Z
MMK$85DD*41D)>=+#NF_<L/R.[JJK>'Q9$QM'K4R/6!(YM,)@(N#LE"B\LG\'
M?5U(#Z,)[#V=&@;I2)O!PS4.BTC@\.(R*9ML-@3L:[CF^V'H9XDF'X^=#O\
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M\_D44^<$,&4W&X03='G\.@4EDKC<JD7W#IUYK"VO3TZ\^X;E^G/8#LU"I97
M Q=6+?L@DWHP(B8K"T*A)5.1KTQUV(&;??E*\9N MB3"=8FH6=6V&N&,UVT@
MZ\/CD=2'R.(I#)M6I4G-NTU-[=?=W;AO//U*ZKPQK'*V-!XX;E=IQZ>2\W2U
M;2,LU']T7W8\TJ1*B!;N0F3=9NX/$T:K=?%':";E)F\-)-7;]4!E5+5JDJZ(
MZVX<U^:WWE5#\0NUQ-<QV" T;Z,U19E@MK! TO$!$ZB57L)98Z(H+L(L2P;
ME2"S4%5-(ZNE)!-V;S1^#D>9 ' +16?RI_"X#)2H/J&_\]?YTNK7V]_2Q*:E
MOGQVM,Q@R2F7:N"W8VCSF,+A*1HRL8FBXK'L%&X.\$21&#IJH_8TF:$Y-MBH
M0HSOU1Y(ES(%C#4XX_/Y\26ZNCIU/1O\6G1W51$]V>N 9$;B$OK[*1Q[2<([
MJ26C"<9LP78<;MJYJT4HF1TC7(:V"L?!E^R8^/L+-2AA>&DP LU()S)9G6IP
M1)SU6B97DJVW:<XOX^GHOX^[JKF>J=KR.9]E9VVG-L GSX9V6[70X3$W_=-[
MK*$@L.LZT(O#HXEU%U@R Q9B'CXH:W&K?/11908P:SW*2CG_ (!R@^\^<H;6
MMU [AT#GO]W4IC>57E<=TT:OFZS-\V;O&CC3*;AJZ13<-UT\_P!U-9!;7=)7
M3/\ SZ[Z[:Y_Y\<(NI2BT80;H-$(X!1:-22)ELU2$#TV[<NVUUU;E4$=&^$T
MB2&NFFJ+Y/75TEKKKC177&N/81=UA%'"VSC"2>'&R>B.R^$]?6V13VWWT2V5
M]GGRGINHIOHGG;RZ[*;[8QC.VV<D7\111;Z9302213RHLKG1%/1/3*KA7===
M7.NF-=<J+KJ*++;^SS**J;J;YVWWVSDB^O"+SJ4/B2"#YJA%XZBV*-MV9)ND
M$&)H$6BGM]1J^2T;83=MM_;GSH.-5$MO;GS:Y]O"+NL-&NN&NNK9OKJQ]GN6
MN$4\89^Q#=MCW7&-?8W]C911OCTO)[$-]TO^3VVUR1?%B+&"\.\#!S$=A^]7
M)/L,6C=IAZ1=>7WE^[]W33]X>N/)IZ[I;SKK>77U%-O+CV$7.X1=/K'8_H3R
M:T!!]#.=M]\EM1C+4GG=1+9!3?+_  AAUYMT-MD=]O5]NR6VR>V<Z9SCA%]F
MH80Q8X&,10UF-PHHM@>U8M6['"RSG9XJKAHBEHWPHJ[WV=*;X3\V[G;9?;.5
M<YVR1?748.T(*E]![+4JLT38+$]6B&I!5BBKNNBS5>X3PY4:)+**+)M]U<HI
MJJ;J:Z8WWVSDBYO"+IR$=CY9PB[*@@Y-VWUUT;NB QD]<(::;[*Z:(K.4%%$
MM=5-ME-==-M<:[[;;XQC;.<\(N6W&#F;E^]:#V35X4416)NV[1!!R16;HZMD
M%7ZZ2>JKQ1!OIH@CNXW4V31TU2TSKIKC7!%]$F3-#W?T&C9'W1MEDT])!)/W
M5GGT?:T;^33'HML^[-_:@GY4L^[H_M/[5IY2+D\(NM)A@YI)- R*&ED$E/62
M1)L6K]))7R[:>JFFZ25TT4\FVVGGUQC;R[;:^WV9SCA%^4 @5JY:O&P@6W>,
M1^1+)T@/:(N68K*B:N1C5=-+55N/RJDDIEFEMHVRHFGOZ?FTUS@B_KT(&)-M
MV1$0,?LU72;Y5H]8-7391\DMHX2>;H+I*);NDG"::Z;C;3*VBVFBNN^-]<;8
M(NSX1=.0CL?+.47I0$')/&^NFC=V0&,GCE#1-39731%=P@HJEKHKONIIKIOK
MC53;;?&,;;9SDBY388-9N'[MH/8M7159-P4<MFB"#@DNBAHV26?K))ZJ/%DF
MZ:;=-1QLIOHAIHEKMA/777!%\_@PC+@:[R*&Y=!D5FP=S[BU]X%-W**;=P@-
M6]+U&**Z"22"R379+15%--/?7;3377!%Q649C8QWL0&Q\&/?[X4QN]9"6#1W
MMA;/F6QLY0;IK;85S]U3&=\^?/W=O;GA%RB84.:231,B1I9%%3*J*1-@U?I)
M*YUSIE1--TDKKHIG7.=<[ZXQMY<YQ[?9GV<(OC\W8_Y]-_@0?SIB=P">_P ,
M9>?0$IG7*@73;T/;J)4SIKG<=C.&>V==<[(Y]F/81<=.)15)INP2C,?38J.F
MKY1DF%&Z-%'K%71=D\W;ZML([.FBR::S5QMIE5NKIHHEOIOKKG!%]%HS&W!'
M!A>/@UR^JR#C4HL)8*$=5VV$]6RV'V[?9SA9OJDEA!3"OG2PFGA/;7&FOL(N
MR>L61)JJR(LVK]DOC7"[1ZW2=-5L:;ZJ:85;KZ*)*8U4TT4UQOIGR[ZZ[8]F
MVN,X(NM1C,;;ILD4(^#01&/LDQJ2(E@FF/)92W1R09::-]=6C[**BB67:&$U
M\I;[IY4\NVV,D7T8QV/C':Q :"#CW[G531P]8C&31VOHLKHLMHLY;H)K*ZJK
M)Z*J:[[[8W5TT4VQG;7&<$7Q>Q:,$M6NA&. 7^C%OHT9:O1 ]UJS:IXQC1LU
MU7;[X;M],8QC1%+&B>N,8QC7'LX1=UA%'".&^$D\(83]'"&--<(X1QKY,)83
M]GDPGC3]IY/+Y?+^U]GL^YPBZ!.'Q)%F^'I1:.),"B::)-BF$&:,R*26VVR2
M3YMJUPB[33VWVV3T<:*:Z;;;9UQC.<^TB^SB+1EV\^(.HX"<O\ZZ:9?.! ]9
MYG1-+"">OO*C?9;RZ(:X1TU\_LU2QA/7&-,8QPBX^(7#M6ZC/6)QK5HLLBX5
M:X!"\-U7#?19-!=1##7TMUD4W#A-%7;7.Z>BZVNFVNJN^-B+NF(]@+:I,1C)
MH.9(^?T6;%LBT:I>HINJIZ3=OHFDGZBN^ZN_ETQYU-]]]O;MMG.2+@I1R/($
M%"Z($,B55V6W5)I"V*9!79QKMJXV4>Z(8<[[+Z[;:K9V5SE77;;&^=L9SPBX
MF\-B"K5DQ4BL;49#4]T1S/<&+W:L$5=_5529-]FN4FJ:BG]LWT0T3UWW_;[8
MSM]WA%S=P %10DLH$$*+&46S8PKN-9[*%6[/39)H@2WV1SL^1:I[;)MDG65=
M$--MM$M==<YQPB_8P(%":*IAA L0FOMKNNF,8-&&BV^F,ZZ[JZM4DM5-M=<Y
MUUVWQG.,9SC&<8SPB^;R.Q\@]1)/P0=\1;^E[N0>#&3EZAZ"F54/1=+(;KI>
MBKMLHEY%-?34SG?3V;9SGA%\EHO&7*;Q%Q'02Z1!_P#%7Z2P@>JF^*>CAO\
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M9NC6RN-B/AHR8%>J=FIA^K<2)L^XUC]H,]B(57!=#ML?BDWN"7V:O3!F>)I
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7PB<(G")PB<(G")PB<(G")PB<(G"+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>g713200g90r82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g90r82.jpg
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MMLY2R2ZZXK1-('@DHC1RFZJ,QR<!P4=FH K7D1(A)?'XNTT'QD%*!3P0LQD
M>.L$DV0(860=LA#1/1L/0;HZ:Z8)==>=ZZ=?Y..$B)%1]2&Q(*%KUN&%DZZB
M+P<+KAVD@@[KQBQ7$;M6\#>(MFJ3N&II:QMTFU;:.!BFK='&A9N>4\J_C_KE
MUZ*&5Y$3H>F2,@=5VO4#HZ_J^$.S+FIG+/8>YJY<FX!J/5J[<,-MF*\)47VC
M2K/;9LH,V1SG3A8N>7G^?E4D1:*Q>#1P'#H5&P,/B,9&,PD;BL6#CX_'(^&'
MHZMV D&#$MV@P2,8M]-$&;!@U;M6R.FJ2*6FFN-<$7?<(CA$<(CA$<(CA$<(
MCA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(
MCA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$F_P *M,YE&+;\&$!A
M<YDD87LGNNC!)/&@]SSVFPMAQ%_4=AD%XQ,2L#<J/W8'>1CHRMJLJ#.*,">&
M&K-OHL^SHN7M@N'W&QO)>QN-GUJ&:+[-=O>L4XC_ $*N*75[<MGTS4%>6'.;
MKM67+CCUK1ZV3O8U^0)U\1E\RC,LL5EU\UBE4P)\O[EY)*[';H2@K+#%>&'(
MI9X0@'OMER=!S6MS"]R>06T4.K>$>[*NX=X/SM;/H=7DPUNWK]VW[!0.F:(D
MUS18@5<5GTM<V@O7TM!+STU%+'-$)^+* H][<Q"2YBB+T>\ CV\P8+O"99RZ
MN .QP!)'_5:]^+BNN3:WA6[RDB$FHA0#7,&1E,>E3+/:P9M-0E;HIN?!R@>X
M*4.@F[2Q1A 1<VDGE>L7 F-+(=H, HO24I1Q\6SL!2+&72^OBM_U6V<>@/SZ
M<Z<?X/66&)WT(Z3321R4E,I+*.I?78Y)Y6:,NI"<D4F)5'$7,B,'3KYR\?ES
MK\TH^<&B!!TX(.BF[M5\MN[V6VR7EVT^,\W&K@<+".$1PB.$6K+X6:[;CKWN
MEV4#U=?-EUXPB7@P:9N! 1#KMG !W&)ZV[KN0)V5U?4[0TC"IQ<TBK@:PAH2
M$'/<X)G#<HS%GR+@>17:$L<9\0MX]?\ 1?1@%AH-76U&FS83Q#E(V*<VGA'K
M,KZZ>R\5C$61RD:[-V>-WF]OFK(.1BN1-6^#5BG9T-%3,%(S]$=7LIF)H$XB
M:\8B!:'Q=L_"6')]8X[/X78<RL9;@'3WOBN<Y'SVX_F4>T=X1^[]KXNLK[2%
M@#?L);G3=-&-W/(9=+:^Z@MI]X+4=V?ED76CVT@C>P1Y([&C9*(:"6CV$L'<
MK*&33]MN998 D,<OCT\P_P!4(TVC0'6WON^M\^T'7B4GP/PK/8R]",1CHVL*
M=K#66595E@S>(R67/W-CPJ!6)T]E]\RF;;/6%E5^5 D ]C,HI7L7@WN?3L-S
M#)4'N/79 *]01993*-1?CL#Q$WM;GTN;[-++JNJ/A+[FF%%!@$)'T*&D5+=(
MNN%Q>Y;L?<,X8S2\D[+ZE6%9*4DA%JS61E71D/&[CC\'K6;GIQL94;L65IR2
M43P078!!SHLEH!.WWQ!( T[ZVP<VHV<0"<#TR[!&^RU*I6/)XV5ALG:S6<P>
M30\Y#EX29BDC@DA=1L]'B8S$UL<,0<BBK%VTUD46G,CC1Y!-$B/=,U%G(H>7
M@BW/XO6_G5KN%A0+VHD=KP[K)V(EM$!MI%=L8H^U9!4('1CJ54,66'@QPA!Q
MJ(K;3?4LN\DK<:@@*VU\DDMOHQVSKJOG;!9%KB^@N+^+C21K7F<<>>!LU[!P
MKM1;278D5X/>:V46/@>PLZ0F$GM=W2V-YS(YJ$92K#D++8':3K=NR<H,@+FN
M)&@TKL=@0P49QGA>A[\"P(S#2PV7^[[]NJ_;/PME_1LLI2N\4I&13<=>L^HN
M-VT>-/(5515U&ND\%[)UD"GAF9V@V9QJ6V%,)<YACV7KS=VB]%0^3F8[7Q61
M*M8PD3*+ _\ 3<\NTM\VGV:;5QYEX73LR,F]F1T."ZUC&49MCO[50) R%G!X
M@R<].>K<,[-@C)H@+MD*PD"<IU.E:W/,130!HV=ILIF-)X307B#P@:"-;WT^
MMUO1JN#"_"CS%I;DQ.ZCX;'M+VDW@S8QF73R>V-(J8HWX3W4BP;AR2/1E].$
M([%V"\NC@NM&;Z'ZURVE,AEX0],%C!D:T8EB%O%QC-I;4D&WCYS?8 5].P7A
M5;&V+VKUK=G*)P8)TWVBB!^=T+/9X@1KBRZY\'V [*#Y#$9X==PPX\](G1&3
MC8J^CT,V#*1=6$&1EG*SL9-H6&(&[#Q:$7XQFRVY/KY=.-9KVFMJ8,>DW@2I
M9M<<_CA>U^UG@TXO9TJ#VS,(B8L:%6'"-7%G"YO(0DE$D)6&E'D:/93[>/7R
M3I;QOGF^%]MELXY/'KYC]JRT7<\6_)?;S&UOL6&5OW1[?0.RY%4%;R*$V#6%
MT>$@N?KAU,M;LBO.9NU]PX7KC)+4<8"3 3+@\KLNOH+=D5)UX,DA M)R!9D2
M(1H?*LN(TQ30RA:+7Y&@NMRY@+6XM#?[.7*)#X7R[8=8$\K@Q%NN9*6P":^$
MJB) $YDI6O-7&O2^BX?;56&"1Z639XRAP.R7Y\HP/GY"QU$)@AWMR-<#$VS[
M;0L91S_D[.<V/^BR9EX4GL<SBH"PS,"J22U=(+2.Q5.:UD,5DTE&5X-A-&[-
M;0*4SF]\3W>*-+AMTC74\<!%#<P@XD#'9FWKF5B)T/V&DRCEX@;:^:Y%M@O_
M +%/RX7A'"(X1);\+PX(UPCU,LV.V_;%>E;#[W=$Z-E R,75/X#$7]7.K?E3
MV=C]XS&Y0#"[J3 3*%AT^,K-EGQ:-Q^-CGKI,>$0TX7INM]+C*X[+V[TV-^+
M6WSK[2#NC:%$=C\]2H7!7TGA\3[ =9>OX(O8Q6<6':\N#=GZONFV7=PCY06E
M"9&0U_2#R&MXP50-I&S)D%7UB;$YZP*,D7;,EA:]^(G9IMM;QG;R"X5':>\-
M!:,=H+ID6G,NH>U[(MV!==I];X[.Q>/346A?';1O1$GPJW1.L8;&&L)'EUW@
MCVG5F1[VR /!\DK*%1%NVE;HO1:,S@+Z%UN/WH)'GTMS<J:EX)R<R:P>IYDU
M+9M))^68=I>Z$8;GI7*B\Q,HQZ+]J[<!Q$)DV<($R6XP#%6084!9JN]T& )L
M.:,M$V*3?3!>7;?_ &6_6T$IEW"\HX1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X
M1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1'"(X1564[9Q(I/KWK"N
M(#9%NSCKR'JPQ-Q,*UKH,P(^^H7L4.W'124VE8M<Q P0A"U823>P?/GQ[ &Y
MPG'F+XQ+F$BCH,LVV'9>_P!5OGX]%RH?V>93KKK$>Q<=IJZ'0V=:L',7K? V
MO%;#(!B\C4"!I4J\960[JT;#"P;5*P6DP)V:SCFL =LC;HDV=.4AF26UM<>/
M6VR_)?FV;5*M/6G'+MK*'6K$4"C6/343J6'-#2+)$HTQJX79NFCO840+AG>[
M5ZU<(:$P)DU'2R2:9./FC 5VQ).BPI*X1'"(X1?C=1-/&N5%-$\;;Z)ZYWVU
MTQLHIMC1-/7.V<>/???.-=-<??;;9QKKC.<^+A%P73 2071P]9CGKEGC"R'I
M3=LY7:85W^]51\]INHAA11#'B4T\GR]T?N9SLG]PB'0X0Z63(/6 YPX:-GK5
M)\Z:ME5FS-WC34BV3<JZ;;HMG.J">'J.N^J2V$=,+Z[83U\1%\\"PC/1JK@<
M*:Z#?.Y9*8:-$-&'I&_C6RUW\WKAKY]3;.5<I93\[OMX]_*SGA%\/<_&M6J
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M&CWS#90BP;N\(N%6>KGR<N6J+G&C==1OC?31;&J*FVFWDZ;8(N%B-Q??R,8
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ML/G^T.:HXPE%52!%<#J/6?O%%RS<\I7]1ZWT"VDL1F*%-UNC*H$/&"X:?3B
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MKZ#TM)",U"V/U<E.+59!H*0A\EA5=WD^DLRA4TF)!TTL*KT*HCCV060'S%"
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MZ)HZ-=5=EC)0%'Q(UEILH])F)"=#B631!3SCW+I1JV<3V!.RR5!RN><D8#6
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M02F4H6\?6W//EY?]$CR]X=N--T3?M5+Q#?:CI#Z HIYNK35ONG'X;RGYJ_\
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MKAA6X0?M>VD4Y\C5()(!C]UBGRB]^DJ\Z,SWC?);Z J%)X23RW=8KKN>EX3
M^FGX.37Y;&_0%.5?N@\+3]&_K!63 _!3](WJJYO*^IQ*9[$^N:;_ ,:%?4 G
MEXPKX/IO)?VCU3<2WZH\IO9L4*\D%HJU74#UG%_F24^NH[R$Q[<X_E+.RF4Q
M@F]2?)W]I$F3<J2M"1CX8063.$ZG!!*=?V02D$?E\=<R]",AYJWJ2-G6SH;)
MI,SB!LFP82"7&!Z^(_%&SO&HUJH[)D3#M42T>QR36#"@332!L1D+IRW-E#Q$
MTQ .<&$@.<0<K>(7))M=KH;$"&U$;G3",-B:[)F+.&<V0EK2]H):P$9GD:VL
M&BY#FJ]JZJ;&K.Y,R?6&SZ1BA4NFLG45.QBL2&^U2[46V"09".3A1-"S"%S)
MG1,4K%_&C<NUC2@09(73P*V:MXM*'DQ'%)'+FRO<,SW:MC)X+@0&!K_"&4.#
M8LKGY2UKB1;*XQDLL<D.7/&USF,9WKI1^&]L%TA<S6(0Y2Z0/#<URT!Q[Y@M
M5UGKB]6OA(X%:\RC\1?0XM&[5B;25AYN=<N0$05FU3DJOB"T,?0@:R%G-FH,
MZ;,Y:R4^B1.F9L0R?:#1L2C.^O71S!E5*]K"PTM2P/;(20W-"8VEA8 #9KB;
M.==Q><P 8Q?:CD@(IX6.>'MJJ=Y86-LY^282O#P\ES;N#1WK;-$8RDE[ELS<
MIZLRJ9W$]74?^>K+ZBD')S =ZE^3N[2)0V-[M%TX[.1+BY;%6$<(GDM?\F;_
M , E^CUYS@[3XSZ5?QL'B'H457QZH9W\CZ_36G-["]_IO+/4<M3$-RJ.C/I"
M47R\JEHX1-PH+U/P7Y+7^LGW*-BF_P!3Y8ZC5<\.W*G\@]9REU3_ !:G^IM_
MNYYH+=2,N=(7/T<(F+].OP"DOSO6^IA'*IC^\P] .T>K/@F[2].>SC5N>02F
M4H6\?6W//EY?]$CR]X=N--T3?M5+Q#?:CI#Z HIYNK35ONG'X;RGYJ_\7'\@
ML?W:'IQV;U-X'X>;HAUPF)<JBLJ6]W"]90/YD#OKV1\MN [G)\I?V4*K&-[S
M%T [2150Y-J&4R]?/7'!_P"/OOJ8ES0Q3<*GR!UVK>PW?J?RG=F]-KY1E<E1
M?O3*XM%(A!G,ID@"--G4D?H-7!\P.#(.5]1FRFR+=4BY;)K*ZIXSOLFGMMOC
M3'E9QXON\L?<Y%)+-4B.-\A$3"0QCGD#.1<AH) OQJ#QSP4'2.ZJ6?[\E0_&
MK6_Y<QC[4Y;?:E5^;5'T,G\JK:YXJX:D4*#4T[2KG=3=^STTTTF\9VWWWV<)
MZZZZZZD\[;;;;9QC77&,YSG.,8QX^8=250:XFFJ  "23#)IIY*]Q^$9Y;>L%
ML$\Y@KZDV^R!?Q0O<'Y/IC_U%U#RW=PGXUX3Y59_V^K6AB>XS^)G:L7F$\_2
M2IR.$7J[>"1_%E]&_P";?6OU&AS\O]U?XR8U^L*CKJ[46YTW0Q]4*X5W^I:W
MOY+Y_P#JH6Y$T.^T?RJG[5B^\G@Y/(=U2O''Y^ME0D<(O0U]BN?BW9S_ #L;
M-_9Q3/.!^R;^,4/ZKIOXBK5IP7=']._J1K93YSM2Z.$1PB.$1PB.$1PB.$1P
MB.$1PB.$1PB.$5>^UE..;\ZZW+5 AM&=Y7-:SG\9A!*6);Y$1^6RB&'XJ+-J
MO6XPN0$ZMTSCILZ)BA[HDB,>/T6Z#C5PHW6+(-B/F]*JNEU1NB*]LIE=T)*!
ME(]++G=70^)D+KM$,\,1_/5L32F* ,U*UBINMLQ\C9,8C5B[V;ER0,BA[-@@
MA$WQN*!'3HEQ;_3GO?[/]])&*TY>\U[1T[;4H&5G'8I49J5$T2\;LVQSQ ]$
M)I3!>)$J]=U&>B3.O&<P86@;;G\7\)*"IF]KV&#(4W"BQ$YEX)F2XM;UV_=;
M3EUXE>;A85<>T1LR!K9L^!%B85[M*!:&SP2_=#G64%&17;='+AFJBKE+?9-/
M;=/._D;;::9SC.==?%+8-''+5ELL;)&\"\Y9&M>VX<RQLX$7%SKSJ-Q5[XZ7
M-&]\;N$8,S'.8;$.N+M(-N;8EZ>^99'Q@S?\JSW]OY:?:='^:4WT$7\JK/MN
MJ_.:CZ:3^9'OF61\8,W_ "K/?V_CVG1_FE-]!%_*GMNJ_.:CZ:3^9.!CRJBP
M &LLINJLJ'&*JJJ;;;J***,D-]U%-]LYVWWWVSG;;;;.=MMLYSG.<YY1)0!+
M( + 2/  T  <; !76/P;/(;Z L/N'U66!\TS7T)7GWH-]I>GCZP7PK=SJ>AD
MZI2=^7U4E'")KO6SU*PS_P )!^M!OE)Q?X1J/V781*X85N$'[7MI%.?(U2"2
M 8_=8I\HO?I*O.C,]XWR6^@*A2>$D\MW6*Z[GI>$P/II^#DU^6QOT!3E7[H/
M"T_1OZP5DP/P4_2-ZJN;ROJ<6O?WMG]B1;ME@+#I6 <[%BU;.-JR2C.Q4HYA
M*!$8E==BSF2;/4\Q&)Q6 J);P=^VT8ZO; ;Z 77NK='Q4=0N&'O>VCHPQPU&
ML>6_>"H?PTCW7[QC8R,ATO)WMWES6JL5<<;ZFL+V.T)_"YK /,+. CC;;OWO
MDOG!V1]\,N4N-;NKW9W/86974@S,1)P!CRD*+5\ $N=59"+B4B$D<H.)QOJN
MJJA("SL=J6?"<LV:L3U))15\BY+!W[YYO4U1P[I;%I:TL+&@]\&.!MG_ .HD
M$D6&2X81F!)TZJF]KLANUX<X/$CG"S2]I%\G*UH.4'8ZV8:$*[/@NIM9$PN>
MU$Y+* MA0L+7@9B)L(!%_<O'BEF:R)RA;$;@V?3GF\EKV([M8@S"2-;9\X]O
M'<H .Y)(2()_H(AL7?(ZD&9P>P5$0$C6Y6NDX.I$K6:G,QEF!KO[1<TN<YIR
MRN&,C94]ZUT;W02DQN=F<(N$I^"<_099'W>7-%A;*X-:"+O(Y6E/)>7<C\,(
ME\VEOK1URU8!N\_3#J-5:QSP\/1'KE4\Y/*$4HTIZV(#\XV/^W;FGB&Y570O
M]"VZ#?*;I6IO_*&KJJF=Q/5U'_GJR^HI!R<P'>I?D[NTB4-C>[1=..SD2XN6
MQ5A'")Y+7_)F_P# )?H]><X.T^,^E7\;!XAZ%%5\>J&=_(^OTUIS>PO?Z;RS
MU'+4Q#<JCHSZ0E%\O*I:.$3<*"]3\%^2U_K)]RC8IO\ 4^6.HU7/#MRI_(/6
M<I=4_P 6I_J;?[N>:"W4C+G2%S]'")B_3K\ I+\[UOJ81RJ8_O,/0#M'JSX)
MNTO3GLXU;GD$IE*%O'UMSSY>7_1(\O>';C3=$W[52\0WVHZ0^@**>;JTU;[I
MQ^&\I^:O_%Q_(+']VAZ<=F]3>!^'FZ(=<)B7*HK*E'=^+OI:M+>C0.Q[>J^O
MS;NN115H'FT_BD5*.A:TEEC1$DW'G2S!VLP5=LGK5)XFCLW4<-'2.JF5&ZNN
MEU[FZ2JJ*&5\%-43,%4]I=%#)(T.$,!RES&N =8@VO>Q!XU6,;WF+H&]I(J/
M_"SZK?Z3'7[\\M<_\R<L'N;B/YA6_P!UG_RU#*P/5CL9U[F5_P!;QF(7O34K
MDA8F21%Q^-V?"#ILDLE'R[E5(>)%G'3]XHFV06<*:-VZFVB"*JNV,)I[[8C<
M7H:V+#:J26CJHXVL:7/DIY6,;>1@&9SF!HN2!J=I 6]AN_4_E.[-Z>ASGBN2
MU+/9:W[VOJ=_+C+?U"6YU/V+/A'%/D47;A0>.>"@Z1W56B5SMJK:S"O/P_@_
MSPC/UTRY\I_ 3=%)U"O3/?M\IOI"]ECGY$5^2;?9 OXH7N#\GTQ_ZBZAY;NX
M3\:\)\JL_P"WU:T,3W&?Q,[5B\PGGZ25.1PB]7;P2/XLOHW_ #;ZU^HT.?E_
MNK_&3&OUA4==7:BW.FZ&/JA7"N_U+6]_)?/_ -5"W(FAWVC^54_:L7WD\')Y
M#NJ5XX_/ULJ$CA%Z&OL5S\6[.?YV-F_LXIGG _9-_&*']5TW\15JTX+NC^G?
MU(ULI\YVI='"(X1'"(X1'"(X1'"(X1'"*GO9>M"\LM+IW-P^D[);5WV'T>F!
M8$Q(4X>.CA:I[4'$)3,8V*<)!BGH)%4()%F9,W>H@%S&Z(G+%X874<$Y56WK
M@.:P'M%;4QB-/6U ZMFD(AL:E0HW2%E1H^&NE6Z2@;VSETI<.9DCV:+S9]/9
M++)#?49,F854U91@7M()3M&RBYUN7HWL/O&RWU?;XPL+\&O7-E06R+&*2^'R
MX!M,*EA+NP]#]3RJJTXU<3:S+8D!N+&Y=)&Z+#M?/$F$WW$&NRT3S[2R(!"X
MNX\GS<F8XT(?'?D\6GFYAX^35Q'"\J(;.NB+U2X$-I"P.O5#*+M=KD.V8+ZI
MZ,]T$U<+Y>DF&==MLN-,IX3PKC.,;>5G7Q8QMOT>'S5H>Z)T31&6@\(YXOF!
M(ME8_DUO9:5770T98)6R.X0.(X,--LMKWS/;RZ6NHN^&%6O_ ,#F_P#1P+_F
M/FY[@UGQE-^_+_DK4]VZ7XNH_<C_ ,U=O'^U%?R,Z&C[(-,$GAPJ/$-%73 -
MHV3<D7231#=QND>65U1T46UV5V315WQIC;.B>^WBUSXEP6JBCDE=)3EL;'R.
M#7R$D,:7$"\0%[#2Y OQA>X\7II9&1-CG#I'M8"6Q@ N( )M*387UL";; 59
MCD.I55>[<>JQK\[1/T$OR9P+?7= _K1J*QC<_P!JS_$EH<MZJB.$3M8U^#D?
M^1!7T!#G.YO"R](_K%7V/P<?D-ZH6)7#ZK+ ^:9KZ$KS[T&^TO3Q]8+X5NYU
M/0R=4I._+ZJ2CA$UWK9ZE89_X2#]:#?*3B_PC4?LNPB5PPK<(/VO;2*<^1JD
M%K53;L&9C]F'(8XIN;O71/-DNJ^2'$HPL<G*M>%@HTNYQ'5BC=Q'(R2?2)AJ
M!E9=U@8LV\ER9U!>V0%(O?Q,6Y6\$\DL<8[%MW\&&@Z$C*TEP#7$VXW9;MS4
MQU.UQ>_AHP!(!)</RL$A>0,UK.> WOF 7OH";.R\9IV)8>]I,IT4B)5H8A-A
M:U*^B8TH(,Z&;%?2B/PL$$C4FT69AR+(O*94#!*%'F!GM(5W*C3K,>_!DFR/
MH3C(]Q:<S)."+00<TA<U@:UV@-WN#;FUC<. (-OG[6/"LC#VVDCX4/(<,L8:
MY[B]MB00QCG6%\PREI(<"FE>#FL+6Q8#9;Q<(ZC)Z,V*]A4KCKMXU([")#'D
MMDU]&Q-EXFQ(828.!QP.^U3;+KB"K'+]@,(X=CFE;QQ^>2 EI:YK9&N:2#8A
MXV$;018@Z&Q%P#<"?PB/@XY@'9FN=&]C@"+M<SC!U!!N"-=0;$BQ+%.02F$D
M?M-252R;L[*[)/U_&BD]8*0YNTEKH?IL<1;QH<U*1]OA]KG579N'(D2#T<AO
MG9)JY?/%4M-=W*V=[IAD43J.ED+&F0--GD#-WLLA;KS$DCDN>55+$)YFU51&
MV1PC+@<GY-W1L#C;G  /B4=$(%#"KM^_(1H0[?%7@4B2=JLT\N7SZ.)JI 73
ME;&,**K"$UUM&&^^V<M]5-\)^+&V>218TFY:+D@G3:6[">6W$H\2/;8!Q  (
M OL#O?#Y[:JQ7@^:9JNH+%D#.L('&X*S>5_LQ<-(XPT'-=V0<N$3%M-6Z6<(
MI-AZ;E=-HBCHFFBFIMIIKC7Q8Q!8U%'%11B-C6 U,8LT6T;%/8>(7-@IK"9I
M9JMYE>YY%/(;NU-S)#<\][<:;GRK*QI>7<C\,(E\VEOK1URU8!N\_3#J-5:Q
MSP\/1'KE4\Y/*$4HTIZV(#\XV/\ MVYIXAN55T+_ $+;H-\INE:F_P#*&KJJ
MF=Q/5U'_ )ZLOJ*0<G,!WJ7Y.[M(E#8WNT73CLY$N+EL581PB>2U_P F;_P"
M7Z/7G.#M/C/I5_&P>(>A15?'JAG?R/K]-:<WL+W^F\L]1RU,0W*HZ,^D)1?+
MRJ6CA$W"@O4_!?DM?ZR?<HV*;_4^6.HU7/#MRI_(/6<I=4_Q:G^IM_NYYH+=
M2,N=(7/T<(F+].OP"DOSO6^IA'*IC^\P] .T>K/@F[2].>SC5N>02F5KQ]H^
M[/4FO>P5K0J;]AJLB\LCDJ<CCL?,RI@S*"GVC=LINT>M5-\;H+ZZ*:;;)[8\
M>,;8\?.EX3A.)3X;1RPT51)&^%KF/;&2UPN1<'C&BIE>/^,J-GA#QCD'.H#_
M .D+Z/\ ^E)3/Y9C?_\ ?DC[B8M^CZKZ)RT['F\X^],0\''V=Z]WE9T[ 4_<
M,#L8T'@?MP4&1,\T+/& OW0"&7I[E%OMG9-MZ6Y0;^=SCR?.K)Z?X=L<K7=/
MA];24E.^JIIH&OJ<K72,+0YW!2&P)X[ E36":3S;/!#C!_+'(G$<I"LJ\_'V
M5[^,&I7^9S!?VU7YSN_L7? -9^MY_P"#H%6,;WF+H!VDBUA>=)4,FV> G_&R
M]-/GM,_V36!RJ]VWXK8OT,/\73K>PW?J?RG=F]>HYS\TJY+4L]EK?O:^IW\N
M,M_4);G4_8L^$<4^11=N%!XYX*#I'=5:)7.VJMK,*\_#^#_/",_73+GRG\!-
MT4G4*],]^WRF^D+V6.?D17Y)M]D"_BA>X/R?3'_J+J'EN[A/QKPGRJS_ +?5
MK0Q/<9_$SM6+S">?I)4Y'"+U=O!(_BR^C?\ -OK7ZC0Y^7^ZO\9,:_6%1UU=
MJ+<Z;H8^J%<*[_4M;W\E\_\ U4+<B:'?:/Y53]JQ?>3P<GD.ZI7CC\_6RH2.
M$7H:^Q7/Q;LY_G8V;^SBF><#]DW\8H?U73?Q%6K3@NZ/Z=_4C6RGSG:ET<(J
M;8[M5X_WG0^+0.W)5)XC?XSK6$AR<3'PZ1638Q"L1%OKN8,E9Q^"CMH:,@#\
MO(UIA*",9$%P\2.F(HK(A+J,/I&6;;-1J+\MM;:VV?ZA?V?]X*DKWK[ .Q10
M;)5XS8Y\)$P<9<E:QA<E8RLEDSJ7CLE,6?8\$K&./H6I&90E+7!2Q$!356.D
MTA)(QOECAZ0"YL/M_P!U:2&R368Q*,2W06\")R< )/I""!",EWPU(NQ0?I,W
M16%R"5Q DL@FOKIN_C$GD !WG'GQ)DBQ40=JEA9)PBI:56M)#NWF/-[7-8AT
MOZJV29BD%6"B=H;!I3')Y3H)G+5F3;5H6F$B=.I&:<.US9Q-DW"Y9  + 'MD
M^6D)9XN>X\>P^OIXE 8"S9<'Z$72)DG8O1A=N"WA"H=#+@LTMEA*D&]6]D;O
MKH99K@? (PZ?H#*L HQ0N5<0>"Y 0D6R&;)B X!NW20+/&-.33Y@5.W1::9E
ME<V(,3,8F8^ 7"=A(JTAEO6!=\+M=EI#8'*U)9 )U9)V3R%0"%(2I]6YT(E(
MS@H%8D#G ]@04PDJFD6#Z=?%Z[?$5=CA86'%K#@@!^L+-S"-B23?"6R[$@88
MM':.JR6BR.5$%UM%-,*HJ:*Z9VUQY6F^NV/'C.,\^[*6IE:'QT\SV&]G,C>Y
MIL;&Q (-B"#SKXOJ:>-Q9)/$QPM=KGM:1<7&A(.H76^^W5WQA0[\H1?]IY[]
MHUGYK4?0R?RKQ[<I/SF#Z5GWKM@T^A$B>X' 99'C+_*2B^&0PLR>N<HI>+SB
MOF4%MU/-I^5KY>WD^+7QX\>?N\\24U1$W/+!-&VX&9\;FMN=@N0!JO;*B"5V
M6.:)[K7RL>UQL-IL"2LMY\%]E0;N=^ZT#^3COTD;RS]S_@ZGRX^JY5W'/?TW
MDR>EBI1RPJ!6>U7ZS:\^>\6^NV/-:LW.K^33]DY;-'O=-T\77"<GR@*[JKW;
MCU6-?G:)^@E^3.!;Z[H']:-16,;G^U9_B2T.6]51'")VL:_!R/\ R(*^@(<Y
MW-X67I']8J^Q^#C\AO5"Q*X?598'S3-?0E>?>@WVEZ>/K!?"MW.IZ&3JE()6
M['4OH.)%&,W;R)L*L)U5"R,,#2.=$WEBCX]I*R<2!AH:'.F)(5#QS*Y@UI'F
M)1$,Q'&52BS3VB,X8WCAXK$AV:TG!'(USSPF7,6 ,#BXANIR@V =>V5UJA[6
MGN 8RTNC$HSEK (R[('N+RT-#G:-S$9B1:^87[N2717L7A(2QGA$X8A,B'-C
M(F00B#SJQVBX1V*R;;'%TZ^C<F=#P:HK'IF#1%NT%XTV3TV=ZJJII[9=*QK!
M)WSF. <"QCY.](S!UHVN(;;7,0&[-=0O+89'/='9K7M):6ODCC.8'*6CA'-N
MZ^EA<\R<KU&D8B8=<JMED?<JO ,G"/)"$=KL7XQ9T(,FRA$<Y5'%6K(FP479
MN45=F9!FT>ML[Y1=-D5M-T]:7BK@^OF<W5KFP.:;$7!IXB-" 1H=A (XPK;A
MK2RBB:[1S73-<+@V(GD!U!(.HV@D'B*L=R/6\M8>4=8)([FU\21EV L0.7N)
M<X*<&6 2#XDT*CRCQ5,)&H/*5 .QN/@XLR4>I@V3%TAJD7)E):ME67$7AM:^
MMIW6>X3R RM S ,S,;;O6L=ES-#1?* ='$O]^2XTY]4T%K#3QD0R%UBY^5[@
MXYG/8#E<YQMF)!.4!GO &KGLNN.$:N&U,ZL,QF-@T4%@'M+%(%&]PA\!*X9-
MJ^DK%L+CFK')*"2:(J%&B3ENX82-R>(JRQJ9518J-O8@_!B+.[*WWMFQMLYK
MF/C< &VNQS;BX(<2<X=HOD:F\IFX)N9WOLSY'9FN8]DC27.)M(U]N5N49+:W
M:OX.BO4*Y@-DL-C1"2FI'83V9RF2$V[!FZ-2&0IJ+.5M6(MNU8,& ]DBP""&
M3=+;=L'%L$WCH@_P[(NZYCC R2 7+BYLCW.-KESGCB&@ %FM'$T $DW)GL(D
MX2.8Y0T-=&QK020&M9IJXDDDW)).TFP L Q+D$IA*9[$^N:;_P :%?4 GEXP
MKX/IO)?VCU3<2WZH\IO9L4*\D%HJU74#UG%_F24^NH[R$Q[<X_E+.RF4Q@F]
M2?)W]I$F3<J2M"7EW(_#")?-I;ZT=<M6 ;O/TPZC56L<\/#T1ZY5/.3RA%*-
M*>MB _.-C_MVYIXAN55T+_0MN@WRFZ5J;_RAJZJIG<3U=1_YZLOJ*0<G,!WJ
M7Y.[M(E#8WNT73CLY$N+EL581PB>2U_R9O\ P"7Z/7G.#M/C/I5_&P>(>A15
M?'JAG?R/K]-:<WL+W^F\L]1RU,0W*HZ,^D)1?+RJ6CA$W"@O4_!?DM?ZR?<H
MV*;_ %/ECJ-5SP[<J?R#UG*7%ML:HJ[;9QKKJGOMMG/W,8QC7.<YSG_LQC'W
M<\T%NK5XSW[Z3X^YGM/1GCQ__<6.?VWG6_<;%OT=5_0O^Y<_1\/SI-_I449^
M<6.?VWCW%Q;]'5?T+_N1.'\'5<E4775,TD-1V'$;'!"["<!B):'&V)U@R+:1
MN//MQSERP5622>:LWK1SE#?;"F$7"*GB\G?7.:1W3TM125D$=3#) ]U,'M;*
MPL):99&AP!VB[2+\H*L^";M+TY[.-,$Y6U,KRKO#-?C2.[7\M9?ZK$\_3G<A
M^+.#?(V]=ZI>(;[4=(?0$LCED6FMJ[V)G^_$[*?S:<?M1@W.8>RE\$X=^L?_
M "TRFL$WB7H?\;%OM<X<K,O/Q]E>_C!J5_F<P7]M5^<[O[%WP#6?K>?^#H%6
M,;WF+H!VDBUA>=)4,FV> G_&R]-/GM,_V36!RJ]VWXK8OT,/\73K>PW?J?RG
M=F]>HYS\TJY+4L]EK?O:^IW\N,M_4);G4_8L^$<4^11=N%!XYX*#I'=5:)7.
MVJMK,*\_#^#_ #PC/UTRY\I_ 3=%)U"O3/?M\IOI"]ECGY$5^2;?9 OXH7N#
M\GTQ_P"HNH>6[N$_&O"?*K/^WU:T,3W&?Q,[5B\PGGZ25.1PB]7;P2/XLOHW
M_-OK7ZC0Y^7^ZO\ &3&OUA4==7:BW.FZ&/JA97W#[F=3:-B5DU=<?8RFZQL<
M[4,J)AH/-Y_'8Y*"@\Z$D(D,]8AB;YN^<MBA-@]8,5DD=M'+MJN@EG91+;7'
MRPC",4K)J:II,/K*FGCJXFOG@IY98F.9)&]X<]C2T%K7!S@3< @G0K,]1!&'
MLDEC8\QDAKG $@@@:'E(T7DO<_4JI".$6\][&S[F=3:*Z+R2L+F[&4W5]B'>
MT,Y*AH3.9_'8W)B@TW"*F$AW[$.4?-WKEJ3*#GP]DNDELFX=M'""6VRB6^N.
M*>R)A&*5N-QU-'A]94T[,-@:^:"GEEB:YDU4Y[7/8TM!:US7.!.@()T*L>$5
M$$5,622QL>9G$-<X D%L8!L>4@A;=7.5*=1PBI_,.JBY>4S"Q8G8"<;L4GV$
MB'8R$%C41]U,;B4IC77P)UK(@S,;:R:+OI9'Y+73>4H/=6LFBI-B]E.'+ BF
MH&;[NBSZGSW]=J^(GK+/(97->P:O[C"L'59DQ$J"EIM3X2=,3\W?(V7BT3LP
M%Z2>-$=F<](V.I(13. R2O#4+- VS=*3GHH6/Q4D2_*/7UY;W\>JF^BZE$41
M4%>4^")/3 NOXRPCS<J019M71+=MKLH[>Y8#D6XP4@Y>*N%6884W;B@S/= 4
M,;H,&;=+0L'752OPB_GCQ_WX_P#/A$>/'_?C_P \<(OYIKIIKKHGKKIIIC&N
MNFF,:ZZZX^YC&NNOBQKC&/\ !C&,8QPB_7")5G9SUS2C^+1_]7AG+K@_P?!X
MY>V>JCBV_2>3'V;5 7)-1JLMU0];*7S=,_\ TO(C&]Q/2Q_:I7!]\_9/_P *
M9URG*UJ@W<[]UH'\G'?I(WEG[G_!U/EQ]5RKN.>_IO)D]+%2CEA4"L]JOUFU
MY\]XM]=L>:U9N=7\FG[)RV:/>Z;IXNN$Y/E 5W57NW'JL:_.T3]!+\F<"WUW
M0/ZT:BL8W/\ :L_Q)1)BXJCCNP?606G7 +:0MM7D?U,3B,C-CC/=?+71V'P]
M*(9)MMG.NS?5=EY]+9?7*6-LJ8SKRUF6)MLTD;<WO;O:,W%I<ZZZ:*LMAF=F
MRQ2NRFSLL;SE.VSK#0VY5G3PD.'[LM'[]DQW)/=!H[1XZ0;;D"*J*[A-@RU6
M4TRZ>J-VKE?1JAA1?=%NNKJGG1%3;7Z7 M<VOH.<\@7S )O8$V%S87L!QGD'
M.GA1K\'(_P#(@KZ ASG<WA9>D?UBKY'X./R&]4+$KA]5E@?-,U]"5Y]Z#?:7
MIX^L%\*W<ZGH9.J5K0R[KI,\JS O!_<LU-.>PHZW8+AK+SU=N(X!2ZZQ6D"#
M!J?$0B:,A11PH*-)K#G<)EP!Y%B&R*& \E4&'(U<GP.N]S,M^';*RSW1EH%.
MR$C,&/ )L[0L>TM.P.LYM7;4L[P/SD>US#)=C9 YWME\X):7L+@+C7.QP<+Z
MMNUW<#^OTN9]=X3UP5(1U>,QUC3D6E!M0N><.IO!HZ3 D+= O!CT4Z58-9J.
M&EX@T9.I <W?QN0/,E"K%YIXU/7 N$$<%P0T0M>XDGA&-+3*T@BX#VAS+9G:
M.V@A>34,-1)4V<'N,SF !MF2.!$+@;ZY"0\D!MG-%@1HMAKK7C&*5A>,8QC&
M-3^,8Q]S&,8E!OQ8QC_LQCE2Q?X1J/V781*R85N$'[7MI%.G(U2"2 8_=8I\
MHO?I*O.C,]XWR6^@*A2>$D\MW6*Z[GI>$P/II^#DU^6QOT!3E7[H/"T_1OZP
M5DP/P4_2-ZJN;ROJ<2F>Q/KFF_\ &A7U )Y>,*^#Z;R7]H]4W$M^J/*;V;%"
MO)!:*M5U ]9Q?YDE/KJ.\A,>W./Y2SLIE,8)O4GR=_:1)DW*DK0EY=R/PPB7
MS:6^M'7+5@&[S],.HU5K'/#P]$>N53SD\H12C2GK8@/SC8_[=N:>(;E5="_T
M+;H-\INE:F_\H:NJJ9W$]74?^>K+ZBD')S =ZE^3N[2)0V-[M%TX[.1+BY;%
M6$<(GDM?\F;_ , E^CUYS@[3XSZ5?QL'B'H4#=J)C%:_Z]VE,IQ(1$4B<?CN
MKTW(CSY 8'%-/;)@CZ2_?NMTV[9'SRJ2?G%=]=?+4TU\?CVQR1P>*2;$Z2*)
MCI)'R%K&,:7.<<CM&M%R3XEJ8AN51T9](6OM\/GI/_I445^<>-?V_G2/<?%?
MT=6?W>3^54M'P^>D_P#I445^<>-?V_CW'Q7]'5G]WD_E1; ?5"9Q.P^O%732
M"R,/+8D?!NG821@'[<F'*MDS)-KNNP?M=U&[E+5P@LCMNEOMKA1+?3.?'KG'
M.<8Q%)!B=7%-&Z*1DC0^-[2U[3P;#8M.HT(.O*KGAVY4_D'K.4]O_P#(7O\
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MD@7MG>&WMQVO>R^<TG!0RRVOP<;Y+7M?(TNM?6U[6NJ/_#--?YBB_P"FG?\
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M\]7@.*TU-&Z:>:CD9%$P7<]YM9K1IJ5LT;VQU4#WD-:V1I<X[ !QE>KY%Y,
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MGB >UX#(F- <QCHF$ "P#(WN8QH[UC'%K0 2L&61WOGN.A&I)T)N?.0"3M)
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MOM8&=RN"2->YE14/;&Y[)'-J87-8^(D2,>1#9KHR"'@V+2"'6(4>000"RQ<
MX YKD.]Z1KJ#Q<JS*6^&:\)OUWFT?1LVG*ZK67L%F,H$@;$INP(R^=(CBJJ:
M#S(PO-1SU=A[9C'3-51/&FN5FKEOA715+?&OPC[ENY[$8)?:U9-4PO:Z%\E/
M5P2 9V:C,R%S0[(\.%^(@VLOH.%II8WF/(]CFR-#VN%\KKBX)%Q<6/SZ@K?V
MZ9VW*;]ZC=8KQG"0E"96_0E367*T #1=@#1D4V@P21F$P[%T\(.68W1^17U9
M-G#]XL@WPFFHZ7WURIMP7%Z6*AQ7$J*$O,-)75=-$9"'/,<,[XV9W -!=E:,
MQ#0"=;!72!YD@AD=;-)%&]UM!=[ XVVZ7.FI-MI*U#O9.?:[LS2_<RG:\J2^
MK9K:"%.L,1F!*(0J=2&.1U_*EK7N@.K(G8D6_;,ES"@H8.';D%$MG.S-DU;Y
M4\VBGKKU?V-L,P^KPBLJ*FBIIYVXE+"V:6%CY&Q>U:-_!A[@7!F=SG9;VN2>
M,JOXV]_#1QYW<&8FN+ XAI=GD&8@&U[:72+IC=7?:(U:A;"7=^9RX.U+5L!F
M06&7C8)D[71VWH5)K!KH/*UUFK&+/"1Z,0R5+OFT)DTOWAQ8$_C$Z]S$GTT#
MJ7B&FP::I-+[D1Q/+:B2%\U)"R.H9231T]0^(!SI0V.6:(-,T<7#,D;+!PL7
M?J(="6LSYVN%V!P:YQ+#(USV!V@:26M=[USLI!#LIT7PGMY=]8)6\<M''=J<
M3*.FBPN-E](+>,].N(5+#408SH;%9&]62'QTD9VCC[SQ+W"G9D-CA-F^CLG(
MA9$A@5N@I<&GJ)*;W)CAD8QTC.'I(6":)DSH'2Q@%TC6<(VS>'9"Z1I$D37Q
MW<#H2U@?F:X$AIRO<<KBW,&DZ FVW*7!IT<0=%O"^QV;IMR^/!W-IQ=5E3:U
M9BE=EDQ]*3SZ1E)0=3!B644]K!.A,NY=.]1X_P!(7]$:85\RAYY3S>FOE[>/
MBO=_1TM#W0&&CIX::(T=/(8X(VQL+WF7,_*T 9G6%SM-E:L)>^2D!>]SR)'M
M!<2XV ;87-S8<2HG[+2_>L]6?Y?SG[.C/)OV+/A3$_D#/XB-:V.> AZ4]0K3
MVJFF*LLZB+FDC(G,TK>J:#/+%<M]Y# VH BP;2^,ADHO&JS\V^LR=:(1%W*I
MW-;)&$@<>K9B#19GXX]9NFQQ[UFJK*JFKJ.,MA-)53-IP>#G,C7&*1YEDJ>]
MIH+RB*"&G<U\E2YY+)&D&,04<;'Q2&[N$C:7^^98V<!E#-7N[W,YSP0UEK$:
MW17E,598G7:X9L*)3+6VJ@A;.>E6R\A@:0(KH[M.*0O,2C=8H)O[+D(P7!3Q
M"QY3<7MJ'C,3>"_<04B&_IHN6DU1655/B%'"YL/M6KF,#2(Y\[+4TLPEDJ3E
MIHWNGC;3Q4>5\DH?PS9AE=$W#(V/BD<,V>-H<=6VU>UM@S5[@&G,Z2X#;92T
MW#CLS^Q$_P +N]_S<Z[?6=S<YS[*W@L$Z3$.K1J8P+;4^*'TR)\GA\_Q1W<7
MY JS]N]6\H_<-^-6$=)4_P %4J2Q/<9_$SM6+0A\'=&NNA ]/R=OV+4(*;OH
M39D0@D7N./664C8T<6IFQG)NS63F(5I.HTYEL?(-@0B(C)&['KLMBAV3Q]J\
MFX2#(.>X]T$N(-C@;24]6^%LU--/+224S9'.964X93$2U,$HB>TO?*^-K@<K
M(Y"V%\Q%9I1$2XR.C#LKPUL@>0/P;CG%F.;F! #02+:D=\&WEWHE!ZX8U\>'
M306&S,)A;E5-)7*GZU*DAE<=;)7#)HH\MN5";4B,S=F:D"%//$K/B<4VKV2$
M=FT+8E+ A9W:((%=7&YZ@U$;H7/X**DJG10M%8UU1B,4T%J2-]++"UE5(TAE
M-++[8C;>=S8)H^&+?I3-8&$.MF=(P.<>#(9$6NO(X2-=>,$W>UH:3WMW-.4&
M8O8V7XUVH?Y.[K_9P;YJ>R)^*]7\HH_XAB^F$;ZSR).J5Z+=Q>J*T_Y.)Q^K
M)3G */?*3Y3!VK5:I/!R>0[JE>2SU6OS/7Z:S$PH]E81E8%7RNL'TM@.S'6?
M07)YR&,B)K"\$78QLH>CLDC81ZFCJ:CKY=CJ^1$2:-&-V!T?^I<3H?;\,++1
M/,%3%4MBG!,$V0/8^&;*'$,DCD>+Y)&AV7/'(S-&ZD0R\$YQNX9F%A<WWS;D
M$.;>VH('&.8M-B)>+=EJ@E%BWF?, +"$1_L3!%ZHGI 4SB1&3M0T;=T),(C;
M"8_+X */V?.K2ITI,;C#+DP05][K'R8"0ZO7"[S349AU7%3T4;)*=TF'SBJA
M:XRMB+Y!70S4N:SW1TT%+5MAHWAKWMX)O"1Y;!?0S1E\I(<&RMX-ULN8 <$Y
MK^(%[GQET@N <Q .MUS*9LYG<?A-.N-AC!+H"%,]KNM;&.AW[M(@3'QB,3RO
MHI&&Y<@W0:MWYK6/A!N3+ULU:MG939VX;MD$5-$M,5E,:3N;Q&G<\/>S"\1=
M(]H+6NEE@J)92QI)+6<(]V1I)(;8$DZI$_A*V%X%@:B&P)N0 ]@%SQFP%SQE
M>L'S\NJ[+S#O#H]4+5ZR^$ N&:6&O%]A?9BQ;-OBM,QPNY)O$86>L$WH.UD:
M+@8/T%F]=]/&NP;JD44\>+.KQ3GZ1[B<4I<1P*DAIQ)FPVGIJ&IX1@:#-' P
MNX,ASLS.1Q#2?[(5/Q*%\-5(YUK3.?(RQN<I<;7Y"E1.[.L)^7EQ][,I$\-S
MZ0Z2R:EG1-RN1E,F3.K2;0\;=J[[+D"N)"X7,Y>N-]UMB*JCK;?*NV=LV@4U
M.UD,8AC#((^"A:&@-BC+!%D8-C6\& RP_)%EHE[R7$N)+SF<2;EQO>YOM-]=
M>-9Y2U369V\["PJI(N58E+8O6?8$,3<T+NFS,E+9.[</7).1F]6I-YKL]>J.
M'3Y]Z([7475W4VTWVWSGGPK*JFPF@FJI6N;2T,&9S(6 EL48#0V-EVCO18-;
M<"PLO4;'SRM8TW?(ZP+CM<X[2==IVE>M5UO@1VJNN]"U?*-F.TFK>EZM@4BV
M&.-W8W8[#X."CQ?8>Z41;*.6.2 YQEHX4;H;K-_-J;(I;;9TU_+.(3LJL0KJ
MF+-P=165,\>86=DFF?(S, 2 [*X7%S8\95XA:611,=M9&QIMLNUH!M\X6L5[
M*XHVI6?7"G.Q;6"A$;N+WY"JH)6/IHY]T#RNFU:75)$(FKOEQEID6D=:MR>N
MNK75?TA+7.5LZ>/3/2/8OK:HXC5X>9WFB90S53:?3@Q4&IHHS*!:^;(2W;:Q
MV*'QN-G!1RY1PAD:POX\F20Y?%?5:*G.V*MHX1>PSUUHVI>NM112KJ2@H2N*
M_&-UBK"+1_1SH,:D9 KL8-.TM73ATMA4@3=N'B_C6SKE97?.NNNOBUQ^3,0K
M:K$*N6IK)WU$[B&NEDMF+8QD8- !9K0 -.)7R*-D4;61M#&C4-&RYU/G.JI)
MX;#\59W4_DG3_6V-<F>XW\9\'^5'LI%K8CN51Y ZS5Y8//TTJ8CA%ZE_@/?Q
M4G2_^38Q^T&8\_,_=I^-&,?*&?P\*N>';E3^0>LY-.?_ .0O?XHY_0[\K VC
MQCTK=7C";_\ 7V_UMO\ ;GGZ_7/U^>$6_;[$X_>1=A?YU)7]DE5\X7[*/PU0
M?JMG\75*S8)N\O3?X&+:;YS-32\J[PS7XTCNU_+67^JQ//TYW(?BS@WR-O7>
MJ7B&^U'2'T!+(Y9%IK:N]B9_OQ.RG\VG'[48-SF'LI?!.'?K'_RTRFL$WB7H
M?\;%OM<X<K,O/Q]E>_C!J5_F<P7]M5^<[O[%WP#6?K>?^#H%6,;WF+H!VDBU
MA>=)4,FV> G_ !LO33Y[3/\ 9-8'*KW;?BMB_0P_Q=.M[#=^I_*=V;UZCG/S
M2KDM2SV6M^]KZG?RXRW]0EN=3]BSX1Q3Y%%VX4'CG@H.D=U5HE<[:JVLPKS\
M/X/\\(S]=,N?*?P$W12=0KTSW[?*;Z0O98Y^1%?DFWV0+^*%[@_)],?^HNH>
M6[N$_&O"?*K/^WU:T,3W&?Q,[5B\PGGZ25.1PB]7;P2/XLOHW_-OK7ZC0Y^7
M^ZO\9,:_6%1UU=J+<Z;H8^J%<*[_ %+6]_)?/_U4+<B:'?:/Y53]JQ?>3P<G
MD.ZI7CC\_6RH2.$7H:^Q7/Q;LY_G8V;^SBF><#]DW\8H?U73?Q%6K3@NZ/Z=
M_4C6RGSG:EU7B4R*YC\9D8%&D<-UC8(N(275LJ+;)H*$A[AGHLIKHV\K;1/9
M;&^^NOWV==<XQ]WQ<^T$C8IX93F(BECD(  )#'AQ UX[67RF8Z6&6(6!DC?&
M"23;.TMO:W%>ZHM\&[L1\7H/\O@O]GY9/=^G^(F\[/YE >X<OQ\?[KD?!N[$
M?%Z#_+X+_9^/=^G^(F\[/YD]PY?CX_W7*W-1:W96\)8Q5]32!)PT=D7.SIK9
M$921VP]=J.--==%F_E^/37?&NV<_<SGQ^+[G(*OJ65=2Z=H<P.:P97 $]ZT#
MB=93-'3NI8&PDM>6EQS"X!S.+MA!V75)/#"RZSWW@R>Y;0Q4.P(8O3[_ $>E
M_=]'2?H"/MR&SE?T!HAJX=>+;&NOFDML;Y\KQ^/Q8SR8[D+?TFP;4[XWB_Z'
M\Z\U]_:=1H/!GCYQS+0EZ&G6X<9-4XW,*\@]FJW1UE(/C%ARN#PP:^ZVC'UI
M^_\ QY4E/B P.<CY(T]IMY-X*T5?$I9$115)8*7CS"0-N=ZQR,O=#PD-1/3^
MT\2:UE/%-,YN(N%+[0D#8&N?'(U@JVPSG*V*5[+/;(Z,JKTQL'6<UK^$A)+W
M-:.!_"<*TEQ +23'F:+ES0="+A2WU/=0V*22<O89+:GA Z4=H>N\VTWFEB5H
M,P\Z0,Y/V#'7%%)&A(I#Y]R$<;I5@K8]*D$UIW+@2$;);0@T"UU<[ZN*MFEC
M@;-%53.BPS$(?P,%2ZV-&/#W4<L9CCL'C_B?:]8VT$3S(WAF/.5>X<H+\KF-
M#IHG=\Y@_P"&O*'M=<W(]YGC]\X93E(61> M([,?#"=9R,"CRYY#0UV WC4>
M<%&PERN)6Z]W-HT27)O_ #S=!9F*4](5V6RIE;=OLCKME577;GP[NLW]$,3$
MA&?)A^<@:%_NC19K#30NO;8O6&?"$.4:7EL.;@I/L7I JSFX?-*?_<9M_B]_
M_P")D5__ &Y__IN?G+3E/F_U5OUY!Y_]%Y2'3\R,!W.1>+G0<4E"U57F.J^5
M20Z(BPB-VV3J:9,:Y*YE9]V/"Q,RG)5V;>(RXD2%-HI,7$?D6QD)L,U,,?U9
MB['24@&1\L0JJ)U3%&Q\KY*5M7":AG!1@OE9P8)EB:UYEA$D>1^;(ZC4Y D)
MN&NX.3(XD- DR.R',;!IO[TDBSK&XM<67+%F^.[-<3EA>X:N09%G0,'O>X*S
MN"'#I%O+ 5!57OVDD LR DNS@Z[D4M:SI%.PVVSR$698JSY4/)CJI!57>-8P
MC!JB T+ZA[75\U#25-),YG!25]5[F1N9)'9C8XC > -IZ:G#>$C9ELOM<>V&
M.$N0?@VR2,>V^81,X8@@W-SF[_WKW7L2JUZ7)*[Z[G1BYI0W24DDXO6!FM1+
M=PIZ*/9H2H"QCL99OGNRKI9F"",1<?9D2BSHDY:L$GA9X]?J.G2T@ZDCH<&E
MI(B>#@H9V9CM<[@I'/D(&@=(\N>6MLT%Q#0&@ ?'A'2SB1VUTC3XA< #E-@
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MNY35YZ:+2T01SNJJLCZ+OCSVF$,*[9\A;3G6_8O(&!UNO_\ +2[;#_P=%SJ
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M>)RQR3LI3.711Y6O?PM-- +.<;"QE#C?B!XUKU<+JBGDA!:TOR]\;D"SVNV
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M?2>(MD;,9-<T+K2Q@56R1RPC+%1EF(%%Y#,H"8$(2(KJ$3A4X$R64R**9$3
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M;ZF21K8J)<CW"(>61! N&#'GQ *-)8\YUMLU\R9P2>9'#GY#5F](98LG3S#
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M0N+8$^AP^-UM+5J[7F$3 5Z;U3G4<!(&7 0A/<OI3+1LD(F#*C\LW(^;UO\
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?$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>59
<FILENAME>g713200g93a29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g93a29.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1M&4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
MY@  !<T          0                         !              7-
M   "Y@                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "Y@    !29VAT;&]N9P  !<T    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   N8     4F=H=&QO
M;F<   7-     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    (.$))300,     !"X     0   *    !0   !X   E@   !"< !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !0 * # 2(
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MCK['@"EC6$G'LQH:WZ3?YS^<W_3L5^OZU=&LO]$6EH):&6N:0QQ=_*_,V_\
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MJN=Z?IM4D<?I)D-:L+)3U%'KJ]E7TWT\AM_VK)<&DD5.LED'=[7-CW_2_/\
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MQ*B7 'Z&_P!NWV_R5KBBMN/]GI_0L#-C/3@;!&UOIZ;6[/S4M>IO^Q,I76@
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M.QZ]H#*7-V%@'M:ST_S-O[J,I&H__]DX0DE-!"$      %4    ! 0    \
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @
M %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !1DU-
M "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %     0   '8!
M*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    "0
M +"':0 $     0   +P   #H "W&P   )Q  +<;    G$$%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#<Z,C$@,C Z,38Z-3D <G(U,#DQ
M-C<       .@ 0 #     ?__  "@ @ $     0  !<V@ P $     0   N8
M        !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H
M  ,    !  (   (!  0    !   !1@("  0    !              !(
M 0   $@    !.$))30/]       (          #_X0%(34T *@    @ " $2
M  ,    !      $:  4    !    ;@$;  4    !    =@$H  ,    !  (
M  $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I  0    !
M    O    .@   /      0   \     !061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD ,C Q.3HP-SHR,2 R,#HQ-CHU.0!R<C4P.3$V-P       Z !
M  ,    !__\  * "  0    !   %S: #  0    !   "Y@         & 0,
M P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P    $  @
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M 0$! 0$! 0'_P  1" #M =L# 1$  A$! Q$!_\0 'P !  $$ P$! 0
M      D&!P@* P0% @$+_\0 6Q   00" 0,# @,#!@<'#PP# P$"! 4&!P (
M$1()$Q05(2(Q019181<C)#(S<1@E)E*!D:$*&4)55M'6&B<T4UABDI26E[&V
MP=/P-SE$1D=7<G-V=X*$E=35_\0 '0$!   ' 0$               (#! 4&
M!P@!"?_$ %$1  (! P,# @,$!P0%" D#!0$" P $$042(083,2)!!Q11(S)A
M<0@50H&1L? S4J'!%B14T?$T8G*"DI32X1<E-D-356.BTX.3LG.CL[3"_]H
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MRD!6-<*IGS!L:UEV(B$;&)(1/GL<T?N>\QK7[IZ'ZU^>2/2M9G_]8%]EK<R
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M;M ::]BLA96DF?#K#8WAA,JC+!NZR\BV<BLJ\KE4<$'VYMXTSW)Q?-G&8_\
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MC@>V.53Z3>^\"PNKQ[5?49K6AM,@Z8=_]*NTIN2ZJN\DAR,*VYN#8.W<>R;
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M?$+I+0^HXS+HVL:O#IE[&LTENQ%\KVT!2:%TDC9;F2%E8-C(&X,N5,*FB?7
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M)Y (H"R91A1XX!O,<YR,$$(AM5Q"E*]6L&-C45SWO<C6M15<J(BKSPD*"6(
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M,83+8!^^S'G(-2\W%O6T%397ES-C5M13P95G9V$PK0184"$%\F7*D&>J,$$
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M'.2,!\-SOPL2$-.R[0Z?^(;V\<-GKT<UU%$@BBU*$AKR.-1MB2YC<A;N.(9
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MX$I'@E/\;YH/35UK5Q=6A6:UFCLI+BW>:)TB>9)856*1G48217<;ERRL <$
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M]-AS36;:N%'R.VBK619QK0B?T./5EE.L2'\7':.(OLA(=6"=F.IB[?3KR.Q
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MLK:VAMYKYHP0>U-=/,D9D W]B,JK!7D5M<G]H_+[J]RJO=5557NOW^ZN7O\
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M!.^]3ZHTS1+'4M5US5]-TJPLXVNWEO;B*SAM;->W&V^:5E[K=UBP)9G/<2)
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MM"S&-&935T>,:9+F/16.9X,$CR-8,:%<5[.S^W@O?MW\>>K]4A!EEN([>WC
M#F5D1"6. "[E57G"@@Y)X %83T!UC\&= ^'NMZ-UE\()?B1UYJ74$UWH^IOK
MFI=-V>D:0-,L8K>)K[0[Q-2O-MZE_=2Z?\M;QX=&:^;=LCN!37PI4NZIX2K
MGUB]SO(#NT,F1W\G(-SV*>5&?XOD (X957MY-5J$5EKE168D $'!5_*29 (
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MLD0+3I$R;I_UW@72)@U7D\C5NR\%O(^O)<N9@F:8_D]BDK%9LW,6WSJ^P_:
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MLK*.>;]87\ MH9;F&XGMFCC@M+BXN(77>Z7(MI53TAA:?K:SOJ$K.D>JM=2
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M#S$G9?)R-<[LWLOE_5[+WX:22&&[F@_MX;&_F@QG/?ALYY(2N,G<)%5E('!
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MZI:0]37UAIEH7W_JUM3LI]2U+L?:-:PQ03RB-6V@2N[*Q0X526R+9J&O]/\
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MFHZS8]>=/W>F:-,BZE,T#+:7$B1N5AN(I)7C<;HY%C12S;"6&"&4'@ZLZ2Z
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M'FULMAZR+5R"R;41&.CQ9>"]>ZUIEKITFES0Q7M[=H#%;MXM1R4NY'7E&7S
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ME2FLV=TN]Y5@EP=\4C! I\_9EFY7'N?'^-3[FUG3D)O7)&Y<LI)/X<GS]/'
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M2WCW[],ZY=<Q#,D L?V6JDDM.*PQVU"9SDCHA2Q[+$L:GQGE1[H\JDKS@49
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I&,;6L&QB(UC&,1&M8UJ=D:UK41&HB=D1$1.*5]<4IQ2G%*<4IQ2O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>60
<FILENAME>g713200g93m30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g93m30.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2HP4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %8< 5H  QLE1QP"   " 0$< E  "')R,C8T-C$W' (% #5-:6-R;W-O
M9G0@4&]W97)0;VEN=" M($E03R!P<F]D=6-T(&1I86=R86US(# W,C(N<'!T
M;3A"24T$)0      $!AXZ)PG9:$FP@U%<#"ZD0DX0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /
M     0 ! \     !  $X0DE-!"8       X             /X   #A"24T$
M#0      !    !XX0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _0      !( -0    $
M+0    8       $X0DE- _<      !P  /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              )-   $%          !
M                          $             !!0   )-
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   )-     %)G:'1L
M;VYG   $%     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   "30    !29VAT;&]N9P  !!0    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     (X0DE-! P
M    (#4    !    H    %H   '@  "HP   (!D &  !_]C_X@Q824-#7U!2
M3T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A
M8W-P35-&5     !)14,@<U)'0@                  ]M8  0    #3+4A0
M("
M     !%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W!T
M   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0    !1D
M;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #U
M "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#   $
M/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER:6=H
M=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P
M   2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.38V
M+3(N,0
M            6%E:(        /-1  $    !%LQ865H@
M     %A96B        !OH@  ./4   .06%E:(        &*9  "WA0  &-I8
M65H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W
M+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
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M<VEG(     !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H "T
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M.K(Z[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^)
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MIK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ /4V,:QH8P!K&@!K0(
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MQ:+7N+7$#:#^D?9O8"75>ZO]'_@OTM?HI*?_T?0#EM9UZVJZXM97C>I74X@
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ML!#J]U9)]ON;ZMMG\YNM_1N_FO0_G?TR.>K]3K(%_3RP]S-K_P#VUQLJIO\
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M6XY CJ[ZF-(HLW;1)V/;^CLL;N9>[8ZWU-]O_GNQ7>F95#VNH&:W-N:YQ+A
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M>PN;[4=)3__3]$JJO_;EUQ8YM1I#"[\UT%CJW_RG>^^O]^OT?W+J%:R,+&R
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M &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '  ( !# %, -@    $ .$))300B      %&34T *@    @
M" $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H  ,    !
M  (   $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I  0
M   !    O    .@ +<;    G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD ,C Q.3HP-SHR,B Q,SHQ,#HR,0!R<C(V-#8Q-P
M Z !  ,    !__\  * "  0    !   $%* #  0    !   "30         &
M 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P    $
M @   @$ !     $   %& @( !     $              $@    !    2
M  $X0DE- _T       @          /_A 4A-30 J    "  ( 1(  P    $
M     1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$  @
M !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $   "\
MZ    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*0 R,#$Y.C W.C(R(#$S.C$P.C(Q ')R,C8T-C$W       #H $  P    '_
M_P  H ( !     $   04H , !     $   )-          8! P #     0 &
M   !&@ %     0   38!&P %     0   3X!*  #     0 "   " 0 $
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M*#,T0D=2T?_$ !0! 0                    #_Q  4$0$
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MMKC>1/N-6/2"Q7+=H[D2:L#^S-OVK''HA";[#=)1$/F"R3D6]17%MPY4'\K
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MD[J4P+8NUC[,V)DY.,2B*N8S'Y*:>O@(T,EF7DD8P"WKVA9Z"."<4JZ=677
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MWCJ^@:\73TG$B3TCT"IDT?D<O8:/5B#T60U:0L6J4$ADPVB=0^[&_;N362Q
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M%U@G+1SU0?U[)1<<01;*/G49%! NVC6'(1UP1"."]X^'XV.DK^.U3#I^OV4
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MQ?DFTDCL1^W!!=S%$UY(N$:1*V?$7*%(O7=9]<(F]JJ:JUX^86"2K"50VJI
M"[H4S,6)PJ/DKV/J8+O)+6E(HB[,&R78$D46"IN3A%4_%GJS<);?=B/$EA>2
MVPI6#=S++N.@QYO#'JO<?ZT+'^8AAGL[%)6TAC>MTYJ5A\UC-&/[.83P:&UC
M<R(5V@Z*F'QR.:), DVTYCXMJ;.];+\L"%5Z/)7=)QTUHJVVM42DZR*2&VIT
MQG *4DY2+C;X>&='K'MQ*71E27+M78R3RXO)@#8>ND?(LPIEV"&=+;GIP]Y!
M3O7V[+FC)+M"4&K=8YO7;]F.L&VG+)MT-E4S(Q'-?3"8YC&E>QQB=/K 6Q7Y
M@1!7@Q<2L2<R2-O L%7/2CKJ56:^1V)0DS>!B7U6&MFL^O<!1Z_.X>J=)0^K
M'L:'06PF-?5><G:[76L(:QB1JU+#>!VBB7U$GKKJ/")@0A^+]M^H<JL:B80I
MTP A7]M698$)E\]*%VS^JX'.8%W9T*HI";6C,:D$+FKN>=JM2EE5QN],0E&4
M3UCJ-06;S!\S *!WUGPKPV]1[KEL'5@\=ZYVOANW[6V>K *DF#/-MQWK6\5[
M7/1Y&3HQ$P+F#>/EX,SM<P!B1')I\\BN!&5\N5WP5T&?=E.]?C=0A-S7A+JM
M?7;8T:I:]:IFD",=>;'UL<E4]9,H%9=@0&>C997?S4'JDJ_L2I2Z<DGK 9!7
M#V>Q$EA_MJLLHU#/IC:_63I#V9ZXTE NMH.*.K&AAH<I<35$G%XA7L>LNT8[
MJM&"\L2B<@&FYM:<_':%APF42&/D9?(@+ :@:>R T%'O QRLNQ_2V\J'OKL9
M;/7K2LH#6N@/NQ-%I4*8SHI(8C9W6]=&(7_H-@*AU^K+I#U_5,0@S$T&KR2!
MTQY".(Z%VZK @^#J&78[Q)/M9FU=5ZW9YB",T=R,#->KUSB52AJ)Q&L>FDKA
M;"-R^N&^9I.-Z[LBGJ;VKP:P+R M$)U#QJ(9RT);92#JI7W(\=U)5) (7&JH
M"#^N3:U61N9*'HT0J8#3<_KSN5550_;FPP%AAPLG2/16ZWQ6:Y*F6Z9%92H#
M"NKAPID;G(3Q6E]>/4#/X'3T!AQ"*2^W(/6=!!16*+M8$*;QB05]9G8"N:2F
MD@(1%".0<YBNR5@6*C7LN)AY**%27WR QHN:9HJA;ACU ZS#)-'IF.I.O64K
MBD8JN%QZ0-8^V1*"XK2!%\6J($W=IYU5RPKPB2?N8NDKLID;NZ4U2V]OTTP&
M<1"B:A@4J>3>'U]&8]+'Z<V3=GA@_5N27TLB;[63.]5'&-]L[:RJ>;[2HQCX
M?Z29VRZSZ;?=P,8G_57KM:EDQ&XK$INOIA:D!VC^\+L Y'&3R61I2)R/>6Q=
M42:VUP]:+1Z0KOR(5=-7"PS8P?;L]T6DA.($ PXGT5ZAF0K2.D^O=8/ H^ 1
M"KA[!6-H928P.OI*M,8''F>^-\+-D(5*7+L[$W:*FA&/$GCUR)>--WCKW@F"
MLZ4JBF4##2J*^B5>,#ZL=6+CH>$9@1KO:(PN.UU%],#A^B+%L@ @L1C$5%-F
MC=!NS"@AK)%+1)MKC@2EP' <!P' <!P' <!P' <!P' C6X*M W56LQJZ3$3P
MH%-0JX0D0C3UJQ--6ZVZ:ON,U"# J+<8SNEIHZ&&Q)@ 89[.!)X.5#O7P]R%
M(ZF\575BE7]9$((E.QZM4JP)W'&N#4?:"%2-?3Z^K-'O7($/%!00:D3F'8^R
MGQ$%%1\<BP]DJ!"Q0%&@P-LPV"JC?PX)QRY:J;06UE(WU.KP?$G9>M<;R=W8
M<VED,Z\V9UO%GI"6W,:PAQ(%(3/1C?:6,HP+10#Q$6%7AA$S[4T:A>:@O'AU
M\ZVVL2MVL<31F<+14+'7H0J:%/X[N2$PJ"UZM-/;TC[4[F5&8C7,6&$TU#V\
M4250*E0L7$&)%('Y,.(*\;W6<7+NL4X^F2TA(^I,VO>>50\(R)-1-0QV&DDA
MF$V;2]LW&-4)*)%2F1*2&&,'&B&(Z9$@B::KEZ.PNJ''NCQM==+[OA#L!82U
MA.Y!LQ#L3<.82AFTKZ5ZA*_MJJVRLB#J W)E?W:\NVPHRX9CI"-%Y2*HET!Z
M$C:Z&<A$^GB ZTNA4W'R>?=AIV]L& 3BLY%(YI9 <Q(E(G.Z2$]>WK-F\TAC
M1LT6#UF"$CP:VC+/P%6JATMH7)OR:[T)%+^,7K::L"3V2]=61]HI;,-IN6T2
ME W0;]:VLWK-;&=6S3:.[[),_M3U/JW3V-UU=_I2LH9^][I9JY&!Q2OBZZS'
M; J^PC*M@%7E27!85ZQ8&0-QYX$3LBQKFF]\DC*3EQ$E)1'-1L^GYSY=&"26
M(_:*,)"XE86\U ,$V.P=:%\5G74#4:E/,97<VPA =UI& ),ZET=<2Z*M>HQ\
MB=H? 9SO"_H+O:((OT@*F)+'I F8#"Q>Y5-T:17,N0XT3\3G5Z'M*\#LB5L%
M(M7(FK!#&(R"8C# *1:4\QM@-#GDMV<1G!DJ_P 1VYII'#*K8N/2,C%!RKQ#
M8LV7)NP[V%>,#KK"WL1,8/W#+)%!G[7$:D\WG;>12!C$ =&VKUY@]:;$%0"&
M7$%KVNKGG^L7;KI[R)>2&%9-*I')BJ[Y9Z'ILWQ<]<;3CO7J-&#=MA676VIX
MK2D+<1F9#&#T]7T*/5;*XZ*F:KV,DD7ZS654Y!#[MX$;QY<NL/="C&7\;(.@
MFX3&RZ;PX'39FE(=:=[P$&\M:66]')1";!; 9O SLRGQ6R# "-ED8^H.*0?:
M1GSV,12?AIL.>#2[E@7P33;C=F(=+'.DT/C'7VS^KL<LBWHA3\UA(>LX6WB$
MS=#)E3L!&UC&JX>#:[FA1,Z3''#6X4K+"DF615(JR:3EB^F-"BN[]4(_AWC0
MIZ)1>CH(M:78&35W0NT-UC=9EIK%0E8R)E6,U%6-4K"6US7\!A4*5UK";@PQ
MZ-$XR"BY\ID8R$3@Q+X^AJ(X'4W=XJNM-^6K8]N3(W;K U:HF8CI@!C<S&,8
MH[>SOKA(NJDCD* XA%RK] TO3\@T%L,;%50P8N&8FQ AD[*2[[3!Q;A\4/6N
MYGUME2\FNR(E[R4LAG9Q6OY\QCKR30^V*ZINN)O73KW8R1;Z0HHSH.KI%JTT
M0P9;R0"Z]LY]GCIZ/$0L?</46O+QG,!F,YE=KJ!H,[AY%U5 R?OV=.SPG7,S
M96-7):=0%5NZ8/2\*G8T;)1I8 O'")A<<-$R]U)(X-8!6P17#O&]UZA/7R\.
MM0Q]9CZOKZ@N:LD[T[,DR\LCU6#X+BM8974+-N1'MB8Q7,*]0T-T?L3!5/91
MR4D)20F'CT@X",[]\8-;V)$;&=5W(#$>MF2$K6E\0D,N(D248C%@VO8= V@0
MDR8^**1:0(/HO,>MU;&8"\:G%-(R6:.7Q<9,&"BH)<.@ISQ4ULUJ@E%.S!I>
M[)M-[& VA99!3&%X@>)Q3M%9?:J.Q;Z5*VAQZ6C>TTLP@*F.Y=;3>9#&#7+<
M=%4-6PYD&&1GQ:R>"=KZ-LR&W.X:]>J8/5W/-Z^.JRX_8,YGE7]=9_UIBA29
MG'9_$8,EFT ED=%[S3 =B_7CL$"A2D;+2=9U8R@;F> X#@. X#@. X#@.! -
MVV;+ZV*TZD $A"0F>6DA!Y'N04>J%T6+F&S"0M4XXR;9;-<DG+V.I:;D"3Y1
MLT;Z;-=1#Y4CA\("@3#OG<>T>9E7#2K2:[6IE+O?*B(N=39R9K]CNOTJ;T1&
M4U+/?*L;/>;W0\8M)0JM(&RV@L.XTKO?<DN@F'J_R]KF^S:)OY*KM%E.NZO9
MI1+:+',IHI?1OJFG6E37%IX4_6ZEMGV5)AKOEKOJDKMFKT-MDM<A+G9GN-8E
M)RZ9M8T"B1T)$P6^B  @,(.),:+.*4OBU])<W,-)@-9MH:!)5$SBYD8I&U'C
ME18^OK(QJC1LGP+1T_:,CE,$F)J4(,9,8@TUGT/5?U\#7'C)OK#BZ[1$E%0)
M*3215LHX3Q@4X8KRLGI@Z/):8>(:>C9N&:5=:8BV!)0T# RX*P%'CL:5VE@3
M 15R8C!XM%Y$V9(Y=N5%]0\@!DQ;E?.-$%5V_NLU'+15%QN$F\!P' <!P' <
M!P' <!P' <!P' <!P' <!P' <!P' HQW#[+]G>O[J#(=>.@]H]U$9,B>5E#V
MO;>I2KFT 4&*#-134FG:LF#/S"Y[1Z]5;J"&:K1GH,4PY<^\X22U#6>S\J_E
M/7N8I!5?!)V'Q'6</2,H(ZW]0J#_ .?RY'Z_/;V$ZDZ=8O6CG#URQTBPX@I(
MF:PW<EL[>IK$18 +'B_(!W,5$1&46QX[[(ZN"4K?81N7 IS,Z^O*1S"L5JHM
M:6'9#7NU%2\I]F3D2E$3B.2&\S$D!Y@*0?APK-8R^1(!0]\.\BE[L(X58VKU
MK9MIG#H !+2"3#IAB'P653<I(XC'E644BI-E-+$!P-=Y)GXX7.Y$U= -Y'%R
MP$@28[[?.-PF" ]YK$FU2V-9B_7$B"?1F!1^?0N)N)D:<.Y6VD%E6/6Z80X\
MVK!HM&##%6OM9&]1$BYEJF"D0Q7&V=\>JX11(_)):@.(HNG76O0;-B97Z2-!
MI3"6GVFK8@R@38?(6F7-3Q#:38$2"=>LDBC)Z(,)QP$Y,LG^R"I12.A*$-[I
M6[8=5W'(6U%;U?+H(\-@8N7GQE"3P78B)6)L]C]F"H"L^FE?!TMAZ!ER#>-'
M!7 ,HP>_4$Q:F3? [R7]N+ABL4I%Z$I(;8!RR(6N?D[US)9'7H,.3;V+5=:M
M-PK-A [5=NP<@=62M,A:Y(BR>I0@ N_R@[=.54!X0:0\CEMR4;+=:PH!N0EL
M*#QZ=OX&H:+2*;D(84E=HP-2.OPK\-6H.&6 4DD1@SV-:OID>C[J-3]N:(.F
M(YAN_P!PLIUN[CD+[LXO7CN "8IJ-KUK.TW:$LDQ$[IJJ4$B\-3,6DM7P1<*
MP+_45"T5?;D'14B#12<'8[&":JXEH%ZN X'H7:MG.4,N6Z#C+9?5RVRLEHKE
MNYTTW3T<(9WUVRDOJFJIIJJG\*F-%%-<;?#OMC(8^G"8:BFS11B4921'&EI(
M/22!"TTV,B<*+*N#[-/1KKJV-+JN'"JQ5'&CY11=;?=?;97?.P,0B&8UQKB(
MQC&N#^97C7 $5C7$HVV^/:2?#AIZ?7]M\YVV,>GU'.V<YRY]<YX'(UBD6T?:
M%-(V U))M2#%,AJ''ZOM&1=YL1+,]'>&^%]6I0AML^(M\*82>O-MG+G15;;.
M^0YPL.)!CV@D(+'AQ3!'5NQ&"V;<>/9M]?7X4&C)HFDV;HZYVSG"2*6FF,YS
MG&OKG@0OUPQC%=&O3'_[N[-_\NR=LXX$\\!P' <!P' <!P' <!P' <!P' <!
MP' <!P' <!P' CF=V_4U69'?K.L^NZW^L_-8$9GDUC40^K98^Q\[@;F0DQWS
MWRGS+;+KY7W?8^81]WX/=3^(*R-?)5X_7UPDJ&;=Q.NZEKAXHWFQ",9M&*)I
MH1QVX0;I.]9"H1TC#AY\3ELJJ&;&EC;=HX0?+CDV2NCC8)*(]ONM;9U!6PZW
M(3,$["L!O6 0C 3@R>"&,R>1&5S9@/E!:)N2S&)H$ L,-:,"$@7'LG93Z>)0
M6W($V2"P8[#>\75^<Q=E*P5C)8:O8.SL3Z,_CLG8RYG%WSX</36(1%4-]HFA
M9NX,A-B,=4'_ &A$M#0=^2&-6)1@X<!W+ON+UR2KRSK1%6"TED1J$"I)9HZA
M@HU)WB ?1Z9%I/0PX2.<.I*W=F(Z>"MG8!,BRW+!2S#=TFX&/]&P=6Y[Q=3V
MB*2SBXXUZJO28["#5N9).\.Q"T?9N],MA@QZME!4A*XN+$O]-=QL@*R,",C[
MPF_,C6[H.P.]S.L\;*Y#EK.$H/=-F7N938&%F_M%A)PL">-7*([9(LQD6(T;
M$QMZ%R2;G9*.<Q<6HYD">P[ 96\['5$V/4W'F4C:G%[Y&O3E:$ K@<[#' +%
MN&=9-)E%G[9!1D[TD G4=HRR]>D-W6?E&BJ;=THB$<!^Q/32%2RPQ,?E=:Q.
M7K'#Y*Q\!X[D&1D$J!%3X,RL5?,@C7$OD^YV-3 *ST1<EC)PS%IB,$:$'\;D
M"#$.E!]HNDX&8D34?D]= ))9L6>3\Q.!T<0#;SL-"@S$F_>%Y.B+;.3Q"*QL
MPR*.&I-==X'"O='&VJ"&VV,!:R"SN)V7%V$SA!E ]&R;@LT:$FZ3IOC9X!,D
M(\;9+M7J#5ZT?"3@HD)(LGC9!TS?LG+5PBFLEOI@,NX#@. X#@.! _7'^SHU
M_&[LW_B3MG@3QP' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <"$;=ZT]=
M.P>X3>^J$I:[MHQA_B-9MRKH/9&8[@I\K]3U!YF(,SD5@CEBSR^PQ]CYO+1M
M[_Q_+I8T"JC?Q#>+IM9;ZVT>@O5'[:DHVC%'2BE*P=:,9#H.$'2>6]?+"5*^
M9F/C;HIJ25E%V\D7::_)+EE&>VZ&P2LIT!Z8-X]F*1?K=4=9Q_<]]J'0RGH@
M+IM$C(=(Q(H>V,%MZN2B*Q9\/ 2L\T%+DE'6PI5[A^.RV?MVSE(/0XZ#]7%M
M9+II GK'27ZBLR/0;-IR.U*N0A@$;&D76K.2(XW)H.8P ;?/>GO[BQ+,7MME
MDGE'8,HC'3CKU#X*?K>/PMRSA\G@;>M#8U673)\L]AC64S>9H"\DWT@<%4%=
M)'8LO?Y)MWJ1134IJT4>;,V YNT#J0O1WK1'6K9@'@;ADP8KJJC6*<OFF60M
M)260*;IL!C7:1918C&<CK*&.V Y#35HR;"=AK=+0<_)-7887_P"F[U V</G:
ME<$7"[Y2/K9W<V'8[K5HXBA*3&HTZ8)N):JDS=!#,Q/E1ZZ2>%$7CIKMC.41
M0A%B$W,NLU,#-XOL+BV1B<5>@"J+8>;/,V4C,Q7:.+1<_/6;<JFVL.11UW$8
MT]"2&;)G30YV':+-GZ>?>PJ$>SOI-1LQ:E7+0*Z!RQT9=RH5)TI%-%]@TQ6D
M]MS5N?28M):*W]UI*[QLDNWT'D!+IBJ<:Y"D [B.19T## D/''UW3KX'%'C
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M&>2V@_,30/5N+M8SWQ$6Y.\!ZJA,TBXCII74ID,&T/&8S&;!E-+R2N2%'L7
MBL@KLU)(JVE-.'W+H,!0'NXR1(N=$M0C.*=C_.#0$"G2<5Z5QSNA3543B5 8
M'-KKOE&@.WL_J(&P%FHY+)M%Y="1L%*F68(GF-E#K4NF:E,GBLD+J!-\/1RI
M,*[T3YX>\4+7T=]PO'S/I6-O"LX;VOHEAUB1D,Y,P"AK-=OPP"O[(VWA;4*T
MF,:<@4R1,S+S<*T5^V QH\^5SKHDW"V(7])8Z)HN]AMKUGVBH<JDLDW7'6-"
M*R(/O>4QZ[:M0]=W!.)(\VT]-OA;I </W&NN-FK);51+*@9?+_TD;Q<1TS7
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M4UB2EOUC#K#4C.AK9EDQH"4E(@IN+3)[#1^7^C/*.KK9DVV6QOLCIG4*+-?
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M:&<$SJA4(GL7QYUI*B; S"I9)*Y,."&&LR+LG1(T1D<$>3Z669(X2PRJ=',
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M74B'&)EIV.)CB$%3CV=(N@5:KL\!/0/J9Y/_ *1$G]S=X:COZP*_N(?9<$+
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MX['RE9;RJSWDD/BQL)@LHDIP.BS9[!L<MWR6=H.N]21^6TUV<KKMA10>S8]
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MAL*Z>#GB?KZZ[Y0<;Y24UV25QHIKMK@,XX#@. X#@.!!/7S^JLW_ ([=@O\
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M;YQC'Q;;9]<Y#E\!P' <!P&<8SC.,_?C/W9Q_JSP*(W[XV.GW8>39LF15?\
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M>!/' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P'
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M&_*AW.<KLE.!G_T'L;^]6D_R G7\RW ?0>QO[U:3_("=?S+<!]![&_O5I/\
M("=?S+<!]"[&?O5I/\@)U_,MP(_B46[7-I1:+@S:E38%$9<)=1++VF)F199"
M)5["6+W(=@EV5]P"R^TS20>^.<Y]UP2^?,:8^7)HYR$@?0>QO[U:3_("=?S+
M<!]![&_O5I/\@)U_,MP'T'L;^]6D_P @)U_,MP'T+L;C\;5I/\@)U_,MP(_$
M17M>G9<V(.[3J?$3=Q&O6H'9Q3,R<B<G&)2Q%9/]/!Z=E?F1;W#-]%_J9%?.
M43"61B#?_.#N,:A('T+L;G\+5I/\@)U_,MP'T'L;^]6D_P @)U_,MP'T'L;^
M]6D_R G7\RW ?0NQG[U:3_("=?S+<".WL5[8[VO&R2%J5/\ 8]"OILR*[)TU
M,T@GVD=R*OW$?PZCV>ROS3TI]+927+ RGGY<6T^I,EL>X7;\"1/H/8W]ZM)_
MD!.OYEN ^@]C?WJTG^0$Z_F6X#Z#V-_>K2?Y 3K^9;@/H78W]ZM)_D!.OYEN
M!'A:*]L5+1A1%I:=3YB#2#62S/;(4S,FX?61/SM7+17! !OV5^:*$<CQTO\
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M3"1;#];=<6)H*W<-\#-&VGRT7SB)MP2:86UX#@. X#@. X#@. X#@. X#@.
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MVHA$R.NX)8</#Q/6[G,4%P=NY,2Z'" :\MT,S^$Z2>OG!<9,8J)(F7YD8V(
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IHWTWT=,&CY#"2;HAL^0"V' <!P' <!P' <!P' <!P' <!P' <!P/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>61
<FILENAME>g713200g93q99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g93q99.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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MZU:HU2"V\/[M\IU;ZR=6KBSZ?:3G73ZQ9Q'P-&F;!J\%1.V6;T++]+S!FS[
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M6->=7)6NZ7?$TTF[%QD[Z%T#3V7PDBD1-)N=5C:[XT^9L7Z92E?V%#Y@T=%
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M@XR>:R&L]5[O(2*#O0;H5>/!0%',3$@=JDX)Z@/[*RB*@G73$0 3)J'(0Q@
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MO/\ 7=O_ +GBG=O^$T_+(^%K^G3UY_KNW_W/%.[?\)I^61\+7].GKS_7=O\
M[GBG=O\ A-/RR/A:_IT]>?Z[M_\ <\4[M_PFGY9'PM?TZ>O/]=V_^YXIW;_A
M-/RR/A:_IT]>?Z[M_P#<\4[M_P )KN,+\6/P_.R>\/>MN+=D:5>=6)%(3,'%
MQ8OS0MT8GCE)-\6F6@S0*].R<(@BN$S )R",^T]A9R6+68$%YQ4"C 9(XZ?
M^^K%1\_(?2 ";R'R 1\@$?+Z (^0^0"/YQ\A\O\ N'BI1[^GGCG\LC/U'QJ.
M]FV>_5I5PW' =!G%T//VSUY:-E63LOK,0AT'C,RY2%4 ON%(X(BNFF8OQ"*)
MQ]L->DU;5HG:-NS]P^"0LD-U%)$X!.#N$>Y<C!P5SG@CSK;+7L_I%VJN.U6F
MVZ'J+J">&9. 2&B<C)YQE&=3@E688)KAVG0T[OI.?/M>Z^ML;6C+2R?1=B=S
MD.XM4XQ*"Z9X:>08KMA68N'!V[U!"4CS*,W+8JK-P5-5T1SI?:*_>X;NI--A
ML;E</WF]9;C!4X2;NMHP3A\2#<,#&T')[%V0T.:UTK51H'::77D>SEB]D$$\
M.GPS^$K<0=_N;O$57C)@;9(&(E&Y$V1D[V;_ "E=M%8K=;@Y25B91)ND@5BS
M=DARQQG"R3TB3Y+S;(J1[9)!=0/04_DLFJX.* !Y['V*[$:!VA[-]H-5UCM&
MFE76DB4VZ-/:_P!%LDT4DUG(IN9TN9V>WA6"1"61D0R280;5V2GU3LU-ID*:
M/%?MJ,F^_N)5D-QWK2.KA;E"8XGA3?.PF$J!&&!&"7K1_0%KN]QV*YV#$(SK
MA;+915$&\7^'N>M"L]5JXM\24XYY UU^LX8-#)J(Q<C84H5P9@HHC'(.VJ3Q
MVB\Q79V*Z=VDMELI)HHT4&[=C+& "I[I$)**<D%]IV\*",D&T^U*\T.&W6SU
M63M%:V%Y/<2[-"BM4M)YV96Q?23QA99/#O2+OAW@7>RL5#IZ6<BM^CVJ!<)Z
MQF8YC=XER#61CH^PLK=4YI Y1%M.U.R,TVJSF.=^A0BT9-QD1/1#E,Z#MBLR
M4C963Z!;R3.A[^'N)5.&4.)(V'DT;@ E3YJRJZG@@C#-YDU2VL+:<?PS4/XC
M9RKOCDDMWM+J$_U075NS.JR(<8DAEE@E4@HX821Q[9Y7K&TXI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*56_>/"RZP7G&-BP59_M-5SW?>R>D=I=9:T
M#8[?2Y.YW_76<C&Z-6YJ3@W+9:1RVU1LHZ92F<ORNJ\NF#5<4?C6+)T@J8.0
M0>,@ #(STZ'X^^N;=>B72"Q6^Z4.RQ3-I8-TZ<Q74)QFQ;JX9J.^MV:.9-2*
M;TZOJNCR+.0J#FQ%,E<&9UY"-<-X=<7";EL152Z2RO)+2:_2UG>RMY8H)[M8
MG-O#-,&,,4DH&Q)) K%%8@L%. <51-U"D\=LT\:W,BO-%"742NB;1(ZQYW,B
M':&(!49 /6NPAO#)ZHUN!QJN5JNVZN1V#=;-4ZK9R>!N\U$OXS,-FC(R-OSM
M>19*(O5[O*'C"2R%Q(LA*,9UV]EFPD=*D,E:U6+$YSYD$_$9_4\5\NGOAJX7
MT=?1XX?H/9LU3AJQ+U2!RJ_]C=-OF-UYA-2S6;>O*_E<Y,*TN&F0D&RJS>68
M1"#MN,E+^V<#2;LRBC,6ZA?7( !^M6$<5+3BE.*4XI54':;_ *9?;G+NB<;_
M &PQ3$?L7VL[N*)_RT9-I1LVJ_ZO]<9?T^\V7_")?:^YUZ[0+]$@KT',8IHJ
M;X.Y(@LJ8< MYGA?IXC\A@?/W5:_Q4M.*56/V_WS4-)TQKT"Z=V$T)OEPK[*
MQ;]N;% DA%]-,(G#JMS7)R(^;1WN^C-DGL3@]%64([^*!WI$Z1C5*ZDXE'NJ
M8 =3T\AZG]/7IZ YJ4?5?J+@/2_+OP0=>:,C2Z<ZEB66?(I(R,S*VVY'K5<J
MDK=K1)RKETO)6FPQ=4A5+!(E!NG)R**\DHV*[>.E%50)).<\^7NQTQ\*QW89
M^<GIM'),/BH4EZE #[57<8M!:'S6!4\BN)*7612)\3,.$C"2"@$W";J2<@*B
MID(YJ]5#5=4>>_N%TK2P(P&SJ%[&% AC.?Y 88\3\LX!W' 4=6(WOL]:6EG;
M/VA[22SM86X/\.TTR$3ZO=C/=I"K%L6\; &XGV[8TZ9D9,0I["]?C8"PJ897
M/W&_7W39<U:<5FPN6\H[MT^L@*R4@P;,V3!C#LT_)RI*>L@1L;'$!XJNV;,G
M:ZFNZWH%O:SZ?;Z>9GNKEF#1E@S-M*_SMWAV8));JH"EN-A)ZIV*[?3:TFKR
M:_!96NGZ-;I=P74"]RMG S,GLCEW=YVD(3N=N)'<,I#%T"UV[IX=&EYO*8RZ
MTB1HD3G^O;32LZO 9*T<%?U)U=)A)%!^<)"&CVLB HE?D2=_#JHMWC=L@9%4
MCM,!RFJ6FNW<FFRZ]K%YJ85XK".6XN9KJ6SB=AM2(S$[5;'BV_>D"LY8X)S.
MF?:1HFI6NOV^@::UC=6&EWNKP1W,4,$.H&SB+,9/9Y682+B/(.TE&?:5P:N8
MZ]M]0ZU:A&]6M*M\MJ67VJMR<SUWU*S"BI;$#51!H>S9#<W")")2,E$PZP6&
MJR0)(@\@6<LW2*5*-".B-AM!/93BPFE:>"2,M9S28[P=V!WEM(?ZV5?&A Y0
M-^'"\.UQM.[0:=)VET^TATS4;:XB@U[3K;(MF-T7]FU6S5B6CCEF4P7,66$<
M[Q'<3)N>P1---%--%%,B221"II))E*1--,A0*0A"% "D(0H 4I2@ %
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M@]*,D\<@H+9NTQ*:/9:9I=[/?I'>7+PS37,T@W,[E6;;$S\H2Y #C#%CG(X
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M@R8J*ER"5SG  !^7_3]*QJX^%CVYOE1O#9E<:[DS1S3>[LIA>/57L_OTQ6,
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MCE?6G,1[$YG'DU][U T7<)I*'_\ >)E$IA\NHKITVC7%LT.I0RSR0*Y:PN)
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MN+ZXV][</N(7(5%4!(XUR2=L:*JC)).,GDFM+N;A[J>2>3&Z0Y('0    >X
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M\)[)L+UJD:U!359<R]'ECRS%!GD55@72BQV3MD)49AC(*NV!O0[./O()G.(
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MA&XX]L6R.L>F\U>Q-W+(7':*LT:VZDKV1U8ZVJX<M%F<A*QKAP5!O+1SB20
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MB[50A<+V6<<G/53F8YEH<@+0*Q81?O\ ?[]U1^]S_5YCU]X]/>/F/2KC@$!
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M>%KVIK>B8;/S^E959$<_L/7Z>_"<KH.KIZ1BD7C_ &)U/7M.HN,U<U&-7;?
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MBBW230;I)H((D*DBBD0J:229  I$TR$ "D(4H 4I2@     !Y<O0 H"J H'
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M<_TD$$<X&23U%>K=*TWLQV7T5[72PXU0$=XY1C).VYE:2:5FP8RA6154EHY
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M6CMJ.XQ]M.O5V=6=R4P]<I))++!)3I',%%0C84D"**+F05E%3^T4A@\EQ5,
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M=!$26<! 5B51U4*N[(Z#)//)K8MUKH.GLS7 @!MRMQ*2 TB_?=%' ",<!V;
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MI?/\Q2D*4 ^GEY<M&TVS=MS0Y).<=Y)CIC[N_ 'N P?.LQ_QQVJV!#K-RP
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M-"5/1;'L$&I--U)TS6XNFVM6R>U!T]N2$^\E=#>)W267?6-A'2313<>>>O\
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M1\;^U%0(>? QC50N",R=6I1T[Q#B8U?HJ5RUIV(HL>[D0?.Y%?:YF9?3#$!
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M)!4KC.<BO;+BMKE-IZ+9Q;)$PN9W1NL<$]E# ;WS+3D[FZ*4GYF^HJJ&DEG
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MO]I^L1:-H,#S">XC[^^;88M,MX)8GGGN8Y I$;(0%4IF3=A%9R ?;1@>/0N
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<XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>62
<FILENAME>g713200g93x36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g93x36.jpg
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M 0$! ?_  !$( /<"2P,!$0 "$0$#$0'_Q  ?   " @,! 0$! 0
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MU=N&R&?VJ:KC757;'W=L8SPCAE<1R%6IX75'"(X1'")<7>ON7->J=A]38C'
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M.-$]-MLXQG[G.KJ:H8TN?3S-:-2YT4C6@<I): /G7(GA<0ULT3G'0 2,)/F
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MLDP)K,-2N@]QOIG71W@=NY:)O5$/'E1%NLX3046U3U7\M'R]-B*F-)=DEA=
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M+.%E%-B6_P"8>_[%ZOVP4A^++V1^8:O_ *V.$L.4>_[$?;!2'XLO9'YAJ_\
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M[DBSMF,:NW:)-JH95O:::V#T7["72+LNMSMH5S+^Y4;#2S1DNS@(U_6ES6L
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M!+/KC!R:R/LT5\ I*Z)18QV"P_;>.IQ^9Q2VXB?(00LU7<U<D ;3:>8E3.X
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M(+(O50&#,LXLD5UFSE[O84^<QZNHYL"U9R RVU+X>C+Y45' %@R@YFO>220
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M&I6?+FJBCA$WVD?5- O9YI_S4Y1,1WZIYUWU*ZT&YTW--4I\PEEI'A+[XO\
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M8_*;?KQ&WQT;D)BMXI*D!;V!1,U%X5BLUIJA5X(["F]DJ,B0K<M-RIS1C(@
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M2$<(F;]3?51CVE,_FV/*?CF^_0Q]+E:\'W/Z5_[*LSR'4JE W;ZV9][1//\
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M QX)80T@-#) 0PY;@O<X9M1<:W[Q@%3CJ6,IY8'1:O8X![7.!+R^-P+Q>Q#
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MY-Y]G5D4A@N]OYA_7C3+N5!6E46[I?X:V_\ 28?\XORR=SW]+_N_^LJ_CO\
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M!^,J-+=XSE_XG<I*VM.:L5B6@3[K$_RZ:!_BFQ_^>"X.;T^"[\2U_P#:C_\
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M_P#X-/R<=_:-5V=.JKC.^#F6=9ZUQ>;!42F;>!F_&D=)?X; _P!6%N5ONO\
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M'7!;D&7*<I[UQ=4>QPE:[=/NM<RB<"Q&9J_NSL_!K EKJ0/#I6=XAL#ZFR,
MNJELT&BP(<(YL:2-P0(</W7:HOG2Q4T<>N<NDY:G?4?*V(PRS\)"VCPV>"(1
MAC8.&GQ6-X!NYSWO%/&7O<ZQ+0&L8!9>#PSXO"YK;.,DS7&]R[*V CB%@,YL
M/:2MW+W*=^+FM+^.'9'\T%"<TU\*'Y04O]D4_P#G*]6+!=T?S[^I&K5^Z*_Q
M179OY8HC_P#(&L>1?P?_ )5X=Z%=_D:E>V*[C-YXNU8M&#I3?])US7KV%6LZ
MC0)!EV'K*WY&[,1J=F9-,JSC$6F &41*I3L&;NMX%=H_<NDXK";&%HHB!?R
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M8A4#%'4DL? 4QF^+TTDE-4?^+D%"RL=P53G$ R_RS<IC<'?%I0),_>MYX)G
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M:ZZ::::XUTTTUQC777777&,:ZZXQC&NN,8QC&,8QCQ<^8E=%KF>ZB_Q9@_\
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MUM;B3EJVZ_ >R]@5F\D\CGE:B#Q&-P$S&[#K:#,CQG)H6.;Z2FZI0)/P(#$
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M<1_O-WLDO_<^:B^%*IIY:S"X(IXI)J:.K;41,D:Z2 R_%7QB5@)=&9&=\P.
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M<9Q_GQGFN<KN3WC[5+YV\ON/V+GJ>$W\&E>,A[S7V8Z==1)BWZVO2D,VK%&
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ME<71FFIV!P,<;Q;,QPU(.FRR@<5IIZB>-\,9>T1!I((%G![S;4@["/(M?O\
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M^V/<'KH2>0L>RL/*SJ=NV8X5I\$9TGH#*DI^6J84&L==6,)MZB.&+7 'ZL#
M[65AA8Q98$Y 1C-W+0Y$0V)8_?ZN7ETXM5Z]5=G*FNLI@;7&UF&$%6A)\SE!
M2A;XA]>%6HE[@<[5"6=-*VCU='?*=^5HQT#2A\H532<.!>CQLW763);[W'0I
M)L2QH=5,5=S2=EE! !H^""<*-11D^4(FI,:81N-@ ,=C@\O(Y)(I%("HT(!C
M\?%$S1DJ_:#QK%RZ732V+C:H?8]P>NA%Y"V#.P\K.IV\:#12?P1G:>H,J0L
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MNE^/;Y%'<AZ=]O;0!N91;D9HMY=BEM5%-W9JO^WG8&N@CNNZQ6L+WEIRO9)
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M2PXJ*$M6,%AD=P<9=X>TG:K4J6BC'4;MN*@_8&NHD JL4[35=/-M(*34POC
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MWKEVV5U3U2RCIX\J<G\>[J\3[HH8(:]E(QE/(Z6,TT4D;BY[<AS%\TH(ML
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01PB.$1PB.$1PB.$1PB__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>63
<FILENAME>g713200g94p77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g94p77.jpg
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M5%:V&1HB(R0T47*4L=4Y04>&E;/&T]93<7>W.$5587B2I*BXT=?_Q  < 0$
M @(# 0              !08!! (#!PC_Q !;$0 ! P(# 0D+!0L*!0,#!0 !
M  (#!!$%$B$Q$R(T05%A<7.Q!C(S<H&1H;*ST? 4%35TP0<C4E-4@Y*3PM+A
M%A="56*"E-/4\21$8X3#-J*C)62T0V5UM>+_V@ , P$  A$#$0 _ ._QPB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")P
MB<(J^O"H]C;4ZF=!.Q=_4JS:N+*@L=C*<>(OQ.IYA$DY9/XG"3=@O@RNJC<D
MUKF/R,K.E6KY%P*WUC_C,H*A]7VO"Y-%W '_ 'YO+L"V:>T?T2.(6(TN6<V,
M*:5+L,"U5*'+*8NI]9I,]%A44G00D'$J3/!&9'R@F(/X\$U=P)JYDPA>'1J(
MJ;D$CI8VZ>GW_'*J=T_".=EDNAT>#'3NP+M77?A!*I\'SVJM92%I@G-<1F8V
MZ,!H]D&$)EXCT4$WGE3'H8_BSR7 -@[&53!3=1@\6$^B;ES#1FV:%I<!MO87
MM<6V'2_-SK8OA$^UI:ENNOA0&W7+LA<C&[.I]5]<9!K&I!&W#Y&BI!-I:168
M'05CR^.O$K*87/$2N72P*0EIWB-;19UNU<!$G(P,'(P7<RXT)\_D4IO!M=@[
M.OBP^]C28S4NO"*B[" ZMK2F+/8@VO86E] %>!/AUI9SN/-]QIV'6/,E'\TI
M60)2&;9)0EPIG:6N?->I01<2+!O.+GDVG9T#0\]PK5>%Q3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$7I$AHXR.?B##!D5$E63H:4%DFJ#X<2'/D-VSU@_9.
MDU6SQD\;*JMW35PDH@X04W253W3WVUR1:JC_ %XH**"VH.,TC4@ *Q)1TPQ$
MAZZB(\:Q*P]99Q$"#)DU$)-FCR)+N%U(NNW334CVRJGJ?9EC;..$NO/B@*(P
MXLQYBE*DP[NG1%.XW6*WAV'%LZ-T5F[?2S%_4WG9WH@@X711UE.Q7"2*RR>F
M-=%-]=B7]&Q<.\ZP];"0*8Q<GU^I0K&[%5 +6"!+5=""@B>+1-'1M%59H/(!
M'+64J1AJFDUCNYU)_L#:I)-A>6J"2:>I+GE691NI:JALG,S>(5G7T5F<C"1Z
M-2&71N&1P')SL<B3/0=% !D^,&M2I0)&!Z:;&/"GKM=B%9IZ-1J#9#373!%L
M'A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%UL*[[B=\1<A[=7B_FTD
ML/K5TB[W=^ %^-9"!HIJ+SU/Z_TR'F4)KN!,XY'X_:I6Y6<H=YS'I MLA&78
M]XOB>R$CHW;H(%V6&@XW-;;;WQ-KGFY;<UN-3<SX2VURY#KO%89T\(EIYV8>
M6LE60J56\I7L8D8RLZ+@]\MY."DTAJ?)1[&94(EA2%CB96(Q_9"<Q5^GAN\A
M[YE,,EQR[;G9MMKQD<HY%'F,^%_;5?$[GUF\*L*T352$^^EQ3YZ=E$+&*1RE
M^L';D+0KR.0!U%ZRBXZ8EFJDR0Q X[(!H0DK'(UKB:V#N7)M7:Q9R;.<-L!R
MN%];FXV:G8MAUEX06R>P_?#K)&8"W>07K9-'WA':V*Q\F\#%3MH27J%)*AA;
M"<&PS^ L)#6&K&4R"8Z@08N<EE9 !=,'TL'AR""0AN3* '7VC*?TM>(VV65V
MW"X)PB<(G")PB<(G")PB@?X4">32K/!Z]PK-KB4FX3/Z\H:?32&2N.OUAQ<#
M)8V'6*""+5=+/DJ80>-DLK,W2:[%\AYQH^;.&JRJ.Y<FZN:#L+AVJGN ]VKS
MCEAR2M;$L:UR2P_N;X)&.1^$!Y0+V=1:NNU$"C>Y\B]N$C#)>8LJ+VI.1\CD
M$QI@\*B<DC@O#B.Q:<#@I@83:ERL+ C\%VO*0;;.+2VNH.W;=9/9'A9+!NJ/
M=9F<$BDEI0E:UA>#XO<,:!R%9^OK2M[]Z9%UMEE/6:@L)9-&TG*QR'KD"*+?
M9T.>ZR(Z)8H-7M?(R20$RV)V$#./*&$Z=!^-5OH+X8\Y)$8HH&ZXDE<6E'1D
MTA&V\C=[KPJ)+]]FO1LPO9XI(#@HXDPK<H(MAG#8:B_,G=]9-6;+5-S%\3LR
M6,NW79Z=Z7:>:WE!Z,!DGA2;1JZPT+%O"D; K!Z]ZCQ>4Z4R=L943  !.==^
M _5J(6#.XU(:C#2Z(+OAD@"645DQ([A0#6C[X*.H.M)]/6V2Q:]P#Y?[I-MI
MY+=/&IV13NS9C;M-7/6*Y::&UX\G^9 (C]B 3AZP*UFTNCH*X)D1AT?FT?C:
MH:&V2VKNOX=8ZE56AM&2[N)3*3.P4B-+P!JC-R6T)!O;:-AMIKYS;2_F-U9+
MPN*<(G")PBA5X1N[+6ZX=%NTEYT>$T/6K6-0R:40UJJ-]<H#B#1)))S*' C.
MBB9-K"QB[Z7NF#A-1F[;@U$'NF[3=;7)<FB[@.4@?'V*!W>60V!2?03?L-37
M:RS7$X3HFHGHW1Y/4C*%DF9I>'6=!_=S+=[H1<ALI@S)Z-/AL.8-JZT$VSA-
M*,,5FL?UV++=7:CC\VATM[]=.E></X6FR#EC[TB%ZPM));X>U.Y4(+"0EIB!
MT6D0CIW8-61B1*0V43T;"&.IV0Q2S]IDJB>W9M8VWASY)[H\9GFY$*0MTO?3
M>[1KOK\YV66I9SX:FVX>-M4TEUGKDB,KJ)>$ E;/SETR5F^,MO!]WC&*KF6C
MEMK4KI :XLD5)D2<9;)/7Z<??M5="C\BWWUTP3)S[2P?IB_H6PXCX1J=-.R-
MTT-#847G5F63V8LF'4Z-MBV6 NLAV:RZ*U+V(&P2.$!=;M'L#UL A(!$;; 2
M+N=;C#A2QK4U-%F IO7CPL6T!YK\_?$<O-S<72M3=U/"M35.ONX52UR-8PR:
MP[KSW<D\'MRM)^XD#F!V+U$>U4Q6;*&$X^RC\@?F%K,0>%& AUMF EH^\@LK
M9G'[TKJ%+DUNK2=F9@(\:YY>;RWN-%+;NS9ED K6\$[&XY8,VC 6^.Q>T MQ
MG%Y09C?PWB;FA9G,MQA-P%>,72.^LDCXLDB0'+LR:&45FJ+S1B]?-G!<6[':
M7LVXX_Z31?S$J,O6[PB7<!^:CM",X%!K_D\Z[<^$3HZA[DM*=/*C&6#3W3A[
M&"4.G)LI :LFHN3NC[4Y):^7DL<C Q@0-P30JYU=+$RK](LD#;L%FFPUM<<Y
M\O-=9<IX9*;)#Y6X:]:A4@)QRI.]5AI!!%HJMW;XITO[4@>MVX_*A"&:^;%S
MAB>UGBRC=%Z;"ZBGD;#!I>2>,%%"9>?C8-GX3<WH]/,MVL_".V\"L2O(A;76
M0[6L,GG8.1T@'N @SGKJ*$V>]W1*G:=ETBCB4-S-*;&]A\%)87J,Q/A#NOS\
MCCP6%)S[9I*?AH&+&7;KLXO)<VXC;CUN.16\<+BG")PB<(G"*E7L$WM9EX2+
MJ_UU#=B;MC\+[$TGW?L.4>I9L28:A)3%'M;JU.YC0I%?46/8U<UDCIJ-#Z-_
M54G\A9>9,SFSG?1,N8[UQL+@MMY;W6A;^\,O9+&E;*D%450.A\H*P/L%**G/
MRIP\/KQ!KUX[Q1'I3+EK+C&1C-H/D4B<2O2PX8VW<O H5\W^"DD:R+T;T@N3
M)KMY-G]II<+>;XXLZ[:^%"DP37LK0\/$A1\H&4KWK%Q.VZUG3XJM!;2ZP]0H
M)V#8GL$M :0)R1=$K!6&N82W);'H)M&XZ2E>2+:>:!@Q W83_9-K;021]BM_
MZUR$U+NNE RN2$7!B12>E*KD)\L[SIET4-&H*")%2+G.FNFF7#U\Y7<K9TTT
MTRHKMY.NN/%C!<%NOA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A%JF'432U>L; %P:J*\B0RV#QN4VB.C\0
M!"V%BR:2M\M))(9PS:,DVTI-R%IGT4Z5-I/7QAMC5 BNY2TTTU)=8Q$>JO6F
M [5TI":%J6**U"Y.O*K7 0.."W%=NI.):@)"O#'#0>DO'%#4?8L8\2V%*-<O
M(^P8@UO+%,VS1(LW)VDGRKQXZH=9-6J+'6@*@T9(2*4RS5HG7\93;J2*<GA$
MJFY5RCH.U3>.9E*8]'Y1+,.]5DI')  ,\93>EA YXV)<\I\_)L7(A^LW76/6
M1O<(.C*F$VML7EA_6QF$ B[::('9ZW'M)R99R-(9J58E)F@+8Z2M^S=(.I%E
M'*A=5XHLONJ2YM:YMR7T6\.%A.$3A$X1.$3A$X1.$6.2R'Q*>Q\C$YU%HY-(
MJ83T1+1F6!!DCCY1%-5-=-(B&,-7@YZFFNDDMIHY;*ZZJIIJ:XQOIKG!%AR%
M%4BV%, 3:G*K;A!4F$S08'0KV))"ATQ H)-04L8#TQ&K1G)@K9%%N)/-T4R@
MY!))%FZ133TUP1?Q:B:0<Z/4W%-U4NF2D0Z8$=%J\B*NA"6AR!(N(E+W7</M
MAU(A94R8)CC:^%";$@5)/6SI)R^=**DO\>CL6J[TZ7==.P<#E-=3FM8DVC\Z
ME$4ELY]20V":+S@E#Y@I.AB$T1-Q4X*EH]Q)7) B0:2(82\^Z*DWJ2C<B\4>
M\+()!N#KTGXYEZU-]'.K-&P%6MX;3%?.8TY$RV-.T9#"H>5W<PR;2A_+SM?8
M;Z@&HIC7"ALBNY;5\+&L(<VVQA?4+EXHY=+D))-[_'QQ[5N>-TO3L->AR,0J
M>M(J0CK/0='W\;@D6!O00]-@J*38!W0L4U7&,TQ:ZXW1JRW00U8+*L]=,-U-
MT\EA;+X1.$3A$X1?A1/173=)7311-339-1-37&^BFF^,Z[Z;Z;8SKMIMKG.N
MVNV,XVQG.,XSC/"+3C3KCUY'QTU#V%#TRRB4DW8*2&+M*OA#:.GE!1#<L+4-
M!$0>@PIN-*J*$V&SYLOLS(*;O6^4W.VRF2S<\ITV+S..O5!.]V"CJCJ?<J"Y
MR[L\8HXK2%K;CK*?X2P^L-ALH%VV9SE[A!##N6M\IGW.$4L+$-_-Z>(L7/*O
M36ZT]<G";E)Q0%)KI/$I$@[26JJ"JIND)>Z1?2Q%SIN!VU72E#UN@\D2:N-M
M#;I!%P2PY63TWU+-SRE>4AUPZ\%F+P85H:F"8TA)!$R?CR%70=ZQ?2^/M/5X
M&5/&CD&HW<R0(P_R(0<63W)C6G^3,W2*/^!PESRE>D_ZO]:"A0V<)]=Z+(FI
M,YD+R1F']20!V4D#N7:#DI6Z-D'$?4=E7,G3$"4Y"N_675-:#!VA+9SJR;82
M)<\I_P!MBRR44Y4,W2C*$TJNMY>C"M<Z0U&40>,'THEIELBSSI&4RHMWH!UR
MT;H-<ZBL-,9;((H>+S2>FNI87O9J^L\D(47S7<%R5K9H[85T3S$0&2$!8OVB
M3!\RA3W(_P!)BS1XQ009.VX-1BBX:(I-EM-T4]-,$6C;8Z2]8+@B5D10_3-<
M!5+83):3N5Q6O*^&S*0;G# TY(UBQMY%26#6\H>BFF)3H>:EF\C;84;F4'J:
MF<8+()!N/C2P\W$N-Z^=$NK?600]#574<*&MW,V^,!ENXA\,2Q&9'J*C8I-6
M%, L;#!H2S2^"PPOAE%1@E!63+%90YPN?,$B#DA).IZ/CC.WCN5+[A83A$X1
M.$3A%A!*LZW,S(+8Q>OH05L*-M56,=G9** 7TR LG'G,+LPLG=,%38MJMA9;
M"K=B^014\ZIY>FWE[>,E^+B7$$:3IDPE-$"U1UB40LAKNRL1$C HJ^2GK)1T
MH^4:31-R)5TE+51ZLL\W;G,/DMW2JCC;3*N^V^276,..KO69V2?FG77:BG)@
MJFZ2*%G%1P!8D22>QOX&O$W[]2/[.GB;N(9S%'6CA535>-Y]1*XW%_Y+PESR
MK<@@0)CXH8! BQP0&%8-!0<,(9-AHH2+'MTVK :,',DD6;!@R:I)-FC-JBDW
M;-TTT44]$]-=<$7(\(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(H=]PKPM3KS#V=I1,/#"5>QC7+VP<'04^D!MYC<T!;H,$R,4T:1BH8
M6QC2LND\VOJR2!&$5ZW #M#T;6&EG1H.60+]/%\<=]@ Y>9:O[G=S9)U<D>F
M_H,-'PR.U.:MPAM,1LI>F[F7CLD:#S]04Z\!OF P)/@$4P]FQ4D;:R[1(:[#
MK;Q1O&FTME\8(!?BO[^)6*<+"<(G")PB<(G"*K6[YSV.J2>EBD8N<[,:UFT^
MZQU ?5/Q:M6PZJ+!NSM;6=9F_B<4#1!H561CM22Z0MS+*RR=C)!)6\JTEL0*
M.\3YH[+(L>+^-@3KKV6XU[<:O^XG<YH2+N96\W$./"/=C^L<B?J!HUMI9E40
MCK5VDM.*)/W&0>5V96'3"OXG&WAN,. CLL1@I70WL\R5*MMRS8:^*#T&X'+\
M7V+D:S[K-Y+V;OP&;>6(O7$7H^CI?"*_!4';QZ6B'AJU;\A,JD#T/'JY*3<R
M4E#4# 2:K!NS5'1X"DBCH-:D0$^*J$MH.DC:.0'[?/YEPG;:S.PU.-[+NRI[
M8.2",1B@;>E4NKV6PF%,H!6A7<*"<TP6%-%(D,M'2< M%#LTFX"5S$T+(Q$-
M+')\%#=7E>L&I8%MAY>+7[;>@I.+VN6($[CAXR<%W3:J.]G06I TN?AH@Z(G
M:\["R;J\ULVO9)O\&=!J[])C:$H=H&@[$*>&")7&$VKU!89H\>EFPTYP3YK^
MY9%!>P%KO^[LCJN3%76E2NI=9D:KZ5,1PU] IF9BE;UO)%Z:2T1!MI+$+8KA
MSO8<O-G#)TA%IO'4R;".NRY0,5C52EBVE_/?M',K)^%A.$3A$X1.$3A$X1.$
M3A%3_='8GL+1UE]@QTUL NK0,_LB.5M1-J@8I"/A/UMN=]7E62 +5TUPO$20
M&0UK=9>5NQ-;S65 2AF.V&KBO) 9?;SJO7(E\?'Q_#E86'+8DCE%SJ.C;R6U
MY5N"R[KN=_7%]/ZEDZS2<3FUIA275]XK7Y6PF$44I^-+1VQK DT.AH(M)2;5
M&VXC:HGT]1D]!;YTK1%9$8R,+K."QH"+\U_+KV64M.N%V!NQE&5C=80<\!HS
MZ+M"96,$]=M#$+EK1181.(">2WT3W0D4!F0X]#9$VVTUV;&P;]#./&GPA%B0
MMV<+"<(G")PB<(G")PB<(M<6R.E). R)&&E9F+D"(]T[8:UXK 6LS*KMFJZC
M<& )6>/*080\*.\-V^2A]ENU:HY5SJLS5VT>MR?'Q;555U7W;N(RO4Y2?#Y$
M]KJ"U/T5%7*0;L(S#;.FU\=N)T_J-:5EH4S8& Z==0BPPXG!4'7,N#I$%S4S
M5"OIR BPV-FRY6Y.._D ^./FV+>G8"Z^PM;7N%#C&1W6-R^Y^G\"I<0, ""T
M,L:(SR=D!?:K$D+ZL'9T5-:VK721V>S;;$@B2$>@($R 1+"=;5;Y+ M;S]@M
MZ=/+T+%HMV!O"&V37$2O(Q.'4O7BDFL"S:WA8>FR8$80$Q\X<D,?#'6"+%1M
M5D"92.+.D"QZP-+5=JLJMU.1U]K<&6R).SE-_CE].TA6H<+"<(G")PB<(G")
MPB<(JAY_?79BM[@GO7^/F9D=EMA6WUHB=7RVVAE4#XW%H3:48OF13VP(E)*Y
MCQ-HW;%/M=YS"H/$+/@Y\_#)SO%Y2:'3R,RYE"42Y "P/%K?;Q6XN>XX[=%E
M(!U>D_GU$4-9U9@9\)C!&WG,5[&:90#R6TH-!(6K:$&L$F%2;-R3*0[#;JBD
M9'%RT5#OG+BLG<DDL/$L5T1NPXL6Y>06Y-;;=G%Z>91/&=I.T:'7J+=A+(DK
MZ#5Z^I86>B\L%1JN7VTU?-'-WG9'9DZB2P,[+E\[TU#ZOM]I$JQCX /\'WEB
M+B'LA+JQB$"RS;7R[/LX[:Z7OQA6SUA)%9-#QKAV/EPTD,T3!%T)SK%?A1N5
M%M6R+YP96@Q$M#EB:RVV=BNL<?;L&)?#\5NV'/1[L:S+BM@\(G")PB<(G")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(M$V_ULI^]G3%U9@ T7RT &
MX@]:B)U/8<,E,*DKH6]D,&GHF&28 ,L&$&G 9AZRB4U:'0#MMZP'K,-AQLXT
M)$!LO4F76"H+ ?C2$P83<YL/)F22S!W;UNY"'D3DN:3IW')> TG&H690=I)6
M+5<% )0P+0J,B-%HI'0(N(O7X%T2_P >2RD#PB<(O3(N5V0]\\:CW1=RT9NG
M+84Q48HOB:Z"&ZJ(]FJ4>#AB3IZIIJV;J$2#%CHLIIL[>-F^%%]"*-OQ[6_^
M!7V&_3;J/_$WPLV'*/3[D^/:W_P*^PWZ;=1_XF^$L.4>GW)\>UO_ (%?8;]-
MNH_\3?"6'*/3[EHL/%8/'C<ODT?\%*5 26P6Y9I/)&#CO0L0?FK8^9;2,XA+
M#(^_6Q*0I&9"S9GRFA9R[U?FVC4JZPJ_;I.-"S_>];W+-/7SWR8;KOX.2S%?
MBZD)*70#=PZZ4N%83+338VS-2N*++]C%%H_)S+62R1N7D K=J7)I2$YH^>+Z
MER&'!8M_:'I]RRE*UK!0//Y4AT0N]&3E1 F/E)&E).G29XD! /#1$$$?F-.R
MN"#P0%(261/Q(UPX49C7A\TZ9HHKE7VZY+?VAZ?<M69!1/,]-6KGP5QS-H21
M$DWD-D9!=#<ST\W-!<QHP@:F&;^^$)1$M'-M@!))\17T?A=LBG6JK'.4.$YL
MPM_>]RR!0AE<$VC#KP;5B/8XSE(:<M0;]7I,_%-YM''8]_'9BDQ>=BUV^DI
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M:1Z,1AZL;>EM119MH3YO.!R?;Q+,JHL>THTCV>-W58$<L>&T8Z:#F9R'5@M
M7[A_&:W:619&[8=F<31L<9MFDICT='83?LG3.41Z6BWNFVR:6R1+;+<?^W;=
M:!KGN+=%BQ:(,E8"6B%N2=&F+/LJ,*Q!K+@-)]>+MA=P2Z#3",*1.5E%+*>%
MI#412CR$D.'8LW"6$\S8<DKV(5XT0"ERS;S:]-Q;B\M^C2][VDIU8[!*78%-
M+&SP4O(-3IS5FG$X;*@,59"8XUBHX@Q:'S;HLPD)?0@8:'S*#0QZ=%5)6W@)
MX<RET,E;5H6"+?'Q_'BT6IIK>'8*>]9'5_=>RD"$&R"D\,557\KA166/+3>"
M9,XC=/5HZ=,Y7',QQ2V-Q2CB425'5=:"JRAAYI)45#C18Z06OK?BV<7DMJO!
M!^UT_DMGUVV<L@Z4-MWM/VYZL!@'JM;8E#WO645;*@J>O26KM%<HA*RM!6 J
M58K)M&:@N<5VV$*"G0 P_F9+>@ ^>WO6BI-WKO"/]8:VO,L$"C<%NGG8GL(=
MF R"2@E7I*YJAVAI&#4X0PT=GW$+C4]CY"=$U5")G61OFD6W4CTF35!'-"!9
MRW-A_9Y/Z7FXR%M6G^R]O6'=MY0LV^.1\/6_:*,UD%:)TXZ)QH)7CWJG1W9>
M2-;1L),BR&1Z2-'-@S"$##.CIJFT=ZP3#Z.E%G3]R1(18 \H)V\Y')T'S^3<
M5LV]8,B!5Y8G5*SZ:L.+D+)KN)XCXAFC92%HZ&+!'A;.&#YO%IFT'Q'6"5QF
M13/)A@RDJPAS'R).0C%@89T**E@#;<'W>?WA:;JSM;;%HEZC9)JA@;7LC5':
MJSXQNA$'A\G5;3KU=M80D&*U"-23=W*RTDKFS=%#62"N=&%I 4<CQRT>/IQ0
M:62+7YB!YP;]G\3M6E&/A!+<4J"R)ZJW!N3'6GJR=[$6@,<P,_$2D\/1B^[R
MJDY5CV+2!ZJ2@,OCP7KA8 68L!CHVT8VO)(Z\CAHY! >&,W(!J!RD#HN![PM
M^=<[\NBW)?,0QF1%$DHSV=[4TWHJRI%ZI"<0RH3]B1.#OB$^R58C6\NV>!XT
M2+Y;KNVIQTT+!6L=!ID-7X8L$6\P](O\;>E3'H>U4KIJN-V%J.]4/7[B31^0
M"M%-EVXV7P.6'8#-6#!UOKHH]%M)=&#3<2_5205?#4VKQ5NW47V03+'\/3JM
MO<(G")PBCGW M"74AU.[-75 ?469K3U V_:D63DXQX8CS@Y7D /R\<T,#1Y<
M"]=,'C@/HU<:MBS)731;*NJF_D>:4+(U('.M,WMW.B5:=A.O-%#+!J867FEM
MA8A:HN5RT&UE;$/+JJLZ4PT3&0"QMB_1+EY)&8ML\,/6KEJV9FXZ"8CR)*<,
MGH,@&A.O-R;=5N2>6C+XWV7Z]52.]1;0RT87>QV2^DC'BLB2+5JA7"L?]5%M
M"Z0]J-7UF!/UJS7!NW3E5N/4;$F223EN[+"C'#NVMEM)I68&Z\"*\?2V/E)[
M,JZ0JV=/IK$6Z8F:D=:_9N6A<HN4:1-B+9/)1;6D85A1HA!9OH&=B6L^JU@J
M62.38#:_+\=G0595PL)PB<(G")PB<(G")PBK4DW;ZW #6RHX&B *;62_[T-^
MI5-CQ O X8T"KTW%KG+2B5,ST[#-CA.)P=M8QG##$SA;"9&Q8&.)DX<W+[E!
MQ9MLXM+GSD=JD8)M=[:G6YO:-22.3MW2XN0X7>%*U;RBQ6AR%%#D:F$43KL8
M1"AG$]$S./DXFLQ2>N(\F28N]V[HBP]'(J%C9M4/DNZ=U:T_ [@,(5Y'(H\Z
MU4_8AF:EH+/6< D5L2L!/7=OL'#HZ>CA:L894!*(B5C0.0ZDK$"@CA^3R@4Q
MC4!-/W)<K"YVZ'FO;W^CBVD*R:N)8TF,1%%&[XF0=(M&3(NY-1 [ 2JQ;0<R
M<N7+V&R5JS-1S<@DZ0*)"7Z&%V;9\@COMMMIMGA<5G7")PB<(G")PB<(G")P
MB<(G")PB<(G")PBPN-V374R.2N,1"?0N526!ODADXCT;E(,X<AA)?=TFB/E8
MD8^=/XZ^649/-$FA=NS<*;M'6NB><H*XT(D6LFNIP4E02%3Z%S U!2GJ.;"(
MM*0<@*0XUYQTCZGE3 2^=NX\4\\Q?)>KRZ3-WYQFZT\SY3=;&A%FG")PBX=:
M/ '!?60. 8=<]J-5"ZFUAC)4OJ'75RNL)U);H;/,#5E\Y65886]%45SE3=+.
M_P O"+\HQN.MB38RW A4##(3J 9E41;%(DT!:*ZKZ!6S[1#5T@)U6TT6U&I*
MZ,]5=-5,(XWUQG!%S7")PBHS6_G5?QF_[6>>D*@':>D]J\?"PK#^G'S,E?O/
MI]5,^57'^$0=2?7<K-@G!Y>N_88I@\@5-+TR+W4</?$-V[QWJP9NGNS0<U4>
MD'6K5#=?+=BS1QE9V\6QIE-JU2QE1=?;1+3&=M\8X11N^VC#_>5[._J"G?[C
MPB?;1A_O*]G?U!3O]QX1:\L^TJZM^*[PV:TOW)U";E YKRH7!K]J\ZF3 $$2
MHAPA+*Q-P^5ML,B39L^T0;FDFRCILV6614W;HYT)\;+]JP8>MU['+A'>>MG;
M N^!8AFR9&4U[?DR)G7%<R\U8%?D9P2EATT_L4Q"9S(3$PBIJ?.)*6 25WZZ
M%O6Q!NU70)=>^H9H=7:9J;];>U/I,^M$+=4E?Z5A>"9-6T8Z'C,=#3 ,53*Z
M$8J091Z'QP!JA%704<L$'8$N&:P]V^;N2?'VKEGTVIY]51*E<=?NV0JNR[(B
MP(C(U6=WQ(VY3-%5SAUSM-XN4$3K0I(##Q\1D)I*2:&#[LD35,/GNQ-_Z03G
M6#X']<50S<$7ZX]PY:U2%2B/O'L_B_96Q)%(8Q-7<>>RN(3*6SJ5R&4SF%GE
M(I'6Y"&S(R=BZHT2U$8$ZBL;L]RS<_%EE!"0T@91D2,BZ[]LY9\)_A#J\7F=
M=7O,GHE"4287,BS*&$)29+OZ]&ZR@!&S8@7 W,;'1Q[%8CO'6HK2)QS086+^
MCF'P?*L868=<59-')FCUO[@#)=%$+*0"R<#$^R4</Z8N U'Y!92Y$L E(U\=
M?2TK$XLL1(G5R1!-". A[)RU'"F+5 LW/9Z-BW9$KYA<'C(.(1NC>TS4%'1K
M86-2?4M:!PAENVTQIA<F=/>LSITJZW\MT4.'"1$T8(+.218@](.G#E4L+(OM
MHP_WE>SOZ@IW^X\(GVT8?[RO9W]04[_<>$3[:,/]Y7L[^H*=_N/"+$CUTUW)
MSD)DAWKYV5('*YD#^4PLAO0]BI*@SY.)2."OB*6C=%%%THO%)=(A&42"3MLF
MF2W<I(Z/4&CE BX1"R*I:CV IIU^[5,Q@^>2^RM6#.IKB:-",NGI"7E9<ZD*
M#=XDG* YLC.Y,\<1.2:E8DBN[8[M ;?U" ]5D6,QHK0$0CQZ+ .L?9QJ$DT(
MC59F6SFHKD*N'-;PU ZVB=?($B[Y\4'P>.-Y3)D0T3'/6@$<G(SVC8>G@P0P
MX)<K,X?:U70%R<=Q#KMV7"JR(W(Y$3T2HZS'+;US,)&1E\L>#F3W#EF$^$LK
M+DY*>;A4![4L>?.2SY!=\IE?A%ILD*I T&"1LA4'>@8"A\HG4F@S2N!O:2E7
M$9S8Q-P;DHK+^FIM!%S8M,H1+IQ]H8])0C0%_P#!X0DW8ZK[.RS?X(![5GX.
M3T7&Y3\,@?67LL-/Z+R!XT7;TO;/J\43E8T,(DYL&"47W @)#(!X%@W,2(*,
M8'".=R:SH@JX.&U2)8^/CX[%Z0@Q0@2 0BK&/6GM'O7->.63N+PPE5-TFP"2
MPLHB<$^NV!HB03ER(8TV:F K:7>O&P<JS9$1J35XS:K)$7%-_M?VDHE\P9]?
M.Y3,U/[/ W+-M&D;[+-04JLB,#X8( R(Y$T)8G%2&H\17D($IA7 7>/JBHP(
M'.!2S)KJADE_CTKE[(D506O)H[+I?37>9,U%QSL0,Q#6/:>LPZXDB_8DB0P_
M&:UFD2C4L'E'0T?@JSE0@RW)M&38>_3<#T=&N"7^+!>EAY02+A^\&]<^W$>?
MOU#>Z9*)P/L##R@1*4V$.M:8L8B4BY\00A F<S\0,D$^#0]R#$SS=@U'2]D:
M$(Z,,%FY^/-\%><J0Z\F\,,$^K'8]QJQ;$&:VFM+6TVTD#,M-D+(+LYKHU<(
M:3YF7GB*LK+-9OB0($S1,\]?)N%)&?\ 618NN% Z45#G#TC#*%[C R#JP)=;
M>K9U$NRQZ(JVE-'Y8T:F1>!%9BM$3SA61F7<C2'$1FXYD=U:%Q* TH.&/F19
MO\6':MK5U<D$JV$QV Q2C^TB0.-L<M6ZCRAYPN1(.G#A9^5-%W28U#5Z;/%G
M;XV<?X12R_+D'KS9/39?.N"PLU^VC#_>5[._J"G?[CPB?;1A_O*]G?U!3O\
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MSV<JK9Y;55TX17A#/N:/_(6GT=/GG+^_=XSNTJ_,[QOBM[ M>W5[)Y][MO\
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M]V]<$<<@FSEP<R%SV!H%B6BYS$Z@#B %W$]\VUG7#]./F9*_>?3ZJ9\K>/\
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M[;_]C'-K#^&TO7,[5K5_ ZGJG*@12A&F+B.W2SLJRAYV0BQ@%\ 1W@#V.-P
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M*"@3(F^9#2)Q".BE&0'22%1[$Q)?5N3YAHW)DG:6D3BS#'AL4;K79+&W>[
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M/9RJMGEM573A%>$,^YH_\A:?1T^><O[]WC.[2K\SO&^*WL"U[=7LGGWNV_\
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M<1/:^*U]'-'3E[ ,#(HD>;V>VP+B*<CECX4Y(:6(Z%MIDTZH(I(Y#FS9?O\
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M>9P;F(&7B;<7/$!<#E("@?#+$L6Q.L]7VM'VD0%SN?5?6,_*HD!DJ/1H%B5
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MAC68>YK18"1G&222\DDDDESG$DN<2222222I#"GNDKP]YNXQO&P 6:T-:
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M':>=+9P9I6I.NT%O +'J:J89 HI\!YQ4Y">#[+KVNZW#PD/!+77CUK5D]E@
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M'[ZV4:#>AI(#;DV"]Z+T%#XG.]YP/*2AQHW*6$>CL0?/A:D1B,AMDYI)K)/
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M(^Q0BQPPW?332?OHB99C*NCR\89R8@\&MAG&>DJYJM[Q2O:VJGP:H,SI*?\
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MGI7\Z."?D6)_H4O^I4-\RU7X</Z3OW$_O83PE7]'IG]8[+]UX_G1P3\BQ/\
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M;I+L3;#V!R4 P.6O,(M([AWG\U5J:,%-HY%^Q@H%5N^%8]O("(J>"X,\0A3
M@3:CB,G!RR,!+-1]V'='A]-#1TF(F&FIVY(8_DM#)D;<NMGDIGR.U)-W.)UM
M>VS4DPZDE>Z22(.>\DN=GD&H',X#8.(66MF_@U? QN&D)._W-BV6L-D4[B%3
MRJ8/[GM5J)KZW)??9WK-M6KY+/9[=],Y%#;ACSP+/UJV;2\-'PSL5)69,R+>
M[[M]G^7G=9_6Q_P6'?Z1</FNA_)QR]_+LM>_?\86&2CH'X&:'*Y$RCP8UIQ2
M8/EJ;=1^(3+L/-8H2?QN]"-E"X2;D3TIVMU%5R\2=55*=3L8L%Y'3X[.639!
MH^(I'&(-_+SNL_K8_P""P[_2)\U4/XAOZ<O-R/YUV(NJH>#@^OU9Q"O*YUK&
MNX,%;PV"07><Q^STP,<AZVP<,BA-(_+IXQ,^CZ,<8T<KRDH6062V3)+:/TU=
M=:O55,];435=2_=:BHD?--)E8S/(\YG.RQM:QMR;V:UK1Q +<9&V)K8V"S6
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M[6$JQKE\'CM)65+)9'['=1H^+!1YPW&CS<G0)1L<6;<X].GH[/+:X7)#^\0
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M\^O';T?',I2\+"A7874L[9=]D+:E%LIFX0\A2]=#JE/P!H790V(R $]!V-I
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M=^<<7+Y<C*>$8-P2-/K0F-1M'W7V*6#(:4/V$*L!1Q;SZPX/69:72(XUIC6
M-(_F&/93'2\/'N$;3Q(]\;,I;F*HQQRIEF6+7V;>33W_ &+CR??"T1,RC4.M
MVHQ=8+XUZK65ZRJ*\&-FM3$#["/.P3)2/R1K*NOX!WHXBJE&/]30^+ZM]Y3L
M5'JQ>?AM6;]!P6;:7&NT:BW&.?GX_*%S13OC?0:I(%;!#JS&UQ=LC:MF,+3B
M-O3NT7,6KFRHC.9>I([;B-6==9C;(9Q%$HU% AI6LJTMF&I&9^D[<39C$8;*
MY4U);4B^R^VPV<ES\<^Q3\I:RF-R5'6UJCL!-&U@0N/2OS$;DC>8@F3DP,;N
MWPX7*6K(8D>:#'RC@>F3V%"5W7HV5'0D6ZRL/;EQ.A^ N<L*3.(;"Y%*&K9%
MXX"C]GB35QMOHBMOJHGIY"FR?BWQKXM\Y\>OR_)S8I8145$4+B6B1V4N%KC0
MG2^G$NBIE,$$LH <8VY@#H#J-ME"6Q^W\WCG53M7> .+1_$IHZHY/-HRT=[$
M70%0J.C4B)M2$F3361>;1T*N*1*GM&3ALY4"MB&J+A!;S:VFYB= RAW')(Y^
MZ[I?, +9-SM:W+G-[\BU<.K75NZYV-9N9C RDF^?-?;R9=%J/L:5OWJK69^4
M >ZIFWIQ((&*?QVM+8C]#AI+*I>/M^F 9>95._@T"B.L>@R8*;OXM/ Q>)V<
M/$:S* F Y6+DQY%::1:DM#Q6U&NNG3?^&Q>67>$=L>&R5Y3Y#KDS*W\'MBQ:
M]-QV#R6];6K= %7E-T!=;B7,9+4'52P+8<8*ANS-5QK1D0HH2*%R!24*/I)E
MD(#_  G+.4<NEK\0XR+:GFOM7@:>$;N*5N 3N#=4&#( 6E76>O7S2X+AD-6V
M+'9YV@J^.3N.B)% $Z,ENXAG7IJ2LHU8BJYS8PDST<FXR"/O4<1Q0@&W79?9
MR#C]WV+TXOX0V;2.9_!]C56N]G2C2M*J!5N2MH>E38RVOMDN[M*V"5TG+6C\
M6"U -&?5&4R1.3/QIO:8"$X'&@]6P"2;R,U(L7N?CE(^Q+#ETU.S78#LOS]N
MJYVS_"-3>II!'8])J/A;TB-(5P)N(;"[?F=E/X2[L"]#])X>"7U<T#*HD-!L
M\!$Y@((W[*.O;R2:OMH5@2'E@@^W$Y2W'VV%].E)7>UT//!WR6TF%CEH]:;J
M^#5=,K"#A(8H:!QY;OFYI)MZK%&HP8AV[\97.V@1DY+1@IILJ@D2?HOB.57*
MI+"_DO\ ^V_:N#G78>^^H]SR"E496:[C;2Z*=<"M<ZW*7KBJ9% YG=_8E;KU
MH.FL\I>DAHA6N22KYG,0BBE3&9LVS";%9MB4F2<AQ@$FA />[1I<WL+\9V\6
MW6^P6UV#.O",HU55BMEV'4FJ&H"V.U]83@/$)]O(\C-.I]#7W=LFD,8>%81%
M59+I*,46YC8<84'Q/T'63-#;\CXAR@IXY.?W$_8F77R CRV]ZX*<=\^P%:&)
MK"9EU6BR\XA>U#D2B];6U:EQ0X/$+N"]@2>\MD:%=]6C-N(#886HG$1)_!>H
MI=YY]-A<L+[Q6OPYR3-"6'+R[0!LMS\_*K!*7LIC<=25M:H[U)JUL&%1R6>8
MCDD;3 $R<&1;9X]'"Y2U9#43[,:]4<#TRGJL4L[]&RJY%#'.RK!N7$K9O")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+PN
M6S=XW7:.T$731TBJV=-7*6B[=RW7TV260715UV36163VV3524UVT4TVVTWUS
MKG..9!((()!!!!!L01J""-00=A1:4K;K%UKIH\XE50=>J.JF3NQ;@&ZDE;5-
M H,><A7;EF]=!W!B, !9!86Y>#A[MP/4<;-%G+%FNHCLJU0WTW*C$L1JV"*K
MKZVJC#@\1U%5/,P/ (#PR21S0X!S@'6N XB]B5ULAAC.:.*-A(L2QC6DC0VN
MT VN ;<P6K8MT!Z<PP24! *%AZ(@K7<FJ14>27/2!N.K29A=8Y*X3'-9 8*9
MB<?D,?T2"EF$7R'3>"T&[%;RFS=%-/27:23M*S,IU"ZU&I5*YF6J"+$#TV8R
MUE)%'6"*@IXI/HNM"9T9:QS+_P"#@>5S2'.',7EDS"B1TMD0!TZ%%S3QDY71
M4)<[%^GW4R@7$O(6(PKL&&L!VW>[M)0S;)OM!$B>0C>M\3QA$3NI> *V"A!-
MM8?\-"<3('WL3T^"A1Z_C*JXE4L*/G6?P=E:T/(9),I*M$Y[*3#2EQ8C,?KM
M*MXO&V5!+60XKLHQC*4IENVLJ06M64HD'+(L,A;(2A'H]"(#"H^$2&+%DDG3
MX.SW#^.U;=;=%>IK$:J+&TR!$I8( "(IZ&+2H,=B&T49R<=%A]=R46>:2*LX
M_&ADWFHH!%Z^*1F-AQ4RE@L<*;,)(:;OB7/QS_'9R*1\-AL5KR*1Z#0< +BT
M0B8ED"CD="M$V(H.('(:-V;%DV2QC1-%%+3&/'GRE%-_*55WW5WWWV+"YQXR
M9D6JS$@T;/V3G3*;AF\02=-7"><XSE-9NOINDKIG.,9SJIIMKX\8SXODYR:Y
MS'!S'.:X:AS26N!Y018CR+!:' M< YIT((!!Z0="N$0AT0;#RHEM%8VW%'6B
MK V,0!C$AYABL@NV69E6:;75L0:*MG+ENJW=IK(J(.%TMM,IJJ:[<I)99;;K
M+))EOEW1[GVO:]LQ-KV%[;;!<61QQWW.-C+VOD:UM[7M>P%[7-K[+E1[B?23
MJK"&YII&J6B[- Z("QMSH[7-FLCXI'9 .E0*&1G<V5(J0Z#BI(($FF<)B6X2
M*(D18YSJ'\MDVREUKG<_;Y5E4XZMT'8RIIW+:W%/2DAFV;&*GAY ['),K-%:
M^CM4.SK:41HJ(D(Y8G6L2CD&--1I-HP.1D4W$EVCUKLLFH2Y^.F_:N5$]=*,
M -F;$#5T0!CQQNN)$-&AQ:8L8-,5""$QBL70T:QV08C]81'@0<-'VC-N@R8C
MQS5OHWSHGC'"77 $>IG7,HQD@]W4\:\S+%F;PTNUR2'D]R0VT)Y=8LR-,CW[
M4N!/"+8LZ>S\.? OAAD3)).1?CGS;?S&$27/QT6[%B*W1'J.MD?C>CHIJ@/:
M FV6"#@\V$EW$7DY.;1H]*0[<PD+F,P 3,V9EP:<2QF:F(V3EB9]F<1*OW3M
M4LW/Q\:;%M0YU_IN2568I(U 0SRJSY$@7+0S&SYJ-=%2LU6L9^1PJS>-W[=Z
MO.5U91ARU>(+(EMO2$-TO)UUU+%SM6,PWJ9UR@ UX,B=2Q<8F3F$(GY9^KJ0
M*'S,PK4JV-U\;.2<P^?R0TXA95HB\C*)4J[:!E,K:L6Z*3ESHL622=JX&5=,
M^ODCD<OGS2OP0&SY6C-7*4^0&LCR\>E$^KTS6,GF@>&R]"0UMN?/1,VX'RK!
M.&D!D[2;L49T/DB#)LDF2Y^SR7O9:%I7P:=-U\VG#BPD0,^D<S*5L_0)PR/2
M"GVD-S4<=F<5@Y"$KB)_)9]'I6B!L:<A#$F96+IEU%SWP&"C8[ V#.,)D)OR
M^4W^P<@[5/N&PZ*U[%(]!H. %Q6'Q,0Q QN.!&B3$4&#C4-&S)@Q:HXUT210
M1TUUQ_+OOMY2BFVZF^^^Q862\(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<
5(G")PB<(G")PB<(G")PB<(G"+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>64
<FILENAME>g713200g95b62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g95b62.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[13R4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <Q(,4
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             !
MQ   !X0          0                         !              >$
M   !Q                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !Q     !29VAT;&]N9P  !X0    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   <0     4F=H=&QO
M;F<   >$     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    '.$))300,      IC     0   *     F   !X   1T    I' !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  F * # 2(
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MGI5O#M_M]C*_S+/^FMB^QU5+WM;O>![&3$N_-;N_-24MDUWV5;:+?1?N82^
M3M#VNM: \.;^DJWUJKB5=9&6ZS-OH=C;2UE5+'-.Z6EMCWV.?^;O:B69%K++
M8?6YS*P_T"8(_G/?ZCC]%^S]QGT/YQ&#[W-!#&B1.KI_ZEJ->(5:5)#C(/+F
M#^R3_P!^3U->RIC7NWO:T!SXC<0-7;?Y2"FAUFRNREV%8[*QF6^G.9B^TLE_
MM'K#=MW.K].SV?0N6DL#(MR[\1]EF2W8,AS11L;N<UF2]E7O#OW&,_-_P/\
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M"F)AK-K8U_X)2^WX'_<FK_/;_>E]OP/^Y-7^>W^]"AV1^Q?T;/S'/9\7[O\
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M QNUUN[>1&AL]7;9O_KHR^54DE/_V0 X0DE-!"$      %4    ! 0    \
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @
M %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !1DU-
M "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %     0   '8!
M*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    "0
M +"':0 $     0   +P   #H "Z/$   )Q  +H\0   G$$%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#<Z,C$@,3@Z,S(Z,C, <G(U,#DQ
M-C<       .@ 0 #     ?__  "@ @ $     0  !X2@ P $     0   <0
M        !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H
M  ,    !  (   (!  0    !   !1@("  0    !              !(
M 0   $@    !.$))30/]       (          #_X0%(34T *@    @ " $2
M  ,    !      $:  4    !    ;@$;  4    !    =@$H  ,    !  (
M  $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I  0    !
M    O    .@   /      0   \     !061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD ,C Q.3HP-SHR,2 Q.#HS,CHR,P!R<C4P.3$V-P       Z !
M  ,    !__\  * "  0    !   'A* #  0    !   !Q          & 0,
M P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P    $  @
M @$ !     $   %& @( !     $              \     !   #P     '_
MX4  :'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G
M:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM
M<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E
M(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU
M-CHR-R @(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O
M=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(CX*(" @(" @
M(" @/'AM<#I#<F5A=&5$871E/C(P,3DM,#<M,C%4,3$Z-#4Z,S<K,#4Z,S \
M+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D
M;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^
M"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#$Y+3 W+3(Q5#$X.C,R.C(S
M*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T
M841A=&4^,C Q.2TP-RTR,50Q.#HS,CHR,RLP-3HS,#PO>&UP.DUE=&%D871A
M1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z
M4')O9'5C97(^06-R;V)A="!$:7-T:6QL97(@,3 N,2XQ-B H5VEN9&]W<RD\
M+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @
M(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM
M;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^"B @
M(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^36EC<F]S
M;V9T(%=O<F0@+2!'96YE<VES($8M,2YD;V-X/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @(" @
M/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @
M(" @(" \<F1F.FQI/G)R-3 Y,38W/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" @(" \9&,Z
M9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B
M"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@
M(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B @(" @(" @(#QX;7!-33I)
M;G-T86YC94E$/GAM<"YI:60Z,$)!.3,V.#="-D%"13DQ,3A%-T-!,# P,S5&
M1C,X,C,\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I$;V-U
M;65N=$E$/GAM<"YD:60Z-T9&1C,V140X,T%"13DQ,4)!13 X,$0P,4,U03=%
M-T4\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA
M;$1O8W5M96YT240^>&UP+F1I9#HW1D9&,S9%1#@S04)%.3$Q0D%%,#@P1# Q
M0S5!-T4W13PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \
M>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z-T9&1C,V140X,T%"13DQ,4)!13 X,$0P,4,U03=%-T4\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,3DM
M,#<M,C%4,3(Z,C(Z-3,K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HP04$Y,S8X-T(V04)%
M.3$Q.$4W0T$P,# S-49&,S@R,SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C Q.2TP-RTR,50Q.#HS,CHR,RLP
M-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV
M97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S
M:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T
M:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z
M<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z,$)!.3,V.#="-D%"13DQ,3A%-T-!,# P,S5&1C,X,C,\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,3DM
M,#<M,C%4,3@Z,S(Z,C,K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@
M(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-33I$97)I
M=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z,$%!.3,V.#="-D%"13DQ,3A%
M-T-!,# P,S5&1C,X,C,\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @
M(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z-T9&1C,V140X,T%"13DQ,4)!
M13 X,$0P,4,U03=%-T4\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @
M(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HW1D9&,S9%1#@S
M04)%.3$Q0D%%,#@P1# Q0S5!-T4W13PO<W12968Z;W)I9VEN86Q$;V-U;65N
M=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N
M861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @(" @/'!H;W1O<VAO
M<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0]
M(G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0'_P  1" ". ET# 1$  A$! Q$!_\0 '@ !  (" @,!
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M<YVW-'8M6;$-=E6*>>66.M&YSXZ[)'ES88W/]8LC!#&EW4@#?59F@AK07<Q
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M82M^7,?9CLH6ZXE.<U>O+:FC@A&Y)#H;(:UH )<][CT9'&T%\CW>JQC7.<=
MJ"= D^"AKH7K]MF/<-Q7CL;9:Y>!.Q[\SL+7VNH;97 C6K;H^.+2&-C)+OR&
MQ%H <-6&$DWH\[X0M"*RASS>)RGW>NSF>Q3ZF(I</5[%*7'T78^_D7F/MLCR
MR.E[:&1NIZ\,DLMD]DTQ\\4D39&GDY6UXHI>>5\SVR->_FC8 =1M Y>4[Z$Z
M V2-\Q/VSD2A*$I0A*4(3C"4I3C"4I2G'C"4IQC&,8QC&,8QC'C&,>,<XOWG
MJ3U)/>3[3[U97MPB<(G")PB<(G")PB<(G")PB<(G")PBXW6VG6UMO(;<:6G*
M7$.I2MM2,X\*2M*\93E.<?CA6,XSC\>00"""-@]X(V"/AXJ" 000"#T((V"/
M80>]<<9N*VPWB&W';C93AQK$9#:&,I7]_"V\-8PCPOU>K"D_17GU><^?/ :&
M^J&\NMCEURZZ]1KIKKWCV]Z-#6C30 / -  Z^X=%%WM!<^K=?'U,/V5JM?OC
M,V83L-4JQ+4)C=9*(FM-1,GKC'JP"HW(D'#5Q@E!0;MKPZ&*&8(PHLP@V[/C
M,/2I7>F8W5L$_(W"0K^HL%+6WJN%.OD2LUJ?8#<&P6FKCM2N$2\$?(,R@ZK.
M[4W:U-F.*'#GX@PDP]&:&-R(Q//W]ZR*3JOKL1.#[#,U[IR=9':S9(PLW(J]
M,DFG:?97R$VVM0"+D)<Y==.23Q64?Q'>R.(.FB#L_P!ZHC)4\18);#G4<S3-
M\$K",U7=JD%,@1._A\"GC;YDK9@X*JD*H%ME=#!S,^XV2*%)TYNLB\#S!3TO
M!1PIC+[+$9HFOU6QM"$=.E]35$IH,4!!:IF,$5U@/7*JY1QHQ31@A&-P%U!\
M6$EUTG#L#!6*;$SQ(\C",,SF)\5J6AY/"*I_N;#MPKVBG7RUA]*)V""GPM#5
M C<+5K4->1%3F3-LWB6W(UH4G4NU%*M:!HKYP?NI@:9IL(<,%5>7/(N3_DF%
M-^?/Y?:I\//N_7IW^/O5X'"A8/L[_HVV%_F/;/\ 8,_A%#KV57]S9Z-?Z,&G
MO]S1?"*?O")PBQ6[6N)2JR2L,IAZ:N*EB..&1O'QADT1D-#P@2%A7TS,+E9,
M0?&]7AM#LA+CJD,H<6FU3JON68Z[7-8'DNDE=]2&&-IDGF?_ %(HFOD=KJ0W
M0!) ,./*-]_L'B3X ?$K2^@.ME&T;+OMP$1I;NR-RF6KAMP]).G"\<U;7'9\
MEYP7$+D)S(<;#63?'0(P]$?"AD0>W*]\N*VI.WSO$5W--HU)7,&.Q$+JF)KM
M@@B=!4 8UHD?#&PRR/$;9)'/+OI'2%G*':6**!D1D<T>O*\OD/,X\SCX@$G7
M30T-= ._04DN<\LRUGKTX=,D-@,FC HHR!N<H&);&C/ESD0>P/'SD(GK^:$?
MC)65D,LJ?PW"3GX;SB/A2E830I2S2ONB62-XAMNAC#(RPL8(XWZD)EDYG;?K
M8#!ZN^7KTUU">>9]\32Q2B"X^"(1Q=F6L;'&_3SVLG.[<FBX!@]7ZHWTV2ZT
MV\VMEYM#K3J%-N-.H2XVXA>,I4A:%8RE:%8SG"DJQG&<9SC.,XY?&QU!((Z@
M@Z(/?L$=Q!Z@^U;%13U#THZY:5D7674Z#!*2KY;9]U-R+IB/<'F#A):G)J@R
MS<:3D+#><SAQ4$?[F/ZT-Y]'ZM'CJ,MQEQ#F&TVVK\D3:-5E.%M,NJ!T,8 ;
MVPA<WMG@#Z\FW=3UZE5XJT,//R-_G'F1W,2_UG=Y'-O7LT-!2BA#1PQE$<=
MA#X[>,);8A16(C*$X_!*&F&VT)QC\L)3C&.<RY\DA+I)'R./4ND>Y[B?:2XD
MJQK]%]O/*)PB<(G")PB<(G")PB<(G"*F_KA(VS7O:/;UILDB @:K-.;7N^*4
M,W-FR2QYR?8:U\&>GZ\=W2=P$FVF)(39'XT+3E69$N%93+Y-,I,AXZ\^?/\
M@\^=_GXJY#A%7][5G^YL]X/]&K:O^[$[A%-2@_VB4K_-*N?['A\(LMX1.$3/
M"*IK2/:O71?NSVRUU6:9M2QE*HL&PDN&%0R8DK(KG@->D1XKR1,IOY%8Y4,=
M"1&?).SV/BY2&L,,>]5]#RG!UVMPIPQE+&8K,99;:>ZG:NN'H[;[Q:H'E:)
MWM:T;RSG[,0M/9[<7:&23+>D-?4^;*D#8S%R7(*3X9K)K1F"9O;N>6RZ<YKI
M^4>O+IQT1HV#XW94&4965$;)!>A/J<^;ZFV6TRW^W"I\:K2QB\X_/+4UQ/X9
MPK.,XSGDOF:V3J*7'3^SLLKCB3\&.M-D^PL!]W0K!VC?ZW_8[P^SK]F^JKHJ
MG;KJ.OOM?*LWNFZMV9JDA6X0 S?=L)U^W>V'+D]=H$2EECV::R29JOV5>;%-
M5QO,60A4H?&8(XGO9WLO#>8_DYC[C<$>:QF,A1==BHUC(Z*O4J3P.=;C!?V#
MWBY&V<R:DEB?"YWT;6BHVK09;DN-RE%\KH(2VHW(673FQ)-:BF@%4_0=O#'!
MVL\7^RB,<@]9Q L1;W_JI_.,1#Y,CA7U2L53+P6:7C\?*'1M;E-*QG'U3E*\
MX5CZI\X^O-'\Q90?6KQQ^!$MRE$0?81+98=]>[2M=JS][\'?HH9%^]&FHO>"
MN:5BPKZ6N,S3AMB/"@TTLQ*>)RS(FR11C8<LT--8?=!!R1+WCL!IK$=A#F,K
M9?2\GJ(N$,T[@ZSEGQUHJ4><@:Z=]ZFZ$0MJSPOL]K%/(SLVV98JI8-S&9^A
M&6-+U/:5.U:PWZW;FI).*W);,W.V=D;:IU5,(L21N-EGTO8]@QW/*R4MB,SW
M-D7>6TEP#I"]R,.93[IVPF=?UAC.%8_A/,N6XD:CX3YQE:'@B7L)\^EI2L>G
MG*C'TVG4^:HMT.HKPW[)W[&D5(H7;\-3Z]Z<SO!CO#O+1W_:2->/1>6">^";
M"O-2UC4G5>K#:YUSL=P6U]?N+=@P*A56G,Y3_#:;,(PE7G"7EX^]F71X.)W]
M+R5L#PCIUZ8/N$DENT1[B8?B!W)N0_LL;_U%W_B/SZ^Y>,U?=!#&<$]KUH,A
M7X)INM$QY+>,X\*3\9;;;;HSN<?BASY2SX5C'J;4GRG(6</'_-XJQ*?_ %F1
MYFGXLJ5*CAON($QZ=SM]4T_Q>W_I9H_BYP_!(^I9[R,ILFW-M6;U>KUI^?AJ
M<C.,Y\X2A6N*[39#>$_P4J1)PYZ?HM:\^<Y@Y1@_F,3B:VNX]A-</Q/SC8N-
M/7J-MUUZ =R<GM>\^[FY?[@:5YQH353RU.%ZW(MBU*]>?MU8[3?487X].5-,
MW(T<88]6/HK$=IK"O[[&>3\^90#45D51W?ZC7JT3KV$TX(2[N_:)TH[)F]D;
M_M%SO[Q*S6OT*C5).$56F52M(3A6$I 5X0'3C"OX6,8'Q(^,85^>/S_/E.>[
M=M?TJY:LGVV+$LQ__MSEZ#6CN:T?  ++.55Z3QC/XX\\(G")PB<(NAM2DHK%
MC4N='&)2!+Y42EPDDHH_&!\CS-DCE8RF?'B_U]Z$K&<2FT*8SC.'/'"*K/V3
MNN#U&HFT"T^QDK37[N2HMAJATCH;.B4&A\NM/SWC0H4UK[7$(J#FN$VV0RF0
MY"5%&PHTL@62^7P&#D5M7"*M_P!II_T9];O]/#IM_P"LX'D'^(_,)X'^R[\B
MK(.2B<(NK-R7(88M,:G0ACD0;.DH)$F52!P]3$9UW$V<PF7 4]#B^CWTEO$V
M)E;*%I^)9\^\3DA:'RQ,+'RATC&F.,\LD@<X#D8[DDT]^^5IY'Z)'JN[C!Z
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MFB_IG_)PBG[PB]5J]"%K]*E^A*E>A&/4M7IQG/I0GZ>I2O'A././.<XQP.I
MV!OQ)T![R? >THHS:ZO@KL3:/M>#B&8VO]6'3X"*T<'X'K.;5%R9U?/R$,^\
M?3)@4)E$X.Q(;=<C2+$4)XQA,JNLN<Z/(49<!6]$F="Z_E(()WNAD+Q!BY R
M>!NRUI;)?=R2N! <VO#%WMLD+$UPE/,W?*PN;U\7@\I_[""T_P!;?[O6)W6_
MN'J\]L;M" !PYZC-:VK\(]')CZA0H>6&X[H1U]PX8NSD:>RV9!&7<J]U&EJ;
MD-2V1KS\Z4U&^1XG-U8[688&$O?=[2-KA5JM[,-[(N?-):Y7?21O=W!VG!P8
M2YX9K.'+M?BFQF*_!7!?$ENYC[S69>2I&;\4TTD8KQO+HXV-IM,].[.V-[I'
MO$Q# [LG:EHK:C=A5C#^X=64N'A?ZR#4S(VZ6):,?]7\Z*?"B83F<?1QM%6)
M83GSEJ8I*?6K=C(]N=')XZJW8!96E9;G^!EDY8F'^KZ/)KP>=KKCP)\HLVC-
MP]EL;%WZ;B+LDQ;[?2+E>"O&3X@5I0/!QWTK\Z/5O0U"MO:B74.T-IDS2NXI
M.2KQA@/5V(^8ZRLAJ0C-BA$A!YM\@0*Q?CV((WUI%X<3&:CRFTYX_A:YA9+&
M>%3B!_/5R/HLWT3*8!B[0ASS9;+%9<Y[Y6F5K(Q]$2&M:0NCSO\ HS<6?)S7
MP%ZIB^*^TXVPL.?E#+>-S198DDD<^#T7'XMAJN9%8KS/CL">0>D")LP=%(%8
MA"M\EO.,A.PVL;(SY1A#%D@UYZ6YCZX]'S"K6>O,(<<5X_68#O)3C'W8^?S[
M)MEP_FLWCYFGN$\<!>1O?UZ]B!H)V!OL??RE<E+P7Q]4)Y\9F.5HV6WN&K[3
MH [)EKBLUOAZW9$#7U5##H'L_L);<;]7<:YI\R@3MDA @?8Z^"HSR74)E_&L
MNM!/MFPY&0E,3,)V?-'+SZY"6$RDI=6SSO"F2MVSEC$,?;;%>='+V%R$.CM#
MF-AG^KBTTL'T?)SF,]207#9;S[."/E2X&+AQQPD["?/L<>;POI7/2=>QUDR!
MMB)HCL#E/*P&*=\%B#F:)8F\P5A/VYN49S*".H;=E"<?V2%-T8LPO/GZ^Z1(
MLXJ<I.,?7.5P6U9QGZ(\X]/.N]+M-^OC+.AXQ34Y0>G@'6(G]_\ 4^Q/3K;2
M1)B+G0;YH9Z$H/P#K44FO>8Q\%]*MG"HZ?).M;"%YQC&5I=H-G)I1G/TRG+U
M>'F8Z_'YJ:><;\?7U^.3\X1M_G*]Z/PZTK$FOM@9,WI[0=>(V.J]?.<3?YRM
MD8O;O'VI=?\ 56CG:=>YQ'L**V_K5G^S[<,"Y\XQXL7Q-<5C.<^,)RDZP.4E
M7GZ>E6,9\_EQ\YT!]:U''[IN: _#4S6$'V@]1XI\[XT:Y[<4._\ >.:N?AJ=
ML9W[M=/%9,*M]3.__@MGKY?Z>?\ DPR.G9\?Y(TEW./QQ^./SQRQ'9K3?S-B
M&7_ERL?_ '7%6HK=2?\ F;->;_E31O\ [KBLAQG&<><9QG&?KC.,^<9QG\^9
M]CVJPO/"+T<5E#:UX0MS*$*5AMOT^\<RG&<X0CUJ0CUJ\>E/J6E/G./4I./.
M</#8Z_#77X;T.OQTAZ G6]> [S[@L6I=M8NH7!R,(-!6,SB$!,4ZU 9FJ<&2
MW(,EW#8XB38]S\6P^RVK,C"U996KW>$9;4NM4LBW#VS8I81SR,Y9@P/W&XL<
M=1OD;KF! ];?0]-:)JT[;;L/;MBFA:7R,#9Q&UY,3RQQU')*WEYVN:-NWMIV
M!TWEG+*M)PBXGLJ2RZI.'%*PTYE.&L)R[E6$9SC#6%_<RYG/T1A?W?5X]7T\
M\(J5NAFP Y#?0<?7K;:;66VQ0-P;>W-2YMOU?9#>@MHXO=5@NU+< >L:#U[9
M:K9[)!*9S&BD;=&2FU +H-8K)H;"8LR7GWIY_P E-M[8FZ:IW%OH.X$7Y_7-
MS0= .T*$"UD84V)V<;V81IT\>9N<!1^99#9-O(^6Y%BQ@(FM5UZ)-GC,H8(6
M*015#;LWGVOMWLF^]:-S:TV5L:Q*I.R*V9OI2*#U< !UDKK".9+&0-,V#K'0
M5V77J&:ERZF3#M5^_&I)B)*<#V^SQ$N*A$\^W\?\E^A^@_VB4K_-*N?['A\(
MLMX1//"+ MD6QZH5B1+'8BNV(H^P!JL2:M2(LJQ$_6W"7,RC]8D6,;1(-G'F
M\>J("&$YF?"8ZLXN4:[+$_T[C'4@8^S=E&@8ZD(YI2TN]42/Z10\W1TTD;#]
M9 'O<V.-KGR2.:R-C07.>]Y#6-:T=22X@:'4[T.NE^=[HH;JC?>[LVQ1+SO(
MU;##=W<'16*O3W<&50[C"=L!4W.M!F:,85/*.)EBG'Q 1#<:6MN01B.^[A3?
MB^,ELW>-\_FAD<K*,B;HQ]*)E9\4%7MXNQA)M2N8R&G#!'6I@1QAD( ?(TD@
M][E_E\X!RN/I_)I2^1O&,XAX8]"JY;/?15Y[U[A^G+BLL*\^)M4[<?SI??Z;
M=GMY&:&Q-$U\M?M1$8KTV@'94HQ_5&P*%7(>7&UHAHID@K;'X^$JRMB78VSC
M%9$REK]&'50J:=:0G#F(TCU*;=;^@"#/2#K=IP,V--%1TMES='HZ?MVP1.WK
M9;5G&MZ.R'#EW6<+?E:9<1DL%7+?I&XS-U\C8#R00]GSEAS'&QK>9KJYEL.<
M2'-NLY?6IPH'0W<(CVG]QWR4UH;D5]S[1V!BZ.;3L0.N2Y]@IOR#XZ#;!PZ1
M8GR$B1+E,N T!V'(>,J0\M(Z,AZ5HH^(OE5L9>3A*])8DX"JM-BK%Z=V-4O#
M.VA,=J.N;1E%V25[HQ$R0;<))7Q;,OU'(?)5_HZP_)ICN+Z/RG\>2_*!9O:M
M<+21XRR8)'V9X[(DQL,.-LP00U"+$%\<3NBFE+0&2=JZI%<9FN[]@9:S7RH.
M.AK.?$*S7I^VP%)SXQZ7'G=1BK(YZ<>?2I5E\^<X\YRG'CF[,.:9KL'PMT>C
M+%TVHR/8XG%QV#_^QOW^WY:<1PS&!Z-Q?Q6W7='9X1P]J+X.<>+8[)U_[G:J
MV+USO'']H^&V!)T'3K#0AR(XEVX@*94HHR6!>J\-V8]&V4?KV;3!*H*QFX;4
MF6_F7%3[X)&EI#O.N\UIS7'<5\473Y"7%!XB=CJL\[,-+7>62R'4S>R#S*#(
M7O':"3F8TZ.U\MM/XJ9QPVK3?):X5]*@8<G:P]/'%T;J(=(7QPVLQ;AB98+F
M%\5JR20 .4D1"U1O>5A'>K[9:!W564-I3E<X6*JFPQZO.,Y7EE.NK993F4MI
MQA2LO@HV5><):2M?E.-J,O/'_2L-E8-:V^..K<9X[T*5NQ+H=-DQ-[QI?368
MVQ*]S*TV.M!N]2-R5.DUX&M%C<Q)BYCS$Z:T0\W0DM#=$^T?M)HU4AN&6NBJ
M?.=QC*(.PJY:==RLYS_>8:NP4#Y=QCZJ:QG+B,?5:<8SCR;Q'ARX,EM^BO/[
M%Z"S1=W;UJW##UUU([Q[%D?A,TR.28X;+/K1;,MNOC[=NBP;#>8WZL4]+E).
MFN%@M=WM) 6U@-[I-I0EVM6^L6!M>/*%A3PLGA6,?CE/P4I[SX_/]GY\V4-R
MI8&Z]JO/_P J:.3^ZXK21VZLKBR*S!(]I+7,9+&Y[7#8+7-#BX$$'8(!&CM9
M5YQ^/G'C]OGEE6%YX1.$3A%QK=::QC+KC;>,_3&5K2C&<_LQE6<>>02!WD#X
MG2]-:YW1K7./?IH)_)<F,^?KCZXS]<9Q^?)7G_+[DX1.$4<>W=?N]JZU[AKV
MN:B&O=T*U&1%!U(]#@D1YEW,J(N4RD:5(B!10DQ 1+EA194J-%$C,>!!)3HL
M*0^\@BT3T4U_]A)6\\5?2[NF=.%K12W-5##VNX6KKM.9'TN'"N#)FJ0YLA?R
M(9942,5<L3@AR4U,XM&1"D!!X0I/(M7F=)]G0VH^]^N1K^U;B7WIM;8I?3UR
MSLZG8LU=HAC3NNH;+ @F<(0850^-M0NX5JFAH@>-!"3W8,XHV*$/O'4D\^>G
M\5&7?M%['4?JST"K^S)U#K<2O=R.K\&\T95?*'[R],?[')DT23B_#]E$:H,*
MQ*L^%S?!D();Q$NSY+MU8]#"I@>E_AY_501T/MT?R[A\?S]ZONX4IPBU%OA<
M5W4EW"RHD<@JY"%:_@CI;7Q$6>4V \U31D22QYQEZ*Y.-L9EH\IQ\*EY2U)0
ME2L;7"!PRM*8.=&*<POOD8>5S(J#77)7-=^R[LX7!A_>+1U) 7B37(X'1#AR
M:/4'F]71[^_?=X]R[C56J*!I6C!M=:RK NHU$&V[\"%$1\1H3<B4XJ1/E>ZQ
MG./B)\MQV7*7Y\NR'G75?>6K.<.3RE[,7)LADK,MJU-KM)I7<SRU@Y6-W^ZQ
M@#6#P: /!(XV1,#(VM8QO<UHT!OJ=#IWGKW=_50PT-VATP1O'8@)3R@^[V@;
MM"0C-8U7K*V_::4AH,,&9=)O.L.#7&,'!Y: HR0FB@K$]B7+DS6&"+"\\!B\
MQ298RHCU8E?=+XXJ&/L":6,11Q\SNA:X=HQX,CW1L#R7N+6/:5K,/>X9R5K)
MP<-LG],BO$Y4V9:[(FR=A! -2NI8^.)ALP7' 33RD\P:"7ASY)#_ !78?8.$
M_#BP&C:^[GSE1F5$O.PWV,XSC'O!X=[%0 N+QG&<MM'K"\CQC.'V%X\9V6\Y
M>[F0XB GJ92RY?+=]W)&?1(=CH?I;!'M!Z+K/0\1!RF[D[-UVFN-3!Q-KL)/
M4QR9G*0/,9!]61M;!V6.'K07V]'*">I>HXRE]R^P>RZ3M&_3]@$:W6W9.+#
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M+;9V=F2O$^=A;R%LCF@N!9L\A![V[Z'HNAH"^*5891L+,B(6"ZR"2*6!MD-
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M1CQX\)0E./'X>/&,8_+FRT/9KX=/R6L+G.ZN<YQ/>7$DG[R5U0RMUT(X4>#
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M=OV/YA[ %'GM=UB+;BT)L'75;NVSWC]E%M0X&57^3&8<>;EL/X;FLR78HMV
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M6F-1;/L97[?8ME VF"R*OAD.)P=AY/?&CX6&LMR!BA,1"8XW]:GW&7LO>_\
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MZ_G_ &00B?=_P<_CG^^2CDJ//GR%Y19CV?/O->VAOZ_3P1I:_./SS]VU>?\
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M9IIQN,A+>?=X+5W,Y""_=R^3?<^:\A3N4XMF*"OB;T3,-<C;4C;'7B;1%/#
M.BB8/I27;<]Q3@2A?9Q#Q7A+MY]V'BO%SV,+7V[5:]BY'WZ==C'.+#,]T+:#
M)&@%S<E*=[<\&^G<<*F4"H$Y0EU&OG#*;"1.GJ]Z1S4"NL1B%GV#:2\1E&84
M[,(.DK*;E2XZY"34Z W&E1GI27<5K7:2"*G"Q\EB](*T;(@XR$/'TIC#>O.(
M^9L0 )=,^)HZN718&.&!U[/7"T4.&JARTH>QLC+%N-[68NB8W=)6VKQB,\0V
MXTH;CP/4*A[T3Z_7C19W?FY[-1%Q7^R9JO7] JM("+GU^+)@$CL49)%/OPY4
M=8E%E0"D#V%RU?,A,I]Q$K#B9\CI,M;#XL;B6U,9!%P]6DQE>?'U&P.FC,G;
M6!)('O=.PWWVK+)'';Y+$TVF]L6MY*K POFR,D+69#).?:O2::9'SV99+<W.
MYK1LNGGD>_P=(YSSZSB3,;2MOLVW:8X6(1[-7@_VCLPN4NPB1M;LY-H,:F"O
MET:"&7Z14)CX3X8@2<R@G)FMSH\),5AMF:K3:]G3X*Z!KIT'P_/SM2&A080Y
MA$6!$CPX[>$)2S&90RWC"&T-(^ZVE.,Y2VVA&%9\J]*$X\^,8X4KZ^$3A$X1
M.$3A$X1.$3A$X1.$3A%QM,LL(]VPTVRWZEK]VTA+:/6XM3CBO2C&$^IQQ:G%
MJ\>5K4I2LY5G.<D7)PB<(O5:$.H6VXG"VW$J0M"L>4J0O&4J3G'YX4G.<9Q^
MS/"*M'II3NL ?>'8@3I;J19= V745GCT$G>"5=+ @-_BD:I3C2I0;+Y%Z ZE
M$:2-A06,L/NX BQLR-)C0Y#4".3X^>I_S^U3'LFAZ79-D3ML.S+.)NQ*AUW6
M<XD#-K@M2*57;P_?6PCD-;$B/[DL5ES1YQW",/SP4V2-PXSA:7D$55G?;HYU
M^T?[-[LR_21=J;GZLJY7>U+L!NUD[-9@5JU=KYBK4$7!-GE39S-3J=1!AZP*
MKS;K;&1(R,B8]*EKDRY%[&Y"3$VQ>@J8^W8BALQ0QY*JVW6:;->6K(XPN(;S
M&&:6,.ZEK9'ZZG:JVZS;4;0=B2*03P/YB.SL,:]L<G3>]<[M[!Z'NV!K2/LO
M.I^Q.DFR=@M[ E )+EW%:DMPEX05=(NRZH;D6*NVB1,=='#O0R/*6JDD%(PS
MZ,/C2>4>K#2G%:F[D^),YSY_B2^Z>[5RWHLU&&>9V/IT,JUUB">G6<]T52.6
MT+;7LB:T<M%D8'+"Q4?DKQV9CGXTPN?LQR6LKB8KU&&"626#T[$FSE*\D3'A
MHC?8KC*4&ZZN?8Y>C0 Z\?9 <?<C-8IJH^<O+6]92Y"+G,<@. AEH4S$8FMX
M];/SXZX-AN15JRP0%QC+3C;R&UIQAM.[66"J.O,38F&@1V,#FEK".O\ .S&,
M:\8V3:^JN]PS?0,?E<^[I)!'\U8G3BUSLID8Y&R3L((.L?CFVI@X=(K<U NT
M'C=#'0"X[:[#;L[ P-O@MGAZ-'J=T$D;./"2VTFEG+-BGF)0$C*8E80F0$ 0
MX\Q=8@RC$=O,AF.]&@_&85U?$?#G$V/P& BS-_%"OGL<Z?+U</'C(KM2V(H7
M5*5Z2M'VPYJ=N:0OB+XS.UX[4<L1D^341D\Q%#7R#'TX9<;99DS5:&]O8EF9
M$(F3R&0Q-]'#@\0@DR=J!(UK&;L3]G_HO2VH*=L)/6L_:SL*WW0B/M-IM:G'
MXP=%1)&( .,)C2@(3$PPZ'(,RI+669$6-)D^\(+:]TV,?XS%X:GB#/Z*9CZ1
MV?.9I&OT(N?D#>5C /YQVSHD]-GHME@.%L5PT+0Q;;#1<,3IA/-VW6$2!G+Z
MK>7^<=OOWT]BL6!U4#77B$P6.89)&%1G#992$K*FWX;:VH\DM.SCW\UYI#CB
M&E/*REEM?NF$MLI0VG;+HED/")PB<(L9ETNIS[$Q;9U=$3++&$O HYJ5!8?G
M-")$MF<] 0ZZA7AA<N.R_P"/'J2M.?2I.%KPHB[QN%#9QA+42*UC'X8;8:1C
M'^3"48QPB^G&,8^F,8QC^3'C_P N$7GA$X1.$3A$X1.$3A$X1.$6.7!Y<>JV
M&2V&&V)V*'(2F 1B=#%BB\B-&<?CCR!,A'EP1T64\VAIZ?+C/QX:59D.M+2W
ME.2*/W4&X;&ONG8%JVWI>IZ(V',,&H1VCU$T+.1&61I!Z.+F3'QL9C,.9(@>
MZ6H=,<DR&V\HEX=0S-:CLD6PCG7S25F:M3%@U?33$>\E#ANY12 >/)BVDO9:
MK!HYXB>BN8S'*2B=2&#@$EV8VZK(^#$:1Z<L-J215I>U2Z]ZP(=4^N^E*[6Q
M="I[7;;JSKVM)IXH:.DTJO6C9XL$89JWF,XT.5-'3)#$Q*6U-D$/.HG)D)>=
MPO(+-V&"U!3OW:'ID#J\\E&Q)7E=$X]Q<P@.#3ZP#PYH< >4Z56Y49<KS0N<
M^(R0RQLGB+6SP&1A:9()'M<(Y&][7:.B!T*V5U=U.&T>1M>@%%S,M8VT6^FR
M[1-C",GBP'8$+.P*3/=<<'/P$-1XPNYUR.VJ&Y':2^PRGP\IK.*<L79-Q-P'
M?I0O8JX1IN[M.3MZ[W-8UK&NDQQJR'36\TD[G'FD)<[>\-M-WACBK'2/=+=P
M>5@SK7REKI34FD9CK;8PUK0&219#$3N8QOJMJO=UT]RWCV"P0KE<;J6OR*EV
MJ3$"Q&HQ'#/RVP6ZP$$5?6<8Q"'L08C4C-@2Y92,\='85@+3)GS2-,B+92FQ
M6K.R60AI-);#68[)7Y1_L:U0&9I/ALNC<^,'Z\D;(^O: *S 9<5@,CFHW".Y
MD'2\.X4EH<\36X6MRUU@/=Z%2L15P[H [(\[7<T!Y-$=.M5YU5U?V9JV=U^]
M#4XYLD/-KH:/#S$V._%CO5J?*/SCYLC'=E&Y8]X1D@_&1#='QXTA<5YGTN/;
M#.Y?*<2SV+.=M?.1D;/#%%*QH9%3EEED;1:WZIAA$KHXP\N/9Z#GEVR>2K4&
M05)*DG):CD[0O:]@<)6R[+HY&2E['L()8.;H8PUKMD$K?G36@MC>O>NATNB1
M];@F8;\]F@1L04MS9S\QQURP'OE\2"PZHDZG!",)5&1AC+B7B*ILG#.(NDI5
M(*,#:]>%D,;23RQC0<XZ+G]Y.WG9.SOVK+0I5\?5CJUH(:\4>],@C9%&7'ZS
MPQA/5YZDN/,3U<I7!*ZR#E&Y31(I-4=(_-)+1!V(XS&D_#L1/$),>'%6TS\-
M&C,^[=6_]UA"O5ZU.*7;5Q9#PB\>,8SY\8\Y_'/CZYX1>>$6/_9YG-EQ9_F!
M3XG S(K _P!]&^5XC*=2^I7N/A/B/?9>2ES+GQ?CSCQA.$_=X19!PB<(G")P
MB<(G")PBQVV@G;/7#%?9(9%_.(+X]V:F(U-4U'E-J9D>B.\MMI2ULK6E"EJS
MA"LX7E*_'IR1=W%;>9C1VI#V)+[;+:'I"6L,)?=0C"5NX92I:6L.*QE6&\+5
MA'GTX5G&//"+GX1.$3A$X1.$3A$X1.$7YT=KDM(Q^[>P;E.F:N8MH+N7H*DS
MYQ?>@L9VK:(%)6@&(\35&IUU61%D:Q^<3PH\J4F6-BZ/Z^([9#!940"12+F/
M'S[_ #YZSO\ CY\^P+]!9.X5(*=KU8,VBNB;+;5$$U6O$C0V"<LRA,=,LJFO
MBI4EJ>84,BK1)GX',2,PXZTO2/=MJPK)0M;W?8VOK !W-0P-YIYJ\4VAV!ZW
M4X390Q&TU9DC79KH]VQ (DQXJ%;G-+0Y#62B1DR6UI6SE:58SDBJYZW!X;/L
MDN@NS9$9;Z-1:'T?:C26DJ4Z[K\I2Q]5V9'QA&%+4A-)-EB66TI7E3HMG*4Y
M<2WRQ4C9/:;5EY1%D8;.)E#_ *I9D(^RAYC^RV.\VE8<[P;#U]BKOM3XR_B,
MY4=V=G#Y.K:CD[N6,S,9)O9 Y6$QSNYG  0]2!LK9VGMR([FQ*P(0SYCOV5=
M/N#/KFJ:=UEJ9VO66X&EXGC1^'$;=MTVA5J<,PV]EFM/$8DEW$N-,93S_P G
MN89FZ.5XG>Q\3L'._ 46/;(TORQ!:+($D<1:]K6R7QR\QA=4JQR!KWN:/NWR
M^<!GY,LKB."XI&2P<011\=7'CT;;8+4MB+&X@BO;M<T>(#9JXG<Z-EN2U;EA
M:Z#LG&V+&,8QC&/IC&/&,8^GTQ_)CZ8_U<W"^(KPE*48\(2E./*E>$XPG'E6
M<J5GQCQCRI6<J5G\<YSG.?KGA%[<(G")PB<(G")PB<(G")PB<(G")PB<(G")
MPBXGUMMLO./*]#2&G%NKQE2<H;2C*EJQE'W\>E.,Y\I^]CQY3]?'"*DKHG$+
M#.UA2]&;OVY-ZP[#:?)V7J_"WYL-5N#3JQ6K;\_MQ&7#%;FN$>'-EB+_ $QW
M7\2W:SI=E@4R%(8(D")])GWD>/GR/X[]RD_9T]FO)]_A]ZNZY*A5_>U9_N;/
M>#_1JVK_ +L3N$72=GIT;6^K-3;P=&EIXX)1W=<W5JOQVI!QZL;!I6((9R R
M^T[&=E#KPS7E0DRT*CMR)V77,9PG/,5AS&8_.M>V5[)\%D).SKM#YY+.+@DR
M5;L6D$/G["&_6KM(ZS7&CQ(.XX.K2R_*+P&*\U*K+D.)</AGV,B]\6/C]-R$
M K27Y8G,E949/N*4QO8[DM/#7-+@5KGK#V0NG8#11.P-_/(.Y=K7O&H Y2?&
M&L10P@,!CD#=OK[@T9!CR!M+ $+)9<YE0$X>N4B%79$ES$Z&ZOE_DJR[N+L7
M:S^2AL,AI3/%[MVL#)HZK86UZE>2%D+2VY9G$3G<G/"^6P_;F0;7VO\ TH>
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M=OB_\=\(G],6D_Q#?:+?NWQ/_O>^$4Q=$;FK'834M,W'3AUD#UV[P9DR")N
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M]7; LNNU$Z&]\$/\U$UFM?-@3>8C>8\&8U&RI[W/OW2*47"*+';W?=IZY:Q
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M < R2ACCLV#& DB>?A_!:HZ6=K(^W=E[AT@#UEK_ %[1=2(,/:_A:^GYQ\J
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M;H$C\@VOU]:>&4#3\':^U]APD7"J3OL@*L&O7++=!>N2M:ES8S135-\QL^N
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MQEA&%MJ:(BWW%OP)2%I=BO\ I?94AU"%I(ODHFB--:PL=@N&O=94RH6NUCQ
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BQ_DQPB\\(G")PB<(G")PB<(G")PB<(G")PB<(G")PB__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>65
<FILENAME>g713200g95n07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g95n07.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!4P)> P$1  (1 0,1 ?_$ .H  0 " P$! 0$!
M       &!P4("00* P(! 0$  04! 0$!            !P,$!08( 0()"A
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MY/A/?'5F.>#[)WJ0>T:=0L>9I<".\.LW'.3X3WQU9CG@^R=ZD'M&G4+'F:7
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MS*GT%]>!;M6V&OJR9)YFV(2'!:F89HQ%IU!YR<L()G"I#"U"L)R?^] >WII
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M\2-7_0$:M;#\#1]%#ZJ*]S^(J?3E\K,WJZ* T T T T T T T T T T T T
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MR,LI6>6!(<?C 3S4P0&8"0:<$.,#$#AD6,>SJZ=*E)MRC%N22>A:4MS'QX>
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M@&@&@&@,)(/\@1^.XS^<;5JUO?L5Z6E_5@5[?Y[^A/ZDC-ZNB@- - - - -
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MCZA^QW[&>U+]G>H?$_3VKVI_4LP_,5N./4F2]CM>BI\4^0Z'?%"*_P"FV/\
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M!G)5L[4Y)\'IBAASS!@S,@R'G3>6!;F@&@&@&@&@&@*_MG]%=E_-_,OS<<M
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MHKCGD=VN@^'_ ,6$R3''_9G4J^ZK^X7?H8_6(T]Y?X&U]++ZISOU-I#XT T
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MS7ADB@%S5HPVZ%^W06FR1G<IY+%3'/2+#9FM48VODH?$#S$VV2=77)8@;RR
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MEX$R[O$L_LZD?O,V<\VYX$>.:!W=Y_YUOPY<0=5IEX$R[O$L_LZ=YFSGFW/
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M=5IEX$R[O$L_LZ=YFSGFW/ CQQW=Y_YUOPY<0=5IEX$R[O$L_LZ=YFSGFW/
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M(<3AT$4H9)>[/ZH:K%86-@!)B-?"(T24G$3D8LFX/&((@A#S><"R((%T: :
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M=X>?^*WX#XX^M7<'OJV=[ ^W:=V>SGG7/#CQ!WAY_P"*WX#XX^M7<'OJV=[
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M'OJV=[ ^W:=V>SGG7/#CQ!WAY_XK?@/CF+;]R=J-BM]6IG5#STA=27APYQO
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M\>ET'@S5'RVZ**Y3.I-:ZB!(J?;(:-KF3A$#U5G.%H,2-(4X.[<<S."T:)^
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M6+'$^S5"E<T!A:AO.6'/Z96A$C-PC2 6[CLA=NX8G,*Z#9-]AK2R:\>J]L^
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MHQ,&R:MK8%WB6(\)U:8YLUC"-.H1YA.5V6\"'8[$C.06I+,P>O=A!,P$]&!
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MGG'/W/\  55ZM= 0N&P^0BD-J\FUY]CA/F[&1!;JNSDS.:NK86!CY5;"#@6
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M:T.W^/Q:60E.'='&_*/9$@9WUFLJ(;BG!,RULNC*>'I&Z*C->A#4(\ $X=
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M,UV4?-2CWQK 78S6H2LO<JYU2&=**P-Q=Y4Y[1YEOL#1M4@,H=*K*H2TU0I
M$ND7"%'VF90^Y-SKLLUKE:8NR0S!%?D?KA 0:6Y8836YX5%K&H90371*!7DX
M9^TB567&:]=W:VYC5<9W*;=U\<L2&L^WJ-#L*NHUN6K&>7&Z;AU2!1#Y)&HN
MPUHE$BC*:$MQ1S\02ZHWY.I+YLY0!9-Y.7:6LMG;@GRE2U4N@1SDNCU1U^K;
MZ:96]JAC96.TA[63B%2IX9E,A4VR[3%^MA"T!E!SE&<KVU 6J:PI08/5 4K+
MS>U(G=8/<<>8Y9C1+'BF'-%%R8]C;PV1!:Z=P3D3>\W%+625LEI,5Z8?T$;
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M#6&C5C+_ -&@'5"=> <K_ $_NS4B=Z.S_,WG I_>FA]V^><[:<*I]T.J$Z\
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MJ))X:#&Y3LSE>1W,J^5QE2A.DH3AK-QDXOR9O6Q>LEK+%/!ZS;6.DVVUI9L
MT T T T!7]3?HKK3YOX;^;C;H"P- - - - - 5_,OC'4WS@.7T5V7H"P- -
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MK [Y57ZR] .N4C\TU@=\JK]9>@'7*1^::P.^55^LO0#KE(_--8'?*J_67H"
MVM,9$*KK)"*J9\7@4!F(<F#<:NR &,QUQQD8L%V2,>0AQ[.>2'.>'W,9T!/N
MN4C\TU@=\JK]9>@'7*1^::P.^55^LO0#KE(_--8'?*J_67H!URD?FFL#OE5?
MK+T ZY2/S36!WRJOUEZ =<I'YIK [Y57ZR] >%S?W![;7!F>:6F3NSNZ%6V.
MS2YGU(O;7-M7IS$BYO<$*NQS4JU"M2FC+-*, (LPL60BQG&<XT!5<$JJHJM!
M$RZRV9QVN2X$3+D\&+@D$V[Q$$,3V H:%<\(B88_,&\,=)FRI@0&NX4?,A<C
M$2<2C!F22\A N+KE(_--8'?*J_67H!URD?FFL#OE5?K+T ZY2/S36!WRJOUE
MZ @,QF,BS(JISFJ9\'(9\XB"$3C5W$S/DNLD/(!R;)%C L8%D7WV0XX!S[/'
MAC($^ZY2/S36!WRJOUEZ =<I'YIK [Y57ZR] .N4C\TU@=\JK]9>@'7*1^::
MP.^55^LO0#KE(_--8'?*J_67H!URD?FFL#OE5?K+T ZY2/S36!WRJOUEZ =<
MI'YIK [Y57ZR] .N4C\TU@=\JK]9>@*Z>).]*;/AW/U).S.$"LC&"C%]6B$+
MC(:JXC#_ /N1DODE\.&>.<9^^QPQG''@!,>F%WF9G'X;5/K*T Z87>9F<?AM
M4^LK0#IA=YF9Q^&U3ZRM .F%WF9G'X;5/K*T Z87>9F<?AM4^LK0#IA=YF9Q
M^&U3ZRM 0*R'A=F/-W_[.38O_P!>U5]\);5F<9X6A#\X!CD60//*,_W<>QPX
MY]G.,<<X GO3"[S,SC\-JGUE: =,+O,S./PVJ?65H!TPN\S,X_#:I]96@'3"
M[S,SC\-JGUE: =,+O,S./PVJ?65H#^@O2\(L"#3,XQG&>.,]W53[&?25H")0
MR7R N06K@%43W.,SUNSR N-78YKA5U;!P 7*LD(>5R0X%][D6. L>SQXXP!/
M^N4C\TU@=\JK]9>@'7*1^::P.^55^LO0#KE(_--8'?*J_67H!URD?FFL#OE5
M?K+T ZY2/S36!WRJOUEZ =<I'YIK [Y57ZR] 0&J9C(@U=6P0U3/C,!@,.#@
MP#C5V #QB.MV,##@RR0#P$6/9QR@XSP^[C&@)]URD?FFL#OE5?K+T ZY2/S3
M6!WRJOUEZ =<I'YIK [Y57ZR] .N4C\TU@=\JK]9>@'7*1^::P.^55^LO0$7
M=W]V=9;52==")1&B03AT."N>U<+/2FF!K"Q@82%@CDO?UV%!@3,CQD9(2N26
M+B/ N2$0%T: : : : : : : ^&&'?%"*_P"FV/\ )B77Y@WWXVMZ6?UF<GW'
MV\_IOY6235J4CMKV-/\ FMRG_+TO_P 2V]=<?]</[+F7_*I_TV3-[L/P%UZ:
M/U2BF;M7=Y;U!-R-@-E8U8[ @-EO-257&<5'-HZB/?%&^>*[28U)7BRGW<@!
MFL1&WLSR<Y+VI&UQ<:EP&66!>D(*,&9T@2>;'Q[MEZY98\W.UE5;:CDP-#!$
M'>QK<AL5A3-$6!1/EVXU-%DB:M%=SS6RE"A3C;<ZA,*0">0@RJ3#YWB8,HH#
MTMG;4UDX-#(_+=K.Z^(-AT+F%H2_RD0J+5B[16JX2]T$U/%AM$>L"7QQ]M./
MC(W&,@THHFG>!+E:-Q1)<'JDQ99X$(.[:I Q5'5#_-Z E3#:ERQ6Q7YKCT>D
M$+G<6K0]/)+XCE.FV>8T2Y'*VV,SMPHIR39=!H4298J(/+;LJ#B%:=$!DZW[
M9^*SJ"U+89%2SQW+L5CC["57+(Q1ACG;O:$CW@;4MER#F13ZU8UY-F=59^Y4
ME<B9I2@1N2N,A3NIZM#@PE*K O6]][%QK]B(-X6V)B@,0=V.7.L=F<"W&Q9Z
MEQJ95%K@=*#F4>0'U1:4>0$N3-8K8<:G<0+UZ-:W)^."0#/#DH".WEO[MNKW
MCR6U<W[?]Q]UPK9IO'N6W&F-2=W@$:CMY;89WLLBQ$>< *WR=O<$@YD>W)OS
MVO;UF'-\5$,J<A"<(X0^= IF*]I_=L[M^25RF1[>JV8450G.94GF:*>R-RAL
MTCNS7:QO/EMPS*,LTO8#W+;MF/;CU$43$)3TCD0_, S1.)X3\I2 -D$N\R_H
M1M7V36/;-;15YOC=5,@)76&5S'Y0@:&&*I:2O;=TY-+=%'>5R)]*LHS;S1:M
MD*1C>%B,$Z6E\DU0B#@LP#2Z!=M@\1IU3)KQBT'M%39=.4=;U-0/:!"[NFLU
M/<+WF<,B3%6Y+X],CK ;C3Q<ZP$)3K(V1<SK@N*14B)C1BGFR] ;%2OMI:3@
M:%?*IMM^W0Q.O6IM!EWDD@A4/9Y,S3$W8E+.T(!6KU53G.TEE-$R24M 'I"L
M$H;BVE-("$Y'=HTIXUB<#(N/:[P0A/5;*Y4)?]83VZX?N.?X;';@@[;!79D5
M;88O+I39*A^ALTED&E#PS]$1Y,K8\H< %(REAA9(TQC<[B;@(JY=M74D*CKF
M_P ZH^^3V1G2C8T<OB,=@CNDL&SDE44#:8X5$($UV?(I\V*G=#N$:4R8:XD2
M(E44> :PPL&% P-LML^]-?N%M@V&JJGG]7,,@H-HN6'--JP>2UQ:C,Z,=U6K
M2%I12?PN3A*5MZ-.[PMG=HRX@*("^,[P,[!("BB3E(&^^@&@*_MG]%=E_-_,
MOS<<M 6!H!H#EU8>]BT80_S^PNX:J,I>K]TL"VHOM.GHI#]8Z0.\Y?(-&L6<
MV2;K<GBC E;LSTJ3)8N=&EQKI F\QZZ:2<_A*G 5_P!J-"IX8S(3*%MZ)O1B
MIM7S)KE,FH5L!!((^Q#;%-&&:*W8ZX0M$L.<FS=W#R<,C"<YO65^%J0I.:JZ
M*)=P(>U=JRQR.70!L8Z6G1:2;PUW6M<-<G*MS9N_RV:2/8:1MW V2IFLIRJ=
MBCLVB>]0A8\A<78*]O/0A+(+/R8B"Z 99/VM=4+P(WQMINX%$ Q$Q2A^G)JR
MJBR(Z)DV]P'=//VDR,)[&6R]^,@])6.A<!KVM$M9W)8G4I42P[/<9BT"V'7M
M%*U2Q>O)4TUG<[XWV1-W!D8%V*^?V.,.-=):^NNY&^YXQ8,B0-=?V/$'NEZ/
M72=.@C+F\/X$CBA3FH2UI^$V@->!=K<@5Y@CZW;;;O;VF41"ZEIM;RZ-L\9N
M%XE$(6[,WJ *(*A<982R3"'O]:;J#'->8T=+*^Z&PTM&$\M&I,, _2*]KU%7
MV5DMP]NMYO,3FD@@SE5\@@<<;IFY8IV24#LUN24V)9<>8WI>X1-1 UF\V/)U
M2)/A;E4E$/*01Z@@PD0&T.U/>.KW263936VUVY0>N&&EMNMO5PYR5RBRV639
MBO22;A4:.1N#?$9?*2(JTK8Y5#4>E9W8ILD;>I4*RW!*7_<8P!O3H"OYE\8Z
MF^<!R^BNR] 6!H!H!H!H!H!H!H!H!H#5^^[83U!(H5*QM8GP0F>81O+<6JPB
M&'IE9#77"WN@1*@.0I\1O)>0<C[[)V,\<<GAG:-E]F9[35ZM"%9472@I8N.M
MCB\,-U8&N;1[0PV>HTZTZ3JJI)QP4M7#!8^)E*_7O3^;Q1W_ "O@S6Y]U-?M
ML.B?'-1[S*'8Y](N(/KWI_-XH[_E?!FG=37[;#HGQQWF4.QSZ1<0?7O3^;Q1
MW_*^#-.ZFOVV'1/CCO,H=CGTBX@^O>G\WBCO^5\&:=U-?ML.B?''>90['/I%
MQ!]>]/YO%'?\KX,T[J:_;8=$^..\RAV.?2+B#Z]Z?S>*._Y7P9IW4U^VPZ)\
M<=YE#L<^D7$([*-Z9,A;4R $$.2Y3R*(/F31/19N!!C$L99*-/R<-X. E@&G
M).!<?O,CY7#/#AEW4U^VPZ)\<=YE#L<^D7$)%]>]/YO%'?\ *^#-.ZFOVV'1
M/CCO,H=CGTBX@^O>G\WBCO\ E?!FG=37[;#HGQQWF4.QSZ1<0FD+WH1.1+NX
M7UG-BPS#"P)SE*L"Q(=SF<!SRE("DV$Y@1?T##PSQQPSQ]C6N[1["9AD-LKV
M$U<6J^>XQ<7#Q-K%^2_.QT/0\,5CG\AVTL<[N'9R@Z%R_FJ4DU/QI/!>4O%X
M5N;C-R&YQ1NB4E8B/*4$'E@- 84,)@<A,!@8<X$'.<9QD(L:T8W(]V@&@*_A
MOQCMGYP&WZ*ZTT!8&@&@&@&@&@&@*_J;]%=:?-_#?S<;= 6!H!H!H!H!H"OY
ME\8ZF^<!R^BNR] 6!H!H!H!H!H!H!H#X88=\4(K_ *;8_P F)=?F#??C:WI9
M_69R?<?;S^F_E9)-6I2.VO8T_P":W*?\O2__ !+;UUQ_UP_LN9?\JG_39,WN
MP_ 77IH_5,XQ[D^SKA]I6^N.VI5+6<H:;VM*N+0L$FGJQ)EDJ@U6H+4LUYO]
M:1$XVOG,VAKYN9VNN\4:T>"E;XY3UD3GITQIX4XL]($GFQP-TW9NQF/J)6I4
MUG"6QB3L4C<>GZ(DT&>HV**R?<TU(E3S'7ZMF:21UXK*04':A[D2J2D+8D4S
M.ZU>!"G.R><!K_6D@[*VQYFDO.FJ3JAXBNVFB[8N-QEK74:"OHU3!A=BL#HL
M=#ZAED2B2N+7!(W:EW%Q0ORIL;G4E"P#&0H&G6<O $HC.X?LPI3&6ZR'RDX&
MWS1I4-C2MCB/9O.IQ/D<OMIXM26R!HK8F-46X2*WF=[GU23E2N?X@G=61R<8
MZYK#%(AEF&: M""[ENS1G=@Q*+1 -3BE%@M[/+X+*7*A'Z)0F:J(*LI%8UIX
MI<<GK5DK613RNWUEK\D;,D>CG^/O#0T)34J9:VIRDX&24;V^SZ @LVI"WII=
MD%;6"\1"P:J8=O5J28 );TK-9I)GUOK]@JMS'-HJE>X6^.SI*FE&X1].J1GJ
ME*\ Q8,$!3*/M!>ST;I;>$[DL#,A+VN3S*(VI,#]JMO/EDV1$*I>+LB;^\S%
M-#*1D#W)Z;9(]0KXOP[+5JMK0-0T@%F$9JLE.,#8R.VYL1E]FV5%66-P=3-H
MS3$_BL_E2_;W)F>).]"T_*28)8\$17*]ULWUQ8E=P"8+1-3BPM;VY)$:TI22
M)-@:92$H#PUQ<5([JJKB5B6/$@4XQ51;U/.T ,F<L:HJ:Q6J15=<3DMI8GA"
MM:DQ2Z..]FN]>NK<$62W(QN=4>2S$JCD" \]-Q.H+)L#=U5#QLJH6(0Y#*H^
MQ6C)6MEKF5QV]I2[D#FY;/8\?!7K!EWE3!%')@?5X7#+PE3F2!.26K-5D+ $
M ;8HJ1I=M2H$3=4-7H$36H2JVQ(B@$42I6Y4AKY=4J%2@3D-)92-0CJIT4QD
MH9> B+CZ@UN#G",P9.0(^R;9-ML:92HU'-OE'Q^.$)V](2P,E3P-J924K2YO
MSVU)BFI P$(2T[8\RES5IP8+P$E4XJC08P8H-$,#/&T=2AZ%2UG4_5IS:M)>
M$ZQN-K^)F(5:>11AMA$@(4I!M&4YY+Y#&9&T+ B#D*IK2$I3,"(* 6$#$USM
MYIBHI*[2JL:]C<$7.L'AM:@;HHVIH_&&.!0)\G,GC45BT1:"T<9C#6GDUEOC
M@HPA2D&+53AD2@9N"D^"@+HT T!7]L_HKLOYOYE^;CEH"P- - 5JXTS3[O8"
M>V7:J*U=+31L*J+)++<8+%UM@)8PN(5I5L<3S)2UFR,AA6)EYY9J,*G"<PLX
MP(@9P,6,@:(#W9[ V=O<I;9,3A,#D%,7+:;,V-ZFE'682N.R6G7+</2;=9,*
M+AE?/KG@4CK?9E)T[:O:@C.);6$++DW"@DE((# 8W8=F )I45X"NPFM\P>K.
M@X:Q)V";@CED]?'9XD[W>D:9ZV*VZ#=)XJ+E%)KS9RG1(%O<;LQDA><%J\)0
MB U[Q*^RWM"^+JMIW16DTVJ=7*JG(W+(6W;EW=KFU.2.'T# TRG:Z96\><8X
ML<E[9><5;$[%"<J'QI-?CEY:)*:[KU:H#<UHWR[ &-FC;,V2U&U1*GHVQ.,%
M<SJ0MQ'!8APH1JGD=AT F:^M2XF*US-OD^ :FB+2N,EYC2K5I M^1%K2"P*0
ME&Z/LHFRN3&)+7M3O$42UI/KL:XDNVB3]NK=J3)7VW)/)$DW<14(X1.JIX_6
M1L\DV5;(]$I)2HD$+S_Y:>X)TA8P-H:O5;%+KLZQ8%7]7U:[VCMJ>JM/F+<]
M[=E,.>(,XQ\N:PREI%&'6;UU'D[VVL".!O;=&7E@4+42)*B-+1* $B#@0&T,
M0JRL:]<Y6]0&N8'!WB=N@WR<.T0B$?C3G,GHQ<Z.9CO*U[*WHE4A=!N3XM49
M4+!G&Y/6'F9%RC3,B GF@*_F7QCJ;YP'+Z*[+T!8&@-3-XE0R2Y*_AK,SQ"+
MVM&XS:#!,K,H2;N9+/#K^@#<PREJ4UU(%JYO=F4XMJDKVURI&A=$QC.[N<;3
M-Z\1"-6<I) YLL.U+M#HO64C::Y?H51S<UMC695]+5"]XB$,9XV^7P&565%L
M15I?4T4A]DN-0]V-[;EA>D,:;5SAD*!8@4<AX1@8*?[:.U-L-)8T.FEAK)!"
MWW:8B@)QK!:K=#U\NMY'7='N:=Q9PL865#$7A;:48FJ5S7!1).>3O"<?=REN
M5X;8\!?M'T9VBH9VU9O>Z797 "MR3!,9$GC$L1-:MQK9AKG<\8K;FE0E4.SJ
M5"93,GNJ$*ID"8VC!EC<S0D<HP]U=0,7>VS6R9M9>XMX2[=Z>LN:VH]25_J;
M=7*)Z)DGM101XVW-M1J*@3)2&4$V0!ZPHW,E&R-Z[,*7(Y >[.><.(UR16!@
M2-GN]LFR:3C8+IG":DX,\6%&Y#-TMB1U/= *EF56[*W0Z,MTO)BX'LA&IO*O
MK$X$),I\HVL2 )&2BR6["4"TMI,"[1UCW(-4FW/2I$ZU!]5UBC$L0(Y@S/"-
MUW"DQ/;-G,E86%I3M:)K0II,RV;W:,AK;1<X[) Y/=T_<HVP#JSH#G9OHX\B
M%?=X=UNG_9Q[F1_^_4J^ZK^X7?H8_6(T]Y?X&V]++ZISRU-I#XT T T T T
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M&PV1MXK_ ' SUYJV?"BUAS!];Q/:#;9)<I9(R-[[$3BTY02W4:A2E(. ZPZ
M: : YW[Z#!\U"BN.>1W:Z#X?_%A,DQQ_V9U*ONJ_N%WZ&/UB-/>7^!M?2R^J
M<[]3:0^- - - - - - - - 2>*3)Z@[H2],ZT:42<03% !&C F/)+S@P05&
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MR=962JKD1Z>F8$WFYIZ1I%?2-9\T*,IU*>OG=([J JF(80H#0J30FD9Y8\9
MV&T T!7\R^,=3?. Y?179>@+ T T T!R*W-;=[[D=\2.>0RD8+<<Q=Y]3D@H
M2[YZY8,9ML\$A[+'D5AUODIJO>D[9JY5))BT.$AS)H,5*39&0]B9GUG/0(D_
M* U[<-MW:5'5SN$J@ER?@QB11V_0ULT)9K29,3"QS)<VR"N&M@7KFE?/&R_4
MEJ'OKFH<GLU3#"(BN2)! 4K@]S( ,1:E1]K78C2ZU\C<+*/K":45NRA3NRS^
M5[53G-:U6/6&[YEHV.6#)H(O8W=KNZ,2]YJDI<M82GB/&-Z<\>'L!Z=S&^@?
M0AH!H!H#G9OHQ]["L_T=UNN./_\ ;(]2K[JO[A=^AC]8C3WE_@;7TLOJG/+4
MVD/C0#0#0#0#0#0%@4ZP2F9SUO31(E4 EH4DJ'-W 0HRG+X'E RC)- '!1@_
MO^(Q<K(0\.'LYX\F'/>'M39UZ4L@LXPJS4DZDWI4'%_-@_/\$I+<6,=+;U97
MV$V;NZ-2.=W4ITX.+4(+0YIKYT_\OABO"\):$ECW/:"#DS:C(4#R,XI.2 P6
M>/$0PE "+.>/]8L9SJ("5#(Z : : : K^&_&.V?G ;?HKK30%@: : : : :
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M "-CGP;H!Y)JK\VE?_(V.?!N@'DFJOS:5_\ (V.?!N@'DFJOS:5_\C8Y\&Z
M>2:J_-I7_P C8Y\&Z @-4U35QE75L896T!&,<!APQC'#HZ(8QBCK<(0A"$W9
MR(0LYXYSGV<YT!/O)-5?FTK_ .1L<^#= /)-5?FTK_Y&QSX-T \DU5^;2O\
MY&QSX-T \DU5^;2O_D;'/@W0#R357YM*_P#D;'/@W0$7=X1"XU+:J71R(1>/
MKC9PZ)#5C(P-+4J-2F5A8QPTQBA D(.&G&<0 >09SD.1 #GAQQC0%T: : :
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MUGE4H2JY?&+>MS7B6+W8R>A1W4]*T*1VT95V7)K0KLAR#*E,0=D.<9QR>=*
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M=/3U#7Q)S!7CF0\IG*!,II<>"-JA;@FD3@6>UD9+0F@7J B*S@\S @+WT T
MT!H5O$ADNFKO"66*(B%BKH>8/><'<O\ WFI9#&\ /O3"_P"[&%^'D7]/*"'A
MGAQX['L[M)=;-UJE>UITZDJL5%Z^.A)XZ,&C 9]L_;;04:=&YG4A&G)M:N&G
M%8:<4S13R![@O!AH_P!BKW;K;.]/..SVW^OCFL=VV5<_<?Z.*?YY ]P7@PT?
M[%7NW3O3SCL]M_KXX[MLJY^X_P!'%'D#W!>##1_L5>[=.]/..SVW^OCCNVRK
MG[C_ $<4>0/<%X,-'^Q5[MT[T\X[/;?Z^..[;*N?N/\ 1Q1Y ]P7@PT?[%7N
MW3O3SCL]M_KXX[MLJY^X_P!'%'D#W!>##1_L5>[=.]/..SVW^OCCNVRKG[C_
M $<4P4BIK<(QMZ=:&*LH\GOT69\X,"LR' 9#)VA@$/'(7!SSA87/(@?T<K&.
M/'''&G>GG'9[;_7QQW;95S]Q_HXIMUMRVBNJ5_-FUEA I<PA*[C29QCN=$6$
MXHX)"8O&1<@HODYQ[.<Y%G.<YSG.<YUHF;YO>YW>ROKZ6-1Z$E\V,?!&*\"7
MQMXMMMMFZY5E5GD]G&SLHX4UI;?SI/PRD_"W\26A)))'3Y.06E(*3DAP LH
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MT;:GAE7_ *-)'ZV= 0&UFZT<5=9.3)C 1 Q 9CD805M(@#$#JZX\H(1BM8S
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MFM3Q-T!7+S/XLJL^'<^TSPT 8%9&,A'5%H\KE"D-5<G(2\P[EB#C <\<XQG
M<YQQX9SCB!,>N$']X)SZ([3\3- .N$']X)SZ([3\3- .N$']X)SZ([3\3- ?
MH5-862/ RV*=!'C[@L5):>,X_P#\-T!D<67',>QAML#AC_\ U-:GB;H!Y2XY
M[VV!Z)K4\3= 0&R;)CHXZW8PW3[&<3ZJ1??53:(,< 6C#ABQ@0X<'&19P'V,
M?=%GAC&,YSC&@)]Y2XY[VV!Z)K4\3= /*7'/>VP/1-:GB;H!Y2XY[VV!Z)K4
M\3= /*7'/>VP/1-:GB;H!Y2XY[VV!Z)K4\3= /*7'/>VP/1-:GB;H" PZR8Z
M&16MG+=/N Y\W"#R:IM$6<8Q5U; X#"&'9R6+B#/L"X9X<,\.&<9R!/O*7'/
M>VP/1-:GB;H!Y2XY[VV!Z)K4\3= /*7'/>VP/1-:GB;H!Y2XY[VV!Z)K4\3=
M /*7'/>VP/1-:GB;H!Y2XY[VV!Z)K4\3= 0&J;)CH*NK8 FZ?9R" PX.<@JF
MT3 9R&.MV,Y"87#A &'CCV,ASG&<>SC.@)]Y2XY[VV!Z)K4\3= /*7'/>VP/
M1-:GB;H!Y2XY[VV!Z)K4\3= /*7'/>VP/1-:GB;H!Y2XY[VV!Z)K4\3= 1=W
ME[3();52-"DE!!Q4X=%(AO<(FD:2Y+!6%C%9"6ND; U(35&1'8S@D!@C1!P(
M6 Y"$6< 71H!H!H!H!H!H!H#YR*^^(4(_P!(1K\C(M<6W/XFI].7RL@NK]K+
MZ3^4E^J!3-Y=A?QHNO\ $%1_E&VM3U[H?[;>>GC]4D38O\+6](OD)Y46]U1:
M=G;C:U=MJ.YBHB]L"=5BPYY93EM870MQ?!1:)S^.Q>)D5-N>M*=.+Q,:ZF*5
M]0'*F1$V$) &IUZM$XA A'+YNA6L=[4&MIS,8%65=;?-T4_M6TMO4-W55W7C
M'%:G:5LJH2;5J";-\_3S6:W-%*E:$K9-5*: N"1RD2%P2S)<DQDC+(I(>A@;
M8;7-P2'=+2,/O-IK2RJG99N)\-8XI:_DY'*SFAH?G)B128E55%BVK W6*RXM
MMZ29'!N?%J9T:%*=84+))Y8A ; Z : : : : : : : : : : : : K^V?T5V
M7\W\R_-QRT!8&@&@&@&@&@&@&@&@&@&@&@*_F7QCJ;YP'+Z*[+T!8&@&@&@&
M@&@&@&@&@&@*&M.Q(S64SA<FE:LQ(U"C$[8,&D)E"T[I)T=*^<49>4R4LT[!
M9B5B4YR/AR0Y#C&<\18XYC)\BS+/:DZ.6P4YTXIRQE&.AO#]YHQ6:YUE^2TX
M5<PFX0G)I81<M*6/@3(G]<&EO?IQ[PO/N+6?[O-J>8ATD.,8/V[V;YZ?1SWA
M]<&EO?IQ[PO/N+3N\VIYB'20XP]N]F^>GT<]X?7!I;WZ<>\+S[BT[O-J>8AT
MD.,/;O9OGI]'/>)9$=R%4S1>-L:)"$*P(,#"0X(US<,X.<YQG*?*Q,2 [(.'
MWV YXXXX]CAK$9OLOG>1T8W&84=6A)X:RE&23\3U6\,?!CNZ<#*97M)D^<59
M4+&KK5HK'5:<6UXUK)8X>'#<\)>I1I9P F%B", PX$$0<\<9P+''&<9_IQG&
M=:^9T_30%?V7\7&WYP*F^E2&Z L#0#0#0#0#0#0%?PWXQVS\X#;]%=:: L#0
M#0#0#0#0#0%?U-^BNM/F_AOYN-N@+ T T T T T!7\R^,=3?. Y?179>@+ T
M T T T T T T!\Y%??$*$?Z0C7Y&1:XMN?Q-3Z<OE9!=7[67TG\I+]4"F;R[
M"_C1=?X@J/\ *-M:GKW0_P!MO/3Q^J2)L7^%K>D7R'XSBHMEU\R"YHRDN65-
M$^MK=*R1.;.%2V[((;,6C<K4NV$DA17;2X1T96&]R(VUQ12I=6I2%2E.2=T'
M"#A2$&2I?-T)<W=FKM@8I:QV!&6V>1>?Q.+QZN(9-V&P']))H=345IM;2#'1
M<?<33E&2*?1QQS4NW0YP3@&2XW$@&,3N2G5D@;0P!%5].M%:[<HBM0LQ4%J5
MO10>'B.YQ:@J^KDL6@J9::(!022$+6%Q;DH1F9*YX8A<V$6"C>; AM?[N=M5
MJA1&UW<D+EJ=SD$?C34L:5QQB!W7S!ODCG"ES.X&IRD3O%YVFB#F%@>DQAK,
M^J$1I"!4H/#S>0/Y0[N]L[G,HK &ZYX2OELV)2*8RUI' U0!Q2.SJ[LL76C<
MBDXFIO0SYS8%I<8/5'DE2G"88F@2T&.5H":'7Q3::$5G9"NRHBA@]S+JX:ZI
MD2]W3H$5@NEO*&E-6C9%0+,D*7=RF1KXE[C3E%Y.& WEB"$ 1B" K.]Z?N1P
MF;55]@QV:N%>NP6:7I654,XQI5&+7=L3J0\Z44%Q95CM'7)&G<4F3V]0M:UJ
M<HX9R-264!;6@*MB%UU7/W1G9H9-6F1N$AB()\P ;<*SD[Y"#FR#/":6LZ_*
M8*!SCJU!9#,).L(-&0H&J&66(1B94 D"73"7QFOXK(9O,WE''HI%&=>_R%[7
MB&%(V-+8G,5+59N"@&'&<V27GDEEA&:8+@  1"S@.0))H!H!H!H!H!H"O[9_
M179?S?S+\W'+0%@: YE;H[@W417=%3Q].P*?/VWBFD+$^[G%#(VQHYDEJ"XY
M43"P@(*=3"YM(#MO<!9G:9+D47)4JSCUK86;@8.<3&@:FJNT WN2&65$[QJE
MWR/Q]NH-P=;FK]UVNWXH4/6XA;5J-\DT,9G]<4W/J%GHB6LSXJ$F:4CPIEI+
M:H9$)QCJ<D,"!G9/O:WZ(B'A^AM&M[J<V4.^V!DZ04U=R*,SY35CQO\ 5:$Z
M"P4Q\;); 'S<?':#@:EN;75Q>%\;33=#@XIV.*3EN %BE[F^T15VK/:K)KRF
MD*:N)U1U>*K+54?>*N+SD5Y36T8XLL"'-8+80%EQFD62/,[@](Q.RO+KG)@!
M+V8MP(.;P(9$NT$WG6 SP*.-NVT,!M:71JIG:1CF=([@'" UZ9:UD=G=$REZ
MAT&=#6R8DQ2,;H+(=%[:D>DBTG,"R!88WA2N0L 7'M7WE[J+@OUJJZVMN#M7
M$4%5K0^.4H'6]A,S&XR#R>5S)7.:,$]>'ER9DK"XSZ2/<7*B#BVIW1 :QY68
M>G'EF)"0-:!;S=\RFV[9<RH$N SQI+'D;!7ZN@MP[3#JU?VNJ.U/DSNPS1\:
MXU*I!?;D7(*:JX#L\0D(6ETRZM9+4E3F+$RIP SK5VD^[I8I1*%&TVQR8^&D
M[2F9C@LVV6FB62A[@C#<JQ%-XVD8[+F:9I8W.5UJTM+?#G _NQ[22A"Y]9&W
M"IM0N0'^H.T;WE@@U62DS:U()E))9!]SJT=:13;Y>3#,IS,Z;F5^QRM<Y'*I
M#B,T5%[08:UC#N24<X3]S$&5E%A++0#;7AR Z4[.KBL>]*3;YY:4/50^3FR:
M6,Q12N!2FK3) R,SR>D9Y/BNIB^RYYB(7-)C ,I\/CXF,$3D\A:84<$!8%RS
M+XQU-\X#E]%=EZ L#0#0#0'(K<W<6X2$7Q(NC%>Y4"B/SZG$5#5-3E9)I!65
MOU:[LL?7VC+)E,!T9:"=XF0)N:^,+LPJI#%1QZ,-J)[3GMPE8W0T#7MPWC;]
MR:YW"18FL9L"3PB/7XI@\F#1%LKIH<DBZYMDU=VNFD3;'5=?S..O[@_JX(AA
M#0TJ)<>HCXW<HU8F,/)2@8BU.T.WPJ6EU@$-IB3&NDBHK=DI9[<A^U^[XP@7
M/\&K#=\\TA<L%,F\BDV(,*72NC(HB30J1-#N-:KF2(:5\4X.0IG #Z$- - -
M <[=] L\B%!XYY/=;KGA_1Q[F28X_P#OU*ONJ_N%WZ&/UB-/>7^!M?2R^J<\
M=3:0^- - ?X)QZ(QTEW2)'E'_?84 $((RQ8]C'-\CB,0QYSPP'&,Y%G/#&,\
M>&L?FDLOCE]5YKJ>K]1Z^MN8?+CCN8:<<-73@7N6QOI7U)99K]>UUJ:N[C\F
M&&[CHPQQT8G7/:I.Y;-820?)42DC!*=*%(H4D%D'*".:*"6,P!? .#!E\,BX
M>QC/'7*UX[1W=1V*FK/7>IKX:VKCHUL-&.!TM:=95K35ZX.[U%KZN.KK8:<,
M?!B;7:MBX*_LOXN-OS@5-]*D-T!8&@&@&@&@&@&@*_AOQCMGYP&WZ*ZTT!8&
M@&@&@&@&@&@*_J;]%=:?-_#?S<;= 6!H!H!H!H!H"OYE\8ZF^<!R^BNR] 6!
MH!H!H!H!H!H!H#YR*^^(4(_TA&OR,BUQ;<_B:GTY?*R"ZOVLOI/Y27ZH%,WE
MV%_&BZ_Q!4?Y1MK4]>Z'^VWGIX_5)$V+_"UO2+Y"EY?V3.),\2IZ3[@%"+,\
MA=UAG+"KK92MB<LN:W+9MB>^4YV96ZS&(X,?# ;ZF$#?V).I(6R&*+T28+PW
MA;B0F2^;H?@K[(MO70MVA_EW41U$\4A.H+EKKZMA0&&Q^V'VR=RED5O8,+BS
M)8>%$6K.B5&[&7-\5A13@-0W)BV=44^@=&5 X%@3_;WV744HZJ;RJDVS%"UF
MO';XJH0XF"Q=VA#16:=_?[W>IK):G:I/8-H+(AUJ\L2+)C<%<:F+6QPE6(1I
MJDS!8%C3C9=9U\5*^TUN2W 1640R4MK(VOK72VWYEIA&4" EI'2K#X[F23^Y
M7AG%%; +ZQK"3ERU(M7-[8G2$MK>6[)'L#PO^S>_U6+\0P[='!Z^9MPS6GD,
MK"Q[:2EK\PW0V[8(3MT99+#W=WN=6VLM3LSE6C#*4\9PW#D!"](:F)E!1)V!
M% 6@T;7Y4Y0S;=$K-G-:/16W:T(W,V\BM*:?JWCK[#H# GU@KJ")F>2W/:SM
M'5$:G)C'(3G$#HJ(6= $I,(2><[I* K5)LCL7%8[OV1POYA'<>[9M1,KS:[5
M3K@F8F)J:HAB&) +Z^?[>E+@ZG.[8K7Y="&B0QIH":O-.9T#*I&<H. T^C?8
MAPUBKIAB:FV8FX2R)1>31&%3?R!MPLU^R2-+O+D)K; &IZLA_<(NUBMO=SAW
M6IRW,S#JPQ5(P*Q&)S\JB /.#L2FQ*O6 8;N@\!9SV<I)''*M-MR&)6E2KM'
MK#MR90=SVV669;3QY&DX(Q,HI$).6!K<U<HBT&3(LJT05ZKD@2H_LB"T#96&
M4TYIX]NKJP5=CN5417;(5&:J2EBFNWF1.46VQPEPO9>W;;7Z>0K;\.-/4C6K
M9<YJQS.0.03DRAS6<^!NKL.VO/&VBH"4D]<2WNUY46W%R-06J*<4$$@$5Z0;
M:9H6).!:5)SL(I.#JPH"A%@*3N+ZI=W@!"<;J:2 #=_0#0#0#0#0%?VS^BNR
M_F_F7YN.6@+ T T T T T T T T T T T!7\R^,=3?. Y?179>@+ T T T T
M T T T T T!JK?=3%6U,(7'CUZA$G#%IV\Y[G&$ LK&YVKM"F-Y6<9S_ '9#
MP>'A]S/.9XXSPQPR>69QF63SE5RVJZ4YK"32B\4M/[R9C\PRK+\UA&GF%)58
M0>*3;6#W/ T4=]10GPL=_P#ZI']C67]M]JNV3X-/B&)]CMFNRPX4^,/J*$^%
MCO\ _5(_L:>V^U7;)\&GQ![';-=EAPI\8?44)\+'?_ZI']C3VWVJ[9/@T^(/
M8[9KLL.%/C&49=BT?(=4:Q[=W)W3(S!' 2*%60$9-SCDX&(LG)>!B#CCPSGC
MPXYX?=SK'9EM#G.;THT<QN)U:,7BHO!+'<Q:BEB_%CCAB\-UF0R_(LHRNHZU
MA0A3JR6#>EO#Q8R;P^'#=T8[AO6P1]MC;<F;6Q,6F3IB2B0!!C/^Z46$L/LY
MSG.?O0ZPQEC.: K^R_BXV_.!4WTJ0W0%@: : : : : : K^&_&.V?G ;?HKK
M30%@: : : : : : K^IOT5UI\W\-_-QMT!8&@&@&@&@&@*_F7QCJ;YP'+Z*[
M+T!8&@&@&@&@&@&@&@/G(K[XA0C_ $A&OR,BUQ;<_B:GTY?*R"ZOVLOI/Y27
MZH%,W#V3Q=MD,KN(:]3(D^4L>J@)6&.7RR, %@URM?(LJ2XT]M(%@L9!CDY.
MP/(,<<!SCCGC/7NA_MMYZ>/U21-B_P +7](OD+1@&Y_93:<LFL#KR_'R6S6O
M2Y&?*(HT63>YT@(20V;HJVF3@SM0W<M;*FN'SQS2M+LJ:@+4[8M5IRU(RLGE
M<N7S=#;3R:1SWRL#TLVIXY: >32.>^5@>EFU/'+0$)GA53U@RBDD_F,VBT<)
M)?E2Z0.=IV^%C9T$7A\DGL@=9 [$RHYOCK*TQ.(N"HY:N,3I \Q@KG.>-)+,
M _&N?)5;$;(ET#DEF.\>5=QY3+UDZO:.B4 7L[6_(SB$<F?6=><G/:GE.9@P
M)62\"'DO.<&%F "!//)I'/?*P/2S:GCEH"!OPZ?C,B11!XG$P)EK@C9W-+%D
MEL6XZR030_3-AKYK?36)JE:UT2Q\Z825&C&X&E 1D9$88:: D@\PH#V5^CJJ
MU(5&+&KR9S"60>9LZ-_BTE:K<M<QM>V9>7SJ-P1#-EY1@DZ@O/$.<A#GA_1H
M \HZJCLLA<%>YG,&V7V+UCZD,"BW+7"ODG5%M*>)+T< ,O$ ?0[8> X[E"#P
M +'#CH"8>32.>^5@>EFU/'+0#R:1SWRL#TLVIXY: C<R8ZWKV(2J?32532.P
MZ#QM\E\LD#A;=K ;V*,QIL5/3\\KAER\PP*-L:T1IYN0A%G  9X8S]S0%$6K
MN'V3T8J3(+DW01RL'%95[K=*1LG&Y:9QMT558S+6UL635,V.D_3KSV<US=B4
MR7(2\F+E/.%)@&F$G! !L6TPJ#O[4V/K%))@],CTWHG9F>6FY;+<6IV:G%,6
ML;W-L<$<W.2+V]>D. :2<4,99I8\"#G(<XSH#(>32.>^5@>EFU/'+0#R:1SW
MRL#TLVIXY: @-K5M'05=9(PN,^SD$!F(L8':UHF SD,=<<XP(LR8B ,/''LX
M%C.,X]C.- 3[R:1SWRL#TLVIXY: >32.>^5@>EFU/'+0#R:1SWRL#TLVIXY:
M >32.>^5@>EFU/'+0#R:1SWRL#TLVIXY: >32.>^5@>EFU/'+0#R:1SWRL#T
MLVIXY: >32.>^5@>EFU/'+0#R:1SWRL#TLVIXY: >32.>^5@>EFU/'+0#R:1
MSWRL#TLVIXY: @,QK:.AD54XPXS[@.?.(1<JUK1%G&,5=9(^(!"F.<EBX@Q[
M(>&>''''AG.,@3[R:1SWRL#TLVIXY: >32.>^5@>EFU/'+0#R:1SWRL#TLVI
MXY: >32.>^5@>EFU/'+0#R:1SWRL#TLVIXY: >32.>^5@>EFU/'+0#R:1SWR
ML#TLVIXY: >32.>^5@>EFU/'+0#R:1SWRL#TLVIXY: @+C6T=Q:,.!TC/N2*
M V2+.<VM:.18R"153C&,&9F/+"'/+SQQC.,"SPXXSPQP GODUC?OG/\ TM6G
MXYZ >36-^^<_]+5I^.>@/]\FD<S]QRL#/_\ UFT_'+0#R:1SWRL#TLVIXY:
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M&T7.R8LUREU0Q6;RB=%5X2TPQS/O&%(9 Y.T3C\:'(+0JMG>HS6R&62F<-K
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M*F(#9C=G3DHL^T]OKG'OK!99H.&VYQ/V^G]R5WT0P35FC=:/[/"ZLD)%:VA
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MT_7/_B_?R#- /US_ .+]_(,T _7/_B_?R#- /US_ .+]_(,T _7/_B_?R#-
5/US_ .+]_(,T _7/_B_?R#- ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>66
<FILENAME>g713200g95p44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g95p44.jpg
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M)E&2US,T0EAA_\0 ' $!  $% 0$               $"! 4&!P,(_\0 71$
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M<!TC1QWK:%B/G)J2DRBPT-\N@&\G.X:Z:VZ.8:+W(=XKG<6=>Y&P=Z[I.N8
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M4CJ.<-XQ#WR.SU5D3+X1F^BWW]P?;7^0^,/;LZCD\L"!U3FM*A8=%J9[-A9
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MK?S]4_6'Y,@LW9,T?2;Z:>E<+II^?OKKYWG;8QF"0T$N(:!O)( '23HI )(
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M.^:IB/9D_2SZMBS]'V-%T.\MRS'EDKE.$3A$X1.$3A$X1.$3A%6.POUWEO\
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M%C$-=LI#!D;9B$M4]!^$M,G3.<753"26Q5+F,<222U\<4Q%R2;,DE?&!_1#
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MJ,M]AKW.=,)3T\3:3J>6@=48)#PDX-RU-9083CU%25L I<296AV"U75$T-1
MUL!Q"2A#H9WSPB0"6.QR\TSS4[>*L;!BTF X]%3TM9B6#5=323&>@-(6XK3[
M&.2"5QF%$RL+986QREIV;UKV[7-E#IJ&FLN(R=F\;J&$,[[.Q$C&"(S>R'QR
M3((;/7\8<JAC1U.-XBXR0DP:CYI@LWV1=NLO,+;J=,X&O%/3UU.&U=/A]5C>
M(2<&Z>MBK(IAA4=/2.=DBK&-GIZ<U9K)J6*H$;]B\%C,A:!S_A4TSS4<V:FG
MKJ;":)F.STDE-)$<1DGJ0TODIG&&:<4_4T=1)!G;M6D/=GN3(I:7QZ-5G Y
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MI6/'JKG"8A(QT>&PM<U[J7#V12N:0YIDFJJNN#;@F[HHZN.%X_HR1N;_ $5
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M'F%S&Y#??*7H%?/;**H[\.QYK68SB3&-#6MJY@UK0&M S;@!8 ="UNI %3*
M !M"+6%AK;06MRK:!UL.F)3UUH*32(BZ,2"14K5ATX6?*96>E#!># B!,B\6
MS]=5T]>N%W+A3/U]U5=]L_J\Q*MSO/25-7"A.$3A$X1.$3A$X1.$7"GX[OQB
M=@?<#5GS09\[+P+]8H?AZGZTK8<-[&'OW^-:<^;6K]7$\/J41J$]V>L4MF4A
M"1.+1^WXF3/222%&(0"%&MGOGN"!8N27;,![)#7],LZ=N$D$M?K[[ZX^OS$X
M[%)-@^(Q0QOEE?2R-9'&TO>]Q&C6M:"YQ/( "2O"I!=3S-:"XF-P  ))-MP
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MG":IR1ODD]T]W6S9)1)F($HJZ/I'(7P>,",+&30YLMLE1,((R_*9'DAD432
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M<6X&;25UNEH@=*#45(W*'>.A-/Q6Q]B,;"-"X;VO(&I?)9IN_<R@:F[K^&E
MR@@Y8H;!7#Q0D$?@HT38DT%,VHQ=SHV2MHW@.JI:?+(\L?EC+<AL(G6GF:_,
MRG?EME>U\K2TJCJ@D9@PC\H66)-["UN31S@;AIMN-SHJLV76I"NYCI"=_:!$
MLBU%LR&=A:S1#,MV01;2F/!]_2+Z&D8M*L$X>J79*;M"A0*]<,?*U40SMDZ>
M=L\6U&5K27%O&!_);XY';LFUBRS!KM6L>W-K=>S'A[<V@!N1K?B_T2=UKBQL
M=U[*U)+I]LK'[AEQ>>SF4R2 3JS8(J.AT'BTS>26:U)#8])[2,$GL@N.'2/6
M'BS4B4TTD\:C$^++10:5FY6/CD&2X[F-;BOY2DB9##%'/#33!TTTL.SAJ97Q
MT[&M922Q[5S(_P":DE@:)'-A:]UPY>(FU8T-:T.:QW&<YN5KW%K!I&X9K <4
MEO&(:#N*J=8L!W@RD,=MW^Q8!/H#'Y]&BNS;#/=RS([OPIYBHWPNXQA6,SF/
MRV'KKX4QH^7CRA!))!%VF@GDX)A-M1;*^"9\,C;WL6AKV&]A_.0OBE _HB0-
M))%U[,=FS7%BQQ:1T6(([CFEKAS7LHZY[JM=]/6SXG:&?>223Z-3W.#\(/7O
M%/CDWE+6*GLJ7X4^-7/ZF_!8ZT?>_P!-?1U'.8=6YWGI/C5@.%"<(G")PB<(
MG")PB<(N%/QW?C$[ ^X&K/F@SYV7@7ZQ0_#U/UI6PX;V,/?O\:TY\VM7Z<(G
M")PB<(G"+O"\.?XGNN/D/N[YT6=SB'"OM@Q'W\'ZK M:KNRYNEOD-5T>C7P)
M^GOWK77WZ)HCS7E:G>>D^-:LKK[Y]OX[%N\7;J"R6DQ'7SH=V+)4:4ZWR&M3
MINQ+G!UVK73:S9"ZN%O88G2!3.3*SQTM3X,?7AP5LB/C>L@3-8D2J[8J@&Z#
ME<-]]!OMI;PW[NZUU%\0\2WMW(>]:-$BC<4.AB_B"6QUL$U(:ZRRZ) W_7ZI
M"&R]CV+&>V9.U1D)DEIUM#E4I.0K 1"3D@(ZIH(J"D6Q'#MH4Y1EOS"Y.;77
M=<6Y]-XWCO\ S=+_ !,.XU[=G*=K,D4A\V8V3*>VJTVK0IULEU)#X34-%3*T
MJ^B=BU?V.D%HDH]>3I:>QBO8E-0D,K4RI'WDP,MR^P3>/JD^$<T 'N6U!OJ;
M;Q;2XO;4:@] Z2^%YIPB<(G")PB<(N"?QH_C+.R'\4/T$UCSZM]#3M*P;IQ'
M]JUR^=N'G;5B?10_L^D5%J#B\#FMR5Q$;+>2AI#Y++@((G[CFHUP?>;%RC4<
MU'-5RSUFR$I/G+E-N\.[I%50S3=8@V G'""0QSM.+SU=+AM;44+8'5,%/+*S
MJESQ$T1QN>Y[A&USI"QK26Q7C$CK,,L8)>->PV&FGKJ6&K,P@EGCC?L TR.S
MO:T,!>YK6!Q(#I+/,;;N$<A 89=7JREVM56-*G)&=:26"]GZTK<[G1N+3!!*
MSE[*]G+O 7R.WQ"2RC="LA[[=\0:@V8_;R#F[$IETN_3QXK\3=7T4#64I@JL
M"K:V+5YFEKJ=V%-;M;M8R&"]<]H8QTCG^K<]E@Q7QHZ 4=5,YU1M:?%Z2EDT
M;LXZ2<8B7;/C.=+-:D:XN<(VM]2&NN7+.K7Z\0=U#C\_HP?M*1#C5L08[CSY
M!(&!C46%S<I,#H;2>(QB7RWVZUBC[<.W1%D';92L[Y<ZCLA(BS*-;3#\8JFU
M,5'BK^IY&DL=GB899IJA]*RFBD-(9Z>GV3JANT<7L:X5F%-+Q)4.C=<5N&4S
MH)*G#F[9ALYN61PCCBA94/GDCZHV4TVT;"[(T,<0:7$2&[.!KA#=?U]"TX!"
M)U,X],)HK8%S2.NXW%8*[U:GB7O=PN+G#(1MKLS(;;OIE);7K(.Q>-V+YV+%
M,9/NP%%"KL:FWR59651K*JDIIZ:E%)AD-9-/5-+HV=65,\4<ILY@R4T-!6R.
M:7M;)(^$/>R-KR;"FIJ?J:GJ)XYYS4UTM+%#3FTCNI:>&21@T=QII:RD8TAK
MG,8V4M8YY:!(-BTQ7"3FWA$505"3"MZ=@UGR./MI1I+A$0F2,PCT0LBK&Y[1
M)-$MA@QG0J1.7JJ[Y[&9#&2\%W(&%]7!-2SHL3K2W#I*APEIJS$JJ@AF=!U-
M)4TQIYJBBKS%<F/.^EDA#0&-GAFCJ@R,96*YJJ&D!K60@QSTM#3U<D0FV\<$
MXFCAJZ,2  /RMJ&2EQ+S%)"^G+WF[U2SFSK K_1$\-KX!74[Y$X9_-^.?'W#
M3MKQ_P#.=3Y:^F>"W:[@WQ"#R5=SFL+/IPB<(G")PB<(G")PB<(G"+B1_N@W
MX>(GY Z]^<4]YU_@/ZRN^.S^1"M@PSL;^\?XFK1KS<5D%:Y?M>;;0:JXI$*[
MA5?GJ<1;*PFP(@6L=H>;2)1=->1S9^ ?SHA7Q*:3'">C202%Y#E7V1;<6&&*
M#A  "R&8T88PS5,DL\T[*LG;03-IW,++6CA:]L#9VPQ:F.,2V#BY[LSWO<[Q
MV(+GESG.$GJFN#;9>1H(:'!K>0 [[DW))/BRGM+8LYGM:6+,$ 1J0U/$1\:B
M.^!R3!JD1!($5HY*7[5IC1N^*B) \9R/U/=+4*]="FS%R-R-6=MEJXL.@@AJ
M((B]C*F5TDMW9CE>6B2-I.K6N8#&#ZMH<7!V8 HV%K6/8VX#W7=RZ&UVZ\A:
M,O/J3>Z\ZR>Q<NLD-4XIZ/'"W%3),E!A5HX*/'9(H/A56U^V(.$RCUXW9I^Y
M^GX@Z7'LDDVR\D<R<WMG&IS1B/FGH(J=]2]KG.%23F80T!K3-4SEHRAI/Y2J
ME <3<1B-@]1F=+8@TO-R<]]-+ %SW6'?D=OY+#D6?F^SP@;.[#FD%K"%Y-RV
M66-.8G-#K(ZWFE>/[FCNC"81QNL&DK,++A,.</2C6 N9:+*88/,+R/5@WV-/
M@^GBW#G.@@AFJ9LD45/#)$PL,4[:23-%(0^,OB?* TSB)S<PM'?B-<J1"2QK
M7.=9K6-<T6+7",\4ZB[2[0NRD<@OI=0M:L[&R]&L@(%)UI':NJT% !*K])-%
MZ[>.#4DL*:/%4TE5M<-7%CSZ9[A?.WPOF/\ LGUM)!WZ=!.[IH'1&H>\@R5-
M2^=V6Y  9'!"-0-13P0A^EL^:Q(L3Z,:6YB=[WEQ\ :W_P"+6W[MU$W+E5KO
MIZV?$[0S[R22?1J>YP?A!Z]XI\<F\I:Q4]E2_"GQJY_4WX+'6C[W^FOHZCG,
M.K<[STGQJP'"A.$3A$X1.$3A$X1.$7"GX[OQB=@?<#5GS09\[+P+]8H?AZGZ
MTK8<-[&'OW^-:<^;6K].$3A$X1.$3A%WC^'!E#7P@:RRYT54;8I2ZLN$T%=$
M%U$,2JS,JZ(K*(N$T5=D_.U35W07T3WSC?9%3&,Z;<0X5]L&(^_@_58%K5=V
M7-TM\AJDWPO!G:1EU+Z[+WU-*$D40<=;:+S68FI:UL&(2<.&S7P#<;I.Y)+[
M5F@F2DTP&1C9\K'HE$FBI?1\]0119JH,4M>5LZV8VOO.\W^P+!9_6'A,V)V^
MF/N\S4A?M/$]!5JV7#E; F(X22)U*"!203+[.K 7)F-16!.*YBKB,2--::QB
M1S2+QG:/&U4V8?06ZT(,P&E[<AMSZ:'?KNTZ.5>2'LSPB++BT8-Q^>5;)(Y*
M^YC>Z(G(@LCL/"Z7< HZ!F<ST7(6#M M%'CA641]J5?IO@U>:-98QC1?&C&4
M:BR!+.&EMXZ=/IYOH5FH1U;Z83>*UZUKV#L'(+KE;5]J5J?BLJL4":KVTI=*
MI\!["M([.ATB&2A=,Q,9+/ DS%(G7\9V-(KC/5-'$8'(""BY\-M_+S;_ !J[
M7"A.$3A$X1.$3A%P3^-'\99V0_BA^@FL>?5OH:=I6#=.(_M6N7SMP\[:L3Z*
M']GTBUEA#1..&A$A".]QYD"48&A#]+5/=1D3%NTGS!VGHMHHCONV=H)+::JI
MJ)[;:8QOIOKG.N=WEBCGBDAE:'Q31OBD8;@.CD:6/:2"#9S21H0=="M3CD?%
M(R6-V62-[9&.%CE>QP<UUB"#9P!U!'.%ZR\WE3D-)X^N874#S*4!9I)F.4FN
M$RTHCK>5M I=??"&%DUV#><2I)-)LHBVWP97RL@ILDURAYBEIVR02B,"2F@E
MIH'7=>."8T[I8QK8AYI:<DN!/Y,6(NZ]9J)BR:,R$LGFCGF;86?-$)A&\Z7!
M:*B8  @?E#<&PMF8R][5#B3 (=*-6X@Y%!D*>L/8,:601CPB-R:(,VX?#@.K
MM'B&\<FLT&$#H#8:>+IS*6K%B;UU)3:[ZV?A-!))'*^#-)%4/JFOVLP)FDF@
MJ'&6T@VS!-34LC(I<\49IJ<1L:((@WW9B-9&Q\;)K,DA9 YNSB($;(IH&AEX
MSLW;*HJ&.DCR2/$\Q>]QE>7>K7-_SFK 0EC$%T&!Z*3QS8$$DJS,254B90_$
MG4+G""(4Z*+!B2$Q#(Q?5YL^;;*#W,0$.6&4U<K;9\ZW"*6OED?4@OAJ*04=
M7 '21BH9%4LJJ4F6*2.5AII=OE#' /;4R-?<6"KI<2J*.-C8"&R0U)J:>4M8
M\PODA,%0!'(Q\;Q/&(LV8<4PL+=;K\G]ZRDN+L9(FPCNIZR(Y&H03,QZ+Q*$
M,6D)!REG-GP9O&(3'8^$V(&I. B+IQ(/0ID$QP1V)6P];&-]F<LPJ".2B,<D
M^QHIIZED4T]15/?4RP.I6R.GJIII<D4$M0UL-RPOE;(,KHQF.Q&9[*H/;%M*
MJ**G>^*&&G:VGCF;4.C$-/%%'FDECA<9+!V6-S#F#S:$N918]?Z(GAM? *ZG
M?(G#/YOQSX^X:=M>/_G.I\M?3/!;M=P;XA!Y*NYS6%GTX1.$3A$X1.$3A$X1
M.$3A%Q(_W0;\/$3\@=>_.*>\Z_P']97?'9_(A6P89V-_>/\ $U:->;BL@G")
MPB<(G")PB<(N^GK9\3M#/O)))]&I[G!^$'KWBGQR;REK%3V5+\*?&KG]3?@L
M=:/O?Z:^CJ.<PZMSO/2?&K <*$X1.$3A$X1.$3A$X1<*?CN_&)V!]P-6?-!G
MSLO OUBA^'J?K2MAPWL8>_?XUISYM:OTX1.$3A$X1.$7>%X<_P 3W7'R'W=\
MZ+.YQ#A7VP8C[^#]5@6M5W9<W2WR&JZ/1KX$_3W[UKK[]$T1YKRM3O/2?&M0
MJ'AZ=NP?9KM@[#--S-,WA+.[%@EWY[LE+ U<6K%.R]&"8I7U+HU,+9&5J?L6
M&6HFY<2&_P"-QC,DUKL<V&LY!)FRHZ&A7GR^85686;W+;AJ+&][\M^;S.1UO
MX?EPO*$M-I/*A.L#L:L:"$^B-&6+VHG-WK]:MM(34T/E9Z:VB_GK?>PZ;:VG
M%UKU=T"8D,LC9&.0M@'&1G62&644&//S\_I4EPN-??$#+?4\FZ]MQ 'VJ[G0
MFKNU5*'+DJ>WM4<]>8#D)'.M#ITXKYZ:*C&-A7/JZ/[$8?C$N+>Z*IMJ'.V
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MT;B?6GMGU!D])T].>K=>@-)JPOJM)B_-Y81Z&8B9F-)0=PK(8G(]/5VD_CI
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M5] PZ4TD^Z=@!MK,I:U2N"$%W*)J5O#'4O;:N'I:.1PR567N]'=T![VA'?\
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MX9PN!)J;C'SL<\$.'K/&S;.J+M041(#O6==?3:LG[YMIOJB[<:*#-2N+7&:
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M?8#C\/2'^T^/3!C'NU_S<'X2=55'MKOH^Y/J,NNGV X_#TA_M/CTP8Q[M?\
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:$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>67
<FILENAME>g713200g99a02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g99a02.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2,.4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
M!   !=P          0                         !              7<
M   "!                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "!     !29VAT;&]N9P  !=P    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   @0     4F=H=&QO
M;F<   7<     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    (.$))300,     !A_     0   *     W   !X   9R   !AC !@
M ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@
M!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(               $
M /;6  $     TRU(4" @
M                       18W!R=    5     S9&5S8P   80   !L=W1P
M=    ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    4
M8EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP
M  "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:
M!#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X
M=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A
M;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2
M<U)'0B!)14,V,3DV-BTR+C$
M                             %A96B        #S40 !     1;,6%E:
M(                     !865H@        ;Z(  #CU   #D%A96B
M  !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)
M14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@
M            9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'
M0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N
M,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M             &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I
M=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M              !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@
M  %865H@      !,"58 4    %<?YVUE87,          0
M          */     G-I9R      0U)4(&-U<G8        $      4 "@ /
M !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P
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M8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]
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MP  1"  W * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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M7](VA?,J22GZ<ZQ1TB_%#.KFL8V\$&Y_IMWP[;[]S/=MWJ>95TZSISZLPUC
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M(IQ-G2#4<7=/Z!P>W=#?SFN?^9L7S&DDI^JDE\JI)*?_V0 X0DE-!"$
M %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3
M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"
M24T$(@     !1DU- "H    (  @!$@ #     0 !   !&@ %     0   &X!
M&P %     0   '8!*  #     0 "   !,0 "    '@   'X!,@ "    %
M )P!.P "    "0   +"':0 $     0   +P   #H "W&P   )Q  +<;    G
M$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#<Z,C$@,3@Z
M,S Z,30 <G(U,#DQ-C<       .@ 0 #     ?__  "@ @ $     0  !=R@
M P $     0   @0         !@$#  ,    !  8   $:  4    !   !-@$;
M  4    !   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
M          !(     0   $@    !.$))30/]       (          #_X0%(
M34T *@    @ " $2  ,    !      $:  4    !    ;@$;  4    !
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M 2@  P    $  @   @$ !     $   %& @( !     $              \
M   !   #P     '_X4  :'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \
M/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z
M:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z
M>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q
M,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z
M<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M
M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O(CX*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,3DM,#<M,C%4,3$Z
M-#4Z,S<K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R
M96%T;W)4;V]L/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]X;7 Z
M0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#$Y+3 W
M+3(Q5#$X.C,P.C$T*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @
M/'AM<#I-971A9&%T841A=&4^,C Q.2TP-RTR,50Q.#HS,#HQ-"LP-3HS,#PO
M>&UP.DUE=&%D871A1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @
M(" @(" @(#QP9&8Z4')O9'5C97(^06-R;V)A="!$:7-T:6QL97(@,3 N,2XQ
M-B H5VEN9&]W<RD\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N
M=',O,2XQ+R(^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @/')D
M9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F
M875L="(^36EC<F]S;V9T(%=O<F0@+2!'96YE<VES($8M,2YD;V-X/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L
M93X*(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q
M/@H@(" @(" @(" @(" @(" \<F1F.FQI/G)R-3 Y,38W/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@
M(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS
M=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U
M<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B @(" @
M(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z,#A!.3,V.#="-D%"13DQ
M,3A%-T-!,# P,S5&1C,X,C,\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @
M(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z.#5&1C,V140X,T%"13DQ,4)!
M13 X,$0P,4,U03=%-T4\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX
M;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HX-49&,S9%1#@S04)%
M.3$Q0D%%,#@P1# Q0S5!-T4W13PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$
M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI3
M97$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z.#5&1C,V140X,T%"13DQ,4)!13 X,$0P,4,U03=%
M-T4\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,3DM,#<M,C%4,3(Z,C8Z-3$K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HP
M-T$Y,S8X-T(V04)%.3$Q.$4W0T$P,# S-49&,S@R,SPO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C Q.2TP-RTR
M,50Q.#HS,#HQ-"LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N
M861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E
M<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F
M<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O
M97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z,#A!.3,V.#="-D%"13DQ,3A%-T-!,# P,S5&1C,X
M,C,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,3DM,#<M,C%4,3@Z,S Z,30K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @
M(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z,#=!.3,V
M.#="-D%"13DQ,3A%-T-!,# P,S5&1C,X,C,\+W-T4F5F.FEN<W1A;F-E240^
M"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z.#5&1C,V
M140X,T%"13DQ,4)!13 X,$0P,4,U03=%-T4\+W-T4F5F.F1O8W5M96YT240^
M"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I
M9#HX-49&,S9%1#@S04)%.3$Q0D%%,#@P1# Q0S5!-T4W13PO<W12968Z;W)I
M9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P
M/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @
M(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D
M93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X
M.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_
M>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!#
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "E > # 1$  A$! Q$!_\0 '@ !
M  (" @,!              <(!@D$!0$" PK_Q !C$   !@("  ,$! <*" <(
M$P ! @,$!08 !P@1$A,A"105,187(D$R45-8DI;1&!DC)%=Q=Y?5UC,V.&%X
M@;:X)28U-SFSMS1"2%)R=H>T)RA#15568G6"A(:1DY2AQM+7\/_$ !P! 0 "
M P$! 0             !!0($!@,'"/_$ %D1  $# P(#! 8&! 8+$ (#  $
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M#.?=&H%(#A@Z(4Q3%([=@>W<9\YZ?BJD7/G_ ,O..FN[PBUG:/=Z-KOF1/\
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MBK#UI/5QZ22@)AE,5:5AI=J^B)))%^R.B]*0CM!%4Q#BF7HG0Y[5K+Y5\/\
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MR6RW4_;;1+>%:VU,P58F]<W'BI-ZFJG%B!U'(%5&M5"M[5D(J>B!?B:KQ4/
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M[64\D[\]N TGI@'(4\P'H'G_ #'CYD!>$MVVU]X@C..6[E# 82D&61UO I*
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MFZ'T QS"'J81&MM[&B:Z$-:";B>@ /\ $Z/'SR?:2NUXOEEDH>!Q))(\#@Z
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M3/BNXP/]S8G S_9P!G&^/J$G&>N,]BS"W:TU[?D01NE*K%G*3KRE)J%8/G*
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M>_U0U=6U-951$^UE0YAQ[L++ZYLH(#JRFA.X#9P:8^/JSLC(\<A3+ V;6D@
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MM8\A=T<K[]4M,,;&L]@^-.K'-1MR?*G:>A*WJ:\V6[[K:HW=2CT.$G8G:#I
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M.TL: UHS@ 8&%DUIO]5IPMT)F3+\4>@;X9 1R#B5L4L8@=B2+@HY-S)O>AZ
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MLJ<W3@BIP*CA.Z6\]K[1Q(2W)[>3=K9<'$#L8*AI/36.J!*[Q8=^]T[7=A3
MW7F0URG(1P*8?,Q6<M5GZ J&Z[!,9,A $0 5N@$^.9=V?;I:&8=\57-"[KV,
MEIGMSX<T>U#1\ 5/ZB]\36QV.E?8K?<(M1[#-17BGDTCM>*0N[1'V(.R[*QZ
M";T]L-L'BZ.O#&J5F;%#_P ?PQEF&1,3\12QQEA] !'Q#X0>GU#/UMKKF[XS
M%Z-4- _G?HJ@OQW ,U=-M]H'"UKJ,F@XWX8E.,MCKA>K3*2>C2:RTBE#N\FJ
M#!_/QN?I]=M"0 /C*UDJYA-X?^-5*M]?3 0[ 1%U(PB++RP$H_PH.12'KLIQ
M+T.!=J(?K#/3_P",4E5 .F>LD36X\<X)& 5']@7$4I/H,=KNX SFSWZR7-QZ
M8 AI:^2HU'(]3E<P="T'*R.&V7KNPB 05ZJ,N83"7RX^Q1+I4#AZ"044G9E0
M. ]@)!(!@$! 0 0ZS8BKZ&?]364LIZ89/$XY[L!V?DJNNX5XFMF3<.'KU1@#
M5JJ;961,T]=0>^$,+2""':L$$$'!RLU*<IP Q#%,40 0$H@(" ^H#V'X\VU0
MD$;$$$=01@_ KVPB811'L3_'72/_ )_37_9O=LK*X?PNT[9_ADO^P5:[3AG^
MT/'W^3MO_P#=%A\[?<I<RS7%IA$PB81:6?:AL;W+VW6,"6K:]V6VD&UGDM8T
M>MZNW]9^0#(D/"HI;8GB6G46_-,(,->?#)*"CYV-<R2*,JL_B8U1C-R"L>DD
M\^?(4CSGIGN^2V$Z'V!JVK\1-3;)&R:TJNGX32-/LI+/76#W7^JX*E-*LQ=(
MOXF+MKYQ)U.LL8XI/=XZP2"\E&()@UD'"CM-0QBCSA4]]I9M;6^Z_9)<R-BZ
MFNM?V!2)K0E^2C;+69!*1C'#B.4!C(-#*I#XV[V/?(+,W[%R1%VS<I*(.4$E
M2F*$'I\/OW^2D=?G[L9^84]Z.B',+K*)VI6F)UY5D_>HV>+9-P]YM=3C6L9!
M/VY$B 47<Y$C!EEX)0WC6<+).XHBA$YA4Y.=AC,1J[E31YD%?6^DQL;@U-/%
M(('C &7S1\CF0.W<<.BV$I ^MW*LBK6V/@Z[5&BCEX5X<=::NHD_1V>]5-&;
MC32N>XGDT%9]8&AN31AD;'PUC@Y]"P.D!I=1+9=G&IR[23G+W-T5E2EB_P 8
M8'%]0(QV>PN ((BI#PD8"LR\'[(."(HQY#E=/FQ39MJL3UYI2V2:LEHF49ZL
M=KHHWF=V.L4,>97G;.GECUG-!PFL6;5PF+Y%-26[AZAXBJ+_ !G]%4-]'XDJ
MX&VR(NP&UUPK"RAIQZW+,CZEP,5/*X6#JM;85*!CH"/,LJBQ2-YKIR?S7D@]
M<*'<R,F^6Z 5G\F^5</WJP@'FN7"AP  $"A<T\#*:%D+,D,&[G'+Y'DDOE>[
MJZ21Y+WN/5Q)7SB[W2HO-QJKE5!C)*AXT0Q-T04T$;6Q4U)3,Z1TU)3LCIX(
MQ]B*-@R2"3%?(*7O4!3X:4H5J9U:14ONOZ\^7?5II9D74;<KI!5%T4C9V]8@
MV<,TIH[]NN50X&6;II*IF2.?.AL,-#/62QU]*^JC%#7SL:RI?3%LE)1SU;<N
M8Q^IKS (W @8#BX'("JI-0:-) .IHR1G9S@WW=>NZFU/S&[4GO"AG2R+<HKJ
MIH>$[A1-,/,43;I>+HRIBB8B*?BZ$P)E$WIW3;.<< -#G' )R&@] 7'&<="=
ML]2!NLU'>M-H579[2==U5A9V2$#./H&3^DM.L-0.,U'N%6THW;)3\='*/SLG
M:*K9ZNU*LDDX**9U/$(=[]PM=1:WPLJ'4KG5$+:B/T:JIZH<J4!['O-/)(&<
MQI#VZ\%S3J&=U EYHSEYT^H-8<,!NP:-6^D=F-NY29E>I4-;,N.GJW8: PV2
MU9KV*5F_+UZ=S2)FT+IV Q#%ZBI&-@)="'DO(*JN)U'+%;W-LY>>+W9FX52V
MH+#+=F/JHZ*EJA:QZ299WT37T@QIY\0J9&2-ZAFN$$ZG-9G4YH.[2WBY6R*K
MIJ&Y5]#!=(?1:^"DJJFGAKZ?5JY%8R![65$.=^7,',W.VY4QB4HAT)2B'XA
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M8B**KA\JY8F7(91!MXR@Y4(K'$(5,I2$*4A"% I"$ "E*4H=%*4H  %*
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M!5!,XI@KX!/X#^'OPCU*+),(F$3")A$PB81,(F$3"*!>2.C$>0NL5*&6W2M
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M].6*=)9Y_5FH]>Z^FK"GY_DS4I4:K%P3^20]Z$7/N[MRQ45;^\#Y_DF)YO\
M">+)4%3=A%JQ]J7P^Y%\Q-;4BI:/V!KV 8T^U1%TE*-L&,L_PNX6F%M-6D*M
M,KS]:GXPS5"F,6=CD&\+*Q4Y%2TH[8K*M47S"-?,GGSL5(('49^'GX'9=+Q"
MX6;ETORTV?MZ]HZ[:5!:-WU&P5DI\W(/+3MUQO?D 7>#.6O<&[KT>:O'U?'
MI2(9NYLEM4=)N7#EBZCV/\74)MC8=WR&-O;U*VT84+U.!A(8"" &$I@*(]B
M&$!Z$0 0$0 >A'H0'_/A%^:I/V6O*N$IEECX6D:-DHJ/VI)VB'TE:-SWBX4>
M\S-NU3R'UI>=RJ6FY:_FI.EOIF0W+4K6VUHM&V"/8K4B7.SF6LK,H.ACW?EO
MY[NBRS[>F,X'801MGP7Z"=)T62U?IO4^M9F:/9)C7VMJ/296PJ&4,><DJM68
MR$>RQC+ 54?B#EBJ[ 52@ITJ'F !^\E8J3L(M3OM'.'.^^1U^T!L'1,O4$)7
M6[.YUI^SNTG&M8*%6MUHUE8V-[?P4U0M@1M[C( E >QTK1DF]5EIQ.9;>XW&
M+2;NTURD8Z'SU\1WKQPIX8;AT1R7VYL^^M->QE3<UK8M+JLO3IU[*6/;H;!Y
M(;!WRVO>P8UU7(@8":JT-<&5(09+S-I<.%T)5VWDDHQ1FB9Y\_O0G./A\/.>
M@Z]JVQX4)A$PB81<=VW*[:N6AS&*1TW6;G,0>CE*LF9,QBB/H!@ PB4?Q]81
M:T/9^\)ME\59*T2&S;C1[,,;JC5''C6Q:*VGFP/=7::F-A3-?MMX3G$TBM[]
M8E]A.D9>+AS/86*1BD",I1\#H_D%)\-O?GN6S?"A,(M6W*[V>[_D)M+<=SK$
MQ1Z$PV_PRV%Q\F91.%6-9'NR;'>*99:W<+$FP9MDYZ"C8NGLH5^9S+A, R31
M8LB%0(11(I!QCP\]58WAOHJ_Z0I>RG>UY:HR.S=T;JN^[;JRU^>96HM<D[6V
M@X=G7*L[L+9C-2#&/A*U%'>2<A'QZ\C,N)-V#)NDJF0"CY?/SGJK>810%R@K
M>Z[?HR^UOCJ^US$;EEF#1M1I_:S1V_IE:E/B3-0]F<L64-8%'<M -2+RM:25
MB7;,+$UC%7R9FB:Q#$'CT6J?6_LQMXUR[Z2E7\[I^LT^+EM%VK=L=%V78-]N
M3ZX<=-L[7VU!V"I6Z?K-7^DDMN6Q;,7DMHRMGCH1:%D_BZD WE&C]!HUC [A
M^[R%.?QW]H Z=G3';MW+>KDJ$PBU4\ON#N[^5VYTGCW8>LZCIJ/UKMJI04Y'
M0EH4W!&I[@TK:]36RAR,:9[]!K!3I*<FX'8PVA=5C:8Y>K-:E'L4V3MS,GCS
M\OG[U(./;^T'S[5.O![CELW05=VO+;DG*-+;(W%L2&N<ZQUH$^:D0+.I:KUY
MJ& 8Q+NSH,YI^ZD(;732?F'#MDU*C)RZ\:V*X;,$7CF4/W?O\>]7APH4'\DM
M36#>NCMCZ@K&QI'4\IL& /6S7N)B$IR0AXM\Z;!.MV\<K(1/F!-0I7\$LLA)
ML7C1O)*NV+I!XB@J4GGN6E35'L@>0&NH?6U/?;>TS*50DTWAMEA"U&P5-S7=
M;TKF2^Y;41OJ2*C?.C"3DL]>/*M.,YM6-CZLTDFXP+Z82KR)9<LB<_O\ /P_
M8OT-X6*81:E.67L]]B\B.4L'MZN7&C42J/J'$T:X71F\V0UW(RK$7$;0C)C7
ML7#,)SZL+;1KZ;8B#B7"R1D=(P2L4X6:A,N'3!6+;^?(^_\ ;.V.WV=BFC@+
MQ6VAQK@=COMQV2ASMYOR^J(<&^M4[ 6J1]5TEIRF::JKOS;,BVE%;!96%2/9
M+ E[N#*,=224,Q<R*$<$BZ*//S6P/"*#^3&G"\A^/&[M$FG#UGZW]6WC7);"
M1M[Z,(I;J\_A4I068*H"Z(Q5>$<*-BKH'733,F19(Q@.44Z;K2JC[)/DBZJC
M>$>[3U-&M[RRV#K&^U!.5VI;J]J/2E]NVD+N];Z1LEO!U:I^U%FM03$N2/N8
MP\$RF-D/UV+I-M7&Z$N\^>U3GP[B?G^>/<OT,%*!"E*'R*4"AWZCT =!V/\
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MGM'J7VYP$A19^'LR-PU-7M)W3<M<9OD[^^^++66M6O:B-'7/5*Y&J2%9B'<
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E!2@&$7881,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>68
<FILENAME>g713200g99f98.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g713200g99f98.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[17>4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <NEPH
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
M;   !W0          0                         !              =T
M   ";                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   ";     !29VAT;&]N9P  !W0    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   FP     4F=H=&QO
M;F<   =T     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    $.$))300,      M0     0   *     T   !X   88    LT !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  T * # 2(
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M[&X;FM#*@'FR1,^I9;:]G?\ P=?_ )[2)M#?22224__2]527RJDDI^H\_?\
M8<C9ZF_TG[?1_G)VF/1_X7_1K$^K7[3^TV?;OM\[';OMGI^GNFO;Z/H>W=_/
M?1_,7SNDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?J=WHZ[]OG,>7
M_F*@?LF\3Z>_:[;]&=NGJ1_(^AO7RVDDI^IOT$_F3&G'"3?0D;=D]HB5\LI)
M*?J5GV7]'L]/C]%MCB/\''\G]U%7RJDDI^JDE\JI)*?_V3A"24T$(0
M50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !,
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))
M300B      %&34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;
M  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
MG $[  (    )    L(=I  0    !    O    .@ +BOL   G$  N*^P  "<0
M061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR,2 Q.3HS
M,SHQ.0!R<C4P.3$V-P       Z !  ,    !__\  * "  0    !   '=* #
M  0    !   ";          & 0,  P    $ !@   1H !0    $   $V 1L
M!0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
M         $@    !    2     $X0DE- _T       @          /_A 4A-
M30 J    "  ( 1(  P    $      1H !0    $   !N 1L !0    $   !V
M 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D
M  "PAVD !     $   "\    Z    \     !   #P     %!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C W.C(Q(#$Y.C,S.C$Y ')R-3 Y
M,38W       #H $  P    '__P  H ( !     $   =TH , !     $   )L
M          8! P #     0 &   !&@ %     0   38!&P %     0   3X!
M*  #     0 "   " 0 $     0   48" @ $     0             #P
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( ,4"70,!$0 "$0$#$0'_Q  >  $
M @(# 0$!            " D&!P0%"@$# O_$ %D0  $$ @( ! ($!@P("@@'
M  0" P4& 0< " D1$A,4(146%Y8B,4%65]4C-3<X475XM+:XU-88&21387>2
MEPHF)W%S@9'1V/ E,C-&6)BQP31'8G*%X?'_Q  > 0$  00# 0$
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MYYA1%*KI/U.I/1WK!JCJ[KV<L%FK&K(B2"9L=H6-F:G92>GY:TV"5*8!:8!
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MZ.Z+]T8#]7\(GV7ZS_1W1?NC ?J_A$^R_6?Z.Z+]T8#]7\(GV7ZS_1W1?NC
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MW=_5]O5GVS\>G;<F%DSHV\2U.*083B+*5!O-/(,YQP>1>3S#RRQUII(Q8/:
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M9N\0, %&#%Q:/5-30.KX=7V\T>KIQJS1F+70:*2_,!"PA5EQ\M5\6$<1=V<
M*,6$2AACD?<+D:/ SU9J\5"6>Z2VPYP%!"3KA.1E?AY284Z6^^TLJ-JT7#0(
MV11W6@FT@1HR5LC-NO8<)6\ZY+Z\<D401S3G9D'ERF,(XR/<G=MPB$(VXB["
MW$6W8=WW=W=;:HP3UJL4%J[+D)P8FDN3Q5X99G<R)G*.K%# /$78&X1CNPL[
M[D[N\&ZGK;LE0436E8'6&JINERG8O8>X0=\VVSL2XT74]D;ALF[37G=7YB&+
M YNBHRUG?J5-+;E7:FTY$0FP2[&P\.Y0E5E=J%],Z"=B)>U:1!O\$U!:VK<_
MK!OLI#M=@+K;4=C;;6M?[ZA-A[R,&41'.AC7>:N=(:/@BWA;!<1#"X^YPZ(:
MC5[$@1:WL/3O>&H$=3XB7HUHV_'VZ4Z^5?=U&8WI><IV#L2DZG[CN[!DK5;9
M"4/;:BG828UQ%LE394?5[BJ$K=$G"0H<<-P0BRTSI3WN7?\ KE+?$U_T:FG]
M+&&W #<5KEYT'6<?>)P_8^IRYZW'NRM@^@J=8F:<RY$U2LC[1KM?3.WFTR-A
MQ'5G)%Q93H+VP@F.I<1K^"KT:K4U)ZGRMZN;>W;.5:"=E5'8@-@[28D#;-89
M4-UR^5L5,8'(U.MBR&R1RY."V#<PJU#UF$<(NSH/03LA08&CT^"IT+$.58*F
M0>L;?#;KF:_&==[%6>Q-_O6S]J1E8AV\8NC6[-<S]51F$6,J0EWZ]G7%]#B:
MB>5)X(IR:ZTWN3KSTS>K>N-=UB_]DS))=FD ;?;,S<)(7Z3N#&6[Q)S-FF D
MRRZ176(R8A:^/-5QLQRLQ-7BYFKMK9F(XBW[U1U])ZVT^#!6&MV>O6Z2LURM
M]Y)N<_4K':+=>;G8Y"S6V\2QU%((J@B[1-R1D@%!0>!HRN1J@H&/!#!CAAVR
M*&/?ZZ=Z$[CT]I;IA9J)''[HU7LJ"GWI>TZSC;3IYQG96CPI/LZBEW5MRS;&
MK^K=?2]WA(N!I39C+.Q;G3G+7$2L>^$TR12.\/ZV;2N/6&L&[COT;M&\0=XW
M+17[^%)4:3D[/ :]W#>:149.YN:U)+HP>PW:K 0^+]%5YUL:)M:96/($!/'+
M"'(HP]_'\"]VO"8>^?FK?VWQOP5>G.4F:JP/E.<^?S3ZUH4I.?/"O1C\N,<F
M&G(6GPNM ?[S"59Q?9G<2@R]"3=M_1W!C#DW<1,G^*M;!.,M39^Q3N+M\6>"
M;U_.S/\ #?\ 9;?R'JZ3A$X1.$3A%^3SS(S3A!#K3##*%.///.(:::;1CU+<
M<<7E*$(3C&<J4I6$IQCSSG&.$6+Q=_HLW)GPD-<ZI+3,61\')14;88DZ2 +P
MI2,C&!#%NDC$86A:,LO-H<PM"T^GU)5C!%EO")PB<(G")PB<(G")PB<(G")P
MBZ>P_M!.?Q/)_P R?X1:IZS?O;^OW^I'5/\ 0.!X1;NX1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$6*7NCU39E)M^N;W"!V2DWRLSE.MU>D$K4#.5JR
M1A,/-Q)>&UMN?#GQIA(KN6G&W4H=RIMQ"\)5@B@,SX3G2I$!5( JD7F616;1
M-6<^9FMP[2EK1L)-B;U\Q-53;-E.M;TQLZ@'AZEU;'NT6XE2M:Q'Z\J@2(]
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MX)N<PM/D=[J91E6?<+:&(K%>$3A$X1.$3A$X1.$3A$X1.$73V']H)S^)Y/\
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M]CO^?NK"[]>C_IH>GXHI5:CG767'B2"+WL8ATE[+RLXLR0F6OP&VTLC!Q8
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M\3SY6&:..**2%N/4FH!&#R1M7W<Y([$TI20B4@D!#TGP-#/>;M]":$81E?C
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MIXDLPPE;8XPP[2%NOOO.(::;2I:U)2G.>=XXY)3"*&,Y99"8(XHQ(Y)#)]A
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M88)]-ZERV(;ET*]ESJ.;NY%3L"T]5W)_4FAD #?O[8%WWW6S*-GSE2"QV9Y
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MI.H/Q?\ HE^Y??M2J?\ FKA_NXV)_P#3ZK>?./FRU\:GZQQ_^OS6R=0?B_\
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MF4/=[=!#UN+L#I%^27*7Z:U9]3$ZWM[NPH_8L' .64FGR=(9C7)\68(BL,O
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MAK[)D]ZU)K76X]B0@LY.":57L$&RQ>864ASS9S7,4[*3,7#IEPQ,23+Z4('
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MLC=/J6[LYV)S;?;D?U0#EW:.$.,,3=MHP%MF]%]T--:=Q.D-/872V!K^6P^
MQU;&8^)^/4>&N&Q3SD#"TEJW,\ENW+MO+9GED?N2U-+N94]E/GGRQZ$^7G^#
MY(QE7JQ\_P >5.+0KSQY_L>/GS)8J/:.6;M](; SM_)B9_?W[\R-GVV;LS;=
ME\#?^4X\19-5?* H:(@DWQOA=I2G2(>;N+ZAU>%7/Y2018G'<,0.FX'?9C8X
MY@-G81W[*(<RL=:<YQ^ OS3CSSG.$K0G.<JSGS^:GL._/^'F/OAPMRM[C8)6
M[=O:%A)V]>[F!._P=^Z^A/\ R:.KWU'\FBC@II^K9T%J[4VFG!]^45&U9CU-
MC@V?_%!!GG@AVV%HX&%F9Q=EZ%_!L[)1J(VT=9K3+I8D42!EUU@R8YE.#0S&
M\.7"O K7GV_> ,:18A@D82Z^U)S1+:5(#?RG<OA'J &"UINS+M(TDE[&,>_M
MQR;/<KQN[[;Q2,UA@;;DTTI"WT9[8'Y<GA;9>UB/%C$4BDJE6@P&KC@#?R\\
M!<<'E+ BW+A9@,L7+.6X@=2A$3L4\;/?=S>"^=*<(G")PB<(NGL/[03G\3R?
M\R?X11\U)28#9/3C5FOK2.LNMW;K;0ZK.CM.>R\[%3VLXF,.PP]A*LL$8')<
M4._A*E,O80ZG&5(QRUO4X,A3MT+0N=>[7FJSBS[.\4\912,S[/L7$GXOL^S[
M/[EF=.Y[(Z6S^$U+AY1@RNG\K0S..E,6DC&[C;45NL\D;[=2+JPBTD>[-(#D
M#OLZT1_@0;$D-?06N+/VFMEA@M9E4B5T>MW7%(",H<_KF8 D:=-V4IG#A6PB
M8N/CTU]P<LF#",BRSG2!E22Q3A(9]QET\?7QUG4MNQ#CCHS8=WQ](#I3XV>.
M6I-8,?:O%&$;P$)E"!QR&Y-U.)CZ!_P_:9K:FR.J<3X087&9#5D.H*7B"(:J
MU!8KZCQNJ:-FKG<?B8).,.F8;=FT^2"6&+(6(+<%<(I6J!+7FR2H])6X*T4W
M8$_M"1M-_B-]V'L!<YY57CH<&WV*<UX3KAB"CH4(]QJK041#K#=#3@J<+<?&
M?R0^YDSUCW-71XPV*EZ?)2V;\6<L9ZW/Y>.(+5B?'GCFACA&0FK0PPN#A[4Q
M.X/R=^?LXK->/<F0Q&<TUC-)4\/IN[X<8SPUP6.;+6KUG"8O':FBU2>1M7YZ
MPGF,A=O-.$[O#CX CECZ48M!QEUW/=#GZUJ&"@JG<3[58M7:8[:4FK13T2!%
M?7*6[$L2QXS))C\M\-#9AI IF/'<<<>'-PO!)+L>A*DXQ\VB/+8NO#5MR69\
M9A]54:D11Q1M:DU TL@L9D?&+HR$(,[NXFWM$XLVSR;'?*)#*:VR.2S.#K8C
M%ZNUYX+:@S%N.[9N/@J?A?+1KS'#!'2ZM]K]:&2S( B$L#CTH0LD[.^,TGP^
M[K.:L]&SMWV=G94UH74>G(MP"N0  6N*A1CXFVF4"5&KTDPQL( VP#/0MAD'
MI.,S/0+:A?7C!#A+MO3T);FQKMDLU:;(38/$XB)XX((PQ]6A)';*E*T$@M?C
MDL"\-B1Y(GG@9QW;DY++9[Y2F!H:O8M)>'^(DTG1\1M:ZYN#9RF2LV-59K4-
M:YA:^I:4N3J22:8LP8V6._BZH5+?S;D2:;CO$$0[3T]T*B=36G7-J8V F1?H
M.V]L[;^BXRD156@S9';6M8O7LC!1L7&R3P\!#0BHW,K$MLI-=RTZW&DJ<6RN
M1(R.)T/#BK5"T-[F5'+97+-''3AK0G)E<=%0E@"*(W&&*)@*2+;D6Q,!.3L\
MCQ#7'RBKVM,1JC#RZ;\M%J316B]%><N:@N9C(5ZNB]5W-35<A:N6Z@2Y.]?:
MTU*X<KP#S K43")C5CPVL^&Y%Q5JMEBL&W).SXL]%WCKU\M^G18ES.AMV+0L
MJ0MEX<E3Y&W3M7;PH.%).$&CVH] PPT6!Z3%G6M;P^ABLV9Y\I+9:S1S>/(R
MJ1!<D@S1;D=J]U#DM3U6^C@(P&-HV$1B#VW/.Y;Y4MVYA\-C,9HNGAWQ.HO#
M[4T<,><MSX&O?T")##6PVGAI5ZN%QV7+:>_#7FELE9*666W9W@&OS#>@-M+A
M(^-;[&RH4A*:'$ZU;/E!=9UO*+OJ>)D)-R#&B0")5]%/M4?!RQD [8D$3C9K
M;GTBN*;,QC/.QZ&LG#'']T$P')@1TWDI0Q];^&XN(YNBT492$U2U'#.<#V!*
M5I&?F43&RH0?*/PT.0M6B\+:-BK4\19_%;2-.;5F5WT_K.[6J#D);MB*E$^<
MP]G(4H,D&+*+''7,?*C<*!^TG],=<X'2=WVE;*_-%E@;&B]0P@D"2(A&*U%Z
M@H ] B&$26"%NRKD@",V60Z\,)EAWS:2EW&<N9DF(P$.'NY.U!,9QY"/%1!
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MJD/GX:F-KGAZU*V30A6,)-^43 >LZ1U7N\!M*<WC<=TCWS:J=6R^J:+*XUA
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M"C06F P11PPQ0@!6&FF\N*0X2\00]5TWIG&Z6HG0QO7();!V9IK,C2SS32"
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M^/O3UQY3PU+,L+;;[RQPF4;<??N3-V]_I[U@-5WKV,TSJ#(XV/JY"CALE;I
MP\][,%266%^'W_$Q8N'W^W'WJ,U=OL+IK2^N-H4#<4KLO:FY(_6=;FU;*VE*
MVZFPTQ?YJ$'FMA3E0^E4NPH-0EC'H5;$.[!#,*-8ACW/?=0XF,16XL?C:=VM
MD)+UO(M1A.2Y=DL5@DN311G<DK]5FB"&0W#A"\#;D,)$+[.VGZ67JZ:TOA,]
MB=2V,[G]30X&C:+.Z@L9'&5K.8LU8[69MXYK#%4BQUF4JSC5>H %,%68N9,3
M9 )VDW[*2$/KB(<U*=>G.QUIT27>TPUD<HLH!%:V5=QK$!"C61V0%E0'G$AR
M<3B:,$<)'P,DP5#ZWV:HYG)F<=0/(%9^>9\45GIS/5D"/'/>&<(AG<V,'=HI
M8NN3.<9LQCNVUT&OM73S5L)6^YV;+%KB_I"7+>6OOB9X:V#?+1WH:L=TIH[$
M1.T5BNUN2-Y(^FTL;$YAC=)[C]@2Z_7+3;X[5JXV^:9["VVM UZ*LS)L/:]
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M7UUG7DI6O#"U%EJ9!G ;OH/J1NC6-] +!;)8^&3-@]D#A3HDT<M]D^(EXV1
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M.  AGS7<*:97C-C>O1T CEF%^@\@C/-R$1K1D3 TTG)VW!I"!B8=R87(V9V
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M]@1,=I?::2:N;812S84>0R551VLKD10#'F/AG'T^AA?K4C/EC/!7*@")'9@
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M.G<)''D1X7P#%40"X')CX61&!AF#F+'Q-B'FS'MR[KNXG5VMH$.NQ\)0J?$
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M>\;UOOPFQG]A:DHV].W6OMC[47.Z^B M[:?U_==GZYTS>#*K7M=-QUDEK/\
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M<.^).BM73=4C&]FXBB!]/T+K@.V+U7K9-V-=8G.TX9RM<1EAL$C/BB/I'==
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8B<(G")PB<(G")PB<(G")PB<(G")PB__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
